These	O
findings	O
were	O
recapitulated	O
in	O
an	O
in	O
vitro	O
system	O
using	O
rabbit	O
reticulocyte	O
lysates	O
that	O
had	O
been	O
largely	O
depleted	O
of	O
endogenous	O
tRNAs	O
and	O
resupplemented	O
with	O
Q	O
-	O
free	O
or	O
Q	O
-	O
containing	O
tRNA	B-CHED
populations	O
.	O

Immunophenotyping	O
of	O
central	O
nervous	O
system	O
(	O
CNS	B-CHED
)	O
infiltrates	O
revealed	O
that	O
CD4	O
(-/-)	O
mice	O
had	O
a	O
significant	O
reduction	O
in	O
numbers	O
of	O
activated	O
macrophages	O
/	O
microglial	O
cells	O
in	O
the	O
brain	O
compared	O
to	O
the	O
numbers	O
in	O
CD8	O
(-/-)	O
and	O
C57BL	O
/	O
6	O
mice	O
,	O
indicating	O
a	O
role	O
for	O
these	O
cells	O
in	O
myelin	O
destruction	O
.	O

TITLE	O
:	O
Assembly	O
of	O
spikes	O
into	O
coronavirus	O
particles	O
is	O
mediated	O
by	O
the	O
carboxy	B-CHED
-	O
terminal	O
domain	O
of	O
the	O
spike	O
protein	B-CHED
.	O

ABSTRACT	O
:	O
The	O
type	O
I	O
glycoprotein	B-CHED
S	O
of	O
coronavirus	O
,	O
trimers	O
of	O
which	O
constitute	O
the	O
typical	O
viral	O
spikes	O
,	O
is	O
assembled	O
into	O
virions	O
through	O
noncovalent	O
interactions	O
with	O
the	O
M	O
protein	B-CHED
.	O

Here	O
we	O
demonstrate	O
that	O
incorporation	O
is	O
mediated	O
by	O
the	O
short	O
carboxy	B-CHED
-	O
terminal	O
segment	O
comprising	O
the	O
transmembrane	O
and	O
endodomain	O
.	O

Calcium	B-CHED
for	O
Preeclampsia	O
Prevention	O
Study	O
Group	O
.	O

We	O
conducted	O
(	O
and	O
reported	O
elsewhere	O
)	O
a	O
randomized	O
,	O
double	O
-	O
masked	O
,	O
placebo	O
-	O
controlled	O
trial	O
calcium	B-CHED
supplementation	O
of	O
4589	O
healthy	O
nulliparas	O
assigned	O
at	O
13	O
-	O
21	O
weeks	O
'	O
gestation	O
.	O

Air	B-CHED
leaks	O
developed	O
in	O
22	O
of	O
80	O
patients	O
or	O
in	O
27	O
.	O
5	O
%.	O

There	O
was	O
a	O
strong	O
positive	O
correlation	O
between	O
the	O
incidence	O
of	O
AL	O
and	O
high	O
ventilatory	O
pressures	O
(	O
PIP	B-CHED
36	O
vs	O
.	O
29	O
.	O
7	O
cm	O
H	O
(	O
2	O
)	O
O	O
,	O
P	O
<	O
0	O
.	O
001	O
),	O
or	O
large	O
tidal	O
volumes	O
(	O
V	O
(	O
T	O
)	O
12	O
vs	O
.	O
9	O
mL	O
/	O
kg	O
,	O
P	O
<	O
0	O
.	O
05	O
),	O
suggesting	O
that	O
large	O
volumes	O
might	O
elicit	O
injury	O
to	O
the	O
pulmonary	O
epithelium	O
.	O

The	O
nucleotide	B-CHED
sequences	O
of	O
amplified	O
440	O
bp	O
products	O
were	O
determined	O
,	O
aligned	O
and	O
the	O
phylogenetic	O
analysis	O
revealed	O
noticeable	O
genetic	O
clusters	B-CHED
among	O
the	O
prevalent	O
feline	O
coronaviruses	O
in	O
the	O
surveyed	O
geographic	O
area	O
.	O

To	O
better	O
understand	O
the	O
RNA	O
-	O
binding	O
properties	O
of	O
this	O
multifunctional	O
protein	B-CHED
,	O
the	O
N	O
protein	B-CHED
was	O
expressed	O
in	O
Escherichia	O
coli	O
as	O
a	O
chimeric	O
protein	B-CHED
fused	O
to	O
glutathione	B-CHED
-	O
S	O
-	O
transferase	O
(	O
GST	O
).	O

Although	O
the	O
core	O
UCYAA	O
sequence	O
is	O
often	O
tandemly	O
repeated	O
in	O
viral	O
genomes	O
,	O
ligands	O
containing	O
one	O
or	O
more	O
repeats	O
of	O
UCYAA	O
showed	O
no	O
difference	O
in	O
binding	O
to	O
the	O
N	O
protein	B-CHED
.	O

Previously	O
we	O
identified	O
the	O
first	O
cleavage	O
event	O
as	O
proteolysis	O
at	O
the	O
Gly	B-CHED
(	O
673	O
)-	O
Gly	B-CHED
(	O
674	O
)	O
dipeptide	B-CHED
bond	O
mediated	O
by	O
the	O
first	O
papain	O
-	O
like	O
proteinase	O
domain	O
(	O
PLPD	O
-	O
1	O
)	O
to	O
release	O
an	O
87	O
-	O
kDa	O
mature	O
protein	B-CHED
.	O

Glycosidase	O
digestion	O
and	O
site	O
-	O
directed	O
mutagenesis	O
studies	O
of	O
the	O
41	O
-	O
kDa	O
protein	B-CHED
demonstrated	O
that	O
it	O
is	O
modified	O
by	O
N	O
-	O
linked	O
glycosylation	O
at	O
the	O
Asn	B-CHED
(	O
2313	O
)	O
residue	O
encoded	O
by	O
nucleotides	B-CHED
7465	O
to	O
7467	O
.	O

ABSTRACT	O
:	O
Transmissible	O
gastroenteritis	O
coronavirus	O
(	O
TGEV	O
)	O
agglutinates	O
erythrocytes	O
of	O
several	O
species	O
by	O
virtue	O
of	O
sialic	B-CHED
acid	I-CHED
binding	O
activity	O
of	O
the	O
surface	O
protein	B-CHED
S	O
.	O
We	O
have	O
isolated	O
and	O
characterized	O
five	O
haemagglutination	O
-	O
defective	O
(	O
HAD	O
)	O
mutants	O
.	O

In	O
four	O
of	O
the	O
HAD	O
mutants	O
a	O
nearby	O
antigenic	O
site	O
is	O
affected	O
in	O
addition	O
to	O
the	O
sialic	B-CHED
acid	I-CHED
binding	O
site	O
,	O
as	O
indicated	O
by	O
reactivity	O
with	O
monoclonal	O
antibodies	O
.	O

ABSTRACT	O
:	O
The	O
acute	O
respiratory	O
distress	O
syndrome	O
is	O
a	O
rare	O
but	O
potentially	O
fatal	O
complication	O
of	O
severe	O
acute	O
iron	O
poisoning	O
and	O
its	O
pathogenesis	O
has	O
been	O
linked	O
with	O
direct	O
and	O
indirect	O
iron	O
toxicity	O
as	O
well	O
as	O
the	O
use	O
of	O
the	O
chelator	B-CHED
drug	O
desferrioxamine	B-CHED
.	O

Accordingly	O
,	O
this	O
domain	O
of	O
the	O
protein	B-CHED
could	O
not	O
be	O
detected	O
on	O
the	O
outside	O
of	O
virions	O
but	O
appeared	O
to	O
be	O
inside	O
,	O
where	O
it	O
was	O
protected	O
from	O
proteolytic	O
degradation	O
.	O

Thiobarbituric	B-CHED
acid	I-CHED
-	O
reactive	O
substances	O
were	O
not	O
increased	O
in	O
plasma	O
,	O
and	O
varied	O
over	O
a	O
wide	O
concentration	O
range	O
in	O
lavage	O
fluid	O
.	O

In	O
addition	O
,	O
markedly	O
enhanced	O
levels	O
of	O
plasminogen	O
activator	O
-	O
inhibitor	B-CHED
I	O
and	O
alpha	O
(	O
2	O
)-	O
antiplasmin	O
were	O
noted	O
in	O
ARDS	O
,	O
ARDS	O
+	O
PNEU	O
,	O
and	O
PNEU	O
-	O
vent	O
,	O
but	O
not	O
in	O
PNEU	O
-	O
spon	O
.	O

The	O
techniques	O
used	O
included	O
lung	O
rest	B-CHED
,	O
pulmonary	O
physiotherapy	O
,	O
diuresis	O
to	O
dry	O
weight	O
using	O
hemofiltration	O
if	O
needed	O
,	O
minimal	O
anticoagulation	O
,	O
and	O
optimal	O
systemic	O
oxygen	B-CHED
delivery	O
.	O

TITLE	O
:	O
Cocaine	B-CHED
causes	O
increased	O
type	O
I	O
interferon	O
secretion	O
by	O
both	O
L929	O
cells	O
and	O
murine	O
macrophages	O
.	O

Seven	O
of	O
the	O
MAbs	O
were	O
shown	O
by	O
sodium	B-CHED
dodecyl	I-CHED
sulfate	I-CHED
-	O
polyacrylamide	B-CHED
gel	O
electrophoresis	O
and	O
Western	O
blot	O
assay	O
to	O
be	O
reactive	O
with	O
the	O
BRV	O
outer	O
capsid	O
protein	B-CHED
,	O
VP7	O
,	O
which	O
has	O
a	O
molecular	O
mass	O
of	O
37	O
.	O
5	O
kDa	O
.	O

Lidocaine	B-CHED
treatment	O
attenuated	O
these	O
changes	O
.	O

ABSTRACT	O
:	O
The	O
replicase	O
gene	O
(	O
gene	O
1	O
)	O
of	O
the	O
coronavirus	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
encodes	O
two	O
co	O
-	O
amino	O
-	O
terminal	O
polyproteins	O
presumed	O
to	O
incorporate	O
all	O
the	O
virus	O
-	O
encoded	O
proteins	B-CHED
necessary	O
for	O
viral	O
RNA	O
synthesis	O
.	O

These	O
results	O
demonstrate	O
that	O
the	O
complexes	O
known	O
to	O
be	O
involved	O
in	O
RNA	O
synthesis	O
contain	O
multiple	O
gene	O
1	O
proteins	B-CHED
and	O
are	O
closely	O
associated	O
with	O
structural	O
proteins	B-CHED
at	O
presumed	O
sites	O
of	O
virion	O
assembly	O
.	O

Lung	O
tissue	O
of	O
anti	O
-	O
CD18	O
-	O
treated	O
rabbits	O
contained	O
less	O
malonyldialdehyde	B-CHED
,	O
a	O
by	O
-	O
product	O
of	O
membrane	O
lipid	B-CHED
peroxidation	O
by	O
PMN	O
oxygen	B-CHED
radicals	I-CHED
(	O
950	O
+/-	O
120	O
versus	O
1	O
,	O
710	O
+/-	O

At	O
2	O
and	O
3	O
d	O
.	O
p	O
.	O
i	O
.,	O
a	O
great	O
number	O
of	O
basal	O
cells	O
were	O
recognized	O
,	O
but	O
the	O
BrdU	B-CHED
labelling	O
index	O
tended	O
to	O
decrease	O
.	O

Chimeric	O
spike	O
protein	B-CHED
mutants	O
containing	O
substitutions	O
of	O
the	O
entire	O
transmembrane	O
anchor	O
and	O
cys	B-CHED
domain	O
with	O
the	O
herpes	O
simplex	O
virus	O
type	O
1	O
glycoprotein	B-CHED
D	O
(	O
gD	O
-	O
1	O
)	O
anchor	O
demonstrated	O
that	O
fusion	O
activity	O
requires	O
the	O
presence	O
of	O
the	O
A59	O
membrane	O
-	O
spanning	O
domain	O
and	O
the	O
portion	O
of	O
the	O
cys	B-CHED
domain	O
that	O
lies	O
upstream	O
of	O
the	O
cytoplasmic	O
tail	O
.	O

The	O
antisera	O
against	O
turkey	O
enteric	O
coronavirus	O
(	O
bluecomb	O
agent	O
),	O
bovine	O
coronavirus	O
(	O
BCV	O
),	O
bovine	O
Breda	O
-	O
1	O
virus	O
,	O
bovine	O
Breda	O
-	O
2	O
virus	O
,	O
avian	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
),	O
avian	O
influenza	O
virus	O
,	O
Newcastle	O
disease	O
virus	O
(	O
NDV	O
),	O
and	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
of	O
swine	O
were	O
evaluated	O
by	O
dot	O
-	O
immunobinding	O
avidin	O
-	O
biotin	B-CHED
-	O
enhanced	O
ELISA	O
and	O
did	O
not	O
react	O
with	O
SSA	O
.	O

Reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
and	O
cycle	O
sequencing	O
techniques	O
were	O
used	O
to	O
elucidate	O
the	O
genetic	O
and	O
deduced	O
amino	B-CHED
acid	I-CHED
relationships	O
among	O
the	O
isolates	O
.	O

ABSTRACT	O
:	O
Acute	O
and	O
chronic	O
demyelination	O
are	O
hallmarks	O
of	O
CNS	B-CHED
infection	O
by	O
the	O
neurotropic	O
JHM	O
strain	O
of	O
mouse	O
hepatitis	O
virus	O
.	O

Cleavage	O
of	O
the	O
N	O
protein	B-CHED
was	O
inhibited	O
by	O
cell	O
-	O
permeative	O
caspase	O
inhibitors	B-CHED
,	O
suggesting	O
that	O
this	O
viral	O
structural	O
protein	B-CHED
is	O
a	O
target	O
for	O
host	O
cell	O
caspases	O
.	O

The	O
severity	O
of	O
burn	O
shock	O
,	O
preclinical	O
diagnosis	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
disseminated	O
intravascular	O
blood	O
coagulation	O
,	O
depth	O
of	O
hemodynamic	O
disorders	O
and	O
disorders	O
in	O
the	O
oxygen	B-CHED
transporting	O
system	O
can	O
serve	O
as	O
a	O
criterion	O
of	O
the	O
compensatory	O
stress	O
and	O
be	O
an	O
indication	O
for	O
active	O
respiratory	O
therapy	O
.	O

The	O
binding	O
site	O
in	O
the	O
amino	O
region	O
of	O
N	O
was	O
either	O
not	O
present	O
or	O
only	O
partially	O
present	O
in	O
the	O
first	O
91	O
residues	O
because	O
no	O
interaction	O
with	O
RNA	O
was	O
observed	O
with	O
the	O
polypeptide	B-CHED
incorporating	O
these	O
residues	O
.	O

Cache	O
Valley	O
virus	O
N	O
expressed	O
with	O
a	O
histidine	B-CHED
tag	O
,	O
bovine	O
serum	O
albumin	O
,	O
and	O
the	O
basic	O
lysozyme	O
protein	B-CHED
did	O
not	O
shift	O
the	O
IBV	O
RNA	O
.	O

In	O
an	O
effort	O
to	O
maximize	O
IFN	O
-	O
alpha	O
antiviral	B-CHED
efficacy	O
,	O
we	O
have	O
explored	O
the	O
therapeutic	O
potential	O
of	O
murine	O
IFN	O
-	O
alpha2	O
(	O
mIFNalpha2	O
)	O
selectively	O
expressed	O
in	O
the	O
liver	O
.	O

To	O
explore	O
the	O
mechanism	O
of	O
action	O
of	O
these	O
inhibitors	B-CHED
,	O
various	O
novel	O
styrylquinoline	B-CHED
derivatives	O
were	O
synthesized	O
and	O
tested	O
against	O
HIV	O
-	O
1	O
IN	O
and	O
in	O
cell	O
-	O
based	O
assays	O
.	O

TITLE	O
:	O
Zinc	B-CHED
chloride	I-CHED
smoke	O
inhalation	O
:	O
a	O
rare	O
cause	O
of	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

Of	O
the	O
four	O
trials	O
in	O
the	O
subgroup	O
using	O
surfactant	B-CHED
routinely	O
,	O
three	O
also	O
used	O
the	O
HVS	O
.	O

The	O
trends	O
in	O
results	O
were	O
similar	O
with	O
surfactant	B-CHED
to	O
those	O
for	O
the	O
HVS	O
subgroup	O
analysis	O
.	O

Planned	O
subgroup	O
analyses	O
include	O
separate	O
comparisons	O
for	O
studies	O
utilizing	O
natural	O
surfactant	B-CHED
extract	O
and	O
synthetic	O
surfactant	B-CHED
.	O

Further	O
analysis	O
of	O
data	O
with	O
regard	O
to	O
surfactant	B-CHED
type	O
was	O
performed	O
.	O

Early	O
selective	O
surfactant	B-CHED
administration	O
given	O
to	O
infants	O
with	O
RDS	O
requiring	O
assisted	O
ventilation	O
leads	O
to	O
a	O
decreased	O
risk	O
of	O
acute	O
pulmonary	O
injury	O
(	O
decreased	O
risk	O
of	O
pneumothorax	O
and	O
pulmonary	O
interstitial	O
emphysema	O
)	O
and	O
a	O
decreased	O
risk	O
of	O
neonatal	O
mortality	O
and	O
chronic	O
lung	O
disease	O
compared	O
to	O
delaying	O
treatment	O
of	O
such	O
infants	O
until	O
they	O
develop	O
established	O
RDS	O
.	O

Only	O
a	O
mutant	O
M	O
protein	B-CHED
in	O
which	O
all	O
three	O
transmembrane	O
domains	O
had	O
been	O
replaced	O
lost	B-CHED
this	O
ability	O
.	O

Specific	O
host	O
protein	B-CHED
interactions	O
with	O
the	O
BCV	O
3	O
'	O
UTR	O
[	O
287	O
nt	O
plus	O
poly	O
(	O
A	O
)	O
tail	O
]	O
were	O
identified	O
using	O
gel	O
mobility	O
shift	O
assays	O
.	O

TITLE	O
:	O
Protection	O
studies	O
on	O
winter	O
dysentery	O
caused	O
by	O
bovine	O
coronavirus	O
in	O
cattle	O
using	O
antigens	B-CHED
prepared	O
from	O
infected	O
cell	O
lysates	O
.	O

We	O
used	O
a	O
recruitment	O
maneuver	O
using	O
40	O
cm	O
H2O	B-CHED
of	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	B-CHED
)	O
and	O
20	O
cm	O
H2O	B-CHED
of	O
pressure	O
controlled	O
ventilation	O
above	O
PEEP	B-CHED
for	O
2	O
mins	O
to	O
successfully	O
recruit	O
the	O
lung	O
.	O

As	O
in	O
coronaviruses	O
,	O
GAV	O
ORF1a	O
encodes	O
a	O
3C	O
-	O
like	O
cysteine	B-CHED
protease	O
domain	O
located	O
between	O
two	O
hydrophobic	O
regions	O
.	O

ORF1b	O
encodes	O
homologues	O
of	O
the	O
'	O
SDD	O
'	O
polymerase	O
,	O
which	O
among	O
(+)-	O
RNA	O
viruses	O
is	O
unique	O
to	O
nidoviruses	O
,	O
as	O
well	O
as	O
metal	B-CHED
-	O
ion	O
-	O
binding	O
and	O
helicase	O
domains	O
.	O

Approximately	O
85	O
participants	O
were	O
selected	O
for	O
their	O
collective	O
expertise	O
in	O
critical	O
care	O
,	O
pulmonary	O
medicine	B-CHED
,	O
cardiovascular	O
medicine	B-CHED
and	O
surgery	O
,	O
pediatrics	O
,	O
nursing	O
,	O
biostatistics	O
,	O
and	O
medical	O
economics	O
.	O

ABSTRACT	O
:	O
Recombinant	O
live	O
oral	O
vaccines	O
expressing	O
pathogen	O
-	O
derived	O
antigens	B-CHED
offer	O
a	O
unique	O
set	O
of	O
attractive	O
properties	O
.	O

Viral	O
antigen	B-CHED
was	O
detected	O
in	O
the	O
cytoplasm	O
of	O
tracheal	O
epithelium	O
from	O
16	O
hr	O
to	O
6	O
days	O
post	O
-	O
inoculation	O
(	O
p	O
.	O
i	O
.)	O
with	O
a	O
peak	O
on	O
4	O
days	O
p	O
.	O
i	O
.	O

These	O
results	O
demonstrate	O
that	O
multiple	O
gene	O
1	O
proteins	B-CHED
segregate	O
into	O
two	O
biochemically	O
distinct	O
but	O
tightly	O
associated	O
membrane	O
populations	O
and	O
that	O
only	O
one	O
of	O
these	O
populations	O
appears	O
to	O
be	O
a	O
site	O
for	O
viral	O
RNA	O
synthesis	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
periodic	O
leg	O
movements	O
(	O
PLM	O
),	O
arousal	O
and	O
respiratory	O
variables	O
in	O
12	O
untreated	O
RLS	O
patients	O
and	O
to	O
measure	O
the	O
acute	O
effects	O
of	O
0	O
.	O
5	O
mg	O
ropinirole	B-CHED
,	O
a	O
nonergoline	O
dopamine	B-CHED
agonist	I-CHED
,	O
as	O
compared	O
with	O
placebo	O
.	O

Thus	O
,	O
0	O
.	O
5	O
mg	O
ropinirole	B-CHED
significantly	O
improved	O
the	O
target	O
variable	O
PLM	O
/	O
h	O
TST	O
,	O
along	O
with	O
objective	O
and	O
subjective	O
sleep	O
quality	O
and	O
morning	O
noopsychic	O
performance	O
,	O
as	O
described	O
in	O
the	O
preceding	O
paper	O
.	O

Biliopancreatic	O
duct	O
pressure	O
was	O
measured	O
during	O
infusion	O
of	O
solutions	O
in	O
SAL	B-CHED
and	O
TAU	B-CHED
groups	O
.	O

Acute	O
pancreatic	O
lesions	O
were	O
still	O
intense	O
on	O
day	O
3	O
in	O
the	O
TAU	B-CHED
group	O
only	O
.	O

TITLE	O
:	O
[	O
From	O
isoflurane	B-CHED
to	O
perfluorohexane	B-CHED
?	O

The	O
patient	O
also	O
developed	O
a	O
subclavian	O
vein	O
thrombosis	O
with	O
extension	O
to	O
the	O
cephalic	O
and	O
basilic	O
veins	O
secondary	O
to	O
placement	O
of	O
a	O
pulmonary	O
artery	O
catheter	O
;	O
anticoagulation	O
with	O
heparin	B-CHED
was	O
required	O
.	O

Oral	O
fludrocortisone	B-CHED
0	O
.	O
1	O
mg	O
/	O
d	O
was	O
initiated	O
with	O
resolution	O
of	O
the	O
hyperkalemia	O
within	O
24	O
hours	O
despite	O
the	O
continued	O
administration	O
of	O
heparin	B-CHED
.	O

Heparin	B-CHED
has	O
the	O
potential	O
to	O
induce	O
hyperkalemia	O
by	O
several	O
mechanisms	O
,	O
including	O
decreased	O
aldosterone	B-CHED
synthesis	O
,	O
reduction	O
in	O
number	O
and	O
affinity	O
of	O
aldosterone	B-CHED
II	O
receptors	O
,	O
and	O
atrophy	O
of	O
the	O
renal	O
zona	O
glomerulosa	O
.	O

Expression	O
of	O
the	O
reporter	O
genes	O
was	O
under	O
the	O
control	O
of	O
a	O
transcription	O
-	O
associated	O
sequence	O
(	O
TAS	B-CHED
)	O
derived	O
from	O
the	O
Beaudette	O
gene	O
5	O
,	O
normally	O
used	O
for	O
the	O
transcription	O
of	O
IBV	O
subgenomic	O
mRNA	B-CHED
5	O
.	O

The	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
was	O
used	O
to	O
evaluate	O
myocardial	O
tissue	O
for	O
the	O
presence	O
of	O
viral	O
genome	O
from	O
feline	O
panleukopenia	O
virus	O
,	O
herpes	O
virus	O
,	O
calici	O
virus	O
,	O
and	O
corona	B-CHED
virus	O
.	O

PEEP	B-CHED
had	O
no	O
effect	O
on	O
cardiac	O
index	O
(	O
baseline	O
I	O
:	O
3	O
.	O
2	O
/	O
6	O
.	O
1	O
-	O
2	O
.	O
5	O
l	O
/	O
min	O
/	O
m2	O
;	O
PEEP	B-CHED
:	O
3	O
.	O
3	O
/	O
5	O
.	O
7	O
-	O
2	O
.	O
3	O
l	O
/	O
min	O
/	O
m2	O
;	O
baseline	O
II	O
:	O
3	O
.	O
4	O
/	O
6	O
.	O
0	O
-	O
2	O
.	O
5	O
l	O
/	O
min	O
/	O
m2	O
);	O
neither	O
did	O
PEEP	B-CHED
have	O
any	O
effect	O
on	O
splanchnic	O
blood	O
flow	O
(	O
baseline	O
I	O
:	O
0	O
.	O
91	O
/	O
1	O
.	O
39	O
-	O
0	O
.	O
62	O
l	O
/	O
min	O
/	O
m2	O
;	O
PEEP	B-CHED
:	O
1	O
.	O
04	O
/	O
1	O
.	O
75	O
-	O
0	O
.	O
54	O
l	O
/	O
min	O
/	O
m2	O
;	O
baseline	O
II	O
:	O
1	O
.	O
07	O
/	O
1	O
.	O
42	O
-	O
0	O
.	O
68	O
l	O
/	O
min	O
/	O
m2	O
,	O
respectively	O
)	O
or	O
perfusion	O
(	O
gastric	O
mucosal	O
-	O
arterial	O
PCO2	O
difference	O
baseline	O
I	O
:	O
2	O
.	O
1	O
/	O
12	O
.	O
8	O
-	O
0	O
.	O
6	O
kPa	O
;	O
PEEP	B-CHED
:	O
1	O
.	O
7	O
/	O
14	O
.	O
5	O
-	O
0	O
.	O
7	O
kPa	O
;	O
baseline	O
II	O
:	O
1	O
.	O
7	O
/	O
8	O
.	O
8	O
-	O
0	O
.	O
1	O
kPa	O
;	O
lactate	B-CHED
uptake	O
baseline	O
I	O
:	O
0	O
.	O
5	O
/	O
1	O
.	O
1	O
-	O
0	O
.	O
3	O
mmol	O
/	O
min	O
/	O
m2	O
;	O
PEEP	B-CHED
:	O
0	O
.	O
4	O
/	O
1	O
.	O
0	O
-	O
0	O
.	O
3	O
mmol	O
/	O
min	O
/	O
m2	O
;	O
baseline	O
II	O
:	O
0	O
.	O
5	O
/	O
0	O
.	O
9	O
-	O
0	O
.	O
3	O
mmol	O
/	O
min	O
/	O
m2	O
;	O
hepatic	O
venous	O
lactate	B-CHED
/	O
pyruvate	B-CHED
baseline	O
I	O
:	O
9	O
.	O
7	O
/	O
10	O
.	O
6	O
-	O
5	O
.	O
7	O
;	O
PEEP	B-CHED
:	O
9	O
.	O
7	O
/	O
14	O
.	O
2	O
-	O
6	O
.	O
4	O
;	O
baseline	O
II	O
:	O
8	O
.	O
4	O
/	O
12	O
.	O
4	O
-	O
7	O
.	O
3	O
;	O
respectively	O
).	O

The	O
SRV	O
antigen	B-CHED
was	O
detected	O
in	O
intestinal	O
tissues	O
soon	O
after	O
infection	O
(	O
i	O
.	O
e	O
.,	O
at	O
2	O
and	O
4	O
DPI	O
),	O
whereas	O
lymphoid	O
tissues	O
such	O
as	O
thymus	O
,	O
bursa	O
,	O
and	O
spleen	O
were	O
positive	O
for	O
SRV	O
antigen	B-CHED
starting	O
at	O
4	O
DPI	O
until	O
8	O
DPI	O
,	O
suggesting	O
virus	O
translocation	O
to	O
lymphoid	O
organs	O
.	O

TITLE	O
:	O
Role	O
of	O
gelatinases	O
MMP	B-CHED
-	O
2	O
and	O
MMP	B-CHED
-	O
9	O
in	O
tissue	O
remodeling	O
following	O
acute	O
lung	O
injury	O
.	O

Caesarian	O
-	O
derived	O
colostrum	O
-	O
deprived	O
pigs	O
were	O
inoculated	O
intratracheally	O
with	O
PRCV	O
,	O
with	O
LPS	B-CHED
from	O
Escherichia	O
coli	O
O111	O
:	O
B4	O
(	O
20	O
microg	O
/	O
kg	O
),	O
or	O
with	O
a	O
combination	O
of	O
the	O
two	O
,	O
and	O
killed	O
at	O
set	O
times	O
after	O
inoculation	O
.	O

Clinical	O
signs	O
,	O
virus	O
replication	O
and	O
(	O
histo	O
)	O
pathological	O
changes	O
in	O
the	O
lungs	O
,	O
percentage	O
of	O
neutrophils	O
and	O
bioactive	O
TNF	O
-	O
alpha	O
and	O
IL	O
-	O
1	O
in	O
broncho	O
-	O
alveolar	O
lavage	O
(	O
BAL	B-CHED
)	O
fluids	O
were	O
examined	O
.	O

In	O
addition	O
,	O
the	O
hemagglutinin	O
-	O
esterase	O
gene	O
capable	O
of	O
encoding	O
a	O
protein	B-CHED
of	O
439	O
amino	B-CHED
acids	I-CHED
(	O
aa	O
)	O
was	O
identified	O
.	O

Lupus	O
anticoagulant	B-CHED
,	O
IgG	O
anticardiolipin	O
and	O
anti	O
-	O
beta2	O
-	O
glycoprotein	B-CHED
I	O
antibodies	O
were	O
positive	O
.	O

High	O
-	O
dose	O
glucocorticoid	B-CHED
,	O
anticoagulation	O
with	O
heparin	B-CHED
,	O
plasmapheresis	O
and	O
cyclophosphamide	B-CHED
improved	O
her	O
clinical	O
condition	O
.	O

In	O
addition	O
,	O
EBV	O
strain	O
typing	O
and	O
detection	O
of	O
the	O
characteristic	O
30	O
-	O
bp	O
deletion	O
of	O
the	O
latent	O
membrane	O
protein	B-CHED
-	O
1	O
(	O
LMP	O
-	O
1	O
)	O
gene	O
were	O
performed	O
by	O
PCR	O
.	O

She	O
had	O
received	O
mefloquine	B-CHED
as	O
prophylaxis	O
,	O
but	O
the	O
patient	O
did	O
not	O
take	O
the	O
medication	O
.	O

TITLE	O
:	O
Coronavirus	O
-	O
induced	O
demyelination	O
occurs	O
in	O
the	O
absence	O
of	O
inducible	O
nitric	B-CHED
oxide	I-CHED
synthase	O
.	O

Previous	O
results	O
suggest	O
that	O
inducible	O
nitric	B-CHED
oxide	I-CHED
synthase	O
(	O
NOS2	O
)	O
contributes	O
transiently	O
to	O
MHV	O
-	O
induced	O
demyelination	O
.	O

The	O
methods	O
used	O
were	O
(	O
1	O
)	O
DNA	O
electrophoresis	O
for	O
detection	O
of	O
DNA	O
fragmentation	O
,	O
and	O
(	O
2	O
)	O
terminal	O
deoxynucleotidyl	O
transferase	O
-	O
mediated	O
deoxyuridine	B-CHED
triphosphate	I-CHED
-	O
fluorescein	B-CHED
nick	O
and	O
labelling	O
(	O
TUNEL	O
).	O

The	O
RT	O
-	O
nested	O
PCR	O
assay	O
was	O
more	O
sensitive	O
than	O
antigen	B-CHED
-	O
based	O
assays	O
on	O
the	O
basis	O
of	O
duration	O
of	O
virus	O
detection	O
in	O
experimentally	O
infected	O
pigs	O
and	O
was	O
directly	O
applicable	O
to	O
nasal	O
as	O
well	O
as	O
fecal	O
specimens	O
from	O
the	O
field	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
inhibition	O
of	O
TNFalpha	O
and	O
NO	O
(	O
via	O
iNOS	O
)	O
production	O
as	O
well	O
as	O
the	O
increment	O
of	O
IL	O
-	O
10	O
production	O
contribute	O
to	O
the	O
beneficial	O
effect	O
of	O
terbutaline	B-CHED
in	O
animals	O
with	O
endotoxic	O
shock	O
.	O

The	O
response	O
to	O
low	O
-	O
dose	O
inhaled	O
nitric	B-CHED
oxide	I-CHED
(	O
5	O
ppm	O
)	O
was	O
measured	O
in	O
each	O
group	O
at	O
the	O
end	O
of	O
the	O
study	O
.	O

At	O
present	O
,	O
the	O
use	O
of	O
the	O
long	O
-	O
acting	O
prostacyclin	B-CHED
analogue	O
ilomedin	O
for	O
ambulant	O
treatment	O
of	O
patients	O
with	O
chronic	O
pulmonary	O
hypertension	O
is	O
under	O
investigation	O
.	O

ABSTRACT	O
:	O
The	O
continued	O
presence	O
of	O
virus	O
-	O
specific	O
CD8	O
(+)	O
T	O
cells	O
within	O
the	O
central	O
nervous	O
system	O
(	O
CNS	B-CHED
)	O
following	O
resolution	O
of	O
acute	O
viral	O
encephalomyelitis	O
implicates	O
organ	O
-	O
specific	O
retention	O
.	O

The	O
role	O
of	O
viral	O
persistence	O
in	O
locally	O
maintaining	O
T	O
cells	O
was	O
investigated	O
by	O
infecting	O
mice	O
with	O
either	O
a	O
demyelinating	O
,	O
paralytic	O
(	O
V	O
-	O
1	O
)	O
or	O
nonpathogenic	O
(	O
V	O
-	O
2	O
)	O
variant	O
of	O
a	O
neurotropic	O
mouse	O
hepatitis	O
virus	O
,	O
which	O
differ	O
in	O
the	O
ability	O
to	O
persist	O
within	O
the	O
CNS	B-CHED
.	O

Nucleotide	B-CHED
sequencing	O
of	O
the	O
S1	O
glycoprotein	B-CHED
is	O
the	O
only	O
method	O
to	O
discriminate	O
between	O
all	O
IBV	O
strains	O
.	O

Psychotropic	B-CHED
drugs	I-CHED
such	O
as	O
phenothiazides	O
,	O
butyrophenones	O
and	O
tricyclic	B-CHED
antidepressants	I-CHED
can	O
also	O
induce	O
pulmonary	O
oedema	O
.	O

TITLE	O
:	O
Toxicity	O
of	O
ingested	O
formalin	B-CHED
and	O
its	O
management	O
.	O

TITLE	O
:	O
[	O
Retinoic	B-CHED
acid	I-CHED
syndrome	O
.	O

ABSTRACT	O
:	O
We	O
characterized	O
a	O
novel	O
28S	O
rRNA	B-CHED
cleavage	O
in	O
cells	O
infected	O
with	O
the	O
murine	O
coronavirus	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
).	O

Furthermore	O
,	O
28S	O
rRNA	B-CHED
cleavage	O
occurred	O
in	O
an	O
MHV	O
-	O
infected	O
mouse	O
embryonic	O
fibroblast	O
cell	O
line	O
derived	O
from	O
RNase	O
L	O
knockout	O
mice	O
.	O

Based	O
on	O
similarities	O
in	O
genome	O
organization	O
and	O
protein	B-CHED
expression	O
,	O
the	O
arteriviruses	O
have	O
recently	O
been	O
grouped	O
together	O
with	O
the	O
coronaviruses	O
and	O
toroviruses	O
in	O
the	O
newly	O
established	O
order	O
Nidovirales	O
.	O

ABSTRACT	O
:	O
Equine	O
arteritis	O
virus	O
(	O
EAV	O
)	O
(	O
ARTERIVIRIDAE	O
:)	O
encodes	O
several	O
structural	O
proteins	B-CHED
.	O

TITLE	O
:	O
Oral	O
immunogenicity	O
of	O
the	O
plant	O
derived	O
spike	O
protein	B-CHED
from	O
swine	O
-	O
transmissible	O
gastroenteritis	O
coronavirus	O
.	O

Furthermore	O
,	O
when	O
potato	O
tubers	O
expressing	O
N	O
-	O
gS	O
were	O
fed	O
directly	O
to	O
mice	O
,	O
they	O
developed	O
serum	O
antibodies	O
specific	O
for	O
gS	O
protein	B-CHED
,	O
demonstrating	O
the	O
oral	O
immunogenicity	O
of	O
the	O
plant	O
derived	O
spike	O
protein	B-CHED
from	O
TGEV	O
.	O

Serum	O
samples	O
of	O
turkeys	O
experimentally	O
infected	O
with	O
TCV	O
collected	O
sequentially	O
from	O
1	O
to	O
63	O
days	O
postinfection	O
were	O
applied	O
to	O
the	O
established	O
antibody	O
-	O
capture	O
ELISA	O
using	O
IBV	O
antigens	B-CHED
.	O

TITLE	O
:	O
Morphologic	O
observations	O
on	O
respiratory	O
tracts	O
of	O
chickens	O
after	O
hatchery	O
infectious	O
bronchitis	O
vaccination	O
and	O
formaldehyde	B-CHED
fumigation	O
.	O

Isolates	O
Ark	O
/	O
213	O
/	O
96	O
,	O
Ark	O
/	O
15C	O
/	O
96	O
,	O
Ark	O
/	O
1529	O
/	O
95	O
,	O
and	O
Ark	O
/	O
1534	O
/	O
95	O
demonstrated	O
a	O
higher	O
degree	O
of	O
predicted	O
S	O
-	O
1	O
amino	B-CHED
acid	I-CHED
similarity	O
to	O
each	O
other	O
(	O
96	O
.	O
5	O
%-	O
98	O
.	O
7	O
%)	O
than	O
to	O
Ark	O
DPI	O
(	O
92	O
.	O
4	O
%-	O
93	O
.	O
7	O
%),	O
Ark	O
99	O
(	O
93	O
.	O
2	O
%-	O
94	O
.	O
7	O
%),	O
and	O
Georgia	O
var	O
(	O
89	O
.	O
3	O
%-	O
90	O
.	O
8	O
%).	O

The	O
diagnosis	O
,	O
primary	O
macroglobulinemia	O
,	O
was	O
made	O
from	O
the	O
following	O
findings	O
:	O
a	O
high	O
level	O
of	O
the	O
lgM	O
1	O
type	O
monoclonal	O
protein	B-CHED
,	O
and	O
an	O
elevated	O
serum	O
viscosity	O
with	O
characteristic	O
""""	O
linked	O
sausage	O
effects	O
""""	O
seen	O
in	O
the	O
retinal	B-CHED
veins	O
.	O

In	O
addition	O
to	O
high	O
-	O
dose	O
methylprednisolone	B-CHED
the	O
patient	O
was	O
given	O
intravenous	O
pulse	O
cyclophosphamide	B-CHED
fortnightly	O
for	O
six	O
weeks	O
and	O
afterwards	O
every	O
4	O
weeks	O
.	O

Intravenous	O
pulse	O
cyclophosphamide	B-CHED
was	O
probably	O
a	O
life	O
saving	O
therapy	O
.	O

ABSTRACT	O
:	O
This	O
report	O
presents	O
a	O
case	O
of	O
severe	O
asthmatic	O
attack	O
and	O
adult	O
respiratory	O
distress	O
syndrome	O
,	O
which	O
occurred	O
in	O
an	O
asthmatic	O
subject	O
following	O
acute	O
short	O
-	O
term	O
exposure	O
to	O
commonly	O
used	O
cleaning	O
detergents	B-CHED
.	O

Treatment	O
of	O
ocular	O
FIP	O
is	O
symptomatic	O
,	O
and	O
the	O
mainstay	O
of	O
palliative	O
therapy	O
is	O
topical	O
or	O
systemic	O
corticosteroids	B-CHED
or	O
both	O
.	O

Serum	O
interleukin	O
-	O
6	O
,	O
polymorphonuclear	O
cell	O
elastase	O
,	O
and	O
C	O
-	O
reactive	O
protein	B-CHED
levels	O
,	O
and	O
the	O
postoperative	O
clinical	O
course	O
were	O
compared	O
between	O
the	O
groups	O
.	O

Relative	O
to	O
those	O
receiving	O
placebo	O
,	O
children	O
receiving	O
vitamin	B-CHED
A	I-CHED
had	O
a	O
significantly	O
smaller	O
risk	O
of	O
severe	O
watery	O
diarrhea	O
(	O
multivariate	O
odds	O
ratio	O
=	O
0	O
.	O
56	O
,	O
95	O
%	O
CI	O
=	O
0	O
.	O
32	O
-	O
0	O
.	O
99	O
,	O
P	O
=.	O
04	O
)	O
but	O
a	O
higher	O
risk	O
of	O
cough	O
and	O
rapid	O
respiratory	O
rate	O
(	O
multivariate	O
odds	O
ratio	O
=	O
1	O
.	O
67	O
,	O
95	O
%	O
CI	O
=	O
1	O
.	O
17	O
-	O
2	O
.	O
36	O
,	O
P	O
=.	O
004	O
).	O

In	O
late	O
1999	O
and	O
early	O
2000	O
,	O
an	O
outbreak	O
of	O
acute	O
illness	O
compatible	O
with	O
HPS	B-CHED
was	O
reported	O
in	O
Los	O
Santos	O
,	O
Panama	O
,	O
with	O
the	O
death	O
of	O
3	O
of	O
the	O
12	O
(	O
25	O
%)	O
suspected	O
cases	O
.	O

Severe	O
oral	O
mucositis	O
(	O
70	O
%	O
vs	O
.	O
32	O
.	O
5	O
%,	O
respectively	O
;	O
P	O
=.	O
036	O
),	O
high	O
-	O
dose	O
chemotherapy	O
with	O
cyclophosphamide	B-CHED
(	O
60	O
%	O
vs	O
.	O
25	O
%,	O
respectively	O
;	O
P	O
=.	O
043	O
),	O
and	O
allogeneic	O
bone	O
marrow	O
transplantation	O
(	O
40	O
%	O
vs	O
.	O
10	O
%,	O
respectively	O
;	O
P	O
=.	O
040	O
)	O
were	O
the	O
only	O
variables	O
found	O
to	O
be	O
significantly	O
associated	O
with	O
the	O
development	O
of	O
complications	O
.	O

Thereafter	O
the	O
calves	O
received	O
one	O
test	O
meal	O
of	O
whole	O
fresh	O
cow	O
'	O
s	O
milk	O
whose	O
lactose	B-CHED
had	O
been	O
hydrolysed	O
by	O
added	O
lactase	O
and	O
one	O
test	O
meal	O
of	O
unprocessed	O
cow	O
'	O
s	O
milk	O
at	O
an	O
interval	O
of	O
24	O
h	O
in	O
a	O
cross	O
-	O
over	O
design	O
trial	O
.	O

Peak	O
plasma	O
glucose	B-CHED
and	O
blood	O
galactose	B-CHED
concentration	O
tended	O
to	O
be	O
delayed	O
after	O
the	O
intake	O
of	O
lactose	B-CHED
-	O
hydrolysed	O
milk	O
,	O
which	O
implies	O
that	O
gastric	O
emptying	O
was	O
probably	O
delayed	O
.	O

N	O
-	O
viral	O
RNA	O
complexes	O
were	O
detected	O
in	O
bovine	O
coronavirus	O
(	O
BCV	O
)-	O
infected	O
cells	O
and	O
in	O
cells	O
transiently	O
expressing	O
the	O
N	O
protein	B-CHED
.	O

Therefore	O
,	O
steroids	B-CHED
may	O
play	O
a	O
role	O
in	O
the	O
treatment	O
of	O
severe	O
cases	O
.	O

A	O
72	O
-	O
year	O
-	O
old	O
white	O
man	B-CHED
was	O
treated	O
by	O
monthly	O
injections	O
of	O
intravesical	O
BCG	B-CHED
immunotherapy	O
for	O
polyposis	O
of	O
the	O
urinary	O
bladder	O
.	O

ABSTRACT	O
:	O
To	O
understand	O
the	O
virus	O
-	O
cell	O
interactions	O
that	O
occur	O
during	O
murine	O
coronavirus	O
infection	O
,	O
six	O
murine	O
cell	O
lines	O
(	O
A3	O
-	O
1M	O
,	O
B16	O
,	O
CMT	O
-	O
93	O
,	O
DBT	B-CHED
,	O
IC	O
-	O
21	O
and	O
J774A	O
.	O
1	O
)	O
were	O
inoculated	O
with	O
eight	O
murine	O
coronaviruses	O
,	O
including	O
prototype	O
strains	O
of	O
both	O
polytropic	O
and	O
enterotropic	O
biotypes	O
,	O
and	O
new	O
isolates	O
.	O

Sequence	O
analysis	O
revealed	O
that	O
the	O
leader	O
-	O
body	O
fusion	O
site	O
of	O
the	O
mRNA	B-CHED
is	O
located	O
at	O
approximately	O
150	O
nucleotides	B-CHED
(	O
nt	O
)	O
downstream	O
of	O
the	O
consensus	O
IG	O
sequence	O
for	O
mRNA	B-CHED
5	O
and	O
did	O
not	O
have	O
sequence	O
homology	O
with	O
any	O
known	O
IG	O
consensus	O
sequences	O
.	O

A	O
D	O
-	O
RNA	O
with	O
the	O
first	O
544	O
,	O
but	O
not	O
as	O
few	O
as	O
338	O
,	O
nucleotides	B-CHED
(	O
nt	O
)	O
of	O
the	O
5	O
'	O
terminus	O
was	O
replicated	O
;	O
the	O
5	O
'	O
untranslated	O
region	O
(	O
UTR	O
)	O
comprises	O
528	O
nt	O
.	O

Mutants	O
of	O
TGEV	O
that	O
lacked	O
sialic	B-CHED
acid	I-CHED
binding	O
activity	O
due	O
to	O
a	O
point	O
mutation	O
in	O
the	O
sialic	B-CHED
acid	I-CHED
binding	O
site	O
of	O
the	O
S	O
protein	B-CHED
were	O
mainly	O
recovered	O
at	O
a	O
lower	O
-	O
density	O
position	O
on	O
the	O
sucrose	B-CHED
gradient	O
(	O
1	O
.	O
18	O
to	O
1	O
.	O
19	O
g	O
/	O
cm	O
(	O
3	O
)).	O

ABSTRACT	O
:	O
Acute	O
infections	O
of	O
the	O
lower	O
respiratory	O
tract	O
first	O
require	O
a	O
weighing	O
up	O
of	O
risks	O
,	O
which	O
is	O
of	O
importance	O
in	O
particular	O
for	O
the	O
decision	O
for	O
or	O
against	O
antibiotic	B-CHED
therapy	O
.	O

Blood	O
samples	O
were	O
drawn	O
for	O
plasma	O
cGMP	B-CHED
determinations	O
.	O

The	O
MAE	O
increased	O
the	O
pulmonary	O
artery	O
pressure	O
(	O
by	O
252	O
%)	O
and	O
decreased	O
the	O
cardiac	O
index	O
(	O
by	O
31	O
%)	O
5	O
minutes	O
after	O
the	O
air	B-CHED
injection	O
(	O
both	O
P	O
<.	O
05	O
).	O

These	O
findings	O
suggest	O
that	O
a	O
lack	O
of	O
increase	O
in	O
the	O
production	O
of	O
the	O
cGMP	B-CHED
may	O
account	O
for	O
the	O
pulmonary	O
hypertension	O
seen	O
in	O
air	B-CHED
embolism	O
-	O
induced	O
ALI	O
.	O

RESULTS	O
:	O
The	O
VAI	O
increased	O
the	O
pulmonary	O
artery	O
pressure	O
(	O
by	O
181	O
%,	O
P	O
<.	O
05	O
)	O
after	O
15	O
minutes	O
of	O
air	B-CHED
infusion	O
without	O
changing	O
the	O
cardiac	O
index	O
.	O

At	O
high	O
salt	B-CHED
concentrations	O
(	O
200	O
to	O
300	O
mM	O
),	O
the	O
M	O
protein	B-CHED
was	O
no	O
longer	O
associated	O
with	O
the	O
nucleocapsid	O
,	O
which	O
resulted	O
in	O
destruction	O
of	O
the	O
core	O
structure	O
.	O

Near	O
-	O
term	O
infants	O
with	O
severe	O
RDS	O
often	O
respond	O
to	O
exogenous	O
surfactant	B-CHED
,	O
suggesting	O
a	O
functional	O
deficiency	O
of	O
endogenous	O
surfactant	B-CHED
at	O
a	O
""""	O
late	O
""""	O
stage	O
in	O
their	O
disease	O
process	O
.	O

RESULTS	O
:	O
A	O
total	O
of	O
30	O
of	O
infants	O
were	O
treated	O
with	O
intubation	O
and	O
surfactant	B-CHED
administration	O
.	O

These	O
replicating	O
and	O
transcribing	O
structures	O
were	O
separated	O
by	O
velocity	O
sedimentation	O
on	O
sucrose	B-CHED
gradients	O
or	O
by	O
gel	O
filtration	O
chromatography	O
on	O
Sepharose	B-CHED
2B	O
and	O
Sephacryl	O
S	O
-	O
1000	O
,	O
and	O
migrated	O
on	O
agarose	B-CHED
gels	O
during	O
electrophoresis	O
,	O
according	O
to	O
their	O
size	O
.	O

TITLE	O
:	O
Nebulized	O
prostacyclin	B-CHED
(	O
PGI2	B-CHED
)	O
in	O
acute	O
respiratory	O
distress	O
syndrome	O
:	O
impact	O
of	O
primary	O
(	O
pulmonary	O
injury	O
)	O
and	O
secondary	O
(	O
extrapulmonary	O
injury	O
)	O
disease	O
on	O
gas	O
exchange	O
response	O
.	O

We	O
diagnosed	O
ARDS	O
,	O
because	O
of	O
the	O
severe	O
respiratory	O
failure	O
resistant	O
to	O
high	O
-	O
dose	O
oxygen	B-CHED
,	O
the	O
diffuse	O
bilateral	O
infiltrates	O
without	O
cardiomegaly	O
on	O
chest	O
radiography	O
,	O
and	O
the	O
normal	O
pulmonary	O
artery	O
wedge	O
pressure	O
.	O

PaO2	O
,	O
oxygen	B-CHED
saturation	O
in	O
arterial	O
blood	O
,	O
and	O
the	O
PaO2	O
/	O
FIO2	O
ratio	O
increased	O
in	O
all	O
patients	O
.	O

Immunohistochemistry	O
was	O
negative	O
for	O
FIP	O
antigen	B-CHED
.	O

In	O
addition	O
,	O
the	O
minimal	O
surface	O
tension	O
(	O
gamma	O
min	O
)	O
of	O
untreated	O
LSA	O
and	O
of	O
LSA	O
after	O
supplementation	O
with	O
additional	O
dipalmitoylated	O
phosphatidylcholine	B-CHED
(	O
DPPC	B-CHED
)	O
was	O
analyzed	O
(	O
pulsating	O
bubble	O
surfactometer	O
).	O

1	O
.	O
7	O
%),	O
whereas	O
the	O
relative	O
amount	O
of	O
unsaturated	O
species	O
in	O
PC	B-CHED
increased	O
significantly	O
in	O
all	O
groups	O
.	O

We	O
conclude	O
that	O
marked	O
changes	O
in	O
the	O
FA	O
composition	O
of	O
the	O
predominant	O
surfactant	B-CHED
PL	O
classes	O
occur	O
,	O
both	O
in	O
ARDS	O
triggered	O
by	O
nonpulmonary	O
events	O
and	O
PNEU	O
.	O

An	O
increased	O
level	O
of	O
IL	O
-	O
8	O
in	O
the	O
donor	B-CHED
BALF	O
was	O
associated	O
with	O
the	O
development	O
of	O
severe	O
early	O
graft	O
dysfunction	O
(	O
p	O
=	O
0	O
.	O
027	O
)	O
and	O
with	O
early	O
recipient	O
mortality	O
(	O
p	O
=	O
0	O
.	O
0034	O
).	O

The	O
nucleotide	B-CHED
and	O
amino	B-CHED
acid	I-CHED
sequence	O
similarity	O
among	O
the	O
DE072	O
strain	O
and	O
other	O
IBV	O
strains	O
was	O
less	O
than	O
71	O
.	O
9	O
%	O
and	O
76	O
.	O
6	O
%,	O
respectively	O
.	O

Further	O
the	O
nucleotide	B-CHED
sequence	O
analysis	O
of	O
the	O
entire	O
spike	O
glycoprotein	B-CHED
gene	O
of	O
the	O
DE072	O
strain	O
demonstrated	O
that	O
most	O
of	O
the	O
gene	O
contained	O
a	O
D1466	O
-	O
like	O
sequence	O
,	O
and	O
five	O
putative	O
cross	O
-	O
over	O
sites	O
were	O
identified	O
.	O

Thus	O
,	O
these	O
results	O
show	O
that	O
infection	O
of	O
the	O
CNS	B-CHED
is	O
characterized	O
by	O
a	O
large	O
influx	O
of	O
CD4	O
T	O
cells	O
specific	O
for	O
MHV	O
and	O
that	O
these	O
cells	O
remain	O
functional	O
,	O
as	O
measured	O
by	O
cytokine	O
secretion	O
,	O
in	O
mice	O
with	O
chronic	O
demyelination	O
.	O

TITLE	O
:	O
Airway	O
effects	O
of	O
marijuana	O
,	O
cocaine	B-CHED
,	O
and	O
other	O
inhaled	O
illicit	O
agents	O
.	O

The	O
mutation	O
occurs	O
in	O
domain	O
II	O
and	O
in	O
a	O
location	O
which	O
corresponds	O
to	O
the	O
hypervariable	O
region	O
of	O
the	O
spike	O
protein	B-CHED
of	O
the	O
coronavirus	O
mouse	O
hepatitis	O
virus	O
.	O

Very	O
few	O
IPC	B-CHED
were	O
present	O
in	O
the	O
spleen	O
and	O
popliteal	O
lymph	O
nodes	O
of	O
infected	O
piglets	O
.	O

TITLE	O
:	O
Lymphocytic	O
hypophysitis	O
in	O
a	O
man	B-CHED
presenting	O
with	O
hypercalcemia	O
.	O

Our	O
data	O
were	O
consistent	O
with	O
an	O
E	O
protein	B-CHED
topology	O
model	O
,	O
in	O
which	O
the	O
N	O
-	O
terminal	O
two	O
-	O
thirds	O
of	O
the	O
transmembrane	O
domain	O
spans	O
the	O
lipid	B-CHED
bilayer	O
twice	O
,	O
exposing	O
the	O
C	O
-	O
terminal	O
region	O
to	O
the	O
cytoplasm	O
or	O
virion	O
interior	O
.	O

ABSTRACT	O
:	O
One	O
missing	O
link	O
in	O
the	O
coronavirus	O
assembly	O
is	O
the	O
physical	O
interaction	O
between	O
two	O
crucial	O
structural	O
proteins	B-CHED
,	O
the	O
membrane	O
(	O
M	O
)	O
and	O
envelope	O
(	O
E	O
)	O
proteins	B-CHED
.	O

The	O
third	O
domain	O
of	O
E	O
that	O
plays	O
a	O
crucial	O
role	O
in	O
virus	O
budding	O
is	O
a	O
putative	O
transmembrane	O
domain	O
present	O
at	O
the	O
N	O
-	O
terminal	O
region	O
,	O
because	O
deletion	O
of	O
the	O
domain	O
resulted	O
in	O
a	O
free	O
distribution	O
of	O
the	O
mutant	O
protein	B-CHED
and	O
in	O
dysfunctional	O
viral	O
assembly	O
.	O

This	O
indicated	O
that	O
the	O
pagC	O
promoter	O
can	O
be	O
used	O
successfully	O
to	O
improve	O
epitope	B-CHED
-	O
display	O
by	O
chimeric	O
fimbriae	O
on	O
Salmonella	O
vaccine	O
strains	O
for	O
the	O
induction	O
of	O
a	O
desired	O
immune	O
response	O
.	O

However	O
,	O
successful	O
discontinuation	O
of	O
iNO	O
therapy	O
was	O
achieved	O
by	O
combination	O
of	O
L	B-CHED
-	I-CHED
Arginine	I-CHED
and	O
dipyridamole	B-CHED
.	O

Exogeous	O
NO	O
may	O
lead	O
to	O
down	O
regulation	O
of	O
endogenous	O
NO	O
production	O
,	O
and	O
further	O
lead	O
to	O
rapid	O
hydrolization	O
of	O
cyclic	O
guanosine	B-CHED
3	O
',	O
5	O
'	O
monophosphate	O
(	O
cGMP	B-CHED
),	O
the	O
smooth	O
muscle	B-CHED
relaxant	I-CHED
,	O
by	O
the	O
enzyme	O
phosphodiesterase	O
.	O

Moreover	O
L	B-CHED
-	I-CHED
Arginine	I-CHED
,	O
the	O
precursor	O
for	O
the	O
formation	O
of	O
endogenous	O
NO	O
,	O
has	O
been	O
found	O
to	O
be	O
deficient	O
in	O
neonates	O
with	O
PPHN	O
,	O
so	O
we	O
speculated	O
that	O
by	O
inhibiting	O
phosphodiesterase	O
and	O
administrating	O
L	B-CHED
-	I-CHED
Arginine	I-CHED
smooth	O
muscle	O
relaxation	O
occurred	O
,	O
and	O
consequent	O
weaning	O
from	O
iNO	O
was	O
achieved	O
.	O

TITLE	O
:	O
Toxicological	O
,	O
medical	O
and	O
industrial	O
hygiene	O
aspects	O
of	O
glutaraldehyde	B-CHED
with	O
particular	O
reference	O
to	O
its	O
biocidal	O
use	O
in	O
cold	O
sterilization	O
procedures	O
.	O

TITLE	O
:	O
Baculovirus	O
expression	O
of	O
turkey	O
coronavirus	O
nucleocapsid	O
protein	B-CHED
.	O

Baculovirus	O
-	O
expressed	O
N	O
proteins	B-CHED
were	O
used	O
as	O
antigen	B-CHED
in	O
an	O
indirect	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
for	O
detection	O
of	O
TCV	O
-	O
specific	O
antibodies	O
.	O

Several	O
host	O
cell	O
proteins	B-CHED
have	O
previously	O
been	O
shown	O
to	O
interact	O
with	O
this	O
regulatory	O
region	O
.	O

Rotational	O
positioning	O
produced	O
significantly	O
more	O
uniform	O
perflubron	B-CHED
distribution	O
during	O
both	O
CMV	O
and	O
HFOV	O
.	O

TITLE	O
:	O
The	O
effects	O
of	O
CO2	B-CHED
on	O
respiratory	O
mechanics	O
in	O
anesthetized	O
paralyzed	O
humans	O
.	O

Interrupter	O
resistance	O
(	O
Rint	O
),	O
additional	O
tissue	O
viscoelastic	O
resistance	O
(	O
deltaR	O
),	O
and	O
quasi	O
-	O
static	O
elastance	O
(	O
Est	O
)	O
of	O
lung	O
(	O
L	O
)	O
and	O
chest	O
wall	O
were	O
assessed	O
by	O
means	O
of	O
the	O
rapid	O
end	O
-	O
inspiratory	O
occlusion	O
method	O
in	O
two	O
groups	O
of	O
seven	O
healthy	O
paralyzed	O
subjects	O
anesthetized	O
with	O
diazepam	B-CHED
or	O
isoflurane	B-CHED
.	O

Because	O
local	O
PaCO2	O
-	O
related	O
changes	O
in	O
bronchomotor	O
tone	O
promote	O
VA	O
/	O
Q	O
matching	O
,	O
this	O
mechanism	O
should	O
be	O
impaired	O
by	O
anesthetics	B-CHED
that	O
cause	O
bronchodilation	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
whether	O
the	O
unique	O
gene	O
expression	O
strategy	O
of	O
the	O
Nidovirales	O
could	O
be	O
utilized	O
to	O
convert	O
them	O
into	O
viral	O
expression	O
vectors	O
by	O
introduction	O
of	O
an	O
additional	O
transcription	O
unit	O
into	O
the	O
EAV	O
genome	O
directing	O
the	O
synthesis	O
of	O
an	O
extra	O
subgenomic	O
mRNA	B-CHED
.	O

Immunoprecipitation	O
analyses	O
of	O
proteins	B-CHED
from	O
metabolically	O
labeled	O
BHK	O
-	O
21	O
cells	O
infected	O
with	O
supernatant	O
of	O
the	O
transfected	O
cultures	O
confirmed	O
that	O
the	O
recombinant	O
virus	O
vector	O
was	O
viable	O
and	O
expressed	O
viral	O
genes	O
as	O
well	O
as	O
the	O
GFP	O
gene	O
.	O

Advances	O
in	O
the	O
care	O
of	O
children	O
with	O
ARDS	O
include	O
the	O
use	O
of	O
lung	O
-	O
protective	O
ventilator	O
strategies	O
,	O
permissive	O
hypercapnia	O
,	O
inhaled	O
nitric	B-CHED
oxide	I-CHED
,	O
high	O
-	O
frequency	O
ventilation	O
,	O
and	O
extra	O
-	O
corporeal	O
life	O
support	O
.	O

TITLE	O
:	O
Mouse	O
hepatitis	O
virus	O
replicase	O
protein	B-CHED
complexes	O
are	O
translocated	O
to	O
sites	O
of	O
M	O
protein	B-CHED
accumulation	O
in	O
the	O
ERGIC	O
at	O
late	O
times	O
of	O
infection	O
.	O

ABSTRACT	O
:	O
A	O
stable	O
recombinant	O
fowl	O
poxvirus	O
(	O
rFPV	O
)	O
expressing	O
the	O
C	O
-	O
terminal	O
region	O
(	O
119	O
amino	B-CHED
acids	I-CHED
)	O
of	O
the	O
nucleocapsid	O
(	O
N	O
)	O
protein	B-CHED
of	O
an	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
strain	O
Ch3	B-CHED
was	O
constructed	O
by	O
inserting	O
the	O
coding	O
sequence	O
within	O
the	O
thymidine	B-CHED
kinase	O
gene	O
of	O
fowl	O
poxvirus	O
(	O
FPV	O
)	O
by	O
homologous	O
recombination	O
.	O

Five	O
of	O
the	O
foreign	O
isolates	O
were	O
further	O
analyzed	O
by	O
S1	O
glycoprotein	B-CHED
gene	O
sequencing	O
in	O
our	O
laboratory	O
.	O

No	O
recurrence	O
of	O
thrombosis	O
occurred	O
with	O
heparin	B-CHED
prophylaxis	O
.	O

Coagulation	O
and	O
metabolic	O
parameters	O
(	O
clotting	O
tests	O
,	O
protein	B-CHED
C	O
,	O
protein	B-CHED
S	O
,	O
prothrombin	O
,	O
aminoacids	O
)	O
were	O
studied	O
but	O
disorders	O
predisposing	O
to	O
thrombosis	O
were	O
not	O
found	O
both	O
in	O
the	O
patient	O
and	O
in	O
her	O
parents	O
.	O

Admission	O
PaO2	O
/	O
FIO2	O
,	O
alveolar	O
-	O
arterial	O
oxygen	B-CHED
difference	O
(	O
DA	O
-	O
aO2	O
)	O
and	O
PaCO2	O
were	O
104	O
+/-	O
48	O
,	O
447	O
+/-	O
120	O
and	O
40	O
+/-	O
10	O
mmHg	O
,	O
respectively	O
.	O

After	O
induction	O
of	O
anaesthesia	O
and	O
placement	O
of	O
vascular	O
catheters	O
,	O
lung	O
injury	O
was	O
induced	O
with	O
0	O
.	O
12	O
ml	O
x	O
kg	O
(-	O
1	O
)	O
oleic	B-CHED
acid	I-CHED
.	O

ABSTRACT	O
:	O
The	O
largest	O
replicative	O
protein	B-CHED
of	O
coronaviruses	O
is	O
known	O
as	O
p195	O
in	O
the	O
avian	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
and	O
p210	O
(	O
p240	O
)	O
in	O
the	O
mouse	O
hepatitis	O
virus	O
.	O

TITLE	O
:	O
Surfactant	B-CHED
and	O
inhaled	O
nitric	B-CHED
oxide	I-CHED
in	O
rats	O
alleviate	O
acute	O
lung	O
injury	O
induced	O
by	O
intestinal	O
ischemia	O
and	O
reperfusion	O
.	O

The	O
authors	O
hypothesize	O
that	O
a	O
combined	O
surfactant	B-CHED
and	O
inhaled	O
nitric	B-CHED
oxide	I-CHED
(	O
iNO	O
)	O
may	O
alleviate	O
I	O
/	O
R	O
-	O
induced	O
ALI	O
.	O

Adult	O
rats	O
(	O
body	O
weight	O
285	O
to	O
315	O
g	O
,	O
n	O
=	O
45	O
)	O
were	O
allocated	O
randomly	O
to	O
either	O
a	O
negative	O
control	O
group	O
(	O
N	O
-	O
Control	O
,	O
n	O
=	O
9	O
)	O
with	O
only	O
sham	O
laparotomy	O
,	O
or	O
groups	O
(	O
n	O
=	O
9	O
each	O
)	O
for	O
induction	O
of	O
I	O
/	O
R	O
by	O
occlusion	O
of	O
superior	O
mesenteric	O
artery	O
,	O
followed	O
by	O
treatment	O
with	O
(	O
1	O
)	O
surfactant	B-CHED
at	O
100	O
mg	O
/	O
kg	O
(	O
Surf	O
),	O
(	O
2	O
)	O
iNO	O
at	O
20	O
ppm	O
(	O
NO	O
),	O
(	O
3	O
)	O
both	O
surfactant	B-CHED
and	O
iNO	O
(	O
SNO	O
),	O
or	O
(	O
4	O
)	O
no	O
surfactant	B-CHED
no	O
iNO	O
(	O
a	O
positive	O
control	O
,	O
P	O
-	O
Control	O
).	O

Striking	O
results	O
were	O
seen	O
with	O
a	O
mAb	O
(	O
1F8	O
)	O
reactive	O
with	O
the	O
positively	O
signaling	B-CHED
molecule	I-CHED
Ly49H	O
,	O
present	O
in	O
MCMV	O
-	O
resistant	O
C57BL	O
/	O
6	O
mice	O
.	O

19	O
.	O
6	O
)	O
who	O
met	B-CHED
one	O
of	O
the	O
following	O
criteria	O
:	O
Pao2	O
<	O
or	O
=	O
65	O
mm	O
Hg	O
with	O
Fio2	O
>	O
or	O
=	O
0	O
.	O
6	O
,	O
or	O
plateau	O
pressure	O
>	O
or	O
=	O
35	O
cm	O
H2O	B-CHED
.	O

Mean	O
airway	O
pressure	O
(	O
Paw	O
)	O
was	O
initially	O
set	O
5	O
cm	O
H2O	B-CHED
greater	O
than	O
Paw	O
during	O
CV	O
,	O
and	O
was	O
subsequently	O
titrated	O
to	O
maintain	O
oxygen	B-CHED
saturation	O
between	O
88	O
%	O
and	O
93	O
%	O
and	O
Fio2	O
<	O
or	O
=	O
0	O
.	O
60	O
.	O

Cytolysis	O
requires	O
interaction	O
of	O
the	O
virus	O
receptor	O
and	O
the	O
viral	O
S	O
glycoprotein	B-CHED
,	O
is	O
independent	O
of	O
other	O
viral	O
-	O
induced	O
components	O
,	O
and	O
is	O
not	O
a	O
unique	O
property	O
of	O
B	O
cells	O
.	O

Neutralizing	O
anti	O
-	O
S	O
-	O
protein	B-CHED
monoclonal	O
antibodies	O
(	O
mAb	O
)	O
and	O
a	O
mAb	O
specific	O
for	O
the	O
viral	O
receptor	O
inhibit	O
lysis	O
.	O

We	O
also	O
provide	O
a	O
hypothesis	O
to	O
explain	O
the	O
mechanism	O
by	O
which	O
amiodarone	B-CHED
causes	O
lung	O
damage	O
.	O

These	O
results	O
show	O
that	O
sequence	O
elements	O
downstream	O
of	O
the	O
noncanonical	O
site	O
can	O
dramatically	O
influence	O
the	O
choice	O
of	O
fusion	O
sites	O
for	O
synthesis	O
of	O
mRNA	B-CHED
5	O
and	O
are	O
interpreted	O
as	O
being	O
most	O
consistent	O
with	O
a	O
mechanism	O
of	O
similarity	O
-	O
assisted	O
RdRp	O
strand	O
switching	O
during	O
minus	O
-	O
strand	O
synthesis	O
.	O

Additionally	O
,	O
a	O
second	O
protein	B-CHED
recognized	O
by	O
the	O
autoAb	O
was	O
detected	O
during	O
FAH	O
purification	O
steps	O
and	O
was	O
identified	O
as	O
liver	O
alcohol	O
dehydrogenase	O
.	O

The	O
apparent	O
loss	O
of	O
initial	O
T	O
cell	O
-	O
mediated	O
immune	O
control	O
in	O
the	O
absence	O
of	O
B	O
cells	O
was	O
investigated	O
by	O
comparing	O
T	O
cell	O
populations	O
in	O
CNS	B-CHED
mononuclear	O
cells	O
from	O
infected	O
muMT	O
and	O
wild	O
-	O
type	O
mice	O
.	O

Acute	O
alcoholic	O
hepatitis	O
is	O
a	O
severe	O
disease	O
,	O
fatal	O
in	O
50	O
%	O
of	O
the	O
cases	O
,	O
and	O
resistant	O
tot	O
corticosteroid	B-CHED
therapy	O
.	O

There	O
was	O
a	O
significant	O
increase	O
in	O
the	O
mean	O
specific	O
antibody	O
titre	O
against	O
all	O
three	O
antigens	B-CHED
in	O
the	O
serum	O
of	O
the	O
vaccinated	O
animals	O
(	O
even	O
in	O
the	O
presence	O
of	O
pre	O
-	O
existing	O
antibody	O
)	O
which	O
was	O
accompanied	O
by	O
increased	O
levels	O
of	O
protective	O
antibodies	O
to	O
rotavirus	O
,	O
coronavirus	O
and	O
E	O
coli	O
F5	O
(	O
K99	O
)	O
in	O
their	O
colostrum	O
and	O
milk	O
for	O
at	O
least	O
28	O
days	O
.	O

ACP	B-CHED
was	O
associated	O
with	O
pulmonary	O
artery	O
hypertension	O
,	O
increased	O
heart	O
rate	O
,	O
and	O
decreased	O
stroke	O
index	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
whether	O
rapid	O
or	O
slowly	O
infused	O
intravenous	O
fat	O
emulsions	O
affect	O
the	O
ratio	O
of	O
prostaglandin	B-CHED
I2	I-CHED
/	O
thromboxane	B-CHED
A2	I-CHED
in	O
arterial	O
blood	O
,	O
pulmonary	O
hemodynamics	O
,	O
and	O
gas	O
exchange	O
.	O

Arterial	O
thromboxane	B-CHED
B2	I-CHED
and	O
6	O
-	O
keto	O
-	O
prostaglandin	B-CHED
-	O
F1alpha	O
plasma	O
concentrations	O
were	O
obtained	O
by	O
radioimmunoassay	O
,	O
and	O
6	O
-	O
keto	O
-	O
prostaglandin	B-CHED
-	O
F1alpha	O
/	O
thromboxane	B-CHED
B2	I-CHED
ratios	O
(	O
P	O
/	O
T	O
ratios	O
)	O
were	O
calculated	O
.	O

An	O
algorithm	O
of	O
the	O
use	O
of	O
Russian	O
lung	O
surfactant	B-CHED
preparations	O
:	O
CT	O
-	O
HL	O
and	O
CT	O
-	O
BL	O
has	O
been	O
developed	O
.	O

We	O
report	O
our	O
experience	O
with	O
the	O
intensive	O
care	O
management	O
of	O
serious	O
OP	O
insecticide	B-CHED
poisonings	O
.	O

The	O
chi	B-CHED
-	O
square	O
test	O
was	O
used	O
for	O
statistical	O
analysis	O
.	O

Thirty	O
-	O
two	O
(	O
68	O
%)	O
of	O
our	O
patients	O
used	O
the	O
OP	O
insecticide	B-CHED
for	O
suicide	O
.	O

Three	O
of	O
the	O
patients	O
who	O
did	O
not	O
receive	O
pralidoxime	B-CHED
because	O
of	O
unavailability	O
died	O
.	O

3	O
for	O
PCV	B-CHED
to	O
25	O
+/-	O

3	O
for	O
PCV	B-CHED
to	O
12	O
+/-	O

Four	O
PCR	O
assays	O
with	O
primers	O
specific	O
for	O
N	O
-	O
protein	B-CHED
of	O
human	O
coronavirus	O
strain	O
229E	O
and	O
three	O
PCR	O
assays	O
with	O
primers	O
specific	O
for	O
the	O
nucleocapsid	O
protein	B-CHED
of	O
human	O
coronavirus	O
strain	O
OC43	O
were	O
performed	O
.	O

When	O
edema	O
was	O
profuse	O
,	O
PV	O
curves	O
displayed	O
a	O
marked	O
lower	O
inflection	O
point	O
(	O
LIP	O
),	O
the	O
UIP	O
at	O
low	O
pressure	O
disappeared	O
but	O
another	O
was	O
seen	O
at	O
high	O
volume	O
above	O
the	O
LIP	O
,	O
and	O
the	O
correlation	O
between	O
Vuip	O
changes	O
and	O
edema	O
severity	O
was	O
lost	B-CHED
.	O

MHV	O
N	O
protein	B-CHED
binds	O
to	O
all	O
MHV	O
mRNAs	O
,	O
whereas	O
envelope	O
M	O
protein	B-CHED
interacts	O
only	O
with	O
mRNA	B-CHED
1	O
.	O

Thus	O
,	O
it	O
was	O
the	O
packaging	O
signal	O
that	O
mediated	O
the	O
selective	O
interaction	O
between	O
M	O
protein	B-CHED
and	O
viral	O
RNA	O
to	O
drive	O
the	O
specific	O
packaging	O
of	O
RNA	O
into	O
virus	O
particles	O
.	O

Compared	O
with	O
control	O
infants	O
who	O
were	O
treated	O
with	O
CV	O
,	O
neonates	O
who	O
were	O
treated	O
with	O
HFOV	O
using	O
a	O
strategy	O
designed	O
to	O
recruit	O
and	O
maintain	O
lung	O
volume	O
and	O
minimize	O
oxygen	B-CHED
exposure	O
had	O
clinical	O
evidence	O
of	O
improved	O
pulmonary	O
outcome	O
and	O
less	O
lung	O
injury	O
.	O

These	O
studies	O
have	O
indicated	O
that	O
adhesion	O
molecules	O
such	O
as	O
intracellular	O
adhesion	O
molecule	O
-	O
1	O
(	O
ICAM	O
-	O
1	O
),	O
neutrophils	O
,	O
platelet	B-CHED
activating	I-CHED
factor	I-CHED
(	O
PAF	B-CHED
),	O
substance	O
P	O
,	O
and	O
chemokines	O
acting	O
via	O
the	O
CCR	O
-	O
1	O
chemokine	O
receptor	O
play	O
a	O
pro	B-CHED
-	O
inflammatory	O
role	O
while	O
complement	O
factor	O
C5a	O
plays	O
an	O
anti	O
-	O
inflammatory	O
role	O
in	O
pancreatitis	O
and	O
lung	O
injury	O
.	O

Three	O
new	O
potential	O
sequence	O
motifs	O
with	O
homology	O
to	O
the	O
alpha	O
-	O
subunit	O
of	O
the	O
polymerase	O
-	O
associated	O
nucleocapsid	O
phosphoprotein	O
of	O
rinderpest	O
virus	O
,	O
the	O
Bowman	O
-	O
Birk	O
type	O
of	O
proteinase	O
inhibitors	B-CHED
,	O
and	O
the	O
metallothionein	O
superfamily	O
of	O
cysteine	B-CHED
rich	O
chelating	O
proteins	B-CHED
have	O
been	O
identified	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
during	O
the	O
acute	O
phase	O
of	O
infection	O
,	O
T	O
lymphocytes	O
are	O
recruited	O
into	O
the	O
CNS	B-CHED
by	O
the	O
chemokines	O
CXCL10	O
and	O
CXCL9	O
.	O

In	O
two	O
independently	O
performed	O
randomised	O
,	O
prospective	O
clinical	O
trials	O
,	O
including	O
patients	O
with	O
systemic	O
inflammatory	O
response	O
syndrome	O
or	O
sepsis	O
,	O
the	O
supplementation	O
of	O
selenium	B-CHED
revealed	O
a	O
significant	O
reduction	O
in	O
multiorgan	O
failure	O
and	O
,	O
especially	O
,	O
a	O
lower	O
incidence	O
of	O
acute	O
renal	O
failure	O
and	O
respiratory	O
distress	O
syndrome	O
.	O

Sequence	O
analyses	O
revealed	O
that	O
these	O
acute	O
PRRSV	O
isolates	O
shared	O
88	O
-	O
95	O
%	O
nucleotide	B-CHED
and	O
88	O
-	O
96	O
%	O
amino	B-CHED
acid	I-CHED
sequence	O
identities	O
to	O
each	O
other	O
,	O
87	O
-	O
97	O
%	O
nucleotide	B-CHED
and	O
84	O
-	O
96	O
%	O
amino	B-CHED
acid	I-CHED
sequence	O
identities	O
with	O
other	O
North	O
American	O
PRRSV	O
isolates	O
and	O
the	O
MLVs	O
.	O

His	O
chest	O
radiograph	O
was	O
not	O
typical	O
for	O
PCP	B-CHED
,	O
and	O
showed	O
no	O
diffuse	O
ground	O
-	O
grass	O
or	O
fine	O
granular	O
opacities	O
.	O

ABSTRACT	O
:	O
The	O
spike	O
(	O
S	O
)	O
glycoprotein	B-CHED
of	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
is	O
a	O
major	O
determinant	O
of	O
neurovirulence	O
.	O

We	O
previously	O
reported	O
that	O
the	O
spike	O
glycoprotein	B-CHED
gene	O
of	O
MHV	O
contains	O
determinants	O
of	O
demyelination	O
and	O
hepatitis	O
.	O

ABSTRACT	O
:	O
Staphylococcus	O
aureus	O
and	O
Streptococcus	O
pyogenes	O
produce	O
a	O
lot	O
of	O
toxins	B-CHED
,	O
some	O
of	O
them	O
responsible	O
for	O
specific	O
diseases	O
.	O

Besides	O
these	O
specific	O
diseases	O
,	O
staphylococcal	O
and	O
streptococcal	O
toxins	B-CHED
may	O
be	O
involved	O
in	O
some	O
syndromes	O
of	O
unknown	O
origin	O
,	O
in	O
which	O
the	O
intervention	O
of	O
superantigens	O
seems	O
very	O
likely	O
.	O

Kawasaki	O
syndrome	O
is	O
among	O
them	O
as	O
strains	O
producing	O
staphylococcal	O
and	O
streptococcal	O
toxins	B-CHED
have	O
been	O
grown	O
from	O
patients	O
with	O
Kawasaki	O
syndrome	O
.	O

As	O
the	O
inflammation	O
subsides	O
,	O
the	O
extent	O
of	O
retinal	B-CHED
vascular	O
leakage	O
is	O
decreased	O
,	O
indicating	O
that	O
BRB	O
breakdown	O
in	O
experimental	O
coronavirus	O
retinopathy	O
(	O
ECOR	O
)	O
is	O
primarily	O
due	O
to	O
inflammation	O
rather	O
than	O
to	O
retinal	B-CHED
cell	O
destruction	O
.	O

Resistance	O
was	O
noted	O
to	O
both	O
chloroquine	B-CHED
and	O
artesunate	B-CHED
.	O

An	O
orchestrated	O
expression	O
of	O
chemokines	O
,	O
including	O
the	O
CCR2	O
ligands	O
monocyte	O
chemoattractant	O
protein	B-CHED
-	O
1	O
/	O
CCL2	B-CHED
and	O
monocyte	O
chemoattractant	O
protein	B-CHED
-	O
3	O
/	O
CCL7	O
,	O
occurs	O
within	O
the	O
CNS	B-CHED
following	O
infection	O
with	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
).	O

We	O
have	O
used	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
),	O
apositive	O
-	O
strand	O
RNA	O
virus	O
,	O
infection	O
of	O
the	O
CNS	B-CHED
to	O
understand	O
the	O
dynamic	O
interaction	O
between	O
viral	O
replication	O
,	O
protection	O
,	O
and	O
pathology	O
with	O
an	O
emphasis	O
on	O
understanding	O
how	O
chemokines	O
participate	O
in	O
these	O
interrelated	O
processes	O
.	O

In	O
wild	O
-	O
type	O
mice	O
plasma	O
cells	O
appeared	O
in	O
the	O
CNS	B-CHED
around	O
the	O
time	O
that	O
virus	O
is	O
cleared	O
.	O

These	O
data	O
suggest	O
that	O
clearance	O
of	O
infectious	O
mouse	O
hepatitis	O
virus	O
strain	O
A59	O
from	O
the	O
CNS	B-CHED
requires	O
Ab	O
production	O
and	O
perhaps	O
B	O
cell	O
support	O
of	O
T	O
cells	O
;	O
however	O
,	O
virus	O
is	O
cleared	O
from	O
the	O
liver	O
without	O
the	O
involvement	O
of	O
Abs	O
or	O
B	O
cells	O
.	O

In	O
this	O
lavage	O
-	O
induced	O
acute	O
respiratory	O
distress	O
syndrome	O
model	O
the	O
administration	O
of	O
C1	O
-	O
INH	O
might	O
be	O
followed	O
by	O
a	O
higher	O
clinical	O
efficacy	O
of	O
exogenously	O
supplied	O
recombinant	O
SP	O
-	O
C	O
surfactant	B-CHED
.	O

There	O
is	O
a	O
significant	O
increase	O
in	O
severe	O
(	O
grades	O
3	O
&	O
4	O
)	O
intraventricular	O
hemorrhage	O
(	O
IVH	O
)	O
and	O
in	O
any	O
pulmonary	O
air	B-CHED
leak	O
syndrome	O
[	O
summary	O
RR	O
1	O
.	O
19	O
(	O
1	O
.	O
03	O
,	O
1	O
.	O
38	O
)]	O
in	O
the	O
HFOV	O
group	O
.	O

Benefits	O
of	O
HFOV	O
in	O
terms	O
of	O
CLD	O
appear	O
to	O
be	O
outweighed	O
by	O
concerns	O
about	O
increased	O
rates	O
of	O
pulmonary	O
air	B-CHED
leak	O
and	O
severe	O
IVH	O
.	O

The	O
animals	O
were	O
taken	O
to	O
8000	O
feet	O
(	O
2440	O
m	O
)	O
in	O
an	O
altitude	O
chamber	O
,	O
and	O
then	O
stepwise	O
increases	O
of	O
either	O
5	O
%	O
FiO2	O
(	O
six	O
animals	O
)	O
or	O
2	O
.	O
5	O
cm	O
H2O	B-CHED
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
six	O
animals	O
)	O
were	O
made	O
until	O
PaO2	O
values	O
exceeded	O
75	O
torr	O
(	O
10	O
.	O
0	O
kPa	O
).	O

We	O
also	O
identified	O
a	O
conserved	O
23	O
-	O
nucleotide	B-CHED
stem	O
-	O
loop	O
structure	O
involving	O
nucleotides	B-CHED
142	O
to	O
132	O
and	O
nucleotides	B-CHED
68	O
to	O
79	O
.	O

The	O
upstream	O
side	O
of	O
this	O
conserved	O
stem	O
-	O
loop	O
is	O
contained	O
within	O
a	O
host	O
protein	B-CHED
binding	O
element	O
(	O
nucleotides	B-CHED
166	O
to	O
129	O
).	O

Two	O
-	O
thirds	O
of	O
the	O
total	O
number	O
of	O
M	O
protein	B-CHED
molecules	O
found	O
in	O
the	O
virion	O
were	O
associated	O
with	O
the	O
cores	O
,	O
and	O
one	O
-	O
third	O
was	O
lost	B-CHED
during	O
core	O
purification	O
.	O

All	O
of	O
the	O
M	O
protein	B-CHED
was	O
susceptible	O
to	O
N	O
-	O
glycosidase	O
F	O
treatment	O
of	O
the	O
native	O
virions	O
,	O
which	O
indicates	O
that	O
all	O
the	O
M	O
protein	B-CHED
molecules	O
are	O
exposed	O
to	O
the	O
virus	O
surface	O
.	O

Single	O
amino	B-CHED
acid	I-CHED
changes	O
within	O
p195	O
/	O
p210	O
as	O
well	O
as	O
within	O
the	O
S	O
glycoprotein	B-CHED
might	O
contribute	O
to	O
the	O
different	O
phenotypes	O
of	O
the	O
BCoV	O
isolates	O
.	O

TITLE	O
:	O
Effect	O
of	O
intravenous	O
taurine	B-CHED
on	O
endotoxin	O
-	O
induced	O
acute	O
lung	O
injury	O
in	O
sheep	O
.	O

Pretreatment	O
with	O
intravenous	O
taurine	B-CHED
significantly	O
reduced	O
these	O
haemodynamic	O
changes	O
.	O

Patients	O
were	O
discharged	O
on	O
tapering	O
doses	O
of	O
benzodiazepines	B-CHED
or	O
pentobarbital	B-CHED
and	O
were	O
free	O
of	O
psychotic	O
symptoms	O
at	O
follow	O
-	O
up	O
.	O

The	O
amino	B-CHED
acid	I-CHED
sequence	O
analysis	O
suggested	O
the	O
presence	O
of	O
several	O
functional	O
motifs	O
within	O
the	O
putative	O
ORF1	O
protein	B-CHED
.	O

Major	O
protein	B-CHED
bands	O
of	O
purified	O
viruses	O
analyzed	O
by	O
SDS	B-CHED
-	O
PAGE	O
were	O
located	O
at	O
200	O
,	O
100	O
-	O
110	O
,	O
50	O
-	O
60	O
,	O
and	O
30	O
-	O
35	O
kDa	O
.	O

Experiment	O
2	O
contained	O
the	O
following	O
four	O
treatments	O
:	O
the	O
control	O
diet	O
;	O
the	O
control	O
diet	O
plus	O
L	B-CHED
-	I-CHED
Arg	I-CHED
(	O
0	O
.	O
20	O
%	O
Arg	B-CHED
of	O
diet	O
);	O
the	O
control	O
diet	O
plus	O
L	O
-	O
Lys	B-CHED
HCl	B-CHED
(	O
0	O
.	O
20	O
%	O
Lys	B-CHED
of	O
diet	O
);	O
and	O
the	O
control	O
diet	O
plus	O
L	B-CHED
-	I-CHED
Arg	I-CHED
-	O
L	B-CHED
-	I-CHED
Glu	I-CHED
(	O
0	O
.	O
10	O
%	O
Arg	B-CHED
of	O
diet	O
).	O

Increasing	O
dietary	O
Arg	B-CHED
,	O
but	O
not	O
Lys	B-CHED
,	O
from	O
100	O
to	O
120	O
%	O
of	O
the	O
NRC	O
recommendation	O
increased	O
(	O
P	O
<	O
or	O
=	O
0	O
.	O
05	O
)	O
Day	O
18	O
BW	O
gain	O
.	O

Increasing	O
dietary	O
Arg	B-CHED
in	O
Experiment	O
3	O
increased	O
plasma	O
Arg	B-CHED
(	O
P	O
<	O
or	O
=	O
0	O
.	O
05	O
),	O
but	O
did	O
not	O
affect	O
plasma	O
Lys	B-CHED
.	O

CBH	O
and	O
APP	B-CHED
levels	O
were	O
not	O
affected	O
by	O
VE	O
.	O

Overall	O
,	O
static	O
compliance	O
was	O
lowest	O
for	O
both	O
tidal	O
volume	O
conditions	O
with	O
PEEP	B-CHED
set	O
at	O
25	O
cmH2O	O
.	O

Low	O
tidal	O
volume	O
ventilation	O
with	O
PEEP	B-CHED
set	O
at	O
5	O
cmH2O	O
results	O
in	O
poor	O
oxygenation	O
and	O
compliance	O
in	O
patients	O
with	O
moderate	O
to	O
severe	O
acute	O
lung	O
injury	O
.	O

Finally	O
,	O
cleavage	O
from	O
the	O
solid	O
support	O
was	O
performed	O
,	O
which	O
also	O
facilitated	O
deprotection	O
of	O
the	O
peptide	B-CHED
side	O
chain	O
functionalities	O
as	O
well	O
as	O
hydrolysis	O
of	O
the	O
poly	O
(	O
epsilon	B-CHED
-	I-CHED
caprolactone	I-CHED
)	O
segments	O
composing	O
the	O
SCK	O
core	O
domain	O
,	O
to	O
yield	O
PTD	B-CHED
-	O
derivatized	O
nanocage	B-CHED
structures	O
(	O
PTD	B-CHED
-	O
nanocage	B-CHED
).	O

To	O
address	O
the	O
role	O
of	O
Ron	O
in	O
ALI	O
,	O
the	O
response	O
of	O
mice	O
deficient	O
in	O
the	O
cytoplasmic	O
domain	O
of	O
Ron	O
(	O
Ron	O
tk	O
-/-)	O
were	O
assessed	O
in	O
response	O
to	O
nickel	B-CHED
exposure	O
.	O

The	O
Oligo	O
data	O
table	O
contains	O
PCR	O
primers	O
and	O
hybridization	O
probes	O
used	O
for	O
detection	O
of	O
viral	O
nucleic	B-CHED
acids	I-CHED
and	O
the	O
Common	O
data	O
table	O
contains	O
the	O
experimental	O
conditions	O
used	O
in	O
their	O
detection	O
.	O

ABSTRACT	O
:	O
Acute	O
postoperative	O
pain	O
and	O
its	O
therapy	O
is	O
a	O
great	O
challenge	O
for	O
all	O
health	O
-	O
care	O
providers	O
in	O
operative	O
medicine	B-CHED
today	O
.	O

Once	O
a	O
parkinsonian	O
syndrome	O
was	O
diagnosed	O
,	O
she	O
was	O
given	O
amantadine	B-CHED
therapy	O
with	O
complete	O
recovery	O
.	O

TITLE	O
:	O
Functional	O
genomics	O
of	O
oxidant	B-CHED
-	O
induced	O
lung	O
injury	O
.	O

No	O
evidence	O
of	O
CV	O
circulation	O
by	O
antigen	B-CHED
or	O
antibody	O
analysis	O
was	O
observed	O
.	O

ABSTRACT	O
:	O
A	O
serodiagnostic	O
ELISA	O
utilizing	O
the	O
recombinant	O
nucleoprotein	O
(	O
rN	O
protein	B-CHED
)	O
of	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
was	O
developed	O
,	O
and	O
evaluated	O
by	O
examining	O
a	O
panel	O
of	O
141	O
virus	O
neutralization	O
(	O
VN	O
)	O
positive	O
and	O
101	O
negative	O
sera	O
.	O

In	O
the	O
interim	O
,	O
supportive	O
care	O
through	O
improvements	O
in	O
mechanical	O
ventilation	O
are	O
beneficial	O
,	O
while	O
specific	O
fluid	O
balance	B-CHED
and	O
nutrition	O
strategies	O
may	O
prove	O
advantageous	O
.	O

ABSTRACT	O
:	O
Mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
infection	O
spreads	O
from	O
MHV	O
-	O
infected	O
DBT	B-CHED
cells	O
,	O
which	O
express	O
the	O
MHV	O
receptor	O
CEACAM1	O
(	O
MHVR	O
),	O
to	O
BHK	O
cells	O
,	O
which	O
are	O
devoid	O
of	O
the	O
receptor	O
,	O
by	O
intercellular	O
membrane	O
fusion	O
(	O
MHVR	O
-	O
independent	O
fusion	O
).	O

ABSTRACT	O
:	O
We	O
have	O
previously	O
shown	O
that	O
the	O
E	O
protein	B-CHED
of	O
the	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
is	O
localized	O
to	O
the	O
Golgi	O
complex	O
when	O
expressed	O
exogenously	O
from	O
cDNA	O
.	O

Thus	O
,	O
the	O
cytoplasmic	O
tail	O
of	O
the	O
E	O
protein	B-CHED
is	O
necessary	O
and	O
sufficient	O
for	O
Golgi	O
targeting	O
.	O

The	O
presence	O
of	O
an	O
appropriate	O
Kozak	O
context	O
led	O
to	O
a	O
higher	O
level	O
of	O
protein	B-CHED
expression	O
.	O

Findings	O
significantly	O
associated	O
with	O
mortality	O
were	O
sepsis	O
,	O
thrombocytopenia	O
,	O
disseminated	O
intravascular	O
coagulation	O
(	O
DIC	B-CHED
),	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
and	O
abdominal	O
and	O
thoracic	O
traumas	O
.	O

In	O
addition	O
,	O
the	O
demonstrated	O
ability	O
to	O
express	O
viral	O
proteins	B-CHED
fused	O
to	O
fluorescent	O
markers	O
in	O
in	O
live	O
cells	O
will	O
allow	O
us	O
to	O
follow	O
specific	O
proteins	B-CHED
or	O
complexes	O
during	O
the	O
course	O
of	O
infection	O
and	O
to	O
determine	O
if	O
exogenously	O
expressed	O
proteins	B-CHED
are	O
able	O
to	O
target	O
to	O
sites	O
of	O
active	O
viral	O
replication	O
.	O

ABSTRACT	O
:	O
Marked	O
proliferation	O
of	O
macrophages	O
engulfing	O
yellow	O
pigments	B-CHED
and	O
fragmented	O
erythrocytes	O
were	O
seen	O
in	O
the	O
air	B-CHED
capillaries	O
and	O
blood	O
capillaries	O
of	O
the	O
lungs	O
of	O
chickens	O
affected	O
with	O
acute	O
fatal	O
viral	O
hydropericardium	O
syndrome	O
,	O
highly	O
pathogenic	O
infectious	O
bursal	O
disease	O
,	O
and	O
highly	O
pathogenic	O
avian	O
influenza	O
.	O

The	O
dorsal	O
side	O
was	O
calculated	O
to	O
have	O
received	O
one	O
eighth	O
of	O
the	O
value	O
of	O
the	O
abdominal	O
side	O
,	O
and	O
much	O
smaller	O
neutron	B-CHED
component	O
.	O

Nitrotyrosine	O
(	O
NT	O
),	O
a	O
specific	O
marker	O
of	O
in	O
vivo	O
ONOO	O
(-)	O
production	O
,	O
was	O
detected	O
with	O
immunohistochemical	O
technique	O
in	O
rat	O
lung	O
during	O
endotoxin	O
shock	O
(	O
LPS	B-CHED
5	O
mg	O
/	O
kg	O
iv	O
).	O

RESULTS	O
:	O
After	O
2	O
or	O
6	O
hours	O
of	O
LPS	B-CHED
intravenous	O
administration	O
,	O
severe	O
lung	O
injury	O
and	O
positive	O
signals	O
of	O
NT	O
occurred	O
with	O
the	O
latter	O
located	O
in	O
the	O
pulmonary	O
macrophages	O
,	O
endothelia	O
,	O
subendothelial	O
and	O
muscular	O
layers	O
of	O
the	O
pulmonary	O
artery	O
.	O

Nevertheless	O
,	O
virus	O
reemerged	O
within	O
the	O
CNS	B-CHED
of	O
all	O
Ab	O
-	O
deficient	O
mice	O
.	O

Although	O
an	O
Ab	O
-	O
independent	O
antiviral	B-CHED
function	O
of	O
B	O
cells	O
was	O
not	O
evident	O
during	O
acute	O
infection	O
,	O
the	O
presence	O
of	O
B	O
cells	O
altered	O
CNS	B-CHED
cellular	O
tropism	O
during	O
viral	O
recrudescence	O
.	O

These	O
data	O
conclusively	O
demonstrate	O
that	O
the	O
Ab	O
component	O
of	O
humoral	O
immunity	O
is	O
critical	O
in	O
preventing	O
virus	O
reactivation	O
within	O
CNS	B-CHED
glial	O
cells	O
.	O

This	O
case	O
is	O
characteristic	O
for	O
acute	O
intoxications	O
with	O
irreversible	O
acetylcholinesterase	B-CHED
inhibitors	I-CHED
,	O
such	O
as	O
organophosphate	O
compounds	O
.	O

The	O
treatment	O
of	O
these	O
potentially	O
severe	O
intoxications	O
includes	O
rapid	O
decontamination	O
and	O
the	O
administration	O
of	O
high	O
doses	O
of	O
atropine	B-CHED
followed	O
by	O
obidoxime	O
.	O

Blood	O
culture	O
and	O
genetic	O
investigation	O
(	O
16	O
s	O
rRNA	B-CHED
polymerase	O
chain	O
reaction	O
with	O
restriction	O
enzyme	O
PstII	O
)	O
confirmed	O
diagnoses	O
of	O
the	O
same	O
species	O
of	O
Streptococcus	O
suis	O
infections	O
.	O

RESULTS	O
:	O
Acute	O
leptospirosis	O
period	O
was	O
characterized	O
with	O
polymorphic	O
clinical	O
picture	O
impeding	O
precise	O
diagnosis	O
and	O
threatening	O
with	O
such	O
complications	O
as	O
bacterial	O
shock	O
,	O
acute	O
renal	O
failure	O
,	O
acute	O
renal	O
-	O
hepatic	O
failure	O
,	O
DIC	B-CHED
-	O
syndrome	O
,	O
respiratory	O
distress	O
.	O

TITLE	O
:	O
The	O
sialate	B-CHED
-	O
4	O
-	O
O	O
-	O
acetylesterases	O
of	O
coronaviruses	O
related	O
to	O
mouse	O
hepatitis	O
virus	O
:	O
a	O
proposal	O
to	O
reorganize	O
group	O
2	O
Coronaviridae	O
.	O

At	O
least	O
three	O
coronavirus	O
strains	O
within	O
group	O
2	O
expressed	O
a	O
structural	O
protein	B-CHED
with	O
sialate	B-CHED
-	O
4	O
-	O
O	O
-	O
acetylesterase	O
activity	O
,	O
distinguishing	O
them	O
from	O
other	O
members	O
of	O
group	O
2	O
,	O
which	O
encode	O
an	O
enzyme	O
specific	O
for	O
5	O
-	O
N	B-CHED
-	I-CHED
acetyl	I-CHED
-	I-CHED
9	I-CHED
-	I-CHED
O	I-CHED
-	I-CHED
acetylneuraminic	I-CHED
acid	I-CHED
.	O

To	O
investigate	O
in	O
vivo	O
cross	O
-	O
protection	O
between	O
the	O
BRCV	O
and	O
CD	O
or	O
WD	O
strains	O
of	O
BCV	O
and	O
to	O
detect	O
nasal	O
and	O
fecal	O
shedding	O
of	O
BCV	O
using	O
the	O
1	O
-	O
step	O
RT	O
-	O
PCR	O
,	O
nested	O
PCR	O
and	O
antigen	B-CHED
-	O
capture	O
ELISA	O
,	O
6	O
colostrum	O
-	O
deprived	O
and	O
two	O
gnotobiotic	O
calves	O
were	O
inoculated	O
with	O
a	O
BRCV	O
,	O
a	O
CD	O
or	O
a	O
WD	O
strain	O
of	O
BCV	O
and	O
then	O
challenged	O
3	O
-	O
4	O
weeks	O
later	O
with	O
either	O
BRCV	O
,	O
CD	O
or	O
WD	O
strains	O
of	O
BCV	O
.	O

Mp	O
-	O
associated	O
HPS	B-CHED
was	O
diagnosed	O
in	O
this	O
case	O
by	O
clinical	O
and	O
laboratory	O
findings	O
,	O
including	O
a	O
bone	O
marrow	O
aspiration	O
specimen	O
and	O
serum	O
Mp	O
antibody	O
titer	O
.	O

Physicians	O
should	O
be	O
aware	O
of	O
HPS	B-CHED
as	O
a	O
complication	O
in	O
Mp	O
infection	O
.	O

Turkeys	O
treated	O
with	O
CY	O
had	O
1	O
-	O
2	O
fold	O
higher	O
immunofluorescent	O
antibody	O
assay	O
(	O
IFA	O
)	O
scores	O
for	O
TCV	O
antigens	B-CHED
(	O
p	O
<	O
0	O
.	O
05	O
)	O
in	O
the	O
intestine	O
than	O
untreated	O
turkeys	O
at	O
9	O
or	O
14	O
days	O
PI	O
.	O

Exposure	O
of	O
adult	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
to	O
hyperoxia	O
for	O
24	O
to	O
48	O
h	O
led	O
to	O
increased	O
expression	O
of	O
pulmonary	O
CYP1A1	O
enzyme	O
,	O
which	O
was	O
preceded	O
by	O
enhancement	O
of	O
the	O
corresponding	O
mRNA	B-CHED
,	O
followed	O
by	O
decline	O
of	O
induction	O
at	O
60	O
h	O
,	O
when	O
the	O
animals	O
displayed	O
severe	O
respiratory	O
distress	O
and	O
lung	O
inflammation	O
.	O

The	O
large	O
RNA	O
is	O
surrounded	O
by	O
a	O
nucleoprotein	O
(	O
protein	B-CHED
N	O
).	O

The	O
envelop	O
contains	O
2	O
or	O
3	O
glycoproteins	B-CHED
:	O
spike	O
protein	B-CHED
(	O
or	O
protein	B-CHED
S	O
),	O
matrix	O
protein	B-CHED
(	O
or	O
protein	B-CHED
M	O
)	O
and	O
a	O
hemagglutinin	O
(	O
or	O
protein	B-CHED
HE	O
).	O

In	O
addition	O
,	O
the	O
IgA	O
and	O
IgG	O
ASC	O
responses	O
detected	O
in	O
the	O
blood	O
on	O
PID	B-CHED
21	O
also	O
correlated	O
with	O
the	O
responses	O
found	O
in	O
the	O
gut	O
associated	O
lymphoid	O
tissues	O
.	O

Stated	O
another	O
way	O
,	O
there	O
is	O
probably	O
no	O
single	O
value	O
for	O
arterial	O
P	O
(	O
CO2	B-CHED
),	O
pH	O
,	O
or	O
P	O
(	O
O2	O
)	O
that	O
by	O
itself	O
constitutes	O
an	O
indication	O
for	O
IPPV	O
.	O

Based	O
on	O
the	O
pathological	O
findings	O
or	O
on	O
the	O
immunohistochemical	O
distribution	O
of	O
viral	O
antigen	B-CHED
,	O
FIP	O
-	O
affected	O
cats	O
were	O
divided	O
in	O
the	O
following	O
groups	O
:	O
subacute	O
against	O
acute	O
lesions	O
;	O
low	O
against	O
strong	O
intensity	O
of	O
positivity	O
;	O
intracellular	O
against	O
extracellular	O
positivities	O
;	O
positive	O
against	O
negative	O
lymph	O
nodes	O
.	O

Following	O
elimination	O
of	O
infectious	O
virus	O
,	O
virus	O
-	O
specific	O
ASC	O
continued	O
to	O
increase	O
within	O
the	O
CNS	B-CHED
and	O
then	O
remained	O
stable	O
during	O
persistence	O
,	O
in	O
contrast	O
to	O
declining	O
T	O
cell	O
numbers	O
.	O

To	O
unequivocally	O
determine	O
their	O
roles	O
in	O
viral	O
cytopathogenicity	O
,	O
we	O
developed	O
a	O
system	O
in	O
which	O
phenotypically	O
chimeric	O
viruses	O
were	O
generated	O
by	O
infecting	O
a	O
closely	O
related	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
in	O
cells	O
that	O
stably	O
express	O
an	O
individual	O
BCV	O
protein	B-CHED
(	O
S	O
or	O
HE	O
).	O

In	O
vitro	O
experiments	O
demonstrated	O
that	O
nitric	B-CHED
oxide	I-CHED
donor	I-CHED
had	O
a	O
direct	O
bactericidal	O
effect	O
against	O
P	O
.	O
aeruginosa	O
and	O
did	O
not	O
modify	O
alveolar	O
neutrophil	O
functions	O
.	O

These	O
polymorphisms	O
led	O
to	O
42	O
amino	B-CHED
acid	I-CHED
changes	O
at	O
38	O
distinct	O
sites	O
.	O

ABSTRACT	O
:	O
IFN	O
-	O
gamma	O
-	O
inducible	O
protein	B-CHED
10	O
(	O
IP	O
-	O
10	O
,	O
CXCL10	O
),	O
a	O
chemokine	O
secreted	O
from	O
cells	O
stimulated	O
with	O
type	O
I	O
and	O
II	O
IFNs	O
and	O
LPS	B-CHED
,	O
is	O
a	O
chemoattractant	O
for	O
activated	O
T	O
cells	O
.	O

The	O
DMVs	O
were	O
found	O
either	O
as	O
separate	O
entities	O
or	O
as	O
small	O
clusters	B-CHED
of	O
vesicles	O
.	O

Nucleotide	B-CHED
sequencing	O
was	O
performed	O
directly	O
on	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
products	O
amplified	O
by	O
reverse	O
transcription	O
(	O
RT	O
)	O
and	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
analysis	O
from	O
fecal	O
samples	O
or	O
isolated	O
viruses	O
.	O

Results	O
suggested	O
that	O
interchange	O
of	O
mice	O
infected	O
with	O
MHV	O
among	O
facilities	O
provided	O
opportunities	O
of	O
introduction	O
of	O
MHV	O
into	O
otherwise	O
MHV	O
-	O
free	O
facilities	O
and	O
that	O
the	O
source	O
of	O
MHV	O
infection	O
could	O
be	O
traced	O
by	O
use	O
of	O
nucleotide	B-CHED
analysis	O
of	O
the	O
N	O
gene	O
.	O

Clinical	O
results	O
of	O
daily	O
MARS	O
treatments	O
of	O
patients	O
with	O
hepatic	O
failure	O
are	O
similar	O
to	O
that	O
of	O
Liver	O
Dialysis	O
,	O
with	O
neurologic	O
and	O
physical	O
improvement	O
occurs	O
in	O
most	O
patients	O
with	O
AHE	B-CHED
,	O
and	O
improved	O
outcome	O
for	O
patients	O
with	O
A	O
-	O
on	O
-	O
C	O
.	O
The	O
system	O
extends	O
the	O
life	O
of	O
patients	O
with	O
hepatorenal	O
syndrome	O
.	O

Concomitantly	O
,	O
ExPLIs	O
inhibited	O
the	O
LPS	B-CHED
-	O
induced	O
activation	O
of	O
NF	O
-	O
kappaB	O
by	O
LPS	B-CHED
but	O
not	O
its	O
activation	O
by	O
TNF	O
-	O
alpha	O
or	O
IL	O
-	O
1	O
.	O

These	O
viruses	O
are	O
,	O
therefore	O
,	O
used	O
to	O
study	O
the	O
role	O
of	O
the	O
immune	O
system	O
in	O
viral	O
clearance	O
from	O
the	O
CNS	B-CHED
,	O
in	O
CNS	B-CHED
demyelination	O
,	O
and	O
in	O
remyelination	O
.	O

TITLE	O
:	O
A	O
biomimetic	O
approach	O
to	O
the	O
synthesis	O
of	O
an	O
antiviral	B-CHED
marine	O
steroidal	O
orthoester	O
.	O

Autopsy	O
revealed	O
full	O
donor	B-CHED
engraftment	O
and	O
no	O
signs	O
of	O
hemophagocytic	O
lymphohistiocytosis	O
or	O
B	O
lymphoproliferative	O
disease	O
.	O

Nucleoli	O
,	O
and	O
proteins	B-CHED
that	O
localize	O
to	O
the	O
nucleolus	O
,	O
have	O
been	O
implicated	O
in	O
cell	O
growth	O
-	O
cell	O
cycle	O
regulation	O
.	O

During	O
16	O
episodes	O
(	O
64	O
%),	O
the	O
bacteremia	O
occurred	O
within	O
15	O
days	O
after	O
the	O
onset	O
of	O
neutropenia	O
consecutive	O
to	O
antimitotic	B-CHED
chemotherapy	O
,	O
and	O
in	O
nine	O
episodes	O
(	O
36	O
%)	O
it	O
has	O
occurred	O
after	O
a	O
period	O
exceeding	O
15	O
days	O
.	O

In	O
six	O
cases	O
the	O
patients	O
had	O
already	O
received	O
antibiotics	B-CHED
with	O
a	O
large	O
antibacterial	O
activity	O
(	O
beta	B-CHED
-	I-CHED
lactam	I-CHED
,	O
fluoroquinolone	O
and	O
/	O
or	O
glycopeptide	B-CHED
+/-	O
aminoside	O
)	O
and	O
in	O
four	O
cases	O
a	O
single	O
antibiotic	B-CHED
(	O
synergistine	O
or	O
cotrimoxazole	O
).	O

Levels	O
of	O
resistance	O
of	O
the	O
enterococci	O
to	O
the	O
beta	B-CHED
-	I-CHED
lactam	I-CHED
(	O
penicillin	B-CHED
,	O
amoxicillin	B-CHED
,	O
and	O
piperacillin	B-CHED
)	O
were	O
variable	O
.	O

ABSTRACT	O
:	O
CEACAM1	O
is	O
a	O
member	O
of	O
the	O
carcinoembryonic	O
antigen	B-CHED
(	O
CEA	O
)	O
family	O
.	O

Purified	O
fgl2	O
protein	B-CHED
generated	O
in	O
a	O
baculovirus	O
expression	O
system	O
had	O
no	O
measurable	O
prothrombinase	O
activity	O
,	O
whereas	O
the	O
activity	O
was	O
restored	O
when	O
the	O
purified	O
protein	B-CHED
was	O
reconstituted	O
into	O
phosphatidyl	B-CHED
-	I-CHED
L	I-CHED
-	I-CHED
serine	I-CHED
-	O
containing	O
vesicles	O
.	O

MHV	O
utilized	O
this	O
p38	O
MAPK	O
-	O
dependent	O
increase	O
in	O
eIF4E	O
phosphorylation	O
to	O
promote	O
virus	O
-	O
specific	O
protein	B-CHED
synthesis	O
and	O
subsequent	O
progeny	O
virus	O
production	O
.	O

On	O
the	O
other	O
hand	O
,	O
binding	O
to	O
the	O
sialic	B-CHED
acid	I-CHED
residues	O
of	O
the	O
high	O
-	O
molecular	O
-	O
mass	O
glycoprotein	B-CHED
was	O
observed	O
regardless	O
of	O
whether	O
the	O
cellular	O
proteins	B-CHED
had	O
been	O
separated	O
under	O
reducing	O
or	O
nonreducing	O
conditions	O
.	O

Indirect	O
immunofluorescence	O
demonstrated	O
that	O
the	O
protein	B-CHED
exhibits	O
a	O
distinct	O
perinuclear	O
punctate	O
staining	O
pattern	O
,	O
suggesting	O
that	O
it	O
is	O
associated	O
with	O
cellular	O
membranes	O
.	O

Treatment	O
of	O
the	O
membrane	O
fraction	O
prepared	O
from	O
cells	O
expressing	O
the	O
16	O
-	O
kDa	O
protein	B-CHED
with	O
Triton	B-CHED
X	I-CHED
-	I-CHED
100	I-CHED
,	O
a	O
high	O
pH	O
,	O
and	O
a	O
high	O
concentration	O
of	O
salts	B-CHED
showed	O
that	O
the	O
protein	B-CHED
may	O
be	O
tightly	O
associated	O
with	O
intracellular	O
membranes	O
.	O

Of	O
20	O
consecutive	O
preterm	O
infants	O
(	O
27	O
-	O
35	O
weeks	O
'	O
gestation	O
)	O
with	O
severe	O
respiratory	O
distress	O
syndrome	O
)	O
who	O
were	O
enrolled	O
14	O
with	O
bovine	O
surfactant	B-CHED
finally	O
were	O
analyzed	O
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
impact	O
of	O
bronchoscopic	O
surfactant	B-CHED
administration	O
,	O
on	O
the	O
biochemical	O
and	O
biophysical	O
surfactant	B-CHED
properties	O
,	O
in	O
patients	O
with	O
severe	O
and	O
early	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
and	O
septic	O
shock	O
.	O

TITLE	O
:	O
Bronchoscopic	O
administration	O
of	O
bovine	O
natural	O
surfactant	B-CHED
in	O
ARDS	O
and	O
septic	O
shock	O
:	O
impact	O
on	O
gas	O
exchange	O
and	O
haemodynamics	O
.	O

No	O
untoward	O
effects	O
on	O
gas	O
exchange	O
,	O
lung	O
mechanics	O
and	O
haemodynamics	O
were	O
noted	O
during	O
the	O
procedure	O
of	O
surfactant	B-CHED
administration	O
.	O

TITLE	O
:	O
Communication	O
between	O
S1N330	O
and	O
a	O
region	O
in	O
S2	O
of	O
murine	O
coronavirus	O
spike	O
protein	B-CHED
is	O
important	O
for	O
virus	O
entry	O
into	O
cells	O
expressing	O
CEACAM1b	O
receptor	O
.	O

Thus	O
,	O
we	O
obtained	O
recombinant	O
viruses	O
from	O
which	O
the	O
two	O
clusters	B-CHED
of	O
group	O
-	O
specific	O
genes	O
were	O
deleted	O
either	O
separately	O
or	O
in	O
combination	O
in	O
a	O
controlled	O
genetic	O
background	O
.	O

A	O
high	O
degree	O
of	O
suspicion	O
is	O
required	O
to	O
make	O
a	O
diagnosis	O
as	O
early	O
as	O
possible	O
in	O
order	O
to	O
avoid	O
the	O
death	O
of	O
a	O
large	O
percentage	O
of	O
patients	O
before	O
cytostatic	B-CHED
treatment	O
begins	O
.	O

Therapy	O
involved	O
a	O
sequential	O
algorithmic	O
approach	O
that	O
included	O
pulmonary	O
artery	O
oximetry	O
,	O
""""	O
best	O
-	O
PEEP	B-CHED
""""	O
determination	O
,	O
optimization	O
of	O
cardiac	O
function	O
,	O
limitation	O
of	O
VO	O
(	O
2	O
),	O
transfusion	O
to	O
hematocrit	O
of	O
35	O
%,	O
frequent	O
bronchoscopy	O
,	O
rational	O
diuresis	O
and	O
,	O
if	O
the	O
FiO	O
(	O
2	O
)	O
was	O
>	O
0	O
.	O
50	O
,	O
a	O
trial	O
of	O
IPP	O
with	O
every	O
-	O
6	O
-	O
hour	O
rotations	O
.	O

Ergotamine	B-CHED
increased	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
plasma	O
triiodothyronine	B-CHED
and	O
respiration	O
rates	O
in	O
Hereford	O
,	O
whereas	O
these	O
traits	O
were	O
unaltered	O
in	O
Brahman	O
.	O

TITLE	O
:	O
Neither	O
B	O
cells	O
nor	O
T	O
cells	O
are	O
required	O
for	O
CNS	B-CHED
demyelination	O
in	O
mice	O
persistently	O
infected	O
with	O
MHV	O
-	O
A59	O
.	O

The	O
individual	O
SNAP	O
items	O
that	O
contributed	O
most	O
to	O
SNAP	O
moderate	O
and	O
severe	O
categories	O
were	O
blood	O
gas	O
items	O
,	O
creatinine	B-CHED
,	O
urine	O
output	O
,	O
blood	O
glucose	B-CHED
,	O
and	O
seizures	O
.	O

Positive	O
reactivity	O
was	O
seen	O
with	O
polyclonal	O
antibodies	O
to	O
the	O
TCV	O
Indiana	O
isolate	O
,	O
the	O
TCV	O
Virginia	O
isolate	O
,	O
TCV	O
-	O
ATCC	O
,	O
and	O
the	O
IBV	O
Massachusetts	O
strain	O
as	O
well	O
as	O
monoclonal	O
antibodies	O
to	O
the	O
TCV	O
North	O
Carolina	O
isolate	O
or	O
the	O
membrane	O
protein	B-CHED
of	O
IBV	O
.	O

Severe	O
hypotension	O
and	O
tachycardia	O
were	O
observed	O
after	O
rocuronium	B-CHED
,	O
without	O
bronchospasm	O
.	O

The	O
second	O
patient	O
was	O
a	O
64	O
-	O
year	O
-	O
old	O
ASA	B-CHED
II	O
man	B-CHED
scheduled	O
for	O
abdominal	O
surgery	O
.	O

Multifactorial	O
respiratory	O
disease	O
was	O
reproduced	O
by	O
combined	O
inoculations	O
with	O
PRCV	O
or	O
PRRSV	O
followed	O
by	O
LPS	B-CHED
from	O
Escherichia	O
coli	O
.	O

The	O
growth	O
rate	O
of	O
birds	O
that	O
received	O
0	O
.	O
5	O
%	O
arginine	B-CHED
was	O
significantly	O
lower	O
than	O
that	O
of	O
birds	O
receiving	O
1	O
.	O
0	O
or	O
3	O
.	O
0	O
%	O
arginine	B-CHED
,	O
whereas	O
the	O
growth	O
of	O
the	O
latter	O
groups	O
did	O
not	O
differ	O
.	O

The	O
percentage	O
and	O
absolute	O
number	O
of	O
heterophil	O
(	O
H	O
)	O
and	O
the	O
H	O
/	O
lymphocyte	O
(	O
L	O
)	O
ratio	O
in	O
the	O
peripheral	O
blood	O
at	O
1	O
DPI	O
significantly	O
increased	O
as	O
dietary	O
arginine	B-CHED
increased	O
.	O

These	O
results	O
show	O
that	O
dietary	O
arginine	B-CHED
influences	O
the	O
character	O
of	O
the	O
chicken	O
cellular	O
response	O
to	O
IBV	O
and	O
the	O
distribution	O
of	O
responding	O
leukocyte	O
subpopulations	O
in	O
a	O
target	O
tissue	O
for	O
the	O
infection	O
.	O

The	O
molecular	O
mechanisms	O
governing	O
leukocyte	O
trafficking	O
and	O
accumulation	O
within	O
the	O
CNS	B-CHED
of	O
MHV	O
-	O
infected	O
mice	O
are	O
just	O
now	O
being	O
understood	O
and	O
recent	O
studies	O
indicate	O
that	O
chemokines	O
and	O
chemokine	O
receptors	O
have	O
an	O
important	O
role	O
in	O
this	O
process	O
.	O

TITLE	O
:	O
The	O
use	O
of	O
bovine	O
serum	O
protein	B-CHED
as	O
an	O
oral	O
support	O
therapy	O
following	O
coronavirus	O
challenge	O
in	O
calves	O
.	O

The	O
virus	O
-	O
specific	O
IgA	O
antibody	O
responses	O
in	O
duodenum	O
,	O
jejunum	O
,	O
and	O
ileum	O
showed	O
negative	O
correlation	O
with	O
duration	O
of	O
TCV	O
antigen	B-CHED
in	O
the	O
corresponding	O
locations	O
of	O
intestine	O
with	O
Spearman	O
'	O
s	O
correlation	O
coefficient	O
of	O
-	O
0	O
.	O
85	O
(	O
p	O
=	O
0	O
.	O
034	O
),	O
-	O
0	O
.	O
74	O
(	O
p	O
=	O
0	O
.	O
096	O
),	O
and	O
-	O
0	O
.	O
75	O
(	O
p	O
=	O
0	O
.	O
084	O
),	O
respectively	O
.	O

After	O
low	O
speed	O
centrifugation	O
,	O
the	O
supernatant	O
was	O
concentrated	O
by	O
ultracentrifugation	O
through	O
a	O
cushion	O
of	O
30	O
or	O
60	O
%	O
sucrose	B-CHED
solution	O
,	O
or	O
by	O
ammonium	B-CHED
sulfate	I-CHED
precipitation	O
.	O

The	O
most	O
effective	O
method	O
for	O
purifying	O
TCoV	O
and	O
removing	O
extraneous	O
materials	O
was	O
size	O
-	O
exclusion	O
chromatography	O
as	O
analyzed	O
by	O
sodium	B-CHED
dodecyl	I-CHED
sulfate	I-CHED
-	O
polyacrylamide	B-CHED
gel	O
electrophoresis	O
.	O

TITLE	O
:	O
Gamma	B-CHED
hydroxybutyric	I-CHED
acid	I-CHED
(	O
GHB	B-CHED
)	O
intoxication	O
.	O

ABSTRACT	O
:	O
Gamma	B-CHED
hydroxybutyric	I-CHED
acid	I-CHED
(	O
GHB	B-CHED
)	O
is	O
a	O
naturally	O
occurring	O
analog	O
of	O
gamma	B-CHED
-	I-CHED
aminobutyric	I-CHED
acid	I-CHED
(	O
GABA	B-CHED
)	O
that	O
has	O
been	O
used	O
in	O
research	O
and	O
clinical	O
medicine	B-CHED
for	O
many	O
years	O
.	O

Increased	O
induction	O
of	O
MMP	B-CHED
,	O
TIMP	O
,	O
and	O
chemokine	O
expression	O
correlated	O
with	O
increased	O
virus	O
replication	O
but	O
not	O
with	O
inflammatory	O
cell	O
infiltration	O
.	O

Mechanical	O
ventilation	O
and	O
PEEP	B-CHED
are	O
still	O
important	O
components	O
of	O
supportive	O
therapy	O
.	O

A	O
repeat	O
screening	O
test	O
for	O
urine	O
porphyrins	B-CHED
was	O
positive	O
,	O
and	O
AIP	O
was	O
confirmed	O
by	O
specific	O
porphobilinogen	B-CHED
deaminase	O
in	O
the	O
blood	O
.	O

In	O
situ	O
hybridization	O
and	O
immunohistochemistry	O
showed	O
undetectable	O
or	O
weak	O
MIF	O
mRNA	B-CHED
and	O
protein	B-CHED
expression	O
in	O
normal	O
lungs	O
.	O

Notwithstanding	O
the	O
patient	O
received	O
support	O
from	O
cardiovascular	B-CHED
drugs	I-CHED
and	O
pulmonary	O
vasodilators	O
cardiopulmonary	O
by	O
-	O
pass	O
was	O
necessary	O
.	O

TF	O
and	O
other	O
coagulation	O
proteins	B-CHED
,	O
including	O
Factor	O
Xa	O
,	O
thrombin	O
,	O
and	O
fibrin	O
,	O
also	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
acute	O
lung	O
injury	O
through	O
multi	O
-	O
level	O
interactions	O
with	O
inflammatory	O
effectors	O
,	O
in	O
which	O
these	O
proteins	B-CHED
coordinately	O
act	O
as	O
regulators	O
of	O
tissue	O
injury	O
responses	O
.	O

The	O
vasopressin	B-CHED
was	O
stopped	O
,	O
and	O
the	O
skin	O
lesion	O
progressed	O
to	O
bullae	O
formation	O
with	O
extensive	O
superficial	O
erosion	O
.	O

Lung	O
levels	O
of	O
macrophage	O
inflammatory	O
protein	B-CHED
(	O
MIP	O
)-	O
2	O
are	O
also	O
increased	O
during	O
pancreatitis	O
,	O
but	O
,	O
in	O
this	O
case	O
,	O
the	O
rise	O
is	O
less	O
profound	O
in	O
GM	O
-	O
CSF	O
-/-	O
mice	O
than	O
in	O
GM	O
-	O
CSF	O
+/+	O
controls	O
.	O

The	O
limited	O
response	O
to	O
S	O
protein	B-CHED
may	O
explain	O
the	O
poor	O
protection	O
of	O
dogs	O
and	O
the	O
possibility	O
of	O
persisting	O
infection	O
.	O

TITLE	O
:	O
Inhaled	O
nitric	B-CHED
oxide	I-CHED
:	O
more	O
than	O
a	O
selective	O
pulmonary	O
vasodilator	B-CHED
.	O

ABSTRACT	O
:	O
Rats	O
fed	O
either	O
a	O
cereal	O
-	O
based	O
or	O
purified	O
diet	O
of	O
variable	O
folate	B-CHED
content	O
(	O
deficient	O
,	O
replete	O
,	O
or	O
supplemented	O
)	O
inadvertently	O
were	O
infected	O
with	O
sialodacryoadenitis	O
virus	O
,	O
which	O
resulted	O
in	O
an	O
increased	O
frequency	O
of	O
hepatic	O
mitochondrial	O
DNA	O
(	O
mtDNA	O
)	O
deletions	O
that	O
persisted	O
for	O
three	O
weeks	O
after	O
the	O
period	O
of	O
acute	O
signs	O
of	O
disease	O
.	O

TITLE	O
:	O
Bench	O
-	O
to	O
-	O
bedside	O
review	O
:	O
lactate	B-CHED
and	O
the	O
lung	O
.	O

Inhibition	O
of	O
NF	O
-	O
kappaB	O
or	O
the	O
upstream	O
MAPK	O
significantly	O
decreased	O
LPS	B-CHED
-	O
stimulated	O
AMPhi	O
activation	O
.	O

Deduced	O
amino	B-CHED
acid	I-CHED
sequences	O
for	O
both	O
HEV	O
strains	O
revealed	O
89	O
/	O
88	O
,	O
80	O
,	O
93	O
/	O
92	O
and	O
95	O
/	O
94	O
%	O
identities	O
with	O
the	O
structural	O
proteins	B-CHED
HE	O
,	O
S	O
,	O
M	O
and	O
N	O
of	O
BCoV	O
and	O
HCoV	O
-	O
OC43	O
,	O
respectively	O
.	O

This	O
conserved	O
multifunctional	O
protein	B-CHED
is	O
also	O
efficient	O
in	O
inducing	O
NDV	O
-	O
specific	O
antibody	O
in	O
chickens	O
.	O

Here	O
,	O
we	O
localized	O
a	O
conserved	O
B	O
-	O
cell	O
immunodominant	O
epitope	B-CHED
(	O
IDE	B-CHED
)	O
spanning	O
residues	O
447	O
to	O
455	O
and	O
successfully	O
generated	O
a	O
recombinant	O
NDV	O
lacking	O
the	O
IDE	B-CHED
by	O
reverse	O
genetics	O
.	O

Chickens	O
immunized	O
with	O
the	O
hybrid	O
recombinants	O
produced	O
specific	O
antibodies	O
against	O
the	O
S2	O
glycoprotein	B-CHED
of	O
MHV	O
and	O
completely	O
lacked	O
antibodies	O
directed	O
against	O
the	O
NP	O
-	O
IDE	B-CHED
.	O

The	O
digoxigenin	B-CHED
-	O
labeled	O
antisense	O
S1	O
riboprobe	O
detected	O
viral	O
mRNA	B-CHED
in	O
the	O
cytoplasm	O
of	O
respiratory	O
epithelial	O
cells	O
in	O
the	O
primary	O
bronchus	O
at	O
24	O
,	O
48	O
,	O
and	O
72	O
HPI	O
.	O

Viral	O
mRNA	B-CHED
was	O
detected	O
in	O
bursa	O
samples	O
collected	O
at	O
48	O
hr	O
.	O

The	O
results	O
indicate	O
the	O
existence	O
of	O
gene	O
5	O
in	O
the	O
genome	O
of	O
TCV	O
and	O
a	O
close	O
relatedness	O
of	O
the	O
TCV	O
gene	O
5	O
to	O
the	O
IBV	O
gene	O
5	O
in	O
location	O
and	O
nucleotide	B-CHED
sequence	O
.	O

rTGEV	O
-	O
Delta3abDeltaE	O
reached	O
high	O
titers	O
(	O
10	O
(	O
7	O
)	O
PFU	B-CHED
/	O
ml	O
)	O
in	O
baby	O
hamster	O
kidney	O
cells	O
expressing	O
porcine	O
aminopeptidase	O
N	O
(	O
BHK	O
-	O
pAPN	O
),	O
the	O
cellular	O
receptor	O
for	O
TGEV	O
,	O
using	O
Sindbis	O
replicon	O
and	O
reached	O
titers	O
up	O
to	O
5	O
x	O
10	O
(	O
5	O
)	O
PFU	B-CHED
/	O
ml	O
in	O
cells	O
stably	O
expressing	O
E	O
protein	B-CHED
under	O
the	O
control	O
of	O
the	O
CMV	O
promoter	O
.	O

The	O
virus	O
titers	O
were	O
proportional	O
to	O
the	O
E	O
protein	B-CHED
expression	O
level	O
.	O

The	O
method	O
,	O
based	O
on	O
the	O
titration	O
of	O
antibodies	O
to	O
semipurified	O
FAH	O
from	O
rat	O
liver	O
,	O
is	O
easy	O
,	O
economical	O
,	O
and	O
does	O
not	O
require	O
the	O
isolation	O
of	O
viral	O
proteins	B-CHED
from	O
large	O
MHV	O
stocks	O
.	O

ABSTRACT	O
:	O
The	O
relationship	O
between	O
the	O
level	O
of	O
particulate	O
air	B-CHED
pollution	O
(	O
PM	O
(	O
10	O
))	O
and	O
the	O
mortality	O
and	O
morbidity	O
rates	O
from	O
respiratory	O
and	O
cardiovascular	O
diseases	O
is	O
well	O
established	O
,	O
but	O
the	O
biological	O
mechanisms	O
responsible	O
for	O
these	O
associations	O
are	O
still	O
unclear	O
.	O

The	O
injurious	O
effects	O
of	O
particulate	O
air	B-CHED
pollution	O
may	O
be	O
either	O
local	O
(	O
in	O
the	O
lung	O
)	O
or	O
systemic	O
.	O

We	O
conclude	O
that	O
exposure	O
to	O
ambient	O
particulate	O
matter	O
air	B-CHED
pollution	O
induces	O
a	O
systemic	O
inflammatory	O
response	O
that	O
includes	O
the	O
release	O
of	O
inflammatory	O
mediators	O
into	O
the	O
circulation	O
that	O
stimulate	O
the	O
bone	O
marrow	O
to	O
release	O
leukocytes	O
and	O
platelets	O
.	O

TITLE	O
:	O
Enhanced	O
green	O
fluorescent	O
protein	B-CHED
expression	O
may	O
be	O
used	O
to	O
monitor	O
murine	O
coronavirus	O
spread	O
in	O
vitro	O
and	O
in	O
the	O
mouse	O
central	O
nervous	O
system	O
.	O

These	O
viruses	O
expressed	O
the	O
EGFP	O
gene	O
from	O
an	O
mRNA	B-CHED
of	O
slightly	O
slower	O
electrophoretic	O
mobility	O
than	O
mRNA	B-CHED
4	O
.	O

ABSTRACT	O
:	O
The	O
cleavage	O
and	O
fusion	O
properties	O
of	O
recombinant	O
murine	O
hepatitis	O
viruses	O
(	O
MHV	O
)	O
were	O
examined	O
to	O
assess	O
the	O
role	O
of	O
the	O
cleavage	O
signal	O
in	O
determining	O
the	O
extent	O
of	O
S	O
protein	B-CHED
cleavage	O
,	O
and	O
the	O
correlation	O
between	O
cleavage	O
and	O
induction	O
of	O
cell	O
-	O
to	O
-	O
cell	O
fusion	O
.	O

The	O
study	O
showed	O
that	O
the	O
two	O
groups	O
were	O
of	O
similar	O
birth	O
weight	O
(	O
mean	O
+/-	O
SEM	B-CHED
):	O
control	O
901	O
+/-	O
73	O
g	O
vs	O
iNO	O
874	O
+/-	O
70	O
g	O
;	O
and	O
gestational	O
age	O
:	O
control	O
27	O
.	O
2	O
+/-	O
0	O
.	O
5	O
wk	O
vs	O
iNO	O
26	O
.	O
8	O
+/-	O
0	O
.	O
5	O
wk	O
.	O

ABSTRACT	O
:	O
Although	O
murine	O
coronavirus	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
enters	O
cells	O
by	O
virus	O
-	O
cell	O
membrane	O
fusion	O
triggered	O
by	O
its	O
spike	O
(	O
S	O
)	O
protein	B-CHED
,	O
it	O
is	O
not	O
well	O
known	O
how	O
the	O
S	O
protein	B-CHED
participates	O
in	O
fusion	O
events	O
.	O

This	O
is	O
the	O
first	O
report	O
on	O
receptor	O
-	O
induced	O
conformational	O
changes	O
of	O
the	O
membrane	O
-	O
anchored	O
fragment	O
of	O
the	O
coronavirus	O
S	O
protein	B-CHED
.	O

ABSTRACT	O
:	O
A	O
field	O
study	O
of	O
a	O
vaccine	O
;	O
prepared	O
by	O
solubilizing	O
cells	O
infected	O
with	O
bovine	O
coronavirus	O
,	O
Triton	B-CHED
X	I-CHED
-	I-CHED
100	I-CHED
,	O
and	O
mixing	O
with	O
an	O
oil	O
adjuvant	B-CHED
,	O
was	O
performed	O
at	O
9	O
farms	O
over	O
4	O
prefectures	O
.	O

Serum	O
and	O
various	O
tissues	O
were	O
collected	O
from	O
all	O
animals	O
and	O
assayed	O
for	O
PCV	B-CHED
,	O
porcine	O
reproductive	O
and	O
respiratory	O
syndrome	O
virus	O
(	O
PRRSV	O
),	O
porcine	O
parvovirus	O
,	O
porcine	O
enterovirus	O
types	O
1	O
-	O
3	O
,	O
swine	O
influenza	O
virus	O
,	O
porcine	O
respiratory	O
coronavirus	O
,	O
transmissible	O
gastroenteritis	O
virus	O
,	O
porcine	O
endogenous	O
retrovirus	O
,	O
porcine	O
lymphotropic	O
herpesvirus	O
type	O
1	O
,	O
and	O
bovine	O
viral	O
diarrhea	O
virus	O
.	O

TITLE	O
:	O
Severe	O
acute	O
pancreatitis	O
is	O
related	O
to	O
increased	O
early	O
urinary	O
levels	O
of	O
the	O
activation	O
Peptide	B-CHED
of	O
pancreatic	O
phospholipase	O
A	O
(	O
2	O
).	O

An	O
increase	O
in	O
the	O
amount	O
of	O
Fas	O
(	O
APO	B-CHED
-	O
1	O
/	O
CD95	O
),	O
caspase	O
-	O
8	O
activation	O
,	O
caspase	O
-	O
8	O
-	O
mediated	O
Bid	O
cleavage	O
,	O
and	O
subsequent	O
translocation	O
of	O
truncated	O
Bid	O
to	O
mitochondria	O
,	O
all	O
of	O
which	O
relate	O
to	O
the	O
Fas	O
-	O
mediated	O
pathway	O
,	O
also	O
occurred	O
in	O
MHV	O
-	O
infected	O
17Cl	B-CHED
-	O
1	O
cells	O
,	O
whereas	O
the	O
formation	O
of	O
the	O
death	O
-	O
inducing	O
signaling	O
complex	O
,	O
a	O
direct	O
indication	O
of	O
the	O
activation	O
of	O
Fas	O
-	O
mediated	O
pathway	O
,	O
was	O
undetectable	O
.	O

TITLE	O
:	O
Targeted	O
RNA	O
recombination	O
of	O
the	O
membrane	O
and	O
nucleocapsid	O
protein	B-CHED
genes	O
between	O
mouse	O
hepatitis	O
virus	O
and	O
bovine	O
coronavirus	O
.	O

Changes	O
in	O
PaO	B-CHED
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
ratio	O
during	O
supine	O
-	O
prone	O
and	O
prone	O
-	O
supine	O
positioning	O
were	O
evaluated	O
.	O

ABSTRACT	O
:	O
Pneumonia	O
in	O
childhood	O
may	O
be	O
associated	O
with	O
surfactant	B-CHED
dysfunction	O
and	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

Seven	O
of	O
the	O
8	O
patients	O
received	O
multiple	O
surfactant	B-CHED
doses	O
.	O

ABSTRACT	O
:	O
Following	O
the	O
introduction	O
of	O
surfactant	B-CHED
in	O
the	O
early	O
1990s	O
and	O
the	O
growing	O
use	O
of	O
antenatal	O
steroids	B-CHED
since	O
that	O
time	O
,	O
the	O
number	O
of	O
infants	O
,	O
term	O
and	O
preterm	O
,	O
suffering	O
severe	O
acute	O
respiratory	O
failure	O
has	O
declined	O
.	O

We	O
present	O
a	O
case	O
of	O
Gemcitabine	B-CHED
toxicity	O
in	O
a	O
patient	O
treated	O
for	O
a	O
lung	O
cancer	O
.	O

Adoptive	O
transfer	O
of	O
CCR5	O
(+/+)-	O
derived	O
CD4	O
(+)	O
T	O
cells	O
to	O
MHV	O
-	O
infected	O
RAG1	O
(-/-)	O
mice	O
resulted	O
in	O
CD4	O
(+)-	O
T	O
-	O
cell	O
entry	O
into	O
the	O
CNS	B-CHED
and	O
clearance	O
of	O
virus	O
from	O
the	O
brain	O
.	O

Collectively	O
these	O
results	O
demonstrate	O
that	O
CCR5	O
signaling	O
is	O
important	O
to	O
migration	O
of	O
CD4	O
(+)	O
T	O
cells	O
to	O
the	O
CNS	B-CHED
following	O
MHV	O
infection	O
.	O

Antigens	B-CHED
expressed	O
in	O
maize	O
(	O
Zea	O
mays	O
)	O
are	O
particularly	O
attractive	O
since	O
they	O
can	O
be	O
deposited	O
in	O
the	O
natural	O
storage	O
vessel	O
,	O
the	O
corn	O
seed	O
,	O
and	O
can	O
be	O
conveniently	O
delivered	O
to	O
any	O
organism	O
that	O
consumes	O
grain	O
.	O

The	O
truncated	O
form	O
of	O
PTB	O
was	O
localized	O
in	O
the	O
cytoplasm	O
,	O
whereas	O
the	O
full	O
-	O
length	O
PTB	O
was	O
present	O
mainly	O
in	O
the	O
nucleus	B-CHED
.	O

CD8	O
(+)	O
T	O
cells	O
inhibit	O
acute	O
viral	O
replication	O
via	O
cell	O
type	O
-	O
specific	O
effector	B-CHED
mechanisms	O
.	O

Confirmatory	O
diagnosis	O
of	O
NIB	O
was	O
made	O
by	O
IBV	O
antigen	B-CHED
-	O
specific	O
immunohistochemical	O
staining	O
of	O
the	O
renal	O
tubular	O
epithelium	O
and	O
virus	O
isolation	O
.	O

ABSTRACT	O
:	O
The	O
spike	O
glycoprotein	B-CHED
(	O
S	O
)	O
of	O
the	O
murine	O
coronavirus	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
binds	O
to	O
viral	O
murine	O
CEACAM	O
receptor	O
glycoproteins	B-CHED
and	O
causes	O
membrane	O
fusion	O
.	O

A	O
novel	O
120	O
-	O
kDa	O
subunit	O
was	O
formed	O
following	O
incubation	O
of	O
the	O
receptor	O
-	O
triggered	O
S	O
(	O
A59	O
)	O
H716D	O
virions	O
with	O
trypsin	O
at	O
4	O
degrees	O
C	O
.	O
The	O
data	O
show	O
that	O
unlike	O
class	O
1	O
fusion	O
glycoproteins	B-CHED
of	O
other	O
enveloped	O
viruses	O
,	O
the	O
murine	O
coronavirus	O
S	O
protein	B-CHED
can	O
be	O
triggered	O
to	O
a	O
membrane	O
-	O
binding	O
conformation	O
at	O
37	O
degrees	O
C	O
either	O
by	O
soluble	O
receptor	O
at	O
neutral	O
pH	O
or	O
by	O
alkaline	O
pH	O
alone	O
,	O
without	O
requiring	O
previous	O
activation	O
by	O
cleavage	O
between	O
S1	O
and	O
S2	O
.	O

The	O
putative	O
3CL	O
(	O
pro	B-CHED
)	O
domain	O
including	O
flanking	O
regions	O
(	O
pp1a	O
residues	O
2793	O
to	O
3143	O
)	O
was	O
fused	O
to	O
the	O
Escherichia	O
coli	O
maltose	B-CHED
-	O
binding	O
protein	B-CHED
(	O
MBP	O
)	O
and	O
,	O
when	O
expressed	O
in	O
E	O
.	O
coli	O
,	O
was	O
found	O
to	O
possess	O
N	O
-	O
terminal	O
autoprocessing	O
activity	O
that	O
was	O
not	O
dependent	O
on	O
the	O
presence	O
of	O
the	O
3CL	O
(	O
pro	B-CHED
)	O
C	O
-	O
terminal	O
domain	O
.	O

The	O
canine	O
samples	O
segregated	O
in	O
two	O
separate	O
clusters	B-CHED
.	O

In	O
a	O
10	O
-	O
month	O
period	O
eight	O
(	O
three	O
gestational	O
,	O
five	O
pre	O
-	O
gestational	O
)	O
women	O
received	O
antenatal	O
corticosteroids	B-CHED
from	O
a	O
total	O
of	O
37	O
diabetic	O
pregnancies	O
.	O

The	O
numbers	O
of	O
systemic	O
inflammatory	O
response	O
syndrome	O
(	O
SIRS	O
)	O
criteria	O
that	O
patients	O
met	B-CHED
were	O
determined	O
,	O
simultaneously	O
.	O

Inspiration	O
increased	O
alveolar	O
recruitment	O
at	O
all	O
PEEP	B-CHED
levels	O
.	O

TITLE	O
:	O
Genetic	O
diversity	O
of	O
avian	O
infectious	O
bronchitis	O
virus	O
California	O
variants	O
isolated	O
between	O
1988	O
and	O
2001	O
based	O
on	O
the	O
S1	O
subunit	O
of	O
the	O
spike	O
glycoprotein	B-CHED
.	O

A	O
high	O
number	O
of	O
mutations	O
at	O
the	O
nucleotide	B-CHED
level	O
(	O
p	O
=	O
0	O
.	O
013	O
)	O
and	O
a	O
>	O
or	O
=	O
6	O
bp	O
deletion	O
in	O
the	O
nucleotide	B-CHED
sequence	O
(	O
p	O
=	O
0	O
.	O
006	O
)	O
was	O
significantly	O
associated	O
with	O
broiler	O
-	O
type	O
chickens	O
.	O

The	O
controls	O
received	O
daily	O
injections	O
of	O
the	O
ZnCl	O
(	O
2	O
)-	O
containing	O
carboxymethyl	B-CHED
-	O
cellulose	B-CHED
(	O
CMC	O
)	O
diluent	O
.	O

CBA	B-CHED
/	O
J	O
mice	O
infected	O
with	O
1	O
x	O
10	O
(	O
6	O
)	O
plaque	O
-	O
forming	O
units	O
(	O
pfu	B-CHED
)	O
reovirus	O
1	O
/	O
L	O
develop	O
follicular	O
bronchiolitis	O
and	O
intra	O
-	O
alveolar	O
fibrosis	O
similar	O
to	O
BOOP	O
.	O

TITLE	O
:	O
Prognostic	O
value	O
of	O
surfactant	B-CHED
proteins	B-CHED
A	O
and	O
D	O
in	O
patients	O
with	O
acute	O
lung	O
injury	O
.	O

A	O
truncated	O
protein	B-CHED
(	O
S	O
(	O
547	O
))	O
that	O
contains	O
the	O
N	O
-	O
terminal	O
547	O
amino	B-CHED
acids	I-CHED
bound	O
to	O
3T3	O
mouse	O
cells	O
that	O
express	O
hAPN	O
but	O
not	O
to	O
mouse	O
3T3	O
cells	O
transfected	O
with	O
empty	O
vector	O
.	O

The	O
rate	O
of	O
conformity	O
between	O
multiplex	O
RT	O
-	O
nPCR	O
and	O
in	O
situ	O
hybridization	O
was	O
100	O
%	O
for	O
the	O
detection	O
of	O
PEDV	O
and	O
TGEV	O
in	O
formalin	B-CHED
-	O
fixed	O
paraffin	O
-	O
embedded	O
jejunal	O
tissues	O
.	O

Levels	O
of	O
surfactant	B-CHED
apoprotein	B-CHED
A	O
(	O
SP	O
-	O
A	O
)	O
fall	O
50	O
-	O
75	O
%	O
in	O
patients	O
with	O
severe	O
lung	O
injury	O
compared	O
to	O
normal	O
patients	O
.	O

Primary	O
endpoint	O
PaO	B-CHED
(	O
2	O
)/	O
FIO	O
(	O
2	O
)	O
at	O
48	O
h	O
,	O
secondary	O
endpoints	O
:	O
PaO	B-CHED
(	O
2	O
)/	O
FIO	O
(	O
2	O
)	O
at	O
2	O
,	O
4	O
,	O
12	O
,	O
and	O
24	O
h	O
,	O
survival	O
,	O
survival	O
without	O
rescue	O
,	O
days	O
on	O
ventilator	O
,	O
subgroups	O
analyzed	O
by	O
analysis	O
of	O
variance	O
to	O
identify	O
patients	O
who	O
might	O
benefit	O
from	O
surfactant	B-CHED
.	O

In	O
the	O
pilot	O
study	O
the	O
PaO	B-CHED
(	O
2	O
)/	O
FIO	O
(	O
2	O
)	O
increased	O
by	O
a	O
mean	O
of	O
100	O
at	O
48	O
h	O
(	O
n	O
=	O
19	O
).	O

A	O
significant	O
difference	O
in	O
PaO	B-CHED
(	O
2	O
)/	O
FIO	O
(	O
2	O
)	O
in	O
favor	O
of	O
surfactant	B-CHED
at	O
48	O
h	O
was	O
found	O
in	O
the	O
subgroup	O
with	O
an	O
initial	O
PaO	B-CHED
(	O
2	O
)/	O
FIO	O
(	O
2	O
)	O
ratio	O
higher	O
than	O
65	O
and	O
in	O
patients	O
without	O
pneumonia	O
.	O

ABSTRACT	O
:	O
To	O
assess	O
the	O
impact	O
of	O
bronchoscopically	O
guided	O
percutaneous	O
dilational	O
tracheostomy	O
(	O
PDT	B-CHED
)	O
on	O
oxygenation	O
in	O
patients	O
with	O
severe	O
respiratory	O
failure	O
ventilated	O
with	O
high	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	B-CHED
).	O

Arterial	O
blood	O
gas	O
tensions	O
were	O
measured	O
immediately	O
before	O
and	O
1	O
and	O
24	O
h	O
after	O
PDT	B-CHED
.	O

Bronchoscopically	O
guided	O
PDT	B-CHED
in	O
our	O
patients	O
on	O
high	O
PEEP	B-CHED
did	O
not	O
jeopardise	O
oxygenation	O
1	O
h	O
and	O
24	O
h	O
following	O
PDT	B-CHED
.	O

Molecular	O
modeling	O
studies	O
led	O
to	O
the	O
synthesis	O
of	O
O	O
-(	O
2	O
-	O
phthalimidoethyl	O
)-	O
N	O
-(	O
p	O
-	O
substituted	O
phenyl	B-CHED
)-	O
N	O
-	O
acylthiocarbamates	O
,	O
which	O
showed	O
in	O
vitro	O
activities	O
against	O
HIV	O
-	O
1	O
in	O
the	O
low	O
nanomolar	O
range	O
.	O

TITLE	O
:	O
Induction	O
of	O
prothrombinase	O
fgl2	O
by	O
the	O
nucleocapsid	O
protein	B-CHED
of	O
virulent	O
mouse	O
hepatitis	O
virus	O
is	O
dependent	O
on	O
host	O
hepatic	O
nuclear	O
factor	O
-	O
4	O
alpha	O
.	O

In	O
uninfected	O
macrophages	O
and	O
macrophages	O
infected	O
with	O
MHV	O
-	O
2	O
,	O
an	O
unidentified	O
protein	B-CHED
occupies	O
the	O
HNF4	O
cis	O
-	O
element	O
.	O

Endothelial	O
cells	O
form	O
a	O
major	O
capillary	O
barrier	O
,	O
and	O
disruption	O
of	O
the	O
barrier	O
appears	O
to	O
involve	O
a	O
decreased	O
level	O
of	O
ATP	B-CHED
in	O
the	O
cells	O
.	O

We	O
examined	O
the	O
effect	O
of	O
PEP	B-CHED
on	O
oleic	B-CHED
acid	I-CHED
-	O
induced	O
lung	O
injury	O
in	O
guinea	O
pigs	O
.	O

We	O
suggest	O
that	O
PEP	B-CHED
is	O
a	O
promising	O
candidate	O
to	O
prevent	O
hypoxemia	O
in	O
acute	O
lung	O
injuries	O
associated	O
with	O
increased	O
vascular	O
permeability	O
,	O
such	O
as	O
ARDS	O
.	O

Patient	O
plasma	O
inhibited	O
LPS	B-CHED
-	O
induced	O
stimulation	O
of	O
a	O
monocyte	O
cell	O
line	O
,	O
and	O
this	O
inhibition	O
was	O
accentuated	O
by	O
complicated	O
disease	O
.	O

The	O
acute	O
phase	O
response	O
in	O
chickens	O
challenged	O
after	O
12	O
h	O
of	O
activity	O
peaked	O
after	O
4	O
.	O
6	O
d	O
with	O
an	O
increase	O
of	O
24	O
%,	O
whereas	O
the	O
acute	O
phase	O
response	O
in	O
chickens	O
challenged	O
after	O
12	O
h	O
of	O
rest	B-CHED
peaked	O
after	O
3	O
.	O
1	O
d	O
with	O
an	O
increase	O
of	O
51	O
%.	O

To	O
separately	O
evaluate	O
each	O
effector	B-CHED
function	O
specifically	O
in	O
the	O
context	O
of	O
CD8	O
(+)	O
T	O
cells	O
,	O
pathogenesis	O
was	O
analyzed	O
in	O
mice	O
deficient	O
in	O
both	O
perforin	O
and	O
IFN	O
-	O
gamma	O
(	O
PKO	O
/	O
GKO	O
)	O
or	O
selectively	O
reconstituted	O
for	O
each	O
function	O
by	O
transfer	O
of	O
CD8	O
(+)	O
T	O
cells	O
.	O

The	O
data	O
further	O
imply	O
that	O
IFN	O
-	O
gamma	O
plays	O
a	O
crucial	O
role	O
in	O
pathogenesis	O
by	O
regulating	O
the	O
balance	B-CHED
between	O
virus	O
replication	O
in	O
oligodendrocytes	O
,	O
CD8	O
(+)	O
T	O
cell	O
effector	B-CHED
function	O
,	O
and	O
demyelination	O
.	O

These	O
data	O
suggest	O
that	O
infiltrating	O
neutrophils	O
are	O
crucial	O
for	O
limiting	O
virus	O
replication	O
during	O
acute	O
JHMV	O
infection	O
,	O
contribute	O
to	O
the	O
loss	O
of	O
blood	O
brain	O
barrier	O
integrity	O
and	O
play	O
a	O
role	O
in	O
shaping	O
adaptive	O
immunity	O
within	O
the	O
CNS	B-CHED
.	O

ABSTRACT	O
:	O
Recently	O
open	O
lung	O
approach	O
such	O
as	O
recruitment	O
maneuver	O
and	O
high	O
PEEP	B-CHED
has	O
been	O
applied	O
in	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

We	O
conclude	O
that	O
recruitment	O
maneuver	O
and	O
high	O
PEEP	B-CHED
may	O
be	O
useful	O
for	O
RPE	O
developed	O
after	O
PTE	O
.	O

Interestingly	O
,	O
a	O
specific	O
lactogenic	O
immune	O
response	O
against	O
the	O
heterologous	O
protein	B-CHED
has	O
been	O
elicited	O
in	O
sows	O
and	O
their	O
progeny	O
.	O

ABSTRACT	O
:	O
It	O
has	O
been	O
suspected	O
that	O
embryos	O
stored	O
in	O
liquid	O
nitrogen	B-CHED
tanks	O
may	O
become	O
contaminated	O
with	O
murine	O
pathogens	O
,	O
if	O
some	O
pathogens	O
had	O
been	O
introduced	O
to	O
the	O
tanks	O
accidentally	O
.	O

The	O
values	O
of	O
PaO	B-CHED
(	O
2	O
),	O
PaCO	O
(	O
2	O
),	O
pH	O
,	O
actual	O
bicarbonate	B-CHED
(	O
AB	O
),	O
base	O
excess	O
(	O
BE	O
),	O
tidal	O
volume	O
,	O
and	O
respiration	O
rate	O
in	O
groups	O
A	O
and	O
R	O
were	O
significantly	O
different	O
from	O
those	O
in	O
group	O
D	O
(	O
P	O
<	O
0	O
.	O
01	O
),	O
and	O
in	O
groups	O
A	O
and	O
R	O
,	O
the	O
above	O
measurements	O
at	O
every	O
stage	O
after	O
seawater	O
perfusion	O
were	O
significantly	O
different	O
from	O
those	O
before	O
perfusion	O
(	O
P	O
<	O
0	O
.	O
01	O
).	O

TITLE	O
:	O
The	O
inducible	O
nitric	B-CHED
oxide	I-CHED
synthase	I-CHED
inhibitor	I-CHED
BBS	O
-	O
2	O
prevents	O
acute	O
lung	O
injury	O
in	O
sheep	O
after	O
burn	O
and	O
smoke	O
inhalation	O
injury	O
.	O

ABSTRACT	O
:	O
In	O
this	O
study	O
we	O
examined	O
the	O
role	O
of	O
inducible	O
nitric	B-CHED
oxide	I-CHED
synthase	O
(	O
iNOS	O
)	O
in	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
in	O
sheep	O
with	O
severe	O
combined	O
burn	O
and	O
smoke	O
inhalation	O
injury	O
.	O

In	O
this	O
two	O
-	O
step	O
process	O
,	O
we	O
first	O
constructed	O
by	O
targeted	O
recombination	O
a	O
mutant	O
of	O
FIPV	O
,	O
designated	O
mFIPV	O
,	O
in	O
which	O
the	O
ectodomain	O
of	O
the	O
spike	O
glycoprotein	B-CHED
was	O
replaced	O
by	O
that	O
of	O
MHV	O
.	O

Empirical	O
therapy	O
most	O
commonly	O
included	O
antibiotics	B-CHED
,	O
oseltamivir	B-CHED
,	O
and	O
intravenous	O
ribavirin	B-CHED
.	O

Lymphopenia	O
was	O
observed	O
in	O
nine	O
patients	O
,	O
and	O
most	O
patients	O
had	O
mildly	O
elevated	O
aminotransferase	O
levels	O
but	O
normal	O
serum	O
creatinine	B-CHED
levels	O
.	O

Serial	O
chest	O
radiographs	O
showed	O
progressive	O
air	B-CHED
-	O
space	O
disease	O
.	O

All	O
patients	O
received	O
corticosteroid	B-CHED
and	O
ribavirin	B-CHED
therapy	O
a	O
mean	O
(+/-	O
SD	O
)	O
of	O
9	O
.	O
6	O
+/-	O
5	O
.	O
42	O
days	O
after	O
the	O
onset	O
of	O
symptoms	O
,	O
and	O
eight	O
were	O
treated	O
earlier	O
with	O
a	O
combination	O
of	O
beta	B-CHED
-	I-CHED
lactams	I-CHED
and	O
macrolide	B-CHED
for	O
4	O
+/-	O
1	O
.	O
9	O
days	O
,	O
with	O
no	O
clinical	O
or	O
radiologic	O
efficacy	O
.	O

Peripheral	O
air	B-CHED
-	O
space	O
consolidation	O
was	O
commonly	O
observed	O
on	O
thoracic	O
computed	O
tomographic	O
scanning	O
.	O

Coagulation	O
and	O
fibrinolytic	O
proteins	B-CHED
may	O
have	O
an	O
additional	O
role	O
beyond	O
fibrin	O
turnover	O
and	O
inflammation	O
,	O
e	O
.	O
g	O
.,	O
in	O
mechanisms	O
mediating	O
cell	O
recruitment	O
and	O
migration	O
.	O

Replacement	O
glucocorticoid	B-CHED
/	O
mineralocorticoid	B-CHED
therapy	O
over	O
7	O
days	O
appears	O
to	O
be	O
beneficial	O
in	O
such	O
individuals	O
.	O

The	O
National	O
Heart	O
,	O
Lung	O
,	O
and	O
Blood	O
Institute	O
'	O
s	O
ARDS	O
Network	O
currently	O
is	O
testing	O
the	O
use	O
of	O
methylprednisolone	B-CHED
in	O
late	O
ARDS	O
.	O

Genetic	O
characterization	O
indicated	O
that	O
the	O
virus	O
is	O
only	O
distantly	O
related	O
to	O
known	O
coronaviruses	O
(	O
identical	O
in	O
50	O
to	O
60	O
percent	O
of	O
the	O
nucleotide	B-CHED
sequence	O
).	O

However	O
,	O
a	O
novel	O
coronavirus	O
was	O
isolated	O
from	O
patients	O
who	O
met	B-CHED
the	O
case	O
definition	O
of	O
SARS	O
.	O

Leukemic	O
blasts	O
with	O
positive	O
peroxidase	O
stain	O
,	O
but	O
negative	O
periodic	B-CHED
acid	I-CHED
-	O
Schiff	O
stain	O
comprised	O
91	O
.	O
6	O
%	O
on	O
bone	O
marrow	O
specimen	O
.	O

Three	O
patients	O
had	O
travelled	O
to	O
China	O
,	O
including	O
Hong	O
Kong	O
SAR	B-CHED
.	O

The	O
purified	O
recombinant	O
protein	B-CHED
was	O
then	O
evaluated	O
for	O
its	O
antigenicity	O
and	O
reliability	O
in	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
for	O
detection	O
of	O
CCoV	O
antibodies	O
in	O
dog	O
sera	O
.	O

Recently	O
,	O
biologically	O
active	O
lipids	B-CHED
have	O
been	O
also	O
suggested	O
to	O
cause	O
the	O
disorder	O
.	O

The	O
Result	O
of	O
Blast	O
shows	O
only	O
the	O
difference	O
in	O
one	O
nucleic	B-CHED
acid	I-CHED
from	O
the	O
TOR2	O
strain	O
of	O
SARS	O
-	O
associated	O
coronavirus	O
.	O

Nucleotide	B-CHED
-	O
sequence	O
and	O
amino	B-CHED
acid	I-CHED
-	O
sequence	O
alignment	O
of	O
the	O
fragment	O
BNI109	O
with	O
other	O
six	O
known	O
coronavirus	O
show	O
that	O
the	O
fragment	O
BNI109	O
is	O
more	O
close	O
to	O
bovine	O
coronavirus	O
(	O
BCV	O
)	O
and	O
murine	O
hepatitis	O
virus	O
(	O
MHV	O
).	O

Predominant	O
peripheral	O
location	O
;	O
common	O
progression	O
pattern	O
from	O
unilateral	O
focal	O
air	B-CHED
-	O
space	O
opacity	O
to	O
unilateral	O
multifocal	O
or	O
bilateral	O
involvement	O
during	O
treatment	O
;	O
and	O
lack	O
of	O
cavitation	O
,	O
lymphadenopathy	O
,	O
and	O
pleural	O
effusion	O
are	O
the	O
more	O
distinctive	O
radiographic	O
findings	O
of	O
SARS	O
.	O

RESULTS	O
:	O
Initial	O
chest	O
radiographs	O
were	O
abnormal	O
in	O
108	O
of	O
138	O
(	O
78	O
.	O
3	O
%)	O
patients	O
and	O
showed	O
air	B-CHED
-	O
space	O
opacity	O
.	O

Here	O
we	O
describe	O
evidence	O
supporting	O
the	O
structure	O
and	O
a	O
cis	O
-	O
acting	O
function	O
in	O
defective	O
interfering	O
(	O
DI	O
)	O
RNA	O
replication	O
of	O
stem	O
-	O
loop	O
III	O
,	O
the	O
third	O
of	O
four	O
predicted	O
higher	O
-	O
order	O
structures	O
mapping	O
within	O
the	O
210	O
-	O
nucleotide	B-CHED
(	O
nt	O
)	O
5	O
'	O
UTR	O
of	O
the	O
32	O
-	O
kb	O
bovine	O
coronavirus	O
(	O
BCoV	O
)	O
genome	O
.	O

Lung	O
static	O
compliance	O
on	O
day	O
15	O
was	O
severely	O
decreased	O
with	O
bleomycin	B-CHED
alone	O
and	O
showed	O
a	O
further	O
significant	O
decrease	O
when	O
granulocyte	O
colony	O
-	O
stimulating	O
factor	O
was	O
added	O
(	O
controls	O
,	O
3	O
.	O
85	O
+/-	O

0	O
.	O
06	O
mL	O
/	O
kPa	O
;	O
and	O
bleomycin	B-CHED
+	O
granulocyte	O
colony	O
-	O
stimulating	O
factor	O
,	O
0	O
.	O
65	O
+/-	O

The	O
volume	O
of	O
fluids	O
required	O
was	O
significantly	O
smaller	O
in	O
the	O
albumin	O
-	O
treated	O
groups	O
than	O
in	O
the	O
Ringer	O
'	O
s	O
lactate	B-CHED
groups	O
.	O

A	O
second	O
viral	O
protein	B-CHED
corresponding	O
to	O
the	O
predicted	O
approximately	O
139	O
-	O
kDa	O
spike	O
glycoprotein	B-CHED
has	O
also	O
been	O
examined	O
by	O
MALDI	O
-	O
TOF	O
MS	O
(	O
42	O
%	O
coverage	O
).	O

In	O
addition	O
,	O
a	O
common	O
variant	O
associated	O
with	O
a	O
non	O
-	O
conservative	O
aminoacid	O
change	O
in	O
the	O
S1	O
region	O
of	O
the	O
spike	O
protein	B-CHED
,	O
suggests	O
that	O
immunological	O
pressures	O
might	O
be	O
starting	O
to	O
influence	O
the	O
evolution	O
of	O
the	O
SARS	O
virus	O
in	O
human	O
populations	O
.	O

In	O
a	O
patient	O
with	O
severe	O
ARDS	O
,	O
oxygenation	O
failure	O
under	O
maximized	O
ventilatory	O
settings	O
,	O
and	O
subsequent	O
five	O
-	O
organ	O
system	O
failure	O
,	O
an	O
integrated	O
therapeutical	O
approach	O
comprising	O
ECMO	O
,	O
NO	O
,	O
kinetic	O
therapy	O
,	O
surfactant	B-CHED
,	O
and	O
urodilatin	O
did	O
cross	O
-	O
bridge	O
respiratory	O
and	O
vital	O
functions	O
,	O
enabling	O
overall	O
survival	O
.	O

Nutrient	B-CHED
provision	O
was	O
adjusted	O
daily	O
to	O
account	O
for	O
organ	O
and	O
metabolic	O
changes	O
including	O
hepatic	O
,	O
pulmonary	O
,	O
and	O
renal	O
dysfunction	O
.	O

The	O
binding	O
for	O
one	O
protein	B-CHED
-	O
protein	B-CHED
interaction	O
pair	O
(	O
D757	O
-	O
R761	O
motif	O
of	O
the	O
SARS	O
-	O
CoV	O
S	O
protein	B-CHED
to	O
P585	O
-	O
A653	O
domain	O
of	O
CD13	O
)	O
has	O
been	O
simulated	O
by	O
molecular	O
modeling	O
and	O
docking	O
simulation	O
methods	O
.	O

TITLE	O
:	O
A	O
3D	O
model	O
of	O
SARS_CoV	O
3CL	O
proteinase	O
and	O
its	O
inhibitors	B-CHED
design	O
by	O
virtual	O
screening	O
.	O

Bioinformatics	O
analyses	O
were	O
performed	O
to	O
search	O
the	O
homologous	O
proteins	B-CHED
of	O
the	O
SARS	O
-	O
CoV	O
3CL	O
proteinase	O
from	O
the	O
GenBank	O
and	O
PDB	O
database	O
.	O

The	O
secondary	O
structure	O
feature	O
of	O
the	O
protein	B-CHED
was	O
determined	O
by	O
circular	O
dichroism	O
(	O
CD	O
)	O
technique	O
.	O

The	O
possible	O
functions	O
of	O
this	O
protein	B-CHED
were	O
annotated	O
by	O
bioinformatics	O
methods	O
,	O
and	O
its	O
possible	O
three	O
-	O
dimensional	O
model	O
was	O
constructed	O
by	O
molecular	O
modeling	O
.	O

There	O
are	O
many	O
hypotheses	O
to	O
explain	O
this	O
paradox	O
;	O
1	O
)	O
Is	O
it	O
the	O
hygiene	O
theory	O
,	O
namely	O
extensive	O
use	O
of	O
wide	O
spread	O
and	O
too	O
potent	O
antibiotics	B-CHED
which	O
eliminate	O
protective	O
infecting	O
agent	O
?	O

Also	O
,	O
sequences	O
of	O
the	O
nucleotides	B-CHED
and	O
deduced	O
amino	B-CHED
acids	I-CHED
of	O
the	O
Chinju99	O
N	O
gene	O
were	O
analyzed	O
by	O
alignment	O
with	O
those	O
of	O
CV777	O
and	O
Brl	O
/	O
87	O
.	O

Finally	O
,	O
to	O
unequivocally	O
identify	O
this	O
cleavage	O
site	O
,	O
we	O
isolated	O
radiolabeled	O
MP1	O
protein	B-CHED
and	O
determined	O
the	O
position	O
of	O
[(	O
35	O
)	O
S	O
]	O
methionine	B-CHED
residues	O
released	O
by	O
Edman	O
degradation	O
reaction	O
.	O

TITLE	O
:	O
mRNA	B-CHED
cap	O
-	O
1	O
methyltransferase	O
in	O
the	O
SARS	O
genome	O
.	O

These	O
case	O
results	O
suggest	O
that	O
more	O
extensive	O
clinical	O
studies	O
are	O
warranted	O
for	O
combined	O
-	O
modality	O
therapy	O
with	O
INO	O
and	O
exogenous	O
surfactant	B-CHED
in	O
patients	O
with	O
the	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

TITLE	O
:	O
Partial	O
sequence	O
of	O
the	O
spike	O
glycoprotein	B-CHED
gene	O
of	O
transmissible	O
gastroenteritis	O
viruses	O
isolated	O
in	O
Korea	O
.	O

The	O
amino	O
terminal	O
half	O
of	O
the	O
S	O
glycoprotein	B-CHED
gene	O
including	O
antigenic	O
sites	O
A	O
,	O
B	O
,	O
C	O
and	O
D	O
,	O
were	O
amplified	O
by	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
).	O

The	O
haemoglobin	B-CHED
count	O
dropped	O
by	O
more	O
than	O
20	O
g	O
/	O
l	O
from	O
baseline	O
in	O
95	O
(	O
61	O
%)	O
patients	O
.	O

In	O
hospitalized	O
SARS	O
patients	O
,	O
the	O
abnormalities	O
tend	O
to	O
progress	O
to	O
bilateral	O
air	B-CHED
-	O
space	O
consolidation	O
.	O

While	O
there	O
are	O
some	O
controversies	O
about	O
the	O
use	O
of	O
systemic	O
corticosteroids	B-CHED
,	O
Martin	O
et	O
al	O
,	O
in	O
this	O
issue	O
of	O
MSM	O
,	O
present	O
their	O
views	O
on	O
the	O
use	O
of	O
pentoxyfylline	O
(	O
PTX	O
)	O
as	O
a	O
potential	O
agent	O
to	O
be	O
considered	O
for	O
SARS	O
treatment	O
.	O

ABSTRACT	O
:	O
Chemical	O
modification	O
of	O
the	O
proteins	B-CHED
bovine	O
serum	O
albumin	O
,	O
alpha	O
-	O
lactalbumin	O
,	O
beta	O
-	O
lactoglobulin	O
and	O
chicken	O
lysozyme	O
by	O
3	O
-	O
hydroxyphthalic	O
anhydride	O
(	O
3	O
-	O
HP	O
)	O
yielded	O
compounds	O
which	O
exerted	O
antiviral	B-CHED
activity	O
in	O
vitro	O
as	O
compared	O
with	O
the	O
native	O
unmodified	O
proteins	B-CHED
.	O

However	O
,	O
to	O
achieve	O
HSV	O
-	O
1	O
inhibition	O
,	O
significantly	O
higher	O
concentrations	O
of	O
the	O
modified	O
proteins	B-CHED
were	O
required	O
if	O
present	O
before	O
infection	O
as	O
compared	O
to	O
during	O
or	O
after	O
infection	O
.	O

Proteolytical	O
digestion	O
of	O
albumin	O
,	O
alpha	O
-	O
lactalbumin	O
,	O
beta	O
-	O
lactoglobulin	O
and	O
lysozyme	O
by	O
trypsin	O
,	O
chymotrypsin	O
and	O
pepsin	O
yielded	O
several	O
peptide	B-CHED
fragments	O
with	O
antiherpetic	O
activity	O
.	O

Comprehensive	O
measures	O
most	O
commonly	O
included	O
corticosteroids	B-CHED
,	O
antibiotics	B-CHED
,	O
antivirotics	O
,	O
nutritional	O
support	O
and	O
mechanical	O
ventilation	O
.	O

The	O
scores	O
of	O
the	O
acute	O
physiology	O
score	O
(	O
APS	B-CHED
)	O
and	O
year	O
score	O
(	O
YS	O
)	O
in	O
the	O
death	O
group	O
were	O
higher	O
obviously	O
than	O
those	O
of	O
the	O
surviving	O
group	O
(	O
both	O
P	O
<	O
0	O
.	O
01	O
).	O

PEDV	O
nucleic	B-CHED
acid	I-CHED
and	O
antigen	B-CHED
were	O
detected	O
in	O
the	O
duodenum	O
,	O
jejunum	O
and	O
ileum	O
of	O
experimentally	O
infected	O
pigs	O
.	O

TITLE	O
:	O
Identification	O
of	O
an	O
epitope	B-CHED
of	O
SARS	O
-	O
coronavirus	O
nucleocapsid	O
protein	B-CHED
.	O

ABSTRACT	O
:	O
To	O
assess	O
serum	O
antibody	O
responses	O
of	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
to	O
nucleocapsid	O
(	O
N	O
)	O
antigen	B-CHED
of	O
SARS	O
-	O
associated	O
coronavirus	O
.	O

CONCLUSIONS	O
:	O
The	O
antibody	O
responses	O
suggest	O
that	O
N	O
protein	B-CHED
of	O
SARS	O
is	O
immunodominant	O
and	O
plays	O
an	O
important	O
role	O
in	O
viral	O
pathogenesis	O
.	O

RESULTS	O
:	O
Four	O
strains	O
of	O
hybridomas	O
were	O
obtained	O
that	O
produced	O
the	O
mAb	O
specific	O
to	O
the	O
N	O
protein	B-CHED
without	O
detectable	O
cross	O
-	O
reactivity	O
with	O
other	O
pathogens	O
.	O

Lower	O
Acute	O
Physiology	O
and	O
Chronic	O
Health	O
Evaluation	O
II	O
scores	O
and	O
higher	O
baseline	O
ratios	O
of	O
PaO2	O
to	O
fraction	O
of	O
inspired	O
oxygen	B-CHED
were	O
associated	O
with	O
earlier	O
recovery	O
.	O

The	O
best	O
response	O
(	O
no	O
deaths	O
)	O
was	O
seen	O
in	O
the	O
group	O
of	O
60	O
patients	O
receiving	O
early	O
high	O
-	O
dose	O
steroids	B-CHED
and	O
nasal	O
CPAP	O
(	O
continuous	O
airway	O
positive	O
pressure	O
)	O
ventilation	O
;	O
the	O
other	O
three	O
treatment	O
groups	O
had	O
significant	O
mortality	O
.	O

The	O
overall	O
nucleotides	B-CHED
conservation	O
of	O
the	O
homologous	O
ORFs	O
is	O
low	O
(<	O
5	O
%)	O
compared	O
with	O
other	O
known	O
CoVs	O
,	O
implying	O
that	O
HK	O
-	O
39	O
is	O
a	O
newly	O
emergent	O
SARS	O
-	O
CoV	O
phylogenetically	O
distant	O
from	O
other	O
known	O
members	O
.	O

Vancomycin	B-CHED
was	O
used	O
in	O
13	O
.	O
5	O
%	O
of	O
the	O
patients	O
.	O

TITLE	O
:	O
Acute	O
lung	O
injury	O
as	O
a	O
possible	O
adverse	O
drug	O
reaction	O
related	O
to	O
gefitinib	B-CHED
.	O

Long	O
-	O
acting	O
penicillin	B-CHED
regimen	O
given	O
for	O
3	O
-	O
5	O
years	O
for	O
the	O
prevention	O
of	O
rheumatic	O
fever	O
relapse	O
is	O
advocated	O
.	O

Electronic	O
microscopy	O
demonstrated	O
clusters	B-CHED
of	O
virus	O
particles	O
seen	O
in	O
the	O
lung	O
tissue	O
.	O

A	O
mixture	B-CHED
features	O
of	O
serous	O
,	O
fibrinous	O
and	O
hemorrhagic	O
inflammation	O
were	O
seen	O
in	O
most	O
pulmonary	O
alveoli	O
with	O
engorgement	O
of	O
capillary	O
and	O
there	O
were	O
microthrombosis	O
in	O
some	O
capillary	O
.	O

Isolated	O
retinas	O
were	O
analyzed	O
for	O
IFN	O
-	O
gamma	O
mRNA	B-CHED
by	O
RT	O
-	O
PCR	O
,	O
and	O
sera	O
were	O
evaluated	O
for	O
IFN	O
-	O
gamma	O
protein	B-CHED
by	O
ELISA	O
assays	O
.	O

Retinal	B-CHED
IFN	O
-	O
gamma	O
mRNA	B-CHED
was	O
also	O
associated	O
with	O
the	O
upregulation	O
of	O
MHC	O
class	O
I	O
and	O
II	O
molecules	O
within	O
the	O
retina	O
.	O

Both	O
biochemical	O
and	O
functional	O
data	O
show	O
that	O
the	O
coronavirus	O
spike	O
protein	B-CHED
is	O
a	O
class	O
I	O
viral	O
fusion	O
protein	B-CHED
.	O

Mice	O
and	O
chickens	O
vaccinated	O
with	O
the	O
expressed	O
IBV	O
S1	O
glycoprotein	B-CHED
produced	O
antibodies	O
that	O
neutralized	O
IBV	O
infectivity	O
.	O

Confocus	O
microscope	O
immunofluorescence	O
clearly	O
showed	O
that	O
N	O
protein	B-CHED
of	O
MHV	O
entered	O
into	O
the	O
nucleus	B-CHED
of	O
infected	O
cells	O
.	O

Outbreaks	O
of	O
multi	O
-	O
drug	O
resistant	O
(	O
MDR	B-CHED
)	O
tuberculosis	O
and	O
the	O
atypical	O
mycobacteria	O
simulate	O
SARS	O
on	O
clinical	O
,	O
radiologic	O
,	O
epidemiologic	O
,	O
and	O
diagnostic	O
laboratory	O
grounds	O
and	O
it	O
is	O
only	O
logical	O
then	O
to	O
include	O
them	O
in	O
the	O
differential	O
to	O
find	O
a	O
definitive	O
cause	O
and	O
cure	O
for	O
SARS	O
.	O

Transplant	O
immunosuppression	O
consisted	O
of	O
basiliximab	O
induction	O
,	O
corticosteroids	B-CHED
,	O
and	O
tacrolimus	B-CHED
.	O

There	O
was	O
no	O
difference	O
in	O
positive	O
end	O
-	O
expiratory	O
pressure	O
,	O
mean	O
airway	O
pressure	O
,	O
or	O
F	O
(	O
IO	O
)(	O
2	O
),	O
before	O
and	O
after	O
aerosolized	O
PGI	B-CHED
(	O
2	O
)	O
(	O
p	O
>	O
0	O
.	O
05	O
).	O

The	O
changes	O
mainly	O
existed	O
in	O
the	O
mild	O
to	O
moderate	O
elevation	O
of	O
alanine	B-CHED
aminotransferase	O
and	O
aspartate	B-CHED
aminotransferase	O
.	O

Rapidly	O
changing	O
consolidations	O
revealed	O
in	O
chest	O
X	O
-	O
ray	O
images	O
were	O
found	O
to	O
be	O
associated	O
with	O
SARS	O
infections	O
,	O
and	O
they	O
were	O
not	O
affected	O
by	O
treatment	O
with	O
antibiotics	B-CHED
.	O

TITLE	O
:	O
The	O
cytoplasmic	O
tails	O
of	O
infectious	O
bronchitis	O
virus	O
E	O
and	O
M	O
proteins	B-CHED
mediate	O
their	O
interaction	O
.	O

We	O
also	O
examined	O
the	O
ability	O
of	O
the	O
mutant	O
and	O
chimeric	O
E	O
and	O
M	O
proteins	B-CHED
to	O
form	O
VLPs	O
.	O

We	O
assessed	O
the	O
antiviral	B-CHED
potential	O
of	O
recombinant	O
interferons	O
against	O
two	O
clinical	O
isolates	O
of	O
SARS	O
-	O
CoV	O
--	O
FFM	O
-	O
1	O
,	O
from	O
Frankfurt	O
patients	O
,	O
and	O
Hong	O
Kong	O
--	O
replicated	O
in	O
Vero	O
and	O
Caco2	O
cells	O
.	O

Other	O
rare	O
abnormalities	O
included	O
liver	O
injury	O
(	O
elevated	O
alanine	B-CHED
aminotransferase	O
in	O
7	O
.	O
6	O
%)	O
and	O
thrombocytopenia	O
(	O
3	O
.	O
8	O
%).	O

Effective	O
treatment	O
includes	O
various	O
regimens	O
,	O
oxygen	B-CHED
support	O
and	O
small	O
doses	O
of	O
steroids	B-CHED
.	O

Three	O
severe	O
patients	O
had	O
secondary	O
infection	O
after	O
administration	O
of	O
a	O
large	O
dose	O
of	O
glucocorticoid	B-CHED
.	O

Indications	O
for	O
use	O
of	O
glucocorticoid	B-CHED
must	O
strictly	O
controlled	O
and	O
its	O
large	O
dosage	O
is	O
improper	O
.	O

Continual	O
positive	O
airway	O
pressure	O
(	O
CPAP	O
)	O
and	O
glucocorticoid	B-CHED
are	O
effective	O
for	O
control	O
of	O
the	O
disease	O
.	O

Continual	O
positive	O
airway	O
pressure	O
(	O
CPAP	O
)	O
and	O
glucocorticoid	B-CHED
was	O
required	O
that	O
can	O
control	O
deprivation	O
of	O
the	O
disease	O
when	O
toxicosis	O
symptom	O
of	O
patients	O
was	O
severity	O
and	O
shadow	O
of	O
lungs	O
diffuse	O
more	O
and	O
more	O
.	O

Noninvasive	O
as	O
an	O
add	B-CHED
-	O
on	O
management	O
may	O
probably	O
cut	O
down	O
on	O
the	O
dosage	O
and	O
duration	O
of	O
corticosteriod	O
therapy	O
.	O

Treatment	O
by	O
combination	O
of	O
TCM	O
and	O
Western	O
medicine	B-CHED
is	O
encouraged	O
.	O

SARS	O
-	O
CoV	O
virus	O
replicase	O
polyprotein	O
ORF1b	O
is	O
undergoing	O
negative	O
selection	O
;	O
negative	O
selection	O
force	O
is	O
also	O
probably	O
operating	O
on	O
spike	O
protein	B-CHED
gene	O
.	O

The	O
blood	O
glucose	B-CHED
maintained	O
at	O
lower	O
level	O
in	O
the	O
surviving	O
patients	O
when	O
compared	O
with	O
those	O
who	O
died	O
[(	O
9	O
.	O
5	O
+/-	O
2	O
.	O
3	O
)	O
mmol	O
/	O
L	O
vs	O
(	O
6	O
.	O
3	O
+/-	O

In	O
order	O
to	O
keep	O
blood	O
glucose	B-CHED
within	O
the	O
range	O
4	O
.	O
44	O
-	O
7	O
.	O
78	O
mmol	O
/	O
L	O
(	O
80	O
-	O
140	O
mg	O
/	O
dl	O
),	O
only	O
18	O
.	O
8	O
%	O
of	O
the	O
surviving	O
patients	O
needed	O
insulin	B-CHED
intervention	O
as	O
opposed	O
to	O
80	O
.	O
0	O
%	O
of	O
those	O
who	O
died	O
(	O
P	O
=	O
0	O
.	O
03	O
).	O

The	O
amount	O
of	O
insulin	B-CHED
used	O
in	O
the	O
surviving	O
group	O
was	O
significant	O
lower	O
than	O
that	O
in	O
the	O
group	O
who	O
died	O
[(	O
24	O
+/-	O
2	O
)	O
IU	O
/	O
d	O
vs	O
(	O
72	O
+/-	O
9	O
)	O
IU	O
/	O
d	O
]	O
(	O
P	O
=	O
0	O
.	O
01	O
).	O

80	O
.	O
0	O
%	O
of	O
the	O
patients	O
who	O
died	O
need	O
insulin	B-CHED
versus	O
only	O
18	O
.	O
8	O
%	O
of	O
the	O
surviving	O
patients	O
.	O

The	O
amount	O
of	O
insulin	B-CHED
used	O
in	O
the	O
surviving	O
group	O
was	O
significant	O
lower	O
than	O
that	O
in	O
the	O
group	O
who	O
died	O
[(	O
24	O
+/-	O
2	O
)	O
IU	O
/	O
d	O
vs	O
(	O
72	O
+/-	O
9	O
)	O
IU	O
/	O
d	O
]	O
(	O
P	O
=	O
0	O
.	O
01	O
).	O

14	O
cases	O
were	O
not	O
responsive	O
and	O
needed	O
to	O
increase	O
the	O
dosage	O
of	O
corticosteroids	B-CHED
.	O

The	O
administration	O
of	O
corticosteroids	B-CHED
was	O
started	O
(	O
4	O
.	O
8	O
+/-	O
3	O
.	O
5	O
)	O
days	O
from	O
the	O
onset	O
and	O
the	O
maximal	O
dosage	O
using	O
of	O
steroids	B-CHED
was	O
(	O
8	O
.	O
4	O
+/-	O

There	O
were	O
lung	O
infiltrates	O
1	O
to	O
6	O
days	O
after	O
fever	O
and	O
then	O
methylprednisolone	B-CHED
was	O
given	O
to	O
them	O
.	O

By	O
using	O
the	O
methods	O
of	O
immunoinformatics	O
,	O
we	O
analyzed	O
the	O
virus	O
surface	O
protein	B-CHED
and	O
found	O
that	O
the	O
epitopes	O
,	O
which	O
can	O
be	O
recognized	O
by	O
human	O
immune	O
system	O
,	O
are	O
strikingly	O
changed	O
or	O
disappeared	O
to	O
compare	O
with	O
other	O
common	O
human	O
coronavirus	O
.	O

TITLE	O
:	O
Antiviral	B-CHED
activity	O
of	O
limitin	O
against	O
encephalomyocarditis	O
virus	O
,	O
herpes	O
simplex	O
virus	O
,	O
and	O
mouse	O
hepatitis	O
virus	O
:	O
diverse	O
requirements	O
by	O
limitin	O
and	O
alpha	O
interferon	O
for	O
interferon	O
regulatory	O
factor	O
1	O
.	O

While	O
limitin	O
has	O
antiviral	B-CHED
activity	O
as	O
strong	O
as	O
that	O
of	O
IFN	O
-	O
alpha	O
in	O
vitro	O
(	O
the	O
concentration	O
that	O
provided	O
50	O
%	O
inhibition	O
of	O
cytopathic	O
effect	O
is	O
approximately	O
30	O
pg	O
/	O
ml	O
),	O
IFN	O
regulatory	O
factor	O
1	O
(	O
IRF	O
-	O
1	O
)	O
dependencies	O
for	O
induction	O
of	O
an	O
antiviral	B-CHED
state	O
were	O
different	O
for	O
limitin	O
and	O
IFN	O
-	O
alpha	O
.	O

The	O
enzyme	O
exhibited	O
a	O
preference	O
for	O
ATP	B-CHED
,	O
dATP	B-CHED
,	O
and	O
dCTP	B-CHED
over	O
the	O
other	O
NTP	B-CHED
/	O
dNTP	B-CHED
substrates	O
.	O

Activities	O
of	O
three	O
SARS	O
coronavirus	O
enzymes	O
,	O
the	O
helicase	O
and	O
two	O
cysteine	B-CHED
proteinases	O
,	O
which	O
are	O
known	O
to	O
be	O
critically	O
involved	O
in	O
replication	O
,	O
transcription	O
and	O
/	O
or	O
post	O
-	O
translational	O
polyprotein	O
processing	O
,	O
were	O
characterized	O
.	O

CONCLUSIONS	O
:	O
The	O
clinical	O
presentation	O
,	O
chest	O
radiographs	O
,	O
white	O
blood	O
cell	O
count	O
,	O
response	O
to	O
initial	O
antimicrobial	B-CHED
therapy	O
,	O
and	O
outcome	O
in	O
SARS	O
is	O
much	O
different	O
from	O
CAP	O
,	O
differentiate	O
them	O
will	O
be	O
helpful	O
to	O
early	O
recognition	O
,	O
prompt	O
isolation	O
,	O
and	O
prevention	O
of	O
its	O
spread	O
.	O

Thus	O
,	O
both	O
recombinant	O
viruses	O
were	O
highly	O
attenuated	O
and	O
expressed	O
viral	O
antigen	B-CHED
which	O
was	O
restricted	O
to	O
the	O
olfactory	O
bulbs	O
and	O
was	O
markedly	O
absent	O
from	O
other	O
regions	O
of	O
the	O
brains	O
at	O
5	O
days	O
postinfection	O
.	O

The	O
conservation	O
of	O
the	O
N	O
-	O
and	O
O	O
-	O
glycosylation	O
motifs	O
suggests	O
that	O
each	O
of	O
these	O
types	O
of	O
carbohydrate	B-CHED
modifications	O
is	O
beneficial	O
to	O
their	O
respective	O
virus	O
.	O

ABSTRACT	O
:	O
To	O
study	O
the	O
expression	O
of	O
the	O
immune	O
cell	O
markers	O
and	O
their	O
active	O
antigens	B-CHED
in	O
the	O
involved	O
tissues	O
of	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
).	O

The	O
results	O
identify	O
a	O
major	O
role	O
for	O
iNOS	O
in	O
mediating	O
extrapulmonary	O
comorbidity	O
in	O
a	O
clinically	O
relevant	O
and	O
severe	O
trauma	O
model	O
and	O
support	O
the	O
use	O
of	O
highly	O
selective	O
iNOS	O
inhibitors	B-CHED
as	O
novel	O
treatments	O
in	O
critical	O
care	O
medicine	B-CHED
.	O

A	O
SARS	O
-	O
CoV	O
whole	O
-	O
genome	O
approach	O
has	O
been	O
developed	O
aimed	O
at	O
determining	O
the	O
crystal	O
structure	O
of	O
all	O
of	O
its	O
proteins	B-CHED
or	O
domains	O
.	O

The	O
chest	O
radiographs	O
of	O
four	O
related	O
children	O
ranging	O
in	O
age	O
from	O
18	O
months	O
to	O
9	O
years	O
diagnosed	O
as	O
having	O
SARS	O
were	O
reviewed	O
for	O
the	O
presence	O
of	O
air	B-CHED
-	O
space	O
shadowing	O
,	O
air	B-CHED
bronchograms	O
,	O
peribronchial	O
thickening	O
,	O
interstitial	O
disease	O
,	O
pleural	O
effusion	O
,	O
pneumothorax	O
,	O
hilar	O
lymphadenopathy	O
and	O
mediastinal	O
widening	O
.	O

Ill	O
-	O
defined	O
air	B-CHED
-	O
space	O
shadowing	O
was	O
the	O
common	O
finding	O
in	O
all	O
the	O
children	O
.	O

TITLE	O
:	O
[	O
Use	O
of	O
glucocorticoid	B-CHED
in	O
treatment	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
cases	O
].	O

(	O
3	O
)	O
The	O
other	O
59	O
cases	O
were	O
administered	O
with	O
40	O
mg	O
to	O
640	O
mg	O
of	O
methylprednisolone	B-CHED
daily	O
.	O

However	O
,	O
current	O
clinical	O
data	O
showed	O
that	O
glucocorticoid	B-CHED
therapy	O
could	O
not	O
shorten	O
the	O
length	O
of	O
hospitalization	O
for	O
the	O
cases	O
with	O
SARS	O
.	O

The	O
disease	O
was	O
mainly	O
transmitted	O
through	O
air	B-CHED
droplet	O
in	O
a	O
short	O
distance	O
,	O
and	O
overwork	O
induced	O
tiredness	O
was	O
involved	O
in	O
disease	O
stimulation	O
.	O

It	O
also	O
triggers	O
site	O
-	O
specific	O
integrative	O
and	O
excisive	O
recombination	O
in	O
vitro	O
to	O
the	O
same	O
extent	O
as	O
the	O
wild	O
-	O
type	O
protein	B-CHED
.	O

The	O
objectives	O
of	O
the	O
present	O
study	O
are	O
to	O
describe	O
the	O
clinics	O
view	O
of	O
acute	O
infectious	O
gastroenteritis	O
(	O
GE	O
)	O
at	O
the	O
community	O
,	O
in	O
primary	O
and	O
secondary	O
attention	O
health	O
centers	O
,	O
with	O
special	O
references	O
to	O
viral	O
aetiology	O
(	O
VIGE	O
);	O
to	O
correlate	O
with	O
drinkable	O
water	B-CHED
and	O
excrete	O
treatment	O
;	O
to	O
develop	O
for	O
the	O
first	O
time	O
a	O
fast	O
diagnostic	O
using	O
electron	O
microscopy	O
in	O
Río	O
Cuarto	O
,	O
Córdoba	O
,	O
Argentina	O
,	O
considering	O
the	O
university	O
and	O
community	O
collaboration	O
in	O
the	O
viral	O
diagnostic	O
.	O

RESULTS	O
:	O
Among	O
the	O
96	O
cases	O
,	O
26	O
cases	O
(	O
27	O
%)	O
had	O
diarrhea	O
,	O
17	O
(	O
18	O
%)	O
had	O
nausea	O
,	O
6	O
(	O
6	O
%)	O
had	O
vomiting	O
,	O
16	O
(	O
17	O
%)	O
had	O
bellyache	O
,	O
and	O
8	O
(	O
8	O
%)	O
had	O
ALT	B-CHED
elevation	O
.	O

The	O
effectiveness	O
of	O
MARS	O
is	O
correlated	O
with	O
reducing	O
the	O
levels	O
of	O
NO	O
and	O
cytokines	O
,	O
except	O
for	O
completely	O
removing	O
of	O
accumulated	O
toxins	B-CHED
in	O
liver	O
failure	O
patients	O
.	O

RESULTS	O
:	O
MARS	O
therapy	O
was	O
associated	O
with	O
marked	O
reduction	O
of	O
albumin	O
bound	O
toxins	B-CHED
and	O
water	B-CHED
soluble	O
toxins	B-CHED
,	O
together	O
with	O
a	O
significant	O
removal	O
of	O
NO	O
and	O
certain	O
cytokines	O
,	O
such	O
as	O
TNF	O
-	O
alpha	O
,	O
IL	O
-	O
6	O
,	O
IL	O
-	O
8	O
,	O
and	O
INF	O
-	O
gamma	O
.	O

When	O
being	O
admitted	O
to	O
hospital	O
,	O
serum	O
ALT	B-CHED
and	O
(	O
or	O
)	O
AST	O
levels	O
were	O
elevated	O
in	O
37	O
.	O
7	O
%	O
SARS	O
patients	O
.	O

There	O
was	O
a	O
significant	O
difference	O
in	O
ALT	B-CHED
/	O
AST	O
elevation	O
rates	O
between	O
severe	O
and	O
mild	O
clinical	O
type	O
(	O
chi2	O
=	O
19	O
.	O
28	O
,	O
P	O
<	O
0	O
.	O
05	O
).	O

These	O
results	O
have	O
been	O
released	O
on	O
the	O
anti	O
-	O
sars	O
web	O
site	O
maintained	O
by	O
the	O
Centre	O
of	O
Bioinformatics	O
,	O
Peking	O
University	O
(	O
antisars	O
.	O
cbi	B-CHED
.	O
pku	O
.	O
edu	O
.	O
cn	O
)	O
and	O
may	O
be	O
of	O
help	O
for	O
further	O
experimental	O
study	O
.	O

SARS	O
-	O
CoV	O
evolutionally	O
closes	O
to	O
other	O
coronavirus	O
in	O
their	O
corresponding	O
proteins	B-CHED
,	O
such	O
as	O
spike	O
protein	B-CHED
,	O
small	O
membrane	O
protein	B-CHED
and	O
nucleocapsid	O
protein	B-CHED
.	O

Infiltration	O
of	O
pancreatic	O
and	O
lung	O
tissue	O
with	O
neutrophils	O
(	O
measured	O
as	O
increase	O
in	O
myeloperoxidase	O
activity	O
)	O
was	O
associated	O
with	O
enhanced	O
lipid	B-CHED
peroxidation	O
(	O
increased	O
tissue	O
levels	O
of	O
malondialdehyde	B-CHED
).	O

TITLE	O
:	O
Evidence	O
of	O
biological	O
efficacy	O
for	O
prolonged	O
glucocorticoid	B-CHED
treatment	O
in	O
patients	O
with	O
unresolving	O
ARDS	O
.	O

This	O
chapter	O
will	O
review	O
recent	O
data	O
indicating	O
that	O
poor	O
outcome	O
in	O
acute	O
respiratory	O
distress	O
syndrome	O
might	O
be	O
related	O
in	O
part	O
to	O
failure	O
of	O
the	O
activated	O
glucocorticoid	B-CHED
receptors	O
to	O
downregulate	O
the	O
transcription	O
of	O
inflammatory	O
cytokines	O
despite	O
elevated	O
levels	O
of	O
circulating	O
cortisol	B-CHED
.	O

ABSTRACT	O
:	O
The	O
treatment	O
of	O
atypical	O
pneumonia	O
,	O
subsequently	O
termed	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
is	O
controversial	O
,	O
and	O
the	O
efficacy	O
of	O
corticosteroid	B-CHED
therapy	O
is	O
unknown	O
.	O

On	O
the	O
basis	O
of	O
the	O
recently	O
published	O
viral	O
genome	O
and	O
structural	O
features	O
common	O
to	O
the	O
members	O
of	O
the	O
coronavirus	O
family	O
,	O
a	O
model	O
for	O
host	O
cell	O
-	O
virus	O
interaction	O
and	O
possible	O
targets	O
for	O
antiviral	B-CHED
drugs	I-CHED
are	O
presented	O
.	O

In	O
perfused	O
rabbit	O
lungs	O
,	O
continuous	O
infusion	O
of	O
the	O
thromboxane	B-CHED
-	O
A2	O
-	O
mimetic	O
U46619	O
provoked	O
pulmonary	O
hypertension	O
,	O
accompanied	O
by	O
progressive	O
lung	O
oedema	O
formation	O
and	O
severe	O
ventilation	O
-	O
perfusion	O
mismatch	O
with	O
predominance	O
of	O
shunt	O
flow	O
(	O
increasing	O
from	O
approximately	O
2	O
to	O
58	O
%,	O
as	O
assessed	O
by	O
the	O
multiple	O
inert	O
gas	O
elimination	O
technique	O
).	O

The	O
needed	O
equipment	O
includes	O
clothing	O
;	O
footwear	O
;	O
such	O
protective	O
devices	O
as	O
masks	O
,	O
safety	O
glasses	O
,	O
and	O
gloves	O
;	O
disinfectant	B-CHED
solutions	O
;	O
laboratory	O
equipment	O
;	O
and	O
materials	O
for	O
obtaining	O
and	O
transporting	O
samples	O
.	O

ABSTRACT	O
:	O
Reductive	O
metabolism	O
of	O
carbon	B-CHED
tetrachloride	I-CHED
(	O
CCl	B-CHED
(	O
4	O
))	O
is	O
thought	O
to	O
cause	O
lipid	B-CHED
peroxidation	O
which	O
results	O
in	O
hepatic	O
injury	O
.	O

During	O
his	O
illness	O
,	O
serial	O
chest	O
radiographs	O
showed	O
increasingly	O
severe	O
air	B-CHED
-	O
space	O
shadowing	O
in	O
both	O
lungs	O
.	O

Gradient	O
fractionation	O
and	O
biochemical	O
extraction	O
experiments	O
demonstrated	O
that	O
Pol	O
was	O
not	O
an	O
integral	O
membrane	O
protein	B-CHED
but	O
was	O
tightly	O
associated	O
with	O
membranes	O
and	O
coimmunoprecipitated	O
with	O
the	O
replicase	O
proteins	B-CHED
3CLpro	O
,	O
p22	O
,	O
and	O
p12	O
.	O

By	O
immunofluorescence	O
confocal	O
microscopy	O
,	O
Pol	O
colocalized	O
with	O
viral	O
proteins	B-CHED
at	O
replication	O
complexes	O
,	O
distinct	O
from	O
sites	O
of	O
virion	O
assembly	O
,	O
over	O
the	O
entire	O
course	O
of	O
infection	O
.	O

However	O
,	O
a	O
mouse	O
erythroleukemia	O
cell	O
line	O
,	O
CB3	O
,	O
does	O
not	O
express	O
hnRNP	O
A1	O
but	O
still	O
supports	O
MHV	O
replication	O
,	O
suggesting	O
that	O
alternative	O
proteins	B-CHED
can	O
replace	O
hnRNP	O
A1	O
in	O
cellular	O
functions	O
and	O
viral	O
infection	O
.	O

These	O
proteins	B-CHED
displayed	O
MHV	O
RNA	O
-	O
binding	O
affinity	O
and	O
specificity	O
similar	O
to	O
those	O
of	O
hnRNP	O
A1	O
.	O

Our	O
findings	O
demonstrate	O
that	O
the	O
functions	O
of	O
hnRNP	O
A1	O
in	O
MHV	O
RNA	O
synthesis	O
can	O
be	O
replaced	O
by	O
other	O
closely	O
related	O
hnRNPs	O
,	O
further	O
supporting	O
the	O
roles	O
of	O
cellular	O
proteins	B-CHED
in	O
MHV	O
RNA	O
synthesis	O
.	O

The	O
following	O
interventions	O
were	O
systematically	O
reviewed	O
for	O
inclusion	O
in	O
the	O
guidelines	O
:	O
enteral	O
nutrition	O
(	O
EN	O
)	O
versus	O
parenteral	O
nutrition	O
(	O
PN	O
),	O
early	O
versus	O
late	O
EN	O
,	O
dose	O
of	O
EN	O
,	O
composition	O
of	O
EN	O
(	O
protein	B-CHED
,	O
carbohydrates	B-CHED
,	O
lipids	B-CHED
,	O
immune	O
-	O
enhancing	O
additives	O
),	O
strategies	O
to	O
optimize	O
delivery	O
of	O
EN	O
and	O
minimize	O
risks	O
(	O
ie	O
,	O
rate	O
of	O
advancement	O
,	O
checking	O
residuals	O
,	O
use	O
of	O
bedside	O
algorithms	O
,	O
motility	O
agents	O
,	O
small	O
bowel	O
versus	O
gastric	O
feedings	O
,	O
elevation	O
of	O
the	O
head	O
of	O
the	O
bed	O
,	O
closed	O
delivery	O
systems	O
,	O
probiotics	O
,	O
bolus	O
administration	O
),	O
enteral	O
nutrition	O
in	O
combination	O
with	O
supplemental	O
PN	O
,	O
use	O
of	O
PN	O
versus	O
standard	O
care	O
in	O
patients	O
with	O
an	O
intact	O
gastrointestinal	O
tract	O
,	O
dose	O
of	O
PN	O
and	O
composition	O
of	O
PN	O
(	O
protein	B-CHED
,	O
carbohydrates	B-CHED
,	O
IV	O
lipids	B-CHED
,	O
additives	O
,	O
vitamins	B-CHED
,	O
trace	O
elements	O
,	O
immune	O
enhancing	O
substances	O
),	O
and	O
the	O
use	O
of	O
intensive	O
insulin	B-CHED
therapy	O
.	O

The	O
sensitive	O
rate	O
of	O
fluconazole	B-CHED
to	O
fungi	O
was	O
92	O
.	O
4	O
percent	O
.	O

The	O
sensitive	O
rate	O
of	O
fluconazole	B-CHED
to	O
fungi	O
was	O
92	O
.	O
4	O
percent	O
.	O

By	O
univariate	O
analysis	O
,	O
risk	O
factors	O
related	O
to	O
hospital	O
mortality	O
included	O
acute	O
physiology	O
and	O
chronic	O
health	O
evaluationII	O
(	O
APACHEII	O
)	O
score	O
,	O
the	O
systemic	O
inflammatory	O
response	O
syndrome	O
,	O
sepsis	O
,	O
severe	O
sepsis	O
,	O
septic	O
shock	O
,	O
chronic	O
respiratory	O
dysfunction	O
,	O
sepsis	O
-	O
related	O
organ	O
failure	O
assessment	O
(	O
SOFA	O
)	O
score	O
,	O
acute	O
respiratory	O
dysfunction	O
,	O
coagulation	O
dysfunction	O
,	O
central	O
nerves	O
system	O
dysfunction	O
,	O
cardiovascular	O
dysfunction	O
,	O
management	O
of	O
noradrenaline	B-CHED
and	O
continuous	O
venovenous	O
hemofiltration	O
(	O
CVVH	O
).	O

The	O
distribution	O
of	O
occupation	O
was	O
also	O
showed	O
significantly	O
different	O
in	O
the	O
three	O
respective	O
stages	O
(	O
chi	B-CHED
(	O
2	O
)	O
=	O
36	O
.	O
41	O
,	O
P	O
<	O
0	O
.	O
01	O
).	O

Both	O
approaches	O
began	O
with	O
the	O
vectorial	O
profiling	O
of	O
the	O
tetra	B-CHED
-	O
nucleotide	B-CHED
usage	O
pattern	O
V	O
for	O
each	O
virus	O
.	O

TITLE	O
:	O
[	O
Clinical	O
observation	O
on	O
treatment	O
of	O
40	O
SARS	O
uncertain	O
patients	O
with	O
integrative	O
traditional	O
Chinese	O
and	O
Western	O
medicine	B-CHED
].	O

Significantly	O
higher	O
left	O
ventricular	O
index	O
of	O
myocardial	O
performance	O
(	O
IMP	B-CHED
)	O
(	O
0	O
.	O
42	O
+/-	O
0	O
.	O
13	O
versus	O
0	O
.	O
33	O
+/-	O
0	O
.	O
09	O
,	O
P	O
<	O
0	O
.	O
001	O
),	O
longer	O
isovolumic	O
relaxation	O
time	O
(	O
102	O
.	O
9	O
+/-	O
15	O
.	O
7	O
versus	O
81	O
.	O
6	O
+/-	O
14	O
.	O
7	O
ms	O
,	O
P	O
<	O
0	O
.	O
001	O
),	O
lower	O
flow	O
propagation	O
velocity	O
(	O
69	O
.	O
6	O
+/-	O
15	O
.	O
7	O
versus	O
83	O
.	O
8	O
+/-	O
19	O
.	O
7	O
cm	O
/	O
s	O
,	O
P	O
=	O
0	O
.	O
011	O
),	O
and	O
Doppler	O
-	O
derived	O
cardiac	O
output	O
(	O
4	O
.	O
69	O
+/-	O
1	O
.	O
01	O
versus	O
5	O
.	O
49	O
+/-	O
1	O
.	O
04	O
L	O
/	O
min	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
were	O
observed	O
during	O
acute	O
infection	O
when	O
compared	O
with	O
those	O
at	O
30	O
days	O
.	O

Instillation	O
of	O
recombinant	O
FasL	O
(	O
rFasL	O
)	O
into	O
the	O
lung	O
induced	O
neutrophil	O
infiltration	O
and	O
increased	O
pulmonary	O
permeability	O
,	O
as	O
evidenced	O
by	O
increased	O
total	O
protein	B-CHED
in	O
the	O
airspace	O
;	O
both	O
occur	O
in	O
patients	O
with	O
ARDS	O
.	O

These	O
effects	O
were	O
accompanied	O
with	O
a	O
rapid	O
induction	O
of	O
proinflammatory	O
mediators	O
:	O
cytokine	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
(	O
GM	O
-	O
CSF	O
)	O
and	O
the	O
chemokines	O
macrophage	O
inflammatory	O
protein	B-CHED
-	O
2	O
(	O
MIP	O
-	O
2	O
)	O
and	O
KC	O
.	O

All	O
patients	O
,	O
except	O
two	O
,	O
received	O
ribavirin	B-CHED
and	O
steroid	B-CHED
combination	O
therapy	O
.	O

Advanced	O
age	O
,	O
high	O
admission	O
neutrophil	O
count	O
,	O
and	O
high	O
initial	O
lactate	B-CHED
dehydrogenase	O
level	O
were	O
independent	O
correlates	O
of	O
an	O
adverse	O
clinical	O
outcome	O
.	O

SARS	O
-	O
associated	O
coronavirus	O
caused	O
severe	O
illnesses	O
in	O
most	O
patients	O
,	O
despite	O
early	O
treatment	O
with	O
ribavirin	B-CHED
and	O
steroid	B-CHED
.	O

The	O
use	O
of	O
corticosteroids	B-CHED
and	O
psychological	O
supports	O
need	O
further	O
study	O
.	O

In	O
a	O
twin	O
-	O
pregnancy	O
1	O
fetus	O
was	O
lost	B-CHED
while	O
the	O
pregnant	O
'	O
s	O
situation	O
is	O
stable	O
.	O

Heart	O
rate	O
,	O
oxygen	B-CHED
saturation	O
,	O
temperature	O
,	O
and	O
alanine	B-CHED
aminotransferase	O
(	O
ALT	B-CHED
)	O
and	O
aspartate	B-CHED
aminotransferase	O
(	O
AST	O
)	O
levels	O
were	O
recorded	O
daily	O
.	O

Admission	O
radiographic	O
score	O
was	O
correlated	O
with	O
admission	O
AST	O
level	O
(	O
r	O
=	O
0	O
.	O
53	O
,	O
P	O
=.	O
003	O
);	O
treatment	O
radiographic	O
score	O
,	O
with	O
treatment	O
ALT	B-CHED
and	O
AST	O
levels	O
(	O
r	O
=	O
0	O
.	O
43	O
,	O
P	O
=.	O
007	O
;	O
r	O
=	O
0	O
.	O
42	O
,	O
P	O
=.	O
019	O
);	O
and	O
time	O
to	O
maximal	O
radiographic	O
score	O
,	O
with	O
AST	O
level	O
at	O
maximal	O
radiographic	O
score	O
(	O
r	O
=	O
-	O
0	O
.	O
45	O
,	O
P	O
=.	O
006	O
),	O
admission	O
radiographic	O
score	O
(	O
r	O
=	O
-	O
0	O
.	O
55	O
,	O
P	O
<.	O
001	O
),	O
treatment	O
radiographic	O
score	O
(	O
r	O
=	O
-	O
0	O
.	O
58	O
,	O
P	O
<.	O
001	O
),	O
and	O
admission	O
ALT	B-CHED
and	O
AST	O
levels	O
(	O
r	O
=	O
-	O
0	O
.	O
44	O
,	O
P	O
=.	O
007	O
;	O
r	O
=	O
-	O
0	O
.	O
58	O
,	O
P	O
=.	O
001	O
).	O

Pyridoxylidenephloroglucinol	O
is	O
synthesized	O
by	O
Knoevenagel	O
condensation	O
of	O
the	O
vitamin	B-CHED
B6	I-CHED
aldehyde	B-CHED
pyridoxal	B-CHED
with	O
phloroglucinol	B-CHED
.	O

Therefore	O
,	O
a	O
target	O
of	O
interest	O
could	O
be	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
zinc	B-CHED
finger	O
HIV	O
-	O
1	O
RNA	O
-	O
binding	O
nucleocapsid	O
protein	B-CHED
p7	O
(	O
NCp7	O
).	O

Third	O
,	O
despite	O
trends	O
toward	O
commercialization	O
,	O
easier	O
lives	O
,	O
and	O
self	O
-	O
centered	O
individualism	O
,	O
the	O
response	O
of	O
health	O
care	O
professionals	O
to	O
SARS	O
reaffirmed	O
dedication	O
to	O
caring	O
for	O
the	O
sick	O
even	O
at	O
great	O
personal	O
risks	O
as	O
the	O
core	O
ethical	O
principle	O
of	O
medicine	B-CHED
.	O

TITLE	O
:	O
Increased	O
expression	O
of	O
19	O
-	O
kD	O
interacting	O
protein	B-CHED
-	O
3	O
-	O
like	O
protein	B-CHED
and	O
the	O
relationship	O
to	O
apoptosis	O
in	O
the	O
lung	O
of	O
rats	O
with	O
severe	O
acute	O
pancreatitis	O
.	O

These	O
caveolin	O
-	O
binding	O
sites	O
located	O
in	O
replicase	O
1AB	O
,	O
spike	O
protein	B-CHED
,	O
orf3	O
protein	B-CHED
,	O
and	O
M	O
protein	B-CHED
,	O
respectively	O
.	O

Of	O
442973	O
air	B-CHED
passengers	O
screened	O
after	O
measures	O
were	O
implemented	O
,	O
136	O
were	O
sent	O
to	O
a	O
designated	O
hospital	O
for	O
further	O
SARS	O
screening	O
;	O
none	O
was	O
diagnosed	O
as	O
having	O
SARS	O
.	O

This	O
54	O
year	O
-	O
old	O
man	B-CHED
was	O
infected	O
during	O
the	O
Air	B-CHED
France	O
flight	O
from	O
Hanoi	O
to	O
Paris	O
via	O
Bangkok	O
by	O
the	O
index	O
case	O
,	O
who	O
himself	O
had	O
been	O
contaminated	O
at	O
the	O
French	O
hospital	O
in	O
Hanoi	O
and	O
who	O
was	O
hospitalized	O
in	O
a	O
critical	O
state	O
in	O
the	O
Tourcoing	O
hospital	O
shortly	O
after	O
his	O
arrival	O
in	O
France	O
.	O

The	O
results	O
showed	O
that	O
in	O
the	O
69	O
followed	O
-	O
up	O
patients	O
,	O
impairment	O
of	O
the	O
hepatic	O
function	O
was	O
found	O
in	O
5	O
cases	O
,	O
hypoimmune	O
state	O
in	O
18	O
,	O
impediment	O
of	O
ventilation	O
in	O
the	O
distal	O
air	B-CHED
passages	O
with	O
normal	O
major	O
air	B-CHED
passages	O
in	O
15	O
,	O
increased	O
residual	O
volume	O
in	O
40	O
,	O
mild	O
disturbance	O
of	O
pulmonary	O
diffusion	O
function	O
in	O
14	O
,	O
incomplete	O
absorption	O
of	O
inflammatory	O
exudates	O
,	O
focal	O
or	O
multiple	O
interstitial	O
lesions	O
,	O
pulmonary	O
interstitial	O
fibrosis	O
and	O
pleural	O
adhesion	O
in	O
24	O
;	O
increased	O
resistance	O
or	O
mild	O
systolic	O
hypertension	O
in	O
the	O
pulmonary	O
circulation	O
,	O
and	O
segmental	O
ischemia	O
of	O
the	O
left	O
myocardium	O
in	O
34	O
;	O
and	O
decreased	O
visual	O
acuity	O
in	O
2	O
.	O

This	O
tendency	O
can	O
be	O
used	O
as	O
a	O
indicator	B-CHED
for	O
epidemiological	O
study	O
and	O
serum	O
diagnose	O
.	O

Lung	O
injury	O
,	O
obstinate	O
hypoxemia	O
,	O
abnormality	O
metabolize	O
of	O
hyperglycemia	O
and	O
misusing	O
glucocorticoids	B-CHED
and	O
antibiotic	B-CHED
leading	O
to	O
secondary	O
infection	O
are	O
the	O
main	O
reasons	O
for	O
SARS	O
patients	O
dying	O
.	O

Secondary	O
structure	O
studies	O
for	O
the	O
peptide	B-CHED
substrates	O
revealed	O
that	O
substrates	O
with	O
more	O
beta	O
-	O
sheetlike	O
structure	O
tend	O
to	O
react	O
fast	O
.	O

This	O
study	O
provides	O
a	O
basic	O
understanding	O
of	O
the	O
enzyme	O
catalysis	O
and	O
a	O
full	O
substrate	O
specificity	O
spectrum	O
for	O
SARS	O
3C	O
-	O
like	O
proteinase	O
,	O
which	O
are	O
helpful	O
for	O
structural	O
-	O
based	O
inhibitor	B-CHED
design	O
against	O
SARS	O
and	O
other	O
coronavirus	O
.	O

In	O
another	O
experiment	O
,	O
mean	O
plasma	O
D	B-CHED
-	I-CHED
xylose	I-CHED
concentrations	O
in	O
3	O
-	O
day	O
-	O
old	O
turkey	O
poults	O
inoculated	O
with	O
TCV	O
,	O
turkey	O
astrovirus	O
,	O
or	O
a	O
combination	O
of	O
both	O
viruses	O
were	O
significantly	O
lower	O
than	O
in	O
the	O
uninoculated	O
controls	O
.	O

Nucleic	B-CHED
acid	I-CHED
testing	O
for	O
West	O
Nile	O
virus	O
began	O
in	O
the	O
United	O
States	O
in	O
2003	O
under	O
an	O
investigational	O
new	O
drug	O
program	O
.	O

All	O
36	O
patients	O
received	O
a	O
combination	O
of	O
corticosteroids	B-CHED
and	O
ribavirin	B-CHED
.	O

A	O
possible	O
cause	O
of	O
false	O
-	O
positive	O
of	O
SARS	O
-	O
CoV	O
-	O
IgG	O
and	O
IgM	O
antibody	O
in	O
SLE	O
patients	O
is	O
coated	O
antigens	B-CHED
with	O
SARS	O
-	O
CoV	O
and	O
Vero	O
-	O
E6	O
cells	O
in	O
ELISA	O
methods	O
.	O

Although	O
NO	O
is	O
important	O
in	O
maintaining	O
vasodilator	B-CHED
tone	O
,	O
hypoxia	O
-	O
induced	O
pulmonary	O
vasoconstriction	O
is	O
accompanied	O
by	O
an	O
increase	O
instead	O
of	O
a	O
decrease	O
in	O
NO	O
release	O
.	O

TITLE	O
:	O
Pentachlorophenol	B-CHED
poisoning	O
.	O

Long	O
-	O
term	O
exposure	O
has	O
also	O
been	O
reported	O
to	O
result	O
in	O
chronic	O
fatigue	O
or	O
neuropsychiatric	O
features	O
in	O
combination	O
with	O
skin	O
infections	O
(	O
including	O
chloracne	O
),	O
chronic	O
respiratory	O
symptoms	O
,	O
neuralgic	O
pains	O
in	O
the	O
legs	O
,	O
and	O
impaired	O
fertility	O
and	O
hypothyroidism	O
secondary	O
to	O
endocrine	B-CHED
disruption	O
.	O

Apoptotic	O
oligodendrocytes	O
have	O
been	O
detected	O
in	O
the	O
vicinity	O
of	O
the	O
CNS	B-CHED
demyelinating	O
lesions	O
in	O
these	O
animals	O
.	O

This	O
finding	O
provides	O
an	O
explanation	O
for	O
the	O
destruction	O
of	O
oligodendrocytes	O
and	O
the	O
damage	O
of	O
myelin	O
sheath	O
in	O
MHV	O
-	O
infected	O
CNS	B-CHED
and	O
suggests	O
that	O
oligodendrocyte	O
apoptosis	O
may	O
be	O
one	O
of	O
the	O
underlying	O
mechanisms	O
for	O
the	O
pathogenesis	O
of	O
MHV	O
-	O
induced	O
demyelinating	O
diseases	O
in	O
animals	O
.	O

Viral	O
antigens	B-CHED
were	O
also	O
directly	O
detected	O
in	O
nasopharyngeal	O
aspirates	O
from	O
these	O
patients	O
.	O

A	O
further	O
73	O
BAL	B-CHED
samples	O
were	O
obtained	O
from	O
20	O
infants	O
(	O
median	O
age	O
2	O
days	O
,	O
range	O
1	O
to	O
402	O
)	O
receiving	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
for	O
severe	O
respiratory	O
failure	O
.	O

TITLE	O
:	O
Identifying	O
inhibitors	B-CHED
of	O
the	O
SARS	O
coronavirus	O
proteinase	O
.	O

ABSTRACT	O
:	O
In	O
cases	O
of	O
tracheal	O
compression	O
by	O
a	O
mediastinal	O
mass	O
or	O
aortic	O
aneurysm	O
,	O
muscle	B-CHED
relaxant	I-CHED
might	O
induce	O
fetal	O
ventilatory	O
failure	O
.	O

Here	O
we	O
performed	O
DNA	O
microarray	O
analysis	O
on	O
differential	O
gene	O
expression	O
in	O
astrocyte	O
DBT	B-CHED
cells	O
by	O
MHV	O
infection	O
and	O
found	O
that	O
the	O
mRNA	B-CHED
of	O
the	O
proapoptotic	O
gene	O
BNip3	O
was	O
significantly	O
decreased	O
following	O
MHV	O
infection	O
.	O

Deletion	O
analysis	O
showed	O
that	O
the	O
sequence	O
between	O
nucleotides	B-CHED
262	O
and	O
550	O
of	O
the	O
588	O
-	O
base	O
-	O
pair	O
BNip3	O
promoter	O
is	O
necessary	O
and	O
sufficient	O
for	O
driving	O
the	O
BNip3	O
expression	O
and	O
that	O
it	O
contains	O
signals	O
that	O
are	O
responsible	O
for	O
MHV	O
-	O
induced	O
down	O
-	O
regulation	O
of	O
BNip3	O
expression	O
in	O
DBT	B-CHED
cells	O
.	O

Management	O
with	O
glucocorticoids	B-CHED
and	O
noninvasive	O
ventilation	O
can	O
control	O
the	O
progression	O
in	O
these	O
patients	O
effectively	O
.	O

Three	O
of	O
the	O
patients	O
were	O
homozygous	O
for	O
the	O
'	O
common	O
'	O
1528G	O
>	O
C	O
mutation	O
in	O
the	O
alpha	O
-	O
subunit	O
of	O
the	O
MTP	O
,	O
giving	O
rise	O
to	O
long	O
-	O
chain	O
3	B-CHED
-	I-CHED
hydroxyacyl	I-CHED
-	I-CHED
CoA	I-CHED
dehydrogenase	O
deficiency	O
.	O

The	O
average	O
degree	O
of	O
degradation	O
during	O
overnight	O
digestion	O
was	O
found	O
to	O
be	O
approximately	O
51	O
and	O
approximately	O
34	O
%	O
for	O
Cys	B-CHED
and	O
Gln	B-CHED
,	O
respectively	O
;	O
more	O
detailed	O
information	O
on	O
the	O
time	O
course	O
of	O
the	O
reactions	O
was	O
obtained	O
for	O
the	O
peptides	B-CHED
CCTESLVNR	O
and	O
QYYTVFDR	O
.	O

Taking	O
this	O
modification	O
into	O
account	O
while	O
sequencing	O
is	O
likely	O
to	O
increase	O
the	O
probability	O
of	O
protein	B-CHED
identification	O
by	O
peptide	B-CHED
mass	O
fingerprinting	O
,	O
especially	O
for	O
cysteine	B-CHED
-	O
rich	O
proteins	B-CHED
.	O

ABSTRACT	O
:	O
To	O
prevent	O
SARS	O
from	O
spreading	O
through	O
air	B-CHED
travel	O
and	O
in	O
order	O
to	O
rebuild	O
the	O
confidence	O
of	O
the	O
traveling	O
public	O
in	O
the	O
safety	O
of	O
air	B-CHED
travel	O
,	O
ICAO	O
has	O
set	O
up	O
an	O
""""	O
Anti	O
-	O
SARS	O
Airport	O
Evaluation	O
Project	O
.	O

ABSTRACT	O
:	O
The	O
ability	O
to	O
rapidly	O
and	O
reliably	O
develop	O
hypotheses	O
on	O
the	O
function	O
of	O
newly	O
discovered	O
protein	B-CHED
sequences	O
requires	O
systematic	O
and	O
comprehensive	O
analysis	O
.	O

Repeated	O
samplings	O
from	O
both	O
FIP	O
affected	O
and	O
FCoV	O
-	O
exposed	O
cats	O
showed	O
that	O
when	O
FIP	O
appeared	O
in	O
the	O
group	O
,	O
all	O
the	O
cats	O
had	O
increased	O
APP	B-CHED
levels	O
.	O

We	O
also	O
found	O
that	O
SARS	O
-	O
CoV	O
N	O
protein	B-CHED
does	O
not	O
activate	O
NF	O
-	O
kappaB	O
pathway	O
,	O
demonstrating	O
that	O
activation	O
of	O
important	O
cellular	O
pathways	O
by	O
SAS	O
-	O
CoV	O
N	O
protein	B-CHED
is	O
selective	O
.	O

To	O
date	O
there	O
have	O
been	O
over	O
750	O
related	O
deaths	O
and	O
there	O
is	O
clearly	O
an	O
urgent	O
need	O
to	O
develop	O
specific	O
antiviral	B-CHED
drugs	I-CHED
to	O
combat	B-CHED
this	O
disease	O
.	O

Air	B-CHED
pollution	O
was	O
evaluated	O
by	O
air	B-CHED
pollution	O
index	O
(	O
API	O
)	O
derived	O
from	O
the	O
concentrations	O
of	O
particulate	O
matter	O
,	O
sulfur	B-CHED
dioxide	I-CHED
,	O
nitrogen	B-CHED
dioxide	I-CHED
,	O
carbon	B-CHED
monoxide	I-CHED
and	O
ground	O
-	O
level	O
ozone	B-CHED
.	O

Our	O
studies	O
demonstrated	O
a	O
positive	O
association	O
between	O
air	B-CHED
pollution	O
and	O
SARS	O
case	O
fatality	O
in	O
Chinese	O
population	O
by	O
utilizing	O
publicly	O
accessible	O
data	O
on	O
SARS	O
statistics	O
and	O
air	B-CHED
pollution	O
indices	O
.	O

The	O
life	O
cycle	O
of	O
the	O
SARS	O
virus	O
is	O
largely	O
unknown	O
;	O
however	O
,	O
based	O
on	O
the	O
analogy	O
with	O
other	O
coronaviruses	O
,	O
several	O
potential	O
targets	O
for	O
antiviral	B-CHED
development	O
are	O
identified	O
.	O

The	O
survival	O
abilities	O
on	O
the	O
surfaces	O
of	O
eight	O
different	O
materials	O
and	O
in	O
water	B-CHED
were	O
quite	O
comparable	O
,	O
revealing	O
reduction	O
of	O
infectivity	O
after	O
72	O
to	O
96	O
h	O
exposure	O
.	O

We	O
synthesized	O
41	O
peptides	B-CHED
ranging	O
in	O
size	O
from	O
16	O
to	O
25	O
amino	B-CHED
acid	I-CHED
residues	O
of	O
relatively	O
high	O
hydrophilicity	O
.	O

Four	O
epitopic	O
sites	O
,	O
S599	O
,	O
M137	O
,	O
N66	O
,	O
and	O
N371	O
-	O
404	O
,	O
located	O
in	O
the	O
SARS	O
-	O
coronavirus	O
S	O
,	O
M	O
,	O
and	O
N	O
proteins	B-CHED
,	O
respectively	O
,	O
were	O
detected	O
by	O
screening	O
synthesized	O
peptides	B-CHED
.	O

RESULTS	O
:	O
Four	O
epitopic	O
sites	O
,	O
S599	O
,	O
M137	O
,	O
N66	O
,	O
and	O
N371	O
-	O
404	O
,	O
located	O
in	O
the	O
SARS	O
-	O
coronavirus	O
S	O
,	O
M	O
,	O
and	O
N	O
proteins	B-CHED
,	O
respectively	O
,	O
were	O
detected	O
by	O
screening	O
synthesized	O
peptides	B-CHED
.	O

Generally	O
,	O
affected	O
tissues	O
had	O
lower	O
levels	O
of	O
IL	O
-	O
4	O
and	O
IL	O
-	O
12	O
-	O
p40	O
mRNA	B-CHED
and	O
higher	O
levels	O
of	O
IL	O
-	O
10	O
mRNA	B-CHED
.	O

This	O
study	O
showed	O
that	O
immunization	O
with	O
the	O
cell	O
lysate	O
with	O
baculovirus	O
-	O
expressed	O
N	O
protein	B-CHED
was	O
effective	O
in	O
preventing	O
the	O
progression	O
of	O
FIP	O
without	O
inducing	O
ADE	B-CHED
of	O
FIPV	O
infection	O
in	O
cats	O
.	O

As	O
infection	O
progressed	O
from	O
12	O
to	O
21	O
h	O
p	O
.	O
i	O
.,	O
the	O
cytoplasm	O
of	O
the	O
infected	O
cells	O
was	O
filled	O
with	O
numerous	O
large	O
,	O
smooth	O
-	O
membraned	O
vacuoles	O
containing	O
a	O
mixture	B-CHED
of	O
mature	O
virus	O
and	O
spherical	O
cores	O
.	O

The	O
results	O
were	O
compared	O
by	O
Student	O
t	O
-	O
test	O
,	O
Friedman	O
test	O
,	O
chi	B-CHED
-	O
square	O
test	O
,	O
Fishers	O
exact	O
test	O
,	O
and	O
confidence	O
interval	O
.	O

RESULTS	O
:	O
Eighteen	O
children	O
(	O
10	O
males	O
),	O
whose	O
mean	O
age	O
was	O
11	O
.	O
5	O
-/+	O
11	O
.	O
5	O
months	O
,	O
with	O
initial	O
PaO	B-CHED
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
of	O
96	O
.	O
06	O
-/+	O
41	O
.	O
78	O
,	O
participated	O
in	O
the	O
study	O
.	O

CONCLUSION	O
:	O
Prone	O
positioning	O
during	O
mechanical	O
ventilation	O
of	O
children	O
with	O
severe	O
hypoxemia	O
may	O
improve	O
the	O
PaO	B-CHED
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
ratio	O
in	O
the	O
first	O
hour	O
.	O

Using	O
the	O
SARS	O
-	O
CoV	O
PUMC2	O
strain	O
genomic	O
RNA	O
as	O
the	O
template	O
,	O
the	O
cDNA	O
fragments	O
were	O
amplified	O
by	O
RT	O
-	O
PCR	O
,	O
the	O
PCR	O
products	O
were	O
further	O
purified	O
and	O
ligated	O
into	O
the	O
pGEM	B-CHED
-	O
T	O
vector	O
,	O
and	O
all	O
the	O
clones	O
obtained	O
were	O
sequenced	O
.	O

Diffusing	O
capacity	O
for	O
carbon	B-CHED
monoxide	I-CHED
(	O
DLco	O
%)	O
of	O
level	O
2	O
and	O
3	O
were	O
statistically	O
lower	O
than	O
that	O
of	O
level	O
0	O
(	O
P	O
<	O
0	O
.	O
01	O
).	O

Scores	O
of	O
all	O
four	O
part	O
of	O
SGRQ	O
correlated	O
significantly	O
with	O
diffuse	O
capacity	O
of	O
the	O
lung	O
for	O
carbon	B-CHED
monoxide	I-CHED
/	O
pre	O
(	O
DLco	O
%).	O

Diffusion	O
capacity	O
for	O
carbon	B-CHED
monoxide	I-CHED
(	O
DLco	B-CHED
)	O
was	O
impaired	O
in	O
38	O
patients	O
(	O
42	O
.	O
7	O
%);	O
in	O
7	O
patients	O
(	O
7	O
.	O
9	O
%),	O
lung	O
function	O
was	O
restrictive	O
defect	O
combined	O
DLco	B-CHED
impairment	O
;	O
Other	O
patterns	O
of	O
impairment	O
were	O
revealed	O
in	O
3	O
patient	O
.	O

More	O
patients	O
in	O
elderly	O
group	O
were	O
given	O
3rd	O
generation	O
cephalosporin	B-CHED
and	O
imipenem	B-CHED
.	O

Three	O
of	O
thirteen	O
patients	O
had	O
been	O
intubated	O
or	O
received	O
tracheotomy	O
before	O
they	O
entered	O
into	O
ICU	O
,	O
the	O
other	O
patients	O
received	O
treatment	O
of	O
nasal	O
cannula	O
or	O
oxygen	B-CHED
mask	O
.	O

TITLE	O
:	O
The	O
SARS	O
-	O
CoV	O
S	O
glycoprotein	B-CHED
:	O
expression	O
and	O
functional	O
characterization	O
.	O

Together	O
with	O
data	O
for	O
inhibition	O
of	O
binding	O
by	O
antibodies	O
developed	O
against	O
peptides	B-CHED
from	O
S	O
,	O
these	O
findings	O
suggest	O
that	O
the	O
receptor	O
-	O
binding	O
domain	O
is	O
located	O
between	O
amino	B-CHED
acid	I-CHED
residues	O
303	O
and	O
537	O
.	O

These	O
results	O
also	O
confirm	O
that	O
ACE2	O
is	O
a	O
functional	O
receptor	O
for	O
the	O
SARS	O
virus	O
and	O
may	O
help	O
in	O
the	O
elucidation	O
of	O
the	O
mechanisms	O
of	O
SARS	O
-	O
CoV	O
entry	O
and	O
in	O
the	O
development	O
of	O
vaccine	O
immunogens	O
and	O
entry	O
inhibitors	B-CHED
.	O

The	O
present	O
study	O
demonstrated	O
that	O
N	O
protein	B-CHED
in	O
the	O
MHV	O
virion	O
nucleocapsid	O
and	O
in	O
the	O
intracellular	O
genome	O
-	O
length	O
RNP	O
complex	O
that	O
bound	O
to	O
viral	O
envelope	O
M	O
protein	B-CHED
was	O
tightly	O
self	O
-	O
associated	O
such	O
that	O
its	O
association	O
was	O
retained	O
even	O
after	O
extensive	O
RNase	O
A	O
-	O
treatment	O
of	O
the	O
RNP	O
complexes	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
possible	O
benefits	O
and	O
adverse	O
effects	O
of	O
the	O
addition	O
of	O
lopinavir	O
/	O
ritonavir	B-CHED
to	O
a	O
standard	O
treatment	O
protocol	O
for	O
the	O
treatment	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

The	O
75	O
patients	O
treated	O
with	O
lopinavir	O
/	O
ritonavir	B-CHED
were	O
divided	O
into	O
two	O
subgroups	O
for	O
analysis	O
:	O
lopinavir	O
/	O
ritonavir	B-CHED
as	O
initial	O
treatment	O
,	O
and	O
lopinavir	O
/	O
ritonavir	B-CHED
as	O
rescue	O
therapy	O
.	O

The	O
addition	O
of	O
lopinavir	O
/	O
ritonavir	B-CHED
to	O
a	O
standard	O
treatment	O
protocol	O
as	O
an	O
initial	O
treatment	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
appeared	O
to	O
be	O
associated	O
with	O
improved	O
clinical	O
outcome	O
.	O

Prudent	O
corticosteroid	B-CHED
use	O
,	O
vigilant	O
microbiological	O
surveillance	O
and	O
appropriate	O
antibiotics	B-CHED
coverage	O
are	O
the	O
key	O
to	O
successful	O
treatment	O
.	O

The	O
risk	O
factors	O
associated	O
with	O
severe	O
disease	O
were	O
presence	O
of	O
diarrhoea	O
,	O
high	O
peak	O
LDH	O
and	O
CRP	O
,	O
high	O
AST	O
and	O
creatine	B-CHED
kinase	O
on	O
admission	O
and	O
high	O
peak	O
values	O
.	O

On	O
June	O
26	O
,	O
CSTE	O
adopted	O
a	O
position	O
statement	O
to	O
add	B-CHED
SARS	O
-	O
CoV	O
disease	O
to	O
the	O
National	O
Notifiable	O
Disease	O
Surveillance	O
System	O
(	O
NNDSS	O
).	O

Here	O
we	O
demonstrate	O
that	O
a	O
193	O
-	O
amino	B-CHED
acid	I-CHED
fragment	O
of	O
the	O
S	O
protein	B-CHED
(	O
residues	O
318	O
-	O
510	O
)	O
bound	O
ACE2	O
more	O
efficiently	O
than	O
did	O
the	O
full	O
S1	O
domain	O
(	O
residues	O
12	O
-	O
672	O
).	O

In	O
this	O
work	O
,	O
the	O
M	O
protein	B-CHED
of	O
SARS	O
-	O
CoV	O
was	O
expressed	O
in	O
E	O
.	O
coli	O
as	O
fusion	O
protein	B-CHED
with	O
maltose	B-CHED
binding	O
protein	B-CHED
at	O
N	O
-	O
terminus	O
and	O
MxeGyrA	O
intein	O
CBD	O
at	O
C	O
-	O
terminus	O
.	O

ABSTRACT	O
:	O
Autologous	O
islet	O
cell	O
transplantation	O
after	O
near	O
-	O
total	O
or	O
total	O
pancreatic	O
resection	O
can	O
alleviate	O
pain	O
in	O
patients	O
with	O
severe	O
chronic	O
pancreatitis	O
and	O
preserve	O
endocrine	B-CHED
function	O
.	O

Looking	O
further	O
into	O
the	O
future	O
,	O
the	O
high	O
efficacy	O
of	O
the	O
fowl	O
adenovirus	O
vector	O
expressing	O
the	O
IBV	O
S1	O
subunit	O
provides	O
optimism	O
for	O
a	O
live	O
SARS	O
vaccine	O
,	O
if	O
that	O
were	O
deemed	O
to	O
be	O
necessary	O
,	O
with	O
the	O
possibility	O
of	O
including	O
the	O
N	O
protein	B-CHED
gene	O
.	O

Twenty	O
-	O
one	O
probable	O
new	O
genes	O
with	O
more	O
than	O
50	O
amino	B-CHED
acids	I-CHED
have	O
been	O
obtained	O
excluding	O
13	O
ORFs	O
which	O
are	O
similar	O
to	O
the	O
genes	O
of	O
NCBI	O
and	O
relative	O
articles	O
.	O

Three	O
distinct	O
chest	O
radiographic	O
patterns	O
were	O
observed	O
:	O
focal	O
peripheral	O
air	B-CHED
-	O
space	O
disease	O
at	O
presentation	O
with	O
gradual	O
resolution	O
(	O
most	O
common	O
pattern	O
,	O
10	O
/	O
13	O
patients	O
),	O
normal	O
findings	O
on	O
chest	O
radiography	O
at	O
presentation	O
followed	O
by	O
focal	O
air	B-CHED
-	O
space	O
disease	O
(	O
2	O
/	O
13	O
patients	O
),	O
and	O
normal	O
findings	O
on	O
chest	O
radiography	O
at	O
presentation	O
followed	O
by	O
a	O
""""	O
round	O
""""	O
pneumonia	O
pattern	O
(	O
1	O
/	O
13	O
patients	O
).	O

A	O
virus	O
overlay	O
protein	B-CHED
binding	O
assay	O
(	O
VOPBA	O
)	O
was	O
used	O
to	O
identify	O
PEDV	O
binding	O
protein	B-CHED
in	O
permissive	O
cells	O
.	O

ABSTRACT	O
:	O
The	O
Dead	O
Sea	O
in	O
Israel	O
has	O
a	O
very	O
high	O
mineral	B-CHED
content	O
.	O

The	O
interferon	O
alfacon	O
-	O
1	O
treatment	O
group	O
had	O
a	O
shorter	O
time	O
to	O
50	O
%	O
resolution	O
of	O
lung	O
radiographic	O
abnormalities	O
(	O
median	O
time	O
,	O
4	O
days	O
vs	O
9	O
days	O
;	O
P	O
=.	O
001	O
),	O
had	O
better	O
oxygen	B-CHED
saturation	O
(	O
P	O
=.	O
02	O
),	O
resolved	O
their	O
need	O
for	O
supplemental	O
oxygen	B-CHED
more	O
rapidly	O
(	O
median	O
,	O
10	O
days	O
vs	O
16	O
days	O
;	O
P	O
=.	O
02	O
),	O
had	O
less	O
of	O
an	O
increase	O
in	O
creatine	B-CHED
kinase	O
levels	O
(	O
P	O
=.	O
03	O
),	O
and	O
showed	O
a	O
trend	O
toward	O
more	O
rapid	O
resolution	O
of	O
lactate	B-CHED
dehydrogenase	O
levels	O
compared	O
with	O
the	O
group	O
receiving	O
corticosteroids	B-CHED
alone	O
.	O

TITLE	O
:	O
CXC	O
chemokine	O
ligand	B-CHED
10	O
controls	O
viral	O
infection	O
in	O
the	O
central	O
nervous	O
system	O
:	O
evidence	O
for	O
a	O
role	O
in	O
innate	O
immune	O
response	O
through	O
recruitment	O
and	O
activation	O
of	O
natural	O
killer	O
cells	O
.	O

Our	O
results	O
suggest	O
that	O
there	O
is	O
potential	O
for	O
developing	O
this	O
class	O
of	O
beta	B-CHED
-	I-CHED
lactams	I-CHED
into	O
novel	O
anticancer	B-CHED
agents	I-CHED
.	O

A	O
63	O
-	O
year	O
-	O
old	O
man	B-CHED
was	O
admitted	O
to	O
our	O
hospital	O
for	O
intensive	O
care	O
of	O
severe	O
acute	O
respiratory	O
failure	O
with	O
diffuse	O
infiltration	O
in	O
both	O
lungs	O
.	O

Co	O
-	O
infection	O
and	O
other	O
treatable	O
conditions	O
should	O
not	O
be	O
missed	O
and	O
conventional	O
antibiotics	B-CHED
should	O
remain	O
as	O
part	O
of	O
the	O
first	O
-	O
line	O
treatment	O
regimen	O
.	O

Furthermore	O
mice	O
with	O
gp33	O
-	O
41	O
-	O
specific	O
CD8	O
(+)	O
cells	O
exhibited	O
much	O
reduced	O
levels	O
of	O
viral	O
antigen	B-CHED
in	O
the	O
brain	O
as	O
measured	O
by	O
immunohistochemistry	O
using	O
an	O
antibody	O
directed	O
against	O
viral	O
nucleocapsid	O
.	O

We	O
genetically	O
sequenced	O
the	O
gene	O
for	O
the	O
S1	O
unit	O
of	O
the	O
viral	O
spike	O
protein	B-CHED
of	O
viruses	O
from	O
patients	O
with	O
SARS	O
in	O
Hong	O
Kong	O
(	O
138	O
)	O
and	O
Guangdong	O
(	O
three	O
)	O
in	O
February	O
to	O
April	O
,	O
2003	O
.	O

TITLE	O
:	O
Early	O
detection	O
of	O
antibodies	O
against	O
various	O
structural	O
proteins	B-CHED
of	O
the	O
SARS	O
-	O
associated	O
coronavirus	O
in	O
SARS	O
patients	O
.	O

Carbimazole	B-CHED
was	O
stopped	O
and	O
replaced	O
by	O
propylthiouracile	B-CHED
,	O
which	O
also	O
induced	O
vasculitis	O
with	O
secondary	O
cardiac	O
failure	O
.	O

No	O
statistical	O
differences	O
were	O
found	O
in	O
modes	O
of	O
oxygen	B-CHED
therapy	O
and	O
sorts	O
of	O
antibiotics	B-CHED
prescribed	O
among	O
the	O
various	O
transmission	O
generations	O
(	O
P	O
>	O
0	O
.	O
05	O
);	O
however	O
,	O
as	O
with	O
the	O
advanced	O
transmission	O
generations	O
,	O
the	O
number	O
of	O
cases	O
prescribed	O
with	O
methylprednisolone	B-CHED
,	O
human	O
gamma	O
-	O
globulin	O
,	O
interferon	O
-	O
alpha	O
,	O
antiviral	B-CHED
drugs	I-CHED
(	O
oral	O
ribavirin	B-CHED
or	O
oseltamivir	B-CHED
)	O
increased	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
time	O
from	O
admission	O
to	O
starting	O
these	O
medication	O
shortened	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

These	O
genotypes	O
can	O
also	O
be	O
approved	O
by	O
phylogenetic	O
tree	O
of	O
three	O
levels	O
of	O
44	O
loci	O
of	O
mutation	O
,	O
spike	O
glycoprotein	B-CHED
gene	O
and	O
complete	O
genome	O
sequence	O
.	O

By	O
chromatography	O
on	O
nickel	B-CHED
-	O
agarose	B-CHED
column	O
,	O
the	O
expressed	O
N	O
protein	B-CHED
was	O
purified	O
to	O
near	O
homogeneity	O
as	O
judged	O
by	O
sodium	B-CHED
dodecyl	I-CHED
sulfate	I-CHED
-	O
polyacrylamide	B-CHED
gel	O
electrophoresis	O
analysis	O
.	O

PaO2	O
,	O
pH	O
,	O
MAP	O
and	O
survival	O
rate	O
were	O
recorded	O
and	O
plasma	O
NO	O
,	O
TNF	O
-	O
alpha	O
were	O
measured	O
during	O
5	O
-	O
hr	O
after	O
the	O
injection	O
of	O
LPS	B-CHED
.	O

We	O
previously	O
demonstrated	O
that	O
JHM	O
-	O
infected	O
mice	O
that	O
only	O
have	O
CD8	O
T	O
cells	O
specific	O
for	O
an	O
epitope	B-CHED
not	O
in	O
the	O
virus	O
develop	O
demyelination	O
on	O
specific	O
activation	O
of	O
these	O
cells	O
.	O

The	O
administration	O
of	O
morphine	B-CHED
was	O
fundamental	O
to	O
achieving	O
an	O
optimal	O
level	O
of	O
sedation	O
.	O

The	O
optimal	O
level	O
of	O
sedation	O
is	O
achieved	O
with	O
the	O
addition	O
of	O
morphine	B-CHED
.	O

RESULTS	O
:	O
The	O
administration	O
of	O
morphine	B-CHED
was	O
fundamental	O
to	O
achieving	O
an	O
optimal	O
level	O
of	O
sedation	O
.	O

A	O
distinct	O
viral	O
antigen	B-CHED
distribution	O
in	O
specific	O
CNS	B-CHED
cell	O
types	O
revealed	O
different	O
mechanisms	O
of	O
viral	O
control	O
.	O

In	O
addition	O
,	O
psychiatric	O
specialists	O
in	O
six	O
countries	O
have	O
provided	O
their	O
national	O
Psychosomatic	O
Medicine	B-CHED
(	O
Consultation	O
-	O
Liaison	O
)	O
lists	O
as	O
examples	O
of	O
what	O
they	O
regard	O
as	O
the	O
most	O
important	O
teaching	O
materials	O
journals	O
:	O
Australia	O
,	O
Brazil	O
,	O
Greece	O
,	O
Mexico	O
,	O
Portugal	O
,	O
and	O
Taiwan	O
.	O

Antibodies	O
that	O
specifically	O
recognize	O
the	O
SARS	O
-	O
CoV	O
spike	O
and	O
nucleocapsid	O
proteins	B-CHED
may	O
provide	O
a	O
rapid	O
screening	O
method	O
to	O
allow	O
accurate	O
identification	O
and	O
isolation	O
of	O
patients	O
with	O
the	O
virus	O
early	O
in	O
their	O
infection	O
.	O

RESULTS	O
:	O
All	O
patients	O
received	O
high	O
-	O
dose	O
pulse	O
methylprednisolone	B-CHED
(	O
minimum	O
,	O
2	O
.	O
5	O
g	O
total	O
),	O
and	O
all	O
patients	O
who	O
received	O
ventilation	O
received	O
low	O
-	O
pressure	O
,	O
low	O
-	O
volume	O
ventilation	O
.	O

TITLE	O
:	O
Surfactant	B-CHED
lavage	O
with	O
lidocaine	B-CHED
improves	O
pulmonary	O
function	O
in	O
piglets	O
after	O
HCl	B-CHED
-	O
induced	O
acute	O
lung	O
injury	O
.	O

In	O
our	O
HCl	B-CHED
ALI	O
model	O
,	O
SL	O
improved	O
oxygenation	O
and	O
quasi	O
-	O
static	O
lung	O
compliance	O
over	O
C	O
.	O
The	O
pulmonary	O
function	O
effects	O
of	O
SL	O
were	O
further	O
enhanced	O
by	O
the	O
addition	O
of	O
Lidocaine	B-CHED
to	O
the	O
surfactant	B-CHED
suspension	O
.	O

ABSTRACT	O
:	O
The	O
angiotensin	B-CHED
-	O
converting	O
enzyme	O
(	O
ACE	O
)-	O
related	O
carboxypeptidase	O
,	O
ACE2	O
,	O
is	O
a	O
type	O
I	O
integral	O
membrane	O
protein	B-CHED
of	O
805	O
amino	B-CHED
acids	I-CHED
that	O
contains	O
one	O
HEXXH	O
+	O
E	O
zinc	B-CHED
-	O
binding	O
consensus	O
sequence	O
.	O

Glycosylation	O
modification	O
in	O
S	O
protein	B-CHED
was	O
also	O
analyzed	O
and	O
four	O
glycosylation	O
sites	O
were	O
discovered	O
by	O
comparing	O
the	O
mass	O
spectra	O
before	O
and	O
after	O
deglycosylation	O
of	O
the	O
peptides	B-CHED
with	O
PNGase	O
F	O
digestion	O
.	O

Interferon	O
-	O
gamma	O
inducible	O
protein	B-CHED
-	O
10	O
kDa	O
(	O
IP	O
-	O
10	O
)	O
is	O
a	O
CXC	O
chemokine	O
and	O
a	O
chemoattractant	O
for	O
CXCR3	O
+	O
T	O
cells	O
.	O

IP	O
-	O
10	O
mRNA	B-CHED
is	O
expressed	O
in	O
the	O
CNS	B-CHED
during	O
TMEV	O
infection	O
.	O

ABSTRACT	O
:	O
Upregulation	O
of	O
the	O
anti	O
-	O
inflammatory	O
mediators	O
,	O
soluble	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
receptors	O
I	O
and	O
II	O
(	O
sTNFRI	O
/	O
RII	O
)	O
and	O
interleukin	O
-	O
1	O
receptor	O
antagonist	B-CHED
(	O
IL	O
-	O
1RA	O
),	O
by	O
granulocyte	O
colony	O
-	O
stimulating	O
factor	O
(	O
G	O
-	O
CSF	O
)	O
may	O
contribute	O
to	O
the	O
pathophysiology	O
of	O
lung	O
injury	O
.	O

In	O
each	O
of	O
these	O
three	O
viral	O
tests	O
,	O
all	O
cats	O
positive	O
for	O
serum	O
antibody	O
/	O
antigen	B-CHED
were	O
also	O
positive	O
for	O
ascitic	O
antibody	O
/	O
antigen	B-CHED
,	O
while	O
cats	O
negative	O
for	O
serum	O
antibody	O
/	O
antigen	B-CHED
were	O
also	O
negative	O
for	O
ascitic	O
antibody	O
/	O
antigen	B-CHED
.	O

TITLE	O
:	O
The	O
nsp9	O
replicase	O
protein	B-CHED
of	O
SARS	O
-	O
coronavirus	O
,	O
structure	O
and	O
functional	O
insights	O
.	O

The	O
fold	O
superficially	O
resembles	O
an	O
OB	O
-	O
fold	O
with	O
a	O
C	O
-	O
terminal	O
extension	O
and	O
is	O
related	O
to	O
both	O
of	O
the	O
two	O
subdomains	O
of	O
the	O
SARS	O
-	O
CoV	O
3C	O
-	O
like	O
protease	O
(	O
which	O
belongs	O
to	O
the	O
serine	B-CHED
protease	O
superfamily	O
).	O

Belonging	O
to	O
one	O
of	O
the	O
major	O
proteins	B-CHED
associated	O
with	O
SARS_CoV	O
,	O
SARS	O
3C	O
-	O
like	O
protease	O
(	O
SARS_3CL	O
(	O
pro	B-CHED
))	O
functions	O
as	O
a	O
cysteine	B-CHED
protease	O
engaging	O
in	O
the	O
proteolytic	O
cleavage	O
of	O
the	O
viral	O
precursor	O
polyprotein	O
to	O
a	O
series	O
of	O
functional	O
proteins	B-CHED
required	O
for	O
coronavirus	O
replication	O
and	O
is	O
considered	O
as	O
an	O
appealing	O
target	O
for	O
designing	O
anti	O
-	O
SARS	O
agents	O
.	O

To	O
facilitate	O
the	O
studies	O
regarding	O
the	O
functions	O
and	O
structures	O
of	O
SARS_3CL	O
(	O
pro	B-CHED
),	O
in	O
this	O
report	O
the	O
synthetic	O
genes	O
encoding	O
3CL	O
(	O
pro	B-CHED
)	O
of	O
SARS_CoV	O
were	O
assembled	O
,	O
and	O
the	O
plasmid	O
was	O
constructed	O
using	O
pQE30	O
as	O
vector	O
and	O
expressed	O
in	O
Escherichia	O
coli	O
M15	O
cells	O
.	O

After	O
purification	O
,	O
the	O
recombinant	O
protein	B-CHED
was	O
identified	O
by	O
anti	O
-	O
SARS	O
positive	O
sera	O
from	O
recovered	O
SARS	O
patients	O
.	O

The	O
recombinant	O
N	O
-	O
terminal	O
protein	B-CHED
of	O
SARS	O
virus	O
S1	O
subunit	O
displays	O
specific	O
reaction	O
with	O
SARS	O
antibody	O
and	O
may	O
provide	O
a	O
good	O
tool	O
for	O
further	O
research	O
of	O
immune	O
response	O
to	O
SARS	O
virus	O
.	O

TITLE	O
:	O
Mouse	O
hepatitis	O
virus	O
neurovirulence	O
:	O
evidence	O
of	O
a	O
linkage	O
between	O
S	O
glycoprotein	B-CHED
expression	O
and	O
immunopathology	O
.	O

Previously	O
,	O
we	O
found	O
that	O
MHV	O
-	O
JHM	O
neurovirulence	O
was	O
marked	O
by	O
diminished	O
expression	O
of	O
interferon	O
-	O
gamma	O
(	O
IFN	O
-	O
gamma	O
)	O
mRNA	B-CHED
and	O
a	O
reduced	O
presence	O
of	O
CD8	O
T	O
cells	O
in	O
the	O
CNS	B-CHED
concomitant	O
with	O
heightened	O
macrophage	O
inflammatory	O
protein	B-CHED
(	O
MIP	O
)-	O
1	O
transcript	O
levels	O
and	O
greater	O
macrophage	O
infiltration	O
relative	O
to	O
MHV	O
-	O
A59	O
infection	O
.	O

Furthermore	O
,	O
high	O
levels	O
of	O
macrophage	O
-	O
inflammatory	O
protein	B-CHED
(	O
MIP	B-CHED
)-	O
1alpha	O
,	O
MIP	B-CHED
-	O
1beta	O
,	O
and	O
MIP	B-CHED
-	O
2	O
mRNA	B-CHED
were	O
observed	O
at	O
the	O
onset	O
of	O
MHV	O
-	O
JHM	O
infection	O
and	O
correlated	O
with	O
a	O
marked	O
elevation	O
in	O
the	O
number	O
of	O
macrophages	O
in	O
the	O
brain	O
on	O
day	O
7	O
compared	O
to	O
MHV	O
-	O
A59	O
infection	O
.	O

TITLE	O
:	O
Hypothesis	O
links	O
emergence	O
of	O
chloroquine	B-CHED
-	O
resistant	O
malaria	O
and	O
other	O
intracellular	O
pathogens	O
and	O
suggests	O
a	O
new	O
strategy	O
for	O
treatment	O
of	O
diseases	O
caused	O
by	O
intracellular	O
parasites	O
.	O

ABSTRACT	O
:	O
Chloroquine	B-CHED
and	O
related	O
anti	O
-	O
malarial	O
drugs	O
appear	O
to	O
promote	O
apoptosis	O
in	O
T	O
-	O
cells	O
by	O
suppressing	O
NF	O
-	O
kappa	O
-	O
B	O
,	O
which	O
enhances	O
the	O
expression	O
of	O
anti	O
-	O
apoptotic	O
proteins	B-CHED
(	O
e	O
.	O
g	O
.,	O
Bcl	O
-	O
2	O
).	O

The	O
mode	O
of	O
action	O
of	O
chloroquine	B-CHED
in	O
prevention	O
of	O
malaria	O
is	O
not	O
known	O
,	O
but	O
it	O
may	O
be	O
to	O
minimize	O
replication	O
of	O
the	O
parasite	O
in	O
the	O
liver	O
cells	O
,	O
which	O
occurs	O
before	O
invasion	O
of	O
the	O
erythrocytes	O
,	O
by	O
facilitating	O
premature	O
apoptosis	O
of	O
the	O
infected	O
host	O
cells	O
.	O

The	O
hypothesis	O
holds	O
that	O
prophylactic	O
exposure	O
to	O
pro	B-CHED
-	O
apoptotic	O
chloroquine	B-CHED
drugs	O
caused	O
natural	O
selection	O
for	O
strains	O
of	O
viruses	O
and	O
other	O
parasites	O
that	O
have	O
enhanced	O
anti	O
-	O
apoptotic	O
abilities	O
.	O

Avoiding	O
secondary	O
insults	O
is	O
the	O
cornerstone	O
of	O
supportive	O
care	O
,	O
and	O
this	O
is	O
based	O
primarily	O
on	O
aggressive	O
immune	O
surveillance	O
,	O
full	O
nutrition	O
,	O
and	O
unrelenting	O
oxygen	B-CHED
delivery	O
.	O

We	O
also	O
show	O
that	O
prophylactic	O
treatment	O
of	O
SCV	O
-	O
infected	O
macaques	O
with	O
the	O
antiviral	B-CHED
agent	I-CHED
pegylated	O
interferon	O
-	O
alpha	O
(	O
IFN	O
-	O
alpha	O
)	O
significantly	O
reduces	O
viral	O
replication	O
and	O
excretion	O
,	O
viral	O
antigen	B-CHED
expression	O
by	O
type	O
1	O
pneumocytes	O
and	O
pulmonary	O
damage	O
,	O
compared	O
with	O
untreated	O
macaques	O
.	O

9	O
cmH2O	O
and	O
the	O
collapsing	O
PEEP	B-CHED
was	O
13	O
+/-	O

ABSTRACT	O
:	O
We	O
present	O
the	O
case	O
of	O
a	O
4	O
-	O
year	O
-	O
old	O
boy	O
with	O
malaria	O
who	O
developed	O
acute	O
respiratory	O
distress	O
syndrome	O
with	O
severe	O
hypoxemia	O
refractory	O
to	O
mechanical	O
ventilation	O
and	O
inhaled	O
nitric	B-CHED
oxide	I-CHED
.	O

TITLE	O
:	O
Potent	O
neutralization	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
by	O
a	O
human	O
mAb	O
to	O
S1	O
protein	B-CHED
that	O
blocks	O
receptor	O
association	O
.	O

We	O
have	O
identified	O
eight	O
recombinant	O
human	O
single	O
-	O
chain	O
variable	O
region	O
fragments	O
(	O
scFvs	O
)	O
against	O
the	O
S1	O
domain	O
of	O
spike	O
(	O
S	O
)	O
protein	B-CHED
of	O
the	O
SARS	O
-	O
CoV	O
from	O
two	O
nonimmune	O
human	O
antibody	O
libraries	O
.	O

Mapping	O
of	O
the	O
80R	O
epitope	B-CHED
showed	O
it	O
is	O
located	O
within	O
the	O
N	O
-	O
terminal	O
261	O
-	O
672	O
amino	B-CHED
acids	I-CHED
of	O
S	O
protein	B-CHED
and	O
is	O
not	O
glycosylation	O
-	O
dependent	O
.	O

We	O
showed	O
that	O
the	O
secreting	O
forms	O
of	O
S1	O
,	O
S2	O
subunits	O
and	O
the	O
N	O
-	O
terminus	O
of	O
S1	O
subunit	O
(	O
residues	O
18	O
-	O
495	O
)	O
were	O
capable	O
of	O
eliciting	O
SARS	O
-	O
CoV	O
specific	O
antibodies	O
and	O
the	O
region	O
immediate	O
to	O
N	O
-	O
terminus	O
of	O
matured	O
S1	O
protein	B-CHED
contained	O
an	O
important	O
immunogenic	O
determinant	O
for	O
elicitation	O
of	O
SARS	O
-	O
CoV	O
specific	O
antibodies	O
.	O

The	O
clinical	O
progress	O
and	O
virological	O
outcomes	O
were	O
monitored	O
and	O
compared	O
with	O
111	O
patients	O
treated	O
with	O
ribavirin	B-CHED
only	O
who	O
served	O
as	O
historical	O
controls	O
.	O

We	O
constructed	O
specific	O
siRNAs	O
targeting	O
the	O
S	O
gene	O
in	O
SARS	O
-	O
CoV	O
.	O
We	O
demonstrated	O
that	O
the	O
siRNAs	O
could	O
effectively	O
and	O
specifically	O
inhibit	O
gene	O
expression	O
of	O
Spike	O
protein	B-CHED
in	O
SARS	O
-	O
CoV	O
-	O
infected	O
cells	O
.	O

TITLE	O
:	O
Requirements	O
for	O
CEACAMs	O
and	O
cholesterol	B-CHED
during	O
murine	O
coronavirus	O
cell	O
entry	O
.	O

We	O
considered	O
whether	O
cholesterol	B-CHED
was	O
indirectly	O
involved	O
in	O
membrane	O
fusion	O
by	O
condensing	O
CEACAMs	O
into	O
""""	O
lipid	B-CHED
raft	O
""""	O
membrane	O
microdomains	O
,	O
thereby	O
creating	O
opportunities	O
for	O
simultaneous	O
binding	O
of	O
multiple	O
S	O
proteins	B-CHED
that	O
subsequently	O
cooperate	O
in	O
the	O
receptor	O
-	O
triggered	O
membrane	O
fusion	O
process	O
.	O

However	O
,	O
the	O
vast	O
majority	O
of	O
CEACAMs	O
were	O
solubilized	O
by	O
cold	O
Triton	B-CHED
X	I-CHED
-	I-CHED
100	I-CHED
(	O
TX	O
-	O
100	O
),	O
indicating	O
their	O
absence	O
from	O
lipid	B-CHED
rafts	O
.	O

IBV	O
D	O
-	O
RNAs	O
containing	O
the	O
chloramphenicol	B-CHED
acetyltransferase	O
(	O
CAT	O
)	O
reporter	O
gene	O
,	O
under	O
EMCV	O
IRES	O
control	O
,	O
were	O
assessed	O
for	O
IRES	O
-	O
mediated	O
CAT	O
protein	B-CHED
translation	O
.	O

CAT	O
protein	B-CHED
was	O
detected	O
from	O
T7	O
-	O
derived	O
IBV	O
D	O
-	O
RNA	O
transcripts	O
in	O
a	O
cell	O
-	O
free	O
protein	B-CHED
synthesis	O
system	O
and	O
in	O
situ	O
in	O
avian	O
chick	O
kidney	O
(	O
CK	O
)	O
cells	O
following	O
T7	O
-	O
derived	O
D	O
-	O
RNA	O
synthesis	O
from	O
a	O
recombinant	O
fowlpox	O
virus	O
expressing	O
the	O
bacteriophage	O
T7	O
DNA	O
-	O
dependent	O
RNA	O
polymerase	O
.	O

ISAV	O
completely	O
de	O
-	O
O	O
-	O
acetylated	O
glycoprotein	B-CHED
-	O
bound	O
5	O
-	O
N	O
-	O
acetyl	B-CHED
-	O
4	O
-	O
O	O
-	O
acetyl	B-CHED
neuraminic	B-CHED
acid	I-CHED
.	O

The	O
S1	O
glycoprotein	B-CHED
gene	O
of	O
IBV	O
isolates	O
were	O
amplified	O
by	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
analyzed	O
by	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
RFLP	O
)	O
analysis	O
.	O

Korean	O
IBV	O
isolates	O
showed	O
amino	B-CHED
acid	I-CHED
sequence	O
similarity	O
between	O
61	O
.	O
8	O
%	O
(	O
K446	O
-	O
01	O
and	O
K161	O
-	O
02	O
)	O
and	O
96	O
.	O
1	O
%	O
(	O
K281	O
-	O
01	O
and	O
K210	O
-	O
02	O
)	O
with	O
each	O
other	O
and	O
they	O
showed	O
amino	B-CHED
acid	I-CHED
sequence	O
similarity	O
between	O
42	O
.	O
9	O
%	O
(	O
K161	O
-	O
02	O
and	O
GA980470	O
)	O
and	O
96	O
.	O
5	O
%	O
(	O
K203	O
-	O
02	O
and	O
KB8523	O
)	O
compared	O
to	O
non	O
-	O
Korean	O
IBV	O
strains	O
.	O

Other	O
agents	O
,	O
including	O
the	O
HIV	B-CHED
protease	I-CHED
inhibitor	I-CHED
glycyrrhizin	B-CHED
and	O
convalescent	O
plasma	O
,	O
remain	O
to	O
be	O
evaluated	O
.	O

Here	O
,	O
we	O
describe	O
the	O
development	O
and	O
validation	O
of	O
an	O
oligonucleotide	B-CHED
resequencing	O
array	O
for	O
interrogating	O
the	O
entire	O
30	O
-	O
kb	O
SARS	O
-	O
CoV	O
genome	O
in	O
a	O
rapid	O
,	O
cost	O
-	O
effective	O
fashion	O
.	O

Dramatic	O
clinical	O
resolution	O
was	O
obtained	O
by	O
using	O
corticosteroids	B-CHED
.	O

ABSTRACT	O
:	O
The	O
spike	O
(	O
S	O
)	O
glycoprotein	B-CHED
of	O
coronaviruses	O
mediates	O
viral	O
entry	O
into	O
host	O
cells	O
.	O

The	O
risk	O
of	O
acute	O
chest	O
syndrome	O
is	O
significantly	O
associated	O
with	O
high	O
systemic	O
exposure	O
to	O
morphine	B-CHED
and	O
its	O
active	O
metabolite	B-CHED
morphine	B-CHED
-	O
6	O
-	O
glucuronide	B-CHED
after	O
oral	O
administration	O
of	O
slow	O
-	O
release	O
morphine	B-CHED
.	O

ABSTRACT	O
:	O
Nosocomial	O
transmission	O
of	O
droplet	O
-	O
borne	O
respiratory	O
infections	O
such	O
as	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
may	O
be	O
influenced	O
by	O
the	O
choice	O
of	O
oxygen	B-CHED
face	O
mask	O
.	O

High	O
-	O
level	O
allergen	B-CHED
exposure	O
,	O
exposure	O
to	O
tobacco	O
smoke	O
,	O
and	O
lack	O
of	O
breast	O
-	O
feeding	O
showed	O
no	O
association	O
with	O
wheezing	O
.	O

We	O
conclude	O
that	O
prolonged	O
dysregulated	O
cytokine	O
production	O
occurs	O
in	O
SARS	O
and	O
that	O
future	O
studies	O
should	O
be	O
directed	O
at	O
improving	O
anti	O
-	O
inflammatory	O
and	O
antiviral	B-CHED
therapies	O
in	O
order	O
to	O
limit	O
cytokine	O
impairment	O
.	O

Concurrent	O
infection	O
with	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
did	O
not	O
affect	O
the	O
responses	O
to	O
dietary	O
antigens	B-CHED
at	O
weaning	O
,	O
nor	O
did	O
it	O
affect	O
the	O
subsequent	O
development	O
of	O
tolerance	O
.	O

A	O
total	O
of	O
81	O
sera	O
,	O
including	O
67	O
from	O
convalescent	O
patients	O
and	O
seven	O
pairs	O
from	O
two	O
time	O
points	O
of	O
infection	O
,	O
were	O
analyzed	O
,	O
and	O
all	O
showed	O
immunoreactivity	O
towards	O
the	O
nucleocapsid	O
protein	B-CHED
(	O
N	O
).	O

TITLE	O
:	O
Identification	O
of	O
an	O
HLA	O
-	O
A	O
*	O
0201	O
-	O
restricted	O
CD8	O
+	O
T	O
-	O
cell	O
epitope	B-CHED
SSp	O
-	O
1	O
of	O
SARS	O
-	O
CoV	O
spike	O
protein	B-CHED
.	O

Peptides	B-CHED
with	O
high	O
affinity	O
for	O
HLA	O
-	O
A	O
*	O
0201	O
were	O
then	O
assessed	O
for	O
their	O
capacity	O
to	O
elicit	O
specific	O
immune	O
responses	O
mediated	O
by	O
cytotoxic	O
T	O
lymphocytes	O
(	O
CTLs	O
)	O
both	O
in	O
vivo	O
,	O
in	O
HLA	O
-	O
A2	O
.	O
1	O
/	O
K	O
(	O
b	O
)	O
transgenic	O
mice	O
,	O
and	O
in	O
vitro	O
,	O
from	O
peripheral	O
blood	O
lymphocytes	O
(	O
PBLs	O
)	O
harvested	O
from	O
healthy	O
HLA	O
-	O
A2	O
.	O
1	O
(+)	O
donors	O
.	O

Angiotensin	B-CHED
converting	O
enzyme	B-CHED
inhibitors	I-CHED
and	O
angiotensin	B-CHED
II	I-CHED
receptor	O
antagonists	B-CHED
should	O
be	O
discontinued	O
due	O
to	O
fetotoxicity	O
.	O

Mainland	O
China	O
and	O
Hong	O
Kong	O
,	O
SAR	B-CHED
,	O
accounted	O
for	O
87	O
%	O
of	O
all	O
cases	O
and	O
84	O
%	O
of	O
all	O
deaths	O
.	O

Common	O
laboratory	O
features	O
include	O
lymphopenia	O
with	O
depletion	O
of	O
CD4	O
and	O
CD8	O
lymphocytes	O
,	O
thrombocytopenia	O
,	O
prolonged	O
activated	O
partial	O
thromboplastin	O
time	O
,	O
elevated	O
D	O
-	O
Dimer	O
,	O
elevated	O
alanine	B-CHED
transminases	O
,	O
lactate	B-CHED
dehydrogenase	O
and	O
creatinine	B-CHED
kinase	O
.	O

The	O
constellation	O
of	O
compatible	O
clinical	O
and	O
laboratory	O
findings	O
,	O
together	O
with	O
the	O
rather	O
characteristic	O
radiological	O
features	O
especially	O
on	O
HRCT	O
and	O
the	O
lack	O
of	O
clinical	O
response	O
to	O
broad	O
-	O
spectrum	O
antibiotics	B-CHED
,	O
should	O
quickly	O
arouse	O
suspicion	O
of	O
SARS	O
.	O

Nevertheless	O
,	O
lower	O
dosage	O
of	O
steroid	B-CHED
as	O
initial	O
therapy	O
in	O
SARS	O
had	O
also	O
been	O
associated	O
with	O
good	O
clinical	O
outcomes	O
.	O

Poor	O
responders	O
to	O
initial	O
therapy	O
might	O
benefit	O
from	O
rescue	O
steroid	B-CHED
therapy	O
or	O
intravenous	O
Pentaglobin	O
.	O

ABSTRACT	O
:	O
A	O
1	O
.	O
78	O
kb	O
sequence	O
,	O
including	O
the	O
E	O
,	O
M	O
,	O
5a	O
and	O
5b	O
genes	O
,	O
and	O
the	O
intergenic	O
region	O
between	O
the	O
M	O
and	O
5a	O
genes	O
,	O
of	O
six	O
US	O
strains	O
of	O
infectious	O
bronchitis	O
(	O
corona	B-CHED
)	O
virus	O
(	O
IBV	O
)	O
were	O
sequenced	O
and	O
compared	O
to	O
the	O
published	O
sequences	O
for	O
two	O
additional	O
strains	O
.	O

N	O
proteins	B-CHED
of	O
other	O
coronavirus	O
have	O
been	O
reported	O
to	O
be	O
involved	O
in	O
forming	O
the	O
viral	O
core	O
and	O
also	O
in	O
the	O
packaging	O
and	O
transcription	O
of	O
the	O
viral	O
RNA	O
.	O

By	O
using	O
mammalian	O
two	O
-	O
hybrid	O
system	O
and	O
sucrose	B-CHED
gradient	O
fractionations	O
,	O
a	O
homotypic	O
interaction	O
of	O
N	O
,	O
but	O
not	O
M	O
,	O
was	O
detected	O
by	O
the	O
two	O
-	O
hybrid	O
analysis	O
.	O

A	O
review	O
of	O
clinical	O
trial	O
evidence	O
differs	O
from	O
observational	O
studies	O
that	O
demonstrate	O
a	O
clear	O
benefit	O
of	O
the	O
polysaccharide	B-CHED
pneumococcal	O
vaccine	O
in	O
the	O
elderly	O
.	O

TITLE	O
:	O
N	B-CHED
-	I-CHED
acetylcysteine	I-CHED
attenuates	O
lung	O
injury	O
in	O
a	O
rodent	O
model	O
of	O
fracture	O
.	O

Bilateral	O
femur	O
fracture	O
produced	O
a	O
significant	O
lung	O
injury	O
,	O
measured	O
by	O
increases	O
in	O
MPO	O
(	O
25	O
-	O
43	O
microg	O
/	O
g	O
tissue	O
)	O
and	O
BAL	B-CHED
protein	B-CHED
(	O
460	O
-	O
605	O
microg	O
/	O
mL	O
).	O

Here	O
,	O
we	O
show	O
that	O
a	O
DNA	O
vaccine	O
encoding	O
the	O
spike	O
(	O
S	O
)	O
glycoprotein	B-CHED
of	O
the	O
SARS	O
-	O
CoV	O
induces	O
T	O
cell	O
and	O
neutralizing	O
antibody	O
responses	O
,	O
as	O
well	O
as	O
protective	O
immunity	O
,	O
in	O
a	O
mouse	O
model	O
.	O

Because	O
no	O
effective	O
treatments	O
are	O
available	O
,	O
an	O
intensive	O
effort	O
is	O
under	O
way	O
to	O
identify	O
and	O
test	O
promising	O
antiviral	B-CHED
drugs	I-CHED
.	O

These	O
three	O
structures	O
and	O
the	O
coronavirus	O
particles	O
were	O
shown	O
to	O
be	O
positive	O
for	O
viral	O
proteins	B-CHED
and	O
RNA	O
by	O
using	O
ultrastructural	O
immunogold	O
and	O
in	O
situ	O
hybridization	O
assays	O
.	O

In	O
April	O
2003	O
,	O
in	O
response	O
to	O
the	O
SARS	O
outbreak	O
,	O
the	O
federal	O
executive	O
branch	O
acted	O
rapidly	O
to	O
add	B-CHED
SARS	O
to	O
the	O
list	O
of	O
quarantinable	O
communicable	O
diseases	O
.	O

In	O
contrast	O
,	O
IFN	O
-	O
alpha	O
showed	O
an	O
in	O
vitro	O
inhibitory	O
effect	O
starting	O
at	O
concentrations	O
of	O
1000	O
IU	O
/	O
mL	O
.	O
In	O
conclusion	O
,	O
ribavirin	B-CHED
alone	O
is	O
unlikely	O
to	O
be	O
beneficial	O
in	O
the	O
prophylaxis	O
or	O
treatment	O
of	O
SARS	O
CoV	O
infections	O
.	O

The	O
results	O
of	O
the	O
last	O
Critical	O
Assessment	O
of	O
Techniques	O
for	O
Protein	B-CHED
Structure	O
Prediction	O
(	O
CASP5	O
)	O
demonstrated	O
that	O
the	O
quality	O
of	O
homology	O
modeling	O
prediction	O
has	O
improved	O
;	O
reaching	O
a	O
level	O
of	O
reliability	O
that	O
biologists	O
can	O
now	O
confidently	O
use	O
homology	O
modeling	O
.	O

In	O
addition	O
,	O
administration	O
of	O
anti	O
-	O
CCL5	O
improved	O
neurological	O
function	O
and	O
significantly	O
(	O
p	O
<	O
or	O
=	O
0	O
.	O
005	O
)	O
reduced	O
the	O
severity	O
of	O
demyelination	O
and	O
macrophage	O
accumulation	O
within	O
the	O
CNS	B-CHED
.	O

We	O
examined	O
the	O
effects	O
of	O
pioglitazone	B-CHED
,	O
a	O
synthetic	O
ligand	B-CHED
of	O
PPAR	O
-	O
gamma	O
,	O
against	O
lung	O
ischemia	O
-	O
reperfusion	O
injury	O
in	O
rats	O
.	O

Pioglitazone	B-CHED
did	O
not	O
affect	O
the	O
lung	O
in	O
the	O
sham	O
animals	O
.	O

Pioglitazone	B-CHED
treatment	O
before	O
ischemia	O
attenuated	O
lung	O
ischemia	O
-	O
reperfusion	O
injury	O
in	O
rats	O
.	O

Also	O
inactivated	O
preparations	O
of	O
viruses	O
from	O
the	O
paramyxo	O
-	O
(	O
Newcastle	O
disease	O
virus	O
),	O
rhabdo	O
-	O
(	O
rabies	O
virus	O
),	O
corona	B-CHED
-	O
(	O
infectious	O
bronchitis	O
virus	O
)	O
and	O
reovirus	O
(	O
avian	O
reovirus	O
)	O
families	O
led	O
to	O
IgG2a	O
antibody	O
responses	O
;	O
however	O
,	O
the	O
genetic	O
background	O
of	O
the	O
host	O
did	O
result	O
in	O
considerable	O
variation	O
.	O

The	O
factors	O
that	O
delay	O
treatment	O
of	O
TB	O
in	O
N	O
'	O
Djaména	O
are	O
that	O
(	O
1	O
)	O
TB	O
diagnosis	O
in	O
peripheral	O
hospitals	O
lengthens	O
physician	O
delay	O
,	O
and	O
(	O
2	O
)	O
seeking	O
initial	O
treatment	O
outside	O
conventional	O
medicine	B-CHED
lengthens	O
patient	O
delay	O
.	O

The	O
use	O
of	O
corticosteroid	B-CHED
was	O
based	O
on	O
the	O
similarity	O
between	O
SARS	O
and	O
bronchiolitis	O
obliterans	O
organizing	O
pneumonia	O
.	O

CP	O
-	O
1	O
alone	O
had	O
low	O
alpha	O
-	O
helicity	O
and	O
self	O
-	O
associated	O
to	O
form	O
a	O
trimer	O
in	O
phosphate	B-CHED
buffer	B-CHED
(	O
pH	O
7	O
.	O
2	O
).	O

These	O
synthetic	O
peptides	B-CHED
were	O
used	O
to	O
immunize	O
both	O
rabbits	O
and	O
monkeys	O
.	O

Four	O
of	O
our	O
six	O
synthetic	O
peptides	B-CHED
(	O
S2	O
,	O
S3	O
,	O
S5	O
,	O
and	O
S6	O
)	O
elicited	O
SARS	O
-	O
CoV	O
-	O
specific	O
antibodies	O
,	O
of	O
which	O
S5	O
(	O
residues	O
788	O
-	O
820	O
)	O
and	O
S6	O
(	O
residues	O
1002	O
-	O
1030	O
)	O
exhibited	O
immunogenic	O
responses	O
similar	O
to	O
those	O
found	O
in	O
a	O
parallel	O
investigation	O
using	O
truncated	O
recombinant	O
protein	B-CHED
analogs	O
of	O
the	O
SARS	O
-	O
CoV	O
S	O
protein	B-CHED
.	O

This	O
suggested	O
that	O
our	O
S5	O
and	O
S6	O
peptides	B-CHED
may	O
represent	O
two	O
minimum	O
biologically	O
active	O
sequences	O
of	O
the	O
immunogenic	O
regions	O
of	O
the	O
SARS	O
-	O
CoV	O
S	O
protein	B-CHED
.	O

Synthetic	O
peptides	B-CHED
can	O
elicit	O
specific	O
antibodies	O
to	O
SARS	O
-	O
CoV	O
.	O
The	O
study	O
provides	O
insights	O
for	O
the	O
future	O
development	O
of	O
SARS	O
vaccine	O
via	O
the	O
synthetic	O
-	O
peptide	B-CHED
-	O
based	O
approach	O
.	O

TITLE	O
:	O
Antigenicity	O
analysis	O
of	O
different	O
regions	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
nucleocapsid	O
protein	B-CHED
.	O

The	O
cDNA	O
for	O
full	O
-	O
length	O
N	O
protein	B-CHED
and	O
its	O
various	O
regions	O
from	O
the	O
SARS	O
-	O
CoV	O
was	O
cloned	O
and	O
expressed	O
in	O
Escherichia	O
coli	O
.	O

The	O
N	O
protein	B-CHED
is	O
a	O
highly	O
immunogenic	O
protein	B-CHED
of	O
the	O
SARS	O
-	O
CoV	O
.	O
Conformational	O
epitopes	O
are	O
important	O
for	O
this	O
protein	B-CHED
,	O
and	O
antigenicity	O
of	O
the	O
COOH	O
terminus	O
is	O
higher	O
than	O
that	O
of	O
the	O
NH	O
(	O
2	O
)	O
terminus	O
.	O

Four	O
types	O
were	O
identified	O
:	O
good	O
water	B-CHED
repellency	O
and	O
water	B-CHED
resistance	O
,	O
poor	O
air	B-CHED
permeability	O
(	O
Type	O
A	O
PPC	O
);	O
good	O
water	B-CHED
repellency	O
and	O
air	B-CHED
permeability	O
,	O
poor	O
water	B-CHED
resistance	O
(	O
Type	O
B	O
PPC	O
);	O
poor	O
water	B-CHED
repellency	O
,	O
poor	O
water	B-CHED
resistance	O
,	O
and	O
fair	O
air	B-CHED
permeability	O
(	O
Type	O
C	O
PPC	O
);	O
and	O
good	O
water	B-CHED
repellency	O
,	O
poor	O
air	B-CHED
permeability	O
,	O
and	O
fair	O
water	B-CHED
resistance	O
(	O
Type	O
D	O
PPC	O
).	O

Included	O
in	O
the	O
talks	O
were	O
state	O
-	O
of	O
-	O
the	O
-	O
art	O
presentations	O
about	O
infectious	O
clone	O
technology	O
and	O
recombinant	O
viruses	O
,	O
pathogen	O
and	O
receptor	O
interactions	O
at	O
the	O
cellular	O
and	O
molecular	O
level	O
,	O
genomic	O
responses	O
to	O
infection	O
,	O
and	O
new	O
information	O
on	O
antiviral	B-CHED
mechanisms	O
of	O
action	O
.	O

ABSTRACT	O
:	O
Many	O
studies	O
show	O
important	O
disturbances	O
in	O
hormonal	O
balance	B-CHED
in	O
patients	O
with	O
severe	O
sepsis	O
.	O

TITLE	O
:	O
[	O
Glucocorticoid	B-CHED
-	O
induced	O
diabetes	O
in	O
severe	O
acute	O
respiratory	O
syndrome	O
:	O
the	O
impact	O
of	O
high	O
dosage	O
and	O
duration	O
of	O
methylprednisolone	B-CHED
therapy	O
].	O

ABSTRACT	O
:	O
Over	O
-	O
dose	O
glucocorticoid	B-CHED
was	O
frequently	O
used	O
in	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
the	O
aim	O
of	O
the	O
present	O
study	O
is	O
to	O
investigate	O
the	O
frequency	O
and	O
risk	O
factors	O
of	O
corticosteroid	B-CHED
-	O
induced	O
diabetes	O
in	O
this	O
situation	O
.	O

Decreasing	O
the	O
daily	O
maximal	O
dosage	O
may	O
be	O
beneficial	O
to	O
the	O
reduction	O
of	O
corticosteroid	B-CHED
-	O
induced	O
of	O
diabetes	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
ocular	O
manifestations	O
of	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
and	O
to	O
monitor	O
the	O
possible	O
ocular	O
complications	O
arising	O
from	O
the	O
treatment	O
regimen	O
with	O
high	O
-	O
dose	O
systemic	O
corticosteroid	B-CHED
drugs	O
.	O

All	O
participants	O
were	O
surveyed	O
about	O
how	O
they	O
were	O
using	O
personal	O
protective	O
equipment	O
(	O
PPE	B-CHED
),	O
protective	O
drugs	O
and	O
hygiene	O
habits	O
when	O
caring	O
for	O
patients	O
with	O
SARS	O
.	O

The	O
attack	O
rate	O
of	O
HCWs	O
who	O
were	O
rescuing	O
severe	O
SARS	O
patients	O
without	O
any	O
PPE	B-CHED
was	O
61	O
.	O
5	O
%	O
(	O
16	O
/	O
26	O
).	O

TRALI	O
is	O
associated	O
with	O
antibodies	O
to	O
white	O
blood	O
cells	O
and	O
biologically	O
active	O
lipids	B-CHED
in	O
trans	O
-	O
fused	O
blood	O
components	O
.	O

To	O
evaluate	O
the	O
clinical	O
efficacy	O
of	O
low	O
-	O
dose	O
(	O
5	O
-	O
ppm	O
)	O
inhaled	O
nitric	B-CHED
oxide	I-CHED
in	O
patients	O
with	O
acute	O
lung	O
injury	O
.	O

Mortality	O
was	O
similar	O
between	O
groups	O
(	O
20	O
%	O
placebo	O
vs	O
23	O
%	O
nitric	B-CHED
oxide	I-CHED
;	O
P	O
=.	O
54	O
).	O

Days	O
alive	O
and	O
meeting	O
criteria	O
for	O
extubation	O
were	O
also	O
similar	O
:	O
17	O
.	O
0	O
placebo	O
vs	O
16	O
.	O
7	O
nitric	B-CHED
oxide	I-CHED
(	O
P	O
=.	O
89	O
).	O

RESULTS	O
:	O
An	O
intent	O
-	O
to	O
-	O
treat	O
analysis	O
revealed	O
that	O
inhaled	O
nitric	B-CHED
oxide	I-CHED
at	O
5	O
ppm	O
did	O
not	O
increase	O
the	O
number	O
of	O
days	O
patients	O
were	O
alive	O
and	O
off	O
assisted	O
breathing	O
(	O
mean	O
[	O
SD	O
],	O
10	O
.	O
6	O
[	O
9	O
.	O
8	O
]	O
days	O
in	O
the	O
placebo	O
group	O
and	O
10	O
.	O
7	O
[	O
9	O
.	O
7	O
]	O
days	O
in	O
the	O
inhaled	O
nitric	B-CHED
oxide	I-CHED
group	O
;	O
P	O
=.	O
97	O
;	O
difference	O
,	O
-	O
0	O
.	O
1	O
day	O
[	O
95	O
%	O
confidence	O
interval	O
,	O
-	O
2	O
.	O
0	O
to	O
1	O
.	O
9	O
days	O
]).	O

All	O
in	O
-	O
house	O
assays	O
were	O
optimized	O
for	O
assay	O
parameters	O
,	O
including	O
MgCl2	B-CHED
,	O
primer	O
,	O
and	O
probe	O
concentrations	O
.	O

From	O
these	O
23	O
fragments	O
,	O
we	O
identified	O
a	O
fragment	O
of	O
259	O
amino	B-CHED
acids	I-CHED
(	O
amino	B-CHED
acids	I-CHED
441	O
to	O
700	O
)	O
that	O
is	O
a	O
major	O
immunodominant	O
epitope	B-CHED
.	O

Thus	O
,	O
fragment	O
C	O
of	O
spike	O
protein	B-CHED
was	O
identified	O
as	O
an	O
immunodominant	O
antigen	B-CHED
and	O
could	O
be	O
used	O
for	O
serological	O
detection	O
of	O
SARS	O
-	O
CoV	O
infection	O
.	O

There	O
is	O
no	O
proven	O
treatment	O
,	O
although	O
cocktails	O
of	O
broad	O
-	O
spectrum	O
antibiotics	B-CHED
,	O
antiviral	B-CHED
,	O
and	O
immunomodulatory	O
therapy	O
have	O
been	O
tried	O
.	O

Apart	O
from	O
influenza	O
,	O
there	O
are	O
no	O
vaccines	O
and	O
very	O
few	O
antiviral	B-CHED
chemotherapeutic	O
agents	O
available	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
respiratory	O
viral	O
infections	O
-	O
the	O
most	O
common	O
cause	O
of	O
human	O
illness	O
.	O

Where	O
possible	O
,	O
comparisons	O
are	O
made	O
with	O
existing	O
antivirals	B-CHED
.	O

Then	O
,	O
after	O
reducing	O
total	O
PEEP	B-CHED
by	O
decreasing	O
respiratory	O
rate	O
,	O
Pao2	O
/	O
Fio2	O
ratio	O
was	O
reevaluated	O
.	O

During	O
baseline	O
ventilation	O
,	O
PEEP	B-CHED
was	O
10	O
(	O
range	O
,	O
5	O
-	O
17	O
)	O
cm	O
H2O	B-CHED
and	O
after	O
recruitment	O
21	O
(	O
range	O
,	O
18	O
-	O
26	O
)	O
cm	O
H2O	B-CHED
.	O

The	O
maximum	O
amino	B-CHED
acid	I-CHED
sequence	O
identity	O
between	O
ORFs	O
of	O
the	O
newly	O
discovered	O
coronavirus	O
and	O
related	O
group	O
1	O
coronaviruses	O
ranged	O
from	O
43	O
%	O
to	O
67	O
%.	O

Viral	O
loads	O
were	O
significantly	O
associated	O
with	O
a	O
shorter	O
course	O
of	O
illness	O
but	O
not	O
with	O
the	O
use	O
of	O
ribavirin	B-CHED
or	O
steroids	B-CHED
.	O

Amino	B-CHED
acids	I-CHED
270	O
to	O
510	O
were	O
the	O
minimal	O
receptor	O
-	O
binding	O
region	O
of	O
the	O
SARS	O
-	O
CoV	O
S	O
glycoprotein	B-CHED
as	O
determined	O
by	O
flow	O
cytometry	O
.	O

We	O
found	O
that	O
the	O
DNA	O
vaccination	O
induced	O
both	O
N	O
protein	B-CHED
-	O
specific	O
antibody	O
and	O
specific	O
CTL	O
activity	O
to	O
the	O
target	O
.	O

Intravenous	O
immunoglobulin	O
-	O
G	O
might	O
:	O
a	O
)	O
combat	B-CHED
a	O
dysimmune	O
component	O
of	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
,	O
including	O
the	O
reactive	O
cytokine	O
-	O
chemokine	O
storm	O
against	O
respiratory	O
tissues	O
;	O
b	O
)	O
contain	O
some	O
antibodies	O
effective	O
against	O
the	O
coronavirus	O
non	O
-	O
specific	O
components	O
of	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
;	O
c	O
)	O
block	O
host	O
-	O
cell	O
receptors	O
for	O
the	O
virus	O
;	O
and	O
d	O
)	O
counteract	O
secondary	O
infections	O
.	O

Key	O
recommendations	O
,	O
listed	O
by	O
category	O
and	O
not	O
by	O
hierarchy	O
,	O
include	O
early	O
goal	O
-	O
directed	O
resuscitation	O
of	O
the	O
septic	O
patient	O
during	O
the	O
first	O
6	O
hrs	O
after	O
recognition	O
;	O
appropriate	O
diagnostic	O
studies	O
to	O
ascertain	O
causative	O
organisms	O
before	O
starting	O
antibiotics	B-CHED
;	O
early	O
administration	O
of	O
broad	O
-	O
spectrum	O
antibiotic	B-CHED
therapy	O
;	O
reassessment	O
of	O
antibiotic	B-CHED
therapy	O
with	O
microbiology	O
and	O
clinical	O
data	O
to	O
narrow	O
coverage	O
,	O
when	O
appropriate	O
;	O
a	O
usual	O
7	O
-	O
10	O
days	O
of	O
antibiotic	B-CHED
therapy	O
guided	O
by	O
clinical	O
response	O
;	O
source	O
control	O
with	O
attention	O
to	O
the	O
method	O
that	O
balances	O
risks	O
and	O
benefits	O
;	O
equivalence	O
of	O
crystalloid	O
and	O
colloid	O
resuscitation	O
;	O
aggressive	O
fluid	O
challenge	O
to	O
restore	O
mean	O
circulating	O
filling	O
pressure	O
;	O
vasopressor	O
preference	O
for	O
norepinephrine	B-CHED
and	O
dopamine	B-CHED
;	O
cautious	O
use	O
of	O
vasopressin	B-CHED
pending	O
further	O
studies	O
;	O
avoiding	O
low	O
-	O
dose	O
dopamine	B-CHED
administration	O
for	O
renal	O
protection	O
;	O
consideration	O
of	O
dobutamine	B-CHED
inotropic	O
therapy	O
in	O
some	O
clinical	O
situations	O
;	O
avoidance	O
of	O
supranormal	O
oxygen	B-CHED
delivery	O
as	O
a	O
goal	O
of	O
therapy	O
;	O
stress	O
-	O
dose	O
steroid	B-CHED
therapy	O
for	O
septic	O
shock	O
;	O
use	O
of	O
recombinant	O
activated	O
protein	B-CHED
C	O
in	O
patients	O
with	O
severe	O
sepsis	O
and	O
high	O
risk	O
for	O
death	O
;	O
with	O
resolution	O
of	O
tissue	O
hypoperfusion	O
and	O
in	O
the	O
absence	O
of	O
coronary	O
artery	O
disease	O
or	O
acute	O
hemorrhage	O
,	O
targeting	O
a	O
hemoglobin	B-CHED
of	O
7	O
-	O
9	O
g	O
/	O
dL	O
;	O
appropriate	O
use	O
of	O
fresh	O
frozen	O
plasma	O
and	O
platelets	O
;	O
a	O
low	O
tidal	O
volume	O
and	O
limitation	O
of	O
inspiratory	O
plateau	O
pressure	O
strategy	O
for	O
acute	O
lung	O
injury	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
;	O
application	O
of	O
a	O
minimal	O
amount	O
of	O
positive	O
end	O
-	O
expiratory	O
pressure	O
in	O
acute	O
lung	O
injury	O
/	O
acute	O
respiratory	O
distress	O
syndrome	O
;	O
a	O
semirecumbent	O
bed	O
position	O
unless	O
contraindicated	O
;	O
protocols	O
for	O
weaning	O
and	O
sedation	O
/	O
analgesia	O
,	O
using	O
either	O
intermittent	O
bolus	O
sedation	O
or	O
continuous	O
infusion	O
sedation	O
with	O
daily	O
interruptions	O
/	O
lightening	O
;	O
avoidance	O
of	O
neuromuscular	O
blockers	O
,	O
if	O
at	O
all	O
possible	O
;	O
maintenance	O
of	O
blood	O
glucose	B-CHED
<	O
150	O
mg	O
/	O
dL	O
after	O
initial	O
stabilization	O
;	O
equivalence	O
of	O
continuous	O
veno	O
-	O
veno	O
hemofiltration	O
and	O
intermittent	O
hemodialysis	O
;	O
lack	O
of	O
utility	O
of	O
bicarbonate	B-CHED
use	O
for	O
pH	O
>	O
or	O
=	O
7	O
.	O
15	O
;	O
use	O
of	O
deep	O
vein	O
thrombosis	O
/	O
stress	O
ulcer	O
prophylaxis	O
;	O
and	O
consideration	O
of	O
limitation	O
of	O
support	O
where	O
appropriate	O
.	O

Like	O
other	O
known	O
coronaviruses	O
,	O
SARS	O
-	O
CoV	O
is	O
an	O
enveloped	O
virus	O
containing	O
three	O
outer	O
structural	O
proteins	B-CHED
,	O
namely	O
the	O
membrane	O
(	O
M	O
),	O
envelope	O
(	O
E	O
),	O
and	O
spike	O
(	O
S	O
)	O
proteins	B-CHED
.	O

Intranasal	O
or	O
intramuscular	O
inoculations	O
of	O
BALB	O
/	O
c	O
mice	O
with	O
MVA	B-CHED
/	O
S	O
produced	O
serum	O
antibodies	O
that	O
recognized	O
the	O
SARS	O
S	O
in	O
ELISA	O
and	O
neutralized	O
SARS	O
-	O
CoV	O
in	O
vitro	O
.	O

TITLE	O
:	O
IL	O
-	O
1beta	O
induces	O
an	O
exaggerated	O
pro	B-CHED
-	O
and	O
anti	O
-	O
inflammatory	O
response	O
in	O
peritoneal	O
macrophages	O
of	O
children	O
compared	O
with	O
adults	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
IL	O
-	O
1	O
-	O
induced	O
pro	B-CHED
-	O
and	O
anti	O
-	O
inflammatory	O
response	O
of	O
pediatric	O
vs	O
.	O
adult	O
peritoneal	O
macrophages	O
(	O
PMs	B-CHED
).	O

We	O
hypothesized	O
that	O
pediatric	O
PMs	B-CHED
would	O
have	O
an	O
enhanced	O
anti	O
-	O
inflammatory	O
response	O
compared	O
with	O
adult	O
PMs	B-CHED
.	O

There	O
was	O
no	O
IL	O
-	O
10	O
production	O
in	O
IL	O
-	O
1beta	O
-	O
stimulated	O
adult	O
PMs	B-CHED
.	O

TITLE	O
:	O
Identification	O
of	O
novel	O
inhibitors	B-CHED
of	O
the	O
SARS	O
coronavirus	O
main	O
protease	O
3CLpro	O
.	O

There	O
is	O
,	O
therefore	O
,	O
renewed	O
emphasis	O
on	O
preventive	O
strategies	O
by	O
better	O
understanding	O
of	O
the	O
relative	O
importance	O
of	O
various	O
vehicles	O
in	O
the	O
nosocomial	O
spread	O
of	O
viruses	O
and	O
by	O
infection	O
control	O
using	O
microbicides	B-CHED
.	O

TITLE	O
:	O
Old	O
drugs	O
as	O
lead	B-CHED
compounds	I-CHED
for	O
a	O
new	O
disease	O
?	O

In	O
suspension	O
,	O
HCoV	O
-	O
229E	O
gradually	O
lost	B-CHED
its	O
infectivity	O
completely	O
while	O
SARS	O
-	O
CoV	O
retained	O
its	O
infectivity	O
for	O
up	O
to	O
9	O
days	O
;	O
in	O
the	O
dried	O
state	O
,	O
survival	O
times	O
were	O
24	O
h	O
versus	O
6	O
days	O
.	O

Thermal	O
inactivation	O
at	O
56	O
degrees	O
C	O
was	O
highly	O
effective	O
in	O
the	O
absence	O
of	O
protein	B-CHED
,	O
reducing	O
the	O
virus	O
titre	O
to	O
below	O
detectability	O
;	O
however	O
,	O
the	O
addition	O
of	O
20	O
%	O
protein	B-CHED
exerted	O
a	O
protective	O
effect	O
resulting	O
in	O
residual	O
infectivity	O
.	O

ABSTRACT	O
:	O
A	O
commercially	O
available	O
in	O
-	O
practice	O
test	O
for	O
feline	O
coronavirus	O
(	O
FCoV	O
)	O
antibodies	O
(	O
FCoV	O
Immunocomb	O
,	O
Biogal	O
Galed	O
Laboratories	O
)	O
was	O
evaluated	O
by	O
comparison	O
with	O
the	O
gold	B-CHED
standard	O
FCoV	O
immunofluorescent	O
antibody	O
(	O
IFA	O
)	O
test	O
.	O

Tissues	O
from	O
five	O
control	O
cats	O
and	O
from	O
15	O
cats	O
with	O
FIP	O
were	O
examined	O
by	O
immunohistochemistry	O
using	O
monoclonal	O
antibodies	O
against	O
human	O
AGP	O
,	O
FCoV	O
and	O
myeloid	O
antigens	B-CHED
.	O

ABSTRACT	O
:	O
In	O
August	O
2002	O
,	O
scientists	O
and	O
veterinarians	O
from	O
all	O
over	O
the	O
world	O
met	B-CHED
in	O
Scotland	O
to	O
discuss	O
feline	O
coronavirus	O
(	O
FCoV	O
)	O
and	O
feline	O
infectious	O
peritonitis	O
(	O
FIP	O
).	O

ABSTRACT	O
:	O
The	O
surface	O
transmembrane	O
glycoprotein	B-CHED
is	O
responsible	O
for	O
mediating	O
virion	O
attachment	O
to	O
cell	O
and	O
subsequent	O
virus	O
-	O
cell	O
membrane	O
fusion	O
.	O

The	O
crystal	O
structure	O
of	O
the	O
fusion	O
core	O
of	O
mouse	O
hepatitis	O
virus	O
S	O
protein	B-CHED
,	O
which	O
represents	O
the	O
first	O
fusion	O
core	O
structure	O
of	O
any	O
coronavirus	O
,	O
reveals	O
a	O
central	O
hydrophobic	O
coiled	O
coil	O
trimer	O
surrounded	O
by	O
three	O
helices	O
in	O
an	O
oblique	O
,	O
antiparallel	O
manner	O
.	O

D	O
(	O
LCO	B-CHED
)	O
may	O
be	O
more	O
sensitive	O
than	O
HRCT	O
in	O
evaluating	O
the	O
fibrotic	O
changes	O
.	O

(	O
1	O
)	O
During	O
inhalation	O
,	O
the	O
concentration	O
of	O
PFIB	O
remained	O
stable	O
;	O
(	O
2	O
)	O
After	O
inhalation	O
,	O
blood	O
arterial	O
oxygen	B-CHED
partial	O
pressure	O
fell	O
gradually	O
,	O
and	O
eventually	O
met	B-CHED
the	O
criteria	O
for	O
diagnosing	O
ARDS	O
;	O
(	O
3	O
)	O
The	O
level	O
of	O
IL	O
-	O
8	O
in	O
serum	O
rises	O
significantly	O
after	O
inhalation	O
(	O
P	O
<	O
0	O
.	O
05	O
),	O
whereas	O
that	O
of	O
IL	O
-	O
6	O
was	O
not	O
obviously	O
altered	O
(	O
P	O
>	O
0	O
.	O
05	O
);	O
(	O
4	O
)	O
Within	O
6	O
hours	O
after	O
inhalation	O
,	O
no	O
abnormality	O
in	O
canine	O
was	O
observed	O
,	O
but	O
afterwards	O
symptoms	O
gradually	O
appeared	O
,	O
and	O
typical	O
breath	O
of	O
ARDS	O
,	O
such	O
as	O
high	O
frequency	O
and	O
lower	O
level	O
could	O
be	O
seen	O
in	O
later	O
phase	O
;	O
(	O
5	O
)	O
Pathological	O
examination	O
showed	O
severe	O
congestion	O
,	O
edema	O
and	O
atelectasis	O
in	O
most	O
part	O
of	O
both	O
lungs	O
,	O
and	O
signs	O
of	O
anoxia	O
in	O
other	O
organs	O
.	O

TITLE	O
:	O
Detection	O
of	O
specific	O
antibodies	O
to	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
nucleocapsid	O
protein	B-CHED
for	O
serodiagnosis	O
of	O
SARS	O
coronavirus	O
pneumonia	O
.	O

ABSTRACT	O
:	O
To	O
analyze	O
relation	O
between	O
the	O
use	O
of	O
corticosteroids	B-CHED
in	O
the	O
treatment	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
patients	O
and	O
arthralgia	O
as	O
a	O
sequela	O
.	O

Approximately	O
20	O
%	O
of	O
the	O
participants	O
had	O
IES	B-CHED
scores	O
>	O
or	O
=	O
30	O
,	O
indicating	O
the	O
presence	O
of	O
post	O
-	O
traumatic	O
stress	O
disorder	O
(	O
PTSD	O
).	O

These	O
results	O
contribute	O
to	O
characterization	O
of	O
the	O
SARS	O
agent	O
and	O
development	O
of	O
new	O
antiviral	B-CHED
strategies	O
.	O

TITLE	O
:	O
The	O
antiviral	B-CHED
effect	O
of	O
interferon	O
-	O
beta	O
against	O
SARS	O
-	O
coronavirus	O
is	O
not	O
mediated	O
by	O
MxA	O
protein	B-CHED
.	O

FIP	O
is	O
characterized	O
by	O
the	O
overexpression	O
of	O
an	O
acute	O
phase	O
protein	B-CHED
,	O
the	O
alpha1	O
-	O
acid	O
glycoprotein	B-CHED
(	O
AGP	O
).	O

In	O
contrast	O
,	O
during	O
FIP	O
disease	O
,	O
fAGP	O
underwent	O
several	O
modifications	O
in	O
the	O
sialic	B-CHED
acid	I-CHED
content	O
,	O
including	O
decreased	O
expression	O
of	O
both	O
alpha	O
(	O
2	O
-	O
6	O
)-	O
linked	O
and	O
alpha	O
(	O
2	O
-	O
3	O
)-	O
linked	O
sialic	B-CHED
acid	I-CHED
(	O
76	O
and	O
44	O
%,	O
respectively	O
when	O
compared	O
to	O
non	O
-	O
pathological	O
feline	O
AGP	O
).	O

The	O
non	O
-	O
myeloablative	O
conditioning	O
regimen	O
consisted	O
of	O
fludarabine	O
,	O
cyclophosphamide	B-CHED
,	O
rabbit	O
anti	O
-	O
thymocyte	O
globulin	O
and	O
total	O
body	O
irradiation	O
.	O

Individual	O
bobcats	O
with	O
positive	O
FCV	B-CHED
antibody	O
titers	O
had	O
patterns	O
of	O
movement	O
that	O
intercepted	O
park	O
inholdings	O
where	O
domestic	O
cats	O
lived	O
.	O

To	O
assess	O
the	O
extent	O
to	O
which	O
free	O
-	O
ranging	O
cheetahs	O
are	O
exposed	O
to	O
feline	O
and	O
canine	O
viruses	O
,	O
sera	O
from	O
81	O
free	O
-	O
ranging	O
cheetahs	O
sampled	O
between	O
1992	O
and	O
1998	O
were	O
evaluated	O
for	O
antibodies	O
against	O
canine	O
distemper	O
virus	O
(	O
CDV	B-CHED
),	O
feline	O
coronavirus	O
(	O
feline	O
infectious	O
peritonitis	O
virus	O
;	O
FCoV	O
/	O
FIPV	O
),	O
feline	O
herpesvirus	O
1	O
(	O
FHV1	O
),	O
feline	O
panleukopenia	O
virus	O
(	O
FPV	O
),	O
feline	O
immunodeficiency	O
virus	O
(	O
FIV	O
),	O
and	O
feline	O
calicivirus	O
(	O
FCV	B-CHED
)	O
and	O
for	O
feline	O
leukemia	O
virus	O
(	O
FeLV	O
)	O
antigens	B-CHED
.	O

Characterization	O
of	O
the	O
nsp13	O
-	O
associated	O
(	O
deoxy	O
)	O
nucleoside	B-CHED
triphosphatase	O
([	O
dNTPase	O
)	O
activities	O
revealed	O
that	O
all	O
natural	O
nucleotides	B-CHED
and	O
deoxynucleotides	O
are	O
substrates	O
of	O
nsp13	O
,	O
with	O
ATP	B-CHED
,	O
dATP	B-CHED
,	O
and	O
GTP	B-CHED
being	O
hydrolyzed	O
slightly	O
more	O
efficiently	O
than	O
other	O
nucleotides	B-CHED
.	O

TITLE	O
:	O
pH	O
-	O
dependent	O
entry	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
is	O
mediated	O
by	O
the	O
spike	O
glycoprotein	B-CHED
and	O
enhanced	O
by	O
dendritic	O
cell	O
transfer	O
through	O
DC	O
-	O
SIGN	O
.	O

ABSTRACT	O
:	O
The	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
synthesizes	O
several	O
putative	O
viral	O
envelope	O
proteins	B-CHED
,	O
including	O
the	O
spike	O
(	O
S	O
),	O
membrane	O
(	O
M	O
),	O
and	O
small	O
envelope	O
(	O
E	O
)	O
glycoproteins	B-CHED
.	O

ABSTRACT	O
:	O
The	O
p28	O
and	O
p65	O
proteins	B-CHED
of	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
are	O
the	O
most	O
amino	O
-	O
terminal	O
protein	B-CHED
domains	O
of	O
the	O
replicase	O
polyprotein	O
.	O

However	O
,	O
proteolytic	O
separation	O
of	O
p28	O
from	O
p65	O
is	O
necessary	O
for	O
optimal	O
RNA	O
synthesis	O
and	O
virus	O
growth	O
,	O
suggesting	O
important	O
roles	O
for	O
these	O
proteins	B-CHED
in	O
the	O
formation	O
or	O
function	O
of	O
viral	O
replication	O
complexes	O
.	O

While	O
cell	O
-	O
cell	O
fusion	O
was	O
clearly	O
affected	O
by	O
preventing	O
spike	O
protein	B-CHED
cleavage	O
,	O
virus	O
-	O
cell	O
fusion	O
was	O
not	O
,	O
indicating	O
that	O
these	O
events	O
have	O
different	O
requirements	O
.	O

The	O
protein	B-CHED
consists	O
of	O
a	O
five	O
-	O
stranded	O
beta	O
sheet	O
with	O
a	O
folding	O
topology	O
distinct	O
from	O
other	O
RNA	O
-	O
binding	O
proteins	B-CHED
.	O

It	O
appeared	O
that	O
HR2	O
peptides	B-CHED
,	O
but	O
not	O
HR1	O
peptides	B-CHED
,	O
were	O
inhibitory	O
.	O

The	O
stability	O
of	O
this	O
complex	O
,	O
as	O
measured	O
by	O
its	O
resistance	O
to	O
heat	O
dissociation	O
,	O
appeared	O
to	O
be	O
much	O
lower	O
than	O
that	O
of	O
the	O
corresponding	O
MHV	O
complex	O
,	O
which	O
may	O
explain	O
the	O
different	O
inhibitory	O
potencies	O
of	O
the	O
HR2	O
peptides	B-CHED
.	O

ABSTRACT	O
:	O
Pharmacophore	O
modeling	O
can	O
provide	O
valuable	O
insight	O
into	O
ligand	B-CHED
-	O
receptor	O
interactions	O
.	O

Coronavirus	O
envelope	O
spike	O
protein	B-CHED
S	O
is	O
a	O
class	O
I	O
viral	O
fusion	O
protein	B-CHED
which	O
is	O
characterized	O
by	O
the	O
existence	O
of	O
two	O
heptad	O
repeat	O
regions	O
(	O
HR1	O
and	O
HR2	O
)	O
(	O
forming	O
a	O
complex	O
called	O
fusion	O
core	O
).	O

The	O
HR2	O
,	O
either	O
as	O
a	O
synthetic	O
peptide	B-CHED
or	O
as	O
a	O
GST	O
-	O
fusion	O
polypeptide	B-CHED
,	O
is	O
a	O
potent	O
inhibitor	B-CHED
of	O
virus	O
entry	O
.	O

This	O
procedure	O
was	O
adapted	O
to	O
the	O
study	O
of	O
transmissible	O
gastroenteritis	O
coronavirus	O
(	O
TGEV	O
)	O
protein	B-CHED
composition	O
and	O
RNA	O
encapsidation	O
.	O

This	O
protocol	O
relies	O
on	O
virion	O
capture	O
by	O
monoclonal	O
antibodies	O
specific	O
for	O
a	O
virion	O
membrane	O
protein	B-CHED
.	O

TITLE	O
:	O
Glycan	B-CHED
arrays	O
lead	O
to	O
the	O
discovery	O
of	O
autoimmunogenic	O
activity	O
of	O
SARS	O
-	O
CoV	O
.	O
ABSTRACT	O
:	O
Using	O
carbohydrate	B-CHED
microarrays	O
,	O
we	O
characterized	O
the	O
carbohydrate	B-CHED
binding	O
activity	O
of	O
SARS	O
-	O
CoV	O
neutralizing	O
antibodies	O
elicited	O
by	O
an	O
inactivated	O
SARS	O
-	O
CoV	O
vaccine	O
.	O

We	O
found	O
that	O
lectin	O
PHA	O
-	O
L	O
(	O
Phaseolus	O
vulgaris	O
L	O
.),	O
which	O
is	O
specific	O
for	O
a	O
defined	O
complex	O
carbohydrate	B-CHED
of	O
ASOR	O
,	O
stained	O
the	O
SARS	O
-	O
CoV	O
-	O
infected	O
cells	O
specifically	O
and	O
intensively	O
.	O

Taken	O
together	O
,	O
we	O
present	O
immunologic	O
evidence	O
that	O
a	O
carbohydrate	B-CHED
structure	O
of	O
SARS	O
-	O
CoV	O
shares	O
antigenic	O
similarity	O
with	O
host	O
glycan	B-CHED
complex	O
carbohydrates	B-CHED
.	O

The	O
SARS	O
-	O
CoV	O
S	O
protein	B-CHED
was	O
found	O
to	O
be	O
expressed	O
at	O
the	O
cell	O
surface	O
upon	O
transient	O
transfection	O
.	O

Underlying	O
disease	O
includes	O
leukemia	O
,	O
malignant	O
lymphoma	O
,	O
myelodysplastic	O
syndrome	O
(	O
MDS	O
),	O
multiple	O
injury	O
,	O
giant	O
ovarian	O
tumor	O
,	O
prostatic	O
cancer	O
with	O
multiple	O
bone	O
metastasis	O
,	O
lung	O
cancer	O
,	O
breast	O
cancer	O
with	O
multiple	O
lung	O
and	O
bone	O
metastasis	O
,	O
severe	O
pneumoniae	O
,	O
sepsis	O
,	O
hemophagocytic	O
syndrome	O
(	O
HPS	B-CHED
),	O
and	O
rheumatoid	O
arthritis	O
.	O

ABSTRACT	O
:	O
The	O
zinc	B-CHED
metallopeptidase	O
angiotensin	B-CHED
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
is	O
the	O
only	O
known	O
human	O
homologue	O
of	O
the	O
key	O
regulator	O
of	O
blood	O
pressure	O
angiotensin	B-CHED
-	O
converting	O
enzyme	O
(	O
ACE	O
).	O

TITLE	O
:	O
Rapid	O
identification	O
of	O
coronavirus	O
replicase	O
inhibitors	B-CHED
using	O
a	O
selectable	O
replicon	O
RNA	O
.	O

TITLE	O
:	O
Calpain	O
I	O
inhibitor	B-CHED
ameliorates	O
the	O
indices	O
of	O
disease	O
severity	O
in	O
a	O
murine	O
model	O
of	O
cerulein	B-CHED
-	O
induced	O
acute	O
pancreatitis	O
.	O

Recombinant	O
N	O
and	O
S	O
proteins	B-CHED
of	O
SARS	O
-	O
CoV	O
were	O
purified	O
from	O
transformed	O
E	O
.	O
coli	O
.	O

Therefore	O
,	O
inhaled	O
vasodilators	O
such	O
as	O
nitric	B-CHED
oxide	I-CHED
and	O
prostacyclin	B-CHED
have	O
been	O
suggested	O
for	O
the	O
treatment	O
of	O
pulmonary	O
hypertension	O
especially	O
when	O
concomitant	O
hypoxemia	O
is	O
present	O
due	O
to	O
a	O
ventilation	O
-	O
perfusion	O
mismatch	O
.	O

The	O
kit	O
contains	O
reagents	B-CHED
for	O
RNA	O
isolation	O
and	O
purification	O
,	O
cDNA	O
synthesis	O
by	O
reverse	O
transcription	O
of	O
RNA	O
,	O
for	O
PCR	O
and	O
for	O
electrophoretic	O
analysis	O
of	O
amplified	O
products	O
.	O

In	O
Toronto	O
,	O
225	O
residents	O
met	B-CHED
the	O
case	O
definition	O
of	O
SARS	O
,	O
and	O
all	O
but	O
3	O
travel	O
-	O
related	O
cases	O
were	O
linked	O
to	O
the	O
index	O
patient	O
,	O
from	O
Hong	O
Kong	O
.	O

It	O
has	O
been	O
suggested	O
that	O
axonal	O
degeneration	O
and	O
segmental	O
demyelination	O
might	O
be	O
equally	O
prominent	O
pathological	O
features	O
of	O
the	O
neuropathy	O
,	O
depending	O
on	O
the	O
dosage	O
and	O
the	O
length	O
of	O
time	O
of	O
exposure	O
to	O
arsenic	B-CHED
.	O

Canine	O
coronavirus	O
BGF	O
revealed	O
a	O
full	O
length	O
non	O
-	O
structural	O
protein	B-CHED
3b	O
(	O
nsp	O
3b	O
),	O
associated	O
with	O
virulence	O
in	O
other	O
coronaviruses	O
,	O
and	O
a	O
highly	O
divergent	O
region	O
at	O
the	O
amino	O
terminal	O
domain	O
of	O
the	O
membrane	O
protein	B-CHED
that	O
may	O
be	O
implicated	O
in	O
avoiding	O
the	O
host	O
immune	O
reaction	O
.	O

The	O
binding	O
strength	O
of	O
each	O
of	O
the	O
X	O
(	O
j	O
)	O
reagents	B-CHED
to	O
each	O
other	O
is	O
measured	O
,	O
for	O
example	O
by	O
an	O
ELISA	O
assay	O
,	O
giving	O
an	O
N	O
x	O
N	O
matrix	O
K	O
.	O
The	O
matrix	O
K	O
is	O
used	O
to	O
define	O
another	O
set	O
of	O
N	O
reagents	B-CHED
called	O
Y	O
(	O
j	O
),	O
with	O
j	O
=	O
1	O
to	O
N	O
,	O
each	O
of	O
which	O
is	O
a	O
linear	O
combination	O
of	O
the	O
X	O
(	O
j	O
)	O
reagents	B-CHED
and	O
each	O
of	O
which	O
is	O
tailored	O
to	O
be	O
complementary	O
to	O
one	O
of	O
the	O
X	O
(	O
j	O
)	O
reagents	B-CHED
.	O

Cleavage	O
sites	O
were	O
predicted	O
in	O
proteins	B-CHED
such	O
as	O
the	O
cystic	O
fibrosis	O
transmembrane	O
conductance	O
regulator	O
(	O
CFTR	O
),	O
transcription	O
factors	O
CREB	O
-	O
RP	O
and	O
OCT	O
-	O
1	O
,	O
and	O
components	O
of	O
the	O
ubiquitin	O
pathway	O
.	O

Cleavage	O
sites	O
were	O
predicted	O
in	O
proteins	B-CHED
such	O
as	O
the	O
cystic	O
fibrosis	O
transmembrane	O
conductance	O
regulator	O
(	O
CFTR	O
),	O
transcription	O
factors	O
CREB	O
-	O
RP	O
and	O
OCT	O
-	O
1	O
,	O
and	O
components	O
of	O
the	O
ubiquitin	O
pathway	O
.	O

The	O
remaining	O
68	O
received	O
combination	O
treatment	O
at	O
a	O
mean	O
of	O
5	O
.	O
8	O
days	O
after	O
symptom	O
onset	O
,	O
of	O
whom	O
30	O
subsequently	O
required	O
pulsed	O
methylprednisolone	B-CHED
rescue	O
(	O
independent	O
predictors	O
:	O
older	O
age	O
and	O
higher	O
LDH	O
)	O
and	O
18	O
required	O
assisted	O
ventilation	O
(	O
independent	O
predictors	O
:	O
older	O
age	O
,	O
higher	O
oxygen	B-CHED
requirement	O
and	O
creatinine	B-CHED
level	O
).	O

Several	O
putative	O
functional	O
domains	O
such	O
as	O
a	O
papain	O
-	O
like	O
proteinase	O
(	O
PL	O
(	O
pro	B-CHED
)),	O
main	O
protease	O
(	O
M	O
(	O
pro	B-CHED
)),	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	O
),	O
and	O
RNA	O
helicase	O
encoded	O
by	O
the	O
replicase	O
gene	O
are	O
important	O
for	O
virus	O
replication	O
.	O

TITLE	O
:	O
Identification	O
of	O
two	O
antigenic	O
epitopes	O
on	O
SARS	O
-	O
CoV	O
spike	O
protein	B-CHED
.	O

TITLE	O
:	O
Sensitive	O
and	O
specific	O
monoclonal	O
antibody	O
-	O
based	O
capture	O
enzyme	O
immunoassay	O
for	O
detection	O
of	O
nucleocapsid	O
antigen	B-CHED
in	O
sera	O
from	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

We	O
used	O
monoclonal	O
antibodies	O
specifically	O
directed	O
against	O
N	O
protein	B-CHED
to	O
establish	O
a	O
sensitive	O
antigen	B-CHED
capture	O
sandwich	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
for	O
the	O
detection	O
of	O
SARS	O
-	O
CoV	O
.	O
The	O
assay	O
employed	O
a	O
mixture	B-CHED
of	O
three	O
monoclonal	O
antibodies	O
for	O
capture	O
and	O
rabbit	O
polyclonal	O
antibodies	O
for	O
detection	O
of	O
serum	O
antigen	B-CHED
in	O
32	O
cases	O
of	O
clinically	O
probable	O
SARS	O
as	O
defined	O
by	O
the	O
World	O
Health	O
Organization	O
during	O
the	O
epidemic	O
in	O
Guangzhou	O
,	O
China	O
.	O

To	O
avoid	O
or	O
reduce	O
the	O
serious	O
effects	O
of	O
these	O
epidemics	O
,	O
countries	O
should	O
give	O
priority	O
in	O
their	O
national	O
agendas	O
to	O
surveillance	O
of	O
emerging	O
and	O
reemerging	O
diseases	O
and	O
should	O
implement	O
a	O
set	O
of	O
measures	O
to	O
combat	B-CHED
the	O
diseases	O
.	O

The	O
Trx	O
-	O
S2	O
fusion	O
protein	B-CHED
was	O
expressed	O
in	O
E	O
.	O
coli	O
.	O

In	O
addition	O
,	O
this	O
genome	O
also	O
contains	O
nine	O
other	O
potential	O
ORFs	O
varying	O
in	O
length	O
from	O
39	O
to	O
274	O
amino	B-CHED
acids	I-CHED
.	O

Identification	O
of	O
a	O
conserved	O
antigenic	B-CHED
determinant	I-CHED
on	O
the	O
S2	O
domain	O
of	O
the	O
SARS	O
-	O
CoV	O
S	O
protein	B-CHED
,	O
which	O
has	O
the	O
potential	O
for	O
inducing	O
neutralizing	O
antibodies	O
,	O
has	O
implications	O
in	O
the	O
development	O
of	O
effective	O
vaccines	O
against	O
SARS	O
-	O
CoV	O
.	O

ABSTRACT	O
:	O
The	O
PiCCO	O
physiological	O
monitor	O
(	O
Pulsion	O
Medical	O
Systems	O
,	O
Munich	O
,	O
Germany	O
)	O
was	O
used	O
for	O
hemodynamic	O
diagnosis	O
and	O
monitoring	O
of	O
4	O
patients	O
:	O
a	O
polytraumatized	O
female	O
patient	O
with	O
septic	O
shock	O
and	O
ventilator	O
-	O
associated	O
pneumonia	O
;	O
a	O
man	B-CHED
with	O
congestive	O
heart	O
failure	O
and	O
cor	O
pulmonale	O
who	O
developed	O
acute	O
heart	O
failure	O
while	O
recovering	O
from	O
anterior	O
resection	O
of	O
the	O
rectum	O
;	O
a	O
man	B-CHED
with	O
severe	O
head	O
injury	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
;	O
and	O
a	O
polytraumatized	O
male	O
patient	O
with	O
a	O
myocardial	O
contusion	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
whether	O
a	O
panel	O
of	O
commercially	O
available	O
antiviral	B-CHED
drugs	I-CHED
exhibit	O
in	O
vitro	O
anti	O
-	O
SARS	O
-	O
CoV	O
activity	O
.	O

Ophthalmic	B-CHED
practices	O
may	O
need	O
to	O
change	O
as	O
more	O
stringent	O
barrier	O
methods	O
,	O
appropriate	O
quarantine	O
,	O
and	O
isolation	O
measures	O
are	O
vital	O
when	O
managing	O
patients	O
with	O
SARS	O
.	O

CONCLUSIONS	O
:	O
The	O
pGEX	O
-	O
2T	O
/	O
N	O
has	O
been	O
constructed	O
and	O
expressed	O
in	O
the	O
form	O
of	O
fusion	O
protein	B-CHED
GST	O
-	O
N	O
successfully	O
,	O
which	O
lays	O
the	O
foundation	O
for	O
further	O
study	O
of	O
SARS	O
-	O
CoV	O
N	O
protein	B-CHED
.	O

Pulmonary	O
responses	O
to	O
nebulized	O
endotoxin	O
(	O
lipopolysaccharide	B-CHED
,	O
LPS	B-CHED
)	O
were	O
evaluated	O
in	O
wild	O
-	O
type	O
(	O
WT	O
)	O
mice	O
,	O
NOS2	O
null	O
(-/-)	O
mice	O
,	O
and	O
NOS2	O
-	O
chimeric	O
animals	O
derived	O
from	O
bone	O
marrow	O
transplantation	O
.	O

Furthermore	O
,	O
administration	O
of	O
NO	O
donors	O
,	O
independent	O
of	O
cytokine	O
stimulation	O
,	O
decreased	O
SP	O
-	O
B	O
promoter	O
activity	O
and	O
mRNA	B-CHED
expression	O
in	O
mouse	O
lung	O
epithelial	O
cells	O
.	O

This	O
study	O
demonstrates	O
that	O
expression	O
of	O
NOS2	O
in	O
lung	O
epithelial	O
cells	O
is	O
critical	O
for	O
the	O
development	O
of	O
lung	O
injury	O
and	O
mediates	O
surfactant	B-CHED
dysfunction	O
independent	O
of	O
NOS2	O
inflammatory	O
cell	O
expression	O
and	O
cytokine	O
production	O
.	O

The	O
patient	O
was	O
transported	O
to	O
the	O
operating	O
room	O
for	O
hip	O
pinning	O
,	O
and	O
anesthesia	O
was	O
induced	O
with	O
midazolam	O
,	O
fentanyl	B-CHED
,	O
vecuronium	B-CHED
,	O
and	O
isoflurane	B-CHED
.	O

When	O
the	O
patient	O
was	O
turned	O
to	O
the	O
left	O
lateral	O
position	O
,	O
oxygen	B-CHED
saturation	O
suddenly	O
worsened	O
from	O
94	O
%	O
to	O
78	O
%,	O
with	O
Pao2	O
from	O
arterial	O
blood	O
gas	O
measured	O
at	O
54	O
mm	O
Hg	O
.	O

The	O
thermal	O
unfolding	O
of	O
these	O
proteins	B-CHED
begins	O
at	O
domain	O
III	O
,	O
where	O
the	O
structure	O
is	O
least	O
conserved	O
among	O
these	O
proteins	B-CHED
.	O

ABSTRACT	O
:	O
To	O
seek	O
a	O
new	O
delivery	O
system	O
of	O
vaccine	O
for	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
),	O
transgenic	O
potato	O
expressing	O
full	O
-	O
length	O
spike	O
(	O
S	O
)	O
protein	B-CHED
of	O
IBV	O
was	O
produced	O
and	O
its	O
immunogenicity	O
in	O
chickens	O
was	O
investigated	O
.	O

The	O
results	O
indicated	O
that	O
S	O
protein	B-CHED
expressed	O
in	O
transgenic	O
plants	O
might	O
be	O
a	O
new	O
source	O
for	O
the	O
production	O
of	O
Coronaviridae	O
IBV	O
vaccine	O
.	O

The	O
SARS	O
-	O
CoV	O
genome	O
encodes	O
the	O
characteristic	O
essential	O
CoV	O
replication	O
and	O
structural	O
proteins	B-CHED
.	O

The	O
efficiency	O
of	O
incorporation	O
of	O
the	O
chimeric	O
protein	B-CHED
into	O
particles	O
was	O
,	O
however	O
,	O
reduced	O
relative	O
to	O
that	O
in	O
wild	O
-	O
type	O
particles	O
which	O
may	O
explain	O
,	O
at	O
least	O
in	O
part	O
,	O
the	O
reduced	O
infectivity	O
produced	O
by	O
MHV	O
-	O
SGFP	O
infection	O
.	O

A	O
histidine	B-CHED
-	O
tagged	O
form	O
of	O
nsp13	O
,	O
which	O
was	O
expressed	O
in	O
insect	O
cells	O
and	O
purified	O
,	O
is	O
reported	O
to	O
unwind	O
efficiently	O
both	O
partial	O
-	O
duplex	O
RNA	O
and	O
DNA	O
of	O
up	O
to	O
several	O
hundred	O
base	O
pairs	O
.	O

TITLE	O
:	O
Successful	O
therapy	O
of	O
severe	O
pneumonia	O
-	O
associated	O
ARDS	O
after	O
pneumonectomy	O
with	O
ECMO	O
and	O
steroids	B-CHED
.	O

Microwave	O
treatment	O
appears	O
to	O
be	O
a	O
satisfactory	O
method	O
of	O
inactivating	O
virus	O
while	O
preserving	O
nucleic	B-CHED
acid	I-CHED
for	O
PCR	O
identification	O
.	O

TITLE	O
:	O
Egg	O
:	O
embryo	O
weight	O
ratio	O
as	O
an	O
indicator	B-CHED
of	O
dwarfism	O
induced	O
by	O
infectious	O
bronchitis	O
virus	O
.	O

The	O
EC	O
(	O
50	O
),	O
based	O
on	O
ELISA	O
,	O
and	O
SI	O
for	O
Reserpine	B-CHED
,	O
Aescim	O
,	O
and	O
Valinomycin	B-CHED
are	O
3	O
.	O
4	O
microM	O
(	O
SI	O
=	O
7	O
.	O
3	O
),	O
6	O
.	O
0	O
microM	O
(	O
SI	O
=	O
2	O
.	O
5	O
),	O
and	O
0	O
.	O
85	O
microM	O
(	O
SI	O
=	O
80	O
),	O
respectively	O
.	O

In	O
this	O
study	O
,	O
we	O
analyzed	O
the	O
region	O
of	O
the	O
APN	O
gene	O
that	O
encodes	O
a	O
stretch	O
of	O
amino	B-CHED
acid	I-CHED
residues	O
,	O
essential	O
for	O
its	O
HCoV	O
-	O
229E	O
receptor	O
function	O
(	O
amino	B-CHED
acids	I-CHED
260	O
-	O
353	O
).	O

Two	O
organic	O
NO	O
donor	B-CHED
compounds	O
,	O
S	O
-	O
nitroso	B-CHED
-	O
N	B-CHED
-	I-CHED
acetylpenicillamine	I-CHED
(	O
SNAP	O
)	O
and	O
sodium	B-CHED
nitroprusside	I-CHED
(	O
SNP	O
),	O
were	O
tested	O
in	O
a	O
broad	O
range	O
of	O
concentrations	O
.	O

The	O
viral	O
genomic	O
copy	O
(	O
or	O
genomic	O
equivalences	O
,	O
GE	O
)	O
per	O
infectious	O
unit	O
(	O
GE	O
/	O
pfu	B-CHED
)	O
of	O
SARS	O
-	O
CoV	O
used	O
in	O
this	O
study	O
was	O
also	O
established	O
to	O
be	O
approximate	O
1200	O
-	O
1600	O
:	O
1	O
.	O

Initial	O
screening	O
by	O
ELISA	O
,	O
using	O
highly	O
purified	O
virus	O
as	O
the	O
coating	O
antigen	B-CHED
,	O
resulted	O
in	O
the	O
selection	O
of	O
103	O
mAbs	O
to	O
the	O
SARS	O
virus	O
.	O

ABSTRACT	O
:	O
The	O
3	O
'	O
end	O
region	O
nucleotide	B-CHED
sequence	O
,	O
including	O
ORF7	O
,	O
of	O
nine	O
Japanese	O
and	O
two	O
U	O
.	O
S	O
.	O
A	O
.	O
isolates	O
of	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
were	O
determined	O
and	O
compared	O
.	O

By	O
use	O
of	O
an	O
immunofluorescent	O
(	O
IF	O
)	O
test	O
as	O
the	O
""""	O
gold	B-CHED
standard	O
""","	O
both	O
the	O
ELISA	O
and	O
the	O
immunochromatographic	O
test	O
were	O
able	O
to	O
detect	O
immunoglobulin	O
G	O
antibodies	O
to	O
SARS	O
not	O
only	O
from	O
late	O
-	O
convalescent	O
-	O
stage	O
samples	O
(>	O
21	O
days	O
from	O
the	O
onset	O
of	O
clinical	O
symptoms	O
),	O
as	O
previously	O
established	O
,	O
but	O
also	O
from	O
early	O
-	O
acute	O
-	O
phase	O
samples	O
(	O
1	O
to	O
10	O
days	O
from	O
onset	O
).	O

The	O
ELISA	O
was	O
capable	O
of	O
detecting	O
this	O
protein	B-CHED
in	O
SARS	O
CoV	O
cell	O
culture	O
lysates	O
at	O
15	O
50	O
%	O
tissue	O
culture	O
infective	O
doses	O
/	O
ml	O
but	O
did	O
not	O
produce	O
positive	O
signals	O
when	O
tested	O
with	O
cell	O
culture	O
lysates	O
of	O
human	O
coronaviruses	O
OC43	O
and	O
229E	O
.	O

Since	O
the	O
present	O
ELISA	O
is	O
more	O
convenient	O
and	O
economical	O
than	O
reverse	O
transcription	O
-	O
PCR	O
,	O
it	O
may	O
serve	O
as	O
an	O
alternative	O
tool	O
for	O
the	O
early	O
diagnosis	O
of	O
SARS	O
CoV	O
infection	O
in	O
laboratories	O
with	O
limited	O
resources	O
and	O
expertise	O
and	O
for	O
mass	O
screening	O
for	O
the	O
reservoir	O
of	O
SARS	O
CoV	O
.	O
Further	O
studies	O
on	O
serial	O
clinical	O
specimens	O
should	O
reveal	O
the	O
duration	O
of	O
nucleocapsid	O
protein	B-CHED
shedding	O
and	O
may	O
reveal	O
a	O
higher	O
detection	O
rate	O
in	O
SARS	O
patients	O
.	O

Comparing	O
these	O
nucleotide	B-CHED
sequences	O
to	O
DNA	O
databank	O
entries	O
(	O
National	O
Institutes	O
of	O
Health	O
)	O
conclusively	O
identified	O
them	O
as	O
SARS	O
-	O
CoV	O
sequences	O
.	O

By	O
studying	O
the	O
human	O
leukocyte	O
antigen	B-CHED
(	O
HLA	B-CHED
)	O
types	O
A	O
,	O
B	O
,	O
DR	O
,	O
and	O
DQ	O
alleles	O
in	O
90	O
Chinese	O
patients	O
with	O
serologically	O
confirmed	O
SARS	O
infections	O
,	O
we	O
identified	O
a	O
strong	O
association	O
between	O
HLA	B-CHED
-	O
B	O
*	O
0703	O
(	O
OR	O
,	O
4	O
.	O
08	O
;	O
95	O
%	O
CI	O
,	O
2	O
.	O
03	O
-	O
8	O
.	O
18	O
;	O
P	O
=.	O
00072	O
[	O
Bonferroni	O
-	O
corrected	O
P	O
value	O
,	O
P	O
(	O
c	O
)	O
<.	O
0022	O
])	O
and	O
-	O
DRB1	O
*	O
0301	O
(	O
OR	O
,	O
0	O
.	O
06	O
;	O
95	O
%,	O
0	O
.	O
01	O
-	O
0	O
.	O
47	O
;	O
P	O
=.	O
00008	O
[	O
after	O
Bonferroni	O
correction	O
,	O
P	O
<.	O
0042	O
])	O
and	O
the	O
development	O
of	O
SARS	O
.	O

The	O
results	O
showed	O
that	O
only	O
LoVo	O
cells	O
were	O
permissive	O
to	O
SARS	O
-	O
CoV	O
infection	O
as	O
evident	O
by	O
positive	O
findings	O
from	O
indirect	O
immunofluorescence	O
staining	O
for	O
intracellular	O
viral	O
antigens	B-CHED
,	O
in	O
situ	O
hybridization	O
for	O
intracellular	O
viral	O
RNA	O
,	O
and	O
electron	O
microscopy	O
for	O
intracellular	O
viral	O
particles	O
.	O

ABSTRACT	O
:	O
The	O
importance	O
of	O
rapid	O
diagnosis	O
of	O
influenza	O
has	O
increased	O
with	O
the	O
availability	O
of	O
neuraminidase	B-CHED
inhibitors	I-CHED
,	O
which	O
need	O
to	O
be	O
commenced	O
within	O
48	O
hr	O
of	O
symptom	O
onset	O
.	O

To	O
facilitate	O
quantifying	O
pseudovirus	O
-	O
infected	O
cells	O
,	O
which	O
are	O
stained	O
blue	O
with	O
X	O
-	O
Gal	B-CHED
,	O
we	O
devised	O
an	O
automated	O
procedure	O
using	O
an	O
ELISPOT	O
analyzer	O
.	O

In	O
addition	O
,	O
other	O
antiviral	B-CHED
treatment	O
,	O
RNA	O
interference	O
,	O
monoclonal	O
antibody	O
,	O
synthetic	O
peptides	B-CHED
,	O
and	O
vaccines	O
are	O
being	O
developed	O
.	O

ABSTRACT	O
:	O
Complete	O
nucleotide	B-CHED
cDNA	O
sequence	O
(	O
29715	O
nucleotides	B-CHED
)	O
of	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
strain	O
SoD	O
)	O
isolated	O
for	O
the	O
first	O
time	O
in	O
the	O
territory	O
of	O
the	O
Russian	O
Federation	O
was	O
determined	O
.	O

The	O
new	O
pumpless	O
extracorporeal	O
interventional	O
lung	O
assist	O
device	O
(	O
ILA	O
,	O
NovaLung	O
,	O
Hechingen	O
,	O
Germany	O
)	O
was	O
therefore	O
used	O
for	O
carbon	B-CHED
dioxide	I-CHED
elimination	O
to	O
enable	O
a	O
less	O
aggressive	O
ventilation	O
strategy	O
.	O

METHODS	O
:	O
We	O
evaluated	O
271	O
HCWs	O
from	O
SARS	O
units	O
and	O
342	O
healthy	O
control	O
subjects	O
,	O
using	O
the	O
Perceived	O
Stress	O
Scale	O
(	O
PSS	B-CHED
)	O
to	O
assess	O
stress	O
levels	O
and	O
a	O
structured	O
list	O
of	O
putative	O
psychological	O
effects	O
of	O
SARS	O
to	O
assess	O
its	O
psychological	O
effects	O
.	O

ABSTRACT	O
:	O
Three	O
single	O
chain	O
antibodies	O
(	O
scFv	O
)	O
against	O
the	O
proteins	B-CHED
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
were	O
isolated	O
by	O
phage	O
display	O
from	O
an	O
scFv	O
antibody	O
library	O
.	O

HFOV	O
has	O
beneficial	O
effects	O
on	O
Pao	B-CHED
(	O
2	O
)/	O
Fio	O
(	O
2	O
)	O
ratios	O
and	O
OI	O
,	O
and	O
may	O
be	O
an	O
effective	O
rescue	O
therapy	O
for	O
adults	O
with	O
severe	O
oxygenation	O
failure	O
.	O

CONCLUSIONS	O
:	O
In	O
this	O
retrospective	O
,	O
uncontrolled	O
cohort	O
analysis	O
,	O
use	O
of	O
ribavirin	B-CHED
did	O
not	O
appear	O
to	O
confer	O
any	O
benefit	O
for	O
patients	O
with	O
SARS	O
.	O

Intracellularly	O
retained	O
S	O
proteins	B-CHED
only	O
contained	O
endoglycosidase	O
H	O
-	O
sensitive	O
N	B-CHED
-	I-CHED
glycans	I-CHED
,	O
whereas	O
mutant	O
proteins	B-CHED
that	O
migrated	O
to	O
the	O
plasma	O
membrane	O
acquired	O
N	O
-	O
linked	O
oligosaccharides	B-CHED
of	O
the	O
complex	O
type	O
.	O

The	O
disease	O
had	O
the	O
propensity	O
to	O
cause	O
clusters	B-CHED
of	O
pneumonia	O
,	O
particularly	O
in	O
healthcare	O
workers	O
or	O
close	O
family	O
contacts	O
.	O

Its	O
containment	O
represents	O
a	O
new	O
way	O
of	O
working	O
internationally	O
,	O
and	O
demonstrates	O
how	O
intense	O
collaboration	O
in	O
virology	O
,	O
clinical	O
medicine	B-CHED
and	O
epidemiology	O
can	O
rapidly	O
provide	O
the	O
information	O
necessary	O
to	O
create	O
and	O
implement	O
evidence	O
-	O
based	O
control	O
measures	O
.	O

The	O
wild	O
-	O
type	O
S	O
protein	B-CHED
pseudotyped	O
MLV	O
vectors	O
,	O
although	O
at	O
a	O
low	O
efficiency	O
.	O

All	O
of	O
the	O
recombinants	O
retained	O
21	O
amino	B-CHED
acid	I-CHED
substitutions	O
and	O
a	O
7	O
-	O
amino	O
-	O
acid	O
insert	O
found	O
in	O
the	O
N	O
-	O
terminal	O
region	O
of	O
S	O
of	O
MHV	O
/	O
BHK	O
,	O
suggesting	O
that	O
these	O
residues	O
were	O
responsible	O
for	O
the	O
extended	O
host	O
range	O
of	O
MHV	O
/	O
BHK	O
.	O

A	O
total	O
of	O
820	O
travellers	O
returning	O
to	O
Hong	O
Kong	O
by	O
air	B-CHED
were	O
interviewed	O
about	O
their	O
SARS	O
-	O
related	O
behaviours	O
in	O
April	O
2003	O
.	O

We	O
observed	O
that	O
the	O
effects	O
of	O
receiving	O
low	O
tidal	O
volume	O
+	O
PEEP	B-CHED
ventilation	O
were	O
not	O
as	O
good	O
as	O
prone	O
position	O
+	O
low	O
tidal	O
volume	O
+	O
PEEP	B-CHED
ventilation	O
in	O
the	O
dorsal	O
area	O
of	O
the	O
rabbit	O
lung	O
compared	O
to	O
the	O
results	O
of	O
effective	O
local	O
area	O
lung	O
blood	O
perfusion	O
index	O
between	O
two	O
ventilation	O
modes	O
,	O
there	O
showed	O
significantly	O
differences	O
in	O
statistics	O
.	O

(	O
4	O
)	O
No	O
statistical	O
differences	O
were	O
found	O
in	O
ways	O
of	O
oxygen	B-CHED
therapy	O
and	O
classes	O
of	O
antibiotics	B-CHED
prescribed	O
(	O
P	O
>	O
0	O
.	O
05	O
).	O

With	O
descending	O
in	O
infectious	O
generation	O
,	O
cases	O
treated	O
with	O
methylprednisolone	B-CHED
,	O
human	O
gamma	O
-	O
immunoglobulin	O
,	O
interferon	O
-	O
alpha	O
,	O
and	O
antiviral	B-CHED
drugs	I-CHED
(	O
oral	O
ribavirin	B-CHED
or	O
oseltamivir	B-CHED
)	O
increased	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
the	O
duration	O
of	O
their	O
use	O
also	O
increased	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

ABSTRACT	O
:	O
Proteomics	O
was	O
used	O
to	O
identify	O
a	O
protein	B-CHED
encoded	O
by	O
ORF	O
3a	O
in	O
a	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
).	O

A	O
tendency	O
exists	O
for	O
co	O
-	O
mutation	O
between	O
the	O
3a	O
protein	B-CHED
and	O
the	O
spike	O
protein	B-CHED
of	O
SARS	O
-	O
CoV	O
isolates	O
,	O
suggesting	O
that	O
the	O
function	O
of	O
the	O
3a	O
protein	B-CHED
correlates	O
with	O
the	O
spike	O
protein	B-CHED
.	O

TITLE	O
:	O
Oligomerization	O
of	O
the	O
SARS	O
-	O
CoV	O
S	O
glycoprotein	B-CHED
:	O
dimerization	O
of	O
the	O
N	O
-	O
terminus	O
and	O
trimerization	O
of	O
the	O
ectodomain	O
.	O

Notably	O
,	O
the	O
SARS	O
-	O
CoV	O
virion	O
itself	O
was	O
able	O
to	O
induce	O
long	O
-	O
term	O
antibody	O
production	O
even	O
without	O
an	O
adjuvant	B-CHED
.	O

Anti	O
-	O
SARS	O
-	O
CoV	O
antibodies	O
elicited	O
in	O
mice	O
recognized	O
both	O
the	O
spike	O
and	O
nucleocapsid	O
proteins	B-CHED
of	O
the	O
virus	O
and	O
were	O
able	O
to	O
neutralize	O
the	O
virus	O
.	O

Thus	O
,	O
a	O
whole	O
killed	O
virion	O
could	O
serve	O
as	O
a	O
candidate	O
antigen	B-CHED
for	O
a	O
SARS	O
vaccine	O
to	O
elicit	O
both	O
humoral	O
and	O
cellular	O
immunity	O
.	O

The	O
serum	O
samples	O
could	O
neutralize	O
the	O
pseudotype	O
particles	O
bearing	O
the	O
spike	O
glycoproteins	B-CHED
from	O
different	O
SARS	O
-	O
CoV	O
strains	O
,	O
suggesting	O
that	O
the	O
NAbs	O
to	O
SARS	O
-	O
CoV	O
were	O
broadly	O
reactive	O
.	O

To	O
study	O
sequence	O
variation	O
in	O
the	O
SARS	O
-	O
CoV	O
genome	O
,	O
we	O
determined	O
the	O
nucleic	B-CHED
acid	I-CHED
sequence	O
of	O
the	O
S	O
and	O
N	O
genes	O
directly	O
from	O
clinical	O
specimens	O
from	O
10	O
patients	O
--	O
1	O
specimen	O
with	O
no	O
matched	O
SARS	O
-	O
CoV	O
isolate	O
,	O
from	O
2	O
patients	O
;	O
multiple	O
specimens	O
from	O
3	O
patients	O
;	O
and	O
matched	O
clinical	O
-	O
specimen	O
/	O
cell	O
-	O
culture	O
-	O
isolate	O
pairs	O
from	O
6	O
patients	O
.	O

ABSTRACT	O
:	O
Activated	O
protein	B-CHED
C	O
(	O
APC	O
),	O
a	O
natural	O
anticoagulant	B-CHED
,	O
is	O
formed	O
from	O
protein	B-CHED
C	O
by	O
the	O
action	O
of	O
thrombin	O
bound	O
to	O
thrombomodulin	O
on	O
the	O
endothelial	O
cell	O
surface	O
.	O

Inhibition	O
by	O
APC	O
of	O
the	O
endothelial	O
cell	O
damage	O
inhibited	O
the	O
decrease	O
in	O
the	O
endothelial	O
production	O
of	O
prostacyclin	B-CHED
in	O
vivo	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
gene	O
encoding	O
the	O
N	O
protein	B-CHED
was	O
cloned	O
and	O
the	O
protein	B-CHED
was	O
expressed	O
,	O
purified	O
,	O
and	O
refolded	O
as	O
shown	O
by	O
(	O
1	O
)	O
H	O
NMR	O
measurement	O
.	O

Such	O
differences	O
were	O
detected	O
in	O
individual	O
sera	O
from	O
various	O
mouse	O
strains	O
,	O
and	O
were	O
ascribed	O
to	O
the	O
fact	O
that	O
proteins	B-CHED
insolubilized	O
on	O
solid	O
supports	O
expose	O
a	O
variety	O
of	O
conformational	O
and	O
cryptic	O
antigenic	O
determinants	O
.	O

This	O
cross	O
-	O
reaction	O
implies	O
either	O
sequential	O
or	O
conformational	O
epitopes	O
from	O
both	O
the	O
viral	O
proteins	B-CHED
and	O
the	O
autoAg	O
and	O
may	O
differ	O
between	O
individuals	O
.	O

ABSTRACT	O
:	O
High	O
mobility	O
group	O
box	O
1	O
protein	B-CHED
(	O
HMGB1	O
)	O
is	O
released	O
by	O
necrotic	O
cells	O
or	O
activated	O
macrophages	O
/	O
monocytes	O
,	O
and	O
functions	O
as	O
a	O
late	O
mediator	O
of	O
lethal	O
systemic	O
and	O
local	O
pulmonary	O
inflammation	O
.	O

We	O
have	O
genetically	O
dissected	O
these	O
domains	O
in	O
the	O
MHV	O
S	O
protein	B-CHED
to	O
localize	O
the	O
determinants	O
of	O
S	O
incorporation	O
into	O
virions	O
.	O

Our	O
results	O
establish	O
that	O
assembly	O
competence	O
maps	O
to	O
the	O
endodomain	O
of	O
S	O
,	O
which	O
was	O
shown	O
to	O
be	O
sufficient	O
to	O
target	O
a	O
heterologous	O
integral	O
membrane	O
protein	B-CHED
for	O
incorporation	O
into	O
MHV	O
virions	O
.	O

Additionally	O
,	O
we	O
found	O
that	O
the	O
adjacent	O
cysteine	B-CHED
-	O
rich	O
region	O
of	O
the	O
endodomain	O
is	O
critical	O
for	O
fusion	O
of	O
infected	O
cells	O
,	O
confirming	O
results	O
previously	O
obtained	O
with	O
S	O
protein	B-CHED
expression	O
systems	O
.	O

TITLE	O
:	O
Identification	O
and	O
characterization	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
replicase	O
proteins	B-CHED
.	O

ABSTRACT	O
:	O
The	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
encodes	O
proteins	B-CHED
required	O
for	O
RNA	O
transcription	O
and	O
genome	O
replication	O
as	O
large	O
polyproteins	O
that	O
are	O
proteolytically	O
processed	O
by	O
virus	O
-	O
encoded	O
proteinases	O
to	O
produce	O
mature	O
replicase	O
proteins	B-CHED
.	O

ABSTRACT	O
:	O
CEACAM1a	O
glycoproteins	B-CHED
are	O
members	O
of	O
the	O
immunoglobulin	O
(	O
Ig	O
)	O
superfamily	O
and	O
the	O
carcinoembryonic	O
antigen	B-CHED
family	O
.	O

We	O
have	O
now	O
engineered	O
and	O
produced	O
a	O
Ceacam1a	O
-/-	O
mouse	O
that	O
exhibits	O
complete	O
ablation	O
of	O
the	O
CEACAM1a	O
protein	B-CHED
in	O
every	O
tissue	O
where	O
it	O
is	O
normally	O
expressed	O
.	O

ABSTRACT	O
:	O
We	O
demonstrate	O
the	O
feasibility	O
and	O
utility	O
of	O
emergency	O
department	O
(	O
ED	O
)	O
syndromic	O
surveillance	O
using	O
a	O
regional	O
emergency	O
medicine	B-CHED
Internet	O
application	O
to	O
minimize	O
impact	O
on	O
ED	O
and	O
public	O
health	O
staffing	O
.	O

Counts	O
of	O
patient	O
visits	O
meeting	O
syndrome	O
criteria	O
and	O
total	O
patient	O
visits	O
were	O
reported	O
daily	O
on	O
the	O
secure	O
regional	O
emergency	O
medicine	B-CHED
Internet	O
site	O
and	O
downloaded	O
by	O
public	O
health	O
staff	O
.	O

ABSTRACT	O
:	O
Antibody	O
titres	O
to	O
selected	O
pathogens	O
(	O
canine	O
adenovirus	O
[	O
CAV	O
-	O
2	O
],	O
feline	O
herpesvirus	O
[	O
FHV	O
],	O
phocine	O
herpesvirus	O
[	O
PHV	B-CHED
-	O
1	O
],	O
canine	O
distemper	O
virus	O
,	O
dolphin	O
morbillivirus	O
[	O
DMV	O
],	O
phocine	O
distemper	O
virus	O
[	O
PDV	O
],	O
parainfluenza	O
virus	O
type	O
3	O
[	O
PI3	O
],	O
rabies	O
virus	O
,	O
dolphin	O
rhabdovirus	O
[	O
DRV	O
],	O
canine	O
coronavirus	O
,	O
feline	O
coronavirus	O
,	O
feline	O
leukaemia	O
virus	O
,	O
Borrelia	O
burgdorferi	O
and	O
Toxoplasma	O
gondii	O
)	O
were	O
determined	O
in	O
whole	O
blood	O
or	O
serum	O
samples	O
from	O
selected	O
free	O
-	O
ranging	O
terrestrial	O
carnivores	O
and	O
marine	O
mammals	O
,	O
including	O
cougars	O
(	O
Fellis	O
concolor	O
),	O
lynxes	O
(	O
Fellis	O
lynx	O
),	O
American	O
badgers	O
(	O
Taxidea	O
taxus	O
),	O
fishers	O
(	O
Martes	O
pennanti	O
),	O
wolverines	O
(	O
Gulo	O
gulo	O
),	O
wolves	O
(	O
Canis	O
lupus	O
),	O
black	O
bears	O
(	O
Ursus	O
americanus	O
),	O
grizzly	O
bears	O
(	O
Ursus	O
arctos	O
),	O
polar	O
bears	O
(	O
Ursus	O
maritimus	O
),	O
walruses	O
(	O
Odobenus	O
rosmarus	O
)	O
and	O
belugas	O
(	O
Delphinapterus	O
leucas	O
),	O
which	O
had	O
been	O
collected	O
at	O
several	O
locations	O
in	O
Canada	O
between	O
1984	O
and	O
2001	O
.	O

TITLE	O
:	O
[	O
Development	O
of	O
the	O
integrated	O
TCM	O
hepatology	O
with	O
western	O
medicine	B-CHED
].	O

Their	O
combination	O
and	O
unity	O
is	O
the	O
key	O
point	O
for	O
the	O
integration	O
of	O
TCM	O
with	O
western	O
medicine	B-CHED
in	O
order	O
to	O
improve	O
the	O
clinical	O
effectiveness	O
and	O
TCM	O
development	O
.	O

Sixty	O
-	O
five	O
of	O
the	O
patients	O
were	O
confirmed	O
to	O
have	O
common	O
type	O
of	O
SARS	O
,	O
including	O
26	O
males	O
and	O
39	O
females	O
,	O
50	O
cases	O
received	O
methylprednisolone	B-CHED
treatment	O
.	O

Compared	O
with	O
patients	O
of	O
the	O
same	O
group	O
who	O
were	O
not	O
treated	O
with	O
glucocorticoids	B-CHED
,	O
T	O
-	O
lymphocyte	O
counts	O
of	O
non	O
-	O
SARS	O
patients	O
treated	O
with	O
glucocorticoids	B-CHED
had	O
no	O
obvious	O
difference	O
.	O

The	O
damage	O
of	O
several	O
organs	O
was	O
common	O
,	O
including	O
the	O
elevated	O
ALT	B-CHED
or	O
AST	O
in	O
20	O
patients	O
(	O
37	O
.	O
7	O
%),	O
elevated	O
BUN	O
or	O
SCR	O
in	O
6	O
patients	O
(	O
11	O
.	O
3	O
%)	O
and	O
elevated	O
LDH	O
or	O
CK	O
or	O
HBDH	O
in	O
23	O
patients	O
(	O
43	O
.	O
4	O
%).	O

Indirect	O
immunofluorescence	O
test	O
showed	O
a	O
specific	O
antigen	B-CHED
-	O
antibody	O
reactivity	O
between	O
the	O
coronavirus	O
and	O
convalescent	O
-	O
phase	O
sera	O
of	O
SARS	O
patients	O
.	O

Seventy	O
percent	O
of	O
the	O
patients	O
showed	O
a	O
reduction	O
in	O
partial	O
pressure	O
of	O
oxygen	B-CHED
(	O
PaO2	O
),	O
and	O
19	O
%	O
developed	O
various	O
degrees	O
of	O
hypoxemia	O
.	O

This	O
structure	O
shares	O
significant	O
similarity	O
with	O
the	O
fusion	O
core	O
structure	O
of	O
mouse	O
hepatitis	O
virus	O
spike	O
protein	B-CHED
and	O
other	O
viral	O
fusion	O
proteins	B-CHED
,	O
suggesting	O
a	O
conserved	O
mechanism	O
of	O
membrane	O
fusion	O
.	O

The	O
relatively	O
deep	O
grooves	O
on	O
the	O
surface	O
of	O
the	O
central	O
coiled	O
coil	O
will	O
be	O
a	O
good	O
target	O
site	O
for	O
the	O
design	O
of	O
viral	O
fusion	O
inhibitors	B-CHED
.	O

The	O
in	O
vivo	O
mutation	O
rate	O
,	O
however	O
,	O
is	O
consistent	O
with	O
estimates	O
of	O
other	O
RNA	O
viruses	O
at	O
approximately	O
5	O
.	O
7	O
x	O
10	O
-	O
6	O
nucleotide	B-CHED
substitutions	O
per	O
site	O
per	O
day	O
(	O
0	O
.	O
17	O
mutations	O
per	O
genome	O
per	O
day	O
),	O
or	O
two	O
mutations	O
per	O
human	O
passage	O
(	O
adjusted	O
R	O
-	O
square	O
=	O
0	O
.	O
4014	O
).	O

It	O
was	O
found	O
that	O
the	O
bases	B-CHED
of	O
six	O
nucleotide	B-CHED
positions	O
(	O
nt9404	O
,	O
nt9479	O
,	O
nt19838	O
,	O
nt21721	O
,	O
nt22222	O
and	O
nt27827	O
)	O
with	O
high	O
-	O
mutation	O
rate	O
have	O
an	O
important	O
relationship	O
with	O
the	O
SARS	O
epidemic	O
.	O

Chandipura	O
viral	O
antigen	B-CHED
and	O
RNA	O
were	O
detected	O
in	O
brain	O
tissue	O
of	O
a	O
deceased	O
child	O
by	O
immunofluorescent	O
antibody	O
test	O
and	O
PCR	O
.	O

However	O
,	O
a	O
threonine	B-CHED
residue	I-CHED
was	O
not	O
phosphorylated	O
.	O

TITLE	O
:	O
The	O
role	O
of	O
aquaporin	O
-	O
1	O
(	O
AQP1	O
)	O
expression	O
in	O
a	O
murine	O
model	O
of	O
lipopolysaccharide	B-CHED
-	O
induced	O
acute	O
lung	O
injury	O
.	O

ABSTRACT	O
:	O
A	O
murine	O
model	O
of	O
lipopolysaccharide	B-CHED
(	O
LPS	B-CHED
)-	O
induced	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
was	O
used	O
to	O
evaluate	O
whether	O
aquaporin	O
-	O
1	O
(	O
AQP1	O
)	O
is	O
involved	O
in	O
lung	O
inflammation	O
and	O
lung	O
edema	O
formation	O
.	O

Swiss	O
strain	O
mice	O
(	O
n	O
=	O
122	O
)	O
had	O
LPS	B-CHED
(	O
5	O
mg	O
/	O
kg	O
)	O
instilled	O
intratracheally	O
(	O
IT	O
),	O
and	O
were	O
then	O
treated	O
with	O
either	O
0	O
.	O
9	O
%	O
saline	O
or	O
dexamethasone	B-CHED
(	O
5	O
mg	O
/	O
kg	O
/	O
day	O
).	O

Inflammatory	O
cytokines	O
(	O
TNF	O
-	O
alpha	O
,	O
IL	O
-	O
6	O
),	O
protein	B-CHED
concentration	O
in	O
bronchoalveolar	O
lavage	O
(	O
BAL	B-CHED
)	O
fluid	O
,	O
lung	O
wet	O
-	O
to	O
-	O
dry	O
weight	O
ratio	O
,	O
histology	O
,	O
immunohistochemistry	O
,	O
and	O
AQP1	O
Western	O
blot	O
were	O
performed	O
.	O

Addition	O
of	O
chloroquine	B-CHED
to	O
infected	O
cultures	O
could	O
be	O
delayed	O
for	O
up	O
to	O
5h	O
postinfection	O
,	O
without	O
an	O
important	O
drop	O
in	O
antiviral	B-CHED
activity	O
.	O

In	O
this	O
species	O
,	O
proinflammatory	O
chemokines	O
may	O
coordinate	O
a	O
rapid	O
and	O
highly	O
effective	O
innate	O
antiviral	B-CHED
response	O
in	O
the	O
lung	O
,	O
but	O
NK	O
cells	O
and	O
adaptive	O
cellular	O
immunity	O
are	O
not	O
required	O
for	O
viral	O
clearance	O
.	O

ABSTRACT	O
:	O
Ampligen	O
[	O
polyI	O
:	O
polyC12U	O
]	O
is	O
a	O
mismatched	O
double	O
-	O
stranded	O
RNA	O
that	O
acts	O
by	O
inducing	O
interferon	O
production	O
(	O
immunomodulator	B-CHED
)	O
and	O
by	O
activating	O
an	O
intracellular	O
enzyme	O
(	O
RNase	O
-	O
L	O
)	O
against	O
viral	O
RNA	O
transcripts	O
(	O
antiviral	B-CHED
).	O

In	O
the	O
US	O
,	O
Ampligen	O
has	O
been	O
granted	O
orphan	B-CHED
drug	I-CHED
status	O
for	O
the	O
treatment	O
of	O
AIDS	O
,	O
renal	O
cell	O
carcinoma	O
(	O
phase	O
II	O
,	O
completed	O
),	O
chronic	O
fatigue	O
syndrome	O
(	O
phase	O
III	O
)	O
and	O
invasive	O
/	O
metastatic	O
malignant	O
melanoma	O
(	O
phase	O
II	O
).	O

In	O
August	O
2004	O
,	O
Hemispherx	O
announced	O
that	O
it	O
intends	O
to	O
use	O
the	O
proceeds	O
from	O
the	O
private	O
placement	O
of	O
company	O
stock	O
to	O
complete	O
the	O
clinical	O
work	O
for	O
its	O
immunotherapeutics	O
/	O
antivirals	B-CHED
Ampligen	O
and	O
Oragens	O
.	O

In	O
October	O
2003	O
,	O
Hemispherx	O
announced	O
that	O
,	O
based	O
on	O
these	O
promising	O
new	O
results	O
,	O
the	O
company	O
will	O
stockpile	O
injectible	O
and	O
/	O
or	O
oral	O
formats	O
of	O
Ampligen	O
and	O
Alferon	O
N	O
.	O
Independent	O
researchers	O
have	O
demonstrated	O
the	O
antiviral	B-CHED
activity	O
of	O
Ampligen	O
against	O
flaviviruses	O
(	O
West	O
Nile	O
virus	O
,	O
Equine	O
Encephalitis	O
virus	O
,	O
Dengue	O
fever	O
virus	O
and	O
Japanese	O
Encephalitis	O
virus	O
)	O
as	O
well	O
as	O
virus	O
classes	O
associated	O
with	O
bioterrorism	O
.	O

TITLE	O
:	O
Nucleocapsid	O
protein	B-CHED
of	O
SARS	O
coronavirus	O
tightly	O
binds	O
to	O
human	O
cyclophilin	O
A	O
.	O
ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
is	O
responsible	O
for	O
SARS	O
infection	O
.	O

Protein	B-CHED
-	O
protein	B-CHED
interaction	O
analysis	O
using	O
bioinformatics	O
tools	O
indicated	O
that	O
SARS_NP	O
may	O
bind	O
to	O
human	O
cyclophilin	O
A	O
(	O
hCypA	O
),	O
and	O
surface	O
plasmon	O
resonance	O
(	O
SPR	O
)	O
technology	O
revealed	O
this	O
binding	O
with	O
the	O
equilibrium	O
dissociation	O
constant	O
ranging	O
from	O
6	O
to	O
160nM	O
.	O
The	O
probable	O
binding	O
sites	O
of	O
these	O
two	O
proteins	B-CHED
were	O
detected	O
by	O
modeling	O
the	O
three	O
-	O
dimensional	O
structure	O
of	O
the	O
SARS_NP	O
-	O
hCypA	O
complex	O
,	O
from	O
which	O
the	O
important	O
interaction	O
residue	O
pairs	O
between	O
the	O
proteins	B-CHED
were	O
deduced	O
.	O

Breathing	O
reserve	O
was	O
low	O
in	O
four	O
patients	O
and	O
significant	O
oxygen	B-CHED
desaturation	O
was	O
detected	O
in	O
a	O
further	O
four	O
patients	O
.	O

The	O
full	O
-	O
length	O
CKLF1	O
cDNA	O
contains	O
530	O
bp	O
encoding	O
99	O
amino	B-CHED
acid	I-CHED
residues	O
with	O
a	O
CC	O
motif	O
similar	O
to	O
that	O
of	O
other	O
CC	O
family	O
chemokines	O
.	O

This	O
article	O
focusses	O
on	O
the	O
use	O
of	O
infection	O
control	O
masks	O
in	O
routine	O
pediatric	O
healthcare	O
and	O
the	O
tools	O
developed	O
by	O
HSC	B-CHED
staff	O
to	O
reduce	O
the	O
negative	O
psychosocial	O
impact	O
on	O
children	O
and	O
families	O
.	O

There	O
was	O
an	O
increase	O
in	O
reticulin	B-CHED
fiber	O
formation	O
.	O

TITLE	O
:	O
Protein	B-CHED
chip	O
array	O
profiling	O
analysis	O
in	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
identified	O
serum	O
amyloid	O
a	O
protein	B-CHED
as	O
a	O
biomarker	B-CHED
potentially	O
useful	O
in	O
monitoring	O
the	O
extent	O
of	O
pneumonia	O
.	O

The	O
full	O
-	O
length	O
spike	O
protein	B-CHED
(	O
S	O
)	O
was	O
newly	O
synthesized	O
as	O
an	O
endoglycosidase	O
H	O
(	O
endo	O
H	O
)-	O
sensitive	O
glycoprotein	B-CHED
(	O
gp170	O
)	O
that	O
is	O
further	O
modified	O
into	O
an	O
endo	O
H	O
-	O
resistant	O
glycoprotein	B-CHED
(	O
gp180	O
)	O
in	O
the	O
Golgi	O
apparatus	O
.	O

TITLE	O
:	O
Murine	O
coronavirus	O
nonstructural	O
protein	B-CHED
p28	O
arrests	O
cell	O
cycle	O
in	O
G0	O
/	O
G1	O
phase	O
.	O

TITLE	O
:	O
Retroviruses	O
pseudotyped	O
with	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
spike	O
protein	B-CHED
efficiently	O
infect	O
cells	O
expressing	O
angiotensin	B-CHED
-	O
converting	O
enzyme	O
2	O
.	O

We	O
also	O
found	O
that	O
two	O
retroviruses	O
,	O
simian	O
immunodeficiency	O
virus	O
(	O
SIV	O
)	O
and	O
murine	O
leukemia	O
virus	O
,	O
both	O
expressing	O
green	O
fluorescent	O
protein	B-CHED
and	O
pseudotyped	O
with	O
SARS	O
-	O
CoV	O
S	O
protein	B-CHED
or	O
S	O
-	O
protein	B-CHED
variants	O
,	O
efficiently	O
infected	O
HEK293T	O
cells	O
stably	O
expressing	O
ACE2	O
.	O

Infection	O
mediated	O
by	O
an	O
S	O
-	O
protein	B-CHED
variant	O
whose	O
cytoplasmic	O
domain	O
had	O
been	O
truncated	O
and	O
altered	O
to	O
include	O
a	O
fragment	O
of	O
the	O
cytoplasmic	O
tail	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
envelope	O
glycoprotein	B-CHED
was	O
,	O
in	O
both	O
cases	O
,	O
substantially	O
more	O
efficient	O
than	O
that	O
mediated	O
by	O
wild	O
-	O
type	O
S	O
protein	B-CHED
.	O

Finally	O
,	O
we	O
show	O
that	O
a	O
soluble	O
and	O
catalytically	O
inactive	O
form	O
of	O
ACE2	O
potently	O
blocked	O
infection	O
by	O
S	O
-	O
protein	B-CHED
-	O
pseudotyped	O
retrovirus	O
and	O
by	O
SARS	O
-	O
CoV	O
.	O
These	O
results	O
permit	O
studies	O
of	O
SARS	O
-	O
CoV	O
entry	O
inhibitors	B-CHED
without	O
the	O
use	O
of	O
live	O
virus	O
and	O
suggest	O
a	O
candidate	O
therapy	O
for	O
SARS	O
.	O

Furthermore	O
,	O
SPAAN	O
facilitated	O
improved	O
annotation	O
of	O
several	O
proteins	B-CHED
as	O
adhesins	O
.	O

Extracorporeal	O
life	O
support	O
(	O
ECLS	O
)	O
during	O
severe	O
ARDS	O
maintains	O
oxygen	B-CHED
and	O
carbon	B-CHED
dioxide	I-CHED
gas	O
exchange	O
while	O
providing	O
an	O
optimal	O
environment	O
for	O
recovery	O
of	O
pulmonary	O
function	O
.	O

None	O
of	O
the	O
patients	O
who	O
survived	O
required	O
permanent	O
mechanical	O
ventilation	O
or	O
supplemental	O
oxygen	B-CHED
therapy	O
.	O

Although	O
significant	O
increases	O
in	O
Vd	O
(	O
phys	O
)	O
resulted	O
with	O
PPV	B-CHED
combined	O
with	O
TIVA	O
,	O
these	O
adverse	O
changes	O
were	O
much	O
less	O
compared	O
with	O
isoflurane	B-CHED
inhalation	O
and	O
PPV	B-CHED
.	O

ABSTRACT	O
:	O
Some	O
of	O
the	O
structural	O
proteins	B-CHED
of	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
carry	O
major	O
epitopes	O
involved	O
in	O
virus	O
neutralization	O
and	O
are	O
essential	O
for	O
the	O
induction	O
of	O
protective	O
humoral	O
responses	O
and	O
the	O
development	O
of	O
an	O
effective	O
vaccine	O
.	O

The	O
neutralizing	O
ability	O
of	O
antisera	O
directed	O
against	O
the	O
expressed	O
structural	O
proteins	B-CHED
was	O
greater	O
than	O
that	O
of	O
convalescent	O
patient	O
antisera	O
,	O
confirming	O
that	O
,	O
as	O
immunogens	O
,	O
the	O
former	O
induce	O
strong	O
,	O
SARS	O
-	O
CoV	O
-	O
specific	O
neutralizing	O
antibody	O
responses	O
.	O

Some	O
spike	O
proteins	B-CHED
of	O
coronavirus	O
,	O
such	O
as	O
MHV	O
,	O
HCoV	O
-	O
OC43	O
,	O
AIBV	O
and	O
BcoV	O
,	O
are	O
proteolytically	O
cleaved	O
into	O
two	O
subunits	O
,	O
S1	O
and	O
S2	O
.	O

Many	O
studies	O
have	O
shown	O
that	O
the	O
cleavage	O
of	O
spike	O
protein	B-CHED
seriously	O
affects	O
its	O
function	O
.	O

Our	O
results	O
showed	O
that	O
the	O
antibodies	O
could	O
efficiently	O
and	O
specifically	O
bind	O
to	O
their	O
corresponding	O
proteins	B-CHED
from	O
E	O
.	O
coli	O
expressed	O
or	O
lysate	O
of	O
SARS	O
-	O
CoV	O
infected	O
Vero	O
-	O
E6	O
cells	O
by	O
Western	O
blot	O
analysis	O
.	O

Only	O
the	O
use	O
of	O
pulse	O
corticosteroids	B-CHED
was	O
associated	O
with	O
the	O
presence	O
of	O
CT	O
abnormalities	O
(	O
p	O
=	O
0	O
.	O
043	O
,	O
OR	O
6	O
.	O
65	O
,	O
95	O
%	O
CI	O
1	O
.	O
06	O
to	O
41	O
.	O
73	O
).	O

Only	O
the	O
use	O
of	O
pulse	O
corticosteroids	B-CHED
was	O
associated	O
with	O
the	O
presence	O
of	O
CT	O
abnormalities	O
(	O
p	O
=	O
0	O
.	O
043	O
,	O
OR	O
6	O
.	O
65	O
,	O
95	O
%	O
CI	O
1	O
.	O
06	O
to	O
41	O
.	O
73	O
).	O

The	O
recombinant	O
esterases	O
were	O
shown	O
to	O
specifically	O
de	O
-	O
O	O
-	O
acetylate	O
sialic	B-CHED
acids	I-CHED
on	O
glycoconjugates	O
.	O

In	O
this	O
study	O
,	O
we	O
found	O
a	O
new	O
lignan	B-CHED
glycoside	B-CHED
(	O
6	O
)	O
and	O
two	O
new	O
phenylethanoid	O
glycosides	B-CHED
(	O
7	O
,	O
8	O
)	O
together	O
with	O
five	O
known	O
compounds	O
as	O
chemical	O
constituents	O
of	O
Strobilanthes	O
cusia	O
root	O
.	O

The	O
algorithm	O
was	O
tested	O
on	O
42	O
patients	O
with	O
affections	O
of	O
the	O
central	O
nervous	O
system	O
(	O
CNS	B-CHED
)	O
due	O
to	O
severe	O
craniocerebral	O
trauma	O
,	O
spinal	O
trauma	O
,	O
cerebral	O
stroke	O
and	O
multitrauma	O
.	O

Here	O
we	O
show	O
that	O
a	O
recombinant	O
fusion	O
protein	B-CHED
(	O
designated	O
RBD	O
-	O
Fc	O
)	O
containing	O
193	O
-	O
amino	B-CHED
acid	I-CHED
RBD	O
(	O
residues	O
318	O
-	O
510	O
)	O
and	O
a	O
human	O
IgG1	O
Fc	O
fragment	O
can	O
induce	O
highly	O
potent	O
antibody	O
responses	O
in	O
the	O
immunized	O
rabbits	O
.	O

Even	O
with	O
steroid	B-CHED
therapy	O
alone	O
,	O
the	O
mortality	O
rate	O
appeared	O
to	O
be	O
lower	O
when	O
compared	O
with	O
conservative	O
treatment	O
for	O
pneumonia	O
caused	O
by	O
human	O
influenza	O
virus	O
(	O
12	O
.	O
5	O
%	O
vs	O
.	O
42	O
.	O
1	O
%)	O
and	O
hantavirus	O
(	O
13	O
.	O
3	O
%	O
vs	O
.	O
63	O
.	O
4	O
%).	O

In	O
murine	O
coronavirus	O
,	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
),	O
the	O
spike	O
(	O
S	O
)	O
protein	B-CHED
mediates	O
this	O
process	O
.	O

This	O
2	O
-	O
helix	O
polypeptide	B-CHED
subsequently	O
assembled	O
into	O
a	O
typical	O
6	O
-	O
helix	O
bundle	O
.	O

Replicase	O
protein	B-CHED
precursors	O
and	O
mature	O
products	O
are	O
thought	O
to	O
mediate	O
the	O
formation	O
and	O
function	O
of	O
viral	O
replication	O
complexes	O
on	O
the	O
surfaces	O
of	O
intracellular	O
double	O
-	O
membrane	O
vesicles	O
.	O

Here	O
we	O
show	O
that	O
DC	O
-	O
SIGN	O
and	O
DC	O
-	O
SIGNR	O
enhance	O
infection	O
mediated	O
by	O
the	O
glycoprotein	B-CHED
(	O
GP	O
)	O
of	O
Marburg	O
virus	O
(	O
MARV	O
)	O
and	O
the	O
S	O
protein	B-CHED
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
and	O
might	O
promote	O
viral	O
dissemination	O
.	O

Patients	O
with	O
SARS	O
-	O
related	O
psychosis	O
received	O
higher	O
total	O
doses	O
of	O
steroids	B-CHED
and	O
had	O
higher	O
rates	O
of	O
family	O
history	O
of	O
psychiatric	O
illness	O
.	O

The	O
levels	O
of	O
blood	O
glucose	B-CHED
were	O
correlated	O
with	O
the	O
initial	O
,	O
maximum	O
,	O
and	O
cumulative	O
GCS	O
dosages	O
.	O

After	O
GCS	O
administration	O
,	O
SBP	O
and	O
DBP	B-CHED
were	O
increased	O
gradually	O
,	O
and	O
reached	O
their	O
peaks	O
in	O
the	O
fourth	O
week	O
[	O
SBP	O
(	O
117	O
.	O
2	O
+/-	O
14	O
.	O
0	O
)	O
mm	O
Hg	O
and	O
DBP	B-CHED
(	O
72	O
.	O
5	O
+/-	O
9	O
.	O
1	O
)	O
mm	O
Hg	O
vs	O
SBP	O
(	O
120	O
.	O
0	O
+/-	O
12	O
.	O
5	O
)	O
mm	O
Hg	O
and	O
DBP	B-CHED
(	O
74	O
.	O
5	O
+/-	O
8	O
.	O
7	O
)	O
mm	O
Hg	O
,	O
P	O
<	O
0	O
.	O
05	O
,	O
1	O
mm	O
Hg	O
=	O
0	O
.	O
133	O
kPa	O
].	O

TITLE	O
:	O
[	O
Altitude	O
,	O
the	O
ratio	O
of	O
PaO2	O
to	O
fraction	O
of	O
inspired	O
oxygen	B-CHED
,	O
and	O
shunt	O
:	O
impact	O
on	O
the	O
assessment	O
of	O
acute	O
lung	O
injury	O
].	O

Shunt	O
should	O
more	O
often	O
be	O
measured	O
directly	O
or	O
be	O
estimated	O
assuming	O
a	O
constant	O
arteriovenous	O
oxygen	B-CHED
content	O
difference	O
.	O

In	O
this	O
structure	O
-	O
activity	O
relation	O
study	O
,	O
the	O
molecules	O
with	O
the	O
highest	O
predicted	O
binding	O
scores	O
were	O
identified	O
and	O
assayed	O
for	O
ACE2	O
enzymatic	O
inhibitory	O
activity	O
and	O
for	O
their	O
ability	O
to	O
inhibit	O
SARS	O
coronavirus	O
spike	O
protein	B-CHED
-	O
mediated	O
cell	O
fusion	O
.	O

CONCLUSIONS	O
:	O
Our	O
findings	O
suggested	O
""""	O
early	O
""""	O
corticosteroid	B-CHED
treatment	O
was	O
associated	O
with	O
a	O
higher	O
subsequent	O
plasma	O
viral	O
load	O
.	O

The	O
significantly	O
higher	O
levels	O
of	O
IgG	O
antibodies	O
specific	O
to	O
three	O
(	O
S791	O
,	O
M207	O
and	O
N161	O
)	O
of	O
42	O
peptides	B-CHED
were	O
detectable	O
in	O
the	O
post	O
-	O
infection	O
sera	O
from	O
23	O
(	O
51	O
%),	O
27	O
(	O
60	O
%)	O
and	O
19	O
(	O
42	O
%)	O
of	O
45	O
patients	O
,	O
respectively	O
.	O

When	O
the	O
cDNA	O
encoding	O
CD209L	O
from	O
clone	O
2	O
.	O
27	O
was	O
cloned	O
and	O
transfected	O
into	O
Chinese	O
hamster	O
ovary	O
cells	O
,	O
the	O
cells	O
expressed	O
human	O
CD209L	O
glycoprotein	B-CHED
and	O
became	O
susceptible	O
to	O
infection	O
with	O
SARS	O
-	O
CoV	O
.	O
Immunohistochemistry	O
showed	O
that	O
CD209L	O
is	O
expressed	O
in	O
human	O
lung	O
in	O
type	O
II	O
alveolar	O
cells	O
and	O
endothelial	O
cells	O
,	O
both	O
potential	O
targets	O
for	O
SARS	O
-	O
CoV	O
.	O
Several	O
other	O
enveloped	O
viruses	O
including	O
Ebola	O
and	O
Sindbis	O
also	O
use	O
CD209L	O
as	O
a	O
portal	O
of	O
entry	O
,	O
and	O
HIV	O
and	O
hepatitis	O
C	O
virus	O
can	O
bind	O
to	O
CD209L	O
on	O
cell	O
membranes	O
but	O
do	O
not	O
use	O
it	O
to	O
mediate	O
virus	O
entry	O
.	O

Group	O
1	O
was	O
the	O
indicators	O
of	O
impact	O
on	O
patients	O
,	O
including	O
visitor	O
'	O
s	O
condition	O
classification	O
,	O
number	O
of	O
patients	O
that	O
died	O
on	O
arrival	O
(	O
DOA	O
),	O
received	O
cardiopulmonary	O
resuscitation	O
,	O
underwent	O
endotracheal	O
intubation	O
,	O
needed	O
mechanical	O
ventilation	O
,	O
discharged	O
against	O
medical	O
advice	O
(	O
AAD	B-CHED
),	O
died	O
in	O
the	O
ED	O
,	O
and	O
the	O
admission	O
rate	O
to	O
wards	O
.	O

Specificity	O
was	O
100	O
%	O
on	O
normal	O
blood	O
donor	B-CHED
samples	O
,	O
on	O
serum	O
samples	O
associated	O
with	O
infection	O
by	O
other	O
pathogens	O
,	O
and	O
on	O
an	O
interference	O
panel	O
.	O

Two	O
novel	O
small	O
molecule	O
inhibitors	B-CHED
of	O
the	O
SARS	O
-	O
CoV	O
Mpro	O
were	O
identified	O
by	O
high	O
-	O
throughput	O
screening	O
using	O
an	O
internally	O
quenched	O
fluorogenic	O
substrate	O
.	O

The	O
identified	O
inhibitors	B-CHED
have	O
Ki	O
values	O
at	O
low	O
microM	O
range	O
with	O
comparable	O
anti	O
-	O
SARS	O
-	O
CoV	O
activity	O
in	O
cell	O
-	O
based	O
assays	O
.	O

The	O
70	O
patients	O
exposed	O
to	O
the	O
SARS	O
outbreak	O
were	O
isolated	O
from	O
the	O
rest	B-CHED
of	O
the	O
hospital	O
.	O

TITLE	O
:	O
In	O
vitro	O
biochemical	O
and	O
thermodynamic	O
characterization	O
of	O
nucleocapsid	O
protein	B-CHED
of	O
SARS	O
.	O

TITLE	O
:	O
Crystallization	O
and	O
preliminary	O
crystallographic	O
analysis	O
of	O
the	O
fusion	O
core	O
of	O
the	O
spike	O
protein	B-CHED
of	O
the	O
murine	O
coronavirus	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
).	O

ABSTRACT	O
:	O
Crystals	O
of	O
a	O
2	O
-	O
Helix	O
fusion	O
-	O
core	O
construct	O
of	O
MHV	O
spike	O
protein	B-CHED
(	O
commonly	O
referred	O
to	O
as	O
E2	O
)	O
have	O
been	O
grown	O
at	O
291	O
K	O
using	O
PEG	B-CHED
4000	O
as	O
precipitant	O
.	O

Furthermore	O
,	O
a	O
selenomethionine	B-CHED
(	O
SeMet	O
)	O
derivative	O
of	O
MHV	O
spike	O
protein	B-CHED
fusion	O
core	O
has	O
been	O
overexpressed	O
and	O
purified	O
.	O

We	O
believe	O
our	O
experience	O
warrants	O
an	O
increased	O
vigilance	O
against	O
stroke	O
and	O
other	O
thrombotic	O
complications	O
among	O
critically	O
-	O
ill	O
SARS	O
patients	O
in	O
future	O
outbreaks	O
,	O
especially	O
if	O
treatment	O
such	O
as	O
intravenous	O
immunoglobulin	O
,	O
that	O
increases	O
pro	B-CHED
-	O
thrombotic	O
tendency	O
,	O
is	O
contemplated	O
.	O

The	O
plasmid	O
pEGFP	O
-	O
optS	O
,	O
which	O
contains	O
the	O
codon	O
-	O
optimized	O
SARS	O
-	O
CoV	O
S	O
gene	O
and	O
expresses	O
spike	O
-	O
EGFP	O
fusion	O
protein	B-CHED
(	O
S	O
-	O
EGFP	O
)	O
as	O
silencing	O
target	O
and	O
expressing	O
reporter	O
,	O
was	O
transfected	O
with	O
siRNAs	O
into	O
HEK	O
293T	O
cells	O
.	O

ABSTRACT	O
:	O
Many	O
viruses	O
achieve	O
reversible	O
attachment	O
to	O
sialic	B-CHED
acid	I-CHED
(	O
Sia	O
)	O
by	O
encoding	O
envelope	O
glycoproteins	B-CHED
with	O
receptor	O
-	O
binding	O
and	O
receptor	O
-	O
destroying	O
activities	O
.	O

Sialate	B-CHED
-	O
9	O
-	O
O	O
-	O
acetylesterases	O
specific	O
for	O
5	O
-	O
N	B-CHED
-	I-CHED
acetyl	I-CHED
-	I-CHED
9	I-CHED
-	I-CHED
O	I-CHED
-	I-CHED
acetylneuraminic	I-CHED
acid	I-CHED
,	O
described	O
for	O
bovine	O
and	O
human	O
coronaviruses	O
,	O
also	O
occur	O
in	O
equine	O
coronaviruses	O
and	O
in	O
porcine	O
toroviruses	O
.	O

These	O
findings	O
advance	O
the	O
understanding	O
of	O
the	O
morphogenesis	O
of	O
SARS	O
-	O
CoV	O
and	O
enable	O
the	O
generation	O
of	O
safe	O
,	O
conformational	O
mimetics	O
of	O
the	O
SARS	O
virus	O
that	O
may	O
facilitate	O
the	O
development	O
of	O
vaccines	O
and	O
antiviral	B-CHED
drugs	I-CHED
.	O

ABSTRACT	O
:	O
The	O
causative	O
agent	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
is	O
a	O
previously	O
unidentified	O
coronavirus	O
,	O
SARS	O
-	O
CoV	O
.	O
The	O
nucleocapsid	O
(	O
N	O
)	O
protein	B-CHED
of	O
SARS	O
-	O
CoV	O
is	O
a	O
major	O
viral	O
protein	B-CHED
recognized	O
by	O
acute	O
and	O
early	O
convalescent	O
sera	O
from	O
SARS	O
patients	O
.	O

Recombinant	O
hexa	O
-	O
histidine	B-CHED
-	O
tagged	O
N	O
protein	B-CHED
with	O
a	O
molecular	O
mass	O
of	O
47	O
kD	O
was	O
produced	O
in	O
insect	O
cells	O
.	O

The	O
HR1	O
region	O
in	O
coronaviruses	O
is	O
predicted	O
to	O
be	O
considerably	O
longer	O
than	O
that	O
in	O
other	O
type	O
I	O
virus	O
fusion	O
proteins	B-CHED
.	O

ABSTRACT	O
:	O
The	O
CC	O
chemokine	O
ligand	B-CHED
2	O
(	O
CCL2	B-CHED
,	O
monocyte	O
chemoattractant	O
protein	B-CHED
-	O
1	O
)	O
is	O
important	O
in	O
coordinating	O
the	O
immune	O
response	O
following	O
microbial	O
infection	O
by	O
regulating	O
T	O
cell	O
polarization	O
as	O
well	O
as	O
leukocyte	O
migration	O
and	O
accumulation	O
within	O
infected	O
tissues	O
.	O

The	O
present	O
study	O
examines	O
the	O
consequences	O
of	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
infection	O
in	O
mice	O
lacking	O
CCL2	B-CHED
(	O
CCL2	B-CHED
(-/-))	O
in	O
order	O
to	O
determine	O
if	O
signaling	O
by	O
this	O
chemokine	O
is	O
relevant	O
in	O
host	O
defense	O
.	O

Increasing	O
age	O
,	O
male	O
sex	O
,	O
atypical	O
presenting	O
symptoms	O
,	O
presence	O
of	O
comorbid	O
conditions	O
,	O
and	O
high	O
lactate	B-CHED
dehydrogenase	O
level	O
on	O
admission	O
were	O
associated	O
with	O
a	O
greater	O
risk	O
for	O
death	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
the	O
envelope	O
(	O
E	O
)	O
protein	B-CHED
of	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
can	O
induce	O
membrane	O
permeability	O
changes	O
when	O
expressed	O
in	O
Escherichia	O
coli	O
.	O

Site	O
-	O
directed	O
mutagenesis	O
studies	O
revealed	O
that	O
two	O
cysteine	B-CHED
residues	O
of	O
the	O
E	O
protein	B-CHED
were	O
essential	O
for	O
oligomerization	O
,	O
leading	O
to	O
induction	O
of	O
membrane	O
permeability	O
.	O

This	O
is	O
the	O
first	O
report	O
demonstrating	O
that	O
a	O
coronavirus	O
-	O
encoded	O
protein	B-CHED
could	O
modify	O
membrane	O
permeability	O
in	O
E	O
.	O
coli	O
cells	O
.	O

ABSTRACT	O
:	O
Overlapping	O
fragments	O
of	O
genomic	O
RNA	O
spanning	O
6963	O
nucleotides	B-CHED
from	O
5	O
'	O
end	O
of	O
spike	O
(	O
S	O
)	O
protein	B-CHED
gene	O
to	O
3	O
'	O
end	O
of	O
nucleocapsid	O
(	O
N	O
)	O
protein	B-CHED
gene	O
of	O
turkey	O
coronavirus	O
(	O
TCoV	O
)	O
were	O
amplified	O
by	O
reverse	O
-	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
).	O

It	O
is	O
true	O
that	O
most	O
established	O
respiratory	O
pathogens	O
of	O
human	O
beings	O
recur	O
in	O
wintertime	O
,	O
but	O
a	O
new	O
appreciation	O
for	O
the	O
high	O
burden	O
of	O
disease	O
in	O
tropical	O
areas	O
reinforces	O
questions	O
about	O
explanations	O
resting	O
solely	O
on	O
cold	O
air	B-CHED
or	O
low	O
humidity	O
.	O

ABSTRACT	O
:	O
The	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
spike	O
(	O
S	O
)	O
glycoprotein	B-CHED
alone	O
can	O
mediate	O
the	O
membrane	O
fusion	O
required	O
for	O
virus	O
entry	O
and	O
cell	O
fusion	O
.	O

TITLE	O
:	O
Effect	O
of	O
integrated	O
traditional	O
Chinese	O
and	O
Western	O
medicine	B-CHED
on	O
SARS	O
:	O
a	O
review	O
of	O
clinical	O
evidence	O
.	O

Kangfeidian	O
No	O
.	O
4	O
in	O
combination	O
with	O
Western	O
medicine	B-CHED
had	O
no	O
significant	O
effect	O
on	O
symptom	O
improvement	O
such	O
as	O
loss	O
of	O
dyspnea	O
and	O
cough	O
(	O
RR	O
1	O
.	O
50	O
,	O
95	O
%	O
CI	O
(	O
0	O
.	O
41	O
,	O
5	O
.	O
43	O
))	O
and	O
(	O
RR	O
1	O
.	O
29	O
,	O
95	O
%	O
CI	O
(	O
0	O
.	O
30	O
,	O
5	O
.	O
43	O
)).	O

One	O
elderly	O
man	B-CHED
died	O
from	O
cardiorespiratory	O
arrest	O
despite	O
clinical	O
and	O
radiological	O
improvement	O
,	O
and	O
another	O
patient	O
is	O
making	O
good	O
progress	O
.	O

Although	O
inhibitors	B-CHED
of	O
ERK1	O
/	O
2	O
and	O
JNK	O
(	O
PD98059	O
and	O
SP600125	O
)	O
had	O
no	O
effect	O
on	O
phosphorylation	O
status	O
of	O
STAT3	O
,	O
inhibitors	B-CHED
of	O
p38	O
MAPK	O
(	O
SB203580	O
and	O
SB202190	O
)	O
partially	O
inhibited	O
dephosphorylation	O
of	O
STAT3	O
at	O
Tyr	B-CHED
-	O
705	O
.	O

ABSTRACT	O
:	O
T	O
cell	O
accumulation	O
and	O
effector	B-CHED
function	O
following	O
CNS	B-CHED
infection	O
is	O
limited	O
by	O
a	O
paucity	O
of	O
Ag	O
presentation	O
and	O
inhibitory	O
factors	O
characteristic	O
of	O
the	O
CNS	B-CHED
environment	O
.	O

The	O
primer	O
pairs	O
were	O
successfully	O
used	O
in	O
a	O
multiplex	O
RT	O
-	O
PCR	O
to	O
detect	O
nucleic	B-CHED
acid	I-CHED
of	O
TAstV	O
-	O
2	O
and	O
TCV	O
.	O

Fever	O
,	O
malaise	O
,	O
cough	O
,	O
coryza	O
,	O
chills	O
or	O
rigor	O
,	O
sputum	O
production	O
,	O
headache	O
,	O
myalgia	O
,	O
leucopaenia	O
,	O
lymphopaenia	O
,	O
thrombocytopaenia	O
,	O
mildly	O
prolonged	O
activated	O
partial	O
thromboplastin	O
times	O
and	O
elevated	O
lactate	B-CHED
dehydrogenase	O
levels	O
are	O
common	O
presenting	O
features	O
.	O

Radiographic	O
findings	O
are	O
non	O
-	O
specific	O
but	O
high	O
-	O
resolution	O
computed	O
tomography	O
of	O
the	O
thorax	O
in	O
clinically	O
suspected	O
cases	O
may	O
be	O
an	O
early	O
diagnostic	B-CHED
aid	I-CHED
when	O
initial	O
chest	O
radiographs	O
appear	O
normal	O
.	O

The	O
rSCoVN	O
protein	B-CHED
has	O
a	O
high	O
specificity	O
against	O
SARS	O
-	O
CoVN	O
-	O
mAb	O
and	O
SARS	O
positive	O
sera	O
,	O
but	O
has	O
no	O
cross	O
-	O
reaction	O
with	O
normal	O
human	O
serum	O
.	O

CONCLUSIONS	O
:	O
SARS	O
cases	O
may	O
develop	O
leucocytosis	O
,	O
low	O
lymphocyte	O
count	O
,	O
low	O
platelet	O
count	O
,	O
low	O
hemoglobin	B-CHED
level	O
and	O
abnormal	O
liver	O
function	O
.	O

There	O
was	O
a	O
significant	O
negative	O
correlation	O
between	O
overall	O
reticulation	O
and	O
total	O
parenchymal	O
involvement	O
with	O
diffusion	O
capacity	O
adjusted	O
for	O
hemoglobin	B-CHED
at	O
3	O
and	O
6	O
months	O
(	O
P	O
<	O
0	O
.	O
01	O
).	O

TITLE	O
:	O
Low	O
triiodothyronine	B-CHED
(	O
T3	O
)	O
state	O
:	O
a	O
predictor	O
of	O
outcome	O
in	O
respiratory	O
failure	O
?	O

We	O
purified	O
p70	O
with	O
a	O
a	O
one	O
-	O
step	O
RNA	O
affinity	O
purification	O
procedure	O
with	O
the	O
biotin	B-CHED
-	O
labeled	O
5	O
'-	O
UTR	O
.	O

RESULTS	O
:	O
The	O
genome	O
of	O
HCoV	O
-	O
NL63	O
has	O
the	O
following	O
gene	O
order	O
:	O
1a	O
-	O
1b	O
-	O
S	O
-	O
ORF3	O
-	O
E	O
-	O
M	O
-	O
N	O
.	O
The	O
GC	O
content	O
of	O
the	O
HCoV	O
-	O
NL63	O
genome	O
is	O
extremely	O
low	O
(	O
34	O
%)	O
compared	O
to	O
other	O
coronaviruses	O
,	O
and	O
we	O
therefore	O
performed	O
additional	O
analysis	O
of	O
the	O
nucleotide	B-CHED
composition	O
.	O

It	O
is	O
a	O
consequence	O
of	O
this	O
action	O
that	O
ACE2	O
participates	O
in	O
the	O
renin	O
-	O
angiotensin	B-CHED
system	O
.	O

A	O
physiological	B-CHED
role	I-CHED
for	O
ACE2	O
has	O
been	O
implicated	O
in	O
hypertension	O
,	O
cardiac	O
function	O
,	O
heart	O
function	O
and	O
diabetes	O
,	O
and	O
as	O
a	O
receptor	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
.	O

ABSTRACT	O
:	O
Cellular	O
entry	O
of	O
enveloped	O
viruses	O
is	O
often	O
dependent	O
on	O
attachment	O
proteins	B-CHED
expressed	O
on	O
the	O
host	O
cell	O
surface	O
.	O

The	O
surface	O
form	O
of	O
the	O
cells	O
at	O
advanced	O
infection	O
displayed	O
prolific	O
pseudopodia	O
that	O
,	O
in	O
addition	O
to	O
the	O
rest	B-CHED
of	O
the	O
plasma	O
membrane	O
,	O
were	O
also	O
active	O
sites	O
of	O
virus	O
release	O
.	O

ABSTRACT	O
:	O
Serum	O
samples	O
from	O
317	O
patients	O
with	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
were	O
tested	O
for	O
the	O
nucleocapsid	O
(	O
N	O
)	O
protein	B-CHED
of	O
SARS	O
-	O
associated	O
coronavirus	O
,	O
with	O
sensitivities	O
of	O
94	O
%	O
and	O
78	O
%	O
for	O
the	O
first	O
5	O
days	O
and	O
6	O
-	O
10	O
days	O
after	O
onset	O
,	O
respectively	O
.	O

When	O
corrosion	O
,	O
bleaching	O
or	O
gas	O
production	O
have	O
to	O
be	O
avoided	O
,	O
chlorine	B-CHED
compounds	O
may	O
be	O
substituted	O
by	O
phenolic	O
detergent	B-CHED
disinfectants	B-CHED
.	O

Exploring	O
the	O
types	O
of	O
interactions	O
responsible	O
for	O
structural	O
stabilities	O
of	O
its	O
component	O
protein	B-CHED
molecules	O
constitutes	O
one	O
of	O
the	O
approaches	O
to	O
find	O
a	O
destabilization	O
method	O
for	O
the	O
virion	O
particle	O
.	O

RESULTS	O
:	O
Thirty	O
-	O
two	O
patients	O
(	O
24	O
.	O
1	O
%)	O
met	B-CHED
the	O
criteria	O
for	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
and	O
24	O
patients	O
(	O
18	O
.	O
0	O
%)	O
died	O
.	O

TITLE	O
:	O
Recombinant	O
infectious	O
bronchitis	O
coronavirus	O
Beaudette	O
with	O
the	O
spike	O
protein	B-CHED
gene	O
of	O
the	O
pathogenic	O
M41	O
strain	O
remains	O
attenuated	O
but	O
induces	O
protective	O
immunity	O
.	O

TITLE	O
:	O
Overexpression	O
of	O
7a	O
,	O
a	O
protein	B-CHED
specifically	O
encoded	O
by	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
,	O
induces	O
apoptosis	O
via	O
a	O
caspase	O
-	O
dependent	O
pathway	O
.	O

ABSTRACT	O
:	O
Besides	O
genes	O
that	O
are	O
homologous	O
to	O
proteins	B-CHED
found	O
in	O
other	O
coronaviruses	O
,	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
genome	O
also	O
contains	O
nine	O
other	O
potential	O
open	O
reading	O
frames	O
.	O

A	O
series	O
of	O
keto	O
-	O
glutamine	B-CHED
analogues	O
with	O
a	O
phthalhydrazido	O
group	O
at	O
the	O
alpha	O
-	O
position	O
were	O
synthesized	O
and	O
tested	O
as	O
reversible	O
inhibitiors	O
against	O
SARS	O
3CL	O
(	O
pro	B-CHED
).	O

In	O
this	O
study	O
,	O
we	O
examined	O
whether	O
SARS	O
-	O
CoV	O
could	O
productively	O
infect	O
purified	O
monocytes	O
/	O
macrophages	O
(	O
PM	O
)	O
derived	O
from	O
human	O
donor	B-CHED
cells	O
.	O

Of	O
interest	O
,	O
SARS	O
-	O
CoV	O
proteins	B-CHED
were	O
detected	O
only	O
in	O
PM	O
that	O
did	O
not	O
produce	O
significant	O
amounts	O
of	O
interferon	O
(	O
IFN	O
)-	O
alpha	O
,	O
and	O
in	O
one	O
such	O
case	O
,	O
preliminary	O
electron	O
microscope	O
studies	O
demonstrated	O
that	O
SARS	O
-	O
CoV	O
-	O
like	O
particles	O
could	O
enter	O
the	O
cells	O
,	O
possibly	O
via	O
phagocytosis	O
.	O

The	O
improved	O
surface	O
had	O
high	O
immobilization	O
efficiency	O
,	O
good	O
uniformity	O
and	O
satisfactory	O
hybridization	O
efficiency	O
,	O
better	O
than	O
those	O
slides	O
with	O
conventional	O
poly	O
-	O
L	B-CHED
-	I-CHED
lysine	I-CHED
coating	O
.	O

ABSTRACT	O
:	O
Fifty	O
years	O
ago	O
,	O
the	O
age	O
-	O
old	O
scourge	O
of	O
infectious	O
disease	O
was	O
receding	O
in	O
the	O
developed	O
world	O
in	O
response	O
to	O
improved	O
public	O
health	O
measures	O
,	O
while	O
the	O
advent	O
of	O
antibiotics	B-CHED
,	O
better	O
vaccines	O
,	O
insecticides	B-CHED
and	O
improved	O
surveillance	O
held	O
the	O
promise	O
of	O
eradicating	O
residual	O
problems	O
.	O

Together	O
,	O
these	O
results	O
strongly	O
indicate	O
that	O
PBEF	O
is	O
a	O
potential	O
novel	O
biomarker	B-CHED
in	O
ALI	O
and	O
demonstrate	O
the	O
successful	O
application	O
of	O
robust	O
genomic	O
technologies	O
in	O
the	O
identification	O
of	O
candidate	O
genes	O
in	O
complex	O
lung	O
disease	O
.	O

TITLE	O
:	O
Exogenous	O
nitric	B-CHED
oxide	I-CHED
donor	I-CHED
and	O
related	O
compounds	O
protect	O
against	O
lung	O
inflammatory	O
response	O
after	O
hemorrhagic	O
shock	O
and	O
resuscitation	O
.	O

Sodium	B-CHED
nitroprusside	I-CHED
significantly	O
increased	O
MAP	O
and	O
reduced	O
fluid	O
requirements	O
during	O
resuscitation	O
after	O
hemorrhage	O
.	O

RESULTS	O
:	O
Sodium	B-CHED
nitroprusside	I-CHED
significantly	O
increased	O
MAP	O
and	O
reduced	O
fluid	O
requirements	O
during	O
resuscitation	O
after	O
hemorrhage	O
.	O

In	O
this	O
study	O
,	O
the	O
N	O
protein	B-CHED
of	O
SARS	O
-	O
CoV	O
was	O
expressed	O
in	O
Escherichia	O
coli	O
DH5alpha	O
and	O
identified	O
with	O
pooled	O
sera	O
from	O
patients	O
in	O
the	O
convalescence	O
phase	O
of	O
SARS	O
.	O

The	O
study	O
shows	O
that	O
N	O
protein	B-CHED
of	O
SARS	O
-	O
CoV	O
not	O
only	O
is	O
an	O
important	O
B	O
cell	O
immunogen	B-CHED
,	O
but	O
also	O
can	O
elicit	O
broad	O
-	O
based	O
cellular	O
immune	O
responses	O
.	O

The	O
results	O
indicate	O
that	O
the	O
N	O
protein	B-CHED
may	O
be	O
of	O
potential	O
value	O
in	O
vaccine	O
development	O
for	O
specific	O
prophylaxis	O
and	O
treatment	O
against	O
SARS	O
.	O

One	O
of	O
the	O
sera	O
obtained	O
from	O
the	O
fragment	O
encompassing	O
amino	B-CHED
acids	I-CHED
48	O
-	O
358	O
significantly	O
blocked	O
the	O
interaction	O
between	O
CHO	B-CHED
-	O
SG	O
and	O
Vero	O
E6	O
cells	O
.	O

This	O
paper	O
describes	O
an	O
easy	O
and	O
safe	O
cell	O
-	O
based	O
assay	O
suitable	O
for	O
studying	O
the	O
binding	O
between	O
SARS	O
-	O
CoV	O
S	O
protein	B-CHED
and	O
its	O
receptor	O
.	O

Assuming	O
the	O
presence	O
of	O
six	O
molecules	O
per	O
asymmetric	O
unit	O
,	O
the	O
solvent	B-CHED
content	O
is	O
estimated	O
to	O
be	O
about	O
28	O
%.	O

TITLE	O
:	O
Induction	O
of	O
IL	O
-	O
8	O
release	O
in	O
lung	O
cells	O
via	O
activator	O
protein	B-CHED
-	O
1	O
by	O
recombinant	O
baculovirus	O
displaying	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
coronavirus	O
spike	O
proteins	B-CHED
:	O
identification	O
of	O
two	O
functional	O
regions	O
.	O

Recombinant	O
baculovirus	O
expressing	O
different	O
deletion	O
and	O
insertion	O
fragments	O
identified	O
the	O
functional	O
region	O
of	O
S	O
protein	B-CHED
from	O
aa	O
324	O
-	O
688	O
(	O
particularly	O
the	O
N	O
-	O
terminal	O
aa	O
324	O
-	O
488	O
and	O
the	O
C	O
-	O
terminal	O
aa	O
609	O
-	O
688	O
),	O
which	O
is	O
responsible	O
for	O
IL	O
-	O
8	O
production	O
.	O

The	O
results	O
provide	O
three	O
lines	O
of	O
evidence	O
suggesting	O
that	O
the	O
spike	O
glycoprotein	B-CHED
is	O
different	O
from	O
the	O
other	O
coronavirus	O
proteins	B-CHED
:	O
(	O
1	O
)	O
the	O
spike	O
glycoprotein	B-CHED
is	O
more	O
sensitive	O
to	O
mutations	O
,	O
this	O
is	O
the	O
current	O
state	O
of	O
the	O
spike	O
glycoprotein	B-CHED
,	O
(	O
2	O
)	O
the	O
spike	O
glycoprotein	B-CHED
has	O
undergone	O
more	O
mutations	O
in	O
the	O
past	O
,	O
this	O
is	O
the	O
history	O
of	O
spike	O
glycoprotein	B-CHED
,	O
and	O
(	O
3	O
)	O
the	O
spike	O
glycoprotein	B-CHED
has	O
a	O
bigger	O
potential	O
towards	O
future	O
mutations	O
,	O
this	O
is	O
the	O
future	O
of	O
spike	O
glycoprotein	B-CHED
.	O

ProS	O
is	O
subsequently	O
processed	O
into	O
two	O
C	O
-	O
terminal	O
proteins	B-CHED
of	O
approximately	O
110	O
and	O
approximately	O
80	O
kDa	O
.	O

The	O
data	O
also	O
suggest	O
that	O
direct	O
virus	O
-	O
host	O
cell	O
interaction	O
is	O
one	O
of	O
the	O
underlying	O
mechanisms	O
that	O
regulate	O
viral	O
persistence	O
in	O
CNS	B-CHED
cells	O
.	O

Low	O
tidal	O
volume	O
ventilation	O
(	O
6	O
mg	O
/	O
dl	O
/	O
kg	O
)	O
is	O
recommended	O
for	O
ALI	O
.	O
ARDS	O
,	O
but	O
application	O
of	O
a	O
minimum	O
amount	O
of	O
PEEP	B-CHED
,	O
recruitment	O
maneuvers	O
with	O
high	O
PEEP	B-CHED
and	O
prone	O
position	O
are	O
needed	O
to	O
confirm	O
any	O
benefit	O
.	O

IFN	O
-	O
gamma	O
,	O
IL	O
-	O
18	O
,	O
TGF	O
-	O
beta	O
,	O
IL	O
-	O
6	O
,	O
IP	O
-	O
10	O
,	O
MCP	B-CHED
-	O
1	O
,	O
MIG	O
,	O
and	O
IL	O
-	O
8	O
,	O
but	O
not	O
of	O
TNF	O
-	O
alpha	O
,	O
IL	O
-	O
2	O
,	O
IL	O
-	O
4	O
,	O
IL	O
-	O
10	O
,	O
IL	O
-	O
13	O
,	O
or	O
TNFRI	O
,	O
were	O
highly	O
elevated	O
in	O
the	O
acute	O
phase	O
sera	O
of	O
Taiwan	O
SARS	O
patients	O
.	O

TITLE	O
:	O
Structure	O
of	O
a	O
proteolytically	O
resistant	O
core	O
from	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
S2	O
fusion	O
protein	B-CHED
.	O

In	O
these	O
structures	O
,	O
three	O
HR1	O
helices	O
form	O
a	O
parallel	O
coiled	O
-	O
coil	O
trimer	O
,	O
whereas	O
three	O
HR2	O
peptides	B-CHED
pack	O
in	O
an	O
oblique	O
and	O
antiparallel	O
fashion	O
into	O
the	O
coiled	O
-	O
coil	O
hydrophobic	O
grooves	O
,	O
adopting	O
mixed	O
extended	O
and	O
alpha	O
-	O
helical	O
conformations	O
as	O
in	O
postfusion	O
paramyxoviruses	O
F	O
proteins	B-CHED
structures	O
.	O

We	O
discuss	O
a	O
new	O
,	O
conservation	O
medicine	B-CHED
approach	O
to	O
emerging	O
diseases	O
that	O
integrates	O
veterinary	O
,	O
medical	O
,	O
ecologic	O
,	O
and	O
other	O
sciences	O
in	O
interdisciplinary	O
teams	O
.	O

The	O
kinetics	O
of	O
neutralisation	O
antibodies	O
obtained	O
with	O
100x	O
the	O
tissue	O
culture	O
infective	O
dose	O
(	O
TCID50	O
)	O
of	O
the	O
SARS	O
-	O
CoV	O
TW1	O
strain	O
in	O
five	O
patients	O
with	O
SARS	O
nearly	O
paralleled	O
those	O
for	O
IgG	O
.	O
There	O
were	O
no	O
significant	O
differences	O
in	O
the	O
kinetics	O
of	O
the	O
IgG	O
,	O
IgM	O
and	O
IgA	O
responses	O
between	O
patients	O
with	O
or	O
without	O
underlying	O
medical	O
disease	O
,	O
steroid	B-CHED
or	O
intravenous	O
immunoglobulin	O
therapy	O
,	O
or	O
mechanical	O
ventilation	O
.	O

ABSTRACT	O
:	O
Initial	O
in	O
vitro	O
investigations	O
demonstrated	O
type	O
I	O
interferons	O
(	O
IFNs	O
:	O
IFN	O
-	O
alpha	O
,	O
IFN	O
-	O
beta	O
)	O
to	O
inhibit	O
replication	O
of	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
but	O
found	O
the	O
nucleoside	B-CHED
analogue	I-CHED
ribavirin	B-CHED
ineffective	O
in	O
Vero	O
cells	O
.	O

Although	O
many	O
molecular	O
details	O
of	O
the	O
coronavirus	O
life	O
cycle	O
remain	O
to	O
be	O
investigated	O
,	O
the	O
available	O
information	O
suggests	O
that	O
these	O
viruses	O
and	O
their	O
distant	O
nidovirus	O
relatives	O
employ	O
a	O
unique	O
collection	O
of	O
enzymatic	O
activities	O
and	O
other	O
protein	B-CHED
functions	O
to	O
synthesize	O
a	O
set	O
of	O
5	O
'-	O
leader	O
-	O
containing	O
subgenomic	O
mRNAs	O
and	O
to	O
replicate	O
the	O
largest	O
RNA	O
virus	O
genomes	O
currently	O
known	O
.	O

Taken	O
together	O
,	O
the	O
data	O
strongly	O
support	O
the	O
zinc	B-CHED
-	O
binding	O
function	O
of	O
the	O
N	O
-	O
terminal	O
domain	O
of	O
nidovirus	O
helicases	O
.	O

The	O
data	O
also	O
indicated	O
that	O
a	O
known	O
N	O
protein	B-CHED
binding	O
site	O
(	O
involved	O
in	O
transcriptional	O
regulation	O
)	O
consisting	O
of	O
a	O
conserved	O
core	O
sequence	O
present	O
near	O
the	O
5	O
'	O
end	O
of	O
the	O
genome	O
(	O
in	O
the	O
leader	O
sequence	O
)	O
functioned	O
by	O
promoting	O
high	O
association	O
rates	O
of	O
N	O
protein	B-CHED
binding	O
.	O

Further	O
analysis	O
of	O
the	O
leader	O
sequence	O
indicated	O
that	O
the	O
core	O
element	O
was	O
not	O
the	O
only	O
binding	O
site	O
for	O
N	O
protein	B-CHED
and	O
that	O
other	O
regions	O
functioned	O
to	O
promote	O
high	O
-	O
affinity	O
binding	O
.	O

ABSTRACT	O
:	O
This	O
review	O
reports	O
recent	O
findings	O
on	O
lipid	B-CHED
use	O
in	O
artificial	O
nutrition	O
in	O
patients	O
with	O
acute	O
respiratory	O
failure	O
or	O
severe	O
sepsis	O
or	O
undergoing	O
major	O
surgery	O
.	O

The	O
management	O
goal	O
in	O
acute	O
lung	O
injury	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
challenges	O
clinicians	O
to	O
achieve	O
the	O
optimal	O
balance	B-CHED
that	O
both	O
limits	O
the	O
forms	O
of	O
alveolar	O
stress	O
failure	O
and	O
maintains	O
effective	O
gas	O
exchange	O
.	O

ABSTRACT	O
:	O
We	O
describe	O
a	O
39	O
-	O
year	O
-	O
old	O
Japanese	O
man	B-CHED
with	O
post	O
-	O
streptococcal	O
acute	O
glomerulonephritis	O
(	O
PSAGN	O
)	O
super	O
-	O
imposed	O
on	O
long	O
-	O
term	O
immunoglobulin	O
A	O
nephropathy	O
(	O
IgA	O
-	O
N	O
).	O

In	O
those	O
with	O
unsatisfactory	O
resolution	O
of	O
the	O
pulmonary	O
infiltrates	O
,	O
corticosteroid	B-CHED
therapy	O
was	O
associated	O
with	O
rapid	O
radiographic	O
improvement	O
.	O

A	O
33	O
-	O
year	O
-	O
old	O
gravida	O
2	O
para	B-CHED
1	O
fulfilling	O
the	O
World	O
Health	O
Organization	O
case	O
definition	O
for	O
probable	O
SARS	O
was	O
admitted	O
to	O
our	O
institution	O
at	O
31	O
weeks	O
of	O
gestation	O
with	O
fever	O
,	O
a	O
dry	O
cough	O
,	O
and	O
patchy	O
infiltrates	O
on	O
chest	O
X	O
-	O
ray	O
.	O

Another	O
profound	O
finding	O
is	O
that	O
three	O
disulfide	B-CHED
bonds	O
are	O
defined	O
at	O
the	O
C	O
-	O
terminus	O
with	O
the	O
N	O
-	O
terminus	O
of	O
the	O
E	O
(	O
envelope	O
)	O
protein	B-CHED
,	O
based	O
on	O
the	O
typical	O
sequence	O
and	O
positions	O
,	O
thus	O
establishing	O
the	O
structural	O
connection	O
with	O
these	O
two	O
important	O
structural	O
proteins	B-CHED
,	O
if	O
confirmed	O
.	O

The	O
M	O
protein	B-CHED
harbors	O
a	O
higher	O
substitution	O
rate	O
(	O
0	O
.	O
6	O
%	O
correlated	O
to	O
its	O
size	O
)	O
among	O
viral	O
open	O
reading	O
frames	O
(	O
ORFs	O
)	O
from	O
published	O
data	O
.	O

We	O
conducted	O
genome	O
sequencing	O
and	O
phylogenetic	O
analyses	O
of	O
SARS	O
-	O
CoV	O
.	O
Based	O
on	O
genome	O
sequencing	O
,	O
we	O
predicted	O
the	O
E	O
protein	B-CHED
is	O
a	O
transmembrane	O
(	O
TM	O
)	O
protein	B-CHED
characterized	O
by	O
a	O
TM	O
region	O
with	O
strong	O
hydrophobicity	O
and	O
alpha	O
-	O
helix	O
conformation	O
.	O

TITLE	O
:	O
The	O
C	O
-	O
terminal	O
portion	O
of	O
the	O
nucleocapsid	O
protein	B-CHED
demonstrates	O
SARS	O
-	O
CoV	O
antigenicity	O
.	O

One	O
epitope	B-CHED
site	O
located	O
at	O
the	O
C	O
-	O
terminus	O
was	O
confirmed	O
as	O
the	O
most	O
antigenic	O
region	O
in	O
this	O
protein	B-CHED
.	O

Understanding	O
of	O
the	O
epitope	B-CHED
sites	O
could	O
be	O
very	O
significant	O
for	O
developing	O
an	O
effective	O
diagnostic	O
approach	O
to	O
SARS	O
.	O

Based	O
upon	O
the	O
theoretical	O
analysis	O
for	O
hydrophobicity	O
of	O
the	O
S	O
protein	B-CHED
,	O
18	O
peptides	B-CHED
were	O
synthesized	O
.	O

Identification	O
of	O
antigenic	O
regions	O
in	O
the	O
SARS	O
-	O
CoV	O
S	O
protein	B-CHED
may	O
be	O
important	O
for	O
the	O
functional	O
studies	O
of	O
this	O
virus	O
or	O
the	O
development	O
of	O
clinical	O
diagnosis	O
.	O

ABSTRACT	O
:	O
To	O
express	O
nucleocapsid	O
(	O
N	O
)	O
protein	B-CHED
of	O
SARS	O
coronavirus	O
and	O
produce	O
monoclonal	O
antibody	O
(	O
mAb	O
)	O
to	O
N	O
protein	B-CHED
.	O

Fixation	O
of	O
SARS	O
-	O
CoV	O
-	O
infected	O
Vero	O
E6	O
cells	O
with	O
a	O
fixative	B-CHED
including	O
formalin	B-CHED
,	O
glutaraldehyde	B-CHED
,	O
methanol	B-CHED
,	O
and	O
acetone	B-CHED
for	O
5	O
min	O
or	O
longer	O
eliminated	O
all	O
infectivity	O
.	O

ABSTRACT	O
:	O
To	O
assess	O
the	O
risk	O
of	O
aerosol	O
transmission	O
in	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
patients	O
admitted	O
to	O
Hospital	O
through	O
testing	O
the	O
air	B-CHED
samples	O
.	O

Air	B-CHED
samples	O
were	O
collected	O
from	O
7	O
wards	O
and	O
1	O
balcony	O
of	O
the	O
Hospital	O
,	O
3	O
times	O
a	O
day	O
for	O
3	O
continuous	O
days	O
,	O
using	O
bioaerosol	O
sampler	O
type	O
FA	O
-	O
2	O
.	O

ABSTRACT	O
:	O
To	O
report	O
the	O
occurrence	O
of	O
lower	O
extremity	O
avascular	O
abnormalities	O
in	O
124	O
cases	O
of	O
recovered	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
health	O
care	O
workers	O
of	O
four	O
hospitals	O
in	O
Guangzhou	O
and	O
preliminary	O
investigate	O
the	O
correlation	O
with	O
the	O
treatment	O
of	O
steroid	B-CHED
.	O

In	O
124	O
health	O
care	O
workers	O
,	O
38	O
cases	O
have	O
not	O
treated	O
with	O
steroid	B-CHED
,	O
while	O
86	O
cases	O
have	O
treated	O
with	O
varied	O
dosage	O
.	O

CONCLUSIONS	O
:	O
Osteonecrosis	O
definitely	O
exists	O
in	O
the	O
minority	O
of	O
health	O
care	O
workers	O
with	O
recovered	O
SARS	O
in	O
Guangzhou	O
,	O
who	O
had	O
treated	O
with	O
steroid	B-CHED
.	O

Auto	O
-	O
PEEP	B-CHED
can	O
be	O
identified	O
in	O
passively	O
breathing	O
patients	O
by	O
observation	O
of	O
real	O
-	O
time	O
ventilator	O
flow	O
and	O
pressure	O
graphics	O
.	O

The	O
ventilatory	O
pattern	O
should	O
be	O
directed	O
toward	O
minimizing	O
dynamic	O
hyperinflation	O
and	O
auto	O
-	O
PEEP	B-CHED
by	O
using	O
small	O
tidal	O
volume	O
and	O
preserving	O
expiratory	O
time	O
.	O

Polyamine	B-CHED
synthesis	O
was	O
higher	O
in	O
A	O
/	O
J	O
BMMphi	O
than	O
in	O
BALB	O
/	O
c	O
ones	O
,	O
which	O
correlated	O
with	O
the	O
slightly	O
lower	O
levels	O
of	O
ornithine	B-CHED
observed	O
.	O

Difluoromethylornithine	O
treatment	O
,	O
which	O
leads	O
to	O
inhibition	O
of	O
polyamine	B-CHED
synthesis	O
,	O
induced	O
a	O
decreased	O
MHV3	O
multiplication	O
in	O
both	O
BALB	O
/	O
c	O
and	O
A	O
/	O
J	O
BMMphi	O
.	O

The	O
substitution	O
bias	O
of	O
nucleotide	B-CHED
acids	O
and	O
amino	B-CHED
acids	I-CHED
indicates	O
the	O
non	O
-	O
random	O
drift	O
products	O
.	O

Additional	O
analyses	O
show	O
that	O
the	O
first	O
ORFs	O
between	O
S	O
and	O
E	O
genes	O
of	O
some	O
coronaviruses	O
are	O
transmembrane	O
proteins	B-CHED
and	O
share	O
the	O
common	O
motif	O
,	O
indicating	O
the	O
possible	O
common	O
ancestor	O
.	O

Extensive	O
cellular	O
apoptosis	O
(	O
terminal	O
deoxynucleotidyl	O
transferase	O
-	O
mediated	O
deoxyuridine	B-CHED
triphosphate	I-CHED
nick	O
-	O
end	O
labelling	O
staining	O
),	O
including	O
endothelial	O
and	O
alveolar	O
type	O
II	O
cells	O
,	O
was	O
demonstrated	O
,	O
and	O
vascular	O
bed	O
density	O
(	O
CD31	O
immunostaining	O
)	O
decreased	O
in	O
ARDS	O
lungs	O
as	O
compared	O
with	O
controls	O
.	O

TITLE	O
:	O
[	O
Development	O
and	O
preliminary	O
application	O
of	O
monoclonal	O
antibodies	O
against	O
N	O
protein	B-CHED
of	O
SARS	O
virus	O
].	O

ABSTRACT	O
:	O
To	O
develop	O
the	O
monoclonal	O
antibody	O
against	O
N	O
protein	B-CHED
of	O
SARS	O
virus	O
and	O
study	O
its	O
applicability	O
.	O

BALB	O
/	O
c	O
mice	O
were	O
immunized	O
with	O
recombinant	O
N	O
protein	B-CHED
.	O

The	O
infused	O
cells	O
were	O
screened	O
for	O
anti	O
-	O
N	O
protein	B-CHED
antibody	O
with	O
ELISA	O
.	O

The	O
ELISA	O
for	O
detection	O
of	O
SARS	O
virus	O
antigen	B-CHED
was	O
developed	O
with	O
McAb	O
7	O
.	O

CONCLUSIONS	O
:	O
The	O
monoclonal	O
antibody	O
has	O
good	O
specificity	O
and	O
may	O
be	O
used	O
to	O
detect	O
SARS	O
virus	O
antigen	B-CHED
.	O

Among	O
all	O
the	O
patients	O
with	O
abnormal	O
X	O
-	O
ray	O
result	O
,	O
19	O
were	O
male	O
(	O
54	O
.	O
29	O
%),	O
16	O
(	O
45	O
.	O
71	O
%)	O
were	O
female	O
,	O
P	O
>	O
0	O
.	O
01	O
;	O
7	O
(	O
58	O
.	O
33	O
%)	O
were	O
above	O
the	O
age	O
of	O
45	O
;	O
28	O
(	O
34	O
.	O
57	O
%)	O
were	O
below	O
the	O
age	O
of	O
45	O
,	O
P	O
>	O
0	O
.	O
01	O
;	O
hyperpyrexia	O
(>/=	O
39	O
),	O
26	O
(	O
50	O
.	O
00	O
%),	O
below	O
39	O
,	O
9	O
(	O
21	O
.	O
95	O
%);	O
multiple	O
-	O
lesion	O
,	O
22	O
(	O
52	O
.	O
38	O
%),	O
mono	O
-	O
lesion	O
,	O
13	O
(	O
25	O
.	O
49	O
%),	O
P	O
<	O
0	O
.	O
01	O
;	O
glucocorticoid	B-CHED
administration	O
time	O
within	O
5	O
days	O
,	O
22	O
(	O
38	O
.	O
60	O
%)	O
after	O
5	O
days	O
,	O
12	O
(	O
33	O
.	O
33	O
%),	O
P	O
>	O
0	O
.	O
01	O
;	O
within	O
7	O
days	O
,	O
21	O
(	O
30	O
.	O
00	O
%),	O
after	O
7	O
days	O
,	O
14	O
(	O
60	O
.	O
87	O
%),	O
P	O
<	O
0	O
.	O
01	O
.	O

RESULTS	O
:	O
Among	O
all	O
the	O
patients	O
with	O
abnormal	O
X	O
-	O
ray	O
result	O
,	O
19	O
were	O
male	O
(	O
54	O
.	O
29	O
%),	O
16	O
(	O
45	O
.	O
71	O
%)	O
were	O
female	O
,	O
P	O
>	O
0	O
.	O
01	O
;	O
7	O
(	O
58	O
.	O
33	O
%)	O
were	O
above	O
the	O
age	O
of	O
45	O
;	O
28	O
(	O
34	O
.	O
57	O
%)	O
were	O
below	O
the	O
age	O
of	O
45	O
,	O
P	O
>	O
0	O
.	O
01	O
;	O
hyperpyrexia	O
(>/=	O
39	O
),	O
26	O
(	O
50	O
.	O
00	O
%),	O
below	O
39	O
,	O
9	O
(	O
21	O
.	O
95	O
%);	O
multiple	O
-	O
lesion	O
,	O
22	O
(	O
52	O
.	O
38	O
%),	O
mono	O
-	O
lesion	O
,	O
13	O
(	O
25	O
.	O
49	O
%),	O
P	O
<	O
0	O
.	O
01	O
;	O
glucocorticoid	B-CHED
administration	O
time	O
within	O
5	O
days	O
,	O
22	O
(	O
38	O
.	O
60	O
%)	O
after	O
5	O
days	O
,	O
12	O
(	O
33	O
.	O
33	O
%),	O
P	O
>	O
0	O
.	O
01	O
;	O
within	O
7	O
days	O
,	O
21	O
(	O
30	O
.	O
00	O
%),	O
after	O
7	O
days	O
,	O
14	O
(	O
60	O
.	O
87	O
%),	O
P	O
<	O
0	O
.	O
01	O
.	O

There	O
was	O
a	O
statistically	O
significant	O
difference	O
between	O
them	O
(	O
chi	B-CHED
square	O
=	O
8	O
.	O
64	O
,	O
P	O
less	O
than	O
0	O
.	O
005	O
).	O

TITLE	O
:	O
Expression	O
and	O
purification	O
of	O
SARS	O
coronavirus	O
membrane	O
protein	B-CHED
.	O

This	O
means	O
that	O
our	O
pharmacophore	O
model	O
can	O
lead	O
to	O
the	O
discovery	O
of	O
potent	O
anti	O
-	O
SARS	O
-	O
CoV	O
inhibitors	B-CHED
or	O
promising	O
lead	B-CHED
compounds	I-CHED
for	O
further	O
SARS	O
-	O
CoV	O
main	O
proteinase	O
inhibitor	B-CHED
development	O
.	O

TITLE	O
:	O
Prokaryotic	O
expression	O
,	O
refolding	O
,	O
and	O
purification	O
of	O
fragment	O
450	O
-	O
650	O
of	O
the	O
spike	O
protein	B-CHED
of	O
SARS	O
-	O
coronavirus	O
.	O

The	O
N	O
protein	B-CHED
detection	O
rate	O
continually	O
decreased	O
beginning	O
with	O
day	O
10	O
,	O
and	O
N	O
protein	B-CHED
was	O
not	O
detected	O
beyond	O
day	O
19	O
after	O
the	O
onset	O
of	O
symptoms	O
.	O

In	O
all	O
susceptible	O
cell	O
lines	O
mRNA	B-CHED
of	O
the	O
Angiotensin	B-CHED
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
),	O
the	O
functional	O
receptor	O
for	O
SARS	O
-	O
CoV	O
infection	O
,	O
could	O
be	O
detected	O
by	O
RT	O
-	O
PCR	O
.	O

ABSTRACT	O
:	O
Clinical	O
observations	O
and	O
our	O
high	O
-	O
density	O
oligonucleotide	B-CHED
microarray	O
results	O
demonstrated	O
increased	O
expression	O
of	O
proinflammatory	O
chemokines	O
after	O
SARS	O
-	O
CoV	O
infection	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
influence	O
of	O
SARS	O
-	O
CoV	O
infection	O
on	O
CXCL8	O
(	O
interleukin	O
8	O
)	O
and	O
CXCL10	O
(	O
interferon	O
-	O
gamma	O
-	O
inducible	O
protein	B-CHED
10	O
)	O
in	O
human	O
intestinal	O
epithelial	O
(	O
Caco2	O
)	O
cells	O
.	O

Hydrocortisone	B-CHED
neither	O
influenced	O
SARS	O
-	O
CoV	O
titres	O
alone	O
nor	O
in	O
combination	O
with	O
ribavirin	B-CHED
.	O

In	O
this	O
study	O
,	O
we	O
report	O
the	O
first	O
complete	O
genome	O
sequence	O
(	O
30	O
,	O
738	O
nucleotides	B-CHED
)	O
of	O
the	O
prototype	O
HCoV	O
-	O
OC43	O
strain	O
(	O
ATCC	O
VR759	O
).	O

We	O
identified	O
eight	O
human	O
MAbs	O
binding	O
to	O
virus	O
and	O
infected	O
cells	O
,	O
six	O
of	O
which	O
could	O
be	O
mapped	O
to	O
two	O
SARS	O
-	O
CoV	O
structural	O
proteins	B-CHED
:	O
the	O
nucleocapsid	O
(	O
N	O
)	O
and	O
spike	O
(	O
S	O
)	O
proteins	B-CHED
.	O

TITLE	O
:	O
Identification	O
of	O
the	O
membrane	O
-	O
active	O
regions	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
spike	O
membrane	O
glycoprotein	B-CHED
using	O
a	O
16	O
/	O
18	O
-	O
mer	O
peptide	B-CHED
scan	O
:	O
implications	O
for	O
the	O
viral	O
fusion	O
mechanism	O
.	O

High	O
titer	O
S	O
-	O
specific	O
immunoglobulin	O
G	O
antibody	O
responses	O
were	O
elicited	O
in	O
rabbits	O
immunized	O
with	O
DNA	O
against	O
various	O
segments	O
of	O
the	O
S	O
protein	B-CHED
.	O

We	O
also	O
show	O
here	O
that	O
NO	O
inhibits	O
viral	O
protein	B-CHED
and	O
RNA	O
synthesis	O
.	O

Western	O
blot	O
and	O
indirect	O
fluorescence	O
assay	O
showed	O
that	O
the	O
McAbs	O
reacted	O
specifically	O
with	O
nucleocapsid	O
protein	B-CHED
and	O
SARS	O
-	O
CoV	O
.	O
Among	O
the	O
six	O
McAbs	O
,	O
three	O
recognize	O
the	O
epitopes	O
located	O
in	O
the	O
N	O
-	O
terminus	O
of	O
the	O
protein	B-CHED
,	O
whereas	O
the	O
others	O
reacted	O
with	O
those	O
located	O
in	O
the	O
C	O
-	O
terminus	O
.	O

He	O
was	O
diagnosed	O
as	O
having	O
acute	O
respiratory	O
distress	O
syndrome	O
due	O
to	O
severe	O
pneumonia	O
,	O
and	O
was	O
treated	O
with	O
pulse	O
methylprednisolone	B-CHED
and	O
sivelestat	O
sodium	O
in	O
combination	O
with	O
intravenous	O
erythromycin	B-CHED
and	O
ciprofloxacin	B-CHED
.	O

ABSTRACT	O
:	O
Primary	O
graft	O
failure	O
(	O
PGF	B-CHED
)	O
is	O
a	O
severe	O
acute	O
lung	O
injury	O
syndrome	O
that	O
occurs	O
following	O
lung	O
transplantation	O
.	O

The	O
median	O
HLOS	O
in	O
30	O
-	O
day	O
survivors	O
was	O
47	O
days	O
in	O
patients	O
with	O
PGF	B-CHED
vs	O
15	O
days	O
in	O
those	O
without	O
PGF	B-CHED
(	O
p	O
<	O
0	O
.	O
001	O
),	O
and	O
the	O
mean	O
duration	O
of	O
mechanical	O
ventilation	O
was	O
15	O
days	O
in	O
patients	O
with	O
PGF	B-CHED
vs	O
1	O
day	O
in	O
those	O
without	O
PGF	B-CHED
(	O
p	O
<	O
0	O
.	O
001	O
).	O

ABSTRACT	O
:	O
Coronavirus	O
(	O
CoV	O
)	O
entry	O
is	O
mediated	O
by	O
the	O
viral	O
spike	O
(	O
S	O
)	O
glycoprotein	B-CHED
,	O
a	O
class	O
I	O
viral	O
fusion	O
protein	B-CHED
.	O

Here	O
,	O
we	O
characterize	O
an	O
aromatic	B-CHED
amino	I-CHED
acid	I-CHED
rich	O
region	O
within	O
the	O
ectodomain	O
of	O
the	O
S2	O
subunit	O
that	O
both	O
partitions	O
into	O
lipid	B-CHED
membranes	O
and	O
has	O
the	O
capacity	O
to	O
perturb	O
lipid	B-CHED
vesicle	O
integrity	O
.	O

Circular	O
dichroism	O
analysis	O
indicated	O
that	O
peptides	B-CHED
analogous	O
to	O
the	O
aromatic	O
domains	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
CoV	O
,	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
and	O
the	O
human	O
CoV	O
OC43	O
S2	O
subunits	O
,	O
did	O
not	O
have	O
a	O
propensity	O
for	O
a	O
defined	O
secondary	O
structure	O
.	O

Both	O
MAbs	O
bound	O
to	O
S	O
glycoprotein	B-CHED
expressed	O
on	O
transfected	O
cells	O
but	O
differed	O
in	O
their	O
ability	O
to	O
block	O
binding	O
of	O
S	O
glycoprotein	B-CHED
to	O
Vero	O
E6	O
cells	O
.	O

SARS	O
-	O
CoV	O
3CL	O
(	O
pro	B-CHED
)	O
showed	O
substantial	O
pH	O
and	O
temperature	O
-	O
triggered	O
activity	O
switches	O
,	O
and	O
site	O
-	O
directed	O
mutagenesis	O
analysis	O
of	O
SARS	O
-	O
CoV	O
3CL	O
(	O
pro	B-CHED
)	O
revealed	O
that	O
substitutions	O
of	O
His41	O
,	O
Cys145	O
,	O
and	O
His163	O
resulted	O
in	O
complete	O
loss	O
of	O
enzymatic	O
activity	O
,	O
while	O
replacement	O
of	O
Met162	O
with	O
Ala	B-CHED
caused	O
strongly	O
increased	O
activity	O
.	O

The	O
basis	O
of	O
the	O
assay	O
is	O
the	O
cleavage	O
of	O
target	O
RNA	O
by	O
RNase	O
H	O
mediated	O
by	O
sequence	O
-	O
specific	O
chimeric	O
oligonucleotides	B-CHED
followed	O
by	O
sample	O
to	O
residual	O
ratio	O
quantitation	O
(	O
SRRQ	O
)	O
using	O
RRT	O
-	O
PCR	O
.	O

Blood	O
was	O
sampled	O
daily	O
for	O
cultures	O
,	O
a	O
complete	O
blood	O
count	O
,	O
a	O
lactate	B-CHED
level	O
,	O
and	O
various	O
cytokine	O
expression	O
determined	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
).	O

We	O
conclude	O
that	O
the	O
use	O
of	O
a	O
live	O
attenuated	O
AIBV	O
vaccine	O
increases	O
the	O
incidence	O
of	O
epididymal	O
stones	O
in	O
roosters	O
,	O
resulting	O
in	O
decreased	O
sperm	O
production	O
and	O
decreased	O
serum	O
testosterone	B-CHED
concentrations	O
.	O

TITLE	O
:	O
Respiratory	O
infections	O
during	O
air	B-CHED
travel	O
.	O

Issues	O
regarding	O
cabin	O
air	B-CHED
quality	O
and	O
the	O
potential	O
risks	O
of	O
transmission	O
of	O
respiratory	O
infections	O
during	O
flight	O
have	O
been	O
investigated	O
and	O
debated	O
previously	O
,	O
but	O
,	O
with	O
the	O
advent	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
and	O
influenza	O
outbreaks	O
,	O
these	O
issues	O
have	O
recently	O
taken	O
on	O
heightened	O
importance	O
.	O

Twelve	O
severely	O
brain	O
-	O
injured	O
patients	O
with	O
acute	O
lung	O
injury	O
and	O
intracranial	O
pressure	O
higher	O
than	O
applied	O
PEEP	B-CHED
.	O

RESULTS	O
:	O
Among	O
these	O
536	O
patients	O
with	O
SARS	O
,	O
36	O
(	O
6	O
.	O
7	O
%)	O
developed	O
acute	O
renal	O
impairment	O
occurring	O
at	O
a	O
median	O
duration	O
of	O
20	O
days	O
(	O
range	O
5	O
-	O
48	O
days	O
)	O
after	O
the	O
onset	O
of	O
viral	O
infection	O
despite	O
a	O
normal	O
plasma	O
creatinine	B-CHED
level	O
at	O
first	O
clinical	O
presentation	O
.	O

Thus	O
,	O
our	O
Spike	O
protein	B-CHED
-	O
based	O
IFA	O
could	O
offer	O
a	O
safer	O
procedure	O
which	O
can	O
be	O
performed	O
in	O
a	O
BSL	O
-	O
2	O
laboratory	O
as	O
it	O
could	O
mimic	O
the	O
whole	O
virus	O
based	O
-	O
IFA	O
without	O
any	O
loss	O
of	O
sensitivity	O
and	O
specificity	O
.	O

This	O
patient	O
required	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
up	O
to	O
18	O
mm	O
/	O
Hg	O
)	O
and	O
fractional	O
inspiratory	O
oxygen	B-CHED
(	O
up	O
to	O
100	O
%).	O

Regulation	O
of	O
transcription	O
in	O
coronaviruses	O
has	O
been	O
studied	O
by	O
reverse	O
-	O
genetics	O
analysis	O
of	O
the	O
sequences	O
immediately	O
flanking	O
a	O
unique	O
CS	O
in	O
the	O
Transmissible	O
gastroenteritis	O
virus	O
genome	O
(	O
CS	O
-	O
S2	O
),	O
located	O
inside	O
the	O
S	O
gene	O
,	O
that	O
does	O
not	O
lead	O
to	O
detectable	O
amounts	O
of	O
the	O
corresponding	O
mRNA	B-CHED
,	O
in	O
spite	O
of	O
its	O
canonical	O
sequence	O
.	O

Lost	B-CHED
revenue	O
and	O
labour	O
accounted	O
for	O
two	O
thirds	O
of	O
the	O
costs	O
incurred	O
while	O
excess	O
spending	O
on	O
services	O
,	O
materials	O
,	O
supplies	O
and	O
renovation	O
of	O
existing	O
space	O
accounted	O
for	O
the	O
remaining	O
one	O
third	O
.	O

For	O
the	O
thermally	O
induced	O
unfolding	O
at	O
pH	O
7	O
.	O
4	O
,	O
the	O
apparent	O
activation	O
energy	O
(	O
E	O
(	O
app	B-CHED
))	O
and	O
transition	O
midpoint	O
temperature	O
(	O
Tm	O
)	O
were	O
determined	O
to	O
be	O
16	O
.	O
3	O
+/-	O

At	O
higher	O
doses	O
,	O
LPS	B-CHED
induces	O
rapid	O
shock	O
(	O
within	O
10	O
min	O
),	O
leading	O
to	O
death	O
within	O
1	O
h	O
.	O
This	O
type	O
of	O
shock	O
differs	O
from	O
so	O
-	O
called	O
endotoxin	O
shock	O
,	O
in	O
which	O
shock	O
signs	O
and	O
death	O
occur	O
several	O
hours	O
or	O
more	O
later	O
.	O

Clinical	O
characteristics	O
and	O
chronic	O
oxygen	B-CHED
requirement	O
pattern	O
of	O
CLD	O
without	O
RDS	O
seems	O
to	O
be	O
less	O
severe	O
than	O
those	O
of	O
CLD	O
with	O
RDS	O
.	O

Risk	O
factors	O
for	O
infection	O
in	O
HCWs	O
included	O
lack	O
of	O
awareness	O
and	O
preparedness	O
when	O
the	O
disease	O
first	O
struck	O
,	O
poor	O
institutional	O
infection	O
control	O
measures	O
,	O
lack	O
of	O
training	O
in	O
infection	O
control	O
procedures	O
,	O
poor	O
compliance	O
with	O
the	O
use	O
of	O
personal	O
protection	O
equipment	O
(	O
PPE	B-CHED
),	O
exposure	O
to	O
high	O
-	O
risk	O
procedures	O
such	O
as	O
intubation	O
and	O
nebulization	O
,	O
and	O
exposure	O
to	O
unsuspected	O
SARS	O
patients	O
.	O

This	O
motif	O
is	O
missing	O
from	O
the	O
spike	O
protein	B-CHED
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
resulting	O
in	O
high	O
level	O
of	O
surface	O
expression	O
of	O
the	O
spike	O
protein	B-CHED
when	O
it	O
is	O
expressed	O
on	O
its	O
own	O
in	O
vitro	O
.	O

The	O
effects	O
of	O
3a	O
on	O
the	O
internalization	O
of	O
cell	O
surface	O
spike	O
protein	B-CHED
can	O
be	O
examined	O
biochemically	O
and	O
the	O
significance	O
of	O
the	O
interplay	O
between	O
these	O
two	O
viral	O
proteins	B-CHED
during	O
viral	O
infection	O
can	O
be	O
studied	O
using	O
reverse	O
genetics	O
methodology	O
.	O

Clinical	O
profiles	O
,	O
joint	O
symptoms	O
,	O
relevant	O
past	O
medical	O
and	O
drug	O
history	O
,	O
steroid	B-CHED
dose	O
,	O
and	O
radiographic	O
and	O
MR	O
imaging	O
evidence	O
of	O
osteonecrosis	O
and	O
other	O
bone	O
abnormalities	O
were	O
evaluated	O
.	O

TITLE	O
:	O
Characterization	O
of	O
viral	O
proteins	B-CHED
encoded	O
by	O
the	O
SARS	O
-	O
coronavirus	O
genome	O
.	O

In	O
this	O
study	O
,	O
we	O
generated	O
a	O
SARS	O
vaccine	O
candidate	O
by	O
using	O
the	O
live	O
-	O
attenuated	O
modified	O
vaccinia	O
virus	O
Ankara	O
(	O
MVA	B-CHED
)	O
as	O
a	O
vector	O
.	O

The	O
full	O
-	O
length	O
SARS	O
-	O
CoV	O
envelope	O
Spike	O
(	O
S	O
)	O
glycoprotein	B-CHED
gene	O
was	O
introduced	O
into	O
the	O
deletion	O
III	O
region	O
of	O
the	O
MVA	B-CHED
genome	O
.	O

Using	O
fragmented	O
S	O
genes	O
as	O
immunogens	O
,	O
we	O
also	O
mapped	O
a	O
neutralizing	O
epitope	B-CHED
in	O
the	O
region	O
of	O
N	O
-	O
terminal	O
400	O
to	O
600	O
amino	B-CHED
acids	I-CHED
of	O
the	O
S	O
glycoprotein	B-CHED
(	O
S400	O
-	O
600	O
),	O
which	O
overlaps	O
with	O
the	O
angiotensin	B-CHED
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
receptor	O
-	O
binding	O
region	O
(	O
RBR	O
;	O
S318	O
-	O
510	O
).	O

These	O
modifications	O
facilitate	O
(	O
i	O
)	O
the	O
mutagenesis	O
of	O
cloned	O
cDNA	O
by	O
using	O
vaccinia	O
virus	O
-	O
mediated	O
homologous	O
recombination	O
and	O
(	O
ii	O
)	O
the	O
rescue	O
of	O
recombinant	O
coronaviruses	O
by	O
using	O
a	O
stable	O
nucleocapsid	O
protein	B-CHED
-	O
expressing	O
cell	O
line	O
for	O
the	O
electroporation	O
of	O
infectious	O
full	O
-	O
length	O
genomes	O
.	O

Two	O
main	O
assumptions	O
were	O
considered	O
;	O
the	O
first	O
is	O
that	O
protein	B-CHED
E	O
contains	O
one	O
transmembrane	O
alpha	O
-	O
helical	O
domain	O
,	O
with	O
its	O
N	O
-	O
and	O
C	O
-	O
termini	O
located	O
in	O
opposite	O
faces	O
of	O
the	O
lipid	B-CHED
bilayer	O
.	O

TITLE	O
:	O
Antiviral	B-CHED
activity	O
of	O
glycyrrhizic	B-CHED
acid	I-CHED
derivatives	O
against	O
SARS	O
-	O
coronavirus	O
.	O

The	O
introduction	O
of	O
2	O
-	O
acetamido	B-CHED
-	O
beta	O
-	O
d	O
-	O
glucopyranosylamine	O
into	O
the	O
glycoside	B-CHED
chain	O
of	O
GL	O
resulted	O
in	O
10	O
-	O
fold	O
increased	O
anti	O
-	O
SARS	O
-	O
CoV	O
activity	O
compared	O
to	O
GL	O
.	O

ABSTRACT	O
:	O
To	O
determine	O
the	O
different	O
effect	O
of	O
prone	O
-	O
position	O
ventilation	O
(	O
PPV	B-CHED
)	O
in	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
resulting	O
from	O
a	O
pulmonary	O
cause	O
(	O
ARDSp	O
)	O
and	O
that	O
from	O
an	O
extrapulmonary	O
cause	O
(	O
ARDSexp	O
)	O
on	O
oxygenation	O
,	O
respiratory	O
mechanics	O
and	O
hemodynamics	O
.	O

Compared	O
with	O
pre	O
-	O
PPV	B-CHED
,	O
in	O
ARDSp	O
,	O
partial	O
pressure	O
of	O
oxygen	B-CHED
in	O
artery	O
(	O
PaO	B-CHED
(	O
2	O
))/	O
inhaled	O
oxygen	B-CHED
concentration	O
(	O
FiO	O
(	O
2	O
))	O
was	O
not	O
increased	O
after	O
0	O
.	O
5	O
h	O
,	O
and	O
increased	O
only	O
after	O
2	O
h	O
in	O
the	O
prone	O
position	O
(	O
130	O
.	O
6	O
+/-	O

The	O
changes	O
of	O
the	O
PaO	B-CHED
(	O
2	O
)	O
were	O
similar	O
to	O
the	O
PaO	B-CHED
(	O
2	O
)/	O
FiO	O
(	O
2	O
).	O

In	O
ARDSp	O
,	O
the	O
airway	O
resistance	O
was	O
(	O
10	O
.	O
8	O
+/-	O
1	O
.	O
4	O
)	O
cm	O
H2O	B-CHED
.	O
s	O
(-	O
1	O
).	O
L	O
(-	O
1	O
)	O
in	O
the	O
supine	O
position	O
,	O
and	O
it	O
was	O
significantly	O
decreased	O
after	O
2	O
h	O
in	O
the	O
prone	O
position	O
(	O
8	O
.	O
4	O
+/-	O

1	O
.	O
8	O
)	O
cm	O
H2O	B-CHED
.	O
s	O
(-	O
1	O
).	O
L	O
(-	O
1	O
)	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

It	O
improved	O
the	O
PaO	B-CHED
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
ratio	O
rapidly	O
in	O
ARDSexp	O
,	O
but	O
in	O
ARDSp	O
the	O
improvement	O
took	O
a	O
longer	O
time	O
.	O

On	O
the	O
other	O
hand	O
,	O
when	O
a	O
10	O
-	O
fold	O
-	O
higher	O
dose	O
of	O
LPS	B-CHED
(	O
3	O
mg	O
/	O
ml	O
)	O
was	O
used	O
,	O
these	O
responses	O
were	O
only	O
partially	O
dependent	O
on	O
CD14	O
and	O
they	O
were	O
totally	O
dependent	O
on	O
TLR4	O
.	O

In	O
addition	O
,	O
concentrations	O
of	O
GAPDH	O
mRNA	B-CHED
were	O
significantly	O
different	O
between	O
the	O
patients	O
with	O
SARS	O
,	O
follow	O
up	O
specimens	O
,	O
and	O
healthy	O
controls	O
(	O
Kruskal	O
-	O
Wallis	O
test	O
,	O
p	O
<	O
0	O
.	O
05	O
).	O

Finally	O
,	O
SARS	O
-	O
CoV	O
and	O
GAPDH	O
mRNA	B-CHED
were	O
both	O
detected	O
in	O
three	O
follow	O
up	O
urine	O
specimens	O
that	O
were	O
initially	O
negative	O
when	O
the	O
amount	O
of	O
cDNA	O
used	O
was	O
increased	O
from	O
5	O
microl	O
to	O
10	O
and	O
15	O
microl	O
.	O

Development	O
of	O
virus	O
diagnostic	O
tests	O
,	O
antiviral	B-CHED
strategies	O
,	O
and	O
vaccines	O
for	O
each	O
of	O
these	O
pathogens	O
is	O
crucial	O
to	O
limit	O
their	O
impact	O
.	O

Our	O
study	O
revealed	O
the	O
need	O
for	O
the	O
development	O
of	O
improved	O
ventilation	O
and	O
air	B-CHED
-	O
conditioning	O
systems	O
in	O
an	O
isolation	O
ward	O
or	O
a	O
general	O
hospital	O
ward	O
for	O
infectious	O
respiratory	O
diseases	O
.	O

TITLE	O
:	O
New	O
antiviral	B-CHED
drugs	I-CHED
,	O
vaccines	O
and	O
classic	O
public	O
health	O
interventions	O
against	O
SARS	O
coronavirus	O
.	O

The	O
possible	O
clinical	O
use	O
of	O
several	O
synthetic	O
peptides	B-CHED
,	O
including	O
those	O
that	O
mimic	O
the	O
S	O
-	O
binding	O
domain	O
,	O
the	O
HR2	O
fusion	O
protein	B-CHED
and	O
SARS	O
proteinase	O
substrates	O
,	O
will	O
be	O
discussed	O
.	O

Treatment	O
with	O
and	O
overexpression	O
of	O
protein	B-CHED
X4	O
inhibited	O
the	O
growth	O
of	O
Balb	O
/	O
c	O
3T3	O
cells	O
as	O
determined	O
by	O
cell	O
counting	O
and	O
MTT	B-CHED
assays	O
.	O

Treatment	O
with	O
and	O
overexpression	O
of	O
protein	B-CHED
X4	O
inhibited	O
the	O
growth	O
of	O
Balb	O
/	O
c	O
3T3	O
cells	O
as	O
determined	O
by	O
cell	O
counting	O
and	O
MTT	B-CHED
assays	O
.	O

Patients	O
with	O
,	O
versus	O
those	O
without	O
,	O
ARDS	O
also	O
tended	O
to	O
present	O
with	O
more	O
severe	O
lymphopenia	O
and	O
leukocytosis	O
,	O
and	O
with	O
higher	O
levels	O
of	O
LDH	O
and	O
aspartate	B-CHED
aminotransferase	O
.	O

ABSTRACT	O
:	O
The	O
spike	O
(	O
S	O
)	O
protein	B-CHED
of	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
is	O
not	O
only	O
responsible	O
for	O
receptor	O
binding	O
,	O
but	O
also	O
a	O
major	O
antigenic	B-CHED
determinant	I-CHED
capable	O
of	O
inducing	O
protective	O
immunity	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrated	O
that	O
the	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
S	O
protein	B-CHED
is	O
an	O
important	O
immunogenic	O
site	O
in	O
patients	O
with	O
SARS	O
and	O
rabbits	O
immunized	O
with	O
inactivated	O
SARS	O
-	O
CoV	O
.	O
Serum	O
samples	O
from	O
convalescent	O
SARS	O
patients	O
and	O
immunized	O
rabbits	O
had	O
potent	O
neutralizing	O
activities	O
against	O
infection	O
by	O
pseudovirus	O
expressing	O
SARS	O
-	O
CoV	O
S	O
protein	B-CHED
.	O

This	O
study	O
demonstrated	O
that	O
the	O
inactivated	O
SARS	O
-	O
CoV	O
was	O
able	O
to	O
preserve	O
the	O
immunogenicity	O
of	O
S	O
protein	B-CHED
including	O
its	O
major	O
neutralizing	O
domain	O
.	O

This	O
could	O
represent	O
one	O
of	O
the	O
most	O
direct	O
routes	O
from	O
genome	O
sequencing	O
to	O
the	O
discovery	O
of	O
antiviral	B-CHED
drugs	I-CHED
.	O

ABSTRACT	O
:	O
Vero	O
E6	O
cells	O
are	O
commonly	O
used	O
for	O
in	O
vitro	O
studies	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
and	O
for	O
antiviral	B-CHED
evaluation	O
purposes	O
.	O

A	O
better	O
understanding	O
of	O
the	O
SARS	O
-	O
CoV	O
growth	O
kinetics	O
in	O
Vero	O
E6	O
cells	O
is	O
crucial	O
to	O
help	O
elucidate	O
the	O
mechanism	O
of	O
antiviral	B-CHED
activity	O
of	O
selective	O
antiviral	B-CHED
agents	I-CHED
.	O

The	O
present	O
report	O
describes	O
a	O
healthy	O
donor	B-CHED
for	O
allo	O
-	O
HSCT	O
with	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
after	O
4	O
days	O
of	O
G	O
-	O
CSF	O
administration	O
.	O

It	O
is	O
important	O
to	O
recognize	O
that	O
patients	O
evolve	O
from	O
severe	O
ARDS	O
through	O
phases	O
of	O
recovery	O
to	O
the	O
resolution	O
of	O
respiratory	O
failure	O
and	O
that	O
ventilatory	O
management	O
,	O
as	O
well	O
as	O
sedative	B-CHED
and	O
related	O
medication	O
requirements	O
,	O
will	O
vary	O
markedly	O
over	O
the	O
course	O
of	O
this	O
process	O
.	O

Poly	O
ICLC	O
is	O
a	O
synthetic	O
double	O
-	O
stranded	O
RNA	O
(	O
dsRNA	B-CHED
),	O
and	O
an	O
effective	O
interferon	O
-	O
inducer	O
and	O
natural	O
killer	O
cell	O
activator	O
.	O

Together	O
,	O
these	O
studies	O
suggest	O
nucleic	B-CHED
acid	I-CHED
-	O
based	O
immunomodulators	O
are	O
promising	O
antiviral	B-CHED
agents	I-CHED
which	O
can	O
offer	O
effective	O
and	O
non	O
-	O
specific	O
protection	O
against	O
acute	O
respiratory	O
virus	O
infections	O
.	O

The	O
sensitivity	O
of	O
detection	O
,	O
measured	O
by	O
using	O
titered	O
SARS	O
-	O
CoV	O
spiked	O
into	O
human	O
serum	O
,	O
was	O
approximate	O
,	O
equals1	O
PFU	B-CHED
/	O
mL	O
.	O
This	O
approach	O
,	O
applicable	O
to	O
the	O
surveillance	O
of	O
bacterial	O
,	O
viral	O
,	O
fungal	O
,	O
or	O
protozoal	O
pathogens	O
,	O
is	O
capable	O
of	O
automated	O
analysis	O
of	O
>	O
900	O
PCR	O
reactions	O
per	O
day	O
.	O

Polyclonal	O
antibodies	O
against	O
the	O
SARS	O
N	O
protein	B-CHED
have	O
been	O
produced	O
and	O
the	O
strong	O
binding	O
sites	O
of	O
the	O
anti	O
-	O
nucleocapsid	O
protein	B-CHED
(	O
NP	O
)	O
antibodies	O
produced	O
were	O
mapped	O
to	O
aa	O
1	O
-	O
20	O
,	O
aa	O
150	O
-	O
170	O
and	O
aa	O
390	O
-	O
410	O
.	O

Expressed	O
3a	O
protein	B-CHED
was	O
reported	O
to	O
localize	O
to	O
Golgi	O
complex	O
in	O
SARS	O
-	O
CoV	O
infected	O
cells	O
.	O

With	O
the	O
assay	O
of	O
truncated	O
3a	O
protein	B-CHED
,	O
it	O
was	O
shown	O
that	O
3a	O
might	O
contain	O
three	O
transmembrane	O
regions	O
,	O
and	O
the	O
second	O
or	O
third	O
region	O
was	O
properly	O
responsible	O
for	O
Golgi	O
localization	O
.	O

Immunofluorescence	O
assay	O
indicated	O
that	O
3a	O
was	O
co	O
-	O
localized	O
with	O
M	O
protein	B-CHED
in	O
Golgi	O
complex	O
in	O
co	O
-	O
transfected	O
cells	O
.	O

Partial	O
sequencing	O
of	O
isolates	O
from	O
Iran	O
and	O
Saudi	O
Arabia	O
,	O
isolated	O
in	O
2000	O
,	O
revealed	O
approximately	O
95	O
%	O
nucleotide	B-CHED
identity	O
with	O
European	O
isolates	O
,	O
including	O
the	O
two	O
live	O
793	O
/	O
B	O
vaccinal	O
strains	O
,	O
showing	O
that	O
they	O
were	O
not	O
re	O
-	O
isolations	O
of	O
vaccinal	O
virus	O
.	O

ABSTRACT	O
:	O
We	O
hypothesized	O
that	O
host	O
antiviral	B-CHED
genes	O
induced	O
by	O
type	O
I	O
interferons	O
might	O
affect	O
the	O
natural	O
course	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
).	O

The	O
severe	O
acute	O
respiratory	O
syndrome	O
outbreak	O
of	O
2002	O
showed	O
how	O
air	B-CHED
travel	O
can	O
have	O
an	O
important	O
role	O
in	O
the	O
rapid	O
spread	O
of	O
newly	O
emerging	O
infections	O
and	O
could	O
potentially	O
even	O
start	O
pandemics	O
.	O

Results	O
from	O
Affymetrix	O
gene	O
array	O
analysis	O
,	O
assessed	O
on	O
RNA	O
isolated	O
from	O
virally	O
and	O
sham	O
-	O
infected	O
cultures	O
,	O
were	O
compared	O
with	O
parallel	O
protein	B-CHED
assays	O
for	O
cytokine	O
,	O
chemokine	O
,	O
and	O
cell	O
surface	O
markers	O
.	O

In	O
addition	O
,	O
mRNA	B-CHED
expression	O
of	O
nonclassical	O
class	O
I	O
molecules	O
H2	O
-	O
T10	O
,	O
-	O
T17	O
,	O
-	O
M2	O
,	O
and	O
-	O
Q10	B-CHED
,	O
were	O
enhanced	O
three	O
-	O
to	O
fivefold	O
in	O
virus	O
-	O
infected	O
cells	O
compared	O
to	O
sham	O
-	O
infected	O
cells	O
.	O

Cats	O
with	O
URI	O
tended	O
to	O
be	O
housed	O
in	O
isolation	O
,	O
dehydrated	O
,	O
and	O
younger	O
than	O
cats	O
without	O
URI	O
,	O
and	O
infected	O
with	O
FHV	O
,	O
Mycoplasma	O
species	O
,	O
FCV	B-CHED
,	O
or	O
C	O
felis	O
.	O

TITLE	O
:	O
Extravascular	O
lung	O
water	B-CHED
in	O
patients	O
with	O
severe	O
sepsis	O
:	O
a	O
prospective	O
cohort	O
study	O
.	O

Consistently	O
,	O
only	O
short	O
C	O
-	O
terminal	O
truncations	O
of	O
the	O
S	O
protein	B-CHED
were	O
tolerated	O
when	O
introduced	O
into	O
the	O
virus	O
by	O
targeted	O
recombination	O
.	O

TITLE	O
:	O
Design	O
of	O
recombinant	O
protein	B-CHED
-	O
based	O
SARS	O
-	O
CoV	O
entry	O
inhibitors	B-CHED
targeting	O
the	O
heptad	O
-	O
repeat	O
regions	O
of	O
the	O
spike	O
protein	B-CHED
S2	O
domain	O
.	O

This	O
is	O
the	O
first	O
report	O
that	O
demonstrated	O
the	O
incorporation	O
of	O
3a	O
into	O
virion	O
and	O
showed	O
that	O
the	O
SARS	O
-	O
CoV	O
encodes	O
a	O
novel	O
coronavirus	O
structural	O
protein	B-CHED
.	O

Viral	O
maturation	O
requires	O
a	O
main	O
protease	O
(	O
3CL	O
(	O
pro	B-CHED
))	O
to	O
cleave	O
the	O
virus	O
-	O
encoded	O
polyproteins	O
.	O

The	O
P1	O
pocket	O
of	O
the	O
active	O
site	O
binds	O
the	O
Gln	B-CHED
side	O
chain	O
specifically	O
,	O
and	O
the	O
P2	O
and	O
P4	O
sites	O
are	O
clustered	O
together	O
to	O
accommodate	O
large	O
hydrophobic	O
side	O
chains	O
.	O

TITLE	O
:	O
Recombinant	O
nucleocapsid	O
protein	B-CHED
-	O
based	O
IgG	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
for	O
the	O
serological	O
diagnosis	O
of	O
SARS	O
.	O

ABSTRACT	O
:	O
The	O
recombinant	O
nucleocapsid	O
protein	B-CHED
(	O
rNP	O
)	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
was	O
expressed	O
in	O
a	O
baculovirus	O
system	O
.	O

The	O
SARS	O
-	O
CoV	O
rNP	O
-	O
based	O
IgG	O
ELISA	O
has	O
92	O
%	O
of	O
sensitivity	O
and	O
specificity	O
compared	O
with	O
the	O
neutralizing	O
antibody	O
assay	O
and	O
94	O
%	O
sensitivity	O
and	O
specificity	O
compared	O
with	O
the	O
authentic	O
SARS	O
-	O
CoV	O
antigen	B-CHED
-	O
based	O
IgG	O
ELISA	O
.	O

Therefore	O
,	O
analysis	O
of	O
host	O
CD8	O
+	O
T	O
-	O
cell	O
responses	O
to	O
unrelated	O
infections	O
demonstrates	O
that	O
bystander	O
memory	O
CD8	O
+	O
T	O
cells	O
can	O
comprise	O
a	O
significant	O
proportion	O
of	O
CNS	B-CHED
inflammatory	O
cells	O
during	O
virus	O
-	O
induced	O
encephalitis	O
.	O

TITLE	O
:	O
Expression	O
of	O
matrix	O
metalloproteinases	O
and	O
their	O
tissue	O
inhibitor	B-CHED
during	O
viral	O
encephalitis	O
.	O

MMP	B-CHED
activity	O
is	O
partially	O
regulated	O
by	O
a	O
small	O
family	O
of	O
genes	O
encoding	O
tissue	O
inhibitors	B-CHED
of	O
matrix	O
metalloproteinases	O
(	O
TIMPs	O
);	O
among	O
the	O
TIMPs	O
,	O
only	O
TIMP	O
-	O
1	O
mRNA	B-CHED
expression	O
increased	O
in	O
the	O
CNS	B-CHED
following	O
coronavirus	O
infection	O
.	O

ABSTRACT	O
:	O
Bananins	O
are	O
a	O
class	O
of	O
antiviral	B-CHED
compounds	O
with	O
a	O
unique	O
structural	O
signature	O
incorporating	O
a	O
trioxa	O
-	O
adamantane	B-CHED
moiety	O
covalently	O
bound	O
to	O
a	O
pyridoxal	B-CHED
derivative	O
.	O

Inhibitors	B-CHED
to	O
PCR	O
assays	O
were	O
detected	O
at	O
an	O
average	O
rate	O
of	O
7	O
-	O
8	O
%	O
among	O
202	O
clinical	O
specimens	O
.	O

Inhibitors	B-CHED
to	O
PCR	O
assays	O
were	O
detected	O
at	O
an	O
average	O
rate	O
of	O
7	O
-	O
8	O
%	O
among	O
202	O
clinical	O
specimens	O
.	O

To	O
determine	O
the	O
in	O
vivo	O
role	O
of	O
IL	O
-	O
2	O
during	O
CNS	B-CHED
infection	O
,	O
IL	O
-	O
2	O
signaling	O
was	O
inhibited	O
via	O
administration	O
of	O
a	O
neutralizing	O
IL	O
-	O
2	O
-	O
specific	O
monoclonal	O
antibody	O
(	O
mAb	O
).	O

On	O
day	O
20	O
after	O
admission	O
the	O
patient	O
was	O
placed	O
on	O
veno	O
-	O
venous	O
ECMO	O
for	O
lung	O
rest	B-CHED
while	O
awaiting	O
a	O
response	O
to	O
continued	O
medical	O
treatment	O
.	O

Data	O
collected	O
included	O
demographics	O
and	O
responses	O
to	O
these	O
instruments	O
:	O
1	O
)	O
the	O
Coping	O
Orientation	O
to	O
Problems	O
Experienced	O
(	O
COPE	O
)	O
to	O
assess	O
coping	O
strategies	O
,	O
2	O
)	O
the	O
Impact	O
of	O
Event	O
Scale	O
(	O
IES	B-CHED
)	O
to	O
measure	O
psychological	O
reactions	O
,	O
and	O
3	O
)	O
the	O
General	O
Health	O
Questionnaire	O
28	O
(	O
GHQ	O
28	O
)	O
to	O
measure	O
psychiatric	O
morbidity	O
.	O

Psychiatric	O
morbidity	O
was	O
17	O
.	O
7	O
%	O
on	O
the	O
IES	B-CHED
and	O
18	O
.	O
8	O
%	O
on	O
the	O
GHQ	O
28	O
,	O
with	O
the	O
trend	O
for	O
physicians	O
to	O
report	O
lower	O
psychiatric	O
morbidity	O
.	O

During	O
the	O
Toronto	O
outbreaks	O
of	O
SARS	O
,	O
we	O
investigated	O
environmental	O
contamination	O
in	O
SARS	O
units	O
,	O
by	O
employing	O
novel	O
air	B-CHED
sampling	O
and	O
conventional	O
surface	O
swabbing	O
.	O

Seventy	O
(	O
24	O
%)	O
patients	O
had	O
elevated	O
serum	O
ALT	B-CHED
on	O
admission	O
and	O
204	O
(	O
69	O
%)	O
patients	O
had	O
elevated	O
ALT	B-CHED
during	O
the	O
subsequent	O
course	O
of	O
illness	O
.	O

Based	O
on	O
bioinformatics	O
analysis	O
,	O
10	O
antigenic	O
peptides	B-CHED
derived	O
from	O
the	O
S	O
protein	B-CHED
sequence	O
were	O
selected	O
and	O
synthesized	O
.	O

The	O
sequences	O
were	O
similar	O
to	O
those	O
reported	O
by	O
other	O
groups	O
,	O
except	O
that	O
17	O
single	O
nucleotide	B-CHED
variations	O
and	O
two	O
2	O
-	O
nucleotide	B-CHED
deletions	O
,	O
and	O
a	O
1	O
-	O
nucleotide	B-CHED
deletion	O
were	O
found	O
.	O

Of	O
these	O
17	O
sequenced	O
variants	O
,	O
two	O
loci	O
(	O
positions	O
26203	O
and	O
27812	O
)	O
were	O
segregated	O
together	O
as	O
a	O
specific	O
genotype	O
-	O
T	O
:	O
T	O
or	O
C	O
:	O
C	O
.	O
Phylogenetic	O
analysis	O
showed	O
two	O
major	O
clusters	B-CHED
of	O
SARS	O
patients	O
in	O
Taiwan	O
.	O

Regarding	O
the	O
treatment	O
with	O
synthetic	O
ACTH	B-CHED
or	O
vigabatrin	B-CHED
,	O
the	O
control	O
of	O
WS	O
was	O
the	O
same	O
for	O
cryptogenic	O
and	O
symptomatic	O
forms	O
,	O
one	O
drug	O
may	O
be	O
effective	O
if	O
the	O
other	O
drug	O
fails	O
.	O

During	O
the	O
course	O
of	O
illness	O
,	O
he	O
developed	O
clinical	O
features	O
compatible	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
that	O
may	O
have	O
complicated	O
the	O
recovery	O
of	O
his	O
underlying	O
hypersensitivity	O
reaction	O
,	O
which	O
was	O
subsequently	O
controlled	O
with	O
intravenous	O
immune	O
globulin	O
and	O
corticosteroids	B-CHED
.	O

In	O
this	O
study	O
,	O
we	O
demonstrated	O
that	O
a	O
fusion	O
protein	B-CHED
containing	O
RBD	O
linked	O
to	O
human	O
IgG1	O
Fc	O
fragment	O
(	O
designated	O
RBD	O
-	O
Fc	O
)	O
induced	O
high	O
titer	O
of	O
RBD	O
-	O
specific	O
Abs	O
in	O
the	O
immunized	O
mice	O
.	O

A	O
case	O
of	O
a	O
25	O
-	O
year	O
-	O
old	O
male	O
with	O
a	O
severe	O
chest	O
pain	O
associated	O
with	O
ST	O
segment	O
changes	O
,	O
elevated	O
serum	O
C	O
-	O
reactive	O
protein	B-CHED
,	O
myocardial	O
necrosis	O
markers	O
and	O
normal	O
epicardial	O
coronary	O
arteries	O
is	O
presented	O
.	O

Examples	O
are	O
emerging	O
infections	O
such	O
as	O
HIV	O
/	O
AIDS	O
and	O
severe	O
acute	O
respiratory	O
syndrome	O
,	O
deliberate	O
release	O
of	O
microorganisms	O
,	O
such	O
as	O
the	O
anthrax	O
episode	O
in	O
the	O
USA	O
,	O
the	O
increasing	O
problems	O
with	O
organisms	O
resistant	O
to	O
antimicrobial	B-CHED
treatment	O
,	O
such	O
as	O
methicillin	B-CHED
-	O
resistant	O
Staphylococcus	O
aureus	O
,	O
and	O
the	O
threat	O
of	O
a	O
new	O
influenza	O
pandemic	O
with	O
a	O
case	O
fatality	O
rate	O
similar	O
to	O
that	O
in	O
the	O
1918	O
outbreak	O
.	O

New	O
techniques	O
such	O
as	O
new	O
generations	O
of	O
Polymerase	O
Chain	O
Reaction	O
(	O
PCR	O
),	O
rapid	O
methods	O
for	O
nucleic	B-CHED
acid	I-CHED
sequence	O
analyses	O
and	O
microarrays	O
have	O
enabled	O
more	O
rapid	O
identification	O
of	O
organisms	O
and	O
provide	O
powerful	O
tools	O
in	O
the	O
epidemiological	O
analysis	O
of	O
an	O
outbreak	O
.	O

High	O
titers	O
of	O
pathogenic	O
or	O
blood	O
-	O
borne	O
viruses	O
,	O
representing	O
10	O
different	O
families	O
,	O
were	O
added	O
to	O
single	O
-	O
donor	B-CHED
PLT	O
concentrates	O
containing	O
3	O
.	O
0	O
x	O
10	O
(	O
11	O
)	O
to	O
6	O
.	O
0	O
x	O
10	O
(	O
11	O
)	O
PLTs	O
in	O
approximately	O
300	O
mL	O
of	O
35	O
percent	O
plasma	O
and	O
65	O
percent	O
PLT	O
additive	O
solution	O
(	O
InterSol	O
).	O

The	O
laparoscopic	O
access	O
for	O
radical	B-CHED
prostatectomy	O
is	O
a	O
growing	O
alternative	O
to	O
the	O
open	O
surgical	O
procedure	O
.	O

For	O
the	O
two	O
novel	O
sgRNAs	O
,	O
each	O
used	O
a	O
variant	O
of	O
the	O
TRS	O
that	O
has	O
one	O
nucleotide	B-CHED
mismatch	O
in	O
the	O
conserved	O
hexanucleotide	O
core	O
(	O
ACGAAC	O
)	O
in	O
the	O
TRS	O
.	O

The	O
aim	O
of	O
our	O
study	O
was	O
to	O
investigate	O
,	O
in	O
rabbits	O
with	O
hydrochloric	O
(	O
HCl	B-CHED
)	O
acid	O
-	O
induced	O
Acute	O
Lung	O
Injury	O
(	O
ALI	O
),	O
the	O
effects	O
of	O
intra	O
-	O
tracheal	O
(	O
i	O
.	O
t	O
.)	O
dexamethasone	B-CHED
administration	O
on	O
neutrophil	O
and	O
platelet	O
counts	O
,	O
plasma	O
malonyl	B-CHED
dialdehyde	B-CHED
(	O
MDA	B-CHED
)	O
level	O
,	O
histopathology	O
,	O
and	O
arterial	O
blood	O
gases	O
.	O

Both	O
groups	O
received	O
2	O
ml	O
kg	O
(-	O
1	O
)	O
HCl	B-CHED
(	O
hydrochloric	B-CHED
acid	I-CHED
)	O
i	O
.	O
t	O
..	O

Histopathological	O
changes	O
were	O
less	O
severe	O
in	O
the	O
dexamethasone	B-CHED
group	O
.	O

To	O
understand	O
the	O
functional	O
roles	O
of	O
the	O
two	O
structural	O
parts	O
of	O
the	O
SARS	O
-	O
CoV	O
main	O
protease	O
,	O
we	O
generated	O
the	O
full	O
-	O
length	O
of	O
this	O
enzyme	O
as	O
well	O
as	O
several	O
terminally	O
truncated	O
forms	O
,	O
different	O
from	O
each	O
other	O
only	O
by	O
the	O
number	O
of	O
amino	B-CHED
acid	I-CHED
residues	O
at	O
the	O
C	O
-	O
or	O
N	O
-	O
terminal	O
regions	O
.	O

The	O
results	O
showed	O
that	O
the	O
N	O
-	O
terminal	O
1	O
-	O
3	O
amino	B-CHED
acid	I-CHED
-	O
truncated	O
protease	O
maintains	O
76	O
%	O
of	O
enzyme	O
activity	O
and	O
that	O
the	O
major	O
form	O
is	O
a	O
dimer	O
,	O
as	O
in	O
the	O
wild	O
type	O
.	O

TITLE	O
:	O
Differential	O
maturation	O
and	O
subcellular	O
localization	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
surface	O
proteins	B-CHED
S	O
,	O
M	O
and	O
E	O
.	O
ABSTRACT	O
:	O
Post	O
-	O
translational	O
modifications	O
and	O
correct	O
subcellular	O
localization	O
of	O
viral	O
structural	O
proteins	B-CHED
are	O
prerequisites	O
for	O
assembly	O
and	O
budding	O
of	O
enveloped	O
viruses	O
.	O

Pulse	O
-	O
chase	O
labelling	O
and	O
confocal	O
microscopy	O
in	O
the	O
presence	O
of	O
protein	B-CHED
translation	O
inhibitor	B-CHED
cycloheximide	B-CHED
revealed	O
that	O
the	O
E	O
protein	B-CHED
has	O
a	O
short	O
half	O
-	O
life	O
of	O
30	O
min	O
.	O

In	O
conclusion	O
,	O
SARS	O
-	O
CoV	O
surface	O
proteins	B-CHED
S	O
,	O
M	O
and	O
E	O
show	O
differential	O
subcellular	O
localizations	O
when	O
expressed	O
alone	O
suggesting	O
that	O
additional	O
cellular	O
or	O
viral	O
factors	O
might	O
be	O
required	O
for	O
coordinated	O
trafficking	O
to	O
the	O
virus	O
assembly	O
site	O
in	O
the	O
endoplasmic	O
reticulum	O
-	O
Golgi	O
intermediate	O
compartment	O
.	O

Altogether	O
,	O
these	O
results	O
indicate	O
that	O
an	O
MHV	O
infection	O
of	O
the	O
central	O
nervous	O
system	O
(	O
CNS	B-CHED
)	O
leads	O
to	O
an	O
important	O
host	O
genomic	O
response	O
implicating	O
immunity	O
-	O
related	O
genes	O
and	O
to	O
the	O
activation	O
of	O
myelin	O
-	O
reactive	O
autoimmune	O
T	O
cells	O
.	O

ABSTRACT	O
:	O
Although	O
acute	O
inflammatory	O
polyneuropathy	O
(	O
AIP	O
)	O
and	O
immune	O
thrombocytopenic	O
purpura	O
(	O
ITP	B-CHED
)	O
are	O
both	O
believed	O
to	O
be	O
immune	O
-	O
mediated	O
disorders	O
,	O
only	O
a	O
few	O
cases	O
have	O
been	O
reported	O
in	O
which	O
these	O
two	O
diseases	O
co	O
-	O
existed	O
.	O

By	O
reviewing	O
past	O
similar	O
reports	O
,	O
we	O
noticed	O
that	O
AIP	O
associated	O
with	O
ITP	B-CHED
tends	O
to	O
manifest	O
severe	O
sensory	O
impairment	O
and	O
is	O
often	O
preceded	O
by	O
upper	O
respiratory	O
tract	O
infection	O
,	O
but	O
not	O
by	O
gastrointestinal	O
infection	O
.	O

After	O
a	O
single	O
immunization	O
and	O
one	O
boost	O
,	O
rOv	O
-	O
ASP	B-CHED
-	O
1	O
exceeded	O
the	O
efficacy	O
of	O
alum	O
or	O
MPL	O
+	O
TDM	O
adjuvants	B-CHED
in	O
terms	O
of	O
end	O
-	O
point	O
total	O
IgG	O
or	O
IgG1	O
and	O
IgG2a	O
anti	O
-	O
OVA	O
titres	O
.	O

Using	O
a	O
monoclonal	O
antibody	O
(	O
mAb	O
)	O
against	O
SARS	O
-	O
CoV	O
N	O
protein	B-CHED
,	O
screened	O
by	O
SARS	O
-	O
CoV	O
N	O
protein	B-CHED
and	O
matching	O
experiment	O
,	O
a	O
method	O
for	O
quantitative	O
detection	O
of	O
SARS	O
-	O
CoV	O
N	O
protein	B-CHED
by	O
TRFIA	O
was	O
established	O
on	O
the	O
basis	O
of	O
double	O
sandwich	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
and	O
evaluated	O
against	O
the	O
ELISA	O
kit	O
.	O

TITLE	O
:	O
Mannose	B-CHED
-	O
binding	O
lectin	O
in	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
infection	O
.	O

A	O
striking	O
arrangement	O
of	O
conserved	O
asparagine	B-CHED
and	O
glutamine	B-CHED
residues	O
of	O
HR1	O
propagates	O
from	O
two	O
central	O
chloride	B-CHED
ions	B-CHED
,	O
providing	O
hydrogen	B-CHED
-	O
bonding	O
""""	O
zippers	O
""""	O
that	O
strongly	O
constrain	O
the	O
path	O
of	O
the	O
HR2	O
main	O
chain	O
,	O
forcing	O
it	O
to	O
adopt	O
an	O
extended	O
conformation	O
at	O
either	O
end	O
of	O
a	O
short	O
HR2	O
alpha	O
-	O
helix	O
.	O

Better	O
understanding	O
of	O
the	O
molecular	O
basis	O
of	O
viral	O
pathogenesis	O
should	O
contribute	O
significantly	O
towards	O
the	O
development	O
of	O
improved	O
prophylactic	O
,	O
therapeutic	O
and	O
diagnostic	O
reagents	B-CHED
to	O
control	O
infections	O
.	O

ABSTRACT	O
:	O
The	O
causative	O
agent	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
is	O
the	O
SARS	O
-	O
associated	O
coronavirus	O
,	O
SARS	O
-	O
CoV	O
.	O
The	O
viral	O
nucleocapsid	O
(	O
N	O
)	O
protein	B-CHED
plays	O
an	O
essential	O
role	O
in	O
viral	O
RNA	O
packaging	O
.	O

Treatment	O
with	O
steroids	B-CHED
,	O
chemotherapy	O
,	O
interferon	O
-	O
alpha	O
(	O
IFN	O
-	O
alpha	O
),	O
or	O
imatinib	B-CHED
-	O
mesylate	O
may	O
improve	O
the	O
prognosis	O
.	O

RANTES	O
itself	O
could	O
inhibit	O
the	O
replication	O
of	O
SARS	O
-	O
CoV	O
in	O
THP	B-CHED
-	O
1	O
cells	O
when	O
it	O
was	O
added	O
into	O
the	O
culture	O
before	O
or	O
at	O
the	O
same	O
time	O
with	O
the	O
virus	O
;	O
No	O
inhibition	O
effect	O
was	O
shown	O
when	O
RANTES	O
were	O
added	O
into	O
the	O
culture	O
after	O
SARS	O
-	O
CoV	O
infected	O
the	O
cells	O
.	O

TITLE	O
:	O
Evaluation	O
of	O
human	O
monoclonal	O
antibody	O
80R	O
for	O
immunoprophylaxis	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
by	O
an	O
animal	O
study	O
,	O
epitope	B-CHED
mapping	O
,	O
and	O
analysis	O
of	O
spike	O
variants	O
.	O

In	O
addition	O
,	O
the	O
effects	O
of	O
various	O
80R	O
-	O
binding	O
domain	O
amino	B-CHED
acid	I-CHED
substitutions	O
which	O
occur	O
in	O
SARS	O
-	O
like	O
-	O
CoV	O
from	O
civet	O
cats	O
,	O
and	O
which	O
evolved	O
during	O
the	O
2002	O
/	O
2003	O
outbreak	O
and	O
in	O
a	O
2003	O
/	O
2004	O
Guangdong	O
index	O
patient	O
,	O
were	O
analyzed	O
.	O

ABSTRACT	O
:	O
The	O
SARS	O
-	O
nsp13	O
protein	B-CHED
was	O
identified	O
as	O
an	O
mRNA	B-CHED
cap1	O
methyltransferase	O
.	O

A	O
large	O
quantity	O
of	O
the	O
nsp13	O
protein	B-CHED
obtained	O
with	O
this	O
method	O
may	O
be	O
useful	O
for	O
further	O
study	O
of	O
its	O
structure	O
and	O
function	O
.	O

Three	O
S1	O
-	O
and	O
one	O
S2	O
-	O
bt	O
peptides	B-CHED
also	O
induced	O
a	O
delayed	O
type	O
hypersensitivity	O
response	O
indicating	O
the	O
presence	O
of	O
T	O
-	O
cell	O
epitopes	O
.	O

The	O
S2	O
peptide	B-CHED
Sp7	O
(	O
amino	B-CHED
acid	I-CHED
position	O
566	O
-	O
584	O
)	O
previously	O
identified	O
as	O
an	O
immundominant	O
region	O
,	O
was	O
the	O
most	O
antigenic	O
of	O
all	O
peptides	B-CHED
used	O
in	O
this	O
study	O
.	O

From	O
four	O
N	O
peptides	B-CHED
located	O
in	O
the	O
amino	O
-	O
terminal	O
part	O
of	O
the	O
N	O
protein	B-CHED
,	O
only	O
one	O
,	O
Np2	O
(	O
amino	B-CHED
acid	I-CHED
position	O
72	O
-	O
86	O
),	O
was	O
antigenic	O
and	O
also	O
induced	O
a	O
delayed	O
type	O
hypersensitivity	O
response	O
.	O

Ophthalmologists	O
may	O
be	O
particularly	O
susceptible	O
to	O
the	O
infection	O
as	O
routine	O
ophthalmic	B-CHED
examinations	O
like	O
direct	O
ophthalmoscopy	O
and	O
slit	O
-	O
lamp	O
examination	O
are	O
usually	O
performed	O
in	O
a	O
setting	O
that	O
has	O
close	O
doctor	O
-	O
patient	O
contact	O
.	O

SARS	O
is	O
one	O
of	O
the	O
many	O
viruses	O
against	O
which	O
personnel	O
will	O
need	O
protecting	O
in	O
an	O
ophthalmic	B-CHED
setting	O
.	O

TITLE	O
:	O
Antibody	O
responses	O
to	O
individual	O
proteins	B-CHED
of	O
SARS	O
coronavirus	O
and	O
their	O
neutralization	O
activities	O
.	O

In	O
this	O
study	O
,	O
13	O
recombinant	O
proteins	B-CHED
associated	O
with	O
four	O
structural	O
proteins	B-CHED
(	O
S	O
,	O
E	O
,	O
M	O
and	O
N	O
)	O
and	O
five	O
putative	O
uncharacterized	O
proteins	B-CHED
(	O
3a	O
,	O
3b	O
,	O
6	O
,	O
7a	O
and	O
9b	O
)	O
of	O
the	O
SARS	O
-	O
CoV	O
were	O
prepared	O
and	O
used	O
for	O
screening	O
and	O
monitoring	O
their	O
specific	O
IgG	O
antibodies	O
in	O
SARS	O
patient	O
sera	O
by	O
protein	B-CHED
microarray	O
.	O

The	O
results	O
suggest	O
(	O
1	O
)	O
that	O
anti	O
-	O
S	O
and	O
anti	O
-	O
N	O
antibodies	O
are	O
diagnostic	O
markers	O
and	O
in	O
particular	O
that	O
S3	O
is	O
immunogenic	O
and	O
therefore	O
is	O
a	O
good	O
candidate	O
as	O
a	O
subunit	O
vaccine	O
antigen	B-CHED
;	O
and	O
(	O
2	O
)	O
that	O
,	O
from	O
a	O
virus	O
structure	O
viewpoint	O
,	O
the	O
presence	O
in	O
some	O
human	O
sera	O
of	O
antibodies	O
reacting	O
with	O
two	O
recombinant	O
polypeptides	B-CHED
,	O
3a	O
and	O
9b	O
,	O
supports	O
the	O
hypothesis	O
that	O
they	O
are	O
synthesized	O
during	O
the	O
virus	O
cycle	O
.	O

The	O
effects	O
of	O
class	O
-	O
specific	O
protease	B-CHED
inhibitors	I-CHED
on	O
the	O
trans	O
-	O
cleavage	O
activity	O
revealed	O
that	O
this	O
enzyme	O
worked	O
more	O
like	O
a	O
serine	B-CHED
protease	O
rather	O
than	O
the	O
papain	O
protease	O
.	O

This	O
process	O
led	O
to	O
the	O
identification	O
of	O
a	O
single	O
substance	O
lycorine	B-CHED
as	O
an	O
anti	O
-	O
SARS	O
-	O
CoV	O
component	O
with	O
an	O
EC50	O
value	O
of	O
15	O
.	O
7	O
+/-	O

TNF	O
-	O
alpha	O
,	O
IL	O
-	O
6	O
,	O
IL	O
-	O
8	O
,	O
RANTES	O
and	O
MCP	B-CHED
-	O
1	O
levels	O
were	O
increased	O
.	O

We	O
conclude	O
that	O
,	O
formulated	O
as	O
a	O
lozenge	O
,	O
the	O
mixture	B-CHED
could	O
have	O
significant	O
effects	O
in	O
reducing	O
the	O
infectivity	O
of	O
certain	O
infectious	O
viruses	O
in	O
the	O
throat	O
and	O
presumably	O
in	O
cough	O
droplets	O
,	O
thus	O
reducing	O
,	O
theoretically	O
,	O
opportunities	O
for	O
person	O
-	O
to	O
-	O
person	O
transmission	O
.	O

Although	O
some	O
information	O
is	O
lost	B-CHED
due	O
to	O
the	O
approximate	O
description	O
of	O
the	O
Z	O
-	O
curve	O
,	O
the	O
phylogenetic	O
tree	O
constructed	O
based	O
on	O
these	O
parameters	O
is	O
consistent	O
with	O
those	O
of	O
previous	O
analyses	O
.	O

Binding	O
of	O
both	O
cinanserin	O
and	O
its	O
hydrochloride	B-CHED
to	O
bacterially	O
expressed	O
3CLpro	O
of	O
SARS	O
-	O
CoV	O
and	O
the	O
related	O
human	O
coronavirus	O
229E	O
(	O
HCoV	O
-	O
229E	O
)	O
was	O
demonstrated	O
by	O
surface	O
plasmon	O
resonance	O
technology	O
.	O

To	O
determine	O
whether	O
the	O
expression	O
of	O
a	O
single	O
macrophage	O
chemoattractant	O
,	O
in	O
the	O
context	O
of	O
virus	O
infection	O
,	O
could	O
initiate	O
the	O
demyelinating	O
process	O
,	O
we	O
engineered	O
a	O
recombinant	O
coronavirus	O
that	O
expressed	O
the	O
chemokine	O
CCL2	B-CHED
/	O
monocyte	O
chemoattractant	O
protein	B-CHED
-	O
1	O
.	O

CCL2	B-CHED
has	O
been	O
implicated	O
in	O
macrophage	O
infiltration	O
into	O
the	O
central	O
nervous	O
system	O
and	O
is	O
involved	O
in	O
demyelination	O
in	O
many	O
experimental	O
models	O
of	O
demyelination	O
.	O

TITLE	O
:	O
Development	O
in	O
lipid	B-CHED
drugs	O
.	O

ABSTRACT	O
:	O
Lipopeptide	B-CHED
lipid	B-CHED
moieties	O
induce	O
dendritic	O
cell	O
(	O
DC	O
)	O
internalization	O
and	O
epitopes	O
are	O
recognized	O
by	O
MHC	O
,	O
the	O
major	O
histocompatibility	O
complex	O
.	O

N	O
protein	B-CHED
was	O
detected	O
in	O
18	O
IFA	O
IgM	O
-	O
positive	O
serum	O
samples	O
collected	O
from	O
SARS	O
confirmed	O
patients	O
,	O
but	O
not	O
in	O
nine	O
samples	O
collected	O
from	O
SARS	O
recovery	O
patient	O
.	O

We	O
established	O
one	O
hybridoma	O
cell	O
line	O
secreting	O
specific	O
mAb	O
and	O
evaluated	O
this	O
mAb	O
with	O
murine	O
leukemia	O
virus	O
pseudotyped	O
with	O
SARS	O
-	O
CoV	O
spike	O
protein	B-CHED
(	O
MLV	O
/	O
SARS	O
-	O
CoV	O
).	O

In	O
this	O
report	O
,	O
we	O
described	O
the	O
utility	O
of	O
these	O
two	O
new	O
neutralization	O
assays	O
in	O
measuring	O
the	O
neutralizing	O
activities	O
against	O
SCV	O
infection	O
from	O
rabbit	O
sera	O
immunized	O
with	O
various	O
forms	O
of	O
spike	O
protein	B-CHED
of	O
SCV	O
.	O

When	O
given	O
together	O
,	O
endotoxin	O
and	O
oleic	B-CHED
acid	I-CHED
acted	O
synergistically	O
to	O
increase	O
pulmonary	O
edema	O
and	O
to	O
worsen	O
gas	O
exchange	O
and	O
hemodynamics	O
,	O
thereby	O
increasing	O
mortality	O
.	O

This	O
synergism	O
was	O
significantly	O
attenuated	O
by	O
the	O
prior	O
administration	O
of	O
the	O
endotoxin	O
antagonist	B-CHED
E5564	B-CHED
(	O
eritoran	B-CHED
).	O

The	O
NL63	O
spike	O
(	O
S	O
)	O
protein	B-CHED
mediated	O
infection	O
of	O
different	O
target	O
cells	O
compared	O
with	O
the	O
closely	O
related	O
229E	O
-	O
S	O
protein	B-CHED
but	O
facilitated	O
entry	O
into	O
cells	O
known	O
to	O
be	O
permissive	O
to	O
SARS	O
-	O
CoV	O
-	O
S	O
-	O
driven	O
infection	O
.	O

Potent	O
neutralizing	O
activity	O
directed	O
against	O
NL63	O
-	O
but	O
not	O
229E	O
-	O
S	O
protein	B-CHED
was	O
detected	O
in	O
virtually	O
all	O
sera	O
from	O
patients	O
8	O
years	O
of	O
age	O
or	O
older	O
,	O
suggesting	O
that	O
HCoV	O
-	O
NL63	O
infection	O
of	O
humans	O
is	O
common	O
and	O
usually	O
acquired	O
during	O
childhood	O
.	O

The	O
amino	B-CHED
acid	I-CHED
and	O
secondary	O
structure	O
change	O
may	O
be	O
important	O
for	O
viral	O
infection	O
.	O

TITLE	O
:	O
[	O
Computed	O
tomographic	O
criteria	O
as	O
expected	O
effect	O
to	O
inhaled	O
nitric	B-CHED
oxide	I-CHED
in	O
patients	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
].	O

The	O
water	B-CHED
balance	B-CHED
and	O
sodium	O
administration	O
have	O
to	O
be	O
closely	O
monitored	O
to	O
prevent	O
cirrhotic	O
patients	O
undergoing	O
MCT	O
from	O
developing	O
ARDS	O
.	O

ABSTRACT	O
:	O
Preliminary	O
data	O
examining	O
interferon	O
alfacon1	O
treatment	O
of	O
SARS	O
-	O
CoV	O
(	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
corona	B-CHED
virus	O
)-	O
infected	O
patients	O
suggests	O
this	O
therapy	O
is	O
well	O
tolerated	O
and	O
of	O
therapeutic	O
benefit	O
.	O

Sequencing	O
of	O
the	O
complete	O
nucleocapsid	O
gene	O
and	O
downstream	O
regions	O
of	O
goose	O
and	O
pigeon	O
coronaviruses	O
,	O
evidenced	O
the	O
presence	O
of	O
two	O
additional	O
open	O
reading	O
frames	O
for	O
the	O
goose	O
coronavirus	O
with	O
no	O
sequence	O
similarity	O
to	O
known	O
proteins	B-CHED
,	O
but	O
with	O
predicted	O
transmembrane	O
domains	O
for	O
one	O
of	O
the	O
encoded	O
proteins	B-CHED
,	O
and	O
one	O
additional	O
open	O
reading	O
frame	O
for	O
the	O
pigeon	O
coronavirus	O
,	O
with	O
a	O
predicted	O
transmembrane	O
domain	O
,	O
downstream	O
of	O
the	O
nucleocapsid	O
gene	O
.	O

Here	O
we	O
report	O
that	O
four	O
20	O
-	O
mer	O
synthetic	O
peptides	B-CHED
(	O
S	O
protein	B-CHED
fragments	O
),	O
designed	O
to	O
span	O
these	O
sequence	O
variation	O
hotspots	O
,	O
exhibited	O
significant	O
antiviral	B-CHED
activities	O
in	O
a	O
cell	O
line	O
.	O

The	O
peptides	B-CHED
identified	O
in	O
this	O
study	O
could	O
be	O
further	O
developed	O
into	O
antiviral	B-CHED
drugs	I-CHED
.	O

ABSTRACT	O
:	O
The	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
is	O
a	O
non	O
-	O
cardiogenic	O
form	O
of	O
pulmonary	O
oedema	O
characterised	O
by	O
severe	O
hypoxaemia	O
refractory	O
to	O
oxygen	B-CHED
therapy	O
,	O
with	O
diffuse	O
pulmonary	O
infiltrates	O
on	O
chest	O
radiographs	O
.	O

Cases	O
with	O
ARDS	O
were	O
selected	O
from	O
the	O
web	O
site	O
based	O
international	O
registry	O
of	O
patients	O
with	O
catastrophic	O
APS	B-CHED
(	O
CAPS	O
registry	O
)	O
(	O
http	O
://	O
www	O
.	O
med	O
.	O
ub	O
.	O
es	O
/	O
MIMMUN	O
/	O
FORUM	O
/	O
CAPS	O
.	O
HTM	O
)	O
and	O
their	O
characteristics	O
examined	O
.	O

TITLE	O
:	O
Murine	O
coronavirus	O
evolution	O
in	O
vivo	O
:	O
functional	O
compensation	O
of	O
a	O
detrimental	O
amino	B-CHED
acid	I-CHED
substitution	O
in	O
the	O
receptor	O
binding	O
domain	O
of	O
the	O
spike	O
glycoprotein	B-CHED
.	O

Using	O
targeted	O
RNA	O
recombination	O
,	O
we	O
have	O
constructed	O
isogenic	O
recombinant	O
MHV	O
-	O
A59	O
viruses	O
differing	O
only	O
in	O
these	O
specific	O
amino	B-CHED
acids	I-CHED
in	O
S	O
(	O
Q159L	O
-	O
R654H	O
-	O
H716D	O
-	O
E1035D	O
).	O

Three	O
enzyme	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
kits	O
were	O
used	O
to	O
detect	O
SARS	O
-	O
CoV	O
IgG	O
,	O
IgM	O
and	O
N	O
protein	B-CHED
and	O
fluorescent	O
polymerase	O
chain	O
reaction	O
(	O
F	O
-	O
PCR	O
)	O
kit	O
was	O
used	O
to	O
detect	O
SARS	O
-	O
CoV	O
RNA	O
.	O

The	O
effects	O
of	O
1	O
year	O
withdrawal	O
of	O
the	O
ICS	O
fluticasone	B-CHED
propionate	I-CHED
(	O
FP	B-CHED
)	O
after	O
a	O
3	O
month	O
run	O
-	O
in	O
treatment	O
period	O
with	O
FP	B-CHED
combined	O
with	O
the	O
LABA	O
salmeterol	B-CHED
(	O
S	O
)	O
(	O
500	O
microg	O
FP	B-CHED
+	O
50	O
microg	O
S	O
twice	O
daily	O
;	O
SFC	O
)	O
were	O
investigated	O
in	O
patients	O
with	O
COPD	O
in	O
a	O
randomised	O
,	O
double	O
blind	O
study	O
.	O

Immunohistochemistry	O
was	O
used	O
,	O
with	O
monoclonal	O
antibodies	O
,	O
to	O
detect	O
the	O
thyroglobulin	O
(	O
TG	O
),	O
calcitonin	B-CHED
and	O
parathyroid	O
hormone	B-CHED
(	O
PTH	O
)	O
in	O
the	O
thyroid	O
glands	O
.	O

The	O
interaction	O
between	O
SARS	O
coronavirus	O
3C	O
-	O
like	O
(	O
3CL	O
)	O
proteinase	O
and	O
an	O
octapeptide	O
interface	O
inhibitor	B-CHED
was	O
studied	O
by	O
affinity	O
capillary	O
electrophoresis	O
(	O
ACE	O
).	O

ABSTRACT	O
:	O
To	O
evaluate	O
the	O
effects	O
of	O
disease	O
severity	O
,	O
corticosteroids	B-CHED
and	O
social	O
factors	O
on	O
neuropsychiatric	O
complaints	O
in	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
patients	O
,	O
both	O
during	O
acute	O
and	O
convalescent	O
phases	O
.	O

Severe	O
disease	O
,	O
high	O
dose	O
corticosteroids	B-CHED
and	O
being	O
health	O
care	O
workers	O
were	O
independent	O
predictors	O
of	O
neuropsychiatric	O
complaints	O
in	O
both	O
acute	O
and	O
convalescent	O
phases	O
.	O

TITLE	O
:	O
SARS	O
-	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
and	O
the	O
safety	O
of	O
a	O
solvent	B-CHED
/	O
detergent	B-CHED
(	O
S	O
/	O
D	O
)	O
treated	O
immunoglobulin	O
preparation	O
.	O

Treatment	O
with	O
a	O
mixture	B-CHED
of	O
solvent	B-CHED
and	O
detergent	B-CHED
(	O
SD	O
)	O
has	O
successfully	O
been	O
applied	O
to	O
inactivate	O
the	O
most	O
members	O
of	O
the	O
transfusion	O
-	O
relevant	O
viruses	O
without	O
affecting	O
therapeutic	O
properties	O
of	O
the	O
products	O
.	O

TITLE	O
:	O
A	O
human	O
SARS	O
-	O
CoV	O
neutralizing	O
antibody	O
against	O
epitope	B-CHED
on	O
S2	O
protein	B-CHED
.	O

The	O
B1	O
also	O
has	O
potent	O
neutralizing	O
activities	O
against	O
infection	O
by	O
pseudovirus	O
expressing	O
SARS	O
-	O
CoV	O
S	O
protein	B-CHED
in	O
vitro	O
.	O

Finally	O
,	O
we	O
found	O
that	O
the	O
B1	O
recognized	O
an	O
epitope	B-CHED
on	O
S2	O
protein	B-CHED
,	O
especially	O
within	O
amino	B-CHED
acids	I-CHED
1023	O
-	O
1189	O
of	O
S2	O
protein	B-CHED
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
effect	O
of	O
a	O
topically	O
applied	O
nuclear	O
factor	O
-	O
kappaB	O
inhibitor	B-CHED
(	O
IkappaB	O
kinase	O
-	O
NF	O
-	O
kappaB	O
essential	O
modulator	O
binding	O
domain	O
[	O
IKK	O
-	O
NBD	O
]	O
peptide	B-CHED
)	O
on	O
gas	O
exchange	O
,	O
lung	O
function	O
,	O
lung	O
fluids	O
,	O
and	O
inflammation	O
in	O
a	O
piglet	O
model	O
of	O
repeated	O
airway	O
lavage	O
that	O
is	O
characterized	O
by	O
surfactant	B-CHED
deficiency	O
,	O
lung	O
edema	O
,	O
and	O
an	O
inflammatory	O
response	O
.	O

By	O
comparing	O
the	O
155	O
survivors	O
with	O
positive	O
SARS	O
-	O
CoV	O
IgG	O
antibody	O
results	O
and	O
D	O
(	O
LCO	B-CHED
)	O
>	O
or	O
=	O
80	O
%	O
predicted	O
with	O
the	O
50	O
patients	O
with	O
negative	O
SARS	O
-	O
CoV	O
IgG	O
results	O
,	O
we	O
found	O
that	O
53	O
patients	O
with	O
positive	O
SARS	O
-	O
CoV	O
IgG	O
results	O
and	O
a	O
lung	O
diffusion	O
abnormality	O
had	O
endured	O
a	O
much	O
longer	O
course	O
of	O
fever	O
and	O
received	O
larger	O
doses	O
of	O
glucocorticoid	B-CHED
,	O
as	O
well	O
as	O
higher	O
ratios	O
of	O
oxygen	B-CHED
inhalation	O
and	O
noninvasive	O
ventilation	O
treatment	O
.	O

D	O
(	O
LCO	B-CHED
)	O
scores	O
might	O
be	O
more	O
sensitive	O
than	O
HRCT	O
when	O
evaluating	O
lung	O
fibrotic	O
changes	O
.	O

TITLE	O
:	O
[	O
Specific	O
antibodies	O
against	O
the	O
nucleocapsid	O
protein	B-CHED
and	O
S1	O
domain	O
of	O
spike	O
glycoprotein	B-CHED
in	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
].	O

ABSTRACT	O
:	O
To	O
explore	O
the	O
laws	O
of	O
the	O
appearance	O
of	O
the	O
specific	O
serum	O
antibodies	O
against	O
the	O
nucleocapsid	O
(	O
N	O
)	O
protein	B-CHED
and	O
the	O
S1	O
domain	O
of	O
spike	O
(	O
S	O
)	O
glycoprotein	B-CHED
in	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
and	O
to	O
evaluate	O
the	O
value	O
of	O
these	O
two	O
proteins	B-CHED
to	O
be	O
used	O
as	O
diagnostic	O
makers	O
for	O
SARS	O
.	O

CONCLUSIONS	O
:	O
The	O
N	O
protein	B-CHED
and	O
S1	O
protein	B-CHED
may	O
be	O
used	O
as	O
antigens	B-CHED
in	O
the	O
development	O
of	O
serological	O
assay	O
for	O
detection	O
of	O
SARS	O
-	O
CoV	O
infection	O
.	O

TITLE	O
:	O
[	O
An	O
immunofluorescence	O
assay	O
for	O
the	O
detection	O
of	O
SARS	O
associated	O
coronavirus	O
antibody	O
based	O
on	O
recombinant	O
nucleocapsid	O
antigen	B-CHED
and	O
its	O
application	O
].	O

Insect	O
Sf9	O
cells	O
were	O
transfected	O
with	O
the	O
recombinant	O
baculovirus	O
expressing	O
SARS	O
nucleocapsid	O
antigen	B-CHED
and	O
then	O
cultured	O
,	O
fixed	O
by	O
acetone	B-CHED
so	O
as	O
to	O
make	O
SARS	O
-	O
specific	O
antigen	B-CHED
.	O

RESULTS	O
:	O
The	O
recombinant	O
SARS	O
-	O
specific	O
antigen	B-CHED
reacted	O
only	O
with	O
SARS	O
positive	O
sera	O
but	O
not	O
with	O
normal	O
sera	O
.	O

Two	O
other	O
drugs	O
,	O
triclosan	B-CHED
and	O
nelfinavir	O
,	O
were	O
about	O
10	O
times	O
less	O
potent	O
.	O

ABSTRACT	O
:	O
The	O
avian	O
coronavirus	O
Infectious	O
bronchitis	O
virus	O
(	O
IBV	O
),	O
like	O
other	O
coronaviruses	O
,	O
expresses	O
several	O
small	O
nonstructural	O
(	O
ns	O
)	O
proteins	B-CHED
in	O
addition	O
to	O
those	O
from	O
gene	O
1	O
(	O
replicase	O
)	O
and	O
the	O
structural	O
proteins	B-CHED
.	O

The	O
3a	O
gene	O
encodes	O
a	O
non	O
-	O
structural	O
viral	O
protein	B-CHED
,	O
which	O
is	O
predicted	O
to	O
be	O
a	O
transmembrane	O
protein	B-CHED
.	O

Finally	O
,	O
brefeldin	B-CHED
A	I-CHED
powerfully	O
blocks	O
the	O
viroporin	O
activity	O
of	O
the	O
E	O
protein	B-CHED
in	O
BHK	O
cells	O
,	O
suggesting	O
that	O
an	O
intact	O
vesicular	O
system	O
is	O
necessary	O
for	O
this	O
coronavirus	O
to	O
permeabilize	O
mammalian	O
cells	O
.	O

Our	O
novel	O
findings	O
thus	O
suggest	O
that	O
the	O
acute	O
SARS	O
-	O
coronavirus	O
infection	O
probably	O
contributes	O
to	O
the	O
initial	O
reduction	O
of	O
DC	O
and	O
T	O
-	O
cell	O
subsets	O
in	O
blood	O
,	O
and	O
that	O
high	O
-	O
dose	O
steroid	B-CHED
administration	O
may	O
subsequently	O
exacerbate	O
and	O
prolong	O
low	O
expression	O
of	O
the	O
cell	O
subsets	O
.	O

ABSTRACT	O
:	O
The	O
dynamics	O
of	O
bovine	O
respiratory	O
syncytial	O
virus	O
(	O
BRSV	O
),	O
bovine	O
parainfluenza	O
virus	O
3	O
(	O
PIV	O
-	O
3	O
),	O
bovine	O
corona	B-CHED
virus	O
(	O
BCoV	O
)	O
and	O
bovine	O
viral	O
diarrhoea	O
virus	O
(	O
BVDV	O
)	O
infections	O
were	O
studied	O
in	O
118	O
dairy	O
herds	O
in	O
south	O
western	O
Sweden	O
.	O

However	O
,	O
there	O
was	O
an	O
obvious	O
improvement	O
in	O
total	O
lung	O
capacity	O
(	O
TLC	O
)	O
and	O
diffusing	O
capacity	O
of	O
the	O
lung	O
for	O
carbon	B-CHED
monoxide	I-CHED
(	O
DLCO	O
)	O
with	O
the	O
elapse	O
of	O
time	O
,	O
and	O
also	O
a	O
significant	O
difference	O
was	O
found	O
between	O
the	O
later	O
stage	O
and	O
the	O
earlier	O
stage	O
.	O

TITLE	O
:	O
Discovery	O
of	O
potent	O
anilide	B-CHED
inhibitors	B-CHED
against	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
3CL	O
protease	O
.	O

ABSTRACT	O
:	O
A	O
diversified	O
library	O
of	O
peptide	B-CHED
anilides	O
was	O
prepared	O
,	O
and	O
their	O
inhibition	O
activities	O
against	O
the	O
SARS	O
-	O
CoV	O
3CL	O
protease	O
were	O
examined	O
by	O
a	O
fluorogenic	O
tetradecapeptide	O
substrate	O
.	O

The	O
antibody	O
responses	O
to	O
the	O
N	O
protein	B-CHED
fragments	O
in	O
mammalian	O
sera	O
revealed	O
that	O
3	O
regions	O
of	O
the	O
N	O
protein	B-CHED
are	O
strong	O
antigenic	O
domains	O
.	O

The	O
antigenic	O
structures	O
identified	O
for	O
the	O
SARS	O
-	O
CoV	O
N	O
protein	B-CHED
,	O
the	O
epitope	B-CHED
-	O
specific	O
mAbs	O
,	O
and	O
the	O
serum	O
antibody	O
profile	O
in	O
SARS	O
patients	O
have	O
potential	O
use	O
in	O
the	O
clinical	O
diagnosis	O
and	O
understanding	O
of	O
the	O
protective	O
immunity	O
to	O
SARS	O
-	O
CoV	O
.	O
RESULTS	O
:	O
We	O
identified	O
5	O
conformational	O
and	O
3	O
linear	O
epitopes	O
within	O
the	O
entire	O
N	O
protein	B-CHED
;	O
3	O
conformational	O
and	O
3	O
linear	O
epitopes	O
were	O
immunodominant	O
.	O

Mutations	O
in	O
the	O
membrane	O
protein	B-CHED
and	O
a	O
deletion	O
in	O
ORF	O
6	O
--	O
8	O
were	O
already	O
observed	O
in	O
passage	O
0	O
,	O
suggesting	O
these	O
amino	B-CHED
acid	I-CHED
substitutions	O
are	O
important	O
in	O
the	O
adaptation	O
of	O
the	O
virus	O
isolate	O
in	O
primate	O
cell	O
culture	O
.	O

TITLE	O
:	O
Structural	O
analysis	O
of	O
inhibition	O
mechanisms	O
of	O
aurintricarboxylic	O
acid	O
on	O
SARS	O
-	O
CoV	O
polymerase	O
and	O
other	O
proteins	B-CHED
.	O

Our	O
model	O
,	O
supported	O
by	O
significant	O
biochemical	O
evidence	O
,	O
suggested	O
receptor	O
-	O
binding	O
residues	O
were	O
concentrated	O
in	O
two	O
segments	O
of	O
S1	O
protein	B-CHED
.	O

ABSTRACT	O
:	O
Because	O
phosphorylation	O
of	O
the	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
nucleocapsid	O
protein	B-CHED
(	O
N	O
)	O
may	O
regulate	O
its	O
multiple	O
roles	O
in	O
viral	O
replication	O
,	O
the	O
dynamics	O
of	O
N	O
phosphorylation	O
were	O
examined	O
.	O

32P	O
-	O
orthophosphate	B-CHED
labeling	O
and	O
Western	O
blot	O
analyses	O
confirmed	O
that	O
N	O
was	O
the	O
only	O
viral	O
protein	B-CHED
that	O
was	O
phosphorylated	O
.	O

We	O
applied	O
the	O
EVW	O
in	O
five	O
sheep	O
before	O
and	O
after	O
a	O
bronchial	O
challenge	O
and	O
an	O
oleic	B-CHED
acid	I-CHED
(	O
OA	O
)	O
acute	O
lung	O
injury	O
model	O
.	O

Correlations	O
were	O
found	O
between	O
the	O
arterial	O
partial	O
pressure	O
of	O
oxygen	B-CHED
(	O
PaO2	O
)	O
and	O
the	O
levels	O
and	O
frequency	O
-	O
dependent	O
features	O
of	O
R	O
and	O
E	O
that	O
are	O
indicative	O
of	O
mechanical	O
heterogeneity	O
and	O
tissue	O
disease	O
.	O

A	O
soluble	O
form	O
of	O
ACE2	O
,	O
lacking	O
its	O
cytosolic	O
and	O
transmembrane	O
domains	O
,	O
has	O
been	O
shown	O
to	O
block	O
binding	O
of	O
the	O
SARS	O
-	O
CoV	O
spike	O
protein	B-CHED
to	O
its	O
receptor	O
.	O

By	O
using	O
inhibitors	B-CHED
with	O
differing	O
potency	O
toward	O
different	O
members	O
of	O
the	O
ADAM	O
(	O
a	O
disintegrin	O
and	O
metalloproteinase	O
)	O
family	O
of	O
proteases	O
,	O
we	O
identified	O
ADAM17	O
as	O
a	O
candidate	O
mediator	O
of	O
stimulated	O
ACE2	O
shedding	O
.	O

Genetic	O
programs	O
regulating	O
the	O
synthesis	O
of	O
the	O
surfactant	B-CHED
proteins	B-CHED
and	O
lipids	B-CHED
required	O
for	O
the	O
production	O
and	O
function	O
of	O
pulmonary	O
surfactant	B-CHED
are	O
highly	O
conserved	O
across	O
vertebrates	O
,	O
and	O
include	O
proteins	B-CHED
that	O
regulate	O
the	O
synthesis	O
and	O
packaging	O
of	O
pulmonary	O
surfactant	B-CHED
proteins	B-CHED
and	O
lipids	B-CHED
.	O

A	O
porcine	O
surfactant	B-CHED
(	O
poractant	O
alfa	O
)	O
acts	O
more	O
rapidly	O
than	O
a	O
bovine	O
preparation	O
(	O
beractant	O
)	O
in	O
infants	O
with	O
moderate	O
to	O
severe	O
RDS	O
.	O

Chronic	O
lung	O
disease	O
remains	O
a	O
problem	O
but	O
it	O
is	O
hoped	O
that	O
early	O
treatment	O
with	O
surfactant	B-CHED
combined	O
with	O
extubation	O
to	O
continuous	O
positive	O
airway	O
pressure	O
will	O
reduce	O
this	O
complication	O
of	O
prematurity	O
.	O

TNF	O
-	O
alpha	O
,	O
IL	O
-	O
1beta	O
,	O
IL	O
-	O
6	O
and	O
neutrophil	O
activator	O
production	O
by	O
the	O
isolated	O
perfused	O
liver	O
,	O
in	O
response	O
to	O
a	O
'	O
second	O
hit	O
'	O
of	O
portal	O
LPS	B-CHED
,	O
does	O
not	O
appear	O
to	O
be	O
enhanced	O
during	O
AP	O
.	O

The	O
SARS	O
hyperimmune	O
globulins	O
prepared	O
were	O
subsequently	O
approved	O
for	O
clinical	O
evaluation	O
by	O
the	O
Chinese	O
National	O
Institute	O
for	O
the	O
Control	O
of	O
Pharmaceutical	B-CHED
&	O
Biological	O
Products	O
.	O

On	O
immunohistochemistry	O
,	O
the	O
tumor	O
showed	O
positive	O
staining	O
for	O
vimentin	O
,	O
whereas	O
antidesmin	O
antibodies	O
and	O
S	O
-	O
100	O
protein	B-CHED
were	O
negative	O
.	O

Notably	O
,	O
the	O
cellular	O
receptor	O
for	O
the	O
virus	O
,	O
angiotensin	B-CHED
-	O
converting	O
enzyme	O
2	O
was	O
expressed	O
at	O
similar	O
levels	O
on	O
Vero	O
E6	O
and	O
CaCo	O
-	O
2	O
cells	O
,	O
but	O
at	O
undetectable	O
levels	O
on	O
OL	O
and	O
C6	O
cells	O
.	O

S	O
-	O
peptide	B-CHED
showed	O
neutralizing	O
antibody	O
titers	O
of	O
<	O
1	O
:	O
20	O
-	O
1	O
:	O
160	O
.	O

The	O
sensitivity	O
of	O
all	O
primers	O
was	O
between	O
0	O
.	O
0004	O
and	O
0	O
.	O
04	O
PFU	B-CHED
with	O
viral	O
cell	O
lysate	O
and	O
between	O
0	O
.	O
004	O
and	O
0	O
.	O
4	O
PFU	B-CHED
in	O
spiked	O
stool	O
specimen	O
per	O
PCR	O
assay	O
.	O

With	O
conventional	O
PCR	O
,	O
analysis	O
was	O
performed	O
using	O
agarose	B-CHED
gel	O
electrophoresis	O
and	O
multiple	O
nonspecific	O
bands	O
were	O
observed	O
.	O

The	O
former	O
was	O
less	O
laborious	O
with	O
shorter	O
time	O
for	O
completion	O
and	O
can	O
easily	O
be	O
adapted	O
to	O
an	O
automated	O
system	O
such	O
as	O
the	O
MagNa	O
Pure	O
-	O
LC	O
,	O
which	O
can	O
extract	O
nucleic	B-CHED
acid	I-CHED
from	O
clinical	O
samples	O
and	O
load	O
it	O
into	O
the	O
sample	O
capillaries	O
of	O
the	O
LightCycler	O
.	O

ABSTRACT	O
:	O
The	O
immunodominant	O
CD8	O
+	O
T	O
-	O
cell	O
epitope	B-CHED
of	O
a	O
highly	O
neurovirulent	O
strain	O
of	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
),	O
JHM	O
,	O
is	O
thought	O
to	O
be	O
essential	O
for	O
protection	O
against	O
virus	O
persistence	O
within	O
the	O
central	O
nervous	O
system	O
.	O

To	O
test	O
whether	O
abrogation	O
of	O
this	O
H	O
-	O
2Db	O
-	O
restricted	O
epitope	B-CHED
,	O
located	O
within	O
the	O
spike	O
glycoprotein	B-CHED
at	O
residues	O
S510	O
to	O
518	O
(	O
S510	O
),	O
resulted	O
in	O
delayed	O
virus	O
clearance	O
and	O
/	O
or	O
virus	O
persistence	O
we	O
selected	O
isogenic	O
recombinants	O
which	O
express	O
either	O
the	O
wild	O
-	O
type	O
JHM	O
spike	O
protein	B-CHED
(	O
RJHM	B-CHED
)	O
or	O
spike	O
containing	O
the	O
N514S	O
mutation	O
(	O
RJHM	B-CHED
(	O
N514S	O
)),	O
which	O
abrogates	O
the	O
response	O
to	O
S510	O
.	O

All	O
patients	O
had	O
nasopharyngeal	O
and	O
throat	O
swabs	O
taken	O
for	O
respiratory	O
virus	O
antigen	B-CHED
detection	O
,	O
culture	O
and	O
RT	O
-	O
PCR	O
.	O

Cirrhotic	O
patients	O
with	O
SAH	B-CHED
showed	O
a	O
significantly	O
higher	O
hypocapnia	O
by	O
comparison	O
with	O
others	O
(	O
31	O
.	O
2	O
+/-	O

HPS	B-CHED
was	O
confirmed	O
in	O
8	O
patients	O
(	O
16	O
%).	O

TITLE	O
:	O
Adverse	O
effects	O
of	O
ribavirin	B-CHED
and	O
outcome	O
in	O
severe	O
acute	O
respiratory	O
syndrome	O
:	O
experience	O
in	O
two	O
medical	O
centers	O
.	O

ABSTRACT	O
:	O
To	O
assess	O
the	O
effect	O
of	O
ribavirin	B-CHED
-	O
induced	O
anemia	O
on	O
the	O
outcome	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
).	O

On	O
multivariate	O
analysis	O
,	O
hemoglobin	B-CHED
level	O
was	O
an	O
independent	O
prognostic	O
correlate	O
of	O
hypoxemia	O
or	O
mortality	O
(	O
odds	O
ratio	O
,	O
2	O
.	O
0	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1	O
.	O
1	O
to	O
3	O
.	O
8	O
;	O
p	O
=	O
0	O
.	O
03	O
).	O

The	O
hemoglobin	B-CHED
began	O
decreasing	O
in	O
two	O
thirds	O
of	O
SARS	O
patients	O
(	O
32	O
of	O
44	O
patients	O
;	O
73	O
%)	O
who	O
were	O
receiving	O
ribavirin	B-CHED
3	O
days	O
after	O
therapy	O
with	O
the	O
antiviral	B-CHED
drug	I-CHED
was	O
started	O
.	O

Hypoxemia	O
developed	O
in	O
one	O
third	O
of	O
SARS	O
patients	O
(	O
17	O
of	O
44	O
patients	O
;	O
39	O
%)	O
who	O
were	O
receiving	O
ribavirin	B-CHED
,	O
all	O
of	O
whom	O
were	O
anemic	O
.	O

When	O
both	O
the	O
liver	O
and	O
lung	O
were	O
perfused	O
,	O
endotoxin	O
caused	O
marked	O
hypoxemia	O
,	O
large	O
increases	O
in	O
perfusate	O
TNF	O
-	O
alpha	O
,	O
IL	O
-	O
6	O
,	O
and	O
8	B-CHED
-	I-CHED
isoprostane	I-CHED
concentrations	O
,	O
and	O
severe	O
lung	O
edema	O
.	O

TITLE	O
:	O
A	O
crucial	O
role	O
of	O
angiotensin	B-CHED
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
in	O
SARS	O
coronavirus	O
-	O
induced	O
lung	O
injury	O
.	O

Fresh	O
fecal	O
specimens	O
were	O
screened	O
for	O
bacteria	O
and	O
bacterial	O
toxins	B-CHED
via	O
bacteriologic	O
culture	O
and	O
ELISA	O
,	O
parvovirus	O
via	O
ELISA	O
,	O
canine	O
coronavirus	O
via	O
nested	O
polymerase	O
chain	O
reaction	O
assay	O
,	O
protozoal	O
cysts	O
and	O
oocysts	O
via	O
a	O
direct	O
fluorescent	O
antibody	O
technique	O
,	O
and	O
parasite	O
ova	O
and	O
larvae	O
via	O
microscopic	O
examination	O
of	O
direct	O
wet	O
mounts	O
and	O
zinc	B-CHED
sulfate	I-CHED
centrifugation	O
flotation	O
.	O

ABSTRACT	O
:	O
Angiotensin	B-CHED
-	O
converting	O
enzyme	O
-	O
2	O
(	O
ACE2	O
)	O
may	O
play	O
an	O
important	O
role	O
in	O
cardiorenal	O
disease	O
and	O
it	O
has	O
also	O
been	O
implicated	O
as	O
a	O
cellular	O
receptor	O
for	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
virus	O
.	O

Although	O
both	O
His505	O
and	O
His345	O
are	O
involved	O
in	O
catalysis	O
,	O
it	O
is	O
His345	O
and	O
not	O
His505	O
that	O
acts	O
as	O
the	O
hydrogen	B-CHED
bond	O
donor	B-CHED
/	O
acceptor	B-CHED
in	O
the	O
formation	O
of	O
the	O
tetrahedral	O
peptide	B-CHED
intermediate	O
.	O

BALB	O
/	O
c	O
mice	O
were	O
immunized	O
with	O
the	O
purified	O
recombinant	O
fusion	O
protein	B-CHED
.	O

These	O
results	O
are	O
consistent	O
with	O
models	O
in	O
which	O
gammadelta	O
T	O
cells	O
mediate	O
demyelination	O
using	O
the	O
same	O
effector	B-CHED
cytokine	O
,	O
IFN	O
-	O
gamma	O
,	O
as	O
CD8	O
T	O
cells	O
and	O
do	O
so	O
without	O
a	O
requirement	O
for	O
signaling	O
through	O
the	O
TCR	O
.	O

However	O
,	O
the	O
MHV	O
receptor	O
is	O
not	O
present	O
in	O
lipid	B-CHED
rafts	O
,	O
and	O
anchoring	O
of	O
the	O
MHV	O
receptor	O
to	O
lipid	B-CHED
rafts	O
did	O
not	O
enhance	O
MHV	O
infection	O
;	O
thus	O
,	O
the	O
mechanism	O
of	O
lipid	B-CHED
rafts	O
involvement	O
is	O
not	O
clear	O
.	O

In	O
this	O
study	O
,	O
we	O
defined	O
the	O
mechanism	O
and	O
extent	O
of	O
lipid	B-CHED
raft	O
involvement	O
in	O
MHV	O
replication	O
.	O

Our	O
results	O
showed	O
that	O
the	O
expression	O
of	O
3a	O
up	O
-	O
regulates	O
the	O
mRNA	B-CHED
levels	O
of	O
all	O
three	O
subunits	O
,	O
Aalpha	O
,	O
Bbeta	O
,	O
and	O
gamma	O
,	O
of	O
fibrinogen	O
.	O

TITLE	O
:	O
Detection	O
of	O
the	O
nucleocapsid	O
protein	B-CHED
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
in	O
serum	O
:	O
comparison	O
with	O
results	O
of	O
other	O
viral	O
markers	O
.	O

The	O
detection	O
rate	O
of	O
the	O
N	O
protein	B-CHED
during	O
days	O
11	O
-	O
15	O
of	O
the	O
disease	O
was	O
still	O
significantly	O
higher	O
than	O
those	O
of	O
anti	O
-	O
SARS	O
-	O
CoV	O
IgG	O
and	O
SARS	O
-	O
CoV	O
RNA	O
.	O

The	O
data	O
demonstrated	O
that	O
detection	O
of	O
the	O
N	O
protein	B-CHED
with	O
the	O
capture	O
ECLIA	O
appears	O
to	O
be	O
more	O
useful	O
than	O
detection	O
of	O
other	O
viral	O
makers	O
for	O
rapid	O
diagnosis	O
of	O
SARS	O
in	O
patients	O
.	O

RICT	O
based	O
on	O
an	O
EIA	O
using	O
the	O
rSN122	O
/	O
rSN21	O
-	O
2	O
pair	O
is	O
a	O
sensitive	O
,	O
specific	O
,	O
and	O
reliable	O
rapid	O
assay	O
for	O
detecting	O
N	O
-	O
Ag	O
in	O
SARS	O
-	O
CoV	O
treated	O
with	O
either	O
heat	O
or	O
Triton	B-CHED
X	I-CHED
-	I-CHED
100	I-CHED
.	O

TITLE	O
:	O
Yeast	O
expression	O
and	O
characterization	O
of	O
SARS	O
-	O
CoV	O
N	O
protein	B-CHED
.	O

SDS	B-CHED
-	O
PAGE	O
and	O
Western	O
blot	O
showed	O
that	O
the	O
N	O
protein	B-CHED
was	O
expressed	O
at	O
a	O
level	O
of	O
3mg	O
/	O
ml	O
of	O
culture	O
medium	O
.	O

ABSTRACT	O
:	O
We	O
report	O
the	O
case	O
of	O
a	O
65	O
-	O
year	O
-	O
old	O
male	O
patient	O
with	O
acute	O
myelogenous	O
leukemia	O
who	O
developed	O
severe	O
respiratory	O
failure	O
after	O
receiving	O
cytarabine	B-CHED
treatment	O
.	O

Comparative	O
sequence	O
analysis	O
of	O
the	O
predicted	O
FCoV	O
proteins	B-CHED
identified	O
16	O
replicase	O
proteins	B-CHED
(	O
nsp1	O
-	O
nsp16	O
)	O
and	O
four	O
structural	O
proteins	B-CHED
(	O
spike	O
,	O
membrane	O
,	O
envelope	O
and	O
nucleocapsid	O
).	O

TITLE	O
:	O
Phosphorylation	O
and	O
subcellular	O
localization	O
of	O
transmissible	O
gastroenteritis	O
virus	O
nucleocapsid	O
protein	B-CHED
in	O
infected	O
cells	O
.	O

The	O
first	O
vaccine	O
tested	O
in	O
clinical	O
trial	O
is	O
made	O
from	O
the	O
inactivated	O
form	O
of	O
SARS	O
-	O
CoV	O
.	O
Several	O
live	O
attenuated	O
,	O
genetically	O
engineered	O
or	O
vector	O
vaccines	O
encoding	O
the	O
SARS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
protein	B-CHED
have	O
been	O
in	O
pre	O
-	O
clinical	O
studies	O
.	O

However	O
,	O
caution	O
should	O
be	O
taken	O
with	O
the	O
safety	O
of	O
whole	O
virus	O
or	O
full	O
-	O
length	O
S	O
protein	B-CHED
-	O
based	O
immunogens	O
in	O
humans	O
because	O
they	O
may	O
induce	O
harmful	O
immune	O
or	O
inflammatory	O
responses	O
.	O

CONCLUSIONS	O
:	O
Nucleic	B-CHED
acid	I-CHED
of	O
SARS	O
-	O
CoV	O
can	O
be	O
excreted	O
through	O
the	O
stool	O
of	O
patients	O
into	O
sewage	O
system	O
,	O
and	O
the	O
possibility	O
of	O
SARS	O
-	O
CoV	O
transmitting	O
through	O
digestive	O
system	O
cannot	O
be	O
excluded	O
.	O

Among	O
78	O
patients	O
,	O
66	O
patients	O
(	O
84	O
.	O
6	O
%)	O
received	O
corticosteroid	B-CHED
.	O

TITLE	O
:	O
Retinal	B-CHED
degeneration	O
in	O
experimental	O
coronavirus	O
retinopathy	O
(	O
ECOR	O
)	O
is	O
associated	O
with	O
increased	O
TNF	O
-	O
alpha	O
,	O
soluble	O
TNFR2	O
and	O
altered	O
TNF	O
-	O
alpha	O
signaling	O
.	O

Following	O
coronavirus	O
injection	O
,	O
TNF	O
-	O
alpha	O
mRNA	B-CHED
was	O
detected	O
at	O
higher	O
levels	O
within	O
the	O
retinas	O
,	O
and	O
concentrations	O
of	O
TNF	O
-	O
alpha	O
(	O
p	O
<	O
0	O
.	O
005	O
)	O
and	O
sTNFR1	O
(	O
p	O
<	O
0	O
.	O
0005	O
)	O
proteins	B-CHED
were	O
increased	O
within	O
the	O
sera	O
of	O
BALB	O
/	O
c	O
but	O
not	O
CD	O
-	O
1	O
mice	O
.	O

Little	O
information	O
is	O
available	O
on	O
SARS	O
-	O
CoV	O
papain	O
-	O
like	O
protease	O
2	O
(	O
PLP2	O
),	O
and	O
development	O
of	O
inhibitors	B-CHED
against	O
PLP2	O
is	O
attractive	O
for	O
antiviral	B-CHED
therapy	O
.	O

In	O
this	O
study	O
,	O
it	O
was	O
shown	O
that	O
3b	O
protein	B-CHED
was	O
predominately	O
localized	O
to	O
nucleus	B-CHED
with	O
EGFP	O
tag	O
at	O
its	O
N	O
-	O
or	O
C	O
-	O
terminus	O
.	O

With	O
construction	O
of	O
serial	O
truncated	O
mutants	O
of	O
3b	O
,	O
a	O
region	O
(	O
residues	O
134	O
-	O
154	O
aa	O
)	O
responsible	O
for	O
nucleolar	O
localization	O
was	O
determinated	O
in	O
3b	O
protein	B-CHED
.	O

Viral	O
antigen	B-CHED
localized	O
primarily	O
to	O
infected	O
alveolar	O
macrophages	O
and	O
type	O
-	O
1	O
pneumocytes	O
by	O
immunohistochemistry	O
.	O

In	O
this	O
study	O
,	O
infection	O
kinetics	O
(	O
titres	O
and	O
antigen	B-CHED
expression	O
)	O
of	O
FIPV	O
79	O
-	O
1146	O
,	O
and	O
FECV	O
79	O
-	O
1683	O
,	O
were	O
determined	O
in	O
peripheral	O
blood	O
monocytes	O
from	O
3	O
donor	B-CHED
cats	O
and	O
compared	O
to	O
those	O
in	O
Crandell	O
feline	O
kidney	O
(	O
CrFK	O
)	O
cells	O
.	O

In	O
this	O
study	O
,	O
we	O
employed	O
an	O
in	O
vitro	O
GST	O
pull	O
-	O
down	O
assay	O
to	O
investigate	O
the	O
interaction	O
between	O
the	O
membrane	O
(	O
M	O
)	O
and	O
the	O
nucleocapsid	O
(	O
N	O
)	O
proteins	B-CHED
.	O

The	O
recent	O
solution	O
of	O
the	O
structure	O
of	O
ACE2	O
,	O
and	O
ACE	O
,	O
has	O
provided	O
new	O
insight	O
into	O
the	O
substrate	O
and	O
inhibitor	B-CHED
profiles	O
of	O
these	O
two	O
key	O
regulators	O
of	O
the	O
RAS	B-CHED
.	O

Lung	O
findings	O
were	O
scored	O
according	O
to	O
extent	O
and	O
then	O
grouped	O
in	O
three	O
categories	O
(	O
ground	O
-	O
glass	O
opacity	O
,	O
interstitial	O
opacity	O
,	O
and	O
air	B-CHED
trapping	O
)	O
for	O
analysis	O
.	O

At	O
the	O
second	O
examination	O
,	O
scores	O
for	O
ground	O
-	O
glass	O
opacity	O
and	O
interstitial	O
opacity	O
correlated	O
with	O
peak	O
lactate	B-CHED
dehydrogenase	O
level	O
;	O
that	O
for	O
air	B-CHED
trapping	O
,	O
with	O
age	O
and	O
peak	O
C	O
-	O
reactive	O
protein	B-CHED
level	O
.	O

The	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
(	O
HPA	B-CHED
)	O
axis	O
dysfunction	O
of	O
the	O
majority	O
resolved	O
within	O
a	O
year	O
.	O

Here	O
,	O
we	O
have	O
applied	O
serine	B-CHED
-	O
scanning	O
mutagenesis	O
to	O
the	O
C	O
-	O
terminal	O
-	O
most	O
heptad	O
-	O
repeat	O
region	O
in	O
the	O
SARS	O
-	O
CoV	O
S	O
glycoprotein	B-CHED
to	O
investigate	O
the	O
functional	O
role	O
of	O
this	O
region	O
in	O
membrane	O
fusion	O
.	O

This	O
review	O
therefore	O
summarizes	O
the	O
current	O
pathophysiological	O
concepts	O
underlying	O
the	O
evolution	O
of	O
acute	O
hypoxemic	O
respiratory	O
failure	O
and	O
focuses	O
on	O
:	O
(	O
1	O
)	O
possible	O
reasons	O
for	O
the	O
development	O
of	O
ALI	O
/	O
ARDS	O
;	O
(	O
2	O
)	O
cellular	O
and	O
humoral	O
mediator	O
responses	O
leading	O
to	O
a	O
sustained	O
and	O
self	O
-	O
perpetuating	O
inflammation	O
of	O
the	O
lung	O
;	O
(	O
3	O
)	O
consequences	O
with	O
regard	O
to	O
fluid	O
balance	B-CHED
,	O
pulmonary	O
perfusion	O
,	O
ventilation	O
,	O
and	O
efficiency	O
of	O
gas	O
exchange	O
;	O
and	O
(	O
4	O
)	O
mechanisms	O
underlying	O
the	O
aggravating	O
complications	O
commonly	O
seen	O
in	O
ARDS	O
,	O
especially	O
ventilator	O
-	O
associated	O
lung	O
injury	O
,	O
ventilator	O
-	O
associated	O
pneumonia	O
,	O
and	O
lung	O
fibrosis	O
.	O

ABSTRACT	O
:	O
A	O
23	O
-	O
year	O
-	O
old	O
man	B-CHED
was	O
admitted	O
to	O
the	O
intensive	O
care	O
unit	O
for	O
respiratory	O
failure	O
,	O
global	O
lower	O
and	O
upper	O
limb	O
palsy	O
,	O
and	O
higher	O
cognitive	O
function	O
deterioration	O
.	O

rNH	O
and	O
rEH	O
proteins	B-CHED
differed	O
markedly	O
with	O
respect	O
to	O
expression	O
levels	O
,	O
cell	O
death	O
kinetics	O
and	O
subcellular	O
localizations	O
that	O
led	O
to	O
different	O
extraction	O
and	O
purification	O
schemes	O
.	O

SARS	O
-	O
CoV	O
virus	O
is	O
able	O
to	O
induce	O
both	O
IFN	O
-	O
alpha	O
and	O
-	O
gamma	O
mRNA	B-CHED
accumulation	O
and	O
protein	B-CHED
release	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
MOI	O
10	O
being	O
the	O
most	O
effective	O
.	O

Neutrophil	O
elastase	O
activities	O
in	O
the	O
bronchoalveolar	O
lavage	O
fluid	O
,	O
serum	O
,	O
and	O
lung	O
tissue	O
were	O
all	O
significantly	O
lower	O
in	O
the	O
sivelestat	O
group	O
than	O
in	O
the	O
lipopolysaccharide	B-CHED
group	O
(	O
p	O
<	O
.	O
05	O
).	O

Immunization	O
of	O
mice	O
with	O
each	O
of	O
the	O
four	O
antigenic	O
epitope	B-CHED
-	O
fused	O
proteins	B-CHED
revealed	O
that	O
all	O
four	O
proteins	B-CHED
could	O
elicit	O
spike	O
protein	B-CHED
specific	O
antisera	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
immune	O
responses	O
against	O
the	O
S2	O
subunit	O
in	O
BALB	O
/	O
c	O
mice	O
,	O
which	O
were	O
vaccinated	O
either	O
with	O
plasmid	O
DNA	O
encoding	O
the	O
S2	O
domain	O
(	O
residues	O
681	O
-	O
1120	O
),	O
the	O
recombinant	O
S2	O
fragment	O
(	O
residues	O
681	O
-	O
980	O
)	O
in	O
incomplete	O
Freund	O
'	O
s	O
adjuvant	B-CHED
,	O
or	O
with	O
inactivated	O
SARS	O
-	O
CoV	O
.	O
The	O
increased	O
number	O
of	O
specific	O
cytotoxic	O
cells	O
(	O
CTLs	O
)	O
and	O
the	O
high	O
titer	O
of	O
specific	O
antibody	O
showed	O
stimulation	O
of	O
both	O
arms	O
of	O
the	O
immune	O
system	O
in	O
these	O
groups	O
.	O

In	O
this	O
study	O
,	O
a	O
secreted	O
recombinant	O
expression	O
plasmid	O
,	O
pVAX	O
-	O
S1	O
,	O
encoding	O
the	O
partial	O
S	O
protein	B-CHED
with	O
a	O
signal	O
peptide	B-CHED
,	O
was	O
constructed	O
and	O
used	O
to	O
immunize	O
BALB	O
/	O
c	O
mice	O
through	O
electroporation	O
.	O

ABSTRACT	O
:	O
The	O
chemokines	O
keratinocyte	O
-	O
Derived	O
Cytokine	O
(	O
KC	O
)	O
and	O
macrophage	O
inflammatory	O
protein	B-CHED
(	O
MIP	O
)-	O
2	O
,	O
murine	O
equivalents	O
of	O
human	O
interleukin	O
8	O
,	O
have	O
been	O
implicated	O
in	O
remote	O
injury	O
after	O
acute	O
hind	O
limb	O
ischemia	O
/	O
reperfusion	O
(	O
I	O
/	O
R	O
).	O

The	O
role	O
of	O
these	O
chemokines	O
during	O
reperfusion	O
may	O
be	O
further	O
investigated	O
by	O
local	O
or	O
oral	O
administration	O
of	O
chemokines	O
or	O
chemokine	O
receptor	O
antagonists	B-CHED
.	O

TITLE	O
:	O
The	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
nucleocapsid	O
protein	B-CHED
is	O
phosphorylated	O
and	O
localizes	O
in	O
the	O
cytoplasm	O
by	O
14	O
-	O
3	O
-	O
3	O
-	O
mediated	O
translocation	O
.	O

TITLE	O
:	O
Intracellular	O
localization	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
nucleocapsid	O
protein	B-CHED
:	O
absence	O
of	O
nucleolar	O
accumulation	O
during	O
infection	O
and	O
after	O
expression	O
as	O
a	O
recombinant	O
protein	B-CHED
in	O
vero	O
cells	O
.	O

Laminar	O
air	B-CHED
flow	O
was	O
from	O
the	O
clean	O
areas	O
to	O
the	O
less	O
clean	O
areas	O
.	O

Diagnosing	O
the	O
disease	O
effectively	O
and	O
accurately	O
at	O
early	O
stage	O
is	O
essential	O
for	O
preventing	O
the	O
disease	O
transmission	O
and	O
performing	O
antiviral	B-CHED
treatment	O
.	O

We	O
report	O
,	O
however	O
,	O
that	O
chloroquine	B-CHED
has	O
strong	O
antiviral	B-CHED
effects	O
on	O
SARS	O
-	O
CoV	O
infection	O
of	O
primate	O
cells	O
.	O

ABSTRACT	O
:	O
The	O
3C	O
-	O
like	O
protease	O
(	O
3CLpro	O
)	O
of	O
SARS	O
-	O
coronavirus	O
mediates	O
the	O
proteolytic	O
processing	O
of	O
replicase	O
polypeptides	B-CHED
1a	O
and	O
1ab	O
into	O
functional	O
proteins	B-CHED
,	O
becoming	O
an	O
important	O
target	O
for	O
the	O
drug	O
development	O
.	O

ABSTRACT	O
:	O
Development	O
of	O
therapeutic	O
agents	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
viral	O
infection	O
using	O
short	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
inhibitors	B-CHED
exemplifies	O
a	O
powerful	O
new	O
means	O
to	O
combat	B-CHED
emerging	O
infectious	O
diseases	O
.	O

TITLE	O
:	O
Pregnancy	O
outcome	O
after	O
exposure	O
to	O
injectable	O
ribavirin	B-CHED
during	O
embryogenesis	O
.	O

ABSTRACT	O
:	O
We	O
describe	O
normal	O
pregnancy	O
outcome	O
in	O
a	O
case	O
of	O
first	O
trimester	O
exposure	O
to	O
injectable	O
ribavirin	B-CHED
in	O
a	O
36	O
-	O
year	O
-	O
old	O
pregnant	O
woman	O
who	O
received	O
three	O
intramuscular	O
injections	O
of	O
ribavirin	B-CHED
for	O
suspected	O
SARS	O
.	O

Compared	O
to	O
the	O
healthy	O
control	O
or	O
the	O
convalescent	O
case	O
,	O
plenty	O
of	O
pro	B-CHED
-	O
inflammatory	O
cytokines	O
such	O
as	O
IL	O
-	O
1	O
,	O
TNF	O
-	O
alpha	O
,	O
IL	O
-	O
8	O
,	O
and	O
MAPK	O
signaling	O
pathway	O
were	O
significantly	O
upregulated	O
in	O
the	O
acute	O
severe	O
case	O
.	O

A	O
structure	O
-	O
assisted	O
optimization	O
program	O
has	O
yielded	O
compounds	O
with	O
fast	O
in	O
vitro	O
inactivation	O
of	O
multiple	O
CoV	O
M	O
(	O
pro	B-CHED
)	O
s	O
,	O
potent	O
antiviral	B-CHED
activity	O
,	O
and	O
extremely	O
low	O
cellular	O
toxicity	O
in	O
cell	O
-	O
based	O
assays	O
.	O

In	O
this	O
paper	O
,	O
we	O
review	O
the	O
current	O
status	O
of	O
the	O
main	O
technologies	O
used	O
to	O
produce	O
monoclonal	O
antibodies	O
(	O
mAbs	O
)	O
from	O
the	O
B	O
cells	O
of	O
antigen	B-CHED
-	O
sensitized	O
animals	O
.	O

One	O
hundred	O
microL	O
10	O
(	O
6	O
)	O
TCID50	O
/	O
mL	O
SARS	O
-	O
CoV	O
,	O
100	O
microL	O
10	O
(	O
6	O
)	O
PFU	B-CHED
/	O
mL	O
recombinant	O
baculovirus	O
expressing	O
hamster	O
'	O
s	O
prion	O
protein	B-CHED
(	O
haPrP	O
)	O
protein	B-CHED
and	O
roughly	O
10	O
(	O
6	O
)	O
E	O
.	O
coli	O
were	O
slowly	O
dropped	O
onto	O
the	O
surfaces	O
of	O
the	O
catalyst	B-CHED
wafers	O
and	O
exposed	O
for	O
5	O
and	O
20	O
min	O
,	O
respectively	O
.	O

In	O
this	O
study	O
,	O
a	O
recombinant	O
protein	B-CHED
(	O
rS268	O
,	O
corresponding	O
to	O
residues	O
268	O
-	O
1255	O
of	O
SARS	O
-	O
CoV	O
S	O
protein	B-CHED
)	O
was	O
expressed	O
in	O
Escherichia	O
coli	O
and	O
was	O
purified	O
to	O
near	O
homogeneity	O
.	O

ABSTRACT	O
:	O
A	O
71	O
-	O
year	O
-	O
old	O
female	O
,	O
who	O
has	O
been	O
treated	O
with	O
steroids	B-CHED
for	O
3	O
weeks	O
,	O
developed	O
a	O
severe	O
pneumonia	O
with	O
septic	O
shock	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

A	O
total	O
of	O
295	O
patients	O
with	O
unexplained	O
respiratory	O
illnesses	O
,	O
admitted	O
to	O
Queen	O
Mary	O
Hospital	O
,	O
Hong	O
Kong	O
SAR	B-CHED
,	O
China	O
,	O
in	O
March	O
to	O
July	O
2003	O
,	O
were	O
evaluated	O
for	O
clinical	O
,	O
radiological	O
,	O
haematological	O
and	O
alanine	B-CHED
transaminase	O
(	O
ALT	B-CHED
)	O
data	O
daily	O
for	O
3	O
days	O
after	O
hospitalisation	O
.	O

We	O
and	O
others	O
previously	O
demonstrated	O
that	O
a	O
major	O
mechanism	O
for	O
neutralizing	O
SARS	O
-	O
CoV	O
was	O
through	O
blocking	O
the	O
interaction	O
between	O
the	O
S	O
glycoprotein	B-CHED
and	O
the	O
cellular	O
receptor	O
angiotensin	B-CHED
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
).	O

Our	O
data	O
have	O
implications	O
for	O
the	O
rational	O
design	O
of	O
vaccine	O
and	O
antiviral	B-CHED
agents	I-CHED
as	O
well	O
as	O
for	O
understanding	O
viral	O
tropism	O
.	O

All	O
disinfectants	B-CHED
tested	O
were	O
shown	O
to	O
be	O
able	O
to	O
reduce	O
the	O
virus	O
load	O
by	O
>	O
3	O
log	O
within	O
5	O
min	O
.	O

The	O
virus	O
is	O
easily	O
inactivated	O
by	O
commonly	O
used	O
disinfectants	B-CHED
.	O

All	O
disinfectants	B-CHED
tested	O
were	O
shown	O
to	O
be	O
able	O
to	O
reduce	O
the	O
virus	O
load	O
by	O
>	O
3	O
log	O
within	O
5	O
min	O
.	O

Our	O
results	O
showed	O
that	O
the	O
SARS	O
-	O
CoV	O
N	O
protein	B-CHED
can	O
significantly	O
activate	O
NF	O
-	O
kappaB	O
only	O
in	O
Vero	O
E6	O
cells	O
,	O
which	O
are	O
susceptible	O
to	O
SARS	O
-	O
CoV	O
infection	O
,	O
but	O
not	O
in	O
Vero	O
or	O
HeLa	O
cells	O
.	O

Our	O
data	O
indicated	O
the	O
possible	O
role	O
of	O
the	O
N	O
protein	B-CHED
in	O
the	O
pathogenesis	O
of	O
SARS	O
.	O

Distribution	O
of	O
substitution	O
categories	O
per	O
codon	O
positions	O
,	O
as	O
well	O
as	O
synonymous	O
and	O
non	O
-	O
synonymous	O
substitutions	O
in	O
coding	O
regions	O
of	O
annotated	O
isolates	O
,	O
was	O
determined	O
,	O
along	O
with	O
amino	B-CHED
acid	I-CHED
(	O
a	O
.	O
a	O
.)	O
property	O
changes	O
.	O

Important	O
questions	O
pertaining	O
to	O
the	O
contribution	O
of	O
HCoV	O
-	O
NL63	O
to	O
ARI	B-CHED
and	O
its	O
impact	O
on	O
public	O
health	O
remain	O
.	O

These	O
results	O
provide	O
further	O
evidence	O
of	O
the	O
importance	O
of	O
HCoV	O
-	O
NL63	O
in	O
ARI	B-CHED
in	O
children	O
.	O

Obstructive	O
apnea	O
is	O
associated	O
with	O
endothelial	O
dysfunction	O
,	O
increased	O
C	O
-	O
reactive	O
protein	B-CHED
and	O
cytokine	O
expression	O
,	O
elevated	O
fibrinogen	O
levels	O
and	O
decreased	O
fibrinolytic	O
activity	O
.	O

When	O
PaCO2	O
falls	O
below	O
the	O
threshold	O
required	O
to	O
stimulate	O
breathing	O
,	O
the	O
central	O
drive	O
to	O
respiratory	O
muscles	O
and	O
air	B-CHED
inflow	O
ceases	O
and	O
central	O
apnea	O
ensues	O
.	O

Apnea	O
,	O
hypoxia	O
,	O
CO2	B-CHED
retention	O
and	O
arousals	O
provoke	O
elevated	O
sympathetic	O
activity	O
,	O
increased	O
afterload	O
and	O
elevated	O
left	O
ventricular	O
transmural	O
pressure	O
,	O
and	O
promote	O
the	O
progression	O
of	O
heart	O
failure	O
.	O

TITLE	O
:	O
Screening	O
and	O
identification	O
of	O
linear	O
B	O
-	O
cell	O
epitopes	O
and	O
entry	O
-	O
blocking	O
peptide	B-CHED
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
associated	O
coronavirus	O
using	O
synthetic	O
overlapping	O
peptide	B-CHED
library	O
.	O

The	O
detection	O
limit	O
was	O
10	O
(	O
0	O
)	O
copies	O
/	O
microL	O
.	O
The	O
results	O
of	O
the	O
asymmetric	O
multiplex	O
nested	O
reverse	O
transcription	O
-	O
PCR	O
were	O
in	O
agreement	O
with	O
the	O
results	O
of	O
the	O
microarray	O
hybridization	O
;	O
no	O
hybridization	O
signal	O
was	O
lost	B-CHED
as	O
happened	O
with	O
applicons	O
from	O
symmetric	O
amplifications	O
.	O

The	O
gene	O
for	O
the	O
SARS	O
-	O
CoV	O
non	O
-	O
structural	O
protein	B-CHED
10	O
,	O
which	O
is	O
located	O
in	O
the	O
open	O
reading	O
frame	O
of	O
pp1a	O
/	O
pp1ab	O
gene	O
,	O
was	O
synthesized	O
and	O
used	O
to	O
screen	O
for	O
the	O
specific	O
cellular	O
gene	O
coding	O
for	O
the	O
protein	B-CHED
interacting	O
with	O
this	O
nsp10	O
protein	B-CHED
in	O
a	O
human	O
embryo	O
lung	O
cDNA	O
library	O
using	O
a	O
yeast	O
trap	O
method	O
.	O

TITLE	O
:	O
Propylene	B-CHED
glycol	I-CHED
-	O
induced	O
lactic	O
acidosis	O
in	O
a	O
patient	O
with	O
normal	O
renal	O
function	O
:	O
a	O
proposed	O
mechanism	O
and	O
monitoring	O
recommendations	O
.	O

He	O
had	O
endotracheal	O
tube	O
(	O
artificially	O
ventilated	O
)	O
and	O
hypovolemic	O
shock	O
with	O
circulatory	O
insufficiency	O
(	O
blood	O
pressure	O
was	O
supported	O
by	O
3	O
catecholamines	B-CHED
).	O

Cytokine	O
/	O
chemokine	O
assay	O
revealed	O
that	O
levels	O
of	O
interferon	O
-	O
gamma	O
-	O
inducible	O
protein	B-CHED
10	O
and	O
Mig	O
in	O
the	O
blood	O
were	O
highly	O
elevated	O
,	O
although	O
the	O
levels	O
of	O
other	O
cytokines	O
and	O
chemokines	O
were	O
close	O
to	O
normal	O
.	O

Treatment	O
with	O
systemic	O
corticosteroids	B-CHED
,	O
intranasal	O
oxygen	B-CHED
and	O
antimicrobials	B-CHED
may	O
be	O
beneficial	O
in	O
foals	O
with	O
clinical	O
signs	O
compatible	O
with	O
ALI	O
/	O
ARDS	O
.	O

We	O
also	O
show	O
antigen	B-CHED
optimization	O
for	O
the	O
SARS	O
-	O
hCoV	O
,	O
as	O
studies	O
revealed	O
that	O
these	O
proteins	B-CHED
contain	O
peptides	B-CHED
which	O
cross	O
-	O
react	O
with	O
more	O
common	O
coronaviruses	O
,	O
a	O
cause	O
of	O
the	O
common	O
cold	O
.	O

The	O
structure	O
of	O
the	O
RBD	O
suggests	O
ways	O
to	O
make	O
truncated	O
disulfide	B-CHED
-	O
stabilized	O
RBD	O
variants	O
for	O
use	O
in	O
the	O
design	O
of	O
coronavirus	O
vaccines	O
.	O

The	O
selected	O
scFvs	O
were	O
characterized	O
under	O
genetics	O
-	O
molecular	O
aspects	O
and	O
for	O
SARS	O
-	O
CoV	O
N	O
protein	B-CHED
detection	O
in	O
ELISA	O
,	O
western	O
blotting	O
and	O
immunocytochemistry	O
.	O

Human	O
scFv	O
antibodies	O
to	O
N	O
protein	B-CHED
of	O
SARS	O
-	O
CoV	O
can	O
be	O
easily	O
isolated	O
by	O
selecting	O
the	O
ETH	B-CHED
-	O
2	O
phage	O
library	O
on	O
immunotubes	O
coated	O
with	O
antigen	B-CHED
.	O

These	O
in	O
vitro	O
selected	O
human	O
scFvs	O
specifically	O
recognize	O
in	O
ELISA	O
and	O
western	O
blotting	O
studies	O
distinct	O
epitopes	O
in	O
N	O
protein	B-CHED
domains	O
and	O
detect	O
in	O
immunohistochemistry	O
investigations	O
SARS	O
-	O
CoV	O
particles	O
in	O
infected	O
Vero	O
cells	O
.	O

Ribavirin	B-CHED
and	O
corticosteroids	B-CHED
were	O
used	O
extensively	O
during	O
the	O
SARS	O
outbreak	O
.	O

The	O
effectiveness	O
of	O
corticosteroids	B-CHED
has	O
only	O
been	O
suggested	O
by	O
uncontrolled	O
observations	O
,	O
and	O
the	O
role	O
of	O
these	O
agents	O
in	O
therapy	O
remains	O
to	O
be	O
established	O
by	O
randomized	O
controlled	O
studies	O
.	O

Both	O
ribavirin	B-CHED
and	O
corticosteroids	B-CHED
have	O
very	O
significant	O
side	O
effects	O
.	O

The	O
changes	O
in	O
body	O
temperature	O
were	O
compared	O
between	O
the	O
SARS	O
patients	O
and	O
those	O
with	O
other	O
respiratory	O
diseases	O
and	O
the	O
effect	O
of	O
glucocorticoid	B-CHED
hormone	B-CHED
on	O
controlling	O
body	O
temperature	O
of	O
the	O
SARS	O
patients	O
was	O
explored	O
.	O

Thus	O
,	O
propagation	O
of	O
CER	B-CHED
cells	O
and	O
culture	O
of	O
IBV	O
can	O
be	O
performed	O
without	O
the	O
use	O
of	O
animal	O
serum	O
or	O
animal	O
protein	B-CHED
.	O

Four	O
cases	O
developed	O
cluster	O
attacks	O
and	O
two	O
cases	O
had	O
status	O
epilepticus	O
after	O
AED	B-CHED
withdrawal	O
.	O

Patients	O
with	O
polytherapy	O
,	O
non	O
-	O
seizure	O
free	O
and	O
symptomatic	O
etiologies	O
were	O
more	O
susceptible	O
to	O
recurrence	O
of	O
seizures	O
after	O
AED	B-CHED
withdrawal	O
.	O

The	O
major	O
risk	O
factors	O
for	O
withdrawal	O
seizures	O
were	O
symptomatic	O
etiologies	O
,	O
polytherapy	O
and	O
non	O
-	O
seizure	O
free	O
before	O
AED	B-CHED
withdrawal	O
.	O

TITLE	O
:	O
ADP	B-CHED
-	O
ribose	B-CHED
-	O
1	O
"""-"	O
monophosphatase	O
:	O
a	O
conserved	O
coronavirus	O
enzyme	O
that	O
is	O
dispensable	O
for	O
viral	O
replication	O
in	O
tissue	O
culture	O
.	O

Immunization	O
with	O
a	O
bivalent	O
vaccine	O
containing	O
the	O
Mass	O
and	O
Ark	O
strains	O
provided	O
good	O
cross	O
-	O
protection	O
,	O
averaging	O
81	O
%	O
against	O
challenge	O
with	O
five	O
variant	O
isolates	O
from	O
the	O
US	O
having	O
amino	B-CHED
acid	I-CHED
identity	O
values	O
ranging	O
from	O
62	O
to	O
69	O
%	O
to	O
Mass	O
and	O
from	O
68	O
to	O
83	O
%	O
to	O
Ark	O
,	O
respectively	O
.	O

At	O
weekly	O
intervals	O
up	O
to	O
3	O
weeks	O
post	O
-	O
infection	O
,	O
excess	O
lachrymation	O
was	O
induced	O
either	O
by	O
placing	O
sodium	B-CHED
chloride	I-CHED
(	O
salt	B-CHED
)	O
crystals	O
on	O
the	O
eyes	O
or	O
by	O
intramuscular	O
injection	O
of	O
carbachol	B-CHED
.	O

Ventilation	O
with	O
high	O
PEEP	B-CHED
and	O
diuresis	O
resulted	O
in	O
a	O
P	O
/	O
F	O
ratio	O
of	O
265	O
after	O
24	O
h	O
.	O
The	O
patient	O
was	O
successfully	O
weaned	O
from	O
the	O
ventilator	O
on	O
the	O
9th	O
day	O
.	O

The	O
ADC	B-CHED
differences	O
between	O
normal	O
and	O
AVN	O
femoral	O
heads	O
were	O
compared	O
.	O

CONCLUSIONS	O
:	O
About	O
one	O
-	O
third	O
patients	O
with	O
SARS	O
who	O
were	O
treated	O
with	O
a	O
high	O
dose	O
of	O
corticosteroid	B-CHED
occurred	O
osteonecrosis	O
.	O

Nevertheless	O
,	O
combination	O
of	O
the	O
intron	O
and	O
the	O
exon	O
splicing	O
enhancers	O
resulted	O
in	O
suppressing	O
the	O
intron	O
-	O
enhancing	O
e	O
STR2	O
protein	B-CHED
expression	O
in	O
in	O
CHO	B-CHED
/	O
dhFr	O
-	O
cells	O
.	O

Our	O
studies	O
also	O
demonstrated	O
the	O
STR2	O
protein	B-CHED
was	O
mainly	O
as	O
the	O
Endo	O
H	O
-	O
sensitive	O
glycoprotein	B-CHED
(	O
115	O
kDa	O
)	O
expressed	O
in	O
Vero	O
E6	O
,	O
QBI	O
-	O
293A	O
,	O
and	O
CHO	B-CHED
/	O
dhFr	O
-	O
cells	O
.	O

TITLE	O
:	O
Early	O
enhanced	O
expression	O
of	O
interferon	O
-	O
inducible	O
protein	B-CHED
-	O
10	O
(	O
CXCL	O
-	O
10	O
)	O
and	O
other	O
chemokines	O
predicts	O
adverse	O
outcome	O
in	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

Oxidative	O
stress	O
was	O
assessed	O
by	O
measuring	O
the	O
levels	O
of	O
erythrocyte	O
reduced	B-CHED
glutathione	I-CHED
(	O
GSH	B-CHED
),	O
tissue	O
malondialdehyde	B-CHED
(	O
MDA	B-CHED
),	O
myeloperoxidase	O
(	O
MPO	O
)	O
and	O
Na	O
(+)-	O
K	O
(+)	O
ATPase	O
.	O

In	O
patients	O
receiving	O
anti	O
-	O
TNF	O
-	O
alpha	O
therapy	O
,	O
especially	O
in	O
combination	O
with	O
corticosteroids	B-CHED
,	O
signs	O
of	O
pulmonary	O
infection	O
should	O
be	O
regarded	O
as	O
very	O
serious	O
,	O
as	O
fulminant	O
pneumonia	O
with	O
ARDS	O
and	O
severe	O
sepsis	O
may	O
develop	O
within	O
24	O
h	O
.	O

We	O
conclude	O
that	O
a	O
vaccine	O
against	O
FCoV	O
should	O
be	O
based	O
on	O
FCoV	O
type	O
1	O
-	O
related	O
antigens	B-CHED
and	O
that	O
for	O
serodiagnosis	O
of	O
FCoV	O
infection	O
TGEV	O
should	O
be	O
used	O
to	O
attain	O
the	O
highest	O
diagnostic	O
efficiency	O
.	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
membrane	O
protein	B-CHED
and	O
5	O
-	O
lipoxygenase	O
-	O
activating	O
protein	B-CHED
(	O
FLAP	O
)	O
are	O
among	O
a	O
large	O
number	O
of	O
membrane	O
proteins	B-CHED
that	O
are	O
poorly	O
expressed	O
when	O
traditional	O
expression	O
systems	O
and	O
methods	O
are	O
employed	O
.	O

Our	O
study	O
suggests	O
that	O
the	O
SARS	O
-	O
CoV	O
genome	O
possibly	O
contains	O
a	O
putative	O
voltage	B-CHED
-	O
gated	O
ion	O
channel	O
,	O
structural	O
proteins	B-CHED
,	O
a	O
carbon	B-CHED
-	O
oxygen	B-CHED
lyase	O
,	O
oxidoreductases	O
acting	O
on	O
the	O
CH	O
-	O
OH	O
group	O
of	O
donors	O
,	O
and	O
an	O
ATP	B-CHED
-	O
binding	O
cassette	O
transporter	O
.	O

The	O
antigen	B-CHED
detection	O
limit	O
for	O
the	O
Con	O
A	O
-	O
S	O
-	O
ELISA	O
was	O
10	O
(	O
5	O
,	O
1	O
)	O
EID	O
(	O
50	O
)/	O
mL	O
.	O
Three	O
homologous	O
and	O
four	O
heterologous	O
IBV	O
strains	O
were	O
similarly	O
detected	O
.	O

In	O
order	O
to	O
validate	O
this	O
plausible	O
anti	O
-	O
inflammatory	O
property	O
,	O
the	O
chemical	O
composition	O
of	O
HCI	O
has	O
been	O
analysed	O
by	O
GC	O
/	O
MS	O
,	O
22	O
components	O
were	O
identified	O
,	O
and	O
the	O
inflammation	O
induced	O
by	O
carrageenan	B-CHED
in	O
the	O
rat	O
pleurisy	O
model	O
and	O
by	O
xylene	B-CHED
in	O
the	O
mice	O
ear	O
edema	O
model	O
was	O
adopted	O
to	O
study	O
the	O
anti	O
-	O
inflammatory	O
activity	O
of	O
HCI	O
.	O

Injection	O
of	O
carrageenan	B-CHED
into	O
the	O
pleural	O
cavity	O
elicited	O
an	O
acute	O
inflammatory	O
response	O
characterized	O
by	O
protein	B-CHED
rich	O
fluid	O
accumulation	O
and	O
leukocyte	O
infiltration	O
in	O
the	O
pleural	O
cavity	O
.	O

In	O
this	O
study	O
,	O
comprehensive	O
HPLC	O
-	O
and	O
FRET	O
-	O
substrate	O
-	O
based	O
screenings	O
of	O
various	O
electrophilic	O
compounds	O
were	O
performed	O
to	O
identify	O
potential	O
M	O
(	O
pro	B-CHED
)	O
inhibitors	B-CHED
.	O

With	O
a	O
crude	O
mortality	O
of	O
9	O
%,	O
its	O
cause	O
was	O
quickly	O
identified	O
as	O
a	O
novel	O
coronavirus	O
that	O
jumped	O
species	O
from	O
animals	O
to	O
man	B-CHED
.	O

ABSTRACT	O
:	O
The	O
main	O
peptidase	O
(	O
M	O
(	O
pro	B-CHED
))	O
from	O
the	O
coronavirus	O
(	O
CoV	O
)	O
causing	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
is	O
one	O
of	O
the	O
most	O
attractive	O
molecular	O
targets	O
for	O
the	O
development	O
of	O
anti	O
-	O
SARS	O
agents	O
.	O

All	O
of	O
them	O
belonged	O
to	O
the	O
IgG2a	O
isotype	O
proved	O
by	O
antigen	B-CHED
mediated	O
ELISA	O
.	O

CONCLUSIONS	O
:	O
Monoclonal	O
antibodies	O
of	O
high	O
specificity	O
against	O
protein	B-CHED
X4	O
have	O
been	O
successfully	O
prepared	O
,	O
which	O
laid	O
the	O
foundation	O
for	O
the	O
further	O
study	O
of	O
protein	B-CHED
X4	O
.	O

TITLE	O
:	O
Cross	O
-	O
reaction	O
of	O
SARS	O
-	O
CoV	O
antigen	B-CHED
with	O
autoantibodies	O
in	O
autoimmune	O
diseases	O
.	O

In	O
addition	O
,	O
our	O
result	O
also	O
demonstrated	O
the	O
cleavage	O
of	O
the	O
V	O
-	O
ATPase	O
G1	O
fusion	O
protein	B-CHED
and	O
the	O
immunoprecipitation	O
of	O
cellular	O
V	O
-	O
ATPase	O
G1	O
by	O
the	O
3CL	O
(	O
pro	B-CHED
).	O

Moreover	O
,	O
loading	O
cells	O
with	O
SNARF	O
-	O
1	O
pH	O
-	O
sensitive	O
dye	B-CHED
showed	O
that	O
the	O
intracellular	O
pH	O
in	O
3CL	O
(	O
pro	B-CHED
)-	O
expressing	O
cells	O
was	O
significantly	O
lower	O
as	O
compared	O
to	O
mock	O
cells	O
.	O

Further	O
analysis	O
confirmed	O
that	O
the	O
mutant	O
S	O
protein	B-CHED
trafficked	O
though	O
the	O
secretory	O
pathway	O
faster	O
than	O
wild	O
-	O
type	O
S	O
protein	B-CHED
.	O

The	O
flexible	O
linkers	O
are	O
intrinsically	O
disordered	O
and	O
represent	O
potential	O
interaction	O
sites	O
with	O
other	O
protein	B-CHED
and	O
protein	B-CHED
-	O
RNA	O
partners	O
.	O

Bioinformatics	O
reveal	O
that	O
other	O
coronavirus	O
N	O
proteins	B-CHED
could	O
share	O
the	O
same	O
modular	O
organization	O
.	O

Allelic	O
discrimination	O
assays	O
were	O
developed	O
based	O
on	O
the	O
use	O
of	O
fluorogenic	O
oligonucleotide	B-CHED
probes	O
(	O
TaqMan	O
).	O

ABSTRACT	O
:	O
Rapid	O
diagnostic	O
tests	O
with	O
a	O
high	O
sensitivity	O
for	O
lower	O
respiratory	O
tract	O
infection	O
(	O
LRTI	O
)	O
could	O
lead	O
to	O
improved	O
patient	O
care	O
and	O
reduce	O
unnecessary	O
antibiotic	B-CHED
use	O
and	O
associated	O
costs	O
.	O

Implementation	O
of	O
real	O
-	O
time	O
PCR	O
for	O
the	O
etiological	O
diagnosis	O
of	O
LRTI	O
increased	O
the	O
diagnostic	O
yield	O
considerably	O
,	O
but	O
it	O
did	O
not	O
reduce	O
antibiotic	B-CHED
use	O
or	O
costs	O
.	O

Although	O
it	O
has	O
been	O
known	O
that	O
TGEV	O
spiker	O
protein	B-CHED
is	O
essential	O
for	O
the	O
viral	O
entry	O
for	O
many	O
years	O
,	O
the	O
detail	O
knowledge	O
of	O
the	O
TGEV	O
fusion	O
protein	B-CHED
core	O
is	O
still	O
very	O
limited	O
.	O

Experiments	O
,	O
including	O
purification	O
and	O
C	O
-	O
terminal	O
amino	B-CHED
acid	I-CHED
sequencing	O
of	O
the	O
CoV	O
-	O
HKU1	O
helicase	O
and	O
trans	O
-	O
cleavage	O
assays	O
of	O
the	O
CoV	O
-	O
HKU1	O
3CL	O
(	O
pro	B-CHED
)	O
will	O
confirm	O
the	O
presence	O
of	O
this	O
novel	O
cleavage	O
site	O
.	O

Analysis	O
of	O
patients	O
with	O
DIC	B-CHED
or	O
ARDS	O
revealed	O
that	O
TF	O
mRNA	B-CHED
correlated	O
with	O
D	O
-	O
dimer	O
,	O
and	O
GE	O
-	O
XDP	B-CHED
correlated	O
with	O
leukocyte	O
count	O
,	O
CRP	O
and	O
D	O
-	O
dimer	O
,	O
suggesting	O
that	O
inflammatory	O
changes	O
due	O
to	O
thrombosis	O
may	O
cause	O
the	O
activation	O
of	O
leukocytes	O
during	O
chemotherapy	O
.	O

ABSTRACT	O
:	O
In	O
order	O
to	O
construct	O
a	O
recombinant	O
Canine	O
adenovirus	O
type	O
2	O
(	O
CAV	O
-	O
2	O
)	O
expressing	O
the	O
spike	O
glycoprotein	B-CHED
of	O
Canine	O
coronavirus	O
(	O
CCV	O
),	O
the	O
S1	O
gene	O
fragment	O
of	O
CCV	O
strain	O
DXMV	O
,	O
encoding	O
major	O
antigenic	O
region	O
A	O
,	O
B	O
,	O
C	O
and	O
D	O
of	O
S	O
protein	B-CHED
,	O
was	O
amplified	O
by	O
RT	O
-	O
PCR	O
and	O
cloned	O
into	O
pVAX1	O
vector	O
.	O

To	O
gain	O
the	O
recombinant	O
Canine	O
adenovirus	O
,	O
the	O
recombinant	O
plasmid	O
pCAV	O
-	O
2	O
-	O
CCV	O
-	O
S1	O
was	O
linearized	O
by	O
Cla	B-CHED
I	O
/	O
Asc	O
I	O
to	O
release	O
recombinant	O
genome	O
,	O
and	O
then	O
transfected	O
into	O
MDCK	O
cell	O
.	O

An	O
X	O
-	O
ray	O
crystal	O
structure	O
of	O
our	O
lead	O
inhibitor	B-CHED
(	O
4	O
)	O
bound	O
to	O
SARS	O
-	O
3CLpro	O
provided	O
important	O
drug	O
-	O
design	O
templates	O
for	O
the	O
design	O
of	O
small	O
-	O
molecule	O
inhibitors	B-CHED
.	O

Western	O
blot	O
analysis	O
of	O
the	O
culture	O
medium	O
from	O
transfection	O
experiments	O
revealed	O
that	O
both	O
E	O
and	O
M	O
expressed	O
alone	O
could	O
be	O
released	O
in	O
sedimentable	O
particles	O
and	O
that	O
E	O
and	O
M	O
proteins	B-CHED
are	O
likely	O
to	O
form	O
VLPs	O
when	O
they	O
are	O
coexpressed	O
.	O

These	O
results	O
indicate	O
that	O
N	O
protein	B-CHED
has	O
an	O
essential	O
role	O
in	O
the	O
packaging	O
of	O
SARS	O
-	O
CoV	O
RNA	O
.	O

A	O
filter	O
binding	O
assay	O
and	O
competition	O
analysis	O
further	O
demonstrated	O
that	O
the	O
N	O
-	O
terminal	O
and	O
C	O
-	O
terminal	O
regions	O
of	O
the	O
SARS	O
-	O
CoV	O
N	O
protein	B-CHED
each	O
contain	O
a	O
binding	O
activity	O
specific	O
to	O
the	O
viral	O
RNA	O
.	O

TITLE	O
:	O
Modulation	O
of	O
the	O
immune	O
response	O
to	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
spike	O
glycoprotein	B-CHED
by	O
gene	O
-	O
based	O
and	O
inactivated	O
virus	O
immunization	O
.	O

Nanospheres	O
with	O
entrapped	O
antigens	B-CHED
have	O
recently	O
been	O
shown	O
to	O
possess	O
significant	O
potential	O
as	O
vaccine	O
delivery	O
systems	O
and	O
adjuvants	B-CHED
.	O

A	O
randomized	O
,	O
placebo	O
-	O
controlled	O
,	O
double	O
-	O
blind	O
field	O
trial	O
study	O
in	O
populations	O
with	O
14	O
,	O
391	O
persons	O
from	O
SARS	O
prevalent	O
cities	O
or	O
provinces	O
in	O
China	O
during	O
May	O
-	O
Jun	O
,	O
2003	O
and	O
Dec	B-CHED
-	O
Apr	B-CHED
,	O
2004	O
.	O

This	O
is	O
a	O
lesson	O
I	O
learned	O
from	O
my	O
father	O
,	O
who	O
was	O
a	O
career	O
pilot	O
in	O
the	O
US	O
Air	B-CHED
Force	O
and	O
instilled	O
this	O
into	O
me	O
and	O
my	O
siblings	O
from	O
a	O
very	O
early	O
age	O
.	O

The	O
education	O
provides	O
a	O
very	O
broad	O
background	O
in	O
systems	O
biology	O
,	O
medicine	B-CHED
,	O
and	O
public	O
health	O
.	O

Specific	O
anti	O
-	O
N	O
scFvs	O
were	O
isolated	O
by	O
panning	O
against	O
a	O
recombinant	O
nucleocapsid	O
protein	B-CHED
and	O
reactivity	O
was	O
confirmed	O
with	O
phage	O
-	O
ELISA	O
.	O

TITLE	O
:	O
Structural	O
insights	O
into	O
SARS	O
coronavirus	O
proteins	B-CHED
.	O

Patients	O
in	O
both	O
groups	O
were	O
treated	O
by	O
gastrolavage	O
,	O
pralidoxime	B-CHED
chloride	I-CHED
,	O
atropine	B-CHED
and	O
other	O
expectant	O
treatment	O
.	O

The	O
incidence	O
of	O
respiratory	O
failure	O
,	O
heart	O
injury	O
,	O
brain	O
injury	O
,	O
atropine	B-CHED
poisoning	O
,	O
intermediate	O
syndrome	O
,	O
liver	O
injury	O
in	O
treatment	O
group	O
(	O
12	O
.	O
64	O
%,	O
5	O
.	O
75	O
%,	O
8	O
.	O
62	O
%,	O
1	O
.	O
72	O
%,	O
4	O
.	O
60	O
%,	O
5	O
.	O
17	O
%	O
respectively	O
)	O
were	O
lower	O
than	O
those	O
in	O
control	O
group	O
(	O
25	O
.	O
63	O
%,	O
13	O
.	O
75	O
%,	O
17	O
.	O
50	O
%,	O
6	O
.	O
25	O
%,	O
7	O
.	O
50	O
%,	O
9	O
.	O
38	O
%	O
respectively	O
,	O
P	O
<	O
0	O
.	O
05	O
or	O
P	O
<	O
0	O
.	O
01	O
).	O

The	O
2	O
patients	O
who	O
died	O
had	O
significantly	O
lower	O
hemoglobin	B-CHED
levels	O
,	O
monocyte	O
counts	O
,	O
albumin	O
levels	O
,	O
and	O
oxygen	B-CHED
saturation	O
levels	O
on	O
admission	O
and	O
had	O
more	O
-	O
extensive	O
involvement	O
visible	O
on	O
chest	O
radiographs	O
.	O

Delayed	O
antibiotic	B-CHED
treatment	O
and	O
thrombocytopenia	O
are	O
risk	O
factors	O
for	O
the	O
development	O
of	O
pulmonary	O
involvement	O
in	O
leptospirosis	O
.	O

Approval	O
of	O
the	O
Institutional	O
Review	O
Board	O
and	O
the	O
Food	O
and	O
Drug	O
Administration	O
was	O
obtained	O
to	O
use	O
nitric	B-CHED
oxide	I-CHED
(	O
NO	O
)	O
with	O
HFJV	O
on	O
a	O
compassionate	O
basis	O
considering	O
the	O
grave	O
situation	O
.	O

We	O
measured	O
systemic	O
and	O
mesenteric	O
(	O
portal	O
venous	O
blood	O
flow	O
,	O
jejunal	O
mucosal	O
perfusion	O
)	O
haemodynamic	O
parameters	O
,	O
mesenteric	O
oxygenation	O
(	O
jejunal	O
tissue	O
oxygen	B-CHED
tension	O
)	O
and	O
systemic	O
cytokines	O
(	O
tumour	O
necrosis	O
factor	O
-	O
alpha	O
and	O
interleukin	O
-	O
6	O
).	O

ABSTRACT	O
:	O
The	O
crystal	O
structure	O
of	O
a	O
conserved	O
domain	O
of	O
nonstructural	O
protein	B-CHED
3	O
(	O
nsP3	O
)	O
from	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
has	O
been	O
solved	O
by	O
single	O
-	O
wavelength	O
anomalous	O
dispersion	O
to	O
1	O
.	O
4	O
A	O
resolution	O
.	O

RBD	O
of	O
SARS	O
-	O
Cov	O
spike	O
protein	B-CHED
was	O
expressed	O
as	O
inclusion	O
body	O
when	O
fused	O
as	O
TrxA	O
tag	O
form	O
in	O
both	O
BL21	O
(	O
DE3	O
)	O
and	O
Rosetta	O
-	O
gamiB	O
(	O
DE3	O
)	O
under	O
many	O
different	O
cultures	O
and	O
induction	O
conditions	O
.	O

In	O
this	O
paper	O
,	O
we	O
get	O
sufficient	O
soluble	O
N	O
terminal	O
GST	O
tagged	O
RBD	O
protein	B-CHED
expressed	O
in	O
E	O
.	O
coli	O
BL21	O
(	O
DE3	O
);	O
data	O
from	O
ELISA	O
and	O
flow	O
cytometry	O
assay	O
demonstrate	O
that	O
the	O
recombinant	O
protein	B-CHED
is	O
functional	O
and	O
binding	O
to	O
ACE2	O
positive	O
Vero	O
E6	O
cell	O
efficiently	O
.	O

ABSTRACT	O
:	O
To	O
study	O
the	O
effects	O
of	O
microcirculation	O
disturbance	O
(	O
MD	O
)	O
on	O
rats	O
with	O
acute	O
severe	O
pancreatitis	O
(	O
ASP	B-CHED
).	O

We	O
developed	O
ASP	B-CHED
rat	O
models	O
,	O
and	O
anatomized	O
separately	O
after	O
1	O
,	O
3	O
,	O
5	O
,	O
7	O
,	O
and	O
9	O
h	O
.	O
We	O
took	O
out	O
blood	O
and	O
did	O
hemorrheologic	O
examination	O
and	O
erythrocyte	O
osmotic	O
fragility	O
test	O
,	O
checked	O
up	O
the	O
water	B-CHED
content	O
,	O
capillary	O
permeability	O
,	O
and	O
genetic	O
expression	O
of	O
intercellular	O
adhesion	O
molecule	O
-	O
1	O
(	O
ICAM	O
-	O
1	O
)	O
in	O
lung	O
tissues	O
,	O
examined	O
the	O
apoptosis	O
degree	O
of	O
blood	O
vessel	O
endothelium	O
while	O
we	O
tested	O
related	O
gene	O
expression	O
of	O
Bax	O
and	O
Bcl	O
-	O
2	O
in	O
lung	O
tissues	O
.	O

RESULTS	O
:	O
Classic	O
plasma	O
markers	O
of	O
endothelial	O
injury	O
,	O
tPA	B-CHED
and	O
sTM	O
significantly	O
elevated	O
in	O
SARS	O
patients	O
in	O
comparison	O
to	O
controls	O
[	O
t	O
-	O
PA	O
:	O
1	O
.	O
48	O
+/-	O

By	O
implementing	O
ANN	O
as	O
a	O
classification	O
engine	O
,	O
we	O
enabled	O
both	O
the	O
prediction	O
of	O
peptides	B-CHED
binding	O
to	O
multiple	O
individual	O
HLA	O
-	O
A2	O
molecules	O
and	O
the	O
prediction	O
of	O
promiscuous	O
binders	O
using	O
a	O
single	O
model	O
.	O

ABSTRACT	O
:	O
Pyrrolobenzoxazepinones	O
(	O
PBOs	O
)	O
represent	O
a	O
new	O
class	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
nonnucleoside	O
reverse	O
transcriptase	O
(	O
RT	O
)	O
inhibitors	B-CHED
(	O
NNRTIs	O
)	O
whose	O
prototype	O
is	O
5	O
.	O

TITLE	O
:	O
Relationships	O
between	O
antimicrobial	B-CHED
use	O
and	O
antimicrobial	B-CHED
resistance	O
in	O
Gram	O
-	O
negative	O
bacteria	O
causing	O
nosocomial	O
infections	O
from	O
1991	O
-	O
2003	O
at	O
a	O
university	O
hospital	O
in	O
Taiwan	O
.	O

Defective	O
interfering	O
(	O
DI	O
)	O
RNA	O
replication	O
assays	O
have	O
demonstrated	O
a	O
role	O
for	O
the	O
3	O
'(+)	O
42	O
host	O
protein	B-CHED
binding	O
element	O
in	O
the	O
MHV	O
life	O
cycle	O
.	O

Using	O
gel	O
mobility	O
shift	O
RNase	O
T1	O
protection	O
assays	O
and	O
secondary	O
structure	O
modeling	O
,	O
we	O
have	O
characterized	O
a	O
possible	O
role	O
for	O
RNA	O
secondary	O
structure	O
in	O
host	O
protein	B-CHED
binding	O
to	O
the	O
3	O
'-	O
terminal	O
42	O
-	O
nucleotide	B-CHED
element	O
.	O

DI	O
RNA	O
replication	O
assays	O
demonstrated	O
that	O
mutations	O
in	O
the	O
3	O
'(+)	O
42	O
host	O
protein	B-CHED
binding	O
element	O
had	O
a	O
deleterious	O
effect	O
on	O
the	O
accumulation	O
of	O
DI	O
RNA	O
.	O

As	O
assessed	O
by	O
immunofluorescence	O
staining	O
and	O
membrane	O
biotinylation	O
,	O
ACE2	O
protein	B-CHED
was	O
more	O
abundantly	O
expressed	O
on	O
the	O
apical	O
than	O
the	O
basolateral	O
surface	O
of	O
polarized	O
airway	O
epithelia	O
.	O

TITLE	O
:	O
SR	O
-	O
rich	O
motif	O
plays	O
a	O
pivotal	O
role	O
in	O
recombinant	O
SARS	O
coronavirus	O
nucleocapsid	O
protein	B-CHED
multimerization	O
.	O

TITLE	O
:	O
A	O
novel	O
fingerprint	O
map	O
for	O
detecting	O
SARS	O
-	O
CoV	O
.	O
ABSTRACT	O
:	O
Spike	O
(	O
S	O
)	O
protein	B-CHED
is	O
the	O
most	O
important	O
membrane	O
protein	B-CHED
on	O
the	O
surface	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
).	O

Inspired	O
by	O
such	O
a	O
mechanism	O
,	O
an	O
in	O
-	O
depth	O
investigation	O
into	O
the	O
genome	O
sequences	O
of	O
S	O
protein	B-CHED
of	O
SARS	O
-	O
CoV	O
and	O
its	O
receptor	O
are	O
conducted	O
thru	O
a	O
mathematical	O
transformation	O
and	O
graphic	O
approach	O
.	O

TITLE	O
:	O
Why	O
are	O
HIV	O
-	O
1	O
fusion	O
inhibitors	B-CHED
not	O
effective	O
against	O
SARS	O
-	O
CoV	O
?	O

As	O
it	O
happens	O
with	O
other	O
viruses	O
peptidic	O
fusion	O
inhibitors	B-CHED
,	O
SARS	O
-	O
CoV	O
S	O
protein	B-CHED
HR2	O
-	O
derived	O
peptides	B-CHED
are	O
potential	O
therapeutic	O
drugs	O
against	O
the	O
virus	O
.	O

It	O
is	O
a	O
matter	O
of	O
discussion	O
if	O
the	O
HIV	O
-	O
1	O
gp41	O
HR2	O
-	O
derived	O
peptide	B-CHED
T20	O
(	O
enfuvirtide	B-CHED
)	O
could	O
be	O
a	O
possible	O
SARS	O
-	O
CoV	O
inhibitor	B-CHED
given	O
the	O
similarities	O
between	O
the	O
two	O
viruses	O
.	O

Sera	O
were	O
collected	O
in	O
large	O
amounts	O
at	O
the	O
peak	O
,	O
where	O
IgG	O
was	O
precipitated	O
using	O
ammonium	B-CHED
sulphate	I-CHED
and	O
subsequently	O
digested	O
with	O
pepsin	O
.	O

Despite	O
this	O
,	O
368	O
reports	O
of	O
potential	O
SARS	O
cases	O
were	O
made	O
to	O
the	O
Health	O
Protection	O
Agency	O
(	O
HPA	B-CHED
)	O
between	O
March	O
and	O
July	O
2003	O
.	O

A	O
previous	O
report	O
(	O
Virology	O
2003	O
,	O
311	O
:	O
16	O
-	O
27	O
)	O
indicated	O
that	O
transfected	O
IBV	O
3b	O
localized	O
to	O
the	O
nucleus	B-CHED
in	O
mammalian	O
cells	O
using	O
a	O
vaccinia	O
-	O
virus	O
expression	O
system	O
.	O

Our	O
results	O
highlight	O
the	O
importance	O
of	O
using	O
cells	O
derived	O
from	O
the	O
natural	O
host	O
when	O
studying	O
coronavirus	O
non	O
-	O
structural	O
proteins	B-CHED
.	O

In	O
infected	O
cells	O
,	O
SARS	O
-	O
CoV	O
N	O
protein	B-CHED
localized	O
exclusively	O
to	O
the	O
cytoplasm	O
.	O

TITLE	O
:	O
Alemtuzumab	O
induction	O
and	O
sirolimus	B-CHED
plus	O
mycophenolate	B-CHED
mofetil	I-CHED
maintenance	O
for	O
CNI	O
and	O
steroid	B-CHED
-	O
free	O
kidney	O
transplant	O
immunosuppression	O
.	O

ABSTRACT	O
:	O
We	O
performed	O
a	O
pilot	O
study	O
in	O
which	O
22	O
kidney	O
recipients	O
(	O
14	O
LD	O
:	O
8	O
DCD	O
)	O
were	O
given	O
alemtuzumab	O
induction	O
(	O
30	O
mg	O
day	O
0	O
and	O
1	O
),	O
steroids	B-CHED
(	O
500	O
mg	O
mp	O
day	O
0	O
and	O
1	O
,	O
none	O
thereafter	O
),	O
mycophenolate	B-CHED
mofetil	I-CHED
(	O
MMF	B-CHED
)	O
maintenance	O
(	O
500	O
mg	O
b	O
.	O
i	O
.	O
d	O
)	O
and	O
sirolimus	B-CHED
(	O
concentration	O
controlled	O
8	O
-	O
12	O
ng	O
/	O
mL	O
).	O

Of	O
19	O
surviving	O
grafts	O
,	O
18	O
(	O
95	O
%)	O
remain	O
steroid	B-CHED
and	O
15	O
(	O
79	O
%)	O
CNI	O
-	O
free	O
.	O

Leukopenia	O
was	O
common	O
and	O
MMF	B-CHED
dose	O
was	O
reduced	O
or	O
eliminated	O
in	O
6	O
/	O
22	O
(	O
27	O
%)	O
patients	O
.	O

Mutation	O
analysis	O
of	O
ORF7a	O
revealed	O
that	O
the	O
domain	O
spanning	O
aa	O
44	O
-	O
82	O
of	O
7a	O
protein	B-CHED
was	O
essential	O
for	O
its	O
cytoplasmic	O
localization	O
and	O
for	O
induction	O
of	O
the	O
cell	O
cycle	O
arrest	O
.	O

In	O
the	O
past	O
,	O
U	O
.	O
S	O
.	O
government	O
-	O
sponsored	O
biomedical	O
researchers	O
have	O
focused	O
on	O
basic	O
research	O
and	O
concept	O
development	O
,	O
leaving	O
product	O
development	O
to	O
the	O
pharmaceutical	B-CHED
industry	O
.	O

The	O
replacement	O
of	O
nucleotide	B-CHED
637	O
of	O
TGEV	O
genome	O
by	O
a	O
T	O
,	O
as	O
in	O
the	O
DI	O
-	O
C	O
sequence	O
,	O
or	O
an	O
A	O
severely	O
affected	O
virus	O
recovery	O
from	O
the	O
cDNA	O
,	O
yielding	O
mutant	O
viruses	O
with	O
low	O
titers	O
and	O
small	O
plaques	O
compared	O
to	O
those	O
of	O
the	O
wild	O
type	O
.	O

No	O
relationship	O
between	O
these	O
observations	O
and	O
RNA	O
secondary	O
-	O
structure	O
predictions	O
was	O
found	O
,	O
indicating	O
that	O
mutations	O
at	O
nucleotide	B-CHED
637	O
most	O
likely	O
had	O
an	O
effect	O
at	O
the	O
protein	B-CHED
level	O
.	O

TITLE	O
:	O
Expression	O
of	O
hemagglutinin	O
esterase	O
protein	B-CHED
from	O
recombinant	O
mouse	O
hepatitis	O
virus	O
enhances	O
neurovirulence	O
.	O

Our	O
findings	O
suggest	O
that	O
the	O
properties	O
of	O
S	O
receptor	O
utilization	O
and	O
/	O
or	O
fusogenicity	O
mainly	O
determine	O
organ	O
and	O
host	O
cell	O
tropism	O
but	O
that	O
HE	O
enhances	O
the	O
efficiency	O
of	O
infection	O
and	O
promotes	O
viral	O
dissemination	O
,	O
at	O
least	O
in	O
some	O
tissues	O
,	O
presumably	O
by	O
serving	O
as	O
a	O
second	O
receptor	O
-	O
binding	O
protein	B-CHED
.	O

We	O
performed	O
bioinformatics	O
analysis	O
on	O
16	O
papain	O
-	O
like	O
protease	O
domains	O
from	O
nine	O
different	O
coronaviruses	O
and	O
identified	O
a	O
putative	O
catalytic	O
triad	O
(	O
Cys1651	O
-	O
His1812	O
-	O
Asp1826	O
)	O
and	O
zinc	B-CHED
-	O
binding	O
site	O
.	O

This	O
similarity	O
in	O
the	O
substrate	O
recognition	O
sites	O
should	O
be	O
considered	O
during	O
the	O
development	O
of	O
SARS	O
-	O
CoV	O
PLpro	O
inhibitors	B-CHED
.	O

SARS	O
-	O
CoV	O
specifically	O
infected	O
HAE	O
via	O
the	O
apical	O
surface	O
and	O
replicated	O
to	O
titers	O
of	O
10	O
(	O
7	O
)	O
PFU	B-CHED
/	O
ml	O
by	O
48	O
h	O
postinfection	O
.	O

Infection	O
was	O
highly	O
cytolytic	O
,	O
as	O
infected	O
ciliated	O
cells	O
were	O
necrotic	O
and	O
shed	O
over	O
time	O
onto	O
the	O
luminal	B-CHED
surface	O
of	O
the	O
epithelium	O
.	O

In	O
comparative	O
testing	O
,	O
only	O
95	O
%	O
ethanol	B-CHED
showed	O
similar	O
levels	O
of	O
activity	O
.	O

In	O
fingerpad	O
tests	O
,	O
the	O
formulation	O
produced	O
a	O
log10	O
reduction	O
factor	O
of	O
the	O
titre	O
of	O
poliovirus	O
type	O
1	O
(	O
Sabin	O
)	O
of	O
3	O
.	O
04	O
in	O
30s	O
compared	O
with	O
1	O
.	O
32	O
by	O
60	O
%	O
propan	B-CHED
-	I-CHED
2	I-CHED
-	I-CHED
ol	I-CHED
.	O

Testing	O
against	O
feline	O
calicivirus	O
produced	O
a	O
log10	O
reduction	O
factor	O
of	O
2	O
.	O
38	O
by	O
the	O
test	O
formulation	O
;	O
in	O
contrast	O
,	O
the	O
log10	O
reduction	O
factors	O
with	O
70	O
%	O
ethanol	B-CHED
and	O
70	O
%	O
propan	B-CHED
-	I-CHED
1	I-CHED
-	I-CHED
ol	I-CHED
were	O
0	O
.	O
68	O
and	O
0	O
.	O
70	O
,	O
respectively	O
.	O

ABSTRACT	O
:	O
Acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
is	O
a	O
devastating	O
disease	O
process	O
characterized	O
by	O
severe	O
acute	O
lung	O
injury	O
,	O
inflammatory	O
cell	O
recruitment	O
to	O
the	O
lung	O
,	O
upregulation	O
of	O
pro	B-CHED
-	O
inflammatory	O
cytokines	O
and	O
increased	O
oxidative	O
stress	O
.	O

TITLE	O
:	O
The	O
putative	O
protein	B-CHED
6	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
:	O
expression	O
and	O
functional	O
characterization	O
.	O

Expression	O
of	O
SARS	O
6	O
protein	B-CHED
in	O
mammalian	O
cells	O
elicits	O
biological	O
activity	O
of	O
stimulating	O
cellular	O
DNA	O
synthesis	O
.	O

In	O
addition	O
,	O
other	O
anti	O
-	O
viral	O
treatment	O
,	O
RNA	O
interference	O
,	O
monoclonal	O
antibody	O
,	O
synthetic	O
peptides	B-CHED
,	O
and	O
vaccines	O
are	O
being	O
developed	O
.	O

Forty	O
-	O
two	O
cats	O
met	B-CHED
the	O
inclusion	O
criteria	O
.	O

TITLE	O
:	O
From	O
genome	O
to	O
drug	O
lead	O
:	O
identification	O
of	O
a	O
small	O
-	O
molecule	O
inhibitor	B-CHED
of	O
the	O
SARS	O
virus	O
.	O

TITLE	O
:	O
Solution	O
structure	O
of	O
the	O
X4	O
protein	B-CHED
coded	O
by	O
the	O
SARS	O
related	O
coronavirus	O
reveals	O
an	O
immunoglobulin	O
like	O
fold	O
and	O
suggests	O
a	O
binding	O
activity	O
to	O
integrin	O
I	O
domains	O
.	O

TITLE	O
:	O
Design	O
and	O
biological	O
activities	O
of	O
novel	O
inhibitory	O
peptides	B-CHED
for	O
SARS	O
-	O
CoV	O
spike	O
protein	B-CHED
and	O
angiotensin	B-CHED
-	O
converting	O
enzyme	O
2	O
interaction	O
.	O

In	O
addition	O
to	O
hostcell	O
receptors	O
,	O
lysosomal	O
cysteine	B-CHED
proteases	O
are	O
required	O
for	O
productive	O
infection	O
by	O
some	O
viruses	O
.	O

Here	O
we	O
show	O
that	O
SARS	O
-	O
CoV	O
,	O
but	O
not	O
HCoV	O
-	O
NL63	O
,	O
utilizes	O
the	O
enzymatic	O
activity	O
of	O
the	O
cysteine	B-CHED
protease	O
cathepsin	O
L	O
to	O
infect	O
ACE2	O
-	O
expressing	O
cells	O
.	O

Expression	O
of	O
exogenous	O
cathepsin	O
L	O
substantially	O
enhanced	O
infection	O
mediated	O
by	O
the	O
SARS	O
-	O
CoV	O
S	O
protein	B-CHED
and	O
by	O
filovirus	O
GP	O
proteins	B-CHED
but	O
not	O
by	O
the	O
HCoV	O
-	O
NL63	O
S	O
protein	B-CHED
or	O
the	O
vesicular	O
stomatitis	O
virus	O
G	O
protein	B-CHED
.	O

NO	O
release	O
and	O
eNOS	O
expression	O
were	O
determined	O
to	O
examine	O
the	O
effect	O
of	O
chronic	O
EtOH	B-CHED
stimulation	O
on	O
endothelial	O
NO	O
metabolism	O
.	O

EtOH	B-CHED
stimulation	O
also	O
increased	O
eNOS	O
interaction	O
with	O
heat	O
shock	O
protein	B-CHED
(	O
hsp90	O
),	O
a	O
molecular	O
chaperone	O
known	O
to	O
enhance	O
eNOS	O
activity	O
.	O

Geldanamycin	B-CHED
,	O
an	O
hsp90	B-CHED
inhibitor	I-CHED
,	O
attenuated	O
chronic	O
EtOH	B-CHED
-	O
mediated	O
increases	O
in	O
NO	O
production	O
.	O

ABSTRACT	O
:	O
The	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
membrane	O
protein	B-CHED
is	O
an	O
abundant	O
virion	O
protein	B-CHED
,	O
and	O
its	O
interaction	O
with	O
the	O
nucleocapsid	O
protein	B-CHED
is	O
crucial	O
for	O
viral	O
assembly	O
and	O
morphogenesis	O
.	O

Here	O
,	O
we	O
show	O
that	O
electrostatic	O
interactions	O
between	O
the	O
carboxyl	O
termini	O
of	O
SARS	O
-	O
CoV	O
membrane	O
protein	B-CHED
and	O
nucleocapsid	O
protein	B-CHED
largely	O
mediate	O
the	O
interaction	O
of	O
these	O
two	O
proteins	B-CHED
.	O

The	O
chip	O
fabrication	O
capabilities	O
have	O
been	O
extended	O
into	O
design	O
and	O
fabricate	O
chips	O
with	O
higher	O
degree	O
of	O
complexity	O
in	O
different	O
materials	O
,	O
such	O
as	O
quartz	B-CHED
,	O
glass	O
,	O
polymethyl	B-CHED
methacrylate	I-CHED
(	O
PMMA	B-CHED
),	O
and	O
polydimethyl	O
siloxane	B-CHED
(	O
PDMS	B-CHED
).	O

Based	O
on	O
the	O
work	O
mentioned	O
above	O
,	O
different	O
functional	O
units	O
,	O
such	O
as	O
membrane	O
,	O
monolithic	O
,	O
isotachophoresis	O
(	O
ITP	B-CHED
)	O
etc	O
were	O
set	O
up	O
and	O
integrated	O
.	O

We	O
also	O
provide	O
an	O
example	O
to	O
illustrate	O
that	O
the	O
carbohydrate	B-CHED
microarray	O
is	O
also	O
a	O
discovery	O
tool	O
;	O
this	O
is	O
particularly	O
useful	O
for	O
identifying	O
immunologic	O
sugar	O
moieties	O
,	O
including	O
complex	O
carbohydrates	B-CHED
of	O
cancer	O
cells	O
and	O
sugar	O
signatures	O
of	O
previously	O
unrecognized	O
microbial	O
pathogens	O
.	O

A	O
subpopulation	O
of	O
the	O
released	O
3a	O
protein	B-CHED
is	O
associated	O
with	O
detergent	B-CHED
-	O
resistant	O
membranes	O
.	O

To	O
determine	O
if	O
either	O
the	O
3a	O
or	O
the	O
3b	O
protein	B-CHED
is	O
required	O
for	O
replication	O
,	O
we	O
first	O
modified	O
their	O
translation	O
initiation	O
codons	O
to	O
prevent	O
translation	O
of	O
the	O
3a	O
and	O
3b	O
proteins	B-CHED
from	O
recombinant	O
infectious	O
bronchitis	O
viruses	O
(	O
rIBVs	O
).	O

Pretreatment	O
of	O
cells	O
with	O
a	O
caspase	O
-	O
9	O
inhibitor	B-CHED
completely	O
blocked	O
caspase	O
-	O
9	O
activation	O
and	O
partially	O
inhibited	O
the	O
apoptosis	O
mediated	O
by	O
MHV	O
infection	O
.	O

Analyses	O
of	O
cytochrome	B-CHED
c	I-CHED
release	O
further	O
revealed	O
an	O
activation	O
of	O
the	O
mitochondrial	O
apoptotic	O
pathway	O
.	O

ABSTRACT	O
:	O
We	O
investigated	O
the	O
structure	O
of	O
the	O
hydrophobic	O
domain	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
E	O
protein	B-CHED
in	O
model	O
lipid	B-CHED
membranes	O
by	O
x	O
-	O
ray	O
reflectivity	O
and	O
x	O
-	O
ray	O
scattering	O
.	O

Continued	O
research	O
is	O
still	O
required	O
to	O
determine	O
the	O
pathogenetic	O
mechanisms	O
involved	O
and	O
to	O
combat	B-CHED
this	O
new	O
emerging	O
human	O
infectious	O
disease	O
.	O

Twenty	O
-	O
four	O
animals	O
were	O
randomly	O
allocated	O
to	O
three	O
equal	O
groups	O
(	O
sham	O
,	O
control	O
,	O
simvastatin	B-CHED
).	O

Prognosis	O
remains	O
very	O
poor	O
,	O
but	O
aggressive	O
treatment	O
is	O
essential	O
,	O
including	O
surgical	O
debridement	O
and	O
the	O
removal	O
of	O
foci	O
of	O
infection	O
along	O
with	O
the	O
use	O
of	O
amphotericin	B-CHED
B	I-CHED
.	O
The	O
clinical	O
utility	O
of	O
newer	O
antifungal	B-CHED
agents	I-CHED
remains	O
to	O
be	O
determined	O
.	O

Eighteen	O
hybridomas	O
secreting	O
the	O
S	O
protein	B-CHED
-	O
specific	O
MAbs	O
were	O
obtained	O
.	O

The	O
median	O
duration	O
from	O
onset	O
of	O
fever	O
to	O
the	O
nadir	O
level	O
or	O
most	O
severe	O
condition	O
was	O
9	O
days	O
for	O
hypoxia	O
,	O
7	O
days	O
for	O
lymphocytopenia	O
,	O
6	O
.	O
5	O
days	O
for	O
thrombocytopenia	O
,	O
9	O
.	O
5	O
days	O
for	O
maximal	O
pulmonary	O
infiltrates	O
;	O
to	O
peak	O
serum	O
levels	O
was	O
9	O
days	O
for	O
C	O
-	O
reactive	O
protein	B-CHED
(	O
CRP	O
),	O
10	O
.	O
5	O
days	O
for	O
IL	O
-	O
6	O
,	O
13	O
.	O
5	O
days	O
for	O
IL	O
-	O
8	O
and	O
12	O
days	O
for	O
TNF	O
-	O
alpha	O
;	O
to	O
defervescence	O
was	O
13	O
days	O
.	O

Among	O
the	O
20	O
isolates	O
of	O
S	O
.	O
pneumoniae	O
,	O
85	O
%	O
(	O
17	O
/	O
20	O
)	O
were	O
susceptible	O
to	O
penicillin	B-CHED
,	O
3	O
(	O
15	O
%)	O
were	O
intermediate	O
,	O
and	O
none	O
were	O
resistant	O
to	O
penicillin	B-CHED
.	O

The	O
results	O
also	O
indicate	O
that	O
the	O
glycyrrhizin	B-CHED
concentrations	O
of	O
3	O
-	O
6	O
months	O
old	O
pot	O
plants	O
were	O
similar	O
or	O
even	O
higher	O
than	O
the	O
previously	O
reported	O
values	O
for	O
3	O
-	O
4	O
years	O
old	O
field	O
-	O
grown	O
plants	O
and	O
confirm	O
that	O
high	O
concentration	O
of	O
glycyrrhizin	B-CHED
production	O
is	O
possible	O
within	O
a	O
very	O
short	O
production	O
period	O
under	O
controlled	O
environments	O
.	O

Secomet	O
-	O
V	O
,	O
therefore	O
,	O
is	O
a	O
broad	O
-	O
spectrum	O
antiviral	B-CHED
,	O
which	O
possibly	O
works	O
by	O
neutralizing	O
viral	O
infectivity	O
,	O
resulting	O
in	O
the	O
prevention	O
of	O
viral	O
attachment	O
.	O

ABSTRACT	O
:	O
Evaluation	O
of	O
a	O
wide	O
variety	O
of	O
pyridine	B-CHED
N	I-CHED
-	I-CHED
oxide	I-CHED
derivatives	O
on	O
their	O
inhibitory	O
activity	O
against	O
feline	O
coronavirus	O
(	O
FIPV	O
strain	O
)	O
and	O
human	O
SARS	O
-	O
CoV	O
(	O
Frankfurt	O
strain	O
-	O
1	O
)	O
in	O
cell	O
culture	O
.	O

The	O
oxide	B-CHED
part	O
on	O
the	O
pyridine	B-CHED
moiety	O
proved	O
indispensable	O
for	O
anti	O
-	O
coronavirus	O
activity	O
.	O

We	O
have	O
previously	O
demonstrated	O
that	O
CNS	B-CHED
gene	O
transfer	O
of	O
AAV2	O
(	O
CU	O
)	O
hCLN2	O
(	O
an	O
AAV2	O
-	O
based	O
vector	O
expressing	O
the	O
human	O
CLN2	O
cDNA	O
)	O
in	O
rats	O
and	O
nonhuman	O
primates	O
mediates	O
long	O
-	O
term	O
TPP	B-CHED
-	O
I	O
expression	O
in	O
the	O
CNS	B-CHED
neurons	O
[	O
Sondhi	O
,	O
D	O
.,	O
Peterson	O
,	O
D	O
.	O
A	O
.,	O
Giannaris	O
,	O
E	O
.	O
L	O
.,	O
Sanders	O
,	O
C	O
.	O
T	O
.,	O
Mendez	O
,	O
B	O
.	O
S	O
.,	O
De	O
,	O
B	O
.,	O
Rostkowski	O
,	O
A	O
.,	O
Blancard	O
,	O
B	O
.,	O
Bjugstad	O
,	O
K	O
.,	O
Sladek	O
,	O
J	O
.	O
R	O
.,	O
Redmond	O
,	O
D	O
.	O
E	O
.,	O
Leopold	O
,	O
P	O
.	O
L	O
.,	O
Kaminsky	O
,	O
S	O
.	O
M	O
.,	O
Hackett	O
,	O
N	O
.	O
R	O
.,	O
and	O
Crystal	O
,	O
R	O
.	O
G	O
.	O
(	O
2005	O
).	O

The	O
present	O
study	O
tests	O
the	O
hypothesis	O
that	O
direct	O
CNS	B-CHED
administration	O
of	O
a	O
clinical	O
-	O
grade	O
AAV2	O
(	O
CU	O
)	O
hCLN2	O
vector	O
to	O
the	O
CNS	B-CHED
of	O
rats	O
and	O
nonhuman	O
primates	O
at	O
doses	O
scalable	O
to	O
humans	O
has	O
a	O
long	O
-	O
term	O
safety	O
profile	O
acceptable	O
for	O
initiating	O
clinical	O
trials	O
.	O

At	O
13	O
,	O
26	O
,	O
and	O
52	O
weeks	O
,	O
vector	O
and	O
phosphate	B-CHED
-	O
buffered	O
salineinjected	O
rats	O
were	O
killed	O
(	O
n	O
=	O
6	O
per	O
time	O
point	O
),	O
and	O
blood	O
,	O
brain	O
,	O
and	O
distant	O
organs	O
were	O
assessed	O
.	O

Diagnostic	O
modeling	O
using	O
a	O
newly	O
modified	O
receiver	O
operator	O
characteristic	O
approach	O
was	O
applied	O
to	O
recently	O
published	O
data	O
from	O
our	O
laboratory	O
on	O
lavaged	O
inflammatory	O
mediators	O
from	O
rodents	O
given	O
intratracheal	O
normal	O
saline	O
,	O
hydrochloric	B-CHED
acid	I-CHED
,	O
small	O
nonacidified	O
gastric	O
particles	O
,	O
or	O
a	O
combination	O
of	O
acid	O
and	O
small	O
gastric	O
particles	O
.	O

Overall	O
,	O
the	O
four	O
types	O
of	O
aspiration	O
were	O
correctly	O
discriminated	O
in	O
85	O
of	O
96	O
rats	O
(	O
89	O
%),	O
72	O
of	O
78	O
wild	O
-	O
type	O
mice	O
(	O
92	O
%),	O
and	O
59	O
of	O
73	O
MCP	B-CHED
-	O
1	O
(-/-)	O
mice	O
(	O
81	O
%)	O
by	O
models	O
that	O
used	O
a	O
maximum	O
of	O
only	O
two	O
mediators	O
.	O

In	O
conclusion	O
,	O
chronic	O
eNOS	O
overexpression	O
may	O
protect	O
the	O
lung	O
from	O
VILI	O
by	O
inhibiting	O
the	O
production	O
of	O
inflammatory	O
chemokines	O
and	O
cytokines	O
that	O
are	O
associated	O
with	O
neutrophil	O
infiltration	O
into	O
the	O
air	B-CHED
space	O
.	O

Four	O
unique	O
genotype	O
clusters	B-CHED
containing	O
isolates	O
with	O
indigenous	O
genotypes	O
were	O
observed	O
.	O

ABSTRACT	O
:	O
To	O
study	O
the	O
pulmonary	O
inflammatory	O
reaction	O
induced	O
by	O
N	O
-	O
protein	B-CHED
of	O
SARS	O
-	O
CoV	O
in	O
rat	O
models	O
and	O
the	O
effects	O
of	O
glucocorticoids	B-CHED
on	O
the	O
inflammatory	O
reaction	O
.	O

ABSTRACT	O
:	O
Hantavirus	O
pulmonary	O
syndrome	O
(	O
HPS	B-CHED
)	O
is	O
an	O
acute	O
disease	O
resulting	O
from	O
infection	O
with	O
any	O
one	O
of	O
a	O
number	O
of	O
New	O
World	O
hantaviruses	O
.	O

Postmortem	O
tissue	O
samples	O
show	O
high	O
levels	O
of	O
viral	O
antigen	B-CHED
within	O
the	O
respiratory	O
endothelium	O
,	O
but	O
it	O
is	O
not	O
clear	O
how	O
the	O
virus	O
can	O
traverse	O
the	O
respiratory	O
epithelium	O
in	O
order	O
to	O
initiate	O
infection	O
in	O
the	O
microvasculature	O
.	O

To	O
demonstrate	O
that	O
MHV	O
can	O
be	O
retargeted	O
to	O
a	O
nonnative	O
receptor	O
on	O
human	O
cells	O
,	O
we	O
produced	O
bispecific	O
adapter	O
proteins	B-CHED
composed	O
of	O
the	O
N	O
-	O
terminal	O
D1	O
domain	O
of	O
mCEACAM1a	O
linked	O
to	O
a	O
short	O
targeting	O
peptide	B-CHED
,	O
the	O
six	O
-	O
amino	O
-	O
acid	O
His	O
tag	O
.	O

TITLE	O
:	O
Important	O
role	O
for	O
the	O
transmembrane	O
domain	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
spike	O
protein	B-CHED
during	O
entry	O
.	O

TITLE	O
:	O
[	O
Receptor	O
-	O
binding	O
ability	O
of	O
fragments	O
260	O
-	O
600	O
and	O
397	O
-	O
796	O
of	O
SARS	O
-	O
associated	O
coronavirus	O
spike	O
protein	B-CHED
].	O

Two	O
different	O
fragments	O
S260	O
-	O
600	O
and	O
S397	O
-	O
796	O
of	O
the	O
SARS	O
-	O
CoV	O
S	O
protein	B-CHED
were	O
expressed	O
in	O
Escherichia	O
coli	O
(	O
E	O
.	O
coli	O
)	O
using	O
a	O
pET	O
expression	O
vector	O
,	O
respectively	O
.	O

ABSTRACT	O
:	O
Lithium	B-CHED
(	O
Eskalith	O
)	O
is	O
commonly	O
used	O
in	O
the	O
treatment	O
of	O
depressive	O
and	O
bipolar	O
affective	O
disorders	O
,	O
in	O
a	O
population	O
at	O
relatively	O
high	O
risk	O
for	O
overdose	O
.	O

This	O
is	O
a	O
rare	O
case	O
of	O
ARDS	O
associated	O
with	O
lithium	B-CHED
intoxication	O
.	O

We	O
examined	O
the	O
relationship	O
between	O
the	O
redox	O
state	O
of	O
the	O
20	O
cysteine	B-CHED
residues	O
of	O
the	O
SARS	O
-	O
CoV	O
(	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
)	O
Spike	O
glycoprotein	B-CHED
S1	O
subdomain	O
and	O
its	O
functional	O
properties	O
.	O

In	O
addition	O
,	O
virus	O
/	O
cell	O
membrane	O
fusion	O
occurred	O
in	O
the	O
presence	O
of	O
sulfhydryl	O
-	O
blocking	O
reagents	B-CHED
and	O
oxidoreductase	O
inhibitors	B-CHED
.	O

Moreover	O
,	O
in	O
order	O
to	O
get	O
the	O
antigen	B-CHED
for	O
ELISA	O
and	O
in	O
vitro	O
stimulation	O
assay	O
,	O
N	O
protein	B-CHED
were	O
expressed	O
and	O
purified	O
from	O
E	O
.	O
coli	O
bacteria	O
.	O

Further	O
experiments	O
in	O
field	O
mouse	O
also	O
support	O
the	O
claim	O
that	O
membrane	O
protein	B-CHED
can	O
augment	O
the	O
N	O
-	O
specific	O
immune	O
responses	O
.	O

Virus	O
challenge	O
test	O
was	O
conducted	O
in	O
BSL3	O
bio	O
safety	O
laboratory	O
with	O
Brandt	O
'	O
s	O
vole	O
SARS	O
-	O
CoV	O
model	O
,	O
and	O
the	O
results	O
indicated	O
that	O
co	O
-	O
immunization	O
of	O
M	O
and	O
N	O
antigens	B-CHED
could	O
reduce	O
the	O
mortality	O
and	O
pathological	O
changes	O
in	O
lung	O
from	O
the	O
virus	O
infection	O
.	O

Using	O
surface	O
-	O
enhanced	O
laser	O
desorption	O
/	O
ionization	O
(	O
SELDI	O
)	O
ProteinChip	O
technology	O
,	O
we	O
profiled	O
and	O
compared	O
serum	O
proteins	B-CHED
of	O
39	O
patients	O
with	O
early	O
-	O
stage	O
SARS	O
infection	O
and	O
39	O
non	O
-	O
SARS	O
patients	O
who	O
were	O
suspected	O
cases	O
during	O
the	O
SARS	O
outbreak	O
period	O
.	O

The	O
SMART	O
debriefing	O
(	O
1	O
)	O
aimed	O
at	O
boosting	O
resilience	O
and	O
catalyzing	O
transformation	O
among	O
persons	O
undergoing	O
stressful	O
events	O
,	O
(	O
2	O
)	O
adopted	O
a	O
growth	O
-	O
oriented	O
and	O
holistic	O
approach	O
of	O
health	O
promotion	O
,	O
and	O
(	O
3	O
)	O
employed	O
methods	O
drawn	O
from	O
various	O
indigenous	O
sources	O
(	O
e	O
.	O
g	O
.	O
Asian	O
philosophies	O
and	O
Traditional	O
Chinese	O
Medicine	B-CHED
).	O

Thus	O
,	O
dose	O
levels	O
for	O
protein	B-CHED
subunit	O
vaccines	O
are	O
likely	O
to	O
be	O
very	O
high	O
and	O
the	O
antigen	B-CHED
may	O
need	O
to	O
be	O
protected	O
from	O
proteolysis	O
for	O
oral	O
delivery	O
to	O
be	O
efficacious	O
.	O

Fusions	O
to	O
carrier	O
molecules	O
can	O
stabilize	O
the	O
expressed	O
antigen	B-CHED
,	O
aid	O
in	O
antigen	B-CHED
enrichment	O
or	O
purification	O
strategies	O
,	O
and	O
facilitate	O
delivery	O
to	O
effector	B-CHED
sites	O
in	O
the	O
gastrointestinal	O
tract	O
.	O

In	O
many	O
coronaviruses	O
,	O
the	O
nucleocapsid	O
protein	B-CHED
(	O
N	O
protein	B-CHED
)	O
has	O
been	O
shown	O
to	O
inhibit	O
cell	O
cycle	O
progression	O
although	O
the	O
mechanism	O
behind	O
this	O
is	O
poorly	O
understood	O
.	O

N	O
protein	B-CHED
expression	O
was	O
found	O
to	O
directly	O
inhibit	O
the	O
activity	O
of	O
the	O
cyclin	O
-	O
CDK	O
complex	O
,	O
resulting	O
in	O
hypophosphorylation	O
of	O
retinoblastoma	O
protein	B-CHED
with	O
a	O
concomitant	O
down	O
-	O
regulation	O
in	O
E2F1	O
-	O
mediated	O
transactivation	O
.	O

These	O
data	O
suggest	O
that	O
the	O
S	O
phase	O
inhibitory	O
activity	O
of	O
the	O
N	O
protein	B-CHED
may	O
have	O
major	O
significance	O
during	O
viral	O
pathogenesis	O
.	O

ABSTRACT	O
:	O
The	O
3a	O
protein	B-CHED
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
associated	O
coronavirus	O
is	O
expressed	O
and	O
transported	O
to	O
the	O
plasma	O
membrane	O
in	O
tissue	O
cells	O
of	O
infected	O
patients	O
.	O

Four	O
herbs	O
may	O
decrease	O
the	O
dosage	O
of	O
corticosteroids	B-CHED
.	O

It	O
is	O
possible	O
that	O
Chinese	O
herbs	O
combined	O
with	O
Western	O
medicines	O
may	O
improve	O
symptoms	O
,	O
quality	O
of	O
life	O
,	O
and	O
lung	O
infiltrate	O
absorption	O
and	O
decrease	O
the	O
corticosteroid	B-CHED
dosage	O
for	O
SARS	O
patients	O
.	O

Human	O
fgl2	O
(	O
hfgl2	O
)	O
was	O
detected	O
in	O
21	O
of	O
23	O
patients	O
(	O
91	O
.	O
30	O
%)	O
with	O
severe	O
AOC	O
hepatitis	O
B	O
,	O
while	O
only	O
1	O
of	O
13	O
patients	O
(	O
7	O
.	O
69	O
%)	O
with	O
mild	O
chronic	O
hepatitis	O
B	O
and	O
cirrhosis	O
had	O
hfgl2	O
mRNA	B-CHED
or	O
protein	B-CHED
expression	O
.	O

By	O
electron	O
spin	O
resonance	O
(	O
ESR	O
)	O
detection	O
,	O
we	O
found	O
that	O
the	O
prescription	O
I	O
,	O
Herba	O
Patriniae	O
and	O
other	O
main	O
herbs	O
in	O
that	O
recipe	O
,	O
could	O
quench	O
effectively	O
the	O
free	O
radicals	B-CHED
generated	O
in	O
the	O
process	O
of	O
lambda	O
-	O
lysogenic	O
cells	O
by	O
UV	O
.	O

In	O
an	O
amazing	O
pace	O
of	O
research	O
,	O
several	O
potent	O
human	O
mAbs	O
targeting	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
S	O
glycoprotein	B-CHED
that	O
can	O
affect	O
infections	O
in	O
animal	O
models	O
have	O
been	O
developed	O
months	O
after	O
the	O
virus	O
was	O
identified	O
in	O
2003	O
.	O

TITLE	O
:	O
Synthesis	O
of	O
cyclopentenyl	O
carbocyclic	O
nucleosides	B-CHED
as	O
potential	O
antiviral	B-CHED
agents	I-CHED
against	O
orthopoxviruses	O
and	O
SARS	O
.	O

TITLE	O
:	O
Design	O
and	O
synthesis	O
of	O
dipeptidyl	O
glutaminyl	B-CHED
fluoromethyl	O
ketones	B-CHED
as	O
potent	O
severe	O
acute	O
respiratory	O
syndrome	O
coronovirus	O
(	O
SARS	O
-	O
CoV	O
)	O
inhibitors	B-CHED
.	O

Lucinactant	O
,	O
a	O
synthetic	O
surfactant	B-CHED
containing	O
a	O
surfactant	B-CHED
protein	B-CHED
-	O
B	O
peptide	B-CHED
analog	O
,	O
has	O
been	O
shown	O
to	O
be	O
effective	O
in	O
animal	O
models	O
and	O
phase	O
II	O
clinical	O
trials	O
.	O

Among	O
preterm	O
lambs	O
with	O
severe	O
RDS	O
,	O
lucinactant	O
produced	O
improvements	O
in	O
gas	O
exchange	O
and	O
lung	O
mechanics	O
similar	O
to	O
those	O
observed	O
with	O
a	O
porcine	O
-	O
derived	O
surfactant	B-CHED
.	O

By	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
antibodies	O
against	O
ADV	O
were	O
detected	O
in	O
55	O
sera	O
(	O
31	O
%),	O
against	O
PRCV	O
in	O
five	O
sera	O
(	O
3	O
%),	O
PPV	B-CHED
in	O
87	O
sera	O
(	O
49	O
%),	O
APP	B-CHED
in	O
93	O
sera	O
(	O
52	O
%),	O
M	O
.	O
hyopneumoniae	O
in	O
38	O
sera	O
(	O
21	O
%),	O
Salmonella	O
spp	O
.	O

TITLE	O
:	O
Specific	O
epitopes	O
of	O
the	O
structural	O
and	O
hypothetical	O
proteins	B-CHED
elicit	O
variable	O
humoral	O
responses	O
in	O
SARS	O
patients	O
.	O

ABSTRACT	O
:	O
A	O
41	O
-	O
year	O
-	O
old	O
,	O
obese	O
man	B-CHED
with	O
a	O
history	O
of	O
incomplete	O
paraplegia	O
of	O
both	O
legs	O
and	O
chronic	O
venous	O
insufficiency	O
with	O
stasis	O
dermatitis	O
presented	O
with	O
acute	O
respiratory	O
and	O
hyperdynamic	O
hemodynamic	O
failure	O
.	O

The	O
initial	O
treatment	O
of	O
atypical	O
pneumonia	O
with	O
ciprofloxacin	B-CHED
failed	O
.	O

After	O
the	O
patient	O
was	O
treated	O
with	O
doxycycline	B-CHED
200	O
mg	O
i	O
.	O
v	O
.	O

The	O
origin	O
of	O
the	O
higher	O
stability	O
of	O
LightUp	O
probe	O
kits	O
compared	O
to	O
others	O
,	O
based	O
on	O
alternative	O
probe	O
technologies	O
,	O
is	O
partly	O
the	O
relatively	O
good	O
stability	O
of	O
cyanine	B-CHED
dyes	I-CHED
but	O
also	O
the	O
resistance	O
towards	O
nucleases	O
and	O
proteases	O
of	O
the	O
synthetic	O
DNA	O
analogue	O
peptide	B-CHED
nucleic	I-CHED
acid	I-CHED
that	O
is	O
used	O
as	O
the	O
sequence	O
recognizing	O
element	O
in	O
LightUp	O
probes	O
.	O

The	O
56th	O
nucleotide	B-CHED
of	O
SARS	O
-	O
CoV	O
5	O
'	O
UTR	O
was	O
found	O
to	O
be	O
the	O
initiation	O
site	O
for	O
transcription	O
.	O

D	O
:	O
The	O
56th	O
nucleotide	B-CHED
and	O
its	O
down	O
stream	O
TRS	O
of	O
SARS	O
-	O
CoV	O
5	O
'	O
UTR	O
plays	O
a	O
key	O
role	O
in	O
regulating	O
transcription	O
.	O

TITLE	O
:	O
Oral	O
immunoadjuvant	B-CHED
activity	O
of	O
Lactobacillus	O
casei	O
subsp	O
.	O

casei	O
in	O
dextran	B-CHED
-	O
fed	O
layer	O
chickens	O
.	O

All	O
nucleic	B-CHED
acid	I-CHED
diagnostic	O
assays	O
were	O
negative	O
for	O
C	O
pneumoniae	O
and	O
M	O
pneumoniae	O
in	O
respiratory	O
samples	O
from	O
patients	O
with	O
SARS	O
having	O
serological	O
evidence	O
for	O
these	O
atypical	O
pathogens	O
.	O

TITLE	O
:	O
Glycosylation	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
triple	O
-	O
spanning	O
membrane	O
proteins	B-CHED
3a	O
and	O
M	O
.	O
ABSTRACT	O
:	O
The	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
open	O
reading	O
frame	O
3a	O
protein	B-CHED
has	O
recently	O
been	O
shown	O
to	O
be	O
a	O
structural	O
protein	B-CHED
.	O

The	O
protein	B-CHED
is	O
encoded	O
by	O
one	O
of	O
the	O
so	O
-	O
called	O
group	O
-	O
specific	O
genes	O
and	O
has	O
no	O
sequence	O
homology	O
with	O
any	O
of	O
the	O
known	O
structural	O
or	O
group	O
-	O
specific	O
proteins	B-CHED
of	O
coronaviruses	O
.	O

It	O
does	O
,	O
however	O
,	O
have	O
several	O
similarities	O
to	O
the	O
coronavirus	O
M	O
proteins	B-CHED
;	O
(	O
i	O
)	O
they	O
are	O
triple	O
membrane	O
spanning	O
with	O
the	O
same	O
topology	O
,	O
(	O
ii	O
)	O
they	O
have	O
similar	O
intracellular	O
localizations	O
(	O
predominantly	O
Golgi	O
),	O
(	O
iii	O
)	O
both	O
are	O
viral	O
structural	O
proteins	B-CHED
,	O
and	O
(	O
iv	O
)	O
they	O
appear	O
to	O
interact	O
with	O
the	O
E	O
and	O
S	O
proteins	B-CHED
,	O
as	O
well	O
as	O
with	O
each	O
other	O
.	O

The	O
proteins	B-CHED
were	O
expressed	O
separately	O
using	O
the	O
vaccinia	O
virus	O
T7	O
expression	O
system	O
,	O
followed	O
by	O
metabolic	O
labeling	O
.	O

O	O
-	O
glycosylation	O
of	O
the	O
3a	O
protein	B-CHED
was	O
indeed	O
confirmed	O
using	O
an	O
in	O
situ	O
O	O
-	O
glycosylation	O
assay	O
of	O
endoplasmic	O
reticulum	O
-	O
retained	O
mutants	O
.	O

Additionally	O
,	O
we	O
provide	O
evidence	O
for	O
the	O
contribution	O
of	O
two	O
kinases	O
,	O
the	O
MAP	O
kinase	O
p38MAPK	O
,	O
and	O
protein	B-CHED
kinase	O
C	O
(	O
PKC	O
)	O
delta	O
to	O
antiviral	B-CHED
protection	O
from	O
MHV	O
-	O
1	O
infection	O
.	O

Based	O
on	O
this	O
,	O
a	O
super	O
-	O
active	O
triple	O
-	O
mutant	O
STI	O
/	O
A	O
with	O
a	O
3	O
.	O
7	O
-	O
fold	O
activity	O
enhancement	O
was	O
thus	O
engineered	O
by	O
mutating	O
residues	O
Ser284	O
,	O
Thr285	O
and	O
Ile286	O
to	O
Ala	B-CHED
.	O
The	O
dynamic	O
light	O
scattering	O
,	O
CD	O
and	O
NMR	O
characterizations	O
indicate	O
that	O
the	O
wild	O
-	O
type	O
(	O
WT	O
)	O
and	O
STI	O
/	O
A	O
mutant	O
share	O
similar	O
structural	O
and	O
dimerization	O
properties	O
,	O
thus	O
implying	O
that	O
in	O
addition	O
to	O
dimerization	O
,	O
the	O
extra	O
domain	O
might	O
have	O
other	O
mechanisms	O
to	O
regulate	O
the	O
catalytic	O
machinery	O
.	O

A	O
logarithmic	O
relationship	O
best	O
described	O
the	O
correlation	O
between	O
compliance	O
and	O
type	O
III	O
procollagen	O
peptide	B-CHED
,	O
in	O
agreement	O
with	O
a	O
collagen	O
-	O
dependent	O
model	O
of	O
maximal	O
distension	O
.	O

TITLE	O
:	O
Differential	O
roles	O
for	O
CXCR3	O
in	O
CD4	O
+	O
and	O
CD8	O
+	O
T	O
cell	O
trafficking	O
following	O
viral	O
infection	O
of	O
the	O
CNS	B-CHED
.	O

However	O
,	O
the	O
mechanisms	O
governing	O
inflammation	O
in	O
response	O
to	O
viral	O
infection	O
of	O
the	O
CNS	B-CHED
are	O
not	O
well	O
understood	O
.	O

The	O
CXC	O
chemokine	O
ligand	B-CHED
10	O
(	O
CXCL10	O
)	O
is	O
expressed	O
following	O
MHV	O
infection	O
and	O
signals	O
T	O
cells	O
to	O
migrate	O
into	O
the	O
CNS	B-CHED
.	O

In	O
days	O
with	O
a	O
lower	O
air	B-CHED
temperature	O
during	O
the	O
epidemic	O
,	O
the	O
risk	O
of	O
increased	O
daily	O
incidence	O
of	O
SARS	O
was	O
18	O
.	O
18	O
-	O
fold	O
(	O
95	O
%	O
confidence	O
interval	O
5	O
.	O
6	O
-	O
58	O
.	O
8	O
)	O
higher	O
than	O
in	O
days	O
with	O
a	O
higher	O
temperature	O
.	O

Fixation	O
of	O
SARS	O
-	O
CoV	O
-	O
infected	O
Vero	O
E6	O
cells	O
with	O
a	O
fixative	B-CHED
including	O
formalin	B-CHED
,	O
glutaraldehyde	B-CHED
,	O
methanol	B-CHED
and	O
acetone	B-CHED
for	O
5	O
min	O
or	O
longer	O
eliminated	O
all	O
infectivity	O
.	O

Apparent	O
loss	O
of	O
memory	O
CD8	O
+	O
effector	B-CHED
function	O
in	O
vivo	O
was	O
supported	O
by	O
a	O
prominent	O
decline	O
in	O
MHC	O
expression	O
on	O
CNS	B-CHED
resident	O
target	O
cells	O
,	O
presumably	O
reflecting	O
diminished	O
IFN	O
-	O
gamma	O
.	O

These	O
results	O
indicated	O
that	O
the	O
region	O
around	O
residues	O
156	O
-	O
175	O
of	O
the	O
N	O
protein	B-CHED
is	O
immunogenic	O
in	O
the	O
mouse	O
,	O
monkey	O
,	O
and	O
human	O
.	O

212	O
IU	O
/	O
L	O
(	O
HRC	O
203	O
)]	O
and	O
histological	O
evidence	O
of	O
hepatic	O
necrosis	O
(<	O
10	O
%	O
in	O
ribavirin	B-CHED
/	O
HRC	O
203	O
vs	O
.	O
90	O
%	O
in	O
untreated	O
controls	O
).	O

ABSTRACT	O
:	O
Recently	O
a	O
method	O
to	O
measure	O
nitric	B-CHED
oxide	I-CHED
(	O
NO	O
)	O
concentration	O
in	O
exhaled	O
air	B-CHED
has	O
been	O
developed	O
.	O

ABSTRACT	O
:	O
A	O
recombinant	O
SARS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
glycoprotein	B-CHED
vaccine	O
produced	O
in	O
insect	O
cells	O
in	O
a	O
pre	O
-	O
clinical	O
development	O
stage	O
is	O
described	O
.	O

Neutralizing	O
antibody	O
titers	O
correlated	O
closely	O
with	O
standard	O
ELISA	O
reactivity	O
against	O
the	O
S	O
glycoprotein	B-CHED
.	O

Significantly	O
enhanced	O
immune	O
responses	O
,	O
manifested	O
by	O
higher	O
titers	O
of	O
serum	O
ELISA	O
and	O
viral	O
neutralizing	O
antibodies	O
,	O
were	O
achieved	O
in	O
adjuvanted	O
groups	O
with	O
fewer	O
doses	O
and	O
lower	O
concentration	O
of	O
S	O
glycoprotein	B-CHED
.	O

Comparison	O
of	O
the	O
sequences	O
of	O
these	O
strains	O
revealed	O
a	O
deletion	O
of	O
58	O
bases	B-CHED
in	O
the	O
3	O
'	O
untranslated	O
region	O
(	O
UTR	O
)	O
of	O
IBV	O
vaccine	O
strains	O
but	O
not	O
in	O
the	O
field	O
isolates	O
.	O

TITLE	O
:	O
[	O
Effect	O
of	O
glucocorticoid	B-CHED
with	O
traditional	O
Chinese	O
medicine	B-CHED
in	O
severe	O
acute	O
aespiratory	O
syndrome	O
(	O
SARS	O
)].	O

CONCLUSIONS	O
:	O
Compared	O
with	O
the	O
group	O
of	O
simplicity	O
western	O
mendicine	O
,	O
in	O
the	O
group	O
of	O
integratived	O
Chinese	O
and	O
western	O
mendicine	O
,	O
time	O
in	O
hospital	O
shorten	O
,	O
pneumonia	O
duration	O
shorten	O
,	O
mortality	O
fall	O
,	O
simultaneity	O
,	O
glucocorticoid	B-CHED
'	O
s	O
average	O
dosage	O
is	O
decreased	O
.	O

CDV	B-CHED
1	O
mg	O
/	O
kg	O
was	O
given	O
three	O
times	O
per	O
week	O
intravenously	O
with	O
intravenous	O
hydration	O
and	O
oral	O
probenecid	B-CHED
.	O

In	O
vitro	O
and	O
in	O
vivo	O
expression	O
of	O
clones	O
with	O
six	O
,	O
seven	O
and	O
eight	O
Ts	O
,	O
respectively	O
,	O
showed	O
the	O
detection	O
of	O
the	O
full	O
-	O
length	O
3a	O
protein	B-CHED
.	O

We	O
also	O
demonstrated	O
that	O
DC	O
-	O
SIGN	O
was	O
inducible	O
in	O
THP	B-CHED
-	O
1	O
as	O
well	O
as	O
A549	O
cells	O
after	O
SARS	O
-	O
CoV	O
infection	O
.	O

The	O
subgroup	O
3	O
strains	O
,	O
represented	O
by	O
isolate	O
chicken	O
/	O
Australia	O
/	O
N2	O
/	O
04	O
,	O
had	O
an	O
S1	O
protein	B-CHED
that	O
shared	O
a	O
low	O
level	O
of	O
identity	O
with	O
both	O
subgroups	O
1	O
and	O
2	O
:	O
61	O
to	O
63	O
%	O
and	O
56	O
to	O
59	O
%,	O
respectively	O
.	O

TITLE	O
:	O
Insulin	B-CHED
attenuates	O
endotoxin	O
-	O
induced	O
acute	O
lung	O
injury	O
in	O
conscious	O
rats	O
.	O

Insulin	B-CHED
and	O
glucose	B-CHED
infusion	O
(	O
0	O
.	O
01	O
mL	O
/	O
min	O
)	O
was	O
started	O
5	O
mins	O
before	O
lipopolysaccharide	B-CHED
and	O
continued	O
for	O
120	O
mins	O
.	O

We	O
also	O
measured	O
plasma	O
nitrate	B-CHED
/	O
nitrite	B-CHED
and	O
methyl	B-CHED
guanidine	B-CHED
.	O

Insulin	B-CHED
is	O
effective	O
in	O
reducing	O
or	O
preventing	O
the	O
lipopolysaccharide	B-CHED
-	O
induced	O
increases	O
in	O
plasma	O
nitrate	B-CHED
/	O
nitrite	B-CHED
and	O
methyl	B-CHED
guanidine	B-CHED
and	O
the	O
occurrence	O
of	O
acute	O
lung	O
injury	O
.	O

The	O
S2	O
-	O
HR2	O
structure	O
,	O
which	O
is	O
the	O
first	O
example	O
of	O
the	O
prefusion	O
form	O
of	O
coronavirus	O
envelope	O
,	O
supports	O
the	O
current	O
model	O
of	O
viral	O
membrane	O
fusion	O
and	O
gives	O
insight	O
into	O
the	O
design	O
of	O
structure	O
-	O
based	O
antagonists	B-CHED
of	O
SARS	O
.	O

The	O
nucleotide	B-CHED
sequence	O
of	O
the	O
S1	O
gene	O
was	O
determined	O
and	O
comparatively	O
analyzed	O
with	O
some	O
sequences	O
of	O
this	O
gene	O
of	O
foreign	O
and	O
Russian	O
vaccine	O
strains	O
and	O
isolates	O
.	O

A	O
total	O
of	O
43	O
samples	O
from	O
outbreaks	O
in	O
both	O
countries	O
were	O
used	O
for	O
PCR	O
amplification	O
and	O
direct	O
sequencing	O
of	O
a	O
624	O
-	O
nucleotide	B-CHED
fragment	O
of	O
the	O
BCoV	O
S	O
gene	O
.	O

The	O
facts	O
that	O
scFv	O
H12	O
bound	O
to	O
the	O
SARS	O
-	O
S1	O
protein	B-CHED
under	O
non	O
-	O
reducing	O
conditions	O
and	O
that	O
it	O
did	O
not	O
bind	O
to	O
monomeric	O
S1	O
protein	B-CHED
under	O
reducing	O
conditions	O
strongly	O
suggest	O
that	O
scFv	O
H12	O
recognizes	O
a	O
conformational	O
epitope	B-CHED
shared	O
by	O
oligomeric	O
S1	O
proteins	B-CHED
.	O

Important	O
developments	O
in	O
the	O
identification	O
,	O
characterization	O
and	O
clinical	O
utility	O
of	O
inhibitors	B-CHED
of	O
human	O
immunodeficiency	O
virus	O
;	O
the	O
hepatitis	O
viruses	O
,	O
hepatitis	O
B	O
,	O
hepatitis	O
C	O
;	O
the	O
herpes	O
family	O
of	O
viruses	O
,	O
herpes	O
simplex	O
viruses	O
1	O
and	O
2	O
,	O
varicella	O
zoster	O
virus	O
,	O
Epstein	O
-	O
Barr	O
virus	O
and	O
human	O
cytomegalovirus	O
;	O
the	O
respiratory	O
viruses	O
,	O
influenza	O
,	O
respiratory	O
syncytial	O
virus	O
,	O
human	O
metapneumovirus	O
,	O
picornaviruses	O
,	O
measles	O
and	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
;	O
human	O
papilloma	O
virus	O
;	O
rotavirus	O
;	O
Ebola	O
virus	O
and	O
West	O
Nile	O
virus	O
,	O
are	O
reviewed	O
.	O

(	O
3	O
)	O
Type	O
II	O
pneumocytes	O
,	O
with	O
mild	O
hyperplasia	O
,	O
atypia	O
,	O
cytomegaly	O
with	O
granular	O
amphophilic	O
cytoplasm	O
and	O
intracytoplasmic	O
lipid	B-CHED
accumulation	O
(	O
5	O
/	O
6	O
).	O

It	O
is	O
interesting	O
to	O
find	O
that	O
extreme	O
comparability	O
exists	O
between	O
AIBV	O
and	O
SARS	O
in	O
amino	B-CHED
acid	I-CHED
substitution	O
pattern	O
.	O

RESULTS	O
:	O
Crude	O
death	O
rate	O
was	O
lower	O
among	O
1188	O
steroid	B-CHED
-	O
treated	O
patients	O
compared	O
to	O
99	O
patients	O
in	O
Group	O
No	O
Steroid	B-CHED
(	O
17	O
.	O
0	O
%	O
vs	O
.	O
28	O
.	O
3	O
%).	O

TITLE	O
:	O
Relation	O
between	O
indocyanine	B-CHED
green	I-CHED
(	O
ICG	B-CHED
)	O
plasma	O
disappearance	O
rate	O
and	O
ICG	B-CHED
blood	O
clearance	O
in	O
critically	O
ill	O
patients	O
.	O

However	O
,	O
the	O
N	O
protein	B-CHED
-	O
targeted	O
Fab	O
or	O
IgG	O
antibodies	O
failed	O
to	O
neutralize	O
the	O
virus	O
.	O

Individual	O
viral	O
proteins	B-CHED
were	O
tested	O
for	O
their	O
abilities	O
to	O
regulate	O
COX	O
-	O
2	O
gene	O
expression	O
.	O

COX	O
-	O
2	O
promoter	O
mutations	O
suggested	O
that	O
activation	O
of	O
COX	O
-	O
2	O
transcription	O
depended	O
on	O
two	O
regulatory	O
elements	O
,	O
a	O
nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
kappaB	O
)	O
binding	O
site	O
,	O
and	O
a	O
CCAAT	O
/	O
enhancer	O
binding	O
protein	B-CHED
(	O
C	O
/	O
EBP	O
)	O
binding	O
site	O
.	O

No	O
cross	O
-	O
reactivity	O
was	O
found	O
between	O
the	O
3	O
N	O
proteins	B-CHED
.	O

Activated	O
partial	O
thromboplastin	O
time	O
(	O
APTT	O
),	O
protein	B-CHED
C	O
(	O
PC	O
),	O
antithrombin	O
III	O
(	O
AT	O
-	O
III	O
),	O
plasminogen	O
activator	O
inhibitor	B-CHED
(	O
PAI	O
),	O
activated	O
protein	B-CHED
C	O
resistance	O
(	O
APC	O
-	O
R	O
),	O
plasminogen	O
(	O
PLG	B-CHED
),	O
von	O
Willebrand	O
'	O
s	O
factor	O
(	O
vWF	O
),	O
D	O
-	O
dimer	O
(	O
D	O
-	O
D	O
),	O
fibrinogen	O
(	O
Fib	O
),	O
and	O
homocysteine	B-CHED
(	O
HCY	B-CHED
)	O
were	O
examined	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
).	O

When	O
part	O
of	O
dsRNA	B-CHED
or	O
in	O
the	O
presence	O
of	O
nonlabeled	O
dsRNA	B-CHED
,	O
the	O
5	O
'-	O
labeled	O
RNA	O
substrates	O
were	O
processed	O
to	O
significantly	O
smaller	O
products	O
,	O
indicating	O
that	O
binding	O
to	O
dsRNA	B-CHED
in	O
cis	O
or	O
trans	O
modulates	O
the	O
exonucleolytic	O
activity	O
of	O
nsp14	O
.	O

The	O
recombinant	O
adenovirus	O
bearing	O
S	O
-	O
protein	B-CHED
gene	O
was	O
generated	O
by	O
ligation	O
method	O
.	O

Four	O
of	O
52	O
patients	O
who	O
had	O
multiple	O
BAL	B-CHED
samples	O
submitted	O
on	O
the	O
same	O
day	O
had	O
negative	O
and	O
positive	O
results	O
by	O
NAT	O
on	O
different	O
samples	O
.	O

Plasma	O
samples	O
from	O
improvers	O
with	O
declining	O
cytokine	O
levels	O
over	O
time	O
elicited	O
a	O
progressive	O
increase	O
in	O
all	O
measured	O
aspects	O
of	O
glucocorticoid	B-CHED
(	O
GC	O
)-	O
induced	O
GRalpha	O
-	O
mediated	O
activity	O
(	O
p	O
=	O
0	O
.	O
0001	O
)	O
and	O
a	O
correspondent	O
reduction	O
in	O
NF	O
-	O
kappaB	O
nuclear	O
binding	O
(	O
p	O
=	O
0	O
.	O
0001	O
)	O
and	O
transcription	O
of	O
TNF	O
-	O
alpha	O
and	O
IL	O
-	O
1beta	O
(	O
regulated	O
,	O
GRalpha	O
-	O
driven	O
response	O
).	O

Prophylactic	O
antibiotics	B-CHED
(	O
e	O
.	O
g	O
.	O
imipenem	B-CHED
500	O
mg	O
i	O
.	O
v	O
.	O

TITLE	O
:	O
Lipoxin	B-CHED
A	O
(	O
4	O
)	O
regulates	O
bronchial	O
epithelial	O
cell	O
responses	O
to	O
acid	O
injury	O
.	O

Acid	O
triggered	O
and	O
early	O
marked	O
increases	O
in	O
COX	O
-	O
2	O
expression	O
and	O
PGE	B-CHED
(	O
2	O
)	O
production	O
,	O
and	O
acid	O
-	O
induced	O
PGE	B-CHED
(	O
2	O
)	O
significantly	O
increased	O
epithelial	O
LXA	O
(	O
4	O
)	O
receptor	O
(	O
ALX	O
)	O
expression	O
.	O

The	O
neurologic	O
signs	O
of	O
limb	O
numbness	O
and	O
water	B-CHED
phobia	O
occurred	O
from	O
61	O
days	O
after	O
the	O
dog	O
bite	O
;	O
the	O
clinical	O
course	O
was	O
progressive	O
,	O
with	O
the	O
most	O
severe	O
clinical	O
manifestations	O
being	O
fever	O
,	O
encephalitis	O
,	O
and	O
ARDS	O
.	O

Strong	O
expression	O
of	O
inducible	O
nitric	B-CHED
oxide	I-CHED
synthase	O
(	O
iNOS	O
)	O
was	O
detected	O
in	O
the	O
alveolar	O
macrophages	O
.	O

To	O
examine	O
the	O
mechanism	O
of	O
inhibition	O
of	O
dengue	O
virus	O
,	O
we	O
developed	O
two	O
replicon	O
systems	O
for	O
dengue	O
type	O
1	O
virus	O
:	O
(	O
i	O
)	O
a	O
stable	O
cell	O
line	O
that	O
harbored	O
replicons	O
containing	O
a	O
luciferase	O
reporter	O
and	O
a	O
neomycin	B-CHED
phosphotransferase	O
selection	O
marker	O
and	O
(	O
ii	O
)	O
a	O
luciferase	O
-	O
expressing	O
replicon	O
that	O
could	O
differentiate	O
between	O
viral	O
translation	O
and	O
RNA	O
replication	O
.	O

Indeed	O
,	O
studies	O
with	O
a	O
neurotropic	O
murine	O
coronavirus	O
,	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
),	O
have	O
provided	O
important	O
insight	O
into	O
the	O
functional	O
roles	O
of	O
chemokines	O
and	O
chemokine	O
receptors	O
in	O
participating	O
in	O
various	O
aspects	O
of	O
host	O
defense	O
as	O
well	O
as	O
disease	O
development	O
within	O
the	O
CNS	B-CHED
.	O

In	O
particular	O
,	O
SARS	O
-	O
CoV	O
did	O
not	O
activate	O
significant	O
transcription	O
of	O
the	O
interferons	O
IFN	O
-	O
alpha	O
,	O
IFN	O
-	O
beta	O
,	O
IFN	O
-	O
lambda1	O
,	O
IFN	O
-	O
lambda2	O
/	O
3	O
,	O
as	O
well	O
as	O
of	O
the	O
interferon	O
-	O
induced	O
antiviral	B-CHED
genes	O
ISG56	O
and	O
MxA	O
,	O
the	O
chemokine	O
RANTES	O
and	O
the	O
interleukine	O
IL	O
-	O
6	O
.	O

Our	O
data	O
indicate	O
that	O
SARS	O
-	O
CoV	O
suppresses	O
the	O
antiviral	B-CHED
cytokine	O
system	O
of	O
non	O
-	O
immune	O
cells	O
to	O
a	O
large	O
extent	O
,	O
thus	O
buying	O
time	O
for	O
dissemination	O
in	O
the	O
host	O
.	O

Surface	O
localization	O
of	O
the	O
fusion	O
protein	B-CHED
was	O
verified	O
by	O
cellular	O
fractionation	O
analyses	O
,	O
immunofluorescence	O
microscopy	O
,	O
and	O
flow	O
cytometry	O
.	O

These	O
are	O
processed	O
primarily	O
by	O
the	O
chymotrypsin	O
-	O
like	O
main	O
proteinases	O
(	O
M	O
(	O
pro	B-CHED
)	O
s	O
).	O

With	O
respect	O
to	O
substrate	O
specificity	O
,	O
the	O
EToV	O
M	O
(	O
pro	B-CHED
)	O
resembles	O
its	O
coronavirus	O
homologue	O
in	O
its	O
preference	O
for	O
P1	O
-	O
Gln	B-CHED
,	O
but	O
its	O
substrate	O
-	O
binding	O
subsite	O
,	O
S1	O
,	O
more	O
closely	O
resembles	O
that	O
of	O
arteri	O
-	O
and	O
ronivirus	O
M	O
(	O
pro	B-CHED
)	O
s	O
,	O
which	O
prefer	O
P1	O
-	O
Glu	B-CHED
.	O

Under	O
the	O
premise	O
that	O
the	O
M	O
(	O
pro	B-CHED
)	O
s	O
of	O
corona	B-CHED
-	O
and	O
toroviruses	O
are	O
more	O
closely	O
related	O
to	O
each	O
other	O
than	O
to	O
those	O
of	O
arteri	O
-	O
and	O
roniviruses	O
,	O
the	O
transition	O
from	O
serine	B-CHED
-	O
to	O
cysteine	B-CHED
-	O
based	O
proteolytic	O
catalysis	O
(	O
or	O
vice	O
versa	O
)	O
must	O
have	O
happened	O
more	O
than	O
once	O
in	O
the	O
course	O
of	O
nidovirus	O
evolution	O
.	O

In	O
this	O
respect	O
,	O
it	O
is	O
of	O
interest	O
that	O
a	O
mutant	O
EToV	O
M	O
(	O
pro	B-CHED
)	O
with	O
a	O
Ser165	O
-->	O
Cys	B-CHED
substitution	O
retained	O
partial	O
enzymatic	O
activity	O
.	O

TITLE	O
:	O
Sialic	B-CHED
acids	I-CHED
as	O
receptor	O
determinants	O
for	O
coronaviruses	O
.	O

For	O
bovine	O
coronavirus	O
(	O
BCoV	O
)	O
and	O
related	O
viruses	O
,	O
binding	O
to	O
cell	O
surface	O
components	O
containing	O
N	O
-	O
acetyl	B-CHED
-	O
9	O
-	O
O	B-CHED
-	I-CHED
acetylneuraminic	I-CHED
acid	I-CHED
is	O
essential	O
for	O
initiation	O
of	O
an	O
infection	O
.	O

These	O
viruses	O
resemble	O
influenza	O
C	O
viruses	O
because	O
they	O
share	O
not	O
only	O
the	O
receptor	O
determinant	O
,	O
but	O
also	O
the	O
presence	O
of	O
an	O
acetylesterase	O
that	O
releases	O
the	O
9	O
-	O
O	O
-	O
acetyl	B-CHED
group	I-CHED
from	O
sialic	B-CHED
acid	I-CHED
and	O
thus	O
abolishes	O
the	O
ability	O
of	O
the	O
respective	O
sialoglycoconjugate	O
to	O
function	O
as	O
a	O
receptor	O
for	O
BCoV	O
.	O
As	O
in	O
the	O
case	O
of	O
influenza	O
viruses	O
,	O
the	O
receptor	O
-	O
destroying	O
enzyme	O
of	O
BCoV	O
is	O
believed	O
to	O
facilitate	O
the	O
spread	O
of	O
virus	O
infection	O
by	O
removing	O
receptor	O
determinants	O
from	O
the	O
surface	O
of	O
infected	O
cells	O
and	O
by	O
preventing	O
the	O
formation	O
of	O
virus	O
aggregates	O
.	O

ABSTRACT	O
:	O
Virus	O
attachment	O
to	O
host	O
cells	O
is	O
mediated	O
by	O
dedicated	O
virion	O
proteins	B-CHED
,	O
which	O
specifically	O
recognize	O
one	O
or	O
,	O
at	O
most	O
,	O
a	O
limited	O
number	O
of	O
cell	O
surface	O
molecules	O
.	O

Receptor	O
binding	O
often	O
involves	O
protein	B-CHED
-	O
protein	B-CHED
interactions	O
,	O
but	O
carbohydrates	B-CHED
may	O
serve	O
as	O
receptor	O
determinants	O
as	O
well	O
.	O

It	O
is	O
suggested	O
that	O
these	O
sialic	B-CHED
acids	I-CHED
represent	O
the	O
endogenous	O
substrate	O
and	O
receptor	O
determinants	O
for	O
murine	O
coronaviruses	O
.	O

ABSTRACT	O
:	O
The	O
renin	O
-	O
angiotensin	B-CHED
system	O
(	O
RAS	B-CHED
)	O
plays	O
a	O
key	O
role	O
in	O
maintaining	O
blood	O
pressure	O
homeostasis	O
,	O
as	O
well	O
as	O
fluid	O
and	O
salt	B-CHED
balance	B-CHED
.	O

ACE2	O
,	O
a	O
close	O
homologue	O
of	O
ACE	O
,	O
functions	O
as	O
a	O
negative	O
regulator	O
of	O
the	O
angiotensin	B-CHED
system	O
and	O
was	O
identified	O
as	O
a	O
key	O
receptor	O
for	O
SARS	O
(	O
severe	O
acute	O
respiratory	O
syndrome	O
)	O
coronavirus	O
infections	O
.	O

Key	O
features	O
,	O
however	O
,	O
distinguish	O
PLpro	O
from	O
characterized	O
deubiquitinating	O
enzymes	O
,	O
including	O
an	O
intact	O
zinc	B-CHED
-	O
binding	O
motif	O
,	O
an	O
unobstructed	O
catalytically	O
competent	O
active	O
site	O
,	O
and	O
the	O
presence	O
of	O
an	O
intriguing	O
,	O
ubiquitin	O
-	O
like	O
N	O
-	O
terminal	O
domain	O
.	O

Both	O
native	O
and	O
selenomethionine	B-CHED
-	O
labelled	O
crystals	O
diffract	O
to	O
1	O
.	O
8	O
angstroms	O
.	O

Maximum	O
parsimony	O
genealogy	O
with	O
a	O
heuristic	O
algorithm	O
using	O
sequences	O
from	O
15	O
field	O
strains	O
studied	O
here	O
and	O
10	O
sequences	O
from	O
GenBank	O
and	O
bredavirus	O
as	O
an	O
outgroup	O
virus	O
showed	O
the	O
existence	O
of	O
two	O
major	O
clusters	B-CHED
(	O
1	O
and	O
2	O
)	O
in	O
this	O
viral	O
species	O
,	O
the	O
Brazilian	O
strains	O
segregating	O
in	O
both	O
of	O
them	O
.	O

The	O
mean	O
nucleotide	B-CHED
identity	O
between	O
the	O
15	O
Brazilian	O
strains	O
was	O
98	O
.	O
34	O
%,	O
with	O
a	O
mean	O
amino	B-CHED
acid	I-CHED
similarity	O
of	O
98	O
%.	O

Strains	O
from	O
cluster	O
2	O
showed	O
a	O
deletion	O
of	O
6	O
amino	B-CHED
acids	I-CHED
inside	O
domain	O
II	O
of	O
the	O
spike	O
protein	B-CHED
that	O
was	O
also	O
found	O
in	O
human	O
coronavirus	O
strain	O
OC43	O
,	O
supporting	O
the	O
recent	O
proposal	O
of	O
a	O
zoonotic	O
spill	O
-	O
over	O
of	O
BCoV	O
.	O
These	O
results	O
contribute	O
to	O
the	O
molecular	O
characterization	O
of	O
BCoV	O
,	O
to	O
the	O
prediction	O
of	O
the	O
efficiency	O
of	O
immunogens	O
,	O
and	O
to	O
the	O
definition	O
of	O
molecular	O
markers	O
useful	O
for	O
epidemiologic	O
surveys	O
on	O
coronavirus	O
-	O
caused	O
diseases	O
.	O

The	O
partial	O
sequences	O
analysed	O
spanned	O
the	O
hypervariable	O
amino	O
terminus	O
region	O
of	O
S1	O
from	O
amino	B-CHED
acid	I-CHED
residues	O
48	O
to	O
219	O
,	O
based	O
on	O
the	O
Beaudette	O
strain	O
.	O

ABSTRACT	O
:	O
There	O
are	O
a	O
number	O
of	O
antivirals	B-CHED
as	O
well	O
as	O
antiviral	B-CHED
strategies	O
that	O
could	O
be	O
envisaged	O
to	O
prevent	O
or	O
treat	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
(	O
or	O
similar	O
)	O
coronavirus	O
(	O
CoV	O
)	O
infections	O
.	O

These	O
results	O
provide	O
a	O
structural	O
rationale	O
for	O
the	O
function	O
of	O
a	O
major	O
determinant	O
of	O
SCV	O
immunogenicity	O
and	O
neutralization	O
,	O
the	O
development	O
of	O
SCV	O
therapeutics	O
based	O
on	O
the	O
antibody	O
paratope	O
and	O
epitope	B-CHED
,	O
and	O
a	O
retrovaccinology	O
approach	O
for	O
the	O
design	O
of	O
anti	O
-	O
SCV	O
vaccines	O
.	O

Olfactory	O
neuropathy	O
,	O
which	O
rarely	O
occurred	O
in	O
typical	O
peripheral	O
neuropathy	O
,	O
could	O
be	O
a	O
special	O
type	O
of	O
neuropathy	O
induced	O
by	O
corona	B-CHED
virus	O
infection	O
in	O
SARS	O
.	O

ABSTRACT	O
:	O
To	O
study	O
the	O
filtration	O
efficiency	O
of	O
a	O
positive	O
pressure	O
powered	O
air	B-CHED
purifying	O
medical	O
protective	O
equipment	O
and	O
the	O
effect	O
of	O
the	O
flow	O
rate	O
on	O
the	O
microenvironment	O
of	O
the	O
equipment	O
.	O

RESULTS	O
:	O
The	O
HEPA	O
filter	O
could	O
filtrate	O
99	O
.	O
99	O
%	O
simulating	O
viruses	O
in	O
the	O
air	B-CHED
.	O

TITLE	O
:	O
Rapid	O
peptide	B-CHED
-	O
based	O
screening	O
on	O
the	O
substrate	O
specificity	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
3C	O
-	O
like	O
protease	O
by	O
matrix	O
-	O
assisted	O
laser	O
desorption	O
/	O
ionization	O
time	O
-	O
of	O
-	O
flight	O
mass	O
spectrometry	O
.	O

Susceptibility	O
of	O
each	O
peptide	B-CHED
substrate	O
to	O
SARS	O
-	O
CoV	O
3CL	O
(	O
pro	B-CHED
)	O
cleavage	O
was	O
monitored	O
simultaneously	O
by	O
matrix	O
-	O
assisted	O
laser	O
desorption	O
/	O
ionization	O
time	O
-	O
of	O
-	O
flight	O
mass	O
spectrometry	O
(	O
MALDI	O
-	O
TOF	O
MS	O
).	O

The	O
hydrophobic	O
pocket	O
in	O
the	O
P2	O
position	O
at	O
the	O
protease	O
cleavage	O
site	O
is	O
crucial	O
to	O
SARS	O
-	O
CoV	O
3CL	O
(	O
pro	B-CHED
)-	O
specific	O
binding	O
,	O
which	O
is	O
limited	O
to	O
substitution	O
by	O
hydrophobic	O
residue	O
.	O

The	O
binding	O
interface	O
of	O
SARS	O
-	O
CoV	O
3CL	O
(	O
pro	B-CHED
)	O
that	O
is	O
facing	O
the	O
P1	O
'	O
position	O
is	O
suggested	O
to	O
be	O
occupied	O
by	O
acidic	O
amino	B-CHED
acids	I-CHED
,	O
thus	O
the	O
P1	O
'	O
position	O
is	O
intolerant	O
to	O
acidic	O
residue	O
substitution	O
,	O
owing	O
to	O
electrostatic	O
repulsion	O
.	O

This	O
finding	O
suggests	O
that	O
IBV	O
requires	O
a	O
greater	O
amount	O
of	O
sialic	B-CHED
acid	I-CHED
on	O
the	O
cell	O
surface	O
to	O
initiate	O
an	O
infection	O
compared	O
with	O
the	O
other	O
two	O
viruses	O
.	O

In	O
agreement	O
with	O
this	O
finding	O
,	O
susceptibility	O
to	O
infection	O
by	O
IBV	O
was	O
connected	O
to	O
the	O
expression	O
of	O
alpha2	O
,	O
3	O
-	O
linked	O
sialic	B-CHED
acid	I-CHED
as	O
indicated	O
by	O
the	O
reactivity	O
with	O
the	O
lectin	O
Maackia	O
amurensis	O
agglutinin	O
.	O

Many	O
antisense	O
oligomers	O
are	O
proven	O
antiviral	B-CHED
agents	I-CHED
in	O
vitro	O
.	O

HPLC	O
and	O
fluorescence	O
-	O
based	O
assays	O
have	O
been	O
used	O
to	O
characterize	O
the	O
protease	O
and	O
to	O
determine	O
the	O
potency	O
of	O
the	O
inhibitors	B-CHED
.	O

Some	O
of	O
these	O
inhibitors	B-CHED
could	O
be	O
developed	O
into	O
potential	O
drug	O
candidates	O
,	O
which	O
may	O
provide	O
a	O
solution	O
to	O
combat	B-CHED
possible	O
reoccurrence	O
of	O
the	O
SARS	O
and	O
other	O
life	O
-	O
threatening	O
viruses	O
with	O
3CL	O
proteases	O
.	O

TITLE	O
:	O
Identification	O
of	O
functionally	O
important	O
negatively	O
charged	O
residues	O
in	O
the	O
carboxy	B-CHED
end	O
of	O
mouse	O
hepatitis	O
coronavirus	O
A59	O
nucleocapsid	O
protein	B-CHED
.	O

ABSTRACT	O
:	O
The	O
coronavirus	O
nucleocapsid	O
(	O
N	O
)	O
protein	B-CHED
is	O
a	O
multifunctional	O
viral	O
gene	O
product	O
that	O
encapsidates	O
the	O
RNA	O
genome	O
and	O
also	O
plays	O
some	O
as	O
yet	O
not	O
fully	O
defined	O
role	O
in	O
viral	O
RNA	O
replication	O
and	O
/	O
or	O
transcription	O
.	O

Treatment	O
involves	O
discontinuation	O
of	O
the	O
offending	O
drug	O
or	O
toxin	O
and	O
treatment	O
with	O
corticosteroids	B-CHED
in	O
severe	O
respiratory	O
failure	O
.	O

ABSTRACT	O
:	O
The	O
spike	O
(	O
S	O
)	O
protein	B-CHED
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
has	O
two	O
major	O
functions	O
:	O
interacting	O
with	O
the	O
receptor	O
to	O
mediate	O
virus	O
entry	O
and	O
inducing	O
protective	O
immunity	O
.	O

Here	O
,	O
we	O
used	O
RBD	O
-	O
Fc	O
,	O
a	O
fusion	O
protein	B-CHED
containing	O
the	O
RBD	O
and	O
human	O
IgG1	O
Fc	O
,	O
as	O
a	O
model	O
in	O
the	O
studies	O
and	O
found	O
that	O
a	O
single	O
amino	B-CHED
acid	I-CHED
substitution	O
in	O
the	O
RBD	O
(	O
R441A	O
)	O
could	O
abolish	O
the	O
immunogenicity	O
of	O
RBD	O
to	O
induce	O
neutralizing	O
antibodies	O
in	O
immunized	O
mice	O
and	O
rabbits	O
.	O

TITLE	O
:	O
Enhancement	O
of	O
the	O
infectivity	O
of	O
SARS	O
-	O
CoV	O
in	O
BALB	O
/	O
c	O
mice	O
by	O
IMP	B-CHED
dehydrogenase	O
inhibitors	B-CHED
,	O
including	O
ribavirin	B-CHED
.	O

Other	O
IMP	B-CHED
dehydrogenase	O
inhibitors	B-CHED
administered	O
near	O
maximum	O
tolerated	O
doses	O
using	O
the	O
same	O
dosing	O
regimen	O
as	O
for	O
ribavirin	B-CHED
were	O
found	O
to	O
slightly	O
enhance	O
virus	O
replication	O
in	O
the	O
lungs	O
.	O

By	O
not	O
inhibiting	O
viral	O
replication	O
in	O
the	O
lungs	O
of	O
infected	O
mice	O
,	O
ribavirin	B-CHED
treatment	O
may	O
have	O
provided	O
a	O
continual	O
source	O
of	O
stimulation	O
for	O
the	O
inflammatory	O
response	O
thought	O
to	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
the	O
infection	O
.	O

S2	O
gene	O
of	O
GD322	O
SARS	O
-	O
CoV	O
is	O
relatively	O
stable	O
during	O
the	O
epidemic	O
spread	O
of	O
the	O
virus	O
,	O
and	O
mutation	O
at	O
the	O
57th	O
amino	B-CHED
acids	I-CHED
of	O
S2	O
protein	B-CHED
may	O
affect	O
the	O
T	O
cell	O
antigen	B-CHED
epitope	B-CHED
.	O

Pressure	O
-	O
controlled	O
ventilation	O
(	O
PCV	B-CHED
),	O
pressure	O
-	O
controlled	O
assisted	O
ventilation	O
(	O
P	O
-	O
ACV	B-CHED
),	O
bilevel	O
positive	O
airway	O
pressure	O
(	O
BIPAP	O
),	O
and	O
pressure	O
support	O
ventilation	O
(	O
PSV	O
)	O
with	O
equal	O
airway	O
pressures	O
and	O
sedation	O
were	O
applied	O
in	O
random	O
order	O
.	O

Health	O
care	O
professionals	O
(	O
HCPs	O
)	O
and	O
hospital	O
systems	O
that	O
bore	B-CHED
the	O
brunt	O
of	O
the	O
SARS	O
outbreak	O
continue	O
to	O
struggle	O
with	O
the	O
aftermath	O
of	O
the	O
crisis	O
.	O

In	O
contrast	O
,	O
TNF	O
-	O
alpha	O
alone	O
or	O
in	O
combination	O
with	O
the	O
TLR	O
ligands	O
was	O
a	O
poor	O
inducer	O
of	O
DC	O
maturation	O
,	O
but	O
co	O
-	O
operated	O
with	O
T	O
-	O
lymphocytes	O
in	O
the	O
presence	O
of	O
antigen	B-CHED
to	O
induce	O
DC	O
maturation	O
.	O

TITLE	O
:	O
HLA	O
-	O
A	O
*	O
0201	O
T	O
-	O
cell	O
epitopes	O
in	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
nucleocapsid	O
and	O
spike	O
proteins	B-CHED
.	O

These	O
peptides	B-CHED
,	O
which	O
had	O
no	O
apparent	O
homologous	O
motif	O
within	O
or	O
between	O
the	O
peptide	B-CHED
pools	O
and	O
spike	O
protein	B-CHED
,	O
were	O
deconvoluted	O
into	O
amino	B-CHED
acid	I-CHED
pairs	O
(	O
AAPs	O
)	O
by	O
Mapitope	O
and	O
the	O
statistically	O
significant	O
pairs	O
(	O
SSPs	O
)	O
were	O
defined	O
.	O

ABSTRACT	O
:	O
The	O
SARS	O
coronavirus	O
main	O
proteinase	O
is	O
a	O
prime	O
target	O
for	O
antiviral	B-CHED
therapy	O
.	O

Virus	O
generates	O
drug	O
resistance	O
through	O
fast	O
mutagenesis	O
and	O
escapes	O
antiviral	B-CHED
treatment	O
.	O

Here	O
,	O
we	O
report	O
effective	O
siRNAs	O
targeting	O
structural	O
genes	O
(	O
i	O
.	O
e	O
.,	O
spike	O
,	O
envelope	O
,	O
membrane	O
,	O
and	O
nucleocapsid	O
)	O
and	O
their	O
antiviral	B-CHED
kinetics	O
.	O

TITLE	O
:	O
Design	O
and	O
synthesis	O
of	O
hydroxyferroquine	O
derivatives	O
with	O
antimalarial	B-CHED
and	O
antiviral	B-CHED
activities	O
.	O

ABSTRACT	O
:	O
We	O
here	O
report	O
a	O
case	O
of	O
71	O
-	O
year	O
-	O
old	O
man	B-CHED
with	O
acute	O
extensive	O
anterior	O
myocardial	O
infarction	O
,	O
who	O
was	O
complicated	O
with	O
ventricular	O
tachycardia	O
(	O
VT	O
)	O
even	O
after	O
successful	O
percutaneous	O
coronary	O
intervention	O
.	O

Here	O
,	O
we	O
generated	O
coronavirus	O
-	O
like	O
particles	O
carrying	O
in	O
their	O
envelope	O
chimeric	O
HCV	O
glycoproteins	B-CHED
composed	O
of	O
the	O
ectodomains	O
of	O
E1	O
and	O
E2	O
,	O
each	O
fused	O
to	O
the	O
transmembrane	O
plus	O
endodomain	O
of	O
the	O
mouse	O
hepatitis	O
coronavirus	O
spike	O
glycoprotein	B-CHED
.	O

The	O
down	O
-	O
regulated	O
proteins	B-CHED
were	O
apolipoprotein	B-CHED
A	O
-	O
I	O
,	O
transferrin	O
and	O
transthyretin	O
.	O

Detectable	O
nasopharyngeal	O
shedding	O
of	O
SARS	O
-	O
CoV	O
was	O
associated	O
with	O
polymorphic	O
alleles	O
of	O
interleukins	O
18	O
(	O
P	O
=.	O
014	O
)	O
and	O
1A	O
(	O
P	O
=.	O
031	O
)	O
and	O
a	O
member	O
of	O
NF	O
kappa	O
B	O
complex	O
(	O
reticuloendotheliosis	O
viral	O
oncogene	O
homolog	O
B	O
[	O
RelB	O
])	O
(	O
P	O
=.	O
034	O
),	O
all	O
of	O
which	O
are	O
proinflammatory	O
in	O
nature	O
,	O
as	O
well	O
as	O
the	O
procoagulation	O
molecule	O
fibrinogen	O
-	O
like	O
protein	B-CHED
2	O
(	O
P	O
=.	O
008	O
).	O

Here	O
we	O
show	O
that	O
the	O
recombinant	O
RBDs	O
derived	O
from	O
the	O
S	O
protein	B-CHED
sequences	O
of	O
Tor2	O
,	O
GD03	O
,	O
and	O
SZ3	O
,	O
the	O
representative	O
strains	O
of	O
human	O
2002	O
-	O
2003	O
and	O
2003	O
-	O
2004	O
SARS	O
-	O
CoV	O
and	O
palm	O
civet	O
SARS	O
-	O
CoV	O
,	O
respectively	O
,	O
induce	O
in	O
the	O
immunized	O
mice	O
and	O
rabbits	O
high	O
titers	O
of	O
cross	O
-	O
neutralizing	O
Abs	O
against	O
pseudoviruses	O
expressing	O
S	O
proteins	B-CHED
of	O
Tor2	O
,	O
GD03	O
,	O
and	O
SZ3	O
.	O

Although	O
HRV	O
-	O
induced	O
upper	O
respiratory	O
illness	O
is	O
often	O
mild	O
and	O
self	O
-	O
limiting	O
,	O
the	O
socioeconomic	O
impact	O
caused	O
by	O
missed	O
school	O
or	O
work	O
is	O
enormous	O
and	O
the	O
degree	O
of	O
inappropriate	O
antibiotic	B-CHED
use	O
is	O
significant	O
.	O

TITLE	O
:	O
Inhibition	O
of	O
feline	O
(	O
FIPV	O
)	O
and	O
human	O
(	O
SARS	O
)	O
coronavirus	O
by	O
semisynthetic	O
derivatives	O
of	O
glycopeptide	B-CHED
antibiotics	B-CHED
.	O

The	O
use	O
of	O
a	O
polymeric	O
emulsifier	B-CHED
allowed	O
for	O
direct	O
comparison	O
of	O
three	O
types	O
of	O
emulsions	O
,	O
water	B-CHED
-	O
in	O
-	O
oil	O
(	O
W	O
/	O
O	O
),	O
oil	O
-	O
in	O
-	O
water	B-CHED
(	O
O	O
/	O
W	O
)	O
and	O
W	O
/	O
O	O
-	O
in	O
-	O
water	B-CHED
(	O
W	O
/	O
O	O
/	O
W	O
),	O
while	O
maintaining	O
an	O
identical	O
content	O
of	O
components	O
for	O
each	O
vehicle	O
.	O

In	O
general	O
,	O
mineral	B-CHED
oil	O
vaccines	O
showed	O
superior	O
efficacy	O
compared	O
to	O
Miglyol	O
840	O
-	O
based	O
vaccines	O
.	O

SARS	O
mimotopes	O
were	O
obtained	O
by	O
phage	O
peptide	B-CHED
library	O
screening	O
.	O

The	O
index	O
of	O
marrow	O
conversion	O
(	O
signal	O
intensity	O
of	O
the	O
femoral	O
neck	O
and	O
intertrochanteric	O
area	O
divided	O
by	O
signal	O
intensity	O
of	O
the	O
greater	O
trochanter	O
multiplied	O
by	O
100	O
%)	O
was	O
quantitatively	O
measured	O
and	O
compared	O
between	O
SARS	O
patients	O
treated	O
with	O
steroid	B-CHED
and	O
without	O
steroid	B-CHED
and	O
the	O
normal	O
control	O
group	O
.	O

RESULTS	O
:	O
In	O
106	O
cases	O
treated	O
with	O
steroid	B-CHED
of	O
the	O
148	O
health	O
care	O
workers	O
,	O
femoral	O
head	O
osteonecrosis	O
was	O
found	O
in	O
4	O
cases	O
,	O
bilateral	O
femoral	O
marrow	O
edema	O
in	O
2	O
cases	O
,	O
femoral	O
marrow	O
infarction	O
in	O
1	O
case	O
.	O

APTT	O
,	O
PC	O
,	O
AT	O
-	O
III	O
,	O
and	O
PLG	B-CHED
can	O
be	O
used	O
as	O
sensitive	O
indicator	B-CHED
for	O
screening	O
high	O
risk	O
populations	O
of	O
osteonecrosis	O
.	O

TITLE	O
:	O
Biochemical	O
evidence	O
for	O
the	O
presence	O
of	O
mixed	O
membrane	O
topologies	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
envelope	O
protein	B-CHED
expressed	O
in	O
mammalian	O
cells	O
.	O

In	O
contrast	O
,	O
parallel	O
experiments	O
showed	O
that	O
the	O
E	O
protein	B-CHED
from	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
spanned	O
the	O
membranes	O
once	O
,	O
with	O
the	O
N	O
-	O
terminus	O
exposed	O
luminally	O
and	O
the	O
C	O
-	O
terminus	O
exposed	O
cytoplasmically	O
(	O
N	O
(	O
exo	O
(	O
lum	O
)-)	O
C	O
(	O
cyto	O
)).	O

Anesthetized	O
female	O
sheep	O
were	O
ventilated	O
with	O
300	O
L	O
of	O
a	O
Cl2	B-CHED
/	O
air	B-CHED
/	O
oxygen	B-CHED
mixture	B-CHED
for	O
30	O
minutes	O
.	O

Following	O
Boc	B-CHED
protection	O
of	O
the	O
ring	O
nitrogen	B-CHED
to	O
yield	O
the	O
N	O
-	O
protected	O
oxazolidine	B-CHED
linker	O
,	O
peptide	B-CHED
synthesis	O
was	O
performed	O
efficiently	O
on	O
this	O
resin	O
.	O

In	O
the	O
current	O
study	O
,	O
arsenic	B-CHED
trioxide	I-CHED
in	O
the	O
dose	O
regimen	O
and	O
schedule	O
employed	O
was	O
found	O
to	O
have	O
no	O
activity	O
in	O
men	O
with	O
refractory	O
germ	O
cell	O
malignancies	O
.	O

ABSTRACT	O
:	O
The	O
nucleocapsid	O
(	O
N	O
)	O
protein	B-CHED
is	O
a	O
structural	O
component	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
and	O
can	O
induce	O
antibody	O
responses	O
in	O
SARS	O
patients	O
during	O
infection	O
.	O

Epitope	B-CHED
mapping	O
study	O
indicated	O
that	O
a	O
cluster	O
of	O
overlapping	O
peptides	B-CHED
located	O
in	O
the	O
C	O
-	O
terminal	O
region	O
(	O
amino	B-CHED
acids	I-CHED
[	O
aa	O
]	O
331	O
to	O
362	O
)	O
of	O
N	O
protein	B-CHED
contained	O
at	O
least	O
two	O
different	O
T	O
-	O
cell	O
epitopes	O
.	O

To	O
produce	O
structural	O
and	O
accessory	O
proteins	B-CHED
,	O
members	O
of	O
the	O
order	O
Nidovirales	O
(	O
corona	B-CHED
-,	O
toro	O
-,	O
arteri	O
-	O
and	O
roniviruses	O
)	O
generate	O
a	O
3	O
'	O
co	O
-	O
terminal	O
nested	O
set	O
of	O
at	O
least	O
three	O
and	O
often	O
seven	O
to	O
nine	O
mRNAs	O
.	O

The	O
internalization	O
was	O
also	O
induced	O
by	O
mAbs	O
against	O
the	O
Spike	O
and	O
Membrane	O
proteins	B-CHED
,	O
suggesting	O
that	O
both	O
proteins	B-CHED
play	O
a	O
role	O
in	O
the	O
process	O
.	O

We	O
recently	O
introduced	O
Cavbase	O
,	O
a	O
method	O
for	O
describing	O
and	O
comparing	O
protein	B-CHED
binding	O
pockets	O
on	O
the	O
basis	O
of	O
the	O
geometrical	O
and	O
physicochemical	O
properties	O
of	O
their	O
active	O
sites	O
.	O

Flow	O
cytometry	O
(	O
FACS	O
)	O
analysis	O
,	O
however	O
,	O
showed	O
only	O
HRC1	O
and	O
HRC2	O
anti	O
-	O
sera	O
could	O
bind	O
to	O
native	O
S	O
protein	B-CHED
expressed	O
on	O
the	O
cell	O
surface	O
of	O
Chinese	O
hamster	O
ovary	O
cells	O
,	O
i	O
.	O
e	O
.,	O
the	O
cell	O
surface	O
structure	O
of	O
the	O
S	O
glycoprotein	B-CHED
precluded	O
the	O
ability	O
of	O
the	O
HRN1	O
or	O
HRN2	O
anti	O
-	O
sera	O
to	O
see	O
their	O
respective	O
epitope	B-CHED
sites	O
.	O

Overall	O
,	O
these	O
results	O
clearly	O
demonstrate	O
that	O
the	O
two	O
-	O
stranded	O
coiled	O
-	O
coil	O
template	O
acts	O
as	O
an	O
excellent	O
presentation	O
system	O
for	O
eliciting	O
helix	O
-	O
specific	O
antibodies	O
against	O
highly	O
conserved	O
viral	O
antigens	B-CHED
and	O
HRC1	O
and	O
HRC2	O
peptides	B-CHED
may	O
represent	O
potential	O
candidates	O
for	O
use	O
in	O
a	O
peptide	B-CHED
vaccine	O
against	O
the	O
SARS	O
-	O
CoV	O
.	O

ABSTRACT	O
:	O
Entry	O
of	O
SARS	O
coronavirus	O
into	O
its	O
target	O
cell	O
requires	O
large	O
-	O
scale	O
structural	O
transitions	O
in	O
the	O
viral	O
spike	O
(	O
S	O
)	O
glycoprotein	B-CHED
in	O
order	O
to	O
induce	O
fusion	O
of	O
the	O
virus	O
and	O
cell	O
membranes	O
.	O

ABSTRACT	O
:	O
The	O
coronavirus	O
responsible	O
for	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
contains	O
a	O
small	O
envelope	O
protein	B-CHED
,	O
E	O
,	O
with	O
putative	O
involvement	O
in	O
host	O
apoptosis	O
and	O
virus	O
morphogenesis	O
.	O

CoV	O
genome	O
replication	O
takes	O
place	O
in	O
the	O
cytoplasm	O
in	O
a	O
membrane	O
-	O
protected	O
microenvironment	O
and	O
may	O
control	O
the	O
cell	O
machinery	O
by	O
locating	O
some	O
of	O
their	O
proteins	B-CHED
in	O
the	O
host	O
cell	O
nucleus	B-CHED
.	O

CoV	O
N	O
proteins	B-CHED
have	O
RNA	O
chaperone	O
activity	O
that	O
may	O
help	O
initiate	O
template	O
switching	O
.	O

Both	O
viral	O
and	O
cellular	O
proteins	B-CHED
are	O
required	O
for	O
replication	O
and	O
transcription	O
,	O
and	O
the	O
role	O
of	O
selected	O
proteins	B-CHED
is	O
addressed	O
.	O

The	O
most	O
recent	O
literature	O
is	O
reviewed	O
,	O
and	O
emphasis	O
is	O
placed	O
on	O
current	O
controversies	O
,	O
most	O
notably	O
the	O
risk	O
/	O
benefit	O
ratio	O
of	O
fiberoptic	O
bronchoscopy	O
and	O
BAL	B-CHED
in	O
patients	O
with	O
severe	O
hypoxemia	O
.	O

Ten	O
of	O
the	O
RBD	O
-	O
specific	O
mAbs	O
were	O
mapped	O
to	O
four	O
distinct	O
groups	O
of	O
conformational	O
epitopes	O
(	O
designated	O
Group	O
A	O
to	O
D	O
),	O
and	O
all	O
of	O
which	O
had	O
potent	O
neutralizing	O
activity	O
against	O
S	O
protein	B-CHED
-	O
pseudotyped	O
SARS	O
viruses	O
.	O

Surprisingly	O
,	O
most	O
neutralizing	O
epitopes	O
(	O
Groups	O
A	O
to	O
C	O
)	O
could	O
be	O
completely	O
disrupted	O
by	O
single	O
amino	B-CHED
acid	I-CHED
substitutions	O
(	O
e	O
.	O
g	O
.,	O
D429A	O
,	O
R441A	O
or	O
D454A	O
)	O
or	O
by	O
deletions	O
of	O
several	O
amino	B-CHED
acids	I-CHED
at	O
the	O
N	O
-	O
terminal	O
or	O
C	O
-	O
terminal	O
region	O
of	O
the	O
RBD	O
;	O
however	O
,	O
the	O
Group	O
D	O
epitope	B-CHED
was	O
not	O
sensitive	O
to	O
the	O
mutations	O
,	O
highlighting	O
its	O
importance	O
for	O
vaccine	O
development	O
.	O

ABSTRACT	O
:	O
Tuberculosis	O
miliar	O
is	O
a	O
very	O
rare	O
complication	O
of	O
bacillus	O
Calmette	O
-	O
Guérin	O
(	O
BCG	B-CHED
)	O
immunotherapy	O
that	O
is	O
associated	O
to	O
high	O
mortality	O
.	O

TITLE	O
:	O
Emodin	B-CHED
blocks	O
the	O
SARS	O
coronavirus	O
spike	O
protein	B-CHED
and	O
angiotensin	B-CHED
-	O
converting	O
enzyme	O
2	O
interaction	O
.	O

ABSTRACT	O
:	O
Most	O
strains	O
of	O
murine	O
coronavirus	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
express	O
a	O
cleavable	O
spike	O
glycoprotein	B-CHED
that	O
mediates	O
viral	O
entry	O
and	O
pH	O
-	O
independent	O
cell	O
-	O
cell	O
fusion	O
.	O

Mutagenesis	O
was	O
used	O
to	O
delineate	O
a	O
novel	O
eight	O
amino	B-CHED
acid	I-CHED
motif	O
that	O
was	O
necessary	O
and	O
sufficient	O
for	O
nucleolar	O
retention	O
of	O
N	O
protein	B-CHED
and	O
colocalize	O
with	O
nucleolin	O
and	O
fibrillarin	O
.	O

Comparison	O
of	O
the	O
coronavirus	O
NoRSs	O
with	O
known	O
cellular	O
and	O
other	O
viral	O
NoRSs	O
revealed	O
that	O
these	O
motifs	O
have	O
conserved	O
arginine	B-CHED
residues	O
.	O

A	O
vanadium	B-CHED
substituted	O
polyoxotungstate	O
,	O
PM	O
-	O
1001	O
has	O
antiviral	B-CHED
activity	O
against	O
FluV	O
A	O
,	O
RSV	O
,	O
parainfluenza	O
virus	O
(	O
PfluV	O
)	O
type	O
2	O
,	O
Dengue	O
fiver	O
virus	O
,	O
HIV	O
-	O
1	O
and	O
SARS	O
coronavirus	O
in	O
vitro	O
.	O

Nasopharyngeal	O
swabs	O
were	O
processed	O
for	O
study	O
of	O
respiratory	O
viruses	O
through	O
antigen	B-CHED
detection	O
by	O
indirect	O
immunofluorescence	O
assay	O
,	O
isolation	O
of	O
viruses	O
in	O
cell	O
culture	O
and	O
detection	O
of	O
nucleic	B-CHED
acids	I-CHED
by	O
two	O
independent	O
multiplex	O
RT	O
-	O
PCR	O
assays	O
.	O

Compound	O
5f	O
shows	O
significant	O
inhibition	O
with	O
an	O
IC	O
(	O
50	O
)	O
of	O
0	O
.	O
37	O
microM	O
.	O
Further	O
study	O
showed	O
that	O
,	O
unlike	O
the	O
irreversible	O
covalent	O
binding	O
of	O
isatin	B-CHED
derivatives	O
to	O
human	O
rhinovirus	O
3C	O
protease	O
,	O
the	O
compounds	O
tested	O
in	O
this	O
study	O
are	O
all	O
noncovalent	O
reversible	O
inhibitors	B-CHED
.	O

TITLE	O
:	O
Discovery	O
of	O
a	O
novel	O
family	O
of	O
SARS	O
-	O
CoV	O
protease	B-CHED
inhibitors	I-CHED
by	O
virtual	O
screening	O
and	O
3D	O
-	O
QSAR	O
studies	O
.	O

Development	O
of	O
drug	O
resistance	O
against	O
clinical	O
anti	O
-	O
HBV	O
drug	O
lamivudine	B-CHED
due	O
to	O
long	O
-	O
term	O
use	O
and	O
rebound	O
of	O
viral	O
DNA	O
after	O
cessation	O
of	O
treatment	O
has	O
been	O
a	O
major	O
setback	O
of	O
the	O
current	O
therapy	O
.	O

The	O
Naval	O
Health	O
Research	O
Center	O
conducted	O
laboratory	O
-	O
based	O
surveillance	O
for	O
febrile	O
respiratory	O
infections	O
at	O
the	O
2003	O
Cobra	O
Gold	B-CHED
Exercise	O
in	O
Thailand	O
.	O

Seventeen	O
individuals	O
met	B-CHED
the	O
case	O
definition	O
for	O
febrile	O
respiratory	O
illness	O
,	O
and	O
diagnostic	O
specimens	O
were	O
obtained	O
from	O
16	O
.	O

Our	O
results	O
show	O
that	O
the	O
binding	O
of	O
the	O
HRC	O
analogs	O
to	O
HRN	B-CHED
does	O
not	O
correlate	O
with	O
the	O
coiled	O
-	O
coil	O
stability	O
of	O
the	O
HRC	O
analogs	O
,	O
but	O
their	O
interactions	O
with	O
HRC	O
does	O
correlate	O
with	O
their	O
stability	O
,	O
except	O
for	O
HRC7	O
.	O

This	O
study	O
also	O
suggested	O
three	O
types	O
of	O
potential	O
peptide	B-CHED
inhibitors	B-CHED
against	O
viral	O
entry	O
can	O
be	O
designed	O
,	O
those	O
that	O
simultaneously	O
inhibit	O
interaction	O
with	O
HRC	O
and	O
HRN	B-CHED
and	O
those	O
that	O
are	O
either	O
HRC	O
-	O
specific	O
or	O
HRN	B-CHED
-	O
specific	O
.	O

The	O
N	O
protein	B-CHED
is	O
a	O
highly	O
immunogenic	O
phosphoprotein	O
also	O
implicated	O
in	O
viral	O
genome	O
replication	O
and	O
in	O
modulating	O
cell	O
signaling	O
pathways	O
.	O

ABSTRACT	O
:	O
Our	O
previous	O
reports	O
,	O
both	O
experimental	O
and	O
human	O
studies	O
,	O
have	O
shown	O
the	O
importance	O
of	O
fibrinogen	O
-	O
like	O
protein	B-CHED
-	O
2	O
(	O
fgl2	O
)	O
prothrombinase	O
in	O
the	O
development	O
of	O
fulminant	O
viral	O
hepatitis	O
,	O
a	O
disease	O
with	O
a	O
mortality	O
of	O
more	O
than	O
80	O
%	O
in	O
cases	O
lacking	O
immediate	O
organ	O
transplantation	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
efficacy	O
and	O
safety	O
profiles	O
of	O
corticosteroid	B-CHED
therapy	O
in	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
patients	O
.	O

Data	O
of	O
these	O
patients	O
retrieved	O
from	O
a	O
database	O
were	O
retrospectively	O
analyzed	O
by	O
logistic	O
regression	O
and	O
Cox	O
regression	O
for	O
the	O
effect	O
of	O
corticosteroid	B-CHED
therapy	O
on	O
death	O
,	O
hospitalization	O
days	O
,	O
and	O
complication	O
presentation	O
.	O

Considering	O
the	O
clinical	O
course	O
and	O
laboratory	O
data	O
,	O
this	O
was	O
probably	O
drug	O
-	O
induced	O
lung	O
injury	O
caused	O
by	O
oseltamivir	B-CHED
.	O

TITLE	O
:	O
Amino	B-CHED
acids	I-CHED
15	O
-	O
28	O
in	O
the	O
ectodomain	O
of	O
SARS	O
coronavirus	O
3a	O
protein	B-CHED
induces	O
neutralizing	O
antibodies	O
.	O

In	O
this	O
case	O
,	O
eosinophilia	O
was	O
possibly	O
caused	O
by	O
constitutive	O
activation	O
of	O
tyrosine	B-CHED
kinase	O
produced	O
by	O
the	O
FIP1L1	O
-	O
PDGFRalpha	O
fusion	O
transcript	O
.	O

PEDV	O
,	O
porcine	O
GAR	B-CHED
,	O
and	O
TGEV	O
infection	O
were	O
26	O
.	O
3	O
%,	O
13	O
.	O
2	O
%,	O
and	O
2	O
.	O
7	O
%	O
respectively	O
.	O

The	O
mixture	B-CHED
of	O
both	O
mAbs	O
showed	O
neutralization	O
of	O
SARS	O
-	O
CoV	O
in	O
a	O
synergistic	O
fashion	O
by	O
recognizing	O
different	O
epitopes	O
on	O
the	O
receptor	O
-	O
binding	O
domain	O
.	O

When	O
surviving	O
cells	O
were	O
treated	O
with	O
the	O
JNK	O
-	O
specific	O
inhibitor	B-CHED
,	O
SP600125	O
,	O
at	O
50h	O
.	O
p	O
.	O
i	O
.,	O
all	O
cells	O
died	O
,	O
suggesting	O
that	O
the	O
JNK	O
signaling	O
pathway	O
is	O
necessary	O
for	O
maintenance	O
of	O
persistently	O
infected	O
cells	O
.	O

SARS	O
coronavirus	O
E	O
protein	B-CHED
forms	O
cation	B-CHED
-	O
selective	O
ion	O
channels	O
.	O

We	O
now	O
report	O
that	O
three	O
other	O
E	O
proteins	B-CHED
also	O
form	O
cation	B-CHED
-	O
selective	O
ion	O
channels	O
.	O

These	O
results	O
show	O
that	O
the	O
response	O
to	O
a	O
single	O
virus	O
-	O
specific	O
CD4	O
T	O
-	O
cell	O
epitope	B-CHED
may	O
contribute	O
to	O
a	O
pathogenic	O
host	O
response	O
in	O
the	O
setting	O
of	O
acute	O
viral	O
disease	O
and	O
that	O
abrogation	O
of	O
this	O
response	O
ameliorates	O
clinical	O
disease	O
without	O
diminishing	O
virus	O
clearance	O
.	O

The	O
MDD	B-CHED
system	O
can	O
distinguish	O
the	O
13	O
respiratory	O
viruses	O
,	O
which	O
helps	O
diagnosis	O
of	O
respiratory	O
viral	O
infection	O
.	O

The	O
remaining	O
eight	O
ORFs	O
encodes	O
for	O
accessory	O
proteins	B-CHED
,	O
varying	O
in	O
length	O
from	O
39	O
to	O
274	O
amino	B-CHED
acids	I-CHED
,	O
which	O
are	O
unique	O
to	O
SARS	O
-	O
CoV	O
.	O
This	O
review	O
will	O
summarize	O
the	O
expeditious	O
research	O
on	O
these	O
accessory	O
viral	O
proteins	B-CHED
in	O
three	O
major	O
areas	O
:	O
(	O
i	O
)	O
the	O
detection	O
of	O
antibodies	O
against	O
accessory	O
proteins	B-CHED
in	O
the	O
serum	O
of	O
infected	O
patients	O
,	O
(	O
ii	O
)	O
the	O
expression	O
,	O
processing	O
and	O
cellular	O
localization	O
of	O
the	O
accessory	O
proteins	B-CHED
,	O
and	O
(	O
iii	O
)	O
the	O
effects	O
of	O
the	O
accessory	O
proteins	B-CHED
on	O
cellular	O
functions	O
.	O

These	O
in	O
-	O
depth	O
molecular	O
and	O
biochemical	O
characterizations	O
of	O
the	O
SARS	O
-	O
CoV	O
accessory	O
proteins	B-CHED
,	O
which	O
have	O
no	O
homologues	O
in	O
other	O
coronaviruses	O
,	O
may	O
offer	O
clues	O
as	O
to	O
why	O
the	O
SARS	O
-	O
CoV	O
causes	O
such	O
a	O
severe	O
and	O
rapid	O
attack	O
in	O
humans	O
,	O
while	O
other	O
coronaviruses	O
that	O
infect	O
humans	O
seem	O
to	O
be	O
more	O
forgiving	O
.	O

TITLE	O
:	O
[	O
Influence	O
of	O
ambroxol	O
on	O
paraquat	B-CHED
-	O
induced	O
lung	O
tissue	O
injury	O
and	O
change	O
of	O
pulmonary	O
surfactant	B-CHED
-	O
associated	O
protein	B-CHED
A	O
in	O
the	O
experimental	O
rats	O
].	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
influence	O
of	O
ambroxol	O
on	O
paraquat	B-CHED
poisoning	O
induced	O
acute	O
lung	O
tissue	O
injury	O
and	O
the	O
change	O
of	O
pulmonary	O
surfactant	B-CHED
associated	O
protein	B-CHED
A	O
in	O
the	O
experimental	O
rats	O
.	O

One	O
hundred	O
and	O
twenty	O
healthy	O
adult	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
were	O
randomizedly	O
assigned	O
into	O
normal	O
saline	O
(	O
NS	O
)	O
group	O
(	O
n	O
=	O
24	O
),	O
paraquat	B-CHED
poisoning	O
induced	O
lung	O
tissue	O
injury	O
model	O
(	O
PQ	O
)	O
group	O
(	O
n	O
=	O
48	O
)	O
and	O
ambroxol	O
treatment	O
(	O
AT	O
)	O
group	O
(	O
n	O
=	O
48	O
).	O

CONCLUSIONS	O
:	O
Ambroxol	O
plays	O
a	O
role	O
in	O
facilitating	O
synthesis	O
and	O
secretion	O
of	O
pulmonary	O
surfactant	B-CHED
protein	B-CHED
A	O
and	O
relieves	O
the	O
lung	O
tissue	O
injury	O
induced	O
by	O
paraquat	B-CHED
poisoning	O
.	O

Clinical	O
(	O
temperature	O
,	O
FiO2	O
)	O
and	O
laboratory	O
[	O
leukocyte	O
,	O
lymphocyte	O
,	O
neutrophil	O
,	O
platelet	O
,	O
lactate	B-CHED
dehydrogenase	O
(	O
LDH	O
),	O
albumin	O
]	O
trends	O
in	O
groups	O
with	O
and	O
without	O
an	O
adversarial	O
event	O
were	O
presented	O
.	O

Audits	O
of	O
these	O
laboratories	O
in	O
2004	O
showed	O
that	O
laboratory	O
safety	O
and	O
containment	O
requirements	O
as	O
recommended	O
were	O
generally	O
met	B-CHED
.	O

Although	O
interaction	O
between	O
7a	O
protein	B-CHED
and	O
another	O
SCoV	O
accessory	O
protein	B-CHED
,	O
3a	O
,	O
has	O
been	O
reported	O
,	O
3a	O
protein	B-CHED
was	O
dispensable	O
for	O
assembly	O
of	O
7a	O
protein	B-CHED
into	O
VLPs	O
.	O

Moreover	O
,	O
progress	O
in	O
the	O
drug	O
development	O
based	O
on	O
different	O
molecular	O
targets	O
is	O
also	O
summarized	O
,	O
including	O
1	O
)	O
Compounds	O
that	O
block	O
the	O
S	O
protein	B-CHED
-	O
ACE2	O
-	O
mediated	O
viral	O
entry	O
;	O
2	O
)	O
Compounds	O
targeting	O
SARS	O
-	O
CoV	O
M	O
(	O
pro	B-CHED
);	O
3	O
)	O
Compounds	O
targeting	O
papain	O
-	O
like	O
protease	O
2	O
(	O
PLP2	O
);	O
4	O
)	O
Compounds	O
targeting	O
SARS	O
-	O
CoV	O
RdRp	O
;	O
5	O
)	O
Compounds	O
targeting	O
SARS	O
-	O
CoV	O
helicase	O
;	O
6	O
)	O
Active	O
compounds	O
with	O
unspecified	O
targets	O
;	O
and	O
7	O
)	O
Research	O
on	O
siRNA	O
.	O

Disruption	O
of	O
E	O
protein	B-CHED
may	O
reduce	O
viral	O
infectivity	O
.	O

Thirty	O
-	O
four	O
spontaneously	O
breathing	O
(	O
SB	O
-	O
PCP	B-CHED
)	O
and	O
20	O
ventilated	O
HIV	O
-	O
positive	O
patients	O
with	O
PCP	B-CHED
(	O
V	O
-	O
PCP	B-CHED
),	O
ten	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
11	O
spontaneously	O
breathing	O
patients	O
with	O
bacterial	O
pneumonia	O
(	O
PNEU	O
),	O
and	O
22	O
healthy	O
volunteers	O
.	O

Analysis	O
of	O
neutral	O
lipid	B-CHED
classes	O
showed	O
a	O
significant	O
increase	O
in	O
the	O
relative	O
content	O
of	O
triglycerides	B-CHED
and	O
a	O
reduction	O
in	O
free	O
fatty	B-CHED
acids	I-CHED
in	O
V	O
-	O
PCP	B-CHED
compared	O
with	O
controls	O
.	O

TITLE	O
:	O
Effects	O
of	O
enteral	O
feeding	O
with	O
eicosapentaenoic	B-CHED
acid	I-CHED
,	O
gamma	B-CHED
-	I-CHED
linolenic	I-CHED
acid	I-CHED
,	O
and	O
antioxidants	B-CHED
in	O
mechanically	O
ventilated	O
patients	O
with	O
severe	O
sepsis	O
and	O
septic	O
shock	O
.	O

In	O
patients	O
with	O
severe	O
sepsis	O
or	O
septic	O
shock	O
and	O
requiring	O
mechanical	O
ventilation	O
and	O
tolerating	O
enteral	O
nutrition	O
,	O
a	O
diet	O
enriched	O
with	O
EPA	B-CHED
,	O
GLA	B-CHED
,	O
and	O
elevated	O
antioxidants	B-CHED
contributed	O
to	O
better	O
ICU	O
and	O
hospital	O
outcomes	O
and	O
was	O
associated	O
with	O
lower	O
mortality	O
rates	O
.	O

Recombinant	O
IBVs	O
based	O
on	O
the	O
Beaudette	O
strain	O
expressing	O
the	O
Beaudette	O
spike	O
protein	B-CHED
(	O
Beau	O
-	O
R	O
)	O
or	O
that	O
from	O
the	O
virulent	O
M41	O
strain	O
(	O
BeauR	O
-	O
M41	O
(	O
S	O
))	O
were	O
assessed	O
for	O
their	O
potential	O
as	O
prototype	O
vaccines	O
for	O
application	O
to	O
18	O
-	O
day	O
-	O
old	O
embryos	O
.	O

Additional	O
predictors	O
in	O
the	O
full	O
model	O
included	O
haziness	O
or	O
infiltrates	O
on	O
chest	O
radiography	O
,	O
less	O
than	O
95	O
%	O
oxygen	B-CHED
saturation	O
on	O
room	O
air	B-CHED
,	O
high	O
lactate	B-CHED
dehydrogenase	O
level	O
,	O
and	O
high	O
neutrophil	O
and	O
low	O
platelet	O
counts	O
.	O

ABSTRACT	O
:	O
Research	O
on	O
risk	O
factors	O
for	O
premenstrual	O
syndrome	O
(	O
PMS	B-CHED
)	O
is	O
lacking	O
for	O
the	O
Gulf	O
countries	O
of	O
the	O
Middle	O
East	O
,	O
a	O
region	O
with	O
unique	O
cultural	O
features	O
that	O
might	O
influence	O
expectations	O
and	O
self	O
-	O
perception	O
of	O
the	O
disease	O
.	O

TITLE	O
:	O
Crystal	O
structure	O
of	O
nonstructural	O
protein	B-CHED
10	O
from	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
reveals	O
a	O
novel	O
fold	O
with	O
two	O
zinc	B-CHED
-	O
binding	O
motifs	O
.	O

A	O
distinct	O
clustering	O
of	O
basic	O
residues	O
on	O
the	O
protein	B-CHED
surface	O
suggests	O
a	O
nucleic	B-CHED
acid	I-CHED
-	O
binding	O
function	O
.	O

Two	O
-	O
dimensional	O
images	O
of	O
the	O
S	O
,	O
M	O
,	O
and	O
N	O
structural	O
proteins	B-CHED
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
and	O
two	O
other	O
coronaviruses	O
were	O
refined	O
to	O
a	O
resolution	O
of	O
approximately	O
4	O
nm	O
.	O

TITLE	O
:	O
Synthesis	O
of	O
stilbene	B-CHED
derivatives	O
with	O
inhibition	O
of	O
SARS	O
coronavirus	O
replication	O
.	O

This	O
is	O
a	O
prospective	O
case	O
series	O
study	O
of	O
22	O
patients	O
with	O
septic	O
shock	O
,	O
11	O
patients	O
with	O
severe	O
sepsis	O
,	O
and	O
20	O
healthy	O
volunteers	O
at	O
the	O
Department	O
of	O
Emergency	O
and	O
Critical	O
Care	O
Medicine	B-CHED
,	O
Nara	O
Medical	O
University	O
Hospital	O
,	O
Japan	O
.	O

Although	O
more	O
data	O
are	O
required	O
to	O
draw	O
definitive	O
conclusions	O
,	O
our	O
findings	O
suggested	O
the	O
need	O
for	O
oxygen	B-CHED
supplementation	O
during	O
such	O
procedures	O
in	O
nonhuman	O
primates	O
,	O
despite	O
the	O
fact	O
that	O
human	O
patients	O
undergoing	O
bronchoscopy	O
and	O
lavage	O
do	O
not	O
routinely	O
get	O
oxygen	B-CHED
unless	O
they	O
are	O
already	O
compromised	O
.	O

This	O
information	O
may	O
be	O
applied	O
toward	O
the	O
design	O
of	O
other	O
3CL	O
protease	B-CHED
inhibitors	I-CHED
.	O

Data	O
analyzed	O
were	O
from	O
a	O
clinical	O
trial	O
of	O
zanamivir	B-CHED
in	O
children	O
5	O
-	O
12	O
years	O
of	O
age	O
and	O
from	O
a	O
trial	O
of	O
oseltamivir	B-CHED
in	O
children	O
1	O
-	O
12	O
years	O
of	O
age	O
.	O

Cough	O
(	O
positive	O
predictive	O
value	O
,	O
70	O
%;	O
95	O
%	O
CI	O
,	O
64	O
%-	O
75	O
%),	O
but	O
not	O
fever	O
,	O
was	O
the	O
best	O
predictor	O
of	O
influenza	O
virus	O
-	O
positive	O
status	O
in	O
children	O
aged	O
5	O
-	O
12	O
years	O
in	O
the	O
oseltamivir	B-CHED
trials	O
,	O
but	O
neither	O
cough	O
nor	O
fever	O
were	O
successful	O
predictors	O
in	O
young	O
children	O
1	O
-	O
4	O
years	O
of	O
age	O
.	O

In	O
this	O
study	O
,	O
potential	O
HLA	O
-	O
A	O
*	O
0201	O
-	O
restricted	O
spike	O
(	O
S	O
)	O
and	O
nucleocapsid	O
protein	B-CHED
-	O
derived	O
peptides	B-CHED
were	O
selected	O
from	O
an	O
online	O
database	O
and	O
screened	O
for	O
potential	O
CTL	O
epitopes	O
by	O
in	O
vitro	O
refolding	O
and	O
T2	O
cell	O
-	O
stabilization	O
assays	O
.	O

Thus	O
,	O
P15	O
may	O
be	O
a	O
novel	O
SARS	O
-	O
associated	O
coronavirus	O
-	O
specific	O
CTL	O
epitope	B-CHED
and	O
a	O
potential	O
target	O
for	O
characterization	O
of	O
virus	O
control	O
mechanisms	O
and	O
evaluation	O
of	O
candidate	O
SARS	O
vaccines	O
.	O

ABSTRACT	O
:	O
Alemtuzumab	O
was	O
used	O
as	O
an	O
induction	O
agent	O
in	O
205	O
renal	O
transplant	O
recipients	O
undergoing	O
207	O
living	O
donor	B-CHED
renal	O
transplants	O
.	O

Postoperatively	O
,	O
patients	O
were	O
treated	O
with	O
tacrolimus	B-CHED
monotherapy	O
,	O
and	O
immunosuppression	O
was	O
weaned	O
when	O
possible	O
.	O

Most	O
(	O
81	O
.	O
3	O
%)	O
episodes	O
of	O
ACR	O
in	O
the	O
alemtuzumab	O
group	O
were	O
Banff	O
1	O
(	O
a	O
or	O
b	O
)	O
and	O
were	O
sensitive	O
to	O
steroid	B-CHED
pulses	O
for	O
the	O
treatment	O
of	O
rejection	O
.	O

This	O
study	O
represents	O
the	O
largest	O
series	O
to	O
date	O
of	O
live	O
donor	B-CHED
renal	O
transplant	O
recipients	O
undergoing	O
alemtuzumab	O
induction	O
,	O
and	O
confirms	O
the	O
short	O
-	O
term	O
safety	O
and	O
efficacy	O
of	O
this	O
approach	O
.	O

Stool	O
samples	O
have	O
been	O
shown	O
to	O
be	O
appropriate	O
for	O
diagnostic	O
testing	O
for	O
SARS	O
CoV	O
,	O
although	O
it	O
has	O
been	O
recognized	O
to	O
be	O
a	O
heterogeneous	O
and	O
difficult	O
sample	O
that	O
contains	O
amplification	O
inhibitors	B-CHED
.	O

Among	O
50	O
randomly	O
picked	O
clones	O
,	O
12	O
Fabs	O
specially	O
reacted	O
with	O
S	O
protein	B-CHED
by	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
.	O

These	O
data	O
showed	O
that	O
the	O
number	O
of	O
virus	O
copies	O
was	O
significantly	O
reduced	O
in	O
the	O
M1A	B-CHED
-	O
treated	O
group	O
,	O
suggesting	O
an	O
important	O
role	O
for	O
M1A	B-CHED
in	O
passive	O
immunoprophylaxis	O
against	O
the	O
SARS	O
virus	O
.	O

We	O
have	O
synthesised	O
and	O
characterised	O
the	O
first	O
generation	O
of	O
a	O
red	O
-	O
shifted	O
internally	O
quenched	O
fluorogenic	O
substrate	O
(	O
RS	O
-	O
IQFS	O
)	O
for	O
3CLpro	O
based	O
on	O
resonance	O
energy	O
transfer	O
between	O
the	O
donor	B-CHED
and	O
acceptor	B-CHED
pair	O
CAL	O
Fluor	B-CHED
Red	O
610	O
and	O
Black	O
Hole	O
Quencher	O
-	O
1	O
(	O
Km	O
and	O
kcat	O
values	O
of	O
14	O
microM	O
and	O
0	O
.	O
65	O
min	O
-	O
1	O
).	O

The	O
conserved	O
structural	O
determinants	O
of	O
this	O
site	O
may	O
provide	O
a	O
framework	O
for	O
attempting	O
to	O
design	O
antiviral	B-CHED
drugs	I-CHED
to	O
interfere	O
with	O
the	O
infectious	O
nidovirus	O
life	O
cycle	O
.	O

RESULTS	O
:	O
Overall	O
,	O
273	O
absences	O
>	O
7	O
days	O
were	O
recorded	O
and	O
36	O
clusters	B-CHED
of	O
at	O
least	O
two	O
absences	O
>	O
7	O
days	O
were	O
identified	O
;	O
a	O
total	O
of	O
94	O
HCW	O
were	O
involved	O
in	O
these	O
clusters	B-CHED
.	O

ABSTRACT	O
:	O
The	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
nucleocapsid	O
protein	B-CHED
(	O
NP	O
)	O
is	O
one	O
of	O
the	O
predominant	O
antigenic	O
protein	B-CHED
and	O
the	O
most	O
abundant	O
shed	O
antigen	B-CHED
throughout	O
the	O
SARS	O
-	O
CoV	O
infection	O
.	O

The	O
5	O
'	O
end	O
two	O
-	O
thirds	O
of	O
the	O
single	O
-	O
stranded	O
positive	O
-	O
sense	O
viral	O
genomic	O
RNA	O
,	O
gene	O
1	O
,	O
encodes	O
16	O
mature	O
proteins	B-CHED
.	O

Expression	O
of	O
nsp1	O
,	O
the	O
most	O
N	O
-	O
terminal	O
gene	O
1	O
protein	B-CHED
,	O
prevented	O
Sendai	O
virus	O
-	O
induced	O
endogenous	O
IFN	O
-	O
beta	O
mRNA	B-CHED
accumulation	O
without	O
inhibiting	O
dimerization	O
of	O
IFN	O
regulatory	O
factor	O
3	O
,	O
a	O
protein	B-CHED
that	O
is	O
essential	O
for	O
activation	O
of	O
the	O
IFN	O
-	O
beta	O
promoter	O
.	O

In	O
contrast	O
to	O
nsp1	O
-	O
induced	O
mRNA	B-CHED
destablization	O
,	O
no	O
degradation	O
of	O
the	O
28S	O
and	O
18S	O
rRNAs	O
occurred	O
in	O
either	O
nsp1	O
-	O
expressing	O
cells	O
or	O
SCoV	O
-	O
infected	O
cells	O
.	O

NL63	O
-	O
S	O
does	O
not	O
exhibit	O
significant	O
homology	O
to	O
SARS	O
-	O
S	O
but	O
is	O
highly	O
related	O
to	O
the	O
S	O
-	O
protein	B-CHED
of	O
hCoV	O
-	O
229E	O
,	O
which	O
enters	O
target	O
cells	O
by	O
engaging	O
CD13	O
.	O

TITLE	O
:	O
Antigenic	O
and	O
cellular	O
localisation	O
analysis	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
nucleocapsid	O
protein	B-CHED
using	O
monoclonal	O
antibodies	O
.	O

The	O
monoclonal	O
antibodies	O
bound	O
to	O
the	O
central	O
and	O
carboxyterminal	O
half	O
of	O
the	O
nucleocapsid	O
protein	B-CHED
indicating	O
prominent	O
exposure	O
and	O
immunogenicity	O
of	O
this	O
part	O
of	O
the	O
protein	B-CHED
.	O

This	O
report	O
summarizes	O
the	O
recommendations	O
from	O
a	O
WHO	O
Technical	O
Meeting	O
on	O
Animal	O
Models	O
and	O
Antibody	O
Assays	O
for	O
Evaluating	O
Candidate	O
SARS	O
Vaccines	O
held	O
on	O
25	O
-	O
26	O
August	O
2005	O
in	O
South	O
Mimms	O
,	O
UK	O
,	O
provides	O
guidance	O
on	O
the	O
use	O
of	O
animal	O
models	O
,	O
and	O
outlines	O
the	O
steps	O
to	O
develop	O
standard	O
reagents	B-CHED
and	O
assays	O
for	O
immunological	O
evaluation	O
of	O
candidate	O
SARS	O
vaccines	O
.	O

TITLE	O
:	O
Extremely	O
low	O
exposure	O
of	O
a	O
community	O
to	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
:	O
false	O
seropositivity	O
due	O
to	O
use	O
of	O
bacterially	O
derived	O
antigens	B-CHED
.	O

ABSTRACT	O
:	O
Pharmaceutical	B-CHED
expenditure	O
(	O
PE	O
)	O
of	O
the	O
National	O
Health	O
Insurance	O
(	O
NHI	O
)	O
programme	O
in	O
Taiwan	O
grew	O
from	O
62	O
.	O
2	O
billion	O
Taiwan	O
new	O
dollars	O
(	O
NT	O
dollars	O
)	O
in	O
1996	O
to	O
NT94	O
.	O
5	O
dollars	O
billion	O
in	O
2003	O
.	O
The	O
government	O
has	O
been	O
introducing	O
many	O
strategies	O
to	O
control	O
PE	O
since	O
the	O
inception	O
of	O
NHI	O
including	O
price	O
adjustment	O
based	O
on	O
the	O
prices	O
of	O
international	O
products	O
or	O
existing	O
products	O
(	O
inter	O
-	O
brands	O
comparison	O
),	O
or	O
market	O
price	O
and	O
volume	O
survey	O
;	O
delegation	O
of	O
financial	O
responsibility	O
to	O
regional	O
bureaux	O
;	O
co	O
-	O
payment	O
for	O
outpatient	O
drugs	O
;	O
generic	O
grouping	O
(	O
the	O
reference	O
pricing	O
scheme	O
based	O
on	O
chemical	O
equivalence	O
);	O
a	O
global	O
budget	O
payment	O
system	O
for	O
clinics	O
and	O
hospitals	O
;	O
and	O
reduction	O
in	O
the	O
flat	O
daily	O
payment	O
rate	O
of	O
the	O
drugs	O
for	O
clinics	O
.	O

Chlorine	B-CHED
had	O
fairly	O
better	O
efficiency	O
on	O
microorganism	O
inactivation	O
than	O
chlorine	B-CHED
dioxide	I-CHED
with	O
the	O
same	O
dosage	O
.	O

As	O
an	O
initial	O
step	O
toward	O
provision	O
of	O
an	O
oral	O
vaccine	O
against	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
we	O
have	O
expressed	O
a	O
partial	O
spike	O
(	O
S	O
)	O
protein	B-CHED
of	O
SARS	O
-	O
CoV	O
in	O
the	O
cytosol	O
of	O
nuclear	O
-	O
transformed	O
plants	O
and	O
in	O
the	O
chloroplasts	O
of	O
plastid	O
-	O
transformed	O
plants	O
.	O

In	O
the	O
construction	O
of	O
both	O
nuclear	O
and	O
plastid	O
transformation	O
vectors	O
,	O
a	O
2	O
-	O
kilobase	O
nucleotide	B-CHED
sequence	O
encoding	O
amino	B-CHED
acids	I-CHED
1	O
-	O
658	O
of	O
the	O
SARS	O
-	O
CoV	O
spike	O
protein	B-CHED
(	O
S1	O
)	O
was	O
modified	O
with	O
nucleotide	B-CHED
changes	O
,	O
but	O
not	O
amino	B-CHED
acid	I-CHED
changes	O
,	O
to	O
optimize	O
codon	O
usage	O
for	O
expression	O
in	O
plants	O
.	O

When	O
the	O
S1	O
was	O
expressed	O
in	O
transplastomic	O
tobacco	O
,	O
S1	O
messenger	B-CHED
RNA	I-CHED
and	O
its	O
corresponding	O
protein	B-CHED
were	O
detected	O
on	O
Northern	O
and	O
Western	O
blot	O
analyses	O
,	O
respectively	O
.	O

TITLE	O
:	O
Molecular	O
modeling	O
studies	O
of	O
peptide	B-CHED
drug	O
candidates	O
against	O
SARS	O
.	O

Pulmonary	O
function	O
tests	O
,	O
including	O
spirometry	O
and	O
carbon	B-CHED
monoxide	I-CHED
diffusing	O
capacity	O
(	O
DLCO	O
),	O
as	O
well	O
as	O
symptom	O
-	O
limited	O
cardiopulmonary	O
exercise	O
testing	O
(	O
CPET	O
)	O
with	O
an	O
incremental	O
protocol	O
using	O
an	O
electronically	O
braked	O
cycle	O
ergometer	O
,	O
were	O
performed	O
by	O
13	O
previously	O
healthy	O
hospital	O
workers	O
14	O
months	O
after	O
SARS	O
recovery	O
.	O

We	O
studied	O
exhaled	O
air	B-CHED
and	O
particle	O
dispersion	O
through	O
an	O
oronasal	O
mask	O
attached	O
to	O
a	O
human	O
-	O
patient	O
simulator	O
(	O
HPS	B-CHED
)	O
during	O
noninvasive	O
positive	O
-	O
pressure	O
ventilation	O
(	O
NPPV	O
).	O

When	O
IPAP	O
was	O
increased	O
to	O
18	O
cm	O
H2O	B-CHED
,	O
the	O
vertical	O
plume	O
extended	O
to	O
0	O
.	O
45	O
m	O
above	O
the	O
patient	O
with	O
some	O
horizontal	O
spreading	O
along	O
the	O
ward	O
ceiling	O
.	O

To	O
assess	O
this	O
risk	O
,	O
a	O
human	O
lung	O
model	O
(	O
respiration	O
rate	O
,	O
12	O
breaths	O
/	O
min	O
)	O
was	O
designed	O
to	O
test	O
the	O
potential	O
for	O
a	O
simple	O
oxygen	B-CHED
mask	O
at	O
a	O
common	O
setting	O
(	O
4	O
L	O
/	O
min	O
)	O
to	O
disperse	O
potentially	O
infectious	O
exhaled	O
air	B-CHED
into	O
the	O
surrounding	O
area	O
.	O

One	O
of	O
these	O
is	O
the	O
3b	O
protein	B-CHED
,	O
which	O
is	O
encoded	O
by	O
the	O
second	O
open	O
reading	O
frame	O
in	O
subgenomic	O
RNA	O
3	O
and	O
contains	O
154	O
amino	B-CHED
acids	I-CHED
.	O

The	O
3bDelta124	O
-	O
154	O
mutant	O
behaves	O
in	O
a	O
similar	O
manner	O
indicating	O
that	O
the	O
localization	O
of	O
the	O
3b	O
protein	B-CHED
does	O
not	O
seems	O
to	O
be	O
important	O
for	O
the	O
cell	O
-	O
death	O
pathways	O
since	O
full	O
-	O
length	O
3b	O
is	O
localized	O
predominantly	O
to	O
the	O
nucleolus	O
,	O
while	O
the	O
mutant	O
is	O
found	O
to	O
be	O
concentrated	O
in	O
the	O
peri	O
-	O
nuclear	O
regions	O
.	O

In	O
29	O
studies	O
of	O
steroid	B-CHED
use	O
,	O
25	O
were	O
inconclusive	O
and	O
four	O
were	O
classified	O
as	O
causing	O
possible	O
harm	O
.	O

To	O
determine	O
whether	O
HECV	O
-	O
4408	O
infects	O
gnotobiotic	O
calves	O
and	O
induces	O
cross	O
-	O
protective	O
immunity	O
against	O
the	O
virulent	O
enteric	O
BCoV	O
DB2	O
strain	O
,	O
gnotobiotic	O
calves	O
(	O
n	O
=	O
4	O
)	O
were	O
orally	O
inoculated	O
with	O
HECV	O
-	O
4408	O
and	O
then	O
challenged	O
with	O
BCoV	O
DB2	O
at	O
postinoculation	O
day	O
(	O
PID	B-CHED
)	O
21	O
.	O

Coronavirus	O
nucleoproteins	O
(	O
N	O
)	O
are	O
nonspecific	O
RNA	O
-	O
binding	O
proteins	B-CHED
with	O
long	O
disordered	O
regions	O
.	O

During	O
construction	O
of	O
an	O
infectious	O
clone	O
from	O
a	O
Vero	O
cell	O
-	O
adapted	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
),	O
we	O
found	O
that	O
a	O
G	O
-	O
C	O
point	O
mutation	O
at	O
nucleotide	B-CHED
position	O
15526	O
,	O
causing	O
Arg	B-CHED
-	O
to	O
-	O
Pro	B-CHED
mutation	O
at	O
amino	B-CHED
acid	I-CHED
position	O
132	O
of	O
the	O
helicase	O
protein	B-CHED
,	O
is	O
lethal	O
to	O
the	O
infectivity	O
of	O
IBV	O
on	O
Vero	O
cells	O
.	O

Substitution	O
mutation	O
of	O
the	O
Arg132	O
residue	O
to	O
a	O
positively	O
charged	O
amino	B-CHED
acid	I-CHED
Lys	B-CHED
affected	O
neither	O
the	O
infectivity	O
of	O
the	O
in	O
vitro	O
-	O
synthesized	O
transcripts	O
nor	O
the	O
growth	O
properties	O
of	O
the	O
rescued	O
virus	O
.	O

Finally	O
,	O
according	O
to	O
recent	O
studies	O
,	O
the	O
stabilization	O
of	O
the	O
trimeric	O
bundle	O
is	O
linked	O
to	O
a	O
higher	O
fusion	O
activity	O
of	O
the	O
spike	O
protein	B-CHED
,	O
and	O
the	O
possible	O
influence	O
of	O
the	O
GxxxG	O
motif	O
on	O
this	O
feature	O
is	O
discussed	O
.	O

In	O
our	O
study	O
,	O
the	O
highest	O
creatinine	B-CHED
levels	O
were	O
found	O
in	O
patients	O
with	O
the	O
lowest	O
ex	O
vivo	O
TNF	O
-	O
alpha	O
production	O
.	O

STAT1	O
tyrosine	B-CHED
phosphorylation	O
was	O
elevated	O
by	O
IFN	O
combination	O
treatment	O
,	O
however	O
,	O
only	O
the	O
hyper	O
-	O
transactivation	O
of	O
GAS	O
but	O
not	O
ISRE	O
was	O
observed	O
.	O

The	O
most	O
promising	O
vaccine	O
candidates	O
contain	O
purified	O
recombinant	O
protective	O
antigen	B-CHED
.	O

The	O
nucleotide	B-CHED
and	O
amino	B-CHED
acid	I-CHED
similarities	O
between	O
the	O
eight	O
IB	O
vaccine	O
strains	O
and	O
the	O
field	O
strain	O
,	O
tl	O
/	O
CH	O
/	O
LDT3	O
/	O
03	O
,	O
which	O
was	O
isolated	O
from	O
a	O
teal	O
(	O
Anas	O
sp	O
.),	O
were	O
not	O
more	O
than	O
81	O
.	O
1	O
%	O
and	O
79	O
.	O
2	O
%,	O
respectively	O
.	O

TITLE	O
:	O
Amino	B-CHED
acids	I-CHED
1	O
to	O
422	O
of	O
the	O
spike	O
protein	B-CHED
of	O
SARS	O
associated	O
coronavirus	O
are	O
required	O
for	O
induction	O
of	O
cyclooxygenase	O
-	O
2	O
.	O

The	O
resultant	O
plasmid	O
pPIC9K	O
-	O
S1	O
was	O
transformed	O
into	O
Pichia	O
pastoris	O
GS	O
115	O
and	O
the	O
protein	B-CHED
expression	O
was	O
induced	O
with	O
methanol	B-CHED
.	O

hUbc9	O
,	O
a	O
ubiquitin	O
conjugating	O
enzyme	O
of	O
sumoylation	O
system	O
,	O
was	O
found	O
to	O
interact	O
specifically	O
with	O
the	O
N	O
protein	B-CHED
,	O
implying	O
the	O
post	O
-	O
translational	O
sumoylation	O
of	O
the	O
N	O
protein	B-CHED
.	O

The	O
two	O
proteins	B-CHED
were	O
also	O
shown	O
to	O
colocalize	O
in	O
the	O
cytoplasm	O
of	O
the	O
transfected	O
293T	O
cells	O
.	O

The	O
m	O
-	O
PCR	O
were	O
more	O
sensitive	O
,	O
had	O
the	O
advantages	O
of	O
a	O
shorter	O
delay	O
in	O
specific	O
diagnosis	O
,	O
and	O
a	O
lower	O
cost	O
than	O
DFA	B-CHED
and	O
culture	O
.	O

In	O
conclusion	O
,	O
according	O
to	O
the	O
requirements	O
of	O
speed	O
and	O
low	O
cost	O
of	O
the	O
methods	O
,	O
and	O
to	O
achieve	O
the	O
highest	O
rate	O
of	O
detection	O
of	O
respiratory	O
viruses	O
,	O
the	O
combined	O
use	O
of	O
DFA	B-CHED
and	O
m	O
-	O
PCR	O
is	O
today	O
likely	O
to	O
be	O
the	O
best	O
way	O
to	O
improve	O
diagnosis	O
of	O
respiratory	O
illnesses	O
in	O
children	O
.	O

Effective	O
methods	O
for	O
inactivating	O
the	O
SARS	O
-	O
CoV	O
in	O
protein	B-CHED
solutions	O
are	O
described	O
in	O
this	O
report	O
.	O

The	O
presence	O
of	O
bovine	O
serum	O
albumin	O
limited	O
the	O
ability	O
of	O
UVC	O
and	O
UVA	O
to	O
inactivate	O
SARS	O
-	O
CoV	O
and	O
octanoic	B-CHED
acid	I-CHED
treatment	O
does	O
not	O
reduce	O
the	O
infectivity	O
of	O
SARS	O
-	O
CoV	O
-	O
spiked	O
protein	B-CHED
solutions	O
.	O

Heat	O
,	O
UVC	O
irradiation	O
,	O
and	O
S	O
/	O
D	O
treatments	O
effectively	O
inactivate	O
SARS	O
-	O
CoV	O
,	O
whereas	O
octanoic	B-CHED
acid	I-CHED
treatment	O
is	O
insufficient	O
for	O
inactivation	O
of	O
the	O
virus	O
.	O

We	O
generated	O
a	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
spike	O
protein	B-CHED
-	O
expressing	O
recombinant	O
vaccinia	O
virus	O
(	O
RVV	O
-	O
S	O
)	O
using	O
highly	O
attenuated	O
strain	O
LC16m8	O
.	O

TITLE	O
:	O
Viral	O
ion	O
channel	O
proteins	B-CHED
in	O
model	O
membranes	O
:	O
a	O
comparative	O
study	O
by	O
X	O
-	O
ray	O
reflectivity	O
.	O

TITLE	O
:	O
Complete	O
genomic	O
sequences	O
,	O
a	O
key	O
residue	O
in	O
the	O
spike	O
protein	B-CHED
and	O
deletions	O
in	O
nonstructural	O
protein	B-CHED
3b	O
of	O
US	O
strains	O
of	O
the	O
virulent	O
and	O
attenuated	O
coronaviruses	O
,	O
transmissible	O
gastroenteritis	O
virus	O
and	O
porcine	O
respiratory	O
coronavirus	O
.	O

In	O
addition	O
,	O
some	O
oxidative	O
stress	O
sensitive	O
genes	O
,	O
heat	O
shock	O
proteins	B-CHED
,	O
transcription	O
factors	O
,	O
and	O
cytokines	O
showed	O
remarkable	O
elevation	O
.	O

TITLE	O
:	O
Expression	O
of	O
elevated	O
levels	O
of	O
pro	B-CHED
-	O
inflammatory	O
cytokines	O
in	O
SARS	O
-	O
CoV	O
-	O
infected	O
ACE2	O
+	O
cells	O
in	O
SARS	O
patients	O
:	O
relation	O
to	O
the	O
acute	O
lung	O
injury	O
and	O
pathogenesis	O
of	O
SARS	O
.	O

Since	O
its	O
associated	O
morbidity	O
and	O
mortality	O
have	O
been	O
postulated	O
to	O
be	O
due	O
to	O
immune	O
dysregulation	O
,	O
we	O
investigated	O
which	O
of	O
the	O
viral	O
proteins	B-CHED
is	O
responsible	O
for	O
chemokine	O
overexpression	O
.	O

By	O
immobilizing	O
the	O
DNA	O
probe	O
through	O
the	O
use	O
of	O
GBP	O
-	O
fused	O
cSA	B-CHED
,	O
specific	O
hybridization	O
of	O
the	O
target	O
DNA	O
prepared	O
from	O
Salmonella	O
could	O
also	O
be	O
achieved	O
.	O

Bioassay	O
results	O
reveal	O
salient	O
features	O
of	O
the	O
structure	O
-	O
activity	O
relationship	O
of	O
the	O
new	O
compounds	O
:	O
(	O
1	O
)	O
removal	O
of	O
the	O
7	O
-	O
hydroxy	B-CHED
group	I-CHED
of	O
the	O
quercetin	B-CHED
moiety	O
decreases	O
the	O
bioactivity	O
of	O
the	O
derivatives	O
;	O
(	O
2	O
)	O
acetoxylation	O
of	O
the	O
sugar	O
moiety	O
abolishes	O
inhibitor	B-CHED
action	O
;	O
(	O
3	O
)	O
introduction	O
of	O
a	O
large	O
sugar	O
substituent	O
on	O
7	O
-	O
hydroxy	B-CHED
of	O
quercetin	B-CHED
can	O
be	O
tolerated	O
;	O
(	O
4	O
)	O
replacement	O
of	O
the	O
galactose	B-CHED
moiety	O
with	O
other	O
sugars	O
does	O
not	O
affect	O
inhibitor	B-CHED
potency	O
.	O

In	O
the	O
multivariate	O
analysis	O
,	O
only	O
three	O
factors	O
were	O
significant	O
:	O
delay	O
to	O
isolation	O
,	O
admission	O
to	O
a	O
non	O
-	O
isolation	O
facility	O
and	O
higher	O
lactate	B-CHED
dehydrogenase	O
levels	O
of	O
>	O
650	O
IU	O
/	O
L	O
(	O
OR	O
6	O
.	O
4	O
,	O
23	O
.	O
8	O
and	O
4	O
.	O
7	O
respectively	O
).	O

Serum	O
IgG	O
blocked	O
binding	O
of	O
the	O
S	O
-	O
protein	B-CHED
to	O
the	O
ACE2	O
receptor	O
and	O
neutralized	O
SARS	O
-	O
CoV	O
infection	O
in	O
vitro	O
.	O

Moreover	O
,	O
the	O
role	O
of	O
S	O
and	O
M	O
proteins	B-CHED
as	O
important	O
surface	O
antigens	B-CHED
is	O
confirmed	O
.	O

One	O
hundred	O
millimolars	O
sodium	B-CHED
tetraborate	I-CHED
buffer	B-CHED
containing	O
20	O
mM	O
sodium	B-CHED
dihydrogen	I-CHED
phosphate	I-CHED
with	O
a	O
final	O
pH	O
9	O
.	O
8	O
was	O
used	O
as	O
a	O
running	O
buffer	B-CHED
.	O

PaO	B-CHED
(	O
2	O
),	O
SaO	O
(	O
2	O
)	O
and	O
PaO	B-CHED
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
were	O
increased	O
by	O
68	O
mm	O
Hg	O
,	O
9	O
.	O
5	O
%,	O
and	O
104	O
.	O
7	O
%	O
respectively	O
.	O

The	O
combination	O
of	O
acute	O
renal	O
failure	O
and	O
sepsis	O
is	O
associated	O
with	O
a	O
high	O
mortality	O
rate	O
,	O
namely	O
in	O
patients	O
with	O
a	O
nitric	B-CHED
oxide	I-CHED
-	O
induced	O
systemic	O
reduction	O
in	O
peripheral	O
vascular	O
resistances	O
and	O
septic	O
shock	O
.	O

Further	O
,	O
MHV	O
infection	O
did	O
not	O
inhibit	O
IFN	O
-	O
beta	O
production	O
mediated	O
by	O
known	O
host	O
pattern	O
recognition	O
receptors	O
(	O
PRRs	O
)	O
(	O
RIG	O
-	O
I	O
,	O
Mda	B-CHED
-	O
5	O
,	O
and	O
TLR3	O
).	O

Of	O
the	O
eight	O
putative	O
accessory	O
proteins	B-CHED
encoded	O
by	O
the	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
only	O
two	O
-	O
open	O
reading	O
frame	O
3a	O
(	O
ORF3a	O
)	O
and	O
ORF7a	O
-	O
have	O
been	O
identified	O
in	O
virus	O
-	O
infected	O
cells	O
to	O
date	O
.	O

TITLE	O
:	O
Suppression	O
of	O
coronavirus	O
replication	O
by	O
inhibition	O
of	O
the	O
MEK	B-CHED
signaling	O
pathway	O
.	O

ABSTRACT	O
:	O
We	O
previously	O
demonstrated	O
that	O
infection	O
of	O
cultured	O
cells	O
with	O
murine	O
coronavirus	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
resulted	O
in	O
activation	O
of	O
the	O
mitogen	B-CHED
-	O
activated	O
protein	B-CHED
kinase	O
(	O
Raf	O
/	O
MEK	B-CHED
/	O
ERK	O
)	O
signal	O
transduction	O
pathway	O
(	O
Y	O
.	O
Cai	O
et	O
al	O
.,	O
Virology	O
355	O
:	O
152	O
-	O
163	O
,	O
2006	O
).	O

These	O
findings	O
indicate	O
that	O
the	O
Raf	O
/	O
MEK	B-CHED
/	O
ERK	O
signaling	O
pathway	O
is	O
involved	O
in	O
MHV	O
RNA	O
synthesis	O
.	O

Cox	O
regression	O
analysis	O
demonstrated	O
that	O
a	O
>	O
or	O
=	O
85	O
%	O
increase	O
in	O
baseline	O
serum	O
creatinine	B-CHED
(	O
hazard	O
rate	O
,	O
2	O
.	O
30	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1	O
.	O
30	O
-	O
4	O
.	O
08	O
),	O
oliguria	O
(	O
hazard	O
rate	O
,	O
2	O
.	O
51	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1	O
.	O
24	O
-	O
5	O
.	O
08	O
),	O
and	O
the	O
number	O
of	O
antibiotics	B-CHED
(	O
hazard	O
rate	O
,	O
2	O
.	O
64	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1	O
.	O
51	O
-	O
4	O
.	O
63	O
)	O
predicted	O
longer	O
duration	O
of	O
weaning	O
.	O

ABSTRACT	O
:	O
Synthetic	O
decapeptides	O
(	O
N	O
=	O
206	O
)	O
covering	O
the	O
entire	O
sequence	O
of	O
mouse	O
liver	O
fumarylacetoacetate	B-CHED
hydrolase	O
(	O
FAH	O
)	O
were	O
used	O
to	O
analyze	O
the	O
specificities	O
of	O
the	O
autoantibodies	O
(	O
autoAb	O
)	O
elicited	O
towards	O
this	O
enzyme	O
in	O
mice	O
infected	O
with	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
).	O

Moreover	O
,	O
the	O
spectrum	O
of	O
peptides	B-CHED
recognized	O
by	O
the	O
autoAb	O
of	O
a	O
given	O
mouse	O
did	O
not	O
change	O
significantly	O
with	O
time	O
,	O
which	O
suggests	O
that	O
the	O
MHV	O
-	O
elicited	O
autoimmune	O
response	O
does	O
not	O
induce	O
an	O
epitope	B-CHED
recognition	O
spreading	O
.	O

The	O
data	O
were	O
expressed	O
corrected	O
and	O
uncorrected	O
for	O
urine	O
creatinine	B-CHED
(	O
Cr	O
).	O

National	O
pandemic	O
plans	O
prioritize	O
beneficiary	O
access	O
to	O
antiviral	B-CHED
drugs	I-CHED
and	O
vaccines	O
for	O
some	O
countries	O
.	O

4	O
.	O
25	O
mmol	O
/	O
L	O
,	O
MMS	B-CHED
was	O
3532	O
+/-	O

0	O
.	O
52	O
ml	O
/(	O
kg	O
.	O
hr	O
)	O
and	O
the	O
adrenalin	B-CHED
dosage	O
1	O
.	O
36	O
+/-	O

0	O
.	O
48	O
microg	O
/(	O
kg	O
.	O
min	O
),	O
and	O
dopamine	B-CHED
16	O
.	O
35	O
+/-	O

We	O
commenced	O
treatment	O
with	O
high	O
-	O
dose	O
pulse	O
methylprednisolone	B-CHED
and	O
neutrophil	B-CHED
elastase	I-CHED
inhibitor	I-CHED
under	O
mechanical	O
ventilation	O
.	O

The	O
culture	O
of	O
CRCoV	O
will	O
enable	O
analysis	O
of	O
the	O
expression	O
and	O
function	O
of	O
this	O
and	O
other	O
CRCoV	O
proteins	B-CHED
as	O
well	O
as	O
allowing	O
the	O
study	O
of	O
the	O
role	O
of	O
CRCoV	O
in	O
the	O
aetiology	O
of	O
canine	O
infectious	O
respiratory	O
disease	O
.	O

TITLE	O
:	O
Receptor	O
-	O
binding	O
domain	O
of	O
SARS	O
-	O
CoV	O
spike	O
protein	B-CHED
induces	O
long	O
-	O
term	O
protective	O
immunity	O
in	O
an	O
animal	O
model	O
.	O

Our	O
previous	O
studies	O
have	O
shown	O
that	O
the	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
SARS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
protein	B-CHED
elicits	O
highly	O
potent	O
neutralizing	O
antibody	O
responses	O
in	O
the	O
immunized	O
animals	O
.	O

Sera	O
were	O
analyzed	O
for	O
antibodies	O
against	O
feline	O
immunodeficiency	O
virus	O
(	O
FIV	O
),	O
feline	O
calicivirus	O
(	O
FCV	B-CHED
),	O
feline	O
herpesvirus	O
1	O
(	O
feline	O
rhinotracheitis	O
:	O
FHV1	O
),	O
feline	O
/	O
canine	O
parvovirus	O
(	O
FPV	O
/	O
CPV	O
),	O
feline	O
infectious	O
peritonitis	O
virus	O
(	O
feline	O
coronavirus	O
:	O
FIPV	O
),	O
and	O
canine	O
distemper	O
virus	O
(	O
CDV	B-CHED
)	O
or	O
for	O
the	O
presence	O
of	O
feline	O
leukemia	O
virus	O
(	O
FeLV	O
)	O
antigens	B-CHED
.	O

Based	O
on	O
this	O
integrated	O
assay	O
platform	O
,	O
8	O
new	O
SARS	O
-	O
CoV	O
3CL	O
(	O
pro	B-CHED
)	O
inhibitors	B-CHED
were	O
discovered	O
.	O

The	O
in	O
-	O
vivo	O
filtration	O
tests	O
illustrated	O
that	O
N95	O
respirators	O
filtered	O
out	O
97	O
%	O
of	O
potassium	B-CHED
chloride	I-CHED
(	O
KCl	B-CHED
)	O
solution	O
,	O
while	O
surgical	O
masks	O
filtered	O
out	O
95	O
%	O
of	O
KCl	B-CHED
solution	O
.	O

There	O
is	O
also	O
evidence	O
stemming	O
from	O
newly	O
presented	O
C	O
-	O
L	O
follow	O
-	O
up	O
studies	O
that	O
the	O
remarkable	O
advances	O
in	O
intensive	O
care	O
treatment	O
,	O
organ	O
transplantation	O
medicine	B-CHED
and	O
cardiac	O
surgery	O
with	O
cardiopulmonary	O
bypass	O
within	O
the	O
past	O
decade	O
have	O
an	O
important	O
impact	O
on	O
the	O
general	O
hospital	O
inpatients	O
;	O
psychosocial	O
outcome	O
.	O

ABSTRACT	O
:	O
Animal	O
models	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
infection	O
of	O
humans	O
are	O
needed	O
to	O
elucidate	O
SARS	O
pathogenesis	O
and	O
develop	O
vaccines	O
and	O
antivirals	B-CHED
.	O

We	O
developed	O
transgenic	O
mice	O
expressing	O
human	O
angiotensin	B-CHED
-	O
converting	O
enzyme	O
2	O
,	O
a	O
functional	O
receptor	O
for	O
the	O
virus	O
,	O
under	O
the	O
regulation	O
of	O
a	O
global	O
promoter	O
.	O

All	O
three	O
proteins	B-CHED
were	O
able	O
to	O
inhibit	O
expression	O
from	O
an	O
interferon	O
-	O
stimulated	O
response	O
element	O
(	O
ISRE	O
)	O
promoter	O
after	O
infection	O
with	O
Sendai	O
virus	O
,	O
while	O
only	O
ORF	O
3b	O
and	O
ORF	O
6	O
proteins	B-CHED
were	O
able	O
to	O
inhibit	O
expression	O
from	O
the	O
ISRE	O
promoter	O
after	O
treatment	O
with	O
interferon	O
.	O

This	O
indicates	O
that	O
N	O
protein	B-CHED
inhibits	O
only	O
the	O
synthesis	O
of	O
interferon	O
,	O
while	O
ORF	O
3b	O
and	O
ORF	O
6	O
proteins	B-CHED
inhibit	O
both	O
interferon	O
synthesis	O
and	O
signaling	O
.	O

Thus	O
,	O
it	O
appears	O
that	O
these	O
three	O
interferon	O
antagonists	B-CHED
of	O
SARS	O
-	O
CoV	O
inhibit	O
the	O
interferon	O
response	O
by	O
different	O
mechanisms	O
.	O

The	O
recovered	O
deletion	O
mutant	O
grew	O
in	O
Vero	O
E6	O
,	O
Huh	O
-	O
7	O
,	O
and	O
CaCo	O
-	O
2	O
cells	O
to	O
titers	O
20	O
-,	O
200	O
-,	O
and	O
200	O
-	O
fold	O
lower	O
than	O
the	O
recombinant	O
wild	O
-	O
type	O
virus	O
,	O
respectively	O
,	O
indicating	O
that	O
although	O
the	O
E	O
protein	B-CHED
has	O
an	O
effect	O
on	O
growth	O
,	O
it	O
is	O
not	O
essential	O
for	O
virus	O
replication	O
.	O

To	O
discern	O
virulence	O
mechanisms	O
,	O
we	O
compared	O
the	O
in	O
vitro	O
growth	O
properties	O
of	O
rJ	O
.	O
6	O
,	O
a	O
recombinant	O
JHM	O
expressing	O
the	O
SARS	O
peptide	B-CHED
,	O
with	O
isogenic	O
rJ	O
.	O
6	O
-	O
KO	O
,	O
which	O
has	O
an	O
inactive	O
ORF	O
containing	O
a	O
mutated	O
initiation	O
codon	O
and	O
a	O
termination	O
codon	O
at	O
internal	O
position	O
27	O
.	O

The	O
rJ	O
.	O
6	O
infections	O
were	O
also	O
set	O
apart	O
by	O
early	O
viral	O
protein	B-CHED
accumulation	O
and	O
by	O
robust	O
expansion	O
via	O
syncytia	O
,	O
a	O
characteristic	O
feature	O
of	O
JHM	O
virus	O
dissemination	O
.	O

The	O
SARS	O
coronavirus	O
encodes	O
a	O
novel	O
membrane	O
protein	B-CHED
6	O
that	O
can	O
accelerate	O
replication	O
of	O
a	O
related	O
mouse	O
virus	O
,	O
a	O
property	O
that	O
may	O
explain	O
its	O
ability	O
to	O
increase	O
in	O
vivo	O
virus	O
virulence	O
.	O

We	O
present	O
the	O
case	O
of	O
a	O
35	O
-	O
year	O
-	O
old	O
man	B-CHED
with	O
AIDS	O
,	O
who	O
was	O
admitted	O
to	O
our	O
medical	O
ICU	O
for	O
pneumonia	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

In	O
this	O
study	O
,	O
we	O
designed	O
small	O
interference	O
RNAs	O
(	O
siRNAs	O
)	O
targeting	O
sgRNA	O
2	O
,	O
3	O
and	O
7	O
and	O
tested	O
their	O
efficiency	O
and	O
specificity	O
in	O
silencing	O
the	O
protein	B-CHED
translated	O
from	O
the	O
targeted	O
sgRNA	O
.	O

Our	O
results	O
demonstrated	O
that	O
siRNA	O
7	O
could	O
inhibit	O
sgRNA	O
7	O
,	O
which	O
showed	O
19	O
/	O
19	O
nucleotides	B-CHED
(	O
nt	O
)	O
matching	O
,	O
and	O
sgRNA	O
8	O
,	O
which	O
showed	O
18	O
/	O
19	O
nt	O
matching	O
;	O
but	O
,	O
it	O
did	O
not	O
inhibit	O
the	O
full	O
-	O
length	O
genomic	O
mRNA	B-CHED
which	O
showed	O
17	O
/	O
19	O
nt	O
matching	O
.	O

Indirect	O
immunofluorescence	O
assays	O
showed	O
that	O
in	O
the	O
infected	O
cells	O
expressing	O
each	O
of	O
the	O
siRNAs	O
,	O
there	O
was	O
aspecific	O
silencing	O
of	O
S	O
,	O
3a	O
and	O
7a	O
,	O
respectively	O
,	O
but	O
the	O
expression	O
of	O
nucleocapsid	O
protein	B-CHED
was	O
not	O
affected	O
.	O

In	O
addition	O
,	O
two	O
new	O
single	O
nucleotide	B-CHED
variations	O
(	O
SNVs	O
),	O
T21615A	O
and	O
T21901A	O
,	O
were	O
discovered	O
,	O
not	O
previously	O
reported	O
elsewhere	O
.	O

Levels	O
of	O
chemokines	O
/	O
cytokines	O
involved	O
in	O
immunoreaction	O
in	O
response	O
to	O
virus	O
infection	O
were	O
detected	O
in	O
the	O
supernatants	O
of	O
those	O
cells	O
cultured	O
with	O
the	O
Spike	O
glycoprotein	B-CHED
by	O
liquid	O
chip	O
system	O
.	O

212	O
),	O
(	O
1	O
,	O
676	O
+/-	O
199	O
)	O
ng	O
/	O
L	O
,	O
all	O
P	O
<	O
0	O
.	O
05	O
]	O
was	O
detected	O
in	O
the	O
HUVEC	O
12	O
h	O
after	O
Spike	O
glycoprotein	B-CHED
(	O
5	O
,	O
20	O
,	O
40	O
mg	O
/	O
L	O
)	O
stimulation	O
respectively	O
,	O
and	O
presented	O
with	O
a	O
significant	O
dose	O
-	O
dependent	O
response	O
.	O

Individual	O
cysteine	B-CHED
clusters	B-CHED
were	O
altered	O
via	O
cysteine	B-CHED
-	O
to	O
-	O
alanine	B-CHED
amino	B-CHED
acid	I-CHED
replacement	O
and	O
the	O
modified	O
S	O
glycoproteins	B-CHED
were	O
tested	O
for	O
their	O
transport	O
to	O
cell	O
-	O
surfaces	O
and	O
ability	O
to	O
cause	O
cell	O
fusion	O
in	O
transient	O
transfection	O
assays	O
.	O

These	O
results	O
show	O
that	O
the	O
S	O
cytoplasmic	O
domain	O
is	O
palmitoylated	O
and	O
that	O
palmitoylation	O
of	O
the	O
membrane	O
proximal	O
cysteine	B-CHED
clusters	B-CHED
I	O
and	O
II	O
may	O
be	O
important	O
for	O
S	O
-	O
mediated	O
cell	O
fusion	O
.	O

With	O
availability	O
of	O
high	O
titers	O
of	O
adenoviruses	O
and	O
uniform	O
and	O
rapid	O
infection	O
,	O
this	O
approach	O
would	O
have	O
foreseeable	O
wide	O
applications	O
both	O
in	O
experimental	O
biology	O
and	O
molecular	O
medicine	B-CHED
.	O

The	O
amino	B-CHED
acid	I-CHED
sequences	O
had	O
82	O
-	O
99	O
%	O
similarity	O
to	O
previous	O
sequences	O
stored	O
in	O
the	O
GenBank	O
database	O
.	O

TITLE	O
:	O
Experience	O
with	O
paraquat	B-CHED
poisoning	O
in	O
a	O
respiratory	O
intensive	O
care	O
unit	O
in	O
North	O
India	O
.	O

Here	O
,	O
we	O
demonstrated	O
that	O
,	O
among	O
five	O
accessory	O
proteins	B-CHED
of	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
tested	O
,	O
3a	O
/	O
X1	O
and	O
7a	O
/	O
X4	O
were	O
capable	O
of	O
activating	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappaB	O
)	O
and	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinase	O
(	O
JNK	O
),	O
and	O
significantly	O
enhanced	O
interleukin	O
8	O
(	O
IL	O
-	O
8	O
)	O
promoter	O
activity	O
.	O

ABSTRACT	O
:	O
Chemical	O
denaturant	O
sensitivity	O
of	O
the	O
dimeric	O
main	O
protease	O
from	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
to	O
guanidinium	B-CHED
chloride	I-CHED
was	O
examined	O
in	O
terms	O
of	O
fluorescence	O
spectroscopy	O
,	O
circular	O
dichroism	O
,	O
analytical	O
ultracentrifuge	O
,	O
and	O
enzyme	O
activity	O
change	O
.	O

Different	O
mutants	O
of	O
the	O
full	O
-	O
length	O
protease	O
(	O
W31	O
and	O
W207	O
/	O
W218	O
),	O
with	O
tryptophanyl	O
residue	O
(	O
s	O
)	O
mutated	O
to	O
phenylalanine	B-CHED
at	O
the	O
C	O
-	O
terminal	O
or	O
N	O
-	O
terminal	O
domain	O
,	O
respectively	O
,	O
were	O
constructed	O
.	O

ABSTRACT	O
:	O
A	O
combination	O
of	O
protein	B-CHED
-	O
ligand	B-CHED
docking	O
and	O
ligand	B-CHED
-	O
based	O
QSAR	O
approaches	O
has	O
been	O
elaborated	O
,	O
aiming	O
to	O
speed	O
-	O
up	O
the	O
process	O
of	O
virtual	O
screening	O
.	O

Two	O
compounds	O
among	O
them	O
showed	O
promising	O
activity	O
that	O
was	O
comparable	O
to	O
mizoribine	O
and	O
ribavirin	B-CHED
.	O

Dimerization	O
inhibitors	B-CHED
are	O
usually	O
targeted	O
to	O
the	O
dimerization	O
interface	O
and	O
need	O
to	O
compete	O
with	O
the	O
attractive	O
forces	O
between	O
subunits	O
to	O
be	O
effective	O
.	O

Slide	O
microscopy	O
and	O
/	O
or	O
the	O
use	O
of	O
rapid	O
antigen	B-CHED
tests	O
are	O
standard	O
diagnostic	O
tools	O
.	O

Treatment	O
with	O
a	O
Fas	O
/	O
Fc	O
chimera	O
,	O
which	O
blocks	O
Fas	O
-	O
Fas	O
ligand	B-CHED
-	O
mediated	O
apoptosis	O
,	O
inhibited	O
the	O
formation	O
of	O
the	O
complexes	O
and	O
blocked	O
the	O
activation	O
of	O
caspase	O
-	O
8	O
and	O
apoptosis	O
in	O
MHV	O
-	O
infected	O
cells	O
.	O

Antibodies	O
were	O
examined	O
for	O
reactivity	O
against	O
a	O
recombinant	O
S1	O
protein	B-CHED
,	O
to	O
which	O
200	O
antibodies	O
reacted	O
.	O

First	O
,	O
the	O
receptor	O
of	O
HCoV	O
229E	O
,	O
human	O
aminopeptidase	O
N	O
(	O
hAPN	O
or	O
CD13	O
)	O
is	O
expressed	O
mainly	O
on	O
human	O
dendritic	O
cells	O
(	O
DCs	O
)	O
and	O
macrophages	O
indicating	O
that	O
targeting	O
of	O
HCoV	O
229E	O
-	O
based	O
vectors	O
to	O
professional	O
antigen	B-CHED
presenting	O
cells	O
can	O
be	O
achieved	O
by	O
receptor	O
-	O
mediated	O
transduction	O
.	O

BAL	B-CHED
with	O
dilute	O
porcine	O
surfactant	B-CHED
administered	O
slowly	O
in	O
2	O
.	O
5	O
mL	O
aliquots	O
improved	O
oxygenation	O
and	O
chest	O
x	O
-	O
ray	O
findings	O
,	O
without	O
causing	O
major	O
adverse	O
effects	O
,	O
in	O
mechanically	O
ventilated	O
term	O
infants	O
with	O
ARDS	O
due	O
to	O
MAS	B-CHED
.	O

TITLE	O
:	O
The	O
lesson	O
of	O
supplementary	O
treatment	O
with	O
Chinese	O
medicine	B-CHED
on	O
severe	O
laboratory	O
-	O
confirmed	O
SARS	O
patients	O
.	O

In	O
2003	O
,	O
123	O
SARS	O
cases	O
in	O
Beijing	O
were	O
subjected	O
to	O
a	O
strictly	O
western	O
medicine	B-CHED
(	O
WM	B-CHED
)	O
treatment	O
,	O
or	O
a	O
combined	O
treatment	O
(	O
WM	B-CHED
plus	O
Herba	O
houttuyniae	O
injection	O
,	O
addition	O
of	O
individualized	O
herbal	O
treatments	O
when	O
necessary	O
),	O
of	O
which	O
115	O
were	O
followed	O
till	O
death	O
or	O
discharge	O
;	O
8	O
were	O
transferred	O
and	O
lost	B-CHED
to	O
follow	O
-	O
up	O
.	O

All	O
of	O
the	O
clinical	O
data	O
and	O
survival	O
time	O
during	O
72	O
hours	O
were	O
collected	O
and	O
analyzed	O
,	O
including	O
the	O
collection	O
of	O
bronchioalveolar	O
lavage	O
fluid	O
(	O
BALF	O
)	O
for	O
the	O
determination	O
of	O
total	O
protein	B-CHED
(	O
TP	O
),	O
total	O
phospholipids	B-CHED
(	O
TPL	O
),	O
disaturated	O
phosphatidyl	B-CHED
choline	B-CHED
(	O
DSPC	O
),	O
and	O
measurement	O
of	O
alveolar	O
tension	O
.	O

Based	O
on	O
extensively	O
scientific	O
cooperation	O
and	O
almost	O
two	O
-	O
year	O
'	O
s	O
studies	O
,	O
remarkable	O
achievements	O
have	O
been	O
made	O
in	O
the	O
understanding	O
of	O
the	O
phylogenetic	O
property	O
and	O
the	O
genome	O
organization	O
of	O
SARS	O
-	O
CoV	O
,	O
as	O
well	O
as	O
the	O
detailed	O
characters	O
of	O
the	O
major	O
proteins	B-CHED
involved	O
in	O
SARS	O
-	O
CoV	O
life	O
cycle	O
.	O

Predictive	O
model	O
was	O
built	O
for	O
substrate	O
structure	O
and	O
activity	O
relationships	O
and	O
can	O
be	O
applied	O
in	O
inhibitor	B-CHED
design	O
.	O

It	O
is	O
expected	O
that	O
inhibitors	B-CHED
targeting	O
CoV	O
M	O
(	O
pro	B-CHED
)	O
s	O
could	O
be	O
developed	O
into	O
wide	O
-	O
spectrum	O
antiviral	B-CHED
drugs	I-CHED
against	O
existing	O
and	O
possible	O
future	O
emerging	O
CoV	O
-	O
associated	O
diseases	O
.	O

However	O
,	O
when	O
BALB	O
/	O
c	O
mice	O
were	O
orally	O
immunized	O
with	O
the	O
Salmonella	O
vector	O
expressing	O
the	O
TGEV	O
epitopes	O
from	O
either	O
one	O
of	O
the	O
fusion	O
constructs	O
or	O
both	O
together	O
,	O
the	O
highest	O
level	O
of	O
anti	O
-	O
TGEV	O
antibody	O
was	O
obtained	O
with	O
the	O
987P	O
-	O
TGEV	O
immunogen	B-CHED
-	O
displaying	O
vector	O
.	O

This	O
study	O
also	O
suggests	O
a	O
potential	O
strategy	O
for	O
the	O
development	O
of	O
improved	O
HCoV	O
-	O
NL63	O
fusion	O
inhibitors	B-CHED
.	O

Buffered	O
300	O
-	O
500	O
mM	O
NaCl	B-CHED
was	O
selected	O
after	O
comparison	O
of	O
several	O
buffers	O
previously	O
reported	O
for	O
similar	O
types	O
of	O
assays	O
,	O
and	O
200	O
-	O
500	O
mM	O
NaCl	B-CHED
was	O
found	O
to	O
be	O
the	O
optimal	O
ionic	O
strength	O
for	O
the	O
hybridization	O
temperatures	O
(	O
25	O
and	O
50	O
degrees	O
C	O
)	O
and	O
probe	O
designs	O
used	O
here	O
.	O

The	O
results	O
indicate	O
that	O
the	O
MHV	O
N	O
protein	B-CHED
is	O
a	O
type	O
I	O
IFN	O
antagonist	B-CHED
that	O
likely	O
plays	O
a	O
role	O
in	O
circumventing	O
the	O
innate	O
immune	O
response	O
.	O

Our	O
results	O
show	O
that	O
proteins	B-CHED
encompassing	O
a	O
remarkably	O
diverse	O
range	O
of	O
primary	O
amino	B-CHED
acid	I-CHED
sequences	O
can	O
provide	O
E	O
protein	B-CHED
function	O
in	O
MHV	O
.	O

ABSTRACT	O
:	O
The	O
baculovirus	O
surface	O
display	O
technique	O
has	O
provided	O
an	O
ideal	O
tool	O
to	O
display	O
foreign	O
proteins	B-CHED
with	O
natural	O
conformation	O
,	O
functions	O
,	O
and	O
immunogenicity	O
.	O

In	O
this	O
work	O
,	O
we	O
explored	O
the	O
application	O
of	O
this	O
technique	O
on	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
spike	O
(	O
S	O
)	O
protein	B-CHED
,	O
and	O
further	O
analyzed	O
the	O
immunogenicity	O
of	O
displayed	O
S	O
protein	B-CHED
.	O

After	O
surgery	O
he	O
developed	O
renal	O
failure	O
,	O
methicillin	B-CHED
-	O
resistant	O
Staphylococcus	O
aureus	O
pneumonia	O
,	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

TITLE	O
:	O
Expression	O
,	O
purification	O
and	O
characterization	O
of	O
recombinant	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
non	O
-	O
structural	O
protein	B-CHED
1	O
.	O

These	O
crystal	O
structures	O
reveal	O
that	O
the	O
first	O
residue	O
of	O
this	O
protease	O
is	O
important	O
for	O
sustaining	O
the	O
substrate	O
-	O
binding	O
pocket	O
and	O
inhibitor	B-CHED
binding	O
.	O

TITLE	O
:	O
The	O
synergistic	O
interaction	O
of	O
interferon	O
types	O
I	O
and	O
II	O
leads	O
to	O
marked	O
reduction	O
in	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
replication	O
and	O
increase	O
in	O
the	O
expression	O
of	O
mRNAs	O
for	O
interferon	O
-	O
induced	O
proteins	B-CHED
.	O

These	O
results	O
demonstrate	O
that	O
SARS	O
-	O
CoV	O
,	O
although	O
only	O
moderately	O
sensitive	O
to	O
the	O
antiviral	B-CHED
action	O
of	O
the	O
individual	O
types	O
of	O
IFN	O
,	O
is	O
highly	O
sensitive	O
to	O
a	O
combination	O
of	O
type	O
I	O
and	O
II	O
IFNs	O
,	O
which	O
suggests	O
that	O
such	O
combinations	O
may	O
have	O
potential	O
in	O
the	O
treatment	O
of	O
SARS	O
-	O
CoV	O
infections	O
.	O

TITLE	O
:	O
Human	O
coronavirus	O
229E	O
encodes	O
a	O
single	O
ORF4	O
protein	B-CHED
between	O
the	O
spike	O
and	O
the	O
envelope	O
genes	O
.	O

Remarkably	O
,	O
our	O
analyses	O
revealed	O
that	O
the	O
laboratory	O
adapted	O
,	O
prototype	O
HCoV	O
-	O
229E	O
has	O
a	O
2	O
-	O
nucleotide	B-CHED
deletion	O
in	O
the	O
ORF4a	O
/	O
b	O
region	O
,	O
whereas	O
all	O
clinical	O
isolates	O
carry	O
a	O
single	O
ORF	O
,	O
660	O
nt	O
in	O
size	O
,	O
encoding	O
a	O
single	O
protein	B-CHED
of	O
219	O
amino	B-CHED
acids	I-CHED
,	O
which	O
is	O
a	O
homologue	O
of	O
the	O
ORF3	O
proteins	B-CHED
encoded	O
by	O
HCoV	O
-	O
NL63	O
and	O
PEDV	O
.	O

These	O
results	O
suggest	O
that	O
lipid	B-CHED
rafts	O
could	O
contribute	O
to	O
SARS	O
-	O
CoV	O
infection	O
in	O
the	O
early	O
replication	O
process	O
in	O
Vero	O
E6	O
cells	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
serum	O
levels	O
of	O
nitric	B-CHED
oxide	I-CHED
(	O
NO	O
)	O
in	O
patients	O
diagnosed	O
with	O
severe	O
leptospirosis	O
.	O

Here	O
,	O
we	O
report	O
the	O
crystal	O
structure	O
of	O
M	O
(	O
pro	B-CHED
)	O
at	O
a	O
resolution	O
of	O
1	O
.	O
82	O
Angstroms	O
,	O
in	O
space	O
group	O
P2	O
(	O
1	O
)	O
at	O
pH	O
6	O
.	O
0	O
.	O

In	O
the	O
unbound	O
form	O
,	O
the	O
active	O
sites	O
and	O
the	O
S1	O
specificity	O
pockets	O
of	O
both	O
protomers	O
of	O
M	O
(+	O
A	O
(-	O
1	O
))(	O
pro	B-CHED
)	O
are	O
observed	O
in	O
a	O
collapsed	O
(	O
catalytically	O
incompetent	O
)	O
conformation	O
;	O
whereas	O
they	O
are	O
in	O
an	O
open	O
(	O
catalytically	O
competent	O
)	O
conformation	O
in	O
the	O
APE	O
-	O
bound	O
form	O
.	O

TITLE	O
:	O
Development	O
and	O
validation	O
of	O
a	O
high	O
-	O
throughput	O
screen	O
for	O
inhibitors	B-CHED
of	O
SARS	O
CoV	O
and	O
its	O
application	O
in	O
screening	O
of	O
a	O
100	O
,	O
000	O
-	O
compound	O
library	O
.	O

ABSTRACT	O
:	O
The	O
nonstructural	O
protein	B-CHED
1	O
(	O
nsp1	O
)	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
has	O
179	O
residues	O
and	O
is	O
the	O
N	O
-	O
terminal	O
cleavage	O
product	O
of	O
the	O
viral	O
replicase	O
polyprotein	O
that	O
mediates	O
RNA	O
replication	O
and	O
processing	O
.	O

Later	O
on	O
,	O
viral	O
nucleocapsids	O
have	O
to	O
be	O
transported	O
to	O
the	O
budding	O
sites	O
in	O
the	O
Golgi	O
region	O
where	O
the	O
viral	O
glycoproteins	B-CHED
accumulate	O
and	O
particle	O
formation	O
occurs	O
.	O

This	O
may	O
exacerbate	O
hypoglycaemia	O
that	O
can	O
occur	O
in	O
malaria	O
;	O
patients	O
treated	O
with	O
intravenous	O
quinine	B-CHED
therefore	O
require	O
careful	O
monitoring	O
.	O

Laboratory	O
data	O
showed	O
a	O
severe	O
anion	B-CHED
gap	O
metabolic	O
acidosis	O
,	O
with	O
a	O
serum	O
lactate	B-CHED
level	O
of	O
185	O
mg	O
/	O
dL	O
.	O
An	O
initial	O
diagnosis	O
of	O
cyanide	B-CHED
intoxication	O
was	O
considered	O
and	O
she	O
was	O
given	O
sodium	O
nitrite	B-CHED
and	O
sodium	B-CHED
thiosulfate	I-CHED
i	O
.	O
v	O
.	O

We	O
investigated	O
the	O
importance	O
of	O
the	O
hydrophobic	O
domain	O
of	O
the	O
mouse	O
hepatitis	O
coronavirus	O
(	O
MHV	O
)	O
A59	O
E	O
protein	B-CHED
.	O

ABSTRACT	O
:	O
Recombinant	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
nucleocapsid	O
and	O
spike	O
protein	B-CHED
-	O
based	O
immunoglobulin	O
G	O
immunoassays	O
were	O
developed	O
and	O
evaluated	O
.	O

Cleavage	O
of	O
signal	O
peptide	B-CHED
at	O
the	O
C	O
-	O
terminus	O
of	O
HCV	O
core	O
protein	B-CHED
by	O
SPP	O
was	O
characterized	O
in	O
this	O
study	O
.	O

The	O
cleavage	O
efficiency	O
of	O
SPP	O
is	O
inversely	O
proportional	O
to	O
the	O
length	O
of	O
C	O
-	O
terminal	O
extension	O
of	O
the	O
signal	O
peptide	B-CHED
:	O
the	O
longer	O
the	O
extension	O
,	O
the	O
less	O
efficiency	O
the	O
cleavage	O
is	O
.	O

Therefore	O
,	O
the	O
sequence	O
of	O
the	O
signal	O
peptide	B-CHED
is	O
important	O
but	O
not	O
the	O
sole	O
determinant	O
for	O
its	O
cleavage	O
by	O
SPP	O
.	O

Thus	O
,	O
our	O
results	O
suggest	O
that	O
both	O
sequences	O
of	O
the	O
signal	O
peptide	B-CHED
and	O
the	O
E	O
.	O
R	O
.-	O
associated	O
domain	O
are	O
important	O
for	O
the	O
signal	O
peptide	B-CHED
cleavage	O
of	O
HCV	O
core	O
protein	B-CHED
by	O
SPP	O
.	O

Data	O
on	O
the	O
Beijing	O
SARS	O
epidemic	O
were	O
used	O
to	O
map	O
spatial	O
clusters	B-CHED
of	O
identified	O
contacts	O
and	O
to	O
estimate	O
transmission	O
of	O
SARS	O
using	O
a	O
model	O
with	O
a	O
time	O
-	O
dependent	O
transmission	O
rate	O
.	O

Pro	B-CHED
-	O
inflammatory	O
cytokines	O
and	O
chemokines	O
,	O
particularly	O
IP	O
-	O
10	O
,	O
IL	O
-	O
8	O
,	O
and	O
MCP	B-CHED
-	O
1	O
,	O
are	O
elevated	O
in	O
the	O
lungs	O
and	O
peripheral	O
blood	O
,	O
but	O
there	O
is	O
an	O
unusual	O
lack	O
of	O
an	O
antiviral	B-CHED
interferon	O
(	O
IFN	O
)	O
response	O
.	O

To	O
carry	O
out	O
analysis	O
of	O
intra	O
-	O
strand	O
nucleotide	B-CHED
distribution	O
several	O
graphical	O
methods	O
have	O
been	O
developed	O
.	O

GraphDNA	O
is	O
a	O
platform	O
-	O
independent	O
,	O
Open	O
Source	O
,	O
tool	O
for	O
the	O
analysis	O
of	O
nucleotide	B-CHED
trends	O
in	O
DNA	O
sequences	O
.	O

TITLE	O
:	O
Comparative	O
immunization	O
in	O
BALB	O
/	O
c	O
mice	O
with	O
recombinant	O
replication	O
-	O
defective	O
adenovirus	O
vector	O
and	O
DNA	O
plasmid	O
expressing	O
a	O
SARS	O
-	O
CoV	O
nucleocapsid	O
protein	B-CHED
gene	O
.	O

TITLE	O
:	O
Exosomal	O
vaccines	O
containing	O
the	O
S	O
protein	B-CHED
of	O
the	O
SARS	O
coronavirus	O
induce	O
high	O
levels	O
of	O
neutralizing	O
antibodies	O
.	O

Moreover	O
,	O
it	O
was	O
found	O
through	O
the	O
ligand	B-CHED
-	O
receptor	O
docking	O
studies	O
that	O
of	O
the	O
11	O
cleavable	O
peptides	B-CHED
,	O
NH2	O
-	O
ATLQ	O
/	O
AIAS	O
-	O
COOH	O
and	O
NH2	O
-	O
ATLQ	O
/	O
AENV	O
-	O
COOH	O
had	O
the	O
highest	O
affinity	O
with	O
SARS	O
CoV	O
M	O
(	O
pro	B-CHED
).	O

These	O
HIV	O
-	O
1	O
-	O
capturing	O
nanospheres	O
and	O
protein	B-CHED
-	O
loaded	O
gamma	O
-	O
PGA	B-CHED
nanoparticles	B-CHED
have	O
shown	O
unique	O
potential	O
as	O
vaccine	O
carriers	O
.	O

The	O
exceptional	O
form	O
was	O
due	O
to	O
a	O
38	O
-	O
nucleotide	B-CHED
deletion	O
and	O
a	O
frame	O
shift	O
in	O
ORF3b	O
that	O
introduced	O
an	O
early	O
stop	O
codon	O
.	O

By	O
phylogenetic	O
analysis	O
of	O
the	O
structural	O
proteins	B-CHED
,	O
the	O
spike	O
(	O
S	O
)	O
protein	B-CHED
was	O
found	O
to	O
cluster	O
with	O
feline	O
coronavirus	O
type	O
II	O
strain	O
79	O
-	O
1683	O
,	O
whereas	O
,	O
the	O
envelope	O
(	O
E	O
),	O
membrane	O
(	O
M	O
)	O
and	O
nucleocapsid	O
(	O
N	O
)	O
proteins	B-CHED
segregated	O
together	O
with	O
the	O
reference	O
strain	O
Purdue	O
of	O
transmissible	O
gastroenteritis	O
virus	O
of	O
swine	O
.	O

ABSTRACT	O
:	O
To	O
assess	O
the	O
therapeutic	O
effect	O
of	O
Caspase	O
-	O
1	O
inhibitors	B-CHED
(	O
ICE	O
-	O
I	O
)	O
on	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
in	O
experimental	O
severe	O
acute	O
pancreatitis	O
(	O
SAP	O
).	O

Caspase	O
-	O
1	O
inhibitors	B-CHED
ameliorated	O
the	O
severity	O
of	O
ALI	O
in	O
SAP	O
.	O

Caspase	O
-	O
1	O
inhibitors	B-CHED
ameliorated	O
the	O
severity	O
of	O
ALI	O
in	O
SAP	O
.	O

Of	O
these	O
,	O
94	O
%	O
would	O
assist	O
in	O
immunization	O
clinics	O
,	O
84	O
%	O
in	O
antibiotic	B-CHED
clinics	O
,	O
58	O
%	O
in	O
assessment	O
centres	O
,	O
52	O
%	O
in	O
treatment	O
centres	O
,	O
41	O
%	O
with	O
declaration	O
of	O
death	O
,	O
26	O
%	O
with	O
home	O
care	O
,	O
and	O
23	O
%	O
with	O
telephone	O
counseling	O
.	O

TITLE	O
:	O
The	O
3a	O
Protein	B-CHED
of	O
SARS	O
-	O
coronavirus	O
Induces	O
Apoptosis	O
in	O
Vero	O
E6	O
Cells	O
.	O

In	O
vitro	O
experiments	O
of	O
chromatin	O
condensation	O
and	O
DNA	O
fragmentation	O
suggest	O
that	O
the	O
3a	O
protein	B-CHED
may	O
trigger	O
apoptosis	O
.	O

Our	O
data	O
show	O
that	O
over	O
-	O
expression	O
of	O
a	O
single	O
SARS	O
-	O
CoV	O
protein	B-CHED
can	O
induce	O
apoptosis	O
in	O
vitro	O
.	O

TITLE	O
:	O
[	O
Expression	O
of	O
predicted	O
B	O
cell	O
epitope	B-CHED
peptide	B-CHED
in	O
S2	O
subunit	O
of	O
SARS	O
coronavirus	O
spike	O
protein	B-CHED
in	O
E	O
.	O
coli	O
and	O
identification	O
of	O
its	O
mimic	O
antigenicity	O
].	O

The	O
cDNA	O
sequence	O
encoding	O
the	O
B	O
cell	O
epitope	B-CHED
peptide	B-CHED
was	O
constructed	O
artificially	O
by	O
PCR	O
and	O
then	O
cloned	O
into	O
the	O
downstream	O
of	O
chaperone	O
10	O
gene	O
in	O
vector	O
pET28a	O
(+)	O
to	O
construct	O
pET28	O
-	O
chap10	O
-	O
S2epi	O
plasmid	O
.	O

The	O
fusion	O
protein	B-CHED
,	O
chap10	O
-	O
S2epi	O
,	O
was	O
expressed	O
in	O
E	O
.	O
coli	O
BL21	O
(	O
DE3	O
)	O
and	O
identified	O
by	O
SDS	B-CHED
-	O
PAGE	O
and	O
Western	O
blot	O
.	O

The	O
rabbit	O
was	O
immunized	O
by	O
purified	O
Chap10	O
-	O
S2epi	O
for	O
the	O
preparation	O
of	O
antiserum	O
,	O
which	O
was	O
used	O
to	O
identify	O
the	O
mimic	O
antigenicity	O
of	O
Chap10	O
-	O
S2epi	O
to	O
S2	O
protein	B-CHED
by	O
ELISA	O
.	O

The	O
antiserum	O
from	O
the	O
animal	O
immunized	O
by	O
Chap10	O
-	O
S2epi	O
recognized	O
full	O
length	O
of	O
SARS	O
coronavirus	O
S2	O
spike	O
protein	B-CHED
.	O

TITLE	O
:	O
Isolation	O
and	O
identification	O
of	O
four	O
infectious	O
bronchitis	O
virus	O
strains	O
in	O
China	O
and	O
analyses	O
of	O
their	O
S1	O
glycoprotein	B-CHED
gene	O
.	O

TITLE	O
:	O
The	O
short	O
-	O
term	O
effect	O
of	O
hyperoncotic	O
albumin	O
,	O
given	O
alone	O
or	O
with	O
furosemide	B-CHED
,	O
on	O
oxygenation	O
in	O
sepsis	O
-	O
induced	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

Antiviral	B-CHED
activity	O
was	O
analysed	O
by	O
determining	O
infective	O
virus	O
titres	O
by	O
TCID50	O
,	O
viral	O
RNA	O
synthesis	O
by	O
Northern	O
blot	O
analysis	O
and	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
,	O
and	O
viral	O
protein	B-CHED
synthesis	O
by	O
SDS	B-CHED
-	O
PAGE	O
analysis	O
after	O
35S	O
-	O
methionine	B-CHED
-	O
labelling	O
.	O

We	O
further	O
showed	O
that	O
M	O
protein	B-CHED
-	O
induced	O
apoptosis	O
involved	O
mitochondrial	O
release	O
of	O
cytochrome	B-CHED
c	I-CHED
protein	B-CHED
,	O
and	O
could	O
be	O
suppressed	O
by	O
caspase	O
inhibitors	B-CHED
.	O

ABSTRACT	O
:	O
To	O
understand	O
the	O
association	O
between	O
the	O
outbreak	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
and	O
meteorological	O
factors	O
and	O
air	B-CHED
pollution	O
.	O

In	O
univariate	O
analyses	O
,	O
daily	O
average	O
temperature	O
(	O
DAT	O
),	O
daily	O
average	O
air	B-CHED
pressure	O
(	O
DAAP	O
),	O
and	O
daily	O
average	O
relative	O
humidity	O
(	O
DARH	O
)	O
were	O
inversely	O
associated	O
with	O
secondary	O
attack	O
rate	O
(	O
P	O
<	O
0	O
.	O
001	O
);	O
a	O
significant	O
positive	O
association	O
was	O
found	O
for	O
daily	O
hours	O
of	O
sunshine	O
(	O
DHS	O
)	O
(	O
P	O
<	O
0	O
.	O
001	O
).	O

However	O
,	O
because	O
of	O
ecological	O
fallacy	O
and	O
uncontrolled	O
confounding	O
effects	O
that	O
may	O
have	O
biased	O
the	O
results	O
,	O
the	O
association	O
between	O
the	O
SARS	O
outbreak	O
and	O
these	O
meteorological	O
factors	O
and	O
air	B-CHED
pollution	O
deserve	O
further	O
investigation	O
.	O

Samples	O
were	O
tested	O
for	O
antibodies	O
to	O
feline	O
immunodeficiency	O
virus	O
,	O
Dirofilaria	O
immitis	O
,	O
feline	O
panleukopenia	O
virus	O
,	O
feline	O
herpesvirus	O
,	O
feline	O
coronavirus	O
,	O
canine	O
distemper	O
virus	O
,	O
and	O
Toxoplasma	O
gondii	O
and	O
for	O
feline	O
leukemia	O
virus	O
(	O
FeLV	O
)	O
antigen	B-CHED
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
analyze	O
the	O
thrombotic	O
risk	O
,	O
assessed	O
by	O
platelet	O
aggregation	O
and	O
aspirin	B-CHED
non	O
-	O
responsiveness	O
,	O
in	O
patients	O
with	O
an	O
acute	O
coronary	O
syndrome	O
complicated	O
by	O
an	O
infection	O
.	O

Aspirin	B-CHED
non	O
-	O
responsiveness	O
was	O
defined	O
as	O
a	O
closure	O
time	O
of	O
<	O
or	O
=	O
193	O
s	O
measured	O
by	O
PFA	B-CHED
-	O
100	O
.	O

The	O
CRP	O
levels	O
were	O
independently	O
associated	O
with	O
platelet	O
aggregation	O
and	O
aspirin	B-CHED
non	O
-	O
responsiveness	O
(	O
P	O
<	O
0	O
.	O
001	O
,	O
P	O
<	O
0	O
.	O
001	O
,	O
respectively	O
).	O

The	O
efficacy	O
of	O
ranpirnase	O
was	O
compared	O
with	O
that	O
of	O
doxorubicin	B-CHED
(	O
head	O
-	O
to	O
-	O
head	O
).	O

It	O
also	O
increased	O
the	O
lung	O
weight	O
/	O
bodyweight	O
ratio	O
,	O
lung	O
weight	O
gain	O
,	O
exhaled	O
nitric	B-CHED
oxide	I-CHED
(	O
NO	O
),	O
the	O
protein	B-CHED
concentration	O
in	O
bronchoalveolar	O
lavage	O
and	O
microvascular	O
permeability	O
.	O

The	O
results	O
suggest	O
that	O
the	O
inflammatory	O
responses	O
and	O
ALI	O
following	O
infusion	O
of	O
LPS	B-CHED
are	O
due	O
to	O
the	O
production	O
of	O
NO	O
,	O
free	O
radicals	B-CHED
and	O
pro	B-CHED
-	O
inflammatory	O
cytokines	O
through	O
the	O
iNOS	O
system	O
.	O

To	O
determine	O
the	O
significance	O
of	O
the	O
positive	O
charge	O
at	O
position	O
227	O
,	O
we	O
substituted	O
the	O
arginine	B-CHED
with	O
lysine	B-CHED
(	O
K	O
),	O
aspartic	B-CHED
acid	I-CHED
(	O
D	O
),	O
glutamic	B-CHED
acid	I-CHED
(	O
E	O
),	O
or	O
alanine	B-CHED
(	O
A	O
)	O
and	O
studied	O
these	O
by	O
reverse	O
genetics	O
in	O
the	O
context	O
of	O
a	O
MHV	O
full	O
-	O
length	O
infectious	O
clone	O
.	O

Recovered	O
R227E	O
viruses	O
had	O
second	O
-	O
site	O
changes	O
within	O
the	O
M	O
protein	B-CHED
carboxy	B-CHED
tail	O
that	O
were	O
partially	O
compensatory	O
.	O

Significantly	O
,	O
most	O
of	O
the	O
second	O
site	O
changes	O
in	O
the	O
R227E	O
mutant	O
viruses	O
were	O
previously	O
shown	O
to	O
compensate	O
for	O
the	O
removal	O
of	O
negative	O
charges	O
in	O
the	O
N	O
protein	B-CHED
.	O

TITLE	O
:	O
Heterologous	O
viral	O
RNA	O
export	O
elements	O
improve	O
expression	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
spike	O
protein	B-CHED
and	O
protective	O
efficacy	O
of	O
DNA	O
vaccines	O
against	O
SARS	O
.	O

Among	O
these	O
analogues	O
,	O
two	O
compounds	O
,	O
namely	O
,	O
1	O
and	O
11	O
,	O
exhibited	O
promising	O
anti	O
-	O
SARS	O
-	O
CoV	O
activity	O
that	O
was	O
comparable	O
to	O
those	O
of	O
mizoribine	O
and	O
ribavirin	B-CHED
,	O
which	O
are	O
known	O
anti	O
-	O
SARS	O
-	O
CoV	O
agents	O
.	O

ABSTRACT	O
:	O
This	O
article	O
summarizes	O
the	O
significant	O
developments	O
and	O
new	O
discoveries	O
in	O
both	O
the	O
virology	O
and	O
antiviral	B-CHED
research	O
associated	O
with	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
CoV	O
)	O
that	O
were	O
reported	O
in	O
2005	O
and	O
2006	O
.	O

Nine	O
mAbs	O
raising	O
from	O
the	O
three	O
(	O
poly100	O
)	O
S1	O
proteins	B-CHED
recognized	O
five	O
different	O
epitopes	O
of	O
the	O
S1	O
subunit	O
,	O
designated	O
as	O
S1	O
-	O
A	O
,	O
B	O
,	O
C	O
,	O
D	O
and	O
E	O
.	O
Epitopes	O
S1	O
-	O
C	O
and	O
S1	O
-	O
D	O
are	O
common	O
for	O
the	O
three	O
IBV	O
strains	O
,	O
while	O
S1	O
-	O
A	O
and	O
S1	O
-	O
B	O
exist	O
on	O
ZJ971	O
and	O
M41	O
strains	O
,	O
and	O
S1	O
-	O
E	O
was	O
a	O
strain	O
-	O
specific	O
epitope	B-CHED
for	O
SC	O
strain	O
.	O

Immunocytochemistry	O
indicated	O
that	O
all	O
the	O
mAbs	O
to	O
the	O
(	O
poly100	O
)	O
S1	O
proteins	B-CHED
can	O
react	O
with	O
the	O
homologous	O
S1	O
glycoprotein	B-CHED
expressed	O
in	O
Vero	O
cells	O
.	O

Antiviral	B-CHED
medications	O
should	O
be	O
reserved	O
for	O
cases	O
where	O
the	O
benefits	O
outweigh	O
the	O
risks	O
.	O

ABSTRACT	O
:	O
Carbohydrate	B-CHED
-	O
binding	O
agents	O
(	O
CBAs	O
)	O
inhibit	O
HIV	O
-	O
1	O
and	O
it	O
is	O
proposed	O
that	O
therapy	O
with	O
such	O
agents	O
may	O
have	O
important	O
implications	O
for	O
the	O
future	O
of	O
anti	O
-	O
HIV	O
therapy	O
.	O

The	O
latter	O
phenomenon	O
will	O
result	O
in	O
creating	O
'	O
holes	O
'	O
in	O
the	O
protective	O
glycan	B-CHED
shield	O
of	O
the	O
HIV	O
envelope	O
,	O
whereby	O
the	O
immune	O
system	O
may	O
become	O
triggered	O
to	O
produce	O
neutralizing	O
antibodies	O
against	O
previously	O
hidden	O
immunogenic	O
epitopes	O
of	O
gp120	O
.	O

In	O
pulmonary	O
fibrosis	O
and	O
in	O
the	O
postinjury	O
phase	O
of	O
acute	O
lung	O
injury	O
,	O
the	O
angiogenic	O
/	O
angiostatic	O
balance	B-CHED
is	O
also	O
affected	O
.	O

Specifically	O
,	O
the	O
unmethylated	O
CpG	O
ODN	O
(	O
and	O
/	O
or	O
the	O
phosphorothioate	O
group	O
)	O
activates	O
the	O
immune	O
system	O
,	O
but	O
this	O
potentially	O
important	O
anti	O
-	O
cancer	O
effect	O
is	O
lost	B-CHED
when	O
the	O
immune	O
cells	O
undergo	O
premature	O
apoptosis	O
apparently	O
because	O
their	O
Bcl	O
-	O
2	O
levels	O
have	O
been	O
lowered	O
by	O
the	O
antisense	O
effect	O
of	O
G3139	O
.	O

Yet	O
Drak2	O
-	O
/	O
-	O
mice	O
are	O
resistant	O
to	O
MOG	O
-	O
induced	O
experimental	O
autoimmune	O
encephalomyelitis	O
(	O
EAE	O
),	O
suggesting	O
that	O
DRAK2	O
may	O
influence	O
T	O
cell	O
trafficking	O
into	O
the	O
CNS	B-CHED
.	O

In	O
order	O
to	O
further	O
characterize	O
the	O
molecular	O
mechanisms	O
governing	O
T	O
cell	O
activation	O
and	O
accumulation	O
within	O
the	O
CNS	B-CHED
in	O
response	O
to	O
viral	O
infection	O
,	O
MHV	O
was	O
instilled	O
into	O
the	O
CNS	B-CHED
of	O
Drak2	O
-	O
/	O
-	O
mice	O
.	O

Six	O
risk	O
factors	O
were	O
significant	O
in	O
the	O
final	O
multiple	O
-	O
logistic	O
regression	O
model	O
:	O
minimum	O
distance	O
between	O
beds	O
of	O
<	O
or	O
=	O
1	O
m	O
(	O
odds	O
ratio	O
[	O
OR	O
],	O
6	O
.	O
94	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
],	O
1	O
.	O
68	O
-	O
28	O
.	O
75	O
),	O
availability	O
of	O
washing	O
or	O
changing	O
facilities	O
for	O
staff	O
(	O
OR	O
,	O
0	O
.	O
12	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
02	O
-	O
0	O
.	O
97	O
),	O
whether	O
resuscitation	O
was	O
ever	O
performed	O
in	O
the	O
ward	O
(	O
OR	O
,	O
3	O
.	O
81	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
04	O
-	O
13	O
.	O
87	O
),	O
whether	O
staff	O
members	O
worked	O
while	O
experiencing	O
symptoms	O
(	O
OR	O
,	O
10	O
.	O
55	O
;	O
95	O
%	O
CI	O
,	O
2	O
.	O
28	O
-	O
48	O
.	O
87	O
),	O
whether	O
any	O
host	O
patients	O
(	O
index	O
patient	O
or	O
the	O
first	O
patient	O
with	O
SARS	O
admitted	O
to	O
a	O
ward	O
)	O
required	O
oxygen	B-CHED
therapy	O
(	O
OR	O
,	O
4	O
.	O
30	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
00	O
-	O
18	O
.	O
43	O
),	O
and	O
whether	O
any	O
host	O
patients	O
required	O
bi	O
-	O
level	O
positive	O
airway	O
pressure	O
ventilation	O
(	O
OR	O
,	O
11	O
.	O
82	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
97	O
-	O
70	O
.	O
80	O
).	O

These	O
risks	O
warrant	O
the	O
cautious	O
use	O
of	O
naloxone	B-CHED
and	O
adequate	O
monitoring	O
of	O
the	O
cardiorespiratory	O
status	O
of	O
the	O
patient	O
after	O
naloxone	B-CHED
administration	O
where	O
indicated	O
.	O

It	O
has	O
been	O
speculated	O
for	O
sometime	O
that	O
phosphorylation	O
could	O
play	O
an	O
important	O
role	O
in	O
regulation	O
of	O
coronavirus	O
N	O
protein	B-CHED
functions	O
.	O

Based	O
on	O
the	O
X	O
-	O
ray	O
structures	O
of	O
SARS	O
-	O
CoV	O
spike	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
in	O
complex	O
with	O
its	O
functional	O
receptor	O
(	O
angiotensin	B-CHED
-	O
converting	O
enzyme	O
2	O
,	O
ACE2	O
),	O
we	O
perform	O
computational	O
simulations	O
of	O
interactions	O
between	O
three	O
representative	O
RBD	O
mutants	O
and	O
four	O
host	O
species	O
-	O
specific	O
receptors	O
.	O

Phylogenetic	O
analysis	O
of	O
the	O
polymorphic	O
region	O
of	O
the	O
S	O
glycoprotein	B-CHED
gene	O
of	O
these	O
isolates	O
,	O
together	O
with	O
those	O
of	O
other	O
known	O
strains	O
,	O
classified	O
the	O
BCoV	O
strains	O
and	O
isolates	O
into	O
four	O
clusters	B-CHED
.	O

In	O
the	O
surfactant	B-CHED
group	O
PaO	B-CHED
(	O
2	O
)/	O
FIO	O
(	O
2	O
)	O
increased	O
from	O
100	O
+/-	O
20	O
mmHg	O
at	O
baseline	O
to	O
140	O
+/-	O
20	O
(	O
6	O
h	O
),	O
163	O
+/-	O
26	O
(	O
12	O
h	O
),	O
and	O
187	O
+/-	O
30	O
mmHg	O
(	O
24h	O
).	O

RNA	O
has	O
been	O
shown	O
to	O
bind	O
to	O
the	O
N	O
-	O
terminal	O
domain	O
(	O
NTD	O
),	O
although	O
recently	O
the	O
C	O
-	O
terminal	O
half	O
of	O
the	O
protein	B-CHED
has	O
also	O
been	O
implicated	O
in	O
RNA	O
binding	O
.	O

Corticosteroids	B-CHED
were	O
introduced	O
in	O
the	O
treatment	O
of	O
severe	O
infection	O
as	O
early	O
as	O
in	O
the	O
1940s	O
.	O

This	O
finding	O
prompted	O
renewed	O
interest	O
in	O
a	O
replacement	O
therapy	O
with	O
low	O
doses	O
of	O
corticosteroids	B-CHED
during	O
longer	O
periods	O
.	O

The	O
use	O
of	O
high	O
-	O
dose	O
ribavirin	B-CHED
is	O
appropriate	O
only	O
for	O
the	O
treatment	O
of	O
infectious	O
diseases	O
for	O
which	O
ribavirin	B-CHED
has	O
proven	O
clinical	O
efficacy	O
,	O
or	O
in	O
the	O
context	O
of	O
a	O
clinical	O
trial	O
.	O

For	O
upregulation	O
of	O
TNF	O
-	O
alpha	O
and	O
fAPN	O
in	O
macrophages	O
,	O
viral	O
replication	O
in	O
macrophages	O
is	O
necessary	O
,	O
and	O
their	O
expressions	O
were	O
increased	O
by	O
ADE	B-CHED
of	O
FIPV	O
infection	O
.	O

The	O
latter	O
include	O
dysregulation	O
of	O
cytokines	O
/	O
chemokines	O
,	O
deficiencies	O
in	O
the	O
innate	O
immune	O
response	O
,	O
direct	O
infection	O
of	O
immune	O
cells	O
,	O
direct	O
viral	O
cytopathic	O
effects	O
,	O
down	O
-	O
regulation	O
of	O
lung	O
protective	O
angiotensin	B-CHED
converting	O
enzyme	O
2	O
,	O
autoimmunity	O
,	O
and	O
genetic	O
factors	O
.	O

Mutations	O
targeting	O
residues	O
in	O
or	O
near	O
either	O
zinc	B-CHED
-	O
binding	O
finger	O
generated	O
nonviable	O
phenotypes	O
,	O
demonstrating	O
that	O
both	O
domains	O
are	O
essential	O
to	O
nsp10	O
function	O
and	O
MHV	O
replication	O
.	O

Currently	O
,	O
no	O
antiviral	B-CHED
drugs	I-CHED
are	O
available	O
to	O
treat	O
CoV	O
infections	O
;	O
thus	O
,	O
potential	O
drug	O
targets	O
need	O
to	O
be	O
identified	O
and	O
characterized	O
.	O

Furthermore	O
,	O
by	O
using	O
K48	O
-	O
linked	O
hexa	O
-	O
ubiquitin	O
substrate	O
and	O
ubiquitin	O
-	O
vinylsulfone	O
inhibitor	B-CHED
specific	O
for	O
deubiquitinating	O
enzymes	O
(	O
DUBs	O
),	O
we	O
confirmed	O
that	O
,	O
like	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
CoV	O
PLpro	O
,	O
HCoV	O
-	O
NL63	O
PLP2	O
has	O
DUB	O
activity	O
.	O

The	O
identification	O
of	O
the	O
replicase	O
products	O
and	O
characterization	O
of	O
HCoV	O
-	O
NL63	O
PLP	O
DUB	O
activity	O
will	O
facilitate	O
comparative	O
studies	O
of	O
CoV	O
proteases	O
and	O
aid	O
in	O
the	O
development	O
of	O
novel	O
antiviral	B-CHED
reagents	B-CHED
directed	O
against	O
human	O
pathogens	O
such	O
as	O
HCoV	O
-	O
NL63	O
and	O
SARS	O
-	O
CoV	O
.	O

One	O
potential	O
target	O
for	O
SARS	O
-	O
CoV	O
antiviral	B-CHED
drug	I-CHED
development	O
is	O
the	O
3C	O
-	O
like	O
protease	O
(	O
3CLpro	O
).	O

We	O
demonstrate	O
for	O
the	O
first	O
time	O
the	O
utility	O
of	O
a	O
highly	O
sensitive	O
and	O
novel	O
Alexa488	O
-	O
QSY7	O
FRET	O
-	O
based	O
peptide	B-CHED
substrate	O
designed	O
for	O
routine	O
analysis	O
and	O
high	O
-	O
throughput	O
screening	O
,	O
and	O
show	O
that	O
kinetic	O
constants	O
determined	O
from	O
FRET	O
-	O
based	O
assays	O
that	O
are	O
uncorrected	O
for	O
inner	O
-	O
filter	O
effects	O
can	O
lead	O
to	O
artifacts	O
.	O

HIV	O
and	O
influenza	O
,	O
two	O
clear	O
threats	O
to	O
human	O
health	O
,	O
have	O
been	O
shown	O
to	O
rely	O
on	O
expression	O
of	O
specific	O
oligosaccharides	B-CHED
to	O
evade	O
detection	O
by	O
the	O
host	O
immune	O
system	O
.	O

Additionally	O
,	O
other	O
viruses	O
such	O
as	O
Hendra	O
,	O
SARS	O
-	O
CoV	O
,	O
influenza	O
,	O
hepatitis	O
and	O
West	O
Nile	O
rely	O
on	O
N	O
-	O
linked	O
glycosylation	O
for	O
crucial	O
functions	O
such	O
as	O
entry	O
into	O
host	O
cells	O
,	O
proteolytic	O
processing	O
and	O
protein	B-CHED
trafficking	O
.	O

The	O
human	O
diphtheria	O
toxin	O
(	O
DT	O
)	O
receptor	O
(	O
DTR	O
),	O
heparin	B-CHED
-	O
binding	O
epidermal	O
growth	O
factor	O
-	O
like	O
growth	O
factor	O
(	O
HB	O
-	O
EGF	O
),	O
was	O
expressed	O
under	O
the	O
control	O
of	O
the	O
lysozyme	O
M	O
(	O
LysM	O
)	O
gene	O
promoter	O
in	O
the	O
mice	O
.	O

Previously	O
,	O
SARS	O
CoV	O
3C	O
-	O
like	O
protease	O
(	O
3CLpro	O
)	O
has	O
been	O
demonstrated	O
to	O
induce	O
apoptosis	O
via	O
the	O
activation	O
of	O
caspase	O
-	O
3	O
and	O
caspase	O
-	O
9	O
(	O
Lin	B-CHED
,	O
C	O
.	O
W	O
.,	O
Lin	B-CHED
,	O
K	O
.	O
H	O
.,	O
Hsieh	O
,	O
T	O
.	O
H	O
.,	O
Shiu	O
,	O
S	O
.	O
Y	O
.	O
et	O
al	O
.,	O
FEMS	O
Immunol	O
.	O

TITLE	O
:	O
The	O
SARS	O
coronavirus	O
spike	O
glycoprotein	B-CHED
is	O
selectively	O
recognized	O
by	O
lung	O
surfactant	B-CHED
protein	B-CHED
D	O
and	O
activates	O
macrophages	O
.	O

In	O
addition	O
,	O
16	O
healthy	O
subjects	O
were	O
included	O
in	O
an	O
experimental	O
lipopolysaccharide	B-CHED
challenge	O
model	O
.	O

We	O
have	O
recently	O
obtained	O
evidence	O
that	O
one	O
or	O
more	O
of	O
the	O
15	O
proteins	B-CHED
encoded	O
by	O
gene	O
1	O
are	O
also	O
determinants	O
of	O
pathogenicity	O
.	O

ABSTRACT	O
:	O
Positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	B-CHED
)	O
and	O
inspired	O
oxygen	B-CHED
fraction	O
(	O
F	O
(	O
IO	O
(	O
2	O
)))	O
are	O
the	O
primary	O
means	O
of	O
improving	O
P	O
(	O
aO	O
(	O
2	O
))	O
during	O
mechanical	O
ventilation	O
.	O

TITLE	O
:	O
Cell	O
cycle	O
dependent	O
nucleolar	O
localization	O
of	O
the	O
coronavirus	O
nucleocapsid	O
protein	B-CHED
.	O

None	O
of	O
the	O
surviving	O
patients	O
relapsed	O
or	O
received	O
routine	O
secondary	O
antifungal	B-CHED
prophylaxis	O
.	O

ABSTRACT	O
:	O
A	O
190	O
-	O
nucleotide	B-CHED
(	O
nt	O
)	O
packaging	O
signal	O
(	O
PS	O
)	O
located	O
in	O
the	O
3	O
'	O
end	O
of	O
open	O
reading	O
frame	O
1b	O
in	O
the	O
mouse	O
hepatitis	O
virus	O
,	O
a	O
group	O
IIa	O
coronavirus	O
,	O
was	O
previously	O
postulated	O
to	O
direct	O
genome	O
RNA	O
packaging	O
.	O

We	O
propose	O
that	O
repeating	O
AA	O
bulges	O
are	O
characteristic	O
features	O
of	O
group	O
IIa	O
PSs	B-CHED
.	O

Particularly	O
noteworthy	O
,	O
the	O
majority	O
of	O
nucleotide	B-CHED
changes	O
in	O
the	O
AH65	O
-	O
E	O
-	O
TC	O
isolate	O
occurred	O
at	O
the	O
identical	O
positions	O
as	O
the	O
mutations	O
occurring	O
in	O
the	O
AH65	O
-	O
R	O
strain	O
from	O
the	O
same	O
animal	O
.	O

The	O
aim	O
of	O
this	O
paper	O
is	O
to	O
present	O
the	O
first	O
case	O
report	O
of	O
a	O
patient	O
with	O
Down	O
'	O
s	O
syndrome	O
(	O
DS	O
)	O
who	O
died	O
of	O
a	O
fulminant	O
NMO	B-CHED
.	O

A	O
severe	O
destruction	O
of	O
medulla	O
and	O
cervical	O
cord	O
with	O
a	O
very	O
high	O
degree	O
of	O
demyelination	O
of	O
the	O
optic	O
nerves	O
was	O
typical	O
of	O
monophasic	O
NMO	B-CHED
(	O
Devic	O
'	O
s	O
disease	O
).	O

RESULTS	O
:	O
The	O
results	O
indicate	O
that	O
there	O
were	O
inverse	O
association	O
between	O
the	O
number	O
of	O
daily	O
cases	O
and	O
maximum	O
and	O
/	O
or	O
minimum	O
temperatures	O
whereas	O
air	B-CHED
pressure	O
was	O
found	O
to	O
be	O
positively	O
associated	O
with	O
SARS	O
transmission	O
.	O

It	O
most	O
commonly	O
presents	O
either	O
as	O
a	O
superficial	O
ulcer	O
on	O
the	O
glans	O
or	O
around	O
the	O
corona	B-CHED
.	O

The	O
N	O
-	O
terminal	O
part	O
of	O
the	O
9b	O
protein	B-CHED
was	O
used	O
to	O
raise	O
polyclonal	O
antibodies	O
in	O
rabbits	O
,	O
and	O
these	O
antibodies	O
could	O
detect	O
9b	O
protein	B-CHED
in	O
infected	O
cells	O
.	O

We	O
previously	O
reported	O
the	O
isolation	O
of	O
HCoV	O
-	O
229E	O
/	O
myelin	O
basic	O
protein	B-CHED
(	O
MBP	O
)	O
cross	O
-	O
reactive	O
T	O
-	O
cell	O
lines	O
(	O
TCL	O
)	O
in	O
MS	O
patients	O
.	O

To	O
investigate	O
antigenic	O
cross	O
-	O
reactivity	O
at	O
the	O
molecular	O
level	O
,	O
155	O
long	O
-	O
term	O
T	O
-	O
cell	O
clones	O
(	O
TCC	B-CHED
)	O
were	O
derived	O
from	O
32	O
MS	O
patients	O
by	O
in	O
vitro	O
selection	O
with	O
MBP	O
,	O
proteolipid	O
protein	B-CHED
(	O
PLP	O
)	O
or	O
HCoV	O
(	O
strains	O
229E	O
and	O
OC43	O
).	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
apoptosis	O
effect	O
of	O
SARS	O
coronavirus	O
nucleocapsid	O
protein	B-CHED
on	O
cultured	O
cell	O
lines	O
and	O
to	O
explore	O
the	O
possible	O
pathway	O
of	O
apoptosis	O
.	O

After	O
removal	O
of	O
serum	O
in	O
COS	B-CHED
-	O
1	O
cells	O
,	O
we	O
observed	O
the	O
loss	O
of	O
DeltaPsim	O
,	O
the	O
increase	O
of	O
ROS	B-CHED
and	O
cytochrome	B-CHED
C	I-CHED
release	O
into	O
cytosol	O
and	O
subsequent	O
activation	O
of	O
caspase	O
-	O
3	O
and	O
PARP	B-CHED
cleavage	O
.	O

In	O
order	O
to	O
understand	O
the	O
acquired	O
tropism	O
of	O
the	O
Beaudette	O
strain	O
,	O
we	O
compared	O
the	O
S	O
protein	B-CHED
sequences	O
of	O
several	O
IBV	O
strains	O
.	O

The	O
peaks	O
of	O
the	O
epidemic	O
correspond	O
well	O
with	O
the	O
occurrence	O
of	O
major	O
infection	O
clusters	B-CHED
in	O
the	O
hospitals	O
.	O

RESULTS	O
:	O
The	O
peaks	O
of	O
the	O
epidemic	O
correspond	O
well	O
with	O
the	O
occurrence	O
of	O
major	O
infection	O
clusters	B-CHED
in	O
the	O
hospitals	O
.	O

ABSTRACT	O
:	O
The	O
renin	O
-	O
angiotensin	B-CHED
-	O
aldosterone	B-CHED
system	O
(	O
RAAS	O
)	O
is	O
a	O
key	O
regulator	O
of	O
systemic	O
blood	O
pressure	O
and	O
renal	O
function	O
and	O
a	O
key	O
player	O
in	O
renal	O
and	O
cardiovascular	O
disease	O
.	O

Antibody	O
titers	O
against	O
canine	O
distemper	O
virus	O
(	O
CDV	B-CHED
),	O
canine	O
parvovirus	O
(	O
CPV	O
),	O
and	O
canine	O
adenovirus	O
(	O
CAV	O
)	O
in	O
the	O
three	O
facilities	O
in	O
which	O
red	O
pandas	O
were	O
vaccinated	O
were	O
highly	O
variable	O
.	O

The	O
16	O
-	O
year	O
-	O
old	O
patient	O
had	O
a	O
history	O
of	O
smoking	O
and	O
therapy	O
-	O
refractant	O
hemoptysis	O
and	O
,	O
later	O
,	O
acute	O
macrohematuria	O
with	O
renal	O
insufficiency	O
necessitating	O
hemodialysis	O
(	O
initial	O
creatinine	B-CHED
4	O
.	O
2	O
mg	O
/	O
dl	O
).	O

We	O
observed	O
that	O
(	O
i	O
)	O
the	O
5	O
'-	O
terminal	O
186	O
nt	O
of	O
the	O
nsp1	O
coding	O
region	O
are	O
necessary	O
and	O
sufficient	O
for	O
DI	O
RNA	O
replication	O
,	O
(	O
ii	O
)	O
two	O
Mfold	O
-	O
predicted	O
stem	O
-	O
loops	O
within	O
the	O
186	O
-	O
nt	O
sequence	O
,	O
named	O
SLV	O
(	O
nt	O
239	O
to	O
310	O
)	O
and	O
SLVI	O
(	O
nt	O
311	O
to	O
340	O
),	O
are	O
supported	O
by	O
RNase	O
structure	O
probing	O
and	O
by	O
nucleotide	B-CHED
covariation	O
among	O
closely	O
related	O
group	O
2	O
coronaviruses	O
,	O
and	O
(	O
iii	O
)	O
SLVI	O
is	O
a	O
required	O
higher	O
-	O
order	O
structure	O
for	O
DI	O
RNA	O
replication	O
based	O
on	O
mutation	O
analyses	O
.	O

The	O
effect	O
of	O
LiCl	B-CHED
on	O
the	O
replication	O
of	O
IBV	O
was	O
examined	O
in	O
cell	O
culture	O
using	O
two	O
model	O
cell	O
types	O
;	O
Vero	O
cells	O
,	O
an	O
African	O
Green	O
monkey	O
kidney	O
-	O
derived	O
epithelial	O
cell	O
line	O
;	O
and	O
DF	O
-	O
1	O
cells	O
,	O
an	O
immortalized	O
chicken	O
embryo	O
fibroblast	O
cell	O
line	O
.	O

Host	O
cell	O
protein	B-CHED
synthesis	O
still	O
took	O
place	O
in	O
LiCl	B-CHED
-	O
treated	O
cells	O
and	O
the	O
level	O
of	O
a	O
standard	O
cellular	O
housekeeping	O
protein	B-CHED
remained	O
unchanged	O
,	O
indicating	O
that	O
the	O
effect	O
of	O
LiCl	B-CHED
was	O
specifically	O
against	O
IBV	O
.	O

There	O
are	O
no	O
skin	O
lesions	O
and	O
it	O
improves	O
promptly	O
with	O
antibiotics	B-CHED
.	O

At	O
the	O
time	O
of	O
MHV	O
-	O
induced	O
host	O
translational	O
shutoff	O
,	O
downregulation	O
of	O
numerous	O
mRNAs	O
,	O
many	O
of	O
which	O
encode	O
protein	B-CHED
translation	O
-	O
related	O
factors	O
,	O
was	O
observed	O
.	O

To	O
evaluate	O
the	O
mechanisms	O
behind	O
this	O
event	O
,	O
we	O
investigated	O
the	O
roles	O
of	O
SARS	O
-	O
CoV	O
proteins	B-CHED
in	O
the	O
regulation	O
of	O
IL	O
-	O
6	O
.	O

These	O
results	O
provided	O
new	O
insights	O
into	O
understanding	O
the	O
mechanism	O
involved	O
in	O
the	O
function	O
of	O
SARS	O
-	O
CoV	O
N	O
protein	B-CHED
and	O
pathogenesis	O
of	O
the	O
virus	O
.	O

ABSTRACT	O
:	O
The	O
nucleocapsid	O
(	O
N	O
)	O
protein	B-CHED
of	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
is	O
involved	O
in	O
the	O
pathological	O
reaction	O
to	O
SARS	O
and	O
is	O
a	O
key	O
antigen	B-CHED
for	O
the	O
development	O
of	O
a	O
sensitive	O
diagnostic	O
assay	O
.	O

We	O
invited	O
SARS	O
survivors	O
from	O
the	O
same	O
hospitals	O
(	O
non	O
-	O
health	O
care	O
workers	O
,	O
n	O
=	O
63	O
;	O
health	O
care	O
workers	O
,	O
n	O
=	O
33	O
)	O
to	O
complete	O
the	O
PSS	B-CHED
-	O
10	O
again	O
in	O
2004	O
.	O

At	O
the	O
peak	O
of	O
the	O
2003	O
SARS	O
outbreak	O
,	O
we	O
assessed	O
health	O
care	O
workers	O
in	O
2	O
acute	O
care	O
Hong	O
Kong	O
general	O
hospitals	O
with	O
the	O
Perceived	O
Stress	O
Scale	O
(	O
PSS	B-CHED
-	O
10	O
).	O

TITLE	O
:	O
The	O
two	O
fACEs	O
of	O
the	O
tissue	O
renin	O
-	O
angiotensin	B-CHED
systems	O
:	O
implication	O
in	O
cardiovascular	O
diseases	O
.	O

The	O
neutralizing	O
epitopes	O
were	O
identified	O
using	O
peptides	B-CHED
to	O
block	O
the	O
neutralizing	O
effect	O
of	O
guinea	O
pig	O
antisera	O
.	O

The	O
ISA	O
/	O
CpG	O
formulation	O
generated	O
anti	O
-	O
D2	O
IgG	O
titer	O
comparable	O
to	O
those	O
obtained	O
from	O
Freund	O
'	O
s	O
adjuvant	B-CHED
formulation	O
,	O
but	O
generated	O
fewer	O
antibodies	O
against	O
D1	O
or	O
TM	O
peptides	B-CHED
.	O

These	O
results	O
suggest	O
that	O
synthetic	O
peptide	B-CHED
D2	O
would	O
be	O
useful	O
as	O
a	O
component	O
of	O
SARS	O
vaccine	O
candidates	O
.	O

TITLE	O
:	O
GxxxG	O
motif	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
spike	O
glycoprotein	B-CHED
transmembrane	O
domain	O
is	O
not	O
involved	O
in	O
trimerization	O
and	O
is	O
not	O
important	O
for	O
entry	O
.	O

ABSTRACT	O
:	O
Surfactant	B-CHED
therapy	O
has	O
significantly	O
changed	O
clinical	O
practice	O
in	O
neonatology	O
over	O
the	O
last	O
25	O
years	O
.	O

Advancements	O
in	O
the	O
development	O
of	O
synthetic	O
surfactants	B-CHED
are	O
promising	O
,	O
yet	O
to	O
date	O
none	O
has	O
been	O
shown	O
to	O
be	O
superior	O
to	O
natural	O
preparations	O
.	O

Whether	O
children	O
with	O
other	O
lung	O
diseases	O
benefit	O
from	O
surfactant	B-CHED
therapy	O
is	O
less	O
clear	O
.	O

However	O
,	O
more	O
research	O
is	O
needed	O
to	O
establish	O
potential	O
beneficial	O
effects	O
of	O
surfactant	B-CHED
administration	O
in	O
children	O
with	O
lung	O
diseases	O
other	O
than	O
RDS	O
.	O

Ongoing	O
research	O
is	O
essential	O
to	O
continue	O
to	O
improve	O
therapeutic	O
prospects	O
for	O
children	O
with	O
serious	O
respiratory	O
disease	O
involving	O
disturbances	O
in	O
surfactant	B-CHED
.	O

During	O
the	O
experiment	O
,	O
blood	O
samples	O
were	O
taken	O
from	O
cervical	O
artery	O
and	O
subjected	O
to	O
blood	O
-	O
gas	O
analysis	O
at	O
different	O
time	O
points	O
after	O
oleic	B-CHED
acid	I-CHED
injection	O
.	O

Pretreatment	O
with	O
rupatadine	O
has	O
a	O
beneficial	O
effect	O
on	O
acute	O
lung	O
injury	O
induced	O
by	O
oleic	B-CHED
acid	I-CHED
in	O
rabbits	O
.	O

The	O
SARS	O
-	O
CoV	O
entered	O
caveolin	O
-	O
1	O
-	O
negative	O
HepG2	O
cells	O
,	O
and	O
the	O
entry	O
was	O
significantly	O
inhibited	O
by	O
treatment	O
with	O
chlorpromazine	B-CHED
,	O
an	O
inhibitor	B-CHED
for	O
clathrin	O
-	O
dependent	O
endocytosis	O
,	O
and	O
by	O
small	O
interfering	O
RNA	O
-	O
mediated	O
gene	O
silencing	O
for	O
the	O
clathrin	O
heavy	O
chain	O
.	O

We	O
hypothesized	O
that	O
platelet	B-CHED
-	I-CHED
activating	I-CHED
factor	I-CHED
(	O
PAF	B-CHED
)	O
and	O
associated	O
downstream	O
signaling	O
pathways	O
play	O
a	O
role	O
in	O
the	O
PLY	O
-	O
induced	O
development	O
of	O
acute	O
lung	O
injury	O
.	O

Ventilated	O
and	O
blood	O
-	O
free	O
-	O
perfused	O
lungs	O
of	O
wild	O
-	O
type	O
and	O
PAF	B-CHED
receptor	O
-	O
deficient	O
mice	O
were	O
challenged	O
with	O
recombinant	O
PLY	O
.	O

PLY	O
and	O
exogenous	O
PAF	B-CHED
increased	O
thromboxane	B-CHED
B2	I-CHED
in	O
lung	O
effluate	O
,	O
and	O
thromboxane	B-CHED
receptor	O
inhibition	O
by	O
BM	O
13505	O
diminished	O
the	O
pressor	O
response	O
to	O
PLY	O
.	O

Unrelated	O
to	O
the	O
pulmonary	O
arterial	O
pressor	O
response	O
,	O
microvascular	O
leakage	O
of	O
PLY	O
was	O
diminished	O
in	O
lungs	O
of	O
PAF	B-CHED
receptor	O
-	O
deficient	O
mice	O
as	O
well	O
.	O

ABSTRACT	O
:	O
The	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
coronavirus	O
nucleocapsid	O
(	O
N	O
)	O
protein	B-CHED
is	O
involved	O
in	O
virus	O
replication	O
and	O
modulation	O
of	O
cell	O
processes	O
.	O

TITLE	O
:	O
The	O
nonstructural	O
protein	B-CHED
8	O
(	O
nsp8	O
)	O
of	O
the	O
SARS	O
coronavirus	O
interacts	O
with	O
its	O
ORF6	O
accessory	O
protein	B-CHED
.	O

We	O
expressed	O
the	O
two	O
proteins	B-CHED
as	O
fusion	O
proteins	B-CHED
in	O
the	O
yeast	O
two	O
-	O
hybrid	O
system	O
to	O
demonstrate	O
protein	B-CHED
-	O
protein	B-CHED
interactions	O
and	O
tested	O
the	O
same	O
using	O
a	O
yeast	O
genetic	O
cross	O
.	O

However	O
,	O
other	O
functions	O
of	O
SARS	O
-	O
CoV	O
S	O
protein	B-CHED
such	O
as	O
proteolytic	O
cleavage	O
and	O
its	O
implications	O
to	O
viral	O
infection	O
are	O
incompletely	O
understood	O
.	O

Endocrine	B-CHED
pancreas	O
islets	O
were	O
unremarkable	O
and	O
contained	O
insulin	B-CHED
-	O
positive	O
beta	O
cells	O
and	O
glucagon	B-CHED
-	O
positive	O
alpha	O
cells	O
.	O

Duration	O
of	O
argatroban	B-CHED
infusion	O
for	O
ECMO	O
averaged	O
4	O
+/-	O

TITLE	O
:	O
Proteinase	O
dysbalance	O
in	O
pathology	O
:	O
the	O
neprilysin	O
(	O
NEP	O
)	O
and	O
angiotensin	B-CHED
-	O
converting	O
enzyme	O
(	O
ACE	O
)	O
families	O
.	O

The	O
second	O
exemplar	O
involves	O
the	O
newly	O
appreciated	O
complexity	O
of	O
the	O
renin	O
-	O
angiotensin	B-CHED
system	O
as	O
a	O
regulator	O
of	O
the	O
cardiovascular	O
system	O
.	O

Lastly	O
,	O
we	O
found	O
that	O
expression	O
of	O
the	O
SDF	O
-	O
1	O
receptor	O
CXCR4	O
rises	O
in	O
a	O
similar	O
temporal	O
pattern	O
on	O
neutrophils	O
in	O
both	O
the	O
blood	O
and	O
airspace	O
of	O
LPS	B-CHED
-	O
injured	O
mice	O
and	O
that	O
Ab	O
-	O
mediated	O
SDF	O
-	O
1	O
blockade	O
significantly	O
attenuates	O
late	O
but	O
not	O
early	O
pulmonary	O
neutrophilia	O
in	O
this	O
model	O
.	O

The	O
authors	O
report	O
a	O
second	O
case	O
of	O
HbS	O
/	O
Québec	O
-	O
CHORI	O
,	O
a	O
severe	O
compound	O
heterozygous	O
sickling	O
disorder	O
and	O
their	O
experience	O
managing	O
this	O
patient	O
with	O
hydroxyurea	B-CHED
.	O

The	O
E	O
.	O
coli	O
-	O
mycobacterium	O
expression	O
shuttle	O
plasmid	O
pR	O
-	O
alpha	O
-	O
S1	O
was	O
constructed	O
by	O
inserting	O
the	O
S1	O
gene	O
to	O
the	O
pRR3	O
with	O
human	O
mycobacterium	O
tuberculosis	O
HSP70	O
promoter	O
and	O
a	O
signal	O
peptide	B-CHED
.	O

Sequential	O
chest	O
computed	O
tomography	O
scans	O
in	O
this	O
case	O
indicate	O
that	O
absorption	O
of	O
marginal	O
air	B-CHED
-	O
space	O
consolidation	O
with	O
extended	O
central	O
ground	O
glass	O
attenuation	O
in	O
concordance	O
with	O
a	O
new	O
infiltrate	O
on	O
another	O
lung	O
field	O
appeared	O
to	O
create	O
wandering	O
infiltrate	O
.	O

RESULTS	O
:	O
The	O
spot	O
map	O
effectively	O
illustrated	O
clusters	B-CHED
by	O
residency	O
,	O
with	O
the	O
inner	O
-	O
city	O
sustaining	O
the	O
highest	O
attack	O
rate	O
(	O
33	O
.	O
42	O
per	O
100	O
,	O
000	O
),	O
followed	O
by	O
an	O
easterly	O
distribution	O
5	O
-	O
30km	O
away	O
(	O
21	O
.	O
62	O
per	O
10	O
,	O
000	O
),	O
and	O
lowest	O
in	O
districts	O
60	O
-	O
160km	O
away	O
(	O
9	O
.	O
21	O
per	O
100	O
,	O
000	O
).	O

Then	O
we	O
measured	O
the	O
numbers	O
of	O
total	O
cells	O
and	O
neutrophils	O
and	O
the	O
levels	O
of	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)-	O
alpha	O
and	O
cytokine	O
-	O
induced	O
neutrophil	O
chemoattractant	O
(	O
CINC	B-CHED
)	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
(	O
BALF	O
).	O

Moreover	O
,	O
recent	O
studies	O
have	O
demonstrated	O
that	O
ACE2	O
protects	O
murine	O
lungs	O
from	O
acute	O
lung	O
injury	O
as	O
well	O
as	O
SARS	O
-	O
Spike	O
protein	B-CHED
-	O
mediated	O
lung	O
injury	O
,	O
suggesting	O
a	O
dual	O
role	O
of	O
ACE2	O
in	O
SARS	O
infections	O
and	O
protection	O
from	O
ARDS	O
.	O

In	O
addition	O
,	O
we	O
identified	O
the	O
expression	O
of	O
inducible	O
nitric	B-CHED
oxide	I-CHED
synthase	O
(	O
iNOS	O
)	O
using	O
immunohistochemical	O
stain	O
.	O

TITLE	O
:	O
Should	O
preschool	O
wheezers	O
ever	O
be	O
treated	O
with	O
inhaled	O
corticosteroids	B-CHED
?	O

Pure	O
virus	O
-	O
associated	O
symptoms	O
may	O
be	O
treated	O
with	O
intermittent	O
beta	O
-	O
2	O
agonist	B-CHED
or	O
anticholinergics	B-CHED
by	O
inhalation	O
.	O

In	O
this	O
study	O
,	O
colostrum	O
-	O
deprived	O
calves	O
were	O
experimentally	O
infected	O
with	O
a	O
Korean	O
WD	O
-	O
BCoV	O
strain	O
and	O
examined	O
for	O
viremia	O
,	O
enteric	O
and	O
nasal	O
virus	O
shedding	O
as	O
well	O
as	O
for	O
viral	O
antigen	B-CHED
expression	O
and	O
virus	O
-	O
associated	O
lesions	O
in	O
the	O
small	O
and	O
large	O
intestines	O
and	O
the	O
upper	O
and	O
lower	O
respiratory	O
tract	O
from	O
1	O
to	O
8	O
days	O
after	O
an	O
oral	O
infection	O
.	O

ABSTRACT	O
:	O
Yeasts	O
are	O
attractive	O
organisms	O
for	O
recombinant	O
protein	B-CHED
production	O
.	O

Autoselection	O
systems	O
for	O
expressing	O
single	O
or	O
pairs	O
of	O
proteins	B-CHED
are	O
described	O
.	O

We	O
demonstrate	O
the	O
versatility	O
of	O
this	O
system	O
by	O
expressing	O
proteins	B-CHED
from	O
a	O
number	O
of	O
organisms	O
and	O
include	O
several	O
large	O
and	O
problematic	O
products	O
.	O

Serum	O
samples	O
from	O
16	O
layers	O
and	O
9	O
broiler	O
flocks	O
were	O
screened	O
against	O
M	O
-	O
41	O
,	O
D	O
-	O
274	O
,	O
D	O
-	O
1466	O
,	O
and	O
4	O
-	O
91	O
strain	O
antigens	B-CHED
using	O
hemagglutination	O
inhibition	O
assay	O
.	O

The	O
M	O
-	O
41	O
antigen	B-CHED
was	O
also	O
detected	O
in	O
lungs	O
and	O
tracheal	O
tissues	O
of	O
the	O
clinically	O
positive	O
infectious	O
bronchitis	O
cases	O
.	O

Although	O
steroids	B-CHED
cannot	O
be	O
used	O
as	O
a	O
monotherapy	O
in	O
the	O
treatment	O
of	O
avian	O
influenza	O
,	O
there	O
might	O
be	O
a	O
potential	O
role	O
for	O
their	O
use	O
as	O
an	O
adjunct	O
treatment	O
to	O
antiviral	B-CHED
therapy	O
if	O
appropriate	O
dosages	O
can	O
be	O
determined	O
.	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
is	O
caused	O
by	O
a	O
novel	O
coronavirus	O
(	O
CoV	O
),	O
SARS	O
-	O
CoV	O
.	O
In	O
previous	O
studies	O
,	O
we	O
showed	O
that	O
a	O
SARS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
glycoprotein	B-CHED
-	O
based	O
modified	O
vaccinia	O
Ankara	O
(	O
MVA	B-CHED
-	O
S	O
)	O
vaccine	O
could	O
induce	O
strong	O
neutralizing	O
antibody	O
(	O
Nab	O
)	O
response	O
which	O
might	O
have	O
played	O
a	O
critical	O
role	O
in	O
protecting	O
Chinese	O
rhesus	O
monkeys	O
from	O
the	O
pathogenic	O
viral	O
challenge	O
.	O

Moreover	O
,	O
gamma	O
-	O
chain	O
-	O
deficient	O
mice	O
that	O
lack	O
receptors	O
for	O
immune	O
complexes	O
were	O
protected	O
from	O
LPS	B-CHED
-	O
induced	O
pulmonary	O
inflammation	O
.	O

TITLE	O
:	O
Do	O
glucocorticoids	B-CHED
decrease	O
mortality	O
in	O
acute	O
respiratory	O
distress	O
syndrome	O
?	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
analyse	O
the	O
role	O
of	O
glucocorticoids	B-CHED
in	O
decreasing	O
mortality	O
in	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
both	O
in	O
the	O
acute	O
and	O
the	O
fibroproliferative	O
phases	O
.	O

The	O
study	O
population	O
included	O
patients	O
with	O
ARDS	O
treated	O
with	O
glucocorticoids	B-CHED
.	O

More	O
research	O
is	O
required	O
to	O
establish	O
the	O
role	O
of	O
steroids	B-CHED
in	O
specific	O
subgroups	O
of	O
patients	O
with	O
severe	O
sepsis	O
and	O
early	O
ARDS	O
who	O
have	O
relative	O
adrenal	O
insufficiency	O
and	O
patients	O
with	O
late	O
ARDS	O
7	O
-	O
14	O
days	O
after	O
the	O
onset	O
of	O
disease	O
.	O

CONCLUSIONS	O
:	O
Exogenous	O
leptin	O
attenuates	O
inflamma	O
-	O
tory	O
changes	O
,	O
and	O
reduces	O
pro	B-CHED
-	O
inflammatory	O
cytokines	O
,	O
nitric	B-CHED
oxide	I-CHED
levels	O
,	O
and	O
CD40	O
expression	O
in	O
cerulein	B-CHED
-	O
induced	O
AP	O
and	O
may	O
be	O
protective	O
in	O
AP	O
associated	O
ALI	O
.	O

TITLE	O
:	O
siRNAs	O
targeting	O
terminal	O
sequences	O
of	O
the	O
SARS	O
-	O
associated	O
coronavirus	O
membrane	O
gene	O
inhibit	O
M	O
protein	B-CHED
expression	O
through	O
degradation	O
of	O
M	O
mRNA	B-CHED
.	O

ABSTRACT	O
:	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SCoV	O
)	O
M	O
protein	B-CHED
plays	O
a	O
key	O
role	O
in	O
viral	O
assembly	O
and	O
budding	O
.	O

Although	O
this	O
chlorine	B-CHED
HAZMAT	O
incident	O
did	O
not	O
cause	O
severe	O
injuries	O
,	O
and	O
only	O
a	O
limited	O
number	O
of	O
persons	O
required	O
admission	O
to	O
the	O
hospital	O
,	O
some	O
valuable	O
lessons	O
were	O
learned	O
.	O

After	O
resolution	O
of	O
discordant	O
results	O
by	O
using	O
a	O
second	O
unique	O
PCR	O
assay	O
and	O
by	O
using	O
a	O
combined	O
reference	O
standard	O
of	O
positivity	O
,	O
the	O
RVP	O
test	O
detected	O
180	O
of	O
183	O
true	O
positives	O
,	O
for	O
a	O
sensitivity	O
of	O
98	O
.	O
5	O
%,	O
whereas	O
DFA	B-CHED
and	O
culture	O
detected	O
only	O
126	O
of	O
183	O
true	O
positives	O
,	O
for	O
a	O
sensitivity	O
of	O
68	O
.	O
8	O
%.	O

PCR	O
assays	O
for	O
hBoV	O
DNA	O
were	O
performed	O
using	O
the	O
primer	O
sets	O
for	O
noncapsid	O
protein	B-CHED
(	O
NP1	O
)	O
and	O
nonstructural	O
protein	B-CHED
(	O
NS1	O
)	O
genes	O
.	O

Kaletra	O
(	O
400	O
mg	O
ritonavir	B-CHED
and	O
100	O
mg	O
lopinavir	O
),	O
a	O
protease	B-CHED
inhibitor	I-CHED
used	O
in	O
the	O
treatment	O
of	O
human	O
immunodeficiency	O
virus	O
infection	O
,	O
may	O
be	O
considered	O
for	O
early	O
treatment	O
of	O
SARS	O
patients	O
,	O
preferably	O
in	O
a	O
randomised	O
double	O
-	O
blind	O
placebo	O
-	O
controlled	O
clinical	O
trial	O
setting	O
.	O

Activation	O
of	O
the	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
axis	O
with	O
the	O
production	O
of	O
cortisol	B-CHED
is	O
a	O
fundamental	O
component	O
of	O
the	O
stress	O
response	O
and	O
is	O
essential	O
for	O
survival	O
of	O
the	O
host	O
.	O

Here	O
,	O
we	O
present	O
three	O
crystal	O
structures	O
of	O
SARS	O
3CL	O
(	O
pro	B-CHED
)	O
in	O
complex	O
with	O
each	O
of	O
two	O
members	O
of	O
a	O
new	O
class	O
of	O
peptide	B-CHED
-	O
based	O
phthalhydrazide	O
inhibitors	B-CHED
.	O

Most	O
significantly	O
,	O
our	O
crystallographic	O
data	O
are	O
consistent	O
with	O
a	O
scenario	O
in	O
which	O
a	O
water	B-CHED
molecule	O
,	O
possibly	O
via	O
indirect	O
coordination	O
from	O
the	O
carbonyl	B-CHED
oxygen	B-CHED
of	O
Thr26	O
,	O
has	O
initiated	O
nucleophilic	O
attack	O
on	O
the	O
enzyme	O
-	O
bound	O
inhibitor	B-CHED
.	O

TITLE	O
:	O
Heat	O
shock	O
protein	B-CHED
90	O
inhibitors	B-CHED
prolong	O
survival	O
,	O
attenuate	O
inflammation	O
,	O
and	O
reduce	O
lung	O
injury	O
in	O
murine	O
sepsis	O
.	O

We	O
hypothesized	O
that	O
Hsp90	B-CHED
inhibitors	I-CHED
may	O
ameliorate	O
the	O
inflammation	O
and	O
ALI	O
associated	O
with	O
severe	O
sepsis	O
.	O

Compared	O
with	O
them	O
,	O
mice	O
receiving	O
either	O
radicicol	B-CHED
or	O
17	B-CHED
-	I-CHED
AAG	I-CHED
before	O
endotoxin	O
exhibited	O
prolonged	O
survival	O
,	O
reduced	O
or	O
abolished	O
increases	O
in	O
systemic	O
and	O
pulmonary	O
inflammatory	O
parameters	O
,	O
attenuated	O
capillary	O
leak	O
,	O
and	O
restored	O
,	O
normal	O
lung	O
function	O
.	O

Hsp90	B-CHED
inhibitors	I-CHED
may	O
offer	O
a	O
new	O
pharmacological	O
tool	O
in	O
the	O
management	O
of	O
severe	O
sepsis	O
and	O
severe	O
sepsis	O
-	O
induced	O
ALI	O
.	O

Infection	O
was	O
only	O
slightly	O
reduced	O
in	O
the	O
presence	O
of	O
substances	O
inhibiting	O
proteases	O
of	O
endosomal	O
compartments	O
,	O
precluding	O
that	O
the	O
endocytic	O
uptake	O
is	O
required	O
to	O
activate	O
the	O
fusion	O
potential	O
of	O
the	O
S	O
protein	B-CHED
by	O
its	O
cleavage	O
.	O

Despite	O
therapy	O
that	O
included	O
intravenous	O
antibiotics	B-CHED
,	O
intravenous	O
immune	O
globulin	O
and	O
other	O
supportive	O
measures	O
,	O
the	O
patient	O
succumbed	O
to	O
his	O
illness	O
.	O

In	O
previous	O
studies	O
,	O
intravenously	O
administered	O
PAMP	O
had	O
variable	O
effects	O
on	O
specific	O
primary	O
and	O
secondary	O
immune	O
responses	O
of	O
poultry	O
to	O
systemically	O
administered	O
antigens	B-CHED
.	O

TITLE	O
:	O
Induction	O
of	O
T	O
-	O
cell	O
response	O
by	O
a	O
DNA	O
vaccine	O
encoding	O
a	O
novel	O
HLA	O
-	O
A	O
*	O
0201	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
epitope	B-CHED
.	O

The	O
application	O
of	O
using	O
the	O
N220	O
peptide	B-CHED
sequence	O
with	O
a	O
single	O
-	O
chain	O
-	O
trimer	O
(	O
SCT	O
)	O
approach	O
to	O
produce	O
a	O
potential	O
DNA	O
vaccine	O
candidate	O
was	O
investigated	O
in	O
HLA	O
-	O
A2	O
.	O
1K	O
(	O
b	O
)	O
transgenic	O
mice	O
.	O

In	O
addition	O
,	O
the	O
SARS	O
-	O
CoV	O
S	O
-	O
protein	B-CHED
receptor	O
-	O
binding	O
domain	O
inhibited	O
entry	O
mediated	O
by	O
the	O
HCoV	O
-	O
NL63	O
S	O
protein	B-CHED
.	O

We	O
determined	O
the	O
requirement	O
for	O
the	O
nsp7	O
to	O
nsp10	O
proteins	B-CHED
and	O
their	O
processing	O
during	O
murine	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
replication	O
.	O

Shortening	O
the	O
CPP	O
length	O
,	O
modifying	O
it	O
with	O
a	O
mannosylated	O
serine	B-CHED
moiety	O
or	O
replacing	O
it	O
with	O
the	O
R	O
(	O
9	O
)	O
F	O
(	O
2	O
)	O
CPP	O
significantly	O
decreased	O
the	O
efficacy	O
of	O
the	O
resulting	O
PPMO	O
(	O
CPP	O
-	O
PMO	O
conjugate	O
).	O

We	O
attribute	O
the	O
success	O
of	O
this	O
CPP	O
to	O
its	O
stability	O
in	O
serum	O
and	O
its	O
capacity	O
to	O
transport	O
PMO	O
to	O
RNA	O
targets	O
in	O
a	O
manner	O
superior	O
to	O
that	O
of	O
poly	O
-	O
arginine	B-CHED
CPPs	O
.	O

Also	O
,	O
several	O
lines	O
of	O
breakthroughs	O
have	O
been	O
record	O
-	O
brokenly	O
obtained	O
,	O
that	O
included	O
the	O
finding	O
of	O
ACE2	O
,	O
a	O
functional	O
receptor	O
for	O
the	O
SARS	O
-	O
CoV	O
,	O
solution	O
of	O
the	O
3CL	O
(	O
pro	B-CHED
)	O
structure	O
,	O
a	O
first	O
crystal	O
structure	O
of	O
SARS	O
-	O
related	O
macromolecules	B-CHED
,	O
revealing	O
of	O
bats	O
as	O
natural	O
reservoirs	O
for	O
SARS	O
-	O
like	O
viruses	O
and	O
the	O
possible	O
involvement	O
of	O
civet	O
cats	O
in	O
the	O
SARS	O
emergence	O
.	O

TITLE	O
:	O
Expression	O
,	O
post	O
-	O
translational	O
modification	O
and	O
biochemical	O
characterization	O
of	O
proteins	B-CHED
encoded	O
by	O
subgenomic	O
mRNA8	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
.	O

TITLE	O
:	O
Expression	O
of	O
a	O
synthetic	O
neutralizing	O
epitope	B-CHED
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
fused	O
with	O
synthetic	O
B	O
subunit	O
of	O
Escherichia	O
coli	O
heat	O
labile	O
enterotoxin	O
in	O
rice	O
endosperm	O
.	O

In	O
this	O
study	O
,	O
we	O
assess	O
and	O
describe	O
the	O
ability	O
of	O
transgenic	O
rice	O
plants	O
to	O
express	O
a	O
fusion	O
protein	B-CHED
consisting	O
of	O
the	O
B	O
-	O
subunit	O
of	O
the	O
Escherichia	O
coli	O
heat	O
-	O
labile	O
enterotoxin	O
(	O
LTB	O
)	O
and	O
a	O
synthetic	O
core	O
-	O
neutralizing	O
epitope	B-CHED
(	O
COE	O
)	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
),	O
inducing	O
an	O
enteric	O
disease	O
that	O
is	O
seen	O
most	O
predominantly	O
in	O
piglets	O
.	O

A	O
highly	O
significant	O
correlation	O
was	O
observed	O
between	O
PaO2	O
/	O
FiO2	O
and	O
minimum	O
surface	O
tension	O
(	O
r	O
=	O
-	O
0	O
.	O
83	O
;	O
p	O
<	O
0	O
.	O
001	O
),	O
SP	O
-	O
C	O
(	O
r	O
=	O
0	O
.	O
64	O
;	O
p	O
<	O
0	O
.	O
001	O
),	O
and	O
DPPC	B-CHED
(	O
r	O
=	O
0	O
.	O
59	O
;	O
p	O
=	O
0	O
.	O
003	O
).	O

RESULTS	O
:	O
At	O
T0	O
,	O
a	O
severe	O
and	O
highly	O
significant	O
reduction	O
in	O
SP	O
-	O
A	O
,	O
SP	O
-	O
B	O
and	O
SP	O
-	O
C	O
,	O
the	O
LA	O
fraction	O
,	O
PC	O
and	O
phosphatidylglycerol	B-CHED
(	O
PG	O
)	O
percentages	O
,	O
and	O
dipalmitoylation	O
of	O
PC	O
(	O
DPPC	B-CHED
)	O
was	O
encountered	O
.	O

TITLE	O
:	O
Specific	O
plant	O
terpenoids	B-CHED
and	O
lignoids	O
possess	O
potent	O
antiviral	B-CHED
activities	O
against	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
.	O

In	O
this	O
study	O
,	O
we	O
tested	O
four	O
DNA	O
-	O
vaccine	O
constructs	O
:	O
(	O
1	O
)	O
pLL70	O
,	O
containing	O
cDNA	O
for	O
the	O
SARS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
gene	O
;	O
(	O
2	O
)	O
pcDNA	O
-	O
SS	O
,	O
containing	O
codon	O
-	O
optimized	O
S	O
gene	O
for	O
SARS	O
-	O
CoV	O
S	O
protein	B-CHED
(	O
residues	O
12	O
-	O
1255	O
)	O
fused	O
with	O
a	O
leader	O
sequence	O
derived	O
from	O
the	O
human	O
CD5	O
gene	O
;	O
(	O
3	O
)	O
pcDNA	O
-	O
St	O
,	O
containing	O
the	O
gene	O
encoding	O
the	O
N	O
-	O
portion	O
of	O
the	O
codon	O
-	O
optimized	O
S	O
gene	O
(	O
residues	O
12	O
-	O
532	O
)	O
with	O
the	O
CD5	O
leader	O
sequence	O
;	O
(	O
4	O
)	O
pcDNA	O
-	O
St	O
-	O
VP22C	O
,	O
containing	O
the	O
gene	O
encoding	O
the	O
N	O
-	O
portion	O
of	O
the	O
codon	O
-	O
optimized	O
S	O
protein	B-CHED
with	O
the	O
CD5	O
leader	O
sequence	O
fused	O
with	O
the	O
C	O
-	O
terminal	O
138	O
amino	B-CHED
acids	I-CHED
of	O
the	O
bovine	O
herpesvirus	O
-	O
1	O
(	O
BHV	O
-	O
1	O
)	O
major	O
tegument	O
protein	B-CHED
VP22	O
.	O

Sequence	O
analysis	O
of	O
the	O
haemagglutination	O
-	O
esterase	O
and	O
spike	O
proteins	B-CHED
of	O
the	O
strain	O
detected	O
in	O
one	O
rectal	O
sample	O
(	O
339	O
/	O
06	O
)	O
showed	O
a	O
high	O
genetic	O
relatedness	O
with	O
recent	O
BCoV	O
isolates	O
(	O
98	O
-	O
99	O
%	O
amino	B-CHED
acid	I-CHED
identity	O
),	O
with	O
several	O
unique	O
amino	B-CHED
acid	I-CHED
substitutions	O
in	O
the	O
S	O
protein	B-CHED
.	O

We	O
previously	O
showed	O
that	O
one	O
such	O
protein	B-CHED
,	O
encoded	O
by	O
ORF6	O
,	O
enhanced	O
the	O
growth	O
of	O
mouse	O
hepatitis	O
virus	O
in	O
tissue	O
culture	O
cells	O
and	O
in	O
mice	O
.	O

Yet	O
Sendai	O
virus	O
-	O
infected	O
cells	O
showed	O
substantial	O
Cxcl2	O
mRNA	B-CHED
induction	O
and	O
a	O
simultaneous	O
increase	O
in	O
levels	O
of	O
secreted	O
CXCL2	O
protein	B-CHED
.	O

ABSTRACT	O
:	O
Apelin	O
constitutes	O
a	O
novel	O
endogenous	O
peptide	B-CHED
system	O
suggested	O
to	O
be	O
involved	O
in	O
a	O
broad	O
range	O
of	O
physiological	O
functions	O
,	O
including	O
cardiovascular	O
function	O
,	O
heart	O
development	O
,	O
control	O
of	O
fluid	O
homeostasis	O
,	O
and	O
obesity	O
.	O

CDS	B-CHED
had	O
a	O
significantly	O
higher	O
incidence	O
of	O
ALI	O
and	O
ARDS	O
than	O
children	O
without	O
Down	O
syndrome	O
.	O

To	O
our	O
knowledge	O
,	O
there	O
has	O
been	O
no	O
report	O
on	O
IFV	O
in	O
veterinary	O
medicine	B-CHED
.	O

The	O
graphs	O
of	O
characteristic	O
distributions	O
of	O
dinucleotide	B-CHED
GC	O
for	O
the	O
coding	O
sequences	O
of	O
the	O
first	O
exon	O
of	O
beta	O
-	O
globin	B-CHED
gene	O
of	O
eleven	O
different	O
species	O
and	O
the	O
construction	O
of	O
phylogenetic	O
tree	O
of	O
twenty	O
four	O
coronavirus	O
genomes	O
illustrate	O
the	O
utility	O
of	O
the	O
approach	O
.	O

Intensive	O
treatment	O
with	O
plasmapheresis	O
,	O
high	O
-	O
dose	O
intravenous	O
immunoglobulin	O
,	O
high	O
-	O
dose	O
corticosteroids	B-CHED
,	O
cyclophosphamide	B-CHED
,	O
and	O
anticoagulants	B-CHED
eventually	O
led	O
to	O
full	O
recovery	O
.	O

ABSTRACT	O
:	O
The	O
proteins	B-CHED
encoded	O
by	O
gene	O
7	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
have	O
been	O
demonstrated	O
to	O
have	O
proapoptotic	O
activity	O
when	O
expressed	O
from	O
cDNA	O
but	O
appear	O
to	O
be	O
dispensable	O
for	O
virus	O
replication	O
.	O

To	O
identify	O
the	O
molecule	O
that	O
interacts	O
with	O
JHMV	O
,	O
we	O
focused	O
on	O
heparan	B-CHED
sulfate	I-CHED
(	O
HS	O
)	O
since	O
it	O
works	O
as	O
a	O
receptor	O
of	O
a	O
mutant	O
MHV	O
-	O
rec1	O
that	O
infects	O
in	O
an	O
MHVR	O
-	O
independent	O
fashion	O
.	O

TITLE	O
:	O
Absence	O
of	O
E	O
protein	B-CHED
arrests	O
transmissible	O
gastroenteritis	O
coronavirus	O
maturation	O
in	O
the	O
secretory	O
pathway	O
.	O

Studies	O
of	O
the	O
rTGEV	O
-	O
DeltaE	O
subcellular	O
localization	O
by	O
confocal	O
and	O
immunoelectron	O
microscopy	O
in	O
infected	O
E	O
(-)	O
cells	O
showed	O
that	O
in	O
the	O
absence	O
of	O
E	O
protein	B-CHED
virus	O
trafficking	O
was	O
arrested	O
in	O
the	O
intermediate	O
compartment	O
.	O

The	O
active	O
component	O
in	O
sonicates	O
appeared	O
to	O
be	O
a	O
merozoite	O
-	O
associated	O
protein	B-CHED
.	O

TITLE	O
:	O
Functional	O
genomics	O
highlights	O
differential	O
induction	O
of	O
antiviral	B-CHED
pathways	O
in	O
the	O
lungs	O
of	O
SARS	O
-	O
CoV	O
-	O
infected	O
macaques	O
.	O

Recent	O
studies	O
using	O
extended	O
courses	O
of	O
low	O
-	O
to	O
-	O
moderate	O
doses	O
of	O
steroids	B-CHED
have	O
found	O
favorable	O
results	O
;	O
however	O
,	O
these	O
results	O
must	O
be	O
interpreted	O
with	O
caution	O
due	O
to	O
limitations	O
in	O
the	O
data	O
.	O

One	O
trial	O
of	O
steroids	B-CHED
in	O
septic	O
shock	O
found	O
a	O
survival	O
benefit	O
in	O
patients	O
who	O
failed	O
to	O
increase	O
their	O
baseline	O
cortisol	B-CHED
by	O
greater	O
than	O
9	O
microg	O
/	O
dL	O
in	O
response	O
to	O
adrenocorticotropic	B-CHED
hormone	I-CHED
,	O
but	O
these	O
results	O
were	O
not	O
reproduced	O
in	O
a	O
subsequent	O
Phase	O
3	O
trial	O
.	O

Three	O
key	O
areas	O
for	O
retention	O
of	O
subjects	O
are	O
identified	O
from	O
the	O
literature	O
:	O
(	O
a	O
)	O
respect	O
for	O
patients	O
:	O
respect	O
for	O
their	O
ideas	O
and	O
their	O
time	O
commitment	O
to	O
the	O
research	O
project	O
;	O
(	O
b	O
)	O
tracking	O
:	O
collect	O
information	O
on	O
many	O
patient	O
contacts	O
at	O
the	O
initiation	O
of	O
the	O
study	O
and	O
outline	O
tracking	O
procedures	O
for	O
subjects	O
lost	B-CHED
to	O
follow	O
-	O
up	O
;	O
and	O
(	O
c	O
)	O
study	O
personnel	O
:	O
interpersonal	O
skills	O
must	O
be	O
reinforced	O
,	O
flexible	O
working	O
hours	O
mandated	O
,	O
and	O
support	O
offered	O
.	O

The	O
current	O
study	O
further	O
elucidates	O
the	O
inhibitory	O
mode	O
of	O
action	O
of	O
CBA	B-CHED
.	O

This	O
effect	O
was	O
associated	O
with	O
an	O
81	O
%	O
reduction	O
(	O
P	O
=	O
0	O
.	O
02	O
)	O
of	O
the	O
AUC	O
(	O
area	O
under	O
the	O
curve	O
)	O
of	O
the	O
oxidized	O
metabolite	B-CHED
APC	O
(	O
7	O
-	O
ethyl	B-CHED
-	O
10	O
-[	O
4	O
-	O
N	O
-(	O
5	O
-	O
aminopentanoic	O
-	O
acid	O
)-	O
1	O
-	O
piperidino	O
]-	O
carbonyloxycamptothecin	O
).	O

We	O
mapped	O
a	O
strong	O
inhibitory	O
activity	O
to	O
SARS	O
-	O
CoV	O
nonstructural	O
protein	B-CHED
1	O
(	O
nsp1	O
)	O
and	O
show	O
that	O
expression	O
of	O
nsp1	O
significantly	O
inhibited	O
the	O
activation	O
of	O
all	O
three	O
virus	O
-	O
dependent	O
signaling	O
pathways	O
.	O

Site	O
-	O
directed	O
mutagenesis	O
analyses	O
have	O
identified	O
seven	O
glycosylation	O
sites	O
on	O
the	O
S	O
protein	B-CHED
critical	O
for	O
DC	O
/	O
L	O
-	O
SIGN	O
-	O
mediated	O
virus	O
entry	O
.	O

Among	O
25	O
patients	O
who	O
underwent	O
virus	O
studies	O
,	O
influenza	O
A	O
(	O
H3N2	B-CHED
)	O
(	O
n	O
=	O
7	O
)	O
was	O
the	O
most	O
frequently	O
identified	O
agent	O
.	O

Our	O
data	O
suggest	O
that	O
regulation	O
of	O
IRF	O
-	O
3	O
-	O
dependent	O
innate	O
antiviral	B-CHED
defenses	O
by	O
PLpro	O
may	O
contribute	O
to	O
the	O
establishment	O
of	O
SARS	O
-	O
CoV	O
infection	O
.	O

The	O
present	O
study	O
analyses	O
data	O
-	O
bases	B-CHED
for	O
the	O
current	O
knowledge	O
on	O
vaccination	O
strategies	O
.	O

ABSTRACT	O
:	O
On	O
the	O
basis	O
of	O
our	O
previous	O
study	O
on	O
antiviral	B-CHED
agents	I-CHED
against	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
,	O
a	O
series	O
of	O
nucleoside	B-CHED
analogues	I-CHED
whose	O
5	O
'-	O
hydroxyl	B-CHED
groups	O
are	O
masked	O
by	O
various	O
protective	O
groups	O
such	O
as	O
carboxylate	B-CHED
,	O
sulfonate	B-CHED
,	O
and	O
ether	B-CHED
were	O
synthesized	O
and	O
evaluated	O
to	O
develop	O
novel	O
anti	O
-	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
agents	O
.	O

In	O
particular	O
,	O
the	O
5	O
'-	O
O	O
-	O
benzoyl	B-CHED
analogue	O
exhibited	O
the	O
highest	O
potency	O
with	O
an	O
EC	O
(	O
50	O
)	O
of	O
6	O
.	O
1	O
microM	O
in	O
a	O
cell	O
-	O
based	O
HCV	O
replicon	O
assay	O
.	O

ABSTRACT	O
:	O
The	O
coronavirus	O
responsible	O
for	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
-	O
CoV	O
)	O
contains	O
a	O
small	O
envelope	O
protein	B-CHED
,	O
E	O
,	O
with	O
putative	O
involvement	O
in	O
host	O
cell	O
apoptosis	O
and	O
virus	O
morphogenesis	O
.	O

Herein	O
,	O
we	O
show	O
that	O
this	O
peptide	B-CHED
,	O
reconstituted	O
in	O
lipid	B-CHED
bilayers	O
,	O
shows	O
sodium	O
conductance	O
.	O

IFN	O
-	O
alpha	O
production	O
in	O
PDC	B-CHED
and	O
PBMC	O
exposed	O
to	O
different	O
stimuli	O
was	O
significantly	O
lower	O
in	O
patients	O
than	O
in	O
controls	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

The	O
appearance	O
of	O
the	O
PCV	B-CHED
-	O
2b	O
genotype	O
in	O
Canada	O
may	O
explain	O
the	O
death	O
rate	O
increase	O
related	O
to	O
PMWS	O
,	O
but	O
this	O
relationship	O
has	O
to	O
be	O
confirmed	O
.	O

To	O
investigate	O
if	O
mRNA	B-CHED
secondary	O
structure	O
improves	O
stability	O
of	O
the	O
complex	O
,	O
we	O
tested	O
a	O
pseudoknot	O
,	O
originating	O
from	O
the	O
genomic	O
RNA	O
of	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
),	O
a	O
member	O
of	O
the	O
positive	O
-	O
stranded	O
coronavirus	O
group	O
.	O

The	O
important	O
role	O
of	O
the	O
early	O
secretory	O
pathway	O
in	O
formation	O
of	O
the	O
replication	O
complexes	O
was	O
also	O
demonstrated	O
by	O
the	O
inhibition	O
of	O
coronaviral	O
replication	O
when	O
the	O
ER	O
export	O
machinery	O
was	O
blocked	O
by	O
use	O
of	O
the	O
kinase	O
inhibitor	B-CHED
H89	O
or	O
by	O
expression	O
of	O
a	O
mutant	O
,	O
Sar1	O
[	O
H79G	O
].	O

Biochemical	O
analyses	O
demonstrated	O
decreased	O
activities	O
of	O
respiratory	O
chain	O
complexes	O
[	O
II	O
+	O
III	O
]	O
and	O
decreased	O
CoQ	B-CHED
(	O
10	O
)	O
concentrations	O
in	O
skeletal	O
muscle	O
and	O
renal	O
cortex	O
.	O

TITLE	O
:	O
Persistent	O
memory	O
CD4	O
+	O
and	O
CD8	O
+	O
T	O
-	O
cell	O
responses	O
in	O
recovered	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
patients	O
to	O
SARS	O
coronavirus	O
M	O
antigen	B-CHED
.	O

The	O
epitope	B-CHED
screening	O
from	O
30	O
synthetic	O
overlapping	O
peptides	B-CHED
that	O
cover	O
the	O
entire	O
SARS	O
-	O
CoV	O
M	O
protein	B-CHED
identified	O
four	O
human	O
T	O
-	O
cell	O
immunodominant	O
peptides	B-CHED
,	O
p21	O
-	O
44	O
,	O
p65	O
-	O
91	O
,	O
p117	O
-	O
140	O
and	O
p200	O
-	O
220	O
.	O

The	O
mean	O
NNU	O
/	O
NNC	O
ratio	O
of	O
the	O
six	O
amino	B-CHED
acids	I-CHED
using	O
either	O
NNC	O
or	O
NNU	O
as	O
codon	O
is	O
3	O
.	O
262	O
,	O
suggesting	O
cytosine	B-CHED
deamination	O
.	O

Among	O
the	O
16	O
dinucleotides	B-CHED
,	O
CpG	O
was	O
most	O
markedly	O
suppressed	O
(	O
mean	O
relative	O
abundance	O
0	O
.	O
509	O
).	O

In	O
the	O
first	O
part	O
of	O
this	O
review	O
,	O
we	O
will	O
discuss	O
these	O
different	O
properties	O
of	O
the	O
N	O
-	O
protein	B-CHED
in	O
a	O
consolidated	O
manner	O
.	O

Mechanisms	O
for	O
antiviral	B-CHED
activity	O
of	O
Glycyrrhiza	O
spp	O
.	O
include	O
reduced	O
transport	O
to	O
the	O
membrane	O
and	O
sialylation	O
of	O
hepatitis	O
B	O
virus	O
surface	O
antigen	B-CHED
,	O
reduction	O
of	O
membrane	O
fluidity	O
leading	O
to	O
inhibition	O
of	O
fusion	O
of	O
the	O
viral	O
membrane	O
of	O
HIV	O
-	O
1	O
with	O
the	O
cell	O
,	O
induction	O
of	O
interferon	O
gamma	O
in	O
T	O
-	O
cells	O
,	O
inhibition	O
of	O
phosphorylating	O
enzymes	O
in	O
vesicular	O
stomatitis	O
virus	O
infection	O
and	O
reduction	O
of	O
viral	O
latency	O
.	O

It	O
was	O
indicated	O
that	O
the	O
N	O
and	O
E	O
genes	O
amplified	O
from	O
sample	O
BJ8081	O
were	O
1134	O
bp	O
and	O
234	O
bp	O
in	O
length	O
and	O
the	O
predicted	O
proteins	B-CHED
including	O
377	O
amino	B-CHED
acids	I-CHED
and	O
77	O
amino	B-CHED
acids	I-CHED
,	O
respectively	O
.	O

The	O
region	O
of	O
amino	B-CHED
acids	I-CHED
15	O
-	O
37	O
for	O
E	O
protein	B-CHED
was	O
probably	O
the	O
transmembrane	O
domain	O
.	O

ABSTRACT	O
:	O
Membrane	O
(	O
M	O
)	O
protein	B-CHED
genes	O
of	O
20	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
strains	O
isolated	O
in	O
China	O
between	O
1995	O
and	O
2004	O
were	O
sequenced	O
and	O
analyzed	O
.	O

The	O
M	O
genes	O
of	O
twenty	O
isolates	O
were	O
composed	O
of	O
672	O
to	O
681	O
nucleotides	B-CHED
,	O
encoding	O
polypeptides	B-CHED
of	O
223	O
to	O
226	O
amino	B-CHED
acid	I-CHED
residues	O
.	O

Proper	O
treatment	O
,	O
however	O
,	O
depends	O
on	O
correct	O
identification	O
of	O
the	O
pathogen	O
involved	O
as	O
antibiotics	B-CHED
provide	O
little	O
or	O
no	O
benefit	O
with	O
viral	O
infections	O
.	O

Here	O
we	O
describe	O
a	O
rapid	O
and	O
sensitive	O
genotyping	O
assay	O
and	O
microarray	O
for	O
URI	O
identification	O
using	O
standard	O
amplification	O
and	O
hybridization	O
techniques	O
,	O
with	O
electrochemical	O
detection	O
(	O
ECD	O
)	O
on	O
a	O
semiconductor	O
-	O
based	O
oligonucleotide	B-CHED
microarray	O
.	O

Furthermore	O
,	O
these	O
mutant	O
proteins	B-CHED
demonstrated	O
lower	O
cleavage	O
specificities	O
for	O
uridylate	B-CHED
than	O
wild	O
-	O
type	O
(	O
WT	O
)	O
mNsp15	O
.	O

Moderate	O
two	O
-	O
way	O
cross	O
-	O
reactivity	O
between	O
SARS	O
-	O
CoV	O
and	O
porcine	O
CoVs	O
(	O
transmissible	O
gastroenteritis	O
CoV	O
[	O
TGEV	O
]	O
and	O
porcine	O
respiratory	O
CoV	O
[	O
PRCV	O
])	O
was	O
mediated	O
through	O
the	O
N	O
but	O
not	O
the	O
spike	O
protein	B-CHED
,	O
whereas	O
weaker	O
cross	O
-	O
reactivity	O
occurred	O
with	O
feline	O
(	O
feline	O
infectious	O
peritonitis	O
virus	O
)	O
and	O
canine	O
CoVs	O
.	O

The	O
TGEV	O
and	O
SARS	O
-	O
CoV	O
N	O
proteins	B-CHED
are	O
RNA	O
chaperons	O
with	O
long	O
disordered	O
regions	O
.	O

However	O
,	O
the	O
relative	O
contributions	O
of	O
type	O
I	O
IFN	O
(	O
IFN	O
-	O
I	O
)	O
to	O
direct	O
,	O
cell	O
-	O
type	O
-	O
specific	O
virus	O
control	O
or	O
CD8	O
T	O
-	O
cell	O
-	O
mediated	O
effectors	O
in	O
the	O
CNS	B-CHED
are	O
unclear	O
.	O

Furthermore	O
,	O
increased	O
pathogenesis	O
was	O
associated	O
with	O
significantly	O
enhanced	O
accumulation	O
of	O
neutrophils	O
,	O
tumor	O
necrosis	O
factor	O
alpha	O
,	O
interleukin	O
-	O
6	O
,	O
chemokine	O
(	O
C	O
-	O
C	O
motif	O
)	O
ligand	B-CHED
2	O
,	O
and	O
IFN	O
-	O
gamma	O
within	O
the	O
CNS	B-CHED
.	O

ABSTRACT	O
:	O
One	O
of	O
the	O
most	O
striking	O
and	O
dramatic	O
genomic	O
changes	O
observed	O
in	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
isolated	O
from	O
humans	O
soon	O
after	O
its	O
zoonotic	O
transmission	O
from	O
palm	O
civets	O
was	O
the	O
acquisition	O
of	O
a	O
characteristic	O
29	O
-	O
nucleotide	B-CHED
deletion	O
.	O

Our	O
data	O
indicate	O
that	O
the	O
phosphorylated	O
form	O
of	O
the	O
IBV	O
N	O
protein	B-CHED
plays	O
a	O
role	O
in	O
virus	O
biology	O
.	O

ABSTRACT	O
:	O
The	O
3C	O
-	O
like	O
main	O
proteinase	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
,	O
SARS	O
-	O
CoV	O
M	O
(	O
pro	B-CHED
),	O
is	O
widely	O
considered	O
to	O
be	O
a	O
major	O
drug	O
target	O
for	O
the	O
development	O
of	O
anti	O
-	O
SARS	O
treatment	O
.	O

The	O
docking	O
results	O
suggest	O
two	O
major	O
modes	O
for	O
the	O
initial	O
binding	O
of	O
these	O
inhibitors	B-CHED
to	O
the	O
active	O
site	O
of	O
SARS	O
-	O
CoV	O
M	O
(	O
pro	B-CHED
).	O

Most	O
importantly	O
,	O
our	O
results	O
provide	O
the	O
structural	O
basis	O
for	O
rational	O
design	O
of	O
wide	O
-	O
spectrum	O
antiviral	B-CHED
drugs	I-CHED
targeting	O
the	O
chymotrypsin	O
-	O
like	O
cysteine	B-CHED
proteinases	O
from	O
coronaviruses	O
and	O
picornaviruses	O
.	O

Reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
on	O
the	O
partial	O
ORF3	O
gene	O
including	O
51	O
nucleotide	B-CHED
deletions	O
revealed	O
that	O
all	O
PEDVs	O
fell	O
into	O
two	O
types	O
,	O
wild	O
-	O
and	O
attenuated	O
-	O
type	O
PEDVs	O
.	O

Therefore	O
,	O
large	O
deletion	O
region	O
,	O
which	O
is	O
comprise	O
17	O
amino	B-CHED
acid	I-CHED
deletions	O
caused	O
by	O
51	O
nucleotide	B-CHED
deletions	O
and	O
is	O
seen	O
in	O
all	O
PED	O
live	O
vaccine	O
strains	O
,	O
may	O
be	O
important	O
site	O
for	O
PEDV	O
pathogenicity	O
,	O
and	O
we	O
can	O
use	O
it	O
for	O
differentiation	O
of	O
wild	O
-	O
and	O
attenuated	O
-	O
type	O
PEDVs	O
.	O

ABSTRACT	O
:	O
Macrophages	O
and	O
microglia	O
are	O
critical	O
in	O
the	O
acute	O
inflammatory	O
response	O
and	O
act	O
as	O
final	O
effector	B-CHED
cells	O
of	O
demyelination	O
during	O
chronic	O
infection	O
with	O
the	O
neutrotropic	O
MHV	O
-	O
JHM	O
strain	O
of	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
-	O
JHM	O
).	O

TITLE	O
:	O
Evaluation	O
of	O
the	O
protection	O
conferred	O
by	O
commercial	O
vaccines	O
and	O
attenuated	O
heterologous	O
isolates	O
in	O
China	O
against	O
the	O
CK	O
/	O
CH	O
/	O
LDL	B-CHED
/	O
97I	O
strain	O
of	O
infectious	O
bronchitis	O
coronavirus	O
.	O

ABSTRACT	O
:	O
The	O
peptides	B-CHED
derived	O
from	O
the	O
heptad	O
repeat	O
(	O
HRP	O
)	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SCoV	O
)	O
spike	O
protein	B-CHED
(	O
sHRPs	O
)	O
are	O
known	O
to	O
inhibit	O
SCoV	O
infection	O
,	O
yet	O
their	O
efficacies	O
are	O
fairly	O
low	O
.	O

Other	O
talks	O
covered	O
the	O
live	O
,	O
attenuated	O
intranasal	O
influenza	O
vaccine	O
,	O
monoclonals	O
for	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
mechanisms	O
of	O
antiviral	B-CHED
resistance	O
in	O
influenza	O
B	O
,	O
and	O
novel	O
inhibitors	B-CHED
for	O
influenza	O
,	O
RSV	O
and	O
rhinovirus	O
infections	O
.	O

Our	O
effort	O
is	O
to	O
draft	O
our	O
guidelines	O
of	O
combining	O
traditional	O
Chinese	O
medicine	B-CHED
and	O
western	O
medicine	B-CHED
as	O
a	O
supplement	O
to	O
SSC	O
guidelines	O
.	O

Three	O
potential	O
caveolin	O
-	O
1	O
-	O
binding	O
sites	O
were	O
reported	O
to	O
be	O
present	O
in	O
the	O
3a	O
protein	B-CHED
.	O

Laboratory	O
examinations	O
showed	O
increased	O
serum	O
protein	B-CHED
content	O
and	O
decreased	O
albumin	O
/	O
globulin	O
ratio	O
.	O

Blood	O
plasma	O
was	O
assayed	O
for	O
testosterone	B-CHED
concentration	O
.	O

Plasma	O
testosterone	B-CHED
concentrations	O
and	O
sperm	O
concentrations	O
among	O
treatment	O
groups	O
were	O
different	O
only	O
at	O
16	O
and	O
19	O
weeks	O
of	O
age	O
,	O
respectively	O
.	O

Inhibition	O
of	O
Bcl	O
-	O
2	O
-	O
related	O
anti	O
-	O
apoptotic	O
pathway	O
was	O
further	O
supported	O
by	O
the	O
diminution	O
of	O
S2	O
-	O
induced	O
apoptosis	O
in	O
Vero	O
E6	O
cells	O
over	O
-	O
expressing	O
Bcl	O
-	O
xL	O
.	O
In	O
addition	O
,	O
modulation	O
of	O
CCN	B-CHED
E2	O
and	O
CDKN	O
1A	O
implied	O
the	O
possible	O
control	O
of	O
cell	O
cycle	O
arrest	O
at	O
G1	O
/	O
S	O
phase	O
.	O

A	O
vector	O
containing	O
a	O
fused	O
5	O
'	O
UTR	O
and	O
enhanced	O
green	O
fluorescent	O
protein	B-CHED
(	O
eGFP	O
)	O
was	O
co	O
-	O
transfected	O
with	O
the	O
DNAzyme	O
into	O
E6	O
cells	O
and	O
the	O
cells	O
expressing	O
eGFP	O
were	O
visualized	O
with	O
fluorescence	O
microscopy	O
and	O
analyzed	O
by	O
fluorescence	O
-	O
activated	O
cell	O
sorting	O
(	O
FACS	O
).	O

Cells	O
exposed	O
to	O
hypoxia	O
generate	O
reactive	B-CHED
oxygen	I-CHED
species	I-CHED
which	O
activate	O
PKC	O
zeta	O
which	O
in	O
turn	O
phosphorylates	O
the	O
Na	O
,	O
K	O
-	O
ATPase	O
at	O
the	O
Ser18	O
residue	O
in	O
the	O
N	O
-	O
terminus	O
of	O
the	O
alpha1	O
-	O
subunit	O
leading	O
the	O
ubiquitination	O
of	O
any	O
of	O
the	O
four	O
lysines	O
(	O
K16	O
,	O
K17	O
,	O
K19	O
,	O
K20	O
)	O
adjacent	O
to	O
the	O
Ser18	O
residue	O
.	O

Other	O
pathologic	O
changes	O
,	O
including	O
vasculitis	O
,	O
degeneration	O
,	O
and	O
necrosis	O
,	O
were	O
found	O
in	O
the	O
extrapulmonary	O
organs	O
of	O
transgenic	O
mice	O
,	O
and	O
viral	O
antigen	B-CHED
was	O
found	O
in	O
brain	O
.	O

These	O
mice	O
will	O
be	O
valuable	O
for	O
testing	O
potential	O
vaccine	O
and	O
antiviral	B-CHED
drug	I-CHED
therapies	O
and	O
for	O
furthering	O
our	O
understanding	O
of	O
SARS	O
pathogenesis	O
.	O

ABSTRACT	O
:	O
A	O
phase	O
I	O
trial	O
was	O
initiated	O
to	O
establish	O
the	O
dose	O
-	O
limiting	O
toxicities	O
(	O
DLTs	O
)	O
and	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
chronomodulated	O
5	B-CHED
-	I-CHED
fluorouracil	I-CHED
and	O
cisplatin	B-CHED
given	O
concurrently	O
with	O
preoperative	O
radiotherapy	O
in	O
patients	O
with	O
esophageal	O
cancer	O
.	O

Two	O
of	O
six	O
patients	O
treated	O
at	O
the	O
starting	O
dose	O
-	O
level	O
experienced	O
acute	O
DLTs	O
(	O
esophagitis	O
,	O
asthenia	O
)	O
which	O
required	O
de	O
-	O
escalation	O
of	O
5	B-CHED
-	I-CHED
fluorouracil	I-CHED
.	O

Without	O
definitively	O
ruling	O
out	O
any	O
possible	O
impact	O
of	O
chronomodulation	O
in	O
that	O
setting	O
,	O
our	O
data	O
reinforce	O
the	O
need	O
of	O
a	O
better	O
selection	O
of	O
patients	O
aimed	O
to	O
be	O
treated	O
by	O
CRT	B-CHED
plus	O
surgery	O
.	O

Subsequently	O
,	O
we	O
determined	O
the	O
crystal	O
structure	O
of	O
this	O
mutant	O
and	O
discovered	O
a	O
complete	O
crystallographic	O
dimer	O
dissociation	O
of	O
SARS	O
-	O
CoV	O
3CL	O
(	O
pro	B-CHED
).	O

The	O
complex	O
structures	O
reveal	O
two	O
major	O
inhibition	O
modes	O
:	O
Hg	O
(	O
2	O
+)-	O
PMA	B-CHED
is	O
coordinated	O
to	O
C	O
(	O
44	O
),	O
M	O
(	O
49	O
)	O
and	O
Y	O
(	O
54	O
)	O
with	O
a	O
square	O
planar	O
geometry	O
at	O
the	O
S3	O
pocket	O
,	O
whereas	O
each	O
Zn	O
(	O
2	O
+)	O
of	O
the	O
four	O
zinc	B-CHED
-	O
inhibitors	B-CHED
is	O
tetrahedrally	O
coordinated	O
to	O
the	O
H	O
(	O
41	O
)-	O
C	O
(	O
145	O
)	O
catalytic	O
dyad	O
.	O

For	O
anti	O
-	O
SARS	O
drug	O
design	O
,	O
this	O
Zn	O
(	O
2	O
+)-	O
centered	O
coordination	O
pattern	O
would	O
serve	O
as	O
a	O
starting	O
platform	O
for	O
inhibitor	B-CHED
optimization	O
.	O

Then	O
the	O
antigenic	O
property	O
of	O
Z	O
protein	B-CHED
to	O
SARS	O
-	O
CoV	O
spike	O
protein	B-CHED
was	O
analyzed	O
by	O
dot	O
-	O
blot	O
and	O
ELISA	O
assay	O
.	O

Dot	O
blot	O
analysis	O
showed	O
that	O
SARS	O
-	O
CoV	O
spike	O
protein	B-CHED
,	O
which	O
was	O
expressed	O
and	O
purified	O
from	O
mammal	O
cells	O
,	O
can	O
be	O
detected	O
by	O
anti	O
-	O
Z	O
sera	O
from	O
rabbit	O
.	O

With	O
respect	O
to	O
the	O
deduced	O
amino	B-CHED
acid	I-CHED
sequence	O
,	O
the	O
Korean	O
IBV	O
isolates	O
had	O
71	O
.	O
5	O
-	O
99	O
.	O
3	O
%	O
similarity	O
with	O
each	O
other	O
and	O
44	O
.	O
9	O
-	O
80	O
.	O
3	O
%	O
similarity	O
with	O
non	O
-	O
Korean	O
IBV	O
strains	O
.	O

This	O
study	O
shows	O
that	O
infection	O
and	O
spread	O
of	O
MHV	O
-	O
JHM	O
in	O
the	O
brain	O
are	O
dependent	O
upon	O
the	O
viral	O
spike	O
glycoprotein	B-CHED
.	O

ABSTRACT	O
:	O
Despite	O
recent	O
advances	O
in	O
intensive	O
care	O
medicine	B-CHED
,	O
acute	O
lung	O
injury	O
and	O
its	O
more	O
severe	O
form	O
,	O
acute	O
respiratory	O
distress	O
syndrome	O
pose	O
major	O
therapeutic	O
problems	O
.	O

For	O
the	O
scenario	O
of	O
cardiac	O
arrest	O
of	O
an	O
average	O
stranger	O
,	O
more	O
respondents	O
would	O
perform	O
CCPR	O
than	O
SCPR	O
in	O
the	O
pre	O
-	O
SARS	O
era	B-CHED
(	O
83	O
.	O
6	O
%	O
vs	O
.	O
61	O
.	O
3	O
%,	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
in	O
the	O
post	O
-	O
SARS	O
era	B-CHED
(	O
77	O
.	O
4	O
%	O
vs	O
.	O
28	O
.	O
9	O
%,	O
p	O
<	O
0	O
.	O
001	O
).	O

As	O
it	O
has	O
been	O
already	O
suggested	O
for	O
other	O
viral	O
fusion	O
proteins	B-CHED
such	O
as	O
HIV	O
gp41	O
,	O
the	O
region	O
of	O
the	O
SARS	O
-	O
CoV	O
protein	B-CHED
where	O
the	O
PTM	O
peptide	B-CHED
resides	O
could	O
be	O
involved	O
in	O
the	O
merging	O
of	O
the	O
viral	O
and	O
target	O
cell	O
membranes	O
working	O
synergistically	O
with	O
other	O
membrane	O
-	O
active	O
regions	O
of	O
the	O
SARS	O
-	O
CoV	O
S	O
glycoprotein	B-CHED
to	O
heighten	O
the	O
fusion	O
process	O
and	O
therefore	O
might	O
be	O
essential	O
for	O
the	O
assistance	O
and	O
enhancement	O
of	O
the	O
viral	O
and	O
cell	O
fusion	O
process	O
.	O

ABSTRACT	O
:	O
The	O
SARS	O
-	O
CoV	O
accessory	O
protein	B-CHED
7a	O
is	O
a	O
type	O
I	O
membrane	O
protein	B-CHED
with	O
an	O
extracellular	O
domain	O
of	O
81	O
amino	B-CHED
acid	I-CHED
residues	O
.	O

The	O
binding	O
is	O
increased	O
upon	O
artificial	O
cell	O
activation	O
with	O
phorbol	B-CHED
ester	I-CHED
.	O

The	O
greater	O
mechanical	O
stability	O
of	O
pseudoknots	O
compared	O
to	O
hairpins	O
,	O
and	O
their	O
kinetic	O
insensitivity	O
to	O
force	O
supports	O
the	O
hypothesis	O
that	O
-	O
1	O
frameshifting	O
depends	O
on	O
the	O
difficulty	O
of	O
unfolding	O
the	O
mRNA	B-CHED
.	O

Virus	O
titers	O
were	O
maximal	O
by	O
24	O
h	O
and	O
peaked	O
at	O
approximately	O
10	O
(	O
5	O
)	O
pfu	B-CHED
/	O
mL	O
.	O
Two	O
cell	O
types	O
within	O
the	O
cultures	O
were	O
infected	O
.	O

Before	O
hospitalization	O
,	O
her	O
HbA	O
(	O
1c	O
)	O
level	O
was	O
8	O
.	O
1	O
%	O
on	O
approximately	O
100	O
U	O
/	O
day	O
of	O
insulin	B-CHED
.	O

When	O
the	O
patient	O
'	O
s	O
plasma	O
glucose	B-CHED
level	O
was	O
22	O
.	O
5	O
mmol	O
/	O
l	O
,	O
her	O
plasma	O
C	O
-	O
peptide	B-CHED
level	O
was	O
0	O
.	O
9	O
nmol	O
/	O
l	O
and	O
her	O
serum	O
insulin	B-CHED
level	O
was	O
294	O
pmol	O
/	O
l	O
.	O

Anti	O
-	O
insulin	B-CHED
and	O
anti	O
-	O
islet	O
-	O
cell	O
antibodies	O
were	O
not	O
detected	O
,	O
but	O
anti	O
-	O
insulin	B-CHED
-	O
receptor	O
antibodies	O
were	O
found	O
.	O

Plasmapheresis	O
was	O
initiated	O
,	O
inducing	O
a	O
striking	O
acute	O
decline	O
in	O
insulin	B-CHED
needs	O
.	O

ABSTRACT	O
:	O
This	O
study	O
was	O
conducted	O
to	O
evaluate	O
the	O
effects	O
of	O
4	O
Chinese	O
herbal	O
polysaccharides	B-CHED
on	O
the	O
production	O
of	O
serum	O
antibodies	O
and	O
the	O
proliferation	O
of	O
peripheral	O
T	O
lymphocytes	O
,	O
including	O
subpopulations	O
in	O
vaccinated	O
chickens	O
.	O

At	O
the	O
same	O
time	O
as	O
the	O
first	O
vaccination	O
,	O
the	O
chickens	O
in	O
groups	O
1	O
to	O
8	O
were	O
intramuscularly	O
injected	O
with	O
4	O
polysaccharides	B-CHED
at	O
high	O
and	O
low	O
dosages	O
,	O
respectively	O
,	O
once	O
a	O
day	O
for	O
3	O
successive	O
days	O
starting	O
on	O
the	O
day	O
of	O
the	O
first	O
vaccination	O
.	O

Collectively	O
,	O
these	O
findings	O
indicate	O
that	O
the	O
4	O
polysaccharides	B-CHED
possess	O
significant	O
immune	O
-	O
enhancing	O
properties	O
in	O
chickens	O
.	O

The	O
CLEIA	O
showed	O
no	O
cross	O
-	O
reactivities	O
to	O
recombinant	O
N	O
proteins	B-CHED
of	O
common	O
human	O
CoV	O
(	O
229E	O
,	O
OC43	O
,	O
and	O
NL63	O
)	O
or	O
lysates	O
of	O
cells	O
infected	O
with	O
229E	O
and	O
OC43	O
.	O

RESULTS	O
:	O
Cimicifuga	O
rhizoma	O
,	O
Meliae	O
cortex	O
,	O
Coptidis	O
rhizoma	O
,	O
Phellodendron	O
cortex	O
and	O
Sophora	O
subprostrata	O
radix	O
decreased	O
the	O
MHV	O
production	O
and	O
the	O
intracellular	O
viral	O
RNA	O
and	O
protein	B-CHED
expression	O
with	O
EC50	O
values	O
ranging	O
from	O
2	O
.	O
0	O
to	O
27	O
.	O
5	O
microg	O
/	O
ml	O
.	O

Conversely	O
,	O
the	O
prolonged	O
administration	O
of	O
beta	B-CHED
-	I-CHED
adrenergic	I-CHED
antagonists	I-CHED
during	O
the	O
recovery	O
phase	O
after	O
cardiac	O
surgery	O
resulted	O
in	O
a	O
lower	O
number	O
of	O
traumatic	O
memories	O
and	O
a	O
lower	O
incidence	O
of	O
stress	O
symptoms	O
at	O
6	O
months	O
after	O
surgery	O
.	O

After	O
intratracheal	O
(	O
i	O
.	O
t	O
.)	O
inoculation	O
,	O
virus	O
antigen	B-CHED
-	O
positive	O
alveolar	O
cells	O
and	O
macrophages	O
were	O
found	O
in	O
lung	O
and	O
infectious	O
virus	O
was	O
detected	O
in	O
lymphoid	O
and	O
intestinal	O
tissues	O
.	O

She	O
eventually	O
responded	O
to	O
high	O
-	O
dose	O
methylprednisolone	B-CHED
.	O

TITLE	O
:	O
SARS	O
coronavirus	O
accessory	O
proteins	B-CHED
.	O

We	O
conclude	O
by	O
providing	O
some	O
questions	O
for	O
future	O
studies	O
that	O
will	O
greatly	O
advance	O
our	O
knowledge	O
about	O
the	O
biological	O
significance	O
and	O
contributions	O
of	O
the	O
accessory	O
proteins	B-CHED
in	O
the	O
development	O
of	O
SARS	O
in	O
humans	O
.	O

Substitutions	O
in	O
the	O
active	O
site	O
residues	O
serine	B-CHED
293	O
and	O
proline	O
343	O
allowed	O
Nsp15	O
to	O
cleave	O
at	O
cytidylate	B-CHED
,	O
whereas	O
mutation	O
of	O
leucine	B-CHED
345	O
rendered	O
Nsp15	O
able	O
to	O
cleave	O
at	O
purines	B-CHED
as	O
well	O
as	O
pyrimidines	B-CHED
.	O

The	O
induction	O
of	O
SARS	O
PUPs	O
genes	O
expression	O
in	O
different	O
temperatures	O
,	O
induction	O
times	O
,	O
IPTG	B-CHED
concentrations	O
and	O
A	O
values	O
of	O
E	O
.	O
coli	O
cells	O
were	O
performed	O
.	O

Oral	O
and	O
intranasal	O
inoculations	O
of	O
recombinant	O
L	O
.	O
casei	O
into	O
pregnant	O
sow	O
and	O
mice	O
resulted	O
in	O
high	O
levels	O
of	O
serum	O
immunoglobuline	O
G	O
(	O
IgG	O
)	O
and	O
mucosal	O
IgA	O
,	O
as	O
demonstrated	O
by	O
rnELISA	O
(	O
recombinant	O
N	O
protein	B-CHED
ELISA	O
)	O
using	O
recombinant	O
N	O
protein	B-CHED
.	O

TITLE	O
:	O
Inhibition	O
of	O
human	O
coronavirus	O
229E	O
infection	O
in	O
human	O
epithelial	O
lung	O
cells	O
(	O
L132	O
)	O
by	O
chloroquine	B-CHED
:	O
involvement	O
of	O
p38	O
MAPK	O
and	O
ERK	O
.	O

Recommendations	O
specific	O
to	O
pediatric	O
severe	O
sepsis	O
include	O
:	O
greater	O
use	O
of	O
physical	O
examination	O
therapeutic	O
end	O
points	O
(	O
2C	O
);	O
dopamine	B-CHED
as	O
the	O
first	O
drug	O
of	O
choice	O
for	O
hypotension	O
(	O
2C	O
);	O
steroids	B-CHED
only	O
in	O
children	O
with	O
suspected	O
or	O
proven	O
adrenal	O
insufficiency	O
(	O
2C	O
);	O
a	O
recommendation	O
against	O
the	O
use	O
of	O
recombinant	O
activated	O
protein	B-CHED
C	O
in	O
children	O
(	O
1B	O
).	O

It	O
was	O
suggested	O
that	O
AHFC	O
can	O
balance	B-CHED
the	O
immune	O
state	O
of	O
mouse	O
model	O
of	O
acute	O
hepatic	O
failure	O
infected	O
with	O
MHV	O
-	O
3	O
virus	O
mainly	O
through	O
regulating	O
the	O
expression	O
of	O
immune	O
related	O
genes	O
,	O
decrease	O
the	O
immune	O
damage	O
and	O
inhibit	O
liver	O
cell	O
apoptosis	O
of	O
mouse	O
acute	O
hepatic	O
failure	O
model	O
obviously	O
so	O
as	O
to	O
increase	O
the	O
survival	O
rate	O
of	O
mouse	O
models	O
of	O
acute	O
hepatic	O
failure	O
.	O

TITLE	O
:	O
Angiotensin	B-CHED
-	O
converting	O
enzyme	O
insertion	O
/	O
deletion	O
polymorphism	O
is	O
not	O
associated	O
with	O
susceptibility	O
and	O
outcome	O
in	O
sepsis	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

ABSTRACT	O
:	O
The	O
insertion	O
/	O
deletion	O
(	O
I	O
/	O
D	O
)	O
of	O
a	O
289	O
base	O
pair	O
Alu	O
repeat	O
sequence	O
polymorphism	O
in	O
the	O
angiotensin	B-CHED
-	O
converting	O
enzyme	O
gene	O
(	O
ACE	O
)	O
has	O
been	O
shown	O
to	O
predict	O
susceptibility	O
and	O
outcome	O
in	O
the	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

ABSTRACT	O
:	O
The	O
administration	O
of	O
hyper	O
immune	O
sera	O
to	O
prevent	O
or	O
treat	O
life	O
-	O
threatening	O
infections	O
is	O
a	O
remarkable	O
milestone	O
in	O
medicine	B-CHED
and	O
biotechnology	O
that	O
has	O
been	O
achieved	O
more	O
than	O
a	O
century	O
ago	O
.	O

Antibodies	O
to	O
human	O
leukocyte	O
antigen	B-CHED
(	O
HLA	O
),	O
granulocytes	O
,	O
platelets	O
,	O
and	O
/	O
or	O
plasma	O
proteins	B-CHED
are	O
implicated	O
in	O
some	O
of	O
the	O
ANHTRs	O
.	O

FCV3	O
-	O
70	O
monoclonal	O
antibody	O
produced	O
immunolabelling	O
of	O
group	O
1	O
coronavirus	O
antigen	B-CHED
in	O
tissue	O
samples	O
from	O
eight	O
animals	O
,	O
the	O
antigen	B-CHED
being	O
present	O
in	O
the	O
cytoplasm	O
of	O
macrophages	O
in	O
the	O
different	O
types	O
of	O
granulomatous	O
lesions	O
.	O

SDS	B-CHED
-	O
PAGE	O
and	O
Western	O
blot	O
revealed	O
that	O
the	O
ORF10	O
and	O
X5	O
genes	O
have	O
been	O
expressed	O
in	O
the	O
two	O
hosts	O
.	O

We	O
have	O
previously	O
shown	O
that	O
ACE2	O
can	O
be	O
shed	O
from	O
the	O
cell	O
surface	O
in	O
response	O
to	O
phorbol	B-CHED
esters	B-CHED
by	O
a	O
process	O
involving	O
TNF	O
-	O
alpha	O
converting	O
enzyme	O
(	O
TACE	O
;	O
ADAM17	O
).	O

TITLE	O
:	O
Spike	O
protein	B-CHED
region	O
(	O
aa	O
636789	O
)	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
is	O
essential	O
for	O
induction	O
of	O
neutralizing	O
antibodies	O
.	O

Prevention	O
includes	O
epidemiological	O
control	O
of	O
donor	B-CHED
populations	O
;	O
checks	O
on	O
each	O
donor	B-CHED
'	O
s	O
health	O
condition	O
;	O
analysis	O
of	O
each	O
donation	O
for	O
the	O
main	O
pathogens	O
using	O
serological	O
methods	O
;	O
additional	O
analysis	O
of	O
all	O
plasma	O
for	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
),	O
hepatitis	O
B	O
virus	O
(	O
HBV	O
),	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
),	O
hepatitis	O
A	O
virus	O
(	O
HAV	O
)	O
and	O
the	O
B19	O
virus	O
,	O
using	O
nucleic	B-CHED
acid	I-CHED
amplification	O
techniques	O
(	O
NAT	O
).	O

Isolated	O
RNAs	O
were	O
observed	O
to	O
efficiently	O
inhibit	O
double	B-CHED
-	I-CHED
stranded	I-CHED
DNA	I-CHED
unwinding	O
activity	O
of	O
the	O
helicase	O
by	O
up	O
to	O
approximately	O
85	O
%	O
with	O
an	O
IC	O
(	O
50	O
)	O
value	O
of	O
1	O
.	O
2nM	O
but	O
show	O
a	O
slight	O
effect	O
on	O
ATPase	O
activity	O
of	O
the	O
protein	B-CHED
in	O
the	O
presence	O
of	O
cofactor	B-CHED
,	O
poly	O
(	O
rU	O
).	O

Organochlorine	B-CHED
pesticides	I-CHED
are	O
toxic	O
to	O
the	O
central	O
nervous	O
system	O
and	O
sensitize	O
the	O
myocardium	O
to	O
catecholamines	B-CHED
.	O

Physicians	O
working	O
in	O
remote	O
and	O
rural	O
areas	O
need	O
to	O
be	O
educated	O
about	O
early	O
diagnosis	O
and	O
proper	O
management	O
using	O
supportive	O
care	O
and	O
antidotes	B-CHED
,	O
wherever	O
available	O
.	O

To	O
develop	O
and	O
apply	O
a	O
safe	O
neutralization	O
assay	O
for	O
SARS	O
-	O
CoV	O
,	O
lentiviral	O
SARS	O
-	O
CoV	O
S	O
pseudotypes	O
had	O
been	O
constructed	O
based	O
on	O
a	O
three	O
plasmid	O
system	O
,	O
which	O
contained	O
pVRC8304	O
(	O
harboring	O
codon	O
optimized	O
full	O
-	O
length	O
SARS	O
-	O
CoV	O
S	O
protein	B-CHED
),	O
pCMV	O
delta	O
8	O
.	O

Dual	O
tracer	B-CHED
gases	O
of	O
CO2	B-CHED
and	O
SF6	B-CHED
are	O
employed	O
simultaneously	O
to	O
quantify	O
the	O
amount	O
of	O
the	O
exhaust	O
air	B-CHED
coming	O
out	O
of	O
the	O
upper	O
part	O
of	O
the	O
window	O
of	O
a	O
floor	O
that	O
re	O
-	O
enters	O
the	O
lower	O
part	O
of	O
the	O
open	O
-	O
window	O
at	O
the	O
immediate	O
upper	O
floor	O
.	O

ABSTRACT	O
:	O
We	O
have	O
analyzed	O
the	O
intracellular	O
transport	O
of	O
the	O
spike	O
(	O
S	O
)	O
protein	B-CHED
of	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
),	O
an	O
avian	O
coronavirus	O
.	O

The	O
in	O
vitro	O
evolution	O
of	O
icSZ16	O
-	O
S	O
K479N	O
on	O
human	O
airway	O
epithelial	O
(	O
HAE	O
)	O
cells	O
produced	O
two	O
viruses	O
(	O
icSZ16	O
-	O
S	O
K479N	O
D8	O
and	O
D22	O
)	O
with	O
enhanced	O
growth	O
on	O
HAE	O
cells	O
and	O
on	O
delayed	O
brain	O
tumor	O
cells	O
expressing	O
the	O
SARS	O
-	O
CoV	O
receptor	O
,	O
human	O
angiotensin	B-CHED
I	O
converting	O
enzyme	O
2	O
(	O
hACE2	O
).	O

To	O
look	O
for	O
viruses	O
which	O
are	O
non	O
detectable	O
by	O
antigen	B-CHED
detection	O
assays	O
(	O
rhinovirus	O
,	O
coronavirus	O
,	O
bocavirus	O
,	O
polyomavirus	O
...)	O
or	O
in	O
severe	O
or	O
complicated	O
respiratory	O
lower	O
infections	O
,	O
the	O
use	O
of	O
molecular	O
tools	O
is	O
highly	O
indicated	O
.	O

To	O
date	O
,	O
12	O
structures	O
have	O
been	O
determined	O
by	O
X	O
-	O
ray	O
crystallography	O
or	O
NMR	O
from	O
the	O
28	O
proteins	B-CHED
encoded	O
by	O
SARS	O
-	O
CoV	O
.	O
One	O
key	O
protein	B-CHED
,	O
the	O
SARS	O
-	O
CoV	O
main	O
protease	O
(	O
M	O
(	O
pro	B-CHED
)),	O
has	O
been	O
the	O
focus	O
of	O
considerable	O
structure	O
-	O
based	O
drug	O
discovery	O
efforts	O
.	O

ABSTRACT	O
:	O
Mannan	B-CHED
-	O
binding	O
lectin	O
(	O
MBL	O
)	O
is	O
a	O
collectin	O
that	O
mediates	O
activation	O
of	O
the	O
complement	O
system	O
and	O
is	O
of	O
importance	O
for	O
host	O
defenses	O
.	O

In	O
addition	O
,	O
macrophage	O
infiltration	O
into	O
the	O
CNS	B-CHED
was	O
unaffected	O
in	O
MHV	O
-	O
infected	O
CCR1	O
-/-	O
mice	O
when	O
compared	O
to	O
CCR1	O
+/+	O
mice	O
.	O

ABSTRACT	O
:	O
Gemcitabine	B-CHED
is	O
a	O
new	O
important	O
drug	O
used	O
to	O
treat	O
solid	O
tumors	O
including	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
,	O
pancreatic	O
,	O
bladder	O
and	O
breast	O
cancers	O
.	O

The	O
N199	O
protein	B-CHED
proved	O
to	O
be	O
more	O
specific	O
in	O
swine	O
sera	O
screening	O
than	O
whole	O
viral	O
and	O
N	O
protein	B-CHED
(	O
P	O
<	O
0	O
.	O
001	O
).	O

We	O
report	O
a	O
case	O
of	O
ARDS	O
following	O
therapeutic	O
embolization	O
with	O
ethylene	B-CHED
vinyl	B-CHED
alcohol	O
copolymer	B-CHED
for	O
cerebral	O
AVM	O
under	O
general	O
anaesthesia	O
.	O

One	O
should	O
be	O
vigilant	O
and	O
anticipate	O
this	O
complication	O
following	O
therapeutic	O
embolization	O
with	O
ethylene	B-CHED
vinyl	B-CHED
alcohol	O
polymer	B-CHED
for	O
the	O
treatment	O
of	O
cerebral	O
AVM	O
.	O

Tricuspid	O
jet	O
velocity	O
showed	O
significant	O
positive	O
correlations	O
with	O
B	O
-	O
type	O
natriuretic	O
peptide	B-CHED
(	O
rho	O
=	O
0	O
.	O
54	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
and	O
cardiac	O
troponin	O
I	O
(	O
rho	O
=	O
0	O
.	O
42	O
,	O
P	O
<	O
0	O
.	O
01	O
).	O

ABSTRACT	O
:	O
3C	O
-	O
like	O
protease	O
(	O
3CL	O
pro	B-CHED
)	O
plays	O
pivotal	O
roles	O
in	O
the	O
life	O
cycle	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
and	O
only	O
the	O
dimeric	O
protease	O
is	O
proposed	O
as	O
the	O
functional	O
form	O
.	O

Guided	O
by	O
the	O
crystal	O
structure	O
and	O
molecular	O
dynamics	O
simulations	O
,	O
we	O
performed	O
systematic	O
mutation	O
analyses	O
to	O
identify	O
residues	O
critical	O
for	O
3CL	O
pro	B-CHED
dimerization	O
and	O
activity	O
in	O
this	O
study	O
.	O

ABSTRACT	O
:	O
Coronavirus	O
envelope	O
(	O
E	O
)	O
proteins	B-CHED
play	O
an	O
important	O
,	O
not	O
fully	O
understood	O
role	O
(	O
s	O
)	O
in	O
the	O
virus	O
life	O
cycle	O
.	O

To	O
understand	O
the	O
role	O
of	O
the	O
conserved	O
residues	O
and	O
the	O
necessity	O
of	O
palmitoylation	O
,	O
three	O
cysteines	O
at	O
positions	O
40	O
,	O
44	O
,	O
and	O
47	O
were	O
changed	O
singly	O
and	O
in	O
various	O
combinations	O
to	O
alanine	B-CHED
.	O

Mutant	O
E	O
proteins	B-CHED
localized	O
properly	O
in	O
infected	O
cells	O
.	O

TITLE	O
:	O
Determination	O
and	O
application	O
of	O
immunodominant	O
regions	O
of	O
SARS	O
coronavirus	O
spike	O
and	O
nucleocapsid	O
proteins	B-CHED
recognized	O
by	O
sera	O
from	O
different	O
animal	O
species	O
.	O

ABSTRACT	O
:	O
Both	O
,	O
the	O
influenza	O
C	O
(	O
INF	O
-	O
C	O
)	O
virus	O
haemagglutinin	O
esterase	O
fusion	O
and	O
bovine	O
coronavirus	O
(	O
BCoV	O
)	O
haemagglutinin	O
esterase	O
surface	O
glycoproteins	B-CHED
exhibit	O
a	O
lectin	O
binding	O
capability	O
and	O
a	O
receptor	O
-	O
destroying	O
9	O
-	O
O	O
-	O
acetyl	B-CHED
esterase	O
activity	O
that	O
recognise	O
9	B-CHED
-	I-CHED
O	I-CHED
-	I-CHED
acetyl	I-CHED
-	I-CHED
N	I-CHED
-	I-CHED
acetylneuraminic	I-CHED
acid	I-CHED
(	O
Neu5	O
,	O
9Ac	O
(	O
2	O
))-	O
containing	O
glycans	B-CHED
.	O

Two	O
weeks	O
previously	O
,	O
amoxapine	B-CHED
(	O
75	O
mg	O
/	O
day	O
)	O
had	O
been	O
administered	O
for	O
the	O
first	O
time	O
.	O

We	O
concluded	O
that	O
acute	O
respiratory	O
distress	O
may	O
be	O
associated	O
with	O
amoxapine	B-CHED
treatment	O
.	O

Treatment	O
included	O
glucocorticoids	B-CHED
,	O
antibiotics	B-CHED
,	O
and	O
respiratory	O
therapy	O
.	O

Six	O
workers	O
'	O
self	O
-	O
perceived	O
physical	O
demands	O
level	O
(	O
PDC	B-CHED
)	O
matched	O
with	O
the	O
physical	O
demands	O
level	O
identified	O
by	O
the	O
FCE	O
.	O

The	O
emergency	O
preparedness	O
training	O
programme	O
met	B-CHED
its	O
aims	O
and	O
objectives	O
satisfactorily	O
,	O
and	O
resulted	O
in	O
positive	O
shifts	O
in	O
knowledge	O
and	O
attitudinal	O
/	O
behavioural	O
intentions	O
for	O
public	O
health	O
staff	O
.	O

Using	O
a	O
panel	O
of	O
SARS	O
-	O
CoV	O
recombinants	O
bearing	O
the	O
S	O
glycoproteins	B-CHED
from	O
isolates	O
representing	O
the	O
zoonotic	O
and	O
human	O
early	O
,	O
middle	O
,	O
and	O
late	O
phases	O
of	O
the	O
epidemic	O
,	O
we	O
identified	O
23	O
monoclonal	O
antibodies	O
(	O
MAbs	O
)	O
with	O
neutralizing	O
activity	O
against	O
one	O
or	O
multiple	O
SARS	O
-	O
CoV	O
spike	O
variants	O
and	O
determined	O
the	O
presence	O
of	O
at	O
least	O
six	O
distinct	O
neutralizing	O
profiles	O
in	O
the	O
SARS	O
-	O
CoV	O
S	O
glycoprotein	B-CHED
.	O

We	O
also	O
rescued	O
a	O
two	O
-	O
segmented	O
virus	O
expressing	O
GFP	O
and	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
spike	O
S	O
protein	B-CHED
,	O
which	O
is	O
about	O
200	O
kDa	O
.	O

S	O
Delta19	O
proteins	B-CHED
with	O
other	O
double	O
alanine	B-CHED
substitutions	O
reduced	O
cell	O
-	O
cell	O
fusion	O
further	O
,	O
from	O
40	O
%	O
to	O
less	O
than	O
20	O
%	O
of	O
wild	O
-	O
type	O
levels	O
.	O

Microglia	O
isolated	O
from	O
naïve	O
mice	O
expressed	O
high	O
levels	O
of	O
these	O
mRNAs	O
,	O
whereas	O
they	O
were	O
near	O
detection	O
limits	O
in	O
oligodendroglia	O
;	O
nevertheless	O
,	O
Class	O
I	O
protein	B-CHED
was	O
undetectable	O
on	O
both	O
cell	O
types	O
.	O

Although	O
this	O
good	O
sensitivity	O
cannot	O
be	O
reached	O
with	O
the	O
metal	B-CHED
label	B-CHED
(	O
0	O
.	O
5	O
nM	O
),	O
the	O
use	O
of	O
this	O
label	B-CHED
allows	O
a	O
considerable	O
decrease	O
of	O
the	O
analysis	O
time	O
.	O

TITLE	O
:	O
Molecular	O
characterization	O
and	O
phylogenetic	O
analysis	O
of	O
membrane	O
protein	B-CHED
genes	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
isolates	O
in	O
China	O
.	O

The	O
M	O
protein	B-CHED
genes	O
of	O
six	O
Chinese	O
PEDV	O
isolates	O
consisted	O
of	O
692	O
nucleotides	B-CHED
containing	O
a	O
single	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
of	O
681	O
nucleotides	B-CHED
,	O
which	O
encoded	O
a	O
226aa	O
-	O
long	O
peptide	B-CHED
.	O

The	O
M	O
protein	B-CHED
of	O
six	O
isolates	O
had	O
three	O
main	O
transmembrane	O
domains	O
(	O
aa20	O
-	O
38	O
,	O
aa43	O
-	O
65	O
,	O
aa75	O
-	O
97	O
).	O

The	O
six	O
PEDV	O
isolates	O
showed	O
nucleotide	B-CHED
sequence	O
homology	O
between	O
98	O
.	O
8	O
and	O
100	O
%	O
and	O
deduced	O
amino	B-CHED
acid	I-CHED
sequence	O
homology	O
between	O
98	O
.	O
2	O
and	O
100	O
%	O
with	O
each	O
other	O
.	O

On	O
the	O
basis	O
of	O
the	O
phylogenetic	O
relationship	O
of	O
M	O
protein	B-CHED
genes	O
,	O
six	O
Chinese	O
PEDV	O
isolates	O
composed	O
of	O
a	O
separate	O
cluster	O
including	O
one	O
Chinese	O
strain	O
JS	O
-	O
2004	O
-	O
02	O
,	O
however	O
,	O
not	O
including	O
the	O
Chinese	O
strain	O
LJB	O
/	O
03	O
.	O

Ions	B-CHED
were	O
generated	O
by	O
laser	O
shots	O
and	O
flied	O
in	O
a	O
time	O
of	O
flight	O
mode	O
to	O
the	O
ion	O
detector	O
according	O
to	O
their	O
mass	O
over	O
charge	O
(	O
m	O
/	O
z	O
)	O
ratio	O
.	O

Treatment	O
of	O
cells	O
with	O
either	O
SARS	O
-	O
CoV	O
spike	O
protein	B-CHED
or	O
spike	O
-	O
bearing	O
pseudoviruses	O
resulted	O
in	O
the	O
translocation	O
of	O
angiotensin	B-CHED
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
),	O
the	O
functional	O
receptor	O
of	O
SARS	O
-	O
CoV	O
,	O
from	O
the	O
cell	O
surface	O
to	O
endosomes	O
.	O

Positive	O
antibody	O
titers	O
were	O
found	O
only	O
against	O
CDV	B-CHED
,	O
CPV	O
,	O
and	O
T	O
.	O
gondii	O
.	O

TITLE	O
:	O
Coronavirus	O
spike	O
protein	B-CHED
inhibits	O
host	O
cell	O
translation	O
by	O
interaction	O
with	O
eIF3f	O
.	O

It	O
is	O
,	O
in	O
fact	O
,	O
the	O
outcome	O
of	O
an	O
imbalance	O
-	O
decompensation	O
of	O
the	O
organism	O
'	O
s	O
defence	O
mechanisms	O
,	O
in	O
which	O
the	O
oxygen	B-CHED
supply	O
to	O
the	O
mitochondria	O
is	O
hampered	O
by	O
a	O
macro	O
and	O
/	O
or	O
microcirculation	O
failure	O
.	O

TITLE	O
:	O
The	O
SARS	O
-	O
Coronavirus	O
PLnc	O
domain	O
of	O
nsp3	O
as	O
a	O
replication	O
/	O
transcription	O
scaffolding	O
protein	B-CHED
.	O

The	O
viral	O
components	O
of	O
the	O
complex	O
are	O
encoded	O
by	O
the	O
giant	O
replicase	O
gene	O
,	O
which	O
is	O
expressed	O
in	O
the	O
form	O
of	O
two	O
polyproteins	O
(	O
pp1a	O
and	O
pp1ab	O
)	O
that	O
are	O
processed	O
into	O
16	O
cleavage	O
products	O
(	O
nonstructural	O
proteins	B-CHED
1	O
-	O
16	O
).	O

The	O
column	O
matrix	O
has	O
the	O
ability	O
to	O
bind	O
to	O
proteins	B-CHED
such	O
as	O
HRPO	O
with	O
vicinal	O
diols	B-CHED
.	O

The	O
patient	O
was	O
managed	O
with	O
supplemental	O
potassium	B-CHED
,	O
octreotide	B-CHED
,	O
and	O
oxygen	B-CHED
therapy	O
.	O

These	O
phenomena	O
were	O
correlated	O
with	O
increased	O
oxidant	B-CHED
production	O
.	O

Accordingly	O
,	O
ectopic	O
expression	O
of	O
G6PD	O
in	O
G6PD	O
-	O
deficient	O
cells	O
or	O
addition	O
of	O
antioxidant	B-CHED
(	O
such	O
as	O
alpha	B-CHED
-	I-CHED
lipoic	I-CHED
acid	I-CHED
)	O
to	O
G6PD	O
-	O
knockdown	O
cells	O
attenuated	O
the	O
increased	O
susceptibility	O
to	O
HCoV	O
229E	O
infection	O
.	O

The	O
costs	O
of	O
death	O
and	O
morbidity	O
in	O
lost	B-CHED
wages	O
,	O
lost	B-CHED
taxes	O
,	O
and	O
rehabilitative	O
costs	O
,	O
let	O
alone	O
the	O
emotional	O
costs	O
,	O
are	O
enormous	O
.	O

Use	O
of	O
inhaled	O
nitric	B-CHED
oxide	I-CHED
in	O
patients	O
with	O
severe	O
traumatic	O
brain	O
injury	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
will	O
show	O
a	O
benefit	O
through	O
improved	O
physiological	O
parameters	O
,	O
a	O
decrease	O
in	O
biochemical	O
markers	O
of	O
inflammation	O
and	O
brain	O
injury	O
,	O
thus	O
leading	O
to	O
better	O
outcomes	O
.	O

Inhaled	O
nitric	B-CHED
oxide	I-CHED
therapy	O
in	O
traumatic	O
brain	O
injury	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
could	O
result	O
in	O
increased	O
numbers	O
of	O
lives	O
saved	O
,	O
decreased	O
patient	O
morbidity	O
,	O
decreased	O
hospital	O
costs	O
,	O
decreased	O
insurance	O
carrier	O
and	O
government	O
rehabilitation	O
costs	O
,	O
increased	O
tax	O
revenue	O
secondary	O
to	O
occupational	O
rehabilitation	O
,	O
and	O
families	O
could	O
still	O
have	O
their	O
loved	O
ones	O
among	O
them	O
.	O

Cerebral	O
haemorrhage	O
may	O
result	O
from	O
the	O
use	O
of	O
amphetamines	B-CHED
or	O
cocaine	B-CHED
.	O

MDMA	B-CHED
is	O
a	O
major	O
cause	O
of	O
acute	O
severe	O
hyponatraemia	O
and	O
also	O
has	O
been	O
linked	O
with	O
hepatic	O
syndromes	O
.	O

TITLE	O
:	O
[	O
Evaluation	O
of	O
the	O
efficacy	O
and	O
safety	O
of	O
corticosteroid	B-CHED
in	O
the	O
treatment	O
of	O
severe	O
SARS	O
in	O
Guangdong	O
province	O
with	O
multi	O
-	O
factor	O
regression	O
analysis	O
].	O

RESULTS	O
:	O
(	O
1	O
)	O
Small	O
dose	O
of	O
steroid	B-CHED
seemed	O
to	O
have	O
protective	O
effect	O
,	O
but	O
it	O
did	O
not	O
reach	O
significant	O
level	O
.	O

The	O
binding	O
of	O
S1188HA	O
was	O
not	O
affected	O
by	O
depleting	O
plasma	O
membrane	O
cholesterol	B-CHED
.	O

Taken	O
together	O
,	O
our	O
results	O
support	O
that	O
lipid	B-CHED
rafts	O
serve	O
as	O
an	O
entry	O
port	O
for	O
SARS	O
-	O
CoV	O
.	O

Two	O
patients	O
orally	O
ingested	O
large	O
amounts	O
of	O
the	O
organophosphorous	O
agent	O
oxydemeton	B-CHED
-	I-CHED
methyl	I-CHED
in	O
suicide	O
attempts	O
,	O
resulting	O
in	O
the	O
hypercholinergic	O
syndrome	O
in	O
both	O
.	O

We	O
treated	O
porcine	O
respiratory	O
coronavirus	O
(	O
PRCV	O
)-	O
infected	O
conventional	O
pigs	O
with	O
the	O
corticosteroid	B-CHED
dexamethasone	B-CHED
(	O
DEX	O
)	O
as	O
a	O
model	O
for	O
SARS	O
.	O

Our	O
findings	O
suggest	O
that	O
future	O
glucocorticoid	B-CHED
treatment	O
of	O
SARS	O
patients	O
should	O
be	O
reconsidered	O
in	O
the	O
context	O
of	O
potential	O
local	O
immunosuppression	O
of	O
immune	O
responses	O
in	O
lung	O
and	O
systemic	O
Th1	O
cytokine	O
-	O
biased	O
suppression	O
.	O

Of	O
the	O
15	O
patients	O
that	O
presented	O
ARI	B-CHED
,	O
10	O
(	O
67	O
%)	O
were	O
intubated	O
in	O
the	O
first	O
3h	O
following	O
extubation	O
.	O

Among	O
children	O
that	O
did	O
not	O
develop	O
ARI	B-CHED
,	O
the	O
predominant	O
motor	O
pattern	O
was	O
:	O
28	O
with	O
quadriplegia	O
,	O
38	O
diplegia	O
,	O
10	O
hemiplegia	O
,	O
12	O
with	O
involuntary	O
movement	O
(	O
choeroathethosis	O
)	O
and	O
six	O
without	O
motor	O
involvement	O
.	O

TITLE	O
:	O
Aryl	O
methylene	B-CHED
ketones	B-CHED
and	O
fluorinated	O
methylene	B-CHED
ketones	B-CHED
as	O
reversible	O
inhibitors	B-CHED
for	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
3C	O
-	O
like	O
proteinase	O
.	O

Compound	O
11d	O
,	O
2	O
-(	O
5	O
-	O
bromopyridin	O
-	O
3	O
-	O
yl	O
)-	O
1	O
-(	O
5	O
-(	O
4	O
-	O
chlorophenyl	O
)	O
furan	B-CHED
-	I-CHED
2	I-CHED
-	I-CHED
yl	I-CHED
)	O
ethanone	O
and	O
its	O
alpha	O
-	O
monofluorinated	O
analogue	O
12d	O
,	O
gave	O
the	O
best	O
reversible	O
inhibition	O
with	O
IC	O
(	O
50	O
)	O
values	O
of	O
13	O
mircoM	O
and	O
28	O
microM	O
,	O
respectively	O
.	O

ABSTRACT	O
:	O
The	O
main	O
protease	O
(	O
M	O
(	O
pro	B-CHED
))	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
plays	O
an	O
essential	O
role	O
in	O
the	O
extensive	O
proteolytic	O
processing	O
of	O
the	O
viral	O
polyproteins	O
(	O
pp1a	O
and	O
pp1ab	O
),	O
and	O
it	O
is	O
an	O
important	O
target	O
for	O
anti	O
-	O
SARS	O
drug	O
development	O
.	O

Meanwhile	O
,	O
the	O
N	O
-	O
finger	O
deletion	O
mutant	O
of	O
SARS	O
-	O
CoV	O
M	O
(	O
pro	B-CHED
)	O
also	O
exists	O
as	O
both	O
a	O
stable	O
monomer	O
and	O
a	O
stable	O
dimer	O
,	O
and	O
the	O
dimer	O
is	O
formed	O
through	O
the	O
same	O
C	O
-	O
terminal	O
-	O
domain	O
interaction	O
as	O
that	O
in	O
the	O
M	O
(	O
pro	B-CHED
)-	O
C	O
dimer	O
.	O

Six	O
days	O
before	O
the	O
operation	O
,	O
he	O
had	O
a	O
high	O
-	O
grade	O
fever	O
,	O
and	O
elevated	O
leukocyte	O
count	O
and	O
C	O
-	O
reactive	O
protein	B-CHED
concentration	O
,	O
but	O
this	O
was	O
resolved	O
by	O
an	O
intravenous	O
antibiotic	B-CHED
.	O

ABSTRACT	O
:	O
In	O
the	O
past	O
few	O
years	O
,	O
the	O
classical	O
concept	O
of	O
the	O
renin	O
-	O
angiotensin	B-CHED
system	O
(	O
RAS	B-CHED
)	O
has	O
experienced	O
substantial	O
conceptual	O
changes	O
.	O

With	O
regard	O
to	O
Ang	O
(	O
1	O
-	O
7	O
),	O
the	O
identification	O
of	O
ACE2	O
and	O
of	O
Mas	B-CHED
as	O
a	O
receptor	O
implicated	O
in	O
its	O
actions	O
contributed	O
to	O
decisively	O
establish	O
this	O
heptapeptide	O
as	O
a	O
biologically	O
active	O
member	O
of	O
the	O
RAS	B-CHED
cascade	O
.	O

TITLE	O
:	O
Amiodarone	B-CHED
alters	O
late	O
endosomes	O
and	O
inhibits	O
SARS	O
coronavirus	O
infection	O
at	O
a	O
post	O
-	O
endosomal	O
level	O
.	O

We	O
found	O
that	O
(	O
1	O
)	O
amiodarone	B-CHED
associates	O
with	O
different	O
cell	O
membranes	O
and	O
accumulates	O
in	O
acidic	O
organelles	O
;	O
(	O
2	O
)	O
the	O
diethylamino	O
-	O
beta	O
-	O
ethoxy	B-CHED
group	I-CHED
is	O
an	O
important	O
determinant	O
of	O
uptake	O
;	O
(	O
3	O
)	O
vacuoles	O
forming	O
upon	O
exposure	O
to	O
amiodarone	B-CHED
are	O
enlarged	O
late	O
endosomes	O
;	O
(	O
4	O
)	O
amiodarone	B-CHED
inhibits	O
the	O
spreading	O
in	O
vitro	O
of	O
SARS	O
coronavirus	O
;	O
and	O
(	O
5	O
)	O
trypsin	O
cleavage	O
of	O
the	O
viral	O
spike	O
protein	B-CHED
before	O
infection	O
,	O
which	O
permits	O
virus	O
entry	O
through	O
the	O
plasma	O
membrane	O
,	O
does	O
not	O
impair	O
amiodarone	B-CHED
antiviral	B-CHED
activity	O
.	O

We	O
conclude	O
that	O
amiodarone	B-CHED
alters	O
late	O
compartments	O
of	O
the	O
endocytic	O
pathway	O
and	O
inhibits	O
SARS	O
coronavirus	O
infection	O
by	O
acting	O
after	O
the	O
transit	O
of	O
the	O
virus	O
through	O
endosomes	O
.	O

ABSTRACT	O
:	O
Acute	O
lung	O
injury	O
results	O
in	O
a	O
severe	O
inflammatory	O
response	O
,	O
which	O
leads	O
to	O
priming	O
and	O
activation	O
of	O
leucocytes	O
,	O
release	O
of	O
reactive	O
oxygen	B-CHED
and	O
reactive	B-CHED
nitrogen	I-CHED
species	I-CHED
,	O
destruction	O
of	O
pulmonary	O
endothelium	O
,	O
extravasation	O
of	O
protein	B-CHED
-	O
rich	O
fluid	O
into	O
the	O
interstitium	O
and	O
formation	O
of	O
oedema	O
.	O

ABSTRACT	O
:	O
A	O
series	O
of	O
trifluoromethyl	B-CHED
ketones	B-CHED
as	O
SARS	O
-	O
CoV	O
3CL	O
protease	B-CHED
inhibitors	I-CHED
was	O
developed	O
.	O

There	O
were	O
no	O
statistical	O
differences	O
in	O
48	O
-	O
hour	O
Ranson	O
scores	O
,	O
CT	O
scores	O
,	O
24	O
-	O
hour	O
acute	O
physiology	O
and	O
chronic	O
heath	O
evaluation	O
II	O
scores	O
(	O
APACHE	O
II	O
scores	O
),	O
and	O
the	O
levels	O
of	O
24	O
-	O
hour	O
serum	O
triglyceride	B-CHED
(	O
TG	O
)	O
and	O
serum	O
glucose	B-CHED
in	O
the	O
two	O
groups	O
(	O
P	O
>	O
0	O
.	O
05	O
).	O

ABSTRACT	O
:	O
Infection	O
of	O
the	O
monocyte	O
/	O
macrophage	O
lineage	O
with	O
feline	O
infectious	O
peritonitis	O
virus	O
(	O
FIPV	O
)	O
is	O
enhanced	O
in	O
the	O
presence	O
of	O
anti	O
-	O
FIPV	O
antibodies	O
(	O
antibody	O
-	O
dependent	O
enhancement	O
or	O
ADE	B-CHED
).	O

Virus	O
receptor	O
-	O
blocking	O
experiments	O
using	O
anti	O
-	O
fAPN	O
antibodies	O
at	O
4	O
or	O
37	O
degrees	O
C	O
and	O
experiments	O
using	O
fAPN	O
-	O
negative	O
U937	O
cells	O
revealed	O
that	O
fAPN	O
is	O
not	O
involved	O
in	O
ADE	B-CHED
of	O
FIPV	O
infection	O
.	O

TITLE	O
:	O
Phytochemical	O
analysis	O
and	O
in	O
vitro	O
antiviral	B-CHED
activities	O
of	O
the	O
essential	O
oils	O
of	O
seven	O
Lebanon	O
species	O
.	O

Moreover	O
,	O
we	O
measured	O
cytokine	O
mRNA	B-CHED
expression	O
in	O
lung	O
and	O
spleen	O
samples	O
.	O

#	O
21	O
is	O
a	O
long	O
-	O
term	O
producer	O
of	O
the	O
infectious	O
SARS	O
-	O
coronavirus	O
,	O
although	O
the	O
incorporation	O
rate	O
of	O
spike	O
(	O
S	O
)	O
protein	B-CHED
into	O
virions	O
is	O
significantly	O
lower	O
.	O

We	O
demonstrated	O
,	O
using	O
a	O
viral	O
-	O
like	O
particle	O
formation	O
system	O
,	O
that	O
the	O
S	O
mutations	O
were	O
involved	O
in	O
the	O
lower	O
incorporation	O
of	O
the	O
S	O
protein	B-CHED
into	O
virions	O
,	O
although	O
the	O
M	O
mutation	O
that	O
disrupts	O
the	O
glycosylation	O
was	O
not	O
present	O
in	O
this	O
phenotype	O
.	O

TITLE	O
:	O
Formic	B-CHED
acid	I-CHED
:	O
a	O
rare	O
but	O
deadly	O
source	O
of	O
carbon	B-CHED
monoxide	I-CHED
poisoning	O
.	O

ABSTRACT	O
:	O
Formic	B-CHED
acid	I-CHED
decomposes	O
upon	O
contact	O
with	O
strong	O
acids	O
producing	O
carbon	B-CHED
monoxide	I-CHED
.	O

A	O
26	O
-	O
year	O
-	O
old	O
man	B-CHED
committed	O
suicide	O
by	O
mixing	O
2	O
.	O
5	O
L	O
of	O
formic	B-CHED
acid	I-CHED
and	O
2	O
.	O
5	O
L	O
of	O
sulfuric	B-CHED
acid	I-CHED
in	O
three	O
beakers	O
and	O
staying	O
in	O
a	O
closed	O
room	O
.	O

Her	O
symptoms	O
improved	O
after	O
oxygen	B-CHED
therapy	O
.	O

One	O
of	O
these	O
domains	O
is	O
located	O
within	O
the	O
previously	O
described	O
SARS	O
-	O
unique	O
domain	O
,	O
and	O
there	O
is	O
a	O
nucleic	B-CHED
acid	I-CHED
chaperone	O
-	O
like	O
domain	O
located	O
immediately	O
downstream	O
of	O
the	O
papain	O
-	O
like	O
proteinase	O
domain	O
.	O

We	O
also	O
identified	O
a	O
novel	O
cysteine	B-CHED
-	O
coordinated	O
metal	B-CHED
ion	O
-	O
binding	O
domain	O
.	O

Overall	O
,	O
the	O
ensemble	O
of	O
data	O
surveyed	O
here	O
paint	O
a	O
more	O
complete	O
picture	O
of	O
nsp3	O
as	O
a	O
conserved	O
component	O
of	O
the	O
viral	O
protein	B-CHED
processing	O
machinery	O
,	O
which	O
is	O
intimately	O
associated	O
with	O
viral	O
RNA	O
in	O
its	O
role	O
as	O
a	O
virion	O
component	O
.	O

Indeed	O
,	O
clusters	B-CHED
of	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
particles	O
have	O
been	O
detected	O
in	O
the	O
cytoplasm	O
of	O
renal	O
tubular	O
epithelial	O
cells	O
in	O
postmortem	O
studies	O
,	O
explaining	O
the	O
presence	O
of	O
infectious	O
virus	O
in	O
the	O
urine	O
of	O
SARS	O
patients	O
.	O

ALSV	O
labeled	O
with	O
two	O
different	O
fluorescent	O
proteins	B-CHED
(	O
CFP	O
-	O
ALSV	O
and	O
YFP	O
-	O
ALSV	O
)	O
were	O
used	O
to	O
investigate	O
the	O
distribution	O
of	O
identical	O
,	O
but	O
differently	O
labeled	O
viruses	O
in	O
mixed	O
infection	O
.	O

In	O
lingering	O
pneumonia	O
2	O
-	O
3	O
times	O
more	O
often	O
than	O
in	O
mild	O
acute	O
CP	O
feces	O
contain	O
escherichia	O
with	O
low	O
enzymatic	O
activity	O
,	O
lactose	B-CHED
-	O
negative	O
,	O
staphylococci	O
.	O

CONCLUSIONS	O
:	O
Long	O
-	O
term	O
administration	O
of	O
antibiotics	B-CHED
in	O
patients	O
with	O
lingering	O
and	O
complicated	O
CP	O
destroys	O
balance	B-CHED
of	O
intestinal	O
microflora	O
and	O
thus	O
influences	O
the	O
course	O
of	O
CP	O
.	O

ABSTRACT	O
:	O
Based	O
on	O
a	O
five	O
-	O
letter	O
model	O
of	O
the	O
20	O
amino	B-CHED
acids	I-CHED
,	O
we	O
propose	O
a	O
new	O
2	O
-	O
D	O
graphical	O
representation	O
of	O
protein	B-CHED
sequence	O
.	O

The	O
lung	O
weight	O
changes	O
,	O
exhaled	O
nitric	B-CHED
oxide	I-CHED
,	O
protein	B-CHED
concentration	O
in	O
bronchoalveolar	O
lavage	O
,	O
and	O
Evans	O
blue	O
content	O
in	O
lung	O
tissue	O
were	O
determined	O
.	O

The	O
inducible	O
nitric	B-CHED
oxide	I-CHED
synthase	O
was	O
up	O
-	O
regulated	O
.	O

Pre	O
-	O
or	O
posttreatment	O
with	O
propofol	B-CHED
was	O
capable	O
of	O
reversing	O
the	O
oleic	B-CHED
acid	I-CHED
-	O
induced	O
changes	O
and	O
attenuating	O
the	O
extent	O
of	O
ALI	O
.	O

To	O
establish	O
specific	O
diagnostic	O
methods	O
,	O
we	O
generated	O
nine	O
clones	O
of	O
monoclonal	O
antibodies	O
to	O
nucleocapsid	O
protein	B-CHED
(	O
NP	O
)	O
of	O
SARS	O
-	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
).	O

The	O
information	O
about	O
binding	O
sites	O
and	O
epitopes	O
of	O
monoclonal	O
antibodies	O
may	O
be	O
useful	O
for	O
the	O
development	O
of	O
new	O
diagnostic	O
methods	O
for	O
SARS	O
and	O
for	O
analyzing	O
the	O
function	O
of	O
N	O
protein	B-CHED
of	O
SARS	O
-	O
CoV	O
.	O

Intranasal	O
administration	O
of	O
LPS	B-CHED
,	O
another	O
elastase	O
inducer	O
,	O
showed	O
an	O
effect	O
similar	O
to	O
that	O
of	O
Pp	O
infection	O
.	O

The	O
competitive	O
inhibition	O
of	O
the	O
sense	O
peptide	B-CHED
in	O
the	O
competitive	O
ELISA	O
reveals	O
the	O
affinity	O
binding	O
between	O
the	O
DP	O
and	O
SARS	O
S	O
protein	B-CHED
is	O
specific	O
and	O
directed	O
towards	O
the	O
target	O
SP	O
of	O
the	O
S	O
protein	B-CHED
.	O

ABSTRACT	O
:	O
Sequencing	O
and	O
reversion	O
analysis	O
of	O
murine	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
temperature	O
-	O
sensitive	O
(	O
ts	O
)	O
viruses	O
has	O
identified	O
putative	O
ts	O
mutations	O
in	O
the	O
replicase	O
nonstructural	O
proteins	B-CHED
(	O
nsp	O
'	O
s	O
)	O
of	O
these	O
coronaviruses	O
.	O

We	O
have	O
examined	O
neural	O
cell	O
tropism	O
of	O
demyelinating	O
and	O
nondemyelinating	O
strains	O
of	O
MHV	O
in	O
order	O
to	O
determine	O
whether	O
central	O
nervous	O
system	O
(	O
CNS	B-CHED
)	O
cell	O
tropism	O
plays	O
a	O
role	O
in	O
demyelination	O
.	O

M	O
,	O
N	O
and	O
S2	O
protein	B-CHED
of	O
SARS	O
-	O
CoV	O
were	O
detected	O
by	O
western	O
blotting	O
and	O
immunohistochemistry	O
analysis	O
.	O

The	O
BCoV	O
S	O
protein	B-CHED
plays	O
a	O
fundamental	O
role	O
in	O
viral	O
attachment	O
and	O
entry	O
into	O
the	O
host	O
cell	O
,	O
and	O
is	O
cleaved	O
into	O
two	O
subunits	O
termed	O
S1	O
(	O
amino	O
terminal	O
)	O
and	O
S2	O
(	O
carboxy	B-CHED
terminal	O
).	O

In	O
nearly	O
every	O
published	O
case	O
report	O
of	O
attempted	O
therapy	O
for	O
clinical	O
FIP	O
,	O
glucocorticoids	B-CHED
have	O
been	O
used	O
;	O
there	O
are	O
,	O
however	O
,	O
no	O
controlled	O
studies	O
that	O
evaluate	O
the	O
effect	O
of	O
glucocorticoids	B-CHED
as	O
a	O
therapy	O
for	O
FIP	O
.	O

The	O
virus	O
was	O
only	O
able	O
to	O
infect	O
cells	O
when	O
pseudotyped	O
with	O
the	O
VSV	O
G	O
protein	B-CHED
.	O

These	O
results	O
indicate	O
that	O
alpha2	O
,	O
3	O
-	O
linked	O
sialic	B-CHED
acid	I-CHED
plays	O
an	O
important	O
role	O
for	O
infection	O
of	O
the	O
respiratory	O
epithelium	O
by	O
IBV	O
.	O

ABSTRACT	O
:	O
This	O
study	O
was	O
designated	O
to	O
investigate	O
whether	O
extravascular	O
lung	O
water	B-CHED
index	O
(	O
EVLI	O
)	O
is	O
an	O
independent	O
predictor	O
for	O
mortality	O
outcome	O
in	O
patients	O
with	O
severe	O
sepsis	O
.	O

To	O
further	O
map	O
epitopes	O
of	O
the	O
MER	O
,	O
seven	O
overlapping	O
mini	O
-	O
fragments	O
covering	O
MER	O
nucleotides	B-CHED
were	O
separately	O
synthesized	O
and	O
expressed	O
in	O
Escherichia	O
coli	O
BL21	O
with	O
a	O
GST	O
tag	O
.	O

Furthermore	O
,	O
Pepscan	O
of	O
the	O
two	O
linear	O
epitopes	O
demonstrated	O
that	O
SS2	O
((	O
748	O
)	O
YSNIGVCK	O
(	O
755	O
))	O
and	O
SS6	O
((	O
764	O
)	O
LQDGQVKI	O
(	O
771	O
))	O
are	O
two	O
core	O
epitopes	O
on	O
S1D5	O
and	O
S1D6	O
,	O
respectively	O
,	O
located	O
on	O
the	O
S	O
protein	B-CHED
of	O
PEDV	O
.	O

Interestingly	O
,	O
this	O
feature	O
can	O
be	O
lost	B-CHED
during	O
cell	O
culture	O
adaptation	O
by	O
a	O
single	O
mutation	O
in	O
the	O
cleavage	O
motif	O
;	O
this	O
,	O
however	O
,	O
preserves	O
a	O
heparan	B-CHED
sulfate	I-CHED
binding	O
motif	O
and	O
renders	O
infection	O
by	O
the	O
virus	O
heparan	B-CHED
sulfate	I-CHED
dependent	O
.	O

Proliferative	O
and	O
necrotising	O
pneumonia	O
(	O
PNP	B-CHED
)	O
was	O
diagnosed	O
in	O
two	O
animals	O
,	O
while	O
severe	O
acute	O
interstitial	O
pneumonia	O
characterised	O
by	O
the	O
presence	O
of	O
abundant	O
hyaline	O
membrane	O
in	O
the	O
alveoli	O
and	O
fibrin	O
in	O
the	O
bronchioles	O
was	O
found	O
in	O
one	O
pig	O
.	O

In	O
one	O
case	O
,	O
obliterating	O
thrombi	O
in	O
the	O
lymph	O
and	O
blood	O
vessels	O
were	O
directly	O
connected	O
to	O
areas	O
of	O
tissue	O
necrosis	O
and	O
were	O
associated	O
with	O
abundant	O
PCV2	O
antigen	B-CHED
.	O

Interferon	O
alfacon	O
1	O
demonstrated	O
significant	O
antiviral	B-CHED
activity	O
in	O
neutral	O
red	O
uptake	O
assay	O
and	O
virus	O
yield	O
reduction	O
assay	O
.	O

Polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
is	O
a	O
widely	O
used	O
and	O
suitable	O
tool	O
for	O
the	O
amplification	O
and	O
detection	O
of	O
extraneous	O
nucleic	B-CHED
acids	I-CHED
.	O

Diluted	O
samples	O
of	O
avian	O
infectious	O
laryngotracheitis	O
,	O
avian	O
infectious	O
bronchitis	O
and	O
avian	O
infectious	O
bursal	O
disease	O
viruses	O
have	O
been	O
analysed	O
using	O
standardised	O
procedures	O
and	O
reagents	B-CHED
.	O

Finally	O
,	O
the	O
weak	O
inhibition	O
profile	O
of	O
different	O
AdoMet	B-CHED
analogues	O
indicates	O
that	O
nsp16	O
has	O
evolved	O
an	O
atypical	O
AdoMet	B-CHED
binding	O
site	O
.	O

RJHM	O
was	O
also	O
unable	O
to	O
elicit	O
a	O
secondary	O
CD8	O
(+)	O
T	O
-	O
cell	O
response	O
in	O
the	O
brain	O
following	O
peripheral	O
immunization	O
against	O
a	O
viral	O
epitope	B-CHED
.	O

Notably	O
,	O
the	O
weak	O
CD8	O
(+)	O
T	O
-	O
cell	O
response	O
elicited	O
by	O
RJHM	O
was	O
unique	O
to	O
CNS	B-CHED
infection	O
,	O
since	O
peripheral	O
inoculation	O
induced	O
a	O
robust	O
CD8	O
(+)	O
T	O
-	O
cell	O
response	O
in	O
the	O
spleen	O
.	O

He	O
was	O
administered	O
the	O
combination	O
of	O
intravenous	O
pazufloxacin	O
and	O
erythromycin	B-CHED
,	O
corticosteroid	B-CHED
,	O
and	O
sivelestat	O
for	O
two	O
weeks	O
.	O

Imai	O
et	O
al	O
.	O
(	O
2008	O
)	O
now	O
report	O
that	O
ALI	O
is	O
triggered	O
by	O
the	O
signaling	O
of	O
oxidized	B-CHED
phospholipids	I-CHED
through	O
Toll	O
-	O
like	O
receptor	O
4	O
(	O
TLR4	O
)	O
and	O
the	O
adaptor	O
protein	B-CHED
TRIF	O
.	O

Moreover	O
,	O
deletion	O
of	O
ncf1	O
,	O
which	O
controls	O
ROS	B-CHED
production	O
,	O
improves	O
the	O
severity	O
of	O
H5N1	O
-	O
mediated	O
ALI	O
.	O

Lack	O
of	O
efficacy	O
of	O
promazine	B-CHED
on	O
SARS	O
-	O
CoV	O
replication	O
in	O
a	O
mouse	O
model	O
.	O

ABSTRACT	O
:	O
Phenothiazine	B-CHED
and	O
derivatives	O
were	O
tested	O
for	O
inhibition	O
of	O
SARS	O
-	O
CoV	O
replication	O
.	O

Phenothiazine	B-CHED
slightly	O
inhibited	O
SARS	O
-	O
CoV	O
replication	O
in	O
a	O
neutral	O
red	O
(	O
NR	O
)	O
uptake	O
assay	O
.	O

Adding	O
a	O
propylamino	O
group	O
to	O
give	O
promazine	B-CHED
reduced	O
virus	O
yields	O
(	O
VYR	O
assay	O
)	O
with	O
an	O
EC	O
(	O
90	O
)=	O
8	O
.	O
3	O
+/-	O
2	O
.	O
8	O
microM	O
,	O
but	O
without	O
selectivity	O
.	O

Various	O
substitutions	O
in	O
the	O
basic	O
phenothiazine	B-CHED
structure	O
did	O
not	O
promote	O
efficacy	O
.	O

Intraperitoneal	O
treatment	O
with	O
promazine	B-CHED
using	O
a	O
prophylactic	O
(-	O
4h	O
)/	O
therapeutic	O
regimen	O
of	O
1	O
,	O
10	O
,	O
or	O
50mg	O
/(	O
kg	O
day	O
)	O
did	O
not	O
reduce	O
virus	O
lung	O
titers	O
at	O
day	O
3	O
,	O
yet	O
prolonged	O
virus	O
replication	O
to	O
14	O
days	O
.	O

Connecting	O
to	O
the	O
HR2	O
region	O
is	O
a	O
Trp	B-CHED
-	O
rich	O
region	O
which	O
is	O
absolutely	O
conserved	O
in	O
members	O
of	O
coronaviruses	O
.	O

RESULTS	O
:	O
Thirteen	O
trials	O
that	O
enrolled	O
a	O
total	O
of	O
1559	O
patients	O
met	B-CHED
our	O
inclusion	O
criteria	O
.	O

We	O
present	O
two	O
scrub	O
typhus	O
cases	O
(	O
a	O
man	B-CHED
and	O
a	O
girl	O
)	O
who	O
died	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

In	O
the	O
present	O
study	O
,	O
we	O
demonstrated	O
that	O
HEPIS	O
was	O
capable	O
of	O
suppressing	O
chloramphenicol	B-CHED
acetyltransferase	O
(	O
CAT	O
)	O
gene	O
expression	O
controlled	O
by	O
different	O
enhancerelements	O
in	O
a	O
transcription	O
assay	O
.	O

Ten	O
observational	O
studies	O
met	B-CHED
inclusion	O
criteria	O
(	O
total	O
n	O
=	O
331	O
).	O

All	O
surviving	O
patient	O
responded	O
well	O
to	O
antibiotic	B-CHED
therapy	O
,	O
and	O
the	O
average	O
duration	O
to	O
defervescence	O
after	O
treatment	O
was	O
1	O
.	O
8	O
days	O
.	O

The	O
oxygenation	O
parameters	O
,	O
protein	B-CHED
and	O
histological	O
data	O
were	O
similar	O
,	O
except	O
for	O
the	O
fact	O
that	O
significantly	O
more	O
normal	O
alveoli	O
were	O
observed	O
upon	O
protective	O
ventilation	O
.	O

Although	O
bottom	O
ash	B-CHED
resulted	O
from	O
HW	O
incinerators	O
has	O
not	O
been	O
classified	O
as	O
hazardous	O
material	O
,	O
the	O
results	O
of	O
this	O
study	O
indicated	O
that	O
this	O
type	O
of	O
waste	O
ash	B-CHED
contained	O
high	O
levels	O
of	O
PAHs	B-CHED
thus	O
need	O
special	O
treatment	O
before	O
landfill	O
.	O

ABSTRACT	O
:	O
It	O
is	O
believed	O
today	O
that	O
nucleocapsid	O
protein	B-CHED
(	O
N	O
)	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
CoV	O
is	O
one	O
of	O
the	O
most	O
promising	O
antigen	B-CHED
candidates	O
for	O
vaccine	O
design	O
.	O

Three	O
gene	O
fragments	O
[	O
N1	O
(	O
1	O
-	O
1269	O
nt	O
),	O
N2	O
(	O
1	O
-	O
327	O
nt	O
)	O
and	O
N3	O
(	O
328	O
-	O
1269	O
nt	O
)-	O
expressing	O
the	O
same	O
proteins	B-CHED
of	O
N1	O
,	O
N2	O
and	O
N3	O
,	O
respectively	O
]	O
of	O
SARS	O
-	O
N	O
were	O
cloned	O
into	O
pVAX	O
-	O
1	O
and	O
used	O
to	O
immunize	O
BALB	O
/	O
c	O
mice	O
by	O
electroporation	O
.	O

The	O
identification	O
of	O
antigenic	O
N	O
protein	B-CHED
fragments	O
has	O
implications	O
to	O
provide	O
basic	O
information	O
for	O
the	O
design	O
of	O
DNA	O
vaccine	O
against	O
SARS	O
-	O
CoV	O
.	O
The	O
present	O
results	O
not	O
only	O
suggest	O
that	O
DNA	O
immunization	O
with	O
pVax	O
-	O
N3	O
could	O
be	O
used	O
as	O
potential	O
DNA	O
vaccination	O
approaches	O
to	O
induce	O
antibody	O
in	O
BALB	O
/	O
c	O
mice	O
,	O
but	O
also	O
illustrates	O
that	O
gene	O
immunization	O
with	O
these	O
SARS	O
DNA	O
vaccines	O
can	O
generate	O
different	O
immune	O
responses	O
.	O

TITLE	O
:	O
Fusion	O
core	O
structure	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
):	O
in	O
search	O
of	O
potent	O
SARS	O
-	O
CoV	O
entry	O
inhibitors	B-CHED
.	O

Molecular	O
modeling	O
analysis	O
suggested	O
that	O
ADS	O
-	O
J1	O
may	O
bind	O
to	O
the	O
deep	O
pocket	O
of	O
the	O
hydrophobic	O
groove	O
on	O
the	O
surface	O
of	O
the	O
central	O
coiled	O
-	O
coil	O
of	O
SARS	O
-	O
CoV	O
S	O
HR	O
protein	B-CHED
and	O
prevent	O
the	O
entrance	O
of	O
the	O
SARS	O
-	O
CoV	O
into	O
the	O
host	O
cells	O
.	O

Furthermore	O
,	O
the	O
histopathologic	O
findings	O
indicated	O
that	O
alveolitis	O
with	O
leukocyte	O
infiltration	O
in	O
the	O
alveolar	O
space	O
was	O
less	O
severe	O
in	O
the	O
CoPPIX	O
-	O
treated	O
mice	O
than	O
in	O
the	O
mice	O
treated	O
with	O
LPS	B-CHED
alone	O
.	O

In	O
contrast	O
,	O
no	O
obvious	O
difference	O
was	O
observed	O
between	O
the	O
ZnPPIX	O
group	O
and	O
the	O
LPS	B-CHED
group	O
.	O

Ethyl	B-CHED
pyruvate	B-CHED
has	O
been	O
tested	O
in	O
human	O
volunteers	O
and	O
shown	O
to	O
be	O
safe	O
at	O
clinically	O
relevant	O
doses	O
.	O

They	O
show	O
that	O
the	O
major	O
species	O
barriers	O
are	O
determined	O
by	O
interactions	O
between	O
four	O
ACE2	O
residues	O
(	O
residues	O
31	O
,	O
35	O
,	O
38	O
,	O
and	O
353	O
)	O
and	O
two	O
RBD	O
residues	O
(	O
residues	O
479	O
and	O
487	O
),	O
that	O
early	O
civet	O
SARS	O
-	O
CoV	O
isolates	O
were	O
prevented	O
from	O
infecting	O
human	O
cells	O
due	O
to	O
imbalanced	O
salt	B-CHED
bridges	O
at	O
the	O
hydrophobic	O
virus	O
/	O
receptor	O
interface	O
,	O
and	O
that	O
SARS	O
-	O
CoV	O
has	O
evolved	O
to	O
gain	O
sustained	O
infectivity	O
for	O
human	O
cells	O
by	O
eliminating	O
unfavorable	O
free	O
charges	O
at	O
the	O
interface	O
through	O
stepwise	O
mutations	O
at	O
positions	O
479	O
and	O
487	O
.	O

TITLE	O
:	O
siRNA	O
silencing	O
of	O
angiotensin	B-CHED
-	O
converting	O
enzyme	O
2	O
reduced	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
replications	O
in	O
Vero	O
E6	O
cells	O
.	O

Mainly	O
positive	O
-	O
strand	O
RNAs	O
were	O
synthesized	O
and	O
protein	B-CHED
synthesis	O
was	O
not	O
required	O
for	O
RTC	O
activity	O
in	O
vitro	O
.	O

Viruses	O
lacking	O
E	O
protein	B-CHED
were	O
highly	O
attenuated	O
in	O
the	O
highly	O
sensitive	O
hACE	O
-	O
2	O
Tg	O
mice	O
,	O
in	O
contrast	O
to	O
the	O
minimal	O
rSARS	O
-	O
CoV	O
-	O
Delta	O
[	O
6	O
-	O
9b	O
]	O
and	O
wt	O
viruses	O
.	O

Clinical	O
and	O
general	O
laboratory	O
manifestations	O
included	O
fever	O
,	O
chills	O
,	O
rigor	O
,	O
myalgia	O
,	O
malaise	O
,	O
diarrhoea	O
,	O
cough	O
,	O
dyspnoea	O
,	O
pneumonia	O
,	O
lymphopenia	O
,	O
neutrophilia	O
,	O
thrombocytopenia	O
,	O
and	O
elevated	O
serum	O
lactate	B-CHED
dehydrogenase	O
(	O
LD	O
),	O
alanine	B-CHED
aminotransferase	O
(	O
ALT	B-CHED
)	O
and	O
creatine	B-CHED
kinase	O
(	O
CK	O
)	O
activities	O
.	O

Additionally	O
,	O
the	O
enriched	O
target	O
cDNA	O
were	O
amplified	O
through	O
a	O
general	O
symmetry	O
PCR	O
and	O
then	O
was	O
selectively	O
isolated	O
from	O
the	O
double	O
strands	O
PCR	O
products	O
by	O
applying	O
the	O
silica	B-CHED
coated	O
superparamagnetic	O
nanoparticles	B-CHED
again	O
.	O

ABSTRACT	O
:	O
The	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
envelope	O
spike	O
(	O
S	O
)	O
glycoprotein	B-CHED
,	O
a	O
Class	O
I	O
viral	O
fusion	O
protein	B-CHED
,	O
is	O
responsible	O
for	O
the	O
fusion	O
between	O
the	O
membranes	O
of	O
the	O
virus	O
and	O
the	O
target	O
cell	O
.	O

In	O
contrast	O
,	O
the	O
spike	O
protein	B-CHED
of	O
HNL63	O
-	O
CoV	O
(	O
NL63	O
-	O
S	O
),	O
a	O
CoV	O
that	O
uses	O
ACE2	O
as	O
a	O
receptor	O
and	O
mainly	O
induces	O
the	O
common	O
cold	O
,	O
caused	O
neither	O
of	O
these	O
cellular	O
responses	O
.	O

Critical	O
illness	O
-	O
related	O
corticosteroid	B-CHED
insufficiency	O
is	O
caused	O
by	O
adrenal	O
insufficiency	O
together	O
with	O
tissue	O
corticosteroid	B-CHED
resistance	O
and	O
is	O
characterized	O
by	O
an	O
exaggerated	O
and	O
protracted	O
proinflammatory	O
response	O
.	O

Critical	O
illness	O
-	O
related	O
corticosteroid	B-CHED
insufficiency	O
should	O
be	O
suspected	O
in	O
hypotensive	O
patients	O
who	O
have	O
responded	O
poorly	O
to	O
fluids	O
and	O
vasopressor	O
agents	O
,	O
particularly	O
in	O
the	O
setting	O
of	O
sepsis	O
.	O

Hydrocortisone	B-CHED
in	O
a	O
dose	O
of	O
200	O
mg	O
/	O
day	O
in	O
four	O
divided	O
doses	O
or	O
as	O
a	O
continuous	O
infusion	O
in	O
a	O
dose	O
of	O
240	O
mg	O
/	O
day	O
(	O
10	O
mg	O
/	O
hr	O
)	O
for	O
>	O
or	O
=	O
7	O
days	O
is	O
recommended	O
for	O
septic	O
shock	O
.	O

Dexamethasone	B-CHED
is	O
not	O
recommended	O
to	O
treat	O
critical	O
illness	O
-	O
related	O
corticosteroid	B-CHED
insufficiency	O
.	O

ABSTRACT	O
:	O
Measurements	O
of	O
extravascular	O
lung	O
water	B-CHED
(	O
EVLW	O
)	O
correlate	O
to	O
the	O
degree	O
of	O
pulmonary	O
edema	O
and	O
have	O
substantial	O
prognostic	O
information	O
in	O
critically	O
ill	O
patients	O
.	O

Our	O
homology	O
-	O
reduced	O
data	O
set	O
and	O
implementations	O
of	O
BCPred	O
as	O
well	O
as	O
the	O
APP	B-CHED
method	O
are	O
publicly	O
available	O
through	O
our	O
web	O
-	O
based	O
server	O
,	O
BCPREDS	O
,	O
at	O
:	O
http	O
://	O
ailab	O
.	O
cs	O
.	O
iastate	O
.	O
edu	O
/	O
bcpreds	O
/.	O

Chi	B-CHED
-	O
square	O
test	O
was	O
used	O
to	O
compare	O
the	O
profile	O
of	O
the	O
older	O
adult	O
suicide	O
cases	O
in	O
the	O
pre	O
-	O
SARS	O
,	O
peri	O
-	O
SARS	O
and	O
post	O
-	O
SARS	O
periods	O
.	O

TITLE	O
:	O
The	O
SARS	O
-	O
associated	O
stigma	O
of	O
SARS	O
victims	O
in	O
the	O
post	O
-	O
SARS	O
era	B-CHED
of	O
Hong	O
Kong	O
.	O

Mortality	O
rates	O
were	O
comparable	O
regardless	O
of	O
whether	O
patients	O
were	O
PaO	B-CHED
(	O
2	O
)/	O
F	O
(	O
I	O
)	O
O	O
(	O
2	O
)	O
responders	O
or	O
their	O
PaCO	O
(	O
2	O
)	O
decreased	O
by	O
>	O
or	O
=	O
1	O
mmHg	O
.	O

AT	O
II	O
cells	O
were	O
isolated	O
and	O
purified	O
from	O
rats	O
with	O
ALI	O
/	O
ARDS	O
induced	O
by	O
oleic	B-CHED
acid	I-CHED
,	O
and	O
their	O
morphology	O
was	O
observed	O
using	O
electron	O
microscopy	O
and	O
optical	O
microscopy	O
.	O

The	O
second	O
antibody	O
in	O
the	O
kit	O
was	O
replaced	O
with	O
horseradish	O
peroxidase	O
-	O
conjugated	B-CHED
protein	I-CHED
-	O
A	O
(	O
HRP	O
-	O
SPA	O
)	O
based	O
on	O
the	O
characteristics	O
of	O
binding	O
between	O
Staphylococcus	O
aureus	O
protein	B-CHED
A	O
(	O
SPA	O
)	O
and	O
mammal	O
IgG	O
Fc	O
fragment	O
.	O

The	O
role	O
of	O
the	O
immune	O
system	O
is	O
to	O
contain	O
and	O
control	O
the	O
spread	O
of	O
virus	O
within	O
the	O
CNS	B-CHED
,	O
and	O
paradoxically	O
,	O
this	O
response	O
may	O
also	O
be	O
pathological	O
.	O

We	O
therefore	O
considered	O
the	O
use	O
of	O
an	O
DeltaE1	O
/	O
DeltaE2	O
type	O
5	O
vector	O
(	O
Ad5	O
)	O
to	O
deliver	O
genes	O
to	O
PER	O
.	O
C6	O
cells	O
growing	O
in	O
suspension	O
with	O
the	O
aim	O
to	O
achieve	O
high	O
protein	B-CHED
yield	O
.	O

FACS	O
and	O
ELISA	O
assays	O
demonstrated	O
the	O
biological	O
activity	O
of	O
the	O
transiently	O
produced	O
proteins	B-CHED
.	O

TCoV	O
polyprotein	O
pp1a	O
and	O
pp1ab	O
were	O
predicted	O
to	O
be	O
processed	O
to	O
15	O
non	O
-	O
structure	O
proteins	B-CHED
(	O
nsp2	O
-	O
nsp16	O
),	O
with	O
nsp1	O
missing	O
.	O

The	O
whole	O
genome	O
consists	O
of	O
27	O
,	O
749	O
nucleotides	B-CHED
for	O
540	O
and	O
27	O
,	O
816	O
nucleotides	B-CHED
for	O
ATCC	O
,	O
excluding	O
the	O
poly	O
(	O
A	O
)	O
tail	O
.	O

After	O
the	O
animals	O
were	O
anesthetized	O
with	O
ketamine	B-CHED
and	O
xylazine	O
,	O
the	O
abdominal	O
cavity	O
was	O
opened	O
and	O
ligated	O
just	O
below	O
the	O
ileocaecal	O
valve	O
with	O
3	O
-	O
0	O
silk	O
.	O

ABSTRACT	O
:	O
Epitope	B-CHED
-	O
based	O
vaccines	O
designed	O
to	O
induce	O
antibody	O
responses	O
specific	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
are	O
being	O
developed	O
as	O
a	O
means	O
for	O
increasing	O
vaccine	O
potency	O
.	O

CSF	O
-	O
total	O
protein	B-CHED
(	O
TP	O
)	O
was	O
measured	O
and	O
albumin	O
and	O
IgG	O
concentrations	O
were	O
measured	O
in	O
paired	O
CSF	O
/	O
serum	O
samples	O
;	O
Q	O
(	O
alb	O
)	O
and	O
IgG	O
index	O
were	O
calculated	O
.	O

Q	O
(	O
alb	O
)	O
and	O
IgG	O
index	O
were	O
significantly	O
higher	O
in	O
cats	O
with	O
brain	O
tumors	O
and	O
cats	O
with	O
CNS	B-CHED
-	O
FIP	O
compared	O
with	O
other	O
groups	O
.	O

TITLE	O
:	O
Structure	O
of	O
a	O
SARS	O
coronavirus	O
-	O
derived	O
peptide	B-CHED
bound	O
to	O
the	O
human	O
major	O
histocompatibility	O
complex	O
class	O
I	O
molecule	O
HLA	O
-	O
B	O
*	O
1501	O
.	O

Conversion	O
from	O
the	O
prefusion	O
state	O
to	O
the	O
postfusion	O
state	O
requires	O
passage	O
through	O
the	O
transition	O
state	O
,	O
a	O
state	O
that	O
may	O
give	O
insight	O
into	O
the	O
design	O
of	O
structure	O
-	O
based	O
antagonists	B-CHED
of	O
SARS	O
-	O
CoV	O
in	O
particular	O
,	O
as	O
well	O
as	O
other	O
enveloped	O
viruses	O
in	O
general	O
.	O

This	O
was	O
followed	O
by	O
observation	O
(	O
group	O
III	O
);	O
treatment	O
with	O
conventional	O
therapy	O
including	O
protective	O
ventilation	O
,	O
steroids	B-CHED
,	O
and	O
nitric	B-CHED
oxide	I-CHED
(	O
group	O
IV	O
);	O
or	O
femoral	O
arteriovenous	O
iLA	O
Novalung	O
placement	O
,	O
near	O
-	O
static	O
ventilation	O
,	O
steroids	B-CHED
,	O
and	O
nitric	B-CHED
oxide	I-CHED
(	O
group	O
V	O
).	O

CONCLUSIONS	O
:	O
Compared	O
with	O
CMV	O
or	O
CMV	O
+	O
PS	O
,	O
HFOV	O
or	O
HFOV	O
+	O
PS	O
can	O
decrease	O
the	O
concentration	O
of	O
caspase	O
-	O
3	O
and	O
p73	O
,	O
reduce	O
the	O
mRNA	B-CHED
expression	O
of	O
caspase	O
-	O
3	O
and	O
p73	O
in	O
the	O
lung	O
homogenates	O
,	O
as	O
a	O
result	O
lung	O
tissue	O
apoptosis	O
in	O
inhalation	O
injury	O
may	O
be	O
suppressed	O
.	O

Our	O
results	O
showed	O
that	O
MHV	O
-	O
2	O
gene	O
expression	O
and	O
infectivity	O
were	O
significantly	O
inhibited	O
when	O
cells	O
were	O
treated	O
with	O
chemical	O
and	O
physiologic	O
blockers	O
of	O
the	O
clathrin	O
-	O
mediated	O
pathway	O
,	O
such	O
as	O
chlorpromazine	B-CHED
and	O
hypertonic	O
sucrose	B-CHED
medium	O
.	O

Many	O
of	O
the	O
bat	O
astroviruses	O
form	O
distinct	O
phylogenetic	O
clusters	B-CHED
in	O
the	O
genus	O
Mamastrovirus	O
within	O
the	O
family	O
Astroviridae	O
.	O

ABSTRACT	O
:	O
The	O
hemagglutinin	O
-	O
esterases	O
(	O
HEs	O
)	O
are	O
a	O
family	O
of	O
viral	O
envelope	O
glycoproteins	B-CHED
that	O
mediate	O
reversible	O
attachment	O
to	O
O	O
-	O
acetylated	O
sialic	B-CHED
acids	I-CHED
by	O
acting	O
both	O
as	O
lectins	O
and	O
as	O
receptor	O
-	O
destroying	O
enzymes	O
(	O
RDEs	O
).	O

CONCLUSIONS	O
:	O
Further	O
evaluation	O
of	O
these	O
long	O
-	O
acting	O
albumin	O
-	O
IFN	O
fusion	O
proteins	B-CHED
as	O
prophylactic	O
or	O
therapeutic	O
agents	O
against	O
these	O
viral	O
agents	O
of	O
bioterrorism	O
in	O
relevant	O
primate	O
models	O
is	O
warranted	O
.	O

The	O
SAIL	O
protein	B-CHED
yielded	O
less	O
crowded	O
and	O
better	O
resolved	O
spectra	O
than	O
uniform	O
(	O
13	O
)	O
C	O
and	O
(	O
15	O
)	O
N	O
labeling	O
,	O
and	O
enabled	O
the	O
homodimeric	O
solution	O
structure	O
of	O
this	O
protein	B-CHED
to	O
be	O
determined	O
.	O

As	O
we	O
and	O
others	O
have	O
demonstrated	O
,	O
infection	O
by	O
this	O
virus	O
depends	O
on	O
cathepsin	O
proteases	O
present	O
in	O
endosomal	O
compartments	O
of	O
the	O
target	O
cell	O
,	O
suggesting	O
that	O
the	O
spike	O
protein	B-CHED
acquires	O
its	O
fusion	O
competence	O
by	O
cleavage	O
during	O
cell	O
entry	O
rather	O
than	O
during	O
virion	O
biogenesis	O
.	O

In	O
this	O
study	O
,	O
we	O
report	O
the	O
structure	O
of	O
HCoV	O
-	O
HKU1	O
M	O
(	O
pro	B-CHED
)	O
in	O
complex	O
with	O
a	O
Michael	O
acceptor	B-CHED
,	O
inhibitor	B-CHED
N3	O
.	O

Combined	O
with	O
structural	O
data	O
from	O
other	O
CoV	O
M	O
(	O
pro	B-CHED
)	O
s	O
,	O
the	O
HCoV	O
-	O
HKU1	O
M	O
(	O
pro	B-CHED
)	O
structure	O
reported	O
here	O
provides	O
insights	O
into	O
both	O
substrate	O
preference	O
and	O
the	O
design	O
of	O
antivirals	B-CHED
targeting	O
CoVs	O
.	O

Plasma	O
protein	B-CHED
C	O
levels	O
are	O
decreased	O
in	O
patients	O
with	O
acute	O
lung	O
injury	O
and	O
are	O
associated	O
with	O
higher	O
mortality	O
and	O
fewer	O
ventilator	O
-	O
free	O
days	O
.	O

Shedding	O
of	O
SARS	O
-	O
CoV	O
peaks	O
at	O
day	O
10	O
after	O
the	O
onset	O
of	O
symptoms	O
,	O
which	O
theoretically	O
allows	O
ample	O
time	O
for	O
antiviral	B-CHED
treatment	O
.	O

ABSTRACT	O
:	O
Type	O
I	O
interferons	O
(	O
IFN	O
)	O
include	O
multiple	O
IFN	O
-	O
alpha	O
subtypes	O
which	O
exhibit	O
considerable	O
amino	B-CHED
acid	I-CHED
identity	O
and	O
activate	O
the	O
same	O
cell	O
-	O
surface	O
receptor	O
.	O

We	O
demonstrate	O
that	O
the	O
compounds	O
inhibited	O
SARS	O
-	O
CoV	O
replication	O
-	O
dependent	O
GFP	O
expression	O
in	O
the	O
replicon	O
cells	O
and	O
reduced	O
SARS	O
-	O
CoV	O
viral	O
protein	B-CHED
accumulation	O
and	O
viral	O
RNA	O
copy	O
number	O
in	O
the	O
replicon	O
cells	O
.	O

ABSTRACT	O
:	O
Paraquat	B-CHED
is	O
a	O
bipyridil	O
herbicide	B-CHED
and	O
in	O
appropriate	O
and	O
careful	O
usage	O
,	O
will	O
not	O
be	O
health	O
threatening	O
.	O

Pulse	O
therapy	O
with	O
cyclophosphamide	B-CHED
and	O
methylprednisolone	B-CHED
may	O
be	O
effective	O
in	O
preventing	O
respiratory	O
failure	O
and	O
reducing	O
mortality	O
in	O
patients	O
with	O
moderate	O
to	O
severe	O
paraquat	B-CHED
poisoning	O
.	O

The	O
cerebrospinal	O
fluid	O
protein	B-CHED
concentration	O
was	O
5	O
.	O
03	O
g	O
.	O

Mainstay	O
of	O
treatment	O
consists	O
of	O
appropriate	O
antimalarial	B-CHED
drug	O
therapy	O
,	O
fluid	O
replacement	O
,	O
and	O
renal	O
replacement	O
therapy	O
.	O

We	O
commenced	O
treatment	O
with	O
pulsed	O
steroids	B-CHED
and	O
strictly	O
managed	O
fluid	O
balance	B-CHED
under	O
mechanical	O
ventilation	O
.	O

Electronic	O
microscopy	O
and	O
functional	O
assay	O
results	O
indicate	O
that	O
pseudotyped	O
viruses	O
containing	O
both	O
HA	O
and	O
NA	O
proteins	B-CHED
express	O
hemagglutination	O
and	O
are	O
capable	O
of	O
infecting	O
cells	O
expressing	O
alpha	O
-	O
2	O
,	O
3	O
-	O
linked	O
sialic	B-CHED
acid	I-CHED
receptors	O
.	O

Results	O
from	O
a	O
capture	O
assay	O
show	O
that	O
DC	O
-	O
SIGN	O
-	O
expressing	O
cells	O
(	O
including	O
B	O
-	O
THP	B-CHED
-	O
1	O
/	O
DC	O
-	O
SIGN	O
and	O
T	O
-	O
THP	B-CHED
-	O
1	O
/	O
DC	O
-	O
SIGN	O
)	O
and	O
peripheral	O
blood	O
dendritic	O
cells	O
are	O
capable	O
of	O
transferring	O
H5N1	O
pseudotyped	O
and	O
RG	O
virus	O
particles	O
to	O
target	O
cells	O
;	O
this	O
action	O
can	O
be	O
blocked	O
by	O
anti	O
-	O
DC	O
-	O
SIGN	O
monoclonal	O
antibodies	O
.	O

ABSTRACT	O
:	O
DUBs	O
(	O
deubiquitinating	O
enzymes	O
)	O
are	O
a	O
family	O
of	O
proteases	O
responsible	O
for	O
the	O
specific	O
removal	O
of	O
ubiquitin	O
attached	O
to	O
target	O
proteins	B-CHED
and	O
thus	O
control	O
the	O
free	O
cellular	O
pools	O
of	O
this	O
molecule	O
.	O

To	O
gain	O
insight	O
into	O
the	O
C	O
-	O
terminal	O
recognition	O
region	O
of	O
ubiquitin	O
by	O
DUBs	O
,	O
we	O
synthesized	O
positional	O
scanning	O
libraries	O
of	O
fluorigenic	O
tetrapeptides	B-CHED
and	O
tested	O
them	O
on	O
three	O
examples	O
of	O
human	O
DUBs	O
[	O
OTU	O
-	O
1	O
(	O
ovarian	O
tumour	O
1	O
),	O
Iso	O
-	O
T	O
(	O
isopeptidase	O
T	O
)	O
and	O
UCH	O
-	O
L3	O
(	O
ubiquitin	O
C	O
-	O
terminal	O
hydrolase	O
L3	O
)]	O
and	O
one	O
viral	O
ubiquitin	O
-	O
specific	O
protease	O
,	O
namely	O
PLpro	O
(	O
papain	O
-	O
like	O
protease	O
)	O
from	O
SARS	O
(	O
severe	O
acute	O
respiratory	O
syndrome	O
)	O
virus	O
.	O

We	O
identified	O
several	O
amino	B-CHED
acid	I-CHED
substitutions	O
,	O
including	O
Y442F	O
and	O
V601G	O
in	O
the	O
S1	O
domain	O
and	O
D757N	O
and	O
A834V	O
in	O
the	O
S2	O
region	O
.	O

This	O
goal	O
can	O
be	O
accomplished	O
by	O
designing	O
inhibitors	B-CHED
against	O
a	O
target	O
,	O
such	O
as	O
the	O
main	O
protease	O
3CL	O
(	O
pro	B-CHED
)	O
(	O
M	O
(	O
pro	B-CHED
)),	O
which	O
is	O
highly	O
conserved	O
among	O
all	O
coronaviruses	O
.	O

Furthermore	O
,	O
Structure	O
Activity	O
Relationship	O
(	O
SAR	B-CHED
)	O
studies	O
of	O
these	O
compounds	O
have	O
led	O
to	O
the	O
identification	O
of	O
a	O
pharmacophore	O
that	O
accurately	O
defines	O
the	O
essential	O
molecular	O
features	O
required	O
for	O
the	O
high	O
affinity	O
.	O

Treatment	O
with	O
antiviral	B-CHED
drugs	I-CHED
demonstrated	O
that	O
the	O
replication	O
could	O
be	O
significantly	O
inhibited	O
by	O
0	O
.	O
4	O
mg	O
/	O
ml	O
of	O
cysteine	B-CHED
proteinase	I-CHED
inhibitor	I-CHED
E	O
-	O
64D	O
,	O
but	O
not	O
by	O
ribavirin	B-CHED
.	O

Results	O
show	O
that	O
the	O
robust	O
immunoswab	O
method	O
of	O
detecting	O
SARS	O
-	O
CoV	O
NP	O
antigen	B-CHED
can	O
be	O
developed	O
into	O
an	O
easy	O
and	O
effective	O
way	O
of	O
identifying	O
SARS	O
suspected	O
individuals	O
during	O
a	O
future	O
SARS	O
epidemic	O
,	O
thereby	O
reducing	O
and	O
containing	O
the	O
transmission	O
.	O

The	O
key	O
feature	O
of	O
this	O
simple	O
immunoswab	O
diagnostic	O
assay	O
is	O
its	O
ability	O
to	O
detect	O
the	O
presence	O
of	O
the	O
SARS	O
-	O
CoV	O
antigen	B-CHED
within	O
45	O
-	O
60	O
min	O
with	O
the	O
availability	O
of	O
the	O
body	O
fluid	O
samples	O
.	O

Incorporation	O
of	O
S	O
protein	B-CHED
of	O
vAcBS	O
(	O
BS	O
)	O
into	O
VLPs	O
was	O
confirmed	O
by	O
western	O
blot	O
and	O
immunogold	O
labeling	O
.	O

The	O
observed	O
difference	O
in	O
DC	O
-	O
stimulating	O
activity	O
between	O
BVLPs	O
and	O
SARS	O
CoV	O
VLPs	O
was	O
very	O
likely	O
due	O
to	O
the	O
S	O
protein	B-CHED
.	O

Our	O
data	O
have	O
demonstrated	O
for	O
the	O
first	O
time	O
that	O
SL	O
-	O
CoV	O
VLPs	O
formed	O
by	O
membrane	O
proteins	B-CHED
of	O
different	O
origins	O
,	O
one	O
from	O
SL	O
-	O
CoV	O
isolated	O
from	O
bats	O
(	O
BS	O
)	O
and	O
the	O
other	O
two	O
from	O
human	O
SARS	O
-	O
CoV	O
(	O
E	O
and	O
M	O
),	O
activated	O
immature	O
DCs	O
and	O
enhanced	O
the	O
expression	O
of	O
co	O
-	O
stimulatory	O
molecules	O
and	O
the	O
secretion	O
of	O
cytokines	O
.	O

Seventy	O
-	O
eight	O
consenting	O
symptomatic	O
patients	O
with	O
organophosphate	O
poisoning	O
were	O
assessed	O
prospectively	O
with	O
daily	O
physical	O
examination	O
and	O
RNS	B-CHED
.	O

TITLE	O
:	O
Phosphorylation	O
of	O
the	O
arginine	B-CHED
/	O
serine	B-CHED
dipeptide	B-CHED
-	O
rich	O
motif	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
nucleocapsid	O
protein	B-CHED
modulates	O
its	O
multimerization	O
,	O
translation	O
inhibitory	O
activity	O
and	O
cellular	O
localization	O
.	O

The	O
central	O
domain	O
of	O
the	O
nucleocapsid	O
protein	B-CHED
contains	O
several	O
arginine	B-CHED
/	O
serine	B-CHED
(	O
RS	O
)	O
dipeptides	B-CHED
,	O
the	O
biological	O
significance	O
of	O
which	O
has	O
not	O
been	O
well	O
investigated	O
.	O

The	O
nucleocapsid	O
protein	B-CHED
could	O
suppress	O
translation	O
and	O
its	O
RS	O
motif	O
is	O
essential	O
for	O
such	O
an	O
activity	O
.	O

To	O
identify	O
the	O
domains	O
of	O
this	O
protein	B-CHED
that	O
are	O
responsible	O
for	O
Golgi	O
localization	O
,	O
we	O
have	O
generated	O
a	O
set	O
of	O
mutant	O
proteins	B-CHED
and	O
analyzed	O
their	O
subcellular	O
localizations	O
by	O
indirect	O
immunofluorescence	O
confocal	O
microscopy	O
.	O

When	O
the	O
TMD	O
of	O
human	O
CD4	O
was	O
replaced	O
with	O
the	O
ORF7b	O
TMD	O
,	O
the	O
resulting	O
chimeric	O
protein	B-CHED
localized	O
to	O
the	O
Golgi	O
complex	O
.	O

In	O
the	O
intrinsic	O
pathway	O
,	O
there	O
was	O
activation	O
of	O
caspase	O
-	O
9	O
and	O
cytochrome	B-CHED
c	I-CHED
release	O
from	O
the	O
mitochondria	O
.	O

In	O
direct	O
Annexin	O
V	O
staining	O
assays	O
,	O
the	O
3a	O
protein	B-CHED
-	O
expressing	O
cells	O
showed	O
increased	O
apoptosis	O
that	O
was	O
attenuated	O
with	O
the	O
p38	O
MAPK	O
inhibitor	B-CHED
SB203580	O
.	O

TITLE	O
:	O
Relationship	O
between	O
treatment	O
resistance	O
to	O
hemoperfusion	O
using	O
a	O
polymyxin	B-CHED
B	I-CHED
-	O
immobilized	O
fiber	O
column	O
and	O
oxidative	O
stress	O
.	O

Catastrophic	O
antiphospholipid	O
syndrome	O
(	O
CAPS	O
)	O
is	O
a	O
small	O
subset	O
of	O
APS	B-CHED
characterized	O
by	O
widespread	O
systemic	O
thrombotic	O
disease	O
with	O
multiorgan	O
failure	O
.	O

ABSTRACT	O
:	O
We	O
previously	O
demonstrated	O
pre	O
-	O
B	O
-	O
cell	O
colony	O
enhancing	O
factor	O
(	O
PBEF	O
)	O
as	O
a	O
biomarker	B-CHED
in	O
sepsis	O
and	O
sepsis	O
-	O
induced	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
with	O
genetic	O
variants	O
conferring	O
ALI	O
susceptibility	O
.	O

This	O
study	O
aimed	O
to	O
analyze	O
the	O
clinical	O
and	O
laboratory	O
characteristics	O
of	O
systemic	O
-	O
onset	O
juvenile	O
idiopathic	O
arthritis	O
(	O
SoJIA	O
)	O
with	O
macrophage	O
activation	O
syndrome	O
(	O
MAS	B-CHED
)	O
in	O
13	O
patients	O
.	O

It	O
is	O
essentially	O
important	O
to	O
recognize	O
and	O
treat	O
MAS	B-CHED
earlier	O
in	O
order	O
to	O
lower	O
the	O
mortality	O
.	O

ABSTRACT	O
:	O
Hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
constitutes	O
a	O
serious	O
menace	O
to	O
man	B-CHED
.	O

For	O
the	O
overall	O
patient	O
population	O
,	O
treatment	O
with	O
rSP	O
-	O
C	O
surfactant	B-CHED
significantly	O
improved	O
oxygenation	O
(	O
p	O
=	O
0	O
.	O
002	O
)	O
but	O
had	O
no	O
effect	O
on	O
mortality	O
(	O
32	O
.	O
6	O
%).	O

rSP	O
-	O
C	O
surfactant	B-CHED
improved	O
oxygenation	O
in	O
patients	O
with	O
ARDS	O
irrespective	O
of	O
the	O
predisposition	O
.	O

Samples	O
also	O
were	O
tested	O
for	O
feline	O
leukemia	O
virus	O
antigens	B-CHED
.	O

The	O
majority	O
of	O
the	O
title	O
compounds	O
showed	O
moderate	O
to	O
good	O
activities	O
against	O
HIV	O
-	O
1	O
with	O
an	O
IC	O
(	O
50	O
)	O
range	O
from	O
6	O
.	O
67	O
microM	O
to	O
0	O
.	O
12	O
microM	O
.	O
Among	O
them	O
,	O
6	O
-(	O
3	O
,	O
5	O
-	O
dimethylbenzyl	O
)	O
analogue	O
5q	O
exhibited	O
the	O
most	O
potent	O
anti	O
-	O
HIV	O
-	O
1	O
activity	O
(	O
IC	O
(	O
50	O
)=	O
0	O
.	O
12	O
microM	O
,	O
SI	O
>	O
2642	O
),	O
which	O
was	O
about	O
40	O
-	O
fold	O
more	O
active	O
than	O
the	O
reference	O
compounds	O
1	B-CHED
-[(	I-CHED
2	I-CHED
-	I-CHED
hydroxyethoxy	I-CHED
)	I-CHED
methyl	I-CHED
]-	I-CHED
6	I-CHED
-(	I-CHED
phenylsulfanyl	I-CHED
)	I-CHED
thymine	I-CHED
(	O
HEPT	B-CHED
)	O
and	O
2	B-CHED
',	I-CHED
3	I-CHED
'-	I-CHED
dideoxyinosine	I-CHED
(	O
DDI	B-CHED
).	O

In	O
the	O
crystal	O
,	O
the	O
wild	O
-	O
type	O
HCoV	O
-	O
229E	O
protein	B-CHED
forms	O
a	O
trimer	O
of	O
dimers	O
,	O
whereas	O
the	O
mutant	O
and	O
SARS	O
-	O
CoV	O
Nsp9	O
are	O
organized	O
in	O
rod	O
-	O
like	O
polymers	B-CHED
.	O

The	O
corresponding	O
mutations	O
in	O
SARS	O
-	O
CoV	O
Nsp9	O
do	O
not	O
hamper	O
nucleic	B-CHED
acid	I-CHED
binding	O
.	O

So	O
far	O
,	O
experimental	O
evidence	O
supports	O
the	O
role	O
of	O
oxidants	B-CHED
and	O
oxidative	O
injury	O
in	O
the	O
pathogenesis	O
of	O
ALI	O
/	O
ARDS	O
.	O

TITLE	O
:	O
The	O
altered	O
adrenal	O
axis	O
and	O
treatment	O
with	O
glucocorticoids	B-CHED
during	O
critical	O
illness	O
.	O

Later	O
,	O
we	O
screened	O
his	O
sera	O
for	O
antibodies	O
to	O
anti	O
-	O
aminoacyl	O
tRNA	B-CHED
synthetase	O
to	O
diagnose	O
anti	O
-	O
aminoacyl	O
tRNA	B-CHED
synthetase	O
syndrome	O
because	O
anti	O
-	O
PL	O
-	O
12	O
antibodies	O
were	O
positive	O
.	O

TITLE	O
:	O
Molecular	O
dynamic	O
simulations	O
analysis	O
of	O
ritonavir	B-CHED
and	O
lopinavir	O
as	O
SARS	O
-	O
CoV	O
3CL	O
(	O
pro	B-CHED
)	O
inhibitors	B-CHED
.	O

However	O
,	O
it	O
was	O
found	O
that	O
a	O
mixture	B-CHED
of	O
two	O
HIV	O
-	O
1	O
proteinase	O
inhibitors	B-CHED
,	O
lopinavir	O
and	O
ritonavir	B-CHED
,	O
exhibited	O
some	O
signs	O
of	O
effectiveness	O
against	O
the	O
SARS	O
virus	O
.	O

This	O
study	O
showed	O
that	O
ApNPV	O
significantly	O
enhanced	O
inflammatory	O
cytokine	O
mRNA	B-CHED
expression	O
in	O
chicken	O
PBMC	O
and	O
HD	O
11	O
cells	O
through	O
the	O
clathrin	O
-	O
dependent	O
endocytic	O
and	O
endosomal	O
maturation	O
pathway	O
,	O
and	O
up	O
-	O
regulated	O
nitric	B-CHED
oxide	I-CHED
production	O
in	O
HD	O
11	O
cells	O
.	O

SARS	O
6	O
and	O
SARS	O
8b	O
proteins	B-CHED
are	O
localised	O
to	O
the	O
endoplasmic	O
reticulum	O
and	O
nucleus	B-CHED
/	O
cytoplasm	O
,	O
respectively	O
,	O
and	O
both	O
proteins	B-CHED
stimulate	O
host	O
cell	O
DNA	O
synthesis	O
.	O

DFA	B-CHED
and	O
RT	O
-	O
PCR	O
for	O
influenza	O
,	O
parainfluenza	O
,	O
respiratory	O
syncytial	O
virus	O
,	O
adenovirus	O
,	O
enterovirus	O
,	O
coronavirus	O
,	O
rhinovirus	O
,	O
and	O
metapneumovirus	O
were	O
performed	O
on	O
nasal	O
washes	O
and	O
61	O
.	O
8	O
%	O
resulted	O
positive	O
.	O

We	O
show	O
that	O
the	O
three	O
peptides	B-CHED
interact	O
with	O
lipid	B-CHED
membranes	O
depending	O
on	O
lipid	B-CHED
composition	O
and	O
experiments	O
using	O
equimolar	O
mixtures	O
of	O
these	O
peptides	B-CHED
show	O
that	O
different	O
segments	O
of	O
the	O
protein	B-CHED
may	O
act	O
in	O
a	O
synergistic	O
way	O
suggesting	O
that	O
several	O
membrane	O
-	O
active	O
regions	O
could	O
participate	O
in	O
the	O
fusion	O
process	O
of	O
the	O
SARS	O
-	O
CoV	O
.	O

Like	O
other	O
coronaviruses	O
,	O
the	O
SARS	O
virus	O
also	O
utilizes	O
a	O
surface	O
glycoprotein	B-CHED
,	O
namely	O
the	O
spike	O
protein	B-CHED
,	O
to	O
infect	O
host	O
cells	O
.	O

The	O
spike	O
protein	B-CHED
of	O
SARS	O
virus	O
consists	O
of	O
1	O
,	O
255	O
amino	B-CHED
acid	I-CHED
residues	O
and	O
can	O
be	O
divided	O
into	O
two	O
sub	O
-	O
domains	O
,	O
S1	O
and	O
S2	O
.	O

ABSTRACT	O
:	O
Mouse	O
susceptibility	O
to	O
experimental	O
infections	O
with	O
flaviviruses	O
is	O
significantly	O
influenced	O
by	O
a	O
cluster	O
of	O
genes	O
on	O
chromosome	O
5	O
encoding	O
a	O
family	O
of	O
proteins	B-CHED
with	O
enzymatic	O
properties	O
,	O
the	O
2	O
'-	O
5	O
'	O
oligoadenylate	O
synthetases	O
(	O
OAS	O
).	O

This	O
finding	O
is	O
surprising	O
because	O
coronaviruses	O
bud	O
from	O
a	O
pre	O
-	O
Golgi	O
compartment	O
which	O
is	O
expected	O
to	O
be	O
low	O
in	O
cholesterol	B-CHED
compared	O
to	O
the	O
plasma	O
membrane	O
.	O

Recent	O
studies	O
have	O
shown	O
that	O
SARS	O
-	O
CoV	O
VLP	O
formation	O
depends	O
on	O
either	O
M	O
and	O
E	O
proteins	B-CHED
or	O
M	O
and	O
N	O
proteins	B-CHED
.	O

This	O
suggests	O
that	O
the	O
mechanism	O
of	O
SARS	O
-	O
CoV	O
assembly	O
differs	O
from	O
that	O
of	O
other	O
studied	O
coronaviruses	O
,	O
which	O
only	O
require	O
M	O
and	O
E	O
proteins	B-CHED
for	O
VLP	O
formation	O
.	O

The	O
inhibitor	B-CHED
strongly	O
reduced	O
uptake	O
to	O
20	O
.	O
3	O
+/-	O
1	O
.	O
1	O
%	O
of	O
uptake	O
in	O
untreated	O
cells	O
.	O

TITLE	O
:	O
[	O
Antiviral	B-CHED
activity	O
of	O
arbidol	O
and	O
its	O
derivatives	O
against	O
the	O
pathogen	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
in	O
the	O
cell	O
cultures	O
].	O

The	O
promising	O
antiviral	B-CHED
agent	I-CHED
is	O
arbidol	O
mesylate	O
that	O
is	O
nearly	O
5	O
times	O
as	O
effective	O
as	O
arbidol	O
in	O
reducing	O
the	O
reproduction	O
of	O
SARS	O
virus	O
in	O
the	O
cultured	O
cells	O
.	O

Insertion	O
of	O
arbidol	O
,	O
arbidol	O
mesylate	O
,	O
and	O
ribavirin	B-CHED
into	O
the	O
nutrient	B-CHED
medium	O
2	O
hours	O
after	O
infection	O
of	O
porcine	O
embryonic	O
renal	O
cells	O
caused	O
a	O
reduction	O
in	O
the	O
accumulation	O
of	O
the	O
pathogen	O
by	O
2	O
.	O
5	O
,	O
2	O
.	O
1	O
,	O
and	O
2	O
.	O
6	O
Ig	O
,	O
respectively	O
.	O

Of	O
these	O
,	O
43	O
with	O
osteonecrosis	O
received	O
a	O
significantly	O
higher	O
cumulative	O
and	O
peak	O
methylprednisolone	B-CHED
-	O
equivalent	O
dose	O
than	O
71	O
patients	O
with	O
no	O
osteonecrosis	O
identified	O
by	O
MRI	O
.	O

Patients	O
with	O
diaphyseal	O
osteonecrosis	O
received	O
a	O
significantly	O
higher	O
cumulative	O
methylprednisolone	B-CHED
-	O
equivalent	O
dose	O
than	O
those	O
with	O
epiphyseal	O
osteonecrosis	O
.	O

Infection	O
with	O
recombinant	O
SARS	O
-	O
CoV	O
viruses	O
bearing	O
disruptions	O
in	O
the	O
gene	O
7	O
coding	O
region	O
showed	O
no	O
significant	O
change	O
in	O
replication	O
kinetics	O
,	O
tissue	O
tropism	O
,	O
morbidity	O
,	O
or	O
mortality	O
suggesting	O
that	O
the	O
ORF7a	O
(	O
7a	O
)	O
and	O
ORF7b	O
(	O
7b	O
)	O
proteins	B-CHED
are	O
not	O
required	O
for	O
virus	O
replication	O
in	O
immunosuppressed	O
hamsters	O
.	O

The	O
protein	B-CHED
has	O
been	O
crystallized	O
and	O
the	O
crystals	O
diffracted	O
to	O
1	O
.	O
8	O
A	O
resolution	O
.	O

Among	O
207	O
patients	O
receiving	O
insulin	B-CHED
therapy	O
,	O
1	O
.	O
9	O
%	O
were	O
euglycemic	O
,	O
20	O
.	O
8	O
%	O
had	O
blood	O
glucose	B-CHED
levels	O
<	O
or	O
=	O
8	O
.	O
3	O
mmol	O
/	O
L	O
,	O
and	O
1	O
.	O
0	O
%	O
were	O
hypoglycemic	O
.	O

ABSTRACT	O
:	O
Localisation	O
of	O
both	O
viral	O
and	O
cellular	O
proteins	B-CHED
to	O
the	O
nucleolus	O
is	O
determined	O
by	O
a	O
variety	O
of	O
factors	O
including	O
nucleolar	O
localisation	O
signals	O
(	O
NoLSs	O
),	O
but	O
how	O
these	O
signals	O
operate	O
is	O
not	O
clearly	O
understood	O
.	O

To	O
explore	O
this	O
possibility	O
,	O
we	O
introduced	O
a	O
furin	O
-	O
like	O
cleavage	O
sequence	O
in	O
the	O
S	O
protein	B-CHED
at	O
amino	B-CHED
acids	I-CHED
798	O
to	O
801	O
and	O
found	O
that	O
the	O
mutated	O
S	O
protein	B-CHED
was	O
cleaved	O
and	O
induced	O
cell	O
fusion	O
without	O
trypsin	O
treatment	O
when	O
expressed	O
on	O
the	O
cell	O
surface	O
.	O

When	O
the	O
intrusion	O
,	O
avoidance	O
and	O
hyperarousal	O
PTS	O
symptom	O
clusters	B-CHED
were	O
entered	O
into	O
the	O
model	O
,	O
hyperarousal	O
was	O
found	O
to	O
be	O
significantly	O
associated	O
with	O
alcohol	O
abuse	O
/	O
dependence	O
symptoms	O
.	O

The	O
sequences	O
of	O
the	O
M	O
gene	O
and	O
M	O
protein	B-CHED
share	O
83	O
.	O
9	O
-	O
97	O
.	O
9	O
%	O
and	O
83	O
.	O
6	O
-	O
96	O
.	O
5	O
%	O
homologous	O
identities	O
,	O
respectively	O
,	O
compared	O
with	O
29	O
IBV	O
reference	O
strains	O
derived	O
from	O
different	O
regions	O
or	O
countries	O
,	O
which	O
revealed	O
that	O
there	O
are	O
still	O
significant	O
variations	O
between	O
strains	O
.	O

Interactions	O
between	O
SARS	O
-	O
CoV	O
M	O
and	O
other	O
structural	O
proteins	B-CHED
but	O
not	O
interactions	O
between	O
S	O
and	O
E	O
,	O
S	O
and	O
NC	O
,	O
or	O
E	O
and	O
NC	O
were	O
further	O
demonstrated	O
by	O
co	O
-	O
immunoprecipitation	O
assay	O
.	O

A	O
model	O
for	O
the	O
interactions	O
between	O
SARS	O
-	O
CoV	O
M	O
protein	B-CHED
and	O
other	O
structural	O
proteins	B-CHED
is	O
proposed	O
.	O

We	O
assessed	O
the	O
potential	O
of	O
prime	O
-	O
boost	O
vaccination	O
protocols	O
based	O
on	O
the	O
nucleocapsid	O
(	O
NC	O
)	O
protein	B-CHED
co	O
-	O
administered	O
with	O
a	O
derivative	O
of	O
the	O
mucosal	O
adjuvant	B-CHED
MALP	O
-	O
2	O
or	O
expressed	O
by	O
modified	O
Vaccinia	O
virus	O
Ankara	O
(	O
MVA	B-CHED
-	O
NC	O
)	O
to	O
stimulate	O
humoral	O
and	O
cellular	O
immune	O
responses	O
at	O
systemic	O
and	O
mucosal	O
levels	O
.	O

In	O
addition	O
,	O
we	O
engineered	O
the	O
heterologous	O
green	O
fluorescent	O
protein	B-CHED
gene	O
in	O
place	O
of	O
open	O
reading	O
frame	O
3	O
(	O
ORF3	O
)	O
of	O
the	O
NL63	O
clone	O
,	O
simultaneously	O
creating	O
a	O
unique	O
marker	O
for	O
NL63	O
infection	O
and	O
demonstrating	O
that	O
the	O
ORF3	O
protein	B-CHED
product	O
is	O
nonessential	O
for	O
the	O
replication	O
of	O
NL63	O
in	O
cell	O
culture	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
a	O
cellular	O
model	O
of	O
adhesion	O
to	O
investigate	O
whether	O
natural	O
antibodies	O
of	O
the	O
ABO	O
system	O
could	O
block	O
the	O
S	O
protein	B-CHED
and	O
angiotensin	B-CHED
-	O
converting	O
enzyme	O
2	O
interaction	O
.	O

ABSTRACT	O
:	O
Acute	O
liver	O
injury	O
(	O
ALI	O
)	O
following	O
acetaminophen	B-CHED
overdose	O
(	O
AO	O
)	O
occurs	O
in	O
less	O
than	O
10	O
%	O
of	O
cases	O
,	O
but	O
that	O
risk	O
is	O
increased	O
among	O
alcoholics	O
and	O
those	O
with	O
chronic	O
alcoholic	O
liver	O
disease	O
.	O

TITLE	O
:	O
Genome	O
-	O
wide	O
analysis	O
of	O
protein	B-CHED
-	O
protein	B-CHED
interactions	O
and	O
involvement	O
of	O
viral	O
proteins	B-CHED
in	O
SARS	O
-	O
CoV	O
replication	O
.	O

ABSTRACT	O
:	O
Analyses	O
of	O
viral	O
protein	B-CHED
-	O
protein	B-CHED
interactions	O
are	O
an	O
important	O
step	O
to	O
understand	O
viral	O
protein	B-CHED
functions	O
and	O
their	O
underlying	O
molecular	O
mechanisms	O
.	O

Three	O
pairs	O
of	O
the	O
interactions	O
identified	O
were	O
detected	O
in	O
both	O
directions	O
:	O
non	O
-	O
structural	O
protein	B-CHED
(	O
nsp	O
)	O
10	O
and	O
nsp14	O
,	O
nsp10	O
and	O
nsp16	O
,	O
and	O
nsp7	O
and	O
nsp8	O
.	O

Finally	O
,	O
haplotype	O
analyses	O
revealed	O
strong	O
acute	O
lung	O
injury	O
associations	O
with	O
2	O
-	O
4	O
single	O
nucleotide	B-CHED
polymorphism	O
haplotypes	O
,	O
all	O
involving	O
His21Pro	O
(	O
p	O
<	O
0	O
.	O
008	O
).	O

We	O
used	O
chi	B-CHED
(	O
2	O
),	O
analysis	O
of	O
variance	O
,	O
and	O
analysis	O
of	O
covariance	O
analyses	O
to	O
test	O
for	O
differences	O
between	O
the	O
1999	O
and	O
2005	O
samples	O
for	O
infection	O
control	O
program	O
components	O
and	O
ARO	O
rates	O
.	O

The	O
Institute	O
of	O
Medicine	B-CHED
coined	O
the	O
term	O
'	O
emerging	O
and	O
reemerging	O
diseases	O
'	O
to	O
explain	O
that	O
the	O
world	O
had	O
entered	O
an	O
era	B-CHED
in	O
which	O
the	O
vulnerability	O
to	O
epidemics	O
in	O
the	O
United	O
States	O
and	O
globally	O
was	O
greater	O
than	O
ever	O
.	O

Multivariate	O
logistic	O
regression	O
analyses	O
indicated	O
that	O
children	O
without	O
a	O
copy	O
of	O
the	O
A1	O
allele	O
of	O
the	O
variable	O
nucleotide	B-CHED
tandem	O
repeat	O
polymorphism	O
in	O
intron	O
2	O
of	O
the	O
interleukin	O
-	O
1	O
receptor	O
antagonist	B-CHED
gene	O
were	O
more	O
likely	O
to	O
need	O
positive	O
pressure	O
ventilation	O
compared	O
to	O
those	O
with	O
one	O
or	O
two	O
copies	O
of	O
this	O
allele	O
(	O
odds	O
ratio	O
=	O
2	O
.	O
65	O
,	O
confidence	O
interval	O
,	O
1	O
.	O
02	O
-	O
6	O
.	O
90	O
).	O

TITLE	O
:	O
The	O
immunoreactivity	O
of	O
a	O
chimeric	O
multi	O
-	O
epitope	B-CHED
DNA	O
vaccine	O
against	O
IBV	O
in	O
chickens	O
.	O

The	O
phylogenetic	O
analysis	O
of	O
the	O
nucleotide	B-CHED
sequences	O
of	O
the	O
isolates	O
showed	O
that	O
they	O
were	O
closely	O
related	O
to	O
each	O
other	O
,	O
and	O
formed	O
a	O
separate	O
cluster	O
apart	O
from	O
the	O
U	O
.	O
S	O
.	O
A	O
.	O
and	O
European	O
strains	O
.	O

ABSTRACT	O
:	O
The	O
antiviral	B-CHED
role	O
of	O
CD4	O
(+)	O
T	O
cells	O
in	O
virus	O
-	O
induced	O
pathologies	O
of	O
the	O
central	O
nervous	O
system	O
(	O
CNS	B-CHED
)	O
has	O
not	O
been	O
explored	O
extensively	O
.	O

To	O
distinguish	O
bystander	O
from	O
direct	O
antiviral	B-CHED
contributions	O
of	O
CD4	O
(+)	O
T	O
cells	O
in	O
virus	O
clearance	O
and	O
pathology	O
,	O
memory	O
CD4	O
(+)	O
T	O
cells	O
purified	O
from	O
wild	O
type	O
(	O
wt	O
),	O
perforin	O
-	O
deficient	O
(	O
PKO	O
),	O
and	O
IFN	O
-	O
gamma	O
-	O
deficient	O
(	O
GKO	O
)	O
immune	O
donors	O
were	O
transferred	O
to	O
immunodeficient	O
SCID	O
mice	O
prior	O
to	O
CNS	B-CHED
challenge	O
.	O

Despite	O
substantial	O
IFN	O
-	O
gamma	O
-	O
independent	O
antiviral	B-CHED
activity	O
,	O
IFN	O
-	O
gamma	O
was	O
crucial	O
in	O
providing	O
protection	O
from	O
death	O
.	O

TITLE	O
:	O
Neuroprotective	O
effect	O
of	O
apolipoprotein	B-CHED
D	O
against	O
human	O
coronavirus	O
OC43	O
-	O
induced	O
encephalitis	O
in	O
mice	O
.	O

We	O
previously	O
demonstrated	O
that	O
apoD	O
protects	O
against	O
neuropathology	O
by	O
controlling	O
the	O
level	O
of	O
peroxidated	O
lipids	B-CHED
.	O

Here	O
,	O
we	O
further	O
investigated	O
the	O
biological	B-CHED
function	I-CHED
of	O
apoD	O
in	O
a	O
mouse	O
model	O
of	O
acute	O
encephalitis	O
.	O

The	O
peak	O
of	O
creatine	B-CHED
phosphokinase	O
level	O
can	O
be	O
predictive	O
for	O
the	O
development	O
of	O
acute	O
renal	O
failure	O
because	O
myoglobin	B-CHED
level	O
may	O
return	O
to	O
normal	O
within	O
6	O
hours	O
after	O
muscle	O
injury	O
.	O

DPD	O
activity	O
was	O
evaluated	O
by	O
Peripheral	O
Blood	O
Mononuclear	O
Cell	O
(	O
PBMC	O
)	O
radioassay	O
,	O
genotyping	O
of	O
DPYD	O
gene	O
by	O
Denaturing	O
High	O
Performance	O
Liquid	O
Chromatography	O
(	O
DHPLC	O
),	O
or	O
2	O
-(	O
13	O
)	O
C	O
uracil	B-CHED
breath	O
test	O
(	O
UraBT	O
).	O

RESULTS	O
:	O
Of	O
23	O
patients	O
with	O
excessive	O
toxicities	O
from	O
5	B-CHED
-	I-CHED
FU	I-CHED
and	O
/	O
or	O
capecitabine	B-CHED
,	O
7	O
(	O
30	O
%)	O
were	O
DPD	O
deficient	O
with	O
a	O
median	O
age	O
of	O
66	O
years	O
,	O
M	O
:	O
F	O
ratio	O
=	O
1	O
.	O
3	O
:	O
1	O
and	O
ethnicities	O
included	O
Caucasian	O
(	O
71	O
%),	O
African	O
-	O
American	O
(	O
14	O
%)	O
and	O
South	O
-	O
Asian	O
(	O
14	O
%).	O

TITLE	O
:	O
Spike	O
protein	B-CHED
,	O
S	O
,	O
of	O
human	O
coronavirus	O
HKU1	O
:	O
role	O
in	O
viral	O
life	O
cycle	O
and	O
application	O
in	O
antibody	O
detection	O
.	O

ABSTRACT	O
:	O
We	O
report	O
the	O
discovery	O
and	O
optimization	O
of	O
a	O
potent	O
inhibitor	B-CHED
against	O
the	O
papain	O
-	O
like	O
protease	O
(	O
PLpro	O
)	O
from	O
the	O
coronavirus	O
that	O
causes	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
-	O
CoV	O
).	O

Following	O
LPS	B-CHED
stimulation	O
,	O
the	O
anti	O
-	O
inflammatory	O
activity	O
of	O
ASODN	O
against	O
the	O
IRAK	O
-	O
1	O
gene	O
expression	O
is	O
evidenced	O
by	O
the	O
lower	O
expression	O
of	O
inflammatory	O
chemokines	O
,	O
cytokines	O
and	O
acute	O
-	O
phase	O
proteins	B-CHED
compared	O
to	O
control	O
cells	O
.	O

Antiviral	B-CHED
therapy	O
of	O
viral	O
respiratory	O
infections	O
is	O
often	O
unnecessary	O
in	O
the	O
competent	O
hosts	O
because	O
most	O
of	O
them	O
are	O
selflimiting	O
and	O
effective	O
agents	O
are	O
not	O
always	O
available	O
.	O

Refolding	O
of	O
SARS	O
N	O
-	O
protein	B-CHED
during	O
production	O
and	O
purification	O
showed	O
the	O
presence	O
of	O
two	O
additional	O
protein	B-CHED
bands	O
by	O
SDS	B-CHED
-	O
PAGE	O
.	O

Definitive	O
diagnosis	O
of	O
FIP	O
was	O
made	O
by	O
histopathology	O
and	O
by	O
immunohistochemical	O
demonstration	O
of	O
coronavirus	O
antigen	B-CHED
in	O
macrophages	O
within	O
kidney	O
and	O
skin	O
lesions	O
.	O

Further	O
characterization	O
showed	O
that	O
this	O
internalization	O
process	O
was	O
independent	O
from	O
phosphatases	O
and	O
tyrosine	B-CHED
kinases	O
but	O
did	O
depend	O
on	O
serine	B-CHED
/	O
threonine	B-CHED
kinases	O
.	O

ABSTRACT	O
:	O
Although	O
in	O
different	O
groups	O
,	O
the	O
coronaviruses	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
and	O
NL63	O
use	O
the	O
same	O
receptor	O
,	O
angiotensin	B-CHED
converting	O
enzyme	O
(	O
ACE	O
)-	O
2	O
,	O
for	O
entry	O
into	O
the	O
host	O
cell	O
.	O

Based	O
on	O
sequence	O
similarity	O
,	O
human	O
PP11	O
was	O
included	O
in	O
a	O
protein	B-CHED
family	O
whose	O
characterized	O
members	O
are	O
XendoU	O
,	O
a	O
Xenopus	O
laevis	O
endoribonuclease	O
involved	O
in	O
small	O
nucleolar	O
RNA	O
processing	O
,	O
and	O
Nsp15	O
,	O
an	O
endoribonuclease	O
essential	O
for	O
coronavirus	O
replication	O
.	O

The	O
role	O
of	O
stereochemistry	O
and	O
tert	B-CHED
-	I-CHED
butyl	I-CHED
substitution	O
of	O
the	O
phthalimidoethyl	O
moiety	O
on	O
activity	O
was	O
also	O
investigated	O
.	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
is	O
a	O
lifethreatening	O
emerging	O
respiratory	O
disease	O
caused	O
by	O
the	O
coronavirus	O
,	O
SARS	O
-	O
CoV	O
.	O
The	O
nucleocapsid	O
(	O
N	O
)	O
protein	B-CHED
of	O
SARS	O
-	O
CoV	O
is	O
highly	O
antigenic	O
and	O
may	O
be	O
a	O
suitable	O
candidate	O
for	O
diagnostic	O
applications	O
.	O

Six	O
S	O
glycoprotein	B-CHED
fragments	O
were	O
expressed	O
in	O
Escherichia	O
coli	O
BL21	O
and	O
yeast	O
KM71H	O
strains	O
.	O

The	O
microchip	O
electrophoresis	O
with	O
PMMA	B-CHED
chip	O
provided	O
a	O
rapid	O
,	O
sensitive	O
and	O
reliable	O
method	O
for	O
analysis	O
of	O
multiplex	O
PCR	O
products	O
.	O

In	O
addition	O
,	O
trypsin	O
induced	O
cleavage	O
of	O
the	O
229E	O
S	O
protein	B-CHED
.	O

Under	O
mechanical	O
ventilation	O
,	O
she	O
was	O
administered	O
several	O
antibiotics	B-CHED
and	O
dopamine	B-CHED
.	O

ABSTRACT	O
:	O
One	O
of	O
the	O
first	O
lines	O
of	O
defence	O
against	O
viral	O
infection	O
is	O
the	O
innate	O
immune	O
response	O
and	O
the	O
induction	O
of	O
antiviral	B-CHED
type	O
I	O
interferons	O
(	O
IFNs	O
).	O

TITLE	O
:	O
Differential	O
activities	O
of	O
cellular	O
and	O
viral	O
macro	O
domain	O
proteins	B-CHED
in	O
binding	O
of	O
ADP	B-CHED
-	O
ribose	B-CHED
metabolites	B-CHED
.	O

ABSTRACT	O
:	O
Macro	O
domain	O
is	O
a	O
highly	O
conserved	O
protein	B-CHED
domain	O
found	O
in	O
both	O
eukaryotes	O
and	O
prokaryotes	O
.	O

Ganglioside	B-CHED
-	O
induced	O
differentiation	O
-	O
associated	O
protein	B-CHED
2	O
did	O
not	O
show	O
affinity	O
for	O
ADP	B-CHED
-	O
ribose	B-CHED
or	O
its	O
derivatives	O
,	O
but	O
instead	O
bound	O
poly	O
(	O
A	O
).	O

In	O
this	O
study	O
,	O
we	O
report	O
that	O
a	O
minimal	O
HR2	O
peptide	B-CHED
,	O
P6	O
of	O
23	O
-	O
mer	O
,	O
can	O
block	O
the	O
fusion	O
of	O
SARS	O
-	O
CoV	O
with	O
an	O
IC	O
(	O
50	O
)	O
of	O
1	O
.	O
04	O
+/-	O
0	O
.	O
22	O
microM	O
.	O
This	O
finding	O
supports	O
the	O
structural	O
prediction	O
of	O
the	O
deep	O
groove	O
of	O
HR1	O
trimer	O
as	O
a	O
target	O
for	O
fusion	O
inhibitors	B-CHED
,	O
and	O
suggests	O
P6	O
as	O
a	O
potential	O
lead	O
peptide	B-CHED
for	O
future	O
drug	O
development	O
.	O

Here	O
we	O
show	O
,	O
by	O
focusing	O
on	O
a	O
dominant	O
neutralization	O
epitope	B-CHED
,	O
that	O
contemporaneous	O
-	O
and	O
cross	O
-	O
strain	O
nAb	O
responses	O
against	O
SARS	O
-	O
CoV	O
spike	O
protein	B-CHED
exist	O
during	O
natural	O
infection	O
.	O

This	O
research	O
provides	O
critical	O
information	O
for	O
appropriate	O
HW	O
incineration	O
ash	B-CHED
management	O
plans	O
.	O

Its	O
spike	O
glycoprotein	B-CHED
(	O
S	O
)	O
is	O
processed	O
by	O
host	O
furin	O
enzyme	O
to	O
produce	O
S1	O
and	O
S2	O
fragments	O
,	O
the	O
latter	O
being	O
crucial	O
for	O
fusion	O
with	O
the	O
host	O
membrane	O
.	O

Several	O
structural	O
analogues	O
of	O
Q7R	O
,	O
quercetin	B-CHED
,	O
apigenin	B-CHED
,	O
luteolin	B-CHED
and	O
catechin	B-CHED
,	O
also	O
showed	O
moderate	O
anti	O
-	O
PEDV	O
activity	O
.	O

Antiviral	B-CHED
drugs	I-CHED
and	O
natural	O
compounds	O
revealed	O
ribavirin	B-CHED
,	O
interferon	O
-	O
alpha	O
,	O
coumarin	B-CHED
and	O
tannic	O
acid	O
have	O
relative	O
weaker	O
efficacy	O
compared	O
to	O
Q7R	O
.	O

In	O
lung	O
tissue	O
E	O
.	O
coli	O
antigen	B-CHED
was	O
found	O
up	O
to	O
4	O
dpi	O
.	O

Within	O
two	O
hours	O
of	O
iLA	O
treatment	O
,	O
arterial	O
oxygen	B-CHED
partial	O
pressure	O
/	O
inspired	O
oxygen	B-CHED
fraction	O
ratio	O
increased	O
significantly	O
and	O
a	O
fast	O
improvement	O
in	O
arterial	O
carbon	B-CHED
dioxide	I-CHED
partial	O
pressure	O
and	O
pH	O
was	O
observed	O
.	O

HCoV	O
-	O
NL63	O
virus	O
stock	O
of	O
increased	O
infectivity	O
will	O
be	O
beneficial	O
in	O
antiviral	B-CHED
screening	O
,	O
animal	O
modelling	O
of	O
disease	O
,	O
and	O
other	O
experimental	O
tasks	O
.	O

In	O
this	O
report	O
,	O
one	O
of	O
these	O
replicase	O
proteins	B-CHED
,	O
nsp9	O
of	O
the	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
is	O
systematically	O
studied	O
using	O
both	O
biochemical	O
and	O
reverse	O
genetic	O
approaches	O
.	O

The	O
results	O
showed	O
that	O
substitution	O
mutation	O
of	O
a	O
conserved	O
Gly	B-CHED
(	O
G98	O
)	O
residue	O
in	O
the	O
C	O
-	O
terminal	O
alpha	O
-	O
helix	O
domain	O
with	O
an	O
Asp	B-CHED
greatly	O
destabilized	O
the	O
IBV	O
nsp9	O
homodimer	O
and	O
abolished	O
its	O
RNA	O
-	O
binding	O
activity	O
.	O

Meanwhile	O
,	O
mutations	O
of	O
some	O
positively	O
charged	O
residues	O
in	O
the	O
beta	O
-	O
barrel	O
regions	O
of	O
the	O
IBV	O
nsp9	O
protein	B-CHED
significantly	O
reduced	O
its	O
RNA	O
-	O
binding	O
activity	O
,	O
but	O
with	O
no	O
obvious	O
effect	O
on	O
dimerization	O
of	O
the	O
protein	B-CHED
.	O

The	O
active	O
form	O
of	O
the	O
TCoV	O
nsp15	O
was	O
a	O
homohexamer	O
and	O
disulfide	B-CHED
bond	O
was	O
essential	O
for	O
the	O
enzymatic	O
activity	O
.	O

ABSTRACT	O
:	O
Propagation	O
of	O
new	O
human	O
respiratory	O
virus	O
pathogens	O
in	O
established	O
cell	O
lines	O
is	O
hampered	O
by	O
a	O
lack	O
of	O
predictability	O
regarding	O
cell	O
line	O
permissivity	O
and	O
by	O
availability	O
of	O
suitable	O
antibody	O
reagents	B-CHED
to	O
detect	O
infection	O
in	O
cell	O
lines	O
that	O
do	O
not	O
exhibit	O
significant	O
cytopathic	O
effect	O
.	O

Recently	O
,	O
molecular	O
methods	O
have	O
been	O
used	O
to	O
amplify	O
and	O
identify	O
novel	O
nucleic	B-CHED
acid	I-CHED
sequences	O
directly	O
from	O
clinical	O
samples	O
,	O
but	O
these	O
methods	O
may	O
be	O
hampered	O
by	O
the	O
quantity	O
of	O
virus	O
present	O
in	O
respiratory	O
secretions	O
at	O
different	O
time	O
points	O
following	O
the	O
onset	O
of	O
infection	O
.	O

To	O
establish	O
proof	O
-	O
of	O
-	O
principle	O
human	O
coronavirus	O
NL63	O
(	O
HCoV	O
-	O
NL63	O
)	O
was	O
evaluated	O
,	O
and	O
the	O
first	O
visualization	O
of	O
HCoV	O
-	O
NL63	O
virus	O
by	O
transmission	O
electron	O
microscopy	O
(	O
TEM	B-CHED
)	O
is	O
reported	O
.	O

Initial	O
propagation	O
of	O
human	O
respiratory	O
secretions	O
onto	O
HAE	O
cultures	O
followed	O
by	O
TEM	B-CHED
and	O
WTA	O
of	O
culture	O
supernatant	O
may	O
be	O
a	O
useful	O
approach	O
for	O
visualization	O
and	O
detection	O
of	O
new	O
human	O
respiratory	O
pathogens	O
that	O
have	O
eluded	O
identification	O
by	O
traditional	O
approaches	O
.	O

The	O
CCoV	O
-	O
II	O
strains	O
were	O
strictly	O
related	O
to	O
porcine	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
in	O
the	O
N	O
-	O
terminal	O
domain	O
of	O
the	O
spike	O
protein	B-CHED
,	O
whereas	O
in	O
the	O
other	O
parts	O
of	O
the	O
genome	O
,	O
a	O
higher	O
genetic	O
relatedness	O
to	O
recent	O
CCoV	O
-	O
II	O
isolates	O
was	O
observed	O
.	O

The	O
fusion	O
protein	B-CHED
was	O
analyzed	O
for	O
reactivity	O
with	O
SARS	O
patients	O
'	O
sera	O
and	O
with	O
anti	O
-	O
sera	O
against	O
the	O
two	O
human	O
coronaviruses	O
HCoV	O
229E	O
and	O
HCoV	O
OC43	O
by	O
ELISA	O
,	O
IFA	O
and	O
immunoblot	O
assays	O
.	O

Serological	O
results	O
showed	O
that	O
the	O
diagnostic	O
sensitivity	O
and	O
specificity	O
of	O
the	O
truncated	O
S	O
-	O
N	O
fusion	O
protein	B-CHED
derived	O
the	O
SARS	O
virus	O
were	O
>	O
99	O
%	O
(	O
457	O
/	O
460	O
)	O
and	O
100	O
.	O
00	O
%	O
(	O
650	O
/	O
650	O
),	O
respectively	O
.	O

The	O
present	O
study	O
shows	O
that	O
:	O
(	O
1	O
)	O
the	O
ratio	O
of	O
peripheral	O
blood	O
sIg	O
(+)	O
CD21	O
(-)	O
B	O
-	O
cells	O
was	O
higher	O
in	O
cats	O
with	O
FIP	O
than	O
in	O
SPF	O
cats	O
,	O
(	O
2	O
)	O
the	O
albumin	O
-	O
to	O
-	O
globulin	O
ratio	O
has	O
negative	O
correlation	O
with	O
the	O
ratio	O
of	O
peripheral	O
blood	O
sIg	O
(+)	O
CD21	O
(-)	O
B	O
-	O
cell	O
,	O
(	O
3	O
)	O
cells	O
strongly	O
expressing	O
mRNA	B-CHED
of	O
the	O
plasma	O
cell	O
master	O
gene	O
,	O
B	O
-	O
lymphocyte	O
-	O
induced	O
maturation	O
protein	B-CHED
1	O
(	O
Blimp	O
-	O
1	O
),	O
were	O
increased	O
in	O
peripheral	O
blood	O
in	O
cats	O
with	O
FIP	O
,	O
(	O
4	O
)	O
mRNA	B-CHED
expression	O
of	O
B	O
-	O
cell	O
differentiation	O
/	O
survival	O
factors	O
,	O
IL	O
-	O
6	O
,	O
CD40	O
ligand	B-CHED
,	O
and	O
B	O
-	O
cell	O
-	O
activating	O
factor	O
belonging	O
to	O
the	O
tumor	O
necrosis	O
factor	O
family	O
(	O
BAFF	O
),	O
was	O
enhanced	O
in	O
macrophages	O
in	O
cats	O
with	O
FIP	O
,	O
and	O
(	O
5	O
)	O
mRNAs	O
of	O
these	O
B	O
-	O
cell	O
differentiation	O
/	O
survival	O
factors	O
were	O
overexpressed	O
in	O
antibody	O
-	O
dependent	O
enhancement	O
(	O
ADE	B-CHED
)-	O
induced	O
macrophages	O
.	O

TITLE	O
:	O
Viral	O
protease	B-CHED
inhibitors	I-CHED
.	O

ABSTRACT	O
:	O
This	O
review	O
provides	O
an	O
overview	O
of	O
the	O
development	O
of	O
viral	O
protease	B-CHED
inhibitors	I-CHED
as	O
antiviral	B-CHED
drugs	I-CHED
.	O

Thus	O
,	O
we	O
discuss	O
the	O
biochemistry	O
of	O
HIV	O
-	O
1	O
protease	O
,	O
inhibitor	B-CHED
development	O
,	O
clinical	O
use	O
of	O
inhibitors	B-CHED
,	O
and	O
evolution	O
of	O
resistance	O
.	O

The	O
most	O
striking	O
immunological	O
finding	O
was	O
the	O
presence	O
of	O
positive	O
IgG	O
anti	O
-	O
GQ1b	O
,	O
IgM	O
anti	O
-	O
GMI	O
and	O
IgM	O
anti	O
-	O
asialo	B-CHED
GM1	I-CHED
titres	O
.	O

Small	O
-	O
angle	O
X	O
-	O
ray	O
scattering	O
data	O
show	O
that	O
the	O
protein	B-CHED
is	O
in	O
an	O
extended	O
conformation	O
and	O
that	O
the	O
two	O
structural	O
domains	O
of	O
the	O
SARS	O
-	O
CoV	O
N	O
protein	B-CHED
are	O
far	O
apart	O
.	O

ABSTRACT	O
:	O
The	O
nuclear	O
magnetic	O
resonance	O
(	O
NMR	O
)	O
structure	O
of	O
a	O
central	O
segment	O
of	O
the	O
previously	O
annotated	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
unique	O
domain	O
(	O
SUD	O
-	O
M	O
,	O
for	O
""""	O
middle	O
of	O
the	O
SARS	O
-	O
unique	O
domain	O
""")"	O
in	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
nonstructural	O
protein	B-CHED
3	O
(	O
nsp3	O
)	O
has	O
been	O
determined	O
.	O

SUD	O
-	O
M	O
(	O
527	O
-	O
651	O
)	O
also	O
shows	O
three	O
-	O
dimensional	O
structure	O
homology	O
with	O
several	O
helicases	O
and	O
nucleoside	B-CHED
triphosphate	I-CHED
-	O
binding	O
proteins	B-CHED
,	O
but	O
it	O
does	O
not	O
contain	O
the	O
motifs	O
of	O
catalytic	O
residues	O
found	O
in	O
these	O
structural	O
homologues	O
.	O

The	O
primer	O
combinations	O
were	O
:	O
oligonucleotide	B-CHED
pair	O
2Bp	O
/	O
4Bm	O
,	O
which	O
is	O
in	O
a	O
region	O
of	O
gene	O
1	O
that	O
is	O
moderately	O
conserved	O
among	O
all	O
species	O
of	O
coronavirus	O
(	O
1	O
);	O
and	O
UTR11	O
-/	O
UTR41	O
+,	O
which	O
are	O
in	O
a	O
highly	O
conserved	O
part	O
of	O
the	O
3	O
'	O
untranslated	O
region	O
of	O
avian	O
coronaviruses	O
related	O
to	O
infectious	O
bronchitis	O
virus	O
(	O
2	O
).	O

This	O
strategy	O
allows	O
the	O
sequencing	O
of	O
some	O
50	O
-	O
100	O
nucleotides	B-CHED
from	O
the	O
3	O
'-	O
end	O
of	O
the	O
virus	O
genome	O
,	O
representing	O
sufficient	O
sequence	O
information	O
for	O
initiation	O
of	O
further	O
genomic	O
characterization	O
in	O
a	O
rapid	O
amplification	O
of	O
cDNA	O
ends	O
(	O
5	O
'-	O
RACE	O
)	O
and	O
primer	O
walking	O
strategy	O
.	O

Partial	O
deletion	O
of	O
the	O
cytoplasmic	O
domain	O
of	O
SARS	O
-	O
CoV	O
S	O
protein	B-CHED
(	O
SARS	O
-	O
CoV	O
-	O
St19	O
)	O
allowed	O
efficient	O
incorporation	O
into	O
the	O
VSV	O
particle	O
that	O
enabled	O
the	O
generation	O
of	O
a	O
high	O
titer	O
of	O
pseudotype	O
virus	O
.	O

This	O
system	O
enabled	O
high	O
-	O
throughput	O
analysis	O
of	O
SARS	O
-	O
CoV	O
S	O
protein	B-CHED
-	O
mediated	O
cell	O
entry	O
by	O
measuring	O
alkaline	O
phosphatase	O
activity	O
.	O

In	O
this	O
virus	O
the	O
ectodomain	O
of	O
the	O
spike	O
glycoprotein	B-CHED
is	O
replaced	O
by	O
that	O
of	O
a	O
coronavirus	O
with	O
a	O
different	O
species	O
tropism	O
.	O

Conversely	O
,	O
the	O
IBV	O
3a	O
and	O
IBV	O
3b	O
proteins	B-CHED
are	O
nonstructural	O
proteins	B-CHED
.	O

Antibodies	O
were	O
raised	O
in	O
rabbits	O
following	O
inoculation	O
with	O
IBV	O
-	O
specific	O
peptides	B-CHED
and	O
GST	O
fusion	O
proteins	B-CHED
,	O
and	O
were	O
screened	O
by	O
immunofluorescence	O
,	O
radioimmunoprecipitation	O
,	O
and	O
immunoblotting	O
.	O

TITLE	O
:	O
Production	O
of	O
coronavirus	O
nonstructural	O
proteins	B-CHED
in	O
soluble	O
form	O
for	O
crystallization	O
.	O

Electron	O
cryomicroscopy	O
(	O
cryo	O
-	O
EM	O
)	O
instead	O
employs	O
a	O
porous	O
support	O
film	O
,	O
to	O
which	O
the	O
specimen	O
is	O
adsorbed	O
and	O
flash	B-CHED
-	O
frozen	O
.	O

TITLE	O
:	O
Large	O
-	O
scale	O
preparation	O
of	O
UV	O
-	O
inactivated	O
SARS	O
coronavirus	O
virions	O
for	O
vaccine	O
antigen	B-CHED
.	O

FIPV	O
-	O
induced	O
p38	O
MAPK	O
activation	O
was	O
observed	O
in	O
primary	O
feline	O
blood	O
-	O
derived	O
mononuclear	O
cells	O
individually	O
purified	O
from	O
multiple	O
SPF	O
cats	O
,	O
as	O
was	O
the	O
inhibition	O
of	O
TNF	O
-	O
alpha	O
production	O
by	O
pyridinyl	B-CHED
imidazole	B-CHED
inhibitors	B-CHED
.	O

TITLE	O
:	O
Effects	O
of	O
dietary	O
glutamine	B-CHED
supplementation	O
on	O
lung	O
injury	O
induced	O
by	O
lipopolysaccharide	B-CHED
administration	O
.	O

This	O
study	O
indicates	O
that	O
dietary	O
Gln	B-CHED
administration	O
resulted	O
in	O
higher	O
inflammatory	O
cytokine	O
production	O
,	O
with	O
more	O
neutrophils	O
recruited	O
at	O
the	O
early	O
stage	O
of	O
ALI	O
.	O

In	O
this	O
chapter	O
,	O
I	O
describe	O
specific	O
protein	B-CHED
-	O
protein	B-CHED
interactions	O
suggested	O
by	O
a	O
novel	O
model	O
of	O
immune	O
signaling	O
,	O
the	O
Signaling	O
Chain	O
HOmoOLigomerization	O
(	O
SCHOOL	O
)	O
model	O
,	O
to	O
be	O
critical	O
for	O
cell	O
activation	O
mediated	O
by	O
multichain	O
immune	O
recognition	O
receptors	O
(	O
MIRRs	O
)	O
expressed	O
on	O
different	O
cells	O
of	O
the	O
hematopoietic	O
system	O
.	O

Thus	O
,	O
an	O
important	O
application	O
of	O
the	O
SCHOOL	O
model	O
is	O
that	O
global	O
therapeutic	O
strategies	O
targeting	O
key	O
protein	B-CHED
-	O
protein	B-CHED
interactions	O
involved	O
in	O
MIRR	O
triggering	O
and	O
transmembrane	O
signal	O
transduction	O
may	O
be	O
used	O
to	O
treat	O
a	O
diverse	O
set	O
of	O
immune	O
-	O
mediated	O
diseases	O
.	O

As	O
an	O
illustration	O
of	O
this	O
tension	O
,	O
donor	B-CHED
deferral	O
measures	O
imposed	O
by	O
globalisation	O
-	O
induced	O
risks	O
such	O
as	O
vCJD	O
and	O
WNV	O
have	O
resulted	O
in	O
the	O
loss	O
of	O
the	O
safest	O
and	O
most	O
committed	O
portion	O
of	O
the	O
blood	O
donor	B-CHED
population	O
in	O
many	O
Western	O
countries	O
,	O
leading	O
to	O
an	O
increased	O
risk	O
to	O
safety	O
and	O
supply	O
.	O

ABSTRACT	O
:	O
We	O
are	O
developing	O
a	O
method	O
for	O
real	O
-	O
time	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
visualization	O
of	O
convection	O
-	O
enhanced	O
delivery	O
(	O
CED	B-CHED
)	O
of	O
adeno	O
-	O
associated	O
viral	O
vectors	O
(	O
AAV	O
)	O
to	O
the	O
primate	O
brain	O
.	O

The	O
genome	O
of	O
Ark	O
DPI	O
consists	O
of	O
27	O
,	O
620	O
nucleotides	B-CHED
,	O
excluding	O
poly	O
(	O
A	O
)	O
tail	O
,	O
and	O
comprises	O
ten	O
open	O
reading	O
frames	O
.	O

TITLE	O
:	O
Glycogen	B-CHED
synthase	O
kinase	O
-	O
3	O
regulates	O
the	O
phosphorylation	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
nucleocapsid	O
protein	B-CHED
and	O
viral	O
replication	O
.	O

Mass	O
spectrometric	O
analysis	O
and	O
deletion	O
mapping	O
showed	O
that	O
the	O
major	O
phosphorylation	O
sites	O
were	O
located	O
at	O
the	O
central	O
serine	B-CHED
-	O
arginine	B-CHED
(	O
SR	O
)-	O
rich	O
motif	O
that	O
contains	O
several	O
glycogen	B-CHED
synthase	O
kinase	O
(	O
GSK	O
)-	O
3	O
substrate	O
consensus	O
sequences	O
.	O

Reverse	O
transcription	O
-	O
PCR	O
analyses	O
revealed	O
that	O
the	O
reduction	O
of	O
GCN2	O
protein	B-CHED
was	O
not	O
due	O
to	O
decreased	O
transcription	O
or	O
stability	O
of	O
GCN2	O
mRNA	B-CHED
.	O

Although	O
reported	O
as	O
a	O
liver	O
and	O
lymph	O
node	O
sinusoidal	O
endothelial	O
cell	O
-	O
specific	O
molecule	O
,	O
LSECtin	O
could	O
be	O
detected	O
in	O
the	O
MUTZ	O
-	O
3	O
dendritic	O
-	O
like	O
cell	O
line	O
at	O
the	O
messenger	B-CHED
RNA	I-CHED
(	O
mRNA	B-CHED
)	O
and	O
protein	B-CHED
level	O
,	O
and	O
immunohistochemistry	O
analysis	O
on	O
human	O
liver	O
revealed	O
its	O
presence	O
in	O
Kupffer	O
cells	O
coexpressing	O
the	O
myeloid	O
marker	O
CD68	O
.	O

ECMO	O
allowed	O
epinephrine	B-CHED
and	O
norepinephrine	B-CHED
to	O
be	O
progressively	O
discontinued	O
,	O
and	O
protective	O
mechanical	O
ventilation	O
.	O

No	O
direct	O
interactions	O
among	O
SARS	O
-	O
CoV	O
E	O
protein	B-CHED
with	O
either	O
alpha	O
-	O
or	O
gamma	O
-	O
ENaC	O
were	O
indentified	O
.	O

Instead	O
,	O
the	O
downregulation	O
of	O
ENaC	O
activity	O
by	O
SARS	O
proteins	B-CHED
was	O
partially	O
or	O
completely	O
restored	O
by	O
administration	O
of	O
inhibitors	B-CHED
of	O
PKCalpha	O
/	O
beta1	O
and	O
PKCzeta	O
.	O

ABSTRACT	O
:	O
SARS	O
-	O
CoV	O
has	O
four	O
major	O
structural	O
proteins	B-CHED
:	O
the	O
N	O
,	O
S	O
,	O
M	O
,	O
and	O
E	O
proteins	B-CHED
.	O

Co	O
-	O
immunoprecipitation	O
analyses	O
demonstrated	O
an	O
interaction	O
between	O
the	O
N	O
and	O
M	O
proteins	B-CHED
,	O
suggesting	O
that	O
N	O
protein	B-CHED
binds	O
directly	O
to	O
M	O
protein	B-CHED
to	O
be	O
incorporated	O
into	O
VLP	O
.	O

The	O
importance	O
of	O
differences	O
in	O
FIPV	O
serotype	O
on	O
the	O
induction	O
of	O
ADE	B-CHED
remains	O
unclear	O
.	O

TITLE	O
:	O
Pumpless	O
extracorporeal	O
removal	O
of	O
carbon	B-CHED
dioxide	I-CHED
combined	O
with	O
ventilation	O
using	O
low	O
tidal	O
volume	O
and	O
high	O
positive	O
end	O
-	O
expiratory	O
pressure	O
in	O
a	O
patient	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

Extracorporeal	O
removal	O
of	O
carbon	B-CHED
dioxide	I-CHED
by	O
interventional	O
lung	O
assist	O
may	O
be	O
a	O
useful	O
tool	O
to	O
enable	O
'	O
ultraprotective	O
'	O
ventilation	O
in	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

Several	O
crystal	O
structures	O
of	O
3C	O
(	O
pro	B-CHED
)	O
from	O
CVB3	O
and	O
3CL	O
(	O
pro	B-CHED
)	O
from	O
CoV	O
-	O
229E	O
and	O
SARS	O
-	O
CoV	O
in	O
complex	O
with	O
the	O
inhibitors	B-CHED
were	O
solved	O
.	O

Immunization	O
experiments	O
with	O
no	O
adjuvants	B-CHED
were	O
performed	O
with	O
BALB	O
/	O
c	O
mice	O
.	O

SARS	O
-	O
CoV	O
nonstructural	O
protein	B-CHED
9	O
(	O
nsp9	O
)	O
was	O
identified	O
as	O
an	O
essential	O
protein	B-CHED
with	O
RNA	O
/	O
DNA	O
-	O
binding	O
activity	O
,	O
and	O
yet	O
its	O
biological	B-CHED
function	I-CHED
within	O
the	O
replication	O
complex	O
remains	O
unknown	O
.	O

We	O
demonstrate	O
that	O
sialic	B-CHED
acid	I-CHED
binding	O
is	O
important	O
for	O
the	O
infection	O
of	O
primary	O
chicken	O
kidney	O
cells	O
and	O
the	O
tracheal	O
epithelium	O
by	O
all	O
four	O
strains	O
.	O

MVTT	O
-	O
S	O
,	O
however	O
,	O
was	O
capable	O
of	O
inducing	O
consistently	O
20	O
-	O
to	O
-	O
100	O
-	O
fold	O
higher	O
levels	O
of	O
Nabs	O
than	O
MVA	B-CHED
-	O
S	O
when	O
inoculated	O
via	O
either	O
intranasal	O
or	O
intraoral	O
routes	O
.	O

All	O
strains	O
contained	O
an	O
open	O
reading	O
frame	O
for	O
the	O
nonstructural	O
protein	B-CHED
7b	O
,	O
which	O
is	O
not	O
present	O
in	O
TGEV	O
,	O
indicating	O
that	O
the	O
strains	O
were	O
related	O
to	O
the	O
previously	O
described	O
CCoV	O
strain	O
UCD	O
-	O
1	O
.	O

In	O
the	O
end	O
,	O
we	O
had	O
four	O
rule	O
sets	O
using	O
mean	O
airway	O
pressure	O
,	O
plateau	O
pressure	O
,	O
total	O
respiratory	O
rate	O
and	O
oxygen	B-CHED
saturation	O
(	O
SpO	O
(	O
2	O
)),	O
where	O
the	O
specificity	O
/	O
sensitivity	O
rates	O
were	O
either	O
80	O
%/	O
60	O
%	O
or	O
90	O
%/	O
50	O
%.	O

In	O
the	O
present	O
study	O
,	O
we	O
used	O
gel	O
shift	O
assays	O
to	O
demonstrate	O
that	O
calmodulin	O
,	O
an	O
intracellular	O
calcium	B-CHED
-	O
binding	O
protein	B-CHED
implicated	O
in	O
the	O
regulation	O
of	O
other	O
ectodomain	O
shedding	O
events	O
,	O
binds	O
a	O
16	O
-	O
amino	B-CHED
acid	I-CHED
synthetic	O
peptide	B-CHED
corresponding	O
to	O
residues	O
762	O
-	O
777	O
within	O
the	O
cytoplasmic	O
domain	O
of	O
human	O
ACE2	O
,	O
forming	O
a	O
calcium	B-CHED
-	O
dependent	O
calmodulin	O
-	O
peptide	B-CHED
complex	O
.	O

Furthermore	O
,	O
we	O
have	O
demonstrated	O
that	O
ACE2	O
expressed	O
in	O
Chinese	O
hamster	O
ovary	O
cells	O
specifically	O
binds	O
to	O
glutathione	B-CHED
-	O
S	O
-	O
transferase	O
-	O
calmodulin	O
,	O
but	O
not	O
glutathione	B-CHED
-	O
S	O
-	O
transferase	O
alone	O
,	O
in	O
pull	O
-	O
down	O
assays	O
using	O
cell	O
lysates	O
.	O

Using	O
a	O
cross	O
-	O
sectional	O
survey	O
,	O
EMTs	O
in	O
Toronto	O
,	O
Ont	B-CHED
.,	O
were	O
surveyed	O
1	O
year	O
after	O
the	O
SARS	O
outbreak	O
during	O
mandatory	O
training	O
on	O
the	O
use	O
of	O
personal	O
protective	O
equipment	O
in	O
airway	O
management	O
during	O
the	O
outbreak	O
and	O
just	O
before	O
taking	O
the	O
survey	O
.	O

In	O
nonoutbreak	O
conditions	O
,	O
only	O
the	O
antimicrobial	B-CHED
airway	O
filter	O
was	O
most	O
often	O
reported	O
to	O
be	O
always	O
used	O
(	O
52	O
.	O
0	O
%),	O
while	O
other	O
items	O
were	O
used	O
at	O
an	O
intermediate	O
frequency	O
.	O

As	O
reported	O
in	O
this	O
study	O
,	O
using	O
high	O
throughput	O
screening	O
against	O
approximately	O
6800	O
small	O
molecules	O
,	O
we	O
have	O
identified	O
several	O
novel	O
inhibitors	B-CHED
of	O
SARS	O
-	O
CoV	O
3CL	O
(	O
pro	B-CHED
)	O
with	O
IC	O
(	O
50	O
)	O
of	O
low	O
microM	O
.	O
Interestingly	O
,	O
one	O
of	O
them	O
equally	O
inhibited	O
both	O
3C	O
(	O
pro	B-CHED
)	O
and	O
3CL	O
(	O
pro	B-CHED
)	O
from	O
PV	O
and	O
CoV	O
,	O
respectively	O
.	O

This	O
study	O
examined	O
the	O
effect	O
of	O
antioxidant	B-CHED
N	B-CHED
-	I-CHED
acetylcysteine	I-CHED
amide	B-CHED
(	O
NACA	O
)	O
on	O
the	O
progression	O
of	O
lung	O
inflammation	O
after	O
exposure	O
to	O
a	O
moderate	O
level	O
of	O
blast	O
overpressure	O
(	O
140	O
kPa	O
).	O

ABSTRACT	O
:	O
The	O
Murine	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
strain	O
A59	O
ns2	O
protein	B-CHED
is	O
a	O
30	O
-	O
kDa	O
nonstructural	O
protein	B-CHED
that	O
is	O
expressed	O
from	O
a	O
subgenomic	O
mRNA	B-CHED
in	O
the	O
cytoplasm	O
of	O
virus	O
-	O
infected	O
cells	O
.	O

For	O
comparison	O
,	O
we	O
also	O
describe	O
the	O
crystal	O
structure	O
of	O
the	O
homologous	O
X	O
-	O
domain	O
from	O
Human	O
Coronavirus	O
229E	O
,	O
a	O
Group	O
-	O
1	O
coronavirus	O
,	O
which	O
does	O
bind	O
ADP	B-CHED
-	O
ribose	B-CHED
.	O

Patients	O
with	O
AE	O
showed	O
acute	O
respiratory	O
deterioration	O
with	O
severe	O
hypoxemia	O
(	O
mean	O
PaO	B-CHED
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
ratio	O
,	O
131	O
).	O

Normalization	O
of	O
pCO	O
(	O
2	O
)	O
levels	O
permitted	O
significant	O
reduction	O
in	O
the	O
dosages	O
of	O
analgesics	O
and	O
sedatives	B-CHED
.	O

The	O
percentage	O
differences	O
between	O
the	O
nucleotide	B-CHED
sequences	O
of	O
genes	O
3	O
and	O
5	O
and	O
the	O
3	O
'	O
untranslated	O
region	O
of	O
turkey	O
/	O
UK	O
/	O
412	O
/	O
00	O
when	O
compared	O
with	O
those	O
of	O
IBVs	O
were	O
similar	O
to	O
the	O
differences	O
observed	O
when	O
different	O
strains	O
of	O
IBV	O
were	O
compared	O
with	O
each	O
other	O
.	O

Progress	O
is	O
being	O
made	O
with	O
respect	O
to	O
making	O
nucleic	B-CHED
acid	I-CHED
approaches	O
more	O
suitable	O
for	O
use	O
in	O
diagnostic	O
laboratories	O
.	O

Robotic	O
workstations	O
are	O
now	O
available	O
for	O
extraction	O
of	O
nucleic	B-CHED
acid	I-CHED
from	O
many	O
samples	O
in	O
a	O
short	O
time	O
,	O
for	O
routine	O
diagnosis	O
.	O

ABSTRACT	O
:	O
A	O
purified	O
recombinant	O
spike	O
(	O
S	O
)	O
protein	B-CHED
was	O
studied	O
for	O
its	O
effect	O
on	O
stimulating	O
human	O
peripheral	O
blood	O
monocyte	O
macrophages	O
(	O
PBMC	O
).	O

An	O
NF	O
-	O
kappaB	O
inhibitor	B-CHED
,	O
TPCK	B-CHED
(	O
N	B-CHED
-	I-CHED
Tosyl	I-CHED
-	I-CHED
L	I-CHED
-	I-CHED
Phenylalanine	I-CHED
Chloromethyl	I-CHED
Ketone	I-CHED
)	O
could	O
suppress	O
IL	O
-	O
8	O
production	O
and	O
secretion	O
in	O
response	O
to	O
S	O
protein	B-CHED
in	O
PBMC	O
and	O
THP	B-CHED
-	O
1	O
cells	O
and	O
in	O
HCoV	O
-	O
229E	O
virus	O
-	O
infected	O
PBMC	O
.	O

The	O
results	O
further	O
suggested	O
that	O
released	O
or	O
secreted	O
S	O
protein	B-CHED
could	O
activate	O
blood	O
monocytes	O
through	O
recognition	O
by	O
toll	O
-	O
like	O
receptor	O
(	O
TLR	O
)	O
2	O
ligand	B-CHED
.	O

Recombinant	O
human	O
activated	O
protein	B-CHED
C	O
(	O
APC	O
)	O
can	O
significantly	O
reduce	O
the	O
mortality	O
of	O
patients	O
with	O
severe	O
sepsis	O
.	O

Anti	O
-	O
coagulation	O
and	O
pro	B-CHED
-	O
fibrinolysis	O
activity	O
may	O
be	O
two	O
of	O
the	O
possible	O
mechanisms	O
by	O
which	O
activated	O
protein	B-CHED
C	O
attenuated	O
endotoxin	O
-	O
induced	O
ALI	O
.	O

The	O
general	O
condition	O
,	O
serum	O
total	O
bilirubin	B-CHED
,	O
albumin	O
,	O
creatinine	B-CHED
,	O
and	O
prothrombin	O
activity	O
,	O
Child	O
-	O
Turcotte	O
-	O
Pugh	O
(	O
CTP	B-CHED
)	O
score	O
,	O
and	O
model	O
for	O
end	O
-	O
stage	O
liver	O
disease	O
(	O
MELD	O
)	O
score	O
48	O
h	O
before	O
operation	O
were	O
recorded	O
.	O

Univariate	O
analysis	O
showed	O
that	O
preoperative	O
senior	O
age	O
,	O
severe	O
hepatitis	O
B	O
,	O
high	O
serum	O
total	O
bilirubin	B-CHED
,	O
low	O
prothrombin	O
activity	O
,	O
and	O
high	O
CTP	B-CHED
and	O
MELD	O
scores	O
,	O
and	O
large	O
amount	O
of	O
blood	O
loss	O
and	O
RBC	O
infusion	O
during	O
operation	O
were	O
all	O
risk	O
factors	O
of	O
ALI	O
following	O
OLT	O
(	O
all	O
P	O
<	O
0	O
.	O
05	O
).	O

Logistic	O
stepwise	O
regression	O
analysis	O
screened	O
out	O
serum	O
total	O
bilirubin	B-CHED
as	O
an	O
independent	O
predictor	O
for	O
ALI	O
following	O
OLT	O
.	O

ABSTRACT	O
:	O
Molecular	O
analysis	O
of	O
the	O
polymorphic	O
region	O
of	O
the	O
bovine	O
coronavirus	O
(	O
BCoV	O
)-	O
S	O
gene	O
using	O
recent	O
Japanese	O
field	O
isolates	O
and	O
reference	O
strains	O
revealed	O
that	O
the	O
148	O
isolates	O
collected	O
from	O
1999	O
to	O
2008	O
from	O
13	O
prefectures	O
,	O
covering	O
all	O
regions	O
of	O
Japan	O
(	O
Hokkaido	O
,	O
Tohoku	O
,	O
Kanto	O
,	O
Chubu	O
,	O
Kinki	O
,	O
Chugoku	O
,	O
Shikoku	O
,	O
and	O
Kyusyu	O
region	O
)	O
and	O
divided	O
into	O
3	O
clusters	B-CHED
,	O
show	O
distinctive	O
divergence	O
from	O
the	O
prototype	O
enteric	O
BCoV	O
strains	O
.	O

Using	O
IHC	O
,	O
antigens	B-CHED
of	O
IBV	O
were	O
detected	O
in	O
nasal	O
epithelium	O
,	O
trachea	O
,	O
lung	O
,	O
spleen	O
,	O
myocardial	O
vasculature	O
,	O
liver	O
,	O
gastrointestinal	O
tract	O
,	O
kidney	O
,	O
skin	O
,	O
sclera	O
of	O
the	O
eye	O
,	O
spinal	O
cord	O
,	O
as	O
well	O
as	O
in	O
brain	O
neurons	O
of	O
the	O
inoculated	O
embryos	O
.	O

Enteral	O
administration	O
of	O
fish	O
oil	O
,	O
antioxidants	B-CHED
and	O
physiologic	O
amounts	O
of	O
arginine	B-CHED
improve	O
oxygenation	O
and	O
clinical	O
outcomes	O
in	O
ICU	O
patients	O
with	O
impaired	O
oxygenation	O
.	O

The	O
genetically	O
engineered	O
attenuated	O
form	O
of	O
the	O
virus	O
or	O
viral	O
vector	O
vaccine	O
encoding	O
for	O
the	O
SARS	O
-	O
CoV	O
spike	O
glycoprotein	B-CHED
has	O
been	O
shown	O
to	O
elicit	O
protective	O
immunity	O
in	O
vaccinated	O
animals	O
.	O

ABSTRACT	O
:	O
The	O
N7	O
-	O
methylguanosine	B-CHED
(	O
m7G	B-CHED
)	O
cap	O
is	O
the	O
defining	O
structural	O
feature	O
of	O
eukaryotic	O
mRNAs	O
.	O

Out	O
of	O
the	O
seven	O
positive	O
clones	O
observed	O
by	O
yeast	O
two	O
-	O
hybrid	O
assay	O
,	O
only	O
the	O
Ddx5	O
(	O
Asp	B-CHED
-	O
Glu	B-CHED
-	O
Ala	B-CHED
-	O
Asp	B-CHED
box	O
polypeptide	B-CHED
5	O
)	O
protein	B-CHED
showed	O
specific	O
interaction	O
with	O
SARS	O
-	O
CoV	O
helicase	O
.	O

ABSTRACT	O
:	O
As	O
anti	O
-	O
HCV	O
aryl	O
diketoacids	O
(	O
ADK	O
)	O
are	O
good	O
metal	B-CHED
chelators	B-CHED
,	O
we	O
anticipated	O
that	O
ADKs	O
might	O
serve	O
as	O
potential	O
inhibitors	B-CHED
of	O
SARS	O
CoV	O
(	O
SCV	O
)	O
NTPase	O
/	O
helicase	O
(	O
Hel	O
)	O
by	O
mimicking	O
the	O
binding	O
modes	O
of	O
the	O
bismuth	B-CHED
complexes	O
which	O
effectively	O
competes	O
for	O
the	O
Zn	O
(	O
2	O
+)	O
ion	O
binding	O
sites	O
in	O
SCV	O
Hel	O
thereby	O
disrupting	O
and	O
inhibiting	O
both	O
the	O
NTPase	O
and	O
helicase	O
activities	O
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
there	O
might	O
be	O
ADK	O
-	O
specific	O
binding	O
site	O
in	O
the	O
SCV	O
Hel	O
,	O
which	O
warrants	O
further	O
investigations	O
with	O
diverse	O
ADKs	O
to	O
provide	O
valuable	O
insights	O
into	O
rational	O
design	O
of	O
specific	O
SCV	O
Hel	O
inhibitors	B-CHED
.	O

Histopathological	O
analysis	O
of	O
adult	O
male	O
BALB	O
/	O
C	O
mice	O
after	O
N	O
-	O
protein	B-CHED
infection	O
showed	O
progressive	O
inflammatory	O
reactions	O
,	O
especially	O
pulmonary	O
edema	O
,	O
in	O
accordance	O
with	O
a	O
moderately	O
(	O
approximately	O
13	O
%)	O
elevated	O
level	O
of	O
W	O
/	O
D	O
ratio	O
at	O
24	O
h	O
.	O
Although	O
adult	O
groups	O
underwent	O
a	O
progressive	O
lung	O
inflammation	O
in	O
the	O
acute	O
phase	O
accompanied	O
by	O
raised	O
levels	O
of	O
TNF	O
-	O
alpha	O
in	O
serum	O
,	O
no	O
significant	O
changes	O
in	O
lung	O
TNF	O
-	O
alpha	O
level	O
were	O
reported	O
simultaneously	O
.	O

Sixty	O
-	O
eight	O
percent	O
of	O
the	O
recombinant	O
protein	B-CHED
sequence	O
was	O
confirmed	O
by	O
LC	O
-	O
ESI	O
-	O
MS	O
/	O
MS	O
analysis	O
.	O

Then	O
arterial	O
oxygen	B-CHED
partial	O
pressure	O
(	O
PaO2	O
),	O
lung	O
histology	O
,	O
lung	O
tissue	O
nitric	B-CHED
oxide	I-CHED
(	O
NO	O
)	O
production	O
and	O
expression	O
of	O
nitric	B-CHED
oxide	I-CHED
synthases	O
(	O
NOS	O
)	O
were	O
detected	O
at	O
0	O
.	O
5	O
,	O
1	O
,	O
2	O
,	O
3	O
or	O
4	O
h	O
after	O
LPS	B-CHED
injection	O
.	O

TITLE	O
:	O
Thermostability	O
of	O
the	O
N	O
-	O
terminal	O
RNA	O
-	O
binding	O
domain	O
of	O
the	O
SARS	O
-	O
CoV	O
nucleocapsid	O
protein	B-CHED
:	O
experiments	O
and	O
numerical	O
simulations	O
.	O

ABSTRACT	O
:	O
Differential	O
scanning	O
calorimetry	O
,	O
circular	O
dichroism	O
spectroscopy	O
,	O
nuclear	O
magnetic	O
resonance	O
spectroscopy	O
,	O
and	O
numerical	O
simulations	O
were	O
used	O
to	O
study	O
the	O
thermostability	O
of	O
the	O
N	O
-	O
terminal	O
RNA	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
the	O
SARS	O
-	O
CoV	O
nucleocapsid	O
protein	B-CHED
.	O

ABSTRACT	O
:	O
Exogenous	O
surfactant	B-CHED
has	O
been	O
explored	O
as	O
a	O
potential	O
therapy	O
for	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

Treatment	O
of	O
animals	O
with	O
a	O
PPS	O
aerosol	O
significantly	O
increased	O
the	O
phospholipid	B-CHED
content	O
in	O
the	O
BALF	O
,	O
improved	O
lung	O
function	O
,	O
reduced	O
pulmonary	O
oedema	O
,	O
decreased	O
total	O
protein	B-CHED
and	O
TNF	O
-	O
alpha	O
concentrations	O
in	O
BALF	O
,	O
ameliorated	O
lung	O
injury	O
and	O
improved	O
animal	O
survival	O
.	O

The	O
aim	O
of	O
this	O
work	O
was	O
to	O
see	O
whether	O
a	O
severe	O
liver	O
injury	O
,	O
which	O
releases	O
endogenous	O
adjuvants	B-CHED
,	O
i	O
.	O
e	O
.	O
danger	O
signals	O
,	O
could	O
elicit	O
a	O
broader	O
spectrum	O
of	O
autoAb	O
and	O
perhaps	O
signs	O
of	O
autoimmune	O
hepatitis	O
.	O

These	O
have	O
important	O
implications	O
in	O
the	O
pathogenesis	O
of	O
SARS	O
,	O
providing	O
opportunities	O
for	O
developing	O
vaccines	O
and	O
antivirals	B-CHED
against	O
SARS	O
-	O
CoV	O
.	O
4	O
.	O

The	O
present	O
study	O
analyzed	O
the	O
activities	O
of	O
nsp1	O
proteins	B-CHED
from	O
the	O
group	O
2	O
bat	O
CoV	O
strains	O
Rm1	O
,	O
133	O
,	O
and	O
HKU9	O
-	O
1	O
,	O
belonging	O
to	O
groups	O
2b	O
,	O
2c	O
,	O
and	O
2d	O
,	O
respectively	O
.	O

The	O
results	O
of	O
our	O
studies	O
suggested	O
a	O
conserved	O
function	O
among	O
nsp1	O
proteins	B-CHED
of	O
SARS	O
-	O
CoV	O
and	O
group	O
2	O
bat	O
CoVs	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
evaluate	O
the	O
safety	O
of	O
extended	O
prone	O
position	O
ventilation	O
(	O
PPV	B-CHED
)	O
and	O
its	O
impact	O
on	O
respiratory	O
function	O
in	O
patients	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

ABSTRACT	O
:	O
Health	O
authorities	O
must	O
rely	O
on	O
quarantine	O
,	O
isolation	O
,	O
and	O
other	O
non	O
-	O
pharmaceutical	B-CHED
interventions	O
to	O
contain	O
outbreaks	O
of	O
newly	O
emerging	O
human	O
diseases	O
.	O

Symptoms	O
did	O
not	O
improve	O
with	O
steroid	B-CHED
or	O
immunoglobulin	O
treatment	O
,	O
but	O
improvement	O
in	O
symptoms	O
was	O
observed	O
after	O
plasmapheresis	O
.	O

In	O
addition	O
,	O
we	O
generated	O
information	O
on	O
lymphocyte	O
subsets	O
and	O
mitogen	B-CHED
-	O
mediated	O
proliferation	O
of	O
splenocytes	O
.	O

This	O
evidence	O
-	O
based	O
emergency	O
medicine	B-CHED
(	O
EBM	O
)	O
review	O
evaluates	O
the	O
evidence	O
regarding	O
the	O
impact	O
of	O
1	O
:	O
1	O
ratio	O
of	O
FFP	O
:	O
PRBC	O
transfusion	O
on	O
survival	O
of	O
emergency	O
department	O
(	O
ED	O
)	O
patients	O
with	O
severe	O
trauma	O
.	O

8ab	O
protein	B-CHED
was	O
found	O
to	O
up	O
-	O
regulate	O
the	O
synthesis	O
of	O
endogenous	O
ER	O
-	O
resident	O
chaperons	O
involved	O
in	O
protein	B-CHED
folding	O
through	O
the	O
activation	O
of	O
the	O
transcription	O
factor	O
ATF6	O
,	O
while	O
it	O
showed	O
no	O
effect	O
on	O
the	O
CHOP	B-CHED
induction	O
and	O
XBP1	O
splicing	O
associated	O
with	O
the	O
unfolded	O
protein	B-CHED
response	O
(	O
UPR	O
).	O

TITLE	O
:	O
Lemierre	O
'	O
s	O
syndrome	O
followed	O
by	O
acute	O
respiratory	O
distress	O
syndrome	O
successfully	O
rescued	O
by	O
antibiotics	B-CHED
and	O
hemoperfusion	O
with	O
polymyxin	B-CHED
B	I-CHED
-	O
immobilized	O
fiber	O
.	O

A	O
30	O
-	O
year	O
-	O
old	O
,	O
previously	O
healthy	O
man	B-CHED
presented	O
with	O
sore	O
throat	O
,	O
fever	O
,	O
rigor	O
,	O
and	O
dyspnea	O
.	O

This	O
includes	O
potential	O
mechanisms	O
of	O
presynaptic	O
feedback	O
which	O
may	O
reduce	O
acetylcholine	B-CHED
release	O
and	O
postsynaptic	O
receptor	O
desensitization	O
and	O
provides	O
some	O
explanation	O
for	O
the	O
time	O
course	O
of	O
IMS	O
.	O

Although	O
for	O
the	O
majority	O
of	O
the	O
above	O
-	O
mentioned	O
diseases	O
process	O
data	O
from	O
randomised	O
,	O
controlled	O
trials	O
are	O
lacking	O
,	O
it	O
is	O
evident	O
from	O
clinical	O
experience	O
that	O
surfactant	B-CHED
replacement	O
which	O
counterbalances	O
surfactant	B-CHED
inactivation	O
seems	O
to	O
improve	O
oxygenation	O
and	O
lung	O
function	O
in	O
many	O
babies	O
with	O
ARDS	O
without	O
apparent	O
negative	O
side	O
effects	O
.	O

ABSTRACT	O
:	O
The	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
CoV	O
E	O
gene	O
fragment	O
was	O
cloned	O
and	O
expressed	O
as	O
a	O
recombinant	O
protein	B-CHED
fused	O
with	O
a	O
myc	O
tag	O
at	O
the	O
N	O
-	O
terminus	O
in	O
vitro	O
and	O
in	O
Vero	O
E6	O
cells	O
.	O

Further	O
analysis	O
based	O
on	O
their	O
nucleotide	B-CHED
and	O
amino	B-CHED
acid	I-CHED
sequences	O
in	O
hypervariable	O
region	O
(	O
HVR	O
)	O
1	O
and	O
the	O
intervening	O
sequence	O
including	O
HVRs	O
1	O
and	O
2	O
(	O
HVR1	O
/	O
2	O
)	O
of	O
the	O
S1	O
gene	O
was	O
done	O
to	O
determine	O
the	O
genetic	O
relationships	O
among	O
them	O
and	O
reference	O
strains	O
.	O

The	O
effects	O
of	O
grafting	O
either	O
type	O
of	O
BMMSCs	O
on	O
fibrotic	O
lung	O
injury	O
were	O
then	O
assessed	O
by	O
transfer	O
experiments	O
in	O
a	O
murine	O
bleomycin	B-CHED
-	O
induced	O
lung	O
fibrosis	O
model	O
,	O
in	O
which	O
donor	B-CHED
cells	O
were	O
administered	O
3	O
days	O
after	O
challenge	O
.	O

The	O
localization	O
of	O
ACE2	O
expression	O
in	O
the	O
endocrine	B-CHED
part	O
of	O
the	O
pancreas	O
suggests	O
that	O
SARS	O
coronavirus	O
enters	O
islets	O
using	O
ACE2	O
as	O
its	O
receptor	O
and	O
damages	O
islets	O
causing	O
acute	O
diabetes	O
.	O

Furthermore	O
,	O
although	O
transforming	O
growth	O
factor	O
beta	O
mRNA	B-CHED
was	O
not	O
affected	O
,	O
IL	O
-	O
10	O
was	O
increased	O
in	O
the	O
CNS	B-CHED
in	O
the	O
absence	O
of	O
IL	O
-	O
12	O
.	O

ABSTRACT	O
:	O
Ethyl	B-CHED
pyruvate	B-CHED
(	O
EtP	B-CHED
)	O
may	O
prolong	O
survival	O
and	O
ameliorate	O
organ	O
dysfunction	O
in	O
a	O
variety	O
of	O
models	O
of	O
critical	O
illness	O
,	O
e	O
.	O
g	O
.	O
severe	O
sepsis	O
and	O
acute	O
respiratory	O
syndrome	O
,	O
by	O
modulation	O
of	O
the	O
expression	O
of	O
inflammatory	O
mediators	O
.	O

Based	O
on	O
the	O
diagnosis	O
of	O
acute	O
pneumonia	O
and	O
ARDS	O
,	O
intravenous	O
administration	O
of	O
sivelestat	O
sodium	B-CHED
hydrate	I-CHED
(	O
100	O
mg	O
/	O
day	O
),	O
and	O
continuous	O
infusion	O
of	O
hydrocortisone	B-CHED
(	O
200	O
mg	O
/	O
day	O
)	O
were	O
started	O
.	O

Toll	O
-	O
like	O
receptor	O
-	O
3	O
(	O
TLR	O
-	O
3	O
)	O
is	O
an	O
integral	O
part	O
of	O
the	O
host	O
'	O
s	O
innate	O
immune	O
system	O
and	O
serves	O
as	O
an	O
important	O
signaling	O
pathway	O
for	O
the	O
recognition	O
of	O
dsRNA	B-CHED
for	O
the	O
triggering	O
of	O
antiviral	B-CHED
and	O
inflammatory	O
responses	O
to	O
combat	B-CHED
viral	O
infections	O
.	O

ABSTRACT	O
:	O
Nonstructural	O
protein	B-CHED
1	O
(	O
nsp1	O
),	O
a	O
28	O
-	O
kDa	O
protein	B-CHED
in	O
the	O
bovine	O
coronavirus	O
(	O
BCoV	O
)	O
and	O
closely	O
related	O
mouse	O
hepatitis	O
coronavirus	O
,	O
is	O
the	O
first	O
protein	B-CHED
cleaved	O
from	O
the	O
open	O
reading	O
frame	O
1	O
(	O
ORF	O
1	O
)	O
polyprotein	O
product	O
of	O
genome	O
translation	O
.	O

ABSTRACT	O
:	O
Carcinoembryonic	O
antigen	B-CHED
-	O
related	O
cell	O
adhesion	O
molecule	O
1	O
(	O
CEACAM1	O
)	O
regulates	O
intestinal	O
immunological	O
homeostasis	O
.	O

The	O
Acute	O
Lung	O
Rescue	O
Team	O
(	O
ALRT	O
)	O
was	O
developed	O
to	O
facilitate	O
transport	O
of	O
these	O
patients	O
out	O
of	O
the	O
combat	B-CHED
theater	O
.	O

ALRT	O
patients	O
required	O
a	O
mean	O
positive	O
end	O
expiratory	O
pressure	O
of	O
19	O
.	O
0	O
cm	O
H2O	B-CHED
+/-	O

It	O
can	O
extend	O
to	O
the	O
rest	B-CHED
of	O
the	O
trunk	O
and	O
the	O
limbs	O
but	O
characteristically	O
spares	O
the	O
extremities	O
.	O

Using	O
mRNA	B-CHED
display	O
selection	O
and	O
directed	O
evolution	O
,	O
we	O
designed	O
novel	O
antibody	O
-	O
like	O
protein	B-CHED
affinity	O
reagents	B-CHED
that	O
target	O
SARS	O
N	O
protein	B-CHED
with	O
high	O
affinity	O
and	O
selectivity	O
.	O

Using	O
a	O
novel	O
interferon	O
(	O
IFN	O
)	O
antagonism	O
screen	O
,	O
we	O
show	O
that	O
the	O
SARS	O
-	O
CoV	O
proteome	O
contains	O
several	O
replicase	O
,	O
structural	O
,	O
and	O
accessory	O
proteins	B-CHED
that	O
antagonize	O
the	O
IFN	O
pathway	O
.	O

ABSTRACT	O
:	O
The	O
multimerization	O
/	O
self	O
-	O
interaction	O
of	O
viral	O
proteins	B-CHED
is	O
an	O
important	O
step	O
in	O
the	O
process	O
of	O
viral	O
assembly	O
and	O
maturation	O
.	O

Both	O
a	O
rapid	O
viral	O
culture	O
with	O
direct	O
fluorescence	O
antibody	O
(	O
DFA	B-CHED
)	O
staining	O
and	O
a	O
PCR	O
-	O
based	O
assay	O
(	O
MultiCode	O
-	O
PLx	O
Respiratory	O
Virus	O
Panel	O
)	O
were	O
performed	O
on	O
patients	O
with	O
hematologic	O
malignancies	O
,	O
who	O
underwent	O
collection	O
of	O
a	O
nasopharyngeal	O
swab	O
or	O
bronchoalveolar	O
lavage	O
from	O
October	O
2006	O
to	O
April	O
2007	O
.	O

Structure	O
comparison	O
has	O
been	O
carried	O
out	O
to	O
search	O
for	O
DUBs	O
with	O
a	O
similar	O
structure	O
to	O
that	O
of	O
PLpro	O
,	O
and	O
we	O
have	O
tried	O
to	O
dock	O
6MP	O
and	O
6TG	O
into	O
these	O
DUBs	O
to	O
investigate	O
the	O
potential	O
use	O
of	O
6MP	O
and	O
6TG	O
as	O
cellular	O
DUB	O
inhibitors	B-CHED
.	O

TITLE	O
:	O
Identification	O
of	O
viral	O
peptide	B-CHED
fragments	O
for	O
vaccine	O
development	O
.	O

The	O
random	O
dissection	O
approach	O
described	O
here	O
should	O
be	O
applicable	O
to	O
other	O
viral	O
proteins	B-CHED
for	O
isolating	O
soluble	O
viral	O
surface	O
protein	B-CHED
fragments	O
,	O
and	O
may	O
provide	O
alternatives	O
to	O
the	O
full	O
-	O
length	O
proteins	B-CHED
(	O
subunits	O
)	O
or	O
linear	O
short	O
peptides	B-CHED
in	O
search	O
for	O
antigen	B-CHED
or	O
vaccine	O
candidates	O
.	O

M	O
protein	B-CHED
physically	O
associates	O
with	O
RIG	O
-	O
I	O
,	O
TBK1	O
,	O
IKKepsilon	O
,	O
and	O
TRAF3	O
and	O
likely	O
sequesters	O
some	O
of	O
them	O
in	O
membrane	O
-	O
associated	O
cytoplasmic	O
compartments	O
.	O

The	O
majority	O
of	O
CNS	B-CHED
-	O
infiltrating	O
CD8	O
T	O
cells	O
expressed	O
PD	O
-	O
1	O
,	O
with	O
the	O
highest	O
levels	O
on	O
virus	O
-	O
specific	O
CD8	O
T	O
cells	O
.	O

TITLE	O
:	O
"["""	O
Liquid	O
ecstasy	O
""":"	O
gamma	B-CHED
-	I-CHED
butyrolactone	I-CHED
withdrawal	O
delirium	O
with	O
rhabdomyolysis	O
and	O
dialysis	O
dependent	O
renal	O
failure	O
].	O

ABSTRACT	O
:	O
Targeted	O
treatment	O
of	O
inflammatory	O
diseases	O
of	O
the	O
central	O
nervous	O
system	O
(	O
CNS	B-CHED
)	O
remains	O
problematic	O
due	O
to	O
the	O
complex	O
pathogenesis	O
of	O
these	O
disorders	O
and	O
difficulty	O
in	O
drug	O
delivery	O
.	O

We	O
further	O
demonstrated	O
that	O
the	O
blockade	O
of	O
3a	O
'	O
s	O
potassium	B-CHED
channel	O
activity	O
abolished	O
caspase	O
-	O
dependent	O
apoptosis	O
.	O

This	O
report	O
provides	O
the	O
first	O
evidence	O
that	O
ion	O
channel	O
activity	O
of	O
3a	O
is	O
required	O
for	O
its	O
pro	B-CHED
-	O
apoptotic	O
function	O
.	O

TITLE	O
:	O
The	O
role	O
of	O
surfactant	B-CHED
treatment	O
in	O
preterm	O
infants	O
and	O
term	O
newborns	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

Various	O
pre	O
-	O
and	O
postnatal	O
factors	O
,	O
such	O
as	O
exposure	O
to	O
chorioamnionitis	O
,	O
pneumonia	O
,	O
sepsis	O
and	O
asphyxia	O
,	O
induce	O
an	O
injurious	O
inflammatory	O
response	O
in	O
the	O
lungs	O
of	O
preterm	O
infants	O
,	O
which	O
may	O
subsequently	O
affect	O
surfactant	B-CHED
function	O
,	O
synthesis	O
and	O
alveolar	O
stability	O
.	O

TITLE	O
:	O
Molecular	O
determinants	O
for	O
subcellular	O
localization	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
open	O
reading	O
frame	O
3b	O
protein	B-CHED
.	O

The	O
mitochondrial	O
antiviral	B-CHED
signaling	O
adaptor	O
,	O
MAVS	O
(	O
IPS	O
-	O
1	O
,	O
VISA	O
or	O
Cardif	O
)	O
is	O
critical	O
for	O
host	O
defenses	O
to	O
viral	O
infection	O
by	O
inducing	O
type	O
-	O
1	O
interferons	O
(	O
IFN	O
-	O
I	O
),	O
however	O
its	O
role	O
in	O
virus	O
-	O
induced	O
apoptotic	O
responses	O
has	O
not	O
been	O
elucidated	O
.	O

In	O
those	O
with	O
acute	O
lung	O
injury	O
(	O
ALI	O
)/	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
there	O
was	O
a	O
significant	O
increase	O
from	O
baseline	O
in	O
the	O
partial	O
pressure	O
of	O
arterial	O
oxygen	B-CHED
(	O
PaO2	O
)	O
to	O
fraction	O
of	O
inspired	O
oxygen	B-CHED
(	O
FiO2	O
)	O
ratio	O
at	O
24	O
hours	O
in	O
the	O
CVVH	O
group	O
(	O
n	O
=	O
16	O
,	O
174	O
+/-	O

We	O
determined	O
that	O
the	O
ACE2	O
cleavage	O
site	O
resides	O
between	O
amino	B-CHED
acid	I-CHED
716	O
and	O
the	O
putative	O
transmembrane	O
domain	O
starting	O
at	O
amino	B-CHED
acid	I-CHED
741	O
.	O

We	O
found	O
that	O
two	O
of	O
these	O
GFP	O
-	O
N	O
-	O
domain	O
fusion	O
proteins	B-CHED
were	O
selectively	O
packaged	O
into	O
virions	O
as	O
the	O
result	O
of	O
tight	O
binding	O
to	O
the	O
N	O
protein	B-CHED
in	O
the	O
viral	O
nucleocapsid	O
,	O
in	O
a	O
manner	O
that	O
did	O
not	O
involve	O
association	O
with	O
either	O
M	O
protein	B-CHED
or	O
RNA	O
.	O

The	O
cytotoxic	O
effect	O
of	O
extracts	O
on	O
swine	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
and	O
HL	O
-	O
60	O
was	O
assessed	O
by	O
MTT	B-CHED
method	O
.	O

Leaf	O
extracts	O
had	O
better	O
virucidal	O
activity	O
than	O
roots	O
,	O
and	O
ethyl	B-CHED
acetate	I-CHED
extracts	O
exhibited	O
the	O
highest	O
efficacy	O
among	O
extracts	O
tested	O
.	O

The	O
aims	O
of	O
this	O
study	O
were	O
to	O
validate	O
a	O
colorimetric	O
method	O
to	O
measure	O
total	O
sialic	B-CHED
acid	I-CHED
(	O
TSA	B-CHED
)	O
in	O
feline	O
serum	O
and	O
to	O
investigate	O
the	O
serum	O
concentration	O
of	O
TSA	B-CHED
in	O
clinically	O
healthy	O
cats	O
seronegative	O
(	O
n	O
=	O
9	O
)	O
and	O
seropositive	O
(	O
n	O
=	O
48	O
)	O
for	O
feline	O
coronavirus	O
(	O
FCoV	O
),	O
and	O
in	O
cats	O
affected	O
by	O
feline	O
infectious	O
peritonitis	O
(	O
FIP	O
,	O
n	O
=	O
28	O
),	O
tumors	O
(	O
n	O
=	O
20	O
),	O
or	O
inflammation	O
(	O
n	O
=	O
16	O
).	O

Both	O
the	O
antibody	O
titre	O
and	O
the	O
degree	O
of	O
AGP	O
sialylation	O
were	O
negatively	O
correlated	O
with	O
TSA	B-CHED
levels	O
,	O
suggesting	O
that	O
increased	O
TSA	B-CHED
may	O
contribute	O
to	O
reduce	O
the	O
burden	O
of	O
FCoVs	O
.	O

Mutations	O
of	O
selected	O
lysine	B-CHED
residues	O
on	O
the	O
surface	O
of	O
the	O
SUD	O
-	O
N	O
subdomain	O
lead	O
to	O
reduction	O
of	O
G	O
-	O
quadruplex	O
binding	O
,	O
whereas	O
mutations	O
in	O
the	O
SUD	O
-	O
M	O
subdomain	O
abolish	O
it	O
.	O

The	O
possible	O
re	O
-	O
emergence	O
of	O
SARS	O
or	O
SARS	O
-	O
like	O
infections	O
suggests	O
a	O
need	O
for	O
minimal	O
traumatic	O
techniques	O
for	O
following	O
the	O
alveolar	O
compartment	O
,	O
e	O
.	O
g	O
.	O
during	O
testing	O
of	O
antivirals	B-CHED
.	O

Moreover	O
,	O
combinations	O
of	O
monoclonal	O
antibodies	O
have	O
been	O
shown	O
to	O
have	O
a	O
broader	O
spectrum	O
of	O
antiviral	B-CHED
activity	O
.	O

Respiratory	O
specimens	O
were	O
collected	O
from	O
1055	O
infants	O
and	O
young	O
children	O
hospitalised	O
with	O
ARI	B-CHED
in	O
2003	O
-	O
2004	O
.	O

ABSTRACT	O
:	O
Angiotensin	B-CHED
converting	O
enzyme	O
2	O
(	O
ACE2	O
),	O
a	O
monocarboxylase	O
that	O
degrades	O
angiotensin	B-CHED
II	I-CHED
to	O
angiotensin	B-CHED
1	O
-	O
7	O
,	O
is	O
also	O
the	O
functional	O
receptor	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
and	O
is	O
highly	O
expressed	O
in	O
the	O
lungs	O
and	O
heart	O
.	O

We	O
studied	O
mice	O
infected	O
with	O
the	O
human	O
strain	O
of	O
the	O
SARS	O
-	O
CoV	O
and	O
encephalomyocarditis	O
virus	O
and	O
examined	O
ACE2	O
mRNA	B-CHED
and	O
protein	B-CHED
expression	O
.	O

The	O
cell	O
infection	O
was	O
not	O
alleviated	O
by	O
either	O
pre	O
-	O
treatment	O
of	O
cells	O
with	O
GD	O
or	O
addition	O
of	O
the	O
drug	O
post	O
infection	O
,	O
confirming	O
that	O
the	O
inhibitory	O
effect	O
of	O
GD	O
,	O
unlike	O
LiCl	B-CHED
,	O
on	O
IBV	O
is	O
a	O
viral	O
factor	O
,	O
rather	O
than	O
a	O
cellular	O
factor	O
.	O

Our	O
data	O
indicate	O
that	O
GD	O
and	O
LiCl	B-CHED
have	O
potential	O
to	O
prevent	O
IBV	O
infection	O
in	O
vitro	O
through	O
different	O
antiviral	B-CHED
mechanisms	O
.	O

Additional	O
T	O
-	O
cell	O
epitopes	O
within	O
the	O
SARS	O
-	O
CoV	O
spike	O
protein	B-CHED
that	O
may	O
contribute	O
to	O
cell	O
-	O
mediated	O
immunity	O
in	O
vivo	O
were	O
also	O
identified	O
.	O

Further	O
studies	O
are	O
necessary	O
to	O
assess	O
the	O
potential	O
of	O
the	O
Polyprenyl	O
Immunostimulant	B-CHED
.	O

The	O
resulting	O
holistic	O
approach	O
to	O
emerging	O
infections	O
links	O
microbiology	O
,	O
veterinary	O
medicine	B-CHED
,	O
human	O
medicine	B-CHED
,	O
ecology	O
,	O
public	O
health	O
and	O
epidemiology	O
.	O

ABSTRACT	O
:	O
Systemic	O
administration	O
of	O
corticosteroid	B-CHED
,	O
plasmapheresis	O
and	O
high	O
-	O
dose	O
immunoglobulin	O
therapy	O
(	O
IVIG	O
)	O
are	O
the	O
main	O
treatment	O
of	O
Stevens	O
-	O
Johnson	O
syndrome	O
(	O
SJS	O
)	O
and	O
toxic	O
epidermal	O
necrolysis	O
(	O
TEN	O
).	O

Corticosteroid	B-CHED
was	O
administered	O
systemically	O
in	O
all	O
cases	O
except	O
one	O
case	O
of	O
TEN	O
which	O
developed	O
methicillin	B-CHED
resistant	O
staphylococcus	O
aureus	O
(	O
MRSA	O
)	O
pneumoniae	O
before	O
the	O
onset	O
of	O
the	O
eruption	O
.	O

Methylprednisolone	B-CHED
(	O
mPSL	O
)	O
pulse	O
therapy	O
(	O
1000	O
mg	O
/	O
day	O
)	O
or	O
mini	O
pulse	O
therapy	O
(	O
less	O
than	O
600	O
mg	O
/	O
day	O
of	O
mPSL	O
)	O
was	O
selected	O
by	O
8	O
cases	O
of	O
SJS	O
and	O
9	O
cases	O
of	O
TEN	O
.	O

Although	O
corticosteroids	B-CHED
may	O
enhance	O
the	O
risk	O
of	O
sepsis	O
,	O
prompt	O
treatment	O
with	O
systemic	O
corticosteroids	B-CHED
seems	O
to	O
reduces	O
morbidity	O
and	O
improves	O
outcome	O
of	O
SJS	O
and	O
TEN	O
patients	O
.	O

ABSTRACT	O
:	O
Neutrophil	O
elastase	O
plays	O
an	O
important	O
role	O
in	O
the	O
development	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
and	O
disseminated	O
intravascular	O
coagulation	O
(	O
DIC	B-CHED
)	O
in	O
sepsis	O
.	O

It	O
is	O
possible	O
that	O
sivelestat	O
improves	O
the	O
outcome	O
of	O
septic	O
patients	O
associated	O
with	O
ARDS	O
and	O
DIC	B-CHED
.	O

Second	O
,	O
chlorhexidine	B-CHED
(	O
CHX	O
)	O
and	O
hexamidine	O
(	O
HXM	O
)	O
were	O
assessed	O
for	O
their	O
potential	O
anti	O
-	O
HCoV	O
229E	O
antiseptic	O
activities	O
.	O

TITLE	O
:	O
Inhibition	O
of	O
matrix	O
metalloproteinase	O
-	O
9	O
with	O
doxycycline	B-CHED
reduces	O
pancreatitis	O
-	O
associated	O
lung	O
injury	O
.	O

Active	O
MMP	B-CHED
-	O
9	O
in	O
lung	O
tissue	O
was	O
measured	O
with	O
fluorescent	O
assay	O
(	O
ELISA	O
).	O

Mitigating	O
and	O
managing	O
the	O
risk	O
requires	O
an	O
appreciation	O
of	O
the	O
connectedness	O
between	O
human	O
,	O
livestock	O
and	O
wildlife	O
health	O
,	O
and	O
of	O
the	O
factors	O
and	O
processes	O
that	O
disrupt	O
the	O
balance	B-CHED
.	O

We	O
herein	O
report	O
detailed	O
SARs	O
for	O
each	O
of	O
the	O
regions	O
of	O
the	O
ProTide	B-CHED
.	O

Survival	O
rates	O
declined	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
with	O
88	O
%	O
survival	O
when	O
treated	O
with	O
5	O
mg	O
/	O
kg	O
chloroquine	B-CHED
and	O
13	O
%	O
survival	O
when	O
treated	O
with	O
1	O
mg	O
/	O
kg	O
chloroquine	B-CHED
.	O

Longitudinal	O
study	O
of	O
71	O
former	O
SARS	O
patients	O
(	O
mainly	O
health	O
care	O
workers	O
)	O
who	O
had	O
been	O
treated	O
with	O
corticosteroids	B-CHED
,	O
with	O
an	O
observation	O
time	O
of	O
36	O
months	O
.	O

The	O
sole	O
factor	O
explaining	O
AVN	O
in	O
the	O
hip	O
was	O
the	O
total	O
dose	O
of	O
corticosteroids	B-CHED
received	O
.	O

TITLE	O
:	O
Neonicotinoid	O
insecticides	B-CHED
:	O
an	O
emerging	O
cause	O
of	O
acute	O
pesticide	B-CHED
poisoning	O
.	O

ABSTRACT	O
:	O
Neonicotinoids	O
are	O
a	O
relatively	O
new	O
class	O
of	O
insecticides	B-CHED
.	O

Most	O
exposures	O
involved	O
suicidal	O
ingestions	O
of	O
imidacloprid	B-CHED
alone	O
.	O

Rats	O
with	O
LC	O
+	O
CASP	O
also	O
had	O
distinct	O
aspects	O
of	O
inflammation	O
compared	O
with	O
CASP	O
alone	O
,	O
i	O
.	O
e	O
.,	O
significantly	O
higher	O
levels	O
of	O
IL	O
-	O
10	O
(	O
5	O
and	O
24	O
h	O
),	O
IL	O
-	O
1beta	O
(	O
24	O
h	O
),	O
CINC	B-CHED
-	O
1	O
(	O
24	O
h	O
),	O
and	O
MCP	B-CHED
-	O
1	O
(	O
24	O
h	O
),	O
and	O
significantly	O
lower	O
levels	O
of	O
MPO	O
(	O
5	O
h	O
),	O
MIP	O
-	O
2	O
(	O
5	O
h	O
),	O
and	O
CINC	B-CHED
-	O
1	O
(	O
5	O
h	O
).	O

RESULTS	O
:	O
Rats	O
with	O
LC	O
+	O
CASP	O
had	O
lower	O
mean	O
PaO	B-CHED
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
ratios	O
compared	O
with	O
LC	O
alone	O
at	O
24	O
h	O
,	O
and	O
higher	O
BAL	B-CHED
albumin	O
concentrations	O
compared	O
with	O
either	O
LC	O
or	O
CASP	O
alone	O
.	O

NO	O
rapidly	O
combines	O
with	O
the	O
oxygen	B-CHED
radical	I-CHED
superoxide	B-CHED
to	O
form	O
reactive	O
and	O
highly	O
toxic	O
nitrogen	B-CHED
species	O
such	O
as	O
peroxynitrite	B-CHED
.	O

The	O
control	O
of	O
NO	O
formation	O
involves	O
poly	O
(	O
ADP	B-CHED
-	O
ribose	B-CHED
)	O
polymerase	O
and	O
its	O
ability	O
to	O
up	O
-	O
regulate	O
the	O
activity	O
of	O
nuclear	O
transcription	O
factors	O
through	O
ribosylation	O
.	O

Evidence	O
supports	O
dropping	O
the	O
hemoglobin	B-CHED
transfusion	O
threshold	O
to	O
7	O
g	O
/	O
dL	O
once	O
profound	O
hypoxia	O
and	O
shock	O
have	O
resolved	O
.	O

Promising	O
therapies	O
for	O
pediatric	O
ALI	O
/	O
ARDS	O
based	O
on	O
pediatric	O
studies	O
include	O
endotracheal	O
surfactant	B-CHED
,	O
high	O
-	O
frequency	O
oscillatory	O
ventilation	O
,	O
noninvasive	O
ventilation	O
,	O
and	O
use	O
of	O
extracorporeal	O
membrane	O
oxygenation	O
as	O
a	O
rescue	O
therapy	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
MRI	O
to	O
observe	O
the	O
lesion	O
size	O
changes	O
of	O
ONFH	O
induced	O
by	O
corticosteroid	B-CHED
administration	O
in	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
patients	O
.	O

Among	O
the	O
examined	O
series	O
,	O
the	O
most	O
cytotoxic	O
derivatives	O
(	O
11	O
,	O
12	O
,	O
14	O
,	O
16	O
,	O
18	O
,	O
19	O
,	O
20	O
,	O
21	O
,	O
23	O
,	O
25	O
-	O
30	O
)	O
against	O
mock	O
-	O
infected	O
MT	O
-	O
4	O
cells	O
(	O
CC50	O
<	O
8	O
.	O
0	O
microM	O
)	O
were	O
evaluated	O
against	O
a	O
panel	O
of	O
human	O
cell	O
lines	O
derived	O
from	O
haematological	O
and	O
solid	O
tumours	O
,	O
using	O
6	B-CHED
-	I-CHED
mercaptopurine	I-CHED
(	O
6	B-CHED
-	I-CHED
MP	I-CHED
)	O
and	O
etoposide	B-CHED
as	O
reference	O
drugs	O
.	O

TITLE	O
:	O
Studies	O
on	O
membrane	O
topology	O
,	O
N	O
-	O
glycosylation	O
and	O
functionality	O
of	O
SARS	O
-	O
CoV	O
membrane	O
protein	B-CHED
.	O

These	O
results	O
strongly	O
indicate	O
that	O
chGM	O
-	O
CSF	O
can	O
be	O
used	O
as	O
a	O
molecular	O
adjuvant	B-CHED
to	O
enhance	O
the	O
protective	O
immunity	O
induced	O
by	O
an	O
IBV	O
-	O
specific	O
DNA	O
vaccine	O
.	O

Lipopolysaccharide	B-CHED
administration	O
results	O
in	O
significant	O
lung	O
injury	O
with	O
impaired	O
AFC	O
,	O
while	O
dobutamine	B-CHED
improves	O
alveolar	O
fluid	O
reabsorption	O
with	O
elevation	O
of	O
aquaporin	O
-	O
1	O
and	O
aquaporin	O
-	O
5	O
.	O

ABSTRACT	O
:	O
The	O
nsp14	O
protein	B-CHED
,	O
an	O
exoribonuclease	O
of	O
the	O
DEDD	O
superfamily	O
encoded	O
by	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
was	O
expressed	O
in	O
fusion	O
with	O
different	O
affinity	O
tags	O
.	O

Detailed	O
time	O
course	O
experiments	O
showed	O
that	O
a	O
peptide	B-CHED
furin	O
inhibitor	B-CHED
,	O
decanoyl	B-CHED
-	O
Arg	B-CHED
-	O
Val	B-CHED
-	O
Lys	B-CHED
-	O
Arg	B-CHED
-	O
chloromethylketone	O
,	O
blocked	O
both	O
viral	O
entry	O
and	O
syncytium	O
formation	O
.	O

TITLE	O
:	O
Synthesis	O
and	O
evaluation	O
of	O
in	O
vitro	O
antiviral	B-CHED
activity	O
of	O
2	O
-[	O
3	O
-(	O
substituted	O
phenyl	B-CHED
)-	O
4	O
,	O
5	O
-	O
dihydro	O
-	O
1H	O
-	O
5	O
-	O
pyrazolyl	O
]	O
benzofuran	B-CHED
-	O
3	O
-	O
yl	O
chloride	B-CHED
derivatives	O
.	O

We	O
describe	O
a	O
28	O
-	O
year	O
-	O
old	O
man	B-CHED
who	O
was	O
brought	O
to	O
the	O
emergency	O
department	O
with	O
a	O
new	O
-	O
onset	O
seizure	O
and	O
clinical	O
signs	O
and	O
symptoms	O
consistent	O
with	O
advanced	O
delirium	O
tremens	O
.	O

Although	O
the	O
cornerstone	O
of	O
treatment	O
for	O
AWS	O
remains	O
benzodiazepines	B-CHED
,	O
this	O
case	O
highlights	O
the	O
potential	O
utility	O
of	O
phenobarbital	B-CHED
in	O
patients	O
with	O
resistant	O
AWS	O
.	O

Ninety	O
-	O
six	O
percent	O
of	O
the	O
nurses	O
preferred	O
nebulizer	O
over	O
MDI	B-CHED
with	O
spacer	O
.	O

In	O
the	O
in	O
-	O
patient	O
setting	O
during	O
an	O
outbreak	O
of	O
an	O
airborne	O
infection	O
,	O
for	O
treatment	O
of	O
acute	O
airflow	O
obstruction	O
,	O
MDI	B-CHED
with	O
spacer	O
was	O
acceptable	O
and	O
preferred	O
by	O
a	O
high	O
percentage	O
of	O
patients	O
.	O

The	O
GBP	O
domain	O
of	O
the	O
fusion	O
protein	B-CHED
serves	O
as	O
an	O
anchoring	O
component	O
onto	O
the	O
gold	B-CHED
surface	O
,	O
exploiting	O
the	O
gold	B-CHED
binding	O
affinity	O
of	O
the	O
domain	O
,	O
whereas	O
the	O
SCVme	O
domain	O
is	O
a	O
recognition	O
element	O
for	O
anti	O
-	O
SCVme	O
antibody	O
,	O
the	O
target	O
analyte	O
in	O
this	O
study	O
.	O

The	O
fusion	O
protein	B-CHED
-	O
coated	O
SPR	O
chip	O
at	O
the	O
best	O
packing	O
density	O
had	O
a	O
lower	O
limit	O
of	O
detection	O
of	O
200	O
ng	O
mL	O
(-	O
1	O
)	O
anti	O
-	O
SCVme	O
within	O
10	O
min	O
and	O
also	O
allowed	O
selective	O
detection	O
of	O
anti	O
-	O
SCVme	O
with	O
significantly	O
low	O
responses	O
for	O
non	O
-	O
specific	O
mouse	O
IgG	O
at	O
all	O
tested	O
concentrations	O
.	O

The	O
mean	O
values	O
were	O
determined	O
for	O
the	O
treatment	O
data	O
:	O
fatal	O
disease	O
onset	O
(	O
32	O
.	O
65	O
days	O
),	O
treatment	O
interval	O
(	O
29	O
.	O
15	O
days	O
),	O
number	O
of	O
antibiotic	B-CHED
treatments	O
(	O
2	O
.	O
65	O
),	O
number	O
of	O
different	O
antibiotics	B-CHED
(	O
1	O
.	O
89	O
),	O
and	O
day	O
of	O
death	O
(	O
61	O
.	O
81	O
days	O
).	O

Results	O
showed	O
that	O
Penn	O
-	O
98	O
-	O
1	O
behaved	O
like	O
MHV	O
-	O
2	O
,	O
thus	O
establishing	O
a	O
role	O
for	O
the	O
spike	O
protein	B-CHED
in	O
viral	O
growth	O
.	O

The	O
nucleocapsid	O
DNA	O
vaccine	O
had	O
good	O
immunogenicity	O
and	O
can	O
induce	O
specific	O
humoral	O
and	O
cellular	O
immunity	O
in	O
BALB	O
/	O
c	O
mice	O
,	O
while	O
IL	O
-	O
2	O
plays	O
an	O
immunoadjuvant	B-CHED
role	O
and	O
enhances	O
specific	O
immune	O
responses	O
.	O

Gene	O
silencing	O
of	O
PABP	O
,	O
hnRNP	O
Q	O
,	O
and	O
glutamyl	B-CHED
-	O
prolyl	B-CHED
-	O
tRNA	B-CHED
synthetase	O
(	O
EPRS	O
)	O
caused	O
a	O
significant	O
2	O
to	O
3	O
-	O
fold	O
reduction	O
of	O
viral	O
RNA	O
synthesis	O
.	O

Over	O
a	O
2	O
-	O
year	O
period	O
,	O
94	O
study	O
patients	O
underwent	O
RSI	O
,	O
of	O
which	O
35	O
received	O
etomidate	B-CHED
(	O
37	O
%).	O

Serum	O
and	O
BAL	B-CHED
fluid	O
IL	O
-	O
1beta	O
,	O
IL	O
-	O
6	O
,	O
IL	O
-	O
8	O
,	O
IL	O
-	O
10	O
,	O
TNF	O
-	O
alpha	O
,	O
C	O
-	O
reactive	O
protein	B-CHED
,	O
and	O
endotoxins	O
on	O
the	O
first	O
day	O
of	O
ICU	O
admission	O
were	O
obtained	O
.	O

Serum	O
and	O
BAL	B-CHED
fluid	O
levels	O
of	O
the	O
studied	O
cytokines	O
on	O
admission	O
may	O
provide	O
valuable	O
prognostic	O
information	O
for	O
patients	O
with	O
severe	O
CAP	O
.	O

ABSTRACT	O
:	O
The	O
envelope	O
(	O
E	O
)	O
protein	B-CHED
from	O
coronaviruses	O
is	O
a	O
small	O
polypeptide	B-CHED
that	O
contains	O
at	O
least	O
one	O
alpha	O
-	O
helical	O
transmembrane	O
domain	O
.	O

Studies	O
using	O
wild	O
bat	O
sera	O
revealed	O
that	O
it	O
is	O
highly	O
likely	O
that	O
the	O
immunodominant	O
epitopes	O
overlap	O
with	O
the	O
major	O
neutralizing	O
sites	O
of	O
the	O
SL	O
-	O
CoV	O
S	O
protein	B-CHED
.	O

ABSTRACT	O
:	O
Historically	O
,	O
ships	O
brought	O
infectious	O
diseases	O
to	O
the	O
continents	O
of	O
the	O
world	O
,	O
but	O
in	O
this	O
modern	O
era	B-CHED
,	O
infectious	O
diseases	O
and	O
pandemics	O
are	O
primarily	O
spread	O
through	O
aviation	O
as	O
a	O
mode	O
of	O
travel	O
.	O

TITLE	O
:	O
The	O
use	O
of	O
an	O
endothelium	O
-	O
targeted	O
cationic	O
copolymer	B-CHED
to	O
enhance	O
the	O
barrier	O
function	O
of	O
lung	O
capillary	O
endothelial	O
monolayers	O
.	O

We	O
hypothesized	O
that	O
biomimetic	O
polymers	B-CHED
could	O
be	O
used	O
to	O
enhance	O
passive	O
barrier	O
function	O
by	O
reducing	O
the	O
porosity	O
of	O
the	O
endothelial	O
glycocalyx	O
and	O
attenuate	O
mechanotransduction	O
by	O
restricting	O
the	O
motion	O
of	O
the	O
glycoproteins	B-CHED
implicated	O
in	O
signal	O
transduction	O
.	O

To	O
this	O
end	O
,	O
cationic	O
copolymers	B-CHED
containing	O
methacrylamidopropyl	O
trimethylammonium	B-CHED
chloride	I-CHED
(	O
P	O
-	O
TMA	B-CHED
Cl	O
)	O
have	O
been	O
developed	O
as	O
an	O
infusible	O
therapy	O
to	O
target	O
the	O
lung	O
capillary	O
glycocalyx	O
in	O
order	O
to	O
mechanically	O
enhance	O
the	O
capillary	O
barrier	O
and	O
turn	O
off	O
pressure	O
-	O
induced	O
mechanotransduction	O
.	O

Decreases	O
in	O
L	O
(	O
p	O
)	O
across	O
endothelial	O
monolayers	O
in	O
the	O
presence	O
of	O
P	O
-	O
TMA	B-CHED
Cl	O
is	O
evidence	O
of	O
a	O
dampening	O
of	O
mechanotransduction	O
-	O
induced	O
barrier	O
dysfunction	O
.	O

The	O
current	O
study	O
determines	O
the	O
antigen	B-CHED
-	O
specificity	O
of	O
the	O
T	O
lymphocytes	O
present	O
during	O
chronic	O
disease	O
and	O
evaluates	O
how	O
blocking	O
CXCL10	O
signaling	O
affects	O
retention	O
of	O
virus	O
-	O
specific	O
T	O
cells	O
within	O
the	O
CNS	B-CHED
.	O

TITLE	O
:	O
Oral	O
immunization	O
of	O
mice	O
with	O
recombinant	O
Lactococcus	O
lactis	O
expressing	O
porcine	O
transmissible	O
gastroenteritis	O
virus	O
spike	O
glycoprotein	B-CHED
.	O

Pus	B-CHED
was	O
detected	O
in	O
the	O
peritoneal	O
cavity	O
by	O
abdominal	O
paracentesis	O
in	O
a	O
27	O
-	O
year	O
-	O
old	O
woman	O
who	O
had	O
no	O
predisposing	O
features	O
for	O
severe	O
peritonitis	O
.	O

During	O
treatment	O
,	O
sudden	O
fever	O
,	O
hypoxemia	O
and	O
chest	O
radiography	O
-	O
confirmed	O
interstitial	O
shadows	O
throughout	O
the	O
lung	O
fields	O
were	O
noted	O
,	O
and	O
the	O
patient	O
was	O
referred	O
to	O
the	O
Department	O
of	O
Internal	O
Medicine	B-CHED
.	O

RS3PE	O
complicated	O
by	O
interstitial	O
pneumonia	O
was	O
diagnosed	O
,	O
and	O
steroid	B-CHED
pulse	O
therapy	O
and	O
immunosuppressant	B-CHED
therapy	O
were	O
initiated	O
.	O

ABSTRACT	O
:	O
The	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
generates	O
16	O
nonstructural	O
proteins	B-CHED
(	O
nsp	O
'	O
s	O
)	O
through	O
proteolytic	O
cleavage	O
of	O
a	O
large	O
precursor	O
protein	B-CHED
.	O

In	O
order	O
to	O
gain	O
a	O
better	O
understanding	O
of	O
their	O
functions	O
,	O
we	O
attempted	O
to	O
identify	O
host	O
proteins	B-CHED
that	O
interact	O
with	O
nsp	O
'	O
s	O
during	O
SARS	O
-	O
CoV	O
infections	O
.	O

For	O
nsp2	O
,	O
we	O
identified	O
an	O
interaction	O
with	O
two	O
host	O
proteins	B-CHED
,	O
prohibitin	O
1	O
(	O
PHB1	O
)	O
and	O
PHB2	O
.	O

ABSTRACT	O
:	O
Protein	B-CHED
motions	O
on	O
all	O
timescales	O
faster	O
than	O
molecular	O
tumbling	O
are	O
encoded	O
in	O
the	O
spectral	O
density	O
.	O

With	O
each	O
declamping	O
,	O
the	O
gas	O
flow	O
through	O
the	O
membrane	O
lung	O
was	O
set	O
to	O
10	O
l	O
of	O
oxygen	B-CHED
/	O
min	O
.	O

Due	O
to	O
sufficient	O
CO2	B-CHED
elimination	O
during	O
av	O
-	O
ECLA	O
,	O
the	O
VTs	O
could	O
be	O
reduced	O
to	O
0	O
-	O
2	O
ml	O
/	O
kg	O
without	O
the	O
risk	O
of	O
decompensated	O
respiratory	O
acidosis	O
.	O

ABSTRACT	O
:	O
We	O
describe	O
here	O
the	O
design	O
,	O
synthesis	O
,	O
molecular	O
modeling	O
,	O
and	O
biological	O
evaluation	O
of	O
a	O
series	O
of	O
small	O
molecule	O
,	O
nonpeptide	O
inhibitors	B-CHED
of	O
SARS	O
-	O
CoV	O
PLpro	O
.	O

We	O
subsequently	O
carried	O
out	O
structure	O
-	O
activity	O
relationship	O
studies	O
and	O
optimized	O
the	O
lead	O
structure	O
to	O
potent	O
inhibitors	B-CHED
that	O
have	O
shown	O
antiviral	B-CHED
activity	O
against	O
SARS	O
-	O
CoV	O
infected	O
Vero	O
E6	O
cells	O
.	O

Interestingly	O
,	O
its	O
methylamine	B-CHED
derivative	O
,	O
49	O
,	O
displayed	O
good	O
enzyme	O
inhibitory	O
potency	O
(	O
IC	O
(	O
50	O
)	O
=	O
1	O
.	O
3	O
microM	O
)	O
and	O
the	O
most	O
potent	O
SARS	O
antiviral	B-CHED
activity	O
(	O
EC	O
(	O
50	O
)	O
=	O
5	O
.	O
2	O
microM	O
)	O
in	O
the	O
series	O
.	O

We	O
have	O
carried	O
out	O
computational	O
docking	O
studies	O
and	O
generated	O
a	O
predictive	O
3D	O
-	O
QSAR	O
model	O
for	O
SARS	O
-	O
CoV	O
PLpro	O
inhibitors	B-CHED
.	O

RESULTS	O
:	O
Compared	O
to	O
low	O
PEEP	B-CHED
,	O
PaO	B-CHED
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
ratio	O
and	O
alveolar	O
recruitment	O
were	O
increased	O
with	O
high	O
PEEP	B-CHED
.	O

Although	O
there	O
are	O
many	O
animal	O
-	O
specific	O
adenoviruses	O
and	O
occasionally	O
they	O
have	O
been	O
noted	O
to	O
infect	O
man	B-CHED
,	O
rarely	O
have	O
they	O
been	O
studied	O
as	O
potential	O
zoonotic	O
pathogens	O
.	O

ABSTRACT	O
:	O
Tramadol	O
is	O
a	O
synthetic	O
,	O
centrally	O
acting	O
analgesic	B-CHED
for	O
the	O
treatment	O
of	O
moderate	O
to	O
severe	O
pain	O
.	O

TITLE	O
:	O
Recombinant	O
receptor	O
-	O
binding	O
domain	O
of	O
SARS	O
-	O
CoV	O
spike	O
protein	B-CHED
expressed	O
in	O
mammalian	O
,	O
insect	O
and	O
E	O
.	O
coli	O
cells	O
elicits	O
potent	O
neutralizing	O
antibody	O
and	O
protective	O
immunity	O
.	O

Our	O
results	O
show	O
that	O
all	O
rRBD	O
proteins	B-CHED
expressed	O
in	O
the	O
above	O
systems	O
maintained	O
intact	O
conformation	O
,	O
being	O
able	O
to	O
induce	O
highly	O
potent	O
neutralizing	O
antibody	O
responses	O
and	O
complete	O
protective	O
immunity	O
against	O
SARS	O
-	O
CoV	O
challenge	O
in	O
mice	O
,	O
albeit	O
the	O
rRBD	O
expressed	O
in	O
293T	O
cells	O
elicited	O
stronger	O
humoral	O
immune	O
responses	O
with	O
significantly	O
higher	O
neutralizing	O
activity	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
than	O
those	O
expressed	O
in	O
Sf9	O
and	O
E	O
.	O
coli	O
cells	O
.	O

TITLE	O
:	O
RNA	O
aptamer	O
-	O
based	O
sensitive	O
detection	O
of	O
SARS	O
coronavirus	O
nucleocapsid	O
protein	B-CHED
.	O

Using	O
a	O
chemiluminescence	O
immunosorbent	O
assay	O
and	O
a	O
nanoarray	O
aptamer	O
chip	O
with	O
the	O
selected	O
aptamer	O
as	O
an	O
antigen	B-CHED
-	O
capturing	O
agent	O
,	O
we	O
could	O
sensitively	O
detect	O
N	O
protein	B-CHED
at	O
a	O
concentration	O
as	O
low	O
as	O
2	O
pg	O
/	O
ml	O
.	O

These	O
aptamer	O
-	O
antibody	O
hybrid	O
immunoassays	O
may	O
be	O
useful	O
for	O
rapid	O
,	O
sensitive	O
detection	O
of	O
SARS	O
-	O
CoV	O
N	O
protein	B-CHED
.	O

They	O
had	O
nucleotide	B-CHED
sequence	O
identities	O
of	O
97	O
-	O
98	O
%	O
and	O
amino	B-CHED
acid	I-CHED
sequence	O
identities	O
96	O
-	O
98	O
%	O
in	O
common	O
with	O
Chinese	O
IBVs	O
(	O
strain	O
A2	O
,	O
SH	O
and	O
QXIBV	O
).	O

A	O
protein	B-CHED
central	O
to	O
physiological	O
barrier	O
properties	O
is	O
vasodilator	B-CHED
-	O
stimulated	O
phosphoprotein	O
(	O
VASP	O
).	O

Moreover	O
,	O
we	O
found	O
that	O
the	O
HCoV	O
-	O
OC43	O
N	O
protein	B-CHED
contains	O
three	O
RNA	O
-	O
binding	O
regions	O
in	O
its	O
N	O
-	O
terminal	O
region	O
(	O
residues	O
1	O
-	O
173	O
)	O
and	O
central	O
-	O
linker	O
region	O
(	O
residues	O
174	O
-	O
232	O
and	O
233	O
-	O
300	O
).	O

In	O
an	O
outbreak	O
caused	O
by	O
novel	O
agents	O
,	O
it	O
is	O
important	O
to	O
know	O
the	O
effectiveness	O
of	O
disinfectants	B-CHED
and	O
antiseptics	O
to	O
prevent	O
or	O
reduce	O
the	O
possibility	O
of	O
human	O
-	O
to	O
-	O
human	O
transmission	O
via	O
surfaces	O
.	O

The	O
mechanism	O
of	O
axonal	O
loss	O
and	O
demyelination	O
in	O
MHV	O
infection	O
is	O
dependent	O
on	O
successful	O
transport	O
of	O
virus	O
from	O
gray	O
matter	O
to	O
white	O
matter	O
using	O
the	O
MHV	O
host	O
attachment	O
spike	O
glycoprotein	B-CHED
.	O

Despite	O
antibiotic	B-CHED
administration	O
,	O
infiltration	O
progressed	O
to	O
the	O
entire	O
right	O
lung	O
and	O
upper	O
left	O
lung	O
after	O
12	O
hours	O
,	O
and	O
he	O
developed	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
and	O
multiple	O
organ	O
failure	O
.	O

When	O
over	O
-	O
expressed	O
in	O
HEK	O
293	O
cells	O
,	O
the	O
full	O
-	O
length	O
protein	B-CHED
but	O
not	O
the	O
variant	O
with	O
the	O
deletion	O
caused	O
interferon	O
beta	O
induction	O
and	O
cleavage	O
of	O
procaspase	O
3	O
.	O

This	O
difference	O
could	O
explain	O
earlier	O
observations	O
of	O
enhanced	O
virulence	O
of	O
Frankfurt	O
-	O
1	O
in	O
Hamsters	O
as	O
compared	O
to	O
other	O
SARS	O
-	O
Coronavirus	O
reference	O
strains	O
and	O
identifies	O
the	O
SARS	O
-	O
CoV	O
7b	O
protein	B-CHED
as	O
an	O
attenuating	O
factor	O
with	O
the	O
SARS	O
-	O
Coronavirus	O
genome	O
.	O

This	O
trypsin	O
-	O
or	O
CPL	O
-	O
mediated	O
conversion	O
to	O
6HB	O
can	O
be	O
blocked	O
by	O
a	O
heptad	O
repeat	O
peptide	B-CHED
known	O
to	O
block	O
the	O
formation	O
of	O
6HB	O
.	O

TITLE	O
:	O
SARS	O
-	O
coronavirus	O
spike	O
S2	O
domain	O
flanked	O
by	O
cysteine	B-CHED
residues	O
C822	O
and	O
C833	O
is	O
important	O
for	O
activation	O
of	O
membrane	O
fusion	O
.	O

TITLE	O
:	O
Serum	O
lipopolysaccharide	B-CHED
binding	O
protein	B-CHED
levels	O
predict	O
severity	O
of	O
lung	O
injury	O
and	O
mortality	O
in	O
patients	O
with	O
severe	O
sepsis	O
.	O

ADCML	O
assays	O
,	O
using	O
FIPV	O
strain	O
79	O
-	O
1146	O
and	O
its	O
deletion	O
mutant	O
strain	O
Delta	O
3abc	O
/	O
Delta	O
7ab	O
,	O
were	O
performed	O
on	O
:	O
(	O
i	O
)	O
CrFK	O
cells	O
that	O
show	O
surface	O
-	O
expressed	O
viral	O
antigens	B-CHED
,	O
(	O
ii	O
)	O
monocytes	O
without	O
surface	O
-	O
expressed	O
viral	O
proteins	B-CHED
due	O
to	O
retention	O
and	O
(	O
iii	O
)	O
monocytes	O
with	O
surface	O
-	O
expressed	O
viral	O
proteins	B-CHED
since	O
the	O
antibody	O
-	O
mediated	O
internalization	O
of	O
these	O
proteins	B-CHED
was	O
blocked	O
.	O

ABSTRACT	O
:	O
Hemagglutinin	O
esterases	O
(	O
HEs	O
),	O
closely	O
related	O
envelope	O
glycoproteins	B-CHED
in	O
influenza	O
C	O
and	O
corona	B-CHED
-	O
and	O
toroviruses	O
,	O
mediate	O
reversible	O
attachment	O
to	O
O	O
-	O
acetylated	O
sialic	B-CHED
acids	I-CHED
(	O
Sias	O
).	O

According	O
to	O
the	O
changes	O
of	O
CD4	O
(+)	O
T	O
cell	O
,	O
immunosuppressive	B-CHED
agents	I-CHED
(	O
CsA	B-CHED
/	O
FK506	O
+	O
MMF	O
+	O
Pred	O
)	O
were	O
adjusted	O
,	O
and	O
the	O
effects	O
of	O
CMV	O
pneumonia	O
occurring	O
were	O
investigated	O
.	O

These	O
findings	O
show	O
that	O
DNA	O
vaccines	O
,	O
even	O
epitope	B-CHED
-	O
based	O
DNA	O
vaccines	O
using	O
LAMP	O
as	O
chimera	O
,	O
can	O
elicit	O
both	O
humoral	O
and	O
cellular	O
immune	O
responses	O
.	O

TITLE	O
:	O
The	O
challenges	O
of	O
""""	O
continuing	O
medical	O
education	O
""""	O
in	O
a	O
pandemic	O
era	B-CHED
.	O

TITLE	O
:	O
Macrophage	O
interleukin	O
-	O
6	O
and	O
tumour	O
necrosis	O
factor	O
-	O
alpha	O
are	O
induced	O
by	O
coronavirus	O
fixation	O
to	O
Toll	O
-	O
like	O
receptor	O
2	O
/	O
heparan	B-CHED
sulphate	I-CHED
receptors	O
but	O
not	O
carcinoembryonic	O
cell	O
adhesion	O
antigen	B-CHED
1a	O
.	O

Carcinoembryonic	O
cell	O
adhesion	O
antigen	B-CHED
1a	O
(	O
CEACAM1a	O
)	O
is	O
the	O
specific	O
receptor	O
for	O
the	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
),	O
a	O
coronavirus	O
known	O
to	O
induce	O
acute	O
viral	O
hepatitis	O
in	O
mice	O
.	O

We	O
previously	O
generated	O
human	O
mAbs	O
specific	O
to	O
the	O
S1	O
region	O
of	O
SARS	O
-	O
CoV	O
S	O
protein	B-CHED
.	O

Glycogen	B-CHED
content	O
in	O
the	O
heart	O
and	O
kidney	O
was	O
higher	O
in	O
the	O
ALI	O
-	O
EX	O
group	O
than	O
the	O
CTRL	O
-	O
EX	O
group	O
.	O

ALI	O
-	O
EX	O
caused	O
a	O
greater	O
thickening	O
of	O
the	O
alveolar	O
walls	O
,	O
more	O
areas	O
of	O
atelectasis	O
and	O
a	O
greater	O
abundance	O
of	O
inflammatory	O
cells	O
in	O
comparison	O
to	O
ALI	O
-	O
P	O
.	O
These	O
results	O
demonstrate	O
that	O
glycogen	B-CHED
content	O
in	O
ALI	O
,	O
induced	O
by	O
an	O
herbicide	B-CHED
that	O
is	O
highly	O
toxic	O
to	O
humans	O
and	O
animals	O
,	O
is	O
altered	O
in	O
different	O
tissues	O
depending	O
on	O
the	O
location	O
of	O
the	O
injury	O
.	O

The	O
recombinant	O
fusion	O
protein	B-CHED
Orf	O
9b	O
was	O
expressed	O
by	O
IPTG	B-CHED
induction	O
and	O
purifed	O
.	O

Oseltamivir	B-CHED
and	O
antibiotics	B-CHED
were	O
administered	O
.	O

Treatment	O
with	O
PCN	B-CHED
significantly	O
increased	O
survival	O
and	O
was	O
marked	O
by	O
enhanced	O
viral	O
clearance	O
,	O
accelerated	O
induction	O
of	O
viral	O
-	O
specific	O
antibody	O
production	O
,	O
and	O
significant	O
decreases	O
in	O
morbidity	O
and	O
lung	O
damage	O
.	O

To	O
understand	O
whether	O
this	O
suppression	O
is	O
through	O
inhibition	O
of	O
protein	B-CHED
kinase	O
R	O
(	O
PKR	O
),	O
the	O
double	O
-	O
stranded	O
-	O
RNA	O
-	O
dependent	O
kinase	O
that	O
is	O
one	O
of	O
the	O
main	O
kinases	O
responsible	O
for	O
phosphorylation	O
of	O
eIF	O
-	O
2alpha	O
,	O
cells	O
infected	O
with	O
IBV	O
were	O
analyzed	O
by	O
Western	O
blotting	O
.	O

The	O
recombinant	O
PEDV	O
N	O
protein	B-CHED
showed	O
the	O
antigenic	O
specificity	O
,	O
and	O
was	O
located	O
on	O
the	O
bacterial	O
cell	O
walls	O
of	O
pPG	B-CHED
-	O
1	O
-	O
n	O
transformed	O
L	O
.	O
casei	O
.	O

The	O
proteolytic	O
cleavage	O
of	O
poly	O
(	O
ADP	B-CHED
-	O
ribose	B-CHED
)	O
polymerases	O
(	O
PARPs	B-CHED
)	O
confirmed	O
the	O
activation	O
of	O
executioner	O
caspases	O
.	O

It	O
is	O
not	O
known	O
whether	O
these	O
cells	O
are	O
maintained	O
by	O
proliferation	O
of	O
T	O
cells	O
that	O
entered	O
the	O
CNS	B-CHED
during	O
acute	O
infection	O
or	O
are	O
newly	O
recruited	O
from	O
Ag	O
-	O
experienced	O
or	O
naive	O
T	O
cell	O
pools	O
.	O

The	O
serum	O
C	O
-	O
reactive	O
protein	B-CHED
(	O
CRP	O
)	O
level	O
recovered	O
more	O
quickly	O
in	O
patients	O
in	O
the	O
PCD	O
group	O
compared	O
to	O
those	O
in	O
the	O
surgery	O
group	O
(	O
P	O
<	O
0	O
.	O
001	O
).	O

The	O
serum	O
C	O
-	O
reactive	O
protein	B-CHED
(	O
CRP	O
)	O
level	O
recovered	O
more	O
quickly	O
in	O
patients	O
in	O
the	O
PCD	O
group	O
compared	O
to	O
those	O
in	O
the	O
surgery	O
group	O
(	O
P	O
<	O
0	O
.	O
001	O
).	O

We	O
also	O
demonstrate	O
that	O
glycosaminoglycan	B-CHED
had	O
no	O
effect	O
on	O
infection	O
of	O
the	O
cells	O
by	O
IBV	O
.	O

TITLE	O
:	O
Design	O
and	O
efficient	O
synthesis	O
of	O
novel	O
arylthiourea	O
derivatives	O
as	O
potent	O
hepatitis	O
C	O
virus	O
inhibitors	B-CHED
.	O

After	O
A	O
/	O
H5N1	O
infection	O
was	O
confirmed	O
,	O
antiviral	B-CHED
treatment	O
with	O
oseltamivir	B-CHED
and	O
A	O
/	O
H5N1	O
vaccinated	O
plasma	O
were	O
used	O
on	O
day	O
11	O
.	O

While	O
the	O
anti	O
-	O
microbiological	O
properties	O
of	O
nitric	B-CHED
oxide	I-CHED
-	O
derived	O
reactive	O
nitrogen	B-CHED
intermediates	O
(	O
RNI	B-CHED
)	O
such	O
as	O
peroxynitrite	B-CHED
,	O
are	O
known	O
,	O
the	O
mechanism	O
of	O
these	O
effects	O
are	O
as	O
yet	O
poorly	O
studied	O
.	O

ABSTRACT	O
:	O
Enveloped	O
viruses	O
enter	O
cells	O
by	O
viral	O
glycoprotein	B-CHED
-	O
mediated	O
binding	O
to	O
host	O
cells	O
and	O
subsequent	O
fusion	O
of	O
virus	O
and	O
host	O
cell	O
membranes	O
.	O

The	O
S	O
proteins	B-CHED
are	O
set	O
apart	O
from	O
other	O
viral	O
and	O
cellular	O
membrane	O
fusion	O
proteins	B-CHED
by	O
their	O
extensively	O
palmitoylated	O
membrane	O
-	O
associated	O
tails	O
.	O

Viruses	O
with	O
fewer	O
palmitoylated	O
S	O
protein	B-CHED
cysteines	O
entered	O
cells	O
slowly	O
and	O
had	O
reduced	O
specific	O
infectivities	O
.	O

These	O
findings	O
indicate	O
that	O
lipid	B-CHED
adducts	O
anchoring	O
S	O
proteins	B-CHED
into	O
virus	O
membranes	O
are	O
necessary	O
for	O
the	O
rapid	O
,	O
productive	O
S	O
protein	B-CHED
refolding	O
events	O
that	O
culminate	O
in	O
membrane	O
fusions	O
.	O

These	O
studies	O
reveal	O
a	O
previously	O
unappreciated	O
role	O
for	O
covalently	O
attached	O
lipids	B-CHED
on	O
the	O
endodomains	O
of	O
viral	O
proteins	B-CHED
eliciting	O
membrane	O
fusion	O
reactions	O
.	O

Clinical	O
suspicion	O
favored	O
warning	O
local	O
health	O
authorities	O
about	O
a	O
new	O
case	O
of	O
HPS	B-CHED
.	O

The	O
pattern	O
of	O
reactivity	O
indicated	O
the	O
existence	O
of	O
two	O
major	O
epitope	B-CHED
cores	O
(	O
i	O
.	O
e	O
.,	O
sequences	O
9	O
-	O
23	O
and	O
30	O
-	O
44	O
),	O
and	O
sequence	O
comparison	O
permitted	O
the	O
identification	O
of	O
two	O
minimal	O
epitopes	O
,	O
DSDFPIQ	O
(	O
amino	B-CHED
acids	I-CHED
9	O
-	O
15	O
)	O
and	O
IGDQILD	O
(	O
amino	B-CHED
acids	I-CHED
36	O
-	O
42	O
).	O

Mutational	O
analysis	O
of	O
sequences	O
9	O
-	O
23	O
and	O
30	O
-	O
44	O
indicated	O
that	O
residues	O
9	O
-	O
12	O
(	O
DSDF	O
)	O
from	O
the	O
first	O
major	O
N	O
-	O
terminal	O
epitope	B-CHED
,	O
and	O
residue	O
36	O
(	O
I	O
)	O
from	O
the	O
second	O
,	O
were	O
the	O
key	O
amino	B-CHED
acids	I-CHED
energetically	O
important	O
for	O
Ab	O
contact	O
.	O

The	O
small	O
open	O
reading	O
frames	O
situated	O
between	O
the	O
spike	O
and	O
envelope	O
genes	O
of	O
the	O
three	O
Korean	O
CRCoV	O
isolates	O
were	O
found	O
to	O
encode	O
three	O
nonstructural	O
proteins	B-CHED
(	O
4	O
.	O
9	O
kDa	O
,	O
2	O
.	O
7	O
kDa	O
,	O
and	O
12	O
.	O
8	O
kDa	O
in	O
size	O
),	O
as	O
were	O
the	O
British	O
(	O
CRCoV	O
G9142	O
)	O
and	O
Italian	O
(	O
CRCoV	O
240	O
-	O
05	O
)	O
strains	O
.	O

ABSTRACT	O
:	O
The	O
envelope	O
glycoproteins	B-CHED
S1	O
and	O
S2	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
mediate	O
viral	O
entry	O
by	O
conformational	O
change	O
from	O
a	O
prefusion	O
state	O
to	O
a	O
postfusion	O
state	O
that	O
enables	O
fusion	O
of	O
the	O
viral	O
and	O
target	O
membranes	O
.	O

After	O
adjusting	O
for	O
a	O
reduced	O
opportunity	O
of	O
patients	O
dying	O
early	O
to	O
receive	O
neuraminidase	B-CHED
inhibitors	I-CHED
,	O
neuraminidase	B-CHED
inhibitor	I-CHED
treatment	O
(	O
vs	O
no	O
treatment	O
)	O
was	O
associated	O
with	O
improved	O
survival	O
(	O
odds	O
ratio	O
,	O
8	O
.	O
5	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1	O
.	O
2	O
-	O
62	O
.	O
8	O
).	O

We	O
report	O
a	O
case	O
of	O
a	O
22	O
-	O
year	O
-	O
old	O
man	B-CHED
with	O
Down	O
syndrome	O
who	O
presented	O
with	O
isolated	O
fire	O
-	O
induced	O
smoke	O
inhalation	O
injury	O
.	O

TITLE	O
:	O
Nuclear	O
magnetic	O
resonance	O
structure	O
of	O
the	O
nucleic	B-CHED
acid	I-CHED
-	O
binding	O
domain	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
nonstructural	O
protein	B-CHED
3	O
.	O

TITLE	O
:	O
A	O
rare	O
case	O
of	O
neuroleptic	B-CHED
malignant	O
syndrome	O
presenting	O
with	O
serious	O
hyperthermia	O
treated	O
with	O
a	O
non	O
-	O
invasive	O
cooling	O
device	O
:	O
a	O
case	O
report	O
.	O

Lowering	O
of	O
body	O
temperature	O
,	O
however	O
,	O
may	O
be	O
a	O
major	O
clinical	O
problem	O
because	O
hyperthermia	O
in	O
neuroleptic	B-CHED
malignant	O
syndrome	O
is	O
typically	O
unresponsive	O
to	O
antipyretic	B-CHED
agents	O
while	O
manual	O
cooling	O
proves	O
difficult	O
due	O
to	O
peripheral	O
vasoconstriction	O
.	O

While	O
still	O
on	O
steroid	B-CHED
therapy	O
,	O
the	O
patient	O
developed	O
an	O
interstitial	O
pneumonia	O
with	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
,	O
which	O
required	O
immediate	O
admission	O
to	O
the	O
intensive	O
care	O
unit	O
where	O
extracorporeal	O
membrane	O
oxygenation	O
therapy	O
was	O
administered	O
continuously	O
for	O
37	O
days	O
.	O

The	O
pathophysiology	O
of	O
MAS	B-CHED
is	O
multifactorial	O
and	O
complex	O
.	O

TITLE	O
:	O
Murine	O
hepatitis	O
virus	O
nonstructural	O
protein	B-CHED
4	O
regulates	O
virus	O
-	O
induced	O
membrane	O
modifications	O
and	O
replication	O
complex	O
function	O
.	O

Three	O
animals	O
received	O
angiotensin	B-CHED
-	O
converting	O
enzyme	O
2	O
without	O
lipopolysaccharide	B-CHED
pretreatment	O
.	O

Alignment	O
and	O
comparison	O
of	O
the	O
15E2	O
-	O
defined	O
epitope	B-CHED
sequence	O
with	O
the	O
sequences	O
of	O
other	O
corona	B-CHED
-	O
viruses	O
indicated	O
that	O
the	O
epitope	B-CHED
is	O
well	O
conserved	O
among	O
chicken	O
and	O
turkey	O
coronaviruses	O
.	O

TITLE	O
:	O
Identification	O
of	O
a	O
new	O
region	O
of	O
SARS	O
-	O
CoV	O
S	O
protein	B-CHED
critical	O
for	O
viral	O
entry	O
.	O

To	O
understand	O
the	O
mechanism	O
by	O
which	O
a	O
virus	O
escapes	O
from	O
antibody	O
-	O
mediated	O
neutralization	O
,	O
we	O
have	O
investigated	O
the	O
interactions	O
of	O
non	O
-	O
neutralizing	O
and	O
neutralizing	O
antibodies	O
at	O
an	O
epitope	B-CHED
cluster	O
on	O
the	O
spike	O
protein	B-CHED
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
).	O

ABSTRACT	O
:	O
To	O
unscramble	O
the	O
relationship	O
between	O
protein	B-CHED
function	O
and	O
protein	B-CHED
structure	O
,	O
it	O
is	O
essential	O
to	O
assess	O
the	O
protein	B-CHED
similarity	O
from	O
different	O
aspects	O
.	O

In	O
addition	O
,	O
the	O
method	O
itself	O
provides	O
a	O
new	O
and	O
quantitative	O
tool	O
to	O
view	O
a	O
protein	B-CHED
structure	O
.	O

CONCLUSIONS	O
:	O
This	O
study	O
established	O
a	O
safe	O
dose	O
range	O
and	O
demonstrated	O
the	O
feasibility	O
of	O
prolonged	O
,	O
repeated	O
dosing	O
of	O
pf	O
-	O
tPA	B-CHED
.	O

SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
a	O
virus	O
that	O
causes	O
severe	O
lung	O
damage	O
,	O
encodes	O
an	O
array	O
of	O
proteins	B-CHED
able	O
to	O
inhibit	O
induction	O
and	O
signaling	O
of	O
type	O
-	O
I	O
interferons	O
.	O

Moreover	O
,	O
JHMV	O
infection	O
of	O
CXCR2	O
-/-	O
mice	O
resulted	O
in	O
an	O
approximate	O
60	O
%	O
reduction	O
of	O
PMN	O
migration	O
into	O
the	O
CNS	B-CHED
,	O
yet	O
these	O
mice	O
survived	O
infection	O
and	O
controlled	O
viral	O
replication	O
within	O
the	O
brain	O
.	O

TITLE	O
:	O
Strategies	O
for	O
targeting	O
tetraspanin	O
proteins	B-CHED
:	O
potential	O
therapeutic	O
applications	O
in	O
microbial	O
infections	O
.	O

Recent	O
data	O
have	O
indicated	O
that	O
members	O
of	O
the	O
tetraspanin	O
superfamily	O
,	O
proteins	B-CHED
with	O
a	O
widespread	O
distribution	O
in	O
eukaryotic	O
organisms	O
and	O
33	O
members	O
in	O
humans	O
,	O
may	O
provide	O
such	O
an	O
approach	O
.	O

Tetraspanins	O
traverse	O
the	O
membrane	O
four	O
times	O
,	O
but	O
are	O
distinguished	O
from	O
other	O
four	O
-	O
pass	O
membrane	O
proteins	B-CHED
by	O
the	O
presence	O
of	O
conserved	O
charged	O
residues	O
in	O
the	O
transmembrane	O
domains	O
and	O
a	O
defining	O
'	O
signature	O
'	O
motif	O
in	O
the	O
larger	O
of	O
the	O
two	O
extracellular	O
domains	O
(	O
the	O
EC2	O
).	O

TITLE	O
:	O
Corticosteroid	B-CHED
therapy	O
for	O
acute	O
lung	O
injury	O
,	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
and	O
severe	O
pneumonia	O
:	O
a	O
meta	O
-	O
analysis	O
of	O
randomized	O
controlled	O
trials	O
.	O

Low	O
-	O
dose	O
corticosteroids	B-CHED
administered	O
within	O
14	O
days	O
of	O
disease	O
onset	O
may	O
reduce	O
all	O
-	O
cause	O
mortality	O
in	O
patients	O
with	O
acute	O
lung	O
injury	O
,	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
and	O
severe	O
pneumonia	O
.	O

The	O
coverage	O
was	O
the	O
following	O
one	O
:	O
admittance	O
in	O
ICU	O
57	O
.	O
8	O
%,	O
mechanical	O
ventilation	O
34	O
.	O
9	O
%,	O
oxygen	B-CHED
therapy	O
16	O
.	O
9	O
%,	O
antibiotics	B-CHED
87	O
.	O
9	O
%.	O

We	O
determined	O
the	O
crystal	O
structure	O
of	O
NL63	O
-	O
CoV	O
spike	O
protein	B-CHED
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
complexed	O
with	O
human	O
ACE2	O
.	O

FACS	O
analyses	O
revealed	O
that	O
the	O
anti	O
-	O
CD134	O
antibodies	O
bound	O
to	O
a	O
cryptic	O
epitope	B-CHED
on	O
the	O
receptor	O
that	O
was	O
only	O
exposed	O
when	O
SU	O
bound	O
to	O
CD134	O
.	O

In	O
this	O
study	O
we	O
have	O
analyzed	O
the	O
phenotypes	O
of	O
recombinant	O
FCoVs	O
that	O
are	O
based	O
on	O
the	O
genetic	O
background	O
of	O
type	O
I	O
FCoV	O
strain	O
Black	O
but	O
encode	O
the	O
type	O
II	O
FCoV	O
strain	O
79	O
-	O
1146	O
S	O
protein	B-CHED
.	O

Enhanced	O
production	O
of	O
cytokines	O
(	O
tumor	O
necrosis	O
factor	O
alpha	O
[	O
TNF	O
-	O
alpha	O
]	O
and	O
interleukin	O
-	O
6	O
[	O
IL	O
-	O
6	O
])	O
and	O
chemokines	O
(	O
CXCL10	O
,	O
CCL2	B-CHED
,	O
CCL3	B-CHED
,	O
and	O
CCL5	O
)	O
correlated	O
with	O
migration	O
of	O
NK	O
cells	O
,	O
macrophages	O
,	O
and	O
plasmacytoid	O
dendritic	O
cells	O
(	O
pDC	B-CHED
)	O
into	O
the	O
lungs	O
.	O

Antibody	O
titers	O
against	O
canine	O
distemper	O
virus	O
(	O
CDV	B-CHED
)	O
in	O
two	O
facilities	O
in	O
which	O
giant	O
pandas	O
were	O
vaccinated	O
were	O
variable	O
.	O

Viral	O
Nucleocapsid	O
and	O
Spike	O
protein	B-CHED
targets	O
seem	O
to	O
co	O
-	O
opt	O
downregulated	O
miR	O
-	O
223	O
and	O
miR	O
-	O
98	O
respectively	O
within	O
BASCs	O
to	O
control	O
the	O
various	O
stages	O
of	O
BASC	O
differentiation	O
,	O
activation	O
of	O
inflammatory	O
chemokines	O
,	O
and	O
downregulation	O
of	O
ACE2	O
.	O

We	O
prospectively	O
evaluated	O
the	O
response	O
to	O
oseltamivir	B-CHED
and	O
prolonged	O
corticosteroid	B-CHED
treatment	O
in	O
patients	O
with	O
ALI	O
-	O
ARDS	O
and	O
suspected	O
H1N1	O
influenza	O
.	O

In	O
ARDS	O
patients	O
,	O
with	O
and	O
without	O
confirmed	O
H1N1	O
influenza	O
,	O
prolonged	O
low	O
-	O
to	O
-	O
moderate	O
dose	O
corticosteroid	B-CHED
treatment	O
was	O
well	O
tolerated	O
and	O
associated	O
with	O
significant	O
improvement	O
in	O
lung	O
injury	O
and	O
multiple	O
organ	O
dysfunction	O
scores	O
and	O
a	O
low	O
hospital	O
mortality	O
.	O

He	O
received	O
piperacillin	B-CHED
,	O
sulbactam	B-CHED
and	O
levoflaxacin	O
,	O
ample	O
fluid	O
and	O
non	O
-	O
invasive	O
ventilation	O
as	O
well	O
as	O
intermittent	O
catecholamine	B-CHED
treatment	O
.	O

Recombinant	O
urate	B-CHED
oxidase	O
(	O
rasburicase	O
)	O
is	O
a	O
newer	O
agent	O
that	O
directly	O
cleaves	O
uric	B-CHED
acid	I-CHED
.	O

Intravenous	O
azithromycin	B-CHED
treatment	O
was	O
used	O
to	O
cure	O
pneumonia	O
in	O
both	O
of	O
our	O
patients	O
.	O

The	O
aim	O
of	O
this	O
review	O
of	O
the	O
literature	O
is	O
to	O
provide	O
current	O
information	O
on	O
the	O
epidemiology	O
of	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)-	O
infected	O
patients	O
admitted	O
to	O
ICU	O
during	O
the	O
era	B-CHED
of	O
highly	O
active	O
antiretroviral	O
therapy	O
(	O
HAART	O
)	O
and	O
to	O
highlight	O
issues	O
related	O
to	O
HAART	O
that	O
are	O
relevant	O
to	O
the	O
intensivist	O
.	O

A	O
32	O
-	O
year	O
-	O
old	O
man	B-CHED
had	O
acute	O
onset	O
of	O
fever	O
,	O
dry	O
cough	O
,	O
rhinorrhea	O
,	O
and	O
sore	O
throat	O
2	O
days	O
after	O
returning	O
from	O
Dongguan	O
,	O
China	O
.	O

As	O
history	O
taking	O
found	O
clustering	O
of	O
influenza	O
-	O
like	O
illness	O
,	O
oseltamivir	B-CHED
was	O
given	O
immediately	O
under	O
the	O
impression	O
of	O
severe	O
influenza	O
illness	O
.	O

A	O
case	O
-	O
control	O
study	O
was	O
used	O
to	O
compare	O
the	O
ICU	O
cohort	O
to	O
Salt	B-CHED
Lake	O
County	O
residents	O
.	O

In	O
this	O
study	O
,	O
three	O
hybridoma	O
cell	O
lines	O
secreting	O
specific	O
monoclonal	O
antibodies	O
against	O
the	O
RBD	O
of	O
the	O
S	O
protein	B-CHED
were	O
generated	O
and	O
their	O
exact	O
binding	O
sites	O
were	O
identified	O
.	O

Sequence	O
comparison	O
between	O
native	O
epitopes	O
and	O
these	O
mimotopes	O
further	O
confirmed	O
the	O
binding	O
sites	O
,	O
and	O
revealed	O
key	O
amino	B-CHED
acid	I-CHED
residues	O
involved	O
in	O
antibody	O
binding	O
.	O

The	O
smallest	O
N	O
-	O
protein	B-CHED
domain	O
analyzed	O
with	O
RNA	O
chaperone	O
activity	O
,	O
facilitating	O
DNA	O
and	O
RNA	O
annealing	O
,	O
contained	O
the	O
central	O
unstructured	O
region	O
(	O
amino	B-CHED
acids	I-CHED
117	O
to	O
268	O
).	O

CONCLUSIONS	O
:	O
Impact	O
of	O
sepsis	O
,	O
DIC	B-CHED
and	O
duration	O
of	O
trauma	O
that	O
predict	O
progression	O
of	O
ALI	O
exists	O
throughout	O
the	O
entire	O
treatment	O
period	O
while	O
aspiration	O
of	O
gastric	O
contents	O
and	O
APACHE	O
II	O
score	O
might	O
affect	O
aggravation	O
of	O
ALI	O
only	O
during	O
the	O
early	O
period	O
;	O
due	O
to	O
deterioration	O
of	O
pulmonary	O
function	O
and	O
severely	O
traumatic	O
injury	O
,	O
advanced	O
age	O
is	O
still	O
an	O
independent	O
risk	O
factor	O
;	O
patients	O
with	O
these	O
risk	O
factors	O
need	O
aggressive	O
supportive	O
cares	O
as	O
early	O
as	O
possible	O
in	O
order	O
to	O
prevent	O
further	O
aggravations	O
.	O

ABSTRACT	O
:	O
A	O
21	O
-	O
year	O
old	O
man	B-CHED
was	O
referred	O
to	O
our	O
hospital	O
with	O
severe	O
respiratory	O
distress	O
and	O
diffuse	O
infiltrative	O
shadows	O
on	O
chest	O
radiograph	O
.	O

TITLE	O
:	O
TACE	O
antagonists	B-CHED
blocking	O
ACE2	O
shedding	O
caused	O
by	O
the	O
spike	O
protein	B-CHED
of	O
SARS	O
-	O
CoV	O
are	O
candidate	O
antiviral	B-CHED
compounds	O
.	O

Since	O
the	O
downregulation	O
of	O
ACE2	O
by	O
SARS	O
-	O
S	O
protein	B-CHED
was	O
proposed	O
as	O
an	O
etiological	O
event	O
in	O
the	O
severe	O
clinical	O
manifestations	O
,	O
our	O
data	O
suggest	O
that	O
TACE	O
antagonists	B-CHED
block	O
SARS	O
-	O
CoV	O
infection	O
and	O
also	O
attenuate	O
its	O
severe	O
clinical	O
outcome	O
.	O

To	O
set	O
PEEP	B-CHED
in	O
each	O
individual	O
patient	O
,	O
the	O
use	O
of	O
the	O
expiratory	O
limb	O
of	O
the	O
pressure	O
-	O
volume	O
curve	O
has	O
been	O
suggested	O
.	O

However	O
,	O
in	O
the	O
most	O
severe	O
patients	O
,	O
recruitment	O
maneuver	O
has	O
to	O
be	O
considered	O
and	O
higher	O
PEEP	B-CHED
applied	O
.	O

To	O
individualize	O
PEEP	B-CHED
,	O
the	O
expiratory	O
phase	O
has	O
to	O
be	O
considered	O
,	O
and	O
the	O
esophageal	O
pressure	O
measurement	O
to	O
compute	O
the	O
transpulmonary	O
pressure	O
should	O
be	O
progressively	O
introduced	O
in	O
clinical	O
practice	O
.	O

This	O
was	O
specific	O
,	O
since	O
SARS	O
-	O
CoV	O
M	O
did	O
not	O
retain	O
an	O
unrelated	O
glycoprotein	B-CHED
in	O
the	O
Golgi	O
.	O

Here	O
,	O
we	O
have	O
investigated	O
the	O
role	O
of	O
the	O
nucleocapsid	O
protein	B-CHED
in	O
MHV	O
-	O
induced	O
disease	O
.	O

ABSTRACT	O
:	O
This	O
study	O
uses	O
statistical	O
predictive	O
modeling	O
and	O
hierarchical	O
cluster	O
analyses	O
to	O
examine	O
inflammatory	O
mediators	O
and	O
cells	O
in	O
bronchoalveolar	O
lavage	O
(	O
BAL	B-CHED
)	O
as	O
putative	O
biomarkers	O
in	O
rats	O
with	O
blunt	O
trauma	O
lung	O
contusion	O
(	O
LC	O
),	O
gastric	O
aspiration	O
(	O
combined	O
acid	O
and	O
small	O
gastric	O
food	O
particles	O
,	O
CASP	O
),	O
or	O
a	O
combination	O
of	O
the	O
two	O
.	O

Even	O
in	O
developed	O
countries	O
,	O
the	O
occurrence	O
of	O
spontaneous	O
air	B-CHED
-	O
leaks	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
still	O
represent	O
the	O
most	O
severe	O
clinical	O
presentation	O
in	O
early	O
childhood	O
,	O
with	O
a	O
high	O
fatality	O
rate	O
.	O

During	O
the	O
2006	O
-	O
2007	O
outbreak	O
in	O
Rome	O
,	O
Italy	O
,	O
a	O
young	O
infant	O
presented	O
with	O
ARDS	O
/	O
spontaneous	O
air	B-CHED
-	O
leak	O
and	O
needed	O
aggressive	O
ventilatory	O
management	O
and	O
haemodynamic	O
support	O
.	O

Among	O
the	O
candidate	O
proteins	B-CHED
,	O
annexin	O
A2	O
,	O
which	O
was	O
identified	O
by	O
mass	O
spectrometry	O
analysis	O
and	O
had	O
the	O
highest	O
score	O
by	O
Mascot	O
data	O
search	O
,	O
was	O
further	O
characterized	O
and	O
investigated	O
for	O
its	O
role	O
as	O
an	O
autoantigen	O
.	O

A	O
rapid	O
increase	O
of	O
partial	O
pressure	O
of	O
arterial	O
oxygen	B-CHED
/	O
fraction	O
of	O
inspired	O
oxygen	B-CHED
(	O
PaO2	O
/	O
FiO2	O
)	O
from	O
64	O
(	O
48	O
to	O
86	O
)	O
mmHg	O
to	O
120	O
(	O
84	O
to	O
171	O
)	O
mmHg	O
and	O
a	O
decrease	O
of	O
PaCO2	O
from	O
63	O
(	O
50	O
to	O
80	O
)	O
mmHg	O
to	O
33	O
(	O
29	O
to	O
39	O
)	O
mmHg	O
were	O
observed	O
after	O
start	O
of	O
the	O
extracorporeal	O
support	O
(	O
P	O
<	O
0	O
.	O
001	O
).	O

These	O
results	O
provide	O
further	O
mechanistic	O
details	O
of	O
the	O
pro	B-CHED
-	O
apoptotic	O
effects	O
of	O
the	O
SARS	O
-	O
CoV	O
3a	O
protein	B-CHED
,	O
and	O
suggest	O
a	O
potential	O
role	O
for	O
it	O
in	O
attenuating	O
interferon	O
responses	O
and	O
innate	O
immunity	O
.	O

Both	O
types	O
of	O
viruses	O
translate	O
their	O
genetic	O
information	O
into	O
polyprotein	O
precursors	O
that	O
are	O
processed	O
by	O
virally	O
encoded	O
3C	O
proteases	O
(	O
3C	O
(	O
pro	B-CHED
))	O
and	O
3C	O
-	O
like	O
proteases	O
(	O
3CL	O
(	O
pro	B-CHED
)),	O
respectively	O
,	O
to	O
generate	O
functional	O
viral	O
proteins	B-CHED
.	O

The	O
study	O
of	O
the	O
protease	O
cleavage	O
motif	O
within	O
the	O
S1	O
protein	B-CHED
found	O
12	O
different	O
cleavage	O
motifs	O
,	O
of	O
which	O
3	O
motifs	O
are	O
shared	O
by	O
both	O
isolated	O
and	O
published	O
strains	O
,	O
2	O
motifs	O
unique	O
to	O
isolated	O
strains	O
,	O
and	O
7	O
motifs	O
unique	O
to	O
published	O
strains	O
,	O
further	O
bolstering	O
the	O
notion	O
of	O
no	O
new	O
predominant	O
strains	O
.	O

ABSTRACT	O
:	O
Antiviral	B-CHED
therapy	O
and	O
vaccination	O
are	O
important	O
strategies	O
for	O
controlling	O
pandemic	O
2009	O
influenza	O
A	O
(	O
H1N1	O
)	O
but	O
efficacy	O
depends	O
on	O
the	O
timing	O
of	O
administration	O
and	O
is	O
often	O
limited	O
by	O
supply	O
shortage	O
.	O

Although	O
the	O
evidence	O
base	O
of	O
most	O
non	O
pharmaceutical	B-CHED
interventions	O
(	O
NPIs	O
)	O
and	O
personal	O
protection	O
measures	O
is	O
debated	O
,	O
it	O
appears	O
on	O
the	O
basis	O
of	O
past	O
experience	O
that	O
NPIs	O
implemented	O
the	O
most	O
systematically	O
,	O
the	O
earliest	O
,	O
and	O
for	O
the	O
longest	O
time	O
could	O
reduce	O
overall	O
mortality	O
rates	O
and	O
spread	O
out	O
epidemic	O
peaks	O
.	O

Introduction	O
of	O
lysine	B-CHED
residues	O
in	O
the	O
hydrophobic	O
stretch	O
of	O
S	O
also	O
resulted	O
in	O
a	O
block	O
of	O
entry	O
,	O
suggesting	O
the	O
borders	O
of	O
the	O
actual	O
transmembrane	O
domain	O
.	O

Pharmacologic	O
strategies	O
(	O
including	O
steroids	B-CHED
)	O
investigated	O
for	O
the	O
treatment	O
of	O
severe	O
respiratory	O
failure	O
are	O
also	O
reviewed	O
.	O

More	O
recently	O
,	O
several	O
small	O
and	O
one	O
moderate	O
-	O
size	O
multicenter	O
randomized	O
controlled	O
trial	O
(	O
RCT	O
)	O
investigated	O
low	O
-	O
to	O
-	O
moderate	O
-	O
dose	O
prolonged	O
corticosteroid	B-CHED
treatment	O
.	O

Experts	O
differ	O
in	O
their	O
recommendations	O
regarding	O
corticosteroids	B-CHED
for	O
late	O
-	O
stage	O
ARDS	O
,	O
although	O
one	O
consensus	O
group	O
supported	O
a	O
""""	O
weak	O
""""	O
recommendation	O
of	O
low	O
-	O
to	O
-	O
moderate	O
-	O
dose	O
corticosteroids	B-CHED
for	O
ARDS	O
of	O
<	O
14	O
days	O
duration	O
.	O

TITLE	O
:	O
Engineering	O
a	O
novel	O
endopeptidase	O
based	O
on	O
SARS	O
3CL	O
(	O
pro	B-CHED
).	O

In	O
this	O
study	O
,	O
we	O
developed	O
a	O
mutant	O
3CLpro	O
(	O
T25G	O
)	O
with	O
an	O
expanded	O
S1	O
'	O
space	O
that	O
demonstrates	O
43	O
.	O
5	O
-	O
fold	O
better	O
k	O
(	O
cat	O
)/	O
K	O
(	O
m	O
)	O
compared	O
with	O
wild	O
-	O
type	O
in	O
cleaving	O
substrates	O
with	O
a	O
larger	O
Met	B-CHED
at	O
P1	O
'	O
and	O
is	O
suitable	O
for	O
tag	O
removal	O
from	O
recombinant	O
fusion	O
proteins	B-CHED
.	O

Two	O
vectors	O
for	O
expressing	O
fusion	O
proteins	B-CHED
with	O
the	O
T25G	O
recognition	O
site	O
(	O
Ala	B-CHED
-	O
Val	B-CHED
-	O
Leu	B-CHED
-	O
Gln	B-CHED
[	O
downward	O
arrow	O
]	O
Met	B-CHED
)	O
in	O
Escherichia	O
coli	O
and	O
yeast	O
were	O
constructed	O
.	O

TITLE	O
:	O
[	O
Application	O
of	O
bioactive	O
mutant	O
TNF	O
alpha	O
to	O
a	O
mucosal	O
vaccine	O
adjuvant	B-CHED
].	O

In	O
this	O
report	O
,	O
we	O
examined	O
the	O
potential	O
of	O
mTNF	O
-	O
K90R	O
as	O
a	O
mucosal	O
adjuvant	B-CHED
and	O
evaluated	O
its	O
effectiveness	O
and	O
safety	O
.	O

Paradoxically	O
,	O
prolonged	O
administration	O
of	O
immunosuppressive	B-CHED
agents	I-CHED
because	O
of	O
acute	O
graft	O
-	O
versus	O
-	O
host	O
disease	O
had	O
a	O
protective	O
effect	O
on	O
the	O
development	O
of	O
allo	O
-	O
LS	O
(	O
P	O
=	O
.	O
004	O
).	O

Two	O
weeks	O
after	O
cyclosporine	B-CHED
was	O
discontinued	O
,	O
however	O
,	O
she	O
was	O
readmitted	O
with	O
an	O
acute	O
relapse	O
of	O
macrophage	O
activating	O
syndrome	O
manifested	O
by	O
spiking	O
fever	O
,	O
arthralgias	O
,	O
maculopapular	O
rash	O
and	O
leukocytosis	O
.	O

We	O
believe	O
that	O
cyclosporine	B-CHED
is	O
a	O
cornerstone	O
for	O
the	O
treatment	O
of	O
Still	O
'	O
s	O
disease	O
.	O

Our	O
study	O
focuses	O
on	O
hCoV	O
-	O
NL63	O
open	O
reading	O
frame	O
3	O
(	O
ORF	O
3	O
)	O
which	O
is	O
a	O
highly	O
conserved	O
accessory	O
protein	B-CHED
among	O
coronaviruses	O
.	O

Subcellular	O
localization	O
studies	O
using	O
recombinant	O
ORF	O
3	O
protein	B-CHED
transfected	O
in	O
Huh	O
-	O
7	O
cells	O
revealed	O
occurrence	O
in	O
ERGIC	O
,	O
Golgi	O
-	O
and	O
lysosomal	O
compartments	O
.	O

Using	O
N	O
-	O
terminally	O
FLAG	O
-	O
tagged	O
ORF	O
3	O
protein	B-CHED
and	O
an	O
antiserum	O
specific	O
to	O
the	O
C	O
-	O
terminus	O
we	O
verified	O
the	O
proposed	O
topology	O
of	O
an	O
extracellular	O
N	O
-	O
terminus	O
and	O
a	O
cytosolic	O
C	O
-	O
terminus	O
.	O

In	O
contrast	O
,	O
nucleotide	B-CHED
and	O
amino	B-CHED
acid	I-CHED
sequence	O
similarities	O
observed	O
with	O
the	O
spike	O
(	O
S	O
)	O
protein	B-CHED
were	O
only	O
79	O
.	O
5	O
and	O
79	O
.	O
6	O
%,	O
respectively	O
.	O

ABSTRACT	O
:	O
Due	O
to	O
the	O
complexity	O
of	O
biological	O
membrane	O
,	O
computer	O
simulation	O
of	O
transmembrane	O
protein	B-CHED
'	O
s	O
folding	O
is	O
challenging	O
.	O

Therefore	O
,	O
this	O
implicit	O
membrane	O
environment	O
,	O
though	O
in	O
lattice	O
space	O
,	O
can	O
make	O
an	O
elaborate	O
balance	B-CHED
between	O
different	O
driving	O
forces	O
for	O
the	O
membrane	O
protein	B-CHED
'	O
s	O
folding	O
,	O
thus	O
offering	O
a	O
potential	O
means	O
for	O
the	O
simulation	O
of	O
transmembrane	O
protein	B-CHED
oligomers	O
in	O
feasible	O
time	O
.	O

Within	O
the	O
pediatric	O
cohort	O
,	O
single	O
nucleotide	B-CHED
polymorphisms	O
rs16834493	O
,	O
rs820463	O
,	O
and	O
rs9840993	O
were	O
genotyped	O
in	O
the	O
African	O
American	O
patients	O
,	O
whereas	O
single	O
nucleotide	B-CHED
polymorphisms	O
rs960224	O
,	O
rs33264	O
,	O
rs11718105	O
,	O
and	O
rs9289225	O
were	O
genotyped	O
in	O
the	O
Caucasian	O
patients	O
.	O

One	O
single	O
nucleotide	B-CHED
polymorphism	O
(	O
rs820336	O
)	O
was	O
genotyped	O
in	O
both	O
groups	O
.	O

No	O
association	O
between	O
the	O
selected	O
single	O
nucleotide	B-CHED
polymorphisms	O
in	O
the	O
myosin	O
light	O
chain	O
kinase	O
gene	O
and	O
either	O
the	O
need	O
for	O
positive	O
-	O
pressure	O
ventilation	O
or	O
the	O
development	O
of	O
acute	O
lung	O
injury	O
/	O
acute	O
respiratory	O
distress	O
syndrome	O
was	O
observed	O
in	O
children	O
with	O
community	O
-	O
acquired	O
pneumonia	O
.	O

Preliminary	O
diagnostic	O
submissions	O
to	O
the	O
California	O
Animal	O
Health	O
and	O
Food	O
Safety	O
Laboratory	O
System	O
(	O
CAHFS	O
)	O
were	O
negative	O
for	O
known	O
bacterial	O
,	O
parasitic	O
,	O
fungal	O
,	O
and	O
viral	O
pathogens	O
,	O
as	O
well	O
as	O
for	O
toxins	B-CHED
,	O
making	O
the	O
etiology	O
of	O
this	O
disease	O
unknown	O
.	O

43	O
mm	O
Hg	O
(	O
mean	O
partial	O
pressure	O
of	O
oxygen	B-CHED
,	O
70	O
+/-	O

TITLE	O
:	O
Lactic	B-CHED
acid	I-CHED
bacteria	O
efficiently	O
protect	O
human	O
and	O
animal	O
intestinal	O
epithelial	O
and	O
immune	O
cells	O
from	O
enteric	O
virus	O
infection	O
.	O

In	O
order	O
to	O
elucidate	O
the	O
possible	O
mechanism	O
responsible	O
for	O
the	O
antiviral	B-CHED
activity	O
,	O
the	O
induction	O
of	O
reactive	B-CHED
oxygen	I-CHED
species	I-CHED
(	O
ROS	B-CHED
)	O
release	O
as	O
well	O
as	O
the	O
attachment	O
ability	O
of	O
LAB	O
on	O
the	O
cell	O
lines	O
was	O
investigated	O
.	O

Further	O
,	O
while	O
the	O
C	O
-	O
terminal	O
region	O
is	O
required	O
for	O
preventing	O
STAT1	O
translocation	O
to	O
the	O
nucleus	B-CHED
,	O
our	O
results	O
also	O
indicated	O
that	O
the	O
N	O
-	O
terminal	O
18	O
amino	B-CHED
acids	I-CHED
were	O
necessary	O
for	O
maximal	O
inhibition	O
.	O

Twenty	O
-	O
six	O
papers	O
were	O
identified	O
that	O
met	B-CHED
the	O
study	O
inclusion	O
criteria	O
.	O

He	O
was	O
discharged	O
and	O
followed	O
-	O
up	O
as	O
an	O
outpatient	O
,	O
and	O
was	O
given	O
oral	O
warfarin	B-CHED
and	O
prednisolone	B-CHED
.	O

Due	O
to	O
its	O
rapid	O
action	O
,	O
artesunate	B-CHED
was	O
likely	O
responsible	O
for	O
the	O
good	O
clinical	O
outcome	O
in	O
this	O
case	O
;	O
however	O
,	O
in	O
order	O
to	O
clarify	O
the	O
role	O
of	O
this	O
new	O
combination	O
therapy	O
,	O
further	O
studies	O
are	O
required	O
.	O

Treatment	O
with	O
the	O
glucosidase	O
inhibitor	B-CHED
N	B-CHED
-	I-CHED
butyl	I-CHED
-	O
deoxynojirimycin	O
(	O
NB	B-CHED
-	I-CHED
DNJ	I-CHED
)	O
inhibited	O
N	B-CHED
-	I-CHED
glycan	I-CHED
processing	O
as	O
evidenced	O
by	O
the	O
appearance	O
of	O
glycans	B-CHED
of	O
composition	O
Glc	B-CHED
(	O
3	O
)	O
Man	B-CHED
(	O
7	O
-	O
9	O
)	O
GlcNAc	B-CHED
(	O
2	O
).	O

However	O
,	O
some	O
complex	O
glycans	B-CHED
remained	O
suggesting	O
the	O
presence	O
of	O
an	O
alpha	O
-	O
endomannosidase	O
.	O

In	O
addition	O
,	O
the	O
largest	O
number	O
of	O
amino	B-CHED
acid	I-CHED
variations	O
was	O
accumulated	O
in	O
the	O
S1	O
N	O
-	O
terminal	O
region	O
,	O
leading	O
to	O
the	O
presence	O
of	O
hypervariability	O
in	O
the	O
isolates	O
.	O

Sequence	O
comparisons	O
at	O
the	O
peptide	B-CHED
level	O
of	O
the	O
S	O
proteins	B-CHED
revealed	O
that	O
all	O
seven	O
Korean	O
isolates	O
shared	O
diverse	O
similarities	O
ranging	O
from	O
a	O
93	O
.	O
6	O
%	O
to	O
99	O
.	O
6	O
%	O
identity	O
with	O
each	O
other	O
but	O
exhibited	O
a	O
92	O
.	O
2	O
%	O
to	O
93	O
.	O
7	O
%	O
identity	O
with	O
other	O
reference	O
strains	O
.	O

We	O
conducted	O
a	O
retrospective	O
cohort	O
study	O
of	O
74	O
patients	O
with	O
pandemic	O
H1N1	O
infection	O
,	O
including	O
23	O
patients	O
who	O
either	O
developed	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
or	O
died	O
(	O
ARDS	O
-	O
death	O
group	O
),	O
14	O
patients	O
with	O
desaturation	O
requiring	O
oxygen	B-CHED
supplementation	O
and	O
who	O
survived	O
without	O
ARDS	O
(	O
survived	O
-	O
without	O
-	O
ARDS	O
group	O
),	O
and	O
37	O
patients	O
with	O
mild	O
disease	O
without	O
desaturation	O
(	O
mild	O
-	O
disease	O
group	O
).	O

We	O
present	O
a	O
fully	O
automated	O
search	O
method	O
,	O
EpiSearch	O
that	O
predicts	O
the	O
possible	O
location	O
of	O
conformational	O
epitopes	O
on	O
the	O
surface	O
of	O
an	O
antigen	B-CHED
.	O

Input	O
options	O
of	O
the	O
program	O
include	O
mapping	O
of	O
a	O
single	O
peptide	B-CHED
or	O
a	O
set	O
of	O
peptides	B-CHED
on	O
the	O
antigen	B-CHED
structure	O
,	O
and	O
the	O
results	O
of	O
the	O
calculation	O
can	O
be	O
visualized	O
on	O
our	O
interactive	O
web	O
server	O
.	O

Telomere	O
-	O
poor	O
or	O
telomere	O
-	O
free	O
'	O
ghost	O
'	O
nuclei	B-CHED
were	O
a	O
regular	O
finding	O
in	O
these	O
RS	O
cells	O
.	O

The	O
placHK2	O
amplicon	O
vector	O
was	O
injected	O
into	O
substantia	O
nigra	O
of	O
mice	O
that	O
were	O
subsequently	O
administered	O
rotenone	B-CHED
or	O
MPTP	B-CHED
.	O

The	O
spike	O
(	O
S	O
)	O
glycoprotein	B-CHED
has	O
been	O
identified	O
as	O
a	O
major	O
target	O
of	O
protective	O
immunity	O
and	O
contains	O
3	O
regions	O
that	O
are	O
targeted	O
by	O
neutralizing	O
antibodies	O
in	O
the	O
S1	O
and	O
S2	O
domains	O
.	O

RESULTS	O
:	O
Distinct	O
but	O
partially	O
overlapping	O
sets	O
of	O
amino	B-CHED
acids	I-CHED
were	O
identified	O
that	O
are	O
critical	O
to	O
the	O
binding	O
of	O
MAbs	O
with	O
differential	O
neutralization	O
profiles	O
.	O

Human	O
tissue	O
culture	O
cells	O
transiently	O
expressing	O
7a	O
and	O
Ap4A	O
-	O
hydrolase	O
tagged	O
with	O
EGFP	O
and	O
Ds	O
-	O
Red2	O
respectively	O
show	O
these	O
proteins	B-CHED
co	O
-	O
localize	O
in	O
the	O
cytoplasm	O
.	O

There	O
were	O
no	O
differences	O
in	O
cortisol	B-CHED
in	O
those	O
infants	O
with	O
and	O
without	O
SNAP	O
>	O
or	O
=	O
10	O
during	O
the	O
study	O
period	O
.	O

There	O
were	O
no	O
differences	O
in	O
cortisol	B-CHED
in	O
those	O
infants	O
with	O
and	O
without	O
SNAP	O
>	O
or	O
=	O
10	O
during	O
the	O
study	O
period	O
.	O

TITLE	O
:	O
Self	O
-	O
assembly	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
membrane	O
protein	B-CHED
.	O

Based	O
on	O
our	O
homology	O
model	O
of	O
the	O
kinase	O
domain	O
of	O
MLK3	O
,	O
the	O
region	O
containing	O
the	O
cleavage	O
site	O
is	O
predicted	O
to	O
reside	O
on	O
a	O
flexible	O
solvent	B-CHED
-	O
accessible	O
loop	O
.	O

Dissemination	O
of	O
the	O
findings	O
will	O
help	O
to	O
bridge	O
gaps	O
and	O
rectify	O
inconsistencies	O
in	O
current	O
pandemic	O
planning	O
and	O
response	O
strategies	O
for	O
SARS	O
and	O
SARS	O
-	O
like	O
diseases	O
,	O
as	O
well	O
as	O
add	B-CHED
valuable	O
knowledge	O
towards	O
the	O
development	O
of	O
national	O
and	O
international	O
emerging	O
infectious	O
disease	O
policies	O
.	O

TITLE	O
:	O
Achieving	O
a	O
golden	O
mean	O
:	O
mechanisms	O
by	O
which	O
coronaviruses	O
ensure	O
synthesis	O
of	O
the	O
correct	O
stoichiometric	O
ratios	O
of	O
viral	O
proteins	B-CHED
.	O

There	O
is	O
substantial	O
experimental	O
and	O
pre	O
-	O
clinical	O
evidence	O
showing	O
that	O
the	O
S	O
protein	B-CHED
is	O
a	O
promising	O
lead	O
for	O
vaccines	O
and	O
therapeutics	O
.	O

Our	O
data	O
show	O
that	O
the	O
neutralizing	O
mAbs	O
bind	O
to	O
the	O
angiotensin	B-CHED
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
the	O
SARS	O
S	O
protein	B-CHED
.	O

We	O
found	O
that	O
NL63	O
PLP2	O
deconjugated	O
ubiquitin	O
(	O
Ub	O
)	O
and	O
the	O
Ub	O
-	O
line	O
molecule	O
ISG15	O
from	O
cellular	O
substrates	O
and	O
processed	O
both	O
lysine	B-CHED
-	O
48	O
-	O
and	O
lysine	B-CHED
-	O
63	O
-	O
linked	O
polyubiquitin	O
chains	O
.	O

The	O
improved	O
oxygen	B-CHED
tension	O
allowed	O
for	O
a	O
reduction	O
in	O
mean	O
airway	O
pressure	O
and	O
oxygen	B-CHED
concentration	O
as	O
well	O
the	O
safe	O
aeromedical	O
evacuation	O
of	O
the	O
patient	O
from	O
the	O
combat	B-CHED
theater	O
.	O

Further	O
,	O
prospective	O
studies	O
are	O
required	O
to	O
validate	O
the	O
magnitude	O
of	O
response	O
to	O
inhaled	O
prostacyclin	B-CHED
during	O
HFPV	O
.	O

TITLE	O
:	O
Inhaled	O
aerosolized	O
insulin	B-CHED
:	O
a	O
""""	O
topical	O
""""	O
anti	O
-	O
inflammatory	O
treatment	O
for	O
acute	O
lung	O
injury	O
and	O
respiratory	O
distress	O
syndrome	O
?	O

Limited	O
access	O
to	O
medical	O
care	O
,	O
antibiotics	B-CHED
,	O
and	O
vaccinations	O
remains	O
a	O
major	O
problem	O
in	O
developing	O
countries	O
.	O

Based	O
on	O
the	O
corresponding	O
protein	B-CHED
coding	O
sequences	O
of	O
these	O
amino	B-CHED
acid	I-CHED
segments	O
,	O
the	O
influences	O
of	O
GC	O
content	O
of	O
palindromes	O
and	O
palindrome	O
densities	O
in	O
protein	B-CHED
coding	O
segments	O
on	O
the	O
relations	O
between	O
the	O
folding	O
rates	O
and	O
the	O
average	O
polarities	O
were	O
studied	O
.	O

Results	O
showed	O
that	O
the	O
folding	O
rates	O
correlated	O
positively	O
with	O
the	O
GC	O
content	O
of	O
palindromes	O
and	O
the	O
palindrome	O
density	O
,	O
and	O
protein	B-CHED
coding	O
sequences	O
do	O
carry	O
the	O
information	O
which	O
can	O
influence	O
the	O
folding	O
rates	O
of	O
peptide	B-CHED
chains	O
or	O
protein	B-CHED
structures	O
.	O

Sequence	O
analysis	O
of	O
a	O
405	O
-	O
nucleotide	B-CHED
region	O
of	O
the	O
highly	O
conserved	O
RNA	O
polymerase	O
gene	O
(	O
pol	O
)	O
showed	O
that	O
all	O
coronaviruses	O
detected	O
in	O
this	O
study	O
are	O
genetically	O
closely	O
related	O
,	O
with	O
99	O
.	O
5	O
-	O
100	O
%	O
nucleotide	B-CHED
identity	O
,	O
and	O
belong	O
to	O
group	O
2	O
of	O
the	O
coronaviruses	O
.	O

The	O
most	O
closely	O
related	O
virus	O
sequence	O
in	O
GenBank	O
was	O
SARS	O
bat	O
isolate	O
Rp3	O
/	O
2004	O
(	O
DQ071615	O
)	O
within	O
the	O
SARS	O
-	O
like	O
CoV	O
cluster	O
,	O
sharing	O
85	O
%	O
nucleotide	B-CHED
identity	O
and	O
95	O
.	O
6	O
%	O
amino	B-CHED
acid	I-CHED
identity	O
.	O

The	O
latter	O
viruses	O
entered	O
directly	O
from	O
cell	O
surface	O
,	O
when	O
receptor	O
-	O
bound	O
viruses	O
were	O
treated	O
with	O
proteases	O
that	O
activate	O
fusion	O
activity	O
of	O
their	O
S	O
proteins	B-CHED
.	O

Cotransfection	O
of	O
individual	O
shRNA	O
plasmids	O
and	O
pcDNA3	O
.	O
0	O
-	O
mfgl2	O
and	O
pcDNA3	O
.	O
0	O
-	O
mTNFR1	O
expression	O
constructs	O
into	O
Chinese	O
hamster	O
ovary	O
(	O
CHO	B-CHED
)	O
cells	O
significantly	O
inhibited	O
mfgl2	O
and	O
mTNFR1	O
gene	O
expression	O
,	O
as	O
evidenced	O
by	O
fluorescence	O
microscopy	O
,	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
,	O
and	O
Western	O
blotting	O
.	O

The	O
antigen	B-CHED
for	O
ELISA	O
was	O
prepared	O
by	O
ultracentrifugation	O
of	O
culture	O
supernatants	O
of	O
RAW	O
264	O
cells	O
infected	O
with	O
MNV	O
-	O
S7	O
.	O

No	O
deletions	O
or	O
insertions	O
were	O
detected	O
in	O
the	O
H16	O
genome	O
sequence	O
after	O
continuous	O
passage	O
in	O
vitro	O
;	O
however	O
,	O
we	O
found	O
27	O
nucleotide	B-CHED
mutations	O
in	O
strain	O
H165	O
compared	O
with	O
strain	O
H16	O
,	O
resulting	O
in	O
16	O
amino	B-CHED
acid	I-CHED
changes	O
distributed	O
among	O
the	O
genes	O
1	O
,	O
S	O
,	O
3	O
,	O
and	O
sM	O
.	O
An	O
A	O
to	O
G	O
nucleotide	B-CHED
mutation	O
was	O
found	O
in	O
the	O
intergenic	O
region	O
between	O
the	O
3a	O
and	O
3b	O
genes	O
.	O

Messenger	B-CHED
RNA	I-CHED
expression	O
levels	O
of	O
transforming	O
growth	O
factor	O
-	O
beta4	O
(	O
TGF	O
-	O
beta4	O
)	O
are	O
also	O
upregulated	O
in	O
cortisosterone	O
-	O
treated	O
birds	O
.	O

Translation	O
in	O
mammalian	O
cells	O
expressing	O
2B	O
protein	B-CHED
is	O
inhibited	O
by	O
hygromycin	B-CHED
B	I-CHED
(	O
HB	O
)	O
but	O
remains	O
unaffected	O
in	O
mock	O
cells	O
,	O
which	O
are	O
not	O
permeable	O
to	O
the	O
inhibitor	B-CHED
.	O

TITLE	O
:	O
Morphing	O
low	O
-	O
affinity	O
ligands	O
into	O
high	O
-	O
avidity	O
nanoparticles	B-CHED
by	O
thermally	O
triggered	O
self	O
-	O
assembly	O
of	O
a	O
genetically	O
encoded	O
polymer	B-CHED
.	O

TITLE	O
:	O
Identification	O
of	O
key	O
amino	B-CHED
acid	I-CHED
residues	O
required	O
for	O
horseshoe	O
bat	O
angiotensin	B-CHED
-	O
I	O
converting	O
enzyme	O
2	O
to	O
function	O
as	O
a	O
receptor	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
.	O

Recently	O
,	O
we	O
demonstrated	O
that	O
a	O
recombinant	O
MVTT	O
expressing	O
the	O
spike	O
glycoprotein	B-CHED
of	O
SARS	O
-	O
CoV	O
(	O
namely	O
MVTT	O
-	O
S	O
)	O
is	O
superior	O
to	O
the	O
non	O
-	O
replicating	O
modified	O
vaccinia	O
Ankara	O
(	O
MVA	B-CHED
-	O
S	O
)	O
for	O
inducing	O
high	O
level	O
of	O
neutralizing	O
antibodies	O
through	O
mucosal	O
vaccination	O
.	O

TITLE	O
:	O
Effectiveness	O
of	O
nitric	B-CHED
oxide	I-CHED
during	O
spontaneous	O
breathing	O
in	O
experimental	O
lung	O
injury	O
.	O

We	O
retrospectively	O
reviewed	O
data	O
of	O
58	O
patients	O
with	O
severe	O
ARDS	O
(	O
the	O
ratios	O
of	O
partial	O
arterial	O
oxygen	B-CHED
tension	O
to	O
fraction	O
of	O
inspired	O
oxygen	B-CHED
,	O
PaO2	O
/	O
F	O
(	O
I	O
)	O
O2	O
ratio	O
<	O
150	O
).	O

RESULTS	O
:	O
In	O
85	O
BAL	B-CHED
samples	O
from	O
82	O
patients	O
,	O
median	O
viral	O
loads	O
were	O
as	O
follows	O
:	O
for	O
RSV	O
(	O
n	O
=	O
35	O
),	O
2	O
.	O
6	O
x	O
10	O
(	O
6	O
)	O
copies	O
/	O
mL	O
;	O
for	O
parainfluenza	O
virus	O
(	O
n	O
=	O
35	O
),	O
4	O
.	O
9	O
x	O
10	O
(	O
7	O
)	O
copies	O
/	O
mL	O
;	O
for	O
influenza	O
virus	O
(	O
n	O
=	O
9	O
),	O
6	O
.	O
8	O
x	O
10	O
(	O
5	O
)	O
copies	O
/	O
mL	O
;	O
for	O
MPV	O
(	O
n	O
=	O
7	O
),	O
3	O
.	O
9	O
x	O
10	O
(	O
7	O
)	O
copies	O
/	O
mL	O
;	O
and	O
for	O
CoV	O
(	O
n	O
=	O
4	O
),	O
1	O
.	O
8	O
x	O
10	O
(	O
5	O
)	O
copies	O
/	O
mL	O
.	O
Quantitative	O
viral	O
load	O
was	O
not	O
associated	O
with	O
mechanical	O
ventilation	O
or	O
death	O
.	O

Control	O
pigs	O
received	O
a	O
saline	O
infusion	O
,	O
whereas	O
ALF	O
pigs	O
received	O
acetaminophen	B-CHED
intravenously	O
for	O
12	O
hours	O
to	O
maintain	O
blood	O
concentrations	O
between	O
200	O
-	O
300	O
mg	O
/	O
l	O
.	O

CONCLUSIONS	O
:	O
We	O
have	O
developed	O
a	O
reproducible	O
large	O
animal	O
model	O
of	O
acetaminophen	B-CHED
-	O
induced	O
liver	O
failure	O
,	O
which	O
allows	O
in	O
-	O
depth	O
investigation	O
of	O
the	O
pathophysiological	O
basis	O
of	O
this	O
condition	O
.	O

Interestingly	O
,	O
MHV	O
has	O
a	O
cell	O
-	O
type	O
-	O
dependent	O
ability	O
to	O
resist	O
the	O
antiviral	B-CHED
effects	O
of	O
IFN	O
-	O
alpha	O
/	O
beta	O
.	O

Corn	O
oil	O
was	O
mixed	O
with	O
distilled	O
water	B-CHED
to	O
form	O
fatty	O
micelles	O
.	O

N	B-CHED
-	I-CHED
acetylcysteine	I-CHED
(	O
an	O
antioxidant	B-CHED
),	O
and	O
NOS	O
inhibitors	B-CHED
such	O
as	O
Nomega	O
nitro	B-CHED
-	O
L	B-CHED
-	I-CHED
arginine	I-CHED
methyl	B-CHED
ester	B-CHED
(	O
L	O
-	O
NAME	O
),	O
S	O
-	O
methylisothiourea	O
(	O
SMT	O
)	O
or	O
L	O
-	O
N6	O
(	O
1	O
-	O
iminoethyl	O
)-	O
lysine	B-CHED
(	O
L	O
-	O
Nil	O
)	O
were	O
able	O
to	O
abrogate	O
the	O
FES	O
or	O
the	O
fat	O
embolism	O
-	O
induced	O
changes	O
.	O

ABSTRACT	O
:	O
This	O
study	O
aimed	O
to	O
develop	O
a	O
visual	O
protein	B-CHED
chip	O
that	O
can	O
differentiate	O
the	O
antibodies	O
induced	O
by	O
avian	O
influenza	O
virus	O
,	O
Newcastle	O
disease	O
virus	O
,	O
infectious	O
bronchitis	O
virus	O
and	O
infectious	O
bursal	O
disease	O
virus	O
,	O
simultaneously	O
.	O

The	O
protein	B-CHED
chip	O
was	O
used	O
to	O
test	O
known	O
serum	O
samples	O
of	O
the	O
four	O
poultry	O
diseases	O
and	O
field	O
serum	O
samples	O
.	O

The	O
median	O
duration	O
from	O
the	O
onset	O
of	O
the	O
illness	O
to	O
hospital	O
admission	O
was	O
4	O
.	O
1	O
days	O
(	O
1	O
-	O
5	O
days	O
)	O
and	O
from	O
the	O
onset	O
to	O
first	O
dose	O
of	O
oseltamivir	B-CHED
was	O
5	O
.	O
5	O
days	O
(	O
2	O
-	O
12	O
days	O
),	O
from	O
onset	O
to	O
mechanical	O
ventilation	O
initiation	O
was	O
6	O
.	O
8	O
days	O
(	O
4	O
-	O
12	O
days	O
).	O

Intensive	O
intravenous	O
insulin	B-CHED
therapy	O
was	O
performed	O
for	O
50	O
days	O
.	O

Diabetes	O
mellitus	O
as	O
a	O
rare	O
immunological	O
complication	O
of	O
haemolytic	O
uremic	O
syndrome	O
was	O
suspected	O
on	O
the	O
following	O
evidence	O
:	O
positive	O
anti	O
-	O
GAD	O
antibodies	O
(	O
ELISA	O
),	O
elevated	O
levels	O
of	O
glycosylated	O
haemoglobin	B-CHED
A1c	O
,	O
three	O
-	O
fold	O
reduction	O
of	O
blood	O
C	O
-	O
peptide	B-CHED
concentration	O
,	O
negative	O
family	O
history	O
for	O
diabetes	O
.	O

Despite	O
potent	O
antiviral	B-CHED
T	O
-	O
lymphocyte	O
activity	O
,	O
sterile	O
immunity	O
is	O
not	O
achieved	O
,	O
and	O
MHV	O
chronically	O
persists	O
within	O
oligodendrocytes	O
.	O

The	O
linear	O
motif	O
(	O
11	O
)	O
DSPAPIIKLGG	O
(	O
21	O
),	O
located	O
at	O
the	O
N	O
-	O
terminus	O
of	O
the	O
N	O
protein	B-CHED
,	O
was	O
identified	O
as	O
the	O
epitope	B-CHED
bound	O
by	O
2D2	O
.	O

In	O
this	O
study	O
,	O
we	O
expressed	O
a	O
219	O
-	O
mer	O
(	O
residues	O
318	O
-	O
536	O
)	O
RBD	O
protein	B-CHED
in	O
Chinese	O
hamster	O
ovary	O
(	O
CHO	B-CHED
)-	O
K1	O
cells	O
(	O
RBD219	O
-	O
CHO	B-CHED
),	O
and	O
tested	O
its	O
immune	O
responses	O
and	O
protective	O
immunity	O
in	O
a	O
mouse	O
model	O
.	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
spread	O
during	O
the	O
winter	O
of	O
2003	O
,	O
and	O
attempts	O
have	O
been	O
made	O
to	O
develop	O
vaccines	O
against	O
SARS	O
corona	B-CHED
virus	O
(	O
SARS	O
-	O
CoV	O
).	O

The	O
method	O
was	O
useful	O
,	O
convenient	O
and	O
efficient	O
for	O
rapid	O
identification	O
of	O
CTL	O
epitopes	O
derived	O
from	O
SARS	O
-	O
CoV	O
proteins	B-CHED
and	O
will	O
be	O
possibly	O
applicable	O
for	O
other	O
pathogens	O
to	O
develop	O
a	O
peptide	B-CHED
-	O
based	O
vaccine	O
.	O

We	O
report	O
our	O
first	O
experiences	O
in	O
application	O
of	O
initially	O
heparin	B-CHED
-	O
free	O
ECMO	O
in	O
severe	O
trauma	O
patients	O
with	O
resistant	O
cardiopulmonary	O
failure	O
and	O
coexisting	O
bleeding	O
shock	O
retrospectively	O
and	O
describe	O
blood	O
coagulation	O
management	O
on	O
ECMO	O
.	O

We	O
used	O
a	O
new	O
miniaturised	O
ECMO	O
device	O
(	O
PLS	O
-	O
Set	O
,	O
MAQUET	O
Cardiopulmonary	O
AG	O
,	O
Hechingen	O
,	O
Germany	O
)	O
and	O
performed	O
initially	O
heparin	B-CHED
-	O
free	O
ECMO	O
.	O

Prior	O
to	O
ECMO	O
median	O
oxygenation	O
ratio	O
(	O
OR	O
)	O
was	O
47	O
(	O
36	O
-	O
90	O
)	O
mmHg	O
,	O
median	O
paCO	O
(	O
2	O
)	O
was	O
67	O
(	O
36	O
-	O
89	O
)	O
mmHg	O
and	O
median	O
norepinephrine	B-CHED
demand	O
was	O
3	O
.	O
0	O
(	O
1	O
.	O
0	O
-	O
13	O
.	O
5	O
)	O
mg	O
/	O
h	O
.	O

Positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	B-CHED
),	O
peak	O
inspiratory	O
pressures	O
(	O
PIPs	O
),	O
Fio	O
(	O
2	O
),	O
oxygen	B-CHED
saturation	O
(	O
Sao	O
(	O
2	O
)),	O
and	O
tidal	O
volume	O
in	O
mL	O
/	O
kg	O
PBW	O
were	O
compared	O
.	O

The	O
average	O
Fio	O
(	O
2	O
)	O
and	O
PIP	B-CHED
were	O
significantly	O
escalated	O
depending	O
on	O
the	O
P	O
/	O
F	O
ratio	O
.	O

RESULTS	O
:	O
A	O
total	O
of	O
28	O
,	O
706	O
ABGs	O
from	O
11	O
,	O
445	O
operative	O
cases	O
met	B-CHED
criteria	O
for	O
inclusion	O
.	O

Differing	O
amino	B-CHED
acid	I-CHED
sequences	O
of	O
all	O
three	O
viruses	O
may	O
affect	O
the	O
antigenicity	O
and	O
/	O
or	O
pathogenicity	O
of	O
these	O
viruses	O
and	O
may	O
merit	O
further	O
study	O
.	O

The	O
potential	O
benefits	O
and	O
safety	O
of	O
the	O
use	O
of	O
remifentanil	B-CHED
in	O
parturients	O
with	O
high	O
pulmonary	O
artery	O
pressures	O
are	O
discussed	O
.	O

In	O
contrast	O
,	O
the	O
Ser	B-CHED
(	O
32	O
)	O
amino	B-CHED
acid	I-CHED
substitution	O
totally	O
abolished	O
enzymatic	O
activity	O
while	O
receptor	O
binding	O
increased	O
,	O
as	O
observed	O
by	O
agglutination	O
of	O
Atlantic	O
salmon	O
red	O
blood	O
cells	O
.	O

Furthermore	O
,	O
SJL	O
mice	O
produced	O
antiviral	B-CHED
antibodies	O
after	O
MHV	O
-	O
A59	O
inoculation	O
with	O
10	O
(	O
5	O
)	O
PFU	B-CHED
,	O
but	O
cB61ba	O
mice	O
did	O
not	O
.	O

Eight	O
studies	O
met	B-CHED
the	O
inclusion	O
criteria	O
.	O

RESULTS	O
:	O
Eight	O
studies	O
met	B-CHED
the	O
inclusion	O
criteria	O
.	O

We	O
recommend	O
that	O
the	O
mental	O
and	O
psychological	O
well	O
-	O
being	O
of	O
the	O
community	O
,	O
in	O
particular	O
older	O
adults	O
,	O
be	O
taken	O
into	O
careful	O
account	O
when	O
developing	O
epidemic	O
control	O
measures	O
to	O
combat	B-CHED
the	O
future	O
outbreak	O
of	O
diseases	O
in	O
the	O
community	O
.	O

TITLE	O
:	O
In	O
vitro	O
reconstitution	O
of	O
SARS	O
-	O
coronavirus	O
mRNA	B-CHED
cap	O
methylation	O
.	O

The	O
S	B-CHED
-	I-CHED
adenosyl	I-CHED
-	I-CHED
L	I-CHED
-	I-CHED
methionine	I-CHED
(	O
AdoMet	B-CHED
)-	O
dependent	O
(	O
guanine	B-CHED
-	O
N7	O
)-	O
methyltransferase	O
(	O
N7	O
-	O
MTase	O
)	O
activity	O
was	O
recently	O
attributed	O
to	O
nsp14	O
,	O
whereas	O
nsp16	O
has	O
been	O
predicted	O
to	O
be	O
the	O
AdoMet	B-CHED
-	O
dependent	O
(	O
nucleoside	B-CHED
-	O
2	O
'	O
O	O
)-	O
methyltransferase	O
.	O

We	O
show	O
that	O
MHV	O
infection	O
activated	O
both	O
transcription	O
factors	O
,	O
the	O
IFN	O
regulatory	O
factor	O
3	O
(	O
IRF	O
-	O
3	O
)	O
and	O
nuclear	O
factor	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
),	O
as	O
evidenced	O
by	O
phosphorylation	O
and	O
nuclear	O
translocation	O
of	O
IRF	O
-	O
3	O
and	O
an	O
increased	O
promoter	O
binding	O
activity	O
for	O
IRF	O
-	O
3	O
and	O
NF	O
-	O
kappaB	O
.	O
Furthermore	O
,	O
the	O
cytoplasmic	O
pattern	O
recognition	O
receptor	O
retinoic	B-CHED
acid	I-CHED
-	O
inducible	O
gene	O
I	O
(	O
RIG	O
-	O
I	O
)	O
was	O
induced	O
by	O
MHV	O
infection	O
.	O

Murine	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
PLP2	O
and	O
orthologs	O
recognize	O
and	O
cleave	O
at	O
a	O
position	O
following	O
a	O
p4	O
-	O
Leu	B-CHED
-	O
X	O
-	O
Gly	B-CHED
-	I-CHED
Gly	I-CHED
-	O
p1	O
tetrapeptide	B-CHED
,	O
but	O
it	O
is	O
unknown	O
whether	O
these	O
residues	O
are	O
sufficient	O
to	O
result	O
in	O
processing	O
by	O
PLP2	O
at	O
sites	O
normally	O
cleaved	O
by	O
PLP1	O
.	O

Thus	O
,	O
the	O
p4	O
-	O
p1	O
residues	O
are	O
necessary	O
for	O
PLP2	O
processing	O
but	O
require	O
a	O
specific	O
protein	B-CHED
or	O
cleavage	O
site	O
context	O
for	O
optimal	O
PLP	O
recognition	O
and	O
cleavage	O
.	O

Carbon	B-CHED
dioxide	I-CHED
is	O
removed	O
by	O
a	O
pump	O
-	O
driven	O
modified	O
ECMO	O
machine	O
with	O
veno	O
-	O
venous	O
bypass	O
,	O
while	O
oxygenation	O
is	O
accomplished	O
by	O
high	O
levels	O
of	O
positive	O
end	O
-	O
expiratory	O
pressure	O
,	O
with	O
a	O
respiratory	O
rate	O
of	O
3	O
-	O
5	O
breaths	O
/	O
min	O
.	O

A	O
pair	O
of	O
primers	O
(	O
P1	O
and	O
P4	O
)	O
specific	O
for	O
CDV	B-CHED
corresponding	O
to	O
the	O
highly	O
conserved	O
region	O
of	O
the	O
CDV	B-CHED
genome	O
were	O
used	O
as	O
a	O
common	O
primer	O
pair	O
in	O
the	O
first	O
-	O
round	O
PCR	O
of	O
the	O
nested	O
PCR	O
.	O

This	O
may	O
not	O
be	O
optimal	O
because	O
it	O
may	O
present	O
an	O
excessive	O
supply	O
of	O
linoleic	B-CHED
acid	I-CHED
.	O

Analysis	O
of	O
the	O
effects	O
of	O
these	O
lethal	O
mutations	O
on	O
RNA	O
synthesis	O
suggested	O
that	O
processing	O
intermediates	O
,	O
such	O
as	O
the	O
nsp6	O
-	O
7	O
,	O
nsp12	O
-	O
13	O
,	O
nsp13	O
-	O
14	O
,	O
nsp14	O
-	O
15	O
,	O
and	O
nsp15	O
-	O
16	O
precursors	O
,	O
may	O
function	O
in	O
negative	O
-	O
stranded	O
genomic	O
RNA	O
replication	O
,	O
whereas	O
mature	O
proteins	B-CHED
may	O
be	O
required	O
for	O
subgenomic	O
RNA	O
(	O
sgRNA	O
)	O
transcription	O
.	O

Either	O
of	O
the	O
two	O
mutations	O
was	O
proved	O
to	O
enhance	O
significantly	O
the	O
3CLpro	O
-	O
mediated	O
cleavage	O
efficiency	O
at	O
the	O
nsp15	O
-	O
16	O
site	O
with	O
a	O
P1	O
-	O
Asn	B-CHED
substitution	O
and	O
compensate	O
for	O
the	O
detrimental	O
effects	O
on	O
recovery	O
of	O
infectious	O
virus	O
.	O

No	O
clinical	O
symptoms	O
,	O
lung	O
lesions	O
,	O
lung	O
cell	O
infiltration	O
or	O
induction	O
of	O
IFN	O
-	O
alpha	O
,	O
IL	O
-	O
1	O
,	O
IL	O
-	O
6	O
,	O
IL	O
-	O
12	O
and	O
TNF	O
-	O
alpha	O
in	O
BAL	B-CHED
were	O
detected	O
.	O

Etanercept	O
was	O
administered	O
at	O
the	O
time	O
of	O
LPS	B-CHED
inoculation	O
via	O
the	O
same	O
routes	O
and	O
dose	O
as	O
in	O
the	O
initial	O
experiment	O
.	O

Half	O
of	O
the	O
animals	O
from	O
each	O
group	O
were	O
euthanized	O
at	O
4	O
and	O
the	O
rest	B-CHED
at	O
8h	O
after	O
LPS	B-CHED
inoculation	O
.	O

ABSTRACT	O
:	O
A	O
tetrahydroquinoline	B-CHED
oxocarbazate	O
(	O
PubChem	O
CID	O
23631927	O
)	O
was	O
tested	O
as	O
an	O
inhibitor	B-CHED
of	O
human	O
cathepsin	O
L	O
(	O
EC	O
3	O
.	O
4	O
.	O
22	O
.	O
15	O
)	O
and	O
as	O
an	O
entry	O
blocker	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
and	O
Ebola	O
pseudotype	O
virus	O
.	O

Overall	O
,	O
the	O
oxocarbazate	O
CID	O
23631927	O
was	O
a	O
subnanomolar	O
,	O
slow	O
-	O
binding	O
,	O
reversible	O
inhibitor	B-CHED
of	O
human	O
cathepsin	O
L	O
that	O
blocked	O
SARS	O
-	O
CoV	O
and	O
Ebola	O
pseudotype	O
virus	O
entry	O
in	O
human	O
cells	O
.	O

TITLE	O
:	O
Quantitative	O
proteomics	O
using	O
stable	O
isotope	O
labeling	O
with	O
amino	B-CHED
acids	I-CHED
in	O
cell	O
culture	O
reveals	O
changes	O
in	O
the	O
cytoplasmic	O
,	O
nuclear	O
,	O
and	O
nucleolar	O
proteomes	O
in	O
Vero	O
cells	O
infected	O
with	O
the	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
.	O

Fractionation	O
of	O
cells	O
into	O
cytoplasmic	O
,	O
nuclear	O
,	O
and	O
nucleolar	O
extracts	O
was	O
used	O
to	O
reduce	O
sample	O
complexity	O
and	O
provide	O
information	O
on	O
the	O
trafficking	O
of	O
proteins	B-CHED
between	O
the	O
different	O
compartments	O
.	O

Ingenuity	O
Pathway	O
Analysis	O
revealed	O
that	O
proteins	B-CHED
that	O
changed	O
in	O
response	O
to	O
infection	O
could	O
be	O
grouped	O
into	O
different	O
functional	O
categories	O
.	O

ABSTRACT	O
:	O
As	O
a	O
follow	O
up	O
of	O
an	O
anti	O
-	O
Flaviviridae	O
project	O
,	O
a	O
new	O
series	O
of	O
variously	O
substituted	O
2	O
-	O
styryl	O
-	O
benzimidazoles	B-CHED
were	O
synthesized	O
and	O
tested	O
in	O
vitro	O
for	O
biological	O
activity	O
.	O

Compounds	O
were	O
tested	O
in	O
cell	O
-	O
based	O
assays	O
against	O
viruses	O
representative	O
of	O
:	O
i	O
)	O
two	O
of	O
the	O
three	O
genera	O
of	O
the	O
Flaviviridae	O
family	O
,	O
i	O
.	O
e	O
.	O
Pestiviruses	O
and	O
Flaviviruses	O
;	O
ii	O
)	O
other	O
RNA	O
virus	O
families	O
,	O
such	O
as	O
Retroviridae	O
,	O
Picornaviridae	O
,	O
Paramyxoviridae	O
,	O
Rhabdoviridae	O
and	O
Reoviridae	O
;	O
iii	O
)	O
two	O
DNA	O
virus	O
families	O
(	O
Herpesviridae	O
and	O
Poxviridae	O
)	O
as	O
well	O
as	O
for	O
cytotoxicity	O
tests	O
,	O
run	O
in	O
parallel	O
with	O
antiviral	B-CHED
assays	O
,	O
against	O
MDBK	O
,	O
BHK	O
and	O
Vero	O
76	O
cells	O
.	O

Thus	O
,	O
in	O
Japan	O
,	O
CHDF	O
with	O
a	O
polymethylmethacrylate	B-CHED
membrane	O
is	O
now	O
widely	O
applied	O
for	O
non	O
-	O
renal	O
indications	O
,	O
not	O
only	O
for	O
patients	O
with	O
sepsis	O
but	O
also	O
patients	O
with	O
cytokine	O
-	O
induced	O
critical	O
illness	O
(	O
such	O
as	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
severe	O
acute	O
pancreatitis	O
),	O
even	O
when	O
those	O
patients	O
do	O
not	O
present	O
with	O
renal	O
dysfunction	O
.	O

This	O
study	O
sought	O
to	O
discover	O
the	O
host	O
proteins	B-CHED
that	O
interact	O
with	O
SARS	O
-	O
CoV	O
NP	O
.	O

p42	O
is	O
a	O
subunit	O
of	O
the	O
26S	O
proteasome	O
;	O
this	O
large	O
,	O
multi	O
-	O
protein	B-CHED
complex	O
is	O
a	O
component	O
of	O
the	O
ubiquitin	O
-	O
proteasome	O
pathway	O
,	O
which	O
is	O
involved	O
in	O
a	O
variety	O
of	O
basic	O
cellular	O
processes	O
and	O
inflammatory	O
responses	O
.	O

Thus	O
,	O
the	O
TSL	O
-	O
1	O
-	O
induced	O
apoptosis	O
was	O
further	O
confirmed	O
by	O
cell	O
morphology	O
,	O
subG1	O
peak	O
accumulation	O
,	O
poly	O
(	O
adenosine	B-CHED
diphosphate	B-CHED
[	O
ADP	B-CHED
]-	O
ribose	B-CHED
)	O
polymerase	O
(	O
PARP	B-CHED
)	O
cleavage	O
,	O
propidium	B-CHED
iodide	I-CHED
(	O
PI	O
)-	O
Annexin	O
-	O
V	O
double	O
staining	O
,	O
and	O
terminal	O
deoxynucleotidyl	O
transferase	O
-	O
mediated	O
dUTP	B-CHED
nick	O
end	O
-	O
labeling	O
(	O
TUNEL	O
)	O
assay	O
.	O

Stress	O
-	O
induced	O
phosphorylation	O
of	O
eukaryotic	O
translation	O
initiation	O
factor	O
2alpha	O
(	O
eIF2alpha	O
)	O
generally	O
results	O
in	O
impaired	O
initiation	O
of	O
protein	B-CHED
synthesis	O
,	O
but	O
the	O
sensitivity	O
of	O
MHV	O
infection	O
to	O
proteasome	B-CHED
inhibitors	I-CHED
was	O
unchanged	O
in	O
cells	O
lacking	O
a	O
phosphorylatable	O
eIF2alpha	O
.	O

The	O
non	O
-	O
structural	O
proteins	B-CHED
of	O
the	O
viral	O
replication	O
complex	O
are	O
thought	O
to	O
be	O
associated	O
with	O
these	O
newly	O
synthesized	O
membranes	O
.	O

In	O
this	O
study	O
,	O
we	O
tested	O
the	O
efficacy	O
of	O
live	O
attenuated	O
Salmonella	O
enterica	O
serovar	O
Typhimurium	O
designed	O
to	O
secrete	O
swine	O
IFN	O
-	O
alpha	O
(	O
swIFN	O
-	O
alpha	O
)	O
protein	B-CHED
for	O
preventing	O
the	O
clinical	O
signs	O
caused	O
by	O
infection	O
with	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
),	O
one	O
of	O
the	O
diarrhea	O
-	O
causing	O
viruses	O
in	O
the	O
swine	O
industry	O
.	O

ABSTRACT	O
:	O
We	O
have	O
designed	O
and	O
synthesized	O
a	O
novel	O
series	O
of	O
alpha	O
-	O
amino	O
cyclic	O
boronates	B-CHED
and	O
incorporated	O
them	O
successfully	O
in	O
several	O
acyclic	O
templates	O
at	O
the	O
P1	O
position	O
.	O

Gel	O
-	O
shift	O
experiments	O
showed	O
that	O
both	O
SUD	O
-	O
C	O
and	O
SUD	O
-	O
MC	O
bind	O
to	O
single	O
-	O
stranded	O
RNA	O
and	O
recognize	O
purine	B-CHED
bases	I-CHED
more	O
strongly	O
than	O
pyrimidine	B-CHED
bases	I-CHED
,	O
whereby	O
SUD	O
-	O
MC	O
binds	O
to	O
a	O
more	O
restricted	O
set	O
of	O
purine	B-CHED
-	O
containing	O
RNA	O
sequences	O
than	O
SUD	O
-	O
M	O
.	O
NMR	O
chemical	O
shift	O
perturbation	O
experiments	O
with	O
observations	O
of	O
(	O
15	O
)	O
N	O
-	O
labeled	O
proteins	B-CHED
further	O
resulted	O
in	O
delineation	O
of	O
RNA	O
binding	O
sites	O
(	O
i	O
.	O
e	O
.,	O
in	O
SUD	O
-	O
M	O
,	O
a	O
positively	O
charged	O
surface	O
area	O
with	O
a	O
pronounced	O
cavity	O
,	O
and	O
in	O
SUD	O
-	O
C	O
,	O
several	O
residues	O
of	O
an	O
anti	O
-	O
parallel	O
beta	O
-	O
sheet	O
).	O

TITLE	O
:	O
Synthesis	O
,	O
docking	O
studies	O
,	O
and	O
evaluation	O
of	O
pyrimidines	B-CHED
as	O
inhibitors	B-CHED
of	O
SARS	O
-	O
CoV	O
3CL	O
protease	O
.	O

The	O
estimated	O
dose	O
of	O
SARS	O
-	O
CoV	O
for	O
apartment	O
residents	O
during	O
the	O
outbreak	O
,	O
which	O
was	O
back	O
-	O
calculated	O
from	O
the	O
reported	O
number	O
of	O
cases	O
,	O
ranged	O
from	O
16	O
to	O
160	O
PFU	B-CHED
/	O
person	O
,	O
depending	O
on	O
the	O
floor	O
.	O

These	O
results	O
showed	O
that	O
there	O
was	O
an	O
interaction	O
between	O
ET	O
-	O
1	O
and	O
NO	O
in	O
a	O
VILI	O
model	O
and	O
changing	O
the	O
balance	B-CHED
of	O
ET	O
-	O
1	O
and	O
NO	O
levels	O
might	O
contribute	O
to	O
the	O
pathophysiologic	O
process	O
of	O
VILI	O
.	O

We	O
observed	O
also	O
10	O
infections	O
A	O
/	O
H1N1	O
influenza	O
during	O
pregnancy	O
,	O
with	O
good	O
oseltamivir	B-CHED
tolerance	O
and	O
without	O
recent	O
perinathal	O
complications	O
.	O

TITLE	O
:	O
Corticosteroids	B-CHED
as	O
adjunctive	O
therapy	O
in	O
severe	O
blastomycosis	O
-	O
induced	O
acute	O
respiratory	O
distress	O
syndrome	O
in	O
an	O
immunosuppressed	O
patient	O
.	O

The	O
child	O
was	O
observed	O
after	O
one	O
year	O
,	O
plaque	O
removal	O
was	O
carried	O
out	O
and	O
fluoride	B-CHED
varnish	O
was	O
placed	O
on	O
all	O
teeth	O
.	O

Phosphorylation	O
levels	O
induced	O
by	O
interleukin	O
-	O
6	O
in	O
STAT1	O
and	O
STAT3	O
and	O
by	O
combination	O
of	O
phorbol	B-CHED
12	I-CHED
-	I-CHED
myristate	I-CHED
13	I-CHED
-	I-CHED
acetate	I-CHED
and	O
calcium	B-CHED
ionophore	I-CHED
A23187	O
in	O
extracellular	O
signal	O
-	O
regulated	O
kinases	O
1	O
/	O
2	O
,	O
members	O
of	O
a	O
mitogen	B-CHED
-	O
activated	O
protein	B-CHED
kinase	O
family	O
,	O
were	O
depressed	O
in	O
patients	O
'	O
monocytes	O
,	O
whereas	O
phosphorylation	O
levels	O
induced	O
by	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
in	O
STAT5	O
was	O
normal	O
.	O

ABSTRACT	O
:	O
Multiple	O
sclerosis	O
(	O
MS	O
)	O
is	O
a	O
human	O
demyelinating	O
disease	O
characterized	O
by	O
multifocal	O
regions	O
of	O
inflammation	O
,	O
progressive	O
myelin	O
loss	O
within	O
the	O
central	O
nervous	O
system	O
(	O
CNS	B-CHED
),	O
and	O
eventual	O
failure	O
to	O
remyelinate	O
damaged	O
axons	O
.	O

Three	O
different	O
and	O
intertwined	O
mechanisms	O
of	O
lung	O
toxicity	O
have	O
been	O
suggested	O
:	O
(	O
i	O
)	O
a	O
direct	O
toxic	O
effect	O
;	O
(	O
ii	O
)	O
an	O
immune	O
-	O
mediated	O
mechanism	O
;	O
and	O
(	O
iii	O
)	O
the	O
angiotensin	B-CHED
enzyme	O
system	O
activation	O
.	O

We	O
searched	O
the	O
PubMed	O
database	O
for	O
clinical	O
trials	O
that	O
examined	O
the	O
use	O
of	O
the	O
following	O
therapies	O
in	O
severe	O
acute	O
lung	O
injury	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
:	O
recruitment	O
maneuvers	O
,	O
high	O
positive	O
end	O
-	O
expiratory	O
pressure	O
,	O
prone	O
position	O
,	O
high	O
-	O
frequency	O
oscillatory	O
ventilation	O
,	O
glucocorticoids	B-CHED
,	O
inhaled	O
nitric	B-CHED
oxide	I-CHED
,	O
buffer	B-CHED
therapy	O
,	O
and	O
extracorporeal	O
life	O
support	O
.	O

TITLE	O
:	O
Angiotensin	B-CHED
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
proteins	B-CHED
of	O
different	O
bat	O
species	O
confer	O
variable	O
susceptibility	O
to	O
SARS	O
-	O
CoV	O
entry	O
.	O

We	O
report	O
a	O
case	O
of	O
bilateral	O
pneumonia	O
in	O
an	O
80	O
year	O
old	O
caucasian	O
man	B-CHED
who	O
developed	O
very	O
rapidly	O
an	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
with	O
a	O
PaO2	O
/	O
FiO2	O
ratio	O
of	O
55	O
,	O
requiring	O
mechanical	O
ventilation	O
and	O
adrenergic	O
support	O
.	O

To	O
search	O
for	O
such	O
cellular	O
proteins	B-CHED
,	O
yeast	O
two	O
-	O
hybrid	O
screening	O
was	O
carried	O
out	O
by	O
using	O
the	O
nonstructural	O
protein	B-CHED
14	O
(	O
nsp14	O
)	O
from	O
the	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
as	O
a	O
bait	O
protein	B-CHED
,	O
leading	O
to	O
the	O
identification	O
of	O
DDX1	O
,	O
a	O
cellular	O
RNA	O
helicase	O
in	O
the	O
DExD	O
/	O
H	O
helicase	O
family	O
,	O
as	O
a	O
potential	O
interacting	O
partner	O
.	O

ABSTRACT	O
:	O
Mannose	B-CHED
-	O
binding	O
lectin	O
(	O
MBL	O
)	O
is	O
a	O
serum	O
protein	B-CHED
that	O
plays	O
an	O
important	O
role	O
in	O
host	O
defenses	O
as	O
an	O
opsonin	O
and	O
through	O
activation	O
of	O
the	O
complement	O
system	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
interactions	O
between	O
MBL	O
and	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
spike	O
(	O
S	O
)	O
glycoprotein	B-CHED
(	O
SARS	O
-	O
S	O
).	O

To	O
reduce	O
potential	O
false	O
positive	O
SNPs	O
due	O
to	O
the	O
low	O
coverage	O
assembly	O
,	O
a	O
low	O
upper	O
-	O
limit	O
was	O
placed	O
on	O
sequence	O
coverage	O
and	O
a	O
high	O
lower	O
-	O
limit	O
on	O
the	O
quality	O
of	O
the	O
discrepant	O
bases	B-CHED
at	O
a	O
potential	O
variant	O
site	O
.	O

TITLE	O
:	O
Palmitoylation	O
of	O
SARS	O
-	O
CoV	O
S	O
protein	B-CHED
is	O
necessary	O
for	O
partitioning	O
into	O
detergent	B-CHED
-	O
resistant	O
membranes	O
and	O
cell	O
-	O
cell	O
fusion	O
but	O
not	O
interaction	O
with	O
M	O
protein	B-CHED
.	O

We	O
sought	O
to	O
determine	O
the	O
effects	O
of	O
telbivudine	B-CHED
on	O
the	O
immune	O
system	O
,	O
particularly	O
on	O
cytokine	O
production	O
and	O
T	O
-	O
cell	O
response	O
,	O
using	O
an	O
animal	O
model	O
with	O
mouse	O
hepatitis	O
virus	O
strain	O
3	O
(	O
MHV	O
-	O
3	O
)-	O
induced	O
hepatitis	O
.	O

The	O
effects	O
of	O
telbivudine	B-CHED
on	O
virus	O
replication	O
and	O
cytokine	O
production	O
were	O
investigated	O
in	O
vitro	O
using	O
MHV	O
-	O
3	O
-	O
infected	O
macrophages	O
,	O
and	O
the	O
effects	O
on	O
T	O
-	O
cell	O
response	O
were	O
investigated	O
in	O
vivo	O
in	O
an	O
MHV	O
-	O
3	O
-	O
induced	O
viral	O
hepatitis	O
model	O
.	O

Telbivudine	B-CHED
had	O
no	O
effect	O
on	O
MHV	O
-	O
3	O
replication	O
in	O
macrophages	O
.	O

These	O
data	O
demonstrate	O
that	O
HB	O
-	O
EGF	O
may	O
be	O
a	O
potential	O
novel	O
systemic	O
anti	B-CHED
-	I-CHED
inflammatory	I-CHED
agent	I-CHED
for	O
the	O
prevention	O
of	O
the	O
systemic	O
inflammatory	O
response	O
syndrome	O
(	O
SIRS	O
)	O
after	O
intestinal	O
injury	O
.	O

A	O
TGEV	O
derived	O
vector	O
(	O
rTGEV	O
)	O
was	O
generated	O
,	O
expressing	O
PRRSV	O
wild	O
type	O
or	O
modified	O
GP5	O
and	O
M	O
proteins	B-CHED
,	O
described	O
as	O
the	O
main	O
inducers	O
of	O
neutralizing	O
antibodies	O
and	O
cellular	O
immune	O
response	O
,	O
respectively	O
.	O

When	O
the	O
amount	O
of	O
virus	O
preinoculated	O
into	O
the	O
test	O
cells	O
was	O
increased	O
to	O
mimic	O
the	O
high	O
viral	O
load	O
present	O
in	O
the	O
target	O
cells	O
of	O
FIP	O
cats	O
,	O
GNA	B-CHED
and	O
nelfinavir	O
by	O
themselves	O
lost	B-CHED
their	O
inhibitory	O
effect	O
.	O

However	O
,	O
when	O
the	O
two	O
agents	O
were	O
added	O
together	O
to	O
FCoV	O
-	O
infected	O
cells	O
,	O
a	O
synergistic	O
antiviral	B-CHED
effect	O
defined	O
by	O
complete	O
blockage	O
of	O
viral	O
replication	O
was	O
observed	O
.	O

HCoV	O
-	O
OC43	O
N	O
-	O
NTD	O
was	O
crystallized	O
at	O
293	O
K	O
using	O
PEG	B-CHED
1500	O
as	O
a	O
precipitant	O
and	O
a	O
99	O
.	O
9	O
%	O
complete	O
native	O
data	O
set	O
was	O
collected	O
to	O
1	O
.	O
7	O
A	O
resolution	O
at	O
100	O
K	O
with	O
an	O
overall	O
R	O
(	O
merge	O
)	O
of	O
5	O
.	O
0	O
%.	O

Nsp1	O
proteins	B-CHED
of	O
group	O
I	O
coronaviruses	O
interacted	O
with	O
host	O
ribosomal	O
40S	O
subunit	O
and	O
did	O
not	O
inhibit	O
IRF	O
-	O
3	O
activation	O
.	O

Viral	O
nucleic	B-CHED
acid	I-CHED
was	O
present	O
in	O
5	O
of	O
98	O
sera	O
(	O
5	O
%)	O
from	O
a	O
single	O
colony	O
of	O
free	O
-	O
ranging	O
bats	O
.	O

A	O
comprehensive	O
analysis	O
of	O
care	O
as	O
each	O
patient	O
transitioned	O
through	O
the	O
combat	B-CHED
theater	O
to	O
the	O
echelon	O
IV	O
trauma	O
center	O
in	O
Europe	O
was	O
performed	O
.	O

Drowning	O
associated	O
with	O
combat	B-CHED
operations	O
was	O
associated	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
cardiovascular	O
shock	O
.	O

CONCLUSIONS	O
:	O
Drowning	O
associated	O
with	O
combat	B-CHED
operations	O
was	O
associated	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
cardiovascular	O
shock	O
.	O

Based	O
on	O
activity	O
,	O
the	O
strains	O
Probio	O
-	O
38	O
and	O
Probio	O
-	O
37	O
were	O
selected	O
as	O
potential	O
probiotics	O
and	O
identified	O
as	O
Lactobacillus	O
plantarum	O
Probio	O
-	O
38	O
and	O
Lactobacillus	O
salivarius	O
Probio	O
-	O
37	O
respectively	O
by	O
16S	B-CHED
rRNA	B-CHED
gene	O
sequencing	O
.	O

The	O
strains	O
were	O
resistant	O
to	O
5	O
%	O
porcine	O
bile	O
and	O
exhibited	O
antimicrobial	B-CHED
activity	O
against	O
all	O
the	O
13	O
enteric	O
bacterial	O
pathogens	O
tested	O
.	O

The	O
presence	O
of	O
respiratory	O
virus	O
was	O
associated	O
with	O
increased	O
levels	O
of	O
interferon	O
gamma	O
-	O
inducible	O
protein	B-CHED
10	O
(	O
IP	O
-	O
10	O
)	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
eotaxin	O
-	O
1	O
(	O
p	O
=	O
0	O
.	O
017	O
)	O
in	O
BAL	B-CHED
.	O

TITLE	O
:	O
The	O
7a	O
accessory	O
protein	B-CHED
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
acts	O
as	O
an	O
RNA	O
silencing	O
suppressor	O
.	O

Studies	O
using	O
POMxp	O
showed	O
that	O
5min	O
treatment	O
at	O
room	O
temperature	O
with	O
800μg	O
/	O
ml	O
PPs	O
resulted	O
in	O
at	O
least	O
a	O
3log	O
reduction	O
in	O
the	O
titers	O
of	O
influenza	O
viruses	O
PR8	O
(	O
H1N1	O
),	O
X31	O
(	O
H3N2	B-CHED
),	O
and	O
a	O
reassortant	O
H5N1	O
virus	O
derived	O
from	O
a	O
human	O
isolate	O
.	O

The	O
girl	O
developed	O
sterile	O
pneumonitis	O
during	O
a	O
disease	O
flare	O
-	O
up	O
,	O
and	O
high	O
-	O
dose	O
corticosteroid	B-CHED
therapy	O
was	O
quickly	O
initiated	O
.	O

ABSTRACT	O
:	O
Heroin	B-CHED
use	O
carries	O
a	O
large	O
burden	O
of	O
morbidity	O
and	O
mortality	O
.	O

Here	O
,	O
we	O
show	O
that	O
mutations	O
in	O
the	O
viral	O
spike	O
glycoprotein	B-CHED
,	O
reproducibly	O
acquired	O
during	O
viral	O
persistence	O
in	O
human	O
neural	O
cell	O
cultures	O
,	O
led	O
to	O
a	O
drastically	O
modified	O
virus	O
-	O
induced	O
neuropathology	O
in	O
BALB	O
/	O
c	O
mice	O
,	O
characterized	O
by	O
flaccid	O
paralysis	O
and	O
demyelination	O
.	O

Overall	O
,	O
the	O
results	O
presented	O
here	O
show	O
that	O
sizeable	O
nearest	O
-	O
neighbor	O
effects	O
are	O
seen	O
only	O
for	O
residues	O
preceding	O
proline	O
,	O
where	O
Pro	B-CHED
introduces	O
an	O
overestimation	O
,	O
on	O
average	O
,	O
of	O
1	O
.	O
73	O
ppm	O
in	O
the	O
computed	O
(	O
13	O
)	O
C	O
(	O
alpha	O
)	O
chemical	O
shifts	O
.	O

It	O
has	O
been	O
reported	O
that	O
the	O
serum	O
levels	O
of	O
prolactin	O
(	O
PRL	O
),	O
follicle	O
stimulating	O
hormone	B-CHED
(	O
FSH	O
),	O
and	O
luteinizing	O
hormone	B-CHED
(	O
LH	O
)	O
of	O
SARS	O
patients	O
are	O
significantly	O
higher	O
than	O
those	O
of	O
control	O
groups	O
,	O
while	O
estradiol	B-CHED
(	O
E2	O
),	O
pregnancy	O
hormone	B-CHED
(	O
P	O
),	O
and	O
thyroid	O
stimulating	O
hormone	B-CHED
(	O
TSH	B-CHED
)	O
are	O
considerably	O
lower	O
than	O
those	O
of	O
normal	O
controls	O
.	O

This	O
phenomenon	O
suggests	O
that	O
the	O
adenohypophyseal	O
endocrine	B-CHED
cells	O
in	O
SARS	O
patients	O
may	O
be	O
damaged	O
.	O

These	O
findings	O
indicated	O
that	O
alterations	O
occurred	O
in	O
the	O
patients	O
'	O
adenohypophyseal	O
endocrine	B-CHED
cells	O
,	O
and	O
these	O
changes	O
were	O
consistent	O
with	O
the	O
serum	O
levels	O
of	O
relevant	O
endocrine	B-CHED
hormones	B-CHED
reported	O
previously	O
.	O

TITLE	O
:	O
Serum	O
protein	B-CHED
electrophoresis	O
in	O
155	O
cats	O
.	O

ABSTRACT	O
:	O
All	O
serum	O
protein	B-CHED
electrophoresis	O
(	O
SPE	O
)	O
results	O
obtained	O
between	O
2002	O
and	O
2009	O
from	O
clinical	O
cases	O
presented	O
to	O
the	O
University	O
of	O
Bristol	O
Feline	O
Centre	O
were	O
examined	O
retrospectively	O
.	O

The	O
most	O
commonly	O
used	O
RM	O
is	O
conventional	O
sustained	O
inflation	O
,	O
associated	O
with	O
respiratory	O
and	O
cardiovascular	O
side	O
effects	O
,	O
which	O
may	O
be	O
minimized	O
by	O
newly	O
proposed	O
strategies	O
:	O
prolonged	O
or	O
incremental	O
PEEP	B-CHED
elevation	O
;	O
pressure	O
-	O
controlled	O
ventilation	O
with	O
fixed	O
PEEP	B-CHED
and	O
increased	O
driving	O
pressure	O
;	O
pressure	O
-	O
controlled	O
ventilation	O
applied	O
with	O
escalating	O
PEEP	B-CHED
and	O
constant	O
driving	O
pressure	O
;	O
and	O
long	O
and	O
slow	O
increase	O
in	O
pressure	O
.	O

ABSTRACT	O
:	O
The	O
coronavirus	O
nucleocapsid	O
(	O
N	O
)	O
protein	B-CHED
plays	O
an	O
essential	O
role	O
in	O
virion	O
assembly	O
via	O
interactions	O
with	O
the	O
large	O
,	O
positive	O
-	O
strand	O
RNA	O
viral	O
genome	O
and	O
the	O
carboxy	B-CHED
-	O
terminal	O
endodomain	O
of	O
the	O
membrane	O
protein	B-CHED
(	O
M	O
).	O

Our	O
genetic	O
results	O
were	O
corroborated	O
by	O
the	O
demonstration	O
that	O
the	O
expressed	O
amino	O
-	O
terminal	O
segment	O
of	O
nsp3	O
bound	O
selectively	O
to	O
N	O
protein	B-CHED
from	O
infected	O
cells	O
,	O
and	O
this	O
interaction	O
was	O
RNA	O
independent	O
.	O

Three	O
subjects	O
were	O
treated	O
with	O
norepinephrine	B-CHED
.	O

The	O
papain	O
-	O
like	O
protease	O
1	O
(	O
PL1	O
(	O
pro	B-CHED
))	O
domain	O
is	O
present	O
in	O
nonstructural	O
protein	B-CHED
3	O
(	O
nsp3	O
)	O
of	O
alphacoronaviruses	O
and	O
subgroup	O
2a	O
betacoronaviruses	O
.	O

Serum	O
DNA	O
,	O
interleukin	O
-	O
6	O
(	O
IL	O
-	O
6	O
),	O
and	O
malonaldehyde	B-CHED
(	O
MDA	B-CHED
)	O
concentrations	O
were	O
measured	O
and	O
were	O
found	O
to	O
be	O
significantly	O
higher	O
in	O
patients	O
with	O
moderate	O
and	O
severe	O
OSAHS	O
groups	O
than	O
those	O
in	O
the	O
mild	O
OSAHS	O
and	O
control	O
groups	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

In	O
stepwise	O
multiple	O
regression	O
analysis	O
,	O
only	O
MDA	B-CHED
and	O
miniSaO	O
(	O
2	O
)	O
were	O
suggested	O
as	O
significant	O
independent	O
predictors	O
for	O
the	O
serum	O
DNA	O
concentrations	O
.	O

which	O
is	O
widely	O
used	O
as	O
an	O
antiinflammatory	B-CHED
agent	I-CHED
in	O
traditional	O
Chinese	O
medicine	B-CHED
.	O

A	O
real	O
-	O
time	O
fluorescence	O
quantitative	O
PCR	O
assay	O
was	O
used	O
to	O
determine	O
mRNA	B-CHED
content	O
of	O
IBV	O
N	O
gene	O
.	O

In	O
contrast	O
,	O
in	O
pigs	O
with	O
ARDS	O
-	O
like	O
syndrome	O
ventilated	O
with	O
small	O
VT	O
,	O
DeltaPP	O
is	O
not	O
a	O
good	O
indicator	B-CHED
of	O
severe	O
hemorrhage	O
.	O

Using	O
high	O
-	O
throughput	O
mRNA	B-CHED
profiling	O
,	O
we	O
examined	O
the	O
transcriptional	O
response	O
of	O
wild	O
-	O
type	O
(	O
WT	O
),	O
type	O
I	O
interferon	O
receptor	O
knockout	O
(	O
IFNAR1	O
-/-),	O
and	O
STAT1	O
knockout	O
(	O
STAT1	O
-/-)	O
mice	O
infected	O
with	O
a	O
recombinant	O
mouse	O
-	O
adapted	O
SARS	O
-	O
CoV	O
(	O
rMA15	O
)	O
to	O
better	O
understand	O
the	O
contribution	O
of	O
specific	O
gene	O
expression	O
changes	O
to	O
disease	O
progression	O
.	O

The	O
protein	B-CHED
is	O
synthesized	O
using	O
solid	O
phase	O
peptide	B-CHED
synthesis	O
and	O
reconstituted	O
into	O
artificial	O
lipid	B-CHED
bilayers	O
that	O
forms	O
cation	B-CHED
-	O
selective	O
ion	O
channels	O
with	O
a	O
main	O
conductance	O
level	O
of	O
8	O
.	O
9	O
±	O
0	O
.	O
8pS	O
at	O
elevated	O
temperature	O
(	O
38	O
.	O
5	O
°	O
C	O
).	O

Several	O
human	O
HLA	O
-	O
A	O
*	O
0201	O
restricted	O
CTL	O
epitopes	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
spike	O
(	O
S	O
)	O
protein	B-CHED
have	O
been	O
identified	O
in	O
HLA	O
-	O
A	O
*	O
0201	O
transgenic	O
(	O
Tg	O
)	O
mice	O
,	O
but	O
the	O
mechanisms	O
and	O
properties	O
of	O
immune	O
responses	O
are	O
still	O
not	O
well	O
understood	O
.	O

Results	O
showed	O
that	O
peptide	B-CHED
-	O
specific	O
CD8	O
(+)	O
T	O
cells	O
secreted	O
IFN	O
-	O
γ	O
,	O
TNF	O
-	O
α	O
and	O
IL	O
-	O
2	O
and	O
expressed	O
CD107a	O
/	O
b	O
on	O
cell	O
surface	O
.	O

RESULTS	O
:	O
Sophorae	O
radix	O
,	O
Acanthopanacis	O
cortex	O
and	O
Torilis	O
fructus	O
reduced	O
intracellular	O
viral	O
RNA	O
levels	O
with	O
comparable	O
reductions	O
in	O
viral	O
proteins	B-CHED
and	O
MHV	O
-	O
A59	O
production	O
.	O

Thus	O
we	O
can	O
speculate	O
that	O
as	O
an	O
acute	O
response	O
protein	B-CHED
and	O
a	O
pattern	O
-	O
recognition	O
molecule	O
of	O
the	O
innate	O
immune	O
system	O
,	O
MBL	O
may	O
play	O
a	O
role	O
in	O
protecting	O
against	O
HCMV	O
infection	O
in	O
children	O
,	O
and	O
MBL	O
gene	O
mutations	O
may	O
be	O
a	O
significant	O
risk	O
factor	O
for	O
the	O
development	O
of	O
infantile	O
HCMV	O
infection	O
.	O

Significantly	O
better	O
oxygenation	O
with	O
higher	O
PaO	B-CHED
(	O
2	O
)	O
and	O
alveolar	O
-	O
arterial	O
oxygen	B-CHED
difference	O
was	O
noted	O
in	O
the	O
Surf	O
and	O
Bude	O
+	O
Surf	O
groups	O
,	O
compared	O
with	O
the	O
control	O
group	O
(	O
p	O
<	O
0	O
.	O
05	O
),	O
but	O
there	O
were	O
no	O
significant	O
differences	O
between	O
the	O
Surf	O
and	O
Bude	O
+	O
Surf	O
groups	O
.	O

Intratracheal	O
administration	O
of	O
a	O
corticosteroid	B-CHED
combined	O
with	O
surfactant	B-CHED
may	O
be	O
an	O
effective	O
method	O
for	O
alleviating	O
local	O
pulmonary	O
inflammation	O
in	O
severe	O
RDS	O
.	O

TITLE	O
:	O
A	O
conserved	O
domain	O
in	O
the	O
coronavirus	O
membrane	O
protein	B-CHED
tail	O
is	O
important	O
for	O
virus	O
assembly	O
.	O

Alanine	B-CHED
substitutions	O
for	O
the	O
first	O
four	O
or	O
the	O
last	O
four	O
residues	O
resulted	O
in	O
viruses	O
with	O
significantly	O
crippled	O
phenotypes	O
and	O
proteins	B-CHED
that	O
failed	O
to	O
assemble	O
VLPs	O
or	O
to	O
be	O
rescued	O
into	O
the	O
envelope	O
.	O

Here	O
,	O
we	O
identified	O
tylophorine	O
compounds	O
,	O
including	O
naturally	O
occurring	O
and	O
synthetic	O
phenanthroindolizidines	O
and	O
phenanthroquinolizidines	O
,	O
as	O
potent	O
in	O
vitro	O
inhibitors	B-CHED
of	O
enteropathogenic	O
coronavirus	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
).	O

TITLE	O
:	O
Atrial	O
natriuretic	O
peptide	B-CHED
attenuates	O
LPS	B-CHED
-	O
induced	O
lung	O
vascular	O
leak	O
:	O
role	O
of	O
PAK1	O
.	O

C57BL	O
/	O
6J	O
mice	O
or	O
ANP	O
knockout	O
mice	O
(	O
Nppa	O
(-/-))	O
were	O
treated	O
with	O
LPS	B-CHED
(	O
0	O
.	O
63	O
mg	O
/	O
kg	O
intratracheal	O
)	O
with	O
or	O
without	O
ANP	O
(	O
2	O
μg	O
/	O
kg	O
iv	O
).	O

Molecular	O
inhibition	O
of	O
PAK1	O
suppressed	O
the	O
protective	O
effects	O
of	O
ANP	O
treatment	O
against	O
LPS	B-CHED
-	O
induced	O
lung	O
injury	O
and	O
endothelial	O
barrier	O
dysfunction	O
.	O

The	O
studies	O
of	O
structure	O
-	O
activity	O
relationship	O
suggested	O
that	O
1H	O
-	O
benzo	O
[	O
d	O
]	O
imidazole	B-CHED
ring	O
at	O
arylthio	O
moiety	O
strongly	O
improved	O
the	O
anti	O
-	O
HIV	O
activity	O
and	O
consistent	O
with	O
the	O
experimental	O
data	O
.	O

The	O
results	O
of	O
molecular	O
modeling	O
and	O
docking	O
within	O
the	O
RT	O
non	O
-	O
nucleoside	B-CHED
binding	O
site	O
using	O
AutoDock	O
confirmed	O
that	O
the	O
3	O
series	O
,	O
similar	O
to	O
other	O
non	O
-	O
nucleoside	B-CHED
reverse	B-CHED
transcriptase	I-CHED
inhibitors	I-CHED
such	O
as	O
N	O
-(	O
5	O
-	O
chloro	B-CHED
-	O
2	O
-	O
pyridinyl	B-CHED
)-	O
N	O
'-[	O
2	O
-(	O
4	O
-	O
ethoxy	B-CHED
-	O
3	O
-	O
fluoro	B-CHED
-	O
2	O
-	O
pyridinyl	B-CHED
)	O
ethyl	B-CHED
]-	O
thiourea	B-CHED
(	O
PETT	O
),	O
was	O
assumed	O
in	O
a	O
butterfly	O
-	O
like	O
conformation	O
and	O
helped	O
to	O
rationalize	O
some	O
SARs	O
and	O
the	O
biological	O
activity	O
data	O
.	O

The	O
reaction	O
is	O
performed	O
in	O
one	O
step	O
in	O
a	O
single	O
tube	O
at	O
65	O
°	O
C	O
for	O
45	O
min	O
,	O
with	O
hydroxynaphthol	O
blue	O
(	O
HNB	O
)	O
dye	B-CHED
added	O
prior	O
to	O
amplification	O
.	O

A	O
rapid	O
development	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
significant	O
hypoxemia	O
and	O
hypercapnia	O
with	O
the	O
low	O
efficiency	O
of	O
various	O
therapeutic	O
measures	O
and	O
hence	O
progressive	O
organ	O
dysfunction	O
determine	O
the	O
essence	B-CHED
of	O
the	O
severe	O
course	O
of	O
the	O
disease	O
.	O

TITLE	O
:	O
Antiviral	B-CHED
treatment	O
for	O
severe	O
EBV	O
infections	O
in	O
apparently	O
immunocompetent	O
patients	O
.	O

The	O
role	O
of	O
antivirals	B-CHED
in	O
the	O
management	O
of	O
severe	O
EBV	O
infections	O
is	O
debatable	O
.	O

Specifically	O
21	O
patients	O
with	O
CNS	B-CHED
involvement	O
(	O
meningoencephalitis	O
,	O
cerebellitis	O
),	O
4	O
with	O
peripheral	O
nervous	O
system	O
involvement	O
(	O
Guillain	O
-	O
Barré	O
,	O
myeloradiculitis	O
,	O
facial	O
nerve	O
palsy	O
),	O
5	O
with	O
hepatitis	O
and	O
15	O
with	O
other	O
afflictions	O
(	O
including	O
adult	O
respiratory	O
distress	O
syndrome	O
,	O
thrombocytopenia	O
,	O
aplastic	O
anemia	O
,	O
acute	O
renal	O
failure	O
,	O
ulcerations	O
,	O
myocarditis	O
,	O
and	O
frosted	O
branch	O
vasculitis	O
)	O
received	O
antiviral	B-CHED
medications	O
.	O

TITLE	O
:	O
The	O
coronavirus	O
nucleocapsid	O
protein	B-CHED
is	O
dynamically	O
associated	O
with	O
the	O
replication	O
-	O
transcription	O
complexes	O
.	O

Using	O
fluorescent	O
recovery	O
after	O
photobleaching	O
,	O
we	O
showed	O
that	O
the	O
N	O
protein	B-CHED
,	O
unlike	O
the	O
nonstructural	O
protein	B-CHED
2	O
,	O
is	O
dynamically	O
associated	O
with	O
the	O
RTCs	O
.	O

Protein	B-CHED
6	O
is	O
minimally	O
bifunctional	O
,	O
with	O
an	O
N	O
-	O
terminal	O
lipophilic	O
part	O
implicated	O
in	O
accelerating	O
viral	O
growth	O
and	O
a	O
C	O
-	O
terminal	O
hydrophilic	O
part	O
interfering	O
with	O
general	O
protein	B-CHED
import	O
into	O
the	O
nucleus	B-CHED
.	O

Furthermore	O
,	O
we	O
found	O
that	O
the	O
C	O
-	O
terminal	O
tail	O
of	O
protein	B-CHED
6	O
impeded	O
nuclear	O
import	O
only	O
in	O
the	O
context	O
of	O
a	O
lipophilic	O
N	O
-	O
terminus	O
,	O
which	O
could	O
be	O
derived	O
from	O
membrane	O
proteins	B-CHED
unrelated	O
to	O
protein	B-CHED
6	O
.	O

These	O
findings	O
are	O
discussed	O
in	O
the	O
context	O
of	O
the	O
proposed	O
protein	B-CHED
6	O
structure	O
.	O

TITLE	O
:	O
Status	O
dystonicus	O
resembling	O
the	O
intrathecal	O
baclofen	B-CHED
withdrawal	O
syndrome	O
:	O
a	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
.	O

Our	O
patient	O
subsequently	O
underwent	O
the	O
placement	O
of	O
an	O
intrathecal	O
baclofen	B-CHED
pump	O
without	O
incident	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
∼	O
115	O
kDa	O
glycoform	O
of	O
S	O
(	O
TR2	O
)	O
protein	B-CHED
was	O
capable	O
of	O
increasing	O
after	O
gene	O
amplification	O
.	O

Our	O
results	O
show	O
that	O
the	O
four	O
varieties	O
of	O
cherries	O
contain	O
substantially	O
high	O
antioxidants	B-CHED
and	O
antiviral	B-CHED
activities	O
.	O

A	O
62	O
-	O
year	O
-	O
old	O
woman	O
with	O
Pneumocystis	O
jirovecii	O
pneumonia	O
(	O
PCP	B-CHED
)	O
was	O
admitted	O
to	O
our	O
intensive	O
care	O
unit	O
for	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

The	O
first	O
patient	O
received	O
TMP	B-CHED
6	O
.	O
4	O
mg	O
/	O
kg	O
/	O
day	O
and	O
SMX	B-CHED
32	O
mg	O
/	O
kg	O
/	O
day	O
,	O
corresponding	O
to	O
50	O
%	O
of	O
the	O
recommended	O
high	O
-	O
dose	O
TMP	B-CHED
/	O
SMX	B-CHED
regimen	O
in	O
PCP	B-CHED
patients	O
.	O

Data	O
on	O
TMP	B-CHED
and	O
SMX	B-CHED
pharmacokinetics	O
in	O
CVVHDF	O
are	O
lacking	O
and	O
dosing	O
recommendations	O
are	O
inconclusive	O
.	O

In	O
both	O
patients	O
,	O
CVVHDF	O
clearance	O
of	O
TMP	B-CHED
ranged	O
from	O
21	O
.	O
5	O
to	O
28	O
.	O
9	O
mL	O
/	O
min	O
,	O
corresponding	O
with	O
normal	O
renal	O
clearance	O
(	O
20	O
-	O
80	O
mL	O
/	O
min	O
).	O

Twenty	O
-	O
two	O
(	O
13	O
%)	O
newborns	O
in	O
the	O
CPAP	O
group	O
subsequently	O
required	O
ETT	O
ventilation	O
within	O
24	O
h	O
:	O
these	O
babies	O
had	O
higher	O
initial	O
oxygen	B-CHED
requirements	O
than	O
those	O
successfully	O
transported	O
on	O
CPAP	O
alone	O
.	O

Membrane	O
(	O
M	O
)	O
and	O
envelope	O
(	O
E	O
)	O
proteins	B-CHED
are	O
major	O
structural	O
proteins	B-CHED
of	O
the	O
SARS	O
-	O
CoV	O
.	O
The	O
M	O
protein	B-CHED
has	O
been	O
determined	O
as	O
a	O
protective	O
antigen	B-CHED
in	O
humoral	O
responses	O
.	O

A	O
nonameric	O
epitope	B-CHED
Mn2	O
and	O
a	O
decameric	O
epitope	B-CHED
Md3	O
derived	O
from	O
the	O
M	O
protein	B-CHED
were	O
identified	O
and	O
used	O
for	O
the	O
evaluation	O
of	O
M	O
protein	B-CHED
-	O
specific	O
immunity	O
.	O

Responses	O
stimulated	O
by	O
M	O
protein	B-CHED
-	O
specific	O
CTL	O
epitopes	O
have	O
been	O
found	O
in	O
the	O
PBMCs	O
of	O
donors	O
who	O
had	O
recovered	O
from	O
SARS	O
infection	O
.	O

This	O
,	O
together	O
with	O
previous	O
reports	O
of	O
a	O
strong	O
humoral	O
response	O
against	O
the	O
M	O
protein	B-CHED
,	O
may	O
help	O
to	O
further	O
explain	O
the	O
immunogenicity	O
of	O
SARS	O
and	O
serves	O
as	O
potential	O
targets	O
for	O
SARS	O
-	O
CoV	O
vaccine	O
design	O
.	O

Specifically	O
,	O
cell	O
-	O
mediated	O
responses	O
were	O
diminished	O
in	O
T3	O
-	O
injured	O
mice	O
,	O
as	O
seen	O
by	O
reduction	O
in	O
virus	O
-	O
specific	O
CD4	O
(+)	O
T	O
lymphocyte	O
proliferation	O
and	O
IFN	O
-	O
γ	O
production	O
and	O
decreased	O
numbers	O
of	O
activated	O
antigen	B-CHED
presenting	O
cells	O
compared	O
to	O
infected	O
un	O
-	O
injured	O
mice	O
.	O

This	O
study	O
describes	O
a	O
contribution	O
of	O
acetylcholine	B-CHED
to	O
the	O
airway	O
constrictive	O
and	O
lumenal	O
obstructive	O
response	O
after	O
inhalation	O
injury	O
and	O
identifies	O
low	O
-	O
dose	O
nebulization	O
of	O
tiotropium	O
bromide	B-CHED
as	O
a	O
potentially	O
efficacious	O
therapy	O
for	O
burn	O
patients	O
with	O
severe	O
inhalation	O
injury	O
.	O

Study	O
quality	O
criteria	O
,	O
defined	O
as	O
a	O
baseline	O
quality	O
of	O
life	O
assessment	O
,	O
the	O
absence	O
of	O
major	O
exclusion	O
criteria	O
,	O
a	O
description	O
of	O
nonresponders	O
,	O
and	O
a	O
comparison	O
with	O
a	O
reference	O
population	O
were	O
met	B-CHED
in	O
only	O
four	O
studies	O
(	O
8	O
%).	O

In	O
this	O
multicenter	O
,	O
double	O
-	O
blind	O
trial	O
,	O
340	O
patients	O
presenting	O
to	O
the	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
with	O
an	O
onset	O
of	O
severe	O
ARDS	O
within	O
the	O
previous	O
48	O
hours	O
were	O
randomly	O
assigned	O
to	O
receive	O
,	O
for	O
48	O
hours	O
,	O
either	O
cisatracurium	B-CHED
besylate	I-CHED
(	O
178	O
patients	O
)	O
or	O
placebo	O
(	O
162	O
patients	O
).	O

Severe	O
ARDS	O
was	O
defined	O
as	O
a	O
ratio	O
of	O
the	O
partial	O
pressure	O
of	O
arterial	O
oxygen	B-CHED
(	O
PaO2	O
)	O
to	O
the	O
fraction	O
of	O
inspired	O
oxygen	B-CHED
(	O
FIO2	O
)	O
of	O
less	O
than	O
150	O
,	O
with	O
a	O
positive	O
end	O
-	O
expiratory	O
pressure	O
of	O
5	O
cm	O
or	O
more	O
of	O
water	B-CHED
and	O
a	O
tidal	O
volume	O
of	O
6	O
to	O
8	O
ml	O
per	O
kilogram	O
of	O
predicted	O
body	O
weight	O
.	O

TITLE	O
:	O
Dendritic	O
cell	O
-	O
specific	O
antigen	B-CHED
delivery	O
by	O
coronavirus	O
vaccine	O
vectors	O
induces	O
long	O
-	O
lasting	O
protective	O
antiviral	B-CHED
and	O
antitumor	O
immunity	O
.	O

Single	O
application	O
of	O
only	O
low	O
vector	O
doses	O
elicited	O
strong	O
and	O
long	O
-	O
lasting	O
cytotoxic	O
T	O
-	O
cell	O
responses	O
,	O
providing	O
protective	O
antiviral	B-CHED
and	O
antitumor	O
immunity	O
.	O

Analysis	O
of	O
the	O
3	O
'	O
UTR	O
and	O
S1	O
gene	O
nucleotide	B-CHED
sequences	O
for	O
the	O
five	O
IB	O
virus	O
strains	O
that	O
could	O
not	O
be	O
classified	O
indicated	O
that	O
four	O
belonged	O
to	O
one	O
of	O
the	O
subgroups	O
,	O
and	O
one	O
was	O
a	O
potential	O
recombinant	O
strain	O
(	O
between	O
strains	O
from	O
subgroups	O
2	O
and	O
3	O
).	O

SAP	O
model	O
was	O
reproduced	O
by	O
reverse	O
injection	O
of	O
sodium	B-CHED
deoxycholate	I-CHED
into	O
the	O
common	O
bile	O
-	O
pancreatic	O
duct	O
of	O
rats	O
.	O

ABSTRACT	O
:	O
Ubiquitination	O
is	O
a	O
critical	O
regulator	O
of	O
the	O
host	O
immune	O
response	O
to	O
viral	O
infection	O
,	O
and	O
many	O
viruses	O
,	O
including	O
coronaviruses	O
,	O
encode	O
proteins	B-CHED
that	O
target	O
the	O
ubiquitination	O
system	O
.	O

After	O
tracheostomy	O
,	O
the	O
patient	O
was	O
treated	O
with	O
antibiotic	B-CHED
therapy	O
guided	O
by	O
serial	O
surveillance	O
cultures	O
of	O
endotracheal	O
aspirates	O
.	O

During	O
vancomycin	B-CHED
(	O
VCM	B-CHED
)	O
therapy	O
for	O
MRSA	O
VAP	O
,	O
MRSA	O
bacteremia	O
occurred	O
even	O
though	O
the	O
trough	O
value	O
of	O
VCM	B-CHED
was	O
sufficiently	O
high	O
.	O

ABSTRACT	O
:	O
The	O
spike	O
proteins	B-CHED
of	O
coronaviruses	O
associate	O
with	O
cellular	O
molecules	O
to	O
mediate	O
infection	O
of	O
their	O
target	O
cells	O
.	O

A	O
T7	O
phage	O
display	O
cDNA	O
library	O
from	O
N2a	O
cells	O
was	O
constructed	O
,	O
and	O
the	O
library	O
was	O
screened	O
with	O
the	O
soluble	O
PHE	B-CHED
-	O
CoV	O
S	O
glycoproteins	B-CHED
.	O

Furthermore	O
,	O
double	O
-	O
stranded	O
siRNA	O
targeted	O
against	O
NCAM	O
inhibited	O
PHE	B-CHED
-	O
CoV	O
infection	O
.	O

RESULTS	O
:	O
We	O
identified	O
Neural	O
Cell	O
Adhesion	O
Molecule	O
(	O
NCAM	O
)	O
as	O
a	O
novel	O
interacting	O
partner	O
of	O
the	O
PHE	B-CHED
-	O
CoV	O
S	O
protein	B-CHED
.	O

This	O
ubiquitous	O
trimethylxanthine	B-CHED
,	O
pervasively	O
used	O
in	O
the	O
human	O
diet	O
and	O
beverages	O
,	O
significantly	O
impacts	O
on	O
major	O
acute	O
neonatal	O
morbidities	O
including	O
apnea	O
of	O
prematurity	O
,	O
bronchopulmonary	O
dysplasia	O
,	O
patent	O
ductus	O
arteriousus	O
with	O
or	O
without	O
surgical	O
ligation	O
and	O
post	O
-	O
operative	O
apnea	O
.	O

Comparison	O
of	O
the	O
entire	O
deduced	O
aa	O
sequences	O
of	O
the	O
S	O
and	O
HE	O
glycoproteins	B-CHED
revealed	O
no	O
specific	O
differences	O
that	O
would	O
account	O
for	O
discrimination	O
between	O
bovine	O
-	O
like	O
CoV	O
strains	O
from	O
zoo	O
ruminants	O
and	O
BcoVs	O
strains	O
.	O

ABSTRACT	O
:	O
A	O
membrane	O
(	O
M	O
),	O
protein	B-CHED
-	O
based	O
ELISA	O
was	O
developed	O
to	O
detect	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
).	O

Lymphopenia	O
and	O
increased	O
creatine	B-CHED
kinase	O
levels	O
were	O
frequently	O
observed	O
(	O
83	O
%	O
and	O
65	O
%	O
among	O
PCR	O
+	O
and	O
PCR	O
-	O
respectively	O
).	O

Oxygen	B-CHED
therapy	O
,	O
nebulised	O
medication	O
and	O
ventilatory	O
support	O
are	O
treatments	O
used	O
in	O
clinical	O
practice	O
to	O
treat	O
influenzal	O
infection	O
are	O
thought	O
to	O
generate	O
droplets	O
or	O
aerosols	O
.	O

ABSTRACT	O
:	O
The	O
coronavirus	O
small	O
envelope	O
(	O
E	O
)	O
protein	B-CHED
plays	O
a	O
crucial	O
,	O
but	O
poorly	O
defined	O
,	O
role	O
in	O
the	O
assembly	O
of	O
virions	O
.	O

Reconstruction	O
of	O
one	O
variant	O
M	O
gene	O
in	O
a	O
ΔE	O
background	O
showed	O
that	O
expression	O
of	O
the	O
M	O
*	O
protein	B-CHED
markedly	O
enhanced	O
the	O
growth	O
of	O
the	O
ΔE	O
mutant	O
and	O
that	O
the	O
M	O
*	O
protein	B-CHED
was	O
incorporated	O
into	O
assembled	O
virions	O
.	O

We	O
hypothesized	O
that	O
the	O
spatial	O
orientation	O
of	O
TMPRSS2	O
vis	O
-	O
a	O
-	O
vis	O
S	O
protein	B-CHED
is	O
a	O
key	O
mechanism	O
underling	O
this	O
phenomenon	O
.	O

ABSTRACT	O
:	O
Five	O
monoclonal	O
antibodies	O
(	O
MAbs	O
)	O
against	O
recombinant	O
nucleocapsid	O
protein	B-CHED
(	O
NP	O
)	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
causing	O
coronavirus	O
(	O
CoV	O
)	O
were	O
developed	O
by	O
hybridoma	O
technology	O
.	O

Associated	O
falciparum	O
infection	O
was	O
excluded	O
by	O
repeated	O
PBF	O
examination	O
,	O
and	O
by	O
negative	O
P	O
.	O
falciparum	O
malaria	O
antigen	B-CHED
tests	O
.	O

In	O
all	O
cases	O
,	O
ARDS	O
was	O
diagnosed	O
by	O
the	O
presence	O
of	O
hypoxia	O
with	O
PaO	B-CHED
(	O
2	O
)	O
/	O
FiO	O
(	O
2	O
)	O
ratio	O
<	O
200	O
and	O
bilateral	O
pulmonary	O
infiltration	O
,	O
and	O
by	O
excluding	O
cardiac	O
disease	O
by	O
echocardiography	O
.	O

We	O
have	O
previously	O
identified	O
the	O
putative	O
causal	O
mutation	O
of	O
MHV	O
-	O
Wüts18	O
as	O
a	O
C	O
to	O
U	O
transition	O
at	O
codon	O
2446	O
in	O
ORF1b	O
,	O
which	O
results	O
in	O
a	O
substitution	O
of	O
proline	O
12	O
with	O
serine	B-CHED
in	O
non	O
-	O
structural	O
protein	B-CHED
16	O
.	O

The	O
rapid	O
induction	O
of	O
autoantibodies	O
in	O
ARDS	O
and	O
severe	O
sepsis	O
suggests	O
that	O
ongoing	O
systemic	O
inflammation	O
and	O
associated	O
tissue	O
destruction	O
mediate	O
the	O
break	O
in	O
tolerance	O
against	O
these	O
self	O
proteins	B-CHED
.	O

ABSTRACT	O
:	O
A	O
series	O
of	O
pyrazolone	O
compounds	O
as	O
possible	O
SARS	O
-	O
CoV	O
3CL	O
protease	B-CHED
inhibitors	I-CHED
were	O
designed	O
,	O
synthesized	O
,	O
and	O
evaluated	O
by	O
in	O
vitro	O
protease	O
assay	O
using	O
fluorogenic	O
substrate	O
peptide	B-CHED
in	O
which	O
several	O
showed	O
potent	O
inhibition	O
against	O
the	O
3CL	O
protease	O
.	O

Gln	B-CHED
is	O
the	O
best	O
residue	O
at	O
P1	O
position	O
,	O
but	O
observable	O
cleavage	O
can	O
be	O
detected	O
with	O
His	O
and	O
Met	B-CHED
substitutions	O
.	O

Noteworthy	O
,	O
solvent	B-CHED
exposed	O
sites	O
such	O
as	O
P5	O
,	O
P3	O
and	O
P3	O
'	O
positions	O
favour	O
positively	O
charged	O
residues	O
over	O
negatively	O
charged	O
one	O
,	O
suggesting	O
that	O
electrostatic	O
interactions	O
may	O
play	O
a	O
role	O
in	O
catalysis	O
.	O

Our	O
results	O
demonstrated	O
a	O
strong	O
structure	O
-	O
activity	O
relationship	O
between	O
the	O
3CL	O
(	O
pro	B-CHED
)	O
and	O
its	O
substrate	O
.	O

The	O
substrate	O
specificity	O
profiled	O
in	O
this	O
study	O
may	O
provide	O
insights	O
into	O
a	O
rational	O
design	O
of	O
peptidomimetic	B-CHED
inhibitors	B-CHED
.	O

Positive	O
cell	O
clones	O
were	O
selected	O
by	O
cotransfecting	O
pTRE	O
-	O
Tight	O
-	O
SARS	O
-	O
N	O
with	O
the	O
linear	O
marker	O
pPUR	O
to	O
BHK	O
-	O
21	O
Tet	O
-	O
on	O
cells	O
in	O
the	O
presence	O
of	O
puromycin	B-CHED
.	O

The	O
expression	O
of	O
SARS	O
-	O
CoV	O
nucleocapsid	O
protein	B-CHED
was	O
tightly	O
regulated	O
by	O
the	O
varying	O
concentration	O
of	O
doxcycline	O
in	O
the	O
constructed	O
double	O
-	O
stable	O
cell	O
line	O
.	O

In	O
these	O
cases	O
we	O
determined	O
H1N1	O
Inf	O
A	O
pandemic	O
variant	O
by	O
detection	O
of	O
Inf	O
A	O
Matrix	O
Protein	B-CHED
2	O
gene	O
M2	O
and	O
the	O
specific	O
H1	O
gene	O
for	O
influenza	O
pandemic	O
H1N1	O
2009	O
with	O
reverse	O
transcriptase	O
polymerase	O
chain	O
reaction	O
Inf	O
A	O
/	O
H1N1	O
(	O
Roche	O
).	O

Oseltamivir	B-CHED
,	O
oxygen	B-CHED
therapy	O
and	O
antibiotic	B-CHED
therapy	O
were	O
effective	O
for	O
improvement	O
of	O
the	O
disease	O
and	O
final	O
recovery	O
of	O
all	O
these	O
patients	O
.	O

We	O
conducted	O
a	O
systematic	O
study	O
of	O
the	O
effect	O
of	O
density	O
on	O
the	O
performance	O
of	O
nanotube	B-CHED
biosensors	O
and	O
discovered	O
that	O
this	O
parameter	O
is	O
crucial	O
to	O
achieving	O
consistently	O
high	O
performance	O
.	O

Finally	O
,	O
we	O
used	O
the	O
density	O
-	O
optimized	O
nanotube	B-CHED
biosensors	O
to	O
detect	O
the	O
nucleocapsid	O
(	O
N	O
)	O
protein	B-CHED
of	O
the	O
SARS	O
virus	O
and	O
demonstrated	O
improved	O
detection	O
limits	O
under	O
physiological	O
conditions	O
.	O

Higher	O
rate	O
of	O
infants	O
in	O
severe	O
group	O
needed	O
mechanical	O
ventilation	O
or	O
high	O
frequency	O
oscillation	O
,	O
volume	O
expansion	O
,	O
bicarbonate	B-CHED
infusion	O
or	O
vasopressors	O
therapy	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

(	O
5	O
)	O
Four	O
patients	O
died	O
,	O
the	O
mortality	O
was	O
therefore	O
3	O
.	O
2	O
%	O
with	O
the	O
main	O
cause	O
of	O
septicemia	O
complicating	O
of	O
MOSF	O
,	O
but	O
their	O
prognosis	O
was	O
improved	O
while	O
comprehensive	O
treatment	O
measures	O
including	O
early	O
mechanical	O
ventilation	O
and	O
broad	O
spectrum	O
antibiotics	B-CHED
were	O
taken	O
into	O
account	O
.	O

TITLE	O
:	O
Using	O
evidence	O
-	O
based	O
medicine	B-CHED
to	O
protect	O
healthcare	O
workers	O
from	O
pandemic	O
influenza	O
:	O

Research	O
evidence	O
was	O
obtained	O
from	O
97	O
studies	O
reporting	O
the	O
protectiveness	O
of	O
antiviral	B-CHED
prophylaxis	O
,	O
seasonal	O
vaccination	O
,	O
and	O
mask	O
use	O
.	O

Despite	O
strong	O
evidence	O
for	O
vaccination	O
and	O
antiviral	B-CHED
prophylaxis	O
providing	O
significant	O
protection	O
,	O
clinicians	O
believed	O
they	O
required	O
the	O
additional	O
combinations	O
of	O
both	O
masks	O
and	O
face	O
shields	O
.	O

ABSTRACT	O
:	O
Treatment	O
of	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
and	O
its	O
most	O
severe	O
form	O
,	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
remain	O
unsolved	O
problems	O
of	O
intensive	O
care	O
medicine	B-CHED
.	O

TGEV	O
nsp1	O
also	O
suppressed	O
protein	B-CHED
translation	O
in	O
cell	O
-	O
free	O
HeLa	O
cell	O
extract	O
;	O
however	O
,	O
it	O
did	O
not	O
affect	O
translation	O
in	O
rabbit	O
reticulocyte	O
lysate	O
(	O
RRL	O
).	O

ABSTRACT	O
:	O
The	O
coronavirus	O
(	O
CoV	O
)	O
E	O
protein	B-CHED
plays	O
an	O
important	O
role	O
in	O
virus	O
assembly	O
.	O

TITLE	O
:	O
Structural	O
analysis	O
of	O
soft	O
multicomponent	O
nanoparticle	B-CHED
clusters	B-CHED
.	O

Here	O
,	O
we	O
combine	O
electrospray	O
differential	O
mobility	O
analysis	O
(	O
ES	O
-	O
DMA	B-CHED
),	O
which	O
rapidly	O
measures	O
the	O
size	O
of	O
the	O
entire	O
cluster	O
,	O
with	O
transmission	O
electron	O
microscopy	O
(	O
TEM	B-CHED
),	O
which	O
detects	O
the	O
hard	O
components	O
,	O
to	O
determine	O
the	O
presence	O
and	O
composition	O
of	O
the	O
softer	O
components	O
.	O

C	O
-	O
reactive	O
protein	B-CHED
(	O
CRP	O
)	O
was	O
higher	O
than	O
50	O
mg	O
/	O
L	O
in	O
all	O
these	O
cases	O
,	O
and	O
was	O
higher	O
than	O
200	O
mg	O
/	O
L	O
in	O
2	O
cases	O
.	O

In	O
the	O
nvA	B-CHED
(	O
H1N1	O
)-	O
ARDS	O
group	O
,	O
the	O
serum	O
cytokine	O
samples	O
were	O
obtained	O
on	O
admission	O
and	O
3	O
days	O
later	O
.	O

Further	O
data	O
suggest	O
that	O
neither	O
the	O
internal	O
(	O
I	O
)	O
protein	B-CHED
nor	O
nonstructural	O
proteins	B-CHED
ns4	O
,	O
and	O
ns2	O
are	O
significant	O
contributors	O
to	O
neurovirulence	O
.	O

Both	O
agents	O
are	O
reported	O
to	O
be	O
mu	B-CHED
-	I-CHED
opioid	I-CHED
receptor	I-CHED
agonists	I-CHED
and	O
monoamine	B-CHED
-	O
reuptake	O
inhibitors	B-CHED
.	O

In	O
contrast	O
to	O
pure	O
opioid	B-CHED
agonists	I-CHED
,	O
both	O
drugs	O
are	O
believed	O
to	O
have	O
lower	O
risks	O
of	O
respiratory	O
depression	O
,	O
tolerance	O
,	O
and	O
dependence	O
.	O

ABSTRACT	O
:	O
Increasing	O
the	O
intracellular	O
Zn	O
(	O
2	O
+)	O
concentration	O
with	O
zinc	B-CHED
-	O
ionophores	B-CHED
like	O
pyrithione	B-CHED
(	O
PT	O
)	O
can	O
efficiently	O
impair	O
the	O
replication	O
of	O
a	O
variety	O
of	O
RNA	O
viruses	O
,	O
including	O
poliovirus	O
and	O
influenza	O
virus	O
.	O

Ten	O
sheep	O
weighing	O
53	O
±	O
4	O
(	O
SD	O
)	O
kg	O
were	O
anesthetized	O
and	O
ventilated	O
with	O
100	O
%	O
oxygen	B-CHED
.	O

Oleic	B-CHED
acid	I-CHED
was	O
injected	O
into	O
the	O
pulmonary	O
circulation	O
until	O
PaO2	O
:	O
FiO2	O
≤	O
60	O
mm	O
Hg	O
,	O
followed	O
by	O
transition	O
to	O
a	O
protective	O
CMV	O
protocol	O
(	O
n	O
=	O
5	O
)	O
or	O
TLV	O
(	O
n	O
=	O
5	O
)	O
for	O
24	O
hours	O
.	O

The	O
sedimentation	O
velocity	O
data	O
for	O
the	O
protein	B-CHED
with	O
or	O
without	O
lipid	B-CHED
were	O
evaluated	O
using	O
the	O
c	O
(	O
s	O
,	O
f	O
(	O
r	O
))	O
two	O
-	O
dimensional	O
distribution	O
model	O
,	O
which	O
provides	O
a	O
precise	O
and	O
quantitative	O
means	O
of	O
analyzing	O
the	O
protein	B-CHED
'	O
s	O
conformational	O
changes	O
.	O

Intranasal	O
treatment	O
with	O
mDEF201	O
ranging	O
from	O
10	O
(	O
6	O
)	O
to	O
10	O
(	O
8	O
)	O
PFU	B-CHED
significantly	O
protected	O
mice	O
against	O
a	O
lethal	O
SARS	O
-	O
CoV	O
infection	O
in	O
a	O
dose	O
dependent	O
manner	O
up	O
to	O
12h	O
post	O
infection	O
(	O
p	O
<	O
0	O
.	O
001	O
).	O

It	O
isn	B-CHED
'	O
t	O
every	O
day	O
that	O
a	O
doctor	O
becomes	O
a	O
patient	O
.	O

Severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
gripped	O
the	O
world	O
in	O
2003	O
,	O
spreading	O
via	O
air	B-CHED
-	O
links	O
and	O
throwing	O
the	O
global	O
economy	O
into	O
disarray	O
.	O

MHV	O
-	O
A59	O
virus	O
is	O
the	O
main	O
cause	O
of	O
elevated	O
NF	O
-	O
κB	O
expression	O
and	O
CD4	O
(+)/	O
CD8	O
(+)/	O
ratio	O
,	O
while	O
damp	B-CHED
-	O
heat	O
syndrome	O
is	O
responsible	O
for	O
increased	O
AQP4	O
expression	O
,	O
and	O
their	O
synergistic	O
effect	O
results	O
in	O
increased	O
IFN	O
-	O
γ	O
/	O
IL	O
-	O
4	O
ratio	O
.	O

All	O
relevant	O
meta	O
-	O
analyses	O
were	O
identified	O
by	O
a	O
computerized	O
search	O
of	O
PubMed	O
using	O
combinations	O
of	O
the	O
following	O
terms	O
:	O
acute	O
lung	O
injury	O
,	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
positive	O
end	O
-	O
expiratory	O
pressure	O
,	O
mechanical	O
ventilation	O
,	O
prone	O
position	O
,	O
drotrecogin	O
,	O
activated	O
protein	B-CHED
C	O
,	O
sepsis	O
,	O
and	O
septic	O
patients	O
.	O

Prospective	O
,	O
observational	O
,	O
multicenter	O
study	O
from	O
23	O
June	O
2009	O
through	O
11	O
February	O
2010	O
,	O
reported	O
in	O
the	O
European	O
Society	O
of	O
Intensive	O
Care	O
Medicine	B-CHED
(	O
ESICM	O
)	O
H1N1	O
registry	O
.	O

Early	O
use	O
of	O
corticosteroids	B-CHED
in	O
patients	O
affected	O
by	O
pandemic	O
(	O
H1N1	O
)	O
v	O
influenza	O
A	O
infection	O
did	O
not	O
result	O
in	O
better	O
outcomes	O
and	O
was	O
associated	O
with	O
increased	O
risk	O
of	O
superinfections	O
.	O

ABSTRACT	O
:	O
We	O
developed	O
a	O
two	O
-	O
layer	O
,	O
four	O
-	O
channel	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)-	O
capillary	O
electrophoresis	O
microdevice	O
that	O
integrates	O
nucleic	B-CHED
acid	I-CHED
amplification	O
,	O
sample	O
cleanup	O
and	O
concentration	O
,	O
capillary	O
electrophoretic	O
separation	O
,	O
and	O
detection	O
for	O
multiplex	O
analysis	O
of	O
four	O
human	O
respiratory	O
viral	O
pathogens	O
,	O
influenza	O
A	O
,	O
influenza	O
B	O
,	O
coronavirus	O
OC43	O
,	O
and	O
human	O
metapneumovirus	O
.	O

Biotinylated	O
and	O
fluorescently	O
labeled	O
double	O
-	O
stranded	O
(	O
ds	O
)	O
deoxyribonucleic	B-CHED
acid	I-CHED
(	O
DNA	O
)	O
amplification	O
products	O
are	O
generated	O
in	O
a	O
100	O
nL	O
PCR	O
reactor	O
incorporating	O
an	O
integrated	O
heater	O
and	O
a	O
temperature	O
sensor	O
.	O

When	O
a	O
two	O
-	O
step	O
reverse	O
transcription	O
PCR	O
amplification	O
is	O
employed	O
,	O
the	O
device	O
can	O
detect	O
ribonucleic	B-CHED
acid	I-CHED
(	O
RNA	O
)	O
analogues	O
of	O
all	O
four	O
viral	O
targets	O
with	O
detection	O
limits	O
in	O
the	O
range	O
of	O
25	O
-	O
100	O
copies	O
/	O
reactor	O
.	O

TITLE	O
:	O
Comparison	O
of	O
two	O
oral	O
symptom	O
-	O
triggered	O
pharmacological	O
inpatient	O
treatments	O
of	O
acute	O
alcohol	O
withdrawal	O
:	O
clomethiazole	O
vs	O
.	O
clonazepam	B-CHED
.	O

Existing	O
continuous	O
infusions	O
of	O
midazolam	O
,	O
opioids	O
,	O
and	O
neuromuscular	O
blockers	O
were	O
continued	O
during	O
surgery	O
and	O
were	O
augmented	O
by	O
a	O
variety	O
of	O
parenteral	O
agents	O
,	O
including	O
propofol	B-CHED
,	O
fentanyl	B-CHED
,	O
and	O
ketamine	B-CHED
during	O
surgery	O
.	O

Sodium	B-CHED
bicarbonate	I-CHED
(	O
50	O
ml	O
8	O
.	O
4	O
%)	O
only	O
for	O
excessive	O
hyperkaliemia	O
,	O
metabolic	O
acidosis	O
,	O
or	O
intoxication	O
with	O
tricyclic	B-CHED
antidepressants	I-CHED
.	O

4000	O
IU	O
),	O
enoxaparin	B-CHED
,	O
bivalirudin	B-CHED
or	O
fondaparinux	B-CHED
depending	O
on	O
the	O
diagnosis	O
(	O
STEMI	O
or	O
non	O
-	O
STEMI	O
-	O
ACS	O
)	O
and	O
the	O
planned	O
therapeutic	O
strategy	O
.	O

This	O
patient	O
had	O
taken	O
an	O
undetermined	O
amount	O
of	O
ammonium	B-CHED
vanadate	B-CHED
12h	O
after	O
ingesting	O
.	O

The	O
vanadium	B-CHED
concentration	O
was	O
6	O
.	O
22	O
mg	O
/	O
L	O
,	O
corresponding	O
to	O
6000	O
times	O
higher	O
than	O
normal	O
concentration	O
in	O
the	O
general	O
population	O
.	O

The	O
latency	O
and	O
the	O
brutality	O
of	O
clinical	O
picture	O
degradation	O
seem	O
to	O
be	O
in	O
consideration	O
of	O
systemic	O
poisoning	O
by	O
vanadium	B-CHED
leading	O
to	O
inhibition	O
of	O
the	O
cellular	O
respiratory	O
process	O
.	O

ABSTRACT	O
:	O
Electrical	O
discharge	O
processes	O
are	O
emerging	O
as	O
water	B-CHED
treatment	O
technologies	O
applicable	O
to	O
both	O
the	O
degradation	O
of	O
organic	O
contaminants	O
as	O
well	O
as	O
inactivation	O
of	O
pathogens	O
.	O

This	O
study	O
demonstrates	O
the	O
inactivation	O
of	O
a	O
virus	O
using	O
the	O
streamer	O
corona	B-CHED
discharge	O
process	O
(	O
SCDP	O
)	O
with	O
MS2	O
phage	O
as	O
a	O
surrogate	O
.	O

In	O
patients	O
who	O
met	B-CHED
ILI	O
criteria	O
,	O
nasopharyngeal	O
swabs	O
were	O
taken	O
for	O
RIDT	O
and	O
RT	O
-	O
PCR	O
.	O

RESULTS	O
:	O
433	O
patients	O
were	O
consulted	O
by	O
a	O
general	O
practitioner	O
and	O
reported	O
symptoms	O
of	O
an	O
acute	O
respiratory	O
tract	O
infection	O
,	O
128	O
(	O
30	O
%)	O
of	O
them	O
met	B-CHED
inclusion	O
criteria	O
for	O
ILI	O
and	O
were	O
tested	O
with	O
RIDT	O
:	O
31	O
children	O
younger	O
than	O
14	O
years	O
and	O
97	O
adults	O
.	O

To	O
this	O
end	O
,	O
we	O
implement	O
a	O
memetic	O
algorithm	O
for	O
the	O
problem	O
and	O
demonstrate	O
the	O
effectiveness	O
of	O
the	O
arithmetic	O
-	O
harmonic	O
cut	O
on	O
a	O
number	O
of	O
datasets	O
including	O
a	O
cancer	O
type	O
dataset	O
and	O
a	O
corona	B-CHED
virus	O
dataset	O
.	O

A	O
synthetic	O
cholera	O
toxin	O
B	O
subunit	O
gene	O
(	O
CTB	O
)	O
was	O
fused	O
with	O
a	O
synthetic	O
neutralizing	O
epitope	B-CHED
gene	O
of	O
the	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
sCTB	O
-	O
sCOE	O
),	O
and	O
the	O
sCTB	O
-	O
sCOE	O
fusion	O
gene	O
was	O
introduced	O
into	O
a	O
plant	O
expression	O
vector	O
under	O
the	O
control	O
of	O
the	O
ubiquitin	O
promoter	O
.	O

However	O
,	O
pooled	O
data	O
from	O
two	O
meta	O
-	O
analyses	O
showed	O
significant	O
higher	O
survival	O
in	O
the	O
most	O
severe	O
patients	O
both	O
with	O
the	O
use	O
of	O
higher	O
PEEP	B-CHED
and	O
prone	O
positioning	O
.	O

Prompt	O
recognition	O
and	O
treatment	O
with	O
antivirals	B-CHED
improves	O
outcomes	O
.	O

For	O
both	O
patients	O
,	O
a	O
presumptive	O
treatment	O
combining	O
oseltamivir	B-CHED
and	O
broad	O
-	O
spectrum	O
antibiotics	B-CHED
was	O
started	O
at	O
the	O
time	O
of	O
hospital	O
admission	O
,	O
24	O
hours	O
at	O
least	O
before	O
obtaining	O
the	O
results	O
of	O
the	O
virological	O
and	O
bacteriological	O
analyses	O
.	O

3	O
cases	O
showed	O
N	O
protein	B-CHED
antibody	O
positive	O
in	O
the	O
serum	O
,	O
and	O
positive	O
immunohistochemical	O
expression	O
in	O
most	O
of	O
the	O
cytoplasm	O
in	O
the	O
gastric	O
tissue	O
mucous	O
gland	O
epithelial	O
cells	O
.	O

TITLE	O
:	O
Analysis	O
of	O
systemic	O
corticosteroid	B-CHED
usage	O
and	O
survival	O
in	O
patients	O
requiring	O
mechanical	O
ventilation	O
for	O
severe	O
community	O
-	O
acquired	O
pneumonia	O
.	O

During	O
hospitalization	O
the	O
foal	O
developed	O
hyperglycemia	O
concomitantly	O
with	O
low	O
insulin	B-CHED
concentration	O
and	O
an	O
adequate	O
response	O
to	O
exogenous	O
insulin	B-CHED
therapy	O
supported	O
a	O
diagnosis	O
of	O
Type	O
1	O
diabetes	O
mellitus	O
.	O

On	O
follow	O
up	O
assessment	O
the	O
foal	O
was	O
found	O
to	O
be	O
a	O
healthy	O
euglycemic	O
animal	O
with	O
normal	O
insulin	B-CHED
concentration	O
at	O
11	O
months	O
of	O
age	O
.	O

Three	O
chemically	O
synthesized	O
peptides	B-CHED
recognizing	O
the	O
pAPN	O
showed	O
effective	O
inhibition	O
ability	O
to	O
TGEV	O
infection	O
in	O
vitro	O
.	O

A	O
putative	O
TxxF	O
motif	O
was	O
identified	O
in	O
the	O
S	O
protein	B-CHED
of	O
TGEV	O
.	O

Although	O
ribosomal	O
/	O
nucleic	B-CHED
acid	I-CHED
binding	O
proteins	B-CHED
were	O
enriched	O
in	O
the	O
Golgi	O
-	O
fractions	O
of	O
mouse	O
hepatitis	O
virus	O
-	O
infected	O
cells	O
,	O
proteins	B-CHED
annotated	O
to	O
localize	O
to	O
several	O
organelles	O
of	O
the	O
secretory	O
pathway	O
were	O
overrepresented	O
among	O
the	O
proteins	B-CHED
that	O
were	O
depleted	O
from	O
these	O
fractions	O
upon	O
infection	O
.	O

ABSTRACT	O
:	O
Porcine	O
respiratory	O
coronavirus	O
is	O
related	O
genetically	O
to	O
porcine	O
transmissible	O
gastroenteritis	O
virus	O
with	O
a	O
large	O
deletion	O
in	O
S	O
protein	B-CHED
.	O

While	O
PRRSV	O
also	O
inhibited	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
-	O
α	O
)	O
synthesis	O
by	O
pDC	B-CHED
responding	O
to	O
either	O
agent	O
,	O
only	O
the	O
interleukin	O
-	O
2	O
(	O
IL	O
-	O
2	O
)	O
and	O
IL	O
-	O
6	O
production	O
instigated	O
by	O
ODN	O
D19	O
exposure	O
was	O
blocked	O
.	O

Thus	O
,	O
as	O
supported	O
by	O
a	O
demonstrated	O
resilience	O
of	O
pDC	B-CHED
to	O
PRRSV	O
infection	O
,	O
this	O
pathogen	O
may	O
interact	O
with	O
a	O
cell	O
surface	O
protein	B-CHED
(	O
s	O
)	O
to	O
selectively	O
impede	O
the	O
completion	O
of	O
cascades	O
involved	O
in	O
cytokine	O
production	O
by	O
stimulated	O
pDC	B-CHED
.	O

ABSTRACT	O
:	O
Central	O
nervous	O
system	O
(	O
CNS	B-CHED
)	O
infections	O
and	O
autoimmune	O
inflammatory	O
disorders	O
are	O
often	O
associated	O
with	O
retention	O
of	O
antibody	O
-	O
secreting	O
cells	O
(	O
ASC	O
).	O

Therefore	O
,	O
the	O
factors	O
associated	O
with	O
ASC	O
migration	O
,	O
differentiation	O
,	O
and	O
survival	O
are	O
all	O
induced	O
during	O
acute	O
viral	O
encephalomyelitis	O
,	O
prior	O
to	O
ASC	O
accumulation	O
in	O
the	O
CNS	B-CHED
.	O

ABSTRACT	O
:	O
Mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
produces	O
a	O
series	O
of	O
subgenomic	O
RNAs	O
for	O
viral	O
protein	B-CHED
expression	O
.	O

Previously	O
,	O
a	O
13	O
-	O
residue	O
deletion	O
in	O
the	O
MHV	O
spike	O
(	O
S	O
)	O
protein	B-CHED
endodomain	O
was	O
found	O
to	O
reduce	O
syncytium	O
formation	O
dramatically	O
while	O
inhibiting	O
virus	O
replication	O
slightly	O
.	O

The	O
replication	O
and	O
foreign	O
protein	B-CHED
expression	O
of	O
the	O
S	O
-	O
mutated	O
recombinants	O
were	O
found	O
to	O
be	O
more	O
efficient	O
in	O
L2	O
cells	O
than	O
in	O
Neuro	O
-	O
2a	O
and	O
NIH	O
/	O
3T3	O
cells	O
.	O

ABSTRACT	O
:	O
Immunization	O
with	O
the	O
spike	O
protein	B-CHED
(	O
S	O
)	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
coronavirus	O
(	O
CoV	O
)	O
in	O
mice	O
is	O
known	O
to	O
produce	O
neutralizing	O
antibodies	O
and	O
to	O
prevent	O
the	O
infection	O
caused	O
by	O
SARS	O
-	O
CoV	O
.	O
Polyethylenimine	O
25K	O
(	O
PEI	B-CHED
)	O
is	O
a	O
cationic	O
polymer	B-CHED
which	O
effectively	O
delivers	O
the	O
plasmid	O
DNA	O
.	O

As	O
all	O
eight	O
active	O
sites	O
are	O
bound	O
with	O
inhibitors	B-CHED
,	O
the	O
polyvalent	O
nature	O
of	O
the	O
interaction	O
between	O
AO	O
-	O
M	O
(	O
pro	B-CHED
)	O
and	O
its	O
polyprotein	O
substrates	O
with	O
multiple	O
cleavage	O
sites	O
,	O
would	O
make	O
AO	O
-	O
M	O
(	O
pro	B-CHED
)	O
functionally	O
much	O
more	O
superior	O
than	O
the	O
M	O
(	O
pro	B-CHED
)	O
active	O
dimer	O
for	O
polyprotein	O
processing	O
.	O

Three	O
residues	O
(	O
Arg4	O
,	O
Glu290	O
,	O
and	O
Arg298	O
),	O
which	O
contribute	O
to	O
the	O
active	O
dimer	O
conformation	O
of	O
mature	O
M	O
(	O
pro	B-CHED
),	O
are	O
selected	O
for	O
mutational	O
analyses	O
.	O

Genetic	O
analysis	O
of	O
the	O
complete	O
M	O
and	O
ORF3	O
genes	O
showed	O
that	O
each	O
PEDV	O
group	O
had	O
several	O
unique	O
characteristics	O
,	O
and	O
this	O
indicated	O
that	O
specific	O
groups	O
of	O
PEDVs	O
may	O
be	O
differentiated	O
from	O
the	O
other	O
PEDVs	O
by	O
specific	O
nucleotide	B-CHED
differences	O
.	O

To	O
detect	O
the	O
T	O
helper	O
(	O
Th	O
)	O
1	O
epitope	B-CHED
,	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
obtained	O
from	O
FIPV	O
-	O
infected	O
cats	O
were	O
cultured	O
with	O
each	O
peptide	B-CHED
,	O
and	O
Th1	O
-	O
type	O
immune	O
responses	O
were	O
measured	O
using	O
feline	O
interferon	O
(	O
fIFN	O
)-	O
γ	O
production	O
as	O
an	O
index	O
.	O

In	O
the	O
S2	O
domain	O
of	O
type	O
II	O
FIPV	O
,	O
4	O
peptides	B-CHED
containing	O
linear	O
immunodominant	O
antibody	O
-	O
binding	O
epitopes	O
were	O
identified	O
in	O
the	O
HR2	O
region	O
.	O

Four	O
monoclonal	O
antibodies	O
(	O
mAbs	O
)	O
against	O
the	O
N	O
-	O
terminal	O
half	O
of	O
spike	O
protein	B-CHED
(	O
S1	O
protein	B-CHED
)	O
of	O
TGEV	O
were	O
identified	O
.	O

An	O
initial	O
clinical	O
presentation	O
of	O
acute	O
bronchiolitis	O
developed	O
into	O
an	O
extremely	O
severe	O
course	O
of	O
disease	O
characterized	O
by	O
pneumothorax	O
,	O
pneumomediastinum	O
,	O
and	O
acute	O
respiratory	O
failure	O
with	O
pronounced	O
air	B-CHED
-	O
leak	O
syndrome	O
.	O

ABSTRACT	O
:	O
The	O
N	O
-	O
terminal	O
S1	O
region	O
of	O
the	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
spike	O
(	O
S	O
)	O
glycoprotein	B-CHED
contains	O
four	O
antigenic	O
sites	O
(	O
C	O
,	O
B	O
,	O
D	O
and	O
A	O
,	O
from	O
the	O
N	O
-	O
to	O
the	O
C	O
-	O
terminal	O
end	O
)	O
and	O
is	O
engaged	O
in	O
host	O
-	O
cell	O
receptor	O
recognition	O
.	O

This	O
domain	O
was	O
recognized	O
by	O
neutralizing	O
antibodies	O
belonging	O
to	O
the	O
antigenic	O
site	O
A	O
and	O
therefore	O
could	O
be	O
used	O
as	O
an	O
immunogen	B-CHED
for	O
the	O
prevention	O
of	O
viral	O
infection	O
.	O

The	O
organization	O
of	O
the	O
four	O
modules	O
in	O
the	O
S1	O
region	O
of	O
the	O
TGEV	O
S	O
glycoprotein	B-CHED
is	O
discussed	O
.	O

An	O
RT	O
-	O
PCR	O
/	O
ESI	O
-	O
MS	O
respiratory	O
virus	O
surveillance	O
kit	O
designed	O
to	O
detect	O
respiratory	O
syncytial	O
virus	O
,	O
influenza	O
A	O
and	O
B	O
,	O
parainfluenza	O
types	O
1	O
-	O
4	O
,	O
Adenoviridae	O
types	O
A	O
-	O
F	O
,	O
Coronaviridae	O
,	O
human	O
bocavirus	O
,	O
and	O
human	O
metapneumovirus	O
was	O
evaluated	O
using	O
both	O
mock	O
-	O
ups	O
and	O
frozen	O
archived	O
NPA	B-CHED
(	O
N	O
=	O
280	O
),	O
95	O
of	O
which	O
were	O
positive	O
by	O
clinical	O
virology	O
methods	O
.	O

To	O
examine	O
if	O
nasal	O
LTB4	B-CHED
can	O
produce	O
neutrophil	O
activity	O
and	O
to	O
explore	O
whether	O
or	O
not	O
LTB4	B-CHED
can	O
condition	O
neutrophils	O
to	O
exert	O
virucidal	O
effects	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Twenty	O
-	O
three	O
healthy	O
subjects	O
received	O
nasal	O
LTB4	B-CHED
in	O
a	O
randomized	O
and	O
sham	O
-	O
controlled	O
design	O
.	O

HRV	O
-	O
16	O
replication	O
was	O
lower	O
in	O
subjects	O
receiving	O
LTB4	B-CHED
,	O
but	O
this	O
difference	O
failed	O
to	O
reach	O
statistical	O
significance	O
.	O

However	O
,	O
IFITM	O
proteins	B-CHED
did	O
not	O
reduce	O
cellular	O
cathepsin	O
activity	O
or	O
limit	O
access	O
of	O
virions	O
to	O
acidic	O
intracellular	O
compartments	O
.	O

The	O
percentage	O
of	O
calves	O
,	O
1	O
-	O
7	O
days	O
old	O
,	O
with	O
inadequate	O
serum	O
concentrations	O
of	O
α	O
-	O
tocopherol	B-CHED
and	O
β	O
-	O
carotene	B-CHED
were	O
significantly	O
higher	O
in	O
HM	O
herds	O
compared	O
to	O
LM	O
herds	O
and	O
also	O
associated	O
with	O
higher	O
odds	O
of	O
being	O
a	O
HM	O
herd	O
(	O
OR	O
=	O
1	O
.	O
02	O
;	O
p	O
=	O
0	O
.	O
023	O
and	O
OR	O
=	O
1	O
.	O
05	O
;	O
p	O
=	O
0	O
.	O
0028	O
,	O
respectively	O
).	O

PLpro	O
antagonized	O
IFN	O
-	O
α	O
-	O
induced	O
responses	O
such	O
as	O
interferon	O
-	O
stimulated	O
response	O
element	O
-	O
and	O
AP	O
-	O
1	O
-	O
driven	O
promoter	O
activation	O
,	O
protein	B-CHED
kinase	O
R	O
,	O
2	O
'-	O
5	O
'-	O
oligoadenylate	O
synthetase	O
(	O
OAS	O
),	O
interleukin	O
(	O
IL	O
)-	O
6	O
and	O
IL	O
-	O
8	O
expression	O
,	O
and	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
(	O
STAT	O
)	O
1	O
(	O
Tyr701	O
),	O
STAT1	O
(	O
Ser727	O
)	O
and	O
c	O
-	O
Jun	O
phosphorylation	O
.	O

Combination	O
treatment	O
of	O
IFN	O
-	O
α	O
and	O
the	O
proteasome	B-CHED
inhibitor	I-CHED
MG	O
-	O
132	O
showed	O
a	O
time	O
-	O
dependent	O
restoration	O
of	O
ERK1	O
protein	B-CHED
levels	O
and	O
significant	O
increase	O
of	O
ERK1	O
,	O
STAT1	O
and	O
c	O
-	O
Jun	O
phosphorylation	O
in	O
PLpro	O
-	O
expressing	O
cells	O
.	O

ABSTRACT	O
:	O
Lung	O
-	O
protective	O
ventilation	O
with	O
a	O
low	O
tidal	O
volume	O
,	O
plateau	O
pressure	O
<	O
30	O
cm	O
H	O
(	O
2	O
)	O
O	O
.	O
oxygen	B-CHED
saturation	O
>	O
90	O
%	O
and	O
permissive	O
hypercapnia	O
results	O
in	O
reduction	O
of	O
the	O
mortality	O
rate	O
in	O
patients	O
with	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

The	O
latest	O
guidelines	O
for	O
analgesia	O
and	O
sedation	O
in	O
intensive	O
care	O
medicine	B-CHED
demand	O
consistent	O
monitoring	O
of	O
the	O
level	O
of	O
sedation	O
and	O
the	O
intensity	O
of	O
pain	O
.	O

These	O
results	O
clearly	O
suggested	O
that	O
increased	O
oxidant	B-CHED
levels	O
led	O
to	O
oxidative	O
stress	O
,	O
antioxidant	B-CHED
deficiency	O
attenuating	O
lung	O
inflammation	O
and	O
tissue	O
damage	O
.	O

LPS	B-CHED
administration	O
resulted	O
in	O
multiple	O
organ	O
failure	O
,	O
leading	O
to	O
increased	O
mortality	O
.	O

Univariate	O
analysis	O
demonstrated	O
two	O
linkage	O
disequilibrium	O
-	O
tag	O
single	O
nucleotide	B-CHED
polymorphisms	O
,	O
rs1130866	O
(	O
also	O
known	O
as	O
SP	O
-	O
B	O
+	O
1580	O
C	O
/	O
T	O
)	O
and	O
rs3024793	O
,	O
were	O
associated	O
with	O
the	O
need	O
for	O
mechanical	O
ventilation	O
in	O
African	O
American	O
children	O
(	O
p	O
=	O
.	O
016	O
and	O
p	O
=	O
.	O
030	O
,	O
respectively	O
).	O

Genetic	O
variations	O
in	O
the	O
gene	O
coding	O
for	O
surfactant	B-CHED
protein	B-CHED
B	O
are	O
associated	O
with	O
more	O
severe	O
lung	O
injury	O
as	O
indicated	O
by	O
the	O
association	O
of	O
specific	O
single	O
nucleotide	B-CHED
polymorphism	O
genotypes	O
and	O
haplotypes	O
with	O
the	O
need	O
for	O
mechanical	O
ventilation	O
in	O
African	O
American	O
children	O
with	O
community	O
-	O
acquired	O
pneumonia	O
.	O

One	O
month	O
after	O
vaccination	O
(	O
T1	O
),	O
both	O
groups	O
showed	O
significant	O
increases	O
in	O
the	O
antibody	O
geometric	O
mean	O
titers	O
(	O
GMTs	O
)	O
for	O
all	O
antigens	B-CHED
.	O

However	O
,	O
healthy	O
controls	O
showed	O
higher	O
values	O
for	O
antigens	B-CHED
A	O
/	O
H1N1	O
and	O
A	O
/	O
H3N2	B-CHED
(	O
p	O
=	O
0	O
.	O
002	O
and	O
0	O
.	O
001	O
,	O
respectively	O
).	O

Methods	O
applied	O
to	O
anti	O
-	O
viral	O
research	O
include	O
(	O
i	O
)	O
ligand	B-CHED
-	O
based	O
approaches	O
that	O
rely	O
on	O
known	O
active	O
compounds	O
to	O
extrapolate	O
biological	O
activity	O
,	O
such	O
as	O
machine	O
learning	O
techniques	O
or	O
classical	O
QSAR	O
,	O
(	O
ii	O
)	O
structure	O
-	O
based	O
methods	O
that	O
rely	O
on	O
an	O
experimentally	O
determined	O
3D	O
structure	O
of	O
the	O
targets	O
,	O
such	O
as	O
molecular	O
docking	O
or	O
molecular	O
dynamics	O
,	O
and	O
(	O
iii	O
)	O
universal	O
approaches	O
that	O
can	O
be	O
applied	O
in	O
a	O
structure	O
-	O
or	O
ligand	B-CHED
-	O
based	O
way	O
,	O
such	O
as	O
3D	O
QSAR	O
or	O
3D	O
pharmacophore	O
elucidation	O
.	O

We	O
highlight	O
how	O
computational	O
approaches	O
have	O
helped	O
in	O
discovering	O
anti	O
-	O
viral	O
activities	O
of	O
natural	B-CHED
products	I-CHED
and	O
give	O
an	O
overview	O
on	O
polypharmacology	O
approaches	O
that	O
help	O
to	O
optimize	O
drugs	O
against	O
several	O
viruses	O
or	O
help	O
to	O
optimize	O
the	O
metabolic	O
profile	O
of	O
and	O
anti	B-CHED
-	I-CHED
viral	I-CHED
drug	I-CHED
.	O

Sequence	O
alignment	O
and	O
structural	O
bioinformatics	O
analyses	O
revealed	O
that	O
the	O
catalytic	O
residues	O
(	O
Cys51	O
and	O
His148	O
)	O
are	O
highly	O
conserved	O
in	O
FMDV	O
Lb	O
(	O
pro	B-CHED
)	O
of	O
all	O
seven	O
serotypes	O
and	O
that	O
the	O
topology	O
of	O
FMDV	O
Lb	O
(	O
pro	B-CHED
)	O
is	O
remarkably	O
similar	O
to	O
that	O
of	O
ubiquitin	O
-	O
specific	O
protease	O
14	O
(	O
USP14	O
),	O
a	O
cellular	O
deubiquitylation	O
enzyme	O
(	O
DUB	O
),	O
and	O
to	O
that	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
papain	O
-	O
like	O
protease	O
(	O
PLpro	O
),	O
a	O
coronaviral	O
DUB	O
.	O

Four	O
variables	O
affected	O
time	O
to	O
recovery	O
of	O
consciousness	O
:	O
age	O
(	O
hazard	O
ratio	O
,	O
0	O
.	O
98	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
97	O
-	O
0	O
.	O
99	O
;	O
p	O
=	O
0	O
.	O
009	O
),	O
bilateral	O
absence	O
of	O
light	O
reflexes	O
(	O
hazard	O
ratio	O
,	O
0	O
.	O
51	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
27	O
-	O
0	O
.	O
97	O
;	O
p	O
=	O
0	O
.	O
041	O
),	O
multiplicity	O
of	O
CCL	B-CHED
(	O
hazard	O
ratio	O
,	O
0	O
.	O
40	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
25	O
-	O
0	O
.	O
66	O
;	O
p	O
<	O
0	O
.	O
001	O
),	O
and	O
total	O
GCS	O
on	O
admission	O
(	O
hazard	O
ratio	O
,	O
1	O
.	O
45	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
23	O
-	O
1	O
.	O
71	O
;	O
p	O
<	O
0	O
.	O
001	O
).	O

From	O
immunofluorescence	O
microscopy	O
,	O
the	O
localization	O
of	O
c	O
-	O
myc	O
tagged	O
3CLpro	O
was	O
detected	O
both	O
in	O
the	O
cytoplasm	O
and	O
nucleus	B-CHED
of	O
transfected	O
A549	O
cells	O
.	O

TITLE	O
:	O
Evidence	O
that	O
TMPRSS2	O
activates	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
spike	O
protein	B-CHED
for	O
membrane	O
fusion	O
and	O
reduces	O
viral	O
control	O
by	O
the	O
humoral	O
immune	O
response	O
.	O

The	O
virus	O
was	O
able	O
to	O
spread	O
from	O
vaccinated	O
chickens	O
to	O
groups	O
of	O
non	O
-	O
vaccinated	O
chickens	O
,	O
and	O
in	O
the	O
vaccinated	O
birds	O
the	O
virus	O
was	O
found	O
frequently	O
in	O
oro	B-CHED
-	O
pharyngeal	O
and	O
cloacal	O
swabs	O
.	O

Yet	O
in	O
critical	O
illness	O
other	O
factors	O
also	O
affect	O
respiratory	O
muscle	O
function	O
,	O
including	O
prolonged	O
use	O
of	O
neuromuscular	O
blocking	O
agents	O
,	O
administration	O
of	O
corticosteroids	B-CHED
,	O
and	O
sepsis	O
.	O

Then	O
,	O
the	O
difference	O
in	O
epitope	B-CHED
which	O
those	O
MAbs	O
recognise	O
was	O
demonstrated	O
by	O
competitive	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
and	O
IFN	O
-	O
γ	O
neutralisation	O
tests	O
.	O

We	O
describe	O
a	O
unique	O
SLE	O
patient	O
who	O
was	O
diagnosed	O
with	O
recurrent	O
APS	B-CHED
presented	O
with	O
axillary	O
venous	O
thrombosis	O
and	O
subsequent	O
superficial	O
edema	O
and	O
compartment	O
syndrome	O
.	O

ABSTRACT	O
:	O
Urtica	O
dioica	O
agglutinin	O
(	O
UDA	B-CHED
)	O
is	O
a	O
small	O
plant	O
monomeric	O
lectin	O
,	O
8	O
.	O
7	O
kDa	O
in	O
size	O
,	O
with	O
an	O
N	B-CHED
-	I-CHED
acetylglucosamine	I-CHED
specificity	O
that	O
inhibits	O
viruses	O
from	O
Nidovirales	O
in	O
vitro	O
.	O

Then	O
,	O
UDA	B-CHED
was	O
tested	O
for	O
efficacy	O
in	O
a	O
lethal	O
SARS	O
-	O
CoV	O
-	O
infected	O
BALB	O
/	O
c	O
mouse	O
model	O
.	O

BALB	O
/	O
c	O
mice	O
were	O
infected	O
with	O
two	O
LD50	O
(	O
575	O
PFU	B-CHED
)	O
of	O
virus	O
for	O
4	O
h	O
before	O
the	O
mice	O
were	O
treated	O
intraperitoneally	O
with	O
UDA	B-CHED
at	O
20	O
,	O
10	O
,	O
5	O
or	O
0	O
mg	O
/	O
kg	O
/	O
day	O
for	O
4	O
days	O
.	O

At	O
day	O
6	O
after	O
virus	O
exposure	O
,	O
all	O
groups	O
of	O
mice	O
receiving	O
UDA	B-CHED
had	O
much	O
lower	O
lung	O
weights	O
than	O
did	O
the	O
placebo	O
-	O
treated	O
mice	O
.	O

Analysis	O
of	O
the	O
nucleotide	B-CHED
sequences	O
of	O
RT	O
-	O
PCR	O
products	O
revealed	O
98	O
%	O
homology	O
with	O
the	O
reference	O
strains	O
.	O

ABSTRACT	O
:	O
Green	O
fluorescent	O
protein	B-CHED
(	O
GFP	O
)-	O
tagged	O
mouse	O
hepatitis	O
coronavirus	O
nonstructural	O
protein	B-CHED
4	O
(	O
nsp4	O
)	O
was	O
shown	O
to	O
localize	O
to	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
and	O
to	O
be	O
recruited	O
to	O
the	O
coronavirus	O
replicative	O
structures	O
.	O

Kinetic	O
studies	O
demonstrated	O
that	O
they	O
are	O
noncompetitive	O
inhibitors	B-CHED
,	O
they	O
do	O
not	O
bind	O
to	O
the	O
RNase	O
H	O
active	O
site	O
or	O
to	O
the	O
classical	O
NNRTI	O
binding	O
pocket	O
,	O
even	O
though	O
efavirenz	B-CHED
binding	O
negatively	O
influenced	O
K	O
-	O
49	O
/	O
KNA	O
-	O
53	O
binding	O
and	O
vice	O
versa	O
.	O

Evidence	O
supports	O
the	O
use	O
of	O
NIV	O
during	O
fibreoptic	O
bronchoscopy	O
,	O
especially	O
with	O
high	O
risks	O
of	O
endotracheal	O
intubation	O
(	O
ETI	B-CHED
),	O
such	O
as	O
in	O
immunocompromised	O
patients	O
.	O

Molecular	O
simulations	O
indicated	O
that	O
(-)-	O
α	O
-	O
pinene	B-CHED
and	O
(-)-	O
β	O
-	O
pinene	B-CHED
specifically	O
interact	O
with	O
the	O
active	O
site	O
which	O
is	O
located	O
at	O
the	O
N	O
terminus	O
of	O
phosphorylated	O
nucleocapsid	O
(	O
N	O
)	O
protein	B-CHED
,	O
with	O
the	O
former	O
being	O
more	O
potent	O
than	O
the	O
latter	O
.	O

To	O
improve	O
the	O
functionality	O
of	O
the	O
vaccine	O
and	O
investigate	O
its	O
potential	O
as	O
a	O
delivery	O
vector	O
for	O
foreign	O
antigens	B-CHED
and	O
immunomodulatory	O
proteins	B-CHED
,	O
we	O
developed	O
a	O
derivative	O
of	O
ts	O
-	O
11	O
expressing	O
infectious	O
bronchitis	O
virus	O
-	O
S1	O
glycoprotein	B-CHED
(	O
IBV	O
-	O
S1	O
)	O
and	O
releasing	O
chicken	O
interleukin	O
-	O
6	O
into	O
the	O
extracellular	O
milieu	O
(	O
MG	O
ts	O
-	O
11	O
C3	O
(+	O
CS	O
))	O
using	O
a	O
transposon	O
-	O
based	O
delivery	O
vector	O
.	O

In	O
comparison	O
,	O
the	O
positive	O
rate	O
of	O
spike	O
(	O
S	O
)	O
protein	B-CHED
-	O
specific	O
antibodies	O
was	O
100	O
%,	O
which	O
was	O
tested	O
by	O
spike	O
protein	B-CHED
-	O
based	O
ELISA	O
at	O
1	O
/	O
100	O
dilution	O
;	O
4	O
samples	O
at	O
month	O
60	O
were	O
included	O
.	O

TITLE	O
:	O
In	O
vitro	O
inhibition	O
of	O
porcine	O
hemagglutinating	O
encephalomyelitis	O
virus	O
replication	O
with	O
siRNAs	O
targeting	O
the	O
spike	O
glycoprotein	B-CHED
and	O
replicase	O
polyprotein	O
genes	O
.	O

ABSTRACT	O
:	O
The	O
specific	O
effect	O
of	O
rna	O
interference	O
on	O
the	O
replication	O
of	O
porcine	O
hemagglutinating	O
encephalomyelitis	O
virus	O
(	O
phe	B-CHED
-	O
cov	O
)	O
was	O
explored	O
.	O

Examination	O
of	O
CPE	O
demonstrated	O
that	O
the	O
four	O
siRNAs	O
were	O
capable	O
of	O
protecting	O
cells	O
against	O
PHE	B-CHED
-	O
CoV	O
invasion	O
with	O
very	O
high	O
specificity	O
and	O
efficiency	O
.	O

In	O
the	O
context	O
of	O
CoV	O
RNA	O
synthesis	O
,	O
these	O
cellular	O
ribonucleoproteins	O
might	O
also	O
participate	O
in	O
RNA	O
-	O
protein	B-CHED
complexes	O
to	O
bring	O
into	O
physical	O
proximity	O
TRS	O
-	O
L	O
and	O
distant	O
TRS	O
-	O
B	O
,	O
as	O
proposed	O
for	O
CoV	O
discontinuous	O
transcription	O
.	O

The	O
nascent	O
minus	O
-	O
stranded	O
RNA	O
would	O
then	O
be	O
transferred	O
by	O
a	O
template	O
switch	O
process	O
to	O
the	O
TRS	O
-	O
L	O
,	O
which	O
acts	O
as	O
the	O
acceptor	B-CHED
RNA	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
effect	O
of	O
dexamethasone	B-CHED
(	O
Dx	O
)	O
combined	O
with	O
modified	O
Dachengqi	O
Decoction	O
(	O
DCQD	O
),	O
a	O
Chinese	O
herbal	O
decoction	O
for	O
purgation	O
,	O
on	O
patients	O
with	O
severe	O
acute	O
on	O
patients	O
with	O
severe	O
acute	O
,	O
a	O
Chinese	O
herbal	O
decoction	O
for	O
purgation	O
,	O
on	O
patients	O
with	O
severe	O
acute	O
pancreatitis	O
(	O
SAP	O
)	O
accompanied	O
with	O
systematic	O
inflammatory	O
response	O
syndrome	O
(	O
SIRS	O
).	O

ABSTRACT	O
:	O
The	O
coronavirus	O
(	O
CoV	O
)	O
discontinuous	O
transcription	O
mechanism	O
is	O
driven	O
by	O
long	O
-	O
distance	O
RNA	O
-	O
RNA	O
interactions	O
between	O
transcription	O
-	O
regulating	O
sequences	O
(	O
TRSs	O
)	O
located	O
at	O
the	O
5	O
'	O
terminal	O
leader	O
(	O
TRS	O
-	O
L	O
)	O
and	O
also	O
preceding	O
each	O
mRNA	B-CHED
-	O
coding	O
sequence	O
(	O
TRS	O
-	O
B	O
).	O

During	O
CoV	O
infection	O
,	O
PTB	O
relocalized	O
from	O
the	O
nucleus	B-CHED
to	O
novel	O
cytoplasmic	O
structures	O
different	O
from	O
replication	O
-	O
transcription	O
sites	O
in	O
which	O
stress	O
granule	O
markers	O
T	O
-	O
cell	O
intracellular	O
antigen	B-CHED
-	O
1	O
(	O
TIA	O
-	O
1	O
)	O
and	O
TIA	O
-	O
1	O
-	O
related	O
protein	B-CHED
(	O
TIAR	O
)	O
colocalized	O
.	O

We	O
recently	O
reported	O
that	O
the	O
initial	O
expressions	O
of	O
viral	O
antigens	B-CHED
in	O
the	O
brain	O
are	O
detected	O
in	O
the	O
infiltrating	O
monocyte	O
lineage	O
and	O
in	O
ependymal	O
cells	O
.	O

The	O
role	O
of	O
inhaled	O
ribavirin	B-CHED
in	O
adults	O
is	O
controversial	O
,	O
but	O
it	O
might	O
have	O
a	O
therapeutic	O
potential	O
for	O
severe	O
RSV	O
infection	O
-	O
induced	O
ARDS	O
in	O
adults	O
.	O

Ten	O
key	O
themes	O
emerged	O
from	O
our	O
qualitative	O
analysis	O
of	O
written	O
comments	O
,	O
including	O
family	O
-	O
work	O
balance	B-CHED
,	O
antiviral	B-CHED
prophylaxis	O
,	O
and	O
mistrust	O
or	O
fear	O
towards	O
health	O
care	O
workers	O
.	O

ABSTRACT	O
:	O
A	O
62	O
-	O
year	O
-	O
old	O
female	O
was	O
admitted	O
to	O
our	O
hospital	O
for	O
investigation	O
of	O
acute	O
progressive	O
renal	O
insufficiency	O
and	O
a	O
systemic	O
inflammatory	O
reaction	O
,	O
despite	O
treatment	O
with	O
several	O
antibiotics	B-CHED
.	O

Using	O
cycloheximide	B-CHED
and	O
puromycin	B-CHED
,	O
we	O
have	O
studied	O
the	O
effect	O
of	O
translation	O
inhibition	O
on	O
the	O
RNA	O
synthesis	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
and	O
mouse	O
hepatitis	O
virus	O
.	O

ABSTRACT	O
:	O
Fundamental	O
step	O
of	O
an	O
adaptive	O
immune	O
response	O
to	O
pathogen	O
or	O
vaccine	O
is	O
the	O
binding	O
of	O
short	O
peptides	B-CHED
(	O
also	O
called	O
epitopes	O
)	O
to	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
molecules	O
.	O

Activation	O
of	O
the	O
viral	O
spike	O
(	O
S	O
)-	O
protein	B-CHED
by	O
host	O
cell	O
proteases	O
is	O
essential	O
for	O
viral	O
infectivity	O
.	O

Virological	O
diagnosis	O
using	O
virus	O
culture	O
,	O
antigen	B-CHED
detection	O
,	O
and	O
polymerase	O
chain	O
reaction	O
methods	O
on	O
nasal	O
swab	O
specimens	O
would	O
be	O
attempted	O
for	O
all	O
these	O
visits	O
irrespective	O
of	O
triggers	O
.	O

TITLE	O
:	O
Identification	O
of	O
a	O
Golgi	O
complex	O
-	O
targeting	O
signal	O
in	O
the	O
cytoplasmic	O
tail	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
envelope	O
protein	B-CHED
.	O

Through	O
site	O
-	O
directed	O
mutagenesis	O
,	O
we	O
demonstrate	O
that	O
a	O
predicted	O
beta	O
-	O
hairpin	O
structural	O
motif	O
in	O
the	O
tail	O
is	O
sufficient	O
for	O
Golgi	O
complex	O
localization	O
of	O
a	O
reporter	O
protein	B-CHED
.	O

Steroid	B-CHED
therapy	O
associated	O
with	O
oseltamivir	B-CHED
achieved	O
an	O
evident	O
and	O
rapid	O
improvement	O
.	O

ABSTRACT	O
:	O
Metformin	B-CHED
is	O
an	O
oral	O
antidiabetic	B-CHED
agent	O
,	O
used	O
to	O
reduce	O
blood	O
glucose	B-CHED
concentration	O
in	O
patients	O
with	O
non	O
-	O
insulin	B-CHED
-	O
dependent	O
diabetes	O
mellitus	O
.	O

Bronchoalveolar	O
lavage	O
and	O
serum	O
from	O
patients	O
with	O
acute	O
exacerbation	O
of	O
idiopathic	O
pulmonary	O
fibrosis	O
,	O
stable	O
disease	O
,	O
and	O
acute	O
lung	O
injury	O
were	O
tested	O
for	O
viral	O
nucleic	B-CHED
acid	I-CHED
using	O
multiplex	O
polymerase	O
chain	O
reaction	O
,	O
pan	B-CHED
-	O
viral	O
microarray	O
,	O
and	O
high	O
-	O
throughput	O
cDNA	O
sequencing	O
.	O

To	O
learn	O
more	O
about	O
the	O
molecular	O
evolutionary	O
characteristics	O
of	O
the	O
circulating	O
field	O
strains	O
,	O
the	O
coding	O
region	O
of	O
major	O
spike	O
1	O
(	O
S1	O
)	O
protein	B-CHED
gene	O
of	O
these	O
strains	O
was	O
RT	O
-	O
PCR	O
amplified	O
and	O
sequenced	O
.	O

TITLE	O
:	O
Ammonia	B-CHED
disinfection	O
of	O
hatchery	O
waste	O
for	O
elimination	O
of	O
single	O
-	O
stranded	O
RNA	O
viruses	O
.	O

Bacteriophage	O
MS2	O
was	O
also	O
monitored	O
as	O
a	O
stable	O
indicator	B-CHED
.	O

We	O
report	O
the	O
case	O
of	O
a	O
44	O
-	O
year	O
-	O
old	O
man	B-CHED
infected	O
with	O
HIV	O
and	O
HCV	O
with	O
a	O
high	O
CD4	O
cell	O
count	O
who	O
developed	O
acute	O
respiratory	O
distress	O
syndrome	O
associated	O
with	O
influenza	O
virus	O
A	O
/	O
H1N1v	O
infection	O
.	O

Patients	O
seem	O
to	O
have	O
benefit	O
from	O
antiviral	B-CHED
therapy	O
especially	O
in	O
first	O
48	O
hours	O
.	O

Nasopharyngeal	O
aspiration	O
fluid	O
samples	O
were	O
sent	O
for	O
virus	O
culture	O
,	O
for	O
direct	O
immunofluorescence	O
test	O
of	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
for	O
rapid	O
influenza	O
viral	O
identification	O
,	O
and	O
for	O
polymerase	O
chain	O
reaction	O
of	O
human	O
metapneumovirus	O
(	O
hMPV	O
),	O
human	O
boca	O
virus	O
(	O
hBoV	O
),	O
and	O
human	O
corona	B-CHED
virus	O
.	O

In	O
addition	O
,	O
measurement	O
of	O
plasma	O
membrane	O
voltage	B-CHED
gated	O
ion	O
channel	O
activity	O
by	O
whole	O
-	O
cell	O
patch	O
clamp	O
suggested	O
that	O
E	O
protein	B-CHED
was	O
not	O
present	O
in	O
the	O
plasma	O
membrane	O
.	O

Overall	O
,	O
the	O
majority	O
of	O
IL	O
-	O
10	O
-	O
producing	O
CD8	O
(+)	O
T	O
cells	O
were	O
specific	O
for	O
the	O
immunodominant	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
class	O
I	O
epitope	B-CHED
.	O

Unlike	O
CD8	O
(+)	O
T	O
cells	O
,	O
a	O
large	O
proportion	O
of	O
CD4	O
(+)	O
T	O
cells	O
within	O
the	O
CNS	B-CHED
retained	O
IL	O
-	O
10	O
production	O
throughout	O
persistence	O
.	O

Using	O
PRRSV	O
,	O
transmissible	O
gastroenteritis	O
virus	O
,	O
porcine	O
epidemic	O
diarrhea	O
virus	O
,	O
pseudorabies	O
virus	O
,	O
and	O
avian	O
infectious	O
bronchitis	O
virus	O
as	O
coating	O
antigens	B-CHED
,	O
a	O
virus	O
-	O
based	O
ELISA	O
was	O
established	O
.	O

This	O
review	O
provides	O
a	O
summary	O
of	O
the	O
related	O
literatures	O
on	O
the	O
study	O
of	O
the	O
quaternary	O
structure	O
,	O
activation	O
,	O
and	O
self	O
-	O
maturation	O
of	O
M	O
(	O
pro	B-CHED
)	O
over	O
the	O
past	O
years	O
.	O

We	O
introduced	O
venovenous	O
(	O
V	O
-	O
V	O
)	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
to	O
rest	B-CHED
the	O
lung	O
,	O
and	O
V	O
-	O
V	O
ECMO	O
was	O
changed	O
to	O
right	O
and	O
left	O
atrial	O
ECMO	O
because	O
of	O
unsatisfactory	O
oxygen	B-CHED
support	O
on	O
POD	O
23	O
.	O

The	O
ribosomal	O
frameshifting	O
was	O
inhibited	O
by	O
the	O
PNA	B-CHED
,	O
which	O
bound	O
sequence	O
-	O
specifically	O
a	O
pseudoknot	O
structure	O
in	O
the	O
-	O
1	O
PRF	O
signal	O
,	O
in	O
cell	O
lines	O
as	O
assessed	O
using	O
a	O
dual	O
luciferase	O
-	O
based	O
reporter	O
plasmid	O
containing	O
the	O
-	O
1	O
PRF	O
signal	O
.	O

ABSTRACT	O
:	O
Viral	O
and	O
bacterial	O
pathogens	O
may	O
be	O
present	O
in	O
the	O
air	B-CHED
after	O
being	O
released	O
from	O
infected	O
individuals	O
and	O
animals	O
.	O

Four	O
air	B-CHED
-	O
handling	O
units	O
were	O
selected	O
from	O
each	O
building	O
,	O
and	O
a	O
total	O
of	O
64	O
prefilters	O
and	O
final	O
filters	O
were	O
tested	O
for	O
the	O
presence	O
of	O
influenza	O
A	O
,	O
influenza	O
B	O
,	O
respiratory	O
syncytial	O
,	O
corona	B-CHED
,	O
parainfluenza	O
1	O
-	O
3	O
,	O
adeno	O
,	O
orthopox	O
,	O
entero	O
,	O
Ebola	O
,	O
Marburg	O
,	O
Lassa	O
fever	O
,	O
Machupo	O
,	O
eastern	O
equine	O
encephalitis	O
,	O
western	O
equine	O
encephalitis	O
,	O
and	O
Venezuelan	O
equine	O
encephalitis	O
viruses	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
purified	O
recombinant	O
human	O
ADAM17	O
is	O
able	O
to	O
cleave	O
a	O
20	O
-	O
amino	B-CHED
acid	I-CHED
peptide	B-CHED
mimetic	O
corresponding	O
to	O
the	O
extracellular	O
juxtamembrane	O
region	O
of	O
human	O
ACE2	O
between	O
Arg	B-CHED
(	O
708	O
)	O
and	O
Ser	B-CHED
(	O
709	O
).	O

A	O
series	O
of	O
peptide	B-CHED
analogues	O
were	O
also	O
synthesized	O
,	O
showing	O
that	O
glutamate	B-CHED
subtitution	O
at	O
Arg	B-CHED
(	O
708	O
)	O
and	O
/	O
or	O
Arg	B-CHED
(	O
710	O
)	O
attenuated	O
the	O
cleavage	O
process	O
,	O
while	O
alanine	B-CHED
substitution	O
at	O
Arg	B-CHED
(	O
708	O
)	O
and	O
/	O
or	O
Ser	B-CHED
(	O
709	O
)	O
did	O
not	O
inhibit	O
peptide	B-CHED
cleavage	O
by	O
recombinant	O
ADAM17	O
.	O

The	O
observation	O
of	O
the	O
shedding	O
profiles	O
of	O
ACE2	O
mutants	O
expressing	O
CHO	B-CHED
-	O
K1	O
and	O
CHO	B-CHED
-	O
P	O
cells	O
indicates	O
that	O
the	O
Arg	B-CHED
(	O
708	O
)	O
→	O
Glu	B-CHED
(	O
708	O
)	O
mutation	O
and	O
the	O
Arg	B-CHED
(	O
708	O
)	O
Arg	B-CHED
(	O
710	O
)	O
→	O
Glu	B-CHED
(	O
708	O
)	O
Glu	B-CHED
(	O
710	O
)	O
double	O
mutation	O
produced	O
increases	O
in	O
the	O
amount	O
of	O
ACE2	O
shed	O
when	O
stimulated	O
by	O
phorbol	B-CHED
ester	I-CHED
PMA	B-CHED
.	O

We	O
specifically	O
highlighted	O
unique	O
aspects	O
related	O
to	O
respiratory	O
illnesses	O
in	O
the	O
Middle	O
East	O
,	O
for	O
example	O
,	O
climate	O
factors	O
in	O
the	O
desert	O
region	O
,	O
cultural	O
habits	O
,	O
for	O
example	O
,	O
water	B-CHED
-	O
pipe	O
smoking	O
and	O
disorders	O
unique	O
to	O
the	O
region	O
,	O
such	O
as	O
Behçet	O
'	O
s	O
disease	O
.	O

Thus	O
,	O
optic	O
neuritis	O
was	O
dependent	O
on	O
a	O
spike	O
glycoprotein	B-CHED
-	O
mediated	O
mechanism	O
of	O
viral	O
antigen	B-CHED
transport	O
along	O
retinal	B-CHED
ganglion	O
cell	O
axons	O
.	O

The	O
time	O
-	O
of	O
-	O
addition	O
effect	O
of	O
the	O
drug	O
on	O
TGEV	O
infection	O
indicated	O
that	O
LiCl	B-CHED
acted	O
on	O
the	O
initial	O
and	O
late	O
stage	O
of	O
TGEV	O
infection	O
.	O

Moreover	O
,	O
immunofluorescence	O
(	O
IF	O
)	O
and	O
flow	O
cytometry	O
analyses	O
based	O
on	O
staining	O
of	O
Annexin	O
V	O
and	O
propidium	B-CHED
iodide	I-CHED
staining	O
of	O
nuclei	B-CHED
indicated	O
that	O
early	O
and	O
late	O
cell	O
apoptosis	O
induced	O
by	O
TGEV	O
was	O
inhibited	O
efficiently	O
.	O

Moreover	O
,	O
all	O
types	O
of	O
coping	O
served	O
as	O
a	O
buffer	B-CHED
against	O
the	O
negative	O
impact	O
of	O
stressors	O
on	O
perceived	O
general	O
health	O
.	O

The	O
PEEP	B-CHED
levels	O
set	O
in	O
the	O
FOT	O
group	O
were	O
significantly	O
higher	O
compared	O
to	O
those	O
set	O
in	O
the	O
ARDSNet	O
group	O
during	O
the	O
whole	O
trial	O
.	O

Memory	O
T	O
cell	O
responses	O
to	O
a	O
pool	O
of	O
SARS	O
-	O
CoV	O
S	O
peptides	B-CHED
were	O
identified	O
in	O
14	O
of	O
23	O
(	O
60	O
.	O
9	O
%)	O
recovered	O
SARS	O
patients	O
,	O
whereas	O
there	O
was	O
no	O
such	O
specific	O
response	O
in	O
either	O
close	O
contacts	O
or	O
healthy	O
controls	O
.	O

TITLE	O
:	O
Exogenous	O
surfactant	B-CHED
as	O
a	O
component	O
of	O
complex	O
non	O
-	O
ECMO	O
therapy	O
of	O
ARDS	O
caused	O
by	O
influenza	O
A	O
virus	O
(	O
2009	O
H1N1	O
).	O

Briefly	O
,	O
the	O
recombinant	O
RBD	O
protein	B-CHED
(	O
rRBD	O
)	O
was	O
expressed	O
in	O
culture	O
supernatant	O
of	O
mammalian	O
293T	O
cells	O
to	O
obtain	O
a	O
correctly	O
folded	O
protein	B-CHED
with	O
proper	O
conformation	O
and	O
high	O
immunogenicity	O
.	O

The	O
CoVs	O
encode	O
sixteen	O
nonstructural	O
proteins	B-CHED
(	O
nsp	O
1	O
-	O
16	O
)	O
with	O
known	O
or	O
predicted	O
RNA	O
synthesis	O
and	O
modification	O
activities	O
,	O
and	O
it	O
has	O
been	O
proposed	O
that	O
they	O
are	O
also	O
responsible	O
for	O
the	O
evolution	O
of	O
large	O
genomes	O
.	O

The	O
results	O
of	O
a	O
virus	O
neutralization	O
assay	O
indicated	O
that	O
the	O
carboxyl	O
terminal	O
region	O
of	O
the	O
S1	O
protein	B-CHED
(	O
Mod4F	O
/	O
Epi4R	O
)	O
or	O
the	O
combined	O
carboxyl	O
terminal	O
S1	O
and	O
amino	O
terminal	O
S2	O
protein	B-CHED
(	O
4F	O
/	O
4R	O
)	O
possesses	O
the	O
neutralizing	O
epitopes	O
,	O
while	O
the	O
S2	O
fragment	O
(	O
6F	O
/	O
6R	O
)	O
contains	O
antigenic	O
epitopes	O
but	O
not	O
neutralizing	O
epitopes	O
.	O

It	O
raises	O
unanswered	O
questions	O
regarding	O
when	O
,	O
if	O
ever	O
,	O
careproviders	O
should	O
provide	O
active	O
euthanasia	O
to	O
patients	O
who	O
are	O
incompetent	O
,	O
and	O
when	O
,	O
if	O
ever	O
,	O
careproviders	O
should	O
give	O
their	O
own	O
food	O
and	O
water	B-CHED
to	O
patients	O
or	O
others	O
who	O
may	O
otherwise	O
soon	O
die	O
without	O
them	O
.	O

Both	O
serotype	O
I	O
and	O
II	O
FIPVs	O
use	O
fDC	B-CHED
-	O
SIGN	O
for	O
infection	O
of	O
monocyte	O
-	O
derived	O
cells	O
but	O
how	O
is	O
not	O
known	O
.	O

For	O
FIPV	O
II	O
,	O
both	O
fAPN	O
and	O
fDC	B-CHED
-	O
SIGN	O
are	O
involved	O
in	O
infection	O
with	O
only	O
fAPN	O
playing	O
a	O
receptor	O
role	O
at	O
the	O
plasma	O
membrane	O
.	O

TITLE	O
:	O
Inhibitors	B-CHED
of	O
SARS	O
-	O
3CLpro	O
:	O
virtual	O
screening	O
,	O
biological	O
evaluation	O
,	O
and	O
molecular	O
dynamics	O
simulation	O
studies	O
.	O

Furthermore	O
,	O
multinanosecond	O
explicit	O
solvent	B-CHED
simulations	O
were	O
carried	O
out	O
using	O
the	O
docking	O
poses	O
of	O
the	O
identified	O
hits	O
to	O
study	O
the	O
overall	O
stability	O
of	O
the	O
binding	O
site	O
interactions	O
as	O
well	O
as	O
identify	O
important	O
changes	O
in	O
the	O
interaction	O
profile	O
that	O
were	O
not	O
apparent	O
from	O
the	O
docking	O
study	O
.	O

Cumulative	O
analysis	O
of	O
the	O
evaluated	O
compounds	O
and	O
the	O
simulation	O
studies	O
led	O
to	O
the	O
identification	O
of	O
certain	O
protein	B-CHED
-	O
ligand	B-CHED
interaction	O
patterns	O
which	O
would	O
be	O
useful	O
in	O
further	O
structure	O
based	O
design	O
efforts	O
.	O

Cell	O
-	O
to	O
-	O
cell	O
fusion	O
of	O
PEDV	O
-	O
infected	O
cells	O
and	O
cleavage	O
of	O
the	O
spike	O
(	O
S	O
)	O
protein	B-CHED
were	O
observed	O
in	O
cells	O
with	O
protease	O
.	O

In	O
addition	O
,	O
treatment	O
of	O
infected	O
Vero	O
/	O
TMPRSS2	O
cells	O
with	O
the	O
protease	B-CHED
inhibitor	I-CHED
leupeptin	O
strongly	O
blocked	O
the	O
release	O
of	O
virus	O
into	O
the	O
culture	O
fluid	O
.	O

ABSTRACT	O
:	O
Hydrocarbon	B-CHED
ingestions	O
account	O
for	O
a	O
substantial	O
number	O
of	O
accidental	O
poisonings	O
;	O
when	O
aspirated	O
,	O
it	O
can	O
lead	O
to	O
severe	O
pneumonitis	O
.	O

Dexamethasone	B-CHED
is	O
considered	O
the	O
treatment	O
of	O
choice	O
for	O
immune	O
-	O
mediated	O
hemolytic	O
anemia	O
,	O
but	O
may	O
be	O
contra	O
-	O
indicated	O
in	O
foals	O
with	O
severe	O
bacterial	O
infections	O
.	O

The	O
aim	O
of	O
this	O
work	O
was	O
to	O
amplify	O
and	O
diversify	O
the	O
autoimmune	O
response	O
restricted	O
to	O
FAH	O
through	O
the	O
use	O
of	O
the	O
exogenous	O
adjuvant	B-CHED
called	O
PADRE	O
.	O

Results	O
presented	O
herein	O
indicate	O
that	O
,	O
surprisingly	O
,	O
C57BL	O
/	O
6	O
mice	O
developed	O
signs	O
of	O
autoimmune	O
hepatitis	O
-	O
like	O
disease	O
(	O
AIH	O
),	O
including	O
transient	O
hypergammaglobulinemia	O
,	O
elevated	O
transaminases	O
,	O
autoAb	O
directed	O
against	O
different	O
liver	O
proteins	B-CHED
and	O
hepatic	O
cellular	O
infiltrates	O
,	O
indicating	O
that	O
a	O
new	O
model	O
of	O
experimental	O
AIH	O
could	O
be	O
generated	O
by	O
a	O
viral	O
inoculation	O
.	O

Using	O
various	O
cell	O
cycle	O
inhibitors	B-CHED
,	O
we	O
have	O
shown	O
that	O
the	O
nuclear	O
entry	O
of	O
9b	O
is	O
independent	O
of	O
the	O
cell	O
cycle	O
.	O

Here	O
,	O
we	O
showed	O
that	O
nuclear	O
shuttling	O
of	O
9b	O
and	O
its	O
interaction	O
with	O
Crm1	O
are	O
essential	O
for	O
the	O
proper	O
degradation	O
of	O
9b	O
and	O
blocking	O
the	O
nuclear	O
export	O
of	O
this	O
protein	B-CHED
induces	O
apoptosis	O
.	O

Because	O
bats	O
have	O
been	O
implicated	O
as	O
natural	O
reservoirs	O
for	O
several	O
emerging	O
zoonotic	O
viruses	O
,	O
including	O
SARS	O
-	O
like	O
corona	B-CHED
viruses	O
,	O
henipaviruses	O
,	O
and	O
lyssaviruses	O
,	O
understanding	O
how	O
pathogens	O
are	O
maintained	O
within	O
a	O
population	O
becomes	O
vital	O
.	O

EPA	B-CHED
/	O
GLA	B-CHED
has	O
anti	O
-	O
inflammatory	O
benefits	O
,	O
as	O
evidenced	O
by	O
its	O
association	O
with	O
reduction	O
in	O
pulmonary	O
inflammation	O
,	O
improvement	O
in	O
oxygenation	O
and	O
improved	O
clinical	O
outcomes	O
in	O
patients	O
with	O
severe	O
forms	O
of	O
acute	O
lung	O
injury	O
.	O

This	O
research	O
strongly	O
supports	O
L	O
-	O
nucleosides	B-CHED
of	O
a	O
class	O
of	O
D4Ns	O
to	O
be	O
a	O
very	O
promising	O
candidate	O
for	O
antiviral	B-CHED
agents	I-CHED
due	O
to	O
its	O
low	O
cytotoxicity	O
and	O
a	O
good	O
antiviral	B-CHED
activity	O
.	O

We	O
demonstrate	O
the	O
causative	O
role	O
of	O
HSV1	O
in	O
refractory	O
ARDS	O
of	O
a	O
previously	O
healthy	O
18	O
-	O
year	O
-	O
old	O
man	B-CHED
who	O
presented	O
to	O
the	O
intensive	O
care	O
unit	O
with	O
acute	O
respiratory	O
distress	O
after	O
a	O
week	O
of	O
flulike	O
syndrome	O
.	O

For	O
the	O
first	O
time	O
in	O
this	O
condition	O
,	O
we	O
used	O
venovenous	O
ECMO	O
management	O
,	O
to	O
rest	B-CHED
the	O
lung	O
,	O
sustain	O
blood	O
oxygenation	O
and	O
end	O
-	O
organ	O
oxygen	B-CHED
delivery	O
,	O
and	O
promote	O
potential	O
lung	O
recovery	O
.	O

Yet	O
,	O
ACS	O
in	O
hemoglobin	B-CHED
SC	O
disease	O
is	O
not	O
well	O
characterized	O
.	O

We	O
retrospectively	O
reviewed	O
71	O
inpatient	O
episodes	O
of	O
ACS	O
in	O
patients	O
with	O
hemoglobin	B-CHED
SC	O
disease	O
over	O
a	O
20	O
-	O
year	O
period	O
.	O

In	O
our	O
multivariate	O
regression	O
model	O
,	O
time	O
to	O
ACS	O
diagnosis	O
and	O
total	O
number	O
of	O
days	O
of	O
oxygen	B-CHED
supplementation	O
were	O
independent	O
predictors	O
of	O
length	O
of	O
hospitalization	O
in	O
both	O
hemoglobin	B-CHED
SC	O
and	O
SS	O
episodes	O
of	O
ACS	O
.	O

She	O
was	O
followed	O
in	O
our	O
clinic	O
for	O
3	O
years	O
and	O
her	O
respiratory	O
condition	O
on	O
home	O
oxygen	B-CHED
remained	O
stable	O
,	O
as	O
did	O
the	O
liver	O
cirrhosis	O
.	O

TITLE	O
:	O
Evaluation	O
of	O
antiseptic	O
antiviral	B-CHED
activity	O
of	O
chemical	O
agents	O
.	O

Safety	O
advisories	O
from	O
the	O
FDA	O
,	O
CDC	O
,	O
and	O
the	O
relevant	O
pharmaceutical	B-CHED
manufacturers	O
were	O
ambiguous	O
in	O
their	O
description	O
in	O
""""	O
black	O
box	O
""""	O
warning	O
sections	O
of	O
package	O
inserts	O
describing	O
these	O
serious	O
and	O
potentially	O
fatal	O
toxicities	O
.	O

TITLE	O
:	O
Bacterial	O
expression	O
of	O
antigenic	O
sites	O
A	O
and	O
D	O
in	O
the	O
spike	O
protein	B-CHED
of	O
transmissible	O
gastroenteritis	O
virus	O
and	O
evaluation	O
of	O
their	O
inhibitory	O
effects	O
on	O
viral	O
infection	O
.	O

Four	O
antigenic	O
sites	O
A	O
,	O
B	O
,	O
C	O
,	O
and	O
D	O
that	O
reside	O
near	O
the	O
N	O
-	O
terminal	O
domain	O
have	O
been	O
defined	O
in	O
the	O
S	O
protein	B-CHED
.	O

ABSTRACT	O
:	O
High	O
-	O
frequency	O
oscillatory	O
ventilation	O
(	O
HFOV	O
)	O
is	O
usually	O
considered	O
not	O
indicated	O
for	O
treatment	O
of	O
patients	O
with	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
)	O
because	O
of	O
the	O
theoretical	O
risk	O
of	O
air	B-CHED
trapping	O
and	O
hyperinflation	O
.	O

ABSTRACT	O
:	O
The	O
5	O
'	O
140	O
nucleotides	B-CHED
of	O
the	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
5	O
'	O
untranslated	O
region	O
(	O
5	O
'	O
UTR	O
)	O
are	O
predicted	O
to	O
contain	O
three	O
secondary	O
structures	O
,	O
stem	O
-	O
loop	O
1	O
(	O
SL1	O
),	O
SL2	O
,	O
and	O
SL4	O
.	O

It	O
is	O
now	O
well	O
accepted	O
that	O
extracellular	O
purines	B-CHED
and	O
pyrimidines	B-CHED
are	O
promising	O
and	O
physiologically	O
relevant	O
barrier	O
-	O
protective	B-CHED
agents	I-CHED
and	O
their	O
effects	O
are	O
mediated	O
by	O
interaction	O
with	O
cell	O
surface	O
P2Y	O
receptors	O
which	O
belong	O
to	O
the	O
superfamily	O
of	O
G	O
-	O
protein	B-CHED
-	O
coupled	O
receptors	O
.	O

Here	O
,	O
we	O
present	O
an	O
overview	O
of	O
recently	O
identified	O
P2Y	O
receptor	O
agonists	B-CHED
that	O
enhance	O
the	O
pulmonary	O
endothelial	O
barrier	O
and	O
inhibit	O
and	O
/	O
or	O
reverse	O
endothelial	O
barrier	O
disruption	O
.	O

TITLE	O
:	O
Randomized	O
controlled	O
trial	O
of	O
pulse	O
methyl	B-CHED
prednisolone	B-CHED
×	O
placebo	O
in	O
treatment	O
of	O
pulmonary	O
involvement	O
associated	O
with	O
severe	O
leptospirosis	O
.	O

The	O
exclusion	O
criteria	O
include	O
patients	O
aged	O
under	O
15	O
years	O
,	O
a	O
history	O
of	O
hypersensitivity	O
to	O
the	O
use	O
of	O
corticosteroids	B-CHED
,	O
the	O
presence	O
of	O
active	O
infection	O
of	O
fungal	O
,	O
tuberculous	O
or	O
bacterial	O
origin	O
apart	O
from	O
the	O
infection	O
by	O
leptospira	O
itself	O
,	O
the	O
presence	O
of	O
hemoconcentration	O
or	O
atypical	O
lymphocyte	O
count	O
on	O
admission	O
to	O
hospital	O
,	O
the	O
presence	O
of	O
co	O
-	O
morbidities	O
that	O
could	O
be	O
responsible	O
for	O
the	O
radiological	O
and	O
gasometric	O
alterations	O
used	O
to	O
diagnose	O
leptospirotic	O
pneumonitis	O
,	O
evidence	O
of	O
recent	O
cranial	O
trauma	O
,	O
neurosurgery	O
,	O
peptic	O
ulcer	O
,	O
and	O
participation	O
in	O
another	O
clinical	O
trial	O
.	O

ABSTRACT	O
:	O
The	O
management	O
of	O
bronchial	O
fistula	O
associated	O
with	O
acute	O
lung	O
injury	O
raises	O
two	O
major	O
concerns	O
:	O
(	O
1	O
)	O
high	O
ventilation	O
pressures	O
are	O
necessary	O
for	O
lung	O
recruitment	O
but	O
detrimental	O
for	O
fistula	O
healing	O
,	O
and	O
(	O
2	O
)	O
adequate	O
lung	O
recruitment	O
is	O
prevented	O
by	O
large	O
air	B-CHED
leak	O
.	O

ABSTRACT	O
:	O
This	O
review	O
summarizes	O
knowledge	O
and	O
evidence	O
on	O
the	O
use	O
of	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	B-CHED
)	O
in	O
patients	O
with	O
severely	O
hypoxemic	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

No	O
established	O
threshold	O
has	O
been	O
set	O
to	O
define	O
severely	O
hypoxemic	O
ARDS	O
and	O
higher	O
PEEP	B-CHED
.	O

In	O
ARDS	O
,	O
the	O
primary	O
objective	O
of	O
PEEP	B-CHED
is	O
to	O
increase	O
the	O
amount	O
of	O
non	O
-	O
aerated	O
lung	O
at	O
the	O
end	O
of	O
expiration	O
.	O

In	O
early	O
ARDS	O
with	O
a	O
diffuse	O
pattern	O
and	O
severe	O
hypoxemia	O
,	O
higher	O
PEEP	B-CHED
contributes	O
to	O
lung	O
recruitment	O
by	O
maintaining	O
lung	O
recruitment	O
elicited	O
by	O
tidal	O
breath	O
and	O
recruitment	O
maneuvers	O
as	O
well	O
as	O
minimizes	O
the	O
repeated	O
opening	O
and	O
closure	O
with	O
no	O
significant	O
overdistension	O
.	O

Higher	O
PEEP	B-CHED
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
less	O
severe	O
hypoxemic	O
(	O
acute	O
lung	O
injury	O
).	O
To	O
deliver	O
optimal	O
PEEP	B-CHED
to	O
those	O
ARDS	O
patients	O
with	O
the	O
highest	O
lung	O
recruitability	O
,	O
this	O
technique	O
should	O
be	O
monitored	O
at	O
the	O
bedside	O
.	O

RESULTS	O
:	O
WNv	O
antigen	B-CHED
was	O
detected	O
in	O
brain	O
,	O
spleen	O
,	O
heart	O
,	O
kidney	O
,	O
liver	O
,	O
gonads	O
,	O
intestine	O
,	O
lung	O
,	O
and	O
pancreas	O
.	O

Indeed	O
,	O
when	O
these	O
mice	O
were	O
challenged	O
with	O
a	O
low	O
dose	O
(<	O
0	O
.	O
5	O
LD₅₀	O
)	O
of	O
the	O
DENV	O
-	O
2	O
NSx	O
strain	O
,	O
but	O
not	O
the	O
NG	O
-	O
C	O
strain	O
,	O
they	O
all	O
generated	O
dramatic	O
and	O
lethal	O
DENV	O
-	O
2	O
AER	O
/	O
AED	B-CHED
.	O

This	O
DENV	O
-	O
2	O
AER	O
/	O
AED	B-CHED
was	O
blocked	O
by	O
high	O
concentrations	O
of	O
only	O
the	O
NG	O
-	O
C	O
NS1	O
glycoprotein	B-CHED
.	O

These	O
results	O
imply	O
a	O
potential	O
hazard	O
of	O
DENV	O
NS1	O
glycoprotein	B-CHED
-	O
based	O
vaccines	O
,	O
particularly	O
against	O
DENV	O
strains	O
that	O
contain	O
multiple	O
mutations	O
or	O
genetic	O
recombination	O
within	O
or	O
between	O
their	O
DENV	O
E	O
and	O
NS1	O
glycoprotein	B-CHED
-	O
encoding	O
genes	O
.	O

To	O
our	O
knowledge	O
,	O
4	O
cases	O
of	O
ARDS	O
after	O
the	O
onset	O
of	O
lithium	B-CHED
toxicity	O
have	O
been	O
documented	O
.	O

Gag	O
proteins	B-CHED
,	O
encoded	O
by	O
retroviruses	O
,	O
orchestrate	O
the	O
assembly	O
of	O
virus	O
particles	O
in	O
close	O
collaboration	O
with	O
host	O
cell	O
machinery	O
.	O

In	O
addition	O
to	O
retroviruses	O
,	O
many	O
structural	O
proteins	B-CHED
of	O
unrelated	O
viruses	O
,	O
including	O
influenza	O
M1	O
,	O
NEP	O
and	O
NP	O
proteins	B-CHED
,	O
38	O
Borna	O
disease	O
virus	O
N	O
and	O
P	O
proteins28	O
,	O
56	O
and	O
coronavirus	O
N	O
protein	B-CHED
,	O
23	O
,	O
57	O
undergo	O
nuclear	O
localization	O
and	O
bind	O
viral	O
RNAs	O
to	O
form	O
viral	O
ribonuclear	O
protein	B-CHED
(	O
RNP	O
)	O
complexes	O
that	O
are	O
exported	O
from	O
the	O
nucleus	B-CHED
for	O
packaging	O
into	O
virus	O
particles	O
.	O

ABSTRACT	O
:	O
The	O
induction	O
of	O
antigen	B-CHED
specific	O
memory	O
CD8	O
(+)	O
T	O
cells	O
in	O
vivo	O
is	O
very	O
important	O
to	O
new	O
vaccines	O
against	O
infectious	O
diseases	O
.	O

These	O
T	O
reg	O
cells	O
are	O
detected	O
at	O
the	O
same	O
time	O
as	O
effector	B-CHED
T	O
cells	O
(	O
T	O
eff	O
cells	O
)	O
exhibiting	O
the	O
same	O
specificity	O
and	O
can	O
suppress	O
T	O
eff	O
cell	O
proliferation	O
after	O
stimulation	O
with	O
cognate	O
peptide	B-CHED
.	O

These	O
virus	O
-	O
specific	O
T	O
reg	O
cells	O
may	O
be	O
especially	O
effective	O
in	O
inhibiting	O
the	O
immune	O
response	O
during	O
the	O
peak	O
of	O
infection	O
,	O
when	O
virus	O
antigen	B-CHED
is	O
maximal	O
.	O

These	O
results	O
show	O
that	O
pathogen	O
epitope	B-CHED
-	O
specific	O
Foxp3	O
(+)	O
T	O
reg	O
cells	O
can	O
be	O
identified	O
on	O
the	O
basis	O
of	O
cytokine	O
production	O
.	O

ABSTRACT	O
:	O
Low	O
micromolar	O
,	O
non	O
-	O
cytotoxic	O
concentrations	O
of	O
cyclosporin	B-CHED
A	I-CHED
(	O
CsA	B-CHED
)	O
strongly	O
affected	O
the	O
replication	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
human	O
coronavirus	O
229E	O
and	O
mouse	O
hepatitis	O
virus	O
in	O
cell	O
culture	O
,	O
as	O
was	O
evident	O
from	O
the	O
strong	O
inhibition	O
of	O
GFP	O
reporter	O
gene	O
expression	O
and	O
a	O
reduction	O
of	O
up	O
to	O
4	O
logs	O
in	O
progeny	O
titres	O
.	O

Upon	O
high	O
-	O
multiplicity	O
infection	O
,	O
CsA	B-CHED
treatment	O
rendered	O
SARS	O
-	O
CoV	O
RNA	O
and	O
protein	B-CHED
synthesis	O
almost	O
undetectable	O
,	O
suggesting	O
an	O
early	O
block	O
in	O
replication	O
.	O

We	O
wished	O
to	O
determine	O
the	O
potential	O
for	O
pulmonary	O
overexpression	O
of	O
the	O
extracellular	O
isoform	O
of	O
superoxide	B-CHED
dismutase	O
(	O
EC	O
-	O
SOD	O
)	O
to	O
reduce	O
the	O
severity	O
of	O
endotoxin	O
-	O
induced	O
lung	O
injury	O
.	O

Animals	O
were	O
randomly	O
allocated	O
to	O
undergo	O
intratracheal	O
instillation	O
of	O
(	O
1	O
)	O
surfactant	B-CHED
alone	O
(	O
vehicle	O
);	O
(	O
2	O
)	O
adeno	O
-	O
associated	O
virus	O
(	O
AAV	O
)	O
vectors	O
containing	O
a	O
null	O
transgene	O
(	O
AAV	O
-	O
null	O
);	O
and	O
(	O
3	O
)	O
adeno	O
-	O
associated	O
virus	O
vectors	O
containing	O
the	O
EC	O
-	O
SOD	O
transgene	O
(	O
AAV	O
-	O
EC	O
-	O
SOD	O
)	O
and	O
endotoxin	O
was	O
subsequently	O
administered	O
intratracheally	O
.	O

The	O
AAV	O
vector	O
encoding	O
EC	O
-	O
SOD	O
increased	O
lung	O
EC	O
-	O
SOD	O
concentrations	O
,	O
and	O
enhanced	O
the	O
antioxidant	B-CHED
capacity	O
of	O
the	O
lung	O
.	O

The	O
balance	B-CHED
between	O
ACE	O
and	O
ACE2	O
is	O
crucial	O
for	O
controlling	O
AngII	O
levels	O
.	O

Finally	O
,	O
mention	O
is	O
made	O
to	O
the	O
recent	O
discovery	O
of	O
ACE2	O
as	O
a	O
receptor	O
for	O
the	O
SARS	O
Corona	B-CHED
Virus	O
.	O

We	O
describe	O
the	O
clinical	O
features	O
,	O
disease	O
spectrum	O
,	O
and	O
response	O
to	O
antimalarial	B-CHED
chemotherapy	O
,	O
including	O
artemether	B-CHED
-	O
lumefantrine	B-CHED
and	O
artesunate	B-CHED
,	O
in	O
patients	O
with	O
P	O
.	O
knowlesi	O
malaria	O
diagnosed	O
by	O
PCR	O
during	O
December	O
2007	O
-	O
November	O
2009	O
at	O
a	O
tertiary	O
care	O
hospital	O
in	O
Sabah	O
,	O
Malaysia	O
.	O

Likewise	O
,	O
the	O
SARS	O
VLP	O
vaccine	O
,	O
containing	O
4	O
μg	O
of	O
S	O
protein	B-CHED
without	O
adjuvant	B-CHED
,	O
reduced	O
lung	O
virus	O
titer	O
to	O
below	O
detectable	O
level	O
,	O
protected	O
mice	O
from	O
weight	O
loss	O
,	O
and	O
elicited	O
a	O
high	O
level	O
of	O
neutralizing	O
antibodies	O
against	O
SARS	O
-	O
CoV	O
.	O
Sf9	O
cell	O
-	O
produced	O
full	O
length	O
purified	O
SARS	O
S	O
protein	B-CHED
was	O
also	O
an	O
effective	O
vaccine	O
against	O
SARS	O
-	O
CoV	O
but	O
only	O
when	O
co	O
-	O
administered	O
IM	O
with	O
aluminum	B-CHED
hydroxide	I-CHED
.	O

TITLE	O
:	O
Venlafaxine	B-CHED
-	O
induced	O
acute	O
eosinophilic	O
pneumonia	O
.	O

The	O
syndrome	O
rapidly	O
resolved	O
after	O
discontinuation	O
of	O
the	O
drug	O
and	O
upon	O
reception	O
of	O
corticosteroids	B-CHED
in	O
low	O
doses	O
.	O

Pathophysiological	O
mechanisms	O
implicated	O
in	O
the	O
development	O
of	O
AEP	O
in	O
our	O
patient	O
seems	O
to	O
be	O
associated	O
with	O
eotaxin	O
and	O
serotonin	B-CHED
eosinophilic	O
-	O
specific	O
chemoattracting	O
action	O
.	O

Recent	O
studies	O
have	O
shown	O
that	O
many	O
other	O
viruses	O
also	O
encode	O
PBM	O
-	O
containing	O
proteins	B-CHED
that	O
bind	O
to	O
cellular	O
PDZ	O
proteins	B-CHED
.	O

The	O
inhibition	O
or	O
perturbation	O
of	O
the	O
function	O
of	O
cellular	O
PDZ	O
proteins	B-CHED
appears	O
to	O
be	O
a	O
widely	O
used	O
strategy	O
for	O
viruses	O
to	O
enhance	O
their	O
replication	O
,	O
disseminate	O
in	O
the	O
host	O
,	O
and	O
transmit	O
to	O
new	O
hosts	O
.	O

Similarity	O
of	O
coronavirus	O
HKU1	O
with	O
those	O
published	O
in	O
the	O
GenBank	O
at	O
nucleotide	B-CHED
levels	O
was	O
98	O
.	O
18	O
%	O
-	O
100	O
%.	O

ABSTRACT	O
:	O
A	O
series	O
of	O
3	O
(	O
benzylideneamino	O
)-	O
2	O
-	O
phenyl	B-CHED
quinazoline	B-CHED
-	O
4	O
(	O
3H	O
)-	O
ones	O
was	O
synthesized	O
by	O
reaction	O
of	O
3	O
-	O
amino	O
-	O
2	O
-	O
phenyl	B-CHED
-	O
3H	O
-	O
quinazoline	B-CHED
-	O
4	O
-	O
one	O
with	O
various	O
carbonyl	B-CHED
compounds	I-CHED
.	O

We	O
find	O
that	O
an	O
RNA	O
capable	O
of	O
forming	O
only	O
the	O
predicted	O
PK	O
(	O
58	O
nt	O
;	O
3	O
'	O
nucleotides	B-CHED
241	O
-	O
185	O
)	O
adopts	O
the	O
P2	O
stem	O
-	O
loop	O
with	O
little	O
evidence	O
for	O
P1	O
(	O
pk	O
)	O
pairing	O
in	O
0	O
.	O
1	O
M	O
KCl	B-CHED
and	O
the	O
absence	O
of	O
Mg	O
(	O
2	O
+);	O
as	O
Mg	O
(	O
2	O
+)	O
or	O
1	O
M	O
KCl	B-CHED
is	O
added	O
,	O
a	O
new	O
thermal	O
unfolding	O
transition	O
is	O
induced	O
and	O
assignable	O
to	O
P1	O
(	O
pk	O
)	O
pairing	O
.	O

ABSTRACT	O
:	O
Expression	O
of	O
matrix	O
metalloproteinases	O
(	O
MMPs	O
),	O
especially	O
MMP9	O
correlates	O
with	O
blood	O
-	O
brain	O
barrier	O
(	O
BBB	B-CHED
)	O
disruption	O
during	O
many	O
neuroinflammatory	O
diseases	O
.	O

Depletion	O
of	O
neutrophils	O
reduced	O
CNS	B-CHED
accumulation	O
of	O
monocytes	O
and	O
T	O
cells	O
,	O
albeit	O
without	O
affecting	O
overall	O
pathogenesis	O
.	O

The	O
fusion	O
proteins	B-CHED
successfully	O
expressed	O
in	O
transfected	O
Vero	O
E6	O
cells	O
by	O
western	O
blot	O
analysis	O
,	O
and	O
the	O
PEDV	O
N	O
protein	B-CHED
and	O
the	O
B23	O
.	O
1	O
phosphoprotein	O
showed	O
co	O
-	O
localization	O
features	O
in	O
co	O
-	O
transfected	O
cells	O
through	O
confocal	O
microscopy	O
analysis	O
.	O

Sixteen	O
antigenic	O
linear	O
sequences	O
in	O
the	O
N	O
protein	B-CHED
were	O
found	O
using	O
antisera	O
obtained	O
from	O
mice	O
infected	O
naturally	O
with	O
MHV	O
and	O
a	O
peptide	B-CHED
array	O
containing	O
overlapping	O
10	O
-	O
mer	O
peptides	B-CHED
covering	O
the	O
entire	O
N	O
protein	B-CHED
.	O

A	O
dominant	O
memory	O
CD8	O
+	O
T	O
cell	O
response	O
against	O
SARS	O
-	O
CoV	O
nucleocaspid	O
protein	B-CHED
(	O
NP	O
;	O
amino	B-CHED
acids	I-CHED
216	O
to	O
225	O
)	O
was	O
then	O
defined	O
in	O
SARS	O
-	O
recovered	O
individuals	O
carrying	O
HLA	O
-	O
B	O
*	O
40	O
:	O
01	O
,	O
a	O
HLA	O
-	O
B	O
molecule	O
present	O
in	O
approximately	O
one	O
-	O
quarter	O
of	O
subjects	O
of	O
Asian	O
ethnicities	O
.	O

They	O
were	O
able	O
to	O
degranulate	O
and	O
produce	O
gamma	O
interferon	O
,	O
tumor	O
necrosis	O
factor	O
alpha	O
,	O
and	O
macrophage	O
inflammatory	O
proteins	B-CHED
1α	O
and	O
1β	O
after	O
antigenic	O
stimulation	O
.	O

The	O
expression	O
of	O
aquaporins	O
(	O
AQPs	O
)	O
1	O
,	O
AQP5	O
,	O
and	O
estrogen	B-CHED
receptor	O
-	O
β	O
(	O
ERβ	O
)	O
was	O
measured	O
by	O
western	O
blotting	O
and	O
immunohistochemical	O
methods	O
.	O

This	O
assay	O
system	O
can	O
be	O
easily	O
adapted	O
to	O
screen	O
entry	O
inhibitors	B-CHED
against	O
other	O
viruses	O
with	O
the	O
careful	O
selection	O
of	O
matching	O
partner	O
virus	O
envelopes	O
.	O

There	O
were	O
no	O
significant	O
increases	O
in	O
the	O
rates	O
of	O
infections	O
with	O
dexamethasone	B-CHED
.	O

Moreover	O
,	O
HR1	O
and	O
HR2	O
derived	O
free	O
peptides	B-CHED
are	O
inhibitors	B-CHED
of	O
SARS	O
-	O
CoV	O
entry	O
.	O

ABSTRACT	O
:	O
Integrase	O
(	O
IN	O
)	O
represents	O
a	O
clinically	O
validated	O
target	O
for	O
the	O
development	O
of	O
antivirals	B-CHED
against	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
).	O

Antileukocyte	O
antibodies	O
in	O
blood	O
donors	O
plasma	O
,	O
caused	O
TRALI	O
in	O
89	O
%	O
of	O
cases	O
;	O
also	O
it	O
has	O
been	O
found	O
antigen	B-CHED
specificity	O
against	O
leukocyte	O
blood	O
receptor	O
in	O
59	O
%.	O

To	O
explore	O
this	O
,	O
we	O
examined	O
fusion	O
activity	O
using	O
recombinant	O
S	O
proteins	B-CHED
.	O

We	O
also	O
examined	O
the	O
distribution	O
of	O
these	O
S	O
proteins	B-CHED
;	O
the	O
MK	O
-	O
p10	O
and	O
MK	O
-	O
H1381R	O
S	O
proteins	B-CHED
were	O
transported	O
onto	O
the	O
cell	O
surface	O
more	O
efficiently	O
than	O
others	O
.	O

S1	O
genes	O
of	O
these	O
isolated	O
strains	O
and	O
the	O
vaccine	O
strains	O
showed	O
nucleotide	B-CHED
homologies	O
ranging	O
from	O
65	O
.	O
2	O
to	O
82	O
%	O
and	O
amino	B-CHED
acid	I-CHED
homologies	O
ranging	O
from	O
58	O
.	O
4	O
to	O
81	O
.	O
9	O
%.	O

A	O
logical	O
strategy	O
would	O
be	O
to	O
combine	O
antiviral	B-CHED
treatment	O
with	O
drugs	O
that	O
modify	O
excessive	O
host	O
responses	O
or	O
supplement	O
deficient	O
ones	O
.	O

Tidal	O
-	O
volumes	O
used	O
were	O
7	O
.	O
8	O
to	O
8	O
.	O
1	O
ml	O
/	O
kg	O
(	O
ideal	O
body	O
weight	O
),	O
plateau	O
pressures	O
always	O
remained	O
<	O
30	O
cmH2O	O
,	O
without	O
differences	O
between	O
survivors	O
and	O
non	O
-	O
survivors	O
;	O
and	O
mean	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	B-CHED
)	O
levels	O
used	O
were	O
between	O
8	O
to	O
12	O
cm	O
H2O	B-CHED
.	O

Previous	O
studies	O
using	O
peptidic	O
substrates	O
and	O
inhibitors	B-CHED
showed	O
that	O
the	O
substrate	O
specificity	O
of	O
SARS	O
-	O
CoV	O
M	O
(	O
pro	B-CHED
)	O
requires	O
glutamine	B-CHED
in	O
the	O
P1	O
position	O
and	O
a	O
large	O
hydrophobic	O
residue	O
in	O
the	O
P2	O
position	O
.	O

Consequently	O
,	O
we	O
reassessed	O
the	O
substrate	O
specificity	O
of	O
the	O
enzyme	O
by	O
testing	O
the	O
cleavage	O
of	O
20	O
different	O
tetradecapeptide	O
substrates	O
with	O
varying	O
amino	B-CHED
-	I-CHED
acid	I-CHED
residues	I-CHED
in	O
the	O
P2	O
position	O
.	O

About	O
half	O
of	O
them	O
were	O
found	O
in	O
the	O
protein	B-CHED
corona	B-CHED
of	O
CLs	O
.	O

These	O
results	O
may	O
help	O
in	O
designing	O
gene	O
delivery	O
systems	O
capable	O
of	O
binding	O
the	O
minimum	O
possible	O
quantity	O
of	O
proteins	B-CHED
that	O
influence	O
transfection	O
negatively	O
,	O
binding	O
selectively	O
proteins	B-CHED
capable	O
of	O
helping	O
in	O
steering	O
in	O
vivo	O
the	O
vector	O
toward	O
the	O
target	O
,	O
and	O
obtaining	O
more	O
efficient	O
and	O
effective	O
gene	O
therapy	O
.	O

TITLE	O
:	O
Complementary	O
roles	O
of	O
Fas	O
-	O
associated	O
death	O
domain	O
(	O
FADD	O
)	O
and	O
receptor	O
interacting	O
protein	B-CHED
kinase	O
-	O
3	O
(	O
RIPK3	O
)	O
in	O
T	O
-	O
cell	O
homeostasis	O
and	O
antiviral	B-CHED
immunity	O
.	O

Recent	O
studies	O
have	O
demonstrated	O
that	O
receptor	O
-	O
interacting	O
protein	B-CHED
kinases	O
(	O
RIPKs	O
)	O
RIPK1	O
and	O
RIPK3	O
together	O
facilitate	O
TNF	O
-	O
induced	O
necroptosis	O
,	O
but	O
the	O
precise	O
role	O
of	O
RIPKs	O
in	O
the	O
demise	O
of	O
T	O
cells	O
lacking	O
FADD	O
or	O
casp8	O
activity	O
is	O
unknown	O
.	O

Enhanced	O
recovery	O
of	O
these	O
double	O
-	O
mutant	O
T	O
cells	O
following	O
stimulation	O
demonstrates	O
that	O
FADD	O
,	O
casp8	O
,	O
and	O
RIPK3	O
are	O
all	O
essential	O
for	O
clonal	O
expansion	O
,	O
contraction	O
,	O
and	O
antiviral	B-CHED
responses	O
.	O

In	O
the	O
present	O
study	O
we	O
have	O
examined	O
the	O
role	O
of	O
cerebral	O
electron	O
transport	O
chain	O
complexes	O
,	O
including	O
complex	O
I	O
,	O
II	O
,	O
III	O
IV	O
,	O
and	O
pyruvate	B-CHED
dehydrogenase	O
in	O
the	O
non	O
-	O
synaptic	O
mitochondria	O
isolated	O
from	O
the	O
cortex	O
of	O
the	O
thioacetamide	B-CHED
-	O
induced	O
FHF	O
rats	O
.	O

Decreased	O
wet	O
-	O
dry	O
weight	O
ratios	O
of	O
the	O
lungs	O
,	O
lower	O
histological	O
lung	O
injury	O
scores	O
and	O
higher	O
PaO	B-CHED
(	O
2	O
)	O
were	O
found	O
in	O
all	O
low	O
tidal	O
volume	O
/	O
hypercapnia	O
groups	O
(	O
group	O
2	O
,	O
3	O
,	O
4	O
)	O
as	O
compared	O
to	O
the	O
group	O
with	O
conventional	O
tidal	O
volume	O
/	O
normocapnia	O
(	O
group	O
1	O
).	O

Irrespective	O
of	O
the	O
techniques	O
used	O
,	O
the	O
majority	O
of	O
hmAbs	O
specifically	O
reacted	O
with	O
the	O
receptor	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
the	O
spike	O
(	O
S	O
)	O
protein	B-CHED
and	O
likely	O
prevented	O
receptor	O
binding	O
.	O

TITLE	O
:	O
Changes	O
in	O
nonstructural	O
protein	B-CHED
3	O
are	O
associated	O
with	O
attenuation	O
in	O
avian	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
.	O

Using	O
a	O
formal	B-CHED
prospective	O
observational	O
study	O
design	O
,	O
5065	O
CABG	O
patients	O
from	O
70	O
centers	O
were	O
enrolled	O
between	O
November	O
1996	O
and	O
June	O
2000	O
using	O
a	O
systemic	O
sampling	O
protocol	O
.	O

Suppression	O
of	O
the	O
ATR	O
kinase	O
activity	O
by	O
chemical	O
inhibitors	B-CHED
and	O
siRNA	O
-	O
mediated	O
knockdown	O
of	O
ATR	O
reduced	O
the	O
IBV	O
-	O
induced	O
ATR	O
signaling	O
and	O
inhibited	O
the	O
replication	O
of	O
IBV	O
.	O

ABSTRACT	O
:	O
Annexin	O
A2	O
(	O
ANXA2	O
)	O
is	O
a	O
protein	B-CHED
implicated	O
in	O
diverse	O
cellular	O
functions	O
,	O
including	O
exocytosis	O
,	O
DNA	O
synthesis	O
and	O
cell	O
proliferation	O
.	O

It	O
was	O
recently	O
proposed	O
to	O
be	O
involved	O
in	O
RNA	O
metabolism	O
because	O
it	O
was	O
shown	O
to	O
associate	O
with	O
some	O
cellular	O
mRNA	B-CHED
.	O

In	O
this	O
study	O
,	O
an	O
ssDNA	O
aptamer	O
that	O
specifically	O
binds	O
to	O
SARS	O
CoV	O
nucleocapsid	O
protein	B-CHED
was	O
isolated	O
from	O
a	O
DNA	O
library	O
containing	O
45	O
-	O
nuceotide	O
random	O
sequences	O
in	O
the	O
middle	O
of	O
an	O
88mer	O
single	B-CHED
-	I-CHED
stranded	I-CHED
DNA	I-CHED
.	O

Using	O
this	O
approach	O
,	O
an	O
ssDNA	O
aptamer	O
that	O
binds	O
to	O
the	O
nucleocapsid	O
protein	B-CHED
with	O
a	O
K	O
(	O
d	O
)	O
of	O
4	O
.	O
93	O
±	O
0	O
.	O
30nM	O
was	O
identified	O
.	O

Moreover	O
,	O
HR2	O
is	O
both	O
the	O
target	O
for	O
novel	O
antiviral	B-CHED
therapies	O
and	O
,	O
as	O
an	O
isolated	O
peptide	B-CHED
,	O
presents	O
a	O
potential	O
antiviral	B-CHED
therapeutic	O
.	O

In	O
this	O
work	O
,	O
we	O
added	O
a	O
nitroxide	B-CHED
spin	B-CHED
label	I-CHED
to	O
the	O
N	O
-	O
terminal	O
region	O
of	O
HR2	O
and	O
used	O
paramagnetic	O
relaxation	O
enhancement	O
to	O
assess	O
the	O
orientation	O
of	O
the	O
HR2	O
helices	O
under	O
different	O
solution	O
conditions	O
.	O

ABSTRACT	O
:	O
In	O
this	O
study	O
,	O
as	O
a	O
bioisosteric	O
alternative	O
scaffold	O
of	O
the	O
antiviral	B-CHED
aryl	O
diketoacids	O
(	O
ADKs	O
),	O
we	O
used	O
5	O
-	O
hydroxychromone	O
on	O
which	O
two	O
arylmethyloxy	O
substituents	O
were	O
installed	O
.	O

Subtle	O
structural	O
differences	O
in	O
the	O
S2	O
and	O
S3	O
pockets	O
of	O
these	O
proteases	O
make	O
inhibitors	B-CHED
selective	O
,	O
but	O
some	O
dual	O
inhibitors	B-CHED
have	O
been	O
discovered	O
.	O

Antibiotic	B-CHED
treatment	O
was	O
given	O
and	O
favourable	O
progress	O
allowed	O
early	O
discharge	O
.	O

During	O
the	O
peak	O
pandemic	O
2009	O
-	O
2010	O
influenza	O
season	O
in	O
Rhode	O
Island	O
,	O
nearly	O
half	O
of	O
patients	O
admitted	O
with	O
influenza	O
-	O
like	O
symptoms	O
had	O
respiratory	O
viruses	O
other	O
than	O
influenza	O
A	O
.	O
A	O
high	O
proportion	O
of	O
patients	O
were	O
treated	O
with	O
antibiotics	B-CHED
and	O
pH1N1	O
infection	O
had	O
higher	O
mortality	O
compared	O
to	O
other	O
respiratory	O
viruses	O
.	O

Furthermore	O
,	O
we	O
show	O
that	O
treatment	O
with	O
quercetin	B-CHED
,	O
quercitrin	B-CHED
or	O
isoquercitrin	B-CHED
,	O
major	O
water	B-CHED
extractable	O
flavonoids	B-CHED
from	O
H	O
.	O
cordata	O
,	O
significantly	O
blocked	O
HSV	O
-	O
2	O
infection	O
.	O

The	O
prevalence	O
of	O
FCoV	O
antigen	B-CHED
and	O
antibody	O
in	O
Korean	O
cats	O
are	O
expected	O
to	O
gradually	O
increase	O
due	O
to	O
the	O
rising	O
numbers	O
of	O
stray	O
and	O
companion	O
cats	O
.	O

Herein	O
,	O
we	O
show	O
that	O
a	O
single	O
point	O
mutation	O
in	O
the	O
viral	O
spike	O
(	O
S	O
)	O
glycoprotein	B-CHED
(	O
Y241H	O
),	O
acquired	O
during	O
viral	O
persistence	O
in	O
human	O
neural	O
cells	O
,	O
led	O
to	O
a	O
hind	O
-	O
limb	O
paralytic	O
disease	O
in	O
infected	O
mice	O
.	O

Expression	O
of	O
the	O
glial	O
glutamate	B-CHED
transporter	O
GLT	O
-	O
1	O
,	O
responsible	O
for	O
glutamate	B-CHED
homeostasis	O
,	O
was	O
downregulated	O
following	O
infection	O
,	O
and	O
GYKI	O
-	O
52466	O
also	O
significantly	O
restored	O
its	O
steady	O
-	O
state	O
expression	O
level	O
.	O

The	O
results	O
showed	O
that	O
IBV	O
infection	O
of	O
cultured	O
human	O
and	O
animal	O
cells	O
activated	O
the	O
p38	O
mitogen	B-CHED
-	O
activated	O
protein	B-CHED
kinase	O
(	O
MAPK	O
)	O
pathway	O
and	O
induced	O
the	O
expression	O
of	O
IL	O
-	O
6	O
and	O
IL	O
-	O
8	O
.	O

Knockdown	O
of	O
expression	O
of	O
known	O
mediators	O
of	O
the	O
antiviral	B-CHED
signaling	O
pathway	O
revealed	O
that	O
the	O
IL	O
-	O
17	O
-	O
poly	O
(	O
I	O
:	O
C	O
)	O
synergy	O
depends	O
on	O
the	O
presence	O
of	O
the	O
transcriptional	O
factors	O
RelA	O
and	O
IFN	O
regulatory	O
factor	O
3	O
and	O
IκB	O
kinases	O
.	O

We	O
concluded	O
that	O
the	O
inhibition	O
of	O
PEDV	O
production	O
by	O
Q7R	O
is	O
not	O
simply	O
due	O
to	O
a	O
general	O
action	O
as	O
an	O
antioxidants	B-CHED
and	O
is	O
highly	O
specific	O
,	O
as	O
several	O
other	O
antioxidants	B-CHED
(	O
NAC	O
,	O
PDTC	O
,	O
trolox	O
)	O
are	O
inactive	O
against	O
PEDV	O
infection	O
.	O

The	O
admission	O
partial	O
pressure	O
of	O
oxygen	B-CHED
/	O
fraction	O
of	O
inspired	O
oxygen	B-CHED
ratio	O
(	O
p	O
=	O
0	O
.	O
003	O
)	O
and	O
PC	O
volume	O
percentage	O
(	O
p	O
=	O
0	O
.	O
01	O
)	O
were	O
independent	O
predictive	O
factors	O
of	O
ARDS	O
development	O
.	O

APE1	O
is	O
able	O
to	O
cleave	O
CD44	O
mRNA	B-CHED
,	O
microRNAs	O
(	O
miR	O
-	O
21	O
,	O
miR	O
-	O
10b	O
),	O
and	O
three	O
RNA	O
components	O
of	O
SARS	O
-	O
corona	B-CHED
virus	O
(	O
orf1b	O
,	O
orf3	O
,	O
spike	O
)	O
suggesting	O
that	O
,	O
when	O
challenged	O
,	O
it	O
can	O
cleave	O
any	O
RNAs	O
in	O
vitro	O
.	O

APE1	O
does	O
not	O
cleave	O
strong	O
doublestranded	O
regions	O
of	O
RNA	O
and	O
it	O
has	O
a	O
strong	O
preference	O
for	O
3	O
'	O
of	O
pyrimidine	B-CHED
,	O
especially	O
towards	O
UA	O
,	O
CA	O
,	O
and	O
UG	O
sites	O
at	O
single	O
-	O
stranded	O
or	O
weakly	O
paired	O
regions	O
.	O

The	O
most	O
distinctive	O
difference	O
between	O
influenza	O
virus	O
and	O
SARS	O
-	O
CoV	O
is	O
the	O
stage	O
during	O
virus	O
replication	O
in	O
which	O
viral	O
glycoproteins	B-CHED
are	O
cleaved	O
by	O
proteases	O
.	O

In	O
contrast	O
,	O
SARS	O
-	O
CoV	O
S	O
protein	B-CHED
is	O
cleaved	O
by	O
the	O
protease	O
following	O
receptor	O
-	O
induced	O
conformational	O
changes	O
.	O

In	O
support	O
of	O
this	O
model	O
,	O
we	O
reported	O
that	O
the	O
S	O
protein	B-CHED
of	O
mouse	O
hepatitis	O
virus	O
type	O
2	O
(	O
MHV	O
-	O
2	O
),	O
which	O
is	O
highly	O
similar	O
to	O
the	O
S	O
protein	B-CHED
of	O
SARS	O
-	O
CoV	O
,	O
requires	O
two	O
-	O
step	O
conformational	O
changes	O
mediated	O
by	O
sequential	O
receptor	O
binding	O
and	O
proteolysis	O
to	O
be	O
activated	O
for	O
membrane	O
fusion	O
.	O

This	O
conference	O
illuminated	O
the	O
constantly	O
evolving	O
field	O
of	O
antiviral	B-CHED
chemotherapy	O
by	O
providing	O
a	O
forum	O
to	O
present	O
and	O
discuss	O
new	O
antiviral	B-CHED
compounds	O
,	O
new	O
uses	O
for	O
old	O
compounds	O
and	O
exciting	O
clinical	O
results	O
.	O

We	O
present	O
a	O
case	O
of	O
toxic	O
epidermal	O
necrolysis	O
in	O
a	O
healthy	O
46	O
-	O
yr	O
-	O
old	O
female	O
patient	O
who	O
had	O
inhaled	O
glycophosphate	O
(	O
herbicide	B-CHED
)	O
and	O
was	O
treated	O
with	O
paracetamol	B-CHED
,	O
aspirin	B-CHED
,	O
and	O
chlorpheniramine	B-CHED
.	O

The	O
absence	O
of	O
the	O
38	O
-	O
nucleotide	B-CHED
deletion	O
in	O
ORF3b	O
,	O
which	O
is	O
characteristic	O
of	O
CB	O
/	O
05	O
,	O
indicates	O
the	O
need	O
to	O
identify	O
new	O
genetic	O
markers	O
for	O
pantropic	O
variants	O
of	O
CCoV	O
,	O
probably	O
in	O
the	O
spike	O
-	O
protein	B-CHED
gene	O
region	O
.	O

ABSTRACT	O
:	O
The	O
human	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
and	O
the	O
NL63	O
coronaviruses	O
are	O
human	O
respiratory	O
pathogens	O
for	O
which	O
no	O
effective	O
antiviral	B-CHED
treatment	O
exists	O
.	O

We	O
used	O
the	O
SARS	O
-	O
CoV	O
apo	B-CHED
X	O
-	O
ray	O
structure	O
to	O
develop	O
a	O
model	O
of	O
the	O
NL63	O
-	O
PLP2	O
catalytic	O
site	O
.	O

ABSTRACT	O
:	O
The	O
D	O
allele	O
of	O
the	O
insertion	O
/	O
deletion	O
(	O
I	O
/	O
D	O
)	O
polymorphism	O
of	O
a	O
287	O
-	O
bp	O
sequence	O
in	O
the	O
angiotensin	B-CHED
-	O
converting	O
enzyme	O
(	O
ACE	O
)	O
gene	O
has	O
been	O
associated	O
with	O
an	O
increased	O
activity	O
of	O
this	O
enzyme	O
.	O

In	O
Western	O
blot	O
analysis	O
,	O
the	O
antibody	O
elicited	O
by	O
the	O
recombinant	O
protein	B-CHED
pAPN	O
-	O
C	O
could	O
recognize	O
the	O
native	O
pAPN	O
.	O

We	O
now	O
report	O
on	O
underlying	O
mechanisms	O
associated	O
with	O
the	O
induction	O
of	O
programmed	O
cell	O
death	O
(	O
PCD	O
)	O
after	O
infection	O
by	O
the	O
reference	O
HCoV	O
-	O
OC43	O
virus	O
(	O
rOC	O
/	O
ATCC	O
)	O
and	O
a	O
more	O
neurovirulent	O
and	O
cytotoxic	O
HCoV	O
-	O
OC43	O
variant	O
harboring	O
two	O
point	O
mutations	O
in	O
the	O
S	O
glycoprotein	B-CHED
(	O
rOC	O
/	O
U	O
(	O
S183	O
-	O
241	O
)).	O

Structural	O
optimization	O
was	O
carried	O
out	O
based	O
on	O
X	O
-	O
ray	O
crystallographic	O
analyses	O
of	O
the	O
R188I	O
SARS	O
3CL	O
protease	O
in	O
a	O
complex	O
with	O
each	O
inhibitor	B-CHED
to	O
provide	O
a	O
tetrapeptide	B-CHED
aldehyde	B-CHED
with	O
an	O
IC	O
(	O
50	O
)	O
value	O
of	O
98	O
nM	O
.	O
The	O
resulting	O
compound	O
carried	O
no	O
substrate	O
sequence	O
,	O
except	O
for	O
a	O
P	O
(	O
3	O
)	O
site	O
directed	O
toward	O
the	O
outside	O
of	O
the	O
protease	O
.	O

We	O
compared	O
this	O
with	O
white	O
blood	O
cell	O
(	O
WBC	O
)	O
counts	O
,	O
serum	O
C	O
-	O
reactive	O
protein	B-CHED
(	O
CRP	O
),	O
serum	O
procalcitonin	O
(	O
PCT	O
),	O
urine	O
output	O
,	O
creatinine	B-CHED
clearance	O
(	O
CCr	O
),	O
serum	O
creatinine	B-CHED
(	O
SCr	O
),	O
and	O
blood	O
urea	B-CHED
nitrogen	B-CHED
(	O
BUN	O
).	O

While	O
ORF6	O
does	O
not	O
have	O
a	O
global	O
effect	O
on	O
protein	B-CHED
synthesis	O
,	O
quantitative	O
real	O
-	O
time	O
PCR	O
revealed	O
that	O
it	O
down	O
-	O
regulated	O
the	O
mRNA	B-CHED
level	O
of	O
the	O
co	O
-	O
transfected	O
myc	O
-	O
nsp8	O
gene	O
.	O

In	O
addition	O
,	O
SARS	O
-	O
CoV	O
E	O
protein	B-CHED
down	O
-	O
regulated	O
the	O
signaling	O
pathway	O
inositol	B-CHED
-	O
requiring	O
enzyme	O
1	O
(	O
IRE	O
-	O
1	O
)	O
of	O
the	O
unfolded	O
protein	B-CHED
response	O
,	O
but	O
not	O
the	O
PKR	O
-	O
like	O
ER	O
kinase	O
(	O
PERK	B-CHED
)	O
or	O
activating	O
transcription	O
factor	O
6	O
(	O
ATF	O
-	O
6	O
)	O
pathways	O
,	O
and	O
reduced	O
cell	O
apoptosis	O
.	O

After	O
severe	O
trauma	O
,	O
an	O
enteral	O
immuno	O
-	O
enhancing	O
diet	O
,	O
enriched	O
with	O
arginine	B-CHED
,	O
omega	B-CHED
-	I-CHED
3	I-CHED
fatty	I-CHED
acids	I-CHED
,	O
and	O
nucleotides	B-CHED
,	O
decreases	O
infectious	O
complications	O
.	O

Glutamine	B-CHED
should	O
be	O
administered	O
enterally	O
or	O
parenterally	O
whenever	O
total	O
parenteral	O
nutrition	O
is	O
indicated	O
.	O

Patients	O
receiving	O
combined	O
immunosuppressive	O
therapy	O
for	O
steroid	B-CHED
-	O
refractory	O
cGvHD	O
barely	O
responded	O
to	O
pandemic	O
H1N1	O
(	O
2009	O
)	O
vaccination	O
.	O

We	O
found	O
that	O
in	O
particular	O
the	O
exposure	O
of	O
nsp8	O
'	O
s	O
natural	O
N	B-CHED
-	I-CHED
terminal	I-CHED
residue	I-CHED
was	O
paramount	O
for	O
both	O
the	O
protein	B-CHED
'	O
s	O
ability	O
to	O
associate	O
with	O
nsp7	O
and	O
for	O
boosting	O
its	O
RdRp	O
activity	O
.	O

Early	O
therapy	O
with	O
oseltamivir	B-CHED
in	O
severely	O
ill	O
patients	O
,	O
without	O
waiting	O
for	O
laboratory	O
confirmation	O
for	O
diagnosis	O
,	O
will	O
save	O
patients	O
from	O
severe	O
complications	O
.	O

Non	O
-	O
immunosuppressive	O
derivatives	O
of	O
CspA	O
might	O
serve	O
as	O
broad	O
-	O
range	O
CoV	O
inhibitors	B-CHED
applicable	O
against	O
emerging	O
CoVs	O
as	O
well	O
as	O
ubiquitous	O
pathogens	O
of	O
humans	O
and	O
livestock	O
.	O

TITLE	O
:	O
Aerosolized	O
human	O
extracellular	O
superoxide	B-CHED
dismutase	O
prevents	O
hyperoxia	O
-	O
induced	O
lung	O
injury	O
.	O

ABSTRACT	O
:	O
No	O
formal	B-CHED
system	O
exists	O
to	O
review	O
trade	O
restrictions	O
imposed	O
during	O
international	O
public	O
health	O
emergencies	O
rapidly	O
.	O

ABSTRACT	O
:	O
We	O
report	O
the	O
activities	O
of	O
a	O
number	O
of	O
thiazolides	O
[	O
2	O
-	O
hydroxyaroyl	O
-	O
N	O
-(	O
thiazol	O
-	O
2	O
-	O
yl	O
)	O
amides	B-CHED
]	O
against	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
genotypes	O
IA	O
and	O
IB	O
,	O
using	O
replicon	O
assays	O
.	O

We	O
show	O
here	O
that	O
the	O
5	O
'-	O
Cl	O
analogue	B-CHED
4	I-CHED
has	O
closely	O
comparable	O
in	O
vitro	O
activity	O
and	O
a	O
good	O
cell	O
safety	O
index	O
.	O

As	O
such	O
,	O
an	O
awareness	O
of	O
infectious	O
diseases	O
causing	O
central	O
nervous	O
system	O
(	O
CNS	B-CHED
)	O
signs	O
in	O
cats	O
,	O
and	O
their	O
clinical	O
diagnosis	O
and	O
management	O
,	O
is	O
relevant	O
to	O
anyone	O
dealing	O
with	O
cats	O
on	O
a	O
regular	O
basis	O
.	O

All	O
patients	O
benefit	O
from	O
thorough	O
history	O
taking	O
and	O
clinical	O
,	O
neurological	O
and	O
ophthalmic	B-CHED
examinations	O
,	O
which	O
all	O
require	O
minimal	O
equipment	O
.	O

By	O
combining	O
the	O
most	O
favorable	O
residues	O
at	O
P3	O
to	O
P5	O
positions	O
,	O
we	O
identified	O
super	O
-	O
active	O
substrate	O
sequences	O
'	O
VARLQ	O
↓	O
SGF	O
'	O
that	O
can	O
be	O
cleaved	O
efficiently	O
by	O
all	O
3CL	O
(	O
pro	B-CHED
)	O
with	O
relative	O
activity	O
of	O
1	O
.	O
7	O
to	O
3	O
.	O
2	O
,	O
and	O
'	O
VPRLQ	O
↓	O
SGF	O
'	O
that	O
can	O
be	O
cleaved	O
specifically	O
by	O
IBV	O
3CL	O
(	O
pro	B-CHED
)	O
with	O
relative	O
activity	O
of	O
4	O
.	O
3	O
.	O

The	O
ERIC	O
-	O
PCR	O
fingerprints	O
of	O
the	O
3	O
cecal	O
samples	O
from	O
the	O
CPM	O
and	O
LPS	B-CHED
treatment	O
groups	O
clustered	O
together	O
with	O
high	O
coefficients	O
among	O
them	O
.	O

SARS	O
patients	O
were	O
almost	O
universally	O
steroid	B-CHED
naive	O
with	O
no	O
other	O
known	O
predisposition	O
to	O
osteonecrosis	O
.	O

CHDF	O
was	O
performed	O
in	O
12	O
patients	O
,	O
8	O
patients	O
received	O
highdose	O
glucocorticoid	B-CHED
therapy	O
and	O
11	O
patients	O
received	O
sivelestat	O
.	O

Recombinant	O
human	O
APC	O
(	O
continuous	O
infusion	O
24	O
μg	O
/	O
kg	O
per	O
hour	O
)	O
and	O
ceftazidime	B-CHED
(	O
3	O
-	O
g	O
bolus	O
at	O
1	O
and	O
13	O
h	O
)	O
were	O
intravenously	O
administered	O
.	O

AMs	O
secreted	O
significant	O
amounts	O
of	O
tumour	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
-	O
α	O
),	O
regulated	O
on	O
activation	O
normal	O
T	O
-	O
cell	O
expressed	O
and	O
secreted	O
(	O
RANTES	O
/	O
CCL5	O
)	O
and	O
macrophage	O
inflammatory	O
protein	B-CHED
1β	O
(	O
MIP	O
-	O
1β	O
/	O
CCL4	B-CHED
)	O
in	O
response	O
to	O
HCoV	O
-	O
229E	O
infection	O
,	O
but	O
these	O
cells	O
exhibited	O
no	O
detectable	O
increase	O
in	O
IFN	O
-	O
β	O
or	O
interleukin	O
-	O
29	O
in	O
mRNA	B-CHED
levels	O
.	O

FIP	O
was	O
confirmed	O
by	O
histology	O
or	O
immunostaining	O
of	O
feline	O
coronavirus	O
(	O
FCoV	O
)	O
antigen	B-CHED
in	O
effusion	O
or	O
tissue	O
macrophages	O
or	O
both	O
.	O

We	O
also	O
review	O
the	O
functions	O
of	O
coronavirus	O
proteins	B-CHED
,	O
structural	O
,	O
enzymatic	O
,	O
and	O
accessory	O
,	O
with	O
an	O
emphasis	O
on	O
roles	O
in	O
pathogenesis	O
.	O

Other	O
than	O
antiviral	B-CHED
drug	I-CHED
(	O
mainly	O
oseltamivir	B-CHED
)	O
administration	O
and	O
avoidance	O
of	O
corticosteroids	B-CHED
,	O
management	O
of	O
ARDS	O
due	O
to	O
these	O
viruses	O
does	O
not	O
differ	O
from	O
that	O
for	O
ARDS	O
caused	O
by	O
other	O
diseases	O
.	O

To	O
compare	O
the	O
prevalence	O
of	O
HCoV	O
species	O
among	O
children	O
hospitalized	O
for	O
acute	O
respiratory	O
illness	O
and	O
/	O
or	O
fever	O
(	O
ARI	B-CHED
/	O
fever	O
)	O
with	O
that	O
among	O
asymptomatic	O
controls	O
and	O
to	O
assess	O
the	O
severity	O
of	O
outcomes	O
among	O
hospitalized	O
children	O
with	O
HCoV	O
infection	O
compared	O
with	O
other	O
respiratory	O
viruses	O
.	O

Changes	O
in	O
advice	O
with	O
CO	O
variation	O
of	O
about	O
20	O
%	O
were	O
negligible	O
except	O
in	O
cases	O
of	O
high	O
oxygen	B-CHED
consumption	O
.	O

ABSTRACT	O
:	O
Differentiation	O
syndrome	O
(	O
DS	O
)	O
represents	O
a	O
life	O
-	O
threatening	O
complication	O
in	O
patients	O
with	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
undergoing	O
induction	O
therapy	O
with	O
all	O
-	O
trans	O
retinoic	B-CHED
acid	I-CHED
(	O
ATRA	O
)	O
or	O
arsenic	B-CHED
trioxide	I-CHED
(	O
ATO	O
).	O

After	O
examination	O
at	O
rest	B-CHED
,	O
all	O
subjects	O
performed	O
a	O
maximal	O
cycling	O
exercise	O
test	O
.	O

TITLE	O
:	O
Life	O
-	O
threatening	O
hyperkalaemia	O
and	O
multisystem	O
toxicity	O
following	O
first	O
-	O
time	O
exposure	O
to	O
cocaine	B-CHED
.	O

On	O
49th	O
day	O
after	O
the	O
last	O
immunization	O
,	O
splenocytes	O
were	O
prepared	O
from	O
mice	O
immunized	O
with	O
surface	O
-	O
displayed	O
mixture	B-CHED
,	O
secretory	O
mixture	B-CHED
and	O
negative	O
control	O
to	O
be	O
stimulated	O
by	O
purified	O
N	O
and	O
S	O
protein	B-CHED
,	O
respectively	O
.	O

ABSTRACT	O
:	O
Pneumonia	O
is	O
a	O
leading	O
cause	O
of	O
death	O
in	O
adults	O
in	O
the	O
industrialised	O
countries	O
and	O
in	O
the	O
rest	B-CHED
of	O
the	O
world	O
in	O
infants	O
.	O

Those	O
last	O
years	O
new	O
diagnostic	O
tests	O
have	O
been	O
elaborated	O
:	O
antigen	B-CHED
detection	O
in	O
urines	O
or	O
in	O
nasopharyngeal	O
samples	O
,	O
molecular	O
methods	O
allowing	O
to	O
look	O
at	O
one	O
or	O
several	O
pathogens	O
at	O
the	O
same	O
time	O
on	O
a	O
single	O
sample	O
(	O
Multiplex	O
)	O
with	O
an	O
increased	O
sensitivity	O
with	O
regard	O
to	O
the	O
more	O
classical	O
methods	O
.	O

TITLE	O
:	O
Protein	B-CHED
catabolism	O
and	O
requirements	O
in	O
severe	O
illness	O
.	O

Enteral	O
immunonutrition	O
enriched	O
with	O
arginine	B-CHED
,	O
nucleotides	B-CHED
,	O
and	O
omega	B-CHED
-	I-CHED
3	I-CHED
fatty	I-CHED
acids	I-CHED
is	O
indicated	O
in	O
patients	O
with	O
trauma	O
,	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
and	O
mild	O
sepsis	O
.	O

Over	O
the	O
last	O
few	O
years	O
,	O
there	O
have	O
been	O
considerable	O
advances	O
in	O
extracorporeal	O
technology	O
and	O
clinical	O
practice	O
,	O
ushering	O
in	O
a	O
new	O
era	B-CHED
of	O
ECMO	O
.	O

Hollow	O
-	O
fibre	O
oxygenators	O
and	O
Mendler	O
-	O
designed	O
centrifugal	O
pumps	O
have	O
replaced	O
the	O
old	O
silicon	B-CHED
oxygenators	O
and	O
roller	O
pumps	O
.	O

After	O
6	O
hours	O
buprenorphine	B-CHED
treatment	O
,	O
these	O
parameters	O
were	O
normalized	O
.	O

ABSTRACT	O
:	O
An	O
external	O
quality	O
assessment	O
(	O
EQA	O
)	O
panel	O
consisting	O
of	O
a	O
total	O
of	O
48	O
samples	O
in	O
bronchoalveolar	O
lavage	O
(	O
BAL	B-CHED
)	O
fluid	O
or	O
transport	O
medium	O
was	O
prepared	O
in	O
collaboration	O
with	O
Quality	O
Control	O
for	O
Molecular	O
Diagnostics	O
(	O
QCMD	O
)	O
(	O
www	O
.	O
qcmd	O
.	O
org	O
).	O

By	O
using	O
primarily	O
cell	O
-	O
free	O
,	O
in	O
vitro	O
translation	O
systems	O
,	O
the	O
present	O
study	O
revealed	O
that	O
the	O
nsp1	O
induced	O
endonucleolytic	O
RNA	O
cleavage	O
mainly	O
near	O
the	O
5	O
'	O
untranslated	O
region	O
of	O
capped	O
mRNA	B-CHED
templates	O
.	O

A	O
total	O
of	O
1554	O
cases	O
of	O
ARI	B-CHED
patients	O
in	O
Second	O
Affiliated	O
Hospital	O
of	O
Guangzhou	O
Medical	O
College	O
from	O
September	O
2006	O
to	O
September	O
2009	O
,	O
were	O
recruited	O
in	O
the	O
survey	O
.	O

The	O
incidence	O
rate	O
of	O
HPIV	O
and	O
HRV	O
showed	O
no	O
obvious	O
seasonal	O
features	O
;	O
while	O
the	O
prevalence	O
of	O
FluA	O
,	O
FluB	O
,	O
RSV	O
,	O
ADV	O
,	O
MPV	O
and	O
HCoV	O
changed	O
significantly	O
in	O
different	O
seasons	O
.	O
22	O
.	O
2	O
%	O
(	O
227	O
/	O
1024	O
)	O
ARI	B-CHED
patients	O
co	O
-	O
infected	O
other	O
respiratory	O
virus	O
.	O
90	O
.	O
1	O
%	O
(	O
163	O
/	O
181	O
)	O
FluA	O
patients	O
,	O
88	O
.	O
9	O
%	O
(	O
88	O
/	O
99	O
)	O
FluB	O
patients	O
and	O
92	O
.	O
7	O
%	O
(	O
51	O
/	O
55	O
)	O
ADV	O
patients	O
had	O
high	O
fever	O
symptoms	O
.	O

ABSTRACT	O
:	O
Positive	O
-	O
sense	O
RNA	O
((+)	O
RNA	O
)	O
viruses	O
such	O
as	O
hepatitis	O
C	O
virus	O
exploit	O
host	O
cells	O
by	O
subverting	O
host	O
proteins	B-CHED
,	O
remodelling	O
subcellular	O
membranes	O
,	O
co	O
-	O
opting	O
and	O
modulating	O
protein	B-CHED
and	O
ribonucleoprotein	O
complexes	O
,	O
and	O
altering	O
cellular	O
metabolic	O
pathways	O
during	O
infection	O
.	O

Since	O
no	O
specific	O
pharmacologic	O
intervention	O
exists	O
for	O
ARDS	O
,	O
our	O
objective	O
was	O
to	O
determine	O
the	O
effect	O
of	O
treatment	O
with	O
ergothioneine	B-CHED
-	O
a	O
safe	O
agent	O
with	O
multiple	O
anti	O
-	O
inflammatory	O
and	O
antioxidant	B-CHED
properties	O
on	O
the	O
development	O
of	O
lung	O
injury	O
and	O
inflammation	O
in	O
rats	O
insufflated	O
with	O
cytokines	O
found	O
in	O
lung	O
lavages	O
of	O
ARDS	O
patients	O
.	O

CD4	O
T	O
cell	O
depletion	O
subsequent	O
to	O
CD4	O
T	O
cell	O
CNS	B-CHED
migration	O
restored	O
CD8	O
T	O
cell	O
activity	O
and	O
virus	O
control	O
.	O

Principal	O
component	O
analysis	O
(	O
PCA	B-CHED
)	O
performed	O
on	O
BPHS	O
reports	O
generated	O
three	O
principal	O
components	O
,	O
explaining	O
71	O
%	O
of	O
the	O
total	O
variance	O
.	O

The	O
BCV	O
was	O
identified	O
in	O
lung	O
samples	O
[	O
bronchoalveolar	O
lavage	O
(	O
BAL	B-CHED
)	O
collection	O
]	O
as	O
well	O
as	O
in	O
nasal	O
swabs	O
.	O

Thrombocytopenia	O
,	O
chest	O
x	O
-	O
rays	O
with	O
suggestive	O
signs	O
,	O
and	O
receiving	O
supplemental	O
oxygenation	O
were	O
highly	O
sensitive	O
(>	O
95	O
%),	O
while	O
elevated	O
hematocrit	O
was	O
highly	O
specific	O
(	O
83	O
%)	O
in	O
detecting	O
HPS	B-CHED
.	O

Using	O
a	O
sensitive	O
suspect	O
case	O
definition	O
to	O
identify	O
potential	O
HPS	B-CHED
patients	O
that	O
are	O
confirmed	O
by	O
highly	O
specific	O
diagnostic	O
testing	O
will	O
ensure	O
accurate	O
reporting	O
of	O
this	O
disease	O
.	O

EVLW	O
was	O
associated	O
with	O
degree	O
of	O
lung	O
injury	O
and	O
mortality	O
,	O
regardless	O
of	O
the	O
index	O
used	O
,	O
confirming	O
that	O
it	O
may	O
be	O
used	O
as	O
a	O
bedside	O
indicator	B-CHED
of	O
disease	O
severity	O
.	O

To	O
study	O
the	O
function	O
of	O
the	O
SARS	O
-	O
CoV	O
nucleocapsid	O
protein	B-CHED
,	O
we	O
have	O
conducted	O
a	O
yeast	O
two	O
-	O
hybrid	O
screening	O
experiment	O
to	O
identify	O
cellular	O
proteins	B-CHED
that	O
may	O
interact	O
with	O
the	O
SARS	O
-	O
CoV	O
nucleocapsid	O
protein	B-CHED
.	O

The	O
binding	O
domains	O
of	O
these	O
two	O
proteins	B-CHED
were	O
also	O
determined	O
using	O
the	O
yeast	O
two	O
-	O
hybrid	O
system	O
.	O

Cellular	O
pyruvate	B-CHED
kinase	O
activity	O
in	O
hepatoma	O
cells	O
was	O
repressed	O
by	O
SARS	O
-	O
CoV	O
nucleocapsid	O
protein	B-CHED
in	O
either	O
transiently	O
transfected	O
or	O
stably	O
transfected	O
cells	O
.	O

TITLE	O
:	O
Immune	O
responses	O
to	O
mucosal	O
vaccination	O
by	O
the	O
recombinant	O
A1	O
and	O
N	O
proteins	B-CHED
of	O
infectious	O
bronchitis	O
virus	O
.	O

ABSTRACT	O
:	O
Generation	O
of	O
antiviral	B-CHED
IgM	O
is	O
usually	O
considered	O
as	O
a	O
marker	O
of	O
a	O
short	O
-	O
lived	O
initial	O
antibody	O
response	O
that	O
is	O
replaced	O
by	O
hypermutated	O
and	O
more	O
-	O
efficient	O
IgG	O
.	O
However	O
,	O
once	O
viruses	O
have	O
established	O
a	O
particular	O
niche	O
for	O
their	O
persistence	O
(	O
e	O
.	O
g	O
.,	O
within	O
the	O
CNS	B-CHED
),	O
the	O
immune	O
system	O
has	O
to	O
specifically	O
mobilize	O
a	O
broad	O
range	O
of	O
antimicrobial	B-CHED
effectors	O
to	O
contain	O
the	O
pathogen	O
in	O
the	O
long	O
term	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
appropriate	O
B	O
-	O
cell	O
activation	O
within	O
the	O
CNS	B-CHED
-	O
draining	O
lymph	O
node	O
and	O
subsequent	O
CXCR3	O
-	O
mediated	O
migration	O
of	O
antiviral	B-CHED
IgM	O
-	O
secreting	O
cells	O
to	O
the	O
infected	O
CNS	B-CHED
was	O
dependent	O
on	O
CD40	O
-	O
mediated	O
interaction	O
of	O
B	O
cells	O
with	O
T	O
helper	O
cells	O
.	O

These	O
data	O
indicate	O
that	O
the	O
CD40	O
-	O
mediated	O
collaboration	O
of	O
T	O
and	O
B	O
cells	O
is	O
critical	O
to	O
secure	O
neuroprotective	O
IgM	O
responses	O
during	O
viral	O
CNS	B-CHED
infection	O
.	O

Depalmitylation	O
of	O
mouse	O
hepatitis	O
virus	O
S	O
proteins	B-CHED
abolished	O
this	O
interaction	O
,	O
resulting	O
in	O
the	O
failure	O
of	O
S	O
incorporation	O
into	O
virions	O
.	O

This	O
indicated	O
that	O
these	O
palmitylated	O
cysteines	O
are	O
essential	O
for	O
S	O
incorporation	O
,	O
but	O
are	O
not	O
involved	O
in	O
S	O
co	O
-	O
localization	O
mediated	O
by	O
the	O
M	O
protein	B-CHED
.	O

Interestingly	O
,	O
the	O
ORF3	O
gene	O
from	O
an	O
attenuated	O
PEDV	O
encodes	O
a	O
truncated	O
protein	B-CHED
with	O
49	O
nucleotide	B-CHED
deletions	O
,	O
which	O
lacks	O
the	O
ion	O
channel	O
activity	O
.	O

In	O
comparison	O
to	O
three	O
other	O
cases	O
of	O
influenza	O
pneumonia	O
in	O
the	O
same	O
outbreak	O
with	O
known	O
risk	O
factors	O
for	O
severe	O
influenza	O
,	O
such	O
as	O
pregnancy	O
and	O
diabetes	O
mellitus	O
,	O
a	O
much	O
higher	O
viral	O
load	O
was	O
detected	O
in	O
the	O
lungs	O
of	O
this	O
patient	O
despite	O
antiviral	B-CHED
treatment	O
.	O

Samples	O
were	O
tested	O
for	O
antibodies	O
to	O
porcine	O
parvovirus	O
(	O
PPV	B-CHED
),	O
Aujeszky	O
'	O
s	O
disease	O
virus	O
(	O
ADV	O
),	O
porcine	O
circovirus	O
type	O
2	O
(	O
PCV2	O
),	O
swine	O
influenza	O
virus	O
,	O
porcine	O
respiratory	O
and	O
reproductive	O
syndrome	O
virus	O
(	O
PRRSV	O
),	O
porcine	O
respiratory	O
coronavirus	O
(	O
PRCV	O
),	O
transmissible	O
gastroenteritis	O
virus	O
,	O
and	O
swine	O
vesicular	O
disease	O
virus	O
(	O
SVDV	O
).	O

Among	O
them	O
,	O
accessory	O
protein	B-CHED
3b	O
(	O
also	O
known	O
as	O
ORF4	O
)	O
was	O
lately	O
identified	O
as	O
one	O
of	O
the	O
viral	O
interferon	O
antagonist	B-CHED
.	O

In	O
this	O
study	O
,	O
using	O
yeast	O
two	O
-	O
hybrid	O
and	O
co	O
-	O
immunoprecipitation	O
techniques	O
,	O
we	O
have	O
identified	O
a	O
host	O
transcription	O
factor	O
RUNX1b	O
(	O
Runt	O
related	O
transcription	O
factor	O
,	O
isoform	O
b	O
)	O
as	O
a	O
novel	O
interacting	O
partner	O
for	O
SARS	O
-	O
CoV	O
3b	O
protein	B-CHED
.	O

Kinase	O
assay	O
and	O
pharmacological	O
inhibitor	B-CHED
treatment	O
implied	O
that	O
3b	O
also	O
affect	O
RUNX1b	O
transcriptional	O
activity	O
by	O
regulating	O
its	O
ERK	O
dependent	O
phosphorylation	O
levels	O
.	O

Environmental	O
studies	O
have	O
shown	O
that	O
animal	O
coronaviruses	O
remain	O
infectious	O
in	O
water	B-CHED
and	O
sewage	O
for	O
up	O
to	O
a	O
year	O
depending	O
on	O
the	O
temperature	O
and	O
humidity	O
.	O

ABSTRACT	O
:	O
In	O
vitro	O
infection	O
of	O
Vero	O
E6	O
cells	O
by	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
is	O
blocked	O
by	O
hexapeptide	O
Tyr	B-CHED
-	O
Lys	B-CHED
-	O
Tyr	B-CHED
-	I-CHED
Arg	I-CHED
-	O
Tyr	B-CHED
-	O
Leu	B-CHED
.	O

(	O
438	O
)	O
YKYRYL	O
(	O
443	O
)	O
carries	O
the	O
dominant	O
binding	O
epitope	B-CHED
and	O
binds	O
to	O
ACE2	O
with	O
K	O
(	O
D	O
)=	O
46	O
μM	O
.	O
The	O
binding	O
mode	O
was	O
further	O
characterized	O
by	O
saturation	O
transfer	O
difference	O
(	O
STD	O
)	O
NMR	O
spectroscopy	O
and	O
molecular	O
dynamic	O
simulations	O
.	O

We	O
have	O
recently	O
shown	O
increased	O
levels	O
of	O
lung	O
adenosine	B-CHED
inhibit	O
alveolar	O
fluid	O
clearance	O
,	O
an	O
important	O
predictor	O
of	O
outcome	O
in	O
patients	O
with	O
ARDS	O
.	O

Alcohol	O
caused	O
an	O
increase	O
in	O
BAL	B-CHED
fluid	O
adenosine	B-CHED
levels	O
.	O

In	O
primary	O
rat	O
alveolar	O
type	O
II	O
cells	O
alcohol	O
and	O
adenosine	B-CHED
decreased	O
the	O
abundance	O
of	O
the	O
Na	O
,	O
K	O
-	O
ATPase	O
at	O
the	O
basolateral	O
membrane	O
via	O
a	O
mechanism	O
that	O
required	O
activation	O
of	O
the	O
AMPK	O
.	O

ABSTRACT	O
:	O
The	O
hemagglutinin	O
-	O
esterases	O
(	O
HEs	O
),	O
envelope	O
glycoproteins	B-CHED
of	O
corona	B-CHED
-,	O
toro	O
-	O
and	O
orthomyxoviruses	O
,	O
mediate	O
reversible	O
virion	O
attachment	O
to	O
O	O
-	O
acetylated	O
sialic	B-CHED
acids	I-CHED
(	O
O	O
-	O
Ac	O
-	O
Sias	O
).	O

In	O
one	O
lineage	O
of	O
murine	O
coronaviruses	O
,	O
however	O
,	O
HE	O
esterase	O
substrate	O
and	O
lectin	O
ligand	B-CHED
specificity	O
changed	O
dramatically	O
as	O
these	O
viruses	O
evolved	O
to	O
use	O
4	O
-	O
O	O
-	O
acetylated	O
Sias	O
instead	O
.	O

TITLE	O
:	O
Synthesis	O
and	O
antiviral	B-CHED
evaluation	O
of	O
7	O
-	O
O	O
-	O
arylmethylquercetin	O
derivatives	O
against	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SCV	O
)	O
and	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
).	O

In	O
this	O
study	O
,	O
we	O
prepared	O
a	O
series	O
of	O
the	O
7	O
-	O
O	O
-	O
arylmethylquercetin	O
derivatives	O
with	O
various	O
aromatic	O
substituents	O
and	O
evaluated	O
their	O
antiviral	B-CHED
activity	O
against	O
the	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
,	O
SCV	O
)	O
as	O
well	O
as	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
).	O

Consensus	O
of	O
the	O
Spanish	O
Society	O
of	O
Intensive	O
Care	O
Medicine	B-CHED
and	O
Coronary	O
Units	O
-	O
Spanish	O
Society	O
of	O
Parenteral	O
and	O
Enteral	O
Nutrition	O
(	O
SEMICYUC	O
-	O
SENPE	O
):	O
respiratory	O
failure	O
].	O

A	O
SARS	O
vaccine	O
was	O
produced	O
based	O
on	O
recombinant	O
native	O
full	O
-	O
length	O
Spike	O
-	O
protein	B-CHED
trimers	O
(	O
triSpike	O
)	O
and	O
efficient	O
establishment	O
of	O
a	O
vaccination	O
procedure	O
in	O
rodents	O
.	O

Antibody	O
-	O
mediated	O
infection	O
of	O
SARS	O
-	O
CoV	O
triggers	O
entry	O
into	O
human	O
haematopoietic	O
cells	O
via	O
an	O
FcγR	O
-	O
dependent	O
and	O
ACE2	O
-,	O
pH	O
-,	O
cysteine	B-CHED
-	O
protease	O
-	O
independent	O
pathways	O
.	O

The	O
dried	O
virus	O
on	O
smooth	O
surfaces	O
retained	O
its	O
viability	O
for	O
over	O
5	O
days	O
at	O
temperatures	O
of	O
22	O
-	O
25	O
°	O
C	O
and	O
relative	O
humidity	O
of	O
40	O
-	O
50	O
%,	O
that	O
is	O
,	O
typical	O
air	B-CHED
-	O
conditioned	O
environments	O
.	O

TITLE	O
:	O
Coronavirus	O
papain	O
-	O
like	O
proteases	O
negatively	O
regulate	O
antiviral	B-CHED
innate	O
immune	O
response	O
through	O
disruption	O
of	O
STING	O
-	O
mediated	O
signaling	O
.	O

In	O
contrast	O
,	O
mice	O
with	O
pDC	B-CHED
-	O
specific	O
loss	O
of	O
MHC	O
class	O
II	O
expression	O
supported	O
normal	O
CD4	O
(+)	O
T	O
-	O
cell	O
response	O
to	O
LCMV	O
.	O

In	O
6	O
cases	O
,	O
pulse	O
blood	O
oxygen	B-CHED
saturation	O
[	O
SpO	O
(	O
2	O
)]	O
was	O
elevated	O
(	O
0	O
.	O
45	O
-	O
0	O
.	O
92	O
up	O
to	O
0	O
.	O
94	O
-	O
1	O
.	O
00	O
),	O
PEEP	B-CHED
level	O
[	O
cm	O
H	O
(	O
2	O
)	O
O	O
,	O
1	O
cm	O
H	O
(	O
2	O
)	O
O	O
=	O
0	O
.	O
098	O
kPa	O
]	O
and	O
[	O
FiO	O
(	O
2	O
)]	O
were	O
lowered	O
[	O
PEEP	B-CHED
:	O
10	O
.	O
0	O
-	O
22	O
.	O
0	O
down	O
to	O
4	O
.	O
0	O
-	O
15	O
.	O
0	O
;	O
FiO	O
(	O
2	O
):	O
1	O
.	O
00	O
down	O
to	O
0	O
.	O
30	O
-	O
0	O
.	O
60	O
]	O
after	O
treatment	O
with	O
ECMO	O
.	O

Serum	O
sodium	B-CHED
ion	I-CHED
[	O
Na	O
(+),	O
mmol	O
/	O
L	O
:	O
140	O
.	O
61	O
±	O
6	O
.	O
69	O
vs	O
.	O
134	O
.	O
06	O
±	O
4	O
.	O
80	O
],	O
arterial	O
partial	O
pressure	O
of	O
oxygen	B-CHED
[	O
PO	O
(	O
2	O
),	O
mm	O
Hg	O
,	O
1	O
mm	O
Hg	O
=	O
0	O
.	O
133	O
kPa	O
:	O
84	O
.	O
41	O
±	O
30	O
.	O
58	O
vs	O
.	O
59	O
.	O
88	O
±	O
15	O
.	O
19	O
]	O
and	O
pulse	O
oxygen	B-CHED
saturation	O
[	O
SpO	O
(	O
2	O
):	O
0	O
.	O
91	O
±	O
0	O
.	O
08	O
vs	O
.	O
0	O
.	O
78	O
±	O
0	O
.	O
15	O
]	O
were	O
increased	O
(	O
P	O
<	O
0	O
.	O
05	O
or	O
P	O
<	O
0	O
.	O
01	O
).	O

TITLE	O
:	O
Nonstructural	O
proteins	B-CHED
7	O
and	O
8	O
of	O
feline	O
coronavirus	O
form	O
a	O
2	O
:	O
1	O
heterotrimer	O
that	O
exhibits	O
primer	O
-	O
independent	O
RNA	O
polymerase	O
activity	O
.	O

Parvovirus	O
-	O
infected	O
patients	O
also	O
showed	O
significantly	O
lower	O
leukocyte	O
and	O
erythrocyte	O
counts	O
as	O
well	O
as	O
hematocrit	O
,	O
total	O
protein	B-CHED
,	O
and	O
albumin	O
levels	O
compared	O
to	O
all	O
other	O
groups	O
.	O

Studies	O
have	O
established	O
that	O
a	O
relatively	O
uniform	O
spatial	O
distribution	O
of	O
UV	O
-	O
C	O
in	O
the	O
upper	O
room	O
can	O
effectively	O
cleanse	O
the	O
air	B-CHED
of	O
aerosolized	O
pathogens	O
.	O

Moreover	O
,	O
TGEV	O
infection	O
did	O
not	O
induce	O
significant	O
DNA	O
fragmentation	O
in	O
ammonium	B-CHED
chloride	I-CHED
(	O
NH	O
(	O
4	O
)	O
Cl	O
)	O
pretreated	O
PK	O
-	O
15	O
cells	O
or	O
cells	O
infected	O
with	O
UV	O
-	O
inactivated	O
TGEV	O
.	O

ABSTRACT	O
:	O
Positive	O
-	O
strand	O
RNA	O
virus	O
genomes	O
are	O
translated	O
into	O
polyproteins	O
that	O
are	O
processed	O
by	O
viral	O
proteases	O
to	O
yield	O
functional	O
intermediate	O
and	O
mature	O
proteins	B-CHED
.	O

Most	O
of	O
the	O
contigs	O
had	O
low	O
identities	O
to	O
known	O
viral	O
genomic	O
or	O
protein	B-CHED
sequences	O
,	O
suggesting	O
that	O
a	O
large	O
number	O
of	O
novel	O
and	O
genetically	O
diverse	O
insect	O
viruses	O
as	O
well	O
as	O
putative	O
mammalian	O
viruses	O
are	O
transmitted	O
by	O
bats	O
in	O
China	O
.	O

ABSTRACT	O
:	O
θ	O
-	O
Defensins	O
are	O
cyclic	O
octadecapeptides	O
found	O
in	O
nonhuman	O
primates	O
whose	O
broad	O
antiviral	B-CHED
spectrum	O
includes	O
HIV	O
-	O
1	O
,	O
HSV	O
-	O
1	O
,	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
,	O
and	O
influenza	O
A	O
virus	O
(	O
IAV	O
).	O

The	O
novel	O
peptides	B-CHED
also	O
allowed	O
for	O
systemic	O
substitution	O
of	O
key	O
residues	O
to	O
evaluate	O
the	O
role	O
of	O
charge	O
or	O
hydrophobicity	O
on	O
antiviral	B-CHED
activity	O
.	O

Some	O
of	O
these	O
also	O
had	O
strong	O
antibacterial	O
and	O
antifungal	B-CHED
activity	O
.	O

Purified	O
3CL	O
(	O
pro	B-CHED
)	O
was	O
used	O
for	O
inhibition	O
and	O
kinetic	O
assays	O
with	O
seven	O
flavonoid	B-CHED
compounds	O
.	O

However	O
,	O
this	O
case	O
also	O
suggests	O
that	O
the	O
early	O
administration	O
of	O
corticosteroid	B-CHED
therapy	O
as	O
immunomodulation	O
might	O
be	O
effective	O
in	O
selected	O
cases	O
,	O
and	O
that	O
cessation	O
of	O
such	O
therapy	O
during	O
the	O
early	O
phase	O
of	O
ARDS	O
may	O
cause	O
exacerbation	O
of	O
clinical	O
symptoms	O
.	O

This	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
impact	O
of	O
ECMO	O
and	O
CVVHDF	O
on	O
the	O
pharmacokinetics	O
of	O
oseltamivir	B-CHED
carboxylate	B-CHED
(	O
OC	O
)	O
in	O
critically	O
ill	O
patients	O
with	O
pandemic	O
(	O
H1N1	O
)	O
influenza	O
treated	O
with	O
oseltamivir	B-CHED
.	O

All	O
patients	O
were	O
treated	O
with	O
oseltamivir	B-CHED
,	O
and	O
1	O
received	O
in	O
addition	O
zanamivir	B-CHED
.	O

Further	O
observations	O
suggest	O
that	O
the	O
zinc	B-CHED
-	O
binding	O
domain	O
may	O
start	O
to	O
unfold	O
during	O
the	O
first	O
transition	O
.	O

Northern	O
blotting	O
confirmed	O
the	O
production	O
of	O
subgenomic	O
mRNAs	O
coding	O
for	O
the	O
HE	O
,	O
S	O
,	O
NS5a	O
,	O
E	O
,	O
M	O
,	O
and	O
N	O
proteins	B-CHED
.	O

Subgenomic	O
mRNA	B-CHED
analysis	O
revealed	O
a	O
transcription	O
regulatory	O
sequence	O
,	O
5	O
'-	O
UCUAAAC	O
-	O
3	O
'.	O

A	O
comparison	O
of	O
the	O
conserved	O
replicase	O
domains	O
showed	O
that	O
RbCoV	O
HKU14	O
possessed	O
<	O
90	O
%	O
amino	B-CHED
acid	I-CHED
identities	O
to	O
most	O
members	O
of	O
Betacoronavirus	O
1	O
in	O
ADP	B-CHED
-	O
ribose	B-CHED
1	O
″-	O
phosphatase	O
(	O
ADRP	O
)	O
and	O
nidoviral	O
uridylate	B-CHED
-	O
specific	O
endoribonuclease	O
(	O
NendoU	O
),	O
indicating	O
that	O
RbCoV	O
HKU14	O
should	O
represent	O
a	O
separate	O
species	O
.	O

Therefore	O
,	O
an	O
experiment	O
with	O
1	O
-	O
d	O
-	O
old	O
male	O
broilers	O
(	O
Ross	O
308	O
)	O
was	O
carried	O
out	O
to	O
examine	O
the	O
effects	O
of	O
feeding	O
DON	O
-	O
contaminated	O
low	O
-	O
protein	B-CHED
grower	O
diets	O
on	O
performance	O
,	O
serum	O
biochemical	O
parameters	O
,	O
lymphoid	O
organ	O
weight	O
,	O
and	O
antibody	O
titers	O
to	O
infectious	O
bronchitis	O
vaccination	O
in	O
serum	O
and	O
to	O
evaluate	O
the	O
effects	O
of	O
Mycofix	O
select	O
dietary	O
supplementation	O
in	O
either	O
the	O
presence	O
or	O
absence	O
of	O
DON	O
in	O
broilers	O
.	O

Moreover	O
,	O
in	O
birds	O
fed	O
contaminated	O
feeds	O
,	O
there	O
was	O
a	O
tendency	O
to	O
reduce	O
triglycerides	B-CHED
in	O
the	O
plasma	O
(	O
P	O
=	O
0	O
.	O
090	O
),	O
suggesting	O
that	O
DON	O
in	O
the	O
diets	O
affected	O
protein	B-CHED
and	O
lipid	B-CHED
metabolism	O
in	O
broiler	O
chickens	O
.	O

Taken	O
together	O
,	O
our	O
results	O
indicate	O
that	O
the	O
one	O
-	O
step	O
multiplex	O
RT	O
-	O
PCR	O
developed	O
here	O
for	O
the	O
detection	O
of	O
GAR	B-CHED
,	O
GBR	O
,	O
GCR	O
,	O
BCV	O
,	O
and	O
BToV	O
can	O
be	O
expected	O
to	O
be	O
a	O
useful	O
tool	O
for	O
the	O
rapid	O
and	O
cost	O
-	O
effective	O
diagnosis	O
and	O
surveillance	O
of	O
viral	O
diarrhea	O
in	O
adult	O
cattle	O
.	O

Dissection	O
of	O
the	O
underlying	O
immunopathological	O
mechanisms	O
revealed	O
the	O
elaborate	O
Treg	O
-	O
dependent	O
regulation	O
of	O
self	O
-	O
reactive	O
CD4	O
(+)	O
T	O
cell	O
proliferation	O
within	O
the	O
CNS	B-CHED
-	O
draining	O
lymph	O
node	O
and	O
downtuning	O
of	O
CXCR3	O
expression	O
on	O
T	O
cells	O
.	O

Hemostasis	O
is	O
obtained	O
after	O
only	O
one	O
to	O
two	O
small	O
doses	O
of	O
FVIIa	O
(	O
50	O
μg	O
/	O
kg	O
body	O
weight	O
per	O
dose	O
)	O
and	O
after	O
hemostasis	O
the	O
oxygen	B-CHED
transport	O
quickly	O
improves	O
.	O

The	O
range	O
of	O
PaO	B-CHED
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
was	O
42	O
-	O
69	O
.	O
9	O
,	O
alveolar	O
-	O
arterial	O
oxygen	B-CHED
gradient	O
(	O
AaDO	O
(	O
2	O
))	O
602	O
-	O
645	O
,	O
and	O
oxygenation	O
index	O
(	O
OI	O
)	O
27	O
.	O
4	O
-	O
68	O
.	O

These	O
results	O
suggest	O
that	O
multiple	O
cysteine	B-CHED
as	O
well	O
as	O
charged	O
residues	O
concurrently	O
improves	O
the	O
membrane	O
-	O
associated	O
functions	O
of	O
S	O
protein	B-CHED
in	O
viral	O
replication	O
and	O
cytopathogenesis	O
.	O

ABSTRACT	O
:	O
To	O
explore	O
the	O
mechanisms	O
of	O
a	O
novel	O
potassium	B-CHED
channel	O
gene	O
named	O
KCTD9	O
(	O
potassium	B-CHED
channel	O
tetramerization	O
domain	O
containing	O
9	O
)	O
in	O
model	O
of	O
fulminant	O
viral	O
hepatitis	O
induced	O
by	O
murine	O
hepatitis	O
virus	O
3	O
(	O
MHV	O
-	O
3	O
).	O

Patients	O
with	O
pneumonia	O
,	O
when	O
compared	O
with	O
patients	O
without	O
pneumonia	O
,	O
were	O
equally	O
likely	O
to	O
receive	O
influenza	O
antiviral	B-CHED
agents	I-CHED
(	O
78	O
%	O
vs	O
79	O
%)	O
but	O
less	O
likely	O
to	O
receive	O
antiviral	B-CHED
agents	I-CHED
within	O
≤	O
2	O
days	O
of	O
illness	O
onset	O
(	O
28	O
%	O
vs	O
50	O
%;	O
P	O
<	O
.	O
0001	O
).	O

ABSTRACT	O
:	O
Coronaviruses	O
induce	O
in	O
infected	O
cells	O
the	O
formation	O
of	O
replicative	O
structures	O
,	O
consisting	O
of	O
double	O
-	O
membrane	O
vesicles	O
(	O
DMVs	O
)	O
and	O
convoluted	O
membranes	O
,	O
where	O
viral	O
RNA	O
synthesis	O
supposedly	O
takes	O
place	O
and	O
to	O
which	O
the	O
nonstructural	O
proteins	B-CHED
(	O
nsp	O
'	O
s	O
)	O
localize	O
.	O

These	O
results	O
indicate	O
that	O
exogenous	O
NPCs	O
contribute	O
to	O
improved	O
clinical	O
and	O
histological	O
outcome	O
and	O
this	O
is	O
associated	O
with	O
remyelination	O
by	O
this	O
donor	B-CHED
population	O
.	O

Five	O
other	O
patients	O
developed	O
late	O
respiratory	O
failure	O
after	O
24	O
hours	O
of	O
ingestion	O
,	O
and	O
all	O
of	O
them	O
showed	O
progressive	O
RNS	B-CHED
changes	O
indicating	O
severe	O
IMS	O
prior	O
to	O
intubation	O
.	O

Five	O
other	O
patients	O
developed	O
late	O
respiratory	O
failure	O
after	O
24	O
hours	O
of	O
ingestion	O
,	O
and	O
all	O
of	O
them	O
showed	O
progressive	O
RNS	B-CHED
changes	O
indicating	O
severe	O
IMS	O
prior	O
to	O
intubation	O
.	O

CONCLUSIONS	O
:	O
The	O
normal	O
RNS	B-CHED
in	O
all	O
patients	O
developing	O
early	O
respiratory	O
failure	O
suggests	O
that	O
it	O
is	O
due	O
to	O
a	O
central	O
nervous	O
system	O
(	O
CNS	B-CHED
)	O
and	O
muscarinic	O
effect	O
.	O

TITLE	O
:	O
Synthesis	O
,	O
structure	O
-	O
activity	O
relationships	O
and	O
biological	O
evaluation	O
of	O
caudatin	O
derivatives	O
as	O
novel	O
anti	B-CHED
-	I-CHED
hepatitis	I-CHED
B	I-CHED
virus	I-CHED
agents	I-CHED
.	O

TITLE	O
:	O
Effect	O
of	O
anti	B-CHED
-	I-CHED
inflammatory	I-CHED
drugs	I-CHED
on	O
colibacillosis	O
lesions	O
in	O
broilers	O
after	O
Infectious	O
Bronchitis	O
Virus	O
and	O
subsequent	O
Escherichia	O
coli	O
infection	O
.	O

The	O
results	O
demonstrate	O
that	O
(	O
1	O
)	O
STAT3	O
is	O
activated	O
by	O
P	O
.	O
berghei	O
ANKA	O
(	O
PBA	B-CHED
)	O
infection	O
in	O
vivo	O
and	O
Heme	B-CHED
in	O
vitro	O
.	O

Our	O
data	O
indicate	O
that	O
Heme	B-CHED
/	O
HO	O
-	O
1	O
,	O
CXCL10	O
/	O
CXCR3	O
and	O
STAT3	O
molecules	O
as	O
well	O
as	O
related	O
signaling	O
pathways	O
play	O
very	O
important	O
roles	O
in	O
the	O
pathogenesis	O
of	O
severe	O
malaria	O
.	O

CONCLUSIONS	O
:	O
Our	O
data	O
indicate	O
that	O
Heme	B-CHED
/	O
HO	O
-	O
1	O
,	O
CXCL10	O
/	O
CXCR3	O
and	O
STAT3	O
molecules	O
as	O
well	O
as	O
related	O
signaling	O
pathways	O
play	O
very	O
important	O
roles	O
in	O
the	O
pathogenesis	O
of	O
severe	O
malaria	O
.	O

Univariate	O
analysis	O
revealed	O
no	O
significant	O
pre	O
-	O
ECMO	O
risk	O
factor	O
for	O
treatment	O
failure	O
but	O
C	O
-	O
reactive	O
protein	B-CHED
concentration	O
at	O
the	O
time	O
of	O
ECMO	O
differed	O
significantly	O
among	O
patients	O
who	O
did	O
versus	O
did	O
not	O
survive	O
after	O
ECMO	O
.	O

TITLE	O
:	O
Simultaneous	O
treatment	O
of	O
human	O
bronchial	O
epithelial	O
cells	O
with	O
serine	B-CHED
and	O
cysteine	B-CHED
protease	I-CHED
inhibitors	I-CHED
prevents	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
entry	O
.	O

ABSTRACT	O
:	O
The	O
type	O
II	O
transmembrane	O
protease	O
TMPRSS2	O
activates	O
the	O
spike	O
(	O
S	O
)	O
protein	B-CHED
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
on	O
the	O
cell	O
surface	O
following	O
receptor	O
binding	O
during	O
viral	O
entry	O
into	O
cells	O
.	O

In	O
the	O
absence	O
of	O
TMPRSS2	O
,	O
SARS	O
-	O
CoV	O
achieves	O
cell	O
entry	O
via	O
an	O
endosomal	O
pathway	O
in	O
which	O
cathepsin	O
L	O
may	O
play	O
an	O
important	O
role	O
,	O
i	O
.	O
e	O
.,	O
the	O
activation	O
of	O
spike	O
protein	B-CHED
fusogenicity	O
.	O

This	O
study	O
shows	O
that	O
a	O
commercial	O
serine	B-CHED
protease	I-CHED
inhibitor	I-CHED
(	O
camostat	O
)	O
partially	O
blocked	O
infection	O
by	O
SARS	O
-	O
CoV	O
and	O
human	O
coronavirus	O
NL63	O
(	O
HCoV	O
-	O
NL63	O
)	O
in	O
HeLa	O
cells	O
expressing	O
the	O
receptor	O
angiotensin	B-CHED
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
and	O
TMPRSS2	O
.	O

The	O
PHE	B-CHED
-	O
CoV	O
DNA	O
vaccine	O
was	O
constructed	O
by	O
subcloning	O
the	O
S1	O
gene	O
of	O
PHE	B-CHED
-	O
CoV	O
into	O
the	O
pVAX1	O
vector	O
to	O
create	O
the	O
recombinant	O
plasmid	O
pV	O
-	O
S1	O
.	O

Our	O
results	O
showed	O
that	O
the	O
inactivated	O
PHE	B-CHED
-	O
CoV	O
vaccine	O
(	O
IPV	O
)	O
elicited	O
a	O
high	O
level	O
of	O
humoral	O
immunity	O
,	O
resulting	O
in	O
good	O
protection	O
efficacy	O
against	O
PHE	B-CHED
-	O
CoV	O
challenge	O
.	O

The	O
structure	O
-	O
activity	O
relationships	O
(	O
SARs	O
)	O
of	O
GA	O
derivatives	O
were	O
discussed	O
for	O
exploring	O
novel	O
anti	B-CHED
-	I-CHED
HBV	I-CHED
agents	I-CHED
.	O

A	O
new	O
strain	O
of	O
Enterococcus	O
faecium	O
,	O
a	O
non	O
pathogenic	O
lactic	B-CHED
acid	I-CHED
bacteria	O
(	O
LAB	O
)	O
with	O
strong	O
cell	O
adhesion	O
ability	O
,	O
was	O
identified	O
and	O
used	O
as	O
a	O
vaccine	O
vector	O
to	O
deliver	O
two	O
model	O
antigens	B-CHED
.	O

Furthermore	O
,	O
ARV	O
σC	O
,	O
a	O
strong	O
immunogen	B-CHED
of	O
ARV	O
,	O
may	O
be	O
able	O
to	O
serve	O
as	O
an	O
immunoenhancer	O
for	O
other	O
vaccines	O
,	O
especially	O
avian	O
vaccines	O
.	O

A	O
new	O
scorpion	O
venom	O
peptide	B-CHED
derivative	O
Kn2	O
-	O
7	O
was	O
identified	O
as	O
the	O
most	O
potent	O
anti	O
-	O
HIV	O
-	O
1	O
peptide	B-CHED
by	O
screening	O
assays	O
with	O
an	O
EC	O
(	O
50	O
)	O
value	O
of	O
2	O
.	O
76	O
µg	O
/	O
ml	O
(	O
1	O
.	O
65	O
µM	O
)	O
and	O
showed	O
low	O
cytotoxicity	O
to	O
host	O
cells	O
with	O
a	O
selective	O
index	O
(	O
SI	O
)	O
of	O
13	O
.	O
93	O
.	O

Finally	O
,	O
the	O
functional	O
consequences	O
of	O
palmitoylation	O
are	O
discussed	O
regarding	O
binding	O
of	O
proteins	B-CHED
to	O
membranes	O
or	O
membrane	O
rafts	O
,	O
entry	O
of	O
enveloped	O
viruses	O
into	O
target	O
cells	O
by	O
spike	O
-	O
mediated	O
membrane	O
fusion	O
as	O
well	O
as	O
assembly	O
and	O
release	O
of	O
virus	O
particles	O
from	O
infected	O
cells	O
.	O

ABSTRACT	O
:	O
The	O
type	O
II	O
transmembrane	O
serine	B-CHED
proteases	O
TMPRSS2	O
and	O
HAT	B-CHED
activate	O
influenza	O
viruses	O
and	O
the	O
SARS	O
-	O
coronavirus	O
(	O
TMPRSS2	O
)	O
in	O
cell	O
culture	O
and	O
may	O
play	O
an	O
important	O
role	O
in	O
viral	O
spread	O
and	O
pathogenesis	O
in	O
the	O
infected	O
host	O
.	O

The	O
outcome	O
of	O
interest	O
was	O
risk	O
of	O
ARI	B-CHED
transmission	O
.	O

Furthermore	O
,	O
the	O
membrane	O
topology	O
of	O
the	O
E	O
protein	B-CHED
is	O
of	O
considerable	O
debate	O
,	O
and	O
the	O
protein	B-CHED
may	O
adopt	O
more	O
than	O
one	O
topology	O
during	O
infection	O
.	O

We	O
previously	O
showed	O
that	O
the	O
HD	O
of	O
the	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
E	O
protein	B-CHED
is	O
required	O
for	O
the	O
efficient	O
release	O
of	O
infectious	O
virus	O
,	O
an	O
activity	O
that	O
correlated	O
with	O
disruption	O
of	O
the	O
secretory	O
pathway	O
.	O

ABSTRACT	O
:	O
For	O
antiviral	B-CHED
screenings	O
purposes	O
,	O
infection	O
of	O
cell	O
cultures	O
with	O
the	O
virus	O
under	O
study	O
,	O
should	O
ideally	O
result	O
in	O
the	O
induction	O
,	O
within	O
just	O
a	O
few	O
days	O
,	O
of	O
(	O
nearly	O
)	O
complete	O
CPE	O
and	O
allow	O
the	O
calculation	O
of	O
acceptable	O
Z	O
'	O
factors	O
(>	O
0	O
.	O
5	O
).	O

The	O
human	O
Corona	B-CHED
virus	O
NL63	O
(	O
HCoV	O
-	O
NL63	O
)	O
causes	O
only	O
limited	O
CPE	O
on	O
different	O
cell	O
lines	O
(	O
Schildgen	O
et	O
al	O
.,	O
2006	O
).	O

Cultures	O
were	O
subsequently	O
incubated	O
for	O
5	O
days	O
at	O
35	O
°	O
C	O
after	O
which	O
20μL	O
of	O
the	O
peptide	B-CHED
solution	O
was	O
added	O
.	O

However	O
,	O
there	O
are	O
no	O
natural	O
or	O
synthetic	O
compounds	O
currently	O
available	O
that	O
can	O
inhibit	O
SARS	O
-	O
CoV	O
.	O
We	O
examined	O
the	O
inhibitory	O
effects	O
of	O
64	O
purified	O
natural	O
compounds	O
against	O
the	O
activity	O
of	O
SARS	O
helicase	O
,	O
nsP13	O
,	O
and	O
the	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
helicase	O
,	O
NS3h	O
,	O
by	O
conducting	O
fluorescence	O
resonance	O
energy	O
transfer	O
(	O
FRET	O
)-	O
based	O
double	O
-	O
strand	O
(	O
ds	O
)	O
DNA	O
unwinding	O
assay	O
or	O
by	O
using	O
a	O
colorimetry	O
-	O
based	O
ATP	B-CHED
hydrolysis	O
assay	O
.	O

TITLE	O
:	O
[	O
Present	O
state	O
of	O
in	O
vitro	O
and	O
in	O
vivo	O
studies	O
on	O
efficacy	O
of	O
medical	O
nonspecific	O
protective	B-CHED
agents	I-CHED
with	O
respect	O
to	O
genotype	O
IV	O
coronavirus	O
causing	O
severe	O
acute	O
respiratory	O
syndrome	O
].	O

ABSTRACT	O
:	O
The	O
coronavirus	O
E	O
protein	B-CHED
is	O
a	O
small	O
membrane	O
protein	B-CHED
that	O
has	O
an	O
important	O
role	O
in	O
the	O
assembly	O
of	O
virions	O
.	O

Our	O
identification	O
of	O
severe	O
respiratory	O
illness	O
due	O
to	O
adenovirus	O
,	O
especially	O
type	O
11	O
may	O
highlight	O
the	O
need	O
for	O
rapid	O
diagnosis	O
and	O
improved	O
surveillance	O
,	O
which	O
may	O
assist	O
with	O
targeted	O
development	O
of	O
antiviral	B-CHED
agents	I-CHED
or	O
type	O
-	O
specific	O
vaccines	O
.	O

We	O
previously	O
reported	O
that	O
the	O
Onchocerca	O
volvulus	O
recombinant	O
protein	B-CHED
rOv	O
-	O
ASP	B-CHED
-	O
1	O
can	O
induce	O
activation	O
and	O
maturation	O
of	O
naïve	O
human	O
DCs	O
and	O
therefore	O
could	O
be	O
used	O
as	O
an	O
innate	O
adjuvant	B-CHED
to	O
promote	O
balanced	O
Th1	O
and	O
Th2	O
responses	O
to	O
bystander	O
vaccine	O
antigens	B-CHED
in	O
mice	O
.	O

With	O
a	O
few	O
vaccine	O
antigens	B-CHED
,	O
it	O
also	O
promoted	O
a	O
Th1	O
-	O
biased	O
response	O
based	O
on	O
pronounced	O
induction	O
of	O
Th1	O
-	O
associated	O
IgG2a	O
and	O
IgG2b	O
antibody	O
responses	O
and	O
the	O
upregulated	O
production	O
of	O
Th1	O
cytokines	O
,	O
including	O
IL	O
-	O
2	O
,	O
IFN	O
-	O
γ	O
,	O
TNF	O
-	O
α	O
and	O
IL	O
-	O
6	O
.	O

At	O
a	O
concentration	O
of	O
0	O
.	O
05	O
μg	O
mL	O
(-	O
1	O
),	O
(-)-	O
catechin	B-CHED
gallate	B-CHED
and	O
(-)-	O
gallocatechin	B-CHED
gallate	B-CHED
showed	O
more	O
than	O
40	O
%	O
inhibition	O
activity	O
on	O
a	O
nanoparticle	B-CHED
-	O
based	O
RNA	O
oligonucleotide	B-CHED
biochip	O
system	O
.	O

All	O
Cuban	B-CHED
bovine	O
coronavirus	O
sequences	O
were	O
located	O
in	O
a	O
single	O
cluster	O
supported	O
by	O
100	O
%	O
bootstrap	O
and	O
1	O
.	O
00	O
posterior	O
probability	O
values	O
.	O

In	O
contrast	O
,	O
di	O
-,	O
tri	O
-,	O
and	O
longer	O
unpaired	O
ribonucleotide	B-CHED
stretches	O
,	O
as	O
well	O
as	O
3	O
'-	O
modified	O
RNAs	O
,	O
resist	O
nsp10	O
/	O
nsp14	O
-	O
mediated	O
excision	O
.	O

This	O
effect	O
is	O
due	O
to	O
rapid	O
,	O
TRAIL	O
(	O
TNF	O
-	O
related	O
apoptosis	O
-	O
inducing	O
ligand	B-CHED
)-	O
dependent	O
apoptosis	O
of	O
MHV	O
-	O
3	O
-	O
infected	O
macrophages	O
in	O
BTLA	O
-/-	O
mice	O
.	O

The	O
interaction	O
between	O
nonstructural	O
protein	B-CHED
(	O
nsp	O
)	O
10	O
and	O
nsp16	O
has	O
been	O
demonstrated	O
and	O
the	O
crystal	O
structure	O
of	O
SARS	O
-	O
CoV	O
nsp16	O
/	O
10	O
complex	O
has	O
been	O
revealed	O
.	O

ABSTRACT	O
:	O
A	O
85	O
-	O
year	O
-	O
old	O
patient	O
,	O
initially	O
treated	O
for	O
aspiration	O
pneumonia	O
on	O
the	O
intensive	O
care	O
unit	O
acutely	O
complained	O
again	O
of	O
nausea	O
which	O
was	O
immediately	O
treated	O
by	O
an	O
i	O
.	O
v	O
.	O
bolus	O
of	O
metoclopramide	B-CHED
(	O
MCP	B-CHED
).	O

CONCLUSIONS	O
:	O
The	O
development	O
of	O
a	O
severe	O
and	O
acute	O
methemoglobinemia	O
following	O
the	O
administration	O
of	O
MCP	B-CHED
is	O
described	O
in	O
this	O
case	O
report	O
.	O

TITLE	O
:	O
Design	O
,	O
synthesis	O
,	O
antiviral	B-CHED
activity	O
,	O
and	O
SARs	O
of	O
14	O
-	O
aminophenanthroindolizidines	O
.	O

Sufficient	O
albumen	O
by	O
vein	O
and	O
steroid	B-CHED
should	O
be	O
administered	O
for	O
treatment	O
against	O
nephropathy	O
and	O
for	O
control	O
of	O
infection	O
.	O

ABSTRACT	O
:	O
Avian	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
is	O
a	O
member	O
of	O
the	O
group	O
III	O
coronaviruses	O
,	O
which	O
differ	O
from	O
the	O
other	O
groups	O
of	O
coronaviruses	O
in	O
that	O
they	O
do	O
not	O
encode	O
the	O
essential	O
pathogenic	O
factor	O
nonstructural	O
protein	B-CHED
1	O
(	O
nsp1	O
)	O
and	O
instead	O
start	O
with	O
nsp2	O
.	O

Air	B-CHED
transportation	O
for	O
those	O
with	O
severe	O
injuries	O
and	O
diseases	O
played	O
a	O
crucial	O
role	O
in	O
decreasing	O
the	O
mortality	O
and	O
morbidity	O
.	O

As	O
expected	O
,	O
antigen	B-CHED
affinity	O
was	O
shown	O
to	O
correlate	O
directly	O
with	O
neutralization	O
potency	O
toward	O
the	O
icUrbani	O
strain	O
of	O
SARS	O
-	O
CoV	O
.	O
Additionally	O
,	O
the	O
highest	O
-	O
affinity	O
antibody	O
fragment	O
displayed	O
10	O
-	O
fold	O
-	O
increased	O
broad	O
neutralization	O
in	O
vitro	O
and	O
completely	O
protected	O
against	O
several	O
SARS	O
-	O
CoV	O
strains	O
containing	O
substitutions	O
associated	O
with	O
antibody	O
escape	O
.	O

Escape	O
from	O
the	O
highest	O
-	O
affinity	O
variant	O
required	O
reduced	O
selective	O
pressure	O
and	O
multiple	O
substitutions	O
in	O
the	O
binding	O
epitope	B-CHED
.	O

ABSTRACT	O
:	O
In	O
this	O
study	O
,	O
the	O
Japanese	O
strain	O
of	O
type	O
I	O
feline	O
infectious	O
peritonitis	O
virus	O
(	O
FIPV	O
),	O
C3663	O
,	O
was	O
found	O
to	O
have	O
a	O
large	O
deletion	O
of	O
735	O
bp	O
within	O
the	O
gene	O
encoding	O
the	O
spike	O
(	O
S	O
)	O
protein	B-CHED
,	O
with	O
a	O
deduced	O
loss	O
of	O
245	O
aa	O
of	O
the	O
N	O
-	O
terminal	O
region	O
of	O
the	O
S	O
protein	B-CHED
.	O

TITLE	O
:	O
DNA	O
block	B-CHED
copolymers	I-CHED
:	O
functional	O
materials	O
for	O
nanoscience	O
and	O
biomedicine	O
.	O

ABSTRACT	O
:	O
We	O
live	O
in	O
a	O
world	O
full	O
of	O
synthetic	O
materials	O
,	O
and	O
the	O
development	O
of	O
new	O
technologies	O
builds	O
on	O
the	O
design	O
and	O
synthesis	O
of	O
new	O
chemical	O
structures	O
,	O
such	O
as	O
polymers	B-CHED
.	O

One	O
strategy	O
for	O
altering	O
polymer	B-CHED
properties	O
is	O
to	O
combine	O
different	O
polymer	B-CHED
segments	O
within	O
one	O
polymer	B-CHED
,	O
known	O
as	O
block	B-CHED
copolymers	I-CHED
.	O

Furthermore	O
,	O
the	O
appropriate	O
selection	O
of	O
DNA	O
sequence	O
and	O
organic	O
polymer	B-CHED
gives	O
control	O
over	O
the	O
material	O
properties	O
and	O
their	O
self	O
-	O
assembly	O
into	O
supramolecular	O
structures	O
.	O

Susceptibility	O
to	O
vectors	O
carrying	O
SARS	O
coronavirus	O
S	O
or	O
VSV	O
-	O
G	O
glycoproteins	B-CHED
suggests	O
that	O
endocytic	O
and	O
processing	O
pathways	O
utilized	O
by	O
other	O
viruses	O
are	O
intact	O
in	O
these	O
cells	O
.	O

We	O
identified	O
and	O
validated	O
a	O
compound	O
(	O
SSYA10	O
-	O
001	O
)	O
that	O
specifically	O
blocks	O
the	O
double	O
-	O
stranded	O
RNA	O
(	O
dsRNA	B-CHED
)	O
and	O
dsDNA	O
unwinding	O
activities	O
of	O
nsp13	O
,	O
with	O
50	O
%	O
inhibitory	O
concentrations	O
(	O
IC	O
(	O
50	O
)	O
s	O
)	O
of	O
5	O
.	O
70	O
and	O
5	O
.	O
30	O
μM	O
,	O
respectively	O
.	O

His	O
rapid	O
course	O
was	O
complicated	O
by	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
status	O
epilepticus	O
and	O
disseminated	O
intravascular	O
coagulation	O
(	O
DIC	B-CHED
).	O

Compared	O
with	O
microglia	O
,	O
oligodendroglia	O
were	O
characterized	O
by	O
low	O
basal	O
expression	O
of	O
mRNA	B-CHED
encoding	O
viral	O
RNA	O
sensing	O
pattern	O
recognition	O
receptors	O
(	O
PRRs	O
),	O
IFNα	O
/	O
β	O
receptor	O
chains	O
,	O
interferon	O
sensitive	O
genes	O
(	O
ISG	O
),	O
as	O
well	O
as	O
kinases	O
and	O
transcription	O
factors	O
critical	O
in	O
IFNα	O
/	O
β	O
signaling	O
.	O

The	O
limited	O
antiviral	B-CHED
response	O
by	O
oligodendroglia	O
was	O
associated	O
with	O
a	O
high	O
threshold	O
for	O
upregulation	O
of	O
Ikkε	O
and	O
Irf7	O
transcripts	O
,	O
both	O
central	O
to	O
amplifying	O
IFNα	O
/	O
β	O
responses	O
.	O

A	O
1038	O
-	O
nucleotide	B-CHED
fragment	O
was	O
PCR	O
amplified	O
and	O
directly	O
sequenced	O
.	O

We	O
demonstrate	O
that	O
activation	O
of	O
TLR3	O
with	O
the	O
synthetic	O
ligand	B-CHED
poly	O
I	O
:	O
C	O
mediates	O
antiviral	B-CHED
immunity	O
that	O
diminishes	O
(	O
MHV	O
-	O
A59	O
)	O
or	O
suppresses	O
(	O
MHV	O
-	O
JHM	O
,	O
MHV	O
-	O
3	O
)	O
virus	O
production	O
in	O
macrophages	O
.	O

ABSTRACT	O
:	O
The	O
experience	O
with	O
high	O
-	O
flow	O
nasal	O
cannula	O
(	O
HFNC	O
)	O
oxygen	B-CHED
therapy	O
in	O
severe	O
acute	O
respiratory	O
infection	O
(	O
SARI	O
)	O
is	O
limited	O
.	O

Twenty	O
were	O
unable	O
to	O
maintain	O
pulse	O
oxymetry	O
more	O
than	O
92	O
%	O
with	O
conventional	O
oxygen	B-CHED
administration	O
and	O
required	O
HFNC	O
O	O
(	O
2	O
)	O
therapy	O
,	O
which	O
was	O
successful	O
in	O
9	O
(	O
45	O
%).	O

In	O
addition	O
to	O
these	O
two	O
classes	O
,	O
other	O
RT	O
inhibitors	B-CHED
(	O
RTIs	O
)	O
that	O
target	O
RT	O
by	O
distinct	O
mechanisms	O
have	O
been	O
identified	O
and	O
are	O
currently	O
under	O
development	O
.	O

The	O
clinical	O
outcome	O
measures	O
included	O
the	O
mortality	O
rate	O
at	O
28th	O
day	O
,	O
respiratory	O
index	O
(	O
FiO2	O
/	O
PO2	O
),	O
dynamic	O
lung	O
compliance	O
(	O
Cdyn	O
),	O
arterial	O
partial	O
pressure	O
of	O
oxygen	B-CHED
(	O
PaO2	O
),	O
arterial	O
partial	O
pressure	O
of	O
carbon	B-CHED
dioxide	I-CHED
(	O
PaCO2	O
),	O
mechanical	O
ventilation	O
parameters	O
,	O
vasoactive	O
drug	O
dose	O
and	O
lung	O
X	O
-	O
ray	O
changes	O
.	O

In	O
common	O
to	O
other	O
viroporins	O
,	O
coronavirus	O
envelope	O
proteins	B-CHED
increase	O
membrane	O
permeability	O
to	O
ions	B-CHED
.	O

To	O
further	O
analyze	O
this	O
functions	O
,	O
the	O
interaction	O
of	O
SARS	O
-	O
CoV	O
protein	B-CHED
6	O
with	O
other	O
viral	O
and	O
/	O
or	O
cellular	O
factors	O
has	O
been	O
analyzed	O
during	O
SARS	O
-	O
CoV	O
infective	O
cycle	O
.	O

ABSTRACT	O
:	O
Coronavirus	O
(	O
CoV	O
)	O
envelope	O
(	O
E	O
)	O
protein	B-CHED
ion	O
channel	O
activity	O
was	O
determined	O
in	O
channels	O
formed	O
in	O
planar	O
lipid	B-CHED
bilayers	O
by	O
peptides	B-CHED
representing	O
either	O
the	O
transmembrane	O
domain	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
CoV	O
(	O
SARS	O
-	O
CoV	O
)	O
E	O
protein	B-CHED
,	O
or	O
the	O
full	O
-	O
length	O
E	O
protein	B-CHED
.	O

E	O
protein	B-CHED
derived	O
channels	O
showed	O
no	O
cation	B-CHED
preference	O
in	O
non	O
-	O
charged	O
lipid	B-CHED
membranes	O
,	O
whereas	O
they	O
behaved	O
as	O
pores	O
with	O
mild	O
cation	B-CHED
selectivity	O
in	O
negatively	O
-	O
charged	O
lipid	B-CHED
membranes	O
.	O

Ten	O
different	O
amino	B-CHED
acid	I-CHED
sequences	O
were	O
found	O
in	O
the	O
NTD	O
of	O
the	O
spike	O
protein	B-CHED
among	O
these	O
NL63	O
strains	O
and	O
the	O
75	O
partial	O
published	O
sequences	O
of	O
NTDs	O
from	O
strains	O
found	O
at	O
different	O
times	O
throughout	O
the	O
world	O
.	O

A	O
total	O
of	O
172	O
infants	O
(	O
84	O
males	O
and	O
88	O
females	O
)	O
had	O
retinal	B-CHED
evaluation	O
by	O
indirect	O
ophthalmoscopy	O
from	O
the	O
fourth	O
postnatal	O
week	O
and	O
followed	O
up	O
periodically	O
.	O

However	O
,	O
an	O
insignificant	O
relationship	O
was	O
found	O
between	O
the	O
occurrence	O
of	O
ROP	O
and	O
sex	O
,	O
mode	O
of	O
delivery	O
,	O
birth	O
weight	O
,	O
respiratory	O
distress	O
syndrome	O
,	O
patent	O
ductus	O
arteriosus	O
,	O
intraventricular	O
hemorrhage	O
,	O
hypotension	O
,	O
phototherapy	O
,	O
duration	O
of	O
oxygen	B-CHED
therapy	O
,	O
mechanical	O
ventilation	O
,	O
and	O
CPAP	O
(	O
all	O
P	O
>	O
0	O
.	O
05	O
).	O

There	O
were	O
no	O
differences	O
in	O
venous	O
oxygen	B-CHED
saturation	O
and	O
pulmonary	O
vascular	O
resistance	O
between	O
the	O
groups	O
.	O

Inspiratory	O
P	O
(	O
el	O
)/	O
V	O
curves	O
recorded	O
from	O
PEEP	B-CHED
or	O
,	O
even	O
better	O
,	O
expiratory	O
P	O
(	O
el	O
)/	O
V	O
curves	O
allow	O
monitoring	O
in	O
ARDS	O
.	O

There	O
were	O
no	O
differences	O
in	O
venous	O
oxygen	B-CHED
saturation	O
and	O
pulmonary	O
vascular	O
resistance	O
between	O
the	O
groups	O
.	O

However	O
,	O
the	O
mechanism	O
by	O
which	O
SCoV	O
viral	O
proteins	B-CHED
are	O
efficiently	O
produced	O
in	O
infected	O
cells	O
in	O
which	O
host	O
protein	B-CHED
synthesis	O
is	O
impaired	O
by	O
nsp1	O
is	O
unknown	O
.	O

Luciferase	O
activities	O
were	O
significantly	O
suppressed	O
in	O
cells	O
expressing	O
nsp1	O
together	O
with	O
the	O
mRNA	B-CHED
carrying	O
a	O
luciferase	O
gene	O
,	O
while	O
nsp1	O
failed	O
to	O
suppress	O
luciferase	O
activities	O
of	O
the	O
mRNA	B-CHED
flanked	O
by	O
the	O
5	O
'	O
UTR	O
of	O
SCoV	O
.	O
An	O
RNA	O
-	O
protein	B-CHED
binding	O
assay	O
and	O
RNA	O
decay	O
assay	O
revealed	O
that	O
nsp1	O
bound	O
to	O
stem	O
-	O
loop	O
1	O
(	O
SL1	O
)	O
in	O
the	O
5	O
'	O
UTR	O
of	O
SCoV	O
RNA	O
and	O
that	O
the	O
specific	O
interaction	O
with	O
nsp1	O
stabilized	O
the	O
mRNA	B-CHED
carrying	O
SL1	O
.	O

We	O
obtained	O
four	O
hybridoma	O
cell	O
lines	O
secreting	O
mAbs	O
against	O
recombinant	O
N	O
protein	B-CHED
.	O

The	O
best	O
antimalarial	B-CHED
treatment	O
of	O
severe	O
malaria	O
is	O
IV	O
artesunate	B-CHED
.	O

Our	O
results	O
provide	O
a	O
compelling	O
view	O
on	O
CoV	O
cell	O
entry	O
and	O
immune	O
neutralization	O
,	O
and	O
may	O
aid	O
the	O
design	O
of	O
antivirals	B-CHED
or	O
CoV	O
vaccines	O
.	O

The	O
mice	O
were	O
additionally	O
administered	O
exogenous	O
artificial	O
surfactant	B-CHED
in	O
the	O
presence	O
or	O
absence	O
of	O
a	O
new	O
NAI	B-CHED
,	O
laninamivir	O
octanoate	B-CHED
.	O

ABSTRACT	O
:	O
In	O
the	O
search	O
for	O
anti	O
-	O
SARS	O
-	O
CoV	O
,	O
tanshinones	O
derived	O
from	O
Salvia	O
miltiorrhiza	O
were	O
found	O
to	O
be	O
specific	O
and	O
selective	O
inhibitors	B-CHED
for	O
the	O
SARS	O
-	O
CoV	O
3CL	O
(	O
pro	B-CHED
)	O
and	O
PL	O
(	O
pro	B-CHED
),	O
viral	O
cysteine	B-CHED
proteases	O
.	O

IL	O
-	O
17	O
mRNA	B-CHED
levels	O
in	O
liver	O
tissue	O
were	O
quantified	O
by	O
using	O
quantitative	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
,	O
and	O
cytokine	O
IL	O
-	O
17	O
levels	O
in	O
liver	O
tissue	O
and	O
serum	O
were	O
determined	O
by	O
using	O
ELISA	O
in	O
MHV	O
-	O
3	O
-	O
induced	O
murine	O
fulminant	O
hepatitis	O
model	O
.	O

TITLE	O
:	O
Sequence	O
alignment	O
of	O
viral	O
channel	O
proteins	B-CHED
with	O
cellular	O
ion	O
channels	O
.	O

Two	O
of	O
the	O
five	O
isolates	O
showed	O
89	O
and	O
84	O
%	O
amino	B-CHED
acid	I-CHED
sequence	O
identity	O
and	O
89	O
and	O
88	O
%	O
nucleotide	B-CHED
sequence	O
identity	O
to	O
the	O
Egyptian	O
variant	O
1	O
and	O
the	O
IS	O
/	O
885	O
strains	O
,	O
respectively	O
.	O

The	O
low	O
CAI	O
values	O
agree	O
with	O
a	O
low	O
S	O
protein	B-CHED
expression	O
and	O
considering	O
that	O
S	O
protein	B-CHED
is	O
a	O
determinant	O
for	O
attachment	O
and	O
neutralization	O
,	O
this	O
could	O
be	O
a	O
further	O
mechanism	O
besides	O
mRNA	B-CHED
transcription	O
attenuation	O
for	O
a	O
low	O
expression	O
of	O
this	O
protein	B-CHED
leading	O
to	O
an	O
immune	O
camouflage	O
.	O

The	O
source	O
,	O
a	O
gamma	O
unit	O
containing	O
Cobalt	B-CHED
-	O
60	O
pencils	O
,	O
was	O
improperly	O
disposed	O
of	O
by	O
a	O
research	O
institution	O
in	O
violation	O
of	O
national	O
regulations	O
for	O
radiation	O
protection	O
and	O
safety	O
of	O
radioactive	O
sources	O
.	O

A	O
workflow	O
was	O
developed	O
consisting	O
of	O
an	O
optimized	O
fecal	O
nucleic	B-CHED
acid	I-CHED
purification	O
and	O
multiplex	O
reverse	O
transcription	O
quantitative	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
qPCR	O
)	O
for	O
single	O
tube	O
concurrent	O
detection	O
of	O
BCV	O
,	O
BRV	O
,	O
and	O
Cryptosporidium	O
spp	O
.,	O
and	O
an	O
internal	O
control	O
to	O
monitor	O
nucleic	B-CHED
acid	I-CHED
purification	O
efficacy	O
and	O
PCR	O
reagent	B-CHED
functionality	O
.	O

Analytical	O
specificity	O
was	O
confirmed	O
using	O
Canine	O
and	O
Feline	O
coronavirus	O
,	O
Giardia	O
spp	O
.,	O
and	O
noninfected	O
bovine	O
purified	O
nucleic	B-CHED
acid	I-CHED
.	O

We	O
conclude	O
that	O
these	O
compounds	O
have	O
the	O
potential	O
to	O
be	O
developed	O
as	O
antiviral	B-CHED
therapeutics	O
aimed	O
at	O
a	O
single	O
virus	O
or	O
multiple	O
viruses	O
in	O
the	O
picornavirus	O
-	O
like	O
supercluster	O
by	O
targeting	O
3Cpro	O
or	O
3CLpro	O
.	O

We	O
found	O
that	O
SARS	O
-	O
CoV	O
spike	O
glycoprotein	B-CHED
(	O
S	O
protein	B-CHED
),	O
a	O
key	O
molecule	O
for	O
viral	O
entry	O
,	O
binds	O
to	O
calnexin	O
,	O
a	O
molecular	O
chaperone	O
in	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
),	O
but	O
not	O
to	O
calreticulin	O
,	O
a	O
homolog	O
of	O
calnexin	O
.	O

S	O
-	O
pseudovirus	O
produced	O
by	O
calnexin	O
siRNA	O
-	O
treated	O
cells	O
contained	O
S	O
protein	B-CHED
modified	O
with	O
N	B-CHED
-	I-CHED
glycan	I-CHED
side	O
chains	O
differently	O
from	O
other	O
two	O
S	O
proteins	B-CHED
and	O
consisted	O
of	O
two	O
kinds	O
of	O
viral	O
particles	O
:	O
those	O
of	O
normal	O
density	O
with	O
little	O
S	O
protein	B-CHED
and	O
those	O
of	O
high	O
density	O
with	O
abundant	O
S	O
protein	B-CHED
.	O

Intranasal	O
pretreatment	O
of	O
aged	O
mice	O
with	O
poly	O
(	O
I	O
·	O
C	O
)	O
(	O
a	O
TLR3	O
agonist	B-CHED
)	O
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
CpG	O
,	O
R848	O
,	O
or	O
lipopolysaccharide	B-CHED
(	O
TLR9	O
,	O
TLR7	O
/	O
8	O
,	O
or	O
TLR4	O
agonists	B-CHED
),	O
provided	O
a	O
high	O
level	O
of	O
protection	O
[	O
90	O
%	O
to	O
100	O
%	O
survival	O
rate	O
after	O
poly	O
(	O
I	O
·	O
C	O
)	O
treatment	O
]	O
against	O
lethal	O
MA15	O
or	O
IAV	O
challenge	O
and	O
reduced	O
pathological	O
changes	O
and	O
virus	O
loads	O
in	O
the	O
lungs	O
at	O
early	O
times	O
after	O
infection	O
.	O

From	O
mRNA	B-CHED
-	O
1	O
,	O
1a	O
as	O
well	O
as	O
1a	O
+	O
1b	O
are	O
translated	O
;	O
the	O
latter	O
1a	O
+	O
1b	O
results	O
from	O
the	O
translation	O
due	O
to	O
ribosomal	O
frame	O
-	O
shifting	O
facilitated	O
by	O
the	O
pseudoknot	O
structure	O
.	O

ABSTRACT	O
:	O
To	O
determine	O
the	O
antigen	B-CHED
characteristics	O
of	O
different	O
fragments	O
of	O
SARS	O
-	O
CoV	O
N	O
protein	B-CHED
expressed	O
in	O
E	O
.	O
Coli	O
and	O
their	O
application	O
in	O
the	O
serological	O
diagnosis	O
.	O

RESULTS	O
:	O
Western	O
-	O
Bolt	O
results	O
show	O
that	O
all	O
the	O
six	O
fragments	O
have	O
reacted	O
with	O
the	O
SARS	O
patient	O
convalescent	O
sera	O
,	O
but	O
the	O
PN360	O
and	O
PN301	O
showed	O
obvious	O
cross	O
-	O
reaction	O
with	O
sera	O
from	O
SARS	O
-	O
CoV	O
-	O
negative	O
normal	O
adults	O
;	O
sensitivity	O
analysis	O
using	O
an	O
ELISA	O
coating	O
with	O
PN199	O
,	O
PN185	O
,	O
PN155b	O
,	O
PN125	O
as	O
antigen	B-CHED
showed	O
that	O
the	O
PN185	O
and	O
PN155b	O
are	O
better	O
than	O
PN125	O
.	O

The	O
ALI	O
model	O
was	O
developed	O
through	O
the	O
intra	O
-	O
tracheal	O
(	O
IT	O
)	O
administration	O
of	O
LPS	B-CHED
(	O
16mg	O
/	O
kg	O
)	O
to	O
Sprague	O
-	O
Dawley	O
(	O
SD	O
)	O
rats	O
,	O
which	O
formed	O
the	O
LPS	B-CHED
group	O
.	O

Here	O
,	O
we	O
report	O
that	O
M	O
(	O
pro	B-CHED
)-	O
C	O
can	O
reversibly	O
interconvert	O
between	O
these	O
two	O
topological	O
states	O
under	O
physiological	O
conditions	O
.	O

Unfolding	O
of	O
this	O
foldon	O
promotes	O
self	O
-	O
association	O
of	O
M	O
(	O
pro	B-CHED
)-	O
C	O
monomers	O
and	O
functions	O
to	O
mediate	O
the	O
3D	O
domain	O
swapping	O
,	O
without	O
which	O
M	O
(	O
pro	B-CHED
)-	O
C	O
can	O
no	O
longer	O
form	O
the	O
domain	O
-	O
swapped	O
dimer	O
.	O

Endotracheal	O
intubation	O
(	O
ETI	B-CHED
)	O
was	O
required	O
in	O
42	O
patients	O
(	O
60	O
.	O
0	O
%),	O
including	O
38	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

We	O
also	O
discuss	O
the	O
recent	O
progress	O
in	O
the	O
identification	O
of	O
novel	O
chemical	O
inhibitors	B-CHED
of	O
nsP13	O
in	O
the	O
context	O
of	O
our	O
recent	O
discovery	O
of	O
the	O
strong	O
inhibition	O
of	O
the	O
SARS	O
helicase	O
by	O
natural	O
flavonoids	B-CHED
,	O
myricetin	B-CHED
and	O
scutellarein	B-CHED
.	O

Treatment	O
with	O
SB203580	O
and	O
U0126	B-CHED
reduced	O
PLpro	O
-	O
induced	O
expression	O
of	O
TGF	O
-	O
β1	O
,	O
vimentin	O
,	O
and	O
type	O
I	O
collagen	O
.	O

The	O
patient	O
was	O
treated	O
for	O
acute	O
respiratory	O
failure	O
but	O
he	O
showed	O
resistance	O
to	O
glucocorticoids	B-CHED
and	O
cyclosporine	B-CHED
.	O

We	O
examined	O
the	O
rates	O
of	O
DAI	O
by	O
antimicrobial	B-CHED
-	O
resistant	O
pathogens	O
,	O
and	O
30	O
-	O
day	O
and	O
in	O
-	O
hospital	O
mortality	O
in	O
the	O
intensive	O
care	O
unit	O
(	O
ICU	O
).	O

TITLE	O
:	O
Residue	O
analysis	O
of	O
a	O
CTL	O
epitope	B-CHED
of	O
SARS	O
-	O
CoV	O
spike	O
protein	B-CHED
by	O
IFN	O
-	O
gamma	O
production	O
and	O
bioinformatics	O
prediction	O
.	O

Additionally	O
,	O
these	O
one	O
residue	O
mutated	O
peptides	B-CHED
were	O
synthesized	O
,	O
and	O
IFN	O
-	O
gamma	O
production	O
induced	O
by	O
G368	O
,	O
V369	O
,	O
A371	O
,	O
T372	O
and	O
K373	O
mutated	O
S366	O
-	O
374	O
were	O
decreased	O
obviously	O
.	O

Our	O
patient	O
was	O
a	O
74	O
-	O
year	O
-	O
old	O
Japanese	O
man	B-CHED
who	O
was	O
hospitalized	O
for	O
treatment	O
due	O
to	O
worsening	O
of	O
dyspnea	O
and	O
hypoxemia	O
.	O

Eleven	O
(	O
14	O
%)	O
patients	O
received	O
corticosteroid	B-CHED
therapy	O
.	O

It	O
peaked	O
on	O
PBD	B-CHED
10	O
in	O
control	O
group	O
and	O
PBD	B-CHED
6	O
in	O
treatment	O
group	O
.	O

Fluid	O
balance	B-CHED
was	O
lower	O
in	O
treatment	O
group	O
than	O
in	O
control	O
group	O
from	O
PBD	B-CHED
3	O
to	O
7	O
,	O
and	O
it	O
showed	O
statistically	O
significant	O
differences	O
on	O
PBD	B-CHED
4	O
,	O
5	O
,	O
and	O
6	O
(	O
with	O
F	O
values	O
from	O
4	O
.	O
799	O
to	O
8	O
.	O
031	O
,	O
P	O
values	O
below	O
0	O
.	O
05	O
).	O

ABSTRACT	O
:	O
A	O
multiplex	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
(	O
mRT	O
-	O
PCR	O
)	O
assay	O
was	O
developed	O
for	O
the	O
simultaneous	O
detection	O
of	O
canine	O
distemper	O
virus	O
(	O
CDV	B-CHED
),	O
canine	O
respiratory	O
coronavirus	O
(	O
CRCoV	O
)	O
and	O
canine	O
influenza	O
virus	O
(	O
CIV	O
).	O

In	O
the	O
O2	O
-	O
PS	O
-	O
Dex	O
group	O
,	O
lung	O
edema	O
,	O
total	O
protein	B-CHED
,	O
and	O
inflammatory	O
cytokines	O
in	O
BALF	O
were	O
significantly	O
reduced	O
in	O
comparison	O
with	O
the	O
O2	O
-	O
PS	O
group	O
.	O

Inhalation	O
of	O
aerosolized	O
PS	O
generated	O
by	O
the	O
noninvasive	O
apparatus	O
could	O
significantly	O
reduce	O
lung	O
injury	O
,	O
while	O
using	O
oxygen	B-CHED
line	O
available	O
in	O
the	O
clinical	O
wards	O
to	O
generate	O
PS	O
aerosol	O
is	O
more	O
convenient	O
and	O
adds	O
further	O
benefits	O
.	O

RESULTS	O
:	O
Animals	O
treated	O
with	O
air	B-CHED
-	O
PS	O
for	O
20	O
minutes	O
had	O
significantly	O
improved	O
lung	O
function	O
,	O
reduced	O
pulmonary	O
edema	O
,	O
decreased	O
concentration	O
of	O
total	O
protein	B-CHED
and	O
proinflammatory	O
cytokines	O
in	O
BALF	O
,	O
ameliorated	O
lung	O
injury	O
,	O
and	O
improved	O
animal	O
survival	O
.	O

Only	O
a	O
small	O
percentage	O
of	O
US	O
medical	O
schools	O
currently	O
include	O
disaster	O
medicine	B-CHED
in	O
their	O
core	O
curriculum	O
,	O
and	O
even	O
fewer	O
medical	O
schools	O
have	O
incorporated	O
or	O
adopted	O
competency	O
-	O
based	O
training	O
within	O
their	O
disaster	O
medicine	B-CHED
lecture	O
topics	O
and	O
curricula	O
.	O

RESULTS	O
:	O
Of	O
the	O
29	O
(	O
25	O
.	O
2	O
%)	O
medical	O
schools	O
that	O
completed	O
the	O
survey	O
,	O
31	O
%	O
incorporated	O
disaster	O
medicine	B-CHED
into	O
their	O
medical	O
school	O
curricula	O
.	O

CONCLUSIONS	O
:	O
The	O
study	O
demonstrated	O
that	O
spike	O
glycoprotein	B-CHED
of	O
the	O
Massachusetts	O
and	O
the	O
QX	O
-	O
like	O
variants	O
of	O
IBV	O
are	O
molecularly	O
distinct	O
and	O
that	O
this	O
may	O
reflect	O
in	O
differences	O
in	O
the	O
behavior	O
of	O
these	O
viruses	O
in	O
vivo	O
.	O

Recombinant	O
replication	O
-	O
defective	O
adenovirus	O
vectors	O
(	O
rADVs	O
)	O
infect	O
mucosa	O
surface	O
and	O
therefore	O
can	O
serve	O
as	O
a	O
mucosal	O
antigen	B-CHED
delivery	O
vehicle	O
.	O

Cleavage	O
of	O
IBV	O
spike	O
protein	B-CHED
by	O
furin	O
may	O
contribute	O
to	O
the	O
productive	O
IBV	O
infection	O
in	O
these	O
cells	O
.	O

TITLE	O
:	O
Quantitative	O
and	O
sensitive	O
detection	O
of	O
the	O
SARS	O
-	O
CoV	O
spike	O
protein	B-CHED
using	O
bispecific	O
monoclonal	O
antibody	O
-	O
based	O
enzyme	O
-	O
linked	O
immunoassay	O
.	O

Recombinant	O
SARS	O
-	O
CoV	O
S1	O
antigen	B-CHED
was	O
produced	O
and	O
purified	O
for	O
the	O
development	O
of	O
monoclonal	O
and	O
bi	O
-	O
specific	O
monoclonal	O
antibodies	O
.	O

In	O
conclusion	O
,	O
the	O
method	O
described	O
in	O
this	O
study	O
allows	O
sensitive	O
detection	O
of	O
a	O
recombinant	O
SARS	O
spike	O
protein	B-CHED
by	O
sandwich	O
ELISA	O
with	O
bi	O
-	O
specific	O
monoclonal	O
antibody	O
and	O
could	O
be	O
used	O
for	O
the	O
diagnosis	O
of	O
patients	O
suspected	O
with	O
SARS	O
.	O

This	O
review	O
examines	O
antibiotic	B-CHED
misuse	O
and	O
the	O
status	O
of	O
antibiotic	B-CHED
resistance	O
in	O
the	O
Chinese	O
healthcare	O
system	O
.	O

We	O
evaluated	O
the	O
benefits	O
of	O
inhaled	O
epoprostenol	B-CHED
as	O
a	O
less	O
expensive	O
alternative	O
to	O
nitric	B-CHED
oxide	I-CHED
in	O
ventilated	O
surgical	O
intensive	O
care	O
patients	O
with	O
severe	O
hypoxemia	O
.	O

This	O
work	O
compared	O
two	O
different	O
routes	O
of	O
infection	O
(	O
intratracheal	O
versus	O
eye	O
drop	O
)	O
in	O
commercial	O
pullets	O
,	O
looking	O
for	O
differences	O
in	O
the	O
pathology	O
(	O
air	B-CHED
sac	O
and	O
tracheal	O
lesion	O
scores	O
,	O
and	O
tracheal	O
mucosal	O
thickness	O
)	O
and	O
the	O
humoral	O
immune	O
response	O
(	O
measured	O
by	O
serum	O
plate	O
agglutination	O
)	O
of	O
the	O
host	O
.	O

TITLE	O
:	O
Identification	O
of	O
a	O
conserved	O
linear	O
B	O
-	O
cell	O
epitope	B-CHED
in	O
the	O
M	O
protein	B-CHED
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
.	O

ABSTRACT	O
:	O
The	O
major	O
structural	O
protein	B-CHED
of	O
coronaviruses	O
,	O
the	O
membrane	O
(	O
M	O
)	O
protein	B-CHED
,	O
can	O
elicit	O
the	O
formation	O
of	O
protective	O
antibodies	O
,	O
but	O
little	O
information	O
is	O
available	O
about	O
the	O
M	O
protein	B-CHED
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
).	O

The	O
result	O
of	O
WB	O
analysis	O
showed	O
that	O
the	O
4D4	O
-	O
defined	O
epitope	B-CHED
could	O
be	O
recognized	O
by	O
PEDV	O
-	O
positive	O
serum	O
,	O
but	O
not	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)-	O
positive	O
serum	O
.	O

A	O
McAb	O
,	O
4D4	O
,	O
directed	O
against	O
the	O
M	O
protein	B-CHED
of	O
PEDV	O
,	O
was	O
obtained	O
,	O
and	O
the	O
4D4	O
-	O
defined	O
minimal	O
epitope	B-CHED
sequence	O
was	O
195WAFYVR200	O
.	O

RESULTS	O
:	O
One	O
hybridoma	O
cell	O
line	O
secreting	O
anti	O
-	O
M	O
protein	B-CHED
monoclonal	O
antibody	O
(	O
McAb	O
)	O
was	O
generated	O
and	O
designated	O
4D4	O
.	O

Understanding	O
the	O
factors	O
that	O
contribute	O
to	O
the	O
willingness	O
of	O
HCP	B-CHED
to	O
report	O
to	O
work	O
during	O
an	O
influenza	O
public	O
health	O
emergency	O
is	O
critical	O
to	O
emergency	O
planning	O
and	O
preparedness	O
.	O

Information	O
from	O
this	O
review	O
can	O
guide	O
emergency	O
policy	O
makers	O
,	O
planners	O
,	O
and	O
implementers	O
in	O
both	O
understanding	O
and	O
influencing	O
the	O
willingness	O
of	O
HCP	B-CHED
to	O
work	O
during	O
an	O
influenza	O
public	O
health	O
emergency	O
.	O

Use	O
of	O
corticosteroids	B-CHED
to	O
attenuate	O
inflammation	O
remains	O
controversial	O
.	O

As	O
a	O
result	O
of	O
our	O
review	O
,	O
we	O
have	O
added	O
Chapare	O
virus	O
,	O
Lujo	O
virus	O
,	O
and	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
to	O
the	O
list	O
of	O
HHS	O
select	O
agents	O
and	O
toxins	B-CHED
.	O

Nasopharyngeal	O
aspirates	O
were	O
obtained	O
from	O
each	O
case	O
and	O
sent	O
for	O
viral	O
detection	O
by	O
tissue	O
culture	O
,	O
antigen	B-CHED
test	O
,	O
and	O
polymerase	O
chain	O
reaction	O
.	O

TITLE	O
:	O
Expression	O
of	O
avian	O
infectious	O
bronchitis	O
virus	O
multi	O
-	O
epitope	B-CHED
based	O
peptide	B-CHED
EpiC	O
in	O
Lactococcus	O
lactis	O
for	O
oral	O
immunization	O
of	O
chickens	O
.	O

Morbidities	O
included	O
a	O
pyothorax	O
and	O
a	O
persistent	O
air	B-CHED
leak	O
;	O
both	O
made	O
a	O
recovery	O
.	O

Specificity	O
of	O
the	O
PCR	O
and	O
DFA	B-CHED
methods	O
for	O
RSV	O
infections	O
were	O
detected	O
as	O
97	O
%	O
and	O
100	O
%	O
respectively	O
.	O

Specificity	O
of	O
the	O
PCR	O
and	O
DFA	B-CHED
methods	O
for	O
RSV	O
infections	O
were	O
detected	O
as	O
96	O
%	O
and	O
100	O
%	O
respectively	O
.	O

Tissue	O
detection	O
of	O
the	O
protein	B-CHED
showed	O
that	O
it	O
was	O
significantly	O
overexpressed	O
in	O
COPD	O
smokers	O
in	O
comparison	O
to	O
COPD	O
nonsmokers	O
and	O
was	O
only	O
slightly	O
expressed	O
in	O
patients	O
with	O
age	O
-	O
related	O
emphysema	O
.	O

Domestic	O
dogs	O
had	O
antibodies	O
to	O
CDV	B-CHED
,	O
canine	O
adenovirus	O
,	O
canine	O
herpesvirus	O
,	O
and	O
canine	O
parvovirus	O
.	O

ABSTRACT	O
:	O
The	O
use	O
of	O
inhaled	O
nitric	B-CHED
oxide	I-CHED
in	O
patients	O
with	O
traumatic	O
brain	O
injury	O
,	O
intracranial	O
hypertension	O
,	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
has	O
been	O
reported	O
in	O
an	O
intensive	O
care	O
unit	O
setting	O
only	O
in	O
a	O
few	O
case	O
reports	O
.	O

Here	O
we	O
determined	O
crystal	O
structures	O
of	O
porcine	O
APN	O
at	O
1	O
.	O
85	O
Å	O
resolution	O
and	O
its	O
complexes	O
with	O
a	O
peptide	B-CHED
substrate	O
and	O
a	O
variety	O
of	O
inhibitors	B-CHED
.	O

If	O
its	O
effectiveness	O
is	O
confirmed	O
,	O
the	O
use	O
of	O
the	O
technique	O
could	O
lead	O
to	O
further	O
expansion	O
of	O
donor	B-CHED
organ	O
pools	O
and	O
improvements	O
in	O
post	O
-	O
LTx	O
outcomes	O
.	O

The	O
cannulation	O
is	O
performed	O
after	O
intravenous	O
administration	O
of	O
heparin	B-CHED
.	O

ABSTRACT	O
:	O
This	O
health	O
technology	O
policy	O
assessment	O
will	O
answer	O
the	O
following	O
questions	O
:	O
When	O
should	O
in	O
-	O
room	O
air	B-CHED
cleaners	O
be	O
used	O
?	O
How	O
effective	O
are	O
in	O
-	O
room	O
air	B-CHED
cleaners	O
?	O
Are	O
in	O
-	O
room	O
air	B-CHED
cleaners	O
that	O
use	O
combined	O
HEPA	O
and	O
UVGI	O
air	B-CHED
cleaning	O
technology	O
more	O
effective	O
than	O
those	O
that	O
use	O
HEPA	O
filtration	O
alone	O
?	O
What	O
is	O
the	O
Plasmacluster	O
ion	O
air	B-CHED
purifier	O
in	O
the	O
pandemic	O
influenza	O
preparation	O
plan	O
?	O
The	O
experience	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
locally	O
,	O
nationally	O
,	O
and	O
internationally	O
underscored	O
the	O
importance	O
of	O
administrative	O
,	O
environmental	O
,	O
and	O
personal	O
protective	O
infection	O
control	O
measures	O
in	O
health	O
care	O
facilities	O
.	O

A	O
negative	O
-	O
pressure	O
room	O
is	O
one	O
where	O
clean	O
air	B-CHED
flows	O
into	O
the	O
room	O
but	O
contaminated	O
air	B-CHED
does	O
not	O
flow	O
out	O
of	O
it	O
.	O

The	O
effectiveness	O
of	O
an	O
in	O
-	O
room	O
air	B-CHED
cleaner	O
to	O
remove	O
airborne	O
pathogens	O
from	O
room	O
air	B-CHED
depends	O
on	O
several	O
factors	O
,	O
including	O
the	O
airflow	O
rate	O
through	O
the	O
unit	O
'	O
s	O
filter	O
and	O
the	O
airflow	O
patterns	O
in	O
the	O
room	O
.	O

However	O
,	O
and	O
although	O
their	O
effectiveness	O
is	O
variable	O
,	O
the	O
United	O
States	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
has	O
acknowledged	O
in	O
-	O
room	O
air	B-CHED
cleaners	O
as	O
alternative	O
technology	O
for	O
increasing	O
room	O
ventilation	O
when	O
this	O
cannot	O
be	O
achieved	O
by	O
the	O
building	O
'	O
s	O
HVAC	O
system	O
with	O
preference	O
given	O
to	O
fixed	O
recirculating	O
systems	O
over	O
portable	O
ones	O
.	O

Its	O
manufacturer	O
,	O
Sharp	O
Electronics	O
Corporation	O
,	O
says	O
that	O
it	O
can	O
disable	O
airborne	O
microorganisms	O
through	O
the	O
generation	O
of	O
both	O
positive	O
and	O
negative	O
ions	B-CHED
.	O

The	O
cluster	O
ion	O
surrounds	O
the	O
airborne	O
particle	O
,	O
and	O
the	O
positive	O
and	O
negative	O
ions	B-CHED
react	O
to	O
form	O
hydroxyls	O
.	O

The	O
objective	O
of	O
the	O
systematic	O
review	O
was	O
to	O
determine	O
the	O
effectiveness	O
of	O
in	O
-	O
room	O
air	B-CHED
cleaners	O
with	O
built	O
in	O
UVGI	O
lights	O
and	O
HEPA	O
filtration	O
compared	O
with	O
those	O
using	O
HEPA	O
filtration	O
only	O
.	O

Using	O
a	O
glycan	B-CHED
array	O
screen	O
,	O
we	O
have	O
identified	O
5	O
-	O
N	B-CHED
-	I-CHED
acetyl	I-CHED
-	I-CHED
9	I-CHED
-	I-CHED
O	I-CHED
-	I-CHED
acetylneuraminic	I-CHED
acid	I-CHED
as	O
the	O
preferred	O
sugar	O
substrate	O
for	O
BCoV	O
NTD	O
.	O

The	O
aim	O
of	O
this	O
review	O
is	O
to	O
summarise	O
the	O
efforts	O
in	O
the	O
design	O
of	O
new	O
inhibitors	B-CHED
either	O
characterized	O
by	O
a	O
novel	O
mechanism	O
of	O
action	O
or	O
capable	O
of	O
blocking	O
both	O
RT	O
associated	O
functions	O
,	O
as	O
well	O
as	O
pointing	O
out	O
the	O
main	O
binding	O
features	O
of	O
the	O
known	O
RT	O
inhibitors	B-CHED
.	O

The	O
significantly	O
lower	O
values	O
of	O
desmosine	B-CHED
in	O
the	O
study	O
group	O
suggest	O
that	O
this	O
treatment	O
may	O
be	O
protective	O
against	O
lung	O
injury	O
.	O

We	O
show	O
that	O
the	O
amount	O
and	O
the	O
peculiarities	O
of	O
distribution	O
of	O
the	O
protein	B-CHED
intrinsic	O
disorder	O
in	O
the	O
viral	O
shell	O
can	O
be	O
used	O
for	O
the	O
efficient	O
analysis	O
of	O
the	O
behavior	O
and	O
transmission	O
modes	O
of	O
CoV	O
.	O
The	O
proposed	O
model	O
allows	O
categorization	O
of	O
the	O
various	O
CoVs	O
by	O
the	O
peculiarities	O
of	O
disorder	O
distribution	O
in	O
their	O
membrane	O
(	O
M	O
)	O
and	O
nucleocapsid	O
(	O
N	O
).	O

The	O
list	O
of	O
potential	O
maternal	O
risks	O
and	O
complications	O
from	O
severe	O
impaired	O
glucose	B-CHED
tolerance	O
includes	O
,	O
for	O
example	O
,	O
increased	O
rate	O
of	O
Caesarean	O
sections	O
,	O
pre	O
-	O
eclampsia	O
and	O
injuries	O
during	O
delivery	O
.	O

Based	O
on	O
these	O
premises	O
,	O
the	O
main	O
aim	O
of	O
this	O
report	O
was	O
to	O
assess	O
the	O
benefit	O
of	O
screening	O
for	O
impaired	O
glucose	B-CHED
tolerance	O
during	O
pregnancy	O
with	O
regard	O
to	O
patient	O
-	O
relevant	O
outcomes	O
.	O

TITLE	O
:	O
Fine	O
level	O
epitope	B-CHED
mapping	O
and	O
conservation	O
analysis	O
of	O
two	O
novel	O
linear	O
B	O
-	O
cell	O
epitopes	O
of	O
the	O
avian	O
infectious	O
bronchitis	O
coronavirus	O
nucleocapsid	O
protein	B-CHED
.	O

Our	O
results	O
demonstrate	O
that	O
AQ	O
derivatives	O
are	O
promising	O
anti	O
-	O
RNase	O
H	O
inhibitors	B-CHED
.	O

The	O
limit	O
of	O
detection	O
(	O
LOD	O
)	O
was	O
1	O
.	O
31	O
plaque	O
-	O
forming	O
units	O
(	O
PFU	B-CHED
)/	O
mL	O
for	O
human	O
rhinoviruses	O
(	O
hRVs	O
),	O
4	O
.	O
93	O
PFU	B-CHED
/	O
mL	O
for	O
human	O
coronavirus	O
HCoV	O
-	O
229E	O
/	O
NL63	O
,	O
2	O
.	O
67	O
PFU	B-CHED
/	O
mL	O
for	O
human	O
coronavirus	O
HCoV	O
-	O
OC43	O
,	O
18	O
.	O
20	O
PFU	B-CHED
/	O
mL	O
for	O
parainfluenza	O
virus	O
1	O
(	O
PIV	O
)-	O
1	O
,	O
24	O
.	O
57	O
PFU	B-CHED
/	O
mL	O
for	O
PIV	O
-	O
2	O
,	O
1	O
.	O
73	O
PFU	B-CHED
/	O
mL	O
for	O
PIV	O
-	O
3	O
,	O
1	O
.	O
79	O
PFU	B-CHED
/	O
mL	O
for	O
influenza	O
virus	O
group	O
(	O
Flu	O
)	O
A	O
,	O
59	O
.	O
51	O
PFU	B-CHED
/	O
mL	O
for	O
FluB	O
,	O
5	O
.	O
46	O
PFU	B-CHED
/	O
mL	O
for	O
human	O
respiratory	O
syncytial	O
virus	O
(	O
hRSV	O
)-	O
A	O
,	O
17	O
.	O
23	O
PFU	B-CHED
/	O
mL	O
for	O
hRSV	O
-	O
B	O
,	O
9	O
.	O
99	O
PFU	B-CHED
/	O
mL	O
for	O
human	O
adenovirus	O
(	O
ADVs	O
).	O

While	O
in	O
first	O
case	O
severe	O
pain	O
in	O
abdomen	O
with	O
intermittent	O
exacerbation	O
was	O
the	O
only	O
presentation	O
,	O
the	O
second	O
patient	O
presented	O
as	O
accelerated	O
hypertension	O
and	O
acute	O
abdominal	O
crises	O
in	O
whom	O
the	O
clinical	O
course	O
was	O
characterized	O
by	O
development	O
of	O
deep	O
coma	O
due	O
to	O
inappropriate	O
secretion	O
of	O
antidiuretic	B-CHED
hormone	I-CHED
before	O
she	O
made	O
complete	O
recovery	O
.	O

This	O
case	O
involves	O
a	O
74	O
-	O
year	O
-	O
old	O
man	B-CHED
suffering	O
from	O
IgG	O
Kappa	O
myeloma	O
treated	O
with	O
bortezomib	B-CHED
,	O
melphalan	B-CHED
,	O
and	O
dexamethasone	B-CHED
.	O

Antimycotic	O
therapy	O
with	O
voriconazole	B-CHED
200	O
mg	O
twice	O
a	O
day	O
was	O
immediately	O
initiated	O
and	O
the	O
patient	O
was	O
treated	O
for	O
3	O
months	O
.	O

Upon	O
admission	O
,	O
the	O
Acute	O
Physiology	O
and	O
Chronic	O
Health	O
Evaluation	O
score	O
II	O
(	O
APACHE	O
II	O
),	O
SAA	O
,	O
serum	O
C	O
-	O
reactive	O
protein	B-CHED
(	O
CRP	O
)	O
and	O
interleukin	O
-	O
6	O
(	O
IL	O
-	O
6	O
)	O
were	O
measured	O
,	O
as	O
well	O
as	O
on	O
the	O
first	O
,	O
3rd	O
and	O
7th	O
day	O
and	O
were	O
compared	O
between	O
the	O
two	O
groups	O
.	O

The	O
routine	O
laboratory	O
diagnostics	O
,	O
which	O
implies	O
determining	O
of	O
the	O
levels	O
of	O
potassium	B-CHED
,	O
urea	B-CHED
,	O
creatinine	B-CHED
and	O
CK	O
in	O
the	O
serum	O
of	O
all	O
hospitalized	O
heroin	B-CHED
addicts	O
can	O
contribute	O
to	O
timely	O
detection	O
of	O
hyperkalemia	O
and	O
acute	O
kidney	O
weakness	O
and	O
undertaking	O
of	O
appropriate	O
therapeutic	O
measures	O
.	O

CONCLUSIONS	O
:	O
The	O
routine	O
laboratory	O
diagnostics	O
,	O
which	O
implies	O
determining	O
of	O
the	O
levels	O
of	O
potassium	B-CHED
,	O
urea	B-CHED
,	O
creatinine	B-CHED
and	O
CK	O
in	O
the	O
serum	O
of	O
all	O
hospitalized	O
heroin	B-CHED
addicts	O
can	O
contribute	O
to	O
timely	O
detection	O
of	O
hyperkalemia	O
and	O
acute	O
kidney	O
weakness	O
and	O
undertaking	O
of	O
appropriate	O
therapeutic	O
measures	O
.	O

Patients	O
undergoing	O
mechanical	O
ventilation	O
,	O
which	O
puts	O
them	O
at	O
risk	O
of	O
airflow	O
obstruction	O
and	O
the	O
development	O
of	O
intra	O
-	O
abdominal	O
hypertension	O
,	O
should	O
be	O
evaluated	O
for	O
air	B-CHED
-	O
trapping	O
and	O
excessive	O
auto	O
-	O
PEEP	B-CHED
.	O

These	O
results	O
suggest	O
that	O
modulating	O
the	O
amino	B-CHED
acid	I-CHED
residue	I-CHED
at	O
either	O
selected	O
site	O
may	O
alter	O
the	O
conformation	O
of	O
the	O
N	O
protein	B-CHED
and	O
affect	O
the	O
viral	O
RNA	O
-	O
N	O
interaction	O
.	O

RESULTS	O
:	O
Thirty	O
-	O
four	O
patients	O
had	O
characteristics	O
consistent	O
with	O
acute	O
lung	O
injury	O
or	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
were	O
ventilated	O
with	O
high	O
levels	O
of	O
PEEP	B-CHED
[	O
median	O
(	O
inter	O
-	O
quartile	O
range	O
)	O
10	O
.	O
0	O
(	O
10	O
.	O
0	O
-	O
13	O
.	O
5	O
)].	O

TITLE	O
:	O
Immunoreactivity	O
characterisation	O
of	O
the	O
three	O
structural	O
regions	O
of	O
the	O
human	O
coronavirus	O
OC43	O
nucleocapsid	O
protein	B-CHED
by	O
Western	O
blot	O
:	O
implications	O
for	O
the	O
diagnosis	O
of	O
coronavirus	O
infection	O
.	O

ABSTRACT	O
:	O
The	O
coronavirus	O
(	O
CoV	O
)	O
N	O
protein	B-CHED
oligomerizes	O
via	O
its	O
carboxyl	O
terminus	O
.	O

The	O
C	O
-	O
terminal	O
tail	O
peptide	B-CHED
is	O
able	O
to	O
interfere	O
with	O
the	O
oligomerization	O
of	O
the	O
CTD	O
of	O
HCoV	O
-	O
229E	O
N	O
protein	B-CHED
and	O
performs	O
the	O
inhibitory	O
effect	O
on	O
viral	O
titre	O
of	O
HCoV	O
-	O
229E	O
.	O

While	O
many	O
aspirates	O
were	O
dilute	O
and	O
showed	O
no	O
mRNA	B-CHED
signal	O
,	O
viral	O
infection	O
significantly	O
increased	O
the	O
number	O
of	O
samples	O
that	O
were	O
positive	O
for	O
IFN	O
-	O
λ1	O
,	O
IFN	O
-	O
λ2	O
/	O
3	O
,	O
TLR3	O
,	O
RIG	O
-	O
I	O
,	O
and	O
IRF7	O
mRNA	B-CHED
.	O

TITLE	O
:	O
Antiviral	B-CHED
effects	O
of	O
a	O
probiotic	O
Enterococcus	O
faecium	O
strain	O
against	O
transmissible	O
gastroenteritis	O
coronavirus	O
.	O

TITLE	O
:	O
Development	O
of	O
novel	O
entry	O
inhibitors	B-CHED
targeting	O
emerging	O
viruses	O
.	O

Understanding	O
local	O
H5N1	O
poultry	O
outbreaks	O
and	O
chest	O
radiography	O
assist	O
early	O
diagnosis	O
and	O
initiation	O
of	O
antiviral	B-CHED
treatment	O
.	O

In	O
the	O
current	O
manuscript	O
we	O
developed	O
a	O
set	O
of	O
polymer	B-CHED
-	O
based	O
compounds	O
showing	O
prominent	O
anticoronaviral	O
activity	O
.	O

Additional	O
tools	O
exist	O
to	O
display	O
multiple	O
sequence	O
alignments	O
,	O
view	O
phylogenetic	O
trees	O
,	O
visualize	O
3D	O
protein	B-CHED
structures	O
,	O
transfer	O
existing	O
reference	O
genome	O
annotations	O
to	O
new	O
genomes	O
,	O
and	O
store	O
or	O
share	O
results	O
from	O
any	O
search	O
or	O
analysis	O
within	O
personal	O
private	O
'	O
Workbench	O
'	O
spaces	O
for	O
future	O
access	O
.	O

Upon	O
infection	O
,	O
coronaviruses	O
extensively	O
rearrange	O
cellular	O
membranes	O
into	O
organelle	O
-	O
like	O
replicative	O
structures	O
that	O
consist	O
of	O
double	O
-	O
membrane	O
vesicles	O
and	O
convoluted	O
membranes	O
to	O
which	O
the	O
nonstructural	O
proteins	B-CHED
involved	O
in	O
RNA	O
synthesis	O
localize	O
.	O

Crystal	O
structures	O
of	O
the	O
enzyme	O
-	O
inhibitor	B-CHED
complexes	O
showed	O
that	O
the	O
nitrile	B-CHED
warhead	O
inhibits	O
3CL	O
(	O
pro	B-CHED
)	O
by	O
forming	O
a	O
covalent	O
bond	O
with	O
the	O
catalytic	O
Cys145	O
residue	O
,	O
while	O
the	O
AVLQ	O
peptide	B-CHED
forms	O
a	O
number	O
of	O
favourable	O
interactions	O
with	O
the	O
S1	O
-	O
S4	O
substrate	O
-	O
binding	O
pockets	O
.	O

The	O
resultant	O
nucleotide	B-CHED
sequences	O
were	O
compared	O
with	O
the	O
published	O
sequences	O
for	O
non	O
-	O
Korean	O
IBV	O
strains	O
.	O

Previously	O
,	O
we	O
reported	O
the	O
generation	O
of	O
broad	O
-	O
spectrum	O
peptidyl	O
inhibitors	B-CHED
against	O
viruses	O
that	O
possess	O
a	O
3C	O
or	O
3CL	O
protease	O
.	O

An	O
anti	O
-	O
histone	B-CHED
antibody	O
could	O
reduce	O
these	O
changes	O
and	O
protect	O
mice	O
from	O
histone	B-CHED
-	O
induced	O
lethality	O
.	O

ABSTRACT	O
:	O
Patent	O
foramen	O
ovale	O
(	O
PFO	B-CHED
),	O
although	O
frequently	O
observed	O
in	O
adults	O
,	O
rarely	O
causes	O
adverse	O
clinical	O
consequences	O
.	O

The	O
patient	O
was	O
successfully	O
weaned	O
from	O
the	O
ventilator	O
after	O
the	O
percutaneous	O
closure	O
of	O
PFO	B-CHED
through	O
a	O
catheter	O
-	O
deployed	O
double	O
-	O
umbrella	O
device	O
,	O
presenting	O
a	O
full	O
recovery	O
.	O

Wild	O
-	O
type	O
(	O
WT	O
)	O
and	O
B7	O
-	O
H1	O
-/-	O
mice	O
were	O
infected	O
with	O
a	O
gliatropic	O
coronavirus	O
and	O
CD4	O
T	O
cells	O
depleted	O
to	O
specifically	O
block	O
T	O
helper	O
function	O
in	O
the	O
CNS	B-CHED
.	O

CD4	O
depletion	O
in	O
B7	O
-	O
H1	O
-/-	O
mice	O
also	O
decreased	O
inducible	O
nitric	B-CHED
oxide	I-CHED
synthase	O
expression	O
by	O
microglia	O
and	O
macrophages	O
,	O
consistent	O
with	O
decreased	O
microglia	O
/	O
macrophage	O
activation	O
and	O
reduced	O
interferon	O
(	O
IFN	O
)-	O
γ	O
.	O

Enhanced	O
production	O
of	O
IFN	O
-	O
γ	O
,	O
interleukin	O
(	O
IL	O
)-	O
10	O
and	O
IL	O
-	O
21	O
mRNA	B-CHED
was	O
seen	O
in	O
CD4	O
T	O
cells	O
from	O
infected	O
B7	O
-	O
H1	O
-/-	O
compared	O
with	O
WT	O
mice	O
,	O
suggesting	O
that	O
over	O
-	O
activated	O
CD4	O
T	O
cells	O
primarily	O
contribute	O
to	O
the	O
increased	O
pathology	O
.	O

No	O
adverse	O
events	O
occurred	O
under	O
xenon	B-CHED
inhalation	O
.	O

High	O
-	O
efficiency	O
particulate	O
air	B-CHED
(	O
HEPA	O
)	O
filters	O
remove	O
airborne	O
particles	O
of	O
>	O
0	O
.	O
3	O
μm	O
with	O
99	O
.	O
97	O
%	O
efficiency	O
,	O
but	O
they	O
are	O
expensive	O
to	O
maintain	O
.	O

The	O
two	O
virus	O
infection	O
groups	O
both	O
exhibited	O
obvious	O
pathologies	O
in	O
the	O
liver	O
characteristic	O
of	O
chronic	O
viral	O
hepatitis	O
with	O
increased	O
lipid	B-CHED
accumulation	O
in	O
the	O
hepatocytes	O
.	O

TITLE	O
:	O
Transgenic	O
CCL2	B-CHED
expression	O
in	O
the	O
central	O
nervous	O
system	O
results	O
in	O
a	O
dysregulated	O
immune	O
response	O
and	O
enhanced	O
lethality	O
after	O
coronavirus	O
infection	O
.	O

ABSTRACT	O
:	O
Chemokine	O
(	O
C	O
-	O
C	O
motif	O
)	O
ligand	B-CHED
2	O
(	O
CCL2	B-CHED
),	O
a	O
chemoattractant	O
for	O
macrophages	O
,	O
T	O
cells	O
,	O
and	O
cells	O
expressing	O
CCR2	O
,	O
is	O
upregulated	O
during	O
acute	O
and	O
chronic	O
inflammation	O
.	O

The	O
average	O
and	O
median	O
turnaround	O
time	O
were	O
1	O
.	O
6	O
and	O
1	O
.	O
4	O
hours	O
,	O
respectively	O
,	O
in	O
contrast	O
to	O
7	O
and	O
6	O
.	O
5	O
hours	O
documented	O
1	O
year	O
previously	O
at	O
an	O
on	O
-	O
site	O
reference	O
laboratory	O
using	O
a	O
direct	O
fluorescence	O
assay	O
(	O
DFA	B-CHED
)	O
that	O
detected	O
8	O
viral	O
agents	O
.	O

Interestingly	O
,	O
the	O
two	O
constructs	O
have	O
the	O
same	O
binding	O
affinity	O
for	O
nucleic	B-CHED
acids	I-CHED
.	O

Even	O
though	O
the	O
S	O
protein	B-CHED
is	O
the	O
main	O
viral	O
factor	O
influencing	O
coronavirus	O
infection	O
of	O
susceptible	O
cells	O
,	O
our	O
results	O
taken	O
together	O
indicate	O
that	O
a	O
functionally	O
active	O
HE	O
protein	B-CHED
enhances	O
the	O
infectious	O
properties	O
of	O
HCoV	O
-	O
OC43	O
and	O
contributes	O
to	O
efficient	O
virus	O
dissemination	O
in	O
cell	O
culture	O
.	O

The	O
change	O
of	O
mechanical	O
ventilation	O
settings	O
were	O
(	O
pre	O
-	O
ECMO	O
vs	O
2	O
hours	O
post	O
-	O
ECMO	O
):	O
FiO2	O
1	O
.	O
0	O
vs	O
0	O
.	O
55	O
±	O
0	O
.	O
21	O
,	O
PEEP	B-CHED
(	O
11	O
±	O
6	O
)	O
vs	O
(	O
9	O
±	O
6	O
)	O
cm	O
H2O	B-CHED
,	O
V	O
(	O
T	O
)	O
(	O
6	O
.	O
8	O
±	O
2	O
.	O
2	O
)	O
vs	O
(	O
4	O
.	O
4	O
±	O
2	O
.	O
0	O
)	O
ml	O
/	O
kg	O
PBW	O
,	O
peak	O
airway	O
pressure	O
(	O
27	O
±	O
8	O
)	O
vs	O
(	O
24	O
±	O
7	O
)	O
cm	O
H2O	B-CHED
,	O
respiratory	O
rate	O
(	O
37	O
±	O
10	O
)	O
vs	O
(	O
23	O
±	O
10	O
)	O
breaths	O
/	O
min	O
.	O

ABSTRACT	O
:	O
Acute	O
intoxications	O
after	O
ingesting	O
glyphosate	B-CHED
are	O
observed	O
in	O
suicidal	O
or	O
accidental	O
cases	O
.	O

To	O
predict	O
clinical	O
outcomes	O
and	O
to	O
guide	O
treatment	O
support	O
in	O
patients	O
who	O
ingested	O
glyphosate	B-CHED
,	O
blood	O
concentrations	O
of	O
this	O
compound	O
and	O
the	O
taken	O
dose	O
have	O
been	O
useful	O
.	O

Blood	O
gases	O
and	O
hemodynamic	O
parameters	O
were	O
evaluated	O
after	O
changing	O
one	O
of	O
three	O
ECMO	O
settings	O
,	O
namely	O
,	O
circuit	O
blood	O
flow	O
,	O
FiO	O
(	O
2ECMO	O
)	O
(	O
fraction	O
of	O
inspired	O
oxygen	B-CHED
in	O
circuit	O
),	O
or	O
sweep	O
gas	O
flow	O
ventilating	O
the	O
membrane	O
,	O
while	O
leaving	O
the	O
other	O
two	O
parameters	O
at	O
their	O
maximum	O
setting	O
.	O

Ten	O
mechanically	O
ventilated	O
ARDS	O
patients	O
(	O
mean	O
age	O
44	O
±	O
16	O
years	O
;	O
6	O
males	O
;	O
mean	O
hemoglobin	B-CHED
8	O
.	O
0	O
±	O
1	O
.	O
8	O
g	O
/	O
dL	O
)	O
on	O
ECMO	O
for	O
a	O
mean	O
of	O
9	O
.	O
0	O
±	O
3	O
.	O
8	O
days	O
)	O
receiving	O
femoro	O
-	O
jugular	O
vv	O
-	O
ECMO	O
were	O
evaluated	O
.	O

T	O
cell	O
accumulation	O
,	O
localization	O
,	O
and	O
effector	B-CHED
functions	O
were	O
also	O
not	O
affected	O
in	O
either	O
CXCL9	O
(-/-)	O
or	O
CXCL10	O
(-/-)	O
mice	O
,	O
consistent	O
with	O
similar	O
control	O
of	O
infectious	O
virus	O
.	O

We	O
hereby	O
present	O
successful	O
and	O
uncomplicated	O
total	O
thyroidectomy	O
,	O
through	O
a	O
median	O
sternotomy	O
,	O
of	O
a	O
benign	O
,	O
gigantic	O
,	O
bilateral	O
,	O
retrovascular	O
,	O
posterior	O
mediastinal	O
,	O
intrathoracic	O
goiter	O
,	O
encircling	O
the	O
trachea	O
,	O
and	O
causing	O
severe	O
respiratory	O
distress	O
in	O
a	O
63	O
year	O
old	O
man	B-CHED
with	O
history	O
of	O
previous	O
subtotal	O
thyroidectomy	O
.	O

TITLE	O
:	O
Lower	O
tidal	O
volume	O
strategy	O
(≈	O
3	O
ml	O
/	O
kg	O
)	O
combined	O
with	O
extracorporeal	O
CO2	B-CHED
removal	O
versus	O
'	O
conventional	O
'	O
protective	O
ventilation	O
(	O
6	O
ml	O
/	O
kg	O
)	O
in	O
severe	O
ARDS	O
:	O
the	O
prospective	O
randomized	O
Xtravent	O
-	O
study	O
.	O

The	O
use	O
of	O
very	O
low	O
V	O
(	O
T	O
)	O
combined	O
with	O
extracorporeal	O
CO2	B-CHED
removal	O
has	O
the	O
potential	O
to	O
further	O
reduce	O
VILI	O
compared	O
with	O
a	O
'	O
normal	O
'	O
lung	O
protective	O
management	O
.	O

133	O
participants	O
had	O
one	O
or	O
more	O
of	O
the	O
following	O
risk	O
factors	O
:	O
body	O
mass	O
index	O
<	O
16	O
-	O
18	O
.	O
5	O
≥(	O
kg	O
/	O
m	O
(	O
2	O
)),	O
unintentional	O
weight	O
loss	O
>	O
15	O
%	O
in	O
the	O
preceding	O
3	O
-	O
6	O
months	O
,	O
very	O
little	O
or	O
no	O
nutritional	O
intake	O
>	O
10	O
days	O
,	O
history	O
of	O
alcohol	O
or	O
drug	O
abuse	O
and	O
low	O
baseline	O
levels	O
of	O
serum	O
potassium	B-CHED
,	O
phosphate	B-CHED
or	O
magnesium	B-CHED
prior	O
to	O
recruitment	O
.	O

We	O
hypothesized	O
that	O
NOS	O
substrate	O
levels	O
are	O
low	O
in	O
patients	O
with	O
severe	O
sepsis	O
and	O
that	O
low	O
levels	O
of	O
the	O
NOS	O
substrate	O
citrulline	B-CHED
would	O
be	O
associated	O
with	O
end	O
organ	O
damage	O
including	O
ARDS	O
in	O
severe	O
sepsis	O
.	O

Plasma	O
citrulline	B-CHED
levels	O
were	O
below	O
normal	O
in	O
all	O
patients	O
(	O
median	O
9	O
.	O
2	O
uM	O
,	O
IQR	O
5	O
.	O
2	O
-	O
14	O
.	O
4	O
)	O
and	O
were	O
significantly	O
lower	O
in	O
ARDS	O
compared	O
to	O
the	O
no	O
ARDS	O
group	O
(	O
6	O
.	O
0	O
(	O
3	O
.	O
3	O
-	O
10	O
.	O
4	O
)	O
vs	O
.	O
10	O
.	O
1	O
(	O
6	O
.	O
2	O
-	O
16	O
.	O
6	O
),	O
P	O
=	O
0	O
.	O
002	O
).	O

In	O
severe	O
sepsis	O
,	O
levels	O
of	O
the	O
NOS	O
substrate	O
citrulline	B-CHED
are	O
low	O
and	O
are	O
associated	O
with	O
ARDS	O
.	O

TITLE	O
:	O
Multiple	O
functions	O
of	O
angiotensin	B-CHED
-	O
converting	O
enzyme	O
2	O
and	O
its	O
relevance	O
in	O
cardiovascular	O
diseases	O
.	O

Although	O
autophagy	O
has	O
been	O
studied	O
in	O
many	O
animal	O
species	O
,	O
reagents	B-CHED
to	O
study	O
autophagy	O
in	O
avian	O
systems	O
are	O
lacking	O
.	O

Previous	O
studies	O
suggest	O
that	O
the	O
PEDV	O
E	O
protein	B-CHED
plays	O
an	O
important	O
role	O
in	O
the	O
viral	O
assembly	O
process	O
.	O

Further	O
studies	O
show	O
that	O
PEDV	O
E	O
protein	B-CHED
induced	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
stress	O
and	O
activated	O
NF	O
-	O
κB	O
which	O
is	O
responsible	O
for	O
the	O
up	O
-	O
regulation	O
of	O
IL	O
-	O
8	O
and	O
Bcl	O
-	O
2	O
expression	O
.	O

In	O
addition	O
,	O
the	O
PEDV	O
E	O
protein	B-CHED
is	O
able	O
to	O
up	O
-	O
regulate	O
IL	O
-	O
8	O
and	O
Bcl	O
-	O
2	O
expression	O
.	O

Notably	O
,	O
comprehensive	O
experimental	O
approaches	O
ensure	O
that	O
formation	O
of	O
the	O
IFNα	O
NP	O
-	O
corona	B-CHED
does	O
not	O
affect	O
the	O
biological	O
activity	O
of	O
the	O
cytokine	O
,	O
as	O
STAT1	O
signaling	O
was	O
efficiently	O
activated	O
.	O

It	O
was	O
not	O
clear	O
if	O
these	O
differences	O
were	O
due	O
to	O
changes	O
in	O
genomic	O
sequence	O
,	O
the	O
protein	B-CHED
sequence	O
or	O
the	O
frequency	O
of	O
frameshifting	O
.	O

The	O
chickens	O
were	O
administrated	O
combined	O
ND	O
,	O
IB	O
and	O
AI	O
inactivated	O
vaccines	O
containing	O
SPP	O
at	O
10	O
,	O
30	O
and	O
50	O
mg	O
/	O
mL	O
,	O
using	O
an	O
oil	O
adjuvant	B-CHED
vaccine	O
as	O
a	O
control	O
.	O

Supplemental	O
oxygen	B-CHED
is	O
often	O
necessary	O
in	O
both	O
mild	O
and	O
severe	O
lung	O
disease	O
.	O

Chimera	O
experiments	O
demonstrated	O
that	O
the	O
transfer	O
of	O
WT	O
but	O
not	O
ADORA2A	O
(-/-)	O
bone	O
marrow	O
cells	O
into	O
irradiated	O
ADORA2A	O
(-/-)	O
mice	O
reduced	O
lung	O
injury	O
after	O
LPS	B-CHED
plus	O
oxygen	B-CHED
,	O
demonstrating	O
myeloid	O
ADORA2A	O
protection	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
miliary	O
tuberculosis	O
complicated	O
by	O
DIC	B-CHED
and	O
ARDS	O
successfully	O
treated	O
with	O
rTM	O
.	O

Recommendations	O
specific	O
to	O
pediatric	O
severe	O
sepsis	O
include	O
:	O
therapy	O
with	O
face	O
mask	O
oxygen	B-CHED
,	O
high	O
flow	O
nasal	O
cannula	O
oxygen	B-CHED
,	O
or	O
nasopharyngeal	O
continuous	O
PEEP	B-CHED
in	O
the	O
presence	O
of	O
respiratory	O
distress	O
and	O
hypoxemia	O
(	O
2C	O
),	O
use	O
of	O
physical	O
examination	O
therapeutic	O
endpoints	O
such	O
as	O
capillary	O
refill	O
(	O
2C	O
);	O
for	O
septic	O
shock	O
associated	O
with	O
hypovolemia	O
,	O
the	O
use	O
of	O
crystalloids	O
or	O
albumin	O
to	O
deliver	O
a	O
bolus	O
of	O
20	O
mL	O
/	O
kg	O
of	O
crystalloids	O
(	O
or	O
albumin	O
equivalent	O
)	O
over	O
5	O
-	O
10	O
min	O
(	O
2C	O
);	O
more	O
common	O
use	O
of	O
inotropes	O
and	O
vasodilators	O
for	O
low	O
cardiac	O
output	O
septic	O
shock	O
associated	O
with	O
elevated	O
systemic	O
vascular	O
resistance	O
(	O
2C	O
);	O
and	O
use	O
of	O
hydrocortisone	B-CHED
only	O
in	O
children	O
with	O
suspected	O
or	O
proven	O
""""	O
absolute	O
"""'"	O
adrenal	O
insufficiency	O
(	O
2C	O
).	O

TITLE	O
:	O
Is	O
prolonged	O
low	O
-	O
dose	O
glucocorticoid	B-CHED
treatment	O
beneficial	O
in	O
community	O
-	O
acquired	O
pneumonia	O
?	O

Glucocorticoids	B-CHED
are	O
the	O
natural	O
regulators	O
of	O
inflammation	O
,	O
and	O
their	O
production	O
increases	O
during	O
infection	O
.	O

TITLE	O
:	O
Do	O
corticosteroids	B-CHED
improve	O
outcome	O
for	O
any	O
critical	O
illness	O
?	O

ABSTRACT	O
:	O
Corticosteroids	B-CHED
have	O
been	O
widely	O
administered	O
in	O
critically	O
ill	O
patients	O
for	O
various	O
indications	O
.	O

Since	O
the	O
nucleocapsid	O
(	O
N	O
)	O
protein	B-CHED
is	O
highly	O
conserved	O
,	O
it	O
is	O
a	O
candidate	O
protein	B-CHED
for	O
early	O
diagnosis	O
and	O
vaccine	O
development	O
.	O

In	O
addition	O
,	O
kallistatin	O
levels	O
were	O
positively	O
correlated	O
with	O
anti	O
-	O
thrombin	O
III	O
and	O
protein	B-CHED
C	O
and	O
inversely	O
correlated	O
with	O
IL	O
-	O
1β	O
,	O
IL	O
-	O
6	O
,	O
and	O
CRP	O
levels	O
.	O

The	O
patient	O
required	O
intensive	O
care	O
including	O
diuretics	B-CHED
(	O
furosemide	B-CHED
),	O
anti	O
-	O
arrhythmic	O
drugs	O
(	O
amiodarone	B-CHED
and	O
digoxin	B-CHED
),	O
and	O
inotropic	O
drugs	O
(	O
milrinone	B-CHED
and	O
levosimendan	B-CHED
)	O
associated	O
with	O
mechanical	O
ventilation	O
.	O

ABSTRACT	O
:	O
Protein	B-CHED
ubiquitination	O
regulates	O
important	O
innate	O
immune	O
responses	O
.	O

This	O
enzyme	O
is	O
essential	O
for	O
arterivirus	O
replication	O
by	O
cleaving	O
a	O
site	O
within	O
the	O
viral	O
replicase	O
polyproteins	O
and	O
also	O
removes	O
ubiquitin	O
from	O
cellular	O
proteins	B-CHED
.	O

Compared	O
with	O
WT	O
virus	O
infection	O
,	O
IFN	O
-	O
β	O
mRNA	B-CHED
levels	O
in	O
equine	O
cells	O
infected	O
with	O
PLP2	O
mutants	O
were	O
increased	O
by	O
nearly	O
an	O
order	O
of	O
magnitude	O
.	O

TITLE	O
:	O
Acute	O
and	O
sustained	O
effects	O
of	O
aerosolized	O
vs	O
.	O
bolus	O
surfactant	B-CHED
therapy	O
in	O
premature	O
lambs	O
with	O
respiratory	O
distress	O
syndrome	O
.	O

Mechanical	O
failure	O
of	O
the	O
necrotic	O
segment	O
of	O
bone	O
principally	O
occurred	O
within	O
3	O
years	O
after	O
the	O
administration	O
of	O
steroids	B-CHED
.	O

TITLE	O
:	O
Synthesis	O
and	O
biological	O
evaluation	O
of	O
pyridazine	B-CHED
derivatives	O
as	O
novel	O
HIV	O
-	O
1	O
NNRTIs	O
.	O

A	O
marked	O
increase	O
was	O
evident	O
in	O
the	O
mRNA	B-CHED
concentrations	O
of	O
interferon	O
-	O
β	O
and	O
interferon	O
-	O
λ	O
(	O
IL	O
-	O
29	O
)	O
and	O
in	O
a	O
large	O
number	O
of	O
proinflammatory	O
cytokines	O
and	O
chemokines	O
.	O

Furthermore	O
,	O
these	O
compounds	O
have	O
more	O
simple	O
structure	O
than	O
commercial	O
Ribavirin	B-CHED
,	O
and	O
can	O
be	O
synthesized	O
more	O
efficiently	O
.	O

ABSTRACT	O
:	O
A	O
'	O
biosimilar	O
',	O
or	O
'	O
similar	O
biological	O
medicinal	O
product	O
',	O
is	O
a	O
biologic	O
agent	O
that	O
is	O
similar	O
in	O
terms	O
of	O
quality	O
,	O
safety	O
and	O
efficacy	O
to	O
an	O
authorized	O
reference	O
biological	O
medicine	B-CHED
.	O

These	O
data	O
indicate	O
that	O
the	O
S	O
protein	B-CHED
of	O
BToV	O
-	O
Aichi	O
is	O
responsible	O
for	O
its	O
HA	O
activity	O
.	O

Patient	O
characteristics	O
,	O
bronchoalveolar	O
lavage	O
(	O
BAL	B-CHED
)	O
cellularity	O
,	O
rates	O
of	O
respiratory	O
tract	O
infection	O
,	O
colonization	O
,	O
acute	O
rejection	O
,	O
and	O
lymphocytic	O
bronchiolitis	O
were	O
compared	O
between	O
BOS	O
,	O
RAS	B-CHED
,	O
and	O
stable	O
patients	O
.	O

BOS	O
,	O
but	O
especially	O
RAS	B-CHED
patients	O
,	O
experienced	O
more	O
frequent	O
episodes	O
of	O
increased	O
BAL	B-CHED
eosinophilia	O
(≥	O
2	O
%;	O
P	O
<	O
0	O
.	O
0001	O
).	O

Comparing	O
to	O
the	O
turkeys	O
in	O
G1	O
-	O
750DP	O
,	O
significantly	O
less	O
TCoV	O
were	O
detected	O
by	O
IFA	O
in	O
the	O
turkeys	O
in	O
G2	O
-	O
100DPH	O
receiving	O
an	O
extra	O
dose	O
of	O
100μg	O
DNA	O
mixed	O
with	O
PEI	B-CHED
and	O
HA	O
.	O

The	O
sizes	O
of	O
coding	O
regions	O
of	O
some	O
genes	O
varied	O
among	O
IBV	O
isolates	O
due	O
to	O
deletion	O
or	O
insertion	O
of	O
nucleotides	B-CHED
;	O
the	O
nucleotide	B-CHED
similarities	O
of	O
S1	O
,	O
S2	O
,	O
3a	O
,	O
3b	O
and	O
E	O
genes	O
among	O
the	O
27	O
isolates	O
were	O
75	O
.	O
9	O
%-	O
100	O
.	O
0	O
%,	O
85	O
%-	O
100	O
.	O
0	O
%,	O
64	O
.	O
0	O
%-	O
100	O
.	O
0	O
%,	O
60	O
.	O
4	O
%-	O
100	O
.	O
0	O
%	O
and	O
83	O
.	O
1	O
%-	O
100	O
.	O
0	O
%,	O
respectively	O
.	O

TITLE	O
:	O
Tranexamic	B-CHED
acid	I-CHED
-	O
induced	O
toxic	O
epidermal	O
necrolysis	O
.	O

To	O
our	O
knowledge	O
,	O
a	O
well	O
-	O
documented	O
case	O
of	O
TEN	O
following	O
tranexamic	B-CHED
acid	I-CHED
use	O
has	O
not	O
been	O
reported	O
(	O
MEDLINE	O
search	O
to	O
June	O
2012	O
).	O

The	O
Naranjo	O
probability	O
scale	O
indicates	O
a	O
probable	O
relationship	O
between	O
the	O
development	O
of	O
TEN	O
and	O
tranexamic	B-CHED
acid	I-CHED
use	O
in	O
our	O
patient	O
.	O

Clinicians	O
should	O
be	O
made	O
aware	O
of	O
this	O
potential	O
severe	O
cutaneous	O
adverse	O
reaction	O
that	O
may	O
be	O
caused	O
by	O
tranexamic	B-CHED
acid	I-CHED
administration	O
.	O

This	O
report	O
is	O
the	O
first	O
one	O
to	O
present	O
a	O
patient	O
with	O
ARDS	O
in	O
relation	O
to	O
long	O
-	O
standing	O
exposure	O
to	O
a	O
high	O
-	O
concentration	O
mixture	B-CHED
of	O
ethenone	B-CHED
and	O
crotonaldehyde	B-CHED
.	O

The	O
MHV	O
PS	O
is	O
an	O
RNA	O
structure	O
that	O
maps	O
to	O
the	O
region	O
of	O
the	O
replicase	O
gene	O
encoding	O
the	O
nonstructural	O
protein	B-CHED
15	O
subunit	O
of	O
the	O
viral	O
replicase	O
-	O
transcriptase	O
complex	O
.	O

However	O
,	O
HCoV	O
-	O
EMC	O
was	O
markedly	O
more	O
sensitive	O
to	O
the	O
antiviral	B-CHED
state	O
established	O
by	O
ectopic	O
IFN	O
.	O

TITLE	O
:	O
Lack	O
of	O
nasal	O
carriage	O
of	O
novel	O
corona	B-CHED
virus	O
(	O
HCoV	O
-	O
EMC	O
)	O
in	O
French	O
Hajj	O
pilgrims	O
returning	O
from	O
the	O
Hajj	O
2012	O
,	O
despite	O
a	O
high	O
rate	O
of	O
respiratory	O
symptoms	O
.	O

The	O
immune	O
reaction	O
of	O
granuloma	O
formation	O
evolved	O
in	O
order	O
to	O
combat	B-CHED
mycobacteria	O
with	O
the	O
aim	O
of	O
localizing	O
mycobacteria	O
and	O
to	O
avoid	O
spreading	O
of	O
mycobacteria	O
throughout	O
the	O
body	O
.	O

A	O
Gram	O
-	O
positive	O
,	O
chain	O
-	O
forming	O
coccus	O
was	O
isolated	O
from	O
the	O
primary	O
organs	O
and	O
tissues	O
of	O
diseased	O
rabbits	O
and	O
then	O
identified	O
as	O
S	O
.	O
agalactiae	O
by	O
morphology	O
,	O
biochemical	O
and	O
physiological	O
characteristics	O
,	O
16S	B-CHED
rDNA	O
and	O
gyrB	O
gene	O
sequences	O
analysis	O
.	O

Carbon	B-CHED
clearance	O
assay	O
showed	O
no	O
difference	O
,	O
but	O
in	O
vitro	O
lymphoproliferative	O
response	O
to	O
concanavalin	O
A	O
was	O
higher	O
in	O
19	O
-	O
d	O
-	O
old	O
HYPER	O
chicks	O
,	O
independent	O
of	O
temperature	O
treatment	O
.	O

ABSTRACT	O
:	O
We	O
report	O
a	O
case	O
of	O
severe	O
Cushing	O
'	O
s	O
syndrome	O
developing	O
into	O
life	O
-	O
threatening	O
acute	O
respiratory	O
distress	O
syndrome	O
with	O
cryptococcus	O
and	O
cytomegalovirus	O
co	O
-	O
infection	O
soon	O
after	O
hypercortisolism	O
treatment	O
using	O
metyrapone	B-CHED
,	O
an	O
11	O
-	O
beta	O
-	O
hydroxylase	O
inhibitor	B-CHED
.	O

The	O
use	O
of	O
the	O
evolutionarily	O
conserved	O
DPP4	O
protein	B-CHED
from	O
different	O
species	O
as	O
a	O
functional	O
receptor	O
provides	O
clues	O
about	O
the	O
host	O
range	O
potential	O
of	O
hCoV	O
-	O
EMC	O
.	O

We	O
have	O
solved	O
the	O
crystal	O
structure	O
of	O
the	O
N	O
-	O
terminal	O
domain	O
of	O
HCoV	O
-	O
OC43	O
N	O
protein	B-CHED
(	O
N	O
-	O
NTD	O
)	O
(	O
residues	O
58	O
to	O
195	O
)	O
to	O
a	O
resolution	O
of	O
2	O
.	O
0Å	O
.	O

The	O
HCoV	O
-	O
OC43	O
N	O
-	O
NTD	O
is	O
a	O
single	O
domain	O
protein	B-CHED
composed	O
of	O
a	O
five	O
-	O
stranded	O
β	O
-	O
sheet	O
core	O
and	O
a	O
long	O
extended	O
loop	O
,	O
similar	O
to	O
that	O
observed	O
in	O
the	O
structures	O
of	O
N	O
-	O
NTDs	O
from	O
other	O
coronaviruses	O
.	O

The	O
results	O
show	O
that	O
R106	O
plays	O
an	O
important	O
role	O
in	O
the	O
interaction	O
between	O
the	O
N	O
protein	B-CHED
and	O
RNA	O
.	O

CVVH	O
was	O
employed	O
when	O
the	O
values	O
of	O
creatine	B-CHED
phosphokinase	O
(	O
CPK	O
),	O
myoglobin	B-CHED
(	O
Mb	O
),	O
and	O
lactate	B-CHED
dehydrogenase	O
(	O
LDH	O
)	O
increased	O
significantly	O
.	O

Principles	O
of	O
lung	O
-	O
protective	O
ventilation	O
include	O
:	O
a	O
)	O
prevention	O
of	O
volutrauma	O
(	O
tidal	O
volume	O
4	O
to	O
8	O
ml	O
/	O
kg	O
predicted	O
body	O
weight	O
with	O
plateau	O
pressure	O
<	O
30	O
cmH2O	O
);	O
b	O
)	O
prevention	O
of	O
atelectasis	O
(	O
positive	O
end	O
-	O
expiratory	O
pressure	O
≥	O
5	O
cmH2O	O
,	O
as	O
needed	O
recruitment	O
maneuvers	O
);	O
c	O
)	O
adequate	O
ventilation	O
(	O
respiratory	O
rate	O
20	O
to	O
35	O
breaths	O
per	O
minute	O
);	O
and	O
d	O
)	O
prevention	O
of	O
hyperoxia	O
(	O
titrate	O
inspired	O
oxygen	B-CHED
concentration	O
to	O
peripheral	O
oxygen	B-CHED
saturation	O
(	O
SpO2	O
)	O
levels	O
of	O
88	O
to	O
95	O
%).	O

TITLE	O
:	O
The	O
effect	O
of	O
somatostatin	B-CHED
,	O
ulinastatin	O
and	O
Salvia	O
miltiorrhiza	O
on	O
severe	O
acute	O
pancreatitis	O
treatment	O
.	O

The	O
incidences	O
of	O
pancreatic	O
sepsis	O
,	O
multiple	O
organ	O
dysfunction	O
syndrome	O
and	O
mortality	O
were	O
lower	O
in	O
the	O
somatostatin	B-CHED
,	O
somatostatin	B-CHED
+	O
ulinastatin	O
,	O
somatostatin	B-CHED
+	O
S	O
miltiorrhiza	O
and	O
somatostatin	B-CHED
+	O
ulinastatin	O
+	O
S	O
miltiorrhiza	O
subgroups	O
compared	O
with	O
the	O
basic	O
treatment	O
subgroup	O
.	O

ABSTRACT	O
:	O
TMPRSS2	O
(	O
transmembrane	O
serine	B-CHED
proteinase	O
2	O
)	O
is	O
a	O
multidomain	O
type	O
II	O
transmembrane	O
serine	B-CHED
protease	O
that	O
cleaves	O
the	O
surface	O
glycoprotein	B-CHED
HA	O
(	O
haemagglutinin	O
)	O
of	O
influenza	O
viruses	O
with	O
a	O
monobasic	O
cleavage	O
site	O
,	O
which	O
is	O
a	O
prerequisite	O
for	O
virus	O
fusion	O
and	O
propagation	O
.	O

ABSTRACT	O
:	O
This	O
observational	O
study	O
examined	O
the	O
outcome	O
of	O
Taiwanese	O
pediatric	O
patients	O
with	O
paraquat	B-CHED
poisoning	O
and	O
compared	O
these	O
data	O
with	O
the	O
published	O
data	O
on	O
paraquat	B-CHED
poisonings	O
from	O
other	O
international	O
poisoning	O
centers	O
.	O

The	O
coronaviral	O
N7	O
-	O
MTase	O
is	O
unique	O
for	O
its	O
physical	O
linkage	O
with	O
an	O
exoribonuclease	O
(	O
ExoN	O
)	O
harbored	O
in	O
nonstructural	O
protein	B-CHED
14	O
(	O
nsp14	O
)	O
of	O
coronaviruses	O
.	O

The	O
results	O
showed	O
that	O
the	O
ExoN	O
domain	O
is	O
closely	O
involved	O
in	O
the	O
activity	O
of	O
the	O
N7	O
-	O
MTase	O
,	O
suggesting	O
that	O
coronavirus	O
N7	O
-	O
MTase	O
is	O
different	O
from	O
all	O
other	O
viral	O
N7	O
-	O
MTases	O
,	O
which	O
are	O
separable	O
from	O
other	O
structural	O
domains	O
located	O
in	O
the	O
same	O
polypeptide	B-CHED
.	O

ABSTRACT	O
:	O
Amiodarone	B-CHED
pulmonary	O
toxicity	O
(	O
APT	O
)	O
is	O
the	O
most	O
serious	O
side	O
effect	O
of	O
amiodarone	B-CHED
.	O

Despite	O
corticosteroid	B-CHED
pulse	O
therapy	O
,	O
no	O
clinical	O
improvement	O
was	O
noted	O
.	O

Notably	O
,	O
infection	O
mediated	O
by	O
the	O
entry	O
proteins	B-CHED
of	O
Lassa	O
fever	O
virus	O
,	O
influenza	O
A	O
virus	O
and	O
SARS	O
coronavirus	O
was	O
largely	O
unaffected	O
by	O
TIM1	O
expression	O
.	O

Overall	O
ICU	O
mortality	O
during	O
the	O
two	O
decades	O
was	O
37	O
.	O
3	O
%	O
(	O
range	O
25	O
.	O
0	O
%-	O
38	O
.	O
1	O
%)	O
between	O
1995	O
and	O
2001	O
and	O
a	O
non	O
-	O
significant	O
increase	O
in	O
values	O
between	O
36	O
.	O
8	O
%	O
and	O
58	O
.	O
3	O
%	O
during	O
the	O
time	O
interval	O
from	O
2002	O
und	B-CHED
2005	O
.	O

TITLE	O
:	O
Porcine	O
epidemic	O
diarrhea	O
virus	O
N	O
protein	B-CHED
prolongs	O
S	O
-	O
phase	O
cell	O
cycle	O
,	O
induces	O
endoplasmic	O
reticulum	O
stress	O
,	O
and	O
up	O
-	O
regulates	O
interleukin	O
-	O
8	O
expression	O
.	O

The	O
results	O
show	O
that	O
the	O
PEDV	O
N	O
protein	B-CHED
localizes	O
in	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
),	O
inhibits	O
the	O
IEC	O
growth	O
and	O
prolongs	O
S	O
-	O
phase	O
cell	O
cycle	O
.	O

While	O
the	O
full	O
-	O
length	O
ectodomain	O
(	O
S	O
)	O
of	O
the	O
spike	O
protein	B-CHED
,	O
the	O
full	O
-	O
length	O
ectodomain	O
fused	O
to	O
foldon	O
(	O
S	O
-	O
foldon	O
),	O
the	O
S1	O
domain	O
(	O
S1	O
),	O
S1	O
-	O
foldon	O
,	O
and	O
the	O
S2	O
domain	O
(	O
S2	O
)	O
antigens	B-CHED
all	O
elicited	O
comparable	O
antibody	O
titers	O
as	O
measured	O
by	O
ELISA	O
,	O
S	O
-	O
foldon	O
induced	O
a	O
significantly	O
higher	O
titer	O
of	O
neutralizing	O
antibody	O
and	O
S2	O
protein	B-CHED
did	O
not	O
elicit	O
virus	O
neutralizing	O
antibodies	O
.	O

ABSTRACT	O
:	O
Bat	O
SARS	O
-	O
like	O
coronavirus	O
(	O
SL	O
-	O
CoV	O
)	O
has	O
a	O
genome	O
organization	O
almost	O
identical	O
to	O
that	O
of	O
SARS	O
-	O
CoV	O
,	O
but	O
the	O
N	O
-	O
terminus	O
of	O
the	O
Spike	O
(	O
S	O
)	O
proteins	B-CHED
,	O
which	O
interacts	O
with	O
host	O
receptor	O
and	O
is	O
a	O
major	O
target	O
of	O
neutralizing	O
antibodies	O
against	O
CoVs	O
,	O
of	O
the	O
two	O
viruses	O
has	O
only	O
63	O
-	O
64	O
%	O
sequence	O
identity	O
.	O

We	O
previously	O
showed	O
that	O
recombinant	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
(	O
Urbani	O
strain	O
based	O
)	O
lacking	O
envelope	O
(	O
E	O
)	O
protein	B-CHED
expression	O
(	O
rU	O
-	O
ΔE	O
)	O
provided	O
good	O
but	O
not	O
perfect	O
protection	O
in	O
young	O
mice	O
against	O
challenge	O
with	O
virulent	O
mouse	O
-	O
adapted	O
SARS	O
-	O
CoV	O
(	O
MA15	O
).	O

All	O
patients	O
were	O
treated	O
by	O
steroids	B-CHED
with	O
improvement	O
of	O
dyspnea	O
and	O
stabilization	O
of	O
radiographs	O
.	O

There	O
was	O
an	O
accidental	O
leakage	O
of	O
sodium	O
hypochlorite	B-CHED
from	O
an	O
industrial	O
factory	O
in	O
Rayong	O
province	O
in	O
June	O
2010	O
.	O

Acute	O
exposure	O
to	O
high	O
concentration	O
of	O
chlorine	B-CHED
gas	O
causes	O
both	O
significant	O
short	O
and	O
long	O
term	O
respiratory	O
health	O
effects	O
.	O

The	O
investigators	O
present	O
a	O
series	O
of	O
36	O
adults	O
with	O
refractory	O
hypoxemic	O
ARDS	O
(	O
ratio	O
of	O
partial	O
pressure	O
of	O
oxygen	B-CHED
to	O
fraction	O
of	O
inspired	O
oxygen	B-CHED
<	O
50	O
)	O
from	O
17	O
different	O
facilities	O
who	O
,	O
treated	O
with	O
ECMO	O
at	O
a	O
single	O
referral	O
center	O
,	O
had	O
a	O
60	O
%	O
survival	O
rate	O
.	O

Compared	O
to	O
the	O
NS	B-CHED
group	I-CHED
,	O
incidence	O
of	O
renal	O
dysfunction	O
,	O
ARDS	O
,	O
MODS	O
and	O
ACS	O
in	O
the	O
SH	O
and	O
SHG	O
groups	O
was	O
obviously	O
lower	O
.	O

Results	O
indicated	O
that	O
combination	O
of	O
normal	O
saline	O
,	O
HES	O
and	O
glutamine	B-CHED
are	O
more	O
efficient	O
in	O
resuscitation	O
of	O
SAP	O
by	O
relieving	O
inflammation	O
and	O
sustaining	O
the	O
intestinal	O
barrier	O
.	O

TITLE	O
:	O
Monoclonal	O
antibody	O
against	O
membrane	O
protein	B-CHED
of	O
transmissible	O
gastroenteritis	O
virus	O
.	O

TITLE	O
:	O
Expression	O
and	O
Purification	O
of	O
the	O
scFv	O
from	O
hybridoma	O
cells	O
secreting	O
a	O
monoclonal	O
antibody	O
against	O
S	O
PROTEIN	B-CHED
of	O
PEDV	O
.	O

The	O
recombinant	O
scFv	O
/	O
6E6	O
protein	B-CHED
was	O
successfully	O
expressed	O
in	O
recombinant	O
Escherichia	O
coli	O
by	O
IPTG	B-CHED
induction	O
.	O

The	O
transmission	O
tracking	O
analysis	O
technique	O
was	O
established	O
based	O
on	O
the	O
modeling	O
platform	O
ArcGIS	O
Engine	O
Developer	O
Kit	O
9	O
.	O
3	O
,	O
using	O
the	O
techniques	O
of	O
address	O
matching	O
,	O
shortest	O
path	O
analysis	O
and	O
buffer	B-CHED
analysis	O
,	O
and	O
programming	O
by	O
Visual	O
C	O
++.	O

ABSTRACT	O
:	O
Anti	O
-	O
NMDA	B-CHED
receptor	O
encephalitis	O
is	O
a	O
newly	O
characterized	O
severe	O
neuroautoimmune	O
syndrome	O
with	O
a	O
progressive	O
,	O
clinical	O
course	O
.	O

TITLE	O
:	O
Geranylated	O
flavonoids	B-CHED
displaying	O
SARS	O
-	O
CoV	O
papain	O
-	O
like	O
protease	O
inhibition	O
from	O
the	O
fruits	O
of	O
Paulownia	O
tomentosa	O
.	O

Five	O
of	O
these	O
compounds	O
were	O
new	O
geranylated	O
flavonoids	B-CHED
,	O
tomentin	O
A	O
,	O
tomentin	O
B	O
,	O
tomentin	O
C	O
,	O
tomentin	O
D	O
,	O
tomentin	O
E	O
(	O
1	O
-	O
5	O
).	O

TITLE	O
:	O
[	O
Molecular	O
detection	O
assays	O
for	O
2012	O
identified	O
novel	O
human	O
coronavirus	O
(	O
HCoV	O
)	O
and	O
probe	O
modification	O
with	O
locked	B-CHED
nucleic	I-CHED
acid	I-CHED
(	O
LNA	B-CHED
)].	O

The	O
upE	O
and	O
LNA	B-CHED
-	O
TZ1	O
based	O
assays	O
were	O
better	O
than	O
others	O
.	O

CONCLUSIONS	O
:	O
The	O
molecular	O
detection	O
sensitivity	O
and	O
specificity	O
of	O
TaqMan	O
-	O
based	O
real	O
time	O
PCR	O
assay	O
could	O
be	O
improved	O
when	O
probe	O
tagged	O
with	O
LNA	B-CHED
.	O

From	O
November	O
2006	O
to	O
October	O
2009	O
,	O
1169	O
nasopharyngeal	O
aspirates	O
(	O
NPA	B-CHED
)	O
were	O
collected	O
from	O
children	O
under	O
14	O
years	O
old	O
with	O
ARTIs	O
.	O

The	O
functional	O
unit	O
of	O
M	O
(	O
pro	B-CHED
)	O
is	O
a	O
homodimer	O
and	O
each	O
subunit	O
contains	O
a	O
His41	O
/	O
Cys145	O
catalytic	O
dyad	O
.	O

TITLE	O
:	O
The	O
cellular	O
interactome	O
of	O
the	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
nucleocapsid	O
protein	B-CHED
and	O
functional	O
implications	O
for	O
virus	O
biology	O
.	O

The	O
association	O
of	O
selected	O
cellular	O
proteins	B-CHED
with	O
IBV	O
N	O
protein	B-CHED
was	O
confirmed	O
by	O
immunoblotting	O
,	O
cosedimentation	O
,	O
and	O
confocal	O
microscopy	O
.	O

Sequence	O
and	O
phylogenetic	O
analysis	O
of	O
the	O
ECoV	O
isolated	O
showed	O
that	O
putative	O
amino	B-CHED
acid	I-CHED
sequences	O
in	O
S	O
and	O
N	O
genes	O
were	O
highly	O
conserved	O
among	O
ECoV	O
strains	O
.	O

Based	O
on	O
available	O
experimental	O
data	O
,	O
the	O
prediction	O
accuracy	O
is	O
up	O
to	O
90	O
%	O
for	O
S	O
protein	B-CHED
.	O

The	O
compounds	O
were	O
discovered	O
by	O
screening	O
a	O
chemical	O
library	O
of	O
compounds	O
for	O
blocking	O
of	O
entry	O
of	O
HIV	O
-	O
1	O
pseudotyped	O
with	O
SARS	O
-	O
CoV	O
surface	O
glycoprotein	B-CHED
S	O
(	O
SARS	O
-	O
S	O
)	O
but	O
not	O
that	O
of	O
HIV	O
-	O
1	O
pseudotyped	O
with	O
vesicular	O
stomatitis	O
virus	O
surface	O
glycoprotein	B-CHED
G	O
(	O
VSV	O
-	O
G	O
).	O

Studies	O
on	O
their	O
mechanisms	O
of	O
action	O
revealed	O
that	O
the	O
compounds	O
act	O
by	O
three	O
distinct	O
mechanisms	O
:	O
(	O
i	O
)	O
SSAA09E2	O
{	O
N	O
-[[	O
4	O
-(	O
4	O
-	O
methylpiperazin	O
-	O
1	O
-	O
yl	O
)	O
phenyl	B-CHED
]	O
methyl	B-CHED
]-	O
1	B-CHED
,	I-CHED
2	I-CHED
-	I-CHED
oxazole	I-CHED
-	O
5	O
-	O
carboxamide	B-CHED
}	O
acts	O
through	O
a	O
novel	O
mechanism	O
of	O
action	O
,	O
by	O
blocking	O
early	O
interactions	O
of	O
SARS	O
-	O
S	O
with	O
the	O
receptor	O
for	O
SARS	O
-	O
CoV	O
,	O
angiotensin	B-CHED
converting	O
enzyme	O
2	O
(	O
ACE2	O
);	O
(	O
ii	O
)	O
SSAA09E1	O
{[(	O
Z	O
)-	O
1	O
-	O
thiophen	B-CHED
-	O
2	O
-	O
ylethylideneamino	O
]	O
thiourea	B-CHED
}	O
acts	O
later	O
,	O
by	O
blocking	O
cathepsin	O
L	O
,	O
a	O
host	O
protease	O
required	O
for	O
processing	O
of	O
SARS	O
-	O
S	O
during	O
viral	O
entry	O
;	O
and	O
(	O
iii	O
)	O
SSAA09E3	O
[	O
N	O
-(	O
9	O
,	O
10	O
-	O
dioxo	O
-	O
9	O
,	O
10	O
-	O
dihydroanthracen	O
-	O
2	O
-	O
yl	O
)	O
benzamide	B-CHED
]	O
also	O
acts	O
later	O
and	O
does	O
not	O
affect	O
interactions	O
of	O
SARS	O
-	O
S	O
with	O
ACE2	O
or	O
the	O
enzymatic	O
functions	O
of	O
cathepsin	O
L	O
but	O
prevents	O
fusion	O
of	O
the	O
viral	O
membrane	O
with	O
the	O
host	O
cellular	O
membrane	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
activation	O
of	O
the	O
protein	B-CHED
kinase	O
R	O
-	O
like	O
ER	O
kinase	O
(	O
PERK	B-CHED
)	O
pathway	O
of	O
UPR	O
in	O
cells	O
infected	O
with	O
the	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
and	O
its	O
relationship	O
with	O
IBV	O
-	O
induced	O
apoptosis	O
.	O

Interestingly	O
,	O
knockdown	O
of	O
protein	B-CHED
kinase	O
R	O
(	O
PKR	O
)	O
by	O
siRNA	O
and	O
inhibition	O
of	O
the	O
PKR	O
kinase	O
activity	O
by	O
2	B-CHED
-	I-CHED
aminopurine	I-CHED
(	O
2	O
-	O
AP	O
)	O
also	O
reduced	O
the	O
IBV	O
-	O
induced	O
upregulation	O
of	O
GADD153	O
and	O
apoptosis	O
induction	O
.	O

This	O
study	O
provides	O
solid	O
evidence	O
that	O
induction	O
of	O
GADD153	O
by	O
PERK	B-CHED
and	O
PKR	O
plays	O
an	O
important	O
regulatory	O
role	O
in	O
the	O
apoptotic	O
process	O
triggered	O
by	O
IBV	O
infection	O
.	O

Patients	O
ingested	O
dimethyl	B-CHED
-	O
OPs	O
in	O
19	O
cases	O
,	O
diethyl	O
-	O
OPs	O
in	O
8	O
cases	O
and	O
otherwise	O
classified	O
OPs	O
in	O
6	O
cases	O
.	O

Six	O
of	O
them	O
were	O
affected	O
by	O
cblD	O
-	O
MMA	B-CHED
,	O
but	O
only	O
three	O
had	O
a	O
known	O
clinical	O
history	O
.	O

TITLE	O
:	O
Treatment	O
of	O
cerebral	O
malaria	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
with	O
parenteral	O
artesunate	B-CHED
.	O

RNase	O
L	O
activity	O
,	O
as	O
assessed	O
by	O
rRNA	B-CHED
cleavage	O
,	O
was	O
induced	O
by	O
ns2	O
-	O
H126R	O
,	O
but	O
not	O
by	O
A59	O
,	O
and	O
only	O
in	O
macrophages	O
and	O
microglia	O
.	O

Thus	O
,	O
RNase	O
L	O
activation	O
during	O
MHV	O
infection	O
is	O
cell	O
type	O
specific	O
and	O
correlates	O
with	O
relatively	O
high	O
levels	O
of	O
expression	O
of	O
OAS	O
genes	O
,	O
which	O
are	O
necessary	O
but	O
not	O
sufficient	O
for	O
induction	O
of	O
an	O
effective	O
RNase	O
L	O
antiviral	B-CHED
response	O
.	O

To	O
identify	O
important	O
M	O
amino	B-CHED
acid	I-CHED
residues	O
for	O
VLP	O
assembly	O
,	O
we	O
coexpressed	O
N	O
with	O
multiple	O
M	O
mutants	O
containing	O
substitution	O
mutations	O
at	O
the	O
amino	O
-	O
terminal	O
ectodomain	O
,	O
carboxyl	O
-	O
terminal	O
endodomain	O
,	O
or	O
transmembrane	O
segments	O
.	O

Results	O
from	O
cross	O
-	O
linking	O
VLP	O
analyses	O
suggest	O
that	O
the	O
cysteine	B-CHED
residues	O
63	O
,	O
85	O
and	O
158	O
are	O
not	O
in	O
close	O
proximity	O
to	O
the	O
M	O
dimer	O
interface	O
.	O

In	O
contrast	O
,	O
the	O
nsp14	O
could	O
not	O
modify	O
ATP	B-CHED
,	O
CTP	B-CHED
,	O
UTP	B-CHED
,	O
dATP	B-CHED
,	O
dCTP	B-CHED
,	O
dUTP	B-CHED
or	O
cap	O
analog	O
m7GpppA	O
.	O
Critical	O
residues	O
of	O
nsp14	O
essential	O
for	O
the	O
methyltransferase	O
activity	O
on	O
GTP	B-CHED
were	O
identified	O
,	O
which	O
include	O
F73	O
,	O
R84	O
,	O
W86	O
,	O
R310	O
,	O
D331	O
,	O
G333	O
,	O
P335	O
,	O
Y368	O
,	O
C414	O
,	O
and	O
C416	O
.	O

Topics	O
that	O
are	O
covered	O
include	O
severe	O
sepsis	O
and	O
shock	O
,	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
status	O
asthmaticus	O
,	O
diabetic	O
ketoacidosis	O
,	O
poisoning	O
(	O
acetaminophen	B-CHED
,	O
decongestants	O
,	O
prescription	O
medications	O
,	O
selective	O
serotonin	B-CHED
reuptake	O
inhibitors	B-CHED
),	O
and	O
trauma	O
.	O

Moreover	O
,	O
using	O
the	O
Allen	O
Brain	O
Atlas	O
in	O
situ	O
hybridization	O
database	O
,	O
we	O
observed	O
an	O
inverse	O
correlation	O
between	O
ApoD	O
and	O
ApoE	O
mRNA	B-CHED
expression	O
during	O
development	O
and	O
in	O
several	O
regions	O
of	O
the	O
mouse	O
brain	O
,	O
notably	O
in	O
the	O
cortex	O
,	O
hippocampus	O
,	O
plexus	O
choroid	O
,	O
and	O
cerebellum	O
.	O

A	O
systematic	O
study	O
of	O
the	O
oligomerization	O
behavior	O
revealed	O
that	O
altering	O
the	O
intermolecular	O
electrostatic	O
repulsion	O
through	O
changes	O
in	O
solution	O
salt	B-CHED
concentration	O
or	O
phosphorylation	O
-	O
mimicking	O
mutations	O
affects	O
oligomerization	O
propensity	O
.	O

Sequencing	O
of	O
their	O
RNA	O
polymerase	O
(	O
RdRp	O
),	O
spike	O
(	O
S	O
),	O
and	O
nucleocapsid	O
(	O
N	O
)	O
genes	O
revealed	O
that	O
MERS	O
-	O
CoV	O
is	O
more	O
closely	O
related	O
to	O
Pi	O
-	O
BatCoV	O
HKU5	O
in	O
RdRp	O
(	O
92	O
.	O
1	O
%	O
to	O
92	O
.	O
3	O
%	O
amino	B-CHED
acid	I-CHED
[	O
aa	O
]	O
identity	O
)	O
but	O
is	O
more	O
closely	O
related	O
to	O
Ty	O
-	O
BatCoV	O
HKU4	O
in	O
S	O
(	O
66	O
.	O
8	O
%	O
to	O
67	O
.	O
4	O
%	O
aa	O
identity	O
)	O
and	O
N	O
(	O
71	O
.	O
9	O
%	O
to	O
72	O
.	O
3	O
%	O
aa	O
identity	O
).	O

TITLE	O
:	O
Hyposialylated	O
α1	O
-	O
acid	O
glycoprotein	B-CHED
inhibits	O
phagocytosis	O
of	O
feline	O
neutrophils	O
.	O

However	O
,	O
studies	O
over	O
the	O
past	O
several	O
decades	O
suggest	O
that	O
oxidants	B-CHED
formed	O
in	O
the	O
various	O
cells	O
of	O
the	O
lung	O
including	O
endothelial	O
,	O
alveolar	O
,	O
and	O
epithelial	O
cells	O
as	O
well	O
as	O
lung	O
macrophages	O
and	O
neutrophils	O
in	O
response	O
to	O
the	O
factors	O
mentioned	O
above	O
mediate	O
the	O
pathogenesis	O
of	O
ALI	O
.	O

Oxidants	B-CHED
modify	O
cellular	O
proteins	B-CHED
,	O
lipids	B-CHED
,	O
carbohydrates	B-CHED
,	O
and	O
DNA	O
to	O
cause	O
their	O
aberrant	O
function	O
.	O

For	O
example	O
,	O
oxidation	O
of	O
lipids	B-CHED
changes	O
membrane	O
permeability	O
.	O

To	O
counteract	O
the	O
oxidants	B-CHED
an	O
arsenal	O
of	O
antioxidants	B-CHED
exists	O
in	O
the	O
lung	O
to	O
maintain	O
the	O
redox	O
status	O
,	O
but	O
when	O
overwhelmed	O
tissue	O
injury	O
and	O
exacerbation	O
of	O
inflammation	O
occurs	O
.	O

Immunosuppressants	O
/	O
immunomodulators	O
are	O
added	O
in	O
the	O
therapy	O
along	O
with	O
glucocorticoids	B-CHED
for	O
better	O
control	O
of	O
the	O
disease	O
and	O
to	O
reduce	O
the	O
required	O
dose	O
of	O
glucocorticoids	B-CHED
(	O
side	O
effects	O
of	O
longterm	O
high	O
doses	O
glucocorticoide	O
use	O
).	O

In	O
simultaneous	O
-	O
treatment	O
assay	O
,	O
compounds	O
2	O
-	O
5	O
except	O
compound	O
1	O
exhibited	O
antiviral	B-CHED
activities	O
of	O
a	O
50	O
%	O
inhibitory	O
concentration	O
(	O
IC₅₀	O
)	O
with	O
the	O
ranging	O
from	O
10	O
.	O
8	O
±	O
1	O
.	O
4	O
to	O
22	O
.	O
5	O
±	O
2	O
.	O
2	O
μM	O
against	O
PEDV	O
.	O

Compounds	O
1	O
-	O
5	O
were	O
completely	O
blocked	O
binding	O
of	O
viral	O
spike	O
protein	B-CHED
to	O
sialic	B-CHED
acids	I-CHED
at	O
less	O
than	O
36	O
.	O
6	O
μM	O
concentrations	O
by	O
hemagglutination	O
inhibition	O
.	O

Interestingly	O
,	O
compounds	O
4	O
and	O
5	O
inhibited	O
both	O
viral	O
entry	O
by	O
hemagglutination	O
inhibition	O
and	O
viral	O
replication	O
by	O
inhibition	O
of	O
viral	O
RNA	O
and	O
viral	O
protein	B-CHED
synthesis	O
,	O
but	O
not	O
viral	O
protease	O
.	O

TITLE	O
:	O
Design	O
,	O
synthesis	O
,	O
and	O
biological	O
evaluation	O
of	O
novel	O
dipeptide	B-CHED
-	O
type	O
SARS	O
-	O
CoV	O
3CL	O
protease	B-CHED
inhibitors	I-CHED
:	O
structure	O
-	O
activity	O
relationship	O
study	O
.	O

The	O
use	O
of	O
dexmedetomidine	B-CHED
to	O
wean	O
high	O
-	O
dose	O
benzodiazepines	B-CHED
and	O
opiates	O
also	O
permitted	O
successful	O
liberation	O
from	O
mechanical	O
ventilation	O
.	O

The	O
associated	O
hyperviscosity	O
was	O
treated	O
with	O
plasmapheresis	O
to	O
reduce	O
the	O
plasma	O
triglyceride	B-CHED
level	O
.	O

The	O
expressed	O
products	O
were	O
purified	O
by	O
affinity	O
chromatography	O
then	O
analyzed	O
by	O
SDS	B-CHED
-	O
PAGE	O
and	O
Western	O
blotting	O
.	O

Our	O
results	O
showed	O
that	O
the	O
recombinant	O
RBD	O
proteins	B-CHED
were	O
maximally	O
expressed	O
at	O
37	O
degrees	O
C	O
with	O
0	O
.	O

Sequence	O
analysis	O
of	O
S	O
,	O
M	O
and	O
ORE3	O
genes	O
revealed	O
that	O
the	O
central	O
China	O
PEDV	O
isolates	O
had	O
several	O
specific	O
nucleotides	B-CHED
and	O
amino	B-CHED
acids	I-CHED
which	O
were	O
different	O
from	O
PEDV	O
reference	O
strains	O
.	O

In	O
the	O
work	O
reported	O
here	O
,	O
we	O
constructed	O
BCoV	O
chimeras	O
and	O
other	O
mutants	O
of	O
MHV	O
nsp3	O
and	O
obtained	O
complementary	O
genetic	O
evidence	O
for	O
its	O
association	O
with	O
N	O
protein	B-CHED
.	O

ABSTRACT	O
:	O
Acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
is	O
characterized	O
by	O
the	O
formation	O
of	O
a	O
protein	B-CHED
-	O
rich	O
alveolar	O
edema	O
caused	O
by	O
increased	O
permeability	O
of	O
the	O
alveolocapillary	O
membrane	O
.	O

Fluorogenic	O
peptide	B-CHED
assays	O
confirmed	O
that	O
the	O
substitutions	O
modulate	O
furin	O
cleavage	O
.	O

In	O
addition	O
,	O
PHEV	O
caused	O
DNA	O
fragmentation	O
detectable	O
by	O
agarose	B-CHED
gel	O
electrophoresis	O
48h	O
post	O
-	O
infection	O
,	O
increasing	O
with	O
the	O
incubation	O
time	O
.	O

All	O
adult	O
indoor	O
patients	O
positive	O
for	O
malarial	O
infection	O
based	O
on	O
peripheral	O
smear	O
or	O
malarial	O
antigen	B-CHED
(	O
LDH	O
)	O
spot	O
test	O
were	O
included	O
in	O
the	O
study	O
.	O

To	O
date	O
there	O
are	O
few	O
directly	O
supportive	O
clinical	O
studies	O
in	O
ALI	O
;	O
this	O
review	O
explores	O
the	O
compelling	O
evidence	O
suggesting	O
arole	O
for	O
vitamin	B-CHED
D	I-CHED
in	O
ALI	O
and	O
the	O
mechanisms	O
by	O
which	O
it	O
could	O
contribute	O
to	O
pathogenesis	O
.	O

Several	O
fragment	O
compounds	O
synergistically	O
enhanced	O
the	O
inhibitory	O
activity	O
of	O
the	O
lead	O
inhibitors	B-CHED
by	O
approximately	O
an	O
order	O
of	O
magnitude	O
.	O

This	O
suggests	O
that	O
using	O
the	O
binding	O
mode	O
of	O
Man9GlcNAc	O
,	O
instead	O
of	O
those	O
of	O
small	O
glycans	B-CHED
,	O
may	O
provide	O
a	O
platform	O
for	O
the	O
design	O
of	O
DC	O
-	O
SIGNR	O
inhibitors	B-CHED
selective	O
for	O
high	O
mannose	B-CHED
glycans	B-CHED
(	O
like	O
those	O
on	O
HIV	O
).	O

ABSTRACT	O
:	O
Human	O
serum	O
albumin	O
(	O
HSA	O
)	O
is	O
the	O
most	O
abundant	O
circulating	O
protein	B-CHED
and	O
accounts	O
for	O
about	O
70	O
%	O
of	O
the	O
plasma	O
colloid	O
osmotic	O
pressure	O
.	O

Beside	O
the	O
well	O
known	O
capacity	O
to	O
act	O
as	O
plasma	O
-	O
expander	O
,	O
HSA	O
is	O
provided	O
of	O
many	O
other	O
properties	O
which	O
are	O
unrelated	O
to	O
the	O
regulation	O
of	O
fluid	O
compartmentalization	O
,	O
including	O
binding	O
and	O
transport	O
of	O
many	O
endogenous	O
and	O
exogenous	O
substances	O
,	O
antioxidant	B-CHED
function	O
,	O
immuno	O
-	O
modulation	O
,	O
anti	O
-	O
inflammatory	O
activity	O
,	O
and	O
endothelial	O
stabilization	O
.	O

After	O
specific	O
antimalarial	B-CHED
therapy	O
and	O
intensive	O
supportive	O
care	O
,	O
the	O
patient	O
was	O
discharged	O
from	O
the	O
hospital	O
.	O

Amino	B-CHED
acid	I-CHED
identities	O
were	O
>	O
97	O
%	O
for	O
the	O
BCoV	O
strains	O
analysed	O
in	O
this	O
work	O
.	O

The	O
selection	O
pattern	O
along	O
the	O
S	O
glycoprotein	B-CHED
implies	O
adaptive	O
evolution	O
of	O
BCoVs	O
,	O
suggesting	O
a	O
successful	O
mechanism	O
for	O
BCoV	O
to	O
continuously	O
circulate	O
among	O
cattle	O
and	O
other	O
ruminants	O
without	O
disappearance	O
.	O

Of	O
98	O
consecutive	O
ICU	O
patients	O
who	O
died	O
and	O
underwent	O
autopsy	O
,	O
51	O
met	B-CHED
the	O
inclusion	O
criteria	O
.	O

ABSTRACT	O
:	O
As	O
described	O
in	O
the	O
following	O
report	O
,	O
numerous	O
research	O
programs	O
reported	O
during	O
this	O
year	O
'	O
s	O
International	O
Conference	O
on	O
Antiviral	B-CHED
Research	O
(	O
ICAR	O
)	O
in	O
San	O
Francisco	O
resulted	O
in	O
novel	O
agents	O
with	O
antiviral	B-CHED
activity	O
against	O
a	O
number	O
of	O
viral	O
pathogens	O
,	O
including	O
programs	O
aimed	O
at	O
compounds	O
active	O
against	O
specific	O
pathogens	O
as	O
well	O
as	O
broad	O
preclinical	O
research	O
that	O
identified	O
compounds	O
with	O
putative	O
activity	O
against	O
many	O
virus	O
families	O
.	O

ABSTRACT	O
:	O
A	O
series	O
of	O
novel	O
5	O
-	O
pyrazoline	O
substituted	O
4	O
-	O
thiazolidinones	B-CHED
have	O
been	O
synthesized	O
.	O

Children	O
diagnosed	O
with	O
'	O
severe	O
malaria	O
'	O
(	O
World	O
Health	O
Organization	O
,	O
2000	O
),	O
were	O
started	O
on	O
intravenous	O
artesunate	B-CHED
followed	O
by	O
artemether	B-CHED
-	O
lumefantrine	B-CHED
combination	O
.	O

She	O
was	O
initially	O
treated	O
for	O
aspiration	O
pneumonia	O
with	O
ampicillin	B-CHED
/	O
sulbactam	B-CHED
.	O

We	O
also	O
administered	O
a	O
corticosteroid	B-CHED
for	O
severe	O
pneumonia	O
with	O
the	O
expectation	O
of	O
clinical	O
improvement	O
and	O
to	O
avoid	O
intubation	O
.	O

The	O
early	O
use	O
of	O
high	O
doses	O
of	O
corticosteroids	B-CHED
for	O
the	O
prevention	O
of	O
ARDS	O
in	O
septic	O
shock	O
patients	O
or	O
in	O
patients	O
with	O
confirmed	O
ARDS	O
significantly	O
reduced	O
the	O
duration	O
of	O
mechanical	O
ventilation	O
but	O
had	O
no	O
effect	O
or	O
even	O
increased	O
mortality	O
.	O

In	O
a	O
porcine	O
animal	O
model	O
,	O
which	O
is	O
immunologically	O
similar	O
to	O
humans	O
,	O
we	O
present	O
a	O
novel	O
example	O
of	O
how	O
viral	O
proteins	B-CHED
counteract	O
host	O
antiviral	B-CHED
pathways	O
to	O
determine	O
the	O
infection	O
outcome	O
and	O
pathogenesis	O
.	O

Carers	O
lost	B-CHED
on	O
average	O
13	O
hours	O
of	O
work	O
and	O
3	O
hours	O
of	O
leisure	O
time	O
per	O
ILI	O
.	O

A	O
chemically	O
synthesized	O
,	O
TGEV	O
-	O
M7	O
peptide	B-CHED
(	O
pepTGEV	O
-	O
M7	O
;	O
HALTPIKYIPPG	O
)	O
was	O
evaluated	O
for	O
antiviral	B-CHED
activity	O
.	O

We	O
retrieved	O
data	O
for	O
MERS	O
-	O
CoV	O
clusters	B-CHED
from	O
the	O
WHO	O
summary	O
and	O
subsequent	O
reports	O
,	O
and	O
published	O
descriptions	O
of	O
cases	O
,	O
and	O
took	O
into	O
account	O
55	O
of	O
the	O
64	O
laboratory	O
-	O
confirmed	O
cases	O
of	O
MERS	O
-	O
CoV	O
reported	O
as	O
of	O
June	O
21	O
,	O
2013	O
,	O
excluding	O
cases	O
notified	O
in	O
the	O
previous	O
2	O
weeks	O
.	O

17	O
altered	O
cellular	O
proteins	B-CHED
that	O
differentially	O
expressed	O
in	O
TGEV	O
infection	O
were	O
identified	O
.	O

RESULTS	O
:	O
33	O
differentially	O
expressed	O
protein	B-CHED
spots	O
,	O
of	O
which	O
23	O
were	O
up	O
-	O
regulated	O
and	O
10	O
were	O
down	O
-	O
regulated	O
were	O
identified	O
.	O

Also	O
,	O
the	O
effect	O
on	O
lung	O
injury	O
of	O
inhibiting	O
platelet	O
activation	O
by	O
clopidogrel	B-CHED
was	O
investigated	O
.	O

ABSTRACT	O
:	O
We	O
sought	O
to	O
determine	O
the	O
prevalence	O
of	O
and	O
factors	O
associated	O
with	O
acute	O
cor	O
pulmonale	O
(	O
ACP	B-CHED
)	O
and	O
patent	O
foramen	O
ovale	O
(	O
PFO	B-CHED
)	O
at	O
the	O
early	O
phase	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
and	O
to	O
assess	O
their	O
relation	O
with	O
mortality	O
.	O

Factors	O
associated	O
with	O
ACP	B-CHED
,	O
PFO	B-CHED
,	O
and	O
28	O
-	O
day	O
mortality	O
were	O
identified	O
using	O
multivariate	O
regression	O
analysis	O
.	O

Lung	O
injury	O
was	O
established	O
by	O
intravenous	O
infusion	O
of	O
oleic	B-CHED
acid	I-CHED
.	O

TITLE	O
:	O
A	O
sorghum	O
xylanase	O
inhibitor	B-CHED
-	O
like	O
protein	B-CHED
with	O
highly	O
potent	O
antifungal	B-CHED
,	O
antitumor	O
and	O
HIV	O
-	O
1	O
reverse	O
transcriptase	O
inhibitory	O
activities	O
.	O

The	O
antifungal	B-CHED
activity	O
was	O
thermostable	O
and	O
pH	O
-	O
stable	O
.	O

ABSTRACT	O
:	O
Sialic	B-CHED
acid	I-CHED
linked	O
to	O
glycoproteins	B-CHED
and	O
gangliosides	B-CHED
is	O
used	O
by	O
many	O
viruses	O
as	O
a	O
receptor	O
for	O
cell	O
entry	O
.	O

TITLE	O
:	O
Homologous	O
2	O
',	O
5	O
'-	O
phosphodiesterases	O
from	O
disparate	O
RNA	O
viruses	O
antagonize	O
antiviral	B-CHED
innate	O
immunity	O
.	O

Remarkably	O
,	O
therefore	O
,	O
two	O
disparate	O
RNA	O
viruses	O
encode	O
proteins	B-CHED
with	O
homologous	O
2	O
',	O
5	O
'-	O
PDEs	O
that	O
antagonize	O
activation	O
of	O
innate	O
immunity	O
.	O

Considering	O
these	O
data	O
,	O
we	O
diagnosed	O
eosinophilic	O
pneumonia	O
induced	O
by	O
gemcitabine	B-CHED
.	O

The	O
first	O
laboratory	O
-	O
confirmed	O
case	O
,	O
which	O
involved	O
a	O
60	O
-	O
year	O
-	O
old	O
man	B-CHED
from	O
Bisha	O
,	O
the	O
Kingdom	O
of	O
Saudi	O
Arabia	O
(	O
KSA	O
),	O
who	O
died	O
of	O
rapidly	O
progressive	O
community	O
-	O
acquired	O
pneumonia	O
and	O
acute	O
renal	O
failure	O
,	O
was	O
announced	O
by	O
the	O
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
on	O
September	O
23	O
,	O
2012	O
.	O

Here	O
we	O
demonstrate	O
that	O
HCoV	O
-	O
HKU1	O
can	O
infect	O
and	O
be	O
serially	O
propagated	O
in	O
primary	O
human	O
alveolar	O
type	O
II	O
cells	O
at	O
the	O
air	B-CHED
-	O
liquid	O
interface	O
.	O

ABSTRACT	O
:	O
The	O
spike	O
proteins	B-CHED
of	O
a	O
number	O
of	O
coronaviruses	O
are	O
able	O
to	O
bind	O
to	O
sialic	B-CHED
acids	I-CHED
present	O
on	O
the	O
cell	O
surface	O
.	O

Whereas	O
sialic	B-CHED
acid	I-CHED
is	O
the	O
only	O
receptor	O
determinant	O
known	O
so	O
far	O
for	O
IBV	O
,	O
TGEV	O
requires	O
interaction	O
with	O
its	O
receptor	O
aminopeptidase	O
N	O
to	O
initiate	O
infection	O
of	O
cells	O
.	O

TITLE	O
:	O
Performance	O
of	O
a	O
new	O
oxygen	B-CHED
delivery	O
device	O
for	O
potentially	O
infectious	O
critically	O
ill	O
patients	O
.	O

Meanwhile	O
,	O
the	O
CD69	O
expression	O
in	O
hepatic	O
NK	O
cells	O
was	O
highly	O
correlated	O
with	O
the	O
serum	O
level	O
of	O
ALT	B-CHED
and	O
AST	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
construct	O
a	O
SARS	O
-	O
CoV	O
S	O
protein	B-CHED
-	O
specific	O
phage	O
displayed	O
antigen	B-CHED
library	O
for	O
the	O
epitope	B-CHED
characterization	O
of	O
anti	O
-	O
S	O
monoclonal	O
antibodies	O
(	O
mAbs	O
).	O

First	O
,	O
the	O
full	O
-	O
length	O
gene	O
of	O
SARS	O
-	O
S	O
protein	B-CHED
was	O
PCR	O
amplified	O
,	O
purified	O
and	O
then	O
digested	O
with	O
DNase	O
I	O
to	O
obtain	O
DNA	O
fragments	O
in	O
the	O
size	O
range	O
of	O
50	O
-	O
500	O
bp	O
.	O

The	O
most	O
common	O
were	O
influenza	O
A	O
strains	O
(	O
17	O
.	O
9	O
%),	O
with	O
pandemic	O
influenza	O
A	O
(	O
H1N1	O
)	O
2009	O
and	O
seasonal	O
H3N2	B-CHED
strain	O
accounting	O
for	O
52	O
%	O
and	O
43	O
%	O
of	O
these	O
,	O
respectively	O
.	O

In	O
present	O
study	O
,	O
the	O
expression	O
of	O
principal	O
adhesion	O
molecules	O
involved	O
in	O
leukocyte	O
transmigration	O
(	O
CD15s	O
,	O
CD11a	O
,	O
CD11b	O
,	O
CD18	O
,	O
CD49d	O
,	O
and	O
CD54	O
)	O
on	O
peripheral	O
blood	O
leukocytes	O
from	O
cats	O
with	O
naturally	O
occurring	O
FIP	O
(	O
n	O
=	O
15	O
)	O
and	O
controls	O
(	O
n	O
=	O
12	O
)	O
was	O
quantified	O
by	O
flow	O
cytometry	O
using	O
a	O
formaldehyde	B-CHED
-	O
based	O
rapid	O
leukocyte	O
preparation	O
technique	O
.	O

T	O
-	O
and	O
B	O
-	O
lymphocytes	O
from	O
FIP	O
patients	O
exhibit	O
higher	O
expression	O
of	O
both	O
subunits	O
(	O
CD11a	O
and	O
CD18	O
)	O
composing	O
the	O
β2	O
integrin	O
lymphocyte	O
function	O
-	O
associated	O
antigen	B-CHED
(	O
LFA	O
)-	O
1	O
.	O

Recent	O
advances	O
in	O
extracorporeal	O
gas	O
exchange	O
technology	O
have	O
led	O
to	O
the	O
development	O
of	O
systems	O
designed	O
to	O
be	O
safer	O
and	O
simpler	O
by	O
focusing	O
on	O
the	O
clinical	O
benefits	O
of	O
partial	O
extracorporeal	O
carbon	B-CHED
dioxide	I-CHED
removal	O
(	O
ECCO	O

Further	O
studies	O
are	O
required	O
to	O
better	O
understand	O
the	O
impact	O
of	O
coinfections	O
in	O
children	O
with	O
ARI	B-CHED
.	O

ABSTRACT	O
:	O
Mice	O
that	O
are	O
transgenic	O
(	O
Tg	O
)	O
for	O
T	O
cell	O
receptor	O
(	O
TCR	O
)	O
expression	O
are	O
used	O
extensively	O
to	O
analyze	O
longitudinal	O
T	O
cell	O
responses	O
during	O
effector	B-CHED
and	O
memory	O
phases	O
of	O
the	O
T	O
cell	O
response	O
.	O

Symptomatic	O
treatment	O
with	O
protective	O
ventilation	O
,	O
vasopressors	O
,	O
continuous	O
heparin	B-CHED
and	O
insulin	B-CHED
was	O
continued	O
.	O

The	O
clinical	O
and	O
biological	O
course	O
was	O
good	O
in	O
parallel	O
of	O
the	O
normalization	O
of	O
lipid	B-CHED
abnormalities	O
.	O

Negative	O
-	O
staining	O
electron	O
microscopy	O
of	O
feces	O
revealed	O
coronavirus	O
-	O
like	O
particles	O
and	O
a	O
pan	B-CHED
-	O
coronavirus	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
designed	O
to	O
amplify	O
a	O
conserved	O
region	O
of	O
the	O
polymerase	O
gene	O
for	O
all	O
members	O
in	O
the	O
family	O
Coronaviridae	O
produced	O
expected	O
251	O
-	O
bp	O
amplicons	O
.	O

In	O
this	O
study	O
,	O
long	O
-	O
term	O
feline	O
intestinal	O
epithelial	O
cell	O
cultures	O
were	O
established	O
from	O
primary	O
ileocytes	O
and	O
colonocytes	O
by	O
simian	O
virus	O
40	O
(	O
SV40	O
)	O
T	O
-	O
antigen	B-CHED
-	O
and	O
human	O
Telomerase	O
Reverse	O
Transcriptase	O
(	O
hTERT	O
)-	O
induced	O
immortalization	O
.	O

TGEV	O
RNA	O
sequences	O
identified	O
as	O
necessary	O
for	O
viral	O
genome	O
packaging	O
were	O
not	O
sufficient	O
to	O
direct	O
packaging	O
of	O
a	O
heterologous	O
sequence	O
derived	O
from	O
the	O
green	O
fluorescent	O
protein	B-CHED
gene	O
.	O

Endothelial	O
nitric	B-CHED
oxide	I-CHED
synthase	O
(	O
eNOS	O
)	O
was	O
proposed	O
to	O
be	O
a	O
guardian	O
of	O
basal	O
barrier	O
function	O
,	O
since	O
eNOS	O
knock	O
-	O
out	O
mice	O
display	O
an	O
impaired	O
expression	O
of	O
inter	O
-	O
endothelial	O
junction	O
proteins	B-CHED
and	O
as	O
such	O
an	O
increased	O
vascular	O
permeability	O
,	O
as	O
compared	O
to	O
wild	O
type	O
mice	O
.	O

Studies	O
based	O
on	O
laser	O
visualization	O
technique	O
with	O
smoke	O
particles	O
as	O
smokers	O
in	O
the	O
human	O
patient	O
simulator	O
has	O
shown	O
that	O
oxygen	B-CHED
therapy	O
via	O
Hudson	O
mask	O
and	O
nasal	O
cannula	O
could	O
disperse	O
exhaled	O
air	B-CHED
of	O
patients	O
to	O
0	O
.	O
4	O
and	O
1	O
m	O
respectively	O
whereas	O
jet	O
nebulizer	O
could	O
disperse	O
exhaled	O
air	B-CHED
>	O
0	O
.	O
8	O
m	O
from	O
the	O
patient	O
.	O

In	O
particular	O
,	O
RBD	O
of	O
S	O
protein	B-CHED
contains	O
the	O
critical	O
neutralizing	O
domain	O
(	O
CND	O
),	O
which	O
is	O
able	O
to	O
induce	O
highly	O
potent	O
neutralizing	O
antibody	O
response	O
and	O
cross	O
-	O
protection	O
against	O
divergent	O
SARS	O
-	O
CoV	O
strains	O
.	O

TITLE	O
:	O
A	O
safe	O
and	O
convenient	O
pseudovirus	O
-	O
based	O
inhibition	O
assay	O
to	O
detect	O
neutralizing	O
antibodies	O
and	O
screen	O
for	O
viral	O
entry	O
inhibitors	B-CHED
against	O
the	O
novel	O
human	O
coronavirus	O
MERS	O
-	O
CoV	O
.	O
ABSTRACT	O
:	O
Evidence	O
points	O
to	O
the	O
emergence	O
of	O
a	O
novel	O
human	O
coronavirus	O
,	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
),	O
which	O
causes	O
a	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
like	O
disease	O
.	O

ABSTRACT	O
:	O
Microglia	O
,	O
the	O
major	O
resident	O
immune	O
cells	O
in	O
the	O
central	O
nervous	O
system	O
(	O
CNS	B-CHED
)	O
are	O
considered	O
as	O
the	O
key	O
cellular	O
mediators	O
of	O
neuroinflammatory	O
processes	O
.	O

The	O
mean	O
of	O
the	O
highest	O
plasma	O
-	O
free	O
haemoglobin	B-CHED
during	O
MCS	O
was	O
21	O
.	O
0	O
(±	O
42	O
.	O
9	O
)	O
mg	O
/	O
dl	O
.	O

Importantly	O
,	O
we	O
found	O
that	O
a	O
small	O
-	O
molecule	O
inhibitor	B-CHED
that	O
blocks	O
replication	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
CoV	O
and	O
murine	O
CoV	O
also	O
inhibits	O
the	O
activity	O
of	O
MERS	O
-	O
CoV	O
3CLpro	O
.	O

Overall	O
,	O
the	O
protease	O
expression	O
and	O
biosensor	O
assays	O
developed	O
here	O
allow	O
for	O
rapid	O
evaluation	O
of	O
viral	O
protease	O
activity	O
and	O
the	O
identification	O
of	O
protease	B-CHED
inhibitors	I-CHED
.	O

ABSTRACT	O
:	O
On	O
31	O
May	O
2013	O
,	O
the	O
first	O
case	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
infection	O
in	O
Italy	O
was	O
laboratory	O
confirmed	O
in	O
a	O
previously	O
healthy	O
adult	O
man	B-CHED
,	O
who	O
developed	O
pneumonia	O
with	O
moderate	O
respiratory	O
distress	O
after	O
returning	O
from	O
a	O
holiday	O
in	O
Jordan	O
.	O

IL	O
-	O
21	O
receptor	O
deficiency	O
did	O
not	O
affect	O
peripheral	O
T	O
cell	O
activation	O
or	O
trafficking	O
,	O
but	O
dampened	O
granzyme	O
B	O
,	O
gamma	O
interferon	O
and	O
IL	O
-	O
10	O
expression	O
by	O
CNS	B-CHED
T	O
cells	O
and	O
reduced	O
serum	O
and	O
intrathecal	O
humoral	O
responses	O
.	O

Infections	O
were	O
associated	O
with	O
transient	O
lung	O
function	O
loss	O
and	O
high	O
calcineurin	B-CHED
inhibitor	I-CHED
blood	O
levels	O
.	O

TITLE	O
:	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
infection	O
mediated	O
by	O
the	O
transmembrane	O
serine	B-CHED
protease	O
TMPRSS2	O
.	O

A	O
previous	O
randomised	O
controlled	O
Phase	O
II	O
trial	O
suggested	O
that	O
an	O
intravenous	O
(	O
i	O
.	O
v	O
.)	O
infusion	O
of	O
salbutamol	B-CHED
may	O
be	O
beneficial	O
,	O
as	O
it	O
reduced	O
extravascular	O
lung	O
water	B-CHED
and	O
plateau	O
airway	O
pressure	O
.	O

The	O
Beta	O
-	O
Agonist	B-CHED
Lung	O
injury	O
TrIal	O
-	O
2	O
(	O
BALTI	O
-	O
2	O
)	O
was	O
initiated	O
to	O
evaluate	O
the	O
effects	O
of	O
this	O
intervention	O
on	O
mortality	O
in	O
patients	O
with	O
ARDS	O
.	O

Salbutamol	B-CHED
increased	O
28	O
-	O
day	O
mortality	O
:	O
55	O
(	O
34	O
%)	O
of	O
161	O
patients	O
died	O
in	O
the	O
salbutamol	B-CHED
group	O
compared	O
with	O
38	O
(	O
23	O
%)	O
of	O
163	O
in	O
the	O
placebo	O
group	O
(	O
risk	O
ratio	O
1	O
.	O
47	O
,	O
95	O
%	O
confidence	O
interval	O
1	O
.	O
03	O
to	O
2	O
.	O
08	O
).	O

To	O
measure	O
antibodies	O
to	O
the	O
spike	O
(	O
S	O
)	O
protein	B-CHED
of	O
the	O
four	O
common	O
non	O
-	O
SARS	O
HCoVs	O
,	O
recombinant	O
S	O
proteins	B-CHED
of	O
the	O
four	O
HCoVs	O
were	O
expressed	O
and	O
characterised	O
in	O
293	O
T	O
cell	O
.	O

In	O
addition	O
,	O
we	O
ablated	O
expression	O
of	O
the	O
accessory	O
protein	B-CHED
ORF5	O
(	O
rMERS	O
•	O
ORF5	O
)	O
and	O
replaced	O
it	O
with	O
tomato	O
red	O
fluorescent	O
protein	B-CHED
(	O
rMERS	O
-	O
RFP	B-CHED
)	O
or	O
deleted	O
the	O
entire	O
ORF3	O
,	O
4	O
,	O
and	O
5	O
accessory	O
cluster	O
(	O
rMERS	O
-	O
ΔORF3	O
-	O
5	O
).	O

ABSTRACT	O
:	O
In	O
acute	O
glufosinate	B-CHED
poisoning	O
,	O
sudden	O
respiratory	O
arrest	O
and	O
convulsion	O
can	O
occur	O
after	O
a	O
latent	O
period	O
of	O
4	O
-	O
60	O
h	O
.	O
There	O
is	O
still	O
no	O
factor	O
that	O
accurately	O
predicts	O
the	O
occurrence	O
of	O
these	O
symptoms	O
.	O

TITLE	O
:	O
3C	O
protein	B-CHED
of	O
feline	O
coronavirus	O
inhibits	O
viral	O
replication	O
independently	O
of	O
the	O
autophagy	O
pathway	O
.	O

The	O
mechanism	O
underlying	O
the	O
decreased	O
FIPV	O
replication	O
caused	O
by	O
the	O
3C	O
protein	B-CHED
was	O
further	O
investigated	O
;	O
neither	O
the	O
induction	O
nor	O
inhibition	O
of	O
autophagy	O
rescued	O
the	O
viral	O
replication	O
.	O

Selection	O
analysis	O
of	O
the	O
MERS	O
-	O
CoV	O
genomes	O
reveals	O
the	O
expected	O
accumulation	O
of	O
genetic	O
diversity	O
including	O
changes	O
in	O
the	O
S	O
protein	B-CHED
.	O

High	O
-	O
throughput	O
sequencing	O
of	O
the	O
host	O
transcriptome	O
revealed	O
that	O
demyelination	O
is	O
accompanied	O
by	O
numerous	O
transcriptional	O
changes	O
indicative	O
of	O
immune	O
infiltration	O
as	O
well	O
as	O
changes	O
in	O
the	O
cytokine	O
milieu	O
and	O
lipid	B-CHED
metabolism	O
.	O

Notably	O
,	O
MERS	O
-	O
CoV	O
induced	O
significantly	O
higher	O
expression	O
levels	O
of	O
interleukin	O
12	O
,	O
IFN	O
-	O
γ	O
,	O
and	O
chemokines	O
(	O
IP	O
-	O
10	O
/	O
CXCL	O
-	O
10	O
,	O
MCP	B-CHED
-	O
1	O
/	O
CCL	B-CHED
-	O
2	O
,	O
MIP	O
-	O
1α	O
/	O
CCL	B-CHED
-	O
3	O
,	O
RANTES	O
/	O
CCL	B-CHED
-	O
5	O
,	O
and	O
interleukin	O
8	O
)	O
than	O
SARS	O
-	O
CoV	O
.	O
The	O
expression	O
of	O
major	O
histocompatibility	O
complex	O
class	O
I	O
and	O
costimulatory	O
molecules	O
were	O
significantly	O
higher	O
in	O
MERS	O
-	O
CoV	O
-	O
infected	O
MDMs	O
than	O
in	O
SARS	O
-	O
CoV	O
-	O
infected	O
cells	O
.	O

Our	O
results	O
indicate	O
that	O
systemic	O
glucose	B-CHED
levels	O
over	O
150	O
mg	O
/	O
dl	O
are	O
associated	O
with	O
a	O
higher	O
incidence	O
of	O
pneumonia	O
confirming	O
the	O
previous	O
studies	O
in	O
critically	O
ill	O
patients	O
.	O

TITLE	O
:	O
A	O
double	O
-	O
blind	O
block	O
randomized	O
clinical	O
trial	O
on	O
the	O
effect	O
of	O
zinc	B-CHED
as	O
a	O
treatment	O
for	O
diarrhea	O
in	O
neonatal	O
Holstein	O
calves	O
under	O
natural	O
challenge	O
conditions	O
.	O

Pre	O
-	O
treatment	O
liver	O
zinc	B-CHED
concentrations	O
for	O
the	O
71	O
calves	O
in	O
the	O
placebo	O
,	O
zinc	B-CHED
Met	B-CHED
,	O
and	O
ZO	O
treatment	O
groups	O
were	O
710	O
.	O
6	O
(	O
SEM	O
=	O
147	O
.	O
7	O
),	O
852	O
.	O
3	O
(	O
SEM	O
=	O
129	O
.	O
6	O
),	O
and	O
750	O
.	O
7	O
(	O
SEM	O
=	O
202	O
.	O
9	O
)	O
mg	O
/	O
kg	O
dry	O
weight	O
(	O
DW	O
),	O
respectively	O
.	O

Calves	O
treated	O
with	O
zinc	B-CHED
Met	B-CHED
gained	O
on	O
average	O
40	O
g	O
/	O
day	O
during	O
a	O
diarrhea	O
episode	O
compared	O
to	O
a	O
weight	O
loss	O
of	O
67	O
g	O
/	O
day	O
on	O
average	O
in	O
the	O
placebo	O
-	O
treated	O
calves	O
(	O
Power	O
19	O
.	O
9	O
%).	O

at	O
enrollment	O
and	O
treated	O
with	O
zinc	B-CHED
Met	B-CHED
had	O
higher	O
odds	O
of	O
testing	O
negative	O
at	O
exit	O
compared	O
to	O
placebo	O
calves	O
(	O
Odds	O
Ratio	O
(	O
OR	O
)=	O
16	O
.	O
0	O
).	O

TITLE	O
:	O
Diagnostic	O
utility	O
of	O
a	O
direct	O
immunofluorescence	O
test	O
to	O
detect	O
feline	O
coronavirus	O
antigen	B-CHED
in	O
macrophages	O
in	O
effusive	O
feline	O
infectious	O
peritonitis	O
.	O

All	O
patients	O
met	B-CHED
the	O
inclusion	O
criteria	O
of	O
hemodynamic	O
instability	O
with	O
high	O
catecholamine	B-CHED
infusion	O
requirement	O
and	O
100	O
%	O
oxygen	B-CHED
demand	O
in	O
ventilation	O
and	O
ECMO	O
flow	O
.	O

Codon	O
usage	O
(	O
CU	O
)	O
was	O
measured	O
for	O
the	O
viral	O
spike	O
(	O
S	O
),	O
nucleocapsid	O
(	O
N	O
),	O
nonstructural	O
protein	B-CHED
2	O
(	O
NSP2	O
)	O
and	O
papain	O
-	O
like	O
protease	O
(	O
PL	O
(	O
pro	B-CHED
))	O
genes	O
from	O
a	O
diverse	O
set	O
of	O
A	O
.	O
coronavirus	O
lineages	O
and	O
for	O
G	O
.	O
gallus	O
genes	O
(	O
lung	O
surfactant	B-CHED
protein	B-CHED
A	O
,	O
intestinal	O
cholecystokinin	O
,	O
oviduct	O
ovomucin	O
alpha	O
subunit	O
,	O
kidney	O
vitamin	B-CHED
D	I-CHED
receptor	O
and	O
the	O
ubiquitary	O
beta	O
-	O
actin	O
)	O
for	O
different	O
A	O
.	O
coronavirus	O
replicating	O
sites	O
.	O

Effective	O
antivirals	B-CHED
are	O
urgently	O
needed	O
.	O

Combination	O
of	O
mycophenolic	B-CHED
acid	I-CHED
and	O
interferon	O
-	O
β1b	O
lowered	O
the	O
EC50	O
of	O
each	O
drug	O
by	O
1	O
-	O
3	O
times	O
.	O

Surprisingly	O
,	O
a	O
polyclonal	O
antibody	O
to	O
the	O
S	O
protein	B-CHED
of	O
MHV	O
,	O
a	O
group	O
a	O
murine	O
betacoronavirus	O
,	O
cross	O
-	O
reacted	O
in	O
immunoblots	O
with	O
the	O
S2	O
domain	O
of	O
group	O
c	O
MERS	O
-	O
CoV	O
spike	O
protein	B-CHED
.	O

In	O
this	O
paper	O
,	O
to	O
reduce	O
the	O
environmental	O
effects	O
on	O
thermography	O
measurement	O
,	O
we	O
adopted	O
the	O
ear	O
temperature	O
as	O
a	O
new	O
screening	O
indicator	B-CHED
instead	O
of	O
facial	O
skin	O
.	O

TITLE	O
:	O
Screening	O
and	O
antiviral	B-CHED
analysis	O
of	O
phages	O
that	O
display	O
peptides	B-CHED
with	O
an	O
affinity	O
to	O
subunit	O
C	O
of	O
porcine	O
aminopeptidase	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
20	O
-	O
year	O
-	O
old	O
man	B-CHED
with	O
mandibuloacral	O
dysplasia	O
,	O
an	O
extremely	O
rare	O
premature	O
ageing	O
syndrome	O
,	O
and	O
severe	O
symptomatic	O
aortic	O
stenosis	O
,	O
referred	O
to	O
our	O
center	O
for	O
TAVI	O
after	O
being	O
considered	O
unsuitable	O
for	O
surgical	O
aortic	O
valve	O
replacement	O
.	O

Pioneer	O
studies	O
identified	O
cathepsins	O
and	O
type	O
II	O
transmembrane	O
serine	B-CHED
proteases	O
as	O
cellular	O
activators	O
of	O
SARS	O
-	O
CoV	O
and	O
demonstrated	O
that	O
several	O
emerging	O
viruses	O
might	O
exploit	O
these	O
enzymes	O
to	O
promote	O
their	O
spread	O
.	O

Given	O
that	O
estrogens	B-CHED
or	O
androgens	B-CHED
are	O
known	O
to	O
modulate	O
inflammation	O
,	O
their	O
different	O
levels	O
in	O
males	O
and	O
females	O
cannot	O
account	O
for	O
the	O
sexual	O
dimorphism	O
observed	O
in	O
humans	O
and	O
animals	O
from	O
birth	O
to	O
death	O
with	O
regard	O
to	O
inflammation	O
.	O

TITLE	O
:	O
Strategies	O
of	O
highly	O
pathogenic	O
RNA	O
viruses	O
to	O
block	O
dsRNA	B-CHED
detection	O
by	O
RIG	O
-	O
I	O
-	O
like	O
receptors	O
:	O
hide	O
,	O
mask	O
,	O
hit	O
.	O

METHODS	O
:	O
Nasopharyngeal	O
aspirate	O
specimens	O
(	O
NPA	B-CHED
)	O
from	O
349	O
patients	O
(	O
1	O
from	O
each	O
)	O
and	O
130	O
cerebrospinal	O
fluids	O
(	O
CSF	O
)	O
specimens	O
were	O
collected	O
from	O
children	O
who	O
were	O
admitted	O
to	O
the	O
PICU	O
of	O
Second	O
Affiliated	O
Hospital	O
of	O
Shantou	O
University	O
Medical	O
College	O
.	O

TITLE	O
:	O
Inhaled	O
nitric	B-CHED
oxide	I-CHED
does	O
not	O
reduce	O
mortality	O
in	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
regardless	O
of	O
severity	O
:	O
systematic	O
review	O
and	O
meta	O
-	O
analysis	O
.	O

Nitric	B-CHED
oxide	I-CHED
did	O
not	O
reduce	O
mortality	O
in	O
patients	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
risk	O
ratio	O
,	O
1	O
.	O
01	O
[	O
95	O
%	O
CI	O
,	O
0	O
.	O
78	O
-	O
1	O
.	O
32	O
];	O
p	O
=	O
0	O
.	O
93	O
;	O
n	O
=	O
329	O
,	O
six	O
trials	O
)	O
or	O
mild	O
-	O
moderate	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
risk	O
ratio	O
,	O
1	O
.	O
12	O
[	O
95	O
%	O
CI	O
,	O
0	O
.	O
89	O
-	O
1	O
.	O
42	O
];	O
p	O
=	O
0	O
.	O
33	O
;	O
n	O
=	O
740	O
,	O
seven	O
trials	O
).	O

We	O
hypothesized	O
that	O
a	O
loss	O
of	O
5	B-CHED
-	I-CHED
HT	I-CHED
for	O
∼	O
1	O
day	O
would	O
compromise	O
MAP	O
during	O
episodic	O
anoxia	O
.	O

We	O
showed	O
that	O
even	O
if	O
the	O
studied	O
patients	O
had	O
similar	O
clinical	O
phenotype	O
(	O
they	O
all	O
developed	O
severe	O
BPD	O
and	O
they	O
were	O
all	O
cured	O
in	O
the	O
same	O
way	O
in	O
terms	O
of	O
mechanical	O
ventilation	O
,	O
surfactant	B-CHED
administration	O
,	O
antenatal	O
steroid	B-CHED
treatment	O
and	O
ibuprofen	B-CHED
treatment	O
for	O
patent	O
ductus	O
arteriosus	O
),	O
however	O
their	O
BALF	O
protein	B-CHED
profiling	O
displayed	O
significant	O
differences	O
in	O
a	O
subset	O
of	O
proteins	B-CHED
,	O
which	O
could	O
be	O
exploited	O
to	O
facilitate	O
the	O
development	O
of	O
novel	O
effective	O
therapies	O
,	O
distinct	O
for	O
age	O
and	O
severity	O
of	O
the	O
disease	O
.	O

Identified	O
risk	O
factors	O
were	O
summarized	O
using	O
formal	B-CHED
narrative	O
synthesis	O
techniques	O
alongside	O
a	O
random	O
effects	O
meta	O
-	O
analysis	O
.	O

These	O
studies	O
support	O
further	O
development	O
of	O
GRFT	O
as	O
a	O
systemic	O
antiviral	B-CHED
therapeutic	O
agent	O
against	O
enveloped	O
viruses	O
,	O
although	O
deimmunizing	O
the	O
molecule	O
may	O
be	O
necessary	O
if	O
it	O
is	O
to	O
be	O
used	O
in	O
long	O
-	O
term	O
treatment	O
of	O
chronic	O
viral	O
infections	O
.	O

Acute	O
respiratory	O
distress	O
syndrome	O
patients	O
required	O
higher	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
7	O
vs	O
6	O
vs	O
10	O
vs	O
15	O
cm	O
H2O	B-CHED
for	O
no	O
,	O
mild	O
,	O
moderate	O
,	O
or	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
p	O
=	O
0	O
.	O
014	O
),	O
had	O
reduced	O
respiratory	O
system	O
compliance	O
(	O
34	O
vs	O
29	O
vs	O
30	O
vs	O
23	O
L	O
/	O
cm	O
H2O	B-CHED
,	O
p	O
=	O
0	O
.	O
028	O
),	O
and	O
an	O
increased	O
number	O
of	O
ventilator	O
days	O
(	O
no	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
10	O
d	O
;	O
mild	O
acute	O
respiratory	O
distress	O
syndrome	O
acute	O
lung	O
injury	O
,	O
12	O
d	O
;	O
moderate	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
23	O
d	O
;	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
22	O
d	O
;	O
p	O
=	O
0	O
.	O
097	O
).	O

An	O
enigma	O
in	O
understanding	O
the	O
contribution	O
of	O
T	O
cell	O
subsets	O
in	O
pathogenesis	O
resides	O
in	O
their	O
distinct	O
migration	O
pattern	O
across	O
the	O
BBB	B-CHED
(	O
blood	O
brain	O
barrier	O
).	O

These	O
data	O
suggest	O
an	O
MMP	B-CHED
-	O
independent	O
role	O
of	O
TIMP	O
-	O
1	O
in	O
regulating	O
CD4	O
⁺	O
T	O
cell	O
access	O
into	O
the	O
CNS	B-CHED
parenchyma	O
during	O
acute	O
JHMV	O
encephalitis	O
.	O

Using	O
the	O
five	O
best	O
-	O
performing	O
biomarkers	O
(	O
surfactant	B-CHED
protein	B-CHED
-	O
D	O
(	O
SP	O
-	O
D	O
),	O
receptor	O
for	O
advanced	O
glycation	O
end	O
-	O
products	O
(	O
RAGE	O
),	O
interleukin	O
-	O
8	O
(	O
IL	O
-	O
8	O
),	O
club	O
cell	O
secretory	O
protein	B-CHED
(	O
CC	O
-	O
16	O
),	O
and	O
interleukin	O
-	O
6	O
(	O
IL	O
-	O
6	O
))	O
the	O
area	O
under	O
the	O
receiver	O
operator	O
characteristic	O
curve	O
(	O
AUC	O
)	O
was	O
0	O
.	O
75	O
(	O
95	O
%	O
CI	O
:	O
0	O
.	O
7	O
to	O
0	O
.	O
84	O
)	O
for	O
the	O
diagnosis	O
of	O
ARDS	O
.	O

Twenty	O
-	O
seven	O
hospitalised	O
patients	O
with	O
PUUV	O
-	O
infection	O
were	O
examined	O
with	O
lung	O
function	O
tests	O
,	O
chest	O
high	O
-	O
resolution	O
CT	O
(	O
HRCT	O
),	O
echocardiography	O
including	O
speckle	O
tracking	O
strain	O
rate	O
analysis	O
,	O
ECG	O
and	O
measurements	O
of	O
cardiac	O
biomarkers	O
N	O
-	O
terminal	O
pro	B-CHED
-	O
B	O
-	O
type	O
natriuretic	O
peptide	B-CHED
(	O
NT	O
-	O
ProBNP	O
)	O
and	O
troponin	O
T	O
.	O
Patients	O
were	O
re	O
-	O
evaluated	O
after	O
3	O
months	O
.	O

We	O
report	O
here	O
the	O
case	O
of	O
a	O
2	O
-	O
month	O
-	O
old	O
boy	O
with	O
severe	O
respiratory	O
failure	O
and	O
pulmonary	O
hypertension	O
who	O
satisfied	O
ECMO	O
criteria	O
but	O
was	O
successfully	O
treated	O
with	O
repeated	O
bronchoscopy	O
with	O
instillation	O
of	O
N	B-CHED
-	I-CHED
acetylcysteine	I-CHED
.	O

ABSTRACT	O
:	O
Botulism	O
is	O
an	O
acute	O
form	O
of	O
poisoning	O
caused	O
by	O
one	O
of	O
four	O
types	O
(	O
A	O
,	O
B	O
,	O
E	O
,	O
F	O
)	O
toxins	B-CHED
produced	O
by	O
Clostridium	O
botulinum	O
,	O
ananaerobic	O
,	O
spore	O
forming	O
bacillus	O
.	O

TITLE	O
:	O
Aquaporin	O
-	O
4	O
antibodies	O
,	O
CNS	B-CHED
acidosis	O
and	O
neuromyelitis	O
optica	O
:	O
a	O
potential	O
link	O
.	O

ABSTRACT	O
:	O
Neuromyelitis	O
optica	O
(	O
NMO	B-CHED
,	O
Devic	O
'	O
s	O
syndrome	O
)	O
is	O
a	O
severely	O
disabling	O
disorder	O
of	O
the	O
central	O
nervous	O
system	O
characterized	O
by	O
optic	O
neuritis	O
and	O
longitudinally	O
extensive	O
myelitis	O
.	O

An	O
increase	O
in	O
AQP4	O
membrane	O
expression	O
during	O
acute	O
NMO	B-CHED
attacks	O
could	O
potentially	O
enhance	O
the	O
complement	O
-	O
mediated	O
humoral	O
immune	O
reaction	O
against	O
AQP4	O
-	O
expressing	O
astrocytes	O
characteristic	O
for	O
NMO	B-CHED
and	O
,	O
thus	O
,	O
result	O
in	O
more	O
severe	O
astrocytic	O
damage	O
.	O

Sixty	O
-	O
nine	O
faecal	O
samples	O
and	O
126	O
carcasses	O
were	O
tested	O
using	O
pan	B-CHED
-	O
coronavirus	O
RT	O
-	O
PCR	O
.	O

Given	O
that	O
ORF7	O
encodes	O
two	O
proteins	B-CHED
,	O
7a	O
and	O
7b	O
,	O
it	O
was	O
further	O
explored	O
which	O
of	O
these	O
proteins	B-CHED
is	O
active	O
in	O
this	O
mechanism	O
.	O

The	O
present	O
study	O
describes	O
a	O
computational	O
approach	O
known	O
as	O
relative	O
synonymous	O
codon	O
usage	O
(	O
RSCU	O
);	O
used	O
to	O
enhance	O
the	O
expression	O
of	O
IFN	O
-	O
λ	O
protein	B-CHED
in	O
a	O
eukaryotic	O
expression	O
system	O
.	O

TITLE	O
:	O
Fatal	O
colchicine	B-CHED
poisoning	O
by	O
accidental	O
ingestion	O
of	O
Colchicum	O
persicum	O
:	O
a	O
case	O
report	O
.	O

ABSTRACT	O
:	O
Colchicine	B-CHED
poisoning	O
can	O
occur	O
not	O
only	O
by	O
taking	O
dosage	O
form	O
but	O
also	O
by	O
ingesting	O
a	O
plant	O
containing	O
colchicine	B-CHED
.	O

ABSTRACT	O
:	O
The	O
influence	O
of	O
CD25	O
(+)	O
CD4	O
(+)	O
regulatory	O
T	O
cells	O
(	O
Treg	O
)	O
on	O
acute	O
and	O
chronic	O
viral	O
infection	O
of	O
the	O
central	O
nervous	O
system	O
(	O
CNS	B-CHED
)	O
was	O
examined	O
using	O
a	O
glial	O
tropic	O
murine	O
coronavirus	O
.	O

While	O
these	O
measures	O
are	O
sufficient	O
in	O
most	O
patients	O
,	O
a	O
minority	O
develop	O
refractory	O
hypoxemia	O
and	O
may	O
receive	O
additional	O
therapies	O
,	O
including	O
prone	O
positioning	O
,	O
inhaled	O
vasodilators	O
,	O
extracorporeal	O
membrane	O
oxygenation	O
,	O
recruitment	O
maneuvers	O
followed	O
by	O
high	O
PEEP	B-CHED
,	O
and	O
neuromuscular	O
blockade	O
,	O
although	O
recent	O
data	O
suggest	O
that	O
this	O
last	O
option	O
may	O
be	O
warranted	O
earlier	O
in	O
the	O
clinical	O
course	O
before	O
development	O
of	O
refractory	O
hypoxemia	O
.	O

ABSTRACT	O
:	O
Progress	O
in	O
the	O
development	O
of	O
antivirals	B-CHED
for	O
non	O
-	O
influenza	O
respiratory	O
viruses	O
has	O
been	O
slow	O
with	O
the	O
result	O
that	O
many	O
unmet	O
medical	O
needs	O
and	O
few	O
approved	O
agents	O
currently	O
exist	O
.	O

Female	O
sex	B-CHED
hormones	I-CHED
interfere	O
with	O
immune	O
response	O
,	O
and	O
experimental	O
and	O
clinical	O
evidence	O
shows	O
that	O
females	O
are	O
more	O
resistant	O
than	O
males	O
to	O
organ	O
injury	O
caused	O
by	O
gut	O
trauma	O
.	O

Groups	O
of	O
rats	O
received	O
17β	O
estradiol	B-CHED
(	O
E2	O
,	O
280	O
µg	O
/	O
kg	O
,	O
i	O
.	O
v	O
.,	O
single	O
dose	O
)	O
30	O
min	O
after	O
the	O
SMA	O
occlusion	O
(	O
ischemia	O
period	O
)	O
or	O
1	O
h	O
after	O
the	O
unclamping	O
of	O
SMA	O
(	O
reperfusion	O
period	O
).	O

ABSTRACT	O
:	O
The	O
type	O
II	O
transmembrane	O
serine	B-CHED
proteases	O
TMPRSS2	O
and	O
HAT	B-CHED
can	O
cleave	O
and	O
activate	O
the	O
spike	O
protein	B-CHED
(	O
S	O
)	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
for	O
membrane	O
fusion	O
.	O

However	O
,	O
no	O
mechanistic	O
insights	O
into	O
this	O
process	O
were	O
obtained	O
and	O
the	O
relevance	O
of	O
ACE2	O
cleavage	O
for	O
SARS	O
-	O
CoV	O
S	O
protein	B-CHED
(	O
SARS	O
-	O
S	O
)	O
activation	O
has	O
not	O
been	O
determined	O
.	O

Here	O
,	O
we	O
show	O
that	O
arginine	B-CHED
and	O
lysine	B-CHED
residues	O
within	O
ACE2	O
amino	B-CHED
acids	I-CHED
697	O
to	O
716	O
are	O
essential	O
for	O
cleavage	O
by	O
TMPRSS2	O
and	O
HAT	B-CHED
and	O
that	O
ACE2	O
processing	O
is	O
required	O
for	O
augmentation	O
of	O
SARS	O
-	O
S	O
-	O
driven	O
entry	O
by	O
these	O
proteases	O
.	O

Their	O
genome	O
size	O
is	O
about	O
32	O
,	O
000	O
nucleotides	B-CHED
,	O
the	O
largest	O
among	O
all	O
CoVs	O
,	O
as	O
a	O
result	O
of	O
multiple	O
unique	O
open	O
reading	O
frames	O
(	O
NS5a	O
,	O
NS5b	O
,	O
NS5c	O
,	O
NS6	O
,	O
NS7	O
,	O
NS8	O
,	O
NS9	O
,	O
and	O
NS10	O
)	O
between	O
their	O
membrane	O
(	O
M	O
)	O
and	O
nucleocapsid	O
(	O
N	O
)	O
protein	B-CHED
genes	O
.	O

TITLE	O
:	O
Novel	O
treatment	O
with	O
neuroprotective	O
and	O
antiviral	B-CHED
properties	O
against	O
a	O
neuroinvasive	O
human	O
respiratory	O
virus	O
.	O

This	O
suggests	O
that	O
memantine	B-CHED
could	O
be	O
used	O
as	O
an	O
antiviral	B-CHED
agent	I-CHED
while	O
improving	O
neurological	O
symptoms	O
in	O
various	O
neurological	O
diseases	O
with	O
a	O
viral	O
involvement	O
.	O

Hemodynamics	O
,	O
arterial	O
blood	O
gas	O
,	O
and	O
the	O
plasma	O
levels	O
of	O
lactate	B-CHED
,	O
creatinine	B-CHED
and	O
potassium	B-CHED
were	O
measured	O
at	O
0	O
,	O
1	O
,	O
2	O
,	O
3	O
,	O
and	O
4	O
h	O
after	O
treatment	O
.	O

Little	O
is	O
known	O
regarding	O
host	O
proteins	B-CHED
required	O
for	O
their	O
propagation	O
.	O

Here	O
we	O
show	O
the	O
resistance	O
of	O
ferrets	O
to	O
MERS	O
-	O
CoV	O
infection	O
and	O
inability	O
of	O
ferret	O
DDP4	O
to	O
bind	O
MERS	O
-	O
CoV	O
.	O
Site	O
-	O
directed	O
mutagenesis	O
of	O
amino	B-CHED
acids	I-CHED
variable	O
in	O
ferret	O
DPP4	O
thus	O
revealed	O
the	O
functional	O
human	O
DPP4	O
virus	O
binding	O
site	O
.	O

Adenosine	B-CHED
deaminase	O
(	O
ADA	B-CHED
),	O
a	O
DPP4	O
binding	O
protein	B-CHED
,	O
competed	O
for	O
virus	O
binding	O
,	O
acting	O
as	O
a	O
natural	O
antagonist	B-CHED
for	O
MERS	O
-	O
CoV	O
infection	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
25	O
-	O
year	O
-	O
old	O
man	B-CHED
,	O
diagnosed	O
with	O
the	O
Proteus	O
syndrome	O
at	O
the	O
age	O
of	O
6	O
months	O
.	O

An	O
important	O
step	O
in	O
antiviral	B-CHED
drug	I-CHED
development	O
is	O
the	O
screening	O
of	O
potential	O
inhibitors	B-CHED
in	O
cell	O
-	O
based	O
systems	O
.	O

TITLE	O
:	O
Extracellular	O
ATP	B-CHED
mediates	O
the	O
late	O
phase	O
of	O
neutrophil	O
recruitment	O
to	O
the	O
lung	O
in	O
murine	O
models	O
of	O
acute	O
lung	O
injury	O
.	O

In	O
conclusion	O
,	O
this	O
study	O
illustrates	O
that	O
neutrophil	O
recruitment	O
to	O
the	O
lung	O
is	O
mediated	O
by	O
the	O
time	O
-	O
dependent	O
expression	O
of	O
chemotactic	O
factors	O
and	O
suggests	O
that	O
novel	O
strategies	O
,	O
which	O
reduce	O
extracellular	O
ATP	B-CHED
accumulation	O
,	O
may	O
attenuate	O
late	O
neutrophil	O
recruitment	O
and	O
limit	O
lung	O
injury	O
during	O
ALI	O
.	O

AVPdb	O
is	O
anticipated	O
to	O
cater	O
to	O
the	O
needs	O
of	O
scientific	O
community	O
working	O
for	O
the	O
development	O
of	O
antiviral	B-CHED
therapeutics	O
.	O

Finally	O
,	O
we	O
will	O
discuss	O
the	O
challenges	O
of	O
advancing	O
antiviral	B-CHED
aptamer	O
therapeutics	O
and	O
prospects	O
for	O
future	O
success	O
.	O

To	O
determine	O
the	O
reason	O
for	O
recent	O
vaccination	O
failures	O
,	O
we	O
also	O
studied	O
variations	O
in	O
antigenicity	O
of	O
field	O
strains	O
by	O
analyzing	O
the	O
three	O
neutralizing	O
epitope	B-CHED
regions	O
in	O
the	O
S	O
gene	O
.	O

The	O
following	O
genes	O
encoding	O
virulence	O
factors	O
were	O
identified	O
in	O
E	O
.	O
coli	O
:	O
eae	O
,	O
bfp	O
,	O
saa	O
,	O
iucD	O
,	O
papGI	O
,	O
sfa	B-CHED
and	O
hly	O
.	O

The	O
L10H	O
chickens	O
as	O
well	O
as	O
the	O
L10L	O
chickens	O
also	O
showed	O
an	O
increased	O
number	O
of	O
CD4	O
-	O
CD8α	O
-	O
γδ	O
T	O
-	O
cells	O
when	O
an	O
MBL	O
ligand	B-CHED
was	O
added	O
to	O
the	O
vaccine	O
,	O
most	O
pronouncedly	O
after	O
the	O
first	O
vaccination	O
.	O

Furthermore	O
,	O
the	O
higher	O
antibody	O
response	O
in	O
L10H	O
chickens	O
receiving	O
vaccine	O
and	O
FOS	O
makes	O
FOS	O
a	O
potential	O
adjuvant	B-CHED
candidate	O
in	O
an	O
IBV	O
vaccine	O
.	O

ABSTRACT	O
:	O
Efficacy	O
of	O
antitumor	O
vaccination	O
depends	O
to	O
a	O
large	O
extent	O
on	O
antigen	B-CHED
targeting	O
to	O
dendritic	O
cells	O
(	O
DCs	O
).	O

The	O
goal	O
of	O
this	O
study	O
is	O
to	O
characterize	O
the	O
expression	O
of	O
the	O
structural	O
(	O
S	O
,	O
E	O
,	O
M	O
,	O
N	O
)	O
and	O
accessory	O
(	O
ORF	O
3	O
,	O
ORF	O
4a	O
,	O
ORF	O
4b	O
,	O
ORF	O
5	O
)	O
proteins	B-CHED
of	O
MERS	O
-	O
CoV	O
and	O
to	O
determine	O
whether	O
any	O
of	O
these	O
proteins	B-CHED
acts	O
as	O
an	O
interferon	O
antagonist	B-CHED
.	O

Together	O
,	O
our	O
results	O
provide	O
new	O
insights	O
into	O
the	O
function	O
and	O
pathogenic	O
role	O
of	O
the	O
structural	O
and	O
accessory	O
proteins	B-CHED
of	O
MERS	O
-	O
CoV	O
.	O

TITLE	O
:	O
Interferon	O
-	O
β	O
and	O
mycophenolic	B-CHED
acid	I-CHED
are	O
potent	O
inhibitors	B-CHED
of	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
in	O
cell	O
-	O
based	O
assays	O
.	O

Here	O
we	O
compared	O
the	O
susceptibility	O
of	O
MERS	O
-	O
CoV	O
with	O
different	O
IFN	O
products	O
(	O
IFN	O
-	O
α2b	O
,	O
IFN	O
-	O
γ	O
,	O
IFN	O
-	O
universal	O
,	O
IFN	O
-	O
α2a	O
and	O
IFN	O
-	O
β	O
),	O
as	O
well	O
as	O
with	O
two	O
antivirals	B-CHED
,	O
ribavirin	B-CHED
and	O
mycophenolic	B-CHED
acid	I-CHED
(	O
MPA	O
),	O
against	O
MERS	O
-	O
CoV	O
(	O
Hu	O
/	O
Jordan	O
-	O
N3	O
/	O
2012	O
)	O
in	O
vitro	O
.	O

Development	O
of	O
effective	O
therapeutics	O
and	O
vaccines	O
is	O
crucial	O
to	O
save	O
lives	O
and	O
halt	O
the	O
spread	O
of	O
MERS	O
-	O
CoV	O
.	O
Here	O
,	O
we	O
show	O
that	O
a	O
recombinant	O
protein	B-CHED
containing	O
a	O
212	O
-	O
amino	B-CHED
acid	I-CHED
fragment	O
(	O
residues	O
377	O
-	O
588	O
)	O
in	O
the	O
truncated	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
:	O
residues	O
367	O
-	O
606	O
)	O
of	O
MERS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
protein	B-CHED
fused	O
with	O
human	O
IgG	O
Fc	O
fragment	O
(	O
S377	O
-	O
588	O
-	O
Fc	O
)	O
is	O
highly	O
expressed	O
in	O
the	O
culture	O
supernatant	O
of	O
transfected	O
293T	O
cells	O
.	O

These	O
findings	O
indicate	O
that	O
this	O
truncated	O
RBD	O
protein	B-CHED
shows	O
promise	O
for	O
further	O
development	O
as	O
an	O
effective	O
and	O
safe	O
vaccine	O
for	O
the	O
prevention	O
of	O
MERS	O
-	O
CoV	O
infection	O
.	O

ABSTRACT	O
:	O
We	O
have	O
used	O
a	O
combination	O
of	O
virtual	O
screening	O
(	O
VS	O
)	O
and	O
high	O
-	O
throughput	O
screening	O
(	O
HTS	O
)	O
techniques	O
to	O
identify	O
novel	O
,	O
non	O
-	O
peptidic	O
small	O
molecule	O
inhibitors	B-CHED
against	O
human	O
SARS	O
-	O
CoV	O
3CLpro	O
.	O

These	O
single	O
nucleotide	B-CHED
polymorphisms	O
were	O
distributed	O
on	O
five	O
chicken	O
chromosomes	O
(	O
GGA	O
),	O
involving	O
GGA1	O
,	O
GGA3	O
,	O
GGA5	O
,	O
GGA8	O
,	O
and	O
GGA9	O
.	O

Hemodynamics	O
did	O
not	O
change	O
with	O
exception	O
of	O
increased	O
mean	O
pulmonary	O
arterial	O
pressure	O
during	O
PrP	B-CHED
and	O
decrease	O
after	O
PrP	B-CHED
(	O
p	O
<	O
0	O
.	O
001	O
),	O
while	O
norepinephrine	B-CHED
dosage	O
decreased	O
(	O
p	O
=	O
0	O
.	O
03	O
)	O
(	O
MANOVA	O
).	O

Hemodynamics	O
did	O
not	O
change	O
with	O
exception	O
of	O
increased	O
mean	O
pulmonary	O
arterial	O
pressure	O
during	O
PrP	B-CHED
and	O
decrease	O
after	O
PrP	B-CHED
(	O
p	O
<	O
0	O
.	O
001	O
),	O
while	O
norepinephrine	B-CHED
dosage	O
decreased	O
(	O
p	O
=	O
0	O
.	O
03	O
)	O
(	O
MANOVA	O
).	O

TITLE	O
:	O
[	O
Assessment	O
of	O
oxygen	B-CHED
status	O
in	O
critical	O
patients	O
with	O
systemic	O
inflammatory	O
reaction	O
].	O

Given	O
that	O
BCoV	O
is	O
better	O
studied	O
than	O
equine	O
coronaviruses	O
and	O
given	O
the	O
possibility	O
of	O
interspecies	O
transmission	O
of	O
these	O
viruses	O
,	O
this	O
research	O
was	O
designed	O
to	O
compare	O
the	O
partial	O
sequences	O
of	O
the	O
spike	O
glycoprotein	B-CHED
(	O
S	O
),	O
hemagglutinin	O
-	O
esterase	O
protein	B-CHED
(	O
HE	O
),	O
and	O
nucleoprotein	O
(	O
N	O
)	O
genes	O
from	O
coronaviruses	O
from	O
adult	O
cattle	O
with	O
winter	O
dysentery	O
,	O
calves	O
with	O
neonatal	O
diarrhea	O
,	O
and	O
horses	O
.	O

ABSTRACT	O
:	O
The	O
isogenic	O
host	O
attachment	O
spike	O
protein	B-CHED
recombinant	O
demyelinating	O
strain	O
of	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
(	O
RSA59	O
)	O
and	O
the	O
nondemyelinating	O
strain	O
(	O
RSMHV2	O
)	O
differ	O
in	O
their	O
abilities	O
to	O
infect	O
distinct	O
types	O
of	O
neural	O
cells	O
,	O
spread	O
from	O
cell	O
to	O
cell	O
,	O
and	O
induce	O
subsequent	O
demyelination	O
and	O
axonal	O
loss	O
.	O

Its	O
surface	O
receptor	O
glycoproteins	B-CHED
,	O
hemagglutinin	O
(	O
HA	O
)	O
and	O
neuraminidase	O
(	O
NA	O
),	O
are	O
characterized	O
by	O
high	O
antigenic	O
variation	O
,	O
thus	O
a	O
host	O
organism	O
cannot	O
develop	O
permanent	O
resistance	O
.	O

HE	O
proteins	B-CHED
mediate	O
reversible	O
binding	O
to	O
sialic	B-CHED
acid	I-CHED
receptor	O
determinants	O
,	O
very	O
abundant	O
glycan	B-CHED
residues	O
in	O
the	O
enteric	O
and	O
respiratory	O
tracts	O
.	O

K2	O
values	O
were	O
lower	O
in	O
APAP	B-CHED
compared	O
with	O
those	O
in	O
CPAP	O
and	O
CON	O
.	O

K2	O
values	O
were	O
lower	O
in	O
APAP	B-CHED
compared	O
with	O
those	O
in	O
CPAP	O
and	O
CON	O
.	O

Six	O
pentacyclic	O
triterpenes	B-CHED
,	O
but	O
not	O
tetracyclic	O
triterpenes	B-CHED
,	O
significantly	O
inhibited	O
HNE	B-CHED
.	O

The	O
results	O
of	O
nuclear	O
magnetic	O
resonance	O
and	O
HNE	B-CHED
inhibition	O
kinetic	O
analysis	O
showed	O
that	O
the	O
pentacyclic	O
triterpenes	B-CHED
competitively	O
and	O
reversibly	O
inhibited	O
HNE	B-CHED
.	O

TITLE	O
:	O
FJU	O
-	O
C4	O
,	O
a	O
new	O
2	B-CHED
-	I-CHED
pyridone	I-CHED
compound	O
,	O
attenuates	O
lipopolysaccharide	B-CHED
-	O
induced	O
systemic	O
inflammation	O
via	O
p38MAPK	O
and	O
NF	O
-	O
κB	O
in	O
mice	O
.	O

The	O
use	O
of	O
anti	B-CHED
-	I-CHED
inflammatory	I-CHED
agents	I-CHED
to	O
attenuate	O
inflammatory	O
response	O
during	O
acute	O
systemic	O
inflammatory	O
reactions	O
may	O
improve	O
survival	O
rates	O
.	O

Supportive	O
therapies	O
like	O
surfactant	B-CHED
replacement	O
therapy	O
and	O
prone	O
positioning	O
can	O
be	O
beneficial	O
in	O
patients	O
with	O
ARDS	O
in	O
whom	O
severe	O
hypoxemia	O
persists	O
despite	O
high	O
levels	O
of	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	B-CHED
)	O
and	O
plateau	O
pressures	O
.	O

Coagulation	O
studies	O
revealed	O
lupus	O
anticoagulant	B-CHED
.	O

RESULTS	O
:	O
High	O
levels	O
of	O
pro	B-CHED
-	O
inflammatory	O
cytokines	O
IL	O
-	O
1β	O
,-	O
6	O
,-	O
8	O
,-	O
12	O
,	O
tumour	O
necrosis	O
factor	O
alpha	O
and	O
interferon	O
gamma	O
were	O
found	O
in	O
all	O
injured	O
patients	O
compared	O
to	O
healthy	O
controls	O
.	O

There	O
is	O
clearly	O
an	O
urgent	O
need	O
for	O
a	O
novel	O
effective	O
antiviral	B-CHED
therapy	O
for	O
this	O
emerging	O
global	O
threat	O
.	O

RESULTS	O
:	O
In	O
this	O
study	O
we	O
compared	O
S	O
proteins	B-CHED
of	O
SARS	O
-	O
CoV	O
and	O
HCoV	O
-	O
HKU1	O
for	O
their	O
ability	O
to	O
activate	O
the	O
UPR	O
.	O

TITLE	O
:	O
The	O
effects	O
of	O
Nigella	O
sativa	O
(	O
Ns	O
),	O
Anthemis	O
hyalina	O
(	O
Ah	O
)	O
and	O
Citrus	O
sinensis	O
(	O
Cs	O
)	O
extracts	O
on	O
the	O
replication	O
of	O
coronavirus	O
and	O
the	O
expression	O
of	O
TRP	B-CHED
genes	O
family	O
.	O

ABSTRACT	O
:	O
Extracts	O
of	O
Anthemis	O
hyalina	O
(	O
Ah	O
),	O
Nigella	O
sativa	O
(	O
Ns	O
)	O
and	O
peels	O
of	O
Citrus	O
sinensis	O
(	O
Cs	O
)	O
have	O
been	O
used	O
as	O
folk	O
medicine	B-CHED
to	O
fight	O
antimicrobial	B-CHED
diseases	O
.	O

The	O
sequence	O
variations	O
between	O
the	O
two	O
strains	O
were	O
in	O
an	O
antigenic	O
important	O
part	O
of	O
the	O
G	O
protein	B-CHED
.	O

We	O
attribute	O
these	O
prior	O
failures	O
to	O
limited	O
mass	O
transfer	O
of	O
oxygen	B-CHED
to	O
the	O
peritoneum	O
and	O
have	O
designed	O
an	O
oxygen	B-CHED
formulation	O
that	O
overcomes	O
this	O
limitation	O
.	O

ABSTRACT	O
:	O
Excessive	O
reactive	O
oxygen	B-CHED
/	O
nitrogen	B-CHED
species	O
have	O
been	O
associated	O
with	O
the	O
onset	O
,	O
progression	O
,	O
and	O
outcome	O
of	O
sepsis	O
,	O
both	O
in	O
preclinical	O
and	O
clinical	O
studies	O
.	O

Univariate	O
analysis	O
showed	O
that	O
the	O
age	O
,	O
underlying	O
disease	O
scores	O
,	O
history	O
of	O
cardiovascular	O
disease	O
,	O
diabetes	O
mellitus	O
,	O
and	O
cerebrovascular	O
disease	O
,	O
positive	O
blood	O
culture	O
,	O
whether	O
or	O
not	O
complicated	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
or	O
severe	O
sepsis	O
/	O
septic	O
shock	O
,	O
procalcitonin	O
(	O
PCT	O
),	O
acute	O
physiology	O
and	O
chronic	O
health	O
evaluation	O
II	O
(	O
APACHE	O
II	O
),	O
acute	O
pathophysiology	O
score	O
(	O
APS	B-CHED
)	O
and	O
sequential	O
organ	O
failure	O
assessment	O
(	O
SOFA	O
)	O
were	O
found	O
to	O
be	O
the	O
factors	O
related	O
with	O
the	O
prognosis	O
(	O
all	O
P	O
<	O
0	O
.	O
2	O
).	O

Further	O
investigations	O
on	O
the	O
combination	O
and	O
concentrations	O
of	O
the	O
peptides	B-CHED
and	O
fCpG	O
-	O
ODNs	O
,	O
dose	O
,	O
frequency	O
and	O
route	O
of	O
administration	O
are	O
needed	O
.	O

Some	O
of	O
these	O
drugs	O
turned	O
out	O
to	O
be	O
potent	O
inhibitors	B-CHED
of	O
the	O
3a	O
channel	O
.	O

Inflammation	O
,	O
dyslipidemia	O
and	O
altered	O
sex	O
-	O
steroid	B-CHED
milieu	O
mutually	O
concur	O
in	O
determining	O
BPH	B-CHED
/	O
LUTS	O
.	O

We	O
present	O
a	O
42	O
-	O
year	O
-	O
old	O
male	O
admitted	O
after	O
heroin	B-CHED
use	O
with	O
heroin	B-CHED
-	O
related	O
peripheral	O
nervous	O
system	O
complication	O
preceded	O
by	O
an	O
acute	O
gluteal	O
compartment	O
syndrome	O
and	O
severe	O
rhabdomyolysis	O
.	O

Pro	B-CHED
-	O
active	O
surveillance	O
for	O
MERS	O
-	O
CoV	O
in	O
newly	O
diagnosed	O
patients	O
and	O
their	O
contacts	O
will	O
continue	O
.	O

TITLE	O
:	O
Fulminant	O
systemic	O
capillary	O
leak	O
syndrome	O
due	O
to	O
C1	O
inhibitor	B-CHED
deficiency	O
complicating	O
acute	O
dermatomyositis	O
:	O
a	O
case	O
report	O
.	O

A	O
laboratory	O
analysis	O
of	O
her	O
complement	O
system	O
suggested	O
the	O
presence	O
of	O
C1	O
inhibitor	B-CHED
deficiency	O
as	O
the	O
cause	O
for	O
systemic	O
capillary	O
leakage	O
.	O

HR2P	O
can	O
effectively	O
inhibit	O
MERS	O
-	O
CoV	O
replication	O
and	O
its	O
spike	O
protein	B-CHED
-	O
mediated	O
cell	O
-	O
cell	O
fusion	O
.	O

Introduction	O
of	O
hydrophilic	O
residues	O
into	O
HR2P	O
results	O
in	O
significant	O
improvement	O
of	O
its	O
stability	O
,	O
solubility	O
and	O
antiviral	B-CHED
activity	O
.	O

Therefore	O
,	O
the	O
HR2P	O
analogues	O
have	O
good	O
potential	O
to	O
be	O
further	O
developed	O
into	O
effective	O
viral	O
fusion	O
inhibitors	B-CHED
for	O
treating	O
MERS	O
-	O
CoV	O
infection	O
.	O

An	O
epidemiological	O
investigation	O
revealed	O
that	O
all	O
patients	O
had	O
used	O
humidifier	O
disinfectants	B-CHED
in	O
their	O
homes	O
.	O

RESULTS	O
:	O
Between	O
December	O
2012	O
and	O
August	O
2013	O
,	O
114	O
patients	O
were	O
tested	O
for	O
suspected	O
MERS	O
-	O
CoV	O
;	O
of	O
these	O
,	O
11	O
ICU	O
patients	O
(	O
10	O
%)	O
met	B-CHED
the	O
definition	O
of	O
confirmed	O
or	O
probable	O
cases	O
.	O

Five	O
patients	O
showed	O
a	O
severe	O
and	O
persistent	O
neonatal	O
pulmonary	O
hypertension	O
(	O
PPHN	O
)	O
requiring	O
Nitric	B-CHED
Oxide	I-CHED
(	O
NO	O
)	O
and	O
/	O
or	O
sildenafil	B-CHED
administration	O
combined	O
in	O
2	O
cases	O
with	O
high	O
-	O
frequency	O
oscillatory	O
(	O
HFO	O
)	O
ventilation	O
.	O

Perfluorocarbon	O
(	O
PFC	O
),	O
a	O
chemical	B-CHED
compound	I-CHED
known	O
as	O
liquid	O
ventilation	O
medium	O
,	O
is	O
capable	O
of	O
dissolving	O
large	O
amounts	O
of	O
physiologically	O
important	O
gases	O
(	O
mainly	O
oxygen	B-CHED
and	O
carbon	B-CHED
dioxide	I-CHED
).	O

By	O
analyzing	O
pulmonary	O
pathology	O
,	O
partial	O
pressure	O
of	O
oxygen	B-CHED
in	O
the	O
blood	O
(	O
PaO2	O
)	O
and	O
lung	O
wet	O
-	O
dry	O
weight	O
ratio	O
(	O
W	O
/	O
D	O
)	O
of	O
each	O
rat	O
,	O
we	O
found	O
that	O
intravenous	O
infusion	O
of	O
PFC	O
significantly	O
alleviated	O
acute	O
lung	O
injury	O
induced	O
by	O
LPS	B-CHED
.	O

The	O
exact	O
mechanism	O
and	O
predisposing	O
factors	O
such	O
as	O
age	O
,	O
gender	O
,	O
dosage	O
,	O
type	O
and	O
combination	O
of	O
steroid	B-CHED
treatment	O
remain	O
controversial	O
.	O

The	O
incidence	O
of	O
ONFH	O
in	O
patients	O
receiving	O
one	O
type	O
of	O
steroid	B-CHED
was	O
12	O
.	O
5	O
%	O
(	O
21	O
of	O
168	O
),	O
which	O
was	O
much	O
lower	O
than	O
patients	O
receiving	O
two	O
different	O
types	O
(	O
28	O
.	O
6	O
%;	O
96	O
of	O
336	O
)	O
or	O
three	O
different	O
types	O
of	O
steroid	B-CHED
(	O
37	O
.	O
1	O
%;	O
13	O
of	O
35	O
).	O

The	O
viral	O
glycoproteins	B-CHED
need	O
to	O
be	O
primed	O
by	O
protease	O
cleavage	O
,	O
rendering	O
them	O
active	O
for	O
fusion	O
with	O
the	O
host	O
cell	O
membrane	O
.	O

ABSTRACT	O
:	O
The	O
coronavirus	O
nucleocapsid	O
(	O
N	O
)	O
protein	B-CHED
forms	O
a	O
helical	O
ribonucleoprotein	O
with	O
the	O
viral	O
positive	O
-	O
strand	O
RNA	O
genome	O
and	O
binds	O
to	O
the	O
principal	O
constituent	O
of	O
the	O
virion	O
envelope	O
,	O
the	O
membrane	O
(	O
M	O
)	O
protein	B-CHED
,	O
to	O
facilitate	O
assembly	O
and	O
budding	O
.	O

These	O
results	O
more	O
clearly	O
delineate	O
the	O
functions	O
of	O
N	O
protein	B-CHED
and	O
establish	O
a	O
basis	O
for	O
further	O
exploration	O
of	O
the	O
mechanism	O
of	O
genomic	O
RNA	O
packaging	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
specific	O
detection	O
of	O
anti	O
-	O
FCoV	O
antibodies	O
was	O
possible	O
in	O
all	O
plasma	O
,	O
serum	O
,	O
whole	O
blood	O
,	O
and	O
ascitic	O
fluid	O
samples	O
using	O
the	O
ICA	B-CHED
kit	O
with	O
protein	B-CHED
A	O
blotted	O
as	O
the	O
test	O
line	O
(	O
CJNP	O
/	O
TPA	B-CHED
).	O

Upon	O
binding	O
of	O
antibodies	O
,	O
these	O
proteins	B-CHED
are	O
quickly	O
internalised	O
through	O
a	O
new	O
clathrin	O
-	O
and	O
caveolae	O
-	O
independent	O
internalisation	O
pathway	O
.	O

One	O
minute	O
after	O
internalisation	O
started	O
,	O
vesicles	O
had	O
passed	O
the	O
cortical	O
actin	O
,	O
co	O
-	O
localised	O
with	O
microtubules	O
and	O
association	O
with	O
myosin	O
6	O
was	O
lost	B-CHED
.	O

Poisoning	O
with	O
rivastigmine	B-CHED
can	O
be	O
a	O
life	O
-	O
threatening	O
condition	O
.	O

TITLE	O
:	O
Influence	O
of	O
hydrophobic	O
and	O
electrostatic	O
residues	O
on	O
SARS	O
-	O
coronavirus	O
S2	O
protein	B-CHED
stability	O
:	O
insights	O
into	O
mechanisms	O
of	O
general	O
viral	O
fusion	O
and	O
inhibitor	B-CHED
design	O
.	O

The	O
SARS	O
-	O
CoV	O
S2	O
is	O
a	O
potential	O
drug	O
target	O
,	O
as	O
peptidomimetics	B-CHED
against	O
S2	O
act	O
as	O
potent	O
fusion	O
inhibitors	B-CHED
.	O

The	O
24	O
hours	O
urine	O
protein	B-CHED
analysis	O
revealed	O
significant	O
proteinuria	O
and	O
renal	O
biopsy	O
showed	O
global	O
and	O
seg	O
-	O
mental	O
sclerosis	O
in	O
glomeruli	O
,	O
mesangial	O
arteritis	O
,	O
proliferations	O
in	O
visceral	O
epithelial	O
cells	O
(	O
IgA	O
nephropathy	O
).	O

The	O
antiviral	B-CHED
roles	O
of	O
triterpenoids	B-CHED
in	O
licorice	O
against	O
herpes	O
virus	O
,	O
HIV	O
,	O
hepatitis	O
virus	O
,	O
SARS	O
coronavirus	O
and	O
influenza	O
virus	O
were	O
briefly	O
summarized	O
.	O

This	O
work	O
not	O
only	O
provides	O
a	O
new	O
understanding	O
of	O
the	O
abilities	O
of	O
MERS	O
-	O
CoV	O
and	O
closely	O
related	O
bat	O
viruses	O
to	O
subvert	O
virus	O
sensing	O
but	O
also	O
might	O
prove	O
useful	O
in	O
revealing	O
new	O
strategies	O
for	O
the	O
development	O
of	O
vaccines	O
and	O
antivirals	B-CHED
.	O

TITLE	O
:	O
[	O
The	O
prognostic	O
value	O
of	O
extravascular	O
lung	O
water	B-CHED
index	O
in	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
].	O

We	O
also	O
identified	O
peptides	B-CHED
that	O
strongly	O
induce	O
Th1	O
activity	O
from	O
those	O
derived	O
from	O
the	O
structural	O
proteins	B-CHED
(	O
S	O
,	O
M	O
,	O
and	O
N	O
proteins	B-CHED
)	O
of	O
FIPV	O
based	O
on	O
this	O
and	O
previous	O
studies	O
(	O
Satoh	O
et	O
al	O
.	O
[	O
19	O
]).	O

ABSTRACT	O
:	O
The	O
5	O
'-	O
cap	O
structure	O
is	O
a	O
distinct	O
feature	O
of	O
eukaryotic	O
mRNAs	O
and	O
is	O
important	O
for	O
RNA	O
stability	O
and	O
protein	B-CHED
translation	O
by	O
providing	O
a	O
molecular	O
signature	O
for	O
the	O
distinction	O
of	O
self	O
or	O
non	O
-	O
self	O
mRNA	B-CHED
.	O

Eukaryotic	O
viruses	O
generally	O
modify	O
the	O
5	O
'-	O
end	O
of	O
their	O
RNAs	O
to	O
mimic	O
the	O
cellular	O
mRNA	B-CHED
structure	O
,	O
thereby	O
facilitating	O
viral	O
replication	O
in	O
host	O
cells	O
.	O

The	O
structure	O
also	O
revealed	O
an	O
N	O
-	O
cyclohexyl	B-CHED
-	O
2	O
-	O
aminethanesulfonic	O
acid	O
molecule	O
near	O
the	O
catalytic	O
triad	O
,	O
and	O
kinetic	O
studies	O
suggest	O
that	O
this	O
binding	O
site	O
is	O
also	O
used	O
by	O
other	O
PLpro	O
inhibitors	B-CHED
.	O

We	O
found	O
that	O
TGEV	O
N	O
protein	B-CHED
suppressed	O
cell	O
proliferation	O
by	O
causing	O
cell	O
cycle	O
arrest	O
at	O
the	O
S	O
and	O
G2	O
/	O
M	O
phases	O
and	O
apoptosis	O
.	O

Further	O
studies	O
showed	O
that	O
p53	O
inhibitor	B-CHED
attenuated	O
TGEV	O
N	O
protein	B-CHED
induced	O
cell	O
cycle	O
arrest	O
at	O
S	O
and	O
G2	O
/	O
M	O
phases	O
and	O
apoptosis	O
through	O
reversing	O
the	O
expression	O
changes	O
of	O
cdc2	O
,	O
cdk2	O
and	O
cyclin	O
B1	O
and	O
the	O
translocation	O
changes	O
of	O
Bax	O
and	O
cytochrome	B-CHED
c	I-CHED
induced	O
by	O
TGEV	O
N	O
protein	B-CHED
.	O

BAL	B-CHED
supernatants	O
and	O
sera	O
were	O
used	O
to	O
assess	O
cytokines	O
and	O
chemokines	O
secretion	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
.	O

We	O
used	O
a	O
prototype	O
coronavirus	O
--	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)--	O
to	O
develop	O
a	O
conditional	O
biotinylation	O
assay	O
that	O
enables	O
the	O
specific	O
identification	O
and	O
biochemical	O
characterization	O
of	O
viral	O
S	O
proteins	B-CHED
on	O
virions	O
that	O
mediated	O
membrane	O
fusion	O
with	O
the	O
target	O
cell	O
.	O

Cell	O
entry	O
begins	O
with	O
virus	O
spike	O
(	O
S	O
)	O
protein	B-CHED
binding	O
to	O
DPP4	O
receptors	O
.	O

Infection	O
susceptibility	O
correlated	O
with	O
affinities	O
of	O
the	O
receptors	O
for	O
viral	O
spike	O
proteins	B-CHED
.	O

TITLE	O
:	O
Identification	O
of	O
Mycoplasma	O
suis	O
antigens	B-CHED
and	O
development	O
of	O
a	O
multiplex	O
microbead	O
immunoassay	O
.	O

Using	O
human	O
CoV	O
-	O
OC43	O
(	O
HCoV	O
-	O
OC43	O
)	O
as	O
a	O
model	O
for	O
CoV	O
,	O
we	O
present	O
the	O
3D	O
structure	O
of	O
HCoV	O
-	O
OC43	O
N	O
-	O
NTD	O
complexed	O
with	O
ribonucleoside	B-CHED
5	I-CHED
'-	I-CHED
monophosphates	I-CHED
to	O
identify	O
a	O
distinct	O
ribonucleotide	B-CHED
-	O
binding	O
pocket	O
.	O

By	O
targeting	O
this	O
pocket	O
,	O
we	O
identified	O
and	O
developed	O
a	O
new	O
coronavirus	O
N	O
protein	B-CHED
inhibitor	B-CHED
,	O
N	O
-(	O
6	O
-	O
oxo	B-CHED
-	O
5	O
,	O
6	O
-	O
dihydrophenanthridin	O
-	O
2	O
-	O
yl	O
)(	O
N	O
,	O
N	O
-	O
dimethylamino	O
)	O
acetamide	B-CHED
hydrochloride	B-CHED
(	O
PJ34	O
),	O
using	O
virtual	O
screening	O
;	O
this	O
inhibitor	B-CHED
reduced	O
the	O
N	O
protein	B-CHED
'	O
s	O
RNA	O
-	O
binding	O
affinity	O
and	O
hindered	O
viral	O
replication	O
.	O

The	O
antiviral	B-CHED
activity	O
,	O
preclincial	O
PK	O
profile	O
,	O
and	O
toxicology	O
studies	O
in	O
rat	O
and	O
dog	O
supported	O
clinical	O
development	O
of	O
BMS	O
-	O
650032	O
(	O
24	O
).	O

TITLE	O
:	O
Outcome	O
of	O
acute	O
East	O
African	O
trypanosomiasis	O
in	O
a	O
Polish	O
traveller	O
treated	O
with	O
pentamidine	B-CHED
.	O

Viruses	O
detected	O
,	O
based	O
on	O
frequency	O
were	O
Rhinovirus	O
,	O
Adenovirus	O
,	O
human	O
metapneumovirus	O
(	O
hMPV	O
),	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
and	O
corona	B-CHED
virus	O
.	O

The	O
prognosis	O
depends	O
on	O
a	O
rapid	O
identification	O
and	O
treatment	O
with	O
antibiotics	B-CHED
.	O

Sequence	O
comparison	O
of	O
the	O
hexon	O
protein	B-CHED
of	O
one	O
of	O
the	O
THEV	O
strains	O
detected	O
,	O
and	O
strains	O
isolated	O
worldwide	O
,	O
revealed	O
high	O
similarity	O
between	O
them	O
.	O

Accordingly	O
,	O
in	O
contrast	O
to	O
WT	O
mice	O
,	O
TMPRSS2	O
KO	O
mice	O
were	O
highly	O
tolerant	O
of	O
challenge	O
infection	O
by	O
LP	O
IAVs	O
(	O
H1N1	O
,	O
H3N2	B-CHED
,	O
and	O
H7N9	O
)	O
with	O
≥	O
1	O
,	O
000	O
50	O
%	O
lethal	O
doses	O
(	O
LD50	O
)	O
for	O
WT	O
mice	O
.	O

TITLE	O
:	O
Neuroleptic	B-CHED
malignant	O
-	O
like	O
syndrome	O
with	O
a	O
slight	O
elevation	O
of	O
creatine	B-CHED
-	O
kinase	O
levels	O
and	O
respiratory	O
failure	O
in	O
a	O
patient	O
with	O
Parkinson	O
'	O
s	O
disease	O
.	O

ABSTRACT	O
:	O
Neuroleptic	B-CHED
malignant	O
-	O
like	O
syndrome	O
(	O
NMLS	O
)	O
is	O
a	O
rare	O
but	O
catastrophic	O
complication	O
of	O
drug	O
treatment	O
for	O
Parkinson	O
'	O
s	O
disease	O
(	O
PD	O
).	O

Both	O
of	O
these	O
conditions	O
can	O
present	O
with	O
hyperthermia	O
,	O
marked	O
muscle	O
rigidity	O
,	O
altered	O
consciousness	O
,	O
autonomic	O
dysfunction	O
,	O
and	O
elevated	O
serum	O
creatine	B-CHED
-	O
kinase	O
(	O
CK	O
)	O
levels	O
.	O

Here	O
,	O
we	O
show	O
that	O
a	O
chimeric	O
S	O
protein	B-CHED
,	O
containing	O
the	O
six	O
C	O
-	O
terminal	O
amino	B-CHED
acids	I-CHED
of	O
the	O
glycoprotein	B-CHED
G	O
of	O
vesicular	O
stomatitis	O
virus	O
(	O
VSV	O
)	O
is	O
no	O
longer	O
retained	O
intracellularly	O
,	O
despite	O
the	O
presence	O
of	O
the	O
tyrosine	B-CHED
tetrapeptide	B-CHED
motif	O
.	O

TITLE	O
:	O
The	O
free	O
radical	B-CHED
scavenger	I-CHED
Trolox	O
dampens	O
neuronal	O
hyperexcitability	O
,	O
reinstates	O
synaptic	O
plasticity	O
,	O
and	O
improves	O
hypoxia	O
tolerance	O
in	O
a	O
mouse	O
model	O
of	O
Rett	O
syndrome	O
.	O

Our	O
recent	O
assessment	O
of	O
mitochondrial	O
function	O
in	O
MeCP2	O
(	O
methyl	B-CHED
-	O
CpG	O
-	O
binding	O
protein	B-CHED
2	O
)-	O
deficient	O
mouse	O
(	O
Mecp2	O
(-)	O
(/	O
y	O
))	O
hippocampus	O
confirmed	O
early	O
metabolic	O
alterations	O
,	O
an	O
increased	O
oxidative	O
burden	O
,	O
and	O
a	O
more	O
vulnerable	O
cellular	O
redox	O
balance	B-CHED
.	O

Of	O
etiotropic	O
treatment	O
of	O
influenza	O
and	O
other	O
ARVI	O
include	O
a	O
wide	O
spectrum	O
of	O
antiviral	B-CHED
drugs	I-CHED
,	O
among	O
which	O
are	O
the	O
drugs	O
with	O
a	O
restricted	O
spectrum	O
,	O
basically	O
used	O
in	O
influenza	O
,	O
and	O
a	O
general	O
spectrum	O
used	O
in	O
influenza	O
and	O
other	O
ARVI	O
as	O
a	O
prophylactic	O
or	O
therapeutic	O
intention	O
.	O

The	O
expressed	O
protein	B-CHED
,	O
used	O
in	O
ELISA	O
,	O
effectively	O
detected	O
chicken	O
anti	O
-	O
IBV	O
antibodies	O
with	O
high	O
specificity	O
.	O

The	O
CD4	O
(+)	O
T	O
cells	O
rebounded	O
or	O
were	O
preserved	O
in	O
the	O
lung	O
mucosa	O
during	O
chronic	O
viral	O
infection	O
,	O
which	O
correlated	O
with	O
heightened	O
induction	O
of	O
type	O
I	O
IFN	O
signaling	B-CHED
molecules	I-CHED
and	O
innate	O
viral	O
restriction	O
factors	O
.	O

Once	O
there	O
,	O
infection	O
of	O
CNS	B-CHED
cells	O
(	O
neurotropism	O
)	O
could	O
lead	O
to	O
human	O
health	O
problems	O
,	O
such	O
as	O
encephalitis	O
and	O
long	O
-	O
term	O
neurological	O
diseases	O
.	O

Thus	O
,	O
the	O
timing	O
and	O
targeting	O
of	O
native	O
replicase	O
proteins	B-CHED
expressed	O
in	O
real	O
time	O
from	O
native	O
locations	O
in	O
the	O
genome	O
remain	O
unknown	O
.	O

Both	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
increasing	O
MHV	O
-	O
3	O
titers	O
were	O
coincident	O
with	O
increased	O
PLP2	O
mRNA	B-CHED
and	O
decreased	O
ISGylation	O
over	O
the	O
course	O
of	O
infection	O
.	O

We	O
hypothesized	O
that	O
the	O
elevated	O
systemic	O
MMP	B-CHED
-	O
8	O
and	O
TIMP	O
-	O
1	O
are	O
associated	O
with	O
worse	O
outcome	O
in	O
acute	O
respiratory	O
failure	O
.	O

MMP	B-CHED
-	O
8	O
levels	O
were	O
possibly	O
higher	O
in	O
90	O
-	O
day	O
nonsurvivors	O
but	O
performed	O
poorly	O
in	O
predicting	O
outcome	O
.	O

TITLE	O
:	O
Evaluating	O
the	O
virucidal	O
efficacy	O
of	O
hydrogen	B-CHED
peroxide	I-CHED
vapour	O
.	O

Because	O
no	O
small	O
animal	O
model	O
exists	O
to	O
evaluate	O
MERS	O
-	O
CoV	O
pathogenesis	O
or	O
to	O
test	O
vaccines	O
,	O
we	O
constructed	O
a	O
recombinant	O
BtCoV	O
HKU5	O
that	O
expressed	O
a	O
region	O
of	O
the	O
SARS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
glycoprotein	B-CHED
,	O
thereby	O
allowing	O
the	O
recombinant	O
virus	O
to	O
grow	O
in	O
cell	O
culture	O
and	O
in	O
mice	O
.	O

In	O
contrast	O
,	O
sheep	O
treated	O
with	O
a	O
dose	O
of	O
40	O
million	O
adult	O
stem	O
cells	O
returned	O
their	O
levels	O
of	O
oxygen	B-CHED
in	O
their	O
blood	O
to	O
baseline	O
two	O
hours	O
after	O
the	O
cells	O
were	O
infused	O
.	O

Even	O
though	O
the	O
majority	O
of	O
the	O
developed	O
assays	O
showed	O
high	O
sensitivity	O
and	O
specificity	O
,	O
numerous	O
studies	O
reported	O
on	O
cross	O
-	O
reactive	O
antibodies	O
to	O
antigens	B-CHED
from	O
wide	O
-	O
spread	O
common	O
cold	O
associated	O
CoVs	O
.	O

According	O
to	O
the	O
AECC	O
definition	O
,	O
11	O
patients	O
met	B-CHED
criteria	O
for	O
ALI	O
(	O
27	O
.	O
5	O
%),	O
and	O
29	O
patients	O
for	O
ARDS	O
(	O
72	O
.	O
5	O
%).	O

Examinations	O
were	O
performed	O
to	O
diagnose	O
the	O
following	O
infections	O
:	O
feline	O
leukemia	O
virus	O
(	O
FeLV	O
),	O
feline	O
immunodeficiency	O
virus	O
(	O
FIV	O
),	O
feline	O
coronavirus	O
(	O
FCoV	O
),	O
feline	O
calicivirus	O
(	O
FCV	B-CHED
),	O
and	O
feline	O
herpesvirus	O
(	O
FHV	O
).	O

ABSTRACT	O
:	O
to	O
estimate	O
the	O
prevalence	O
of	O
infection	O
by	O
respiratory	O
viruses	O
in	O
pediatric	O
patients	O
with	O
cancer	O
and	O
acute	O
respiratory	O
infection	O
(	O
ARI	B-CHED
)	O
and	O
/	O
or	O
fever	O
.	O

The	O
median	O
age	O
was	O
12	O
±	O
5	O
.	O
2	O
years	O
,	O
51	O
%	O
males	O
,	O
68	O
%	O
whites	O
,	O
32	O
%	O
had	O
repeated	O
ARIs	O
,	O
32	O
%	O
prior	O
antibiotic	B-CHED
use	O
,	O
19	O
.	O
8	O
%	O
cough	O
,	O
and	O
8	O
%	O
contact	O
with	O
ARIs	O
.	O

TITLE	O
:	O
In	O
vitro	O
antiviral	B-CHED
activity	O
of	O
circular	O
triple	O
helix	O
forming	O
oligonucleotide	B-CHED
RNA	O
towards	O
Feline	O
Infectious	O
Peritonitis	O
virus	O
replication	O
.	O

In	O
conclusion	O
,	O
the	O
circular	O
TFOs	O
have	O
the	O
potential	O
to	O
be	O
further	O
developed	O
as	O
antiviral	B-CHED
agents	I-CHED
against	O
FIPV	O
infection	O
.	O

Six	O
herbal	O
extracts	O
,	O
one	O
each	O
from	O
Gentianae	O
Radix	O
(	O
lóng	O
dǎn	O
;	O
the	O
dried	O
rhizome	O
of	O
Gentiana	O
scabra	O
),	O
Dioscoreae	O
Rhizoma	O
(	O
shān	O
yào	O
;	O
the	O
tuber	O
of	O
Dioscorea	O
batatas	O
),	O
Cassiae	O
Semen	O
(	O
jué	O
míng	O
zǐ	O
;	O
the	O
dried	O
seed	O
of	O
Cassia	O
tora	O
)	O
and	O
Loranthi	O
Ramus	O
(	O
sāng	O
jì	O
shēng	O
;	O
the	O
dried	O
stem	O
,	O
with	O
leaf	O
of	O
Taxillus	O
chinensis	O
)	O
(	O
designated	O
as	O
GSH	B-CHED
,	O
DBM	O
,	O
CTH	O
and	O
TCH	O
,	O
respectively	O
),	O
and	O
two	O
from	O
Rhizoma	O
Cibotii	O
(	O
gǒu	O
jǐ	O
;	O
the	O
dried	O
rhizome	O
of	O
Cibotium	O
barometz	O
)	O
(	O
designated	O
as	O
CBE	O
and	O
CBM	O
),	O
were	O
found	O
to	O
be	O
potent	O
inhibitors	B-CHED
of	O
SARS	O
-	O
CoV	O
at	O
concentrations	O
between	O
25	O
and	O
200	O
μg	O
/	O
ml	O
.	O

The	O
resulting	O
selective	O
index	O
values	O
(	O
SI	O
=	O
CC50	O
/	O
EC50	O
)	O
of	O
the	O
most	O
effective	O
extracts	O
CBE	O
,	O
GSH	B-CHED
,	O
DBM	O
,	O
CTH	O
and	O
TCH	O
were	O
>	O
59	O
.	O
4	O
,	O
>	O
57	O
.	O
5	O
,	O
>	O
62	O
.	O
1	O
,	O
>	O
59	O
.	O
4	O
,	O
and	O
>	O
92	O
.	O
9	O
,	O
respectively	O
.	O

TITLE	O
:	O
A	O
conformation	O
-	O
dependent	O
neutralizing	O
monoclonal	O
antibody	O
specifically	O
targeting	O
receptor	O
-	O
binding	O
domain	O
in	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
spike	O
protein	B-CHED
.	O

Biochemical	O
assays	O
reveal	O
that	O
Mersmab1	O
specifically	O
binds	O
to	O
the	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
the	O
MERS	O
-	O
CoV	O
spike	O
protein	B-CHED
and	O
thereby	O
competitively	O
blocks	O
the	O
binding	O
of	O
the	O
RBD	O
to	O
its	O
cellular	O
receptor	O
,	O
dipeptidyl	O
peptidase	O
4	O
(	O
DPP4	O
).	O

Furthermore	O
,	O
alanine	B-CHED
scanning	O
of	O
the	O
RBD	O
has	O
identified	O
several	O
residues	O
at	O
the	O
DPP4	O
-	O
binding	O
surface	O
that	O
serve	O
as	O
neutralizing	O
epitopes	O
for	O
Mersmab1	O
.	O

Experimental	O
and	O
clinical	O
studies	O
have	O
suggested	O
that	O
the	O
pathogenesis	O
of	O
lung	O
injuries	O
in	O
MP	O
infection	O
is	O
associated	O
with	O
a	O
cell	O
-	O
mediated	O
immune	O
reaction	O
,	O
and	O
high	O
responsiveness	O
to	O
corticosteroid	B-CHED
therapy	O
has	O
been	O
reported	O
especially	O
for	O
severe	O
disease	O
.	O

A	O
61	O
-	O
year	O
-	O
old	O
female	O
who	O
had	O
rapidly	O
progressive	O
pneumonia	O
with	O
respiratory	O
distress	O
and	O
bilateral	O
exduation	O
and	O
consolidation	O
changes	O
on	O
chest	O
X	O
-	O
ray	O
and	O
computerized	O
tomography	O
(	O
CT	O
)	O
scan	O
that	O
did	O
not	O
respond	O
to	O
ordinary	O
antibiotics	B-CHED
was	O
diagnosed	O
with	O
influenza	O
A	O
(	O
H7N9	O
)	O
infection	O
in	O
our	O
hospital	O
on	O
July	O
19	O
,	O
2013	O
.	O

Male	O
C57BL	O
/	O
6	O
mice	O
were	O
exposed	O
to	O
low	O
-	O
tidal	O
-	O
volume	O
(	O
6	O
mL	O
/	O
kg	O
)	O
or	O
high	O
-	O
tidal	O
-	O
volume	O
(	O
30	O
mL	O
/	O
kg	O
)	O
mechanical	O
ventilation	O
using	O
room	O
air	B-CHED
with	O
or	O
without	O
2	O
µg	O
/	O
g	O
NF	O
-	O
κB	O
inhibitor	B-CHED
SN50	O
or	O
6	O
µg	O
/	O
g	O
NRF	O
short	O
interfering	O
RNA	O
or	O
100	O
µg	O
/	O
g	O
neutrophil	B-CHED
elastase	I-CHED
inhibitor	I-CHED
administration	O
.	O

Neutrophil	B-CHED
elastase	I-CHED
inhibitor	I-CHED
ameliorated	O
high	O
-	O
tidal	O
-	O
volume	O
ventilation	O
-	O
induced	O
lung	O
injury	O
,	O
neutrophil	O
influx	O
,	O
production	O
of	O
MIP	O
-	O
2	O
and	O
malondialdehyde	B-CHED
,	O
activation	O
of	O
NF	O
-	O
κB	O
and	O
NRF	O
,	O
apoptotic	O
epithelial	O
cell	O
death	O
,	O
and	O
disruption	O
of	O
bronchial	O
microstructure	O
in	O
mice	O
.	O

Understanding	O
the	O
protective	O
effects	O
of	O
neutrophil	B-CHED
elastase	I-CHED
inhibitor	I-CHED
associated	O
with	O
the	O
reduction	O
of	O
MIP	O
-	O
2	O
allow	O
clarification	O
of	O
the	O
pathophysiological	O
mechanisms	O
regulating	O
severe	O
lung	O
inflammation	O
and	O
development	O
of	O
possible	O
therapeutic	O
strategies	O
involved	O
in	O
acute	O
lung	O
injury	O
.	O

ABSTRACT	O
:	O
Dehydroandrographolide	O
and	O
andrographolide	B-CHED
,	O
two	O
natural	O
diterpenoids	B-CHED
isolated	O
from	O
Andrographis	O
paniculata	O
possessed	O
activity	O
against	O
HBV	O
DNA	O
replication	O
with	O
IC50	O
values	O
of	O
22	O
.	O
58	O
and	O
54	O
.	O
07μM	O
and	O
low	O
SI	O
values	O
of	O
8	O
.	O
7	O
and	O
3	O
.	O
7	O
in	O
our	O
random	O
assay	O
.	O

The	O
spike	O
glycoprotein	B-CHED
is	O
the	O
major	O
immunodominant	O
antigen	B-CHED
of	O
coronaviruses	O
and	O
has	O
proven	O
to	O
be	O
an	O
excellent	O
target	O
for	O
vaccine	O
designs	O
that	O
seek	O
to	O
block	O
coronavirus	O
entry	O
and	O
promote	O
antibody	O
targeting	O
of	O
infected	O
cells	O
.	O

TITLE	O
:	O
Effects	O
of	O
virulent	O
and	O
attenuated	O
transmissible	O
gastroenteritis	O
virus	O
on	O
the	O
ability	O
of	O
porcine	O
dendritic	O
cells	O
to	O
sample	O
and	O
present	O
antigen	B-CHED
.	O

However	O
the	O
role	O
of	O
these	O
motifs	O
is	O
not	O
fully	O
understood	O
in	O
the	O
case	O
of	O
3a	O
protein	B-CHED
.	O

In	O
vitro	O
transcription	O
-	O
translation	O
was	O
performed	O
to	O
estimate	O
cell	O
free	O
protein	B-CHED
synthesis	O
.	O

PCR	O
-	O
positive	O
samples	O
underwent	O
pyrosequencing	O
encompassing	O
position	O
1058	O
of	O
the	O
FCoV	O
spike	O
protein	B-CHED
.	O

This	O
identified	O
a	O
methionine	B-CHED
codon	O
at	O
position	O
1058	O
,	O
consistent	O
with	O
the	O
shedding	O
of	O
an	O
enteric	O
form	O
of	O
FCoV	O
,	O
in	O
77	O
%	O
of	O
the	O
faecal	O
samples	O
from	O
cats	O
with	O
FIP	O
,	O
and	O
in	O
100	O
%	O
of	O
the	O
samples	O
from	O
cats	O
without	O
FIP	O
.	O

Despite	O
the	O
close	O
proximity	O
of	O
the	O
three	O
epitopes	O
on	O
the	O
RBD	O
interface	O
,	O
escape	O
from	O
one	O
epitope	B-CHED
did	O
not	O
have	O
a	O
major	O
impact	O
on	O
neutralization	O
with	O
Abs	O
directed	O
to	O
a	O
different	O
epitope	B-CHED
.	O

ABSTRACT	O
:	O
The	O
pathophysiology	O
of	O
hantavirus	O
pulmonary	O
syndrome	O
(	O
HPS	B-CHED
)	O
remains	O
unclear	O
because	O
of	O
a	O
lack	O
of	O
surrogate	O
disease	O
models	O
with	O
which	O
to	O
perform	O
pathogenesis	O
studies	O
.	O

Here	O
we	O
show	O
that	O
rhesus	O
macaques	O
infected	O
with	O
Sin	O
Nombre	O
virus	O
(	O
SNV	O
),	O
the	O
primary	O
etiological	O
agent	O
of	O
HPS	B-CHED
in	O
North	O
America	O
,	O
propagated	O
in	O
deer	O
mice	O
develop	O
HPS	B-CHED
,	O
which	O
is	O
characterized	O
by	O
thrombocytopenia	O
,	O
leukocytosis	O
,	O
and	O
rapid	O
onset	O
of	O
respiratory	O
distress	O
caused	O
by	O
severe	O
interstitial	O
pneumonia	O
.	O

This	O
study	O
presents	O
a	O
unique	O
chronological	O
characterization	O
of	O
SNV	O
infection	O
and	O
provides	O
mechanistic	O
data	O
into	O
the	O
pathophysiology	O
of	O
HPS	B-CHED
in	O
a	O
closely	O
related	O
surrogate	O
animal	O
model	O
.	O

ABSTRACT	O
:	O
ABSTRACT	O
Complete	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
genome	O
sequences	O
were	O
obtained	O
from	O
nasal	O
swabs	O
of	O
dromedary	O
camels	O
sampled	O
in	O
the	O
Kingdom	O
of	O
Saudi	O
Arabia	O
through	O
direct	O
analysis	O
of	O
nucleic	B-CHED
acid	I-CHED
extracts	O
or	O
following	O
virus	O
isolation	O
in	O
cell	O
culture	O
.	O

It	O
is	O
highly	O
desirable	O
to	O
find	O
an	O
approach	O
for	O
rapidly	O
developing	O
potent	O
therapeutics	O
against	O
MERS	O
-	O
CoV	O
,	O
which	O
not	O
only	O
can	O
be	O
implemented	O
for	O
MERS	O
treatment	O
but	O
also	O
can	O
help	O
to	O
develop	O
a	O
platform	O
strategy	O
to	O
combat	B-CHED
future	O
emerging	O
coronaviruses	O
.	O

It	O
therefore	O
may	O
have	O
great	O
potential	O
as	O
a	O
candidate	O
therapeutic	O
and	O
as	O
a	O
reagent	B-CHED
to	O
facilitate	O
the	O
development	O
of	O
vaccines	O
against	O
MERS	O
-	O
CoV	O
.	O

ABSTRACT	O
:	O
Acute	O
Respiratory	O
Infections	O
(	O
ARI	B-CHED
)	O
are	O
some	O
of	O
the	O
most	O
common	O
human	O
diseases	O
worldwide	O
.	O

The	O
changes	O
in	O
hemodynamics	O
,	O
respiratory	O
mechanics	O
and	O
gas	O
exchange	O
under	O
different	O
levels	O
of	O
PEEP	B-CHED
were	O
observed	O
.	O

BHI	O
was	O
slightly	O
decreased	O
with	O
increase	O
in	O
PEEP	B-CHED
(	O
0	O
.	O
78	O
±	O
0	O
.	O
16	O
vs	O
.	O
0	O
.	O
86	O
±	O
0	O
.	O
19	O
,	O
t	O
=	O
1	O
.	O
905	O
,	O
P	O
=	O
0	O
.	O
061	O
).	O

(	O
2	O
)	O
The	O
areas	O
under	O
the	O
ROC	O
curve	O
of	O
0	O
h	O
blood	O
lactate	B-CHED
,	O
6	O
h	O
lactate	B-CHED
clearance	O
rate	O
and	O
APACHE	O
II	O
score	O
for	O
predicting	O
death	O
were	O
0	O
.	O
699	O
±	O
0	O
.	O
083	O
(	O
95	O
%	O
CI	O
:	O
0	O
.	O
567	O
∼	O
0	O
.	O
892	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
0	O
.	O
871	O
±	O
0	O
.	O
119	O
(	O
95	O
%	O
CI	O
:	O
0	O
.	O
724	O
∼	O
0	O
.	O
980	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
0	O
.	O
836	O
±	O
0	O
.	O
063	O
(	O
95	O
%	O
CI	O
:	O
0	O
.	O
713	O
∼	O
0	O
.	O
958	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

(	O
4	O
)	O
Multivariate	O
logistic	O
regression	O
analysis	O
showed	O
that	O
0	O
h	O
blood	O
lactate	B-CHED
(	O
OR	O
=	O
1	O
.	O
318	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
159	O
∼	O
6	O
.	O
882	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
6	O
h	O
lactate	B-CHED
clearance	O
rate	O
(	O
OR	O
=	O
6	O
.	O
921	O
,	O
95	O
%	O
CI	O
:	O
4	O
.	O
469	O
∼	O
15	O
.	O
036	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
APACHEII	O
score	O
(	O
OR	O
=	O
4	O
.	O
417	O
,	O
95	O
%	O
CI	O
:	O
3	O
.	O
058	O
∼	O
10	O
.	O
356	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
were	O
independent	O
risk	O
factors	O
associated	O
with	O
mortality	O
of	O
patients	O
on	O
ECMO	O
.	O

ABSTRACT	O
:	O
We	O
report	O
a	O
case	O
of	O
a	O
49	O
-	O
year	O
-	O
old	O
Japanese	O
man	B-CHED
,	O
who	O
was	O
admitted	O
to	O
our	O
hospital	O
because	O
of	O
severe	O
dyspnea	O
.	O

Nasopharyngeal	O
aspirates	O
were	O
collected	O
from	O
the	O
study	O
groups	O
and	O
the	O
detection	O
of	O
respiratory	O
viruses	O
[	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
)	O
A	O
&	O
B	O
;	O
rhinovirus	O
(	O
RV	O
);	O
human	O
metapneumovirus	O
(	O
hMPV	O
)	O
A	O
&	O
B	O
;	O
influenza	O
virus	O
type	O
A	O
[	O
H1N1	O
,	O
H3N2	B-CHED
,	O
H1N1v	O
],	O
B	O
&	O
C	O
;	O
parainfluenza	O
virus	O
(	O
PIV	O
)	O
type	O
1	O
,	O
2	O
,	O
3	O
&	O
4A	O
/	O
B	O
;	O
adenovirus	O
(	O
AdV	O
);	O
HBoV	O
;	O
coronavirus	O
(	O
CoV	O
229E	O
);	O
enterovirus	O
(	O
EV	O
)],	O
were	O
performed	O
by	O
using	O
a	O
commercial	O
system	O
namely	O
CLART	O
®	O
Pneumovir	O
(	O
Clinical	O
Array	O
Technology	O
,	O
Genomica	O
,	O
Spain	O
)	O
based	O
on	O
the	O
principle	O
of	O
multiplex	O
polymerase	O
chain	O
reaction	O
(	O
M	O
-	O
PCR	O
)	O
and	O
DNA	O
microarray	O
.	O

Clinical	O
data	O
,	O
systemic	O
(	O
C	O
reactive	O
protein	B-CHED
(	O
CRP	O
),	O
IL	O
-	O
6	O
,	O
procalcitonin	O
,	O
amyloid	O
-	O
A	O
,	O
fibrinogen	O
)	O
and	O
lung	O
function	O
parameters	O
were	O
also	O
collected	O
.	O

In	O
the	O
presence	O
of	O
vertebral	O
fracture	O
,	O
treatment	O
options	O
listed	O
in	O
the	O
literature	O
are	O
conservative	O
(	O
rest	B-CHED
,	O
symptomatic	O
therapy	O
,	O
orthosis	O
),	O
because	O
of	O
the	O
high	O
incidence	O
of	O
intra	O
-	O
and	O
perioperative	O
complications	O
(	O
acute	O
respiratory	O
syndrome	O
,	O
vaso	O
-	O
occlusive	O
crisis	O
…),	O
in	O
addition	O
to	O
the	O
increased	O
rate	O
of	O
implant	O
failure	O
.	O

ABSTRACT	O
:	O
Influenza	O
A	O
viruses	O
recruit	O
components	O
of	O
the	O
nuclear	O
import	O
pathway	O
to	O
enter	O
the	O
host	O
cell	O
nucleus	B-CHED
and	O
promote	O
viral	O
replication	O
.	O

MELD	O
was	O
calculated	O
as	O
:	O
MELD	O
=	O
3	O
.	O
8	O
[	O
Ln	O
serum	O
bilirubin	B-CHED
(	O
mg	O
/	O
dl	O
)]	O
+	O
11	O
.	O
2	O
[	O
Ln	O
INR	O
]	O
+	O
9	O
.	O
6	O
[	O
Ln	O
serum	O
creatinine	B-CHED
(	O
mg	O
/	O
dl	O
)]	O
+	O
6	O
.	O
4	O
.	O

TITLE	O
:	O
Design	O
,	O
synthesis	O
,	O
antiviral	B-CHED
activity	O
,	O
and	O
SARs	O
of	O
13a	O
-	O
substituted	O
phenanthroindolizidine	O
alkaloid	B-CHED
derivatives	O
.	O

ABSTRACT	O
:	O
On	O
the	O
basis	O
of	O
our	O
previous	O
structure	O
-	O
activity	O
relationship	O
(	O
SAR	B-CHED
)	O
and	O
antiviral	B-CHED
mechanism	O
studies	O
,	O
a	O
series	O
of	O
13a	O
-	O
substituted	O
phenanthroindolizidine	O
alkaloid	B-CHED
analogues	O
(	O
3a	O
-	O
16a	O
,	O
3b	O
,	O
4b	O
,	O
6b	O
,	O
7b	O
,	O
10b	O
,	O
and	O
14b	O
)	O
were	O
designed	O
targeting	O
tobacco	O
mosaic	O
virus	O
(	O
TMV	O
)	O
RNA	O
,	O
synthesized	O
,	O
and	O
evaluated	O
for	O
their	O
antiviral	B-CHED
activity	O
against	O
TMV	O
for	O
the	O
first	O
time	O
.	O

The	O
present	O
work	O
demonstrates	O
that	O
13a	O
-	O
substituted	O
phenanthroindolizidines	O
can	O
be	O
used	O
as	O
possible	O
lead	B-CHED
compounds	I-CHED
for	O
developing	O
anti	O
-	O
TMV	O
agents	O
.	O

TITLE	O
:	O
Screening	O
of	O
an	O
FDA	O
-	O
approved	O
compound	O
library	O
identifies	O
four	O
small	O
-	O
molecule	O
inhibitors	B-CHED
of	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
replication	O
in	O
cell	O
culture	O
.	O

Together	O
,	O
the	O
work	O
demonstrates	O
the	O
existence	O
of	O
unique	O
and	O
common	O
viral	O
strategies	O
for	O
controlling	O
the	O
global	O
ISG	O
response	O
and	O
provides	O
a	O
novel	O
avenue	O
for	O
viral	O
antagonism	O
via	O
altered	O
histone	B-CHED
modifications	O
.	O

The	O
knowledge	O
of	O
pulse	O
oximetry	O
at	O
room	O
air	B-CHED
and	O
at	O
100	O
%	O
oxygen	B-CHED
allows	O
to	O
estimate	O
the	O
PaO2	O
and	O
the	O
cause	O
of	O
hypoxemia	O
,	O
shunt	O
vs	O
.	O
VA	O
/	O
Q	O
maldistribution	O
.	O

PEEP	B-CHED
from	O
5	O
to	O
10	O
,	O
from	O
10	O
to	O
15	O
and	O
greater	O
than	O
15	O
cmH2O	O
should	O
be	O
set	O
in	O
mild	O
,	O
moderate	O
and	O
severe	O
ARDS	O
,	O
respectively	O
.	O

Interestingly	O
,	O
mutations	O
in	O
the	O
non	O
-	O
nucleoside	B-CHED
RT	O
inhibitor	B-CHED
binding	O
pocket	O
strongly	O
affected	O
RNase	O
H	O
inhibition	O
by	O
the	O
propenone	O
derivatives	O
without	O
decreasing	O
their	O
capacity	O
to	O
inhibit	O
DP	O
activity	O
,	O
which	O
suggests	O
long	O
-	O
range	O
RT	O
structural	O
effects	O
.	O

In	O
the	O
ALVEOLI	O
cohort	O
,	O
the	O
effects	O
of	O
ventilation	O
strategy	O
(	O
high	O
PEEP	B-CHED
vs	O
low	O
PEEP	B-CHED
)	O
on	O
mortality	O
,	O
ventilator	O
-	O
free	O
days	O
and	O
organ	O
failure	O
-	O
free	O
days	O
differed	O
by	O
phenotype	O
(	O
p	O
=	O
0	O
·	O
049	O
for	O
mortality	O
,	O
p	O
=	O
0	O
·	O
018	O
for	O
ventilator	O
-	O
free	O
days	O
,	O
p	O
=	O
0	O
·	O
003	O
for	O
organ	O
-	O
failure	O
-	O
free	O
days	O
).	O

Immunization	O
using	O
vaccines	O
is	O
routine	O
practice	O
;	O
however	O
,	O
to	O
combat	B-CHED
infectious	O
diseases	O
,	O
conventional	O
vaccines	O
as	O
well	O
as	O
new	O
-	O
generation	O
recombinant	O
vaccines	O
alone	O
,	O
due	O
to	O
relatively	O
weak	O
immunogenicity	O
,	O
may	O
not	O
be	O
effective	O
enough	O
to	O
provide	O
optimum	O
immunity	O
.	O

With	O
this	O
in	O
mind	O
,	O
there	O
is	O
a	O
need	O
to	O
incorporate	O
better	O
and	O
more	O
suitable	O
adjuvants	B-CHED
in	O
the	O
vaccines	O
to	O
elicit	O
the	O
elevated	O
immune	O
response	O
in	O
the	O
host	O
.	O

The	O
extra	O
-	O
corporeal	O
carbon	B-CHED
dioxide	I-CHED
removal	O
(	O
ECCO2	O
R	O
),	O
used	O
as	O
an	O
integrated	O
tool	O
with	O
conventional	O
ventilation	O
,	O
is	O
playing	O
a	O
new	O
role	O
in	O
adjusting	O
respiratory	O
acidosis	O
and	O
CO2	B-CHED
.	O

The	O
advantages	O
and	O
disadvantages	O
of	O
inhaled	O
nitric	B-CHED
oxide	I-CHED
(	O
iNO	O
)	O
are	O
better	O
recognized	O
today	O
and	O
iNO	O
is	O
not	O
recommended	O
for	O
ARDS	O
and	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
in	O
children	O
and	O
adults	O
because	O
iNO	O
results	O
in	O
a	O
transient	O
improvement	O
in	O
oxygenation	O
but	O
does	O
not	O
reduce	O
mortality	O
,	O
and	O
may	O
be	O
harmful	O
.	O

Analysis	O
of	O
the	O
whole	O
human	O
-	O
derived	O
virus	O
and	O
15	O
%	O
of	O
the	O
camel	O
-	O
derived	O
virus	O
sequence	O
yielded	O
nucleotide	B-CHED
polymorphism	O
signatures	O
suggestive	O
of	O
cross	O
-	O
species	O
transmission	O
.	O

Two	O
Antimicrobial	B-CHED
Agents	O
and	O
Chemotherapy	O
(	O
AAC	O
)	O
papers	O
screened	O
libraries	O
of	O
approved	O
compounds	O
that	O
may	O
potentially	O
be	O
repurposed	O
as	O
MERS	O
-	O
CoV	O
antivirals	B-CHED
.	O

We	O
had	O
a	O
success	O
in	O
the	O
nucleotide	B-CHED
sequencing	O
of	O
six	O
of	O
the	O
eight	O
positive	O
samples	O
and	O
compared	O
them	O
with	O
those	O
of	O
authentic	O
coronaviruses	O
.	O

By	O
using	O
sialylated	O
compounds	O
as	O
competitive	O
inhibitors	B-CHED
,	O
it	O
was	O
demonstrated	O
that	O
sialyllactose	O
(	O
2	O
,	O
6	O
-	O
α	O
-	O
linked	O
over	O
2	O
,	O
3	O
-	O
α	O
-	O
linked	O
)	O
notably	O
reduced	O
infectivity	O
of	O
NA	O
-	O
treated	O
viruses	O
,	O
whereas	O
bovine	O
submaxillary	O
mucin	O
inhibited	O
both	O
treated	O
and	O
untreated	O
viruses	O
.	O

Furthermore	O
,	O
the	O
most	O
active	O
PLpro	O
inhibitors	B-CHED
(	O
1	O
-	O
6	O
)	O
were	O
proven	O
to	O
be	O
present	O
in	O
the	O
native	O
fruits	O
in	O
high	O
quantities	O
by	O
HPLC	O
chromatogram	O
and	O
liquid	O
chromatography	O
with	O
diode	O
array	O
detection	O
and	O
electrospray	O
ionization	O
mass	O
spectrometry	O
(	O
LC	O
-	O
DAD	O
-	O
ESI	O
/	O
MS	O
).	O

In	O
this	O
protein	B-CHED
we	O
identified	O
one	O
epitope	B-CHED
WDYPKCDRA	O
is	O
highly	O
immunogenic	O
and	O
100	O
%	O
conserved	O
among	O
all	O
available	O
human	O
coronavirus	O
strains	O
.	O

These	O
results	O
demonstrate	O
that	O
human	O
macrophages	O
can	O
be	O
infected	O
by	O
SARS	O
-	O
CoV	O
as	O
a	O
result	O
of	O
IgG	O
-	O
mediated	O
ADE	B-CHED
and	O
indicate	O
that	O
this	O
infection	O
route	O
requires	O
signaling	O
pathways	O
activated	O
downstream	O
of	O
binding	O
to	O
FcγRII	O
receptors	O
.	O

Since	O
cellular	O
immunity	O
is	O
thought	O
to	O
be	O
critical	O
in	O
preventing	O
FIP	O
and	O
because	O
diseased	O
cats	O
often	O
show	O
a	O
significant	O
decrease	O
in	O
interferon	O
-	O
γ	O
(	O
IFN	O
-	O
γ	O
)	O
production	O
,	O
we	O
investigated	O
whether	O
single	O
nucleotide	B-CHED
polymorphisms	O
(	O
SNP	O
)	O
in	O
the	O
feline	O
IFN	O
-	O
γ	O
gene	O
(	O
fIFNG	O
)	O
are	O
associated	O
with	O
the	O
outcome	O
of	O
infection	O
.	O

ABSTRACT	O
:	O
Carbohydrate	B-CHED
structures	O
,	O
including	O
Lewis	B-CHED
X	I-CHED
(	O
Le	O
(	O
x	O
)),	O
which	O
is	O
not	O
synthesized	O
in	O
mutant	O
mice	O
that	O
lack	O
α1	O
,	O
3	O
-	O
fucosyltransferase	O
9	O
(	O
Fut9	O
(-/-)),	O
are	O
involved	O
in	O
cell	O
-	O
cell	O
recognition	O
and	O
inflammation	O
.	O

After	O
5	O
days	O
of	O
recovery	O
,	O
ALI	O
was	O
induced	O
with	O
cotton	O
smoke	O
insufflation	O
,	O
followed	O
by	O
instillation	O
of	O
live	O
Pseudomonas	O
aeruginosa	O
(	O
2	O
.	O
5	O
×	O
10	O
(	O
11	O
)	O
CFU	O
)	O
into	O
both	O
lungs	O
under	O
isoflurane	B-CHED
anaesthesia	O
.	O

The	O
median	O
lung	O
water	B-CHED
content	O
was	O
lower	O
in	O
the	O
higher	O
-	O
dose	O
hMSC	O
-	O
treated	O
group	O
compared	O
with	O
the	O
control	O
group	O
(	O
higher	O
dose	O
:	O
5	O
.	O
0	O
g	O
wet	O
/	O
g	O
dry	O
[	O
IQR	O
4	O
.	O
9	O
-	O
5	O
.	O
8	O
]	O
vs	O
control	O
:	O
6	O
.	O
7	O
g	O
wet	O
/	O
g	O
dry	O
[	O
IQR	O
6	O
.	O
4	O
-	O
7	O
.	O
5	O
]	O
(	O
p	O
=	O
0	O
.	O
01	O
)).	O

The	O
utility	O
of	O
this	O
approach	O
is	O
illustrated	O
by	O
two	O
examples	O
:	O
one	O
is	O
similarity	O
/	O
dissimilarity	O
comparison	O
among	O
different	O
ND6	O
protein	B-CHED
sequences	O
based	O
on	O
their	O
DV	O
-	O
curve	O
figures	O
the	O
other	O
is	O
the	O
phylogenetic	O
analysis	O
among	O
coronaviruses	O
based	O
on	O
their	O
spike	O
proteins	B-CHED
.	O

TITLE	O
:	O
A	O
monomer	O
-	O
dimer	O
nanoswitch	O
that	O
mimics	O
the	O
working	O
principle	O
of	O
the	O
SARS	O
-	O
CoV	O
3CLpro	O
enzyme	O
controls	O
copper	B-CHED
-	O
catalysed	O
cyclopropanation	O
.	O

In	O
contrast	O
,	O
after	O
addition	O
of	O
iron	O
(	O
II	O
)	O
ions	B-CHED
to	O
the	O
CLOSE	O
state	O
a	O
bishomoleptic	O
dimeric	O
[	O
Fe	O
(	O
terpy	B-CHED
)	O
2	O
](	O
2	O
+)	O
complex	O
is	O
formed	O
with	O
the	O
copper	B-CHED
(	O
I	O
)	O
ions	B-CHED
placed	O
in	O
the	O
phenanthroline	B-CHED
cavities	O
(	O
OPEN	O
-	O
II	O
).	O

ABSTRACT	O
:	O
Previous	O
trials	O
of	O
higher	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	B-CHED
)	O
for	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
failed	O
to	O
demonstrate	O
mortality	O
benefit	O
,	O
possibly	O
because	O
of	O
differences	O
in	O
lung	O
recruitability	O
among	O
patients	O
with	O
ARDS	O
.	O

Among	O
patients	O
in	O
whom	O
PEEP	B-CHED
was	O
increased	O
after	O
randomization	O
,	O
an	O
increase	O
in	O
P	O
/	O
F	O
was	O
associated	O
with	O
reduced	O
mortality	O
(	O
multivariable	O
logistic	O
regression	O
;	O
adjusted	O
odds	O
ratio	O
,	O
0	O
.	O
80	O
[	O
95	O
%	O
confidence	O
interval	O
,	O
0	O
.	O
72	O
-	O
0	O
.	O
89	O
]	O
per	O
25	O
-	O
mm	O
Hg	O
increase	O
in	O
P	O
/	O
F	O
),	O
particularly	O
in	O
patients	O
with	O
severe	O
disease	O
(	O
baseline	O
P	O
/	O
F	O
[	O
less	O
-	O
than	O
-	O
or	O
-	O
equal	O
-	O
to	O
]	O
150	O
mm	O
Hg	O
).	O

Some	O
potentially	O
important	O
host	O
factors	O
for	O
the	O
antiviral	B-CHED
response	O
,	O
whose	O
functions	O
remain	O
largely	O
unexplored	O
,	O
are	O
long	O
non	O
-	O
coding	O
RNAs	O
(	O
lncRNAs	O
).	O

TITLE	O
:	O
The	O
molecular	O
era	B-CHED
of	O
surfactant	B-CHED
biology	O
.	O

Meta	O
-	O
analysis	O
of	O
older	O
trials	O
of	O
prostaglandin	B-CHED
E1	I-CHED
also	O
showed	O
no	O
effect	O
.	O

We	O
analysed	O
the	O
prevalence	O
of	O
P	O
.	O
jirovecii	O
pneumonia	O
(	O
PCP	B-CHED
)	O
among	O
HIV	O
-	O
infected	O
and	O
HIV	O
-	O
uninfected	O
patients	O
presented	O
with	O
interstitial	O
pneumonia	O
or	O
acute	O
respiratory	O
syndrome	O
hospitalized	O
in	O
six	O
Croatian	O
tertiary	O
care	O
hospitals	O
.	O

The	O
14	O
avian	O
coronaviruses	O
detected	O
belonged	O
to	O
the	O
gamma	O
-	O
coronaviruses	O
and	O
shared	O
high	O
nucleotide	B-CHED
sequence	O
identity	O
with	O
some	O
previously	O
identified	O
strains	O
in	O
wild	O
waterfowl	O
,	O
but	O
not	O
with	O
infectious	O
bronchitis	O
viruses	O
.	O

ABSTRACT	O
:	O
In	O
the	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
plasma	O
proteins	B-CHED
in	O
alveolar	O
edema	O
liquid	O
are	O
thought	O
to	O
inactivate	O
lung	O
surfactant	B-CHED
and	O
raise	O
surface	O
tension	O
,	O
T	O
.	O
However	O
,	O
plasma	O
protein	B-CHED
-	O
surfactant	B-CHED
interaction	O
has	O
been	O
assessed	O
only	O
in	O
vitro	O
,	O
during	O
unphysiologically	O
large	O
surface	O
area	O
compression	O
(%	O
ΔA	O
).	O

In	O
separate	O
experiments	O
,	O
we	O
find	O
that	O
addition	O
of	O
exogenous	O
surfactant	B-CHED
to	O
the	O
alveolar	O
liquid	O
can	O
,	O
with	O
two	O
cycles	O
of	O
maximal	O
physiologic	O
%	O
ΔA	O
,	O
reduce	O
T	O
by	O
29	O
±	O
11	O
%	O
despite	O
the	O
presence	O
of	O
albumin	O
.	O

Using	O
the	O
method	O
of	O
GST	O
pull	O
-	O
down	O
with	O
the	O
nucleocapsid	O
(	O
N	O
),	O
N	O
protein	B-CHED
was	O
found	O
to	O
interact	O
with	O
swine	O
testes	O
(	O
ST	O
)	O
cells	O
elongation	O
factor	O
1	O
-	O
alpha	O
(	O
EF1A	O
),	O
an	O
essential	O
component	O
of	O
the	O
translational	O
machinery	O
with	O
an	O
important	O
role	O
in	O
cells	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
prevalence	O
of	O
canine	O
parainfluenza	O
virus	O
(	O
CPIV	O
),	O
canine	O
adenovirus	O
type	O
2	O
(	O
CAV	O
-	O
2	O
),	O
canine	O
influenza	O
virus	O
(	O
CIV	O
),	O
canine	O
respiratory	O
coronavirus	O
(	O
CRCoV	O
),	O
canine	O
herpes	O
virus	O
-	O
1	O
(	O
CHV	O
-	O
1	O
),	O
canine	O
distemper	O
virus	O
(	O
CDV	B-CHED
)	O
and	O
Bordetella	O
bronchiseptica	O
in	O
dogs	O
with	O
CIRD	O
and	O
to	O
compare	O
the	O
data	O
with	O
findings	O
in	O
healthy	O
dogs	O
.	O

Nasal	O
and	O
pharyngeal	O
swabs	O
were	O
collected	O
from	O
all	O
dogs	O
and	O
were	O
analysed	O
for	O
CPIV	O
,	O
CAV	O
-	O
2	O
,	O
CIV	O
,	O
CRCoV	O
,	O
CHV	O
-	O
1	O
,	O
CDV	B-CHED
,	O
and	O
B	O
.	O
bronchiseptica	O
by	O
real	O
-	O
time	O
PCR	O
.	O

Early	O
treatment	O
with	O
ceftriaxone	B-CHED
and	O
azithromycin	B-CHED
,	O
along	O
with	O
oseltamivir	B-CHED
in	O
winter	O
months	O
,	O
should	O
be	O
initiated	O
with	O
all	O
cases	O
of	O
severe	O
exacerbations	O
where	O
infection	O
is	O
suspected	O
,	O
and	O
definitely	O
in	O
critical	O
asthma	O
syndrome	O
until	O
infection	O
is	O
excluded	O
by	O
appropriate	O
diagnostic	O
testing	O
.	O

Recently	O
,	O
our	O
laboratories	O
reported	O
a	O
novel	O
mode	O
of	O
regulation	O
of	O
the	O
IFN	O
antiviral	B-CHED
response	O
.	O

Partial	O
S	O
and	O
N	O
genes	O
of	O
HCoV	O
-	O
OC43	O
circulating	O
strains	O
were	O
sequenced	O
followed	O
by	O
phylogenetic	O
analysis	O
and	O
amino	B-CHED
acid	I-CHED
alignment	O
.	O

Furthermore	O
,	O
consensus	O
amino	B-CHED
acids	I-CHED
substitutes	O
for	O
each	O
cluster	O
were	O
also	O
found	O
after	O
alignment	O
of	O
partial	O
S	O
or	O
N	O
sequence	O
coding	O
region	O
in	O
this	O
study	O
.	O

Small	O
diameter	O
autophagosomes	O
were	O
also	O
induced	O
by	O
infection	O
of	O
cells	O
with	O
IBV	O
,	O
and	O
by	O
NSP6	O
proteins	B-CHED
of	O
MHV	O
and	O
SARS	O
and	O
NSP5	O
,	O
NSP6	O
,	O
and	O
NSP7	O
of	O
arterivirus	O
PRRSV	O
.	O

The	O
prophylactic	O
application	O
of	O
antibiotics	B-CHED
after	O
a	O
dog	O
bite	O
should	O
be	O
considered	O
in	O
high	O
-	O
risk	O
individuals	O
with	O
immune	O
deficiency	O
in	O
order	O
to	O
prevent	O
both	O
Capnocytophyga	O
canimorsus	O
sepsis	O
and	O
serious	O
nosocomial	O
complications	O
.	O

Our	O
findings	O
strongly	O
demonstrated	O
that	O
enforced	O
expression	O
of	O
miR	O
-	O
125b	O
could	O
effectively	O
ameliorate	O
the	O
LPS	B-CHED
-	O
induced	O
ALI	O
,	O
suggesting	O
a	O
potential	O
application	O
for	O
miR	O
-	O
125b	O
-	O
based	O
therapy	O
to	O
treat	O
clinical	O
ARDS	O
.	O

From	O
previous	O
experience	O
and	O
analysis	O
of	O
similar	O
silver	B-CHED
metals	B-CHED
,	O
he	O
was	O
able	O
to	O
tell	O
us	O
that	O
the	O
silver	B-CHED
was	O
adulterated	O
with	O
large	O
amount	O
of	O
cadmium	B-CHED
on	O
that	O
day	O
than	O
before	O
.	O

Serum	O
level	O
of	O
cadmium	B-CHED
was	O
2	O
.	O
9	O
μg	O
/	O
L	O
6	O
days	O
after	O
initial	O
exposure	O
.	O

The	O
spike	O
(	O
S	O
)	O
protein	B-CHED
of	O
PEDV	O
is	O
a	O
type	O
1	O
transmembrane	O
envelope	O
glycoprotein	B-CHED
and	O
consists	O
of	O
the	O
S1	O
and	O
S2	O
domains	O
,	O
which	O
are	O
responsible	O
for	O
virus	O
binding	O
and	O
fusion	O
,	O
respectively	O
.	O

The	O
results	O
showed	O
that	O
vaccination	O
with	O
S1	O
protein	B-CHED
efficiently	O
protected	O
neonatal	O
piglets	O
against	O
PEDV	O
.	O

CsA	B-CHED
treatment	O
resulted	O
in	O
significant	O
inhibition	O
of	O
PEDV	O
-	O
triggered	O
apoptosis	O
and	O
suppressed	O
PEDV	O
replication	O
.	O

Title	O
compounds	O
were	O
tested	O
in	O
cell	O
-	O
based	O
assays	O
for	O
cytotoxicity	O
and	O
antiviral	B-CHED
activity	O
against	O
representatives	O
of	O
two	O
DNA	O
virus	O
families	O
as	O
wells	O
as	O
against	O
representatives	O
of	O
RNA	O
virus	O
families	O
containing	O
single	O
-	O
stranded	O
,	O
either	O
positive	O
-	O
sense	O
(	O
ssRNA	O
(+))	O
or	O
negative	O
-	O
sense	O
(	O
ssRNA	O
(-)),	O
and	O
double	O
-	O
stranded	O
genomes	O
(	O
dsRNA	B-CHED
).	O

Person	O
'	O
s	O
chi	B-CHED
-	O
square	O
test	O
was	O
used	O
for	O
statistical	O
analysis	O
.	O

Air	B-CHED
samples	O
were	O
collected	O
both	O
from	O
a	O
room	O
containing	O
experimentally	O
infected	O
pigs	O
and	O
at	O
various	O
distances	O
from	O
the	O
outside	O
of	O
swine	O
farms	O
experiencing	O
acute	O
PEDV	O
outbreaks	O
.	O

In	O
this	O
study	O
,	O
we	O
report	O
our	O
findings	O
on	O
the	O
characterization	O
of	O
one	O
of	O
these	O
mAbs	O
,	O
known	O
as	O
1A9	O
,	O
which	O
binds	O
to	O
the	O
S	O
protein	B-CHED
at	O
a	O
novel	O
epitope	B-CHED
within	O
the	O
S2	O
subunit	O
at	O
amino	B-CHED
acids	I-CHED
1111	O
-	O
1130	O
.	O

In	O
addition	O
,	O
the	O
D1128A	O
mutation	O
was	O
found	O
to	O
exert	O
no	O
effects	O
on	O
the	O
S	O
protein	B-CHED
cell	O
surface	O
expression	O
and	O
incorporation	O
into	O
virion	O
particles	O
,	O
suggesting	O
that	O
the	O
escape	O
virus	O
retains	O
the	O
same	O
viral	O
entry	O
property	O
as	O
the	O
wild	O
-	O
type	O
virus	O
.	O

NeoCoV	O
shared	O
essential	O
details	O
of	O
genome	O
architecture	O
with	O
MERS	O
-	O
CoV	O
.	O
Eighty	O
-	O
five	O
percent	O
of	O
the	O
NeoCoV	O
genome	O
was	O
identical	O
to	O
MERS	O
-	O
CoV	O
at	O
the	O
nucleotide	B-CHED
level	O
.	O

Extracorporeal	O
carbon	B-CHED
dioxide	I-CHED
removal	O
(	O
ECCO₂R	O
)	O
devices	O
allow	O
uncoupling	O
of	O
ventilation	O
from	O
oxygenation	O
,	O
thereby	O
removing	O
carbon	B-CHED
dioxide	I-CHED
and	O
facilitating	O
lower	O
tidal	O
volume	O
ventilation	O
.	O

In	O
this	O
review	O
,	O
we	O
discuss	O
promising	O
novel	O
influenza	O
virus	O
vaccine	O
targets	O
and	O
the	O
use	O
of	O
MVA	B-CHED
for	O
vaccine	O
development	O
against	O
various	O
respiratory	O
viruses	O
.	O

Patients	O
underwent	O
whole	O
-	O
lung	O
computed	O
tomography	O
(	O
CT	O
)	O
scan	O
at	O
5	O
and	O
45	O
cm	O
H2O	B-CHED
.	O

CT	O
-	O
derived	O
PEEP	B-CHED
was	O
computed	O
as	O
the	O
sum	O
of	O
the	O
transpulmonary	O
pressure	O
needed	O
to	O
overcome	O
the	O
maximal	O
superimposed	O
pressure	O
and	O
the	O
pleural	O
pressure	O
needed	O
to	O
lift	O
up	O
the	O
chest	O
wall	O
.	O

Maximal	O
superimposed	O
pressure	O
ranged	O
from	O
6	O
to	O
18	O
cm	O
H2O	B-CHED
,	O
whereas	O
CT	O
-	O
derived	O
PEEP	B-CHED
ranged	O
from	O
7	O
to	O
28	O
cm	O
H2O	B-CHED
.	O

Using	O
a	O
suboptimal	O
dose	O
of	O
each	O
recombinant	O
virus	O
,	O
we	O
demonstrated	O
that	O
IBV	O
S1	O
amino	B-CHED
acid	I-CHED
sequences	O
showing	O
>	O
or	O
=	O
95	O
.	O
8	O
%	O
amino	B-CHED
acid	I-CHED
identity	O
to	O
the	O
S1	O
of	O
the	O
challenge	O
strain	O
differed	O
in	O
their	O
ability	O
at	O
conferring	O
protection	O
.	O

This	O
report	O
details	O
the	O
subsequent	O
sequence	O
and	O
phylogenetic	O
analysis	O
of	O
the	O
TCoV	O
spike	O
glycoprotein	B-CHED
and	O
the	O
comparison	O
of	O
outbreak	O
-	O
associated	O
isolates	O
to	O
sequences	O
in	O
the	O
public	O
database	O
.	O

A	O
sterile	O
cotton	O
-	O
tip	O
swab	O
was	O
dunked	O
in	O
sputum	O
,	O
swirled	O
in	O
700	O
μL	O
of	O
sterile	O
water	B-CHED
(	O
dunk	O
and	O
swirl	O
method	O
)	O
and	O
tested	O
by	O
the	O
FilmArray	O
assay	O
.	O

TITLE	O
:	O
Chimeric	O
influenza	O
-	O
virus	O
-	O
like	O
particles	O
containing	O
the	O
porcine	O
reproductive	O
and	O
respiratory	O
syndrome	O
virus	O
GP5	O
protein	B-CHED
and	O
the	O
influenza	O
virus	O
HA	O
and	O
M1	O
proteins	B-CHED
.	O

In	O
this	O
study	O
,	O
we	O
have	O
developed	O
a	O
chimeric	O
virus	O
-	O
like	O
particle	O
(	O
VLP	O
)	O
vaccine	O
candidate	O
for	O
porcine	O
reproductive	O
and	O
respiratory	O
syndrome	O
virus	O
(	O
PRRSV	O
)	O
and	O
H3N2	B-CHED
influenza	O
virus	O
and	O
investigated	O
its	O
immunogenicity	O
in	O
mice	O
.	O

The	O
HA	O
and	O
M1	O
proteins	B-CHED
from	O
the	O
H3N2	B-CHED
influenza	O
virus	O
and	O
the	O
PRRSV	O
GP5	O
protein	B-CHED
fused	O
to	O
the	O
cytoplasmic	O
and	O
transmembrane	O
domains	O
of	O
the	O
NA	O
protein	B-CHED
were	O
both	O
incorporated	O
into	O
the	O
chimeric	O
VLPs	O
.	O

Antibody	O
-	O
dependent	O
enhancement	O
(	O
ADE	B-CHED
)	O
is	O
a	O
mechanism	O
through	O
which	O
dengue	O
viruses	O
,	O
feline	O
coronaviruses	O
,	O
and	O
HIV	O
viruses	O
take	O
advantage	O
of	O
anti	O
-	O
viral	O
humoral	O
immune	O
responses	O
to	O
infect	O
host	O
target	O
cells	O
.	O

The	O
148	O
-	O
amino	B-CHED
acid	I-CHED
nsp10	O
subunit	O
contains	O
two	O
zinc	B-CHED
fingers	O
and	O
is	O
known	O
to	O
interact	O
with	O
both	O
nsp14	O
and	O
nsp16	O
,	O
stimulating	O
their	O
respective	O
3	O
'-	O
5	O
'	O
exoribonuclease	O
and	O
2	O
'-	O
O	O
-	O
methyltransferase	O
activities	O
.	O

Severe	O
cases	O
can	O
also	O
be	O
presented	O
by	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
toxic	O
megacolon	O
with	O
ileus	O
,	O
pancreatitis	O
,	O
central	O
nervous	O
system	O
(	O
CNS	B-CHED
)	O
disorders	O
and	O
multiple	O
organ	O
failure	O
(	O
MOF	O
).	O

(	O
3	O
)	O
Nucleotides	B-CHED
positioned	O
from	O
-	O
15	O
to	O
-	O
34	O
of	O
the	O
sgmRNA	O
7	O
3	O
'-	O
terminal	O
region	O
are	O
required	O
for	O
efficient	O
(-)-	O
strand	O
sgmRNA	O
synthesis	O
.	O

This	O
process	O
is	O
mainly	O
mediated	O
by	O
its	O
genome	O
-	O
encoded	O
main	O
protease	O
,	O
which	O
is	O
an	O
attractive	O
target	O
for	O
antiviral	B-CHED
drug	I-CHED
design	O
.	O

ABSTRACT	O
:	O
Bronchoscopy	O
and	O
bronchoalveolar	O
lavage	O
(	O
BAL	B-CHED
)	O
are	O
common	O
procedures	O
in	O
intensive	O
care	O
units	O
;	O
however	O
,	O
no	O
contemporaneous	O
safety	O
and	O
outcomes	O
data	O
have	O
been	O
reported	O
,	O
particularly	O
for	O
critically	O
ill	O
patients	O
.	O

ABSTRACT	O
:	O
We	O
report	O
the	O
case	O
of	O
an	O
18	O
-	O
year	O
-	O
old	O
girl	O
presenting	O
with	O
shock	O
following	O
ingestion	O
of	O
85	O
mg	O
of	O
amlodipine	B-CHED
and	O
850	O
mg	O
of	O
atenolol	B-CHED
with	O
suicidal	O
intent	O
.	O

TITLE	O
:	O
Coronaviruses	O
resistant	O
to	O
a	O
3C	O
-	O
like	O
protease	B-CHED
inhibitor	I-CHED
are	O
attenuated	O
for	O
replication	O
and	O
pathogenesis	O
,	O
revealing	O
a	O
low	O
genetic	O
barrier	O
but	O
high	O
fitness	O
cost	O
of	O
resistance	O
.	O

The	O
inhibitor	B-CHED
-	O
resistant	O
viruses	O
also	O
exhibited	O
postponed	O
and	O
reduced	O
production	O
of	O
infectious	O
virus	O
particles	O
.	O

For	O
coronaviruses	O
such	O
as	O
the	O
causative	O
agent	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
(	O
MERS	O
),	O
protease	B-CHED
inhibitors	I-CHED
have	O
been	O
developed	O
and	O
shown	O
to	O
block	O
virus	O
replication	O
,	O
but	O
the	O
consequences	O
of	O
selection	O
of	O
inhibitor	B-CHED
-	O
resistant	O
mutants	O
have	O
not	O
been	O
studied	O
.	O

Nitazoxanide	O
inhibits	O
a	O
broad	O
range	O
of	O
influenza	O
A	O
and	O
B	O
viruses	O
including	O
influenza	O
A	O
(	O
pH1N1	O
)	O
and	O
the	O
avian	O
A	O
(	O
H7N9	O
)	O
as	O
well	O
as	O
viruses	O
that	O
are	O
resistant	O
to	O
neuraminidase	B-CHED
inhibitors	I-CHED
.	O

Increased	O
extra	O
-	O
vascular	O
lung	O
water	B-CHED
(	O
EVLW	O
)	O
is	O
particularly	O
lethal	O
,	O
leading	O
to	O
iatrogenic	O
salt	B-CHED
water	B-CHED
drowning	O
.	O

PEEP	B-CHED
should	O
be	O
set	O
to	O
maximize	O
alveolar	O
recruitment	O
while	O
avoiding	O
overdistention	O
.	O

Mutation	O
of	O
individual	O
cysteine	B-CHED
clusters	B-CHED
in	O
the	O
cysteine	B-CHED
-	O
rich	O
motif	O
of	O
S	O
revealed	O
that	O
all	O
cysteines	O
must	O
be	O
replaced	O
to	O
abolish	O
acylation	O
and	O
incorporation	O
of	O
S	O
into	O
virus	O
-	O
like	O
particles	O
(	O
VLP	O
).	O

Thus	O
,	O
palmitoylation	O
of	O
the	O
S	O
protein	B-CHED
of	O
Alphacoronaviruses	O
is	O
dispensable	O
for	O
S	O
-	O
M	O
interaction	O
,	O
but	O
required	O
for	O
the	O
generation	O
of	O
progeny	O
virions	O
.	O

To	O
understand	O
how	O
bat	O
coronaviruses	O
transmit	O
to	O
humans	O
,	O
we	O
investigated	O
the	O
receptor	O
usage	O
and	O
cell	O
entry	O
activity	O
of	O
the	O
virus	O
-	O
surface	O
spike	O
proteins	B-CHED
of	O
HKU4	O
and	O
HKU5	O
.	O

In	O
mechanically	O
ventilated	O
patients	O
,	O
overdistension	O
induced	O
by	O
high	O
PEEP	B-CHED
settings	O
was	O
associated	O
with	O
CT	O
fibrosis	O
and	O
hospital	O
mortality	O
.	O

Their	O
gene	O
products	O
are	O
designated	O
as	O
""""	O
accessory	O
proteins	B-CHED
""","	O
as	O
reports	O
to	O
date	O
make	O
it	O
clear	O
that	O
these	O
proteins	B-CHED
are	O
not	O
essential	O
for	O
virus	O
replication	O
in	O
vitro	O
.	O

Adjunct	O
therapies	O
used	O
in	O
our	O
patients	O
included	O
inhaled	O
nitric	B-CHED
oxide	I-CHED
[	O
5	O
(	O
7	O
%)],	O
prone	O
position	O
[	O
22	O
(	O
31	O
%)],	O
steroids	B-CHED
[	O
26	O
(	O
37	O
%)],	O
and	O
neuromuscular	O
blockade	O
[	O
26	O
(	O
37	O
%)].	O

Here	O
we	O
report	O
that	O
E	O
protein	B-CHED
PDZ	O
-	O
binding	O
motif	O
(	O
PBM	O
),	O
a	O
domain	O
involved	O
in	O
protein	B-CHED
-	O
protein	B-CHED
interactions	O
,	O
is	O
a	O
major	O
determinant	O
of	O
virulence	O
.	O

Therefore	O
,	O
the	O
E	O
protein	B-CHED
PBM	O
is	O
a	O
virulence	O
domain	O
that	O
activates	O
immunopathology	O
most	O
likely	O
by	O
using	O
syntenin	O
as	O
a	O
mediator	O
of	O
p38	O
MAPK	O
induced	O
inflammation	O
.	O

Clusters	B-CHED
of	O
rapidly	O
-	O
evolving	O
microRNAs	O
were	O
identified	O
,	O
as	O
well	O
as	O
microRNAs	O
predicted	O
to	O
target	O
genes	O
involved	O
in	O
antiviral	B-CHED
immunity	O
,	O
the	O
DNA	O
damage	O
response	O
,	O
apoptosis	O
and	O
autophagy	O
.	O

Our	O
data	O
provide	O
a	O
structural	O
basis	O
for	O
how	O
the	O
glutathione	B-CHED
modification	O
alters	O
recognition	O
by	O
virus	O
-	O
specific	O
T	O
cells	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
a	O
protein	B-CHED
encoded	O
by	O
SARS	O
-	O
CoV	O
designated	O
as	O
open	O
reading	O
frame	O
-	O
9b	O
(	O
ORF	O
-	O
9b	O
)	O
localizes	O
to	O
mitochondria	O
and	O
causes	O
mitochondrial	O
elongation	O
by	O
triggering	O
ubiquitination	O
and	O
proteasomal	O
degradation	O
of	O
dynamin	O
-	O
like	O
protein	B-CHED
1	O
,	O
a	O
host	O
protein	B-CHED
involved	O
in	O
mitochondrial	O
fission	O
.	O

Evidence	O
suggests	O
that	O
the	O
therapeutic	O
benefit	O
of	O
FTY720	B-CHED
occurs	O
by	O
preventing	O
the	O
egress	O
of	O
lymphocytes	O
from	O
lymph	O
nodes	O
thereby	O
inhibiting	O
the	O
infiltration	O
of	O
disease	O
-	O
causing	O
lymphocytes	O
into	O
the	O
central	O
nervous	O
system	O
(	O
CNS	B-CHED
).	O

The	O
severity	O
of	O
neuroinflammation	O
and	O
demyelination	O
in	O
FTY720	B-CHED
-	O
treated	O
mice	O
was	O
examined	O
by	O
flow	O
cytometry	O
and	O
histopathologically	O
,	O
respectively	O
,	O
in	O
the	O
spinal	O
cords	O
of	O
the	O
mice	O
.	O

A	O
similar	O
trend	O
was	O
observed	O
for	O
SARS	O
-	O
CoV	O
PLpro	O
,	O
although	O
it	O
was	O
much	O
more	O
efficient	O
than	O
MERS	O
-	O
CoV	O
PLpro	O
toward	O
ISG15	O
-	O
AMC	O
and	O
peptide	B-CHED
-	O
AMC	O
substrates	O
.	O

Modeling	O
of	O
the	O
interaction	O
between	O
the	O
MERS	O
-	O
CoV	O
spike	O
glycoprotein	B-CHED
and	O
its	O
receptor	O
dipeptidyl	O
peptidase	O
4	O
predicted	O
comparable	O
interaction	O
energies	O
in	O
common	O
marmosets	O
and	O
humans	O
.	O

ABSTRACT	O
:	O
Reduced	O
levels	O
of	O
brain	O
-	O
derived	O
neurotrophic	O
factor	O
(	O
BDNF	O
)	O
are	O
thought	O
to	O
contribute	O
to	O
the	O
pathophysiology	O
of	O
Rett	O
syndrome	O
(	O
RTT	O
),	O
a	O
severe	O
neurodevelopmental	O
disorder	O
caused	O
by	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
in	O
the	O
gene	O
encoding	O
methyl	B-CHED
-	O
CpG	O
-	O
binding	O
protein	B-CHED
2	O
(	O
MeCP2	O
).	O

ABSTRACT	O
:	O
A	O
series	O
of	O
novel	O
pyrimidinylthioacetanilides	O
were	O
designed	O
,	O
synthesized	O
,	O
and	O
evaluated	O
for	O
their	O
biological	O
activity	O
as	O
potent	O
HIV	O
-	O
1	O
non	O
-	O
nucleoside	B-CHED
reverse	B-CHED
transcriptase	I-CHED
inhibitors	I-CHED
(	O
NNRTIs	O
).	O

Two	O
ascites	O
-	O
derived	O
samples	O
of	O
cats	O
with	O
FIP	O
which	O
displayed	O
no	O
alterations	O
of	O
ORF3c	O
harboured	O
mutations	O
in	O
the	O
S2	O
domain	O
of	O
the	O
S	O
protein	B-CHED
gene	O
which	O
resulted	O
in	O
amino	B-CHED
acid	I-CHED
exchanges	O
or	O
deletions	O
.	O

5	O
synthetic	O
siRNAs	O
that	O
each	O
targeted	O
a	O
different	O
region	O
of	O
the	O
FCoV	O
genome	O
were	O
tested	O
individually	O
and	O
in	O
various	O
combinations	O
for	O
their	O
antiviral	B-CHED
effects	O
against	O
2	O
strains	O
of	O
FCoV	O
(	O
feline	O
infectious	O
peritonitis	O
virus	O
WSU	O
79	O
-	O
1146	O
and	O
feline	O
enteric	O
coronavirus	O
WSU	O
79	O
-	O
1683	O
)	O
in	O
cell	O
cultures	O
.	O

TITLE	O
:	O
Automated	O
inhaled	O
nitric	B-CHED
oxide	I-CHED
alerts	O
for	O
adult	O
extracorporeal	O
membrane	O
oxygenation	O
patient	O
identification	O
.	O

He	O
was	O
treated	O
with	O
piperacillin	B-CHED
-	O
tazobactam	O
,	O
amikacin	B-CHED
,	O
oseltamivir	B-CHED
,	O
and	O
methylprednisolone	B-CHED
.	O

The	O
full	O
-	O
length	O
genome	O
of	O
the	O
CK	O
/	O
CH	O
/	O
SD	O
/	O
121220	O
isolate	O
had	O
the	O
highest	O
nucleotide	B-CHED
sequence	O
identity	O
(	O
96	O
.	O
7	O
%)	O
to	O
the	O
YX10	O
strain	O
.	O

Limited	O
human	O
-	O
to	O
-	O
human	O
transmission	O
,	O
leading	O
to	O
some	O
case	O
clusters	B-CHED
,	O
has	O
been	O
reported	O
.	O

This	O
study	O
examined	O
how	O
CD4	O
T	O
cells	O
affect	O
primary	O
and	O
secondary	O
anti	O
-	O
viral	O
CD8	O
T	O
-	O
cell	O
responses	O
within	O
the	O
central	O
nervous	O
system	O
(	O
CNS	B-CHED
)	O
during	O
encephalomyelitis	O
induced	O
by	O
sublethal	O
gliatropic	O
coronavirus	O
.	O

Nevertheless	O
,	O
impaired	O
virus	O
control	O
in	O
the	O
absence	O
of	O
CD4	O
T	O
cells	O
was	O
associated	O
with	O
gradually	O
diminished	O
CNS	B-CHED
CD8	O
T	O
-	O
cell	O
interferon	O
-	O
γ	O
production	O
.	O

Furthermore	O
,	O
within	O
the	O
CD8	O
T	O
-	O
cell	O
population	O
short	O
-	O
lived	O
effector	B-CHED
cells	O
were	O
increased	O
and	O
memory	O
precursor	O
effector	B-CHED
cells	O
were	O
significantly	O
decreased	O
,	O
consistent	O
with	O
higher	O
T	O
-	O
cell	O
turnover	O
.	O

However	O
,	O
memory	O
CD8	O
T	O
cells	O
primed	O
without	O
CD4	O
T	O
cells	O
and	O
transferred	O
into	O
infected	O
CD4	O
-	O
sufficient	O
recipients	O
expanded	O
less	O
efficiently	O
and	O
were	O
not	O
sustained	O
in	O
the	O
CNS	B-CHED
,	O
contrasting	O
with	O
their	O
helped	O
counterparts	O
.	O

By	O
contrast	O
,	O
CD4	O
T	O
cells	O
are	O
essential	O
to	O
prolong	O
primary	O
CD8	O
T	O
-	O
cell	O
function	O
in	O
the	O
CNS	B-CHED
and	O
imprint	O
memory	O
CD8	O
T	O
cells	O
for	O
recall	O
responses	O
.	O

TITLE	O
:	O
Human	O
coronavirus	O
NL63	O
utilizes	O
heparan	B-CHED
sulfate	I-CHED
proteoglycans	B-CHED
for	O
attachment	O
to	O
target	O
cells	O
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
ACE2	O
protein	B-CHED
is	O
required	O
for	O
viral	O
entry	O
but	O
that	O
it	O
is	O
not	O
the	O
primary	O
binding	O
site	O
on	O
the	O
cell	O
surface	O
.	O

TITLE	O
:	O
Design	O
of	O
an	O
epitope	B-CHED
-	O
based	O
peptide	B-CHED
vaccine	O
against	O
spike	O
protein	B-CHED
of	O
human	O
coronavirus	O
:	O
an	O
in	O
silico	O
approach	O
.	O

The	O
epitope	B-CHED
was	O
further	O
tested	O
for	O
binding	O
against	O
the	O
HLA	O
molecules	O
,	O
using	O
in	O
silico	O
docking	O
techniques	O
,	O
to	O
verify	O
the	O
binding	O
cleft	O
epitope	B-CHED
interaction	O
.	O

Using	O
the	O
standard	O
predicted	O
body	O
weight	O
(	O
PBW	O
),	O
we	O
calculated	O
and	O
compared	O
the	O
tidal	O
volume	O
(	O
total	O
Vt	O
and	O
mL	O
/	O
kg	O
PBW	O
)	O
as	O
well	O
as	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	B-CHED
),	O
peak	O
inspiratory	O
pressure	O
(	O
PIP	B-CHED
),	O
Delta	O
P	O
(	O
PIP	B-CHED
-	O
PEEP	B-CHED
),	O
and	O
FiO2	O
.	O

ABSTRACT	O
:	O
The	O
past	O
decade	O
has	O
seen	O
the	O
emergence	O
of	O
several	O
novel	O
viruses	O
that	O
cause	O
respiratory	O
tract	O
infections	O
in	O
human	O
beings	O
,	O
including	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
in	O
Saudi	O
Arabia	O
,	O
an	O
H7N9	O
influenza	O
A	O
virus	O
in	O
eastern	O
China	O
,	O
a	O
swine	O
-	O
like	O
influenza	O
H3N2	B-CHED
variant	O
virus	O
in	O
the	O
USA	O
,	O
and	O
a	O
human	O
adenovirus	O
14p1	O
also	O
in	O
the	O
USA	O
.	O

TITLE	O
:	O
Emerging	O
novel	O
and	O
antimicrobial	B-CHED
-	O
resistant	O
respiratory	O
tract	O
infections	O
:	O
new	O
drug	O
development	O
and	O
therapeutic	O
options	O
.	O

ABSTRACT	O
:	O
The	O
emergence	O
and	O
spread	O
of	O
antimicrobial	B-CHED
-	O
resistant	O
bacterial	O
,	O
viral	O
,	O
and	O
fungal	O
pathogens	O
for	O
which	O
diminishing	O
treatment	O
options	O
are	O
available	O
is	O
of	O
major	O
global	O
concern	O
.	O

This	O
Series	O
paper	O
describes	O
the	O
development	O
and	O
use	O
of	O
new	O
antimicrobial	B-CHED
agents	O
and	O
immune	O
-	O
based	O
and	O
host	O
-	O
directed	O
therapies	O
for	O
a	O
range	O
of	O
conventional	O
and	O
emerging	O
viral	O
,	O
bacterial	O
,	O
and	O
fungal	O
causes	O
of	O
respiratory	O
tract	O
infections	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
conduct	O
an	O
epidemiological	O
and	O
laboratory	O
surveillance	O
of	O
Influenza	O
-	O
Like	O
Illnesses	O
(	O
ILI	O
)	O
in	O
Polish	O
Armed	O
Forces	O
,	O
civilian	O
military	O
personnel	O
and	O
their	O
families	O
in	O
2011	O
/	O
2012	O
epidemic	O
season	O
,	O
under	O
the	O
United	O
States	O
Department	O
of	O
Defense	O
-	O
Global	O
Emerging	O
Infections	O
Surveillance	O
and	O
Response	O
System	O
(	O
DoD	B-CHED
-	O
GEIS	O
).	O

TITLE	O
:	O
Genomic	O
characteristics	O
and	O
changes	O
of	O
avian	O
infectious	O
bronchitis	O
virus	O
strain	O
CK	O
/	O
CH	O
/	O
LDL	B-CHED
/	O
97I	O
after	O
serial	O
passages	O
in	O
chicken	O
embryos	O
.	O

RESULTS	O
:	O
The	O
CK	O
/	O
CH	O
/	O
LDL	B-CHED
/	O
97I	O
virus	O
population	O
contained	O
subpopulations	O
with	O
a	O
mixture	B-CHED
of	O
genetic	O
mutants	O
.	O

Our	O
computational	O
data	O
are	O
in	O
line	O
with	O
available	O
experimental	O
results	O
,	O
such	O
as	O
X	O
-	O
ray	O
geometries	O
,	O
measured	O
pKa	O
values	O
,	O
mutagenesis	O
experiments	O
,	O
and	O
the	O
measured	O
differences	O
between	O
the	O
kinetic	O
parameters	O
of	O
substrates	O
and	O
inhibitors	B-CHED
.	O

The	O
∼	O
30	O
-	O
kb	O
positive	O
-	O
stranded	O
RNA	O
genome	O
of	O
coronaviruses	O
encodes	O
a	O
replication	O
/	O
transcription	O
machinery	O
that	O
is	O
unusually	O
complex	O
and	O
composed	O
of	O
16	O
nonstructural	O
proteins	B-CHED
(	O
nsps	O
).	O

The	O
mRNA	B-CHED
expressions	O
levels	O
of	O
Fgl2	O
and	O
Tnfα	O
were	O
determined	O
by	O
qRT	O
-	O
PCR	O
analyses	O
.	O

RESULTS	O
:	O
We	O
observed	O
that	O
complement	O
activation	O
,	O
coagulation	O
and	O
pro	B-CHED
-	O
inflammatory	O
cytokine	O
production	O
were	O
upregulated	O
in	O
the	O
HBV	O
(+)	O
patients	O
with	O
FH	O
.	O

The	O
high	O
sequence	O
identity	O
in	O
the	O
viral	O
spike	O
protein	B-CHED
prompted	O
us	O
to	O
investigate	O
if	O
HKU4	O
and	O
HKU5	O
can	O
recognize	O
hCD26	O
for	O
cell	O
entry	O
.	O

TITLE	O
:	O
Effect	O
of	O
integrated	O
traditional	O
Chinese	O
medicine	B-CHED
and	O
western	O
medicine	B-CHED
on	O
the	O
treatment	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
:	O
A	O
meta	O
-	O
analysis	O
.	O

The	O
level	O
of	O
serum	O
IL	O
-	O
8	O
was	O
positively	O
correlated	O
with	O
white	O
blood	O
cell	O
count	O
and	O
ISS	O
score	O
,	O
and	O
inversely	O
correlated	O
with	O
oxygen	B-CHED
index	O
.	O

TITLE	O
:	O
Effects	O
of	O
high	O
-	O
volume	O
hemofiltration	O
on	O
alveolar	O
-	O
arterial	O
oxygen	B-CHED
exchange	O
in	O
patients	O
with	O
refractory	O
septic	O
shock	O
.	O

HVHF	O
combined	O
with	O
fluid	O
resuscitation	O
can	O
improve	O
alveolar	O
-	O
arterial	O
-	O
oxygen	B-CHED
exchange	O
,	O
decrease	O
the	O
APACHE	O
II	O
score	O
in	O
patients	O
with	O
refractory	O
septic	O
shock	O
,	O
and	O
thus	O
it	O
increases	O
the	O
survival	O
rate	O
of	O
patients	O
.	O

Health	O
concerns	O
and	O
social	O
experiences	O
motivated	O
the	O
participants	O
to	O
practise	O
tai	O
chi	B-CHED
in	O
post	O
-	O
SARS	O
Hong	O
Kong	O
.	O

ABSTRACT	O
:	O
Acute	O
liver	O
failure	O
(	O
ALF	O
)	O
caused	O
by	O
viral	O
and	O
non	O
-	O
viral	O
hepatitis	O
is	O
often	O
accompanied	O
with	O
severe	O
metabolic	O
disorders	O
,	O
the	O
accumulation	O
of	O
toxic	O
substances	O
and	O
continuous	O
release	O
and	O
accumulation	O
of	O
a	O
large	O
number	O
of	O
endogenous	O
toxins	B-CHED
and	O
inflammatory	O
mediators	O
.	O

Significant	O
improvement	O
was	O
observed	O
in	O
HR	O
,	O
MAP	O
,	O
PaO2	O
/	O
FiO2	O
,	O
total	O
bilirubin	B-CHED
(	O
TBIL	O
)	O
and	O
alanine	B-CHED
aminotransferase	O
(	O
ALT	B-CHED
)	O
levels	O
after	O
treatment	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

BMSCs	O
decreased	O
expression	O
of	O
cleaved	O
caspase	O
-	O
3	O
and	O
the	O
pro	B-CHED
-	O
apoptotic	O
protein	B-CHED
,	O
Bax	O
,	O
whilst	O
increased	O
levels	O
of	O
the	O
anti	O
-	O
apoptotic	O
protein	B-CHED
,	O
Bcl	O
-	O
2	O
,	O
prolonging	O
the	O
lifespan	O
of	O
AMs	O
in	O
vitro	O
.	O

The	O
anti	O
-	O
apoptosis	O
action	O
of	O
BMSCs	O
was	O
reversed	O
by	O
SB216763	O
,	O
a	O
specific	O
inhibitor	B-CHED
of	O
GSK	O
-	O
3β	O
that	O
also	O
activates	O
Wnt	O
/	O
β	O
-	O
catenin	O
signaling	O
.	O

ABSTRACT	O
:	O
The	O
receptor	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
the	O
spike	O
(	O
S	O
)	O
glycoprotein	B-CHED
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
is	O
a	O
major	O
target	O
of	O
protective	O
immunity	O
in	O
vivo	O
.	O

Comparing	O
to	O
the	O
typical	O
reference	O
CCV	O
strains	O
(	O
type	O
II	O
),	O
the	O
nucleotide	B-CHED
sequence	O
of	O
Korean	O
strains	O
had	O
homology	O
ranged	O
from	O
86	O
.	O
3	O
%	O
to	O
98	O
.	O
3	O
%	O
(	O
89	O
.	O
1	O
%	O
to	O
99	O
.	O
2	O
%	O
for	O
the	O
amino	B-CHED
acid	I-CHED
sequence	O
)	O
and	O
87	O
.	O
7	O
%	O
to	O
97	O
.	O
8	O
%	O
(	O
92	O
.	O
4	O
%	O
to	O
100	O
%	O
for	O
the	O
amino	B-CHED
acid	I-CHED
sequence	O
)	O
when	O
compared	O
to	O
FCoV	O
-	O
like	O
CCV	O
strains	O
(	O
type	O
I	O
).	O

A	O
correlation	O
analysis	O
between	O
the	O
codon	O
compositions	O
(	O
A3s	O
,	O
T3s	O
,	O
G3s	O
,	O
C3s	O
,	O
and	O
GC3s	O
),	O
the	O
ENC	O
values	O
,	O
and	O
the	O
nucleotide	B-CHED
contents	O
(	O
A	O
%,	O
T	O
%,	O
G	O
%,	O
C	O
%,	O
and	O
GC	O
%)	O
indicated	O
that	O
mutational	O
bias	O
plays	O
role	O
in	O
shaping	O
the	O
PEDV	O
codon	O
usage	O
bias	O
.	O

Myeloid	O
cells	O
,	O
including	O
monocytes	O
and	O
macrophages	O
,	O
play	O
an	O
important	O
role	O
in	O
this	O
balance	B-CHED
,	O
particularly	O
through	O
the	O
activities	O
of	O
the	O
arginine	B-CHED
-	O
hydrolyzing	O
enzymes	O
nitric	B-CHED
oxide	I-CHED
synthase	O
2	O
(	O
Nos2	O
;	O
iNOS	O
)	O
and	O
arginase	O
1	O
(	O
Arg1	O
).	O

Both	O
proteins	B-CHED
can	O
be	O
frequently	O
found	O
in	O
plasma	O
of	O
patients	O
with	O
different	O
diseases	O
,	O
whereby	O
they	O
have	O
distinct	O
underlying	O
mechanism	O
of	O
formation	O
.	O

RESULTS	O
:	O
Sal	B-CHED
CURB	O
®	O
(	O
Kemin	O
Industries	O
,	O
Des	B-CHED
Moines	O
,	O
IA	O
,	O
USA	O
)	O
is	O
a	O
FDA	O
-	O
approved	O
liquid	O
antimicrobial	B-CHED
used	O
to	O
control	O
Salmonella	O
contamination	O
in	O
poultry	O
and	O
swine	O
diets	O
.	O

Also	O
unclear	O
are	O
the	O
molecular	O
determinants	O
governing	O
the	O
antiviral	B-CHED
activities	O
of	O
TRIM56	O
.	O

CCoV	O
antigen	B-CHED
was	O
found	O
in	O
epithelial	O
cells	O
of	O
small	O
intestinal	O
villi	O
in	O
all	O
puppies	O
and	O
the	O
colon	O
in	O
2	O
of	O
the	O
10	O
puppies	O
where	O
colon	O
specimens	O
were	O
available	O
.	O

Furthermore	O
,	O
entry	O
mediated	O
by	O
the	O
influenza	O
virus	O
hemagglutinin	O
was	O
robustly	O
inhibited	O
by	O
IFITM3	O
but	O
was	O
insensitive	O
to	O
accumulation	O
of	O
endosomal	O
cholesterol	B-CHED
,	O
indicating	O
that	O
modulation	O
of	O
cholesterol	B-CHED
synthesis	O
/	O
transport	O
did	O
not	O
account	O
for	O
the	O
antiviral	B-CHED
activity	O
of	O
IFITM3	O
.	O

Uniaxial	O
stretch	O
(	O
10	O
-	O
30	O
%	O
in	O
strain	O
)	O
was	O
applied	O
to	O
fibroblasts	O
cultured	O
in	O
a	O
silicone	B-CHED
chamber	O
coated	O
with	O
type	O
I	O
collagen	O
using	O
a	O
stretching	O
apparatus	O
.	O

The	O
immune	O
parameters	O
of	O
this	O
region	O
were	O
determined	O
using	O
different	O
in	O
silico	O
tools	O
and	O
Immune	O
Epitope	B-CHED
Database	O
(	O
IEDB	O
).	O

In	O
alveolar	O
epithelial	O
cells	O
,	O
insulin	B-CHED
increased	O
the	O
expression	O
of	O
α	O
-,	O
β	O
-,	O
and	O
γ	O
-	O
ENaC	O
,	O
which	O
was	O
blocked	O
by	O
the	O
mammalian	O
target	O
of	O
rapamycin	B-CHED
complex	O
2	O
(	O
mTORC2	O
)	O
inhibitor	B-CHED
or	O
knockdown	O
of	O
Rictor	O
(	O
a	O
necessary	O
component	O
of	O
mTORC2	O
),	O
and	O
SGK1	O
inhibitor	B-CHED
,	O
respectively	O
.	O

The	O
data	O
revealed	O
that	O
during	O
ALI	O
,	O
insulin	B-CHED
stimulates	O
alveolar	O
fluid	O
clearance	O
by	O
upregulating	O
the	O
expression	O
of	O
α	O
-,	O
β	O
-,	O
and	O
γ	O
-	O
ENaC	O
at	O
the	O
cell	O
surface	O
,	O
which	O
was	O
,	O
at	O
least	O
,	O
partially	O
through	O
activating	O
mTROC2	O
/	O
SGK1	O
signaling	O
pathway	O
.	O

However	O
,	O
the	O
contribution	O
of	O
these	O
cofactors	B-CHED
to	O
immunity	O
and	O
disease	O
incidence	O
has	O
not	O
been	O
determined	O
.	O

RESULTS	O
:	O
Arterial	O
oxygen	B-CHED
tension	O
(	O
PaO2	O
),	O
oxygenation	O
index	O
(	O
OI	O
)	O
as	O
well	O
as	O
dynamic	O
pulmonary	O
compliance	O
were	O
all	O
elevated	O
significantly	O
,	O
whereas	O
peak	O
inspiratory	O
pressure	O
significantly	O
decreased	O
at	O
6h	O
,	O
12h	O
and	O
24h	O
after	O
CRRT	O
respectively	O
;	O
serum	O
cytokine	O
level	O
and	O
CRP	O
significantly	O
decreased	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

However	O
,	O
CK	O
/	O
CH	O
/	O
SD09	O
/	O
005	O
exhibited	O
lower	O
levels	O
of	O
similarity	O
with	O
ck	O
/	O
CH	O
/	O
LDL	B-CHED
/	O
091022	O
and	O
SDIB821	O
/	O
2012	O
in	O
S	O
-	O
3a	O
-	O
3b	O
-	O
3c	O
/	O
E	O
-	O
M	O
-	O
5a	O
-	O
5b	O
-	O
N	O
with	O
a	O
sequence	O
identity	O
of	O
72	O
%	O
-	O
90	O
%.	O

Unlike	O
other	O
influenza	O
viruses	O
,	O
engineering	O
truncations	O
hypothesized	O
to	O
reduce	O
interferon	O
antagonism	O
into	O
the	O
NS1	O
protein	B-CHED
didn	O
'	O
t	O
attenuate	O
bat	O
-	O
influenza	O
.	O

PEDV	O
-	O
specific	O
antigen	B-CHED
was	O
detected	O
in	O
villous	O
enterocytes	O
of	O
challenged	O
pigs	O
by	O
immunohistochemistry	O
(	O
IHC	O
)	O
on	O
dpi	O
1	O
,	O
2	O
,	O
3	O
,	O
4	O
,	O
7	O
,	O
and	O
14	O
.	O

Samples	O
from	O
the	O
corona	B-CHED
of	O
glans	O
penis	O
,	O
penile	O
shaft	O
and	O
scrotum	O
were	O
combined	O
for	O
HPV	O
DNA	O
testing	O
.	O

We	O
report	O
here	O
a	O
carbohydrate	B-CHED
microarray	O
analysis	O
of	O
a	O
number	O
of	O
tumor	O
-	O
associated	O
carbohydrates	B-CHED
for	O
their	O
serum	O
antibody	O
reactivities	O
and	O
potential	O
immunogenicity	O
in	O
humans	O
.	O

The	O
trial	O
will	O
utilise	O
a	O
primary	O
composite	O
end	O
point	O
that	O
incorporates	O
death	O
and	O
days	O
off	O
the	O
ventilator	O
at	O
28	O
days	O
to	O
test	O
the	O
primary	O
hypothesis	O
that	O
adjusting	O
ventilator	O
pressure	O
to	O
achieve	O
positive	O
PTP	B-CHED
values	O
will	O
result	O
in	O
improved	O
mortality	O
and	O
ventilator	O
-	O
free	O
days	O
.	O

The	O
coronavirus	O
spike	O
(	O
S	O
)	O
protein	B-CHED
is	O
the	O
main	O
determinant	O
of	O
viral	O
entry	O
,	O
and	O
although	O
it	O
was	O
previously	O
shown	O
that	O
MERS	O
-	O
CoV	O
S	O
can	O
be	O
activated	O
by	O
various	O
proteases	O
,	O
the	O
details	O
of	O
the	O
mechanisms	O
of	O
proteolytic	O
activation	O
of	O
fusion	O
are	O
still	O
incompletely	O
characterized	O
.	O

ABSTRACT	O
:	O
Substances	O
with	O
gender	O
action	O
on	O
immunity	O
were	O
detected	O
in	O
water	B-CHED
soluble	O
hydrolised	O
matter	O
from	O
reptile	O
carcases	O
.	O

TITLE	O
:	O
Porcine	O
epidemic	O
diarrhea	O
virus	O
infection	O
:	O
inhibition	O
by	O
polysaccharide	B-CHED
from	O
Ginkgo	O
biloba	O
exocarp	O
and	O
mode	O
of	O
its	O
action	O
.	O

The	O
polysaccharide	B-CHED
exhibited	O
potent	O
antiviral	B-CHED
activity	O
against	O
PEDV	O
reducing	O
the	O
formation	O
of	O
a	O
visible	O
CPE	O
[	O
a	O
50	O
%	O
inhibitory	O
concentration	O
(	O
IC50	O
)=	O
1	O
.	O
7	O
±	O
1	O
.	O
3μg	O
/	O
mL	O
],	O
compared	O
to	O
positive	O
control	O
,	O
ribavirin	B-CHED
and	O
it	O
did	O
not	O
show	O
cytotoxicity	O
at	O
100μg	O
/	O
mL	O
[	O
a	O
50	O
%	O
cytotoxicity	O
concentration	O
(	O
CC50	O
)=	O
100μg	O
/	O
mL	O
].	O

Polysaccharide	B-CHED
also	O
showed	O
effective	O
inhibitory	O
effects	O
when	O
added	O
at	O
the	O
viral	O
attachment	O
and	O
entry	O
steps	O
.	O

The	O
most	O
important	O
laboratory	O
findings	O
were	O
thrombocytopenia	O
,	O
elevated	O
hematocrit	O
and	O
hemoglobin	B-CHED
concentrations	O
,	O
elevated	O
liver	O
enzymes	O
,	O
elevated	O
lactate	B-CHED
dehydrogenase	O
and	O
a	O
positive	O
sorology	O
for	O
Hantavirus	O
(	O
ELISA	O
IgM	O
positive	O
).	O

Several	O
""""	O
negative	O
""""	O
randomized	O
controlled	O
trials	O
of	O
high	O
-	O
dose	O
of	O
glucocorticoids	B-CHED
given	O
for	O
a	O
short	O
period	O
of	O
time	O
in	O
the	O
early	O
course	O
of	O
severe	O
sepsis	O
or	O
acute	O
respiratory	O
distress	O
syndrome	O
raised	O
serious	O
doubts	O
on	O
the	O
benefit	O
of	O
this	O
treatment	O
.	O

Recently	O
,	O
a	O
link	O
between	O
septic	O
shock	O
and	O
adrenal	O
insufficiency	O
,	O
or	O
systemic	O
inflammation	O
induced	O
glucocorticoids	B-CHED
receptor	O
resistance	O
had	O
been	O
established	O
.	O

The	O
goal	O
of	O
this	O
article	O
is	O
to	O
review	O
the	O
key	O
role	O
of	O
corticosteroids	B-CHED
in	O
the	O
host	O
response	O
to	O
stress	O
and	O
will	O
update	O
the	O
reader	O
with	O
the	O
new	O
validated	O
indications	O
of	O
corticosteroids	B-CHED
treatment	O
in	O
the	O
ICU	O
.	O

Bladders	O
from	O
12	O
week	O
old	O
male	O
C57BL	O
/	O
6J	O
mice	O
with	O
coronavirus	O
-	O
induced	O
encephalomyelitis	O
(	O
CIE	O
,	O
a	O
chronic	O
,	O
progressive	O
demyelinating	O
disease	O
model	O
of	O
human	O
MS	O
),	O
and	O
age	O
-	O
matched	O
controls	O
,	O
were	O
cut	O
into	O
5	O
-	O
7	O
strips	O
and	O
suspended	O
in	O
physiological	O
muscle	O
baths	O
for	O
tension	O
measurement	O
in	O
response	O
to	O
agonists	B-CHED
and	O
electric	O
field	O
stimulation	O
(	O
EFS	B-CHED
).	O

Bethanechol	B-CHED
(	O
muscarinic	O
receptor	O
agonist	B-CHED
)	O
potency	O
was	O
significantly	O
increased	O
in	O
CIE	O
bladders	O
.	O

Inhaled	O
nitric	B-CHED
oxide	I-CHED
as	O
the	O
first	O
vasodilator	B-CHED
to	O
produce	O
selective	O
pulmonary	O
vasodilation	O
has	O
beneficial	O
effects	O
on	O
gas	O
exchange	O
and	O
ventilation	O
,	O
improving	O
outcome	O
in	O
children	O
with	O
severe	O
hypoxia	O
.	O

TITLE	O
:	O
[	O
Activated	O
C	O
protein	B-CHED
in	O
the	O
treatment	O
of	O
a	O
newborn	O
with	O
sepsis	O
,	O
shock	O
and	O
multiple	O
organ	O
dysfunction	O
systems	O
:	O
case	O
report	O
and	O
literature	O
review	O
].	O

It	O
'	O
s	O
incontestable	O
that	O
the	O
ventilatory	O
strategy	O
of	O
a	O
patient	O
with	O
severe	O
TBI	O
that	O
become	O
to	O
develop	O
ALI	O
or	O
ARDS	O
is	O
an	O
authentic	O
challenge	O
;	O
a	O
predilection	O
for	O
PCV	B-CHED
mode	O
is	O
observed	O
due	O
to	O
the	O
already	O
known	O
protective	O
ventilation	O
strategy	O
.	O

A	O
15	O
-	O
year	O
-	O
old	O
man	B-CHED
with	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
infection	O
and	O
a	O
29	O
-	O
year	O
-	O
old	O
immunocompetent	O
female	O
were	O
admitted	O
in	O
the	O
ICU	O
with	O
primary	O
varicella	O
infection	O
and	O
pneumonia	O
.	O

ABSTRACT	O
:	O
The	O
infectious	O
bronchitis	O
virus	O
is	O
a	O
causative	O
agent	O
of	O
avian	O
infectious	O
bronchitis	O
(	O
AIB	B-CHED
),	O
and	O
is	O
is	O
an	O
important	O
disease	O
that	O
produces	O
severe	O
economic	O
losses	O
to	O
the	O
poultry	O
industry	O
worldwide	O
.	O

Recent	O
AIB	B-CHED
outbreaks	O
in	O
India	O
have	O
been	O
associated	O
with	O
poor	O
growth	O
in	O
broilers	O
,	O
drop	O
in	O
egg	O
production	O
,	O
and	O
thin	O
egg	O
shells	O
in	O
layers	O
.	O

To	O
understand	O
the	O
molecular	O
basis	O
for	O
ubiquitin	O
(	O
Ub	O
)	O
recognition	O
and	O
deconjugation	O
by	O
MERS	O
-	O
CoV	O
PL	O
(	O
pro	B-CHED
),	O
we	O
determined	O
its	O
crystal	O
structure	O
in	O
complex	O
with	O
Ub	O
.	O

A	O
murine	O
model	O
of	O
RBC	O
transfusion	O
followed	O
by	O
LPS	B-CHED
administration	O
was	O
used	O
to	O
determine	O
the	O
effects	O
of	O
RBC	O
transfusion	O
and	O
HMGB1	O
release	O
on	O
LPS	B-CHED
-	O
induced	O
lung	O
inflammation	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
effect	O
of	O
emodin	B-CHED
on	O
lipopolysaccharide	B-CHED
(	O
LPS	B-CHED
)-	O
induced	O
ALI	O
in	O
mice	O
,	O
and	O
its	O
potential	O
bio	O
-	O
mechanism	O
.	O

In	O
our	O
study	O
,	O
BALB	O
/	O
c	O
mice	O
were	O
stimulated	O
with	O
LPS	B-CHED
to	O
induce	O
ALI	O
.	O

Our	O
data	O
indicates	O
that	O
emodin	B-CHED
potently	O
inhibits	O
LPS	B-CHED
-	O
induced	O
pulmonary	O
inflammation	O
,	O
pulmonary	O
edema	O
and	O
MCP	B-CHED
-	O
1	O
and	O
E	O
-	O
selectin	O
expression	O
,	O
and	O
that	O
these	O
effects	O
were	O
very	O
likely	O
mediated	O
by	O
inactivation	O
of	O
NF	O
-	O
κB	O
in	O
mice	O
.	O

These	O
reactions	O
are	O
the	O
first	O
steps	O
of	O
N	O
-	O
linked	O
glycan	B-CHED
processing	O
and	O
are	O
essential	O
for	O
proper	O
folding	O
and	O
function	O
of	O
many	O
glycoproteins	B-CHED
.	O

At	O
the	O
maximal	O
responses	O
(	O
characterised	O
by	O
an	O
increase	O
in	O
lung	O
resistance	O
),	O
the	O
sheep	O
were	O
either	O
not	O
treated	O
or	O
treated	O
with	O
one	O
of	O
the	O
following	O
;	O
nebulized	O
S	O
-	O
1226	O
(	O
perflubron	B-CHED
+	O
12	O
%	O
CO2	B-CHED
),	O
nebulized	O
perflubron	B-CHED
+	O
medical	O
air	B-CHED
,	O
12	O
%	O
CO2	B-CHED
,	O
salbutamol	B-CHED
or	O
medical	O
air	B-CHED
.	O

In	O
this	O
study	O
,	O
liquid	O
chromatography	O
-	O
tandem	O
mass	O
spectrometry	O
coupled	O
to	O
isobaric	O
tags	O
for	O
relative	O
and	O
absolute	O
quantification	O
labeling	O
was	O
used	O
to	O
quantitatively	O
identify	O
differentially	O
expressed	O
cellular	O
proteins	B-CHED
after	O
TGEV	O
infection	O
in	O
PK	O
-	O
15	O
cells	O
.	O

Data	O
suggest	O
that	O
activated	O
microglia	O
and	O
inflammatory	O
mediators	O
contribute	O
to	O
a	O
local	O
CNS	B-CHED
microenvironment	O
that	O
regulates	O
viral	O
replication	O
and	O
IFN	O
-	O
γ	O
production	O
during	O
the	O
acute	O
phase	O
of	O
infection	O
,	O
which	O
in	O
turn	O
can	O
cause	O
phagolysosome	O
maturation	O
and	O
phagocytosis	O
of	O
the	O
myelin	O
sheath	O
,	O
leading	O
to	O
demyelination	O
.	O

During	O
infusion	O
of	O
vancomycin	B-CHED
,	O
he	O
became	O
diaphoretic	O
,	O
hypotensive	O
,	O
and	O
unresponsive	O
,	O
and	O
exhibited	O
respiratory	O
distress	O
and	O
a	O
disseminated	O
red	O
skin	O
rash	O
consistent	O
with	O
a	O
severe	O
allergic	O
reaction	O
referred	O
to	O
as	O
the	O
red	O
man	B-CHED
syndrome	O
.	O

When	O
the	O
patient	O
regained	O
consciousness	O
within	O
an	O
hour	O
,	O
he	O
complained	O
of	O
severe	O
vision	O
loss	O
and	O
demonstrated	O
multiple	O
bilateral	O
branch	O
retinal	B-CHED
artery	O
occlusions	O
.	O

Our	O
results	O
indicate	O
that	O
entry	O
of	O
MHV	O
depends	O
on	O
proteolytic	O
processing	O
of	O
its	O
fusion	O
protein	B-CHED
S	O
by	O
lysosomal	O
proteases	O
.	O

Lack	O
of	O
therapeutic	O
benefits	O
from	O
clinical	O
trials	O
,	O
highlight	O
the	O
importance	O
of	O
detailed	O
in	O
-	O
vivo	O
analysis	O
and	O
characterisation	O
of	O
ARDS	O
patients	O
according	O
to	O
patterns	O
of	O
surfactant	B-CHED
synthesis	O
and	O
metabolism	O
.	O

They	O
had	O
an	O
infusion	O
of	O
methyl	B-CHED
-	O
D9	O
-	O
choline	B-CHED
chloride	I-CHED
and	O
small	O
volume	O
bronchoalveolar	O
lavage	O
fluid	O
(	O
BALF	O
)	O
was	O
obtained	O
at	O
0	O
,	O
6	O
,	O
12	O
,	O
24	O
,	O
48	O
,	O
72	O
and	O
96	O
hours	O
.	O

Compositional	O
analysis	O
and	O
enrichment	O
patterns	O
of	O
stable	O
isotope	O
labelling	O
of	O
surfactant	B-CHED
phosphatidylcholine	B-CHED
(	O
PC	O
)	O
was	O
determined	O
by	O
electrospray	O
ionisation	O
mass	O
spectrometry	O
.	O

In	O
fact	O
,	O
Ifnβ	O
expression	O
is	O
delayed	O
with	O
respect	O
to	O
the	O
peak	O
of	O
viral	O
replication	O
and	O
the	O
accompanying	O
accumulation	O
of	O
double	O
-	O
stranded	O
RNA	O
(	O
dsRNA	B-CHED
).	O

Light	O
microscopy	O
analysis	O
of	O
BAL	B-CHED
cytocentrifugates	O
showed	O
the	O
presence	O
of	O
characteristic	O
large	O
,	O
mononuclear	O
,	O
plasmoblastic	O
/	O
plasmocytoid	O
-	O
like	O
cells	O
never	O
described	O
before	O
.	O

ABSTRACT	O
:	O
Based	O
on	O
a	O
bioinformatics	O
analysis	O
of	O
the	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavvirus	O
(	O
MERS	O
-	O
CoV	O
)	O
S	O
protein	B-CHED
,	O
we	O
synthesized	O
a	O
panel	O
of	O
peptides	B-CHED
coupled	O
to	O
keyhole	O
limpet	O
haemocyanin	O
and	O
used	O
them	O
to	O
raise	O
antibodies	O
in	O
rabbits	O
.	O

TITLE	O
:	O
Angiotensin	B-CHED
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
mediates	O
influenza	O
H7N9	O
virus	O
-	O
induced	O
acute	O
lung	O
injury	O
.	O

The	O
data	O
support	O
experimental	O
findings	O
of	O
a	O
weak	O
cation	B-CHED
selectivity	O
of	O
the	O
channel	O
.	O

TITLE	O
:	O
Overview	O
of	O
the	O
3rd	O
isirv	O
-	O
Antiviral	B-CHED
Group	O
Conference	O
--	O
advances	O
in	O
clinical	O
management	O
.	O

ABSTRACT	O
:	O
This	O
review	O
highlights	O
the	O
main	O
points	O
which	O
emerged	O
from	O
the	O
presentations	O
and	O
discussions	O
at	O
the	O
3rd	O
isirv	O
-	O
Antiviral	B-CHED
Group	O
Conference	O
-	O
advances	O
in	O
clinical	O
management	O
.	O

To	O
identify	O
cell	O
-	O
specific	O
ATF3	O
-	O
dependent	O
mechanisms	O
of	O
susceptibility	O
to	O
ALI	O
/	O
VILI	O
,	O
we	O
generated	O
ATF3	O
chimera	O
by	O
adoptive	O
bone	O
marrow	O
(	O
BM	O
)	O
transfer	O
and	O
randomized	O
to	O
inhaled	O
saline	O
or	O
lipopolysacharide	O
(	O
LPS	B-CHED
)	O
in	O
the	O
presence	O
of	O
mechanical	O
ventilation	O
(	O
MV	O
).	O

TITLE	O
:	O
Tailoring	O
subunit	O
vaccine	O
immunity	O
with	O
adjuvant	B-CHED
combinations	O
and	O
delivery	O
routes	O
using	O
the	O
Middle	O
East	O
respiratory	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
receptor	O
-	O
binding	O
domain	O
as	O
an	O
antigen	B-CHED
.	O

Different	O
vaccination	O
regimens	O
were	O
compared	O
in	O
BALB	O
/	O
c	O
mice	O
immunized	O
3	O
times	O
intramuscularly	O
(	O
i	O
.	O
m	O
.)	O
with	O
a	O
vaccine	O
containing	O
10	O
µg	O
of	O
recombinant	O
MERS	O
-	O
CoV	O
RBD	O
in	O
combination	O
with	O
either	O
aluminium	B-CHED
hydroxide	I-CHED
(	O
alum	O
)	O
alone	O
,	O
alum	O
and	O
polyriboinosinic	O
acid	O
(	O
poly	O
I	O
:	O
C	O
)	O
or	O
alum	O
and	O
cysteine	B-CHED
-	O
phosphate	B-CHED
-	O
guanine	B-CHED
(	O
CpG	O
)	O
oligodeoxynucleotides	O
(	O
ODN	O
).	O

ABSTRACT	O
:	O
Acquisition	O
of	O
new	O
proteins	B-CHED
by	O
viruses	O
usually	O
occurs	O
through	O
horizontal	O
gene	O
transfer	O
or	O
through	O
gene	O
duplication	O
,	O
but	O
another	O
,	O
less	O
common	O
mechanism	O
is	O
the	O
usage	O
of	O
completely	O
or	O
partially	O
overlapping	O
reading	O
frames	O
.	O

Carrageenan	B-CHED
nasal	O
spray	O
showed	O
significant	O
antiviral	B-CHED
efficacy	O
in	O
all	O
three	O
virus	O
subgroups	O
,	O
the	O
highest	O
effectiveness	O
was	O
observed	O
in	O
human	O
corona	B-CHED
virus	O
-	O
infected	O
patients	O
.	O

In	O
contrast	O
,	O
respirators	O
are	O
“	O
medical	O
devices	O
designed	O
to	O
protect	O
the	O
wearer	O
from	O
airborne	O
infectious	O
aerosols	O
transmitted	O
directly	O
from	O
the	O
patient	O
or	O
when	O
artificially	O
created	O
such	O
as	O
during	O
aerosol	O
-	O
generating	O
procedures	O
”,	O
and	O
this	O
is	O
done	O
by	O
filtering	O
the	O
airborne	O
particles	O
(	O
known	O
as	O
an	O
air	B-CHED
-	O
purifying	O
respirator	O
)	O
or	O
supplying	O
clean	O
air	B-CHED
to	O
the	O
person	O
wearing	O
the	O
respirator	O
(	O
known	O
as	O
an	O
atmosphere	O
-	O
supplying	O
respirator	O
).	O

A	O
pan	B-CHED
-	O
coronavirus	O
reverse	O
transcription	O
-	O
PCR	O
screening	O
assay	O
was	O
performed	O
,	O
and	O
all	O
HCoV	O
-	O
positive	O
specimens	O
were	O
subsequently	O
confirmed	O
by	O
sequencing	O
of	O
the	O
PCR	O
products	O
.	O

There	O
was	O
a	O
linear	O
correlation	O
between	O
ELLB	O
and	O
ELPeso	O
during	O
the	O
increase	O
and	O
decrease	O
of	O
PEEP	B-CHED
(	O
R²	O
=	O
0	O
.	O
26	O
and	O
0	O
.	O
42	O
,	O
respectively	O
).	O

After	O
7	O
days	O
of	O
antifungal	B-CHED
treatment	O
,	O
Aspergillus	O
antibodies	O
were	O
undetectable	O
.	O

ABSTRACT	O
:	O
All	O
coronaviruses	O
encode	O
a	O
macrodomain	O
containing	O
ADP	B-CHED
-	O
ribose	B-CHED
-	O
1	O
"""-"	O
phosphatase	O
(	O
ADRP	O
)	O
activity	O
within	O
the	O
N	O
terminus	O
of	O
nonstructural	O
protein	B-CHED
3	O
(	O
nsp3	O
).	O

The	O
nonstructural	O
protein	B-CHED
1	O
(	O
nsp1	O
)	O
of	O
CoVs	O
has	O
attracted	O
considerable	O
attention	O
in	O
this	O
regard	O
as	O
a	O
potential	O
virulence	O
factor	O
and	O
a	O
target	O
for	O
CoV	O
vaccine	O
development	O
because	O
of	O
accumulating	O
evidence	O
that	O
point	O
to	O
its	O
role	O
in	O
the	O
downregulation	O
of	O
host	O
innate	O
immune	O
responses	O
to	O
CoV	O
infection	O
.	O

This	O
review	O
summarizes	O
the	O
current	O
knowledge	O
about	O
the	O
biological	O
functions	O
of	O
CoV	O
nsp1	O
that	O
provides	O
an	O
insight	O
into	O
the	O
novel	O
strategies	O
utilized	O
by	O
this	O
viral	O
protein	B-CHED
to	O
modulate	O
host	O
and	O
viral	O
gene	O
expression	O
during	O
CoV	O
infection	O
.	O

Enlarged	O
air	B-CHED
spaces	O
were	O
significantly	O
more	O
prominent	O
in	O
cases	O
with	O
longer	O
survival	O
after	O
burn	O
(	O
p	O
<	O
0	O
.	O
01	O
),	O
and	O
in	O
cases	O
with	O
the	O
presence	O
of	O
inhalation	O
injury	O
(	O
p	O
<	O
0	O
.	O
01	O
).	O

Coronavirus	O
spike	O
proteins	B-CHED
are	O
the	O
main	O
determinant	O
of	O
entry	O
as	O
they	O
possess	O
both	O
receptor	O
binding	O
and	O
fusion	O
functions	O
.	O

Whereas	O
binding	O
to	O
the	O
host	O
cell	O
receptor	O
is	O
an	O
essential	O
first	O
step	O
in	O
establishing	O
infection	O
,	O
the	O
proteolytic	O
activation	O
step	O
is	O
often	O
critical	O
for	O
the	O
fusion	O
function	O
of	O
spike	O
,	O
as	O
it	O
allows	O
for	O
controlled	O
release	O
of	O
the	O
fusion	O
peptide	B-CHED
into	O
target	O
cellular	O
membranes	O
.	O

Detections	O
were	O
genotyped	O
using	O
a	O
hypervariable	O
region	O
of	O
the	O
gene	O
coding	O
for	O
the	O
S1	O
segment	O
of	O
the	O
spike	O
protein	B-CHED
.	O

In	O
the	O
last	O
years	O
,	O
much	O
effort	O
has	O
been	O
undertaken	O
to	O
address	O
the	O
role	O
of	O
the	O
avian	O
coronavirus	O
spike	O
protein	B-CHED
in	O
the	O
various	O
steps	O
of	O
the	O
virus	O
'	O
live	O
cycle	O
.	O

Additional	O
validation	O
studies	O
with	O
the	O
top	O
3	O
inhibitors	B-CHED
(	O
hexachlorophene	O
,	O
nitazoxanide	O
and	O
homoharringtonine	B-CHED
)	O
demonstrated	O
robust	O
anti	O
-	O
coronavirus	O
activities	O
(	O
a	O
reduction	O
of	O
6	O
to	O
8log10	O
in	O
virus	O
titer	O
)	O
with	O
an	O
IC50	O
ranging	O
from	O
11nM	O
to	O
1	O
.	O
2μM	O
.	O
Furthermore	O
,	O
homoharringtonine	B-CHED
and	O
hexachlorophene	O
exhibited	O
broad	O
antiviral	B-CHED
activity	O
against	O
diverse	O
species	O
of	O
human	O
and	O
animal	O
coronaviruses	O
.	O

ABSTRACT	O
:	O
The	O
simian	O
hemorrhagic	O
fever	O
virus	O
(	O
SHFV	O
)	O
genome	O
differs	O
from	O
those	O
of	O
other	O
members	O
of	O
the	O
family	O
Arteriviridae	O
in	O
encoding	O
three	O
papain	O
-	O
like	O
one	O
proteases	O
(	O
PLP1α	O
,	O
PLP1β	O
and	O
PLP1γ	O
)	O
at	O
the	O
5	O
'	O
end	O
and	O
two	O
adjacent	O
sets	O
of	O
four	O
minor	O
structural	O
proteins	B-CHED
at	O
the	O
3	O
'	O
end	O
.	O

A	O
stable	O
,	O
full	O
-	O
length	O
,	O
infectious	O
SHFV	O
-	O
LVR	O
cDNA	O
clone	O
was	O
constructed	O
and	O
a	O
set	O
of	O
mutant	O
infectious	O
clones	O
was	O
generated	O
each	O
with	O
the	O
start	O
codon	O
of	O
one	O
of	O
the	O
minor	O
structural	O
proteins	B-CHED
mutated	O
.	O

Fluid	O
resuscitation	O
with	O
crystalloids	O
and	O
continuous	O
norepinephrine	B-CHED
infusion	O
was	O
needed	O
because	O
of	O
arterial	O
hypotension	O
.	O

Cefotaxime	B-CHED
and	O
erythromycine	B-CHED
were	O
continued	O
until	O
day	O
7	O
despite	O
the	O
negative	O
results	O
of	O
all	O
bacteriological	O
samples	O
.	O

The	O
outcome	O
was	O
favorable	O
from	O
day	O
3	O
and	O
the	O
patient	O
met	B-CHED
the	O
criteria	O
for	O
extubation	O
on	O
day	O
5	O
.	O

TITLE	O
:	O
Identification	O
and	O
characterisation	O
of	O
small	O
molecule	O
inhibitors	B-CHED
of	O
feline	O
coronavirus	O
replication	O
.	O

Vaccines	O
and	O
antiviral	B-CHED
agents	I-CHED
are	O
urgently	O
needed	O
.	O

CONCLUSIONS	O
:	O
Respiratory	O
pathogens	O
were	O
detected	O
in	O
the	O
air	B-CHED
and	O
on	O
surfaces	O
in	O
the	O
KAAI	O
Airport	O
in	O
Pilgrims	O
City	O
.	O

The	O
viral	O
genome	O
has	O
an	O
abundance	O
of	O
codons	O
that	O
are	O
rare	O
in	O
the	O
host	O
and	O
are	O
decoded	O
by	O
wobble	O
tRNA	B-CHED
pairing	O
,	O
although	O
the	O
phage	O
grows	O
well	O
and	O
expression	O
of	O
most	O
of	O
the	O
genes	O
is	O
detected	O
by	O
mass	O
spectrometry	O
.	O

In	O
a	O
variety	O
of	O
experimental	O
and	O
clinical	O
studies	O
,	O
omega	B-CHED
-	I-CHED
3	I-CHED
fatty	I-CHED
acids	I-CHED
attenuated	O
hyperinflammatory	O
conditions	O
and	O
induced	O
faster	O
recovery	O
.	O

The	O
S2	O
subunit	O
of	O
the	O
S	O
glycoprotein	B-CHED
of	O
SARS	O
-	O
CoV	O
carries	O
out	O
fusion	O
between	O
the	O
virus	O
and	O
the	O
host	O
cells	O
.	O

Current	O
model	O
suggests	O
that	O
a	O
conformational	O
transition	O
,	O
upon	O
receptor	O
recognition	O
,	O
of	O
the	O
two	O
heptad	O
core	O
regions	O
of	O
S2	O
may	O
expose	O
the	O
hydrophobic	O
fusogenic	O
peptide	B-CHED
or	O
fusion	O
peptide	B-CHED
for	O
membrane	O
insertion	O
.	O

The	O
N	O
-	O
terminal	O
fusion	O
peptide	B-CHED
(	O
FP	O
,	O
residues	O
770	O
-	O
788	O
),	O
an	O
internal	O
fusion	O
peptide	B-CHED
(	O
IFP	O
,	O
residues	O
873	O
-	O
888	O
)	O
and	O
the	O
pre	O
-	O
transmembrane	O
region	O
(	O
PTM	O
,	O
residues	O
1185	O
-	O
1202	O
)	O
demonstrated	O
interactions	O
with	O
model	O
lipid	B-CHED
membranes	O
and	O
potentially	O
involved	O
in	O
the	O
fusion	O
process	O
.	O

On	O
day	O
2	O
,	O
the	O
patient	O
showed	O
dyspnea	O
and	O
oxygen	B-CHED
saturation	O
decreased	O
to	O
80	O
%.	O

According	O
to	O
the	O
initial	O
data	O
of	O
PiCCO	O
,	O
EVLWI	O
was	O
9	O
ml	O
/	O
kg	O
,	O
GEDVI	O
was	O
519	O
ml	O
/	O
m²	O
,	O
the	O
oxygenation	O
index	O
was	O
298	O
mmHg	O
,	O
the	O
bedside	O
chest	O
X	O
-	O
ray	O
showed	O
decreased	O
permeability	O
and	O
PEEP	B-CHED
was	O
adjusted	O
to	O
5	O
cmH₂O	O
,	O
suggesting	O
the	O
existence	O
of	O
ARDS	O
.	O

ABSTRACT	O
:	O
P34	O
is	O
an	O
antimicrobial	B-CHED
peptide	B-CHED
produced	O
by	O
a	O
Bacillus	O
sp	O
.	O
strain	O
isolated	O
from	O
the	O
intestinal	O
contents	O
of	O
a	O
fish	O
in	O
the	O
Brazilian	O
Amazon	O
basin	O
with	O
reported	O
antibacterial	O
activity	O
.	O

The	O
results	O
showed	O
that	O
the	O
peptide	B-CHED
P34	O
exhibited	O
antiviral	B-CHED
activity	O
against	O
EAV	O
and	O
FHV	O
-	O
1	O
.	O

The	O
peptide	B-CHED
P34	O
inhibited	O
the	O
replication	O
of	O
EAV	O
by	O
99	O
.	O
9	O
%	O
and	O
FHV	O
-	O
1	O
by	O
94	O
.	O
4	O
%.	O

In	O
this	O
study	O
,	O
the	O
main	O
protease	O
of	O
Porcine	O
epidemic	O
diarrhea	O
virus	O
in	O
complex	O
with	O
a	O
Michael	O
acceptor	B-CHED
was	O
crystallized	O
.	O

TITLE	O
:	O
Crystallization	O
and	O
preliminary	O
crystallographic	O
study	O
of	O
Feline	O
infectious	O
peritonitis	O
virus	O
main	O
protease	O
in	O
complex	O
with	O
an	O
inhibitor	B-CHED
.	O

Thus	O
,	O
our	O
study	O
reveals	O
that	O
coronavirus	O
engages	O
PLPs	O
to	O
escape	O
from	O
the	O
innate	O
antiviral	B-CHED
response	O
of	O
the	O
host	O
by	O
inhibiting	O
p53	O
-	O
IRF7	O
-	O
IFNβ	O
signaling	O
.	O

Hospital	O
monitoring	O
and	O
antiviral	B-CHED
therapy	O
for	O
influenza	O
].	O

The	O
intake	O
of	O
antiviral	B-CHED
medications	O
in	O
the	O
first	O
48	O
hours	O
of	O
the	O
disease	O
could	O
prevent	O
complications	O
.	O

RESULTS	O
:	O
Out	O
of	O
the	O
1203	O
examinees	O
,	O
284	O
(	O
23	O
.	O
6	O
%)	O
were	O
influenza	O
-	O
positive	O
:	O
221	O
(	O
77	O
.	O
8	O
%),	O
24	O
(	O
8	O
.	O
5	O
%),	O
and	O
39	O
(	O
13	O
.	O
7	O
%)	O
patients	O
had	O
influenza	O
A	O
(	O
H3N2	B-CHED
),	O
influenza	O
A	O
(	O
H1N1	O
)	O
pdm09	O
,	O
and	O
influenza	O
B	O
,	O
respectively	O
.	O

Chi	B-CHED
squares	O
tests	O
were	O
used	O
to	O
assess	O
the	O
association	O
between	O
study	O
variables	O
and	O
attitude	O
questions	O
.	O

Patients	O
were	O
then	O
classified	O
according	O
to	O
PaO2	O
/	O
FIO2	O
assessed	O
at	O
clinical	O
,	O
5	O
cm	O
H2O	B-CHED
,	O
or	O
15	O
cm	O
H2O	B-CHED
positive	O
end	O
-	O
expiratory	O
pressure	O
.	O

When	O
patients	O
were	O
classified	O
at	O
5	O
cm	O
H2O	B-CHED
,	O
but	O
not	O
at	O
clinical	O
or	O
15	O
cm	O
H2O	B-CHED
,	O
lung	O
recruitability	O
linearly	O
increases	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
severity	O
(	O
5	O
%	O
[	O
2	O
-	O
12	O
%]	O
vs	O
12	O
%	O
[	O
7	O
-	O
18	O
%]	O
vs	O
23	O
%	O
[	O
12	O
-	O
30	O
%],	O
respectively	O
,	O
p	O
<	O
0	O
.	O
001	O
).	O

ABSTRACT	O
:	O
Aspirin	B-CHED
-	O
exacerbated	O
respiratory	O
disease	O
(	O
AERD	O
),	O
also	O
known	O
as	O
Samter	O
'	O
s	O
triad	O
,	O
is	O
a	O
clinical	O
syndrome	O
which	O
consists	O
of	O
aspirin	B-CHED
(	O
ASA	B-CHED
)	O
intolerance	O
,	O
chronic	O
rhinosinusitis	O
with	O
nasal	O
polyposis	O
,	O
and	O
intrinsic	O
bronchial	O
asthma	O
(	O
Press	O
Med	O
119	O
:	O
48	O
-	O
51	O
,	O
1922	O
).	O

Sixty	O
-	O
one	O
percent	O
(	O
n	O
=	O
68	O
)	O
claimed	O
prior	O
,	O
significant	O
reactions	O
to	O
ASA	B-CHED
,	O
and	O
all	O
patients	O
had	O
features	O
of	O
AERD	O
.	O

Further	O
,	O
it	O
allows	O
patients	O
to	O
tolerate	O
additional	O
ASA	B-CHED
and	O
other	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatories	O
(	O
NSAIDs	B-CHED
)	O
when	O
needed	O
for	O
supplemental	O
analgesia	O
or	O
for	O
cardio	O
-	O
protection	O
.	O

TITLE	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
vaccines	O
formulated	O
with	O
delta	O
inulin	B-CHED
adjuvants	B-CHED
provide	O
enhanced	O
protection	O
while	O
ameliorating	O
lung	O
eosinophilic	O
immunopathology	O
.	O

While	O
all	O
vaccines	O
protected	O
against	O
lethal	O
infection	O
,	O
addition	O
of	O
adjuvant	B-CHED
significantly	O
increased	O
serum	O
neutralizing	O
-	O
antibody	O
titers	O
and	O
reduced	O
lung	O
virus	O
titers	O
on	O
day	O
3	O
postchallenge	O
.	O

ABSTRACT	O
:	O
Hereditary	O
angioedema	O
(	O
HAE	O
)	O
is	O
a	O
rare	O
autosomal	O
dominant	O
disease	O
most	O
commonly	O
associated	O
with	O
defects	O
in	O
C1	O
esterase	O
inhibitor	B-CHED
(	O
C1	O
-	O
INH	O
).	O

ABSTRACT	O
:	O
The	O
objective	O
of	O
the	O
Scandinavian	O
Society	O
of	O
Anaesthesiology	O
and	O
Intensive	O
Care	O
Medicine	B-CHED
(	O
SSAI	O
)	O
task	O
force	O
on	O
mechanical	O
ventilation	O
in	O
adults	O
with	O
the	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
is	O
to	O
formulate	O
treatment	O
recommendations	O
based	O
on	O
available	O
evidence	O
from	O
systematic	O
reviews	O
and	O
randomised	O
trials	O
.	O

CONCLUSIONS	O
:	O
We	O
strongly	O
recommend	O
pressure	O
-	O
and	O
volume	O
limitation	O
and	O
suggest	O
using	O
higher	O
PEEP	B-CHED
and	O
prone	O
ventilation	O
in	O
patients	O
with	O
severe	O
respiratory	O
failure	O
.	O

The	O
data	O
of	O
investigated	O
children	O
'	O
s	O
contingent	O
with	O
intestinal	O
colic	O
prevailed	O
by	O
following	O
comorbidities	O
:	O
SARS	O
--	O
12	O
(	O
18	O
.	O
18	O
%	O
±	O
4	O
.	O
78	O
%),	O
protein	B-CHED
-	O
energy	O
malnutrition	O
--	O
9	O
(	O
12	O
.	O
85	O
%	O
±	O
3	O
.	O
82	O
%),	O
pneumonia	O
--	O
6	O
(	O
8	O
.	O
57	O
%	O
±	O
3	O
.	O
57	O
%),	O
atopic	O
dermatitis	O
--	O
7	O
(	O
10	O
.	O
00	O
%	O
±.	O
3	O
.	O
57	O
%).	O

In	O
addition	O
to	O
its	O
function	O
as	O
a	O
structural	O
protein	B-CHED
,	O
N	O
protein	B-CHED
is	O
involved	O
in	O
cell	O
apoptosis	O
or	O
cell	O
-	O
cycle	O
regulation	O
.	O

To	O
identify	O
cellular	O
proteins	B-CHED
that	O
interacted	O
with	O
N	O
protein	B-CHED
of	O
TGEV	O
,	O
methods	O
of	O
GST	O
pull	O
-	O
down	O
and	O
Co	O
-	O
IP	O
were	O
utilized	O
to	O
precipitate	O
cellular	O
proteins	B-CHED
of	O
swine	O
testicular	O
(	O
ST	O
).	O

Predicted	O
activation	O
for	O
STAT3	O
mediating	O
gene	O
expression	O
relevant	O
for	O
epithelial	O
cell	O
-	O
to	O
-	O
cell	O
adherens	O
and	O
junction	O
signaling	O
in	O
MERS	O
-	O
CoV	O
Eng	O
1	O
infection	O
suggest	O
that	O
these	O
transcriptional	O
differences	O
may	O
be	O
the	O
result	O
of	O
amino	B-CHED
acid	I-CHED
differences	O
in	O
viral	O
proteins	B-CHED
known	O
to	O
modulate	O
innate	O
immunity	O
during	O
MERS	O
-	O
CoV	O
infection	O
.	O

Combining	O
statistical	O
analysis	O
of	O
infection	O
and	O
cytokine	O
-	O
stimulated	O
Calu	O
-	O
3	O
transcriptomics	O
,	O
we	O
identified	O
differential	O
innate	O
responses	O
,	O
including	O
up	O
-	O
regulation	O
of	O
extracellular	O
remodeling	O
genes	O
following	O
MERS	O
-	O
CoV	O
Eng	O
1	O
infection	O
and	O
differential	O
pro	B-CHED
-	O
inflammatory	O
responses	O
.	O

ABSTRACT	O
:	O
Supplemental	O
oxygen	B-CHED
inhalation	O
is	O
frequently	O
used	O
to	O
treat	O
severe	O
respiratory	O
failure	O
;	O
however	O
,	O
prolonged	O
exposure	O
to	O
hyperoxia	O
causes	O
hyperoxic	O
acute	O
lung	O
injury	O
(	O
HALI	O
),	O
which	O
induces	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
leads	O
to	O
high	O
mortality	O
rates	O
.	O

TITLE	O
:	O
No	O
redistribution	O
of	O
lung	O
blood	O
flow	O
by	O
inhaled	O
nitric	B-CHED
oxide	I-CHED
in	O
endotoxemic	O
piglets	O
pretreated	O
with	O
an	O
endothelin	B-CHED
receptor	I-CHED
antagonist	I-CHED
.	O

Endotoxin	O
infusion	O
increased	O
serum	O
ET	O
-	O
1	O
,	O
and	O
INO	O
almost	O
doubled	O
the	O
ratio	O
between	O
mRNA	B-CHED
expression	O
of	O
endothelin	O
receptor	O
A	O
(	O
mediating	O
vasoconstriction	O
)	O
and	O
B	O
(	O
mediating	O
vasodilation	O
and	O
clearance	O
of	O
ET	O
-	O
1	O
)	O
(	O
ET	O
-	O
A	O
/	O
ET	O
-	O
B	O
)	O
in	O
atelectatic	O
lung	O
regions	O
.	O

During	O
the	O
influenza	O
season	O
,	O
pregnant	O
women	O
with	O
suspected	O
influenza	O
should	O
receive	O
prompt	O
empiric	O
antiviral	B-CHED
therapy	O
,	O
regardless	O
of	O
rapid	O
influenza	O
diagnostic	O
test	O
results	O
or	O
vaccination	O
status	O
.	O

TITLE	O
:	O
Inhibitory	O
effects	O
of	O
lithium	B-CHED
chloride	I-CHED
on	O
replication	O
of	O
type	O
II	O
porcine	O
reproductive	O
and	O
respiratory	O
syndrome	O
virus	O
in	O
vitro	O
.	O

Therefore	O
,	O
development	O
of	O
new	O
antiviral	B-CHED
treatment	O
strategies	O
is	O
urgently	O
needed	O
.	O

Since	O
CESAR	O
trial	O
,	O
the	O
clinical	O
application	O
of	O
ECLA	O
for	O
ARDS	O
as	O
a	O
method	O
to	O
achieve	O
lung	O
rest	B-CHED
has	O
wide	O
spread	O
.	O

Western	O
blot	O
analysis	O
also	O
demonstrated	O
their	O
inhibitory	O
effects	O
on	O
PEDV	O
GP6	O
nucleocapsid	O
and	O
GP2	O
spike	O
protein	B-CHED
synthesis	O
during	O
viral	O
replication	O
.	O

Patient	O
groups	O
differed	O
significantly	O
at	O
72	O
hours	O
postpartum	O
for	O
Plt	O
and	O
LDH	O
values	O
and	O
at	O
24	O
and	O
48	O
hours	O
for	O
bilirubin	B-CHED
.	O

ABSTRACT	O
:	O
Mice	O
infected	O
with	O
mouse	O
hepatitis	O
virus	O
A59	O
(	O
MHV	O
-	O
A59	O
)	O
develop	O
autoantibodies	O
(	O
autoAb	O
)	O
to	O
liver	O
and	O
kidney	O
fumarylacetoacetate	B-CHED
hydrolase	O
(	O
FAH	O
)	O
with	O
a	O
concomitant	O
enhancement	O
of	O
transaminases	O
and	O
release	O
of	O
alarmins	O
such	O
as	O
uric	B-CHED
acid	I-CHED
and	O
high	O
-	O
mobility	O
group	O
box	O
protein	B-CHED
1	O
(	O
HMGB1	O
).	O

ABSTRACT	O
:	O
Airborne	O
transmission	O
occurs	O
only	O
when	O
infectious	O
particles	O
of	O
<	O
5	O
μm	O
,	O
known	O
as	O
aerosols	O
,	O
are	O
propelled	O
into	O
the	O
air	B-CHED
.	O

TITLE	O
:	O
Synthesis	O
and	O
Biological	O
Evaluation	O
of	O
Strictosamide	O
Derivatives	O
with	O
Improved	O
Antiviral	B-CHED
and	O
Antiproliferative	O
Activities	O
.	O

TITLE	O
:	O
The	O
nsp1	O
,	O
nsp13	O
,	O
and	O
M	O
proteins	B-CHED
contribute	O
to	O
the	O
hepatotropism	O
of	O
murine	O
coronavirus	O
JHM	O
.	O
WU	O
.	O

By	O
further	O
mapping	O
,	O
we	O
found	O
that	O
polymorphisms	O
in	O
JHM	O
.	O
WU	O
structural	O
protein	B-CHED
M	O
and	O
nonstructural	O
replicase	O
proteins	B-CHED
nsp1	O
and	O
nsp13	O
are	O
essential	O
for	O
liver	O
pathogenesis	O
.	O

TITLE	O
:	O
The	O
effect	O
of	O
estrogen	B-CHED
on	O
the	O
early	O
cytotoxic	O
response	O
to	O
IB	O
virus	O
infection	O
in	O
hen	O
oviduct	O
.	O

Furthermore	O
,	O
the	O
involvement	O
of	O
tachykinin	O
NK1	O
receptors	O
expressed	O
on	O
mast	O
cell	O
membranes	O
was	O
elucidated	O
by	O
their	O
blocking	O
with	O
an	O
antagonist	B-CHED
.	O

Expression	O
levels	O
of	O
a	O
large	O
number	O
of	O
proinflammatory	O
cytokines	O
associated	O
with	O
lung	O
injury	O
were	O
reduced	O
in	O
the	O
lungs	O
of	O
rSARS	O
-	O
CoV	O
-	O
MA15	O
-	O
E	O
*-	O
infected	O
mice	O
,	O
whereas	O
the	O
levels	O
of	O
anti	O
-	O
inflammatory	O
cytokines	O
were	O
increased	O
,	O
both	O
at	O
the	O
mRNA	B-CHED
and	O
protein	B-CHED
levels	O
.	O

Previously	O
,	O
we	O
demonstrated	O
that	O
a	O
SARS	O
-	O
CoV	O
lacking	O
the	O
E	O
protein	B-CHED
was	O
attenuated	O
in	O
vivo	O
.	O

We	O
are	O
investigating	O
potential	O
antiviral	B-CHED
therapeutics	O
against	O
MERS	O
-	O
CoV	O
by	O
using	O
host	O
microRNAs	O
(	O
miRNAs	O
)	O
which	O
may	O
downregulate	O
viral	O
gene	O
expression	O
to	O
quell	O
viral	O
replication	O
.	O

ABSTRACT	O
:	O
The	O
design	O
and	O
evaluation	O
of	O
a	O
novel	O
decahydroisoquinolin	O
scaffold	O
as	O
an	O
inhibitor	B-CHED
for	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
chymotrypsin	O
-	O
like	O
protease	O
(	O
3CL	O
(	O
pro	B-CHED
))	O
are	O
described	O
.	O

ABSTRACT	O
:	O
A	O
series	O
of	O
simple	O
thiourea	B-CHED
derivatives	O
were	O
designed	O
based	O
on	O
the	O
structure	O
of	O
natural	B-CHED
product	I-CHED
harmine	B-CHED
and	O
lead	O
compound	O
and	O
synthesized	O
from	O
amines	B-CHED
in	O
one	O
step	O
.	O

The	O
hydrogen	B-CHED
bond	O
was	O
found	O
to	O
be	O
important	O
but	O
not	O
the	O
more	O
the	O
better	O
.	O

The	O
systematic	O
study	O
provides	O
strong	O
evidence	O
that	O
these	O
simple	O
thiourea	B-CHED
derivatives	O
could	O
become	O
potential	O
TMV	O
inhibitors	B-CHED
.	O

Identification	O
of	O
the	O
surfactant	B-CHED
proteins	B-CHED
,	O
lipid	B-CHED
transporters	O
,	O
and	O
transcriptional	O
networks	O
regulating	O
their	O
expression	O
has	O
provided	O
the	O
tools	O
and	O
insights	O
needed	O
to	O
discern	O
the	O
molecular	O
and	O
cellular	O
processes	O
regulating	O
the	O
production	O
and	O
function	O
of	O
pulmonary	O
surfactant	B-CHED
prior	O
to	O
and	O
after	O
birth	O
.	O

Biophysical	O
and	O
transgenic	O
mouse	O
models	O
have	O
provided	O
insight	O
into	O
the	O
mechanisms	O
underlying	O
surfactant	B-CHED
protein	B-CHED
and	O
alveolar	O
homeostasis	O
.	O

TITLE	O
:	O
Development	O
and	O
validation	O
of	O
a	O
rapid	O
immunochromatographic	O
assay	O
for	O
detection	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
antigen	B-CHED
in	O
dromedary	O
camels	O
.	O

The	O
assay	O
is	O
based	O
on	O
the	O
detection	O
of	O
MERS	O
-	O
CoV	O
nucleocapsid	O
protein	B-CHED
in	O
a	O
short	O
time	O
frame	O
using	O
highly	O
selective	O
monoclonal	O
antibodies	O
at	O
room	O
temperature	O
.	O

A	O
77	O
-	O
year	O
-	O
old	O
man	B-CHED
who	O
was	O
diagnosed	O
with	O
a	O
huge	O
HCC	O
was	O
admitted	O
for	O
TACE	O
.	O

Multiple	O
-	O
sequence	O
alignments	O
identified	O
38	O
nucleotide	B-CHED
substitutions	O
in	O
the	O
whole	O
genome	O
which	O
resulted	O
in	O
26	O
amino	B-CHED
acid	I-CHED
substitutions	O
and	O
a	O
110	O
-	O
bp	O
deletion	O
in	O
the	O
3	O
'	O
untranslated	O
region	O
.	O

We	O
previously	O
demonstrated	O
that	O
residues	O
377	O
-	O
588	O
of	O
MERS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
protein	B-CHED
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
is	O
a	O
very	O
promising	O
MERS	O
subunit	O
vaccine	O
candidate	O
,	O
capable	O
of	O
inducing	O
potent	O
neutralization	O
antibody	O
responses	O
.	O

Using	O
gene	O
silencing	O
,	O
the	O
ATP1A1	O
protein	B-CHED
was	O
shown	O
to	O
be	O
critical	O
for	O
infection	O
of	O
cells	O
with	O
murine	O
hepatitis	O
virus	O
(	O
MHV	O
),	O
feline	O
infectious	O
peritonitis	O
virus	O
(	O
FIPV	O
),	O
and	O
VSV	O
but	O
not	O
with	O
IAV	O
.	O

The	O
mean	O
haemoglobin	B-CHED
concentration	O
in	O
females	O
is	O
significantly	O
lower	O
.	O

A	O
total	O
of	O
61	O
compounds	O
including	O
flavonoids	B-CHED
,	O
phenylpropanoids	B-CHED
,	O
anthraquinones	B-CHED
,	O
triterpenoids	B-CHED
,	O
iridoids	O
,	O
and	O
other	O
types	O
of	O
compounds	O
were	O
unambiguously	O
or	O
tentatively	O
identified	O
by	O
comparing	O
the	O
retention	O
times	O
and	O
accurate	O
mass	O
measurement	O
with	O
reference	O
compounds	O
or	O
literature	O
data	O
.	O

TITLE	O
:	O
On	O
the	O
biased	O
nucleotide	B-CHED
composition	O
of	O
the	O
human	O
coronavirus	O
RNA	O
genome	O
.	O

TITLE	O
:	O
Antiviral	B-CHED
effect	O
of	O
lithium	B-CHED
chloride	I-CHED
on	O
infection	O
of	O
cells	O
by	O
porcine	O
parvovirus	O
.	O

We	O
demonstrate	O
for	O
the	O
first	O
time	O
that	O
inhibition	O
of	O
PPV	B-CHED
replication	O
in	O
swine	O
testis	O
(	O
ST	O
)	O
cells	O
by	O
LiCl	B-CHED
is	O
dose	O
-	O
dependent	O
,	O
and	O
that	O
the	O
antiviral	B-CHED
effect	O
of	O
LiCl	B-CHED
occurred	O
in	O
the	O
early	O
phase	O
of	O
PPV	B-CHED
replication	O
.	O

Further	O
studies	O
are	O
required	O
to	O
explore	O
the	O
mechanism	O
of	O
the	O
antiviral	B-CHED
effect	O
of	O
LiCl	B-CHED
on	O
PPV	B-CHED
infection	O
in	O
vivo	O
.	O

In	O
these	O
latter	O
hosts	O
,	O
the	O
ORF3	O
gene	O
systematically	O
displays	O
one	O
or	O
two	O
identical	O
deletions	O
leading	O
to	O
the	O
synthesis	O
of	O
truncated	O
proteins	B-CHED
gp3	O
-	O
Δ1	O
and	O
gp3	O
-	O
Δ2	O
.	O

All	O
proteins	B-CHED
oligomerise	O
through	O
covalent	O
bonds	O
,	O
are	O
N	O
-	O
glycosylated	O
and	O
are	O
maintained	O
in	O
the	O
ER	O
in	O
non	O
-	O
infected	O
but	O
also	O
in	O
CCoV	O
-	O
II	O
infected	O
cells	O
,	O
without	O
any	O
specific	O
retention	O
signal	O
.	O

TITLE	O
:	O
Protease	B-CHED
inhibitors	I-CHED
targeting	O
coronavirus	O
and	O
filovirus	O
entry	O
.	O

Our	O
results	O
support	O
previous	O
studies	O
that	O
implicate	O
S	O
protein	B-CHED
mutations	O
in	O
the	O
pathogenesis	O
of	O
FIP	O
.	O

TITLE	O
:	O
Tryptophan	B-CHED
-	O
dependent	O
membrane	O
interaction	O
and	O
heteromerization	O
with	O
the	O
internal	O
fusion	O
peptide	B-CHED
by	O
the	O
membrane	O
proximal	O
external	O
region	O
of	O
SARS	O
-	O
CoV	O
spike	O
protein	B-CHED
.	O

To	O
delineate	O
the	O
roles	O
of	O
Trp	B-CHED
residues	O
of	O
MPER	O
in	O
forming	O
these	O
quaternary	O
structures	O
and	O
interacting	O
with	O
membranes	O
,	O
we	O
employed	O
a	O
panel	O
of	O
synthetic	O
peptides	B-CHED
:	O
MPER	O
peptide	B-CHED
(	O
M	O
-	O
wt	O
)	O
and	O
its	O
alanine	B-CHED
(	O
Ala	B-CHED
)	O
and	O
phenylalanine	B-CHED
(	O
Phe	B-CHED
)	O
analogues	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
explore	O
the	O
effects	O
of	O
different	O
tidal	O
volume	O
(	O
VT	O
)	O
ventilation	O
on	O
paraquat	B-CHED
-	O
induced	O
acute	O
lung	O
injury	O
or	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ALI	O
/	O
ARDS	O
)	O
in	O
piglets	O
.	O

TITLE	O
:	O
Preemptive	O
enteral	O
nutrition	O
enriched	O
with	O
eicosapentaenoic	B-CHED
acid	I-CHED
,	O
gamma	B-CHED
-	I-CHED
linolenic	I-CHED
acid	I-CHED
and	O
antioxidants	B-CHED
in	O
severe	O
multiple	O
trauma	O
:	O
a	O
prospective	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
study	O
.	O

Eleven	O
of	O
the	O
15	O
field	O
isolates	O
in	O
this	O
study	O
belonged	O
to	O
genogroup	O
3	O
and	O
were	O
95	O
.	O
8	O
%	O
to	O
100	O
%	O
identical	O
in	O
nucleotide	B-CHED
sequence	O
or	O
95	O
.	O
6	O
%	O
to	O
100	O
%	O
in	O
deduced	O
amino	B-CHED
acid	I-CHED
sequence	O
to	O
each	O
other	O
.	O

Then	O
,	O
we	O
treated	O
different	O
bat	O
cells	O
,	O
mouse	O
embryonic	O
fibroblasts	O
(	O
MEF	B-CHED
)	O
and	O
splenocytes	O
with	O
polyinosinic	O
-	O
polycytidylic	O
acid	O
(	O
polyI	O
:	O
C	O
)	O
and	O
vesicular	O
stomatitis	O
virus	O
(	O
VSV	O
)	O
to	O
assess	O
and	O
compare	O
antiviral	B-CHED
immune	O
responses	O
between	O
bats	O
and	O
mice	O
.	O

TITLE	O
:	O
Chalcones	B-CHED
isolated	O
from	O
Angelica	O
keiskei	O
inhibit	O
cysteine	B-CHED
proteases	O
of	O
SARS	O
-	O
CoV	O
.	O
ABSTRACT	O
:	O
Two	O
viral	O
proteases	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
a	O
chymotrypsin	O
-	O
like	O
protease	O
(	O
3CL	O
(	O
pro	B-CHED
))	O
and	O
a	O
papain	O
-	O
like	O
protease	O
(	O
PL	O
(	O
pro	B-CHED
))	O
are	O
attractive	O
targets	O
for	O
the	O
development	O
of	O
anti	O
-	O
SARS	O
drugs	O
.	O

Administration	O
of	O
methylene	B-CHED
blue	I-CHED
allowed	O
for	O
cessation	O
of	O
epinephrine	B-CHED
infusion	O
within	O
2	O
hours	O
of	O
administration	O
,	O
and	O
reduction	O
in	O
excessive	O
fluid	O
resuscitation	O
.	O

ABSTRACT	O
:	O
Aptamers	O
are	O
in	O
vitro	O
selected	O
DNA	O
or	O
RNA	O
molecules	O
that	O
are	O
capable	O
of	O
binding	O
a	O
wide	O
range	O
of	O
nucleic	O
and	O
non	O
-	O
nucleic	B-CHED
acid	I-CHED
molecules	O
with	O
high	O
affinity	O
and	O
specificity	O
.	O

TITLE	O
:	O
Broad	O
-	O
spectrum	O
inhibitors	B-CHED
against	O
3C	O
-	O
like	O
proteases	O
of	O
feline	O
coronaviruses	O
and	O
feline	O
caliciviruses	O
.	O

This	O
study	O
provides	O
important	O
insights	O
into	O
the	O
structure	O
and	O
function	O
relationships	O
of	O
3CLpro	O
for	O
the	O
design	O
of	O
antiviral	B-CHED
drugs	I-CHED
with	O
broader	O
antiviral	B-CHED
activities	O
.	O

Introducing	O
mutations	O
into	O
a	O
protein	B-CHED
or	O
virus	O
can	O
have	O
either	O
direct	O
or	O
indirect	O
effects	O
on	O
function	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
characterize	O
the	O
HCoV	O
-	O
NL63	O
nucleocapsid	O
protein	B-CHED
.	O

No	O
difference	O
was	O
observed	O
,	O
suggesting	O
that	O
a	O
viroporin	O
other	O
than	O
the	O
E	O
protein	B-CHED
influences	O
the	O
differences	O
in	O
the	O
actions	O
of	O
HMA	O
and	O
DIDS	B-CHED
on	O
FIPV	O
serotypes	O
I	O
and	O
II	O
.	O

Therefore	O
,	O
evaluation	O
of	O
PSP	B-CHED
in	O
kidney	O
dysfunction	O
patients	O
will	O
be	O
difficult	O
.	O

We	O
identified	O
atoms	B-CHED
with	O
common	O
distributed	O
spatial	O
occupancy	O
in	O
PDB	O
structures	O
of	O
N10	O
protein	B-CHED
,	O
N11	O
protein	B-CHED
,	O
an	O
influenza	O
A	O
neuraminidase	O
,	O
an	O
influenza	O
B	O
neuraminidase	O
,	O
and	O
a	O
bacterial	O
neuraminidase	O
.	O

The	O
specific	O
detection	O
of	O
anti	O
-	O
FCoV	O
antibodies	O
was	O
possible	O
in	O
all	O
heparin	B-CHED
-	O
anticoagulated	O
plasma	O
,	O
serum	O
,	O
whole	O
blood	O
,	O
and	O
ascitic	O
fluid	O
samples	O
from	O
anti	O
-	O
FCoV	O
antibody	O
positive	O
cats	O
,	O
and	O
nonspecific	O
reaction	O
was	O
not	O
noted	O
in	O
samples	O
from	O
anti	O
-	O
FCoV	O
antibody	O
negative	O
cats	O
.	O

Additionally	O
,	O
we	O
outline	O
methods	O
for	O
immunofluorescence	O
staining	O
of	O
these	O
cultures	O
for	O
virus	O
detection	O
,	O
characterization	O
of	O
cell	O
tropism	O
,	O
and	O
how	O
to	O
perform	O
antiviral	B-CHED
assays	O
and	O
quantify	O
viral	O
replication	O
.	O

The	O
following	O
protocol	O
describes	O
the	O
process	O
of	O
generating	O
a	O
high	O
-	O
quality	O
RNA	O
preparation	O
from	O
IBV	O
grown	O
in	O
embryonated	O
eggs	O
and	O
then	O
partially	O
purified	O
and	O
concentrated	O
through	O
a	O
30	O
%	O
sucrose	B-CHED
cushion	O
for	O
NGS	O
.	O

Here	O
,	O
we	O
describe	O
the	O
use	O
of	O
transient	O
dominant	O
selection	O
as	O
a	O
method	O
for	O
introducing	O
modifications	O
into	O
the	O
IBV	O
cDNA	O
;	O
this	O
has	O
been	O
successfully	O
used	O
for	O
the	O
substitution	O
of	O
specific	O
nucleotides	B-CHED
,	O
deletion	O
of	O
genomic	O
regions	O
,	O
and	O
the	O
exchange	O
of	O
complete	O
genes	O
.	O

TITLE	O
:	O
Studying	O
coronavirus	O
-	O
host	O
protein	B-CHED
interactions	O
.	O

ABSTRACT	O
:	O
To	O
understand	O
the	O
molecular	O
mechanisms	O
of	O
viral	O
replication	O
and	O
pathogenesis	O
,	O
it	O
is	O
necessary	O
to	O
establish	O
the	O
virus	O
-	O
host	O
protein	B-CHED
interaction	O
networks	O
.	O

Here	O
,	O
we	O
detail	O
the	O
RNAi	O
method	O
we	O
have	O
developed	O
and	O
used	O
to	O
specifically	O
knock	O
down	O
the	O
expression	O
of	O
ezrin	O
,	O
an	O
actin	O
binding	O
protein	B-CHED
that	O
was	O
identified	O
by	O
yeast	O
two	O
-	O
hybrid	O
screening	O
to	O
interact	O
with	O
the	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
Coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
spike	O
(	O
S	O
)	O
protein	B-CHED
.	O

This	O
chapter	O
describes	O
two	O
protocols	O
to	O
quantify	O
activation	O
of	O
the	O
chicken	O
IFN	O
response	O
through	O
analysis	O
of	O
gene	O
expression	O
by	O
real	O
-	O
time	O
quantitative	O
PCR	O
and	O
by	O
quantification	O
of	O
bioactive	O
IFN	O
protein	B-CHED
using	O
a	O
bioassay	O
.	O

ABSTRACT	O
:	O
Transmission	O
electron	O
microscopy	O
(	O
TEM	B-CHED
)	O
is	O
an	O
invaluable	O
technique	O
used	O
for	O
imaging	O
the	O
ultrastructure	O
of	O
samples	O
and	O
it	O
is	O
particularly	O
useful	O
when	O
determining	O
virus	O
-	O
host	O
interactions	O
at	O
a	O
cellular	O
level	O
.	O

The	O
environment	O
inside	O
a	O
TEM	B-CHED
is	O
not	O
favorable	O
for	O
biological	O
material	O
(	O
high	O
vacuum	O
and	O
high	O
energy	O
electrons	O
).	O

After	O
14weeks	O
,	O
he	O
left	O
on	O
rifampicin	B-CHED
and	O
isoniazid	B-CHED
treatment	O
.	O

TITLE	O
:	O
(	O
3Z	O
)-	O
3	O
-(	O
2	O
-[	O
4	O
-(	O
aryl	O
)-	O
1	O
,	O
3	O
-	O
thiazol	O
-	O
2	O
-	O
yl	O
]	O
hydrazin	B-CHED
-	O
1	O
-	O
ylidene	O
)-	O
2	O
,	O
3	O
-	O
dihydro	O
-	O
1H	O
-	O
indol	B-CHED
-	I-CHED
2	I-CHED
-	I-CHED
one	I-CHED
derivatives	O
as	O
dual	O
inhibitors	B-CHED
of	O
HIV	O
-	O
1	O
reverse	O
transcriptase	O
.	O

ABSTRACT	O
:	O
Eukaryotic	O
cellular	O
and	O
most	O
viral	O
RNAs	O
carry	O
a	O
5	O
'-	O
terminal	O
cap	O
structure	O
,	O
a	O
5	O
'-	O
5	O
'	O
triphosphate	B-CHED
linkage	O
between	O
the	O
5	O
'	O
end	O
of	O
the	O
RNA	O
and	O
a	O
guanosine	B-CHED
nucleotide	B-CHED
(	O
cap	O
-	O
0	O
).	O

A	O
computed	O
tomography	O
(	O
CT	O
)	O
scan	O
revealed	O
huge	O
tumours	O
that	O
occupied	O
the	O
peritoneal	O
cavity	O
,	O
with	O
multiple	O
lung	O
,	O
liver	O
,	O
and	O
para	B-CHED
-	O
aortic	O
metastases	O
.	O

Chemotherapy	O
with	O
bleomycin	B-CHED
,	O
etoposide	B-CHED
,	O
and	O
cisplatin	B-CHED
(	O
BEP	O
)	O
was	O
started	O
after	O
admission	O
.	O

fruits	O
,	O
commonly	O
used	O
in	O
Traditional	O
Chinese	O
Medicine	B-CHED
,	O
to	O
affect	O
HIV	O
-	O
1	O
RT	O
functions	O
.	O

Among	O
the	O
S	O
.	O
chinensis	O
fruit	O
lignans	B-CHED
,	O
Schisandrin	O
B	O
and	O
Deoxyschizandrin	O
selectively	O
inhibited	O
the	O
HIV	O
-	O
1	O
RT	O
-	O
associated	O
DNA	O
polymerase	O
activity	O
.	O

The	O
information	O
presented	O
in	O
this	O
study	O
is	O
important	O
for	O
the	O
development	O
of	O
diagnostic	O
reagents	B-CHED
,	O
assays	O
,	O
and	O
potential	O
vaccines	O
against	O
emergent	O
PDCoV	O
strains	O
.	O

Mann	O
-	O
Whitney	O
U	O
,	O
Kruskal	O
-	O
Wallis	O
,	O
chi	B-CHED
-	O
square	O
,	O
and	O
Fisher	O
'	O
s	O
exact	O
tests	O
were	O
used	O
for	O
statistical	O
analysis	O
.	O

CONCLUSIONS	O
:	O
HIV	O
infected	O
patients	O
with	O
ARDS	O
and	O
MDR	B-CHED
bacterial	O
VAP	O
whose	O
HIV	O
replication	O
is	O
controlled	O
by	O
ART	O
could	O
be	O
successfully	O
managed	O
with	O
ECMO	O
.	O

ABSTRACT	O
:	O
Nucleocapsid	O
(	O
N	O
)	O
protein	B-CHED
gene	O
of	O
turkey	O
coronavirus	O
(	O
TCoV	O
)	O
was	O
expressed	O
in	O
a	O
prokaryotic	O
system	O
and	O
used	O
to	O
develop	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
for	O
detection	O
of	O
antibody	O
to	O
TCoV	O
.	O
Anti	O
-	O
TCoV	O
hyperimmune	O
turkey	O
serum	O
and	O
normal	O
turkey	O
serum	O
were	O
used	O
as	O
positive	O
or	O
negative	O
controls	O
for	O
optimization	O
of	O
the	O
ELISA	O
.	O

The	O
GAIT	O
element	O
is	O
involved	O
in	O
the	O
translation	O
silencing	O
of	O
these	O
mRNAs	O
through	O
its	O
interaction	O
with	O
the	O
GAIT	O
complex	O
(	O
EPRS	O
,	O
heterogeneous	O
nuclear	O
ribonucleoprotein	O
Q	O
,	O
ribosomal	O
protein	B-CHED
L13a	O
,	O
and	O
glyceraldehyde	B-CHED
3	I-CHED
-	I-CHED
phosphate	I-CHED
dehydrogenase	O
)	O
to	O
favor	O
the	O
resolution	O
of	O
inflammation	O
.	O

After	O
operation	O
,	O
the	O
patient	O
was	O
on	O
triple	O
medication	O
of	O
tacrolimus	B-CHED
plus	O
mofetil	O
mycophenolate	B-CHED
and	O
prednisone	B-CHED
for	O
immunosuppression	O
.	O

Both	O
the	O
patient	O
and	O
the	O
donor	B-CHED
recovered	O
well	O
without	O
any	O
complications	O
.	O

We	O
describe	O
herein	O
the	O
optimization	O
of	O
dipeptidyl	O
inhibitors	B-CHED
of	O
norovirus	O
3C	O
-	O
like	O
protease	O
using	O
iterative	O
SAR	B-CHED
,	O
X	O
-	O
ray	O
crystallographic	O
,	O
and	O
enzyme	O
and	O
cell	O
-	O
based	O
studies	O
.	O

Intragastric	O
administration	O
of	O
either	O
Ad5	O
-	O
S	O
or	O
Ad41	O
-	O
S	O
induced	O
antigen	B-CHED
-	O
specific	O
IgG	O
and	O
neutralizing	O
antibody	O
in	O
serum	O
;	O
however	O
,	O
antigen	B-CHED
-	O
specific	O
T	O
-	O
cell	O
responses	O
were	O
not	O
detected	O
.	O

Unfortunately	O
,	O
a	O
seafarer	O
on	O
board	O
a	O
bulk	O
carrier	O
died	O
in	O
2008	O
because	O
of	O
acute	O
phosphine	B-CHED
poisoning	O
.	O

CONCLUSIONS	O
:	O
Unfortunately	O
,	O
a	O
seafarer	O
on	O
board	O
a	O
bulk	O
carrier	O
died	O
in	O
2008	O
because	O
of	O
acute	O
phosphine	B-CHED
poisoning	O
.	O

There	O
is	O
an	O
urgent	O
need	O
for	O
developing	O
more	O
effective	O
antiviral	B-CHED
therapies	O
to	O
reduce	O
morbidity	O
and	O
mortality	O
of	O
these	O
emerging	O
viral	O
respiratory	O
tract	O
infections	O
.	O

Furthermore	O
,	O
pretreatment	O
with	O
400	O
mg	O
/	O
kg	O
eucalyptol	B-CHED
prevented	O
LPS	B-CHED
-	O
induced	O
histopathological	O
changes	O
.	O

However	O
,	O
viruses	O
rely	O
on	O
host	O
glycosylation	O
machineries	O
to	O
synthesize	O
and	O
express	O
glycans	B-CHED
and	O
,	O
thereby	O
,	O
may	O
display	O
common	O
carbohydrate	B-CHED
moieties	O
.	O

These	O
include	O
not	O
only	O
the	O
known	O
oligomannosyl	O
antigens	B-CHED
but	O
also	O
previously	O
unrecognized	O
tri	O
-	O
antennary	O
or	O
multi	O
-	O
valent	O
GlcNAc	B-CHED
-	O
terminating	O
N	B-CHED
-	I-CHED
glycan	I-CHED
epitopes	O
(	O
Tri	O
/	O
m	O
-	O
Gn	O
).	O

Subgroup	O
analyses	O
by	O
age	O
at	O
randomisation	O
,	O
routine	O
surfactant	B-CHED
use	O
or	O
not	O
,	O
type	O
of	O
high	O
frequency	O
ventilator	O
(	O
oscillator	O
versus	O
flow	O
interrupter	O
),	O
inspiratory	O
to	O
expiratory	O
(	O
I	O
:	O
E	O
)	O
ratio	O
of	O
high	O
frequency	O
ventilator	O
(	O
1	O
:	O
1	O
versus	O
1	O
:	O
2	O
)	O
and	O
CV	O
strategy	O
(	O
lung	O
protective	O
or	O
not	O
)	O
could	O
not	O
sufficiently	O
explain	O
the	O
heterogeneity	O
.	O

ABSTRACT	O
:	O
Molecular	O
self	O
-	O
assembly	O
,	O
a	O
phenomenon	O
widely	O
observed	O
in	O
nature	O
,	O
has	O
been	O
exploited	O
through	O
organic	O
molecules	O
,	O
proteins	B-CHED
,	O
DNA	O
,	O
and	O
peptides	B-CHED
to	O
study	O
complex	O
biological	O
systems	O
.	O

The	O
nucleotide	B-CHED
identity	O
between	O
the	O
two	O
Jiangxi	O
strains	O
(	O
CH	O
/	O
JX	O
-	O
1	O
/	O
2013	O
and	O
CH	O
/	O
JX	O
-	O
2	O
/	O
2013	O
)	O
and	O
30	O
strains	O
of	O
PEDV	O
identified	O
ante	O
-	O
2010	O
and	O
post	O
-	O
2010	O
ranged	O
from	O
96	O
.	O
3	O
-	O
97	O
.	O
0	O
%	O
and	O
97	O
.	O
3	O
-	O
99	O
.	O
7	O
%,	O
respectively	O
.	O

Western	O
blot	O
analysis	O
using	O
recombinant	O
DcEV	O
VP1	O
polypeptide	B-CHED
showed	O
a	O
high	O
seroprevalence	O
of	O
52	O
%	O
among	O
serum	O
samples	O
from	O
172	O
dromedaries	O
for	O
IgG	O
,	O
concurring	O
with	O
its	O
much	O
higher	O
infection	O
rates	O
in	O
dromedary	O
calves	O
than	O
in	O
adults	O
.	O

nsp3	O
comprises	O
multiple	O
structural	O
domains	O
,	O
including	O
two	O
papain	O
-	O
like	O
proteases	O
(	O
PLPs	O
)	O
and	O
a	O
highly	O
conserved	O
ADP	B-CHED
-	O
ribose	B-CHED
-	O
1	O
″-	O
phosphatase	O
(	O
ADRP	O
)	O
macrodomain	O
.	O

These	O
domains	O
may	O
play	O
direct	O
roles	O
in	O
RNA	O
synthesis	O
,	O
or	O
they	O
may	O
have	O
evolved	O
for	O
other	O
purposes	O
,	O
such	O
as	O
to	O
combat	B-CHED
host	O
innate	O
immunity	O
.	O

TITLE	O
:	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Corona	B-CHED
Virus	O
(	O
MERS	O
CoV	O
):	O
The	O
next	O
steps	O
.	O

ABSTRACT	O
:	O
Developing	O
countries	O
are	O
at	O
risk	O
of	O
importing	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Corona	B-CHED
Virus	O
(	O
MERS	O
CoV	O
)	O
from	O
the	O
Middle	O
East	O
.	O

Bacteria	O
were	O
detected	O
by	O
urinary	O
antigen	B-CHED
,	O
conventional	O
culture	O
and	O
PCR	O
.	O

During	O
PEDV	O
infection	O
,	O
NF	O
-	O
κB	O
p65	O
was	O
found	O
to	O
translocate	O
from	O
the	O
cytoplasm	O
to	O
the	O
nucleus	B-CHED
,	O
and	O
PEDV	O
-	O
dependent	O
NF	O
-	O
κB	O
activity	O
was	O
associated	O
with	O
viral	O
dose	O
and	O
active	O
replication	O
.	O

Severely	O
ill	O
patients	O
with	O
H7N9	O
had	O
significantly	O
longer	O
interval	O
from	O
onset	O
of	O
illness	O
to	O
neuraminidase	B-CHED
inhibitor	I-CHED
treatment	O
and	O
to	O
death	O
.	O

We	O
genotyped	O
the	O
CCL2	B-CHED
G	O
-	O
2518A	O
and	O
MBL	O
codon	O
54	O
variant	O
(	O
A	O
/	O
B	O
)	O
in	O
4	O
case	O
-	O
control	O
populations	O
of	O
Chinese	O
descent	O
,	O
totally	O
consisting	O
of	O
932	O
patients	O
with	O
SARS	O
and	O
982	O
control	O
subjects	O
.	O

The	O
PA	O
and	O
TBBL	O
assays	O
for	O
PON1	O
and	O
the	O
assay	O
for	O
TAC	B-CHED
were	O
validated	O
,	O
providing	O
acceptable	O
precision	O
and	O
linearity	O
although	O
PA	O
and	O
TAC	B-CHED
assays	O
showed	O
limit	O
of	O
detection	O
higher	O
than	O
the	O
values	O
found	O
in	O
some	O
cats	O
with	O
FIP	O
.	O

As	O
a	O
last	O
attempt	O
to	O
improve	O
oxygenation	O
,	O
the	O
patient	O
received	O
nitric	B-CHED
oxide	I-CHED
and	O
sedation	O
with	O
propofol	B-CHED
.	O

Inadequate	O
paralysis	O
was	O
achieved	O
with	O
rocuronium	B-CHED
and	O
cisatracurium	O
in	O
a	O
patient	O
who	O
sustained	O
a	O
significant	O
trauma	O
resulting	O
in	O
quadriplegia	O
.	O

A	O
case	O
series	O
of	O
6	O
patients	O
admitted	O
with	O
a	O
confirmed	O
diagnosis	O
of	O
MERS	O
CoV	O
were	O
treated	O
with	O
ribavirin	B-CHED
and	O
IFN	O
-	O
a2b	O
in	O
addition	O
to	O
supportive	O
management	O
.	O

Only	O
2	O
close	O
contacts	O
out	O
of	O
the	O
54	O
screened	O
(	O
3	O
.	O
7	O
%)	O
were	O
positive	O
for	O
MERS	O
CoV	O
.	O
CONCLUSIONS	O
:	O
Treatment	O
with	O
ribavirin	B-CHED
and	O
IFN	O
-	O
a2b	O
may	O
be	O
effective	O
in	O
patients	O
infected	O
with	O
MERS	O
CoV	O
.	O
There	O
appears	O
to	O
be	O
a	O
low	O
infectivity	O
rate	O
among	O
close	O
contacts	O
of	O
MERS	O
CoV	O
patients	O
.	O

The	O
application	O
of	O
FOB	O
-	O
BAL	B-CHED
using	O
a	O
laryngeal	O
mask	O
airway	O
(	O
LMA	O
)	O
in	O
combination	O
with	O
continuous	O
positive	O
airway	O
pressure	O
(	O
CPAP	O
)	O
may	O
minimize	O
the	O
incidence	O
of	O
hypoxaemia	O
;	O
however	O
,	O
the	O
safety	O
and	O
efficacy	O
of	O
this	O
procedure	O
have	O
not	O
been	O
investigated	O
.	O

Isolated	O
TEMs	O
,	O
when	O
mixed	O
with	O
CoV	O
and	O
LP	O
IAV	O
pseudoparticles	O
,	O
cleaved	O
viral	O
fusion	O
proteins	B-CHED
to	O
fusion	O
-	O
primed	O
fragments	O
and	O
potentiated	O
viral	O
transductions	O
.	O

Moreover	O
,	O
the	O
docking	O
study	O
of	O
all	O
synthesized	O
compounds	O
inside	O
the	O
HLA	O
-	O
A	O
protein	B-CHED
(	O
PDB	O
ID	O
:	O
3OX8	O
)	O
active	O
site	O
were	O
carried	O
out	O
to	O
explore	O
the	O
molecular	O
interactions	O
and	O
a	O
molecular	O
target	O
for	O
activity	O
of	O
phenylpropanoid	B-CHED
derivatives	O
with	O
the	O
protein	B-CHED
using	O
a	O
moe	O
-	O
docking	O
technique	O
.	O

This	O
study	O
identified	O
a	O
new	O
class	O
of	O
potent	O
anti	B-CHED
-	I-CHED
HBV	I-CHED
agents	I-CHED
.	O

The	O
occurrence	O
of	O
A	O
H1N1	O
epidemics	O
in	O
a	O
hematological	O
ward	O
in	O
the	O
post	O
-	O
pandemic	O
period	O
highlights	O
the	O
importance	O
of	O
awareness	O
of	O
this	O
complication	O
,	O
prompt	O
testing	O
and	O
antiviral	B-CHED
treatment	O
.	O

A	O
pathologist	O
blinded	O
to	O
treatment	O
allocation	O
scored	O
hematoxylin	B-CHED
-	O
eosin	O
-	O
stained	O
lung	O
sections	O
for	O
the	O
presence	O
of	O
lung	O
injury	O
.	O

In	O
addition	O
to	O
early	O
appropriate	O
antimicrobial	B-CHED
therapy	O
,	O
transfer	O
to	O
an	O
institution	O
experienced	O
with	O
ECMO	O
should	O
be	O
considered	O
when	O
caring	O
for	O
patients	O
from	O
endemic	O
areas	O
with	O
rapidly	O
progressive	O
respiratory	O
failure	O
.	O

ABSTRACT	O
:	O
Coronaviruses	O
(	O
CoVs	O
)	O
are	O
unique	O
in	O
encoding	O
a	O
3	O
'→	O
5	O
'	O
exoribonuclease	O
within	O
nonstructural	O
protein	B-CHED
14	O
(	O
nsp14	O
-	O
ExoN	O
)	O
that	O
is	O
required	O
for	O
high	O
-	O
fidelity	O
replication	O
,	O
likely	O
via	O
proofreading	O
.	O

No	O
change	O
in	O
5	B-CHED
-	I-CHED
FU	I-CHED
sensitivity	O
was	O
observed	O
for	O
R80A	O
/	O
E82A	O
-	O
ExoN	O
(-)	O
relative	O
to	O
MHV	O
-	O
ExoN	O
(-),	O
indicating	O
that	O
the	O
decreased	O
-	O
fidelity	O
phenotype	O
of	O
R80A	O
/	O
E82A	O
-	O
ExoN	O
(-)	O
is	O
linked	O
to	O
the	O
presence	O
of	O
ExoN	O
activity	O
.	O

Second	O
,	O
due	O
to	O
the	O
low	O
number	O
of	O
MERS	O
cases	O
,	O
pharmaceutical	B-CHED
companies	O
have	O
little	O
incentive	O
to	O
pursue	O
MERS	O
vaccine	O
production	O
as	O
the	O
costs	O
of	O
clinical	O
trials	O
are	O
high	O
.	O

TITLE	O
:	O
Optimization	O
of	O
antigen	B-CHED
dose	O
for	O
a	O
receptor	O
-	O
binding	O
domain	O
-	O
based	O
subunit	O
vaccine	O
against	O
MERS	O
coronavirus	O
.	O

Higher	O
PEEP	B-CHED
levels	O
have	O
been	O
recommended	O
in	O
severe	O
ARDS	O
.	O

We	O
sought	O
to	O
describe	O
the	O
hemodynamic	O
profile	O
associated	O
with	O
either	O
ACP	B-CHED
or	O
PFO	B-CHED
,	O
or	O
both	O
,	O
during	O
the	O
early	O
course	O
of	O
moderate	O
-	O
to	O
-	O
severe	O
ARDS	O
using	O
echocardiography	O
.	O

ACP	B-CHED
was	O
present	O
in	O
36	O
patients	O
,	O
PFO	B-CHED
in	O
21	O
patients	O
,	O
both	O
PFO	B-CHED
and	O
ACP	B-CHED
in	O
8	O
patients	O
and	O
the	O
130	O
remaining	O
patients	O
had	O
neither	O
PFO	B-CHED
nor	O
ACP	B-CHED
.	O

TITLE	O
:	O
Albumin	O
rather	O
than	O
C	O
-	O
reactive	O
protein	B-CHED
may	O
be	O
valuable	O
in	O
predicting	O
and	O
monitoring	O
the	O
severity	O
and	O
course	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
in	O
critically	O
ill	O
patients	O
with	O
or	O
at	O
risk	O
for	O
the	O
syndrome	O
after	O
new	O
onset	O
fever	O
.	O

Immunohistochemical	O
staining	O
showed	O
HEV	O
-	O
and	O
PCV2	O
-	O
antigen	B-CHED
-	O
positive	O
signals	O
in	O
the	O
livers	O
,	O
kidneys	O
,	O
lungs	O
,	O
lymph	O
nodes	O
,	O
and	O
intestine	O
.	O

A	O
series	O
of	O
new	O
curcumin	B-CHED
analogs	O
were	O
synthesized	O
and	O
screened	O
for	O
their	O
inhibitory	O
effects	O
on	O
the	O
production	O
of	O
TNF	O
-	O
α	O
and	O
IL	O
-	O
6	O
in	O
mouse	O
peritoneal	O
macrophages	O
by	O
ELISA	O
.	O

RESULTS	O
:	O
In	O
the	O
study	O
,	O
we	O
synthesized	O
30	O
curcumin	B-CHED
analogs	O
.	O

Meanwhile	O
,	O
compound	O
c26	O
reduced	O
the	O
LPS	B-CHED
-	O
induced	O
inflammatory	O
gene	O
expression	O
in	O
human	O
pulmonary	O
epithelial	O
cells	O
.	O

Coinfections	O
of	O
the	O
influenza	O
A	O
H3N2	B-CHED
virus	O
with	O
TTV	O
,	O
HMPV	O
with	O
TTV	O
,	O
HRV	O
with	O
TTV	O
,	O
and	O
human	O
parainfluenza	O
virus	O
-	O
3	O
with	O
TTV	O
were	O
found	O
in	O
4	O
.	O
7	O
,	O
2	O
.	O
8	O
,	O
19	O
.	O
8	O
,	O
and	O
0	O
.	O
9	O
%	O
of	O
the	O
samples	O
,	O
respectively	O
.	O

The	O
data	O
suggested	O
de	O
-	O
N	O
-	O
sulfated	O
heparin	B-CHED
,	O
but	O
not	O
N	O
-	O
acetyl	B-CHED
-	O
de	O
-	O
O	O
-	O
sulfated	O
heparin	B-CHED
,	O
inhibits	O
PEDV	O
infection	O
.	O

In	O
summary	O
,	O
our	O
studies	O
revealed	O
that	O
heparan	B-CHED
sulfate	I-CHED
acts	O
as	O
the	O
attachment	O
factor	O
of	O
PEDV	O
in	O
Vero	O
cells	O
.	O

TITLE	O
:	O
Vitamin	B-CHED
D	I-CHED
deficiency	O
contributes	O
directly	O
to	O
the	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

TITLE	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
protein	B-CHED
6	O
mediates	O
ubiquitin	O
-	O
dependent	O
proteosomal	O
degradation	O
of	O
N	O
-	O
Myc	O
(	O
and	O
STAT	O
)	O
interactor	O
.	O

For	O
further	O
investigation	O
,	O
we	O
targeted	O
the	O
IFN	O
signaling	O
pathway	O
-	O
mediating	O
protein	B-CHED
,	O
N	O
-	O
Myc	O
(	O
and	O
STAT	O
)	O
interactor	O
(	O
Nmi	O
).	O

Airway	O
pressure	O
release	O
ventilation	O
was	O
the	O
initial	O
choice	O
of	O
treatment	O
reported	O
by	O
most	O
when	O
conventional	O
mechanical	O
ventilation	O
strategy	O
failed	O
followed	O
by	O
inhaled	O
nitric	B-CHED
oxide	I-CHED
and	O
prone	O
positioning	O
.	O

Phylogenetic	O
characterization	O
of	O
this	O
virus	O
revealed	O
that	O
it	O
clusters	B-CHED
within	O
the	O
subfamily	O
Torovirinae	O
,	O
in	O
the	O
family	O
Coronaviridae	O
.	O

We	O
also	O
identified	O
a	O
unique	O
amino	B-CHED
acid	I-CHED
substitution	O
in	O
the	O
spike	O
receptor	O
binding	O
domain	O
that	O
may	O
have	O
implications	O
for	O
receptor	O
binding	O
efficiency	O
.	O

Toxic	O
leukoencephalopathy	O
can	O
occur	O
acutely	O
following	O
an	O
overdose	O
of	O
benzodiazepine	B-CHED
and	O
respiratory	O
failure	O
.	O

The	O
rapid	O
identification	O
of	O
these	O
viral	O
infections	O
could	O
aid	O
in	O
the	O
control	O
of	O
nosocomial	O
transmission	O
,	O
reduce	O
the	O
use	O
of	O
antibiotics	B-CHED
and	O
improve	O
treatment	O
and	O
management	O
strategies	O
.	O

Pretreatment	O
of	O
RD	O
cells	O
with	O
neuraminidase	O
(	O
NA	O
)	O
and	O
trypsin	O
greatly	O
reduced	O
the	O
binding	O
,	O
suggesting	O
that	O
the	O
binding	O
was	O
mediated	O
by	O
sialic	B-CHED
acids	I-CHED
on	O
glycoproteins	B-CHED
.	O

In	O
addition	O
,	O
we	O
determined	O
that	O
the	O
HKU1	O
-	O
HE	O
protein	B-CHED
is	O
an	O
O	O
-	O
acetylesterase	O
and	O
acts	O
as	O
a	O
receptor	O
-	O
destroying	O
enzyme	O
(	O
RDE	O
)	O
for	O
hCoV	O
-	O
HKU1	O
.	O

ABSTRACT	O
:	O
During	O
Ebola	O
virus	O
(	O
EBOV	O
)	O
infection	O
,	O
the	O
type	O
I	O
interferon	O
α	O
/	O
β	O
(	O
IFN	O
-	O
α	O
/	O
β	O
)	O
innate	O
immune	O
response	O
is	O
suppressed	O
by	O
EBOV	O
viral	O
protein	B-CHED
35	O
(	O
VP35	O
),	O
a	O
validated	O
drug	O
target	O
.	O

We	O
established	O
a	O
miniaturized	O
luciferase	O
gene	O
reporter	O
assay	O
in	O
A549	O
cells	O
that	O
measures	O
IFN	O
-	O
β	O
induction	O
by	O
viral	O
dsRNA	B-CHED
and	O
is	O
dose	O
-	O
dependently	O
inhibited	O
by	O
VP35	O
expression	O
.	O

This	O
assay	O
can	O
be	O
used	O
to	O
screen	O
for	O
EBOV	O
VP35	O
inhibitors	B-CHED
.	O

Further	O
studies	O
reproduced	O
the	O
binding	O
pose	O
of	O
16R	O
within	O
the	O
active	O
site	O
of	O
the	O
generated	O
model	O
,	O
where	O
its	O
free	O
energy	O
of	O
binding	O
was	O
shown	O
to	O
equal	O
that	O
of	O
the	O
3CL	O
(	O
pro	B-CHED
)	O
of	O
SARS	O
-	O
CoV	O
,	O
a	O
receptor	O
it	O
is	O
experimentally	O
proven	O
to	O
inhibit	O
.	O

The	O
study	O
population	O
consisted	O
of	O
150	O
rosé	O
veal	O
calves	O
housed	O
in	O
a	O
single	O
air	B-CHED
-	O
space	O
.	O

In	O
the	O
third	O
structure	O
,	O
two	O
of	O
the	O
three	O
protomers	O
in	O
the	O
asymmetric	O
unit	O
form	O
a	O
homodimer	O
similar	O
to	O
that	O
of	O
SARS	O
-	O
CoV	O
3	O
CL	O
(	O
pro	B-CHED
);	O
however	O
,	O
the	O
third	O
protomer	O
adopts	O
a	O
radically	O
different	O
conformation	O
that	O
is	O
likely	O
to	O
correspond	O
to	O
a	O
crystallographic	O
monomer	O
,	O
indicative	O
of	O
substantial	O
structural	O
plasticity	O
in	O
the	O
enzyme	O
.	O

Summarily	O
,	O
endotracheal	O
suctioning	O
may	O
impair	O
gas	O
exchange	O
and	O
decrease	O
lung	O
compliance	O
in	O
ARF	O
patients	O
receiving	O
mechanical	O
ventilation	O
under	O
both	O
PCV	B-CHED
and	O
VCV	O
modes	O
,	O
but	O
endotracheal	O
suctioning	O
effects	O
on	O
gas	O
exchange	O
were	O
more	O
severe	O
and	O
longer	O
-	O
lasting	O
under	O
PCV	B-CHED
mode	O
than	O
VCV	O
.	O

TITLE	O
:	O
Alterations	O
of	O
lung	O
microbiota	O
in	O
a	O
mouse	O
model	O
of	O
LPS	B-CHED
-	O
induced	O
lung	O
injury	O
.	O

Bacterial	O
DNA	O
was	O
extracted	O
and	O
used	O
for	O
qPCR	O
and	O
16S	B-CHED
rRNA	B-CHED
gene	O
-	O
tag	O
(	O
V3	O
-	O
V4	O
)	O
sequencing	O
(	O
Illumina	O
).	O

TITLE	O
:	O
Hypertonic	O
Saline	O
(	O
NaCl	B-CHED
7	O
.	O
5	O
%)	O

TITLE	O
:	O
Psychological	O
autopsy	O
and	O
necropsy	O
of	O
an	O
unusual	O
case	O
of	O
suicide	O
by	O
intravenous	O
toluene	B-CHED
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
case	O
of	O
suicide	O
by	O
intravenous	O
administration	O
of	O
toluene	B-CHED
in	O
the	O
literature	O
.	O

A	O
diagnosis	O
of	O
polytetrafluoroethylene	B-CHED
fume	O
-	O
induced	O
pulmonary	O
edema	O
was	O
made	O
.	O

TITLE	O
:	O
Transcriptome	O
Profiling	O
of	O
the	O
Virus	O
-	O
Induced	O
Innate	O
Immune	O
Response	O
in	O
Pteropus	O
vampyrus	O
and	O
Its	O
Attenuation	O
by	O
Nipah	O
Virus	O
Interferon	O
Antagonist	B-CHED
Functions	O
.	O

Generally	O
,	O
a	O
BPF	O
of	O
more	O
than	O
6	O
mm	O
in	O
size	O
is	O
considered	O
as	O
large	O
.(	O
1	O
)	O
Small	O
BPFs	O
can	O
be	O
easily	O
missed	O
on	O
CT	O
scan	O
chest	O
,	O
but	O
a	O
persistent	O
air	B-CHED
-	O
leak	O
through	O
an	O
adequately	O
placed	O
chest	O
tube	O
should	O
raise	O
suspicion	O
for	O
a	O
BPF	O
.	O

We	O
investigated	O
the	O
S1	O
glycoprotein	B-CHED
of	O
24	O
recent	O
IBV	O
isolates	O
from	O
chickens	O
and	O
demonstrated	O
that	O
two	O
predominant	O
genetic	O
groups	O
were	O
circulating	O
in	O
southern	O
Thailand	O
between	O
2008	O
and	O
2013	O
.	O

ABSTRACT	O
:	O
Phenol	B-CHED
burns	O
can	O
result	O
in	O
multiple	O
organ	O
failure	O
.	O

This	O
is	O
a	O
case	O
report	O
of	O
acute	O
severe	O
phenol	B-CHED
dermal	O
burn	O
after	O
accidental	O
splash	O
of	O
94	O
%	O
phenol	B-CHED
on	O
35	O
-	O
year	O
-	O
old	O
patient	O
'	O
s	O
body	O
who	O
was	O
brought	O
to	O
hospital	O
after	O
90	O
min	O
of	O
exposure	O
.	O

Extensive	O
protein	B-CHED
denaturation	O
was	O
managed	O
with	O
IV	O
albumin	O
and	O
high	O
protein	B-CHED
diet	O
.	O

Here	O
,	O
we	O
describe	O
the	O
establishment	O
of	O
tissue	O
-	O
like	O
assemblies	O
for	O
human	O
lung	O
and	O
neuronal	O
tissue	O
that	O
we	O
infected	O
with	O
a	O
variety	O
of	O
viruses	O
including	O
the	O
respiratory	O
pathogens	O
human	O
parainfluenza	O
virus	O
type	O
3	O
(	O
PIV3	O
),	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
)	O
and	O
SARS	O
corona	B-CHED
virus	O
(	O
SARS	O
-	O
CoV	O
)	O
as	O
well	O
as	O
the	O
human	O
neurotropic	O
herpesvirus	O
,	O
varicella	O
-	O
zoster	O
virus	O
(	O
VZV	O
).	O

ABSTRACT	O
:	O
Salicylate	B-CHED
poisoning	O
is	O
a	O
challenging	O
clinical	O
entity	O
associated	O
with	O
substantial	O
morbidity	O
and	O
mortality	O
.	O

Eighty	O
-	O
four	O
articles	O
met	B-CHED
inclusion	O
criteria	O
,	O
including	O
1	O
controlled	O
clinical	O
trial	O
,	O
3	O
animal	O
studies	O
,	O
and	O
80	O
case	O
reports	O
or	O
case	O
series	O
,	O
yielding	O
an	O
overall	O
very	O
low	O
quality	O
of	O
evidence	O
for	O
all	O
recommendations	O
.	O

The	O
signs	O
and	O
symptoms	O
of	O
salicylate	B-CHED
toxicity	O
listed	O
warrant	O
extracorporeal	O
treatment	O
,	O
as	O
do	O
high	O
concentrations	O
regardless	O
of	O
clinical	O
status	O
.	O

We	O
performed	O
the	O
serratus	O
anterior	O
place	O
block	O
under	O
ultrasound	O
guidance	O
and	O
placed	O
a	O
catheter	O
for	O
continuous	O
infusion	O
of	O
local	B-CHED
anaesthetic	I-CHED
and	O
opioid	O
.	O

A	O
new	O
cluster	O
E	O
was	O
invariably	O
detected	O
from	O
nsp12	O
,	O
S	O
,	O
and	O
N	O
data	O
while	O
the	O
analysis	O
of	O
nsp12	O
and	O
N	O
genes	O
revealed	O
the	O
existence	O
of	O
new	O
F	O
and	O
G	O
clusters	B-CHED
respectively	O
.	O

ABSTRACT	O
:	O
The	O
spike	O
(	O
S	O
)	O
protein	B-CHED
of	O
porcine	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
is	O
located	O
within	O
the	O
viral	O
envelope	O
and	O
is	O
the	O
only	O
structural	O
protein	B-CHED
that	O
possesses	O
epitopes	O
capable	O
of	O
inducing	O
virus	O
-	O
neutralizing	O
antibodies	O
.	O

Antibodies	O
against	O
influenza	O
viruses	O
A	O
/	O
H1N1	O
/	O
pdm09	O
California	O
/	O
07	O
/	O
09	O
,	O
epidemic	O
reference	O
strains	O
of	O
influenza	O
viruses	O
A	O
/	O
H1N1	O
/	O
Brisbane	O
/	O
59	O
/	O
07	O
,	O
A	O
/	O
H3N2	B-CHED
/	O
Victoria	O
/	O
361	O
/	O
201	O
1	O
,	O
B	O
/	O
Wisconsin	O
/	O
1	O
/	O
10	O
,	O
against	O
PI	O
viruses	O
type	O
1	O
,	O
2	O
,	O
3	O
were	O
determined	O
in	O
paired	O
sera	O
by	O
HAI	O
.	O

TITLE	O
:	O
Impact	O
of	O
statin	B-CHED
therapy	O
on	O
mortality	O
in	O
patients	O
with	O
sepsis	O
-	O
associated	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
depends	O
on	O
ARDS	O
severity	O
:	O
a	O
prospective	O
observational	O
cohort	O
study	O
.	O

Statin	B-CHED
therapy	O
improved	O
28	O
-	O
day	O
survival	O
exclusively	O
in	O
the	O
patients	O
with	O
severe	O
ARDS	O
compared	O
with	O
patients	O
without	O
statin	B-CHED
therapy	O
(	O
88	O
.	O
5	O
%	O
and	O
62	O
.	O
5	O
%,	O
respectively	O
;	O
P	O
=	O
0	O
.	O
0193	O
).	O

Patients	O
with	O
severe	O
ARDS	O
who	O
received	O
statin	B-CHED
therapy	O
had	O
significantly	O
more	O
vasopressor	O
-	O
free	O
days	O
compared	O
with	O
those	O
without	O
statin	B-CHED
therapy	O
(	O
13	O
±	O
7	O
and	O
9	O
±	O
7	O
,	O
respectively	O
;	O
P	O
=	O
0	O
.	O
0034	O
),	O
and	O
they	O
also	O
required	O
less	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
therapy	O
and	O
had	O
more	O
ECMO	O
-	O
free	O
days	O
(	O
18	O
±	O
9	O
and	O
15	O
±	O
9	O
,	O
respectively	O
;	O
P	O
=	O
0	O
.	O
0873	O
).	O

We	O
conclude	O
that	O
HGF	O
/	O
c	O
-	O
Met	B-CHED
and	O
TGF	O
-	O
α	O
/	O
EGFR	O
signaling	O
enhances	O
the	O
innate	O
immune	O
responses	O
by	O
human	O
AECs	O
during	O
influenza	O
infections	O
.	O

The	O
concept	O
of	O
exploring	O
the	O
effects	O
of	O
careful	O
recruitment	O
maneuvers	O
during	O
conventional	O
ventilation	O
met	B-CHED
an	O
agreement	O
level	O
of	O
88	O
%,	O
whereas	O
the	O
use	O
of	O
recruitment	O
maneuvers	O
during	O
rescue	O
high	O
-	O
frequency	O
oscillatory	O
ventilation	O
is	O
highly	O
recommended	O
(	O
strong	O
agreement	O
).	O

The	O
concept	O
of	O
exploring	O
the	O
effects	O
of	O
careful	O
recruitment	O
maneuvers	O
during	O
conventional	O
ventilation	O
met	B-CHED
an	O
agreement	O
level	O
of	O
88	O
%,	O
whereas	O
the	O
use	O
of	O
recruitment	O
maneuvers	O
during	O
rescue	O
high	O
-	O
frequency	O
oscillatory	O
ventilation	O
is	O
highly	O
recommended	O
(	O
strong	O
agreement	O
).	O

Overall	O
,	O
the	O
routine	O
use	O
of	O
surfactant	B-CHED
,	O
inhaled	O
nitric	B-CHED
oxide	I-CHED
,	O
glucocorticoids	B-CHED
,	O
prone	O
positioning	O
,	O
endotracheal	O
suctioning	O
,	O
and	O
chest	O
physiotherapy	O
cannot	O
be	O
recommended	O
.	O

Inhaled	O
nitric	B-CHED
oxide	I-CHED
should	O
only	O
be	O
used	O
for	O
patients	O
with	O
documented	O
pulmonary	O
hypertension	O
and	O
/	O
or	O
right	O
ventricular	O
failure	O
.	O

Binding	O
of	O
all	O
coronaviral	O
S1	O
proteins	B-CHED
was	O
dependent	O
on	O
sialic	B-CHED
acids	I-CHED
;	O
however	O
,	O
while	O
chicken	O
CoV	O
S1	O
preferred	O
sialic	B-CHED
acids	I-CHED
type	O
I	O
lactosamine	B-CHED
(	O
Gal	B-CHED
(	O
1	O
-	O
3	O
)	O
GlcNAc	B-CHED
)	O
over	O
type	O
II	O
(	O
Gal	B-CHED
(	O
1	O
-	O
4	O
)	O
GlcNAc	B-CHED
),	O
the	O
fine	O
glycan	B-CHED
specificities	O
of	O
pigeon	O
and	O
partridge	O
CoVs	O
were	O
different	O
,	O
as	O
chicken	O
CoV	O
S1	O
-	O
specific	O
sialylglycopolymers	O
could	O
not	O
block	O
their	O
binding	O
to	O
tissues	O
.	O

A	O
clonidine	B-CHED
infusion	O
was	O
started	O
as	O
the	O
patient	O
developed	O
withdrawal	O
syndrome	O
and	O
was	O
difficult	O
to	O
wean	O
off	O
mechanical	O
ventilation	O
.	O

Reversal	O
of	O
symptoms	O
and	O
successful	O
reweaning	O
was	O
achieved	O
by	O
restarting	O
a	O
low	O
-	O
dose	O
clonidine	B-CHED
infusion	O
followed	O
by	O
slow	O
downward	O
titration	O
and	O
use	O
of	O
oral	O
clonidine	B-CHED
as	O
a	O
step	O
-	O
down	O
measure	O
.	O

Phylogenetically	O
,	O
HCoV	O
-	O
EMC	O
is	O
clustered	O
with	O
Ty	O
-	O
BatCoV	O
HKU4	O
/	O
Pi	O
-	O
BatCoV	O
HKU5	O
with	O
high	O
bootstrap	O
supports	O
,	O
indicating	O
that	O
HCoV	O
-	O
EMC	O
is	O
a	O
group	O
C	O
betaCoV	O
.	O
The	O
major	O
difference	O
between	O
HCoV	O
-	O
EMC	O
and	O
Ty	O
-	O
BatCoV	O
HKU4	O
/	O
Pi	O
-	O
BatCoV	O
HKU5	O
is	O
in	O
the	O
region	O
between	O
S	O
and	O
E	O
,	O
where	O
HCoV	O
-	O
EMC	O
possesses	O
five	O
ORFs	O
(	O
NS3a	O
-	O
NS3e	O
)	O
instead	O
of	O
four	O
,	O
with	O
low	O
(	O
31	O
%-	O
62	O
%)	O
amino	B-CHED
acid	I-CHED
identities	O
to	O
Ty	O
-	O
BatCoV	O
HKU4	O
/	O
Pi	O
-	O
BatCoV	O
HKU5	O
.	O

TITLE	O
:	O
Receptor	O
-	O
binding	O
domains	O
of	O
spike	O
proteins	B-CHED
of	O
emerging	O
or	O
re	O
-	O
emerging	O
viruses	O
as	O
targets	O
for	O
development	O
of	O
antiviral	B-CHED
vaccines	O
.	O

Depletion	O
of	O
the	O
antiviral	B-CHED
double	O
-	O
stranded	O
RNA	O
-	O
activated	O
protein	B-CHED
kinase	O
(	O
PKR	O
)	O
enhanced	O
virus	O
replication	O
in	O
the	O
primary	O
screen	O
,	O
and	O
validation	O
experiments	O
confirmed	O
increased	O
SARS	O
-	O
CoV	O
protein	B-CHED
expression	O
and	O
virus	O
production	O
upon	O
PKR	O
depletion	O
.	O

ABSTRACT	O
:	O
The	O
5	O
'	O
cap	O
structures	O
of	O
eukaryotic	O
mRNAs	O
are	O
important	O
for	O
RNA	O
stability	O
and	O
protein	B-CHED
translation	O
.	O

Our	O
current	O
results	O
demonstrate	O
that	O
stimulation	O
of	O
nsp16	O
2	O
'-	O
O	O
-	O
MTase	O
activity	O
by	O
nsp10	O
is	O
a	O
common	O
mechanism	O
for	O
coronaviruses	O
,	O
and	O
nsp10	O
is	O
functionally	O
interchangeable	O
in	O
the	O
stimulation	O
of	O
nsp16	O
among	O
different	O
coronaviruses	O
,	O
which	O
underlies	O
the	O
rationale	O
for	O
developing	O
inhibitory	O
peptides	B-CHED
.	O

In	O
addition	O
,	O
searches	O
for	O
protein	B-CHED
-	O
protein	B-CHED
interactions	O
using	O
yeast	O
-	O
two	O
hybrid	O
techniques	O
have	O
shed	O
light	O
on	O
possible	O
functional	O
roles	O
for	O
their	O
exposed	O
cytoplasmic	O
domains	O
.	O

Previously	O
,	O
others	O
and	O
we	O
have	O
shown	O
that	O
respiratory	O
pathogens	O
of	O
the	O
genus	O
Gammacoronavirus	O
,	O
including	O
chicken	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
),	O
require	O
specific	O
α2	O
,	O
3	O
-	O
linked	O
sialylated	O
glycans	B-CHED
for	O
attachment	O
and	O
entry	O
.	O

Protein	B-CHED
histochemistry	O
showed	O
that	O
the	O
tissue	O
binding	O
specificity	O
of	O
S1	O
proteins	B-CHED
of	O
turkey	O
,	O
quail	O
,	O
and	O
guineafowl	O
CoVs	O
was	O
limited	O
to	O
intestinal	O
tissues	O
of	O
each	O
particular	O
host	O
,	O
in	O
accordance	O
with	O
the	O
reported	O
pathogenicity	O
of	O
these	O
viruses	O
in	O
vivo	O
.	O

Dendritic	O
cells	O
(	O
DCs	O
)	O
are	O
highly	O
effective	O
antigen	B-CHED
-	O
presenting	O
cells	O
widely	O
distributed	O
beneath	O
the	O
intestinal	O
epithelium	O
,	O
thus	O
making	O
them	O
an	O
early	O
target	O
for	O
virus	O
contact	O
.	O

Consistent	O
with	O
these	O
results	O
,	O
after	O
48	O
h	O
of	O
CV777	O
infection	O
,	O
there	O
is	O
enhancement	O
in	O
the	O
ability	O
of	O
porcine	O
intestinal	O
DCs	O
to	O
sample	O
the	O
antigen	B-CHED
and	O
activate	O
T	O
-	O
cell	O
proliferation	O
in	O
vivo	O
.	O

These	O
results	O
suggest	O
that	O
CV777	O
stimulates	O
the	O
ability	O
of	O
Mo	O
-	O
DCs	O
to	O
sample	O
and	O
present	O
antigen	B-CHED
.	O

Prestimulation	O
of	O
MSCs	O
with	O
a	O
toll	O
-	O
like	O
receptor	O
3	O
agonist	B-CHED
further	O
enhanced	O
the	O
therapeutic	O
effects	O
of	O
the	O
released	O
MVs	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggested	O
that	O
ET	O
-	O
1	O
promotes	O
occurrence	O
and	O
amplification	O
of	O
pathology	O
-	O
related	O
airway	O
inflammation	O
via	O
enhancing	O
VCAM	O
-	O
1	O
expression	O
in	O
an	O
ET	O
receptor	O
/	O
Src	O
/	O
MMP	B-CHED
/	O
EGFR	O
,	O
PDGFR	O
/	O
PI3K	O
/	O
AKT	O
/	O
p42	O
/	O
p44	O
MAPK	O
/	O
Elk	O
-	O
1	O
/	O
p300	O
pathway	O
in	O
HTSMCs	O
.	O

Additionally	O
,	O
all	O
tested	O
disinfectants	B-CHED
except	O
for	O
0	O
.	O
17	O
%	O
sodium	O
hypochlorite	B-CHED
dramatically	O
reduced	O
qRT	O
-	O
PCR	O
values	O
.	O

To	O
evaluate	O
transmission	O
risk	O
,	O
we	O
determined	O
the	O
type	O
,	O
duration	O
,	O
and	O
frequency	O
of	O
patient	O
contact	O
among	O
health	O
care	O
personnel	O
(	O
HCP	B-CHED
),	O
household	O
,	O
and	O
community	O
contacts	O
by	O
using	O
standard	O
questionnaires	O
and	O
,	O
for	O
HCP	B-CHED
,	O
global	O
positioning	O
system	O
(	O
GPS	O
)	O
tracer	B-CHED
tag	O
logs	O
.	O

Most	O
of	O
the	O
HKU1	O
spike	O
MAbs	O
recognized	O
epitopes	O
in	O
the	O
C	O
domain	O
between	O
amino	B-CHED
acids	I-CHED
535	O
and	O
673	O
,	O
indicating	O
that	O
this	O
region	O
is	O
immunodominant	O
.	O

These	O
data	O
suggest	O
that	O
the	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
HKU1	O
spike	O
protein	B-CHED
is	O
located	O
in	O
the	O
C	O
domain	O
,	O
where	O
the	O
spike	O
proteins	B-CHED
of	O
α	O
-	O
CoVs	O
and	O
β	O
-	O
CoVs	O
in	O
groups	O
B	O
and	O
C	O
bind	O
to	O
their	O
specific	O
receptor	O
proteins	B-CHED
.	O

ABSTRACT	O
:	O
RNA	O
interference	O
(	O
RNAi	O
)	O
is	O
a	O
process	O
of	O
eukaryotic	O
posttranscriptional	O
gene	O
silencing	O
that	O
functions	O
in	O
antiviral	B-CHED
immunity	O
in	O
plants	O
,	O
nematodes	O
,	O
and	O
insects	O
.	O

To	O
combat	B-CHED
RNAi	O
-	O
mediated	O
antiviral	B-CHED
responses	O
,	O
many	O
viruses	O
encode	O
viral	O
suppressors	O
of	O
RNA	O
silencing	O
(	O
VSR	O
)	O
to	O
facilitate	O
their	O
replication	O
.	O

Compared	O
with	O
group	O
2	O
,	O
more	O
group	O
1	O
subjects	O
reported	O
dyspnea	O
,	O
more	O
severe	O
disease	O
of	O
longer	O
duration	O
,	O
and	O
treatment	O
for	O
acute	O
illness	O
with	O
prednisone	B-CHED
and	O
antibiotics	B-CHED
.	O

Patients	O
were	O
divided	O
into	O
4	O
groups	O
according	O
to	O
the	O
severity	O
of	O
acute	O
-	O
HCA	O
(	O
i	O
.	O
e	O
.	O
total	O
grade	O
:	O
minimal	O
,	O
1	O
;	O
mild	O
,	O
2	O
;	O
moderate	O
,	O
3	O
-	O
4	O
;	O
severe	O
,	O
5	O
-	O
6	O
)	O
or	O
IAI	O
(	O
i	O
.	O
e	O
.	O
amniotic	O
fluid	O
MMP	B-CHED
-	O
8	O
:	O
minimal	O
,	O
23	O
-	O
100	O
ng	O
/	O
ml	O
;	O
mild	O
,	O
100	O
-	O
400	O
ng	O
/	O
ml	O
;	O
moderate	O
,	O
400	O
-	O
800	O
ng	O
/	O
ml	O
;	O
severe	O
,	O
≥	O
800	O
ng	O
/	O
ml	O
).	O

We	O
then	O
examined	O
the	O
effects	O
of	O
these	O
inhibitors	B-CHED
on	O
the	O
activation	O
of	O
collagen	O
I	O
and	O
α	O
-	O
smooth	O
muscle	O
actin	O
(	O
α	O
-	O
SMA	O
)	O
induced	O
by	O
PDGF	O
or	O
TGFβ1	O
stimulation	O
.	O

We	O
then	O
examined	O
the	O
effects	O
of	O
these	O
inhibitors	B-CHED
on	O
the	O
activation	O
of	O
collagen	O
I	O
and	O
α	O
-	O
smooth	O
muscle	O
actin	O
(	O
α	O
-	O
SMA	O
)	O
induced	O
by	O
PDGF	O
or	O
TGFβ1	O
stimulation	O
.	O

Despite	O
multimodal	O
therapy	O
,	O
including	O
noninvasive	O
positive	O
pressure	O
ventilation	O
,	O
polymyxin	B-CHED
B	I-CHED
-	O
immobilized	O
fiber	O
column	O
hemoperfusion	O
,	O
and	O
methylprednisolone	B-CHED
infusion	O
,	O
his	O
general	O
condition	O
gradually	O
deteriorated	O
.	O

In	O
conclusion	O
,	O
the	O
results	O
suggested	O
that	O
specific	O
and	O
neutralizing	O
chicken	O
scFvs	O
against	O
IBV	O
,	O
which	O
can	O
be	O
safe	O
and	O
economical	O
antibody	O
reagents	B-CHED
,	O
can	O
be	O
produced	O
in	O
vitro	O
through	O
prokaryotic	O
expression	O
.	O

TITLE	O
:	O
Plasma	O
suPAR	O
as	O
a	O
prognostic	O
biological	B-CHED
marker	I-CHED
for	O
ICU	O
mortality	O
in	O
ARDS	O
patients	O
.	O

As	O
a	O
single	O
biological	B-CHED
marker	I-CHED
,	O
the	O
prognostic	O
value	O
for	O
death	O
of	O
plasma	O
suPAR	O
in	O
ARDS	O
patients	O
is	O
low	O
.	O

In	O
this	O
study	O
,	O
we	O
produced	O
an	O
IgY	O
against	O
the	O
PEDV	O
S1	O
protein	B-CHED
and	O
investigated	O
its	O
immunoprophylactic	O
effect	O
in	O
neonatal	O
piglets	O
.	O

A	O
codon	O
-	O
optimized	O
PEDV	O
S1	O
gene	O
consisting	O
of	O
amino	B-CHED
acid	I-CHED
residues	O
25	O
-	O
749	O
was	O
synthesized	O
and	O
used	O
to	O
establish	O
a	O
stable	O
porcine	O
cell	O
line	O
constitutively	O
expressing	O
a	O
recombinant	O
PEDV	O
S1	O
protein	B-CHED
containing	O
the	O
chicken	O
immunoglobulin	O
Fc	O
fragment	O
at	O
its	O
C	O
-	O
terminus	O
.	O

In	O
preclinical	O
models	O
,	O
p38	O
inhibitors	B-CHED
reduce	O
lung	O
injury	O
following	O
pancreatitis	O
and	O
burn	O
injury	O
.	O

We	O
conducted	O
a	O
phase	O
IIa	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
parallel	O
-	O
group	O
study	O
to	O
evaluate	O
the	O
safety	O
and	O
tolerability	O
of	O
dilmapimod	O
,	O
a	O
novel	O
p38	O
mitogen	B-CHED
-	O
activated	O
protein	B-CHED
kinase	I-CHED
inhibitor	I-CHED
,	O
in	O
patients	O
at	O
risk	O
for	O
developing	O
acute	O
respiratory	O
distress	O
syndrome	O
admitted	O
with	O
an	O
Injury	O
Severity	O
Score	O
more	O
than	O
16	O
,	O
excluding	O
head	O
trauma	O
.	O

Among	O
these	O
,	O
the	O
N	O
protein	B-CHED
is	O
known	O
to	O
be	O
the	O
most	O
abundant	O
and	O
multifunctional	O
viral	O
component	O
.	O

We	O
then	O
assessed	O
alterations	O
in	O
production	O
levels	O
of	O
proteins	B-CHED
in	O
the	O
N	O
-	O
expressing	O
PK	O
(	O
PK	O
-	O
PDCoV	O
-	O
N	O
)	O
cells	O
at	O
different	O
time	O
points	O
by	O
means	O
of	O
proteomic	O
analysis	O
.	O

TITLE	O
:	O
Serotonin	B-CHED
Receptor	O
Agonist	B-CHED
5	B-CHED
-	I-CHED
Nonyloxytryptamine	I-CHED
Alters	O
the	O
Kinetics	O
of	O
Reovirus	O
Cell	O
Entry	O
.	O

Severe	O
GBS	O
was	O
defined	O
as	O
the	O
occurrence	O
of	O
respiratory	O
failure	O
,	O
central	O
nervous	O
system	O
(	O
CNS	B-CHED
)	O
involvement	O
,	O
or	O
death	O
.	O

ABSTRACT	O
:	O
To	O
explore	O
the	O
possibility	O
of	O
developing	O
a	O
vaccine	O
against	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
infection	O
,	O
a	O
recombinant	O
swinepox	O
virus	O
(	O
rSPV	O
-	O
SA	O
)	O
expressing	O
a	O
TGEV	O
protective	O
antigen	B-CHED
has	O
been	O
constructed	O
.	O

ABSTRACT	O
:	O
To	O
assess	O
relationships	O
between	O
xanthine	B-CHED
oxidase	O
(	O
XOD	O
)	O
and	O
nephropathogenic	O
infectious	O
bronchitis	O
virus	O
(	O
NIBV	O
)	O
infection	O
,	O
240	O
growing	O
layers	O
(	O
35	O
days	O
old	O
)	O
were	O
randomly	O
divided	O
into	O
two	O
groups	O
(	O
infected	O
and	O
control	O
)	O
of	O
120	O
chickens	O
each	O
.	O

The	O
results	O
indicated	O
that	O
NIBV	O
infection	O
could	O
cause	O
the	O
increases	O
of	O
renal	O
XOD	O
gene	O
transcription	O
and	O
serum	O
XOD	O
activity	O
,	O
leading	O
to	O
hyperuricemia	O
and	O
reduction	O
of	O
antioxidants	B-CHED
in	O
the	O
body	O
.	O

TITLE	O
:	O
Pre	O
-	O
and	O
postexposure	O
efficacy	O
of	O
fully	O
human	O
antibodies	O
against	O
Spike	O
protein	B-CHED
in	O
a	O
novel	O
humanized	O
mouse	O
model	O
of	O
MERS	O
-	O
CoV	O
infection	O
.	O

The	O
major	O
causes	O
of	O
MERS	O
included	O
infection	O
,	O
antiepileptic	B-CHED
drug	O
withdrawal	O
,	O
high	O
-	O
altitude	O
cerebral	O
edema	O
,	O
and	O
cesarean	O
section	O
(	O
C	O
-	O
section	O
).	O

Steroids	B-CHED
and	O
IVIG	O
were	O
the	O
most	O
commonly	O
used	O
therapy	O
for	O
MERS	O
,	O
but	O
their	O
efficiency	O
remained	O
questionable	O
.	O

Nevertheless	O
,	O
lesions	O
exhibited	O
sustained	O
expansion	O
providing	O
a	O
model	O
of	O
dysregulated	O
white	O
matter	O
injury	O
temporally	O
remote	O
from	O
the	O
acute	O
CNS	B-CHED
insult	O
.	O

The	O
early	O
phase	O
occurs	O
temporally	O
with	O
the	O
onset	O
of	O
lung	O
injury	O
,	O
is	O
driven	O
by	O
inflammation	O
and	O
disuse	O
,	O
and	O
is	O
marked	O
predominantly	O
by	O
muscle	O
atrophy	O
from	O
increased	O
protein	B-CHED
degradation	O
.	O

However	O
,	O
the	O
precise	O
functions	O
of	O
the	O
CoV	O
E	O
protein	B-CHED
during	O
infection	O
are	O
still	O
enigmatic	O
.	O

We	O
previously	O
reported	O
that	O
the	O
hydrophobic	O
domain	O
of	O
the	O
IBV	O
E	O
protein	B-CHED
,	O
a	O
putative	O
viroporin	O
,	O
causes	O
disruption	O
of	O
the	O
mammalian	O
secretory	O
pathway	O
when	O
exogenously	O
expressed	O
in	O
cells	O
.	O

Discovery	O
of	O
two	O
forms	O
of	O
CoV	O
E	O
protein	B-CHED
will	O
provide	O
additional	O
targets	O
for	O
antiviral	B-CHED
therapeutics	O
.	O

ABSTRACT	O
:	O
Myd88	O
signaling	O
is	O
critical	O
to	O
the	O
control	O
of	O
numerous	O
central	O
nervous	O
system	O
(	O
CNS	B-CHED
)	O
infections	O
by	O
promoting	O
both	O
innate	O
and	O
adaptive	O
immune	O
responses	O
.	O

Myd88	O
deficiency	O
also	O
specifically	O
blunted	O
myeloid	O
and	O
CD4	O
T	O
cell	O
recruitment	O
into	O
the	O
CNS	B-CHED
without	O
affecting	O
CD8	O
T	O
cells	O
.	O

Ineffective	O
virus	O
control	O
indeed	O
correlated	O
most	O
prominently	O
with	O
reduced	O
antiviral	B-CHED
IFN	O
-	O
γ	O
in	O
the	O
CNS	B-CHED
of	O
Myd88	O
(-/-)	O
mice	O
.	O

TITLE	O
:	O
Methylene	B-CHED
blue	I-CHED
treatment	O
for	O
cytokine	O
release	O
syndrome	O
-	O
associated	O
vasoplegia	O
following	O
a	O
renal	O
transplant	O
with	O
rATG	O
infusion	O
:	O
A	O
case	O
report	O
and	O
literature	O
review	O
.	O

Methylene	B-CHED
blue	I-CHED
(	O
MB	O
)	O
is	O
a	O
direct	O
inhibitor	B-CHED
of	O
iNOS	O
and	O
GC	O
and	O
has	O
been	O
used	O
as	O
an	O
effective	O
treatment	O
for	O
VS	O
following	O
cardiothoracic	O
surgery	O
.	O

Of	O
282	O
patients	O
(	O
mean	O
age	O
,	O
51	O
.	O
6	O
years	O
;	O
45	O
%	O
women	O
;	O
77	O
%	O
white	O
)	O
enrolled	O
in	O
Albuterol	B-CHED
for	O
Treatment	O
of	O
Acute	O
Lung	O
Injury	O
,	O
28	O
(	O
10	O
%)	O
developed	O
new	O
-	O
onset	O
AF	O
during	O
the	O
study	O
.	O

We	O
did	O
not	O
identify	O
associations	O
between	O
new	O
-	O
onset	O
AF	O
and	O
baseline	O
central	O
venous	O
pressure	O
,	O
plasma	O
levels	O
of	O
troponin	O
I	O
,	O
epinephrine	B-CHED
,	O
interleukin	O
6	O
,	O
or	O
interleukin	O
8	O
.	O

Our	O
findings	O
contribute	O
to	O
the	O
proposal	O
that	O
IBV	O
infection	O
induces	O
an	O
increase	O
in	O
the	O
messenger	B-CHED
RNA	I-CHED
(	O
mRNA	B-CHED
)	O
expression	O
of	O
some	O
AvBDs	O
and	O
TLRs	O
,	O
which	O
suggests	O
that	O
AvBDs	O
may	O
play	O
significant	O
roles	O
in	O
the	O
resistance	O
of	O
chickens	O
to	O
IBV	O
replication	O
.	O

Although	O
the	O
mean	O
arterial	O
pressure	O
was	O
similar	O
between	O
these	O
two	O
groups	O
,	O
the	O
median	O
pH	O
and	O
the	O
bicarbonate	B-CHED
ion	I-CHED
(	O
HCO	O
(	O
3	O
)(-))	O
were	O
significantly	O
lower	O
in	O
the	O
NPE	O
group	O
than	O
in	O
the	O
non	O
-	O
NPE	O
group	O
(	O
pH	O
:	O
7	O
.	O
32	O
vs	O
.	O
7	O
.	O
39	O
,	O
P	O
=	O
0	O
.	O
002	O
;	O
HCO	O
(	O
3	O
)(-),	O
20	O
.	O
6	O
mmol	O
/	O
L	O
vs	O
.	O
22	O
.	O
7	O
mmol	O
/	O
L	O
,	O
P	O
=	O
0	O
.	O
01	O
).	O

Moreover	O
,	O
our	O
data	O
demonstrated	O
that	O
CQ	O
increased	O
lysosome	O
-	O
associated	O
membrane	O
protein	B-CHED
-	O
1	O
,	O
lysosome	O
-	O
associated	O
membrane	O
protein	B-CHED
-	O
2	O
and	O
light	O
chain	O
-	O
3	O
expressions	O
,	O
suggesting	O
that	O
the	O
mechanism	O
by	O
which	O
CQ	O
rescues	O
PQ	O
-	O
induced	O
cytotoxicity	O
may	O
be	O
through	O
protection	O
of	O
the	O
lysosomal	O
membrane	O
or	O
up	O
-	O
regulation	O
of	O
autophagy	O
.	O

TITLE	O
:	O
Contrasted	O
patterns	O
of	O
variation	O
and	O
evolutionary	O
convergence	O
at	O
the	O
antiviral	B-CHED
OAS1	O
gene	O
in	O
old	O
world	O
primates	O
.	O

The	O
N	O
-	O
terminal	O
exoribonuclease	O
(	O
ExoN	O
)	O
domain	O
plays	O
a	O
proofreading	O
role	O
for	O
prevention	O
of	O
lethal	O
mutagenesis	O
,	O
and	O
the	O
C	O
-	O
terminal	O
domain	O
functions	O
as	O
a	O
(	O
guanine	B-CHED
-	O
N7	O
)	O
methyl	B-CHED
transferase	O
(	O
N7	O
-	O
MTase	O
)	O
for	O
mRNA	B-CHED
capping	O
.	O

Then	O
three	O
virus	O
batches	O
from	O
independent	O
virus	O
propagations	O
were	O
harvested	O
at	O
interval	O
of	O
16	O
-	O
20	O
h	O
and	O
serial	O
-	O
diluted	O
;	O
The	O
correlation	O
between	O
the	O
calculated	O
titer	O
and	O
the	O
results	O
obtained	O
by	O
Virus	O
Counter	B-CHED
were	O
better	O
than	O
those	O
obtained	O
by	O
using	O
the	O
plaque	O
assay	O
.	O

Clinical	O
background	O
,	O
sedatives	B-CHED
,	O
failure	O
rate	O
of	O
sedation	O
,	O
and	O
complications	O
were	O
evaluated	O
by	O
1	O
)	O
sedative	B-CHED
methods	O
(	O
intermittent	O
only	O
,	O
switched	O
to	O
continuous	O
,	O
or	O
initially	O
continuous	O
)	O
and	O
2	O
)	O
code	O
status	O
(	O
do	O
-	O
not	O
-	O
intubate	O
[	O
DNI	O
]	O
or	O
non	O
-	O
DNI	O
).	O

RESULTS	O
:	O
Of	O
2659	O
women	O
who	O
met	B-CHED
criteria	O
for	O
inclusion	O
in	O
this	O
analysis	O
,	O
8	O
.	O
6	O
%	O
of	O
women	O
experienced	O
serious	O
maternal	O
complications	O
.	O

CONCLUSIONS	O
:	O
In	O
patients	O
with	O
severe	O
ARDS	O
,	O
applicating	O
2	O
-	O
4	O
hours	O
validity	O
of	O
prone	O
position	O
ventilation	O
significantly	O
improves	O
the	O
pulmonary	O
ventilation	O
,	O
more	O
than	O
4	O
h	O
PPV	B-CHED
do	O
not	O
better	O
for	O
patients	O
probably	O
.	O

The	O
control	O
group	O
received	O
an	O
injection	O
of	O
octreotide	B-CHED
injection	O
while	O
the	O
observation	O
group	O
had	O
a	O
combination	O
of	O
ulinastatin	O
and	O
octreotide	B-CHED
.	O

After	O
treatment	O
,	O
the	O
levels	O
of	O
blood	O
amylase	O
,	O
white	O
blood	O
cell	O
(	O
WBC	O
),	O
C	O
-	O
reactive	O
protein	B-CHED
(	O
CRP	O
)	O
and	O
interleukin	O
6	O
(	O
IL	O
-	O
6	O
)	O
of	O
observation	O
group	O
(	O
107	O
.	O
2	O
±	O
9	O
.	O
1	O
U	O
/	O
L	O
,	O
6	O
.	O
2	O
±	O
1	O
.	O
0	O
×	O
10	O
(	O
9	O
)/	O
L	O
,	O
7	O
.	O
3	O
±	O
3	O
.	O
4	O
mg	O
/	O
L	O
,	O
28	O
.	O
3	O
±	O
4	O
.	O
3	O
pg	O
/	O
ml	O
)	O
were	O
significantly	O
lower	O
than	O
those	O
of	O
control	O
group	O
(	O
430	O
.	O
8	O
±	O
20	O
.	O
2	O
)	O
U	O
/	O
L	O
,	O
(	O
11	O
.	O
2	O
±	O
1	O
.	O
2	O
)	O
×	O
10	O
(	O
9	O
)/	O
L	O
,	O
(	O
16	O
.	O
3	O
±	O
5	O
.	O
2	O
)	O
mg	O
/	O
L	O
,	O
(	O
45	O
.	O
3	O
±	O
5	O
.	O
9	O
)	O
ng	O
/	O
L	O
,	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

A	O
sepsis	O
mortality	O
prediction	O
formula	O
(	O
AIIMS	O
Sepsis	O
Score	O
)	O
based	O
on	O
SAPS	O
II	O
,	O
SAPS	O
III	O
,	O
and	O
SOFA	O
scores	O
and	O
hemoglobin	B-CHED
has	O
greater	O
predictive	O
power	O
than	O
these	O
scoring	O
methods	O
individually	O
.	O

While	O
serum	O
total	O
protein	B-CHED
was	O
increased	O
in	O
only	O
17	O
.	O
5	O
%	O
of	O
cats	O
,	O
hyperglobulinaemia	O
was	O
documented	O
in	O
89	O
.	O
1	O
%.	O

The	O
lyophilized	O
FIV	O
RT	O
-	O
iiPCR	O
reagent	B-CHED
,	O
deployed	O
on	O
a	O
user	O
-	O
friendly	O
portable	O
device	O
,	O
has	O
potential	O
utility	O
for	O
rapid	O
and	O
easy	O
point	O
-	O
of	O
-	O
need	O
detection	O
of	O
FIV	O
in	O
cats	O
.	O

To	O
date	O
,	O
there	O
are	O
no	O
effective	O
vaccines	O
or	O
antiviral	B-CHED
treatments	O
available	O
that	O
are	O
capable	O
of	O
limiting	O
the	O
pathogenesis	O
of	O
any	O
human	O
coronaviral	O
infection	O
.	O

In	O
order	O
to	O
elucidate	O
the	O
structural	O
reasons	O
for	O
such	O
potent	O
HKU4	O
-	O
CoV	O
3CL	O
(	O
pro	B-CHED
)	O
inhibition	O
by	O
the	O
peptidomimetics	B-CHED
having	O
the	O
22A	O
backbone	O
,	O
we	O
determined	O
the	O
X	O
-	O
ray	O
structures	O
of	O
HKU4	O
-	O
CoV	O
3CL	O
(	O
pro	B-CHED
)	O
in	O
complex	O
with	O
three	O
peptidomimetic	B-CHED
inhibitors	B-CHED
.	O

We	O
therefore	O
investigated	O
the	O
effects	O
of	O
stress	O
index	O
guided	O
PEEP	B-CHED
titration	O
on	O
pulmonary	O
mechanics	O
and	O
hemodynamics	O
in	O
the	O
prone	O
position	O
in	O
a	O
piglet	O
acute	O
lung	O
injury	O
model	O
.	O

TITLE	O
:	O
Structure	O
-	O
activity	O
relationship	O
studies	O
on	O
quinoxalin	O
-	O
2	O
(	O
1H	O
)-	O
one	O
derivatives	O
containing	O
thiazol	O
-	O
2	O
-	O
amine	B-CHED
against	O
hepatitis	O
C	O
virus	O
leading	O
to	O
the	O
discovery	O
of	O
BH6870	O
.	O

SARs	O
analysis	O
indicated	O
that	O
quinoxalin	O
-	O
2	O
(	O
1H	O
)-	O
one	O
containing	O
a	O
4	O
-	O
aryl	O
-	O
substituted	O
thiazol	O
-	O
2	O
-	O
amine	B-CHED
moiety	O
was	O
optimal	O
for	O
antiviral	B-CHED
activity	O
.	O

Incorporation	O
of	O
more	O
than	O
one	O
halogen	B-CHED
(	O
fluorine	B-CHED
or	O
chlorine	B-CHED
atom	I-CHED
)	O
or	O
a	O
strong	O
electron	O
-	O
withdrawing	O
group	O
on	O
the	O
benzene	B-CHED
ring	I-CHED
of	O
the	O
thiazole	B-CHED
-	O
phenyl	B-CHED
moiety	O
might	O
reduce	O
electron	O
atmosphere	O
density	O
further	O
and	O
resulted	O
in	O
a	O
dramatical	O
loss	O
of	O
activity	O
.	O

BH6870	O
(	O
36	O
),	O
showing	O
higher	O
antiviral	B-CHED
potency	O
and	O
a	O
good	O
cell	O
safety	O
index	O
,	O
was	O
identified	O
.	O

It	O
is	O
the	O
wide	O
application	O
of	O
this	O
technology	O
that	O
makes	O
breakthrough	O
in	O
SDB	O
treatment	O
,	O
and	O
has	O
given	O
rise	O
to	O
a	O
new	O
interdisciplinary	O
area	O
sleep	O
medicine	B-CHED
.	O

ABSTRACT	O
:	O
Hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
enters	O
human	O
hepatocytes	O
through	O
a	O
multistep	O
mechanism	O
involving	O
,	O
among	O
other	O
host	O
proteins	B-CHED
,	O
the	O
virus	O
receptor	O
CD81	O
.	O

These	O
results	O
demonstrate	O
the	O
use	O
of	O
quantitative	O
proteomics	O
to	O
elucidate	O
pathogen	O
entry	O
and	O
underscore	O
the	O
importance	O
of	O
host	O
protein	B-CHED
-	O
protein	B-CHED
interactions	O
during	O
HCV	O
invasion	O
.	O

Alogliptin	O
is	O
mainly	O
metabolized	O
by	O
cytochrome	B-CHED
P450	I-CHED
(	O
CYP2D6	O
)	O
and	O
CYP3A4	O
.	O

Efforts	O
focused	O
solely	O
on	O
the	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
the	O
viral	O
Spike	O
(	O
S	O
)	O
glycoprotein	B-CHED
may	O
not	O
optimize	O
neutralizing	O
antibody	O
(	O
NAb	O
)	O
responses	O
.	O

However	O
,	O
two	O
distinct	O
features	O
were	O
observed	O
in	O
the	O
CCoV	O
-	O
I	O
genome	O
:	O
(	O
i	O
)	O
the	O
presence	O
of	O
an	O
additional	O
ORF	O
between	O
the	O
spike	O
(	O
S	O
)	O
protein	B-CHED
gene	O
and	O
ORF3a	O
;	O
(	O
ii	O
)	O
the	O
diversity	O
of	O
the	O
S	O
protein	B-CHED
,	O
which	O
is	O
more	O
closely	O
related	O
to	O
that	O
of	O
feline	O
coronavirus	O
type	O
I	O
and	O
presents	O
a	O
furin	O
cleavage	O
site	O
.	O

ABSTRACT	O
:	O
To	O
review	O
clinical	O
outcomes	O
data	O
for	O
patients	O
treated	O
with	O
oral	O
ribavirin	B-CHED
for	O
noninfluenza	O
respiratory	O
viral	O
infections	O
(	O
NIRVIs	O
).	O

The	O
mortality	O
rate	O
ranged	O
from	O
0	O
%	O
to	O
31	O
%	O
in	O
malignancy	O
/	O
stem	O
cell	O
transplant	O
recipients	O
treated	O
with	O
oral	O
ribavirin	B-CHED
,	O
and	O
1	O
/	O
108	O
(	O
0	O
.	O
9	O
%)	O
ribavirin	B-CHED
-	O
treated	O
lung	O
transplant	O
recipients	O
died	O
at	O
30	O
days	O
.	O

Minocycline	B-CHED
is	O
commonly	O
used	O
for	O
pneumonia	O
,	O
acute	O
bronchitis	O
,	O
urinary	O
tract	O
infections	O
,	O
and	O
acne	O
and	O
is	O
likely	O
the	O
cause	O
of	O
AEP	O
in	O
our	O
patient	O
.	O

Only	O
a	O
few	O
amino	O
-	O
acid	O
changes	O
in	O
the	O
S1	O
subunit	O
of	O
wild	O
-	O
type	O
IBVS	O
proteins	B-CHED
may	O
result	O
in	O
mutants	O
unaffected	O
by	O
current	O
vaccines	O
.	O

The	O
deduced	O
protein	B-CHED
sequence	O
identities	O
ranged	O
from	O
29	O
.	O
7	O
%	O
(	O
between	O
IBV	O
/	O
Morocco	O
/	O
38	O
and	O
Egypt	O
SCU	O
-	O
14	O
/	O
2013	O
-	O
1	O
)	O
to	O
78	O
.	O
2	O
%	O
(	O
between	O
IBV	O
/	O
Morocco	O
/	O
01	O
and	O
Spain	O
/	O
05	O
/	O
866	O
).	O

RESULTS	O
:	O
The	O
three	O
isolates	O
were	O
found	O
genetically	O
highly	O
distant	O
from	O
known	O
avian	O
IBV	O
based	O
on	O
partial	O
sequences	O
of	O
their	O
S1	O
genes	O
:	O
gammaCoV	O
/	O
chicken	O
/	O
Morocco	O
/	O
I01	O
/	O
2011	O
(	O
IBV	O
/	O
Morocco	O
/	O
01	O
),	O
gammaCoV	O
/	O
chicken	O
/	O
Morocco	O
/	O
I30	O
/	O
2010	O
(	O
IBV	O
/	O
Morocco	O
/	O
30	O
),	O
and	O
gammaCoV	O
/	O
chicken	O
/	O
Morocco	O
/	O
I38	O
/	O
2013	O
(	O
IBV	O
/	O
Morocco	O
/	O
38	O
),	O
nucleotide	B-CHED
sequence	O
identities	O
reached	O
89	O
.	O
5	O
%	O
to	O
90	O
.	O
9	O
%	O
among	O
the	O
three	O
isolates	O
.	O

Immunoadhesins	O
that	O
incorporate	O
normal	O
cellular	O
receptors	O
for	O
viruses	O
or	O
bacterial	O
toxins	B-CHED
hold	O
great	O
,	O
but	O
as	O
yet	O
unrealized	O
,	O
potential	O
for	O
treating	O
infectious	O
disease	O
.	O

TITLE	O
:	O
Crystallographic	O
analysis	O
of	O
the	O
N	O
-	O
terminal	O
domain	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
nucleocapsid	O
protein	B-CHED
.	O

Phylogenetic	O
analysis	O
of	O
complete	O
genome	O
and	O
S	O
protein	B-CHED
sequences	O
of	O
PDCoV	O
/	O
CHJXNI2	O
/	O
2015	O
demonstrated	O
that	O
it	O
was	O
most	O
closely	O
related	O
to	O
Hong	O
Kong	O
and	O
US	O
PDCoVs	O
.	O

Ribavirin	B-CHED
2	O
.	O
0	O
g	O
was	O
given	O
as	O
the	O
first	O
dose	O
,	O
and	O
was	O
switched	O
to	O
600	O
mg	O
every	O
8	O
h	O
(	O
q8h	O
),	O
and	O
it	O
was	O
reduced	O
to	O
600	O
mg	O
q12h	O
after	O
10	O
days	O
,	O
and	O
extenuated	O
since	O
the	O
13th	O
day	O
.	O

TITLE	O
:	O
[	O
ANTIMICROBIAL	B-CHED
ACTIVITY	O
OF	O
POLYAZOLIDINAMMONIUM	O
,	O
MODIFIED	O
WITH	O
HYDRATE	B-CHED
-	O
IONS	B-CHED
OF	O
IODINE	B-CHED
].	O

Further	O
,	O
the	O
nephropathogenicity	O
determinants	O
might	O
be	O
located	O
on	O
the	O
1a	O
,	O
spike	O
,	O
M	O
and	O
accessory	O
proteins	B-CHED
(	O
3a	O
,	O
3b	O
,	O
4b	O
,	O
4c	O
,	O
5a	O
,	O
5b	O
and	O
6b	O
).	O

TITLE	O
:	O
Retinal	B-CHED
Hemorrhages	O
in	O
Severe	O
Non	O
-	O
cerebral	O
Plasmodium	O
vivax	O
Malaria	O
in	O
an	O
Adult	O
.	O

ABSTRACT	O
:	O
Tracheobronchial	O
stenoses	O
(	O
TBSs	O
)	O
are	O
potentially	O
severe	O
manifestations	O
of	O
granulomatosis	O
with	O
polyangiitis	O
(	O
Wegener	O
'	O
s	O
)	O
(	O
GPA	O
)	O
that	O
usually	O
respond	O
poorly	O
to	O
corticosteroids	B-CHED
and	O
immunosuppressive	B-CHED
agents	I-CHED
.	O

However	O
,	O
cyclophosphamide	B-CHED
seemed	O
to	O
effectively	O
treat	O
BSs	O
,	O
but	O
not	O
SGS	O
,	O
and	O
rituximab	O
may	O
be	O
of	O
interest	O
for	O
SGS	O
management	O
.	O

Positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	B-CHED
)	O
was	O
14	O
[	O
10	O
,	O
17	O
]	O
cmH2O	O
.	O

There	O
were	O
no	O
detrimental	O
effects	O
in	O
terms	O
of	O
lung	O
mechanics	O
,	O
auto	O
-	O
PEEP	B-CHED
generation	O
,	O
hemodynamics	O
,	O
or	O
gas	O
exchange	O
.	O

Molecular	O
characterisation	O
of	O
those	O
viruses	O
revealed	O
some	O
nucleotide	B-CHED
and	O
aminoacid	O
differences	O
in	O
relation	O
to	O
reference	O
strains	O
.	O

In	O
particular	O
,	O
SARSr	O
-	O
Rs	O
-	O
BatCoVs	O
from	O
Chinese	O
horseshoe	O
bats	O
(	O
Rhinolophus	O
sinicus	O
)	O
exhibited	O
<	O
40	O
%	O
amino	B-CHED
acid	I-CHED
identities	O
to	O
human	O
/	O
civet	O
SARS	O
-	O
CoV	O
in	O
the	O
ORF8	O
protein	B-CHED
.	O

Our	O
findings	O
offer	O
insight	O
into	O
the	O
evolutionary	O
origin	O
of	O
SARS	O
-	O
CoV	O
ORF8	O
protein	B-CHED
,	O
which	O
was	O
likely	O
acquired	O
from	O
SARSr	O
-	O
CoVs	O
of	O
greater	O
horseshoe	O
bats	O
through	O
recombination	O
.	O

The	O
genome	O
sequences	O
of	O
Tokachi09	O
,	O
Obihiro12	O
-	O
1	O
and	O
Obihiro12	O
-	O
2	O
were	O
30	O
,	O
782	O
,	O
30	O
,	O
916	O
and	O
30	O
,	O
916	O
nucleotides	B-CHED
in	O
length	O
,	O
respectively	O
,	O
excluding	O
the	O
3	O
'-	O
poly	O
(	O
A	O
)	O
tails	O
.	O

A	O
multi	O
-	O
fragment	O
antigen	B-CHED
,	O
termed	O
BE	O
,	O
which	O
was	O
composed	O
of	O
eight	O
antigenic	O
fragments	O
selected	O
from	O
the	O
three	O
major	O
proteins	B-CHED
(	O
S	O
,	O
M	O
,	O
and	O
N	O
)	O
of	O
IBV	O
,	O
was	O
expressed	O
in	O
Escherichia	O
coli	O
.	O

The	O
entire	O
protein	B-CHED
had	O
a	O
molecular	O
weight	O
of	O
61	O
.	O
5	O
kDa	O
.	O

TITLE	O
:	O
Use	O
of	O
Isotope	O
-	O
Edited	O
FTIR	O
to	O
Derive	O
a	O
Backbone	O
Structure	O
of	O
a	O
Transmembrane	O
Protein	B-CHED
.	O

Taken	O
together	O
,	O
we	O
show	O
that	O
isotope	O
-	O
edited	O
FTIR	O
is	O
a	O
powerful	O
tool	O
to	O
analyze	O
small	O
membrane	O
proteins	B-CHED
in	O
their	O
native	O
environment	O
,	O
enabling	O
us	O
to	O
relate	O
the	O
unusual	O
structure	O
of	O
the	O
SARS	O
E	O
protein	B-CHED
to	O
its	O
function	O
.	O

TITLE	O
:	O
Porcine	O
epidemic	O
diarrhea	O
virus	O
inhibits	O
dsRNA	B-CHED
-	O
induced	O
interferon	O
-	O
β	O
production	O
in	O
porcine	O
intestinal	O
epithelial	O
cells	O
by	O
blockade	O
of	O
the	O
RIG	O
-	O
I	O
-	O
mediated	O
pathway	O
.	O

As	O
the	O
key	O
IFN	O
-	O
β	O
transcription	O
factors	O
,	O
we	O
found	O
that	O
dsRNA	B-CHED
-	O
induced	O
activation	O
of	O
IFN	O
regulatory	O
factor	O
3	O
(	O
IRF	O
-	O
3	O
)	O
was	O
inhibited	O
after	O
PEDV	O
infection	O
,	O
but	O
not	O
nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	O
-	O
κB	O
).	O

Taken	O
together	O
,	O
our	O
data	O
demonstrated	O
for	O
the	O
first	O
time	O
that	O
PEDV	O
infection	O
of	O
its	O
target	O
cell	O
line	O
,	O
IECs	O
,	O
inhibited	O
dsRNA	B-CHED
-	O
mediated	O
IFN	O
-	O
β	O
production	O
by	O
blocking	O
the	O
activation	O
of	O
IPS	O
-	O
1	O
in	O
RIG	O
-	O
I	O
-	O
mediated	O
pathway	O
.	O

ABSTRACT	O
:	O
Naloxone	B-CHED
is	O
commonly	O
administered	O
in	O
emergency	O
department	O
(	O
ED	O
)	O
to	O
reverse	O
opioid	O
intoxication	O
.	O

ED	O
patients	O
with	O
moderate	O
to	O
severe	O
opioid	O
-	O
induced	O
ventilatory	O
depression	O
can	O
be	O
reversed	O
using	O
0	O
.	O
04	O
mg	O
IV	O
naloxone	B-CHED
with	O
appropriate	O
dose	O
titration	O
.	O

The	O
most	O
effective	O
and	O
safest	O
dose	O
for	O
yielding	O
a	O
clinically	O
significant	O
increase	O
in	O
PaO2	O
and	O
reduction	O
in	O
pulmonary	O
artery	O
pressure	O
(	O
PAP	B-CHED
)	O
appears	O
to	O
be	O
20	O
-	O
30	O
ng	O
/	O
kg	O
/	O
min	O
in	O
adults	O
and	O
30	O
ng	O
/	O
kg	O
/	O
min	O
in	O
pediatric	O
patients	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
clinical	O
results	O
of	O
the	O
management	O
of	O
gastric	O
varices	O
by	O
balloon	O
-	O
occluded	O
retrograde	O
transvenous	O
obliteration	O
with	O
polidocanol	B-CHED
foam	O
versus	O
ethanolamine	B-CHED
oleate	B-CHED
.	O

Polidocanol	B-CHED
foam	O
can	O
achieve	O
obliteration	O
of	O
gastric	O
varices	O
comparable	O
to	O
that	O
of	O
ethanolamine	B-CHED
oleate	B-CHED
but	O
with	O
a	O
significantly	O
lower	O
sclerosant	O
dose	O
and	O
reduced	O
risk	O
of	O
hemolysis	O
-	O
induced	O
complications	O
and	O
harmful	O
reactions	O
,	O
including	O
pain	O
and	O
fever	O
.	O

No	O
postprocedural	O
rebleeding	O
from	O
the	O
gastric	O
varices	O
was	O
observed	O
during	O
a	O
median	O
follow	O
-	O
up	O
time	O
of	O
39	O
.	O
5	O
months	O
after	O
procedures	O
with	O
ethanolamine	B-CHED
oleate	B-CHED
and	O
34	O
months	O
after	O
procedures	O
with	O
polidocanol	B-CHED
foam	O
.	O

Notably	O
,	O
the	O
N	O
-	O
terminal	O
halves	O
of	O
the	O
capsid	O
proteins	B-CHED
of	O
DcAstV	O
shared	O
≤	O
85	O
%	O
amino	B-CHED
acid	I-CHED
identity	O
,	O
but	O
the	O
C	O
-	O
terminal	O
halves	O
only	O
shared	O
≤	O
49	O
%	O
amino	B-CHED
acid	I-CHED
identity	O
compared	O
with	O
the	O
corresponding	O
proteins	B-CHED
in	O
other	O
AstVs	O
.	O

We	O
studied	O
the	O
novel	O
use	O
of	O
ECMO	O
in	O
the	O
management	O
of	O
a	O
subset	O
of	O
patients	O
with	O
AlP	B-CHED
poisoning	O
.	O

Therefore	O
,	O
ECMO	O
might	O
be	O
considered	O
as	O
a	O
bridge	O
therapy	O
for	O
patients	O
with	O
intractable	O
cardiorespiratory	O
failure	O
caused	O
by	O
AlP	B-CHED
poisoning	O
who	O
are	O
not	O
responding	O
to	O
conventional	O
treatment	O
.	O

Bioinformatics	O
analysis	O
of	O
this	O
non	O
-	O
structural	O
protein	B-CHED
has	O
now	O
revealed	O
a	O
nidoviral	O
signature	O
domain	O
(	O
genetic	O
marker	O
)	O
that	O
is	O
N	O
-	O
terminally	O
adjacent	O
to	O
the	O
RdRp	O
and	O
has	O
no	O
apparent	O
homologs	O
elsewhere	O
.	O

While	O
SARS	O
-	O
CoV	O
nsp1	O
is	O
localized	O
exclusively	O
in	O
the	O
cytoplasm	O
and	O
binds	O
to	O
the	O
40S	O
ribosomal	O
subunit	O
to	O
gain	O
access	O
to	O
translating	O
mRNAs	O
,	O
MERS	O
-	O
CoV	O
nsp1	O
was	O
distributed	O
in	O
both	O
the	O
nucleus	B-CHED
and	O
the	O
cytoplasm	O
and	O
did	O
not	O
bind	O
stably	O
to	O
the	O
40S	O
subunit	O
,	O
suggesting	O
a	O
distinctly	O
different	O
mode	O
of	O
targeting	O
translating	O
mRNAs	O
.	O

This	O
study	O
explored	O
the	O
effects	O
of	O
PPV	B-CHED
on	O
the	O
respiratory	O
and	O
circulatory	O
mechanics	O
of	O
H7N9	O
-	O
infected	O
patients	O
with	O
severe	O
ARDS	O
.	O

Additionally	O
,	O
there	O
were	O
no	O
significant	O
differences	O
in	O
the	O
mean	O
values	O
for	O
arterial	O
pressure	O
(	O
MAP	O
),	O
cardiac	O
index	O
(	O
CI	O
),	O
central	O
venous	O
pressure	O
(	O
CVP	O
),	O
heart	O
rate	O
(	O
HR	O
),	O
lactic	B-CHED
acid	I-CHED
(	O
LAC	B-CHED
)	O
levels	O
or	O
the	O
doses	O
of	O
norepinephrine	B-CHED
(	O
NE	O
)	O
administered	O
when	O
compared	O
pre	O
-	O
PPV	B-CHED
,	O
post	O
-	O
PPV	B-CHED
,	O
and	O
post	O
-	O
SPV	O
.	O

We	O
present	O
data	O
on	O
the	O
effect	O
of	O
cyclophilin	O
A	O
single	O
nucleotide	B-CHED
polymorphism	O
mutants	O
on	O
the	O
replication	O
of	O
human	O
CoV	O
-	O
229E	O
demonstrating	O
the	O
requirement	O
of	O
proper	O
cyclophilin	O
A	O
function	O
for	O
virus	O
propagation	O
.	O

These	O
deposits	O
stained	O
pale	O
red	O
with	O
periodic	B-CHED
acid	I-CHED
-	O
methenamine	B-CHED
silver	B-CHED
stain	O
and	O
red	O
with	O
Masson	O
trichrome	O
stain	O
,	O
and	O
were	O
also	O
observed	O
in	O
the	O
mesangial	O
matrix	O
.	O

TITLE	O
:	O
Phage	O
display	O
technique	O
identifies	O
the	O
interaction	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
open	O
reading	O
frame	O
6	O
protein	B-CHED
with	O
nuclear	O
pore	O
complex	O
interacting	O
protein	B-CHED
NPIPB3	O
in	O
modulating	O
Type	O
I	O
interferon	O
antagonism	O
.	O

After	O
the	O
fifth	O
round	O
of	O
biopanning	O
with	O
Escherichia	O
coli	O
-	O
synthesized	O
ORF6	O
-	O
His	O
tagged	O
protein	B-CHED
,	O
the	O
relative	O
binding	O
affinity	O
of	O
phage	O
clones	O
to	O
ORF6	O
was	O
determined	O
using	O
direct	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
.	O

TITLE	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
E	O
protein	B-CHED
transports	O
calcium	B-CHED
ions	I-CHED
and	O
activates	O
the	O
NLRP3	O
inflammasome	O
.	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
envelope	O
(	O
E	O
)	O
protein	B-CHED
is	O
a	O
viroporin	O
involved	O
in	O
virulence	O
.	O

Interestingly	O
,	O
E	O
protein	B-CHED
IC	O
activity	O
boosted	O
the	O
activation	O
of	O
the	O
NLRP3	O
inflammasome	O
,	O
leading	O
to	O
IL	O
-	O
1β	O
overproduction	O
.	O

We	O
aim	O
to	O
investigate	O
the	O
prevalence	O
and	O
age	O
pattern	O
of	O
viral	O
co	O
-	O
infection	O
in	O
children	O
hospitalized	O
with	O
lower	O
tract	O
acute	O
respiratory	O
infection	O
(	O
LT	O
-	O
ARI	B-CHED
),	O
using	O
molecular	O
techniques	O
.	O

Collectively	O
,	O
these	O
results	O
demonstrated	O
a	O
therapeutic	O
effect	O
of	O
targeting	O
Siglec	O
receptors	O
with	O
a	O
nanoparticle	B-CHED
-	O
based	O
platform	O
under	O
inflammatory	O
conditions	O
.	O

Thus	O
,	O
this	O
assay	O
could	O
be	O
particularly	O
useful	O
to	O
identify	O
the	O
main	O
respiratory	O
viruses	O
directly	O
from	O
clinical	O
samples	O
,	O
after	O
nucleic	B-CHED
acid	I-CHED
extraction	O
,	O
and	O
,	O
also	O
,	O
to	O
screen	O
a	O
large	O
number	O
of	O
patients	O
for	O
epidemiological	O
studies	O
.	O

TITLE	O
:	O
[	O
A	O
Case	O
of	O
Nasopharyngeal	O
Cancer	O
with	O
Febrile	O
Neutropenia	O
Followed	O
by	O
Death	O
during	O
Adjuvant	B-CHED
Chemotherapy	O
].	O

He	O
underwent	O
immediate	O
systemic	O
management	O
,	O
but	O
methicillin	B-CHED
-	O
resistant	O
Staphylococcus	O
aureus	O
(	O
MRSA	O
)	O
pneumonia	O
and	O
enteritis	O
were	O
uncontrolled	O
,	O
resulting	O
in	O
death	O
on	O
day	O
43	O
.	O

TITLE	O
:	O
The	O
ns12	O
.	O
9	O
Accessory	O
Protein	B-CHED
of	O
Human	O
Coronavirus	O
OC43	O
Is	O
a	O
Viroporin	O
Involved	O
in	O
Virion	O
Morphogenesis	O
and	O
Pathogenesis	O
.	O

The	O
use	O
of	O
enteral	O
diets	O
enriched	O
with	O
eicosapentaenoic	B-CHED
acid	I-CHED
(	O
EPA	B-CHED
)	O
and	O
gamma	B-CHED
-	I-CHED
linolenic	I-CHED
acid	I-CHED
(	O
GLA	B-CHED
)	O
has	O
reported	O
promising	O
results	O
,	O
showing	O
an	O
improvement	O
in	O
respiratory	O
variables	O
and	O
haemodynamics	O
.	O

Blood	O
type	O
A	O
is	O
independently	O
associated	O
with	O
AKI	O
risk	O
in	O
critically	O
ill	O
patients	O
with	O
trauma	O
or	O
severe	O
sepsis	O
of	O
European	O
descent	O
,	O
suggesting	O
a	O
role	O
for	O
ABO	O
glycans	B-CHED
in	O
AKI	O
susceptibility	O
.	O

Analysis	O
at	O
the	O
protein	B-CHED
level	O
showed	O
that	O
the	O
virus	O
was	O
closely	O
related	O
to	O
the	O
highly	O
virulent	O
MHV	O
-	O
JHM	O
strain	O
.	O

Genetic	O
recombination	O
analysis	O
and	O
lineage	O
-	O
specific	O
single	O
-	O
nucleotide	B-CHED
polymorphism	O
(	O
SNP	O
)	O
comparison	O
suggest	O
that	O
the	O
imported	O
virus	O
is	O
a	O
recombinant	O
comprising	O
group	O
3	O
and	O
group	B-CHED
5	I-CHED
elements	I-CHED
.	O

Therefore	O
,	O
we	O
generated	O
MVs	O
expressing	O
the	O
spike	O
glycoprotein	B-CHED
of	O
MERS	O
-	O
CoV	O
in	O
its	O
full	O
-	O
length	O
(	O
MERS	O
-	O
S	O
)	O
or	O
a	O
truncated	O
,	O
soluble	O
variant	O
of	O
MERS	O
-	O
S	O
(	O
MERS	O
-	O
solS	O
).	O

Using	O
during	O
ventilatory	O
support	O
of	O
patients	O
with	O
initial	O
symptoms	O
of	O
the	O
syndrome	O
of	O
acute	O
lung	O
damage	O
and	O
reduced	O
lung	O
function	O
restrictive	O
positive	O
end	O
-	O
expiratory	O
pressure	O
of	O
6	O
-	O
10	O
cm	O
of	O
water	B-CHED
column	O
when	O
the	O
conventional	O
(	O
1	O
:	O
2	O
;	O
1	O
:	O
2	O
.	O
5	O
at	O
p	O
≤	O
0	O
.	O
05	O
)	O
and	O
invert	O
(	O
2	O
:	O
1	O
at	O
p	O
≤	O
0	O
,	O
1	O
)	O
ratio	O
inhale	O
/	O
exhale	O
,	O
relatively	O
low	O
tidal	O
volume	O
(	O
6	O
-	O
8	O
ml	O
/	O
kg	O
)	O
allows	O
increase	O
the	O
compliance	O
of	O
the	O
lung	O
tissue	O
to	O
11	O
-	O
29	O
%.	O

The	O
main	O
areas	O
during	O
mechanical	O
ventilation	O
of	O
lungs	O
in	O
patients	O
with	O
a	O
sharp	O
decline	O
in	O
restrictive	O
lung	O
function	O
(	O
ARDS	O
,	O
pneumonia	O
),	O
regardless	O
of	O
the	O
reason	O
it	O
was	O
summoned	O
,	O
optimal	O
value	O
is	O
the	O
observance	O
of	O
the	O
positive	O
end	O
-	O
expiratory	O
pressure	O
,	O
the	O
ratio	O
of	O
inhale	O
/	O
exhale	O
(	O
depending	O
on	O
the	O
degree	O
of	O
hypoxemia	O
),	O
to	O
maintain	O
sufficient	O
blood	O
oxygen	B-CHED
saturation	O
and	O
partial	O
pressure	O
of	O
oxygen	B-CHED
in	O
the	O
blood	O
plasma	O
.	O

TITLE	O
:	O
Kuwanon	O
-	O
L	O
as	O
a	O
New	O
Allosteric	O
HIV	B-CHED
-	I-CHED
1	I-CHED
Integrase	I-CHED
Inhibitor	I-CHED
:	O
Molecular	O
Modeling	O
and	O
Biological	O
Evaluation	O
.	O

Compounds	O
1	O
-	O
3	O
,	O
and	O
6	O
were	O
evaluated	O
for	O
their	O
antiviral	B-CHED
activity	O
against	O
the	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
).	O

The	O
primers	O
and	O
probes	O
for	O
these	O
assays	O
were	O
evaluated	O
and	O
found	O
to	O
have	O
a	O
limit	O
of	O
detection	O
(	O
LOD	O
)	O
of	O
0	O
.	O
005	O
plaque	O
-	O
forming	O
units	O
/	O
PCR	O
(	O
pfu	B-CHED
/	O
PCR	O
).	O

CONCLUSIONS	O
:	O
SAR	B-CHED
for	O
laboratory	O
-	O
confirmed	O
influenza	O
in	O
South	O
Africa	O
was	O
higher	O
than	O
previously	O
reported	O
SARs	O
.	O

The	O
structure	O
of	O
Fab	O
m336	O
in	O
complex	O
with	O
the	O
MERS	O
-	O
CoV	O
receptor	O
-	O
binding	O
domain	O
reveals	O
that	O
its	O
IGHV1	O
-	O
69	O
-	O
derived	O
heavy	O
chain	O
provides	O
more	O
than	O
85	O
%	O
binding	O
surface	O
and	O
that	O
its	O
epitope	B-CHED
almost	O
completely	O
overlaps	O
with	O
the	O
receptor	O
-	O
binding	O
site	O
.	O

The	O
antiviral	B-CHED
screening	O
of	O
levopimaric	O
acid	O
diene	O
adducts	O
derivatives	O
was	O
carried	O
out	O
with	O
minimal	O
effect	O
on	O
SARS	O
and	O
influenza	O
type	O
B	O
viruses	O
.	O

ABSTRACT	O
:	O
We	O
report	O
a	O
unique	O
clinical	O
case	O
about	O
an	O
18	O
-	O
year	O
-	O
old	O
woman	O
,	O
immediately	O
post	O
-	O
partum	O
after	O
an	O
urgent	O
C	O
-	O
section	O
,	O
who	O
survived	O
severe	O
sepsis	O
,	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
and	O
disseminated	O
intravascular	O
coagulation	O
(	O
DIC	B-CHED
)	O
and	O
was	O
successfully	O
treated	O
with	O
11	O
different	O
antibiotics	B-CHED
,	O
massive	O
blood	O
transfusions	O
and	O
repetitive	O
surgeries	O
and	O
was	O
on	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
support	O
for	O
22	O
days	O
.	O

In	O
adenovirus	O
infections	O
mean	O
C	O
-	O
reactive	O
protein	B-CHED
value	O
was	O
72	O
.	O
4	O
mg	O
/	O
L	O
and	O
white	O
blood	O
cell	O
count	O
19	O
.	O
000	O
/	O
µl	O
,	O
both	O
significantly	O
higher	O
than	O
in	O
other	O
viruses	O
(	O
p	O
<	O
0	O
.	O
01	O
).	O

TITLE	O
:	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
Coronavirus	O
ORF7a	O
Inhibits	O
Bone	O
Marrow	O
Stromal	O
Antigen	B-CHED
2	O
Virion	O
Tethering	O
through	O
a	O
Novel	O
Mechanism	O
of	O
Glycosylation	O
Interference	O
.	O

We	O
show	O
that	O
the	O
putative	O
host	O
switches	O
leading	O
to	O
the	O
formation	O
of	O
HCoV	O
-	O
229E	O
were	O
accompanied	O
by	O
major	O
genomic	O
changes	O
,	O
including	O
deletions	O
in	O
the	O
viral	O
spike	O
glycoprotein	B-CHED
gene	O
and	O
loss	O
of	O
an	O
open	O
reading	O
frame	O
.	O

Completion	O
of	O
volume	O
changes	O
in	O
99	O
%	O
of	O
both	O
increase	O
and	O
decrease	O
in	O
PEEP	B-CHED
events	O
required	O
29	O
breaths	O
.	O

TITLE	O
:	O
Identification	O
of	O
a	O
Novel	O
Small	O
Molecule	O
Inhibitor	B-CHED
Against	O
SARS	O
Coronavirus	O
Helicase	O
.	O

In	O
the	O
present	O
work	O
,	O
we	O
describe	O
the	O
resistance	O
of	O
IBV	O
to	O
IFN	O
and	O
the	O
potential	O
role	O
of	O
accessory	O
proteins	B-CHED
herein	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
show	O
that	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
is	O
resistant	O
to	O
IFN	O
treatment	O
and	O
identify	O
a	O
role	O
for	O
accessory	O
protein	B-CHED
3a	O
in	O
the	O
resistance	O
against	O
the	O
type	O
I	O
IFN	O
response	O
.	O

In	O
the	O
groin	O
,	O
sartorius	O
muscle	O
flap	O
is	O
the	O
most	O
used	O
for	O
vascular	O
coverage	O
and	O
small	O
tissue	O
defect	O
reconstruction	O
because	O
of	O
the	O
ease	O
in	O
harvesting	O
and	O
low	O
donor	B-CHED
-	O
site	O
complications	O
.	O

TITLE	O
:	O
Rapid	O
and	O
Effective	O
Virucidal	O
Activity	O
of	O
Povidone	B-CHED
-	O
Iodine	B-CHED
Products	O
Against	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
and	O
Modified	O
Vaccinia	O
Virus	O
Ankara	O
(	O
MVA	B-CHED
).	O

Improved	O
global	O
awareness	O
,	O
together	O
with	O
improved	O
hygiene	O
practices	O
in	O
healthcare	O
facilities	O
,	O
has	O
been	O
highlighted	O
as	O
key	O
strategies	O
in	O
controlling	O
the	O
spread	O
of	O
MERS	O
-	O
CoV	O
.	O
This	O
study	O
tested	O
the	O
in	O
vitro	O
efficacy	O
of	O
three	O
formulations	O
of	O
povidone	B-CHED
iodine	B-CHED
(	O
PVP	B-CHED
-	O
I	O
:	O
4	O
%	O
PVP	B-CHED
-	O
I	O
skin	O
cleanser	O
,	O
7	O
.	O
5	O
%	O
PVP	B-CHED
-	O
I	O
surgical	O
scrub	O
,	O
and	O
1	O
%	O
PVP	B-CHED
-	O
I	O
gargle	O
/	O
mouthwash	O
)	O
against	O
a	O
reference	O
virus	O
(	O
Modified	O
vaccinia	O
virus	O
Ankara	O
,	O
MVA	B-CHED
)	O
and	O
MERS	O
-	O
CoV	O
.	O
According	O
to	O
EN14476	O
,	O
a	O
standard	O
suspension	O
test	O
was	O
used	O
to	O
assess	O
virucidal	O
activity	O
against	O
MVA	B-CHED
and	O
large	O
volume	O
plating	O
was	O
used	O
for	O
MERS	O
-	O
CoV	O
.	O
All	O
products	O
were	O
tested	O
under	O
clean	O
(	O
0	O
.	O
3	O
g	O
/	O
L	O
bovine	O
serum	O
albumin	O
,	O
BSA	O
)	O
and	O
dirty	O
conditions	O
(	O
3	O
.	O
0	O
g	O
/	O
L	O
BSA	O
+	O
3	O
.	O
0	O
mL	O
/	O
L	O
erythrocytes	O
),	O
with	O
application	O
times	O
of	O
15	O
,	O
30	O
,	O
and	O
60	O
s	O
for	O
MVA	B-CHED
,	O
and	O
15	O
s	O
for	O
MERS	O
-	O
CoV	O
.	O
The	O
products	O
were	O
tested	O
undiluted	O
,	O
1	O
:	O
10	O
and	O
1	O
:	O
100	O
diluted	O
against	O
MVA	B-CHED
,	O
and	O
undiluted	O
against	O
MERS	O
-	O
CoV	O
.	O
A	O
reduction	O
in	O
virus	O
titer	O
of	O
≥	O
4	O
log10	O
(	O
corresponding	O
to	O
an	O
inactivation	O
of	O
≥	O
99	O
.	O
99	O
%)	O
was	O
regarded	O
as	O
evidence	O
of	O
virucidal	O
activity	O
.	O

CONCLUSIONS	O
:	O
These	O
data	O
indicate	O
that	O
PVP	B-CHED
-	O
I	O
-	O
based	O
hand	O
wash	O
products	O
for	O
potentially	O
contaminated	O
skin	O
,	O
and	O
PVP	B-CHED
-	O
I	O
gargle	O
/	O
mouthwash	O
for	O
reduction	O
of	O
viral	O
load	O
in	O
the	O
oral	O
cavity	O
and	O
the	O
oropharynx	O
,	O
may	O
help	O
to	O
support	O
hygiene	O
measures	O
to	O
prevent	O
transmission	O
of	O
MERS	O
-	O
CoV	O
.	O

Mean	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
protein	B-CHED
levels	O
was	O
(	O
n	O
=	O
962	O
)	O
113	O
.	O
8	O
±	O
11	O
.	O
8	O
mg	O
/	O
dl	O
.	O

Then	O
we	O
constructed	O
a	O
protein	B-CHED
-	O
protein	B-CHED
interaction	O
network	O
and	O
a	O
transcriptional	O
regulatory	O
network	O
of	O
the	O
proteins	B-CHED
.	O

In	O
the	O
networks	O
,	O
we	O
found	O
5	O
significant	O
proteins	B-CHED
including	O
FAN	O
,	O
CPSF2	O
,	O
AGO1	O
,	O
AGO2	O
and	O
PAX5	O
.	O

By	O
referring	O
to	O
the	O
previous	O
studies	O
,	O
we	O
suggest	O
that	O
proteins	B-CHED
including	O
FAN	O
,	O
CPSF2	O
,	O
AGO1	O
,	O
AGO2	O
,	O
PAX5	O
,	O
STAT1	O
and	O
PDGFB	O
can	O
be	O
used	O
as	O
therapeutic	O
targets	O
of	O
IAV	O
infection	O
.	O

The	O
present	O
study	O
was	O
performed	O
to	O
assess	O
the	O
protocols	O
used	O
for	O
the	O
molecular	O
diagnosis	O
of	O
MERS	O
-	O
CoV	O
by	O
analyzing	O
the	O
nucleotide	B-CHED
sequences	O
of	O
viruses	O
detected	O
between	O
2012	O
and	O
2015	O
,	O
including	O
sequences	O
from	O
the	O
large	O
outbreak	O
in	O
eastern	O
Asia	O
in	O
2015	O
.	O

Experimental	O
studies	O
have	O
demonstrated	O
the	O
feasibility	O
,	O
efficacy	O
and	O
safety	O
of	O
extracorporeal	O
removal	O
of	O
CO2	B-CHED
and	O
some	O
of	O
its	O
effects	O
in	O
humans	O
.	O

Pro	B-CHED
-	O
inflammatory	O
cytokine	O
profiles	O
of	O
PEDV	O
infected	O
suckling	O
pigs	O
differed	O
from	O
those	O
of	O
PEDV	O
infected	O
weaned	O
pigs	O
and	O
coincided	O
with	O
onset	O
of	O
fecal	O
PEDV	O
RNA	O
shedding	O
and	O
serum	O
PEDV	O
RNA	O
titers	O
.	O

TITLE	O
:	O
Porcine	O
epidemic	O
diarrhea	O
virus	O
M	O
protein	B-CHED
blocks	O
cell	O
cycle	O
progression	O
at	O
S	O
-	O
phase	O
and	O
its	O
subcellular	O
localization	O
in	O
the	O
porcine	O
intestinal	O
epithelial	O
cells	O
.	O

ABSTRACT	O
:	O
The	O
oral	O
drug	O
FTY720	B-CHED
affects	O
sphingosine	B-CHED
-	I-CHED
1	I-CHED
-	I-CHED
phosphate	I-CHED
(	O
S1P	B-CHED
)	O
signaling	O
on	O
targeted	O
cells	O
that	O
bear	O
the	O
S1P	B-CHED
receptors	O
S1P1	O
,	O
S1P3	O
,	O
S1P4	O
,	O
and	O
S1P5	O
.	O

Healthcare	O
-	O
associated	O
clusters	B-CHED
of	O
MERS	O
-	O
CoV	O
have	O
been	O
responsible	O
for	O
the	O
majority	O
of	O
reported	O
cases	O
.	O

TITLE	O
:	O
Development	O
of	O
a	O
new	O
portable	O
air	B-CHED
sampler	O
based	O
on	O
electrostatic	O
precipitation	O
.	O

To	O
select	O
the	O
mode	O
of	O
antimicrobial	B-CHED
therapy	O
is	O
most	O
important	O
local	O
monitoring	O
antimicrobial	B-CHED
resistance	O
of	O
pathogens	O
.	O

In	O
the	O
absence	O
of	O
CCoV	O
-	O
I	O
laboratory	O
strain	O
,	O
we	O
used	O
feline	O
coronavirus	O
(	O
FCoV	O
)-	O
I	O
that	O
shares	O
high	O
sequence	O
homology	O
in	O
the	O
S	O
protein	B-CHED
with	O
CCoV	O
-	O
I	O
.	O
77	O
.	O
7	O
%	O
of	O
the	O
sera	O
were	O
positive	O
for	O
neutralizing	O
anti	O
-	O
FCoV	O
-	O
I	O
antibodies	O
.	O

Bleeding	O
from	O
the	O
chest	O
tube	O
site	O
was	O
reported	O
in	O
13	O
.	O
5	O
%	O
of	O
prone	O
positioning	O
maneuvers	O
in	O
1	O
study	O
,	O
and	O
the	O
rest	B-CHED
of	O
the	O
studies	O
reported	O
no	O
evidence	O
of	O
chest	O
tube	O
site	O
bleeding	O
.	O

Many	O
papers	O
have	O
been	O
produced	O
specifically	O
,	O
since	O
the	O
outbreak	O
of	O
carbapenem	B-CHED
-	O
resistant	O
Enterobacteriaceae	O
in	O
2013	O
.	O

Lead	B-CHED
compounds	I-CHED
1	O
-	O
4	O
were	O
further	O
modified	O
to	O
enhance	O
their	O
antiviral	B-CHED
activity	O
and	O
reduce	O
their	O
cytotoxicity	O
.	O

Title	O
compounds	O
were	O
tested	O
in	O
cell	O
-	O
based	O
assays	O
for	O
cytotoxicity	O
and	O
antiviral	B-CHED
activity	O
against	O
RNA	O
virus	O
families	O
containing	O
single	O
-	O
stranded	O
(	O
either	O
positive	O
-	O
sense	O
(	O
ssRNA	O
+)	O
or	O
negative	O
-	O
sense	O
(	O
ssRNA	O
-)),	O
and	O
double	O
-	O
stranded	O
genomes	O
(	O
dsRNA	B-CHED
),	O
and	O
against	O
two	O
representatives	O
of	O
DNA	O
virus	O
families	O
.	O

TITLE	O
:	O
A	O
disparate	O
subset	O
of	O
double	O
-	O
negative	O
T	O
cells	O
contributes	O
to	O
the	O
outcome	O
of	O
murine	O
fulminant	O
viral	O
hepatitis	O
via	O
effector	B-CHED
molecule	O
fibrinogen	O
-	O
like	O
protein	B-CHED
2	O
.	O

ABSTRACT	O
:	O
On	O
the	O
basis	O
of	O
the	O
structure	O
of	O
natural	B-CHED
product	I-CHED
harmine	B-CHED
,	O
lead	O
compound	O
18	O
,	O
and	O
the	O
structure	O
of	O
compounds	O
in	O
part	O
1	O
,	O
a	O
series	O
of	O
thiophosphoramide	O
derivatives	O
1	O
-	O
17	O
were	O
designed	O
and	O
synthesized	O
from	O
various	O
amines	B-CHED
in	O
one	O
step	O
.	O

Most	O
of	O
the	O
compounds	O
showed	O
significantly	O
higher	O
antiviral	B-CHED
activity	O
against	O
tobacco	O
mosaic	O
virus	O
(	O
TMV	O
)	O
than	O
commercial	O
virucide	O
ribavirin	B-CHED
.	O

The	O
infection	O
of	O
target	O
cells	O
by	O
the	O
SARS	O
CoV	O
is	O
mediated	O
through	O
the	O
interaction	O
of	O
the	O
viral	O
Spike	O
(	O
S	O
)	O
protein	B-CHED
(	O
1255	O
amino	B-CHED
acids	I-CHED
)	O
and	O
its	O
cellular	O
receptor	O
,	O
angiotensin	B-CHED
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
).	O

In	O
addition	O
,	O
the	O
RBM	O
is	O
a	O
major	O
antigenic	B-CHED
determinant	I-CHED
,	O
able	O
to	O
elicit	O
production	O
of	O
neutralizing	O
antibodies	O
.	O

TITLE	O
:	O
Lung	O
inhomogeneities	O
,	O
inflation	O
and	O
[	O
18F	O
]	O
2	O
-	O
fluoro	B-CHED
-	O
2	B-CHED
-	I-CHED
deoxy	I-CHED
-	I-CHED
D	I-CHED
-	I-CHED
glucose	I-CHED
uptake	O
rate	O
in	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

Pulmonary	O
intensive	O
care	O
may	O
involve	O
thoracentesis	O
,	O
oxygen	B-CHED
supplementation	O
and	O
in	O
more	O
severe	O
cases	O
assisted	O
ventilation	O
.	O

When	O
the	O
full	O
-	O
length	O
E	O
protein	B-CHED
was	O
deleted	O
or	O
its	O
PDZ	O
-	O
binding	O
motif	O
(	O
PBM	O
)	O
was	O
mutated	O
,	O
the	O
revertant	O
viruses	O
either	O
incorporated	O
a	O
novel	O
chimeric	O
protein	B-CHED
with	O
a	O
PBM	O
or	O
restored	O
the	O
sequence	O
of	O
the	O
PBM	O
on	O
the	O
E	O
protein	B-CHED
,	O
respectively	O
.	O

However	O
,	O
few	O
studies	O
have	O
been	O
conducted	O
on	O
type	O
I	O
FCoV	O
.	O
Here	O
,	O
we	O
compare	O
the	O
effects	O
of	O
cholesterol	B-CHED
on	O
types	O
I	O
and	O
II	O
FCoV	O
infections	O
.	O

When	O
cells	O
were	O
treated	O
methyl	B-CHED
-	O
β	O
-	O
cyclodextrin	B-CHED
(	O
MβCD	O
)	O
and	O
inoculated	O
with	O
type	O
I	O
FCoV	O
,	O
the	O
infection	O
rate	O
decreased	O
significantly	O
,	O
and	O
the	O
addition	O
of	O
exogenous	O
cholesterol	B-CHED
to	O
MβCD	O
-	O
treated	O
cells	O
resulted	O
in	O
the	O
recovery	O
of	O
the	O
infectivity	O
of	O
type	O
I	O
FCoV	O
.	O
Furthermore	O
,	O
exogenous	O
cholesterol	B-CHED
increased	O
the	O
infectivity	O
of	O
type	O
I	O
FCoV	O
.	O
In	O
contrast	O
,	O
the	O
addition	O
of	O
MβCD	O
and	O
exogenous	O
cholesterol	B-CHED
had	O
little	O
effect	O
on	O
the	O
efficiency	O
of	O
type	O
II	O
FCoV	O
infection	O
.	O

If	O
a	O
patient	O
'	O
s	O
condition	O
changes	O
abruptly	O
,	O
it	O
is	O
crucial	O
to	O
promptly	O
respond	O
to	O
the	O
change	O
and	O
to	O
administer	O
mechanical	O
ventilation	O
and	O
appropriate	O
antibiotics	B-CHED
.	O

Open	O
-	O
lung	O
PEEP	B-CHED
(	O
OL	O
-	O
PEEP	B-CHED
)	O
was	O
determined	O
by	O
computed	O
tomography	O
,	O
while	O
Pes	O
-	O
guided	O
PEEP	B-CHED
(	O
Pes	O
-	O
PEEP	B-CHED
)	O
was	O
to	O
maintain	O
PL	O
-	O
exp	O
greater	O
than	O
0	O
.	O

The	O
ΔP	O
values	O
after	O
pECLA	O
implantation	O
decreased	O
from	O
a	O
mean	O
17	O
.	O
1	O
±	O
0	O
.	O
7	O
cm	O
/	O
H2O	B-CHED
to	O
11	O
.	O
9	O
±	O
0	O
.	O
5	O
cm	O
/	O
H2O	B-CHED
(	O
p	O
=	O
0	O
.	O
011	O
).	O

In	O
conclusion	O
,	O
genome	O
of	O
MERS	O
-	O
CoV_	O
China	O
GD01	O
was	O
general	O
conserved	O
although	O
several	O
genetic	O
variations	O
were	O
found	O
among	O
structural	O
and	O
accessory	O
protein	B-CHED
coding	O
genes	O
.	O

Subset	O
analyses	O
identified	O
CCL2	B-CHED
as	O
an	O
additional	O
risk	O
factor	O
for	O
tuberculosis	O
(	O
rs1024611	O
;	O
OR	O
=	O
0	O
.	O
79	O
[	O
0	O
.	O
72	O
-	O
0	O
.	O
88	O
]).	O

The	O
general	O
aircraf	O
-	O
tcabin	O
air	B-CHED
-	O
contaminant	O
transport	O
effect	O
model	O
was	O
applied	O
to	O
datasets	O
from	O
the	O
University	O
of	O
Illinois	O
and	O
Kansas	O
State	O
University	O
and	O
also	O
to	O
case	O
study	O
information	O
from	O
a	O
flight	O
with	O
probable	O
severe	O
acute	O
respiratory	O
syndrome	O
transmission	O
.	O

Similar	O
behavior	O
was	O
observed	O
in	O
tracer	B-CHED
gas	O
,	O
particle	O
experiments	O
,	O
and	O
flight	O
infection	O
data	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

ABSTRACT	O
:	O
Taxine	O
-	O
derived	O
alkaloids	B-CHED
,	O
taxane	B-CHED
-	O
derived	O
substances	O
,	O
and	O
glycosides	B-CHED
seem	O
to	O
be	O
responsible	O
for	O
the	O
toxicity	O
of	O
Taxus	O
spp	O
.	O

by	O
blocking	O
microtubule	O
,	O
sodium	O
and	O
calcium	B-CHED
channels	O
causing	O
conduction	O
abnormalities	O
.	O

ABSTRACT	O
:	O
Nucleocapsid	O
protein	B-CHED
(	O
NP	O
),	O
an	O
essential	O
RNA	O
-	O
binding	O
viral	O
protein	B-CHED
in	O
human	O
coronavirus	O
(	O
CoV	O
)-	O
infected	O
cells	O
,	O
is	O
required	O
for	O
the	O
replication	O
and	O
transcription	O
of	O
viral	O
RNA	O
.	O

Using	O
a	O
molecular	O
cDNA	O
infectious	O
clone	O
to	O
generate	O
a	O
corresponding	O
recombinant	O
virus	O
,	O
we	O
show	O
for	O
the	O
first	O
time	O
that	O
such	O
point	O
mutation	O
in	O
the	O
HCoV	O
-	O
OC43	O
S	O
glycoprotein	B-CHED
creates	O
a	O
functional	O
cleavage	O
site	O
between	O
the	O
S1	O
and	O
S2	O
portions	O
of	O
the	O
S	O
protein	B-CHED
.	O

TITLE	O
:	O
Antiviral	B-CHED
Cystine	B-CHED
Knot	O
α	O
-	O
Amylase	O
Inhibitors	B-CHED
from	O
Alstonia	O
scholaris	O
.	O

In	O
this	O
report	O
,	O
we	O
reveal	O
two	O
crystal	O
structures	O
of	O
SARS	O
3CL	O
(	O
pro	B-CHED
)	O
complexed	O
with	O
two	O
new	O
inhibitors	B-CHED
based	O
on	O
our	O
previous	O
work	O
.	O

These	O
compounds	O
are	O
represented	O
by	O
tenofovir	B-CHED
(	O
PMPA	O
),	O
a	O
medicine	B-CHED
for	O
both	O
HIV	O
and	O
HBV	O
,	O
and	O
adefovir	B-CHED
as	O
an	O
anti	B-CHED
-	I-CHED
HBV	I-CHED
agent	I-CHED
.	O

The	O
structure	O
-	O
activity	O
relationships	O
(	O
SARs	O
)	O
of	O
this	O
skeleton	O
will	O
provide	O
valuable	O
clues	O
to	O
identify	O
more	O
effective	O
adenine	B-CHED
derivatives	O
as	O
antiviral	B-CHED
drugs	I-CHED
.	O

ABSTRACT	O
:	O
The	O
accessory	O
proteins	B-CHED
(	O
3a	O
,	O
3b	O
,	O
6	O
,	O
7a	O
,	O
7b	O
,	O
8a	O
,	O
8b	O
,	O
9b	O
and	O
ORF14	O
),	O
predicted	O
unknown	O
proteins	B-CHED
(	O
PUPs	O
)	O
encoded	O
by	O
the	O
genes	O
,	O
are	O
considered	O
to	O
be	O
unique	O
to	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
genome	O
.	O

Selected	O
characteristic	O
amino	B-CHED
acids	I-CHED
were	O
observed	O
,	O
and	O
phylogenetic	O
analyses	O
showed	O
that	O
the	O
novel	O
H7	O
virus	O
was	O
genetically	O
close	O
to	O
2011	O
duck	O
H7N3	O
viruses	O
in	O
Zhejiang	O
.	O

An	O
important	O
astrocytic	O
response	O
in	O
many	O
areas	O
of	O
the	O
CNS	B-CHED
of	O
all	O
cats	O
,	O
including	O
the	O
periventricular	O
areas	O
of	O
lateral	O
ventricles	O
and	O
fourth	O
ventricle	O
,	O
the	O
molecular	O
layer	O
of	O
the	O
cerebellum	O
and	O
cerebral	O
cortex	O
,	O
was	O
visualized	O
.	O

If	O
criteria	O
are	O
met	B-CHED
,	O
patients	O
must	O
be	O
immediately	O
placed	O
into	O
airborne	O
infection	O
isolation	O
(	O
or	O
a	O
private	O
room	O
until	O
this	O
type	O
of	O
isolation	O
is	O
available	O
)	O
and	O
the	O
emergency	O
practitioner	O
must	O
alert	O
the	O
hospital	O
infection	O
prevention	O
and	O
control	O
team	O
and	O
the	O
local	O
public	O
health	O
department	O
.	O

Pseudotyped	O
viruses	O
are	O
chimeric	O
constructs	O
in	O
which	O
the	O
outer	O
(	O
surface	O
)	O
glycoprotein	B-CHED
(	O
s	O
)	O
of	O
one	O
virus	O
is	O
combined	O
with	O
the	O
replication	O
-	O
defective	O
viral	O
""""	O
core	O
""""	O
of	O
another	O
virus	O
.	O

In	O
non	O
-	O
locally	O
exposed	O
farms	O
,	O
PED	O
was	O
associated	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
with	O
increased	O
feed	O
truck	O
visits	O
to	O
the	O
farm	O
,	O
no	O
visit	O
of	O
the	O
veterinarian	O
,	O
and	O
again	O
a	O
disinfectant	B-CHED
contact	O
time	O
of	O
less	O
than	O
20min	O
.	O

In	O
addition	O
,	O
a	O
lower	O
volume	O
air	B-CHED
sampler	O
was	O
placed	O
<	O
1	O
m	O
from	O
the	O
patient	O
,	O
with	O
another	O
>	O
1	O
m	O
from	O
the	O
patient	O
.	O

In	O
order	O
to	O
solve	O
the	O
problems	O
of	O
conventional	O
PCR	O
--	O
speed	O
,	O
uniform	O
heating	O
and	O
cooling	O
,	O
and	O
massive	O
metal	B-CHED
heating	O
blocks	O
--	O
an	O
innovative	O
optofluidic	O
cavity	O
PCR	O
method	O
using	O
light	O
-	O
emitting	O
diodes	O
(	O
LEDs	O
)	O
is	O
accomplished	O
.	O

To	O
date	O
,	O
the	O
techniques	O
of	O
using	O
high	O
levels	O
of	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	B-CHED
),	O
prompt	O
institution	O
of	O
neuromuscular	O
blockade	O
,	O
and	O
early	O
prolonged	O
prone	O
positioning	O
have	O
been	O
shown	O
to	O
reduce	O
mortality	O
in	O
patients	O
with	O
severe	O
ARDS	O
.	O

PEEP	B-CHED
titration	O
using	O
transpulmonary	O
pressure	O
estimations	O
assisted	O
by	O
esophageal	O
manometry	O
has	O
been	O
shown	O
to	O
result	O
in	O
a	O
substantial	O
improvement	O
in	O
oxygenation	O
.	O

Assessments	O
of	O
viral	O
protein	B-CHED
and	O
RNA	O
levels	O
in	O
infected	O
cells	O
showed	O
that	O
both	O
viruses	O
were	O
impaired	O
in	O
their	O
ability	O
to	O
replicate	O
in	O
these	O
cells	O
.	O

It	O
was	O
the	O
complications	O
of	O
silicone	B-CHED
injections	O
which	O
revealed	O
a	O
severe	O
personality	O
disorder	O
.	O

Here	O
,	O
we	O
show	O
that	O
an	O
upstream	O
duplex	O
formed	O
in	O
-	O
trans	O
,	O
by	O
annealing	O
an	O
antisense	O
to	O
its	O
complementary	O
mRNA	B-CHED
sequence	O
upstream	O
of	O
frameshifting	O
site	O
,	O
can	O
replace	O
an	O
upstream	O
hairpin	O
to	O
attenuate	O
-	O
1	O
PRF	O
efficiently	O
.	O

Changes	O
in	O
various	O
hemodynamic	O
parameters	O
after	O
SAH	B-CHED
were	O
analyzed	O
statistically	O
.	O

TITLE	O
:	O
Assembly	O
of	O
Viral	O
Membrane	O
Proteins	B-CHED
.	O

ABSTRACT	O
:	O
The	O
generation	O
of	O
computational	O
models	O
is	O
an	O
alternative	O
route	O
to	O
obtain	O
reliable	O
structures	O
for	O
the	O
oligomeric	O
state	O
of	O
membrane	O
proteins	B-CHED
.	O

The	O
possible	O
pathogenesis	O
and	O
therapeutic	O
measures	O
of	O
MODS	O
induced	O
by	O
heroin	B-CHED
intoxication	O
and	O
some	O
suggestions	O
for	O
preventing	O
and	O
treating	O
severe	O
complications	O
of	O
heroin	B-CHED
intoxication	O
,	O
based	O
on	O
clinical	O
evidence	O
and	O
the	O
pertinent	O
literature	O
,	O
are	O
discussed	O
in	O
this	O
report	O
.	O

Lipopolysaccharide	B-CHED
(	O
LPS	B-CHED
),	O
a	O
component	O
of	O
Gram	O
-	O
negative	O
bacterial	O
cell	O
walls	O
,	O
plays	O
a	O
major	O
role	O
in	O
the	O
pathogenesis	O
of	O
severe	O
sepsis	O
and	O
septic	O
shock	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
tested	O
the	O
hypothesis	O
that	O
imatinib	B-CHED
would	O
protect	O
against	O
lung	O
injury	O
and	O
systemic	O
inflammation	O
caused	O
by	O
intravenous	O
LPS	B-CHED
in	O
an	O
intact	O
mouse	O
model	O
of	O
endotoxemia	O
mimicking	O
early	O
sepsis	O
.	O

Finally	O
,	O
imatinib	B-CHED
completely	O
prevented	O
mortality	O
in	O
an	O
in	O
vivo	O
,	O
intravenous	O
LPS	B-CHED
mouse	O
model	O
of	O
endotoxemia	O
and	O
lung	O
injury	O
.	O

Both	O
the	O
increase	O
of	O
proteins	B-CHED
and	O
lysophosphatidylcholine	B-CHED
are	O
known	O
to	O
decrease	O
the	O
intrinsic	O
surface	O
activity	O
of	O
surfactant	B-CHED
.	O

Changes	O
in	O
haemodynamics	O
,	O
pulmonary	O
compliance	O
,	O
gas	O
exchange	O
and	O
extravascular	O
lung	O
water	B-CHED
index	O
(	O
EVLWI	O
)	O
were	O
monitored	O
before	O
RM	O
(	O
pre	O
-	O
RM	O
),	O
10	O
minutes	O
after	O
each	O
RM	O
,	O
and	O
four	O
hours	O
after	O
RM3	O
(	O
4	O
hours	O
post	O
-	O
RRM	O
).	O

RESULTS	O
:	O
Compared	O
with	O
those	O
in	O
pre	O
-	O
RM	O
,	O
pulmonary	O
compliance	O
,	O
oxygenation	O
index	O
(	O
ratio	O
of	O
partial	O
pressure	O
of	O
arterial	O
oxygen	B-CHED
to	O
fraction	O
of	O
inspired	O
oxygen	B-CHED
[	O
PaO2	O
/	O
FiO2	O
])	O
and	O
EVLWI	O
remarkably	O
improved	O
in	O
RM1	O
,	O
RM2	O
,	O
RM3	O
and	O
4	O
hours	O
post	O
-	O
RRM	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

Previous	O
studies	O
have	O
shown	O
that	O
MERS	O
-	O
CoV	O
ORF4b	O
antagonizes	O
the	O
early	O
antiviral	B-CHED
alpha	O
/	O
beta	O
interferon	O
(	O
IFN	O
-	O
α	O
/	O
β	O
)	O
response	O
,	O
which	O
may	O
significantly	O
contribute	O
to	O
MERS	O
-	O
CoV	O
pathogenesis	O
;	O
however	O
,	O
the	O
underlying	O
mechanism	O
is	O
poorly	O
understood	O
.	O

MERS	O
-	O
CoV	O
detection	O
for	O
all	O
other	O
254	O
dromedaries	O
in	O
this	O
closed	O
dairy	O
herd	O
was	O
negative	O
by	O
nucleocapsid	O
protein	B-CHED
-	O
capture	O
ELISA	O
and	O
RNA	O
detection	O
.	O

Mean	O
oxygen	B-CHED
transfer	O
was	O
calculated	O
with	O
136	O
.	O
09	O
±	O
30	O
.	O
25	O
mL	O
/	O
min	O
for	O
the	O
ILIAS	O
and	O
129	O
.	O
05	O
±	O
36	O
.	O
28	O
mL	O
/	O
min	O
for	O
the	O
standard	O
ECMO	O
.	O

TITLE	O
:	O
Epitope	B-CHED
-	O
Based	O
Vaccine	O
Target	O
Screening	O
against	O
Highly	O
Pathogenic	O
MERS	O
-	O
CoV	O
:	O
An	O
In	O
Silico	O
Approach	O
Applied	O
to	O
Emerging	O
Infectious	O
Diseases	O
.	O

TITLE	O
:	O
Effect	O
of	O
extracorporeal	O
CO2	B-CHED
removal	O
on	O
right	O
ventricular	O
and	O
hemodynamic	O
parameters	O
in	O
a	O
patient	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

During	O
the	O
past	O
decade	O
,	O
significant	O
progress	O
has	O
been	O
made	O
in	O
the	O
discovery	O
of	O
novel	O
nucleoside	B-CHED
HCV	O
NS5B	O
polymerase	O
inhibitors	B-CHED
.	O

The	O
ACP	B-CHED
risk	O
score	O
had	O
a	O
reasonable	O
discrimination	O
and	O
a	O
good	O
calibration	O
.	O

We	O
also	O
solved	O
the	O
structure	O
of	O
FIPV	O
M	O
(	O
pro	B-CHED
)	O
complexed	O
with	O
two	O
inhibitors	B-CHED
,	O
delineating	O
the	O
structural	O
view	O
of	O
a	O
dual	O
inhibition	O
mechanism	O
.	O

Mutations	O
specifically	O
disrupting	O
the	O
cysteine	B-CHED
protease	O
activity	O
of	O
PEDV	O
nsp5	O
abrogated	O
NEMO	O
cleavage	O
and	O
the	O
inhibition	O
of	O
IFN	O
induction	O
.	O

Mechanistically	O
,	O
the	O
cysteine	B-CHED
protease	O
activity	O
of	O
PEDV	O
nsp5	O
mediates	O
proteolysis	O
of	O
NEMO	O
,	O
the	O
key	O
adaptor	O
for	O
IFN	O
synthesis	O
,	O
and	O
NEMO	O
is	O
cleaved	O
at	O
glutamine	B-CHED
231	O
(	O
Q231	O
).	O

The	O
user	O
-	O
friendly	O
assay	O
detected	O
and	O
differentiated	O
between	O
four	O
viruses	O
[	O
porcine	O
reproductive	O
and	O
respiratory	O
syndrome	O
virus	O
(	O
PRRSV	O
),	O
influenza	O
A	O
virus	O
,	O
porcine	O
circovirus	O
type	O
2	O
,	O
porcine	O
respiratory	O
corona	B-CHED
virus	O
],	O
four	O
bacteria	O
(	O
Mycoplasma	O
hyopneumoniae	O
,	O
Pasteurella	O
multocida	O
,	O
Salmonella	O
enterica	O
serovar	O
Choleraesuis	O
,	O
Streptococcus	O
suis	O
),	O
and	O
further	O
differentiated	O
between	O
type	O
1	O
and	O
type	O
2	O
PRRSV	O
as	O
well	O
as	O
toxigenic	O
and	O
non	O
-	O
toxigenic	O
P	O
.	O
multocida	O
.	O

CsA	B-CHED
and	O
FK506	B-CHED
are	O
targets	O
of	O
clinically	O
relevant	O
immunosuppressive	O
drugs	O
and	O
bind	O
to	O
cellular	O
cyclophilins	O
(	O
Cyps	O
)	O
or	O
FK506	B-CHED
binding	O
proteins	B-CHED
(	O
FKBPs	O
),	O
respectively	O
.	O

Both	O
Cyp	B-CHED
and	O
FKBP	O
have	O
peptidyl	O
-	O
prolyl	B-CHED
cis	O
-	O
trans	O
isomerase	O
(	O
PPIase	O
)	O
activity	O
.	O

ABSTRACT	O
:	O
Vitamin	B-CHED
D	I-CHED
and	O
its	O
receptor	O
have	O
a	O
protective	O
effect	O
on	O
epithelial	O
barriers	O
in	O
various	O
tissues	O
.	O

In	O
addition	O
,	O
a	O
vitamin	B-CHED
D	I-CHED
analog	O
(	O
paricalcitol	B-CHED
)	O
was	O
administered	O
to	O
WT	O
mice	O
in	O
order	O
to	O
investigate	O
the	O
effect	O
of	O
vitamin	B-CHED
D	I-CHED
on	O
the	O
alveolar	O
epithelial	O
barrier	O
following	O
exposure	O
to	O
LPS	B-CHED
.	O

After	O
infection	O
,	O
a	O
significant	O
amount	O
of	O
Cx43	O
was	O
retained	O
in	O
endoplasmic	O
reticulum	O
/	O
endoplasmic	O
reticulum	O
Golgi	O
intermediate	O
complex	O
(	O
ER	O
/	O
ERGIC	O
)	O
and	O
GJ	O
plaque	O
formation	O
was	O
impaired	O
at	O
the	O
cell	O
surface	O
,	O
as	O
evidenced	O
by	O
a	O
reduction	O
of	O
the	O
Triton	B-CHED
X	I-CHED
-	I-CHED
100	I-CHED
insoluble	O
fraction	O
of	O
Cx43	O
.	O

Altered	O
trafficking	O
and	O
impairment	O
of	O
GJ	O
plaque	O
formation	O
may	O
cause	O
the	O
loss	O
of	O
functional	O
channel	O
formation	O
in	O
MHV	O
-	O
infected	O
primary	O
astrocytes	O
,	O
as	O
demonstrated	O
by	O
a	O
reduced	O
number	O
of	O
dye	B-CHED
-	O
coupled	O
cells	O
after	O
a	O
scrape	O
-	O
loading	O
Lucifer	B-CHED
yellow	I-CHED
dye	I-CHED
transfer	O
assay	O
.	O

MERS	O
-	O
CoV	O
RNA	O
was	O
detected	O
in	O
samples	O
from	O
anterooms	O
,	O
medical	O
devices	O
,	O
and	O
air	B-CHED
-	O
ventilating	O
equipment	O
.	O

Our	O
results	O
showed	O
that	O
(+)-	O
catechin	B-CHED
exerts	O
an	O
inhibitory	O
effect	O
on	O
TGEV	O
proliferation	O
in	O
vitro	O
and	O
is	O
involved	O
its	O
antioxidation	O
.	O

TITLE	O
:	O
PEEP	B-CHED
titration	O
during	O
prone	O
positioning	O
for	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

TITLE	O
:	O
Recent	O
insights	O
into	O
the	O
development	O
of	O
therapeutics	O
against	O
coronavirus	O
diseases	O
by	O
targeting	O
N	O
protein	B-CHED
.	O

ABSTRACT	O
:	O
A	O
multicenter	O
retrospective	O
survey	O
of	O
patients	O
poisoned	O
by	O
herbicides	B-CHED
containing	O
glyphosate	B-CHED
salts	B-CHED
in	O
Japan	O
was	O
conducted	O
to	O
identify	O
differences	O
in	O
symptoms	O
and	O
outcome	O
of	O
poisoning	O
.	O

Serum	O
potassium	B-CHED
levels	O
upon	O
arrival	O
were	O
significantly	O
higher	O
(	O
p	O
<	O
0	O
.	O
01	O
),	O
and	O
abnormal	O
electrocardiogram	O
findings	O
were	O
significantly	O
more	O
common	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
in	O
the	O
K	O
-	O
group	O
(	O
n	O
=	O
55	O
)	O
than	O
in	O
the	O
O	O
-	O
group	O
(	O
n	O
=	O
62	O
).	O

The	O
ingestion	O
of	O
products	O
containing	O
glyphosate	B-CHED
isopropylamine	B-CHED
or	O
ammonium	B-CHED
salts	I-CHED
,	O
and	O
polyoxyethyleneamine	O
(	O
POEA	B-CHED
)	O
as	O
a	O
surfactant	B-CHED
,	O
can	O
cause	O
severe	O
organ	O
injury	O
.	O

RESULTS	O
:	O
Serum	O
potassium	B-CHED
levels	O
upon	O
arrival	O
were	O
significantly	O
higher	O
(	O
p	O
<	O
0	O
.	O
01	O
),	O
and	O
abnormal	O
electrocardiogram	O
findings	O
were	O
significantly	O
more	O
common	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
in	O
the	O
K	O
-	O
group	O
(	O
n	O
=	O
55	O
)	O
than	O
in	O
the	O
O	O
-	O
group	O
(	O
n	O
=	O
62	O
).	O

TITLE	O
:	O
Potential	O
Broad	O
Spectrum	O
Inhibitors	B-CHED
of	O
the	O
Coronavirus	O
3CLpro	O
:	O
A	O
Virtual	O
Screening	O
and	O
Structure	O
-	O
Based	O
Drug	O
Design	O
Study	O
.	O

The	O
outbreak	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
in	O
2003	O
and	O
Middle	O
East	O
respiratory	O
syndrome	O
(	O
MERS	O
)	O
less	O
than	O
10	O
years	O
later	O
demonstrates	O
the	O
potential	O
of	O
coronaviruses	O
to	O
cross	O
species	O
boundaries	O
and	O
further	O
highlights	O
the	O
importance	O
of	O
identifying	O
novel	O
lead	B-CHED
compounds	I-CHED
with	O
broad	O
spectrum	O
activity	O
.	O

Most	O
human	O
cases	O
of	O
MERS	O
have	O
been	O
linked	O
to	O
lapses	O
in	O
infection	O
prevention	O
and	O
control	O
(	O
IPC	B-CHED
)	O
in	O
healthcare	O
settings	O
,	O
with	O
approximately	O
20	O
%	O
of	O
all	O
virus	O
detections	O
reported	O
among	O
healthcare	O
workers	O
(	O
HCWs	O
)	O
and	O
higher	O
exposures	O
in	O
those	O
with	O
occupations	O
that	O
bring	O
them	O
into	O
close	O
contact	O
with	O
camels	O
.	O

The	O
antiviral	B-CHED
activity	O
of	O
xiamycin	O
D	O
(	O
2	O
)	O
was	O
also	O
supported	O
by	O
both	O
Western	O
blotting	O
of	O
the	O
GP2	O
spike	O
and	O
GP6	O
nucleocapsid	O
protein	B-CHED
synthesis	O
of	O
PEDV	O
.	O

Upregulation	O
of	O
IL	O
-	O
17	O
resulted	O
in	O
increased	O
severity	O
of	O
ALI	O
as	O
evidenced	O
by	O
decreased	O
body	O
weight	O
and	O
survival	O
rate	O
,	O
elevated	O
level	O
of	O
total	O
protein	B-CHED
and	O
albumin	O
in	O
BAL	B-CHED
fluid	O
,	O
as	O
well	O
as	O
more	O
apparent	O
histopathology	O
changes	O
of	O
lung	O
.	O

No	O
PDCoV	O
antigen	B-CHED
-	O
positive	O
,	O
small	O
and	O
large	O
intestinal	O
villous	O
or	O
crypt	O
epithelial	O
cells	O
,	O
of	O
which	O
cytoplasm	O
was	O
also	O
either	O
vacuolated	O
or	O
morphologically	O
normal	O
,	O
showed	O
positive	O
TUNEL	O
staining	O
.	O

In	O
contrast	O
,	O
by	O
double	O
IF	O
and	O
TUNEL	O
staining	O
,	O
most	O
of	O
the	O
TUNEL	O
-	O
positive	O
signals	O
(	O
apoptotic	O
nuclear	O
fragmentation	O
)	O
were	O
found	O
in	O
PDCoV	O
antigen	B-CHED
-	O
positive	O
LLC	O
-	O
PK	O
and	O
ST	O
cells	O
that	O
also	O
showed	O
cytopathic	O
effects	O
,	O
such	O
as	O
cell	O
rounding	O
,	O
detachment	O
and	O
clumping	O
in	O
clusters	B-CHED
.	O

Meanwhile	O
,	O
the	O
patient	O
group	O
showed	O
decreased	O
FA	O
in	O
the	O
genu	O
of	O
capsule	O
callosum	O
,	O
body	O
of	O
capsule	O
callosum	O
,	O
and	O
bilateral	O
anterior	O
corona	B-CHED
radiate	O
(	O
P	O
<	O
0	O
.	O
05	O
,	O
family	O
wise	O
error	O
[	O
FEW	O
]-	O
corrected	O
).	O

Type	O
1	O
POPE	B-CHED
occurs	O
after	O
a	O
sudden	O
,	O
severe	O
upper	O
airway	O
obstruction	O
,	O
whereas	O
type	O
2	O
POPE	B-CHED
develops	O
after	O
acute	O
relief	O
of	O
chronic	O
airway	O
obstructive	O
.	O

Of	O
the	O
396	O
,	O
449	O
older	O
patients	O
at	O
293	O
trauma	O
centres	O
that	O
met	B-CHED
inclusion	O
criteria	O
,	O
30	O
,	O
761	O
(	O
8	O
%)	O
suffered	O
a	O
MC	O
.	O

The	O
diagnosis	O
was	O
confirmed	O
by	O
NS1	O
antigen	B-CHED
-	O
based	O
ELISA	O
test	O
or	O
dengue	O
serology	O
for	O
IgM	O
and	O
IgG	O
antibodies	O
and	O
the	O
data	O
was	O
analyzed	O
using	O
SPSS	O
16	O
.	O
0	O
statistical	O
software	O
.	O

The	O
other	O
atypical	O
manifestations	O
present	O
were	O
portal	O
hypertension	O
,	O
acalculous	O
cholecystitis	O
,	O
appendicitis	O
,	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
myocarditis	O
,	O
pericardial	O
effusion	O
,	O
paroxysmal	O
supraventricular	O
tachycardia	O
(	O
PSVT	O
),	O
myositis	O
,	O
acute	O
kidney	O
injury	O
(	O
AKI	O
),	O
hemophagocytic	O
syndrome	O
and	O
disseminated	O
intravascular	O
coagulopathy	O
(	O
DIC	B-CHED
).	O

H9N2	O
infection	O
rapidly	O
triggered	O
the	O
activation	O
of	O
innate	O
immunity	O
through	O
phosphorylation	O
of	O
signaling	B-CHED
molecules	I-CHED
including	O
mitogen	B-CHED
-	O
activated	O
protein	B-CHED
kinases	O
(	O
MAPKs	O
)	O
and	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
(	O
STAT	O
)	O
proteins	B-CHED
.	O

icPEDV	O
-	O
ΔORF3	O
-	O
RFP	B-CHED
replicated	O
efficiently	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
was	O
efficiently	O
transmitted	O
among	O
pigs	O
,	O
and	O
produced	O
lethal	O
disease	O
outcomes	O
.	O

ABSTRACT	O
:	O
The	O
oligoadenylate	O
synthetase	O
(	O
OAS	O
)-	O
RNase	O
L	O
pathway	O
is	O
a	O
potent	O
interferon	O
(	O
IFN	O
)-	O
induced	O
antiviral	B-CHED
activity	O
.	O

We	O
also	O
demonstrated	O
translocation	O
of	O
a	O
protein	B-CHED
from	O
the	O
airspaces	O
into	O
plasma	O
(	O
RAGE	O
-	O
receptor	O
for	O
advanced	O
glycation	O
end	O
products	O
).	O

For	O
the	O
comparable	O
ventilator	O
setting	O
,	O
as	O
compared	O
with	O
BIPAPSB	O
group	O
,	O
the	O
BIPAPAP	O
group	O
presented	O
higher	O
EELV	O
(	O
427	O
±	O
47	O
vs	O
.	O
366	O
±	O
38	O
ml	O
)	O
and	O
oxygenation	O
index	O
(	O
293	O
±	O
36	O
vs	O
.	O
226	O
±	O
31	O
mmHg	O
),	O
lower	O
levels	O
of	O
IL	O
-	O
6	O
(	O
216	O
.	O
6	O
±	O
48	O
.	O
0	O
vs	O
.	O
297	O
.	O
5	O
±	O
71	O
.	O
2	O
pg	O
/	O
ml	O
)	O
and	O
IL	O
-	O
8	O
(	O
246	O
.	O
8	O
±	O
78	O
.	O
2	O
vs	O
.	O
357	O
.	O
5	O
±	O
69	O
.	O
3	O
pg	O
/	O
ml	O
)	O
in	O
plasma	O
,	O
and	O
lower	O
express	O
levels	O
of	O
IL	O
-	O
6	O
mRNA	B-CHED
(	O
15	O
.	O
0	O
±	O
3	O
.	O
8	O
vs	O
.	O
21	O
.	O
2	O
±	O
3	O
.	O
7	O
)	O
and	O
IL	O
-	O
8	O
mRNA	B-CHED
(	O
18	O
.	O
9	O
±	O
6	O
.	O
8	O
vs	O
.	O
29	O
.	O
5	O
±	O
7	O
.	O
9	O
)	O
in	O
lung	O
tissues	O
.	O

Anticoagulation	O
is	O
a	O
major	O
concern	O
with	O
ECMO	O
,	O
and	O
the	O
evidence	O
is	O
evolving	O
with	O
respect	O
to	O
diagnostic	O
testing	O
and	O
use	O
of	O
anticoagulants	B-CHED
.	O

RESULTS	O
:	O
Of	O
380	O
children	O
,	O
53	O
children	O
(	O
14	O
%)	O
had	O
AKI	O
(	O
met	B-CHED
any	O
of	O
the	O
RIFLE	O
criteria	O
).	O

Female	O
BALB	O
/	O
c	O
mice	O
were	O
immunized	O
with	O
the	O
purified	O
recombinant	O
S1	O
(	O
rS1	O
)	O
protein	B-CHED
and	O
two	O
monoclonal	O
antibodies	O
,	O
designated	O
8A3A10	O
and	O
12C4G12	O
,	O
were	O
generated	O
by	O
hybridoma	O
technique	O
.	O

The	O
two	O
monoclonal	O
antibodies	O
specifically	O
reacted	O
with	O
PEDV	O
rS1	O
protein	B-CHED
,	O
as	O
proven	O
by	O
Western	O
blot	O
and	O
indirect	O
immunofluorescence	O
assay	O
.	O

ABSTRACT	O
:	O
The	O
functional	O
role	O
of	O
the	O
ELR	O
(+)	O
chemokine	O
CXCL1	O
in	O
host	O
defense	O
and	O
disease	O
following	O
infection	O
of	O
the	O
CNS	B-CHED
with	O
the	O
neurotropic	O
JHM	O
strain	O
of	O
mouse	O
hepatitis	O
virus	O
(	O
JHMV	O
)	O
was	O
examined	O
.	O

Mice	O
in	O
which	O
expression	O
of	O
CXCL1	O
is	O
under	O
the	O
control	O
of	O
a	O
tetracycline	B-CHED
-	O
inducible	O
promoter	O
active	O
within	O
glial	O
fibrillary	O
acidic	O
protein	B-CHED
-	O
positive	O
cells	O
were	O
generated	O
and	O
this	O
allowed	O
for	O
selectively	O
increasing	O
CNS	B-CHED
expression	O
of	O
CXCL1	O
in	O
response	O
to	O
JHMV	O
infection	O
and	O
evaluating	O
the	O
effects	O
on	O
neuroinflammation	O
,	O
control	O
of	O
viral	O
replication	O
,	O
and	O
demyelination	O
.	O

TITLE	O
:	O
Design	O
,	O
synthesis	O
,	O
and	O
biological	O
evaluation	O
of	O
crenatoside	O
analogues	O
as	O
novel	O
influenza	O
neuraminidase	B-CHED
inhibitors	I-CHED
.	O

This	O
work	O
presented	O
design	O
,	O
synthesis	O
of	O
novel	O
crenatoside	O
analogues	O
from	O
readily	O
available	O
d	B-CHED
-	I-CHED
Glucose	I-CHED
and	O
l	B-CHED
-	I-CHED
rhamnose	I-CHED
in	O
a	O
convergent	O
manner	O
.	O

TITLE	O
:	O
Transcutaneous	O
Carbon	B-CHED
Dioxide	I-CHED
Monitoring	O
in	O
Subjects	O
With	O
Acute	O
Respiratory	O
Failure	O
and	O
Severe	O
Hypercapnia	O
.	O

Even	O
after	O
cleaning	O
the	O
monitors	O
with	O
70	O
%	O
alcohol	O
-	O
based	O
disinfectant	B-CHED
,	O
RT	O
-	O
PCR	O
was	O
still	O
weakly	O
positive	O
,	O
and	O
converted	O
to	O
negative	O
only	O
after	O
wiping	O
with	O
diluted	O
sodium	O
chlorite	B-CHED
.	O

ABSTRACT	O
:	O
Mucolipidosis	O
(	O
ML	O
)	O
II	O
alpha	O
/	O
beta	O
is	O
an	O
autosomal	O
recessive	O
disease	O
caused	O
by	O
reduced	O
enzyme	O
activity	O
of	O
N	B-CHED
-	I-CHED
acetylglucosamine	I-CHED
-	O
1	O
-	O
phosphotransferase	O
.	O

The	O
proportion	O
of	O
positively	O
selected	O
sites	O
in	O
ORF1a	O
was	O
much	O
higher	O
than	O
that	O
previously	O
reported	O
for	O
the	O
surface	O
-	O
exposed	O
spike	O
protein	B-CHED
.	O

However	O
,	O
despite	O
diminished	O
germinal	O
center	O
B	O
cells	O
and	O
follicular	O
helper	O
T	O
cells	O
in	O
draining	O
lymph	O
nodes	O
,	O
ASC	O
in	O
bone	O
marrow	O
and	O
antiviral	B-CHED
serum	O
antibody	O
were	O
intact	O
in	O
the	O
absence	O
of	O
CXCL13	O
.	O

However	O
,	O
there	O
are	O
no	O
approved	O
drugs	O
inhibiting	O
RNase	O
H	O
and	O
the	O
efficiency	O
of	O
DNA	B-CHED
polymerase	I-CHED
inhibitors	I-CHED
can	O
be	O
diminished	O
by	O
the	O
presence	O
of	O
drug	O
resistance	O
mutations	O
.	O

Blind	O
docking	O
studies	O
predict	O
that	O
RMNC6	O
could	O
bind	O
two	O
different	O
pockets	O
in	O
the	O
RT	O
:	O
one	O
in	O
the	O
DNA	O
polymerase	O
domain	O
(	O
partially	O
overlapping	O
the	O
non	O
-	O
nucleoside	B-CHED
RT	O
inhibitor	B-CHED
[	O
NNRTI	O
]	O
binding	O
pocket	O
),	O
and	O
a	O
second	O
one	O
close	O
to	O
the	O
RNase	O
H	O
active	O
site	O
.	O

Enzymatic	O
studies	O
showed	O
that	O
RMNC6	O
interferes	O
with	O
efavirenz	B-CHED
(	O
an	O
approved	O
NNRTI	O
)	O
in	O
its	O
binding	O
to	O
the	O
RT	O
polymerase	O
domain	O
,	O
although	O
NNRTI	O
resistance	O
-	O
associated	O
mutations	O
such	O
as	O
K103N	O
,	O
Y181C	O
and	O
Y188L	O
had	O
a	O
minor	O
impact	O
on	O
RT	O
susceptibility	O
to	O
RMNC6	O
.	O

Interestingly	O
,	O
these	O
strains	O
were	O
close	O
to	O
Vietnamese	O
PEDVs	O
on	O
the	O
ORF3	O
genetic	O
tree	O
and	O
showed	O
high	O
(	O
97	O
.	O
0	O
-	O
97	O
.	O
6	O
%)	O
sequence	O
identity	O
to	O
ORF3	O
genes	O
at	O
the	O
nucleotide	B-CHED
level	O
.	O

In	O
addition	O
,	O
antibody	O
neutralization	O
assay	O
and	O
shRNA	O
knockdown	O
experiments	O
indicated	O
a	O
vital	O
role	O
of	O
vimentin	O
in	O
cell	O
binding	O
and	O
uptake	O
of	O
SARS	O
-	O
CoV	O
VLPs	O
and	O
the	O
viral	O
spike	O
protein	B-CHED
.	O

RESULTS	O
:	O
A	O
host	O
intracellular	O
filamentous	O
cytoskeletal	O
protein	B-CHED
vimentin	O
was	O
identified	O
by	O
immunoprecipitation	O
and	O
LC	O
-	O
MS	O
/	O
MS	O
analysis	O
following	O
chemical	O
cross	O
-	O
linking	O
on	O
Vero	O
E6	O
cells	O
that	O
were	O
pre	O
-	O
incubated	O
with	O
the	O
SARS	O
-	O
CoV	O
spike	O
protein	B-CHED
.	O

The	O
DIA	B-CHED
was	O
particularly	O
useful	O
for	O
measuring	O
the	O
titer	O
of	O
IBV	O
vaccine	O
that	O
did	O
not	O
cause	O
apparent	O
stunting	O
but	O
propagated	O
in	O
embryonated	O
chicken	O
eggs	O
such	O
as	O
a	O
heat	O
-	O
adapted	O
vaccine	O
strain	O
.	O

There	O
were	O
not	O
corrletions	O
between	O
IAP	O
and	O
end	O
-	O
expiratory	O
Ptp	B-CHED
(	O
Ptp	B-CHED
-	O
e	O
)	O
and	O
end	O
-	O
inspiratory	O
Ptp	B-CHED
(	O
Ptp	B-CHED
-	O
i	O
)	O
(	O
P	O
>	O
0	O
.	O
05	O
).	O

The	O
gold	B-CHED
standard	O
remains	O
lung	O
-	O
protective	O
mechanical	O
ventilation	O
,	O
using	O
lower	O
-	O
tidal	O
volumes	O
and	O
pressure	O
-	O
limited	O
ventilator	O
titration	O
.	O

In	O
the	O
ICU	O
,	O
patients	O
with	O
sepsis	O
,	O
ARDS	O
,	O
community	O
-	O
acquired	O
pneumonia	O
,	O
exacerbation	O
of	O
chronic	O
obstructive	O
pulmonary	O
disease	O
,	O
severe	O
asthma	O
,	O
or	O
trauma	O
may	O
receive	O
corticosteroids	B-CHED
.	O

It	O
is	O
not	O
rare	O
that	O
ICU	O
patients	O
receive	O
concomitantly	O
neuromuscular	O
blocking	O
drugs	O
and	O
corticosteroids	B-CHED
.	O

TITLE	O
:	O
Cigarette	O
smokers	O
have	O
exaggerated	O
alveolar	O
barrier	O
disruption	O
in	O
response	O
to	O
lipopolysaccharide	B-CHED
inhalation	O
.	O

All	O
MR	O
-	O
RTs	O
exhibited	O
similar	O
sensitivity	O
toward	O
RNase	O
H	O
inhibitors	B-CHED
belonging	O
to	O
different	O
inhibitor	B-CHED
classes	O
,	O
indicating	O
the	O
importance	O
of	O
developing	O
RNase	O
H	O
inhibitors	B-CHED
further	O
as	O
anti	O
-	O
HIV	O
drugs	O
.	O

Lactate	B-CHED
dehydrogenase	O
levels	O
had	O
positive	O
correlations	O
with	O
AST	O
(	O
r	O
=	O
0	O
.	O
95	O
)	O
and	O
ALT	B-CHED
(	O
r	O
=	O
0	O
.	O
87	O
)	O
(	O
all	O
p	O
<	O
0	O
.	O
01	O
).	O

TITLE	O
:	O
Evaluation	O
of	O
antiviral	B-CHED
activities	O
of	O
Houttuynia	O
cordata	O
Thunb	O
.	O

When	O
quercetin	B-CHED
was	O
combined	O
with	O
quercitrin	B-CHED
,	O
enhancement	O
of	O
anti	O
-	O
DENV	O
-	O
2	O
activity	O
and	O
reduced	O
cytotoxicity	O
were	O
observed	O
.	O

Additionally	O
,	O
the	O
epidemic	O
potential	O
of	O
this	O
virus	O
family	O
highlights	O
the	O
need	O
for	O
both	O
vaccines	O
and	O
antivirals	B-CHED
.	O

These	O
morphological	O
airway	O
cultures	O
are	O
also	O
well	O
suited	O
for	O
the	O
identification	O
of	O
antivirals	B-CHED
,	O
evaluation	O
of	O
compound	O
toxicity	O
and	O
viral	O
inhibition	O
.	O

TITLE	O
:	O
Characterization	O
of	O
monoclonal	O
antibodies	O
against	O
feline	O
coronavirus	O
accessory	O
protein	B-CHED
7b	O
.	O

The	O
two	O
mAbs	O
were	O
suitable	O
to	O
detect	O
a	O
24	O
-	O
kDa	O
protein	B-CHED
,	O
which	O
represents	O
the	O
nonglycosylated	O
form	O
of	O
7b	O
in	O
FCoV	O
-	O
infected	O
cells	O
.	O

Anti	O
-	O
infectious	O
therapy	O
was	O
escalated	O
to	O
additional	O
linezolid	B-CHED
and	O
liposomal	O
amphotericine	O
-	O
B	O
.	O
BAL	B-CHED
revealed	O
a	O
significant	O
viral	O
load	O
of	O
HCoV	O
-	O
NL63	O
.	O

Based	O
on	O
successful	O
application	O
of	O
PEG	B-CHED
-	O
IFN	O
against	O
the	O
related	O
SARS	O
coronavirus	O
in	O
animal	O
experiments	O
,	O
a	O
single	O
injection	O
of	O
180	O
μg	O
PEG	B-CHED
-	O
IFN	O
-	O
α2b	O
was	O
applied	O
.	O

HCoV	O
-	O
NL63	O
replication	O
can	O
be	O
reduced	O
by	O
treatment	O
with	O
peg	B-CHED
-	O
IFN	O
if	O
diagnosed	O
early	O
.	O

TITLE	O
:	O
Cryo	O
-	O
electron	O
microscopy	O
structure	O
of	O
a	O
coronavirus	O
spike	O
glycoprotein	B-CHED
trimer	O
.	O

Concomitant	O
use	O
of	O
immunomodulators	O
,	O
such	O
as	O
corticosteroids	B-CHED
or	O
immunoglobulins	O
with	O
antibiotics	B-CHED
effective	O
against	O
M	O
.	O
pneumoniae	O
,	O
can	O
be	O
considered	O
as	O
treatment	O
modalities	O
for	O
most	O
severe	O
cases	O
,	O
such	O
as	O
encephalitis	O
.	O

M	O
protein	B-CHED
rather	O
than	O
M	O
mRNA	B-CHED
is	O
responsible	O
for	O
M	O
-	O
mediated	O
IFN	O
-	O
β	O
induction	O
that	O
is	O
preferentially	O
associated	O
with	O
the	O
activation	O
of	O
the	O
Toll	O
-	O
like	O
receptor	O
(	O
TLR	O
)	O
adaptor	O
proteins	B-CHED
MyD88	O
,	O
TIRAP	O
,	O
and	O
TICAM2	O
but	O
not	O
the	O
RIG	O
-	O
I	O
signaling	O
cascade	O
.	O

Blocking	O
the	O
secretion	O
of	O
M	O
protein	B-CHED
by	O
brefeldin	B-CHED
A	I-CHED
(	O
BFA	O
)	O
failed	O
to	O
reverse	O
the	O
M	O
-	O
mediated	O
IFN	O
-	O
β	O
induction	O
.	O

The	O
antagonist	B-CHED
of	O
both	O
TLR2	O
and	O
TLR4	O
did	O
not	O
impede	O
M	O
-	O
mediated	O
IFN	O
-	O
β	O
induction	O
,	O
indicating	O
that	O
the	O
driving	O
force	O
for	O
the	O
activation	O
of	O
IFN	O
-	O
β	O
production	O
was	O
generated	O
from	O
inside	O
the	O
cells	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
the	O
membrane	O
(	O
M	O
)	O
protein	B-CHED
of	O
SARS	O
-	O
CoV	O
can	O
directly	O
promote	O
the	O
activation	O
of	O
both	O
beta	O
interferon	O
(	O
IFN	O
-	O
β	O
)	O
and	O
NF	O
-	O
κB	O
through	O
a	O
TLR	O
-	O
related	O
signaling	O
pathway	O
independent	O
of	O
TRAF3	O
.	O

These	O
two	O
viruses	O
pose	O
major	O
challenges	O
to	O
clinical	O
management	O
because	O
there	O
are	O
no	O
specific	O
antiviral	B-CHED
drugs	I-CHED
available	O
.	O

ABSTRACT	O
:	O
Carbohydrate	B-CHED
binding	O
agents	O
(	O
CBAs	O
),	O
including	O
natural	O
lectins	O
,	O
are	O
more	O
and	O
more	O
considered	O
as	O
broad	O
-	O
spectrum	O
antivirals	B-CHED
.	O

This	O
meeting	O
summary	O
provides	O
an	O
overview	O
,	O
not	O
only	O
for	O
the	O
conference	O
participants	O
,	O
but	O
also	O
for	O
those	O
interested	O
in	O
the	O
current	O
status	O
of	O
antivirals	B-CHED
for	O
respiratory	O
viruses	O
.	O

Artemether	B-CHED
-	O
lumefantrine	B-CHED
(	O
Riamet	O
(®))	O
is	O
the	O
drug	O
of	O
choice	O
(	O
Grade	O
2C	O
)	O
and	O
dihydroartemisinin	B-CHED
-	O
piperaquine	O
(	O
Eurartesim	O
(®))	O
is	O
an	O
alternative	O
.	O

Severe	O
malaria	O
in	O
any	O
trimester	O
of	O
pregnancy	O
should	O
be	O
treated	O
as	O
for	O
any	O
other	O
patient	O
with	O
artesunate	B-CHED
preferred	O
over	O
quinine	B-CHED
(	O
Grade	O
1C	O
).	O

Children	O
with	O
uncomplicated	O
malaria	O
should	O
be	O
treated	O
with	O
an	O
ACT	O
(	O
artemether	B-CHED
-	O
lumefantrine	B-CHED
or	O
dihydroartemisinin	B-CHED
-	O
piperaquine	O
)	O
as	O
first	O
line	O
treatment	O
(	O
Grade	O
1A	O
).	O

In	O
multivariable	O
analysis	O
,	O
older	O
age	O
,	O
greater	O
severity	O
scores	O
at	O
ICU	O
admission	O
,	O
and	O
hematologic	O
malignancy	O
or	O
liver	O
disease	O
were	O
independently	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
in	O
-	O
hospital	O
death	O
,	O
whereas	O
influenza	O
vaccination	O
prior	O
to	O
ICU	O
admission	O
and	O
adequate	O
antibiotic	B-CHED
administration	O
on	O
ICU	O
admission	O
were	O
associated	O
with	O
a	O
lower	O
risk	O
.	O

Here	O
we	O
prospectively	O
evaluated	O
efficacy	O
and	O
safety	O
of	O
weight	O
-	O
based	O
dosing	O
of	O
eculizumab	O
in	O
eligible	O
pediatric	O
patients	O
with	O
aHUS	O
in	O
an	O
open	O
-	O
label	B-CHED
phase	O
II	O
study	O
.	O

Sequence	O
analysis	O
revealed	O
nucleotide	B-CHED
sequence	O
identities	O
within	O
groups	O
I	O
,	O
II	O
,	O
and	O
III	O
of	O
99	O
.	O
68	O
%-	O
100	O
%,	O
99	O
.	O
36	O
%-	O
100	O
%,	O
and	O
96	O
.	O
42	O
%-	O
100	O
%,	O
respectively	O
.	O

Melatonin	B-CHED
is	O
a	O
well	O
-	O
known	O
anti	O
-	O
inflammatory	O
molecule	O
,	O
which	O
has	O
proven	O
to	O
be	O
effective	O
in	O
ALI	O
induced	O
by	O
many	O
conditions	O
.	O

Our	O
results	O
show	O
that	O
the	O
carboxy	B-CHED
-	O
terminal	O
domain	O
of	O
N	O
protein	B-CHED
,	O
N3	O
,	O
is	O
necessary	O
and	O
sufficient	O
for	O
interaction	O
with	O
M	O
protein	B-CHED
.	O

Unlike	O
its	O
antiviral	B-CHED
actions	O
against	O
positive	O
-	O
strand	O
RNA	O
viruses	O
,	O
the	O
anti	O
-	O
influenza	O
virus	O
activity	O
of	O
TRIM56	O
was	O
independent	O
of	O
the	O
E3	O
ligase	O
activity	O
.	O

The	O
hydroxyproline	B-CHED
level	O
in	O
lung	O
tissue	O
was	O
significantly	O
lower	O
in	O
ALI	O
-	O
EC	O
-	O
T	O
than	O
in	O
ALI	O
-	O
EC	O
and	O
ALI	O
-	O
MV	O
,	O
with	O
most	O
of	O
the	O
lung	O
histopathologic	O
and	O
pathobiologic	O
manifestations	O
in	O
favor	O
of	O
ALI	O
-	O
EC	O
-	O
T	O
.	O
The	O
preliminary	O
data	O
suggested	O
that	O
type	O
II	O
alveolar	O
epithelial	O
cell	O
transplant	O
facilitated	O
lung	O
reparation	O
for	O
ALI	O
in	O
this	O
model	O
.	O

TITLE	O
:	O
Contribution	O
of	O
Lewis	B-CHED
X	I-CHED
Carbohydrate	B-CHED
Structure	O
to	O
Neuropathogenic	O
Murine	O
Coronaviral	O
Spread	O
.	O

In	O
acute	O
exacerbation	O
of	O
COPD	O
ventilator	O
settings	O
need	O
a	O
long	O
expiration	O
and	O
short	O
inspiration	O
time	O
to	O
avoid	O
further	O
hyperinflation	O
and	O
an	O
increase	O
in	O
intrinsic	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	B-CHED
).	O

If	O
severe	O
respiratory	O
acidosis	O
and	O
hypercapnia	O
cannot	O
be	O
managed	O
by	O
mechanical	O
ventilation	O
therapy	O
alone	O
extracorporeal	O
venous	O
CO2	B-CHED
removal	O
may	O
be	O
necessary	O
.	O

TITLE	O
:	O
Antigen	B-CHED
Production	O
in	O
Plant	O
to	O
Tackle	O
Infectious	O
Diseases	O
Flare	O
Up	O
:	O

We	O
analyzed	O
patient	O
history	O
,	O
the	O
partial	O
arterial	O
pressure	O
of	O
oxygen	B-CHED
(	O
PaO2	O
)/	O
fraction	O
of	O
inspired	O
oxygen	B-CHED
(	O
FiO2	O
)	O
ratio	O
,	O
and	O
patient	O
outcome	O
.	O

In	O
light	O
of	O
the	O
broad	O
antiviral	B-CHED
activity	O
of	O
β	O
-	O
defensins	O
,	O
we	O
tested	O
the	O
antiviral	B-CHED
activity	O
of	O
11	O
peptides	B-CHED
derived	O
from	O
mouse	O
β	O
-	O
defensin	O
-	O
4	O
and	O
found	O
that	O
a	O
short	O
peptide	B-CHED
,	O
P9	O
,	O
exhibited	O
potent	O
and	O
broad	O
-	O
spectrum	O
antiviral	B-CHED
effects	O
against	O
multiple	O
respiratory	O
viruses	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
including	O
influenza	O
A	O
virus	O
H1N1	O
,	O
H3N2	B-CHED
,	O
H5N1	O
,	O
H7N7	O
,	O
H7N9	O
,	O
SARS	O
-	O
CoV	O
and	O
MERS	O
-	O
CoV	O
.	O
The	O
antiviral	B-CHED
activity	O
of	O
P9	O
was	O
attributed	O
to	O
its	O
high	O
-	O
affinity	O
binding	O
to	O
viral	O
glycoproteins	B-CHED
,	O
as	O
well	O
as	O
the	O
abundance	O
of	O
basic	O
amino	B-CHED
acids	I-CHED
in	O
its	O
composition	O
.	O

ALI	O
was	O
induced	O
in	O
Wistar	O
rats	O
by	O
intraperitoneal	O
Escherichia	O
coli	O
lipopolysaccharide	B-CHED
(	O
LPS	B-CHED
,	O
5	O
mg	O
/	O
kg	O
).	O

The	O
BAL	B-CHED
neutrophil	O
content	O
was	O
also	O
higher	O
in	O
the	O
LPS	B-CHED
-	O
supine	O
group	O
compared	O
to	O
the	O
LPS	B-CHED
-	O
prone	O
and	O
control	O
groups	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

TITLE	O
:	O
[	O
Mesenchymal	O
Stem	O
Cells	O
Combined	O
with	O
Budesonide	B-CHED
,	O
Almeterol	O
and	O
Azithromycin	B-CHED
for	O
the	O
Treatment	O
of	O
Bronchiolitis	O
Obliterans	O
Syndrome	O
after	O
Hematopoietic	O
Stem	O
Cell	O
Transplantation	O
].	O

TITLE	O
:	O
Clarification	O
of	O
Interaction	O
Mechanism	O
of	O
Mouse	O
Hepatitis	O
Virus	O
(	O
MHV	O
)	O
N	O
and	O
nsp3	O
Protein	B-CHED
with	O
Homology	O
Modeling	O
and	O
Protein	B-CHED
-	O
Protein	B-CHED
Docking	O
Analysis	O
.	O

Therefore	O
,	O
it	O
is	O
necessary	O
to	O
know	O
the	O
definition	O
of	O
the	O
interaction	O
mechanism	O
of	O
N	O
and	O
nsp3	O
protein	B-CHED
in	O
terms	O
of	O
the	O
CoV	O
replication	O
transcription	O
mechanism	O
.	O

As	O
a	O
result	O
,	O
Lys	B-CHED
113	O
,	O
Arg	B-CHED
125	O
,	O
Tyr	B-CHED
127	O
,	O
Glu	B-CHED
173	O
,	O
Tyr	B-CHED
190	O
residues	O
that	O
play	O
an	O
important	O
role	O
in	O
virus	O
replication	O
were	O
determined	O
.	O

One	O
set	O
of	O
MERS	O
-	O
CoV	O
related	O
microarray	O
data	O
and	O
27	O
target	O
genes	O
of	O
ribavirin	B-CHED
and	O
interferon	O
-	O
α	O
were	O
acquired	O
from	O
the	O
online	O
databases	O
.	O

While	O
CDV	B-CHED
and	O
CRCoV	O
infections	O
were	O
exclusively	O
found	O
in	O
dogs	O
younger	O
than	O
one	O
year	O
,	O
the	O
vast	O
majority	O
of	O
infections	O
with	O
P	O
.	O
multocida	O
and	O
B	O
.	O
bronchiseptica	O
were	O
both	O
common	O
either	O
in	O
dogs	O
younger	O
than	O
4	O
months	O
or	O
older	O
than	O
one	O
year	O
.	O

TITLE	O
:	O
Recent	O
progress	O
in	O
the	O
discovery	O
of	O
inhibitors	B-CHED
targeting	O
coronavirus	O
proteases	O
.	O

This	O
review	O
summarizes	O
the	O
recent	O
advances	O
in	O
biological	O
and	O
structural	O
studies	O
,	O
together	O
with	O
the	O
development	O
of	O
inhibitors	B-CHED
targeting	O
CoV	O
proteases	O
,	O
particularly	O
main	O
proteases	O
(	O
M	O
(	O
pro	B-CHED
)	O
s	O
),	O
which	O
could	O
help	O
develop	O
effective	O
treatments	O
to	O
prevent	O
CoV	O
infection	O
.	O

Myeloid	O
differentiation	O
primary	O
response	O
protein	B-CHED
88	O
(	O
MyD88	O
)	O
was	O
upregulated	O
in	O
the	O
trachea	O
during	O
early	O
infection	O
.	O

A	O
60	O
-	O
year	O
-	O
old	O
man	B-CHED
presented	O
with	O
pneumonia	O
and	O
congestive	O
heart	O
failure	O
.	O

TITLE	O
:	O
Spatial	O
Configuration	O
and	O
Three	O
-	O
Dimensional	O
Conformation	O
Directed	O
Design	O
,	O
Synthesis	O
,	O
Antiviral	B-CHED
Activity	O
,	O
and	O
Structure	O
-	O
Activity	O
Relationships	O
of	O
Phenanthroindolizidine	O
Analogues	O
.	O

In	O
terms	O
of	O
clinical	O
period	O
,	O
the	O
days	O
from	O
onset	O
to	O
death	O
[	O
13	O
(	O
4	O
~	O
17	O
)	O
vs	O
14	O
.	O
5	O
(	O
0	O
~	O
52	O
),	O
p	O
=	O
0	O
.	O
045	O
]	O
and	O
to	O
discharge	O
[	O
11	O
(	O
5	O
~	O
24	O
)	O
vs	O
24	O
(	O
0	O
~	O
74	O
),	O
p	O
=	O
0	O
.	O
010	O
]	O
and	O
be	O
hospitalized	O
days	O
[	O
9	O
.	O
5	O
(	O
3	O
~	O
22	O
)	O
vs	O
22	O
(	O
0	O
~	O
69	O
),	O
p	O
=	O
0	O
.	O
040	O
]	O
were	O
much	O
shorter	O
in	O
MERS	O
-	O
HCP	B-CHED
than	O
SARS	O
-	O
HCP	B-CHED
.	O

However	O
,	O
no	O
statistical	O
difference	O
was	O
found	O
in	O
MERS	O
-	O
HCP	B-CHED
and	O
SARS	O
-	O
HCP	B-CHED
.	O

Of	O
6492	O
individuals	O
,	O
321	O
reported	O
an	O
ARI	B-CHED
within	O
7	O
days	O
(	O
4	O
·	O
9	O
%	O
total	O
,	O
5	O
·	O
7	O
%	O
in	O
Rochester	O
,	O
4	O
·	O
4	O
%	O
in	O
Marshfield	O
);	O
swabs	O
were	O
collected	O
from	O
208	O
subjects	O
.	O

Cell	O
tropism	O
and	O
host	O
range	O
is	O
determined	O
in	O
part	O
by	O
the	O
coronavirus	O
spike	O
(	O
S	O
)	O
protein	B-CHED
,	O
which	O
binds	O
cellular	O
receptors	O
and	O
mediates	O
membrane	O
fusion	O
.	O

The	O
indication	O
of	O
VV	O
-	O
ECMO	O
was	O
a	O
severe	O
hypoxemia	O
(	O
PaO2	O
/	O
FiO2	O
ratio	O
<	O
70	O
mmHg	O
)	O
under	O
mechanical	O
ventilation	O
(	O
MV	O
)	O
with	O
a	O
peak	O
inspiratory	O
pressure	O
(	O
PIP	B-CHED
)	O
>	O
35	O
cmH2O	O
and	O
a	O
FiO2	O
>	O
0	O
.	O
8	O
.	O

m336	O
was	O
administered	O
to	O
rabbits	O
intravenously	O
or	O
intranasally	O
before	O
infection	O
with	O
MERS	O
-	O
CoV	O
.	O
Prophylaxis	O
with	O
m336	O
resulted	O
in	O
a	O
reduction	O
of	O
pulmonary	O
viral	O
RNA	O
titers	O
by	O
40	O
-	O
9000	O
-	O
fold	O
,	O
compared	O
with	O
an	O
irrelevant	O
control	O
antibody	O
with	O
little	O
to	O
no	O
inflammation	O
or	O
viral	O
antigen	B-CHED
detected	O
.	O

ABSTRACT	O
:	O
Because	O
HIV	O
-	O
1	O
reverse	O
transcriptase	O
is	O
an	O
enzyme	O
whose	O
catalytic	O
activity	O
depends	O
on	O
its	O
heterodimeric	O
structure	O
,	O
this	O
system	O
could	O
be	O
a	O
target	O
for	O
inhibitors	B-CHED
that	O
perturb	O
the	O
interactions	O
between	O
the	O
protein	B-CHED
subunits	O
,	O
p51	O
and	O
p66	O
.	O

Two	O
CD8	O
(+)	O
T	O
cell	O
responses	O
targeting	O
the	O
SARS	O
-	O
CoV	O
membrane	O
(	O
M	O
)	O
and	O
nucleocapsid	O
(	O
N	O
)	O
proteins	B-CHED
were	O
characterized	O
by	O
determining	O
their	O
HLA	O
restriction	O
and	O
minimal	O
T	O
cell	O
epitope	B-CHED
regions	O
.	O

Coronavirus	O
transcription	O
is	O
regulated	O
by	O
multiple	O
factors	O
,	O
including	O
the	O
extent	O
of	O
base	O
-	O
pairing	O
between	O
transcription	O
-	O
regulating	O
sequences	O
of	O
positive	O
and	O
negative	O
polarity	O
,	O
viral	O
and	O
cell	O
protein	B-CHED
-	O
RNA	O
binding	O
,	O
and	O
high	O
-	O
order	O
RNA	O
-	O
RNA	O
interactions	O
.	O

Similarly	O
,	O
next	O
generation	O
sequencing	O
of	O
all	O
nucleic	B-CHED
acid	I-CHED
in	O
a	O
blood	O
sample	O
is	O
currently	O
possible	O
but	O
impractical	O
for	O
generalized	O
screening	O
.	O

According	O
to	O
a	O
genotyping	O
method	O
developed	O
previously	O
for	O
HCoV	O
-	O
OC43	O
,	O
BCoVs	O
and	O
BCoVs	O
-	O
like	O
are	O
distributed	O
on	O
three	O
main	O
sub	O
-	O
clusters	B-CHED
named	O
C1	O
,	O
C2	O
,	O
and	O
C3	O
.	O

An	O
autopsy	O
revealed	O
multiple	O
foci	O
of	O
air	B-CHED
-	O
space	O
pneumonia	O
containing	O
numerous	O
acid	O
-	O
fast	O
bacilli	O
without	O
granuloma	O
formation	O
,	O
accompanied	O
by	O
diffuse	O
alveolar	O
damage	O
.	O

Though	O
AI	O
-	O
H9N2	O
viruses	O
showed	O
low	O
rate	O
of	O
evolution	O
in	O
comparison	O
to	O
recent	O
strains	O
,	O
few	O
amino	B-CHED
acid	I-CHED
substitutions	O
indicative	O
of	O
antibody	O
selection	O
pressure	O
were	O
observed	O
in	O
the	O
HA	O
gene	O
.	O

These	O
results	O
demonstrated	O
that	O
SL7207	O
(	O
pVAXD	O
-	O
PS1	O
-	O
TS	O
)	O
possess	O
the	O
immunological	O
functions	O
of	O
the	O
two	O
S	O
proteins	B-CHED
of	O
TGEV	O
and	O
PEDV	O
,	O
indicating	O
that	O
SL7207	O
(	O
pVAXD	O
-	O
PS1	O
-	O
TS	O
)	O
is	O
a	O
candidate	O
oral	O
vaccine	O
for	O
TGE	O
and	O
PED	O
.	O

The	O
issue	O
was	O
addressed	O
by	O
comparing	O
the	O
effects	O
on	O
lung	O
function	O
of	O
CMV	O
and	O
HFJV	O
in	O
two	O
rabbit	O
models	O
of	O
neonatal	O
acute	O
lung	O
injury	O
:	O
repetitive	O
saline	O
lung	O
lavage	O
(	O
LAV	O
)	O
and	O
meconium	O
aspiration	O
syndrome	O
(	O
MAS	B-CHED
)	O
induced	O
by	O
intratracheal	O
meconium	O
instillation	O
.	O

Both	O
LAV	O
and	O
MAS	B-CHED
significantly	O
decreased	O
lung	O
compliance	O
,	O
increased	O
airway	O
resistance	O
,	O
and	O
caused	O
severe	O
hypoxemia	O
,	O
hypercarbia	O
,	O
and	O
acidosis	O
.	O

Cellular	O
therapy	O
by	O
reinfusing	O
autologous	O
bone	O
marrow	O
-	O
derived	O
MSCs	O
into	O
MDR	B-CHED
/	O
XDR	O
-	O
TB	O
patients	O
shows	O
promise	O
,	O
whereas	O
adjunctive	O
T	O
cell	O
-	O
based	O
therapies	O
are	O
considered	O
.	O

To	O
improve	O
their	O
status	O
for	O
use	O
as	O
donor	B-CHED
pigs	O
in	O
xenotransplantation	O
,	O
the	O
viruses	O
detected	O
might	O
be	O
eliminated	O
by	O
selection	O
of	O
negative	O
animals	O
,	O
Cesarean	O
section	O
,	O
and	O
vaccination	O
.	O

All	O
of	O
the	O
new	O
compounds	O
were	O
evaluated	O
for	O
their	O
anti	O
-	O
HIV	O
activities	O
in	O
MT	O
-	O
4	O
cells	O
using	O
the	O
MTT	B-CHED
method	O
.	O

Aggressive	O
diagnostic	O
efforts	O
showed	O
sero	O
-	O
positivity	O
for	O
Legionella	O
IgM	O
.	O
The	O
patient	O
recovered	O
following	O
antibiotic	B-CHED
therapy	O
and	O
cesarean	O
delivery	O
.	O

ABSTRACT	O
:	O
The	O
proteasome	B-CHED
inhibitor	I-CHED
bortezomib	B-CHED
is	O
indicated	O
for	O
use	O
in	O
the	O
treatment	O
of	O
multiple	O
myeloma	O
(	O
MM	O
)	O
patients	O
.	O

In	O
addition	O
,	O
the	O
present	O
study	O
reviewed	O
the	O
characteristics	O
,	O
including	O
medical	O
history	O
,	O
clinical	O
manifestations	O
,	O
treatment	O
strategies	O
and	O
outcomes	O
,	O
of	O
all	O
16	O
MM	O
patients	O
with	O
bortezomib	B-CHED
-	O
induced	O
severe	O
pulmonary	O
complications	O
reported	O
previously	O
in	O
Pubmed	O
.	O

We	O
found	O
that	O
purifying	O
selection	O
was	O
the	O
main	O
evolutionary	O
pressure	O
in	O
the	O
protein	B-CHED
-	O
coding	O
regions	O
,	O
while	O
the	O
S1	O
gene	O
bears	O
the	O
greatest	O
positive	O
selection	O
pressure	O
.	O

In	O
this	O
work	O
,	O
a	O
set	O
of	O
point	O
mutants	O
affecting	O
different	O
motifs	O
within	O
the	O
ExoN	O
domain	O
of	O
nsp14	O
was	O
generated	O
,	O
using	O
transmissible	O
gastroenteritis	O
virus	O
as	O
a	O
model	O
of	O
Alphacoronavirus	O
Mutants	O
lacking	O
ExoN	O
activity	O
were	O
nonviable	O
despite	O
being	O
competent	O
in	O
both	O
viral	O
RNA	O
and	O
protein	B-CHED
synthesis	O
.	O

The	O
innate	O
immune	O
response	O
is	O
the	O
first	O
line	O
of	O
antiviral	B-CHED
defense	O
that	O
culminates	O
in	O
the	O
synthesis	O
of	O
interferon	O
and	O
proinflammatory	O
cytokines	O
to	O
control	O
viral	O
replication	O
.	O

In	O
this	O
L	O
.	O
casei	O
vaccine	O
,	O
repetitive	O
peptides	B-CHED
expressed	O
by	O
L	O
.	O
casei	O
(	O
specifically	O
the	O
MDP	B-CHED
and	O
tuftsin	O
fusion	O
protein	B-CHED
(	O
MT	O
))	O
were	O
repeated	O
20	O
times	O
and	O
the	O
D	O
antigenic	O
site	O
of	O
the	O
TGEV	O
spike	O
(	O
S	O
)	O
protein	B-CHED
was	O
repeated	O
6	O
times	O
.	O

All	O
three	O
genotypes	O
contained	O
at	O
least	O
one	O
strain	O
with	O
less	O
than	O
99	O
%	O
nucleotide	B-CHED
sequence	O
identity	O
to	O
the	O
corresponding	O
vaccine	O
strains	O
.	O

Our	O
primary	O
outcome	O
was	O
the	O
correlation	O
between	O
the	O
end	O
tidal	O
CO2	B-CHED
(	O
EtCO2	O
)	O
and	O
the	O
clinical	O
decision	O
of	O
hospital	O
admission	O
and	O
discharge	O
.	O

Previously	O
,	O
we	O
have	O
reported	O
the	O
inhibitors	B-CHED
that	O
target	O
3C	O
-	O
like	O
protease	O
(	O
3CLpro	O
)	O
with	O
broad	O
-	O
spectrum	O
activity	O
against	O
important	O
human	O
and	O
animal	O
coronaviruses	O
.	O

TITLE	O
:	O
Mapping	O
the	O
Specific	O
Amino	B-CHED
Acid	I-CHED
Residues	O
That	O
Make	O
Hamster	O
DPP4	O
Functional	O
as	O
a	O
Receptor	O
for	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
.	O

Through	O
amino	B-CHED
acid	I-CHED
sequence	O
analysis	O
of	O
S	O
proteins	B-CHED
of	O
representative	O
CoVs	O
,	O
we	O
identified	O
a	O
common	O
region	O
as	O
a	O
possible	O
FP	O
(	O
pFP	B-CHED
)	O
that	O
shares	O
the	O
characteristics	O
of	O
FPs	O
of	O
class	O
I	O
viral	O
fusion	O
proteins	B-CHED
,	O
including	O
high	O
Ala	B-CHED
/	O
Gly	B-CHED
content	O
,	O
intermediate	O
hydrophobicity	O
,	O
and	O
few	O
charged	O
residues	O
.	O

Virological	O
analysis	O
determined	O
that	O
the	O
virus	O
belonged	O
to	O
H5	O
clade	O
2	O
.	O
3	O
.	O
4	O
.	O
4	O
and	O
it	O
has	O
obtained	O
partial	O
ability	O
for	O
mammalian	O
adaptation	O
and	O
amantadine	B-CHED
resistance	O
.	O

Purified	O
recombinant	O
protein	B-CHED
was	O
analysed	O
by	O
SDS	B-CHED
-	O
PAGE	O
,	O
Western	O
blot	O
and	O
deglycosylation	O
assay	O
.	O

Individual	O
bedside	O
methods	O
to	O
guide	O
PEEP	B-CHED
/	O
recruitment	O
(	O
e	O
.	O
g	O
.,	O
transpulmonary	O
pressure	O
)	O
are	O
not	O
(	O
yet	O
)	O
available	O
.	O

Of	O
the	O
730	O
patients	O
with	O
ARDS	O
,	O
168	O
(	O
23	O
.	O
0	O
%)	O
met	B-CHED
ECMO	O
inclusion	O
criteria	O
and	O
515	O
(	O
70	O
.	O
5	O
%)	O
never	O
met	B-CHED
ECMO	O
eligibility	O
due	O
to	O
inadequately	O
severe	O
disease	O
.	O

RESULTS	O
:	O
Of	O
the	O
730	O
patients	O
with	O
ARDS	O
,	O
168	O
(	O
23	O
.	O
0	O
%)	O
met	B-CHED
ECMO	O
inclusion	O
criteria	O
and	O
515	O
(	O
70	O
.	O
5	O
%)	O
never	O
met	B-CHED
ECMO	O
eligibility	O
due	O
to	O
inadequately	O
severe	O
disease	O
.	O

Rhesus	O
macaques	O
inoculated	O
with	O
MERS	O
-	O
CoV	O
VLPs	O
and	O
Alum	O
adjuvant	B-CHED
induced	O
virus	O
-	O
neutralizing	O
antibodies	O
titers	O
up	O
to	O
1	O
:	O
40	O
and	O
induced	O
specific	O
IgG	O
antibodies	O
against	O
the	O
receptor	O
binding	O
domain	O
(	O
RBD	O
),	O
with	O
endpoint	O
titers	O
reaching	O
1	O
:	O
1	O
,	O
280	O
.	O

Sequence	O
analysis	O
of	O
the	O
spike	O
protein	B-CHED
(	O
S	O
)	O
genes	O
showed	O
that	O
each	O
specimen	O
had	O
unique	O
characteristics	O
,	O
and	O
that	O
the	O
PEDV1	O
/	O
S	O
/	O
4	O
strain	O
could	O
be	O
differentiated	O
from	O
the	O
others	O
via	O
a	O
unique	O
mutation	O
of	O
the	O
S	O
gene	O
.	O

Urinary	O
protein	B-CHED
excretion	O
steadily	O
increased	O
for	O
a	O
microalbumin	O
to	O
creatinine	B-CHED
ratio	O
of	O
538	O
.	O
4	O
mg	O
/	O
g	O
Cr	O
and	O
a	O
protein	B-CHED
to	O
creatinine	B-CHED
ratio	O
of	O
3	O
,	O
025	O
.	O
8	O
mg	O
/	O
g	O
Cr	O
.	O

The	O
isotope	O
dilution	O
mass	O
spectrometry	O
traceable	O
serum	O
creatinine	B-CHED
level	O
increased	O
to	O
3	O
.	O
0	O
mg	O
/	O
dL	O
.	O
We	O
performed	O
a	O
kidney	O
biopsy	O
8	O
weeks	O
after	O
the	O
onset	O
of	O
symptoms	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
optic	O
nerve	O
damage	O
and	O
vision	O
loss	O
in	O
patients	O
undergoing	O
PPV	B-CHED
.	O

The	O
patient	O
was	O
previously	O
diagnosed	O
with	O
meningoencephalitis	O
of	O
unknown	O
etiology	O
(	O
MUO	O
),	O
caudal	O
occipital	O
malformation	O
,	O
and	O
syringohydromyelia	O
,	O
and	O
was	O
being	O
treated	O
with	O
oral	O
prednisone	B-CHED
and	O
levetiracetam	B-CHED
,	O
and	O
cytarabine	B-CHED
infusions	O
.	O

Methods	O
Antibody	O
-	O
mediated	O
TRALI	O
was	O
experimentally	O
induced	O
in	O
mice	O
by	O
lipopolysaccharide	B-CHED
priming	O
followed	O
by	O
the	O
administration	O
of	O
an	O
anti	O
-	O
MHC	O
I	O
mAb	O
.	O

Furthermore	O
,	O
when	O
platelet	O
functions	O
were	O
defective	O
because	O
of	O
administration	O
of	O
aspirin	B-CHED
or	O
clopidogrel	B-CHED
,	O
or	O
because	O
of	O
glycoprotein	B-CHED
(	O
GP	O
)	O
IIbIIIa	O
deficiency	O
,	O
TRALI	O
still	O
developed	O
but	O
no	O
lung	O
hemorrhages	O
were	O
observed	O
.	O

The	O
initial	O
mean	O
oxygen	B-CHED
index	O
was	O
24	O
.	O
5	O
±	O
10	O
.	O
4	O
,	O
and	O
mean	O
PaO2	O
/	O
FiO2	O
was	O
80	O
.	O
6	O
±	O
25	O
.	O

Three	O
patients	O
in	O
CV	O
with	O
LVRM	O
group	O
failed	O
to	O
wean	O
oxygen	B-CHED
requirement	O
and	O
were	O
cross	O
-	O
over	O
to	O
HFOV	O
group	O
.	O

TITLE	O
:	O
Extensive	O
Viable	O
Middle	O
East	O
Respiratory	O
Syndrome	O
(	O
MERS	O
)	O
Coronavirus	O
Contamination	O
in	O
Air	B-CHED
and	O
Surrounding	O
Environment	O
in	O
MERS	O
Isolation	O
Wards	O
.	O

None	O
of	O
the	O
included	O
studies	O
reported	O
a	O
standardised	O
classification	O
of	O
the	O
protective	O
properties	O
against	O
viral	O
penetration	O
of	O
the	O
PPE	B-CHED
,	O
and	O
only	O
one	O
reported	O
the	O
brand	O
of	O
PPE	B-CHED
used	O
.	O

Collectively	O
,	O
our	O
findings	O
suggest	O
a	O
common	O
and	O
conserved	O
mechanism	O
through	O
which	O
highly	O
pathogenic	O
MERS	O
-	O
CoV	O
and	O
SARS	O
-	O
CoV	O
harness	O
their	O
M	O
proteins	B-CHED
to	O
suppress	O
type	O
I	O
IFN	O
expression	O
at	O
the	O
level	O
of	O
TBK1	O
-	O
dependent	O
phosphorylation	O
and	O
activation	O
of	O
IRF3	O
resulting	O
in	O
evasion	O
of	O
the	O
host	O
innate	O
antiviral	B-CHED
response	O
.	O

Nitazoxanide	O
also	O
suppresses	O
production	O
of	O
pro	B-CHED
-	O
inflammatory	O
cytokines	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
and	O
suppresses	O
interleukin	O
6	O
production	O
in	O
mice	O
.	O

Results	O
Of	O
10	O
samples	O
from	O
cats	O
with	O
CNS	B-CHED
FIP	O
,	O
eight	O
had	O
detectable	O
CSF	O
macrophages	O
,	O
seven	O
of	O
which	O
were	O
positive	O
for	O
FCoV	O
.	O
Ten	O
of	O
11	O
samples	O
from	O
cats	O
with	O
confirmed	O
FIP	O
without	O
neurological	O
signs	O
had	O
macrophages	O
in	O
the	O
CSF	O
,	O
with	O
all	O
10	O
being	O
ICC	O
-	O
positive	O
.	O

CNS	B-CHED
ICC	O
could	O
be	O
helpful	O
to	O
discover	O
pre	O
-	O
neurological	O
stages	O
of	O
CNS	B-CHED
FIP	O
.	O

A	O
decreased	O
expression	O
pattern	O
of	O
induced	O
COX	O
-	O
2	O
and	O
reduced	O
production	O
of	O
downstream	O
PGE2	B-CHED
occurred	O
upon	O
TNF	O
-	O
α	O
stimulation	O
in	O
G6PD	O
-	O
kd	O
A549	O
cells	O
compared	O
with	O
scramble	O
control	O
A549	O
cells	O
.	O

The	O
complete	O
genomic	O
sequence	O
of	O
YC2014	O
and	O
the	O
nucleotide	B-CHED
sequence	O
of	O
S	O
gene	O
were	O
aligned	O
with	O
sequences	O
of	O
published	O
isolates	O
using	O
MEGA	O
5	O
.	O
1	O
software	O
.	O

No	O
studies	O
on	O
the	O
antiviral	B-CHED
activity	O
of	O
nanomaterials	O
on	O
non	O
-	O
enveloped	O
viruses	O
have	O
been	O
reported	O
.	O

The	O
SYBR	B-CHED
green	I-CHED
I	I-CHED
real	O
-	O
time	O
RT	O
-	O
PCR	O
test	O
described	O
herein	O
can	O
be	O
used	O
to	O
rapidly	O
distinguish	O
IBV	O
from	O
other	O
respiratory	O
pathogens	O
,	O
which	O
is	O
important	O
for	O
diagnosis	O
and	O
control	O
of	O
infectious	O
bronchitis	O
outbreaks	O
in	O
Morocco	O
.	O

CONCLUSIONS	O
:	O
The	O
SYBR	B-CHED
green	I-CHED
I	I-CHED
real	O
-	O
time	O
RT	O
-	O
PCR	O
test	O
described	O
herein	O
can	O
be	O
used	O
to	O
rapidly	O
distinguish	O
IBV	O
from	O
other	O
respiratory	O
pathogens	O
,	O
which	O
is	O
important	O
for	O
diagnosis	O
and	O
control	O
of	O
infectious	O
bronchitis	O
outbreaks	O
in	O
Morocco	O
.	O

Propofol	B-CHED
(	O
PROP	B-CHED
)	O
is	O
frequently	O
used	O
as	O
a	O
sedative	B-CHED
in	O
TBI	O
since	O
it	O
has	O
been	O
shown	O
to	O
reduce	O
the	O
cerebral	O
metabolic	O
rate	O
,	O
but	O
it	O
may	O
lead	O
to	O
PROP	B-CHED
-	O
related	O
infusion	O
syndrome	O
and	O
hemodynamic	O
compromise	O
.	O

After	O
ECMO	O
running	O
3	O
days	O
,	O
most	O
factors	O
of	O
the	O
ECMO	O
survival	O
group	O
were	O
better	O
than	O
those	O
of	O
the	O
control	O
group	O
(	O
all	O
P	O
<	O
0	O
.	O
05	O
)	O
except	O
MAP	O
,	O
but	O
most	O
factors	O
between	O
the	O
ECMO	O
non	O
-	O
survival	O
group	O
and	O
the	O
control	O
group	O
were	O
not	O
significantly	O
different	O
(	O
all	O
P	O
>	O
0	O
.	O
05	O
),	O
while	O
the	O
serum	O
lactate	B-CHED
level	O
was	O
higher	O
(	O
t	O
=-	O
3	O
.	O
156	O
,	O
P	O
=	O
0	O
.	O
003	O
)	O
and	O
the	O
MAP	O
lower	O
(	O
t	O
=	O
3	O
.	O
578	O
,	O
P	O
=	O
0	O
.	O
001	O
).	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
feasibility	O
and	O
safety	O
of	O
heparin	B-CHED
-	O
free	O
veno	O
-	O
venous	O
extracorporeal	O
life	O
support	O
(	O
VV	O
ECLS	O
)	O
as	O
a	O
means	O
of	O
salvaging	O
polytrauma	O
patients	O
with	O
life	O
-	O
threatening	O
hypoxemia	O
.	O

Finally	O
,	O
a	O
chimeric	O
antigen	B-CHED
was	O
designed	O
using	O
computational	O
techniques	O
.	O

TITLE	O
:	O
Effect	O
of	O
Extracorporeal	O
Membrane	O
Oxygenation	O
Use	O
on	O
Sedative	B-CHED
Requirements	O
in	O
Patients	O
with	O
Severe	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
.	O

Compared	O
with	O
pre	O
-	O
PPV	B-CHED
,	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	B-CHED
,	O
cmH2O	O
,	O
1	O
cmH2O	O
=	O
0	O
.	O
098kPa	O
)	O
post	O
-	O
PPV	B-CHED
was	O
significantly	O
higher	O
in	O
ILD	O
group	O
[	O
10	O
.	O
0	O
(	O
10	O
.	O
0	O
,	O
12	O
.	O
0	O
)	O
vs	O
.	O
10	O
.	O
0	O
(	O
9	O
.	O
2	O
,	O
12	O
.	O
0	O
),	O
P	O
<	O
0	O
.	O
05	O
],	O
and	O
respiratory	O
rate	O
(	O
RR	O
,	O
times	O
/	O
min	O
)	O
was	O
significantly	O
lower	O
in	O
non	O
-	O
ILD	O
group	O
[	O
24	O
.	O
5	O
(	O
22	O
.	O
0	O
,	O
27	O
.	O
0	O
)	O
vs	O
.	O
25	O
.	O
5	O
(	O
22	O
.	O
8	O
,	O
28	O
.	O
0	O
),	O
P	O
<	O
0	O
.	O
05	O
].	O

The	O
compliance	O
of	O
the	O
respiratory	O
system	O
(	O
Crs	O
,	O
mL	O
/	O
cmH2O	O
)	O
post	O
-	O
PPV	B-CHED
in	O
non	O
-	O
ILD	O
group	O
was	O
significantly	O
lower	O
than	O
that	O
of	O
the	O
ILD	O
group	O
[	O
19	O
.	O
7	O
(	O
16	O
.	O
1	O
,	O
28	O
.	O
6	O
)	O
vs	O
.	O
23	O
.	O
0	O
(	O
19	O
.	O
0	O
,	O
29	O
.	O
7	O
),	O
P	O
<	O
0	O
.	O
05	O
].	O

No	O
significant	O
difference	O
in	O
Crs	O
(	O
mL	O
/	O
cmH2O	O
)	O
before	O
PPV	B-CHED
treatment	O
was	O
found	O
between	O
non	O
-	O
ILD	O
and	O
ILD	O
groups	O
[	O
24	O
.	O
3	O
(	O
15	O
.	O
9	O
,	O
48	O
.	O
9	O
)	O
vs	O
.	O
18	O
.	O
9	O
(	O
12	O
.	O
7	O
,	O
27	O
.	O
3	O
),	O
P	O
>	O
0	O
.	O
05	O
],	O
and	O
Crs	O
was	O
lower	O
after	O
PPV	B-CHED
treatment	O
in	O
both	O
groups	O
,	O
but	O
without	O
significant	O
difference	O
[	O
non	O
-	O
ILD	O
group	O
:	O
22	O
.	O
7	O
(	O
15	O
.	O
2	O
,	O
27	O
.	O
1	O
)	O
vs	O
.	O
24	O
.	O
3	O
(	O
15	O
.	O
9	O
,	O
48	O
.	O
9	O
);	O
ILD	O
group	O
:	O
16	O
.	O
2	O
(	O
12	O
.	O
8	O
,	O
25	O
.	O
6	O
)	O
vs	O
.	O
18	O
.	O
9	O
(	O
12	O
.	O
7	O
,	O
27	O
.	O
3	O
),	O
both	O
P	O
>	O
0	O
.	O
05	O
].	O

Ceftriaxone	B-CHED
was	O
given	O
on	O
the	O
4th	O
day	O
,	O
and	O
it	O
was	O
changed	O
to	O
meropenem	B-CHED
on	O
the	O
3rd	O
day	O
for	O
2	O
weeks	O
.	O

Oxygen	B-CHED
inhalation	O
(	O
6	O
L	O
/	O
min	O
)	O
was	O
given	O
immediately	O
after	O
admission	O
,	O
but	O
the	O
condition	O
of	O
patient	O
worsened	O
with	O
the	O
following	O
symptoms	O
:	O
frequent	O
cough	O
and	O
obvious	O
shortness	O
of	O
breath	O
.	O

The	O
clinical	O
data	O
in	O
two	O
groups	O
were	O
recorded	O
as	O
following	O
:	O
gender	O
,	O
age	O
;	O
respiratory	O
rate	O
,	O
heart	O
rate	O
,	O
and	O
systolic	O
blood	O
pressure	O
at	O
admission	O
;	O
the	O
lowest	O
values	O
of	O
serum	O
creatinine	B-CHED
(	O
SCr	O
),	O
white	O
blood	O
cell	O
count	O
(	O
WBC	O
),	O
platelet	O
count	O
(	O
PLT	O
),	O
hematocrit	O
(	O
Hct	O
),	O
respectively	O
,	O
within	O
24	O
hours	O
after	O
admission	O
;	O
acute	O
physiology	O
and	O
chronic	O
health	O
evaluation	O
II	O
(	O
APACHE	O
II	O
)	O
score	O
,	O
Glasgow	O
coma	O
scale	O
(	O
GCS	O
)	O
score	O
,	O
sequential	O
organ	O
failure	O
assessment	O
(	O
SOFA	O
),	O
systemic	O
inflammatory	O
response	O
syndrome	O
(	O
SIRS	O
)	O
score	O
,	O
injury	O
severity	O
score	O
(	O
ISS	O
)	O
within	O
24	O
hours	O
of	O
final	O
diagnosis	O
;	O
the	O
performance	O
of	O
emergency	O
operation	O
or	O
intubation	O
within	O
24	O
hours	O
;	O
incidence	O
of	O
sepsis	O
,	O
and	O
clinical	O
outcomes	O
.	O

This	O
assay	O
successfully	O
differentiated	O
three	O
PEDV	O
strains	O
:	O
PC22A	O
(	O
the	O
original	O
US	O
virulent	O
),	O
Iowa106	O
(	O
S	O
-	O
INDEL	O
),	O
and	O
PC177	O
(	O
S	O
-	O
197DEL	O
)	O
that	O
was	O
derived	O
from	O
cell	O
culture	O
adaptation	O
and	O
has	O
a	O
197	O
amino	B-CHED
acid	I-CHED
-	O
deletion	O
in	O
the	O
S1	O
domain	O
.	O

To	O
achieve	O
the	O
soluble	O
expression	O
of	O
recombinant	O
proteins	B-CHED
,	O
several	O
chaperone	O
co	O
-	O
expression	O
systems	O
were	O
tested	O
in	O
this	O
study	O
.	O

Finally	O
,	O
immunization	O
of	O
mice	O
with	O
10	O
μg	O
of	O
purified	O
proteins	B-CHED
elicited	O
highly	O
potent	O
serum	O
IgG	O
and	O
serum	O
neutralizing	O
antibody	O
titers	O
.	O

Finally	O
,	O
immunization	O
of	O
mice	O
with	O
10	O
μg	O
of	O
purified	O
proteins	B-CHED
elicited	O
highly	O
potent	O
serum	O
IgG	O
and	O
serum	O
neutralizing	O
antibody	O
titers	O
.	O

Nanotrap	O
particles	O
are	O
hydrogel	O
particles	O
that	O
are	O
coupled	O
to	O
chemical	O
dye	B-CHED
affinity	O
baits	O
that	O
bind	O
a	O
broad	O
range	O
of	O
proteins	B-CHED
and	O
virions	O
.	O

Intracellular	O
trafficking	O
and	O
indirect	O
immunofluorescence	O
analysis	O
suggested	O
that	O
when	O
M	O
protein	B-CHED
was	O
present	O
,	O
wild	O
-	O
type	O
S	O
protein	B-CHED
(	O
wtS	O
)	O
could	O
be	O
retained	O
in	O
the	O
pre	O
-	O
and	O
post	O
-	O
medial	O
Golgi	O
compartments	O
intracellularly	O
and	O
co	O
-	O
localized	O
with	O
M	O
protein	B-CHED
in	O
the	O
Golgi	O
.	O

In	O
contrast	O
,	O
mutant	O
S	O
protein	B-CHED
lacking	O
the	O
ERRS	O
was	O
distributed	O
throughout	O
the	O
ER	O
and	O
only	O
partially	O
co	O
-	O
localized	O
with	O
M	O
protein	B-CHED
.	O

These	O
challenges	O
are	O
attributable	O
mainly	O
to	O
protein	B-CHED
aggregation	O
and	O
insolubility	O
during	O
expression	O
and	O
purification	O
,	O
as	O
well	O
as	O
to	O
very	O
low	O
expression	O
levels	O
associated	O
with	O
the	O
toxicity	O
of	O
some	O
viral	O
proteins	B-CHED
.	O

Using	O
a	O
wheat	O
germ	O
cell	O
-	O
free	O
protein	B-CHED
synthesis	O
system	O
,	O
we	O
successfully	O
prepared	O
large	O
amounts	O
of	O
MERS	O
-	O
CoV	O
NP	O
antigen	B-CHED
in	O
a	O
state	O
that	O
was	O
highly	O
soluble	O
and	O
intact	O
for	O
immunization	O
.	O

Indirect	O
immunofluorescence	O
assay	O
and	O
western	O
blot	O
analysis	O
showed	O
that	O
the	O
MAb	O
was	O
specifically	O
reacted	O
with	O
the	O
overexpressed	O
porcine	O
BST	O
-	O
2	O
protein	B-CHED
in	O
Vero	O
cells	O
.	O

Corticosteroid	B-CHED
therapy	O
was	O
defined	O
as	O
≥	O
150	O
mg	O
cortisol	B-CHED
equivalent	O
in	O
24	O
hours	O
.	O

Management	O
included	O
amphotericin	B-CHED
B	I-CHED
(	O
n	O
=	O
42	O
,	O
98	O
%),	O
vasopressors	O
(	O
n	O
=	O
36	O
,	O
84	O
%),	O
corticosteroids	B-CHED
(	O
n	O
=	O
22	O
,	O
51	O
%),	O
renal	O
replacement	O
(	O
n	O
=	O
13	O
,	O
30	O
%),	O
and	O
ECMO	O
(	O
n	O
=	O
4	O
,	O
11	O
%).	O

Our	O
study	O
constitutes	O
a	O
crucial	O
and	O
a	O
necessary	O
step	O
allowing	O
preventive	O
and	O
veterinary	O
medicine	B-CHED
to	O
support	O
RVA	O
disease	O
controls	O
in	O
the	O
country	O
.	O

The	O
agreement	O
between	O
predicted	O
and	O
experimental	O
data	O
confirmed	O
the	O
proposed	O
common	O
molecular	O
rationale	O
shared	O
by	O
molecules	O
characterized	O
by	O
different	O
chemical	O
scaffolds	O
in	O
binding	O
to	O
the	O
BVDV	O
RdRp	O
,	O
ultimately	O
yielding	O
compound	O
6b	O
(	O
EC50	O
=	O
0	O
.	O
3	O
μM	O
;	O
IC50	O
=	O
0	O
.	O
48	O
μM	O
)	O
as	O
a	O
new	O
,	O
potent	O
inhibitor	B-CHED
of	O
this	O
Pestivirus	O
.	O

Furthermore	O
,	O
the	O
results	O
showed	O
that	O
the	O
prevalent	O
strains	O
of	O
IBV	O
in	O
ducks	O
had	O
no	O
antigen	B-CHED
homology	O
with	O
the	O
vaccine	O
strains	O
widely	O
used	O
in	O
China	O
except	O
the	O
LDT3	O
-	O
strain	O
,	O
making	O
it	O
urgent	O
to	O
explore	O
and	O
develop	O
new	O
IBV	O
vaccines	O
.	O

This	O
coincided	O
with	O
a	O
decline	O
in	O
his	O
serum	O
lactate	B-CHED
.	O

TITLE	O
:	O
[	O
Development	O
of	O
peptidic	O
MERS	O
-	O
CoV	O
entry	O
inhibitors	B-CHED
].	O

The	O
potential	O
drugs	O
against	O
MERS	O
-	O
CoV	O
mainly	O
consist	O
of	O
monoclonal	O
antibodies	O
,	O
peptides	B-CHED
and	O
small	O
molecular	O
agents	O
.	O

In	O
this	O
study	O
,	O
we	O
constructed	O
a	O
full	O
-	O
length	O
cDNA	O
clone	O
of	O
SL	O
-	O
CoV	O
WIV1	O
(	O
rWIV1	O
),	O
an	O
ORFX	O
deletion	O
mutant	O
(	O
rWIV1	O
-	O
ΔX	O
),	O
and	O
a	O
green	O
fluorescent	O
protein	B-CHED
(	O
GFP	B-CHED
)-	O
expressing	O
mutant	O
(	O
rWIV1	O
-	O
GFP	B-CHED
-	O
ΔX	O
).	O

It	O
will	O
therefore	O
be	O
critical	O
to	O
clarify	O
whether	O
and	O
how	O
this	O
protein	B-CHED
contributes	O
to	O
virulence	O
during	O
viral	O
infection	O
.	O

ABSTRACT	O
:	O
The	O
order	O
Nidovirales	O
currently	O
comprises	O
four	O
virus	O
families	O
:	O
Arteriviridae	O
,	O
Coronaviridae	O
(	O
divided	O
into	O
the	O
subfamilies	O
Coronavirinae	O
and	O
Torovirinae	O
),	O
Roniviridae	O
,	O
and	O
the	O
recently	O
recognized	O
Mesoniviridae	O
RNA	O
cap	O
formation	O
and	O
methylation	O
have	O
been	O
best	O
studied	O
for	O
coronaviruses	O
,	O
with	O
emphasis	O
on	O
the	O
identification	O
and	O
characterization	O
of	O
two	O
virus	O
-	O
encoded	O
methyltransferases	O
(	O
MTases	O
)	O
involved	O
in	O
RNA	O
capping	O
,	O
a	O
guanine	B-CHED
-	O
N7	O
-	O
MTase	O
and	O
a	O
ribose	B-CHED
-	O
2	O
'-	O
O	O
-	O
MTase	O
.	O

The	O
results	O
revealed	O
that	O
SARS	O
-	O
CoV	O
PLpro	O
significantly	O
triggered	O
Egr	O
-	O
1	O
dependent	O
activation	O
of	O
TGF	O
-	O
β1	O
promoter	O
via	O
ROS	B-CHED
/	O
p38	O
MAPK	O
/	O
STAT3	O
pathway	O
,	O
correlating	O
with	O
up	O
-	O
regulation	O
of	O
pro	B-CHED
-	O
fibrotic	O
responses	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Qingfei	O
Xiaoyan	O
Wan	O
(	O
QF	O
),	O
a	O
traditional	O
Chinese	O
medicine	B-CHED
(	O
TCM	O
)	O
formula	O
,	O
has	O
been	O
used	O
clinically	O
in	O
China	O
for	O
the	O
treatment	O
of	O
upper	O
respiratory	O
tract	O
infections	O
,	O
acute	O
or	O
chronic	O
bronchitis	O
and	O
pulmonary	O
infection	O
.	O

TITLE	O
:	O
Resolution	O
acute	O
respiratory	O
distress	O
syndrome	O
through	O
reversing	O
the	O
imbalance	O
of	O
Treg	O
/	O
Th17	O
by	O
targeting	O
the	O
cAMP	B-CHED
signaling	O
pathway	O
.	O

TITLE	O
:	O
Characterization	O
of	O
the	O
Antigen	B-CHED
Processing	O
Machinery	O
and	O
Endogenous	O
Peptide	B-CHED
Presentation	O
of	O
a	O
Bat	O
MHC	O
Class	O
I	O
Molecule	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
an	O
affinity	O
purification	O
/	O
mass	O
spectrometry	O
approach	O
to	O
demonstrate	O
that	O
a	O
bat	O
MHC	O
class	O
I	O
molecule	O
,	O
Ptal	B-CHED
-	O
N	O
*	O
01	O
:	O
01	O
,	O
binds	O
antigenic	O
peptides	B-CHED
and	O
associates	O
with	O
peptide	B-CHED
-	O
loading	O
complex	O
components	O
.	O

Previously	O
,	O
a	O
partially	O
disordered	O
crystal	O
structure	O
of	O
a	O
type	O
II	O
HE	O
revealed	O
how	O
the	O
shift	O
in	O
lectin	O
ligand	B-CHED
specificity	O
was	O
achieved	O
.	O

Mice	O
were	O
instilled	O
with	O
increasing	O
doses	O
of	O
LPS	B-CHED
intratracheally	O
to	O
induce	O
different	O
degrees	O
of	O
ARDS	O
.	O

In	O
LPS	B-CHED
-	O
induced	O
severe	O
ARDS	O
,	O
RIP3	O
knock	O
-	O
out	O
alleviated	O
the	O
hypothermia	O
symptom	O
,	O
increased	O
survival	O
rate	O
and	O
ameliorated	O
the	O
lung	O
tissue	O
injury	O
RIP3	O
depletion	O
also	O
attenuated	O
LPS	B-CHED
-	O
induced	O
increase	O
in	O
IL	O
-	O
1α	O
/	O
β	O
,	O
IL	O
-	O
6	O
and	O
HMGB1	O
release	O
,	O
decreased	O
tissue	O
MPO	O
activity	O
,	O
and	O
reduced	O
neutrophil	O
influx	O
and	O
total	O
protein	B-CHED
concentration	O
in	O
BALF	O
in	O
severe	O
ARDS	O
.	O

Further	O
,	O
RIP3	O
depletion	O
reduced	O
the	O
necrotic	O
cells	O
in	O
the	O
lung	O
and	O
decreased	O
the	O
expression	O
of	O
MLKL	O
,	O
but	O
had	O
no	O
impact	O
on	O
cleaved	O
caspase	O
-	O
3	O
in	O
LPS	B-CHED
-	O
induced	O
ARDS	O
.	O

It	O
is	O
concluded	O
that	O
RIP3	O
-	O
mediated	O
necroptosis	O
is	O
a	O
major	O
mechanism	O
of	O
enhanced	O
inflammation	O
and	O
lung	O
tissue	O
injury	O
in	O
high	O
dose	O
LPS	B-CHED
-	O
induced	O
severe	O
ARDS	O
in	O
mice	O
.	O

To	O
evaluate	O
independent	O
factors	O
associated	O
with	O
ACP	B-CHED
,	O
significant	O
univariable	O
risk	O
factors	O
were	O
examined	O
using	O
logistic	O
regression	O
and	O
propensity	O
score	O
analyses	O
.	O

All	O
SCD	O
patients	O
presenting	O
with	O
moderate	O
-	O
to	O
-	O
severe	O
ARDS	O
as	O
a	O
consequence	O
of	O
ACS	O
experienced	O
PVD	O
and	O
more	O
than	O
80	O
%	O
of	O
them	O
exhibited	O
ACP	B-CHED
.	O

However	O
,	O
independent	O
treatments	O
with	O
either	O
SAPK	O
inhibitor	B-CHED
did	O
not	O
inhibit	O
PEDV	O
-	O
induced	O
apoptotic	O
cell	O
death	O
mediated	O
by	O
activation	O
of	O
mitochondrial	O
apoptosis	O
-	O
inducing	O
factor	O
(	O
AIF	O
)	O
suggesting	O
that	O
SAPKs	O
are	O
irrelevant	O
to	O
the	O
apoptosis	O
pathway	O
during	O
PEDV	O
infection	O
.	O

A	O
sequence	O
with	O
a	O
high	O
antigenic	O
index	O
was	O
rapidly	O
synthesized	O
using	O
an	O
in	O
vitro	O
transcription	O
and	O
translation	O
system	O
to	O
yield	O
the	O
diagnostic	O
antigen	B-CHED
.	O

Dendritic	O
cells	O
(	O
DCs	O
)	O
are	O
highly	O
effective	O
antigen	B-CHED
-	O
presenting	O
cells	O
to	O
uptake	O
and	O
present	O
viral	O
antigens	B-CHED
to	O
T	O
cells	O
,	O
which	O
then	O
initiate	O
a	O
distinct	O
immune	O
response	O
.	O

TITLE	O
:	O
Indole	B-CHED
-	O
based	O
,	O
Antiproliferative	O
Agents	O
Targeting	O
Tubulin	O
Polymerization	O
.	O

As	O
an	O
appreciable	O
percentage	O
of	O
influenza	O
cases	O
(	O
37	O
%)	O
presented	O
without	O
defined	O
respiratory	O
symptoms	O
,	O
and	O
thus	O
met	B-CHED
the	O
AFI	O
but	O
not	O
the	O
SARI	O
definition	O
,	O
it	O
is	O
important	O
to	O
consider	O
broader	O
screening	O
criteria	O
(	O
i	O
.	O
e	O
.,	O
AFI	O
)	O
to	O
identify	O
all	O
laboratory	O
-	O
confirmed	O
influenza	O
.	O

In	O
the	O
early	O
summer	O
of	O
2015	O
,	O
Middle	O
East	O
respiratory	O
syndrome	O
(	O
MERS	O
)	O
struck	O
South	O
Korea	O
,	O
and	O
students	O
of	O
Sungkyunkwan	O
University	O
School	O
of	O
Medicine	B-CHED
(	O
SKKUSOM	O
)	O
were	O
at	O
risk	O
of	O
contracting	O
the	O
disease	O
.	O

The	O
latter	O
two	O
are	O
involved	O
in	O
the	O
suppression	O
of	O
the	O
antiviral	B-CHED
innate	O
immune	O
response	O
of	O
the	O
host	O
cell	O
.	O

TITLE	O
:	O
HTCC	O
:	O
Broad	O
Range	O
Inhibitor	B-CHED
of	O
Coronavirus	O
Entry	O
.	O

In	O
multivariate	O
logistic	O
regression	O
models	O
,	O
TAPSE	O
maintained	O
a	O
significant	O
association	O
with	O
mortality	O
independent	O
of	O
age	O
,	O
pH	O
,	O
PaO2	O
∶	O
FiO2	O
ratios	O
,	O
positive	O
end	O
expiratory	O
pressure	O
,	O
PCO2	O
,	O
serum	O
bicarbonate	B-CHED
,	O
plateau	O
pressures	O
,	O
driving	O
pressures	O
,	O
APACHE	O
II	O
,	O
SAPS	O
II	O
,	O
and	O
SOFA	O
scores	O
.	O

In	O
this	O
study	O
,	O
the	O
NTD	O
spanning	O
amino	B-CHED
acid	I-CHED
residues	O
25	O
-	O
229	O
(	O
S25	O
-	O
229	O
)	O
of	O
S1	O
domain	O
of	O
PEDV	O
variant	O
strain	O
was	O
expressed	O
in	O
Escherichia	O
coli	O
BL21	O
(	O
DE3	O
)	O
in	O
the	O
form	O
of	O
inclusion	O
bodies	O
(	O
IBs	O
).	O

Recent	O
evidence	O
suggests	O
that	O
surface	O
TLR2	O
may	O
also	O
contribute	O
to	O
viral	O
detection	O
through	O
recognition	O
of	O
viral	O
coat	O
proteins	B-CHED
but	O
its	O
role	O
in	O
the	O
outcome	O
of	O
acute	O
viral	O
infection	O
remains	O
elusive	O
.	O

ABSTRACT	O
:	O
We	O
report	O
the	O
complete	O
genome	O
sequences	O
of	O
a	O
buffalo	O
coronavirus	O
(	O
BufCoV	O
HKU26	O
)	O
detected	O
from	O
the	O
faecal	O
samples	O
of	O
two	O
domestic	O
water	B-CHED
buffaloes	O
(	O
Bubalus	O
bubalis	O
)	O
in	O
Bangladesh	O
.	O

They	O
possessed	O
98	O
-	O
99	O
%	O
nucleotide	B-CHED
identities	O
to	O
bovine	O
coronavirus	O
(	O
BCoV	O
)	O
genomes	O
,	O
supporting	O
BufCoV	O
HKU26	O
as	O
a	O
member	O
of	O
Betacoronavirus	O
1	O
.	O

These	O
results	O
indicate	O
that	O
nsp12	O
-	O
RdRp	O
likely	O
functions	O
in	O
fidelity	O
regulation	O
and	O
that	O
,	O
despite	O
low	O
sequence	O
conservation	O
,	O
some	O
determinants	O
of	O
RdRp	O
nucleotide	B-CHED
selectivity	O
are	O
conserved	O
across	O
RNA	O
viruses	O
.	O

Importantly	O
,	O
we	O
found	O
that	O
5b	O
-	O
null	O
viruses	O
,	O
unlike	O
wild	O
-	O
type	O
viruses	O
,	O
induce	O
production	O
of	O
high	O
concentrations	O
of	O
type	O
I	O
interferon	O
protein	B-CHED
in	O
vitro	O
,	O
indicating	O
that	O
host	O
shutoff	O
by	O
IBV	O
plays	O
an	O
important	O
role	O
in	O
antagonizing	O
the	O
host	O
'	O
s	O
innate	O
immune	O
response	O
.	O

Altogether	O
,	O
we	O
demonstrate	O
that	O
5b	O
is	O
a	O
functional	O
equivalent	O
of	O
nsp1	O
,	O
thereby	O
answering	O
the	O
longstanding	O
question	O
of	O
whether	O
lack	O
of	O
nsp1	O
in	O
gammacoronaviruses	O
is	O
compensated	O
for	O
by	O
another	O
viral	O
protein	B-CHED
.	O

We	O
studied	O
gene	O
expression	O
and	O
protein	B-CHED
synthesis	O
in	O
chicken	O
cells	O
infected	O
with	O
the	O
important	O
poultry	O
pathogen	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
).	O

On	O
Site	O
One	O
,	O
PEDV	O
was	O
detected	O
by	O
rRT	O
-	O
PCR	O
at	O
6	O
days	O
post	O
exposure	O
(	O
DPE	B-CHED
)	O
in	O
all	O
sample	O
types	O
.	O

The	O
oral	O
fluid	O
IgA	O
response	O
increased	O
through	O
96	O
DPE	B-CHED
and	O
began	O
to	O
decline	O
at	O
the	O
last	O
sampling	O
on	O
111	O
DPE	B-CHED
.	O

More	O
recently	O
,	O
myeloid	O
cells	O
e	O
.	O
g	O
.	O
neutrophils	O
have	O
been	O
implicated	O
in	O
contributing	O
to	O
both	O
host	O
defense	O
and	O
disease	O
in	O
response	O
to	O
viral	O
infection	O
of	O
the	O
CNS	B-CHED
.	O

Herein	O
we	O
describe	O
the	O
case	O
of	O
a	O
previously	O
healthy	O
16	O
-	O
year	O
-	O
old	O
male	O
without	O
history	O
of	O
travel	O
,	O
diagnosed	O
with	O
typhoid	O
fever	O
complicated	O
by	O
septic	O
shock	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
treated	O
with	O
high	O
-	O
dose	O
dexamethasone	B-CHED
.	O

Female	O
BALB	O
/	O
C	O
mice	O
were	O
immunized	O
with	O
individual	O
polypeptide	B-CHED
-	O
KLH	O
,	O
and	O
the	O
total	O
IgG	O
was	O
detected	O
by	O
ELISA	O
as	O
well	O
as	O
the	O
cellular	O
mediated	O
immunity	O
(	O
CMI	O
)	O
was	O
analyzed	O
using	O
ELIs	O
-	O
pot	O
assay	O
.	O

ABSTRACT	O
:	O
Dibenzylbutyrolactone	O
lignans	B-CHED
represent	O
a	O
unique	O
group	O
of	O
plant	O
secondary	B-CHED
metabolites	I-CHED
with	O
increasing	O
significance	O
in	O
medicine	B-CHED
.	O

CONCLUSIONS	O
:	O
The	O
isolation	O
strategies	O
,	O
applied	O
analytical	O
methods	O
and	O
pharmacological	O
activities	O
of	O
dibenzylbutyrolactone	O
lignans	B-CHED
are	O
also	O
thoroughly	O
reviewed	O
.	O

Global	O
health	O
sector	O
has	O
learnt	O
many	O
lessons	O
through	O
the	O
recent	O
outbreak	O
of	O
MERS	O
and	O
SARS	O
,	O
but	O
the	O
need	O
for	O
identifying	O
new	O
antiviral	B-CHED
treatment	O
was	O
not	O
learned	O
.	O

CONCLUSIONS	O
:	O
MERS	O
-	O
CoV	O
infection	O
transmission	O
continues	O
to	O
occur	O
as	O
clusters	B-CHED
in	O
healthcare	O
facilities	O
.	O

Using	O
immunohistochemistry	O
(	O
IHC	O
),	O
IBV	O
antigen	B-CHED
was	O
detected	O
in	O
the	O
intestinal	O
epithelial	O
cells	O
as	O
well	O
as	O
in	O
the	O
proventriculus	O
and	O
pancreas	O
.	O

Five	O
days	O
after	O
infection	O
,	O
six	O
of	O
nine	O
investigated	O
birds	O
showed	O
enteritis	O
associated	O
with	O
IBV	O
antigen	B-CHED
as	O
detected	O
by	O
IHC	O
.	O

The	O
ethanolic	O
flower	O
extract	O
was	O
the	O
most	O
potent	O
inhibitor	B-CHED
of	O
HIV	O
-	O
1	O
RT	O
DNA	O
polymerase	O
RNA	O
-	O
dependent	O
and	O
Ribonuclease	O
H	O
with	O
IC50	O
values	O
of	O
0	O
.	O
26	O
and	O
0	O
.	O
33	O
μg	O
/	O
mL	O
,	O
respectively	O
.	O

ABSTRACT	O
:	O
In	O
January	O
2013	O
,	O
several	O
months	O
after	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
was	O
first	O
identified	O
in	O
Saudi	O
Arabia	O
,	O
Abu	B-CHED
Dhabi	O
,	O
United	O
Arab	O
Emirates	O
,	O
began	O
surveillance	O
for	O
MERS	O
-	O
CoV	O
.	O
We	O
analyzed	O
medical	O
chart	O
and	O
laboratory	O
data	O
collected	O
by	O
the	O
Health	O
Authority	O
-	O
Abu	B-CHED
Dhabi	O
during	O
January	O
2013	O
-	O
May	O
2014	O
.	O

ABSTRACT	O
:	O
Dialysis	O
disequilibrium	O
syndrome	O
(	O
DDS	B-CHED
)	O
is	O
a	O
neurological	O
disorder	O
with	O
varying	O
severity	O
that	O
is	O
postulated	O
to	O
be	O
associated	O
with	O
cerebral	O
oedema	O
.	O

Despite	O
rescue	O
therapies	O
such	O
as	O
pressure	O
control	O
ventilation	O
with	O
high	O
inspiratory	O
pressures	O
,	O
inhaled	O
beta2	O
agonists	B-CHED
and	O
antimuscarinic	O
drugs	O
,	O
intravenous	O
salbutamol	B-CHED
,	O
methylprednisolone	B-CHED
and	O
magnesium	B-CHED
sulfate	I-CHED
,	O
her	O
condition	O
gradually	O
deteriorated	O
.	O

ABSTRACT	O
:	O
During	O
the	O
co	O
-	O
evolution	O
of	O
viruses	O
and	O
their	O
hosts	O
,	O
the	O
viruses	O
have	O
evolved	O
numerous	O
strategies	O
to	O
counter	B-CHED
and	O
evade	O
host	O
antiviral	B-CHED
immune	O
responses	O
in	O
order	O
to	O
establish	O
a	O
successful	O
infection	O
,	O
replicate	O
and	O
persist	O
in	O
the	O
host	O
.	O

The	O
two	O
PEDV	O
isolates	O
,	O
CBR1	O
/	O
2014	O
and	O
EAS1	O
/	O
2014	O
,	O
were	O
28	O
,	O
039	O
and	O
28	O
,	O
033	O
nucleotides	B-CHED
in	O
length	O
and	O
showed	O
96	O
.	O
2	O
%	O
and	O
93	O
.	O
6	O
%	O
similarities	O
at	O
nucleotide	B-CHED
and	O
amino	B-CHED
acid	I-CHED
levels	O
respectively	O
.	O

In	O
total	O
,	O
we	O
have	O
observed	O
1048	O
nucleotide	B-CHED
substitutions	O
throughout	O
the	O
genome	O
.	O

TITLE	O
:	O
Epidemiological	O
investigation	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
in	O
dromedary	O
camel	O
farms	O
linked	O
with	O
human	O
infection	O
in	O
Abu	B-CHED
Dhabi	O
Emirate	O
,	O
United	O
Arab	O
Emirates	O
.	O

TITLE	O
:	O
Successful	O
Management	O
of	O
Aluminium	B-CHED
Phosphide	I-CHED
Poisoning	O
Resulting	O
in	O
Cardiac	O
Arrest	O
.	O

We	O
determined	O
optimal	O
homogenization	O
methods	O
for	O
isolating	O
viral	O
nucleic	B-CHED
acids	I-CHED
from	O
sputum	O
.	O

rOC43	O
-	O
ns2DelRluc	O
was	O
comparable	O
to	O
its	O
parental	O
wild	O
-	O
type	O
virus	O
(	O
HCoV	O
-	O
OC43	O
-	O
WT	O
)	O
with	O
respect	O
to	O
the	O
quantity	O
of	O
the	O
antiviral	B-CHED
activity	O
of	O
chloroquine	B-CHED
and	O
ribavirin	B-CHED
.	O

We	O
showed	O
that	O
chloroquine	B-CHED
strongly	O
inhibited	O
HCoV	O
-	O
OC43	O
replication	O
in	O
vitro	O
,	O
with	O
a	O
50	O
%	O
inhibitory	O
concentration	O
(	O
IC50	O
)	O
of	O
0	O
.	O
33	O
μM	O
.	O
However	O
,	O
ribavirin	B-CHED
showed	O
inhibition	O
of	O
HCoV	O
-	O
OC43	O
replication	O
only	O
at	O
high	O
concentrations	O
which	O
may	O
not	O
be	O
applicable	O
to	O
humans	O
in	O
clinical	O
treatment	O
,	O
with	O
an	O
IC50	O
of	O
10	O
μM	O
.	O
Furthermore	O
,	O
using	O
a	O
luciferase	O
-	O
based	O
small	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
screening	O
assay	O
,	O
we	O
identified	O
double	O
-	O
stranded	O
-	O
RNA	O
-	O
activated	O
protein	B-CHED
kinase	O
(	O
PKR	O
)	O
and	O
DEAD	O
box	O
RNA	O
helicases	O
(	O
DDX3X	O
)	O
that	O
exhibited	O
antiviral	B-CHED
activities	O
,	O
which	O
were	O
further	O
verified	O
by	O
the	O
use	O
of	O
HCoV	O
-	O
OC43	O
-	O
WT	O
.	O

To	O
determine	O
hypercoagulopathy	O
,	O
plasma	O
levels	O
of	O
thrombin	O
-	O
antithrombin	O
complex	O
and	O
plasmin	O
-	O
plasmin	O
inhibitor	B-CHED
complex	O
are	O
continuously	O
monitored	O
in	O
patients	O
with	O
suspected	O
sepsis	O
.	O

One	O
of	O
the	O
ER	O
stress	O
responses	O
is	O
inhibition	O
of	O
the	O
global	O
protein	B-CHED
synthesis	O
to	O
reduce	O
the	O
amount	O
of	O
unfolded	O
proteins	B-CHED
inside	O
the	O
ER	O
lumen	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
PEDV	O
is	O
resistant	O
to	O
the	O
antiviral	B-CHED
effect	O
of	O
IFN	O
.	O

TITLE	O
:	O
Severe	O
stomatitis	O
and	O
ileocecal	O
perforation	O
developed	O
after	O
all	O
-	O
trans	O
retinoic	B-CHED
acid	I-CHED
monotherapy	O
in	O
an	O
HLA	O
-	O
B51	O
-	O
positive	O
patient	O
with	O
acute	O
promyelocytic	O
leukemia	O
.	O

He	O
was	O
diagnosed	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
was	O
treated	O
with	O
antibiosis	O
,	O
oxygen	B-CHED
therapy	O
,	O
and	O
required	O
non	O
-	O
invasive	O
ventilation	O
.	O

All	O
patients	O
responded	O
rapidly	O
by	O
showing	O
improvements	O
in	O
oxygen	B-CHED
index	O
and	O
PaO2	O
/	O
FiO2	O
ratio	O
within	O
first	O
72	O
h	O
of	O
therapy	O
.	O

CONCLUSIONS	O
:	O
The	O
use	O
of	O
thin	O
soft	O
silicone	B-CHED
foam	O
dressings	O
may	O
prevent	O
the	O
development	O
of	O
facial	O
deep	O
tissue	O
injuries	O
in	O
patients	O
receiving	O
prolonged	O
pronation	O
therapy	O
.	O

11	O
patients	O
required	O
long	O
term	O
intermittent	O
NIPPV	O
along	O
with	O
domiciliary	O
oxygen	B-CHED
therapy	O
.	O

Our	O
results	O
demonstrate	O
that	O
while	O
displaying	O
no	O
significant	O
cytotoxicity	O
,	O
griffithsin	O
is	O
a	O
potent	O
inhibitor	B-CHED
of	O
MERS	O
-	O
CoV	O
infection	O
.	O

Records	O
of	O
patients	O
with	O
severe	O
trauma	O
hospitalized	O
in	O
our	O
department	O
from	O
January	O
2010	O
to	O
December	O
2012	O
were	O
extracted	O
from	O
trauma	O
database	O
and	O
analyzed	O
,	O
including	O
gender	O
,	O
age	O
,	O
basic	O
situation	O
after	O
admission	O
[	O
including	O
systolic	O
pressure	O
,	O
diastolic	O
pressure	O
,	O
axillary	O
temperature	O
,	O
heart	O
rate	O
,	O
Injury	O
Severity	O
Score	O
(	O
ISS	O
),	O
Acute	O
Physiology	O
and	O
Chronic	O
Health	O
Evaluation	O
(	O
APACHE	O
)	O
Ⅱ	O
score	O
,	O
Glasgow	O
Coma	O
Score	O
,	O
and	O
urine	O
volume	O
on	O
the	O
first	O
day	O
],	O
the	O
first	O
time	O
determination	O
values	O
of	O
physiological	O
and	O
biochemical	O
indexes	O
after	O
admission	O
(	O
including	O
pH	O
value	O
,	O
base	O
excess	O
,	O
PaCO	O
(	O
2	O
),	O
PaO	B-CHED
(	O
2	O
),	O
standard	O
bicarbonate	B-CHED
ion	I-CHED
,	O
leucocyte	O
count	O
,	O
neutrophile	O
granulocyte	O
,	O
hemoglobin	B-CHED
,	O
platelet	O
count	O
,	O
albumin	O
,	O
urea	B-CHED
nitrogen	B-CHED
,	O
lactic	B-CHED
acid	I-CHED
,	O
blood	O
glucose	B-CHED
,	O
and	O
blood	O
sodium	O
),	O
surgical	O
situation	O
,	O
length	O
of	O
ICU	O
stay	O
,	O
occurrence	O
of	O
major	O
complications	O
[	O
including	O
infection	O
,	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
multiple	O
organ	O
dysfunction	O
syndrome	O
(	O
MODS	O
)/	O
multiple	O
organ	O
failure	O
(	O
MOF	O
)],	O
and	O
death	O
.	O

In	O
patients	O
with	O
severe	O
disease	O
who	O
are	O
unresponsive	O
to	O
symptomatic	O
treatment	O
with	O
benzodiazepines	B-CHED
and	O
baclofen	B-CHED
,	O
or	O
in	O
patients	O
with	O
life	O
-	O
threatening	O
complications	O
,	O
early	O
immunotherapy	O
by	O
intravenous	O
immunoglobulins	O
should	O
be	O
considered	O
.	O

Angiopoietin	O
-	O
2	O
and	O
IL	O
-	O
1	O
receptor	O
antagonist	B-CHED
concentrations	O
did	O
not	O
differ	O
between	O
groups	O
.	O

ABSTRACT	O
:	O
Objectives	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
measurement	O
of	O
acute	O
phase	O
proteins	B-CHED
(	O
APPs	O
)	O
as	O
a	O
diagnostic	O
tool	O
to	O
differentiate	O
between	O
feline	O
infectious	O
peritonitis	O
(	O
FIP	O
)	O
and	O
other	O
diseases	O
in	O
cats	O
with	O
body	O
cavity	O
effusions	O
.	O

At	O
admission	O
,	O
leukopenia	O
(	O
42	O
.	O
6	O
%),	O
thrombocytopenia	O
(	O
46	O
.	O
6	O
%),	O
and	O
elevation	O
of	O
aspartate	B-CHED
aminotransferase	O
(	O
42	O
.	O
7	O
%)	O
were	O
observed	O
.	O

Locally	O
,	O
lung	O
myeloperoxidase	O
(	O
MPO	O
),	O
protein	B-CHED
,	O
IL	O
-	O
6	O
,	O
MCP	B-CHED
-	O
1	O
and	O
G	O
-	O
CSF	O
in	O
brochoalveolar	O
lavage	O
fluid	O
(	O
BALF	O
)	O
were	O
elevated	O
after	O
DH	O
in	O
C5	O
-/-	O
compared	O
to	O
wt	O
.	O

Locally	O
,	O
lung	O
myeloperoxidase	O
(	O
MPO	O
),	O
protein	B-CHED
,	O
IL	O
-	O
6	O
,	O
MCP	B-CHED
-	O
1	O
and	O
G	O
-	O
CSF	O
in	O
brochoalveolar	O
lavage	O
fluid	O
(	O
BALF	O
)	O
were	O
elevated	O
after	O
DH	O
in	O
C5	O
-/-	O
compared	O
to	O
wt	O
.	O

Several	O
vaccine	O
technology	O
platforms	O
targeting	O
the	O
MERS	O
-	O
CoV	O
spike	O
protein	B-CHED
were	O
discussed	O
.	O

TITLE	O
:	O
Alternative	O
autophagy	O
,	O
brefeldin	B-CHED
A	I-CHED
and	O
viral	O
trafficking	O
pathways	O
.	O

Here	O
,	O
we	O
report	O
that	O
the	O
macro	O
domain	O
from	O
hepatitis	O
E	O
virus	O
(	O
HEV	O
)	O
serves	O
as	O
an	O
ADP	B-CHED
-	O
ribose	B-CHED
-	O
protein	B-CHED
hydrolase	O
for	O
mono	O
-	O
ADP	B-CHED
-	O
ribose	B-CHED
(	O
MAR	O
)	O
and	O
poly	O
(	O
ADP	B-CHED
-	O
ribose	B-CHED
)	O
(	O
PAR	O
)	O
chain	O
removal	O
(	O
de	O
-	O
MARylation	O
and	O
de	O
-	O
PARylation	O
,	O
respectively	O
)	O
from	O
mono	O
-	O
and	O
poly	O
(	O
ADP	B-CHED
)-	O
ribosylated	O
proteins	B-CHED
,	O
respectively	O
.	O

The	O
presence	O
of	O
the	O
HEV	O
helicase	O
in	O
cis	O
dramatically	O
increases	O
the	O
binding	O
of	O
the	O
macro	O
domain	O
to	O
poly	O
(	O
ADP	B-CHED
-	O
ribose	B-CHED
)	O
and	O
stimulates	O
the	O
de	O
-	O
PARylation	O
activity	O
.	O

Here	O
,	O
we	O
show	O
that	O
viral	O
macro	O
domains	O
reverse	O
cellular	O
ADP	B-CHED
-	O
ribosylation	O
,	O
potentially	O
cutting	O
the	O
signal	O
of	O
a	O
viral	O
infection	O
in	O
the	O
cell	O
.	O

Patients	O
in	O
the	O
dexamethasone	B-CHED
group	O
will	O
be	O
treated	O
with	O
a	O
daily	O
dose	O
of	O
20	O
mg	O
iv	O
from	O
day	O
1	O
to	O
day	O
5	O
,	O
and	O
10	O
mg	O
iv	O
from	O
day	O
6	O
to	O
day	O
10	O
.	O

Completion	O
of	O
a	O
viral	O
infectious	O
clone	O
system	O
facilitates	O
further	O
study	O
of	O
a	O
virus	O
'	O
s	O
biology	O
,	O
improvement	O
of	O
diagnostic	O
tests	O
,	O
vaccine	O
production	O
and	O
the	O
screening	O
of	O
antiviral	B-CHED
compounds	O
.	O

ABSTRACT	O
:	O
Enzyme	O
immunoassays	O
(	O
EIAs	O
)	O
to	O
detect	O
and	O
quantify	O
antibodies	O
against	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
)	O
and	O
RSV	O
proteins	B-CHED
in	O
human	O
plasma	O
or	O
sera	O
are	O
described	O
.	O

Abelson	O
Kinase	O
Inhibitors	B-CHED
Are	O
Potent	O
Inhibitors	B-CHED
of	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
Coronavirus	O
and	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
Fusion	O
.	O

In	O
this	O
review	O
,	O
we	O
highlight	O
the	O
importance	O
of	O
the	O
S	O
protein	B-CHED
in	O
the	O
MERS	O
-	O
CoV	O
life	O
cycle	O
,	O
summarize	O
recent	O
advances	O
in	O
the	O
development	O
of	O
vaccines	O
and	O
therapeutics	O
based	O
on	O
the	O
S	O
protein	B-CHED
,	O
and	O
discuss	O
strategies	O
that	O
can	O
be	O
explored	O
to	O
develop	O
new	O
medical	O
countermeasures	O
against	O
MERS	O
-	O
CoV	O
.	O

ABSTRACT	O
:	O
A	O
new	O
family	O
of	O
IFNs	O
called	O
type	O
III	O
IFN	O
or	O
IFN	O
-	O
λ	O
has	O
been	O
described	O
,	O
and	O
shown	O
to	O
induce	O
antiviral	B-CHED
activity	O
against	O
several	O
viruses	O
in	O
the	O
cell	O
culture	O
.	O

In	O
this	O
report	O
,	O
we	O
identified	O
and	O
characterized	O
previously	O
unknown	O
and	O
diverse	O
genetic	O
clusters	B-CHED
of	O
bat	O
coronaviruses	O
in	O
the	O
Atlantic	O
Forest	O
Biome	O
,	O
Brazil	O
.	O

TITLE	O
:	O
Viral	O
etiology	O
in	O
adult	O
influenza	O
-	O
like	O
illness	O
/	O
acute	O
respiratory	O
infection	O
and	O
predictivity	O
of	O
C	O
-	O
reactive	O
protein	B-CHED
.	O

During	O
investigation	O
of	O
a	O
multi	O
-	O
facility	O
outbreak	O
of	O
MERS	O
-	O
CoV	O
in	O
Taif	O
,	O
Saudi	O
Arabia	O
,	O
we	O
identified	O
a	O
mixed	O
population	O
of	O
wild	O
-	O
type	O
and	O
variant	O
sequences	O
with	O
a	O
large	O
530	O
nucleotide	B-CHED
deletion	O
in	O
the	O
spike	O
gene	O
from	O
the	O
serum	O
of	O
one	O
patient	O
.	O

TITLE	O
:	O
Antivirals	B-CHED
for	O
Respiratory	O
Viral	O
Infections	O
:	O
Problems	O
and	O
Prospects	O
.	O

We	O
identified	O
the	O
following	O
risk	O
factors	O
(	O
sensitivities	O
/	O
specificities	O
)	O
for	O
mortality	O
in	O
severe	O
leptospirosis	O
:	O
age	O
≥	O
55	O
years	O
(	O
67	O
%/	O
91	O
%);	O
serum	O
urea	B-CHED
≥	O
204	O
mg	O
/	O
dl	O
(	O
100	O
%/	O
70	O
%);	O
creatinine	B-CHED
≥	O
5	O
.	O
2	O
mg	O
/	O
dl	O
(	O
100	O
%/	O
58	O
%);	O
Acute	O
Physiology	O
and	O
Chronic	O
Health	O
Evaluation	O
II	O
score	O
≥	O
39	O
.	O
5	O
(	O
67	O
%/	O
88	O
%);	O
Sequential	O
Organ	O
Failure	O
Assessment	O
score	O
≥	O
20	O
.	O
5	O
(	O
67	O
%/	O
85	O
%);	O
and	O
inspiratory	O
pressure	O
≥	O
31	O
mmHg	O
(	O
84	O
%/	O
85	O
%).	O

We	O
identified	O
the	O
following	O
risk	O
factors	O
(	O
sensitivities	O
/	O
specificities	O
)	O
for	O
mortality	O
in	O
severe	O
leptospirosis	O
:	O
age	O
≥	O
55	O
years	O
(	O
67	O
%/	O
91	O
%);	O
serum	O
urea	B-CHED
≥	O
204	O
mg	O
/	O
dl	O
(	O
100	O
%/	O
70	O
%);	O
creatinine	B-CHED
≥	O
5	O
.	O
2	O
mg	O
/	O
dl	O
(	O
100	O
%/	O
58	O
%);	O
Acute	O
Physiology	O
and	O
Chronic	O
Health	O
Evaluation	O
II	O
score	O
≥	O
39	O
.	O
5	O
(	O
67	O
%/	O
88	O
%);	O
Sequential	O
Organ	O
Failure	O
Assessment	O
score	O
≥	O
20	O
.	O
5	O
(	O
67	O
%/	O
85	O
%);	O
and	O
inspiratory	O
pressure	O
≥	O
31	O
mmHg	O
(	O
84	O
%/	O
85	O
%).	O

Spike	O
glycoprotein	B-CHED
of	O
coronavirus	O
is	O
responsible	O
for	O
induction	O
of	O
neutralizing	O
antibody	O
response	O
.	O

The	O
chimeric	O
VP8	O
-	O
S2	O
gene	O
was	O
cloned	O
and	O
sub	O
-	O
cloned	O
into	O
pGH	B-CHED
and	O
pET32a	O
(+)	O
vectors	O
.	O

IgY	O
was	O
purified	O
from	O
egg	O
yolks	O
using	O
polyethylene	B-CHED
glycol	I-CHED
precipitation	O
method	O
.	O

We	O
obtained	O
anti	O
-	O
VP8	O
-	O
S2	O
IgY	O
by	O
immunizing	O
hens	O
with	O
the	O
recombinant	O
VP8	O
-	O
S2	O
protein	B-CHED
.	O

Of	O
29	O
identified	O
S1	O
genes	O
,	O
the	O
SS2	O
epitope	B-CHED
(	O
Y748SNIGVCK755	O
)	O
was	O
highly	O
conserved	O
,	O
while	O
the	O
SS6	O
epitope	B-CHED
(	O
L764QDGQVKI771	O
)	O
and	O
pAPN	O
receptor	O
-	O
binding	O
region	O
(	O
aa	O
490	O
-	O
615	O
)	O
exhibited	O
amino	O
substitutions	O
.	O

This	O
study	O
aimed	O
at	O
determining	O
the	O
role	O
of	O
the	O
chemokine	O
(	O
C	O
-	O
C	O
motif	O
)	O
ligand	B-CHED
(	O
CCL	B-CHED
)	O
2	O
and	O
CCL7	O
in	O
ARDS	O
.	O

Moreover	O
,	O
CCL2	B-CHED
and	O
CCL7	O
synergised	O
with	O
CXCL8	O
to	O
promote	O
neutrophil	O
migration	O
.	O

However	O
,	O
although	O
protective	O
immune	O
responses	O
could	O
be	O
induced	O
by	O
recombinant	O
S1	O
protein	B-CHED
,	O
the	O
protection	O
rate	O
in	O
chickens	O
was	O
still	O
low	O
(<	O
50	O
%).	O

The	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
induced	O
by	O
LPS	B-CHED
can	O
cause	O
extensive	O
damage	O
to	O
the	O
lung	O
tissue	O
,	O
the	O
severe	O
stage	O
of	O
which	O
is	O
termed	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
when	O
multiple	O
organ	O
dysfunction	O
syndrome	O
may	O
appear	O
.	O

SM	O
synthase	O
(	O
SMS	O
)	O
is	O
a	O
key	O
enzyme	O
in	O
the	O
synthesis	O
of	O
SM	O
,	O
however	O
,	O
the	O
effect	O
of	O
SMS	O
on	O
the	O
inflammatory	O
pathway	O
involving	O
nuclear	O
factor	O
(	O
NF	O
)‑	O
κB	O
induced	O
by	O
LPS	B-CHED
remains	O
to	O
be	O
elucidated	O
.	O

These	O
findings	O
suggested	O
that	O
the	O
degree	O
of	O
lung	O
injury	O
was	O
reduced	O
during	O
the	O
acute	O
inflammatory	O
reaction	O
when	O
NF	O
‑	O
κB	O
was	O
inhibited	O
,	O
and	O
that	O
the	O
expression	O
of	O
SMS2	O
may	O
affect	O
the	O
induction	O
of	O
the	O
NF	O
‑	O
κB	O
pathway	O
by	O
LPS	B-CHED
through	O
CD14	O
.	O

An	O
ELISA	O
using	O
sporozoite	O
antigen	B-CHED
was	O
developed	O
for	O
the	O
specific	O
detection	O
of	O
anti	O
-	O
Cryptosporidium	O
-	O
IgG	O
in	O
blood	O
-	O
and	O
colostral	O
serum	O
.	O

We	O
present	O
a	O
global	O
analysis	O
of	O
diverse	O
virus	O
types	O
,	O
including	O
plus	O
-	O
strand	O
,	O
minus	O
-	O
strand	O
and	O
double	O
-	O
strand	O
RNA	O
viruses	O
,	O
for	O
the	O
impact	O
of	O
this	O
nucleotide	B-CHED
preference	O
on	O
the	O
predicted	O
structure	O
of	O
the	O
RNA	O
genome	O
that	O
is	O
packaged	O
in	O
virion	O
particles	O
and	O
on	O
the	O
codon	O
usage	O
in	O
the	O
viral	O
open	O
reading	O
frames	O
.	O

Without	O
exception	O
,	O
the	O
virus	O
-	O
specific	O
nucleotide	B-CHED
bias	O
was	O
enriched	O
in	O
the	O
unpaired	O
,	O
single	O
-	O
stranded	O
regions	O
of	O
the	O
RNA	O
genome	O
,	O
thus	O
creating	O
an	O
even	O
more	O
striking	O
virus	O
-	O
specific	O
signature	O
.	O

We	O
will	O
discuss	O
molecular	O
and	O
evolutionary	O
scenarios	O
that	O
may	O
be	O
responsible	O
for	O
the	O
diverse	O
nucleotide	B-CHED
biases	O
of	O
RNA	O
viruses	O
.	O

SUD	O
functions	O
as	O
an	O
enhancer	O
to	O
strengthen	O
interaction	O
between	O
RCHY1	O
and	O
nonstructural	O
protein	B-CHED
3	O
,	O
leading	O
to	O
a	O
further	O
increase	O
in	O
in	O
p53	O
degradation	O
.	O

ABSTRACT	O
:	O
Metabolite	B-CHED
-	O
responsive	O
RNA	O
pseudoknots	O
derived	O
from	O
prokaryotic	O
riboswitches	O
have	O
been	O
shown	O
to	O
stimulate	O
-	O
1	O
programmed	O
ribosomal	O
frameshifting	O
(	O
PRF	O
),	O
suggesting	O
-	O
1	O
PRF	O
as	O
a	O
promising	O
gene	O
expression	O
platform	O
to	O
extend	O
riboswitch	O
applications	O
in	O
higher	O
eukaryotes	O
.	O

Thus	O
,	O
RNA	O
-	O
ligand	B-CHED
interaction	O
repertoire	O
provided	O
by	O
in	O
vitro	O
selection	O
becomes	O
accessible	O
to	O
ligand	B-CHED
-	O
specific	O
-	O
1	O
PRF	O
stimulator	O
engineering	O
using	O
SARS	O
-	O
PK	O
as	O
the	O
scaffold	O
for	O
synthetic	O
biology	O
application	O
.	O

Older	O
trials	O
investigating	O
high	O
dose	O
glucocorticoid	B-CHED
treatment	O
reported	O
a	O
lack	O
of	O
a	O
sustained	O
anti	O
-	O
inflammatory	O
effects	O
and	O
an	O
association	O
with	O
ICUAW	O
.	O

Twenty	O
-	O
two	O
percent	O
met	B-CHED
the	O
primary	O
outcome	O
,	O
21	O
%	O
died	O
,	O
and	O
57	O
%	O
developed	O
kidney	O
injury	O
.	O

Here	O
,	O
we	O
developed	O
a	O
cell	O
-	O
based	O
fusion	O
assay	O
for	O
S	O
in	O
a	O
TMPRSS2	O
-	O
dependent	O
manner	O
using	O
cell	O
lines	O
expressing	O
Renilla	O
luciferase	O
(	O
RL	O
)-	O
based	O
split	O
reporter	O
proteins	B-CHED
.	O

Using	O
an	O
avian	O
coronavirus	O
spike	O
protein	B-CHED
as	O
a	O
model	O
antigen	B-CHED
,	O
sVLPs	O
were	O
prepared	O
by	O
incubating	O
100	O
nm	O
gold	B-CHED
nanoparticles	B-CHED
in	O
a	O
solution	O
containing	O
an	O
optimized	O
concentration	O
of	O
viral	O
proteins	B-CHED
.	O

Many	O
intracellular	O
signaling	O
pathways	O
,	O
including	O
the	O
phosphatidylinositol	B-CHED
3	O
-	O
kinase	O
(	O
PI3K	O
)/	O
Akt	O
pathway	O
,	O
are	O
activated	O
by	O
viral	O
infection	O
.	O

Phylogenetic	O
analysis	O
seems	O
to	O
suggest	O
no	O
multiple	O
introduction	O
into	O
the	O
two	O
NHs	O
reporting	O
the	O
two	O
influenza	O
A	O
(	O
H3N2	B-CHED
)	O
outbreaks	O
.	O

ABSTRACT	O
:	O
The	O
discovery	O
of	O
a	O
back	O
-	O
up	O
to	O
the	O
hepatitis	O
C	O
virus	O
NS3	O
protease	B-CHED
inhibitor	I-CHED
asunaprevir	O
(	O
2	O
)	O
is	O
described	O
.	O

TITLE	O
:	O
Deleted	O
in	O
malignant	O
brain	O
tumors	O
1	O
protein	B-CHED
is	O
a	O
potential	O
biomarker	B-CHED
of	O
acute	O
respiratory	O
distress	O
syndrome	O
induced	O
by	O
pneumonia	O
.	O

ABSTRACT	O
:	O
The	O
coronavirus	O
spike	O
protein	B-CHED
is	O
a	O
multifunctional	O
molecular	O
machine	O
that	O
mediates	O
coronavirus	O
entry	O
into	O
host	O
cells	O
.	O

Alternatively	O
,	O
melphalan	B-CHED
at	O
5	O
mg	O
and	O
PSL	O
at	O
32	O
mg	O
were	O
administered	O
,	O
with	O
no	O
amelioration	O
,	O
while	O
serum	O
IgA	O
-	O
λ	O
monoclonal	O
protein	B-CHED
diminished	O
,	O
and	O
IgM	O
-	O
λ	O
M	O
protein	B-CHED
positivity	O
was	O
continuously	O
observed	O
.	O

TITLE	O
:	O
Synbiotics	O
suppress	O
the	O
release	O
of	O
lactate	B-CHED
dehydrogenase	O
,	O
promote	O
non	O
-	O
specific	O
immunity	O
and	O
integrity	O
of	O
jejunum	O
mucosa	O
in	O
piglets	O
.	O

Probiotics	O
and	O
flaxseed	O
applied	O
together	O
seem	O
to	O
be	O
a	O
good	O
source	O
of	O
nutrients	B-CHED
to	O
improve	O
the	O
immune	O
status	O
and	O
the	O
integrity	O
of	O
jejunum	O
mucosa	O
during	O
infection	O
.	O

TITLE	O
:	O
Effect	O
of	O
setting	O
high	O
APRV	O
guided	O
by	O
expiratory	O
inflection	O
point	O
of	O
pressure	O
-	O
volume	O
curve	O
on	O
oxygen	B-CHED
delivery	O
in	O
canine	O
models	O
of	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

Direct	O
exposure	O
to	O
the	O
expired	O
fine	O
droplets	O
or	O
droplet	O
nuclei	B-CHED
results	O
in	O
short	O
-	O
range	O
airborne	O
transmission	O
.	O

Birds	O
of	O
PW	O
variety	O
indicated	O
higher	O
glucose	B-CHED
,	O
total	O
protein	B-CHED
,	O
albumin	O
,	O
uric	B-CHED
acid	I-CHED
,	O
and	O
creatinine	B-CHED
,	O
the	O
lowest	O
cholesterol	B-CHED
under	O
FR	O
and	O
the	O
enhanced	O
antibody	O
titer	O
against	O
NDV	O
and	O
IBV	O
.	O

Specimens	O
were	O
tested	O
for	O
influenza	O
viruses	O
,	O
and	O
a	O
convenience	O
sample	O
of	O
NP	O
/	O
OP	O
specimens	O
was	O
tested	O
for	O
MERS	O
-	O
CoV	O
.	O
Thirty	O
percent	O
of	O
participants	O
met	B-CHED
the	O
case	O
definition	O
for	O
influenza	O
-	O
like	O
illness	O
(	O
ILI	O
),	O
14	O
%	O
tested	O
positive	O
for	O
influenza	O
viruses	O
,	O
and	O
none	O
tested	O
positive	O
for	O
MERS	O
-	O
CoV	O
.	O
Self	O
-	O
reported	O
influenza	O
vaccination	O
was	O
20	O
%.	O

Morbidity	O
and	O
mortality	O
,	O
viral	O
load	O
and	O
immune	O
cell	O
accumulation	O
in	O
the	O
CNS	B-CHED
,	O
and	O
spinal	O
cord	O
demyelination	O
were	O
assessed	O
at	O
defined	O
points	O
post	O
-	O
infection	O
.	O

Except	O
for	O
very	O
early	O
during	O
infection	O
,	O
there	O
were	O
not	O
significant	O
differences	O
in	O
macrophage	O
infiltration	O
into	O
the	O
CNS	B-CHED
between	O
WT	O
and	O
miR	O
-	O
155	O
(-/-)	O
JHMV	O
-	O
infected	O
mice	O
,	O
and	O
the	O
severity	O
of	O
demyelination	O
was	O
similar	O
at	O
14	O
days	O
p	O
.	O
i	O
.	O

RESULTS	O
:	O
We	O
found	O
that	O
for	O
patients	O
with	O
PaO2	O
/	O
FiO2	O
below	O
150	O
mm	O
Hg	O
,	O
but	O
above	O
100	O
mm	O
Hg	O
or	O
an	O
oxygenation	O
index	O
above	O
12	O
(	O
moderate	O
ARDS	O
),	O
higher	O
PEEP	B-CHED
reduces	O
hospital	O
mortality	O
,	O
but	O
the	O
beneficial	O
effect	O
appears	O
to	O
level	O
off	O
for	O
patients	O
with	O
very	O
severe	O
ARDS	O
.	O

ABSTRACT	O
:	O
Sevoflurane	B-CHED
improves	O
gas	O
exchange	O
,	O
and	O
reduces	O
alveolar	O
edema	O
and	O
inflammation	O
in	O
preclinical	O
studies	O
of	O
lung	O
injury	O
,	O
but	O
its	O
therapeutic	O
effects	O
have	O
never	O
been	O
investigated	O
in	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

We	O
did	O
a	O
parallel	O
,	O
open	O
-	O
label	B-CHED
single	O
-	O
center	O
randomized	O
controlled	O
trial	O
at	O
three	O
intensive	O
care	O
units	O
from	O
a	O
French	O
university	O
hospital	O
between	O
April	O
2014	O
and	O
February	O
2016	O
.	O

The	O
patient	O
continued	O
on	O
intravenous	O
artesunate	B-CHED
for	O
a	O
total	O
of	O
48	O
h	O
prior	O
to	O
substitution	O
with	O
artemether	B-CHED
-	O
lumefantrine	B-CHED
,	O
and	O
made	O
a	O
good	O
recovery	O
with	O
resolution	O
of	O
his	O
haemoglobinuria	O
and	O
improvement	O
of	O
his	O
kidney	O
function	O
by	O
day	O
3	O
.	O

Using	O
recombinant	O
ArkDPI	O
S1	O
proteins	B-CHED
,	O
we	O
conducted	O
binding	O
assays	O
on	O
chicken	O
tracheas	O
and	O
embryonic	O
chorioallantoic	O
membrane	O
(	O
CAM	O
).	O

Therefore	O
,	O
offering	O
comparable	O
air	B-CHED
and	O
ground	O
options	O
,	O
with	O
similar	O
staffing	O
and	O
resources	O
,	O
is	O
a	O
hallmark	O
of	O
a	O
mature	O
medical	O
system	O
with	O
an	O
integrated	O
approach	O
to	O
CCT	O
.	O

We	O
present	O
a	O
case	O
of	O
acute	O
chest	O
pain	O
in	O
a	O
58	O
-	O
year	O
-	O
old	O
male	O
with	O
severe	O
asthma	O
,	O
which	O
regressed	O
after	O
sublingual	O
administration	O
of	O
nitroglycerine	B-CHED
.	O

A	O
diagnosis	O
of	O
EGPA	O
was	O
established	O
,	O
and	O
administration	O
of	O
systemic	O
glucocorticoids	B-CHED
was	O
initiated	O
.	O

In	O
rhesus	O
macaques	O
,	O
the	O
spike	O
glycoprotein	B-CHED
peptides	B-CHED
S471	O
-	O
503	O
,	O
S604	O
-	O
625	O
,	O
and	O
S1164	O
-	O
1191	O
elicited	O
antibodies	O
that	O
efficiently	O
prevented	O
infection	O
in	O
non	O
-	O
human	O
primates	O
.	O

Thus	O
,	O
peptide	B-CHED
-	O
based	O
vaccines	O
against	O
SARS	O
-	O
CoV	O
could	O
be	O
engineered	O
to	O
avoid	O
ADE	B-CHED
via	O
elimination	O
of	O
the	O
S597	O
-	O
603	O
epitope	B-CHED
.	O

This	O
review	O
highlights	O
recent	O
advances	O
in	O
the	O
development	O
of	O
biologically	O
active	O
spirooxindoles	O
for	O
their	O
antiviral	B-CHED
potential	O
,	O
primarily	O
focusing	O
on	O
the	O
structure	O
-	O
activity	O
relationships	O
(	O
SARs	O
)	O
and	O
modes	O
of	O
action	O
,	O
as	O
well	O
as	O
future	O
directions	O
to	O
achieve	O
more	O
potent	O
analogues	O
toward	O
a	O
viable	O
antiviral	B-CHED
therapy	O
.	O

All	O
subjects	O
received	O
chimeric	O
antigen	B-CHED
receptor	O
-	O
modified	O
T	O
cell	O
therapy	O
.	O

To	O
describe	O
dexmedetomidine	B-CHED
use	O
in	O
children	O
supported	O
on	O
mechanical	O
ventilation	O
for	O
acute	O
respiratory	O
failure	O
.	O

Dexmedetomidine	B-CHED
as	O
a	O
secondary	O
sedative	B-CHED
usual	O
care	O
patients	O
(	O
n	O
=	O
280	O
;	O
23	O
%)	O
included	O
more	O
children	O
with	O
severe	O
pediatric	O
acute	O
respiratory	O
distress	O
syndrome	O
or	O
organ	O
failure	O
.	O

The	O
use	O
of	O
dexmedetomidine	B-CHED
to	O
facilitate	O
extubation	O
in	O
children	O
intolerant	O
of	O
an	O
awake	O
,	O
intubated	O
state	O
may	O
abbreviate	O
ventilator	O
weaning	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
developed	O
IBV	O
S1	O
glycoprotein	B-CHED
poly	O
-	O
epitope	B-CHED
-	O
based	O
DNA	O
vaccine	O
pV	O
-	O
S1B	O
+	O
S1T	O
consisting	O
of	O
SH1208	O
and	O
Holte	O
strain	O
BF2	O
-	O
restricted	O
T	O
cell	O
epitopes	O
and	O
Australian	O
T	O
strain	O
dominant	O
B	O
cell	O
neutralization	O
epitopes	O
.	O

Despite	O
their	O
biomedical	O
importance	O
,	O
coronavirus	O
S	O
glycoproteins	B-CHED
have	O
proven	O
difficult	O
targets	O
for	O
structural	O
characterization	O
,	O
precluding	O
high	O
-	O
resolution	O
studies	O
of	O
the	O
biologically	O
relevant	O
trimer	O
.	O

Recent	O
technological	O
developments	O
in	O
single	O
particle	O
cryo	O
-	O
electron	O
microscopy	O
allowed	O
us	O
to	O
determine	O
the	O
first	O
structure	O
of	O
a	O
coronavirus	O
S	O
glycoprotein	B-CHED
trimer	O
which	O
provided	O
a	O
framework	O
to	O
understand	O
the	O
mechanisms	O
of	O
viral	O
entry	O
and	O
suggested	O
potential	O
inhibition	O
strategies	O
for	O
this	O
family	O
of	O
viruses	O
.	O

The	O
137	O
patients	O
who	O
met	B-CHED
Pediatric	O
Acute	O
Lung	O
Injury	O
Consensus	O
Conference	O
but	O
not	O
Berlin	O
criteria	O
had	O
an	O
overall	O
mortality	O
rate	O
of	O
13	O
.	O
1	O
%,	O
but	O
29	O
had	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
with	O
31	O
.	O
0	O
%	O
mortality	O
.	O

TITLE	O
:	O
Lavage	O
-	O
induced	O
Surfactant	B-CHED
Depletion	O
in	O
Pigs	O
As	O
a	O
Model	O
of	O
the	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
(	O
ARDS	O
).	O

Astrovirus	O
sequences	O
showed	O
a	O
high	O
level	O
nucleotide	B-CHED
sequence	O
similarity	O
with	O
the	O
Brazilian	O
BAstV	O
sequences	O
available	O
in	O
GenBank	O
.	O

Severe	O
edema	O
results	O
from	O
leakage	O
of	O
fluid	O
and	O
proteins	B-CHED
into	O
tissue	O
.	O

To	O
approach	O
the	O
mechanisms	O
,	O
we	O
employed	O
an	O
unbiased	O
protein	B-CHED
analysis	O
of	O
bronchoalveolar	O
lavage	O
fluid	O
from	O
neutrophil	O
-	O
depleted	O
and	O
neutrophil	O
-	O
replete	O
mice	O
12	O
h	O
after	O
inducing	O
lung	O
injury	O
.	O

Elevated	O
lactate	B-CHED
dehydrogenase	O
(>	O
1	O
,	O
000	O
U	O
/	O
l	O
)	O
was	O
detected	O
in	O
4	O
(	O
66	O
.	O
7	O
%)	O
patients	O
and	O
elevated	O
alanine	B-CHED
aminotransferase	O
was	O
exhibited	O
by	O
5	O
(	O
83	O
/	O
3	O
%)	O
patients	O
.	O

TITLE	O
:	O
Constitutively	O
Expressed	O
IFITM3	O
Protein	B-CHED
in	O
Human	O
Endothelial	O
Cells	O
Poses	O
an	O
Early	O
Infection	O
Block	O
to	O
Human	O
Influenza	O
Viruses	O
.	O

Most	O
of	O
these	O
mutations	O
result	O
in	O
amino	B-CHED
acid	I-CHED
substitutions	O
in	O
the	O
S	O
protein	B-CHED
and	O
these	O
may	O
have	O
a	O
critical	O
role	O
in	O
the	O
switch	O
from	O
FECV	O
to	O
FIPV	O
.	O

The	O
primary	O
determinant	O
of	O
CoV	O
tropism	O
is	O
the	O
viral	O
spike	O
(	O
S	O
)	O
entry	O
protein	B-CHED
.	O

Using	O
this	O
new	O
structural	O
insight	O
,	O
we	O
review	O
the	O
changes	O
in	O
the	O
S	O
protein	B-CHED
that	O
relate	O
to	O
changes	O
in	O
virus	O
tropism	O
.	O

A	O
thorough	O
understanding	O
of	O
the	O
key	O
role	O
of	O
the	O
S	O
protein	B-CHED
in	O
CoV	O
entry	O
is	O
critical	O
to	O
further	O
our	O
understanding	O
of	O
virus	O
cross	O
-	O
species	O
transmission	O
and	O
pathogenesis	O
and	O
for	O
development	O
of	O
intervention	O
strategies	O
.	O

Several	O
smaller	O
subunits	O
(	O
nsp7	O
-	O
nsp10	O
)	O
act	O
as	O
crucial	O
cofactors	B-CHED
of	O
these	O
enzymes	O
and	O
contribute	O
to	O
the	O
emerging	O
""""	O
nsp	O
interactome	O
.	O

The	O
infections	O
identified	O
included	O
:	O
ARI	B-CHED
,	O
avian	O
influenza	O
A	O
(	O
H5N1	O
),	O
influenza	O
A	O
(	O
H1N1	O
)	O
pdm09	O
and	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
infection	O
.	O

She	O
received	O
intravenous	O
gonadotropin	O
-	O
releasing	O
hormone	B-CHED
(	O
GnRH	O
)	O
along	O
with	O
follicle	O
-	O
stimulating	O
hormone	B-CHED
in	O
an	O
outside	O
private	O
clinic	O
.	O

Extracellular	O
trypsin	O
activates	O
PEDV	O
entry	O
when	O
lysosomal	O
cysteine	B-CHED
proteases	O
are	O
inhibited	O
.	O

These	O
results	O
advance	O
our	O
understanding	O
of	O
the	O
molecular	O
mechanism	O
for	O
PEDV	O
entry	O
and	O
identify	O
potential	O
antiviral	B-CHED
targets	O
for	O
curbing	O
the	O
spread	O
of	O
PEDV	O
.	O

ABSTRACT	O
:	O
Human	O
coronavirus	O
229E	O
(	O
HCoV	O
-	O
229E	O
),	O
a	O
causative	O
agent	O
of	O
the	O
common	O
cold	O
,	O
enters	O
host	O
cells	O
via	O
two	O
distinct	O
pathways	O
:	O
one	O
is	O
mediated	O
by	O
cell	O
surface	O
proteases	O
,	O
particularly	O
transmembrane	O
protease	O
serine	B-CHED
2	O
(	O
TMPRSS2	O
),	O
and	O
the	O
other	O
by	O
endosomal	O
cathepsin	O
L	O
.	O
Thus	O
,	O
specific	O
inhibitors	B-CHED
of	O
these	O
proteases	O
block	O
virus	O
infection	O
.	O

Urine	O
samples	O
were	O
collected	O
upon	O
admission	O
,	O
12	O
-	O
24	O
h	O
after	O
admission	O
,	O
and	O
3	O
months	O
post	O
-	O
discharge	O
for	O
calculation	O
of	O
urine	O
α1	O
-	O
microglobulin	O
-,	O
albumin	O
-,	O
IgG	O
-,	O
and	O
IgM	O
/	O
creatinine	B-CHED
ratios	O
.	O

The	O
treatment	O
group	O
had	O
significant	O
improvement	O
in	O
the	O
ratio	O
of	O
partial	O
pressure	O
of	O
oxygen	B-CHED
in	O
arterial	O
blood	O
to	O
fraction	O
of	O
inspired	O
oxygen	B-CHED
and	O
lung	O
injury	O
score	O
(	O
p	O
=	O
0	O
.	O
01	O
),	O
and	O
similar	O
timing	O
to	O
removal	O
of	O
vital	O
organ	O
support	O
(	O
HR	O
0	O
.	O
74	O
,	O
95	O
%	O
CI	O
0	O
.	O
51	O
-	O
1	O
.	O
07	O
;	O
p	O
=	O
0	O
.	O
107	O
).	O

In	O
this	O
study	O
,	O
a	O
trimeric	O
protein	B-CHED
,	O
RBD	O
-	O
Fd	O
,	O
was	O
generated	O
by	O
fusing	O
RBD	O
with	O
foldon	O
trimerization	O
motif	O
.	O

ABSTRACT	O
:	O
Similar	O
to	O
eukaryotic	O
mRNA	B-CHED
,	O
the	O
positive	O
-	O
strand	O
coronavirus	O
genome	O
of	O
~	O
30	O
kilobases	O
is	O
5	O
'-	O
capped	O
and	O
3	O
'-	O
polyadenylated	O
.	O

These	O
results	O
indicated	O
that	O
Nur77	O
decreases	O
ET	O
-	O
1	O
expression	O
by	O
suppressing	O
NF	O
-	O
κB	O
and	O
p38	O
MAPK	O
in	O
LPS	B-CHED
-	O
stimulated	O
A549	O
cells	O
in	O
vitro	O
,	O
and	O
,	O
in	O
an	O
LPS	B-CHED
-	O
induced	O
ARDS	O
rat	O
model	O
,	O
CsnB	O
reduced	O
ET	O
-	O
1	O
expression	O
and	O
lung	O
injury	O
in	O
ARDS	O
rats	O
.	O

The	O
nature	O
of	O
the	O
aromatic	O
group	O
in	O
the	O
position	O
4	O
of	O
the	O
thiazole	B-CHED
was	O
relevant	O
in	O
determining	O
the	O
biological	O
activity	O
.	O

One	O
of	O
the	O
more	O
serious	O
adverse	O
effects	O
includes	O
amiodarone	B-CHED
pulmonary	O
toxicity	O
(	O
APT	O
).	O

TITLE	O
:	O
Concise	O
SAR	B-CHED
Exploration	O
Based	O
on	O
the	O
""""	O
Head	O
-	O
to	O
-	O
Tail	O
""""	O
Approach	O
:	O
Discovery	O
of	O
PI4KIIIα	O
Inhibitors	B-CHED
Bearing	O
Diverse	O
Scaffolds	O
.	O

ABSTRACT	O
:	O
In	O
typical	O
kinase	O
inhibitor	B-CHED
programs	O
,	O
a	O
hinge	O
binder	O
showing	O
best	O
potency	O
with	O
preferential	O
specificity	O
is	O
initially	O
selected	O
,	O
followed	O
by	O
fine	O
-	O
tuning	O
of	O
the	O
accompanying	O
substituents	O
on	O
its	O
core	O
module	O
.	O

A	O
heparin	B-CHED
bolus	O
was	O
given	O
in	O
16	O
cases	O
.	O

Besides	O
the	O
well	O
-	O
known	O
type	O
I	O
interferon	O
(	O
IFN	O
-	O
α	O
/	O
β	O
)	O
response	O
,	O
the	O
protein	B-CHED
kinase	O
R	O
(	O
PKR	O
)-	O
mediated	O
stress	O
response	O
is	O
being	O
recognized	O
as	O
an	O
important	O
innate	O
response	O
pathway	O
.	O

Upon	O
detecting	O
viral	O
dsRNA	B-CHED
,	O
PKR	O
phosphorylates	O
eIF2α	O
,	O
leading	O
to	O
the	O
inhibition	O
of	O
cellular	O
and	O
viral	O
translation	O
and	O
the	O
formation	O
of	O
stress	O
granules	O
(	O
SGs	O
),	O
which	O
are	O
increasingly	O
recognized	O
as	O
platforms	O
for	O
antiviral	B-CHED
signaling	O
pathways	O
.	O

In	O
contrast	O
,	O
p4a	O
failed	O
to	O
suppress	O
stress	O
response	O
pathway	O
activation	O
that	O
is	O
independent	O
of	O
PKR	O
and	O
dsRNA	B-CHED
.	O

TITLE	O
:	O
Disinfection	O
of	O
aircraft	O
:	O
Appropriate	O
disinfectants	B-CHED
and	O
standard	O
operating	O
procedures	O
for	O
highly	O
infectious	O
diseases	O
.	O

There	O
were	O
1	O
,	O
286	O
compounds	O
of	O
FDA	O
-	O
approved	O
drug	O
database	O
that	O
could	O
virtually	O
bind	O
to	O
the	O
RNA	O
-	O
binding	O
region	O
of	O
N	O
protein	B-CHED
.	O

As	O
part	O
of	O
ongoing	O
efforts	O
on	O
HCV	O
NS5A	O
inhibition	O
at	O
Merck	O
,	O
we	O
now	O
describe	O
the	O
discovery	O
of	O
a	O
novel	O
series	O
of	O
chromane	B-CHED
containing	O
NS5A	O
inhibitors	B-CHED
.	O

Whole	O
genome	O
analysis	O
of	O
IBV	O
/	O
Ck	O
/	O
Sudan	O
/	O
AR251	O
-	O
15	O
/	O
2014	O
isolate	O
by	O
next	O
generation	O
sequencing	O
revealed	O
a	O
genome	O
size	O
of	O
27	O
,	O
646	O
nucleotides	B-CHED
harbouring	O
13	O
open	O
reading	O
frames	O
:	O
5	O
'-	O
1a	O
-	O
1b	O
-	O
S	O
-	O
3a	O
-	O
3b	O
-	O
E	O
-	O
M	O
-	O
4b	O
-	O
4c	O
-	O
5a	O
-	O
5b	O
-	O
N	O
-	O
6b	O
-	O
3	O
'.	O

First	O
,	O
we	O
identified	O
a	O
shallow	O
pocket	O
adjacent	O
to	O
the	O
groove	O
in	O
the	O
N	O
-	O
terminal	O
region	O
of	O
NHR	O
trimer	O
as	O
a	O
new	O
drug	O
target	O
,	O
and	O
then	O
we	O
designed	O
several	O
short	O
artificial	O
peptides	B-CHED
to	O
fit	O
this	O
target	O
.	O

WQ	O
-	O
IDL	O
and	O
MT	O
-	O
WQ	O
-	O
IDL	O
were	O
also	O
more	O
effective	O
than	O
WQ	O
in	O
blocking	O
HIV	O
-	O
1	O
Env	O
-	O
mediated	O
membrane	O
fusion	O
and	O
had	O
higher	O
levels	O
of	O
binding	O
affinity	O
with	O
NHR	O
peptide	B-CHED
N46	O
.	O

The	O
inhibition	O
activity	O
of	O
this	O
new	O
conjugated	O
peptide	B-CHED
was	O
significantly	O
enhanced	O
,	O
by	O
77	O
-	O
fold	O
,	O
making	O
it	O
much	O
more	O
potent	O
than	O
T20	O
(	O
enfuvirtide	B-CHED
)	O
and	O
suggesting	O
that	O
the	O
IDL	O
tail	O
can	O
be	O
adopted	O
for	O
optimizing	O
existing	O
HIV	O
-	O
1	O
CHR	O
peptide	B-CHED
fusion	O
inhibitors	B-CHED
.	O

As	O
necroptosis	O
disrupts	O
cellular	O
membranes	O
and	O
allows	O
the	O
release	O
of	O
damage	O
-	O
associated	O
molecular	O
patterns	O
(	O
DAMP	B-CHED
)	O
and	O
possibly	O
induces	O
the	O
production	O
of	O
proinflammatory	O
cytokines	O
,	O
it	O
may	O
represent	O
a	O
proinflammatory	O
cell	O
death	O
mechanism	O
that	O
contributes	O
to	O
excessive	O
neuroinflammation	O
and	O
neurodegeneration	O
and	O
eventually	O
to	O
neurological	O
disorders	O
after	O
a	O
coronavirus	O
infection	O
.	O

We	O
found	O
that	O
regions	O
of	O
intrinsic	O
disorder	O
are	O
rarely	O
conserved	O
among	O
different	O
coronavirus	O
protein	B-CHED
families	O
,	O
with	O
the	O
primary	O
exception	O
of	O
the	O
nucleocapsid	O
.	O

The	O
identified	O
sequence	O
motif	O
is	O
found	O
within	O
the	O
nonstructural	O
protein	B-CHED
(	O
NSP	O
)	O
12	O
and	O
constitutes	O
an	O
antiviral	B-CHED
target	O
potentially	O
effective	O
against	O
the	O
present	O
day	O
and	O
future	O
coronaviruses	O
.	O

The	O
mean	O
log	O
reductions	O
in	O
the	O
viral	O
titers	O
were	O
≥	O
4	O
.	O
07	O
and	O
≥	O
4	O
.	O
42	O
for	O
the	O
pooled	O
and	O
individual	O
donor	B-CHED
plasma	O
,	O
respectively	O
.	O

BNSP333	O
-	O
S1	O
grew	O
to	O
titers	O
similar	O
to	O
those	O
of	O
the	O
parental	O
vaccine	O
vector	O
BNSP333	O
,	O
and	O
the	O
RABV	O
G	O
-	O
MERS	O
-	O
CoV	O
S1	O
fusion	O
protein	B-CHED
was	O
efficiently	O
expressed	O
and	O
incorporated	O
into	O
RABV	O
particles	O
.	O

GILZ	O
was	O
expressed	O
in	O
about	O
¾	O
of	O
the	O
corticosteroid	B-CHED
-	O
treated	O
patients	O
and	O
its	O
expression	O
could	O
also	O
occur	O
independently	O
of	O
corticosteroids	B-CHED
,	O
suggesting	O
that	O
inflammatory	O
signals	O
may	O
also	O
induce	O
neutrophil	O
GILZ	O
expression	O
in	O
vivo	O
.	O

ABSTRACT	O
:	O
Glioma	O
tumor	O
suppressor	O
candidate	O
region	O
gene	O
2	O
protein	B-CHED
(	O
GLTSCR2	O
)	O
is	O
a	O
nucleolar	O
protein	B-CHED
.	O

TITLE	O
:	O
Characterization	O
of	O
anti	O
-	O
MERS	O
-	O
CoV	O
antibodies	O
against	O
various	O
recombinant	O
structural	O
antigens	B-CHED
of	O
MERS	O
-	O
CoV	O
in	O
an	O
imported	O
case	O
in	O
China	O
.	O

ABSTRACT	O
:	O
The	O
first	O
imported	O
case	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
(	O
MERS	O
)	O
in	O
China	O
recently	O
occurred	O
,	O
allowing	O
for	O
the	O
characterization	O
of	O
antibody	O
titers	O
in	O
a	O
series	O
of	O
the	O
patient	O
'	O
s	O
sera	O
using	O
the	O
following	O
methods	O
based	O
on	O
recombinant	O
viral	O
structural	O
antigens	B-CHED
:	O
inactivated	O
MERS	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
),	O
recombinant	O
MERS	O
-	O
CoV	O
spike	O
(	O
S	O
,	O
or	O
fragments	O
of	O
S	O
)	O
ELISA	O
,	O
nucleoprotein	O
(	O
NP	O
)	O
ELISA	O
and	O
MERS	O
S	O
pseudovirus	O
particle	O
-	O
based	O
neutralization	O
test	O
(	O
ppNT	O
).	O

Very	O
few	O
studies	O
on	O
influenza	O
A	O
H1N1pdm09	O
in	O
post	O
-	O
pandemic	O
periods	O
exist	O
,	O
and	O
there	O
is	O
no	O
information	O
on	O
the	O
severity	O
of	O
both	O
seasonal	O
influenza	O
A	O
(	O
H1N1	O
)	O
and	O
A	O
(	O
H3N2	B-CHED
)	O
from	O
the	O
same	O
season	O
,	O
adjusting	O
for	O
potential	O
confounders	O
,	O
including	O
vaccine	O
.	O

We	O
included	O
234	O
patients	O
:	O
146	O
(	O
62	O
.	O
4	O
%)	O
influenza	O
A	O
(	O
H1N1	O
)	O
and	O
88	O
(	O
37	O
.	O
6	O
%)	O
A	O
(	O
H3N2	B-CHED
).	O

Blood	O
and	O
bronchial	O
alveolar	O
lavage	O
fluid	O
(	O
BAL	B-CHED
)	O
from	O
humans	O
(	O
n	O
=	O
10	O
-	O
13	O
)	O
with	O
ARDS	O
and	O
controls	O
(	O
n	O
=	O
5	O
-	O
10	O
)	O
as	O
well	O
as	O
a	O
murine	O
model	O
of	O
ARDS	O
(	O
n	O
=	O
5	O
-	O
6	O
)	O
with	O
controls	O
(	O
n	O
=	O
6	O
-	O
7	O
)	O
were	O
studied	O
.	O

ECMO	O
is	O
a	O
complex	O
network	O
that	O
provides	O
oxygenation	O
and	O
ventilation	O
and	O
allows	O
the	O
lungs	O
to	O
rest	B-CHED
and	O
recover	O
from	O
respiratory	O
failure	O
while	O
minimizing	O
iatrogenic	O
ventilator	O
-	O
induced	O
lung	O
injury	O
.	O

Ribavirin	B-CHED
was	O
found	O
to	O
further	O
potentiate	O
the	O
antiviral	B-CHED
effect	O
of	O
alisporivir	O
in	O
these	O
cell	O
culture	O
-	O
based	O
infection	O
models	O
,	O
but	O
this	O
combination	O
treatment	O
was	O
unable	O
to	O
improve	O
the	O
outcome	O
of	O
SARS	O
-	O
CoV	O
infection	O
in	O
a	O
mouse	O
model	O
.	O

Extracorporeal	O
carbon	B-CHED
dioxide	I-CHED
removal	O
is	O
also	O
being	O
investigated	O
as	O
a	O
preventative	O
,	O
preemptive	O
,	O
and	O
management	O
platform	O
in	O
patients	O
with	O
respiratory	O
failure	O
other	O
than	O
severe	O
ARDS	O
.	O

The	O
summary	O
RR	O
of	O
osteonecrosis	O
was	O
1	O
.	O
57	O
(	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
1	O
.	O
30	O
-	O
1	O
.	O
89	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
per	O
5	O
.	O
0	O
g	O
increase	O
in	O
the	O
cumulative	O
dose	O
of	O
steroids	B-CHED
and	O
was	O
1	O
.	O
29	O
(	O
95	O
%	O
CI	O
1	O
.	O
09	O
-	O
1	O
.	O
53	O
,	O
p	O
=	O
0	O
.	O
003	O
)	O
for	O
each	O
10	O
-	O
day	O
increment	O
of	O
increase	O
in	O
treatment	O
duration	O
.	O

The	O
relationship	O
was	O
non	O
-	O
linear	O
(	O
p	O
SARS	O
patients	O
who	O
received	O
higher	O
cumulative	O
doses	O
and	O
longer	O
treatment	O
durations	O
of	O
steroids	B-CHED
were	O
more	O
likely	O
to	O
develop	O
osteonecrosis	O
,	O
and	O
there	O
were	O
no	O
sex	O
differences	O
in	O
this	O
dose	O
-	O
dependent	O
side	O
effect	O
.	O

This	O
work	O
aimed	O
to	O
investigate	O
the	O
anti	O
-	O
DENV	O
effect	O
and	O
possible	O
mechanism	O
of	O
celastrol	B-CHED
in	O
vitro	O
and	O
in	O
vivo	O
.	O

The	O
precise	O
anti	O
-	O
DENV	O
replication	O
mechanism	O
of	O
celastrol	B-CHED
was	O
clarified	O
using	O
specific	O
RNA	O
silencing	O
and	O
specific	O
inhibitor	B-CHED
.	O

Celastrol	B-CHED
inhibited	O
DENV	O
-	O
1	O
,	O
-	O
2	O
,	O
-	O
3	O
,	O
and	O
-	O
4	O
RNA	O
replication	O
with	O
EC	O
Celastrol	B-CHED
represents	O
a	O
potential	O
anti	O
-	O
DENV	O
agent	O
that	O
induces	O
IFN	O
-	O
α	O
expression	O
and	O
stimulates	O
a	O
downstream	O
antiviral	B-CHED
response	O
,	O
making	O
the	O
therapy	O
a	O
promising	O
drug	O
or	O
dietary	B-CHED
supplement	I-CHED
for	O
the	O
treatment	O
of	O
DENV	O
-	O
infected	O
patients	O
.	O

RESULTS	O
:	O
In	O
the	O
adjusted	O
analysis	O
,	O
a	O
statistically	O
significant	O
relationship	O
between	O
PEEP	B-CHED
and	O
ICP	O
and	O
PEEP	B-CHED
and	O
CPP	O
was	O
found	O
only	O
among	O
observations	O
occurring	O
during	O
periods	O
of	O
severe	O
lung	O
injury	O
.	O

TITLE	O
:	O
Transmissible	O
Gastroenteritis	O
Virus	O
Infection	O
Enhances	O
SGLT1	O
and	O
GLUT2	O
Expression	O
to	O
Increase	O
Glucose	B-CHED
Uptake	O
.	O

In	O
vivo	O
,	O
TGEV	O
primarily	O
targets	O
and	O
infects	O
intestinal	O
epithelial	O
cells	O
,	O
which	O
play	O
an	O
important	O
role	O
in	O
glucose	B-CHED
absorption	O
via	O
the	O
apical	O
and	O
basolateral	O
transporters	O
Na	O
+-	O
dependent	O
glucose	B-CHED
transporter	O
1	O
(	O
SGLT1	O
)	O
and	O
facilitative	O
glucose	B-CHED
transporter	O
2	O
(	O
GLUT2	O
),	O
respectively	O
.	O

In	O
this	O
study	O
,	O
we	O
therefore	O
sought	O
to	O
evaluate	O
the	O
effects	O
of	O
TGEV	O
infection	O
on	O
glucose	B-CHED
uptake	O
and	O
SGLT1	O
and	O
GLUT2	O
expression	O
.	O

However	O
,	O
the	O
transmission	O
of	O
PEEP	B-CHED
into	O
the	O
thoracic	O
cavity	O
depends	O
on	O
the	O
properties	O
of	O
the	O
lungs	O
and	O
the	O
chest	O
wall	O
.	O

Tissue	O
homogenate	O
samples	O
from	O
six	O
sentinel	O
and	O
11	O
donor	B-CHED
animals	O
,	O
over	O
the	O
same	O
2	O
-	O
year	O
period	O
,	O
were	O
negative	O
for	O
the	O
presence	O
of	O
viruses	O
when	O
co	O
-	O
cultured	O
with	O
six	O
different	O
cell	O
lines	O
from	O
four	O
species	O
.	O

The	O
absence	O
of	O
adventitious	O
viruses	O
in	O
separate	O
islet	O
macrobead	O
preparations	O
produced	O
from	O
12	O
individual	O
pancreas	O
donor	B-CHED
animals	O
was	O
confirmed	O
using	O
validated	O
molecular	O
(	O
n	O
=	O
32	O
viruses	O
),	O
in	O
vitro	O
culture	O
(	O
cells	O
from	O
four	O
species	O
),	O
and	O
transmission	O
electron	O
microscopy	O
assays	O
(	O
200	O
cell	O
profiles	O
per	O
donor	B-CHED
animal	O
)	O
over	O
the	O
same	O
2	O
-	O
year	O
period	O
.	O

The	O
problem	O
of	O
finding	O
a	O
potent	O
drug	O
against	O
HCoV	O
strains	O
lies	O
in	O
the	O
inability	O
of	O
finding	O
a	O
drug	O
that	O
stops	O
the	O
viral	O
replication	O
through	O
inhibiting	O
its	O
important	O
proteins	B-CHED
.	O

A	O
clinical	O
trial	O
of	O
early	O
ECMO	O
with	O
CRRT	O
and	O
the	O
administration	O
of	O
cidofovir	B-CHED
in	O
patients	O
with	O
severe	O
ARDS	O
complicating	O
HAdV	O
pneumonia	O
are	O
needed	O
to	O
confirm	O
our	O
results	O
.	O

However	O
,	O
serum	O
triglyceride	B-CHED
levels	O
remained	O
within	O
the	O
normal	O
range	O
(	O
134	O
mg	O
/	O
dL	O
).	O

These	O
epitopes	O
should	O
be	O
eliminated	O
in	O
vaccine	O
design	O
,	O
but	O
there	O
is	O
no	O
reliable	O
method	O
for	O
evaluating	O
an	O
epitope	B-CHED
'	O
s	O
capacity	O
to	O
elicit	O
neutralizing	O
immune	O
responses	O
.	O

As	O
proof	O
-	O
of	O
-	O
concept	O
,	O
we	O
measure	O
the	O
NII	O
for	O
different	O
epitopes	O
on	O
an	O
immunogen	B-CHED
comprised	O
of	O
the	O
receptor	O
-	O
binding	O
domain	O
from	O
MERS	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
).	O

Despite	O
a	O
high	O
degree	O
of	O
homology	O
in	O
their	O
spike	O
protein	B-CHED
genes	O
,	O
cross	O
neutralization	O
test	O
showed	O
low	O
cross	O
protection	O
between	O
3575	O
/	O
08	O
and	O
2575	O
/	O
98	O
,	O
suggesting	O
distinct	O
antigenicity	O
for	O
the	O
two	O
strains	O
.	O

TITLE	O
:	O
Acute	O
oesophageal	O
necrosis	O
in	O
a	O
young	O
man	B-CHED
with	O
cocaine	B-CHED
and	O
alcohol	O
abuse	O
.	O

Children	O
with	O
B	O
/	O
Yamagata	O
infection	O
were	O
more	O
likely	O
to	O
report	O
prolonged	O
absence	O
than	O
children	O
with	O
A	O
/	O
H1N1	O
or	O
A	O
/	O
H3N2	B-CHED
infection	O
[	O
OR	O
(	O
95	O
%	O
CI	O
):	O
2	O
.	O
1	O
(	O
1	O
.	O
0	O
,	O
4	O
.	O
5	O
)	O
and	O
1	O
.	O
7	O
(	O
1	O
.	O
0	O
,	O
2	O
.	O
9	O
),	O
respectively	O
].	O

These	O
findings	O
illustrated	O
the	O
existence	O
of	O
genetic	O
diversity	O
among	O
geographically	O
distinct	O
PEDV	O
strains	O
,	O
and	O
our	O
study	O
has	O
provided	O
an	O
impetus	O
to	O
conduct	O
further	O
research	O
on	O
the	O
PEDV	O
receptor	O
binding	O
protein	B-CHED
and	O
on	O
the	O
new	O
and	O
efficacious	O
vaccines	O
design	O
.	O

Both	O
stable	O
(	O
n	O
=	O
177	O
)	O
and	O
acute	O
(	O
n	O
=	O
78	O
)	O
asthmatics	O
were	O
recruited	O
and	O
categorized	O
into	O
lean	O
(	O
n	O
=	O
77	O
and	O
39	O
respectively	O
),	O
overweight	O
(	O
n	O
=	O
41	O
and	O
17	O
respectively	O
)	O
and	O
obese	O
(	O
n	O
=	O
59	O
and	O
22	O
respectively	O
)	O
groups	O
and	O
compared	O
for	O
clinical	O
characteristics	O
,	O
including	O
sputum	O
and	O
plasma	O
IL	O
-	O
17	O
protein	B-CHED
concentrations	O
,	O
sputum	O
cellularity	O
,	O
spirometry	O
and	O
comorbidities	O
.	O

The	O
significance	O
of	O
the	O
ordering	O
effect	O
,	O
membrane	O
dehydration	O
,	O
changes	O
in	O
the	O
curvature	O
properties	O
and	O
the	O
possible	O
role	O
of	O
negatively	O
charged	O
phospholipids	B-CHED
in	O
helping	O
to	O
overcome	O
the	O
high	O
kinetic	O
barrier	O
involved	O
in	O
the	O
different	O
stages	O
of	O
the	O
SARS	O
-	O
CoV	O
-	O
mediated	O
membrane	O
fusion	O
are	O
discussed	O
.	O

It	O
couples	O
a	O
one	O
-	O
step	O
isothermal	O
RNA	O
amplification	O
method	O
and	O
a	O
bio	O
-	O
optical	O
sensor	O
for	O
simultaneous	O
viral	O
RNA	O
amplification	O
/	O
detection	O
in	O
a	O
label	B-CHED
-	O
free	O
and	O
real	O
-	O
time	O
manner	O
.	O

ABSTRACT	O
:	O
Heroin	B-CHED
use	O
by	O
non	O
-	O
injecting	O
routes	O
of	O
administration	O
(	O
snorting	O
,	O
swallowing	O
,	O
""""	O
chasing	O
the	O
dragon	O
""")"	O
is	O
considered	O
to	O
be	O
safer	O
but	O
is	O
not	O
risk	O
-	O
free	O
for	O
fatal	O
overdose	O
or	O
serious	O
side	O
effects	O
.	O

TITLE	O
:	O
Early	O
experience	O
of	O
a	O
new	O
extracorporeal	O
carbon	B-CHED
dioxide	I-CHED
removal	O
device	O
for	O
acute	O
hypercapnic	O
respiratory	O
failure	O
.	O

Clinical	O
improvement	O
after	O
initiation	O
of	O
antimicrobials	B-CHED
was	O
protracted	O
.	O

The	O
average	O
single	O
nucleotide	B-CHED
polymorphism	O
counts	O
of	O
swab	O
isolates	O
were	O
greater	O
than	O
those	O
found	O
in	O
tissue	O
samples	O
.	O

We	O
have	O
previously	O
shown	O
that	O
a	O
proportion	O
of	O
DBA	B-CHED
/	O
2	O
mice	O
infected	O
with	O
Plasmodium	O
berghei	O
ANKA	O
(	O
PbA	B-CHED
)	O
develop	O
ALI	O
/	O
ARDS	O
and	O
that	O
these	O
mice	O
recapitulate	O
various	O
aspects	O
of	O
the	O
human	O
syndrome	O
,	O
such	O
as	O
pulmonary	O
edema	O
,	O
hemorrhaging	O
,	O
pleural	O
effusion	O
and	O
hypoxemia	O
.	O

In	O
addition	O
,	O
mice	O
with	O
ALI	O
/	O
ARDS	O
produced	O
more	O
neutrophil	O
-	O
attracting	O
chemokines	O
,	O
myeloperoxidase	O
and	O
reactive	B-CHED
oxygen	I-CHED
species	I-CHED
.	O

We	O
also	O
observed	O
that	O
the	O
parasites	O
Plasmodium	O
falciparum	O
and	O
PbA	B-CHED
induced	O
the	O
formation	O
of	O
neutrophil	O
extracellular	O
traps	O
(	O
NETs	O
)	O
ex	O
vivo	O
,	O
which	O
were	O
associated	O
with	O
inflammation	O
and	O
tissue	O
injury	O
.	O

The	O
depletion	O
of	O
neutrophils	O
,	O
treatment	O
with	O
AMD3100	O
(	O
a	O
CXCR4	O
antagonist	B-CHED
),	O
Pulmozyme	O
(	O
human	O
recombinant	O
DNase	O
)	O
or	O
Sivelestat	O
(	O
inhibitor	B-CHED
of	O
neutrophil	O
elastase	O
)	O
decreased	O
the	O
development	O
of	O
malaria	O
-	O
associated	O
ALI	O
/	O
ARDS	O
and	O
significantly	O
increased	O
mouse	O
survival	O
.	O

Using	O
procalcitonin	O
as	O
a	O
biomarker	B-CHED
for	O
severe	O
infection	O
may	O
further	O
assist	O
with	O
risk	O
stratification	O
.	O

Most	O
outpatients	O
with	O
community	O
-	O
acquired	O
pneumonia	O
do	O
not	O
require	O
microbiologic	O
testing	O
of	O
sputum	O
or	O
blood	O
and	O
can	O
be	O
treated	O
empirically	O
with	O
a	O
macrolide	B-CHED
,	O
doxycycline	B-CHED
,	O
or	O
a	O
respiratory	O
fluoroquinolone	O
.	O

Differences	O
in	O
detection	O
among	O
assays	O
seem	O
to	O
be	O
more	O
related	O
to	O
intrinsic	O
factors	O
of	O
an	O
assay	O
than	O
to	O
the	O
PEDV	O
antigen	B-CHED
used	O
.	O

Whole	O
genome	O
sequencing	O
and	O
phylogenetic	O
analysis	O
classified	O
the	O
representative	O
strain	O
into	O
a	O
tentative	O
tenth	O
rotavirus	O
species	O
,	O
we	O
provisionally	O
called	O
Rotavirus	O
J	O
.	O
The	O
novel	O
virus	O
shared	O
a	O
maximum	O
of	O
50	O
%	O
amino	B-CHED
acid	I-CHED
sequence	O
identity	O
within	O
the	O
VP6	O
gene	O
to	O
currently	O
known	O
members	O
of	O
the	O
genus	O
.	O

After	O
start	O
of	O
oseltamivir	B-CHED
treatment	O
and	O
removal	O
of	O
mucus	O
plugs	O
,	O
the	O
patient	O
fully	O
recovered	O
.	O

TITLE	O
:	O
Ultrasensitive	O
Detection	O
of	O
Porcine	O
Epidemic	O
Diarrhea	O
Virus	O
from	O
Fecal	O
Samples	O
Using	O
Functionalized	O
Nanoparticles	B-CHED
.	O

Optimization	O
of	O
the	O
peptide	B-CHED
sequences	O
is	O
expected	O
to	O
produce	O
next	O
-	O
generation	O
anti	O
-	O
MERS	O
-	O
CoV	O
peptides	B-CHED
with	O
improved	O
potency	O
.	O

The	O
pathogenicity	O
of	O
CHN	B-CHED
-	O
HN	O
-	O
2014	O
was	O
further	O
investigated	O
in	O
5	O
-	O
day	O
-	O
old	O
and	O
21	O
-	O
day	O
-	O
old	O
piglets	O
.	O

Our	O
aim	O
was	O
to	O
investigate	O
the	O
relationships	O
between	O
ARDS	O
diagnosis	O
and	O
plasma	O
concentrations	O
of	O
tissue	O
factor	O
(	O
TF	O
),	O
tissue	O
plasminogen	O
activator	O
(	O
t	O
-	O
PA	O
),	O
and	O
plasminogen	O
activator	O
inhibitor	B-CHED
-	O
1	O
(	O
PAI	O
-	O
1	O
)	O
in	O
mechanically	O
ventilated	O
patients	O
at	O
increased	O
risk	O
of	O
developing	O
ARDS	O
.	O

(	O
2	O
)	O
The	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
is	O
a	O
new	O
corona	B-CHED
virus	O
isolated	O
for	O
the	O
first	O
time	O
in	O
a	O
patients	O
who	O
died	O
of	O
severe	O
lower	O
respiratory	O
tract	O
infection	O
in	O
Jeddah	O
(	O
Saudi	O
Arabia	O
)	O
in	O
June	O
2012	O
(	O
Zaki	O
et	O
al	O
.	O
2012	O
).	O

RESULTS	O
:	O
After	O
5	O
days	O
of	O
treatment	O
,	O
the	O
low	O
-	O
and	O
high	O
-	O
dose	O
groups	O
had	O
significant	O
reductions	O
in	O
serum	O
levels	O
of	O
tumor	O
necrosis	O
factor	O
-	O
α	O
,	O
interleukin	O
-	O
6	O
,	O
and	O
C	O
-	O
reactive	O
protein	B-CHED
,	O
and	O
there	O
were	O
no	O
significant	O
differences	O
in	O
the	O
reductions	O
of	O
these	O
markers	O
between	O
the	O
two	O
groups	O
.	O

Of	O
the	O
2580	O
patients	O
who	O
underwent	O
a	O
bronchoalveolar	O
lavage	O
(	O
BAL	B-CHED
)	O
procedure	O
at	O
Tosei	O
General	O
Hospital	O
between	O
May	O
2007	O
and	O
February	O
2015	O
,	O
we	O
retrospectively	O
analysed	O
the	O
data	O
of	O
68	O
DLI	O
patients	O
.	O

In	O
the	O
period	O
from	O
December	O
2014	O
to	O
December	O
2015	O
,	O
sufficient	O
data	O
of	O
Peking	O
University	O
First	O
Hospital	O
Respiratory	O
and	O
Critical	O
Care	O
Medicine	B-CHED
Department	O
for	O
analysis	O
were	O
identified	O
in	O
218	O
subjects	O
.	O

TITLE	O
:	O
Severe	O
Hypoxemia	O
in	O
a	O
Healthy	O
Donor	B-CHED
for	O
Allogeneic	O
Hematopoietic	O
Stem	O
Cell	O
Transplantation	O
after	O
Only	O
the	O
First	O
Administration	O
of	O
Granulocyte	O
-	O
Colony	O
Stimulating	O
Factor	O
.	O

It	O
was	O
found	O
that	O
the	O
down	O
-	O
regulation	O
of	O
TNF	O
-	O
The	O
study	O
found	O
that	O
,	O
as	O
a	O
potential	O
treatment	O
,	O
MSCs	O
could	O
work	O
on	O
multiple	O
S1P	B-CHED
related	O
genes	O
simultaneously	O
.	O

TITLE	O
:	O
Use	O
of	O
Aptamers	O
as	O
Diagnostics	O
Tools	O
and	O
Antiviral	B-CHED
Agents	I-CHED
for	O
Human	O
Viruses	O
.	O

ABSTRACT	O
:	O
Griffithsin	O
(	O
GRFT	O
)	O
is	O
a	O
red	O
alga	O
-	O
derived	O
lectin	O
with	O
demonstrated	O
broad	O
spectrum	O
antiviral	B-CHED
activity	O
against	O
enveloped	O
viruses	O
,	O
including	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
Coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
Japanese	O
encephalitis	O
virus	O
(	O
JEV	O
),	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
),	O
and	O
herpes	O
simplex	O
virus	O
-	O
2	O
(	O
HSV	O
-	O
2	O
).	O

A	O
comparison	O
of	O
predicted	O
protein	B-CHED
sequences	O
also	O
demonstrated	O
the	O
existence	O
of	O
two	O
clade	O
A	O
lineages	O
with	O
unique	O
amino	B-CHED
acid	I-CHED
substitutions	O
,	O
A1	O
(	O
EMC	O
/	O
2012	O
and	O
Jordan	O
-	O
N3	O
/	O
2012	O
)	O
and	O
A2	O
(	O
D998	O
/	O
15	O
and	O
NRCE	O
-	O
HKU205	O
),	O
circulating	O
in	O
humans	O
and	O
camels	O
,	O
respectively	O
.	O

Indeed	O
,	O
a	O
high	O
PEEP	B-CHED
(	O
10	O
-	O
24	O
cm	O
H₂O	O
)	O
appears	O
to	O
be	O
a	O
life	O
-	O
saver	O
in	O
the	O
context	O
of	O
early	O
severe	O
diffuse	O
ARDS	O
;	O
c	O
)	O
tidal	O
volume	O
and	O
plateau	O
pressure	O
cannot	O
be	O
identical	O
for	O
all	O
patients	O
;	O
d	O
)	O
the	O
only	O
remaining	O
rationale	O
for	O
CMV	O
and	O
muscle	O
relaxation	O
is	O
to	O
suppress	O
patient	O
-	O
ventilator	O
asynchrony	O
and	O
to	O
lower	O
VO2	B-CHED
,	O
during	O
the	O
acute	O
cardio	O
-	O
ventilatory	O
distress	O
.	O

ABSTRACT	O
:	O
The	O
second	O
part	O
of	O
this	O
overview	O
on	O
early	O
severe	O
ARDS	O
delineates	O
the	O
pros	O
and	O
cons	O
of	O
the	O
following	O
:	O
a	O
)	O
controlled	O
mechanical	O
ventilation	O
(	O
CMV	O
:	O
lowered	O
oxygen	B-CHED
consumption	O
and	O
perfect	O
patient	O
-	O
to	O
-	O
ventilator	O
synchrony	O
),	O
to	O
be	O
used	O
during	O
acute	O
cardio	O
-	O
ventilatory	O
distress	O
in	O
order	O
to	O
""""	O
buy	O
time	O
""""	O
and	O
correct	O
circulatory	O
insufficiency	O
and	O
metabolic	O
defects	O
(	O
acidosis	O
,	O
etc	O
.);	O
b	O
)	O
spontaneous	O
ventilation	O
(	O
SV	O
:	O
improved	O
venous	O
return	O
,	O
lowered	O
intrathoracic	O
pressure	O
,	O
absence	O
of	O
muscle	O
atrophy	O
).	O

ABSTRACT	O
:	O
The	O
global	O
outbreak	O
of	O
SARS	O
in	O
2002	O
-	O
2003	O
was	O
caused	O
by	O
the	O
infection	O
of	O
a	O
new	O
human	O
coronavirus	O
SARS	O
-	O
CoV	O
.	O
The	O
infection	O
of	O
SARS	O
-	O
CoV	O
is	O
mediated	O
mainly	O
through	O
the	O
viral	O
surface	O
glycoproteins	B-CHED
,	O
which	O
consist	O
of	O
S1	O
and	O
S2	O
subunits	O
and	O
form	O
trimer	O
spikes	O
on	O
the	O
envelope	O
of	O
the	O
virions	O
.	O

The	O
capsid	O
structural	O
protein	B-CHED
of	O
CAstV	O
/	O
INDIA	O
/	O
ANAND	O
/	O
2016	O
showed	O
84	O
.	O
67	O
%	O
similarity	O
with	O
chicken	O
astrovirus	O
isolate	O
CAstV	O
/	O
GA2011	O
,	O
81	O
.	O
06	O
%	O
with	O
CAstV	O
/	O
4175	O
and	O
41	O
.	O
18	O
%	O
with	O
CAstV	O
/	O
Poland	O
/	O
G059	O
/	O
2014	O
isolates	O
.	O

These	O
synthetic	O
viral	O
particles	O
are	O
safer	O
surrogates	O
of	O
native	O
viruses	O
and	O
acquire	O
the	O
tropism	O
and	O
host	O
entry	O
pathway	O
characteristics	O
governed	O
by	O
the	O
heterologous	O
envelope	O
glycoprotein	B-CHED
used	O
.	O

Here	O
,	O
we	O
detail	O
a	O
protocol	O
enabling	O
generation	O
of	O
MLV	O
-	O
based	O
pseudotyped	O
particles	O
,	O
using	O
the	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
spike	O
(	O
S	O
)	O
as	O
an	O
example	O
of	O
a	O
heterologous	O
envelope	O
glycoprotein	B-CHED
to	O
be	O
incorporated	O
.	O

At	O
the	O
time	O
of	O
diagnosis	O
,	O
PaO	B-CHED
We	O
identified	O
62	O
consecutive	O
patients	O
with	O
AE	O
-	O
IPF	O
.	O

The	O
median	O
PaO	B-CHED
CONCLUSIONS	O
:	O
Evaluation	O
of	O
oxygenation	O
with	O
PEEP	B-CHED
may	O
provide	O
useful	O
information	O
for	O
predicting	O
short	O
-	O
term	O
mortality	O
in	O
patients	O
with	O
AE	O
-	O
IPF	O
.	O

RESULTS	O
:	O
A	O
total	O
of	O
1004	O
met	B-CHED
the	O
Berlin	O
definition	O
of	O
ARDS	O
.	O

Interestingly	O
,	O
N	O
protein	B-CHED
importation	O
into	O
the	O
nucleolus	O
is	O
independent	O
of	O
the	O
ability	O
of	O
NPM1	O
to	O
shuttle	O
between	O
the	O
nucleus	B-CHED
and	O
the	O
cytoplasm	O
.	O

A	O
59	O
-	O
year	O
old	O
man	B-CHED
staying	O
near	O
the	O
Belum	O
-	O
Temengor	O
rainforest	O
at	O
the	O
Malaysia	O
-	O
Thailand	O
border	O
was	O
admitted	O
with	O
fever	O
for	O
6	O
days	O
,	O
with	O
respiratory	O
distress	O
.	O

It	O
was	O
due	O
to	O
the	O
presentation	O
of	O
shivering	O
in	O
the	O
ICU	O
,	O
that	O
a	O
blood	O
film	O
was	O
done	O
on	O
the	O
second	O
day	O
that	O
revealed	O
the	O
presence	O
of	O
P	O
.	O
knowlesi	O
with	O
a	O
parasite	O
count	O
of	O
520	O
,	O
000	O
/	O
μL	O
.	O
The	O
patient	O
was	O
subsequently	O
treated	O
with	O
artesunate	B-CHED
-	O
doxycycline	B-CHED
and	O
made	O
a	O
good	O
recovery	O
after	O
nine	O
days	O
in	O
ICU	O
.	O

ABSTRACT	O
:	O
Safety	O
tested	O
Modified	O
Vaccinia	O
virus	O
Ankara	O
(	O
MVA	B-CHED
)	O
is	O
licensed	O
as	O
third	O
-	O
generation	O
vaccine	O
against	O
smallpox	O
and	O
serves	O
as	O
a	O
potent	O
vector	O
system	O
for	O
development	O
of	O
new	O
candidate	O
vaccines	O
against	O
infectious	O
diseases	O
and	O
cancer	O
.	O

As	O
a	O
biologically	O
well	O
-	O
characterized	O
mutant	O
virus	O
,	O
MVA	B-CHED
facilitates	O
fundamental	O
research	O
to	O
elucidate	O
the	O
functions	O
of	O
poxvirus	O
host	O
-	O
interaction	O
factors	O
.	O

TITLE	O
:	O
Antiviral	B-CHED
therapy	O
for	O
respiratory	O
viral	O
infections	O
in	O
immunocompromised	O
patients	O
.	O

In	O
this	O
work	O
,	O
we	O
employ	O
charged	O
tobacco	O
mosaic	O
virus	O
(	O
TMV	O
-	O
wt	O
and	O
TMV	O
-	O
lys	B-CHED
)	O
nanoparticles	B-CHED
in	O
constructing	O
multilayered	O
fibrous	O
networks	O
via	O
electrostatic	O
layer	O
-	O
by	O
-	O
layer	O
(	O
LbL	O
)	O
deposition	O
.	O

Multiple	O
viruses	O
are	O
detected	O
during	O
a	O
single	O
ARI	B-CHED
episode	O
in	O
approximately	O
a	O
quarter	O
of	O
all	O
cases	O
.	O

However	O
,	O
our	O
recent	O
cellular	O
studies	O
reveal	O
that	O
removing	O
the	O
Ubl2	O
domain	O
from	O
MERS	O
PLpro	O
has	O
no	O
effect	O
on	O
its	O
ability	O
to	O
process	O
the	O
viral	O
polyprotein	O
or	O
act	O
as	O
an	O
interferon	O
antagonist	B-CHED
,	O
which	O
involves	O
deubiquitinating	O
and	O
deISGylating	O
cellular	O
proteins	B-CHED
.	O

However	O
,	O
the	O
drug	O
-	O
mediated	O
depletion	O
of	O
lipid	B-CHED
rafts	O
in	O
Vero	O
cells	O
before	O
IBV	O
attachment	O
significantly	O
reduced	O
the	O
expression	O
of	O
viral	O
structural	O
proteins	B-CHED
,	O
suggesting	O
that	O
drug	O
treatment	O
impaired	O
the	O
attachment	O
of	O
IBV	O
to	O
the	O
cell	O
surface	O
.	O

ARMS	O
-	O
I	O
is	O
patented	O
novel	O
formulation	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
influenza	O
,	O
comprising	O
a	O
broad	O
-	O
spectrum	O
antimicrobial	B-CHED
agent	I-CHED
(	O
cetylpyridinium	B-CHED
chloride	I-CHED
,	O
CPC	O
)	O
and	O
components	O
(	O
glycerin	B-CHED
and	O
xanthan	B-CHED
gum	O
)	O
that	O
form	O
a	O
barrier	O
on	O
the	O
host	O
mucosa	O
,	O
thus	O
preventing	O
viral	O
contact	O
and	O
invasion	O
.	O

ABSTRACT	O
:	O
A	O
series	O
of	O
potent	O
and	O
novel	O
acylsulfonamide	O
-	O
bearing	O
triazines	B-CHED
were	O
synthesized	O
and	O
the	O
structure	O
-	O
activity	O
relationships	O
(	O
SARs	O
)	O
as	O
HCV	O
entry	O
inhibitors	B-CHED
were	O
evaluated	O
.	O

They	O
also	O
received	O
a	O
significantly	O
higher	O
number	O
of	O
distinct	O
intravenous	O
antibiotics	B-CHED
,	O
cumulative	O
days	O
of	O
antibiotic	B-CHED
therapy	O
,	O
and	O
exposure	O
to	O
vasopressors	O
and	O
paralytics	O
.	O

This	O
single	O
-	O
sample	O
metabolite	B-CHED
,	O
protein	B-CHED
and	O
lipid	B-CHED
extraction	O
(	O
MPLEx	O
)	O
method	O
resulted	O
in	O
complete	O
inactivation	O
of	O
clinically	O
important	O
bacterial	O
and	O
viral	O
pathogens	O
with	O
exposed	O
lipid	B-CHED
membranes	O
,	O
including	O
Yersinia	O
pestis	O
,	O
Salmonella	O
Typhimurium	O
,	O
and	O
Campylobacter	O
jejuni	O
in	O
pure	O
culture	O
,	O
and	O
Yersinia	O
pestis	O
,	O
Campylobacter	O
jejuni	O
,	O
and	O
West	O
Nile	O
,	O
MERS	O
-	O
CoV	O
,	O
Ebola	O
,	O
and	O
influenza	O
H7N9	O
viruses	O
in	O
infection	O
studies	O
.	O

Serum	O
pretreatment	O
of	O
the	O
nitrocellulose	B-CHED
also	O
eliminated	O
false	O
positives	O
.	O

Langmuir	O
binding	O
analysis	O
determined	O
how	O
the	O
immobilized	O
Ab	O
affinity	O
for	O
the	O
NP	O
-	O
Ab	O
/	O
NS1	O
was	O
impacted	O
by	O
corona	B-CHED
formation	O
conditions	O
,	O
quantified	O
as	O
an	O
effective	O
dissociation	O
constant	O
,	O
K	O

ABSTRACT	O
:	O
A	O
previously	O
healthy	O
young	O
man	B-CHED
with	O
a	O
rare	O
genetic	O
condition	O
presented	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
secondary	O
to	O
pneumonia	O
with	O
septic	O
shock	O
.	O

ABSTRACT	O
:	O
Optimal	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	B-CHED
)	O
is	O
unknown	O
in	O
patients	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
on	O
extracorporeal	O
membrane	O
oxygenation	O
receiving	O
mechanical	O
ventilation	O
with	O
very	O
low	O
tidal	O
volume	O
.	O

Low	O
tidal	O
volume	O
(	O
2	O
.	O
9	O
-	O
4	O
ml	O
/	O
kg	O
ideal	O
body	O
weight	O
)	O
and	O
poor	O
compliance	O
(	O
12	O
.	O
1	O
-	O
18	O
.	O
7	O
ml	O
/	O
cm	O
H	O
The	O
broad	O
variability	O
in	O
optimal	O
PEEP	B-CHED
observed	O
in	O
these	O
patients	O
with	O
severe	O
ARDS	O
under	O
extracorporeal	O
membrane	O
oxygenation	O
reinforces	O
the	O
need	O
for	O
personalized	O
titration	O
of	O
ventilation	O
settings	O
.	O

The	O
overall	O
specificity	O
was	O
100	O
%,	O
but	O
the	O
sensitivity	O
was	O
50	O
%	O
and	O
54	O
.	O
5	O
%	O
for	O
agarose	B-CHED
gel	O
and	O
HNB	O
respectively	O
.	O

Here	O
,	O
we	O
demonstrated	O
that	O
both	O
recombinant	O
porcine	O
IFN	O
-	O
L1	O
(	O
rpIFN	O
-	O
L1	O
)	O
and	O
rpIFN	O
-	O
L3	O
have	O
powerful	O
antiviral	B-CHED
activity	O
against	O
PEDV	O
infection	O
of	O
both	O
Vero	O
E6	O
cells	O
and	O
the	O
intestinal	O
porcine	O
epithelial	O
cell	O
line	O
J2	O
(	O
IPEC	O
-	O
J2	O
).	O

The	O
isolated	O
compounds	O
were	O
broussochalcone	O
B	O
(	O
1	O
),	O
broussochalcone	O
A	O
(	O
2	O
),	O
4	O
-	O
hydroxyisolonchocarpin	O
(	O
3	O
),	O
papyriflavonol	B-CHED
A	I-CHED
(	O
4	O
),	O
3	O
'-(	O
3	O
-	O
methylbut	O
-	O
2	O
-	O
enyl	O
)-	O
3	O
',	O
4	O
,	O
7	O
-	O
trihydroxyflavane	O
(	O
5	O
),	O
kazinol	O
A	O
(	O
6	O
),	O
kazinol	O
B	O
(	O
7	O
),	O
broussoflavan	O
A	O
(	O
8	O
),	O
kazinol	O
F	O
(	O
9	O
),	O
and	O
kazinol	O
J	O
(	O
10	O
).	O

Herein	O
we	O
demonstrated	O
that	O
infection	O
of	O
macrophages	O
with	O
lentiviral	O
particles	O
pseudotyped	O
with	O
MERS	O
-	O
CoV	O
S	O
glycoprotein	B-CHED
results	O
in	O
suppression	O
of	O
macrophage	O
responses	O
since	O
it	O
reduced	O
the	O
capacity	O
of	O
macrophages	O
to	O
produce	O
TNFα	O
and	O
IL	O
-	O
6	O
in	O
naive	O
and	O
LPS	B-CHED
-	O
activated	O
THP	B-CHED
-	O
1	O
macrophages	O
and	O
augmented	O
LPS	B-CHED
-	O
induced	O
production	O
of	O
the	O
immunosuppressive	O
cytokine	O
IL	O
-	O
10	O
.	O

No	O
patient	O
had	O
air	B-CHED
leak	O
syndrome	O
or	O
died	O
.	O

The	O
literature	O
search	O
identified	O
eight	O
articles	O
for	O
review	O
that	O
reported	O
on	O
paramedic	O
exposure	O
trends	O
;	O
the	O
lack	O
of	O
reported	O
blood	O
-	O
borne	O
infections	O
contracted	O
,	O
such	O
as	O
hepatitis	O
B	O
,	O
hepatitis	O
C	O
,	O
and	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
);	O
instances	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
infections	O
;	O
and	O
the	O
higher	O
prevalence	O
of	O
methicillin	B-CHED
-	O
resistant	O
staphylococcus	O
aureus	O
(	O
MRSA	O
)	O
nasal	O
infections	O
amongst	O
paramedics	O
.	O

Samples	O
positive	O
for	O
influenza	O
A	O
were	O
subtyped	O
for	O
A	O
/	O
H1N1pdm09	O
and	O
A	O
/	O
H3N2	B-CHED
whereas	O
influenza	O
B	O
samples	O
were	O
subtyped	O
into	O
B	O
/	O
Yamagata	O
and	O
B	O
/	O
Victoria	O
subtypes	O
,	O
using	O
primers	O
and	O
probes	O
recommended	O
by	O
CDC	O
,	O
USA	O
.	O

Respiratory	O
viruses	O
were	O
detected	O
in	O
46	O
(	O
19	O
.	O
7	O
%)	O
cases	O
,	O
influenza	O
A	O
/	O
H3N2	B-CHED
and	O
rhinoviruses	O
being	O
the	O
most	O
common	O
viruses	O
detected	O
.	O

As	O
the	O
patient	O
did	O
not	O
improve	O
after	O
3	O
days	O
of	O
antibiotics	B-CHED
and	O
donor	B-CHED
-	O
specific	O
HLA	O
antibodies	O
had	O
been	O
detected	O
,	O
an	O
acute	O
antibody	O
-	O
mediated	O
graft	O
rejection	O
was	O
treated	O
with	O
high	O
-	O
dose	O
corticosteroids	B-CHED
,	O
plasma	O
exchange	O
,	O
intravenous	O
immunoglobulin	O
,	O
and	O
rituximab	O
.	O

We	O
therefore	O
investigated	O
the	O
importance	O
of	O
other	O
classes	O
of	O
cellular	O
proteases	O
and	O
found	O
that	O
inhibition	O
of	O
matrix	O
metalloproteinase	O
(	O
MMP	B-CHED
)-	O
and	O
a	O
disintegrin	O
and	O
metalloprotease	O
(	O
ADAM	O
)-	O
family	O
zinc	B-CHED
metalloproteases	O
markedly	O
decreased	O
both	O
entry	O
and	O
cell	O
-	O
cell	O
fusion	O
.	O

The	O
evaluation	O
of	O
the	O
effect	O
of	O
sesquiterpenoids	B-CHED
on	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
replication	O
showed	O
that	O
compounds	O
1	O
-	O
5	O
,	O
12	O
,	O
14	O
,	O
16	O
,	O
17	O
,	O
19	O
,	O
and	O
21	O
increased	O
cell	O
viability	O
against	O
cell	O
death	O
in	O
PEDV	O
-	O
injected	O
cells	O
.	O

Here	O
we	O
show	O
that	O
the	O
coronavirus	O
endonuclease	O
(	O
EndoU	O
)	O
activity	O
is	O
key	O
to	O
prevent	O
early	O
induction	O
of	O
double	O
-	O
stranded	O
RNA	O
(	O
dsRNA	B-CHED
)	O
host	O
cell	O
responses	O
.	O

Collectively	O
our	O
results	O
demonstrate	O
that	O
the	O
coronavirus	O
EndoU	O
efficiently	O
prevents	O
simultaneous	O
activation	O
of	O
host	O
cell	O
dsRNA	B-CHED
sensors	O
,	O
such	O
as	O
Mda5	O
,	O
OAS	O
and	O
PKR	O
.	O

The	O
localization	O
of	O
the	O
EndoU	O
activity	O
at	O
the	O
site	O
of	O
viral	O
RNA	O
synthesis	O
-	O
within	O
the	O
replicase	O
complex	O
-	O
suggests	O
that	O
coronaviruses	O
have	O
evolved	O
a	O
viral	O
RNA	O
decay	O
pathway	O
to	O
evade	O
early	O
innate	O
and	O
intrinsic	O
antiviral	B-CHED
host	O
cell	O
responses	O
.	O

Although	O
antiviral	B-CHED
therapy	O
is	O
available	O
for	O
some	O
respiratory	O
viral	O
infections	O
,	O
further	O
research	O
is	O
needed	O
to	O
determine	O
which	O
groups	O
of	O
patients	O
would	O
benefit	O
.	O

The	O
distribution	O
of	O
these	O
antigens	B-CHED
was	O
comparatively	O
evaluated	O
in	O
different	O
anatomical	O
compartments	O
of	O
thymus	O
,	O
spleen	O
,	O
mesenteric	O
,	O
and	O
tracheobronchial	O
lymph	O
nodes	O
.	O

Since	O
glycyrrhizin	B-CHED
is	O
a	O
competitive	O
inhibitor	B-CHED
of	O
high	O
mobility	O
group	O
box	O
-	O
1	O
(	O
HMGB1	O
),	O
we	O
confirmed	O
that	O
TLR4	O
and	O
RAGE	O
(£	O
associated	O
with	O
PEDV	O
pathogenesis	O
during	O
the	O
infection	O
in	O
Vero	O
cells	O
.	O

ABSTRACT	O
:	O
Healthcare	O
personnel	O
often	O
use	O
incorrect	O
technique	O
for	O
donning	O
and	O
doffing	O
of	O
personal	O
protective	O
equipment	O
(	O
PPE	B-CHED
).	O

The	O
students	O
performed	O
simulations	O
of	O
contaminated	O
PPE	B-CHED
removal	O
with	O
fluorescent	O
lotion	O
on	O
gloves	O
and	O
were	O
assessed	O
for	O
correct	O
PPE	B-CHED
technique	O
and	O
skin	O
and	O
/	O
or	O
clothing	O
contamination	O
.	O

Of	O
27	O
medical	O
students	O
surveyed	O
,	O
only	O
11	O
(	O
41	O
%)	O
reported	O
receiving	O
PPE	B-CHED
training	O
,	O
and	O
none	O
had	O
received	O
training	O
requiring	O
demonstration	O
of	O
proficiency	O
.	O

For	O
100	O
residents	O
,	O
fellows	O
and	O
attending	O
physicians	O
representing	O
67	O
different	O
medical	O
schools	O
,	O
only	O
53	O
%	O
reported	O
receiving	O
training	O
in	O
use	O
of	O
PPE	B-CHED
and	O
only	O
39	O
%	O
selected	O
correct	O
donning	O
and	O
doffing	O
sequence	O
.	O

Reduced	O
cardiac	O
output	O
in	O
the	O
moderate	O
and	O
mild	O
in	O
silico	O
ARDS	O
patients	O
produced	O
significant	O
drops	O
in	O
oxygen	B-CHED
delivery	O
during	O
the	O
RM	O
(	O
average	O
decrease	O
of	O
423	O
ml	O
min	O

Cultures	O
of	O
a	O
model	O
organism	O
,	O
Pseudomonas	O
putida	O
at	O
106	O
-	O
109	O
cfu	O
ml	O
-	O
1	O
in	O
0	O
·	O
85	O
%	O
NaCl	B-CHED
were	O
flushed	O
into	O
the	O
system	O
in	O
volumes	O
of	O
6	O
to	O
20	O
litres	O
to	O
represent	O
single	O
or	O
multiple	O
toilet	O
flushes	O
.	O

In	O
this	O
study	O
,	O
three	O
assays	O
,	O
namely	O
a	O
conventional	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
),	O
a	O
SYBR	B-CHED
Green	I-CHED
I	I-CHED
real	O
-	O
time	O
RT	O
-	O
PCR	O
and	O
a	O
TaqMan	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
targeting	O
the	O
highly	O
conserved	O
M	O
gene	O
of	O
PEDV	O
,	O
were	O
developed	O
and	O
evaluated	O
.	O

We	O
ascertained	O
the	O
epidemiologic	O
link	O
between	O
patients	O
and	O
calculated	O
the	O
secondary	O
attack	O
rate	O
per	O
10	O
,	O
000	O
patients	O
visiting	O
the	O
ER	O
(	O
SAR	B-CHED
/	O
10	O
,	O
000	O
)	O
in	O
3	O
phases	O
of	O
the	O
outbreak	O
.	O

The	O
SAR	B-CHED
/	O
10	O
,	O
000	O
dropped	O
from	O
75	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
],	O
55	O
-	O
99	O
)	O
in	O
phase	O
I	O
to	O
29	O
(	O
95	O
%	O
CI	O
,	O
17	O
-	O
46	O
)	O
and	O
3	O
(	O
95	O
%	O
CI	O
,	O
0	O
-	O
17	O
)	O
in	O
phases	O
II	O
and	O
III	O
,	O
respectively	O
.	O

For	O
viral	O
productivity	O
,	O
we	O
utilized	O
plaque	O
assays	O
to	O
confirm	O
the	O
antiviral	B-CHED
properties	O
of	O
resveratrol	B-CHED
against	O
MERS	O
-	O
CoV	O
.	O
Resveratrol	B-CHED
significantly	O
inhibited	O
MERS	O
-	O
CoV	O
infection	O
and	O
prolonged	O
cellular	O
survival	O
after	O
virus	O
infection	O
.	O

We	O
perceive	O
that	O
resveratrol	B-CHED
can	O
be	O
a	O
potential	O
antiviral	B-CHED
agent	I-CHED
against	O
MERS	O
-	O
CoV	O
infection	O
in	O
the	O
near	O
future	O
.	O

TITLE	O
:	O
Thrombotic	O
microangiopathy	O
caused	O
by	O
methionine	B-CHED
synthase	O
deficiency	O
:	O
diagnosis	O
and	O
treatment	O
pitfalls	O
.	O

ABSTRACT	O
:	O
Inborn	O
errors	O
of	O
cobalamin	B-CHED
(	O
Cbl	B-CHED
)	O
metabolism	O
form	O
a	O
large	O
group	O
of	O
rare	O
diseases	O
.	O

PathChip	O
added	O
substantially	O
to	O
viruses	O
detected	O
for	O
community	O
-	O
ARI	B-CHED
only	O
.	O

Herein	O
,	O
an	O
alternative	O
indirect	O
ELISA	O
for	O
detection	O
of	O
IBV	O
antibody	O
was	O
developed	O
with	O
IBV	O
nonstructural	O
protein	B-CHED
5	O
(	O
nsp5	O
)	O
produced	O
by	O
Escherichia	O
coli	O
.	O

This	O
report	O
outlines	O
the	O
first	O
use	O
of	O
high	O
dose	O
intravenous	O
vitamin	B-CHED
C	I-CHED
as	O
an	O
interventional	O
therapy	O
for	O
ARDS	O
,	O
resulting	O
from	O
enterovirus	O
/	O
rhinovirus	O
respiratory	O
infection	O
.	O

Infusing	O
high	O
dose	O
intravenous	O
vitamin	B-CHED
C	I-CHED
into	O
this	O
patient	O
with	O
virus	O
-	O
induced	O
ARDS	O
was	O
associated	O
with	O
rapid	O
resolution	O
of	O
lung	O
injury	O
with	O
no	O
evidence	O
of	O
post	O
-	O
ARDS	O
fibroproliferative	O
sequelae	O
.	O

TITLE	O
:	O
Heat	O
shock	O
protein	B-CHED
70	O
in	O
lung	O
and	O
kidney	O
of	O
specific	O
-	O
pathogen	O
-	O
free	O
chickens	O
is	O
a	O
receptor	O
-	O
associated	O
protein	B-CHED
that	O
interacts	O
with	O
the	O
binding	O
domain	O
of	O
the	O
spike	O
protein	B-CHED
of	O
infectious	O
bronchitis	O
virus	O
.	O

A	O
binding	O
domain	O
that	O
mediates	O
the	O
attachment	O
of	O
the	O
virus	O
to	O
its	O
receptor	O
has	O
been	O
identified	O
in	O
the	O
S1	O
protein	B-CHED
of	O
prototype	O
IBV	O
strain	O
M41	O
.	O

Although	O
safe	O
in	O
opioid	O
-	O
naive	O
patients	O
,	O
naloxone	B-CHED
may	O
cause	O
severe	O
and	O
even	O
life	O
-	O
threatening	O
complications	O
in	O
opioid	O
-	O
dependent	O
patients	O
,	O
including	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
myocardial	O
infarction	O
.	O

TITLE	O
:	O
MERS	O
-	O
CoV	O
spike	O
nanoparticles	B-CHED
protect	O
mice	O
from	O
MERS	O
-	O
CoV	O
infection	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
protection	O
induced	O
by	O
vaccination	O
with	O
a	O
recombinant	O
MERS	O
-	O
CoV	O
S	O
nanoparticle	B-CHED
vaccine	O
and	O
Matrix	O
-	O
M1	O
adjuvant	B-CHED
combination	O
in	O
mice	O
.	O

Recent	O
years	O
have	O
seen	O
an	O
upsurge	O
in	O
studies	O
investigating	O
the	O
role	O
of	O
lipids	B-CHED
in	O
+	O
RNA	O
virus	O
replication	O
,	O
in	O
particular	O
of	O
sterols	B-CHED
,	O
and	O
uncovered	O
that	O
membrane	O
contact	O
sites	O
and	O
lipid	B-CHED
transfer	O
proteins	B-CHED
are	O
hijacked	O
by	O
viruses	O
and	O
play	O
pivotal	O
roles	O
in	O
VRC	O
formation	O
.	O

In	O
this	O
study	O
,	O
we	O
filtered	O
the	O
significantly	O
expressed	O
genes	O
in	O
mouse	O
pneumonia	O
using	O
mRNA	B-CHED
microarray	O
analysis	O
.	O

Therefore	O
,	O
we	O
hypothesized	O
that	O
patients	O
with	O
elevated	O
pro	B-CHED
-	O
and	O
anti	O
-	O
inflammatory	O
cytokines	O
would	O
have	O
higher	O
mortality	O
rates	O
and	O
that	O
these	O
biomarkers	O
could	O
improve	O
risk	O
stratification	O
of	O
poor	O
outcomes	O
.	O

ABSTRACT	O
:	O
The	O
new	O
emerging	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
(	O
MERS	O
CoV	O
)	O
encodes	O
several	O
resistance	O
proteins	B-CHED
against	O
the	O
innate	O
immune	O
response	O
of	O
the	O
host	O
,	O
including	O
interferon	O
(	O
IFN	O
)	O
resistance	O
.	O

ABSTRACT	O
:	O
IFIT1	O
(	O
IFN	O
-	O
induced	O
protein	B-CHED
with	O
tetratricopeptide	O
repeats	O
-	O
1	O
)	O
is	O
an	O
effector	B-CHED
of	O
the	O
host	O
innate	O
immune	O
antiviral	B-CHED
response	O
that	O
prevents	O
propagation	O
of	O
virus	O
infection	O
by	O
selectively	O
inhibiting	O
translation	O
of	O
viral	O
mRNA	B-CHED
.	O

IFIT1	O
forms	O
a	O
water	B-CHED
-	O
filled	O
,	O
positively	O
charged	O
RNA	O
-	O
binding	O
tunnel	O
with	O
a	O
separate	O
hydrophobic	O
extension	O
that	O
unexpectedly	O
engages	O
the	O
cap	O
in	O
multiple	O
conformations	O
(	O

ABSTRACT	O
:	O
To	O
identify	O
risk	O
factors	O
(	O
RFs	O
)	O
for	O
the	O
development	O
of	O
bacterial	O
complications	O
and	O
the	O
prolonged	O
course	O
of	O
influenza	O
and	O
other	O
acute	O
respiratory	O
viral	O
infections	O
(	O
ARVIs	O
)	O
among	O
inpatients	O
treated	O
in	O
Russian	O
healthcare	O
facilities	O
in	O
the	O
post	O
-	O
pandemic	O
period	O
;	O
to	O
determine	O
the	O
clinical	O
presentation	O
of	O
the	O
disease	O
(	O
flu	O
-	O
like	O
syndrome	O
)	O
in	O
risk	O
-	O
group	O
people	O
and	O
to	O
evaluate	O
the	O
efficacy	O
of	O
antiviral	B-CHED
therapy	O
with	O
arbidol	O
(	O
umifenovir	O
).	O

The	O
incidence	O
of	O
complications	O
was	O
higher	O
,	O
especially	O
in	O
the	O
under	O
2	O
-	O
year	O
-	O
year	O
-	O
old	O
children	O
and	O
in	O
patients	O
with	O
endocrine	B-CHED
,	O
metabolic	O
,	O
or	O
respiratory	O
diseases	O
,	O
with	O
a	O
large	O
proportion	O
of	O
complications	O
being	O
pneumonia	O
.	O

CoVs	O
encode	O
two	O
large	O
polyproteins	O
,	O
which	O
are	O
then	O
processed	O
into	O
15	O
-	O
16	O
nonstructural	O
proteins	B-CHED
(	O
nsps	O
)	O
that	O
make	O
significant	O
contributions	O
to	O
viral	O
replication	O
and	O
transcription	O
by	O
assembling	O
the	O
RNA	O
replicase	O
complex	O
.	O

TITLE	O
:	O
N	B-CHED
-	I-CHED
Acetylcysteine	I-CHED
supplementation	O
alleviates	O
intestinal	O
injury	O
in	O
piglets	O
infected	O
by	O
porcine	O
epidemic	O
diarrhea	O
virus	O
.	O

Group	O
A	O
streptococcus	O
(	O
GAS	O
)	O
is	O
the	O
only	O
established	O
pathogen	O
in	O
PTA	B-CHED
.	O

Culturing	O
of	O
PTA	B-CHED
pus	B-CHED
aspirates	O
often	O
yields	O
a	O
polymicrobial	O
mixture	B-CHED
of	O
aerobes	O
and	O
anaerobes	O
.	O

To	O
explore	O
the	O
microbiology	O
of	O
PTA	B-CHED
with	O
a	O
special	O
attention	O
to	O
Fusobacterium	O
necrophorum	O
(	O
FN	O
).	O

Furthermore	O
,	O
FN	O
was	O
detected	O
significantly	O
more	O
frequently	O
in	O
the	O
tonsillar	O
cores	O
of	O
PTA	B-CHED
patients	O
(	O
56	O
%)	O
compared	O
to	O
the	O
tonsillar	O
cores	O
of	O
the	O
controls	O
(	O
24	O
%)	O
(	O
P	O
=	O
0	O
.	O
001	O
).	O

However	O
,	O
bacteremia	O
during	O
elective	O
tonsillectomy	O
was	O
at	O
least	O
as	O
prevalent	O
as	O
bacteremia	O
during	O
quinsy	O
tonsillectomy	O
,	O
which	O
challenges	O
the	O
distinction	O
made	O
by	O
the	O
European	O
Society	O
of	O
Cardiology	O
between	O
quinsy	O
and	O
elective	O
tonsillectomy	O
,	O
namely	O
that	O
antibiotic	B-CHED
prophylaxis	O
is	O
only	O
recommended	O
to	O
patients	O
undergoing	O
procedures	O
to	O
treat	O
an	O
established	O
infection	O
(	O
i	O
.	O
e	O
.	O
PTA	B-CHED
).	O

Repeated	O
high	O
isolation	O
rates	O
of	O
FN	O
in	O
PTA	B-CHED
pus	B-CHED
aspirates	O
.	O

Development	O
of	O
anti	O
-	O
FN	O
antibodies	O
in	O
FN	O
-	O
positive	O
patients	O
with	O
PTA	B-CHED
.	O

In	O
a	O
series	O
of	O
63	O
patients	O
with	O
PPA	O
,	O
we	O
found	O
that	O
33	O
(	O
52	O
%)	O
patients	O
had	O
concomitant	O
PTA	B-CHED
.	O

Nevertheless	O
,	O
its	O
optimal	O
immunogen	B-CHED
dosage	O
and	O
immunization	O
interval	O
,	O
key	O
factors	O
for	O
human	O
-	O
used	O
vaccines	O
that	O
induce	O
protective	O
immunity	O
,	O
have	O
never	O
been	O
investigated	O
.	O

In	O
this	O
study	O
,	O
we	O
optimized	O
these	O
criteria	O
using	O
a	O
recombinant	O
MERS	O
-	O
CoV	O
RBD	O
protein	B-CHED
fused	O
with	O
Fc	O
(	O
S377	O
-	O
588	O
-	O
Fc	O
)	O
and	O
utilized	O
the	O
optimal	O
immunization	O
schedule	O
to	O
evaluate	O
the	O
protective	O
efficacy	O
of	O
RBD	O
against	O
MERS	O
-	O
CoV	O
infection	O
in	O
human	O
dipeptidyl	O
peptidase	O
4	O
transgenic	O
(	O
hDPP4	O
-	O
Tg	O
)	O
mice	O
.	O

The	O
findings	O
suggest	O
that	O
the	O
dynamics	O
of	O
virion	O
-	O
glycan	B-CHED
interactions	O
contribute	O
to	O
host	O
tropism	O
.	O

RESULTS	O
:	O
The	O
lung	O
tissue	O
which	O
is	O
opened	O
between	O
30	O
and	O
45	O
cmH	B-CHED

TITLE	O
:	O
Effects	O
of	O
early	O
administration	O
of	O
acetazolamide	B-CHED
on	O
the	O
duration	O
of	O
mechanical	O
ventilation	O
in	O
patients	O
with	O
chronic	O
obstructive	O
pulmonary	O
disease	O
or	O
obesity	O
-	O
hypoventilation	O
syndrome	O
with	O
metabolic	O
alkalosis	O
.	O

RESULTS	O
:	O
Agreement	O
among	O
TTW	O
and	O
NS	O
,	O
TTW	O
and	O
NPS	O
,	O
and	O
TTW	O
and	O
BAL	B-CHED
,	O
was	O
very	O
good	O
for	O
identification	O
of	O
P	O
.	O
multocida	O
,	O
M	O
.	O
haemolytica	O
,	O
and	O
M	O
.	O
bovis	O
.	O

The	O
results	O
demonstrated	O
that	O
N30	O
inhibited	O
the	O
replication	O
of	O
H1N1	O
,	O
H3N2	B-CHED
,	O
influenza	O
B	O
viruses	O
,	O
including	O
oseltamivir	B-CHED
and	O
amantadine	B-CHED
resistant	O
strains	O
in	O
vitro	O
.	O

In	O
model	O
organisms	O
,	O
intravenously	O
injected	O
PELs	B-CHED
strongly	O
concentrate	O
drugs	O
in	O
alveoli	O
,	O
even	O
in	O
animal	O
models	O
displaying	O
severe	O
,	O
spatially	O
heterogeneous	O
pathology	O
similar	O
to	O
severe	O
ARDS	O
.	O

In	O
addition	O
,	O
mutations	O
of	O
the	O
catalytic	O
residues	O
of	O
PLP	O
-	O
TM	O
,	O
Cys1274Ser	O
and	O
His1437Lys	O
,	O
reduced	O
DUB	O
activity	O
against	O
Ub	O
-,	O
K48	O
-	O
and	O
K63	O
-	O
conjugated	B-CHED
proteins	I-CHED
,	O
indicating	O
that	O
the	O
DUB	O
activity	O
of	O
the	O
PLP	O
-	O
TM	O
wild	O
-	O
type	O
protein	B-CHED
is	O
not	O
completely	O
dependent	O
on	O
its	O
catalytic	O
activity	O
.	O

mpIL	O
-	O
22	O
up	O
-	O
regulated	O
the	O
expression	O
of	O
the	O
antimicrobial	B-CHED
peptide	B-CHED
beta	O
-	O
defensin	O
(	O
BD	O
-	O
2	O
),	O
cytokine	O
IL	O
-	O
18	O
and	O
IFN	O
-	O
λ	O
.	O

Lung	O
-	O
morphology	O
is	O
one	O
of	O
the	O
ARDS	O
-	O
phenotypes	O
and	O
physiological	O
studies	O
suggest	O
different	O
responses	O
in	O
terms	O
of	O
positive	O
-	O
end	O
-	O
expiratory	O
-	O
pressure	O
(	O
PEEP	B-CHED
)	O
and	O
recruitment	O
-	O
manoeuvres	O
(	O
RM	O
)	O
according	O
to	O
loss	O
of	O
aeration	O
.	O

Although	O
the	O
role	O
of	O
N	O
protein	B-CHED
in	O
viral	O
replication	O
is	O
relatively	O
well	O
described	O
,	O
no	O
structural	O
data	O
are	O
currently	O
available	O
regarding	O
the	O
N	O
proteins	B-CHED
of	O
alphacoronaviruses	O
.	O

Oseltamivir	B-CHED
(	O
75	O
mg	O
)	O
was	O
orally	O
administered	O
on	O
Day	O
1	O
and	O
Day	O
8	O
,	O
and	O
dexamethasone	B-CHED
(	O
1	O
.	O
5	O
mg	O
)	O
was	O
administered	O
once	O
daily	O
from	O
Day	O
3	O
to	O
Day	O
8	O
.	O

TITLE	O
:	O
Immunogenicity	O
of	O
Candidate	O
MERS	O
-	O
CoV	O
DNA	O
Vaccines	O
Based	O
on	O
the	O
Spike	O
Protein	B-CHED
.	O

For	O
endemic	O
zoonoses	O
,	O
32	O
of	O
54	O
ministries	O
responded	O
that	O
they	O
conduct	O
formal	B-CHED
prioritization	O
exercises	O
,	O
most	O
of	O
them	O
annually	O
(	O
69	O
%).	O

For	O
emerging	O
zoonoses	O
,	O
28	O
ministries	O
performed	O
formal	B-CHED
prioritization	O
exercises	O
.	O

The	O
survey	O
is	O
the	O
first	O
comprehensive	O
effort	O
to	O
date	O
to	O
inform	O
the	O
status	O
of	O
zoonoses	O
programmes	O
in	O
LAC	B-CHED
.	O

This	O
study	O
investigated	O
serum	O
concentrations	O
of	O
IP	O
-	O
10	O
in	O
healthy	O
individuals	O
who	O
developed	O
acute	O
respiratory	O
infection	O
(	O
ARI	B-CHED
).	O

Also	O
,	O
IP	O
-	O
10	O
concentration	O
measured	O
early	O
in	O
the	O
course	O
of	O
the	O
ARI	B-CHED
correlates	O
with	O
the	O
daily	O
severity	O
,	O
duration	O
,	O
and	O
illness	O
symptoms	O
.	O

ABSTRACT	O
:	O
The	O
recombinant	O
LaSota	O
strain	O
expressing	O
a	O
chimeric	O
IBV	O
S1	O
gene	O
(	O
rLaSota	O
-	O
S1	O
)	O
was	O
constructed	O
with	O
the	O
S1	O
gene	O
of	O
the	O
LX4	O
type	O
IBV	O
ck	O
/	O
CH	O
/	O
LDL	B-CHED
/	O
091022	O
.	O

The	O
expression	O
of	O
the	O
S1	O
protein	B-CHED
was	O
detected	O
by	O
an	O
indirect	O
immunofluorescence	O
assay	O
and	O
Western	O
blotting	O
.	O

We	O
compared	O
the	O
performance	O
of	O
2	O
size	O
-	O
differentiating	O
air	B-CHED
samplers	O
in	O
disease	O
outbreaks	O
that	O
occurred	O
in	O
swine	O
and	O
poultry	O
facilities	O
.	O

Both	O
air	B-CHED
samplers	O
allowed	O
quantification	O
of	O
particles	O
by	O
size	O
,	O
and	O
measured	O
concentrations	O
of	O
PRRSV	O
,	O
PEDV	O
,	O
and	O
HPAIV	O
stratified	O
by	O
particle	O
size	O
both	O
within	O
and	O
outside	O
swine	O
and	O
poultry	O
facilities	O
.	O

Information	O
regarding	O
EBV	O
placement	O
in	O
mechanically	O
ventilated	O
patients	O
with	O
ARDS	O
and	O
high	O
volume	O
persistent	O
air	B-CHED
leaks	O
is	O
rare	O
and	O
limited	O
to	O
case	O
reports	O
.	O

HIV	O
-	O
1	O
IN	O
and	O
Reverse	O
Transcriptase	O
-	O
associated	O
Ribonuclease	O
H	O
(	O
RNase	O
H	O
)	O
active	O
sites	O
show	O
structural	O
homologies	O
,	O
with	O
the	O
presence	O
of	O
two	O
Mg	O
(	O
II	O
)	O
cofactors	B-CHED
,	O
hence	O
it	O
seems	O
possible	O
to	O
inhibit	O
both	O
enzymes	O
by	O
means	O
of	O
chelating	O
ligands	O
with	O
analogous	O
structural	O
features	O
.	O

We	O
performed	O
comparisons	O
of	O
medians	O
,	O
logistic	O
regression	O
analyses	O
and	O
receiver	O
operating	O
characteristic	O
analyses	O
for	O
initial	O
and	O
day	O
-	O
2	O
levels	O
of	O
each	O
biomarker	B-CHED
.	O

TITLE	O
:	O
The	O
Impact	O
of	O
the	O
Interferon	O
/	O
TNF	O
-	O
Related	O
Apoptosis	O
-	O
Inducing	O
Ligand	B-CHED
Signaling	O
Axis	O
on	O
Disease	O
Progression	O
in	O
Respiratory	O
Viral	O
Infection	O
and	O
Beyond	O
.	O

A	O
prominent	O
regulator	O
of	O
disease	O
outcome	O
,	O
especially	O
in	O
-	O
but	O
not	O
limited	O
to	O
-	O
respiratory	O
viral	O
infection	O
,	O
is	O
the	O
IFN	O
-	O
dependent	O
mediator	O
TRAIL	O
(	O
TNF	O
-	O
related	O
apoptosis	O
-	O
inducing	O
ligand	B-CHED
)	O
produced	O
by	O
several	O
cell	O
types	O
including	O
immune	O
cells	O
such	O
as	O
macrophages	O
or	O
T	O
cells	O
.	O

TITLE	O
:	O
Lithium	B-CHED
chloride	I-CHED
inhibits	O
early	O
stages	O
of	O
foot	O
-	O
and	O
-	O
mouth	O
disease	O
virus	O
(	O
FMDV	O
)	O
replication	O
in	O
vitro	O
.	O

ABSTRACT	O
:	O
The	O
envelope	O
spike	O
(	O
S	O
)	O
proteins	B-CHED
of	O
MERS	O
-	O
CoV	O
and	O
SARS	O
-	O
CoV	O
determine	O
the	O
virus	O
host	O
tropism	O
and	O
entry	O
into	O
host	O
cells	O
,	O
and	O
constitute	O
a	O
promising	O
target	O
for	O
the	O
development	O
of	O
prophylactics	O
and	O
therapeutics	O
.	O

PNA	B-CHED
probes	O
are	O
an	O
attractive	O
alternative	O
to	O
DNA	O
and	O
RNA	O
probes	O
because	O
they	O
are	O
chemically	O
and	O
biologically	O
stable	O
,	O
easily	O
synthesized	O
,	O
and	O
hybridize	O
efficiently	O
with	O
the	O
complementary	O
DNA	O
strands	O
.	O

Two	O
hundred	O
and	O
eighty	O
-	O
eight	O
patients	O
met	B-CHED
the	O
inclusion	O
criteria	O
.	O

Importantly	O
,	O
we	O
show	O
that	O
during	O
infection	O
,	O
the	O
EGFR	O
ligands	O
amphiregulin	O
and	O
heparin	B-CHED
-	O
binding	O
EGF	O
-	O
like	O
growth	O
factor	O
(	O
HB	O
-	O
EGF	O
)	O
are	O
upregulated	O
,	O
and	O
exogenous	O
addition	O
of	O
these	O
ligands	O
during	O
infection	O
leads	O
to	O
enhanced	O
lung	O
disease	O
and	O
altered	O
wound	O
healing	O
dynamics	O
.	O

RESULTS	O
:	O
Six	O
commercial	O
feed	O
acids	O
(	O
UltraAcid	O
P	O
,	O
Activate	O
DA	O
,	O
KEMGEST	O
,	O
Acid	O
Booster	O
,	O
Luprosil	O
,	O
and	O
Amasil	O
),	O
salt	B-CHED
,	O
and	O
sugar	O
were	O
evaluated	O
.	O

Core	O
temperature	O
,	O
hemodynamics	O
,	O
serum	O
glucose	B-CHED
and	O
electrolytes	O
,	O
and	O
P	O
/	O
F	O
were	O
sequentially	O
measured	O
,	O
and	O
medians	O
(	O
interquartile	O
ranges	O
)	O
presented	O
,	O
28	O
-	O
day	O
ventilator	O
-	O
free	O
days	O
,	O
and	O
hospital	O
mortality	O
were	O
calculated	O
in	O
historical	O
controls	O
and	O
eight	O
cooled	O
patients	O
.	O

Different	O
statistical	O
methods	O
(	O
i	O
.	O
e	O
.	O
the	O
independence	O
chi	B-CHED
-	O
square	O
test	O
,	O
the	O
correspondence	O
analysis	O
and	O
the	O
logistic	O
regression	O
model	O
)	O
were	O
used	O
to	O
establish	O
any	O
relationships	O
between	O
the	O
analyzed	O
data	O
.	O

Specific	O
inhibitors	B-CHED
for	O
TGF	O
-	O
βRI	O
,	O
p38	O
MAPK	O
,	O
MEK	B-CHED
,	O
and	O
STAT3	O
proved	O
that	O
SARS	O
-	O
CoV	O
PLpro	O
induced	O
TGF	O
-	O
β1	O
-	O
dependent	O
up	O
-	O
regulation	O
of	O
Type	O
I	O
collagen	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

One	O
protease	O
,	O
transmembrane	O
protease	O
serine	B-CHED
2	O
(	O
TMPRSS2	O
)	O
was	O
recently	O
proven	O
to	O
be	O
crucial	O
for	O
hemagglutinin	O
cleavage	O
of	O
some	O
human	O
influenza	O
viruses	O
.	O

Since	O
the	O
catalytic	O
sites	O
of	O
the	O
diverse	O
serine	B-CHED
proteases	O
linked	O
to	O
influenza	O
,	O
parainfluenza	O
-	O
and	O
coronavirus	O
activation	O
are	O
structurally	O
similar	O
,	O
active	O
site	O
inhibitors	B-CHED
of	O
these	O
airway	O
proteases	O
could	O
have	O
broad	O
therapeutic	O
applicability	O
against	O
multiple	O
respiratory	O
viruses	O
.	O

This	O
article	O
describes	O
the	O
risk	O
communication	O
framework	O
in	O
Taiwan	O
,	O
which	O
has	O
been	O
used	O
to	O
respond	O
to	O
the	O
2009	O
-	O
2016	O
influenza	O
epidemics	O
,	O
Ebola	O
in	O
West	O
Africa	O
(	O
2014	O
-	O
16	O
),	O
and	O
MERS	O
-	O
CoV	O
in	O
South	O
Korea	O
(	O
2015	O
)	O
during	O
the	O
post	O
-	O
SARS	O
era	B-CHED
.	O

Both	O
proteins	B-CHED
are	O
less	O
immunogenic	O
by	O
showing	O
low	O
CpG	O
frequencies	O
.	O

Correspondence	O
analysis	O
reveals	O
the	O
presence	O
of	O
3	O
genetic	O
clusters	B-CHED
based	O
on	O
codon	O
usage	O
in	O
PLpro	O
and	O
3CLpro	O
.	O

Taken	O
together	O
,	O
our	O
findings	O
demonstrate	O
that	O
CCL2	B-CHED
is	O
essential	O
for	O
H7N9	O
virus	O
infection	O
and	O
thus	O
that	O
it	O
is	O
a	O
potential	O
therapeutic	O
target	O
for	O
influenza	O
.	O

The	O
animals	O
received	O
intravenous	O
recombinant	O
human	O
IL	O
-	O
6	O
(	O
rHuIL	O
-	O
6	O
)	O
or	O
vehicle	O
followed	O
by	O
intratracheal	O
lipopolysaccharide	B-CHED
(	O
LPS	B-CHED
)	O
or	O
saline	O
before	O
undergoing	O
low	O
tidal	O
volume	O
mechanical	O
ventilation	O
(	O
MV	O
)	O
for	O
5	O
h	O
.	O
Before	O
sacrifice	O
,	O
right	O
ventricular	O
systolic	O
pressure	O
and	O
cardiac	O
output	O
were	O
measured	O
and	O
total	O
pulmonary	O
resistance	O
was	O
calculated	O
.	O

Results	O
Nine	O
of	O
205	O
cats	O
(	O
4	O
.	O
4	O
%)	O
were	O
viremic	O
by	O
the	O
total	O
FCoV	O
RNA	O
qRT	O
-	O
PCR	O
,	O
and	O
one	O
of	O
these	O
cats	O
had	O
evidence	O
of	O
peripheral	O
FCoV	O
blood	O
replication	O
by	O
an	O
FCoV	O
mRNA	B-CHED
qRT	O
-	O
PCR	O
.	O

ABSTRACT	O
:	O
1	O
,	O
4	O
-	O
Pentadien	O
-	O
3	O
-	O
one	O
derivatives	O
derived	O
from	O
curcumin	B-CHED
possess	O
excellent	O
inhibitory	O
activity	O
against	O
plant	O
viruses	O
.	O

TITLE	O
:	O
Protective	O
Effects	O
of	O
Cell	O
-	O
Free	O
Supernatant	O
and	O
Live	O
Lactic	B-CHED
Acid	I-CHED
Bacteria	O
Isolated	O
from	O
Thai	O
Pigs	O
Against	O
a	O
Pandemic	O
Strain	O
of	O
Porcine	O
Epidemic	O
Diarrhea	O
Virus	O
.	O

We	O
used	O
intravenous	O
lipopolysaccharide	B-CHED
(	O
LPS	B-CHED
)	O
to	O
induce	O
a	O
systemic	O
inflammatory	O
response	O
in	O
a	O
porcine	O
model	O
of	O
lung	O
injury	O
.	O

The	O
EVLP	O
group	O
demonstrated	O
significant	O
improvements	O
hour	O
1	O
to	O
hour	O
4	O
in	O
oxygenation	O
(	O
365	O
.	O
8	O
±	O
53	O
.	O
0	O
vs	O
584	O
.	O
4	O
±	O
21	O
.	O
0	O
mm	O
Hg	O
,	O
p	O
=	O
0	O
.	O
02	O
)	O
and	O
dynamic	O
compliance	O
(	O
9	O
.	O
0	O
±	O
2	O
.	O
8	O
vs	O
15	O
.	O
0	O
±	O
3	O
.	O
6	O
,	O
p	O
=	O
0	O
.	O
02	O
mL	O
/	O
cm	O
H	O
EVLP	O
successfully	O
rehabilitated	O
LPS	B-CHED
-	O
induced	O
lung	O
injury	O
in	O
this	O
preclinical	O
porcine	O
model	O
and	O
may	O
thus	O
provide	O
a	O
means	O
to	O
rehabilitate	O
many	O
types	O
of	O
acute	O
lung	O
injury	O
.	O

ABSTRACT	O
:	O
Plastic	O
bronchitis	O
is	O
used	O
to	O
designate	O
endobronchial	O
plugs	O
of	O
rubber	B-CHED
-	O
like	O
consistency	O
that	O
form	O
into	O
bronchial	O
trees	O
.	O

We	O
present	O
a	O
case	O
of	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
after	O
accidental	O
inhalation	O
of	O
chlorine	B-CHED
in	O
a	O
swimming	O
pool	O
,	O
with	O
noninvasive	O
ventilation	O
used	O
as	O
a	O
treatment	O
with	O
good	O
response	O
in	O
this	O
case	O
.	O

TITLE	O
:	O
Plasminogen	O
Activator	O
Inhibitor	B-CHED
-	O
1	O
Is	O
Critical	O
in	O
Alcohol	O
-	O
Enhanced	O
Acute	O
Lung	O
Injury	O
in	O
Mice	O
.	O

TITLE	O
:	O
Aerosolized	O
tobramycin	B-CHED
for	O
Pseudomonas	O
aeruginosa	O
ventilator	O
-	O
associated	O
pneumonia	O
in	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

HFNC	O
can	O
provide	O
well	O
heated	O
and	O
humidified	O
high	O
flow	O
gas	O
with	O
a	O
high	O
concentration	O
of	O
oxygen	B-CHED
,	O
which	O
can	O
improve	O
the	O
oxygenation	O
and	O
degree	O
of	O
comfort	O
of	O
patients	O
after	O
extubation	O
.	O

In	O
vivo	O
,	O
rat	O
model	O
with	O
ALI	O
induced	O
by	O
intratracheal	O
instillation	O
of	O
LPS	B-CHED
was	O
treated	O
by	O
oral	O
administration	O
of	O
AG1478	O
and	O
451	O
.	O

Acute	O
respiratory	O
failure	O
was	O
a	O
common	O
indicator	B-CHED
for	O
pulmonary	O
manifestation	O
(	O
87	O
%).	O

By	O
combining	O
these	O
substrate	O
profiling	O
and	O
structural	O
data	O
,	O
we	O
were	O
able	O
to	O
design	O
a	O
selective	O
peptide	B-CHED
inhibitor	B-CHED
of	O
APN	O
that	O
was	O
an	O
effective	O
therapeutic	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
against	O
APN	O
-	O
expressing	O
prostate	O
cancer	O
models	O
.	O

Both	O
cases	O
demonstrate	O
how	O
the	O
WHO	O
has	O
struggled	O
to	O
balance	B-CHED
states	O
'	O
concern	O
with	O
managing	O
risk	O
communication	O
against	O
WHO	O
'	O
s	O
right	O
to	O
receive	O
reports	O
from	O
non	O
-	O
state	O
actors	O
.	O

As	O
different	O
respiratory	O
viruses	O
exhibit	O
similar	O
symptoms	O
,	O
simultaneous	O
detection	O
of	O
these	O
viruses	O
in	O
a	O
single	O
reaction	O
mixture	B-CHED
can	O
save	O
time	O
and	O
cost	O
.	O

TITLE	O
:	O
Respiratory	O
alkalosis	O
may	O
impair	O
the	O
production	O
of	O
vitamin	B-CHED
D	I-CHED
and	O
lead	O
to	O
significant	O
morbidity	O
,	O
including	O
the	O
fibromyalgia	O
syndrome	O
.	O

Age	O
<	O
2	O
years	O
(	O
odds	O
ratio	O
[	O
OR	O
]	O
=	O
5	O
.	O
0	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
],	O
1	O
.	O
9	O
-	O
13	O
.	O
1	O
)	O
and	O
cardiovascular	O
(	O
OR	O
=	O
3	O
.	O
9	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
6	O
-	O
9	O
.	O
5	O
),	O
genetic	O
/	O
congenital	O
(	O
OR	O
=	O
2	O
.	O
8	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
1	O
-	O
7	O
.	O
0	O
),	O
and	O
respiratory	O
chronic	O
complex	O
conditions	O
([	O
CCCs	B-CHED
]	O
OR	O
=	O
4	O
.	O
5	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
7	O
-	O
12	O
.	O
0	O
)	O
were	O
associated	O
with	O
receiving	O
respiratory	O
support	O
.	O

The	O
obtained	O
material	O
may	O
be	O
applied	O
for	O
the	O
removal	O
of	O
coronaviruses	O
,	O
purification	O
and	O
concentration	O
of	O
virus	O
samples	O
obtained	O
from	O
biological	O
matrices	O
and	O
for	O
purification	O
of	O
water	B-CHED
from	O
pathogenic	O
coronaviruses	O
.	O

Taken	O
together	O
,	O
our	O
findings	O
demonstrate	O
that	O
coronavirus	O
nsp15	O
is	O
critical	O
for	O
evasion	O
of	O
host	O
dsRNA	B-CHED
sensors	O
in	O
macrophages	O
and	O
reveal	O
that	O
modulating	O
nsp15	O
stability	O
and	O
activity	O
is	O
a	O
strategy	O
for	O
generating	O
live	O
-	O
attenuated	O
vaccines	O
.	O

Lumbar	O
puncture	O
was	O
evaluated	O
for	O
Guillain	O
-	O
Barré	O
syndrome	O
,	O
but	O
cerebrospinal	O
fluid	O
protein	B-CHED
concentration	O
was	O
normal	O
.	O

Respiratory	O
index	O
,	O
white	O
blood	O
cell	O
,	O
hemoglobin	B-CHED
(	O
HBG	O
),	O
platelet	O
(	O
PLT	O
),	O
and	O
other	O
clinical	O
factors	O
were	O
not	O
significantly	O
different	O
between	O
the	O
2	O
groups	O
.	O

TITLE	O
:	O
Deletion	O
of	O
a	O
197	O
-	O
Amino	O
-	O
Acid	O
Region	O
in	O
the	O
N	O
-	O
Terminal	O
Domain	O
of	O
Spike	O
Protein	B-CHED
Attenuates	O
Porcine	O
Epidemic	O
Diarrhea	O
Virus	O
in	O
Piglets	O
.	O

Our	O
data	O
indicate	O
that	O
deletion	O
of	O
this	O
197	O
-	O
aa	O
fragment	O
in	O
the	O
spike	O
protein	B-CHED
can	O
attenuate	O
a	O
highly	O
virulent	O
PEDV	O
,	O
but	O
the	O
virus	O
may	O
lose	O
important	O
epitopes	O
for	O
inducing	O
robust	O
protective	O
immunity	O
.	O

TITLE	O
:	O
Successful	O
treatment	O
of	O
feline	O
leishmaniosis	O
using	O
a	O
combination	O
of	O
allopurinol	B-CHED
and	O
N	O
-	O
methyl	B-CHED
-	O
glucamine	O
antimoniate	O
.	O

TITLE	O
:	O
IL	O
-	O
33	O
protects	O
murine	O
viral	O
fulminant	O
hepatitis	O
by	O
targeting	O
coagulation	O
hallmark	O
protein	B-CHED
FGL2	O
/	O
fibroleukin	O
expression	O
.	O

TITLE	O
:	O
An	O
optimized	O
method	O
for	O
enumerating	O
CNS	B-CHED
derived	O
memory	O
B	O
cells	O
during	O
viral	O
-	O
induced	O
inflammation	O
.	O

Although	O
antibody	O
secreting	O
cells	O
(	O
ASC	O
)	O
within	O
the	O
inflamed	O
CNS	B-CHED
have	O
been	O
extensively	O
examined	O
,	O
memory	O
B	O
cell	O
(	O
Bmem	O
)	O
characterization	O
has	O
been	O
limited	O
as	O
they	O
do	O
not	O
secrete	O
antibody	O
without	O
stimulation	O
.	O

In	O
contrast	O
to	O
our	O
hypothesis	O
,	O
anthropogenic	O
habitat	O
disturbance	O
was	O
not	O
associated	O
with	O
corona	B-CHED
-	O
and	O
astrovirus	O
detection	O
rates	O
in	O
fecal	O
samples	O
.	O

Totals	O
of	O
353	O
and	O
299	O
differentially	O
expressed	O
proteins	B-CHED
were	O
identified	O
upon	O
YC2014	O
and	O
CV777	O
infection	O
,	O
respectively	O
.	O

Here	O
,	O
we	O
describe	O
the	O
use	O
of	O
transient	O
dominant	O
selection	O
as	O
a	O
method	O
for	O
introducing	O
modifications	O
into	O
the	O
IBV	O
cDNA	O
that	O
has	O
been	O
successfully	O
used	O
for	O
the	O
substitution	O
of	O
specific	O
nucleotides	B-CHED
,	O
deletion	O
of	O
genomic	O
regions	O
,	O
and	O
exchange	O
of	O
complete	O
genes	O
.	O

Glypican	O
-	O
3	O
could	O
be	O
considered	O
as	O
a	O
clinically	O
useful	O
biomarker	B-CHED
in	O
hepatocellular	O
carcinoma	O
,	O
lung	O
carcinoma	O
,	O
and	O
ARDS	O
,	O
but	O
further	O
research	O
is	O
needed	O
to	O
confirm	O
and	O
expand	O
on	O
these	O
findings	O
.	O

Bronchoalveolar	O
lavage	O
(	O
BAL	B-CHED
)	O
with	O
normal	O
saline	O
and	O
surfactant	B-CHED
allows	O
the	O
removal	O
of	O
inhaled	O
material	O
,	O
the	O
recruitment	O
of	O
non	O
-	O
ventilating	O
areas	O
and	O
the	O
maintenance	O
of	O
the	O
surfactant	B-CHED
pool	O
size	O
.	O

In	O
this	O
randomised	O
,	O
open	O
-	O
label	B-CHED
,	O
multicentre	O
,	O
phase	O
2	O
trial	O
,	O
29	O
academic	O
medical	O
centres	O
in	O
the	O
USA	O
assessed	O
the	O
safety	O
and	O
efficacy	O
of	O
anti	O
-	O
influenza	O
plasma	O
with	O
haemagglutination	O
inhibition	O
antibody	O
titres	O
of	O
1	O
:	O
80	O
or	O
more	O
to	O
the	O
infecting	O
strain	O
.	O

The	O
comparative	O
analysis	O
of	O
those	O
four	O
isolates	O
revealed	O
97	O
.	O
1	O
-	O
98	O
.	O
6	O
%	O
similarity	O
at	O
the	O
nucleotide	B-CHED
and	O
95	O
.	O
6	O
-	O
98	O
.	O
6	O
%	O
at	O
the	O
amino	B-CHED
acid	I-CHED
level	O
.	O

The	O
characteristics	O
and	O
outcomes	O
of	O
mothers	O
and	O
fetuses	O
were	O
determined	O
through	O
a	O
retrospective	O
chart	O
review	O
and	O
evaluated	O
using	O
Student	O
'	O
s	O
t	O
test	O
,	O
chi	B-CHED
-	O
square	O
test	O
,	O
and	O
Fisher	O
'	O
s	O
exact	O
test	O
.	O

The	O
patients	O
in	O
the	O
obstetric	O
causes	O
group	O
showed	O
significant	O
improvement	O
after	O
delivery	O
in	O
the	O
partial	O
pressure	O
of	O
arterial	O
oxygen	B-CHED
to	O
the	O
fraction	O
of	O
inspired	O
oxygen	B-CHED
and	O
peak	O
inspiratory	O
pressure	O
decrease	O
.	O

Neonatal	O
complications	O
resulting	O
from	O
meconium	O
aspiration	O
syndrome	O
(	O
MAS	B-CHED
)	O
and	O
sepsis	O
were	O
more	O
common	O
in	O
the	O
non	O
-	O
obstetric	O
causes	O
group	O
;	O
however	O
,	O
neurological	O
development	O
impairment	O
was	O
more	O
common	O
in	O
the	O
obstetric	O
causes	O
group	O
.	O

In	O
addition	O
to	O
mAbs	O
with	O
neutralizing	O
epitopes	O
located	O
on	O
the	O
receptor	O
-	O
binding	O
domain	O
,	O
one	O
mAb	O
,	O
5F9	O
,	O
which	O
binds	O
to	O
the	O
N	O
-	O
terminal	O
domain	O
(	O
NTD	O
)	O
of	O
the	O
MERS	O
-	O
CoV	O
S1	O
subunit	O
,	O
showed	O
efficient	O
neutralizing	O
activity	O
against	O
the	O
wild	O
-	O
type	O
MERS	O
-	O
CoV	O
strain	O
EMC	O
/	O
2012	O
,	O
with	O
a	O
half	O
maximal	O
inhibitory	O
concentration	O
of	O
0	O
.	O
2	O
μg	O
/	O
mL	O
.	O
We	O
concluded	O
that	O
a	O
novel	O
neutralizing	O
epitope	B-CHED
for	O
MERS	O
-	O
CoV	O
also	O
resides	O
on	O
the	O
NTD	O
of	O
the	O
S	O
protein	B-CHED
,	O
indicating	O
that	O
the	O
NTD	O
might	O
be	O
important	O
during	O
the	O
viral	O
infection	O
process	O
.	O

Zinc	B-CHED
phosphide	B-CHED
is	O
hydrolyzed	O
by	O
the	O
gastric	O
acid	O
and	O
is	O
transformed	O
into	O
phosphine	B-CHED
gas	O
.	O

Furthermore	O
,	O
the	O
lack	O
of	O
an	O
antidote	B-CHED
and	O
advanced	O
resuscitative	O
measures	O
such	O
as	O
inotropic	O
supportive	O
therapy	O
and	O
renal	O
replacement	O
facilities	O
at	O
most	O
of	O
the	O
peripheral	O
hospitals	O
pose	O
a	O
major	O
challenge	O
in	O
providing	O
timely	O
interventions	O
to	O
prevent	O
deaths	O
.	O

The	O
correlation	O
between	O
serum	O
CC16	O
levels	O
and	O
the	O
severity	O
of	O
ARDS	O
as	O
quantified	O
by	O
PaO	B-CHED
The	O
serum	O
CC16	O
levels	O
in	O
ARDS	O
patients	O
were	O
significantly	O
higher	O
than	O
that	O
in	O
non	O
-	O
ARDS	O
patients	O
(	O
54	O
.	O
44	O
±	O
19	O
.	O
62	O
vs	O
24	O
.	O
13	O
±	O
12	O
.	O
32	O
ng	O
/	O
mL	O
,	O
P	O
=.	O
001	O
).	O

Positive	O
BDR	O
according	O
to	O
the	O
GOLD	B-CHED
criteria	O
was	O
significantly	O
associated	O
with	O
a	O
decreased	O
risk	O
of	O
severe	O
AE	O
(	O
adjusted	O
odds	O
ratio	O
(	O
aOR	O
)	O
=	O
0	O
.	O
38	O
;	O
95	O
%	O
Confidence	O
interval	O
(	O
CI	O
)	O
=	O
0	O
.	O
15	O
-	O
0	O
.	O
93	O
).	O

Among	O
different	O
criteria	O
for	O
positive	O
BDR	O
,	O
the	O
use	O
of	O
the	O
GOLD	B-CHED
ones	O
was	O
significantly	O
associated	O
with	O
a	O
decreased	O
risk	O
of	O
severe	O
AE	O
in	O
COPD	O
patients	O
.	O

Despite	O
initial	O
treatment	O
with	O
oxygen	B-CHED
supplementation	O
and	O
intravenous	O
clindamycin	B-CHED
,	O
the	O
cat	O
developed	O
refractory	O
hypoxemia	O
and	O
hypotension	O
requiring	O
mechanical	O
ventilation	O
and	O
vasopressor	O
support	O
within	O
24	O
hours	O
of	O
hospital	O
admission	O
.	O

Toxoplasma	O
titer	O
testing	O
and	O
antimicrobial	B-CHED
prophylaxis	O
should	O
be	O
considered	O
in	O
cats	O
prior	O
to	O
immunosuppressive	O
treatment	O
with	O
cyclosporine	B-CHED
.	O

ABSTRACT	O
:	O
Hantavirus	O
infection	O
is	O
an	O
acute	O
zoonosis	O
that	O
clinically	O
manifests	O
in	O
two	O
primary	O
forms	O
,	O
hemorrhagic	O
fever	O
with	O
renal	O
syndrome	O
(	O
HFRS	O
)	O
and	O
hantavirus	O
pulmonary	O
syndrome	O
(	O
HPS	B-CHED
).	O

The	O
severe	O
form	O
of	O
hantavirus	O
zoonosis	O
,	O
HPS	B-CHED
,	O
was	O
characterized	O
by	O
the	O
upregulation	O
of	O
a	O
higher	O
number	O
of	O
cytokines	O
than	O
HFRS	O
(	O
40	O
vs	O
21	O
).	O

To	O
predict	O
the	O
potential	O
B	O
cell	O
epitopes	O
of	O
E	O
protein	B-CHED
,	O
three	O
most	O
effective	O
online	O
epitope	B-CHED
prediction	O
programs	O
,	O
the	O
ABCpred	O
,	O
Bepipred	O
,	O
and	O
Protean	O
programs	O
from	O
the	O
LaserGene	O
software	O
were	O
used	O
.	O

The	O
viruses	O
elicited	O
highly	O
overlapping	O
responses	O
in	O
antiviral	B-CHED
genes	O
,	O
though	O
MHV	O
-	O
1	O
induced	O
a	O
lower	O
type	O
I	O
interferon	O
response	O
than	O
the	O
other	O
two	O
viruses	O
.	O

Descriptive	O
analysis	O
,	O
t	O
-	O
tests	O
,	O
Chi	B-CHED
-	O
square	O
tests	O
and	O
binary	O
logistic	O
regression	O
were	O
conducted	O
to	O
compare	O
demographic	O
and	O
other	O
characteristics	O
(	O
comorbidity	O
,	O
contact	O
history	O
)	O
of	O
cases	O
by	O
nationality	O
.	O

In	O
this	O
study	O
,	O
we	O
collected	O
1004	O
samples	O
involving	O
10	O
bat	O
species	O
from	O
7	O
sites	O
from	O
April	O
2015	O
to	O
May	O
2016	O
,	O
and	O
examined	O
the	O
presence	O
of	O
viruses	O
using	O
nucleic	B-CHED
acid	I-CHED
-	O
based	O
methods	O
.	O

Taken	O
together	O
,	O
our	O
present	O
study	O
confirms	O
that	O
both	O
MHV	O
and	O
SARS	O
-	O
CoV	O
N	O
proteins	B-CHED
can	O
perturb	O
the	O
function	O
of	O
cellular	O
PACT	O
to	O
circumvent	O
the	O
innate	O
antiviral	B-CHED
response	O
.	O

However	O
,	O
this	O
strategy	O
does	O
not	O
appear	O
to	O
be	O
used	O
by	O
all	O
CoVs	O
N	O
proteins	B-CHED
.	O

Sequencing	O
of	O
21	O
DBoV1	O
and	O
18	O
DBoV2	O
genomes	O
and	O
phylogenetic	O
analysis	O
showed	O
that	O
DBoV1	O
and	O
DBoV2	O
formed	O
two	O
distinct	O
clusters	B-CHED
,	O
with	O
only	O
32	O
.	O
6	O
-	O
36	O
.	O
3	O
%	O
amino	B-CHED
acid	I-CHED
identities	O
between	O
the	O
DBoV1	O
and	O
DBoV2	O
strains	O
.	O

The	O
amino	B-CHED
acid	I-CHED
sequences	O
of	O
the	O
NS1	O
proteins	B-CHED
of	O
all	O
the	O
DBoV1	O
and	O
DBoV2	O
strains	O
showed	O
<	O
85	O
%	O
identity	O
to	O
those	O
of	O
all	O
the	O
other	O
bocaparvoviruses	O
,	O
indicating	O
that	O
DBoV1	O
and	O
DBoV2	O
are	O
two	O
bocaparvovirus	O
species	O
according	O
to	O
the	O
ICTV	O
criteria	O
.	O

It	O
differs	O
from	O
previous	O
American	O
European	O
Consensus	O
definition	O
by	O
excluding	O
the	O
term	O
Acute	O
Lung	O
Injury	O
,	O
it	O
also	O
removed	O
the	O
requirement	O
for	O
wedge	O
pressure	O
<	O
18	O
and	O
included	O
the	O
requirement	O
of	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	B-CHED
)	O
or	O
continuous	O
positive	O
airway	O
pressure	O
(	O
CPAP	O
)	O
of	O
greater	O
than	O
or	O
equal	O
to	O
5	O
.	O

Median	O
opioid	O
and	O
benzodiazepine	B-CHED
doses	O
on	O
the	O
day	O
of	O
cannulation	O
,	O
0	O
.	O
15	O
mg	O
/	O
kg	O
/	O
hr	O
(	O
3	O
.	O
7	O
mg	O
/	O
kg	O
/	O
d	O
)	O
and	O
0	O
.	O
11	O
mg	O
/	O
kg	O
/	O
hr	O
(	O
2	O
.	O
8	O
mg	O
/	O
kg	O
/	O
d	O
),	O
increased	O
by	O
36	O
%	O
and	O
58	O
%,	O
respectively	O
,	O
by	O
extracorporeal	O
membrane	O
oxygenation	O
day	O
3	O
.	O

In	O
the	O
41	O
patients	O
successfully	O
decannulated	O
prior	O
to	O
study	O
discharge	O
,	O
patients	O
were	O
receiving	O
0	O
.	O
40	O
mg	O
/	O
kg	O
/	O
hr	O
opioids	O
(	O
9	O
.	O
7	O
mg	O
/	O
kg	O
/	O
d	O
)	O
and	O
0	O
.	O
39	O
mg	O
/	O
kg	O
/	O
hr	O
benzodiazepines	B-CHED
(	O
9	O
.	O
4	O
mg	O
/	O
kg	O
/	O
d	O
)	O
at	O
decannulation	O
,	O
an	O
increase	O
from	O
cannulation	O
of	O
108	O
%	O
and	O
192	O
%,	O
respectively	O
(	O
both	O
p	O
<	O
0	O
.	O
001	O
).	O

30	O
-	O
day	O
survival	O
(	O
69	O
%	O
overall	O
)	O
did	O
not	O
differ	O
(	O
p	O
=	O
0	O
.	O
89	O
)	O
between	O
moxifloxacin	B-CHED
monotherapy	O
(	O
n	O
=	O
42	O
),	O
moxifloxacin	B-CHED
combination	O
therapy	O
(	O
n	O
=	O
44	O
),	O
and	O
other	O
antibiotic	B-CHED
treatments	O
(	O
n	O
=	O
83	O
).	O

RESULTS	O
:	O
30	O
-	O
day	O
survival	O
(	O
69	O
%	O
overall	O
)	O
did	O
not	O
differ	O
(	O
p	O
=	O
0	O
.	O
89	O
)	O
between	O
moxifloxacin	B-CHED
monotherapy	O
(	O
n	O
=	O
42	O
),	O
moxifloxacin	B-CHED
combination	O
therapy	O
(	O
n	O
=	O
44	O
),	O
and	O
other	O
antibiotic	B-CHED
treatments	O
(	O
n	O
=	O
83	O
).	O

Here	O
we	O
describe	O
the	O
current	O
epidemiological	O
picture	O
of	O
MERS	O
-	O
CoV	O
,	O
focusing	O
on	O
humans	O
and	O
animals	O
affected	O
by	O
this	O
virus	O
and	O
propose	O
specific	O
intervention	O
strategies	O
that	O
would	O
be	O
appropriate	O
to	O
control	O
MERS	O
-	O
CoV	O
.	O
One	O
-	O
third	O
of	O
MERS	O
-	O
CoV	O
patients	O
develop	O
severe	O
lower	O
respiratory	O
tract	O
infection	O
and	O
succumb	O
to	O
a	O
fatal	O
outcome	O
;	O
these	O
patients	O
would	O
require	O
effective	O
therapeutic	O
antiviral	B-CHED
therapy	O
.	O

Despite	O
initial	O
treatment	O
with	O
steroid	B-CHED
inhalers	O
,	O
her	O
clinical	O
picture	O
rapidly	O
deteriorated	O
requiring	O
emergency	O
intubation	O
and	O
positive	O
pressure	O
ventilation	O
.	O

She	O
was	O
intubated	O
and	O
managed	O
with	O
intravenous	O
antibiotics	B-CHED
and	O
blood	O
transfusion	O
.	O

TITLE	O
:	O
Infection	O
of	O
porcine	O
precision	O
cut	O
intestinal	O
slices	O
by	O
transmissible	O
gastroenteritis	O
coronavirus	O
demonstrates	O
the	O
importance	O
of	O
the	O
spike	O
protein	B-CHED
for	O
enterotropism	O
of	O
different	O
virus	O
strains	O
.	O

However	O
,	O
for	O
TGEV	O
PUR	O
46	O
-	O
MAD	O
no	O
nucleocapsid	O
protein	B-CHED
was	O
detected	O
in	O
the	O
epithelial	O
cells	O
of	O
the	O
tissue	O
.	O

This	O
study	O
is	O
the	O
first	O
to	O
link	O
HSP27	O
to	O
PEDV	O
replication	O
via	O
the	O
innate	O
immunity	O
response	O
,	O
which	O
contributed	O
to	O
further	O
clarify	O
the	O
mechanism	O
of	O
PEDV	O
infection	O
and	O
the	O
development	O
of	O
novel	O
antiviral	B-CHED
therapies	O
.	O

G	O
+	O
C	O
compositional	O
constraint	O
and	O
dinucleotide	B-CHED
composition	O
also	O
plays	O
a	O
role	O
in	O
the	O
overall	O
pattern	O
of	O
BCoV	O
codon	O
usage	O
.	O

ABSTRACT	O
:	O
The	O
present	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
effects	O
of	O
tea	B-CHED
saponins	O
on	O
oxidative	O
stress	O
induced	O
by	O
cyclophosphamide	B-CHED
in	O
chickens	O
.	O

Groups	O
3	O
to	O
4	O
received	O
intramuscular	O
injection	O
of	O
cyclophosphamide	B-CHED
to	O
induce	O
oxidative	O
stress	O
and	O
immunosuppression	O
.	O

The	O
results	O
showed	O
that	O
administration	O
of	O
tea	B-CHED
saponins	O
significantly	O
increased	O
total	O
antioxidant	B-CHED
capacity	O
,	O
total	O
superoxide	B-CHED
dismutase	O
,	O
catalase	O
,	O
glutathione	B-CHED
peroxidase	O
,	O
glutathione	B-CHED
,	O
ascorbic	B-CHED
acid	I-CHED
,	O
and	O
α	O
-	O
tocopherol	B-CHED
,	O
and	O
decreased	O
malondialdehyde	B-CHED
and	O
protein	B-CHED
carbonyl	B-CHED
.	O

The	O
type	O
II	O
transmembrane	O
serine	B-CHED
protease	O
TMPRSS2	O
cleaves	O
and	O
activates	O
SARS	O
S	O
in	O
cell	O
culture	O
and	O
potentially	O
also	O
in	O
the	O
infected	O
host	O
.	O

On	O
the	O
bases	B-CHED
of	O
these	O
results	O
and	O
searching	O
for	O
potential	O
multitarget	O
active	O
drug	O
supplement	O
,	O
we	O
also	O
investigated	O
the	O
anti	O
-	O
HIV	O
-	O
1	O
activity	O
of	O
Hemidesmus	O
indicus	O
,	O
an	O
Ayurveda	O
medicinal	O
plant	O
containing	O
Lupeol	B-CHED
.	O

TITLE	O
:	O
Argatroban	B-CHED
for	O
Heparin	B-CHED
-	O
Induced	O
Thrombocytopenia	O
during	O
Venovenous	O
Extracorporeal	O
Membrane	O
Oxygenation	O
with	O
Continuous	O
Venovenous	O
Hemofiltration	O
.	O

However	O
,	O
if	O
a	O
patient	O
develops	O
heparin	B-CHED
-	O
induced	O
thrombocytopenia	O
(	O
HIT	O
),	O
an	O
alternative	O
anticoagulant	B-CHED
would	O
be	O
required	O
while	O
the	O
patient	O
is	O
maintained	O
on	O
ECMO	O
.	O

Rapamycin	B-CHED
may	O
work	O
as	O
the	O
salvage	O
therapy	O
for	O
severe	O
influenza	O
but	O
it	O
is	O
very	O
difficult	O
to	O
define	O
the	O
appropriate	O
window	O
for	O
such	O
treatment	O
to	O
take	O
effect	O
.	O

Resveratrol	B-CHED
and	O
pterostilbene	B-CHED
are	O
plant	O
stilbenoids	B-CHED
associated	O
with	O
several	O
health	O
-	O
promoting	O
benefits	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
resveratrol	B-CHED
and	O
pterostilbene	B-CHED
completely	O
block	O
HIV	O
-	O
1	O
infection	O
at	O
a	O
low	O
micromolar	O
dose	O
in	O
resting	O
CD4	O
T	O
cells	O
,	O
primarily	O
at	O
the	O
reverse	O
transcription	O
step	O
.	O

The	O
patient	O
,	O
on	O
hemodialysis	O
,	O
presented	O
episodes	O
of	O
respiratory	O
failure	O
,	O
which	O
was	O
interpreted	O
as	O
acute	O
pulmonary	O
edema	O
,	O
but	O
a	O
suspicion	O
of	O
ANCA	B-CHED
-	O
related	O
pulmonary	O
renal	O
syndrome	O
was	O
raised	O
.	O

Nucleotide	B-CHED
sequences	O
of	O
CPPV	O
-	O
1	O
were	O
closely	O
related	O
to	O
sequences	O
detected	O
in	O
other	O
wild	O
carnivores	O
,	O
comparing	O
294	O
nucleotides	B-CHED
of	O
the	O
VP1	O
gene	O
.	O

Here	O
,	O
we	O
describe	O
a	O
transforming	O
growth	O
factor	O
(	O
TGF	O
)-	O
β	O
-	O
triggered	O
mechanism	O
,	O
in	O
which	O
megalin	O
,	O
the	O
primary	O
mediator	O
of	O
alveolar	O
protein	B-CHED
transport	O
,	O
is	O
negatively	O
regulated	O
by	O
glycogen	B-CHED
synthase	O
kinase	O
(	O
GSK	O
)	O
3β	O
,	O
with	O
protein	B-CHED
phosphatase	O
1	O
and	O
nuclear	O
inhibitor	B-CHED
of	O
protein	B-CHED
phosphatase	O
1	O
being	O
involved	O
in	O
the	O
signaling	O
cascade	O
.	O

In	O
an	O
effort	O
to	O
ensure	O
that	O
studies	O
are	O
comprehensive	O
,	O
both	O
internally	O
and	O
externally	O
valid	O
,	O
and	O
with	O
reliable	O
results	O
,	O
the	O
World	O
Health	O
Organization	O
,	O
the	O
Pan	B-CHED
American	O
Health	O
Organization	O
,	O
Institut	O
Pasteur	O
,	O
the	O
networks	O
of	O
Fiocruz	O
,	O
the	O
Consortia	O
for	O
the	O
Standardization	O
of	O
Influenza	O
Seroepidemiology	O
(	O
CONSISE	O
)	O
and	O
the	O
International	O
Severe	O
Acute	O
Respiratory	O
and	O
Emerging	O
Infection	O
Consortium	O
(	O
ISARIC	O
)	O
have	O
generated	O
six	O
standardized	O
clinical	O
and	O
epidemiological	O
research	O
protocols	O
and	O
questionnaires	O
to	O
address	O
key	O
public	O
health	O
questions	O
on	O
ZIKV	O
.	O

Additionally	O
,	O
the	O
synthetic	O
analog	O
of	O
viral	O
double	O
-	O
stranded	O
RNA	O
(	O
poly	O
(	O
I	O
:	O
C	O
)),	O
bacterial	O
lipopolysaccharide	B-CHED
and	O
lipoteichoic	B-CHED
acid	I-CHED
can	O
all	O
markedly	O
increase	O
the	O
expression	O
of	O
miR	O
-	O
200c	O
-	O
3p	O
in	O
a	O
nuclear	O
factor	O

The	O
patient	O
made	O
a	O
successful	O
recovery	O
after	O
early	O
treatment	O
with	O
antiviral	B-CHED
agents	I-CHED
and	O
adequate	O
supportive	O
care	O
.	O

ABSTRACT	O
:	O
This	O
study	O
evaluated	O
the	O
effect	O
of	O
diets	O
differing	O
in	O
standard	O
ileal	O
digestible	O
(	O
SID	O
)	O
lysine	B-CHED
on	O
lysine	B-CHED
intake	O
,	O
growth	O
rate	O
,	O
body	O
composition	O
and	O
age	O
at	O
puberty	O
on	O
maternal	O
line	O
gilts	O
.	O

TITLE	O
:	O
Coronavirus	O
nucleocapsid	O
proteins	B-CHED
assemble	O
constitutively	O
in	O
high	O
molecular	O
oligomers	O
.	O

ABSTRACT	O
:	O
Coronaviruses	O
(	O
CoV	O
)	O
are	O
enveloped	O
viruses	O
and	O
rely	O
on	O
their	O
nucleocapsid	O
N	O
protein	B-CHED
to	O
incorporate	O
the	O
positive	O
-	O
stranded	O
genomic	O
RNA	O
into	O
the	O
virions	O
.	O

The	O
fact	O
that	O
these	O
regions	O
can	O
bind	O
reciprocally	O
between	O
themselves	O
provides	O
a	O
possible	O
molecular	O
basis	O
for	O
N	O
protein	B-CHED
oligomerization	O
.	O

Treating	O
that	O
with	O
steroids	B-CHED
compromised	O
her	O
immune	O
system	O
beyond	O
her	O
pre	O
-	O
existing	O
primary	O
immunodeficiency	O
status	O
.	O

The	O
one	O
sequence	O
from	O
a	O
carcass	O
showed	O
the	O
highest	O
nucleotide	B-CHED
identity	O
(	O
99	O
%)	O
with	O
Bat	O
-	O
CoV	O
-	O
SC2013	O
from	O
China	O
.	O

The	O
conservative	O
LFM	O
group	O
included	O
patients	O
with	O
at	O
least	O
2	O
consecutive	O
days	O
with	O
a	O
negative	O
fluid	O
balance	B-CHED
between	O
day	O
3	O
and	O
day	O
7	O
;	O
other	O
patients	O
were	O
allocated	O
to	O
the	O
liberal	O
LFM	O
group	O
.	O

However	O
,	O
the	O
ADE	B-CHED
activity	O
of	O
FECV	O
79	O
-	O
1683	O
was	O
lower	O
than	O
that	O
of	O
FIPV	O
79	O
-	O
1146	O
.	O

Moreover	O
,	O
an	O
in	O
vitro	O
analysis	O
demonstrated	O
that	O
interleukin	O
-	O
13	O
and	O
-	O
31	O
and	O
hemozoin	O
induced	O
pneumocytic	O
cell	O
injury	O
and	O
apoptosis	O
,	O
as	O
assessed	O
by	O
EB	O
/	O
AO	O
staining	O
,	O
electron	O
microscopy	O
and	O
the	O
up	O
-	O
regulation	O
of	O
CARD	O
-	O
9	O
mRNA	B-CHED
(	O
caspase	O
recruitment	O
domain	O
-	O
9	O
messenger	O
-	O
ribonucleic	B-CHED
acid	I-CHED
).	O

TITLE	O
:	O
Isolated	O
non	O
-	O
cardiogenic	O
pulmonary	O
edema	O
-	O
A	O
rare	O
complication	O
of	O
MDMA	B-CHED
toxicity	O
.	O

We	O
demonstrated	O
that	O
binding	O
of	O
nsp4	O
with	O
nsp3	O
is	O
essential	O
for	O
membrane	O
rearrangement	O
and	O
identified	O
amino	B-CHED
acid	I-CHED
residues	O
in	O
nsp4	O
responsible	O
for	O
the	O
interaction	O
with	O
nsp3	O
.	O

The	O
nucleotide	B-CHED
and	O
amino	B-CHED
acid	I-CHED
sequences	O
from	O
the	O
isolated	O
field	O
strains	O
were	O
compared	O
to	O
42	O
published	O
references	O
.	O

PPV	B-CHED
increased	O
PaO	B-CHED
Our	O
findings	O
suggest	O
that	O
PPV	B-CHED
may	O
improve	O
oxygenation	O
and	O
partially	O
improve	O
hemodynamic	O
parameters	O
during	O
acute	O
exacerbations	O
of	O
ILD	O
.	O

PPV	B-CHED
increased	O
PaO	B-CHED
CONCLUSIONS	O
:	O
Our	O
findings	O
suggest	O
that	O
PPV	B-CHED
may	O
improve	O
oxygenation	O
and	O
partially	O
improve	O
hemodynamic	O
parameters	O
during	O
acute	O
exacerbations	O
of	O
ILD	O
.	O

TITLE	O
:	O
Comprehensive	O
structural	O
analysis	O
of	O
designed	O
incomplete	O
polypeptide	B-CHED
chains	O
of	O
the	O
replicase	O
nonstructural	O
protein	B-CHED
1	O
from	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
.	O

We	O
further	O
characterized	O
the	O
complete	O
spike	O
(	O
S	O
)	O
glycoprotein	B-CHED
genes	O
from	O
the	O
positive	O
samples	O
and	O
found	O
21	O
different	O
S	O
genes	O
with	O
amino	B-CHED
acid	I-CHED
mutations	O
.	O

Interestingly	O
,	O
the	O
domains	O
are	O
nearly	O
identical	O
but	O
differ	O
in	O
their	O
affinities	O
for	O
carbohydrates	B-CHED
.	O

Decomposition	O
of	O
the	O
binding	O
free	O
energy	O
showed	O
that	O
the	O
residues	O
that	O
interact	O
with	O
Man4	O
were	O
different	O
in	O
the	O
three	O
systems	O
,	O
suggesting	O
that	O
the	O
binding	O
mechanism	O
of	O
Man4	O
varies	O
between	O
full	O
-	O
length	O
protein	B-CHED
,	O
SD1	O
and	O
SD2	O
.	O

The	O
results	O
presented	O
here	O
may	O
help	O
to	O
formulate	O
strategies	O
to	O
use	O
scytovirin	O
and	O
promote	O
mutagenesis	O
studies	O
to	O
improve	O
the	O
antiviral	B-CHED
activity	O
of	O
scytovirin	O
.	O

88	O
.	O
2	O
%	O
(	O
45	O
/	O
51	O
)	O
of	O
patients	O
were	O
on	O
recommended	O
ciprofloxacin	B-CHED
prophylaxis	O
.	O

The	O
faecal	O
antigen	B-CHED
capture	O
ELISA	O
and	O
PCR	O
revealed	O
35	O
%	O
prevalence	O
of	O
C	O
.	O
parvum	O
in	O
contrast	O
to	O
25	O
%	O
by	O
mZN	O
staining	O
with	O
a	O
relatively	O
higher	O
prevalence	O
(	O
66	O
·	O
7	O
%)	O
in	O
younger	O
(	O
8	O
-	O
14	O
-	O
day	O
-	O
old	O
)	O
calves	O
.	O

TITLE	O
:	O
The	O
history	O
and	O
epidemiology	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
corona	B-CHED
virus	O
.	O

During	O
the	O
last	O
4	O
years	O
,	O
corona	B-CHED
viruses	O
have	O
become	O
the	O
most	O
important	O
viruses	O
worldwide	O
because	O
of	O
the	O
occurrence	O
of	O
several	O
recent	O
deaths	O
caused	O
by	O
corona	B-CHED
viruses	O
in	O
Saudi	O
Arabia	O
.	O

Tissues	O
were	O
infected	O
with	O
RV	O
-	O
A55	O
,	O
RV	O
-	O
A49	O
,	O
RV	O
-	O
B48	O
,	O
RV	O
-	O
C8	O
,	O
and	O
RV	O
-	O
C15	O
;	O
respiratory	O
EV	O
-	O
D68	O
;	O
influenza	O
virus	O
H3N2	B-CHED
;	O
RSV	O
-	O
B	O
;	O
and	O
human	O
coronavirus	O
(	O
HCoV	O
)-	O
OC43	O
.	O

Their	O
infectious	O
entry	O
requires	O
viral	O
spike	O
(	O
S	O
)	O
proteins	B-CHED
,	O
which	O
attach	O
to	O
cell	O
receptors	O
,	O
undergo	O
proteolytic	O
cleavage	O
,	O
and	O
then	O
refold	O
in	O
a	O
process	O
that	O
catalyzes	O
virus	O
-	O
cell	O
membrane	O
fusion	O
.	O

Here	O
we	O
conjugated	O
fusion	O
-	O
inhibiting	O
peptides	B-CHED
to	O
various	O
lipids	B-CHED
,	O
expecting	O
this	O
to	O
secure	O
peptides	B-CHED
onto	O
cell	O
membranes	O
and	O
thereby	O
increase	O
antiviral	B-CHED
potencies	O
.	O

ABSTRACT	O
:	O
This	O
communication	O
reports	O
fatal	O
Peste	O
des	B-CHED
petits	O
ruminants	O
(	O
PPR	O
)	O
disease	O
in	O
Chowsingha	O
(	O
Tetracerus	O
quadricornis	O
),	O
a	O
member	O
of	O
the	O
subfamily	O
Bovinae	O
and	O
family	O
Bovidae	O
captured	O
in	O
a	O
Zoological	O
Park	O
.	O

Additionally	O
,	O
prediction	O
of	O
N	O
-	O
glycosylation	O
sites	O
showed	O
that	O
most	O
of	O
the	O
BR	O
-	O
I	O
variants	O
(	O
from	O
2003	O
to	O
early	O
2014	O
)	O
had	O
an	O
extra	O
site	O
at	O
amino	B-CHED
acid	I-CHED
position	O
20	O
,	O
whereas	O
the	O
newest	O
variants	O
lacked	O
this	O
extra	O
site	O
.	O

TITLE	O
:	O
Immunogenicity	O
and	O
structures	O
of	O
a	O
rationally	O
designed	O
prefusion	O
MERS	O
-	O
CoV	O
spike	O
antigen	B-CHED
.	O

Here	O
we	O
use	O
structure	O
-	O
based	O
design	O
to	O
develop	O
a	O
generalizable	O
strategy	O
for	O
retaining	O
coronavirus	O
S	O
proteins	B-CHED
in	O
the	O
antigenically	O
optimal	O
prefusion	O
conformation	O
and	O
demonstrate	O
that	O
our	O
engineered	O
immunogen	B-CHED
is	O
able	O
to	O
elicit	O
high	O
neutralizing	O
antibody	O
titers	O
against	O
MERS	O
-	O
CoV	O
.	O
We	O
also	O
determined	O
high	O
-	O
resolution	O
structures	O
of	O
the	O
trimeric	O
MERS	O
-	O
CoV	O
S	O
ectodomain	O
in	O
complex	O
with	O
G4	O
,	O
a	O
stem	O
-	O
directed	O
neutralizing	O
antibody	O
.	O

ABSTRACT	O
:	O
Zinc	B-CHED
chloride	I-CHED
smoke	O
bomb	O
exposure	O
is	O
frequently	O
seen	O
in	O
military	O
drills	O
,	O
combat	B-CHED
exercises	O
,	O
metal	B-CHED
industry	O
works	O
,	O
and	O
disaster	O
simulations	O
.	O

Being	O
vigilant	O
for	O
infectious	O
complications	O
is	O
important	O
due	O
to	O
prolonged	O
steroid	B-CHED
treatment	O
regimen	O
.	O

We	O
further	O
found	O
this	O
inflammation	O
was	O
accompanied	O
by	O
increased	O
recruitment	O
of	O
complement	O
proteins	B-CHED
compared	O
to	O
primary	O
infection	O
.	O

ABSTRACT	O
:	O
Astragalus	O
polysaccharides	B-CHED
(	O
APS	B-CHED
)	O
are	O
biological	O
macromolecules	B-CHED
extracted	O
from	O
Astragalus	O
species	O
that	O
have	O
strong	O
immunoregulatory	O
properties	O
.	O

At	O
most	O
time	O
points	O
,	O
the	O
titer	O
of	O
IBV	O
-	O
specific	O
antibodies	O
,	O
lymphocyte	O
proliferation	O
,	O
and	O
IL	O
-	O
1β	O
,	O
IL	O
-	O
2	O
,	O
IL	O
-	O
8	O
,	O
and	O
TNF	O
-	O
α	O
mRNA	B-CHED
expression	O
levels	O
were	O
higher	O
in	O
three	O
APS	B-CHED
groups	O
than	O
in	O
the	O
vaccine	O
control	O
group	O
,	O
and	O
these	O
increases	O
were	O
dose	O
-	O
dependent	O
.	O

The	O
right	O
ventricle	O
(	O
RV	O
)	O
is	O
the	O
weak	O
link	O
of	O
hemodynamic	O
stability	O
among	O
ARDS	O
patients	O
and	O
its	O
failure	O
,	O
also	O
named	O
""""	O
severe	O
""""	O
acute	O
cor	O
pulmonale	O
(	O
ACP	B-CHED
),	O
is	O
responsible	O
for	O
excess	O
mortality	O
.	O

TITLE	O
:	O
Antibiotics	B-CHED
for	O
persistent	O
cough	O
or	O
wheeze	O
following	O
acute	O
bronchiolitis	O
in	O
children	O
.	O

Future	O
RCTs	O
are	O
needed	O
to	O
evaluate	O
the	O
efficacy	O
of	O
antibiotics	B-CHED
for	O
reducing	O
persistent	O
respiratory	O
symptoms	O
.	O

ABSTRACT	O
:	O
While	O
dispensable	O
for	O
viral	O
replication	O
,	O
coronavirus	O
(	O
CoV	O
)	O
accessory	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
proteins	B-CHED
often	O
play	O
critical	O
roles	O
during	O
infection	O
and	O
pathogenesis	O
.	O

A	O
phylogenetic	O
tree	O
based	O
on	O
a	O
complete	O
genome	O
sequence	O
placed	O
the	O
TGEV	O
AHHF	O
strain	O
between	O
the	O
Purdue	O
and	O
the	O
Miller	O
clusters	B-CHED
.	O

Bivariable	O
logistic	O
regression	O
analyses	O
suggested	O
that	O
high	O
viral	O
load	O
,	O
receipt	O
of	O
high	O
-	O
dose	O
steroids	B-CHED
,	O
and	O
myeloablative	O
conditioning	O
were	O
associated	O
with	O
prolonged	O
shedding	O
.	O

Initially	O
,	O
asthma	O
has	O
been	O
categorized	O
into	O
atopic	O
and	O
nonatopic	O
types	O
,	O
based	O
on	O
antigen	B-CHED
-	O
specific	O
IgE	O
levels	O
.	O

Pre	O
-	O
treatment	O
with	O
rapamycin	B-CHED
significantly	O
restricted	O
not	O
only	O
a	O
1	O
h	O
infection	O
but	O
also	O
a	O
longer	O
infection	O
(	O
24	O
h	O
)	O
with	O
PEDV	O
,	O
while	O
this	O
effect	O
disappeared	O
when	O
autophagy	O
was	O
blocked	O
.	O

The	O
nsp1	O
of	O
CoV	O
is	O
thought	O
to	O
be	O
a	O
major	O
virulence	O
factor	O
because	O
it	O
suppresses	O
protein	B-CHED
synthesis	O
through	O
the	O
degradation	O
of	O
host	O
mRNA	B-CHED
.	O

In	O
this	O
study	O
,	O
we	O
identified	O
amino	B-CHED
acid	I-CHED
residue	I-CHED
in	O
MERS	O
-	O
CoV	O
nsp1	O
that	O
differ	O
from	O
those	O
of	O
SARS	O
-	O
CoV	O
nsp1	O
,	O
and	O
that	O
appear	O
to	O
be	O
crucial	O
for	O
circumventing	O
the	O
translational	O
shutoff	O
.	O

TITLE	O
:	O
The	O
FER	B-CHED
rs4957796	O
TT	O
genotype	O
is	O
associated	O
with	O
unfavorable	O
90	O
-	O
day	O
survival	O
in	O
Caucasian	O
patients	O
with	O
severe	O
ARDS	O
due	O
to	O
pneumonia	O
.	O

In	O
conclusion	O
,	O
FER	B-CHED
rs4957796	O
might	O
act	O
as	O
a	O
prognostic	O
variable	O
for	O
survival	O
in	O
patients	O
with	O
severe	O
ARDS	O
due	O
to	O
pneumonia	O
.	O

Our	O
study	O
also	O
aimed	O
to	O
evaluate	O
the	O
clinical	O
use	O
of	O
various	O
methods	O
in	O
diagnosing	O
respiratory	O
infections	O
under	O
field	O
conditions	O
and	O
to	O
describe	O
the	O
antimicrobial	B-CHED
resistance	O
profile	O
of	O
the	O
main	O
bacterial	O
pathogen	O
(	O
s	O
)	O
found	O
during	O
the	O
study	O
.	O

Serology	O
was	O
used	O
to	O
detect	O
According	O
to	O
the	O
pathology	O
and	O
bacteriology	O
of	O
the	O
lung	O
samples	O
,	O
APP	B-CHED
and	O
APP	B-CHED
was	O
the	O
most	O
common	O
cause	O
for	O
acute	O
respiratory	O
outbreaks	O
in	O
our	O
study	O
.	O

SIV	O
,	O
RESULTS	O
:	O
According	O
to	O
the	O
pathology	O
and	O
bacteriology	O
of	O
the	O
lung	O
samples	O
,	O
APP	B-CHED
and	O

ABSTRACT	O
:	O
Porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
inhibits	O
the	O
host	O
typeⅠinterferon	O
and	O
cellular	O
antiviral	B-CHED
response	O
,	O
but	O
its	O
inhibition	O
mechanism	O
is	O
unclear	O
,	O
and	O
the	O
roles	O
of	O
PEDV	O
nonstructural	O
proteins	B-CHED
in	O
regulating	O
typeⅠinterferon	O
responses	O
have	O
been	O
seldom	O
studied	O
.	O

TITLE	O
:	O
Design	O
,	O
synthesis	O
and	O
antiviral	B-CHED
evaluation	O
of	O
novel	O
heteroarylcarbothioamide	O
derivatives	O
as	O
dual	O
inhibitors	B-CHED
of	O
HIV	O
-	O
1	O
reverse	O
transcriptase	O
-	O
associated	O
RNase	O
H	O
and	O
RDDP	O
functions	O
.	O

TITLE	O
:	O
Development	O
and	O
application	O
of	O
a	O
recombinant	O
M	O
protein	B-CHED
-	O
based	O
indirect	O
ELISA	O
for	O
the	O
detection	O
of	O
porcine	O
deltacoronavirus	O
IgG	O
antibodies	O
.	O

TITLE	O
:	O
Ethyl	B-CHED
pyruvate	B-CHED
reverses	O
development	O
of	O
Pseudomonas	O
aeruginosa	O
pneumonia	O
during	O
sepsis	O
-	O
induced	O
immunosuppression	O
.	O

The	O
review	O
also	O
provides	O
an	O
overview	O
of	O
the	O
properties	O
of	O
small	O
molecules	O
,	O
proteins	B-CHED
,	O
and	O
peptides	B-CHED
that	O
efficiently	O
inhibit	O
the	O
proteolytic	O
activation	O
of	O
the	O
influenza	O
virus	O
.	O

To	O
induce	O
MDA	B-CHED
in	O
a	O
subset	O
of	O
piglets	O
,	O
two	O
sows	O
received	O
a	O
cell	O
culture	O
-	O
adapted	O
PEDV	O
strain	O
,	O
and	O
another	O
two	O
sows	O
were	O
inoculated	O
with	O
field	O
material	O
from	O
German	O
PED	O
outbreaks	O
.	O

Therapeutic	O
options	O
are	O
limited	O
,	O
basically	O
consisting	O
of	O
prophylactic	O
antibiotic	B-CHED
therapy	O
and	O
changing	O
patient	O
'	O
s	O
positions	O
.	O

These	O
values	O
are	O
much	O
lower	O
than	O
the	O
normal	O
vitamin	B-CHED
A	I-CHED
levels	O
;	O
therefore	O
,	O
the	O
calves	O
were	O
diagnosed	O
with	O
hypovitaminosis	O
A	O
.	O

His	O
corresponding	O
blood	O
urea	B-CHED
and	O
serum	O
antistreptolysin	O
O	O
(	O
ASO	B-CHED
)	O
levels	O
were	O
raised	O
with	O
low	O
C3	O
levels	O
.	O

These	O
data	O
suggest	O
that	O
inflammasome	O
signaling	O
is	O
largely	O
protective	O
during	O
murine	O
coronavirus	O
infection	O
,	O
in	O
large	O
part	O
due	O
to	O
the	O
pro	B-CHED
-	O
inflammatory	O
effects	O
of	O
IL	O
-	O
18	O
.	O

ABSTRACT	O
:	O
The	O
avian	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
S1	O
subunit	O
of	O
the	O
spike	O
(	O
S	O
)	O
glycoprotein	B-CHED
mediates	O
viral	O
attachment	O
to	O
host	O
cells	O
and	O
the	O
S2	O
subunit	O
is	O
responsible	O
for	O
membrane	O
fusion	O
.	O

The	O
immune	O
evasion	O
mechanism	O
including	O
type	O
1	O
interferon	O
and	O
protein	B-CHED
kinase	O
R	O
-	O
mediated	O
antiviral	B-CHED
stress	O
responses	O
has	O
been	O
recently	O
attributed	O
to	O
the	O
involvement	O
of	O
MERS	O
-	O
CoV	O
protein	B-CHED
4a	O
(	O
p4a	O
)	O
that	O
masks	O
the	O
viral	O
dsRNA	B-CHED
.	O

Further	O
,	O
mutational	O
and	O
binding	O
free	O
energy	O
analyses	O
suggested	O
that	O
in	O
addition	O
to	O
K63	O
and	O
K67	O
,	O
two	O
other	O
residues	O
,	O
K27	O
and	O
W45	O
,	O
might	O
also	O
be	O
crucial	O
for	O
p4a	O
-	O
dsRNA	B-CHED
stability	O
.	O

ABSTRACT	O
:	O
Objectives	O
The	O
safety	O
and	O
efficacy	O
of	O
the	O
3C	O
-	O
like	O
protease	B-CHED
inhibitor	I-CHED
GC376	O
was	O
tested	O
on	O
a	O
cohort	O
of	O
client	O
-	O
owned	O
cats	O
with	O
various	O
forms	O
of	O
feline	O
infectious	O
peritonitis	O
(	O
FIP	O
).	O

Conclusions	O
and	O
relevance	O
GC376	O
showed	O
promise	O
in	O
treating	O
cats	O
with	O
certain	O
presentations	O
of	O
FIP	O
and	O
has	O
opened	O
the	O
door	O
to	O
targeted	O
antiviral	B-CHED
drug	I-CHED
therapy	O
.	O

On	O
presentation	O
to	O
the	O
emergency	O
department	O
,	O
the	O
patient	O
was	O
hypotensive	O
,	O
tachycardic	O
,	O
tachypneic	O
,	O
with	O
an	O
oxyhemoglobin	B-CHED
saturation	O
in	O
the	O
mid	O
80	O
%	O
range	O
while	O
breathing	O
ambient	O
air	B-CHED
.	O

This	O
information	O
could	O
help	O
in	O
selecting	O
empirical	O
antibiotics	B-CHED
in	O
patients	O
with	O
post	O
-	O
viral	O
pneumonia	O
.	O

ABSTRACT	O
:	O
The	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
(	O
CDC	O
)	O
algorithm	O
for	O
detecting	O
presence	O
of	O
serum	O
antibodies	O
against	O
Middle	O
East	O
Respiratory	O
Syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
in	O
subjects	O
with	O
potential	O
infections	O
with	O
the	O
virus	O
has	O
included	O
screening	O
by	O
indirect	O
ELISA	O
against	O
recombinant	O
nucleocapsid	O
(	O
N	O
)	O
protein	B-CHED
and	O
confirmation	O
by	O
immunofluorescent	O
staining	O
of	O
infected	O
monolayers	O
and	O
/	O
or	O
microneutralization	O
titration	O
.	O

The	O
probability	O
for	O
severe	O
illness	O
originated	O
from	O
delayed	O
utilization	O
of	O
health	O
services	O
,	O
delayed	O
prescription	O
of	O
neuraminidase	B-CHED
inhibitors	I-CHED
(	O
NAIs	O
)	O
and	O
inappropriate	O
use	O
of	O
antibiotics	B-CHED
was	O
assessed	O
.	O

N	B-CHED
-	I-CHED
acetylcysteine	I-CHED
(	O
NAC	O
)	O
is	O
the	O
most	O
commonly	O
used	O
anti	O
-	O
oxidant	B-CHED
.	O

However	O
,	O
the	O
benefit	O
of	O
anti	O
-	O
oxidant	B-CHED
therapy	O
was	O
not	O
consistently	O
demonstrated	O
by	O
previous	O
studies	O
.	O

The	O
activity	O
of	O
caspases	O
,	O
the	O
inhibitory	O
efficacy	O
of	O
caspase	O
-	O
inhibitors	B-CHED
and	O
the	O
expression	O
of	O
apoptotic	O
genes	O
further	O
suggested	O
the	O
activation	O
of	O
apoptosis	O
through	O
both	O
intrinsic	O
and	O
extrinsic	O
pathways	O
in	O
IBV	O
-	O
infected	O
HD11	O
cells	O
.	O

RESULTS	O
:	O
The	O
task	O
force	O
was	O
unable	O
to	O
reach	O
agreement	O
on	O
a	O
single	O
test	O
that	O
can	O
reliably	O
diagnose	O
CIRCI	O
,	O
although	O
delta	O
cortisol	B-CHED
(	O
change	O
in	O
baseline	O
cortisol	B-CHED
at	O
60	O
min	O
of	O
<	O
9	O
μg	O
/	O
dL	O
)	O
after	O
cosyntropin	B-CHED
(	O
250	O
μg	O
)	O
administration	O
and	O
a	O
random	O
plasma	O
cortisol	B-CHED
of	O
<	O
10	O
μg	O
/	O
dL	O
may	O
be	O
used	O
by	O
clinicians	O
.	O

Corticosteroids	B-CHED
are	O
not	O
suggested	O
for	O
patients	O
with	O
major	O
trauma	O
(	O
conditional	O
,	O
low	O
quality	O
of	O
evidence	O
).	O

A	O
multispecialty	O
task	O
force	O
of	O
16	O
international	O
experts	O
in	O
Critical	O
Care	O
Medicine	B-CHED
,	O
endocrinology	O
,	O
and	O
guideline	O
methods	O
,	O
all	O
of	O
them	O
members	O
of	O
the	O
Society	O
of	O
Critical	O
Care	O
Medicine	B-CHED
and	O
/	O
or	O
the	O
European	O
Society	O
of	O
Intensive	O
Care	O
Medicine	B-CHED
.	O

We	O
suggest	O
the	O
use	O
of	O
IV	O
methylprednisolone	B-CHED
1	O
mg	O
/	O
kg	O
/	O
day	O
in	O
patients	O
with	O
early	O
moderate	O
to	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
PaO	B-CHED

It	O
is	O
established	O
that	O
vitamin	B-CHED
D	I-CHED
exhibits	O
anti	O
‑	O
inflammatory	O
effects	O
,	O
however	O
,	O
the	O
specific	O
effect	O
of	O
vitamin	B-CHED
D	I-CHED
on	O
ALI	O
remains	O
largely	O
unknown	O
.	O

Results	O
presented	O
herein	O
offer	O
structure	O
-	O
activity	O
relationships	O
for	O
these	O
pathogens	O
in	O
terms	O
of	O
their	O
susceptibility	O
to	O
inhibition	O
by	O
polymers	B-CHED
,	O
and	O
for	O
polymers	B-CHED
in	O
terms	O
of	O
their	O
anionic	O
charge	O
and	O
hydrophobicity	O
that	O
make	O
up	O
broad	O
-	O
spectrum	O
antiviral	B-CHED
agents	I-CHED
.	O

After	O
immunizing	O
BALB	O
/	O
c	O
mice	O
intramuscularly	O
,	O
rH7HA	O
proteins	B-CHED
formulated	O
in	O
this	O
adjuvant	B-CHED
instead	O
of	O
an	O
alum	O
adjuvant	B-CHED
elicited	O
higher	O
IgG	O
,	O
hemagglutination	O
-	O
inhibition	O
,	O
and	O
virus	O
neutralizing	O
antibodies	O
in	O
sera	O
;	O
induced	O
higher	O
numbers	O
of	O
H7HA	O
-	O
specific	O
IFN	O
-	O
γ	O
-	O
secreting	O
T	O
cells	O
and	O
antibody	O
secreting	O
cells	O
in	O
spleen	O
;	O
and	O
provided	O
improved	O
protection	O
against	O
live	O
virus	O
challenges	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
investigate	O
the	O
correlation	O
between	O
the	O
serum	O
zinc	B-CHED
in	O
patients	O
with	O
HC	O
/	O
ZnCl	O
smoke	O
inhalation	O
lung	O
injury	O
and	O
disease	O
severity	O
.	O

Therefore	O
,	O
we	O
evaluated	O
the	O
protective	O
capabilities	O
of	O
the	O
S2	O
protein	B-CHED
of	O
IBV	O
4	O
/	O
91	O
expressed	O
from	O
rLS	O
.	O

The	O
Purpose	O
of	O
this	O
research	O
is	O
the	O
prediction	O
of	O
the	O
auto	O
-	O
antigen	B-CHED
potency	O
of	O
the	O
myelin	O
proteolipid	O
protein	B-CHED
(	O
PLP	O
)	O
in	O
multiple	O
sclerosis	O
.	O

The	O
study	O
was	O
registered	O
with	O
the	O
Chinese	O
Clinical	O
Trial	O
Registry	O
(	O
ChiCTR	O
-	O
DOD	B-CHED
-	O
16008657	O
).	O

RESULTS	O
:	O
The	O
step	O
with	O
RR	O
of	O
60	O
after	O
lung	O
recruitment	O
had	O
the	O
highest	O
PEEP	B-CHED
when	O
compared	O
with	O
all	O
other	O
steps	O
(	O
17	O
[	O
16	O
,	O
19	O
]	O
vs	O
14	O
[	O
10	O
,	O
17	O
]	O
cmH2O	O
),	O
but	O
had	O
lower	O
driving	O
pressures	O
(	O
13	O
[	O
13	O
,	O
11	O
]	O
vs	O
16	O
[	O
14	O
,	O
17	O
]	O
cmH2O	O
),	O
higher	O
P	O
/	O
F	O
ratios	O
(	O
212	O
[	O
191	O
,	O
243	O
]	O
vs	O
141	O
[	O
105	O
,	O
184	O
]	O
mmHg	O
),	O
lower	O
shunt	O
(	O
23	O
[	O
20	O
,	O
23	O
]	O
vs	O
32	O
[	O
27	O
,	O
49	O
]%),	O
lower	O
dead	O
space	O
ventilation	O
(	O
10	O
[	O
0	O
,	O
15	O
]	O
vs	O
30	O
[	O
20	O
,	O
37	O
]%),	O
and	O
a	O
more	O
homogeneous	O
alveolar	O
ventilation	O
distribution	O
.	O

ABSTRACT	O
:	O
Ricin	O
,	O
a	O
plant	O
-	O
derived	O
toxin	O
originating	O
from	O
the	O
seeds	O
of	O
Ricinus	O
communis	O
(	O
castor	O
beans	O
),	O
is	O
one	O
of	O
the	O
most	O
lethal	O
toxins	B-CHED
known	O
,	O
particularly	O
if	O
inhaled	O
.	O

The	O
present	O
study	O
investigated	O
whether	O
Lianqinjiedu	O
(	O
LQJD	O
)	O
ameliorates	O
lipopolysaccharide	B-CHED
(	O
LPS	B-CHED
)-	O
induced	O
acute	O
lung	O
injury	O
in	O
rats	O
and	O
aimed	O
to	O
determine	O
the	O
anti	O
-	O
inflammatory	O
effects	O
of	O
LQJD	O
.	O

The	O
Intraoperative	O
Norepinephrine	B-CHED
to	O
Control	O
Arterial	O
Pressure	O
(	O
INPRESS	O
)	O
study	O
was	O
a	O
multicenter	O
,	O
randomized	O
,	O
parallel	O
-	O
group	O
clinical	O
trial	O
conducted	O
in	O
9	O
French	O
university	O
and	O
nonuniversity	O
hospitals	O
.	O

To	O
determine	O
if	O
lung	O
recruitment	O
associated	O
with	O
PEEP	B-CHED
titration	O
according	O
to	O
the	O
best	O
respiratory	O
-	O
system	O
compliance	O
decreases	O
28	O
-	O
day	O
mortality	O
of	O
patients	O
with	O
moderate	O
to	O
severe	O
ARDS	O
compared	O
with	O
a	O
conventional	O
low	O
-	O
PEEP	B-CHED
strategy	O
.	O

TITLE	O
:	O
The	O
bulky	O
and	O
the	O
sweet	O
:	O
How	O
neutralizing	O
antibodies	O
and	O
glycan	B-CHED
receptors	O
compete	O
for	O
virus	O
binding	O
.	O

Here	O
,	O
we	O
have	O
solved	O
3D	O
structure	O
,	O
dynamics	O
and	O
micelle	O
localization	O
of	O
a	O
64	O
-	O
residue	O
long	O
fusion	O
peptide	B-CHED
or	O
LFP	O
in	O
DPC	B-CHED
detergent	B-CHED
micelles	O
by	O
NMR	O
methods	O
.	O

TITLE	O
:	O
Characterization	O
of	O
novel	O
monoclonal	O
antibodies	O
against	O
the	O
MERS	O
-	O
coronavirus	O
spike	O
protein	B-CHED
and	O
their	O
application	O
in	O
species	O
-	O
independent	O
antibody	O
detection	O
by	O
competitive	O
ELISA	O
.	O

In	O
this	O
study	O
,	O
novel	O
MAbs	O
against	O
the	O
spike	O
protein	B-CHED
of	O
MERS	O
-	O
CoV	O
were	O
produced	O
and	O
characterized	O
.	O

Recent	O
findings	O
have	O
increased	O
our	O
knowledge	O
of	O
the	O
physiological	O
effects	O
of	O
spontaneous	O
breathing	O
and	O
the	O
application	O
of	O
PEEP	B-CHED
.	O

In	O
smokers	O
and	O
subjects	O
with	O
COPD	O
,	O
both	O
DPP4	O
mRNA	B-CHED
and	O
protein	B-CHED
expression	O
were	O
significantly	O
higher	O
compared	O
to	O
never	O
-	O
smokers	O
.	O

TITLE	O
:	O
Nanoparticulate	O
vacuolar	O
ATPase	O
blocker	O
exhibits	O
potent	O
host	O
-	O
targeted	O
antiviral	B-CHED
activity	O
against	O
feline	O
coronavirus	O
.	O

In	O
light	O
of	O
the	O
pathogenic	O
mechanism	O
of	O
feline	O
coronavirus	O
that	O
relies	O
on	O
endosomal	O
acidification	O
for	O
cytoplasmic	O
entry	O
,	O
a	O
novel	O
vacuolar	O
ATPase	O
blocker	O
,	O
diphyllin	O
,	O
and	O
its	O
nanoformulation	O
are	O
herein	O
investigated	O
for	O
their	O
antiviral	B-CHED
activity	O
against	O
the	O
type	O
II	O
feline	O
infectious	O
peritonitis	O
virus	O
(	O
FIPV	O
).	O

N	O
-	O
2	O
-	O
HACC	O
-	O
CMC	O
/	O
NDV	O
/	O
IBV	O
nanoparticles	B-CHED
(	O
NPs	B-CHED
)	O
(	O
NDV	O
/	O
La	O
Sota	O
and	O
IBV	O
/	O
H120	O
encapsulated	O
in	O
N	O
-	O
2	O
-	O
HACC	O
-	O
CMC	O
NPs	B-CHED
)	O
and	O
N	O
-	O
2	O
-	O
HACC	O
-	O
CMC	O
/	O
NDV	O
-	O
IBV	O
NPs	B-CHED
(	O
the	O
mixing	O
of	O
N	O
-	O
2	O
-	O
HACC	O
-	O
CMC	O
/	O
NDV	O
NPs	B-CHED
and	O
N	O
-	O
2	O
-	O
HACC	O
-	O
CMC	O
/	O
IBV	O
NPs	B-CHED
in	O
a	O
ratio	O
of	O
1	O
:	O
1	O
)	O
were	O
prepared	O
by	O
the	O
polyelectrolyte	B-CHED
composite	O
method	O
,	O
respectively	O
.	O

This	O
is	O
the	O
first	O
study	O
in	O
the	O
field	O
of	O
animal	O
vaccines	O
demonstrating	O
that	O
intranasal	O
administration	O
of	O
chickens	O
with	O
antigens	B-CHED
(	O
NDV	O
and	O
IBV	O
)	O
encapsulated	O
with	O
chitosan	B-CHED
derivative	O
could	O
induce	O
humoral	O
,	O
cellular	O
,	O
and	O
mucosal	O
immune	O
responses	O
,	O
which	O
protected	O
chickens	O
from	O
the	O
infection	O
of	O
highly	O
virulent	O
NDV	O
and	O
IBV	O
.	O

ABSTRACT	O
:	O
In	O
recent	O
years	O
,	O
several	O
studies	O
based	O
on	O
the	O
interaction	O
of	O
self	O
-	O
assembling	O
short	O
peptides	B-CHED
derived	O
from	O
viroporins	O
with	O
model	O
membranes	O
,	O
have	O
improved	O
our	O
understanding	O
of	O
the	O
molecular	O
mechanism	O
of	O
corona	B-CHED
virus	O
(	O
CoV	O
)	O
infection	O
under	O
physiological	O
conditions	O
.	O

We	O
discuss	O
the	O
origins	O
of	O
ROS	B-CHED
within	O
the	O
cell	O
,	O
cellular	O
defense	O
mechanisms	O
against	O
oxidative	O
damage	O
,	O
the	O
role	O
of	O
ROS	B-CHED
in	O
the	O
development	O
of	O
endothelial	O
permeability	O
,	O
and	O
potential	O
therapies	O
targeted	O
at	O
oxidative	O
stress	O
.	O

ABSTRACT	O
:	O
This	O
study	O
aimed	O
to	O
evaluate	O
practical	O
barriers	O
to	O
personal	O
protective	O
equipment	O
(	O
PPE	B-CHED
)	O
use	O
found	O
through	O
health	O
care	O
personnel	O
(	O
HCP	B-CHED
)	O
training	O
sessions	O
held	O
during	O
and	O
after	O
the	O
2015	O
Middle	O
East	O
respiratory	O
syndrome	O
outbreak	O
in	O
Korea	O
.	O

Presence	O
of	O
influenza	O
A	O
and	O
B	O
,	O
parainfluenza	O
1	O
,	O
2	O
,	O
3	O
and	O
4	O
,	O
human	O
adeno	O
-,	O
boca	O
-,	O
corona	B-CHED
-,	O
metapneumo	O
-,	O
rhino	O
-	O
and	O
respiratory	O
syncytial	O
viruses	O
was	O
determined	O
by	O
real	O
-	O
time	O
PCR	O
.	O

Clan	O
CN	O
proteases	O
contain	O
a	O
cysteine	B-CHED
protease	O
domain	O
that	O
is	O
intimately	O
packed	O
with	O
an	O
S	B-CHED
-	I-CHED
adenosyl	I-CHED
-	I-CHED
l	I-CHED
-	I-CHED
methionine	I-CHED
-	O
dependent	O
RNA	O
methyltransferase	O
(	O
SAM	B-CHED
MTase	O
)	O
domain	O
.	O

Within	O
a	O
cleft	O
formed	O
at	O
the	O
interface	O
of	O
these	O
two	O
domains	O
,	O
the	O
peptide	B-CHED
substrate	O
is	O
thought	O
to	O
bind	O
.	O

In	O
cases	O
of	O
severe	O
inflammation	O
of	O
the	O
ciliary	O
body	O
with	O
damage	O
to	O
blood	O
vessel	O
walls	O
and	O
ciliary	O
epithelium	O
(	O
3	O
/	O
15	O
,	O
20	O
%),	O
some	O
macrophages	O
expressed	O
FCoV	O
antigens	B-CHED
,	O
and	O
immunolabeling	O
for	O
calprotectin	O
on	O
consecutive	O
sections	O
suggested	O
that	O
these	O
FCoV	O
-	O
positive	O
macrophages	O
were	O
likely	O
to	O
be	O
recently	O
derived	O
from	O
blood	O
.	O

Because	O
no	O
considerable	O
change	O
in	O
IBV	O
N	O
protein	B-CHED
and	O
viral	O
RNA	O
levels	O
was	O
detected	O
in	O
total	O
cell	O
lysates	O
prepared	O
from	O
the	O
overexpression	O
,	O
knockdown	O
or	O
cleavage	O
of	O
CD59	O
groups	O
,	O
our	O
data	O
indicated	O
that	O
CD59	O
was	O
involved	O
in	O
IBV	O
particle	O
release	O
and	O
that	O
IBV	O
had	O
evolved	O
a	O
mechanism	O
to	O
utilize	O
CD59	O
to	O
evade	O
complement	O
-	O
mediated	O
destruction	O
.	O

This	O
is	O
the	O
first	O
atomic	O
structure	O
of	O
a	O
spike	O
protein	B-CHED
from	O
the	O
deltacoronavirus	O
genus	O
,	O
which	O
is	O
divergent	O
in	O
amino	B-CHED
acid	I-CHED
sequences	O
from	O
the	O
well	O
-	O
studied	O
alpha	O
-	O
and	O
betacoronavirus	O
spike	O
proteins	B-CHED
.	O

Their	O
median	O
Sequential	O
Organ	O
Failure	O
Assessment	O
score	O
was	O
12	O
,	O
PaO	B-CHED
CONCLUSIONS	O
:	O
Cytokine	O
levels	O
,	O
on	O
average	O
,	O
fall	O
rapidly	O
after	O
initiation	O
of	O
VV	O
ECMO	O
,	O
which	O
may	O
be	O
related	O
to	O
the	O
reduction	O
of	O
invasiveness	O
of	O
mechanical	O
ventilation	O
.	O

Using	O
the	O
influenza	O
virus	O
as	O
a	O
model	O
,	O
erythrocyte	O
membrane	O
cloaked	O
nanoparticles	B-CHED
are	O
prepared	O
and	O
modified	O
with	O
magnetic	O
functionalities	O
(	O
RBC	O
-	O
mNP	O
)	O
for	O
virus	O
targeting	O
and	O
isolation	O
.	O

Patient	O
demographics	O
,	O
length	O
of	O
ventilations	O
days	O
,	O
number	O
of	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
admission	O
days	O
,	O
chest	O
radiographic	O
score	O
,	O
chest	O
radiographic	O
deterioration	O
pattern	O
(	O
Types	O
1	O
-	O
4	O
)	O
and	O
peak	O
lactate	B-CHED
dehydrogenase	O
level	O
were	O
compared	O
between	O
the	O
two	O
groups	O
using	O
the	O
student	O
Follow	O
-	O
up	O
chest	O
radiographs	O
were	O
normal	O
in	O
23	O
out	O
of	O
36	O
(	O
64	O
%)	O
patients	O
.	O

77	O
,	O
89	O
,	O
and	O
136	O
differentially	O
expressed	O
proteins	B-CHED
are	O
identified	O
in	O
TGEV	O
infected	O
,	O
ETEC	O
K88	O
infected	O
,	O
and	O
coinfected	O
cells	O
,	O
respectively	O
.	O

They	O
utilize	O
the	O
spike	O
(	O
S	O
)	O
glycoprotein	B-CHED
anchored	O
in	O
the	O
viral	O
envelope	O
to	O
mediate	O
host	O
attachment	O
and	O
fusion	O
of	O
the	O
viral	O
and	O
cellular	O
membranes	O
to	O
initiate	O
infection	O
.	O

We	O
report	O
here	O
the	O
3	O
.	O
5	O
-	O
Å	O
-	O
resolution	O
cryo	O
-	O
electron	O
microscopy	O
structure	O
of	O
the	O
S	O
glycoprotein	B-CHED
trimer	O
from	O
the	O
pathogenic	O
porcine	O
deltacoronavirus	O
(	O
PDCoV	O
),	O
which	O
belongs	O
to	O
the	O
recently	O
identified	O

Thus	O
NMR	O
based	O
metabolomics	O
has	O
provided	O
new	O
insight	O
into	O
ARDS	O
sub	O
-	O
stages	O
and	O
conclusively	O
a	O
precise	O
biomarker	B-CHED
model	O
proposed	O
,	O
reflecting	O
underlying	O
metabolic	O
dysfunction	O
aiding	O
prior	O
clinical	O
decision	O
making	O
.	O

Higher	O
expression	O
levels	O
of	O
IL	O
-	O
12	O
and	O
IFN	O
-	O
γ	O
were	O
recorded	O
in	O
DCs	O
after	O
treatment	O
with	O
Zhejiang08	O
for	O
24	O
h	O
.	O
Furthermore	O
,	O
genome	O
sequencing	O
and	O
phylogenetic	O
analysis	O
revealed	O
high	O
homology	O
between	O
the	O
main	O
antigen	B-CHED
epitopes	O
of	O
Zhejiang08	O
and	O
PEDV	O
pandemic	O
isolates	O
following	O
2011	O
.	O

Complete	O
genome	O
sequencing	O
of	O
isolates	O
from	O
this	O
herd	O
revealed	O
that	O
although	O
the	O
case	O
strain	O
had	O
some	O
unique	O
genetic	O
features	O
including	O
a	O
deduced	O
3	O
amino	B-CHED
acid	I-CHED
deletion	O
,	O
it	O
was	O
in	O
overall	O
very	O
similar	O
to	O
the	O
other	O
PRRS	O
-	O
2	O
viruses	O
circulating	O
in	O
Denmark	O
.	O

In	O
this	O
study	O
,	O
we	O
prepared	O
biodegradable	O
poly	O
(	O
d	O
,	O
l	O
-	O
lactide	O
-	O
co	O
-	O
glycolide	O
)	O
(	O
PLGA	B-CHED
)	O
nanoparticle	B-CHED
-	O
entrapped	O
PEDV	O
killed	O
vaccine	O
antigens	B-CHED
(	O
KAg	B-CHED
)	O
(	O
PLGA	B-CHED
-	O
KAg	B-CHED
).	O

TITLE	O
:	O
Synthesis	O
and	O
biological	O
evaluation	O
of	O
NH	O
ABSTRACT	O
:	O
Neuraminidase	B-CHED
inhibitors	I-CHED
can	O
deter	O
nascent	O
viruses	O
from	O
infecting	O
intact	O
cells	O
by	O
preventing	O
their	O
release	O
from	O
host	O
cells	O
.	O

This	O
key	O
protein	B-CHED
is	O
recognised	O
as	O
a	O
potential	O
target	O
for	O
an	O
effective	O
next	O
-	O
generation	O
antiretroviral	O
therapy	O
,	O
because	O
it	O
could	O
offer	O
the	O
possibility	O
to	O
develop	O
broad	O
-	O
spectrum	O
agents	O
that	O
are	O
less	O
prone	O
to	O
select	O
for	O
resistant	O
strains	O
.	O

Here	O
,	O
we	O
provide	O
a	O
comprehensive	O
overview	O
of	O
the	O
covalent	O
NCp7	O
inhibitors	B-CHED
that	O
have	O
emerged	O
over	O
the	O
past	O
25	O
years	O
of	O
drug	O
discovery	O
campaigns	O
,	O
emphasising	O
,	O
where	O
possible	O
,	O
their	O
structure	O
-	O
activity	O
relationships	O
(	O
SARs	O
)	O
and	O
pharmacophoric	O
features	O
.	O

A	O
total	O
of	O
376	O
camels	O
were	O
screened	O
for	O
MERS	O
-	O
Cov	O
at	O
a	O
live	O
animal	O
market	O
in	O
the	O
Eastern	O
Region	O
of	O
the	O
Emirate	O
of	O
Abu	B-CHED
Dhabi	O
,	O
UAE	O
.	O

RESULTS	O
:	O
The	O
Acute	O
Physiology	O
and	O
Chronic	O
Health	O
Evaluation	O
II	O
scores	O
were	O
significantly	O
lower	O
in	O
the	O
drug	O
-	O
associated	O
ARDS	O
group	O
than	O
in	O
the	O
non	O
-	O
drug	O
-	O
associated	O
ARDS	O
group	O
(	O
median	O
(	O
IQR	O
):	O
18	O
.	O
0	O
(	O
16	O
.	O
5	O
-	O
21	O
.	O
0	O
)	O
vs	O
23	O
.	O
0	O
(	O
18	O
.	O
0	O
-	O
26	O
.	O
0	O
),	O
p	O
<	O
0	O
.	O
001	O
),	O
and	O
the	O
arterial	O
oxygen	B-CHED
tension	O
/	O
fractional	O
inspired	O
oxygen	B-CHED
ratio	O
was	O
higher	O
(	O
148	O
.	O
0	O
(	O
114	O
.	O
1	O
-	O
177	O
.	O
5	O
)	O
vs	O
101	O
.	O
0	O
(	O
71	O
.	O
5	O
-	O
134	O
.	O
0	O
),	O
p	O
=	O
0	O
.	O
003	O
).	O

Secondary	O
nucleotide	B-CHED
peaks	O
identified	O
in	O
the	O
chromatogram	O
for	O
the	O
S1	O
gene	O
sequence	O
revealed	O
that	O
all	O
original	O
vaccines	O
(	O
H120	O
and	O
Ma5	O
)	O
were	O
composed	O
by	O
different	O
subpopulations	O
of	O
IBV	O
.	O

TITLE	O
:	O
Avian	O
infectious	O
bronchitis	O
virus	O
disrupts	O
the	O
melanoma	O
differentiation	O
associated	O
gene	O
5	O
(	O
MDA5	O
)	O
signaling	O
pathway	O
by	O
cleavage	O
of	O
the	O
adaptor	O
protein	B-CHED
MAVS	O
.	O

ABSTRACT	O
:	O
Melanoma	O
differentiation	O
associated	O
gene	O
5	O
(	O
MDA5	O
)	O
and	O
retinoic	B-CHED
acid	I-CHED
-	O
inducible	O
gene	O
-	O
I	O
(	O
RIG	O
-	O
I	O
)	O
selectively	O
sense	O
cytoplasmic	O
viral	O
RNA	O
to	O
induce	O
an	O
antiviral	B-CHED
immune	O
response	O
.	O

We	O
also	O
found	O
that	O
IBV	O
can	O
cleave	O
MAVS	O
,	O
an	O
adaptor	O
protein	B-CHED
downstream	O
of	O
RIG	O
-	O
I	O
and	O
MDA5	O
that	O
acts	O
as	O
a	O
platform	O
for	O
antiviral	B-CHED
innate	O
immunity	O
at	O
an	O
early	O
stage	O
of	O
infection	O
.	O

Acute	O
kidney	O
injury	O
,	O
liver	O
dysfunction	O
,	O
thrombocytopenia	O
,	O
disseminated	O
intravascular	O
coagulopathy	O
(	O
DIC	B-CHED
)	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
are	O
also	O
common	O
in	O
severe	O
malaria	O
.	O

Subjects	O
underwent	O
impedance	O
-	O
based	O
platelet	O
aggregometry	O
in	O
response	O
to	O
platelet	O
agonists	B-CHED
arachidonic	B-CHED
acid	I-CHED
,	O
adenosine	B-CHED
diphosphate	B-CHED
,	O
collagen	O
,	O
and	O
thrombin	O
receptor	O
activating	O
peptide	B-CHED
-	O
6	O
.	O

Potential	O
targets	O
for	O
novel	O
antivirals	B-CHED
and	O
antibodies	O
are	O
discussed	O
as	O
well	O
as	O
lessons	O
learned	O
from	O
treatment	O
development	O
for	O
other	O
RNA	O
viruses	O
.	O

In	O
summary	O
,	O
miR	O
-	O
223	O
is	O
essential	O
for	O
regulating	O
the	O
pathogenesis	O
of	O
DAMP	B-CHED
-	O
induced	O
ALI	O
.	O

Histological	O
examination	O
revealed	O
MERS	O
-	O
CoV	O
enteric	O
infection	O
in	O
all	O
inoculated	O
mice	O
,	O
as	O
shown	O
by	O
the	O
presence	O
of	O
virus	O
-	O
positive	O
cells	O
,	O
progressive	O
inflammation	O
,	O
and	O
epithelial	O
degeneration	O
in	O
small	O
intestines	O
,	O
which	O
were	O
exaggerated	O
in	O
the	O
mice	O
pretreated	O
with	O
the	O
proton	B-CHED
pump	I-CHED
inhibitor	I-CHED
pantoprazole	B-CHED
.	O

Herein	O
,	O
we	O
demonstrate	O
that	O
mice	O
deficient	O
in	O
Msr1	O
are	O
resistant	O
to	O
FH	O
induced	O
by	O
MHV	O
-	O
A59	O
,	O
and	O
the	O
Msr1	O
inhibitor	B-CHED
fucoidan	O
suppresses	O
the	O
progression	O
of	O
FH	O
in	O
mice	O
.	O

TITLE	O
:	O
Corticosteroid	B-CHED
Therapy	O
for	O
Critically	O
Ill	O
Patients	O
with	O
Middle	O
East	O
Respiratory	O
Syndrome	O
.	O

Corticosteroids	B-CHED
were	O
initiated	O
at	O
a	O
median	O
of	O
3	O
.	O
0	O
days	O
(	O
quartile	O
1	O
[	O
Q1	O
]-	O
Q3	O
,	O
1	O
.	O
0	O
-	O
7	O
.	O
0	O
)	O
from	O
ICU	O
admission	O
.	O

Coronavirus	O
RNA	O
synthesis	O
is	O
thought	O
to	O
be	O
associated	O
with	O
replication	O
organelles	O
(	O
ROs	B-CHED
)	O
consisting	O
of	O
modified	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
membranes	O
.	O

Interestingly	O
,	O
IL	O
-	O
36γ	O
enhanced	O
the	O
production	O
of	O
prostaglandin	B-CHED
E2	I-CHED
(	O
PGE2	B-CHED
)	O
during	O
P	O
.	O
aeruginosa	O
infection	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

Consumption	O
of	O
antipyretic	B-CHED
medication	O
before	O
the	O
consultation	O
seemed	O
to	O
reduce	O
the	O
risk	O
of	O
developing	O
GI	O
symptoms	O
for	O
patients	O
with	O
laboratory	O
-	O
confirmed	O
influenza	O
(	O
aOR	O
=	O
0	O
.	O
3	O
;	O
[	O
0	O
.	O
1	O
-	O
0	O
.	O
6	O
];	O
p	O
=	O
0	O
.	O
002	O
).	O

The	O
statistical	O
significance	O
of	O
the	O
data	O
was	O
evaluated	O
with	O
Fisher	O
chi	B-CHED
-	O
square	O
test	O
.	O

Based	O
on	O
typical	O
clinical	O
features	O
,	O
and	O
on	O
positivity	O
for	O
serum	O
GD1b	B-CHED
-	O
IgM	O
antibodies	O
,	O
GBS	O
with	O
proximal	O
conduction	O
failure	O
at	O
multiple	O
radicular	O
levels	O
was	O
postulated	O
,	O
and	O
a	O
standard	O
regime	O
of	O
intravenous	O
immunoglobulin	O
was	O
administered	O
.	O

The	O
expression	O
of	O
viral	O
mRNA	B-CHED
and	O
cytokine	O
(	O
IL	O
-	O
1β	O
,	O
IL	O
-	O
6	O
,	O
IL	O
-	O
8	O
and	O
TNF	O
-	O
α	O
)	O
mRNA	B-CHED
transcripts	O
was	O
determined	O
by	O
real	O
-	O
time	O
quantitative	O
RT	O
-	O
PCR	O
(	O
qRT	O
-	O
PCR	O
).	O

ABSTRACT	O
:	O
RNA	O
viruses	O
are	O
characterized	O
by	O
a	O
high	O
mutation	O
rate	O
,	O
a	O
buffer	B-CHED
against	O
environmental	O
change	O
.	O

We	O
also	O
discuss	O
some	O
general	O
strategies	O
for	O
developing	O
small	O
-	O
molecule	O
viral	O
inhibitors	B-CHED
.	O

Disease	O
occurrence	O
and	O
severity	O
were	O
significantly	O
reduced	O
in	O
dogs	O
vaccinated	O
against	O
classic	O
CIRD	O
agents	O
,	O
canine	O
distemper	O
virus	O
(	O
CDV	B-CHED
),	O
canine	O
adenovirus	O
2	O
(	O
CAV	O
-	O
2	O
)	O
and	O
canine	O
parainfluenza	O
virus	O
(	O
CPIV	O
),	O
but	O
substantial	O
proportions	O
(	O
65	O
.	O
7	O
%;	O
201	O
/	O
306	O
)	O
of	O
vaccinated	O
dogs	O
remained	O
affected	O
.	O

Antituberculosis	O
therapy	O
(	O
rifampicin	B-CHED
,	O
isoniazid	B-CHED
,	O
ethambutol	B-CHED
and	O
pyrazinamide	B-CHED
)	O
was	O
initiated	O
upon	O
Mycobacterium	O
confirmation	O
.	O

In	O
this	O
study	O
,	O
the	O
effects	O
of	O
a	O
routinely	O
used	O
commercial	O
poultry	O
vaccine	O
on	O
the	O
acute	O
phase	O
response	O
(	O
APR	B-CHED
)	O
and	O
H	O
/	O
L	O
ratios	O
in	O
specific	O
pathogen	O
-	O
free	O
(	O
SPF	O
)	O
layer	O
chicks	O
was	O
examined	O
to	O
determine	O
if	O
post	O
vaccination	O
(	O
PV	O
)	O
stress	O
and	O
an	O
APR	B-CHED
occur	O
.	O

All	O
post	O
-	O
treatment	O
swabs	O
collected	O
from	O
coupons	O
in	O
the	O
AHP	O
disinfectant	B-CHED
treatment	O
groups	O
and	O
the	O
positive	O
control	O
group	O
were	O
positive	O
for	O
PEDV	O
via	O
RT	O
-	O
qPCR	O
.	O

For	O
the	O
bioassay	O
,	O
no	O
rectal	O
swabs	O
from	O
pigs	O
in	O
the	O
negative	O
control	O
(	O
0	O
of	O
4	O
)	O
or	O
the	O
AHP	O
disinfectant	B-CHED
treatment	O
groups	O
(	O
0	O
of	O
32	O
)	O
were	O
positive	O
for	O
PEDV	O
.	O

The	O
N	O
proteins	B-CHED
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
),	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
CoV	O
and	O
Middle	O
East	O
respiratory	O
syndrome	O
(	O
MERS	O
)-	O
CoV	O
were	O
also	O
ADP	B-CHED
-	O
ribosylated	O
.	O

Distribution	O
of	O
sequences	O
into	O
geographic	O
clusters	B-CHED
and	O
interleaving	O
of	O
MERS	O
-	O
CoV	O
sequences	O
from	O
camels	O
among	O
those	O
isolated	O
from	O
humans	O
indicated	O
that	O
multiple	O
zoonotic	O
introductions	O
occurred	O
in	O
endemic	O
nations	O
.	O

In	O
addition	O
,	O
the	O
cell	O
-	O
culture	O
-	O
adapted	O
HCoV	O
-	O
OC43	O
lost	B-CHED
the	O
ability	O
to	O
infect	O
and	O
replicate	O
in	O
air	B-CHED
-	O
liquid	O
interface	O
cultures	O
of	O
human	O
bronchial	O
tracheal	O
epithelial	O
cells	O
.	O

Using	O
estimated	O
sensitivity	O
and	O
specificity	O
values	O
from	O
cutoffs	O
determined	O
with	O
the	O
ROC	O
analysis	O
(	O
cutoff	O
level	O
:	O
ST2	O
,	O
21	O
ng	O
/	O
mL	O
;	O
IL	O
-	O
6	O
,	O
61	O
pg	O
/	O
mL	O
;	O
TNFR1	O
,	O
3421	O
pg	O
/	O
mL	O
),	O
we	O
calculated	O
positive	O
predictive	O
values	O
(	O
PPV	B-CHED
)	O
for	O
a	O
range	O
of	O
estimated	O
population	O
prevalence	O
values	O
of	O
IPS	O
.	O

ABSTRACT	O
:	O
We	O
utilized	O
one	O
-	O
step	O
multiplex	O
reverse	O
transcription	O
-	O
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
Luminex	O
xMAP	O
technology	O
to	O
develop	O
a	O
respiratory	O
multiplex	O
liquid	O
-	O
chip	O
assay	O
(	O
rMLA	O
)	O
for	O
simultaneous	O
detection	O
of	O
6	O
common	O
respiratory	O
viruses	O
,	O
including	O
influenza	O
virus	O
type	O
A	O
(	O
FluA	O
)	O
and	O
type	O
B	O
(	O
FluB	O
),	O
para	B-CHED
-	O
influenza	O
virus	O
type	O
3	O
(	O
PIV	O
-	O
3	O
),	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
human	O
metapneumovirus	O
(	O
MPV	O
)	O
and	O
a	O
threatening	O
virus	O
to	O
China	O
,	O
Middle	O
East	O
Respiratory	O
Syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
).	O

Treatment	O
with	O
17β	O
-	O
estradiol	B-CHED
before	O
the	O
induction	O
of	O
intestinal	O
IR	O
prevented	O
the	O
systemic	O
release	O
of	O
IL	O
-	O
10	O
,	O
CINC	B-CHED
-	O
1	O
,	O
and	O
uric	B-CHED
acid	I-CHED
,	O
but	O
it	O
did	O
not	O
affect	O
the	O
leukocytosis	O
.	O

Thus	O
CPMV	O
,	O
despite	O
being	O
a	O
protein	B-CHED
-	O
based	O
nanoparticle	B-CHED
,	O
was	O
much	O
more	O
resistant	O
to	O
the	O
harsh	O
GI	O
conditions	O
than	O
soluble	O
proteins	B-CHED
.	O

These	O
samples	O
included	O
cases	O
from	O
three	O
nosocomial	O
and	O
three	O
household	O
clusters	B-CHED
.	O

Sequence	O
analysis	O
supports	O
the	O
epidemiological	O
data	O
within	O
the	O
clusters	B-CHED
,	O
and	O
further	O
,	O
suggests	O
that	O
these	O
clusters	B-CHED
emerged	O
independently	O
.	O

The	O
mean	O
MERS	O
-	O
CoV	O
infectious	O
titer	O
in	O
pretreatment	O
samples	O
was	O
4	O
.	O
67	O
±	O
0	O
.	O
25	O
log	O
plaque	O
-	O
forming	O
units	O
(	O
pfu	B-CHED
)/	O
mL	O
,	O
which	O
was	O
reduced	O
to	O
undetectable	O
levels	O
after	O
inactivation	O
with	O
amotosalen	O
/	O
UVA	O
demonstrating	O
a	O
mean	O
log	O
reduction	O
of	O
more	O
than	O
4	O
.	O
67	O
±	O
0	O
.	O
25	O
pfu	B-CHED
/	O
mL	O
.	O
Furthermore	O
,	O
inoculation	O
of	O
inactivated	O
plasma	O
on	O
Vero	O
E6	O
cells	O
did	O
not	O
result	O
in	O
any	O
cytopathic	O
effect	O
(	O
CPE	O
)	O
even	O
after	O
7	O
days	O
of	O
incubation	O
and	O
three	O
consecutive	O
passages	O
,	O
nor	O
the	O
detection	O
of	O
MERS	O
RNA	O
compared	O
to	O
pretreatment	O
samples	O
which	O
showed	O
complete	O
CPE	O
within	O
2	O
to	O
3	O
days	O
postinoculation	O
and	O
log	O
viral	O
RNA	O
titer	O
ranging	O
from	O
9	O
.	O
48	O
to	O
10	O
.	O
22	O
copies	O
/	O
mL	O
in	O
all	O
three	O
passages	O
.	O

The	O
complete	O
amino	B-CHED
acid	I-CHED
sequences	O
of	O
the	O
spike	O
protein	B-CHED
were	O
used	O
to	O
perform	O
an	O
epitope	B-CHED
analysis	O
,	O
which	O
was	O
used	O
to	O
determine	O
null	O
mutations	O
in	O
regions	O
SS2	O
,	O
SS6	O
,	O
and	O
2C10	O
compared	O
to	O
the	O
sequences	O
of	O
G2	O
.	O

Pool	O
of	O
viscera	O
were	O
tested	O
by	O
a	O
pan	B-CHED
-	O
coronavirus	O
RT	O
-	O
PCR	O
.	O

Silvestrol	B-CHED
was	O
recently	O
shown	O
to	O
have	O
potent	O
antiviral	B-CHED
activity	O
in	O
Ebola	O
virus	O
-	O
infected	O
human	O
macrophages	O
.	O

TITLE	O
:	O
Severe	O
bilateral	O
optic	O
nerve	O
and	O
retinal	B-CHED
hypoperfusion	O
in	O
a	O
patient	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
septic	O
shock	O
.	O

We	O
conditionally	O
deleted	O
the	O
Abca3	O
gene	O
in	O
AT2	B-CHED
cells	O
in	O
the	O
mature	O
mouse	O
lung	O
.	O

M2	O
-	O
like	O
macrophages	O
were	O
recruited	O
to	O
sites	O
of	O
AT2	B-CHED
cell	O
proliferation	O
during	O
the	O
regenerative	O
process	O
and	O
were	O
present	O
in	O
lung	O
tissue	O
from	O
patients	O
with	O
severe	O
lung	O
disease	O
caused	O
by	O
mutations	O
in	O
ABCA3	O
.	O

Serum	O
FiB	O
>	O
5	O
.	O
15	O
g	O
/	O
L	O
[	O
adjusted	O
odds	O
ratio	O
(	O
OR	O
)	O
1	O
.	O
893	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
):	O
1	O
.	O
141	O
-	O
3	O
.	O
142	O
,	O
P	O
=	O
0	O
.	O
014	O
]	O
and	O
PEEP	B-CHED
>	O
6	O
.	O
5	O
cmH	B-CHED
ARDS	O
development	O
risk	O
could	O
be	O
early	O
recognized	O
by	O
PEEP	B-CHED
>	O
6	O
.	O
5	O
cmH	B-CHED

TITLE	O
:	O
A	O
Case	O
of	O
MDMA	B-CHED
-	O
Associated	O
Cerebral	O
and	O
Pulmonary	O
Edema	O
Requiring	O
ECMO	O
.	O

Furthermore	O
,	O
characterization	O
of	O
the	O
coronavirus	O
fusion	O
peptide	B-CHED
(	O
FP	O
),	O
the	O
segment	O
of	O
the	O
fusion	O
protein	B-CHED
that	O
inserts	O
to	O
a	O
target	O
lipid	B-CHED
bilayer	O
during	O
membrane	O
fusion	O
,	O
has	O
revealed	O
its	O
particular	O
attributes	O
which	O
imparts	O
some	O
of	O
the	O
unusual	O
properties	O
of	O
the	O
S	O
protein	B-CHED
,	O
such	O
as	O
Ca	O

We	O
measured	O
the	O
EAdi	O
as	O
an	O
indicator	B-CHED
of	O
breathing	O
workload	O
in	O
a	O
40	O
-	O
year	O
-	O
old	O
man	B-CHED
suffering	O
from	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
secondary	O
to	O
influenza	O
pneumonia	O
in	O
the	O
process	O
of	O
weaning	O
from	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
).	O

The	O
integration	O
of	O
different	O
hydrophobic	O
and	O
amphiphilic	O
imaging	O
labels	O
,	O
including	O
chelated	O
radioisotopes	O
and	O
paramagnetic	O
or	O
fluorescent	O
lipids	B-CHED
,	O
renders	O
HDL	B-CHED
nanobiologics	O
suitable	O
for	O
diagnostic	O
purposes	O
.	O

Nanoengineering	O
also	O
allows	O
HDL	B-CHED
reconstitution	O
with	O
core	O
payloads	O
,	O
such	O
as	O
diagnostically	O
active	O
nanocrystals	O
,	O
as	O
well	O
as	O
hydrophobic	O
drugs	O
or	O
controlled	O
release	O
polymers	B-CHED
for	O
therapeutic	O
purposes	O
.	O

A	O
translational	O
success	O
story	O
about	O
the	O
escalation	O
of	O
zirconium	B-CHED
-	O
89	O
radiolabeled	O
HDL	B-CHED
(	O

Vancomycin	B-CHED
is	O
a	O
rare	O
drug	O
to	O
cause	O
DRESS	O
syndrome	O
with	O
23	O
cases	O
reported	O
to	O
date	O
.	O

CONCLUSIONS	O
:	O
This	O
is	O
the	O
first	O
case	O
to	O
report	O
pulmonary	O
manifestation	O
as	O
the	O
initial	O
symptom	O
in	O
vancomycin	B-CHED
induced	O
DRESS	O
syndrome	O
.	O

Making	O
use	O
of	O
recombinant	O
viruses	O
either	O
devoid	O
of	O
the	O
E	O
protein	B-CHED
or	O
harboring	O
mutations	O
either	O
in	O
putative	O
transmembrane	O
domain	O
or	O
PDZ	O
-	O
binding	O
motif	O
,	O
we	O
demonstrated	O
that	O
a	O
fully	O
functional	O
HCoV	O
-	O
OC43	O
E	O
protein	B-CHED
is	O
first	O
needed	O
for	O
optimal	O
production	O
of	O
recombinant	O
infectious	O
viruses	O
.	O

TITLE	O
:	O
A	O
Rapid	O
Method	O
for	O
Antigen	B-CHED
-	O
Specific	O
Hybridoma	O
Clone	O
Isolation	O
.	O

We	O
also	O
found	O
that	O
proteins	B-CHED
8b	O
and	O
8ab	O
could	O
physically	O
interact	O
with	O
IRF3	O
.	O

Conventional	O
treatment	O
group	O
was	O
given	O
conventional	O
treatment	O
such	O
as	O
isolation	O
,	O
anti	O
-	O
virus	O
,	O
symptomatic	O
treatment	O
,	O
and	O
traditional	O
Chinese	O
medicine	B-CHED
and	O
so	O
on	O
.	O

Despite	O
lung	O
protective	O
ventilation	O
,	O
prone	O
position	O
and	O
neuromuscular	O
blockade	O
,	O
refractory	O
respiratory	O
failure	O
of	O
unknown	O
etiology	O
supervened	O
(	O
ratio	O
of	O
arterial	O
oxygen	B-CHED
partial	O
pressure	O
to	O
fractional	O
inspired	O
oxygen	B-CHED
46	O
-	O
130	O
)	O
and	O
ECMO	O
was	O
initiated	O
after	O
3	O
-	O
7	O
days	O
of	O
mechanical	O
ventilation	O
.	O

Although	O
injury	O
during	O
muscle	O
paralysis	O
was	O
predominantly	O
in	O
nondependent	O
and	O
middle	O
lung	O
regions	O
at	O
low	O
(	O
vs	O
.	O
high	O
)	O
PEEP	B-CHED
,	O
strong	O
inspiratory	O
effort	O
increased	O
injury	O
(	O
indicated	O
by	O
positron	B-CHED
emission	O
tomography	O
and	O
histology	O
)	O
in	O
dependent	O
lung	O
.	O

Thirty	O
-	O
five	O
Wistar	O
rats	O
(	O
weight	O
±	O
SD	O
,	O
310	O
±	O
19	O
)	O
g	O
received	O
Escherichia	O
coli	O
lipopolysaccharide	B-CHED
(	O
LPS	B-CHED
)	O
intratracheally	O
.	O

After	O
24	O
h	O
,	O
the	O
animals	O
were	O
anaesthetised	O
and	O
randomly	O
allocated	O
to	O
either	O
PCV	B-CHED
(	O
n	O
=	O
14	O
)	O
or	O
PSV	O
(	O
n	O
=	O
14	O
)	O
groups	O
.	O

These	O
changes	O
suggested	O
less	O
type	O
II	O
epithelial	O
cell	O
damage	O
at	O
a	O
PEEP	B-CHED
of	O
5	O
cmH2O	O
.	O

RESULTS	O
:	O
In	O
both	O
PCV	B-CHED
and	O
PSV	O
,	O
peak	O
transpulmonary	O
pressure	O
was	O
lower	O
,	O
whereas	O
E	O
-	O
cadherin	O
tissue	O
expression	O
,	O
which	O
is	O
related	O
to	O
epithelial	O
integrity	O
,	O
was	O
higher	O
at	O
PEEP	B-CHED
=	O
5	O
cmH2O	O
than	O
at	O
PEEP	B-CHED
=	O
2	O
cmH2O	O
.	O

CONCLUSIONS	O
:	O
During	O
PSV	O
,	O
PEEP	B-CHED
of	O
5	O
cmH2O	O
,	O
but	O
not	O
a	O
PEEP	B-CHED
of	O
2	O
cmH2O	O
,	O
reduced	O
lung	O
damage	O
and	O
inflammatory	O
markers	O
while	O
maintaining	O
epithelial	O
cell	O
integrity	O
.	O

TITLE	O
:	O
Ulinastatin	O
Protects	O
Against	O
LPS	B-CHED
-	O
Induced	O
Acute	O
Lung	O
Injury	O
By	O
Attenuating	O
TLR4	O
/	O
NF	O
-	O
κB	O
Pathway	O
Activation	O
and	O
Reducing	O
Inflammatory	O
Mediators	O
.	O

UTI	O
significantly	O
protected	O
animals	O
from	O
LPS	B-CHED
-	O
induced	O
ALI	O
,	O
decreasing	O
the	O
lung	O
wet	O
/	O
dry	O
weight	O
ratio	O
,	O
ALI	O
score	O
,	O
total	O
cells	O
,	O
neutrophils	O
,	O
macrophages	O
,	O
myeloperoxidase	O
activity	O
,	O
and	O
malondialdehyde	B-CHED
content	O
,	O
factors	O
associated	O
with	O
lung	O
histological	O
damage	O
.	O

Furthermore	O
,	O
UTI	O
significantly	O
attenuated	O
LPS	B-CHED
-	O
induced	O
increases	O
in	O
TLR4	O
protein	B-CHED
expression	O
and	O
NF	O
-	O
κB	O
activation	O
in	O
lung	O
tissues	O
.	O

Together	O
,	O
these	O
data	O
suggest	O
that	O
MHV	O
infection	O
can	O
directly	O
affect	O
expression	O
and	O
cellular	O
distribution	O
of	O
Cx43	O
resulting	O
in	O
loss	O
of	O
Cx43	O
-	O
mediated	O
GJIC	O
in	O
meningeal	O
fibroblasts	O
,	O
which	O
may	O
be	O
associated	O
with	O
altered	O
BBB	B-CHED
function	O
observed	O
in	O
acute	O
infection	O
.	O

This	O
protein	B-CHED
is	O
also	O
involved	O
in	O
FCoV	O
tropism	O
and	O
virulence	O
,	O
as	O
well	O
as	O
in	O
the	O
switch	O
from	O
enteric	O
disease	O
to	O
FIP	O
.	O

In	O
addition	O
,	O
patients	O
in	O
the	O
ECMO	O
group	O
had	O
better	O
PaO2	O
/	O
FiO2	O
at	O
days	O
7	O
and	O
14	O
of	O
admission	O
to	O
the	O
ICU	O
(	O
124	O
vs	O
.	O
63	O
,	O
and	O
138	O
vs	O
.	O
36	O
,	O
P	O
<	O
0	O
.	O
05	O
),	O
and	O
less	O
use	O
of	O
norepinephrine	B-CHED
at	O
days	O
1	O
and	O
14	O
(	O
29	O
vs	O
.	O
80	O
%;	O
and	O
36	O
vs	O
.	O
93	O
%,	O
P	O
<	O
0	O
.	O
05	O
).	O

TITLE	O
:	O
Supplementing	O
dietary	O
rosemary	O
(	O
Rosmarinus	O
officinalis	O
L	O
.)	O
powder	O
and	O
vitamin	B-CHED
E	I-CHED
in	O
broiler	O
chickens	O
:	O
evaluation	O
of	O
humoral	O
immune	O
response	O
,	O
lymphoid	O
organs	O
,	O
and	O
blood	O
proteins	B-CHED
.	O

ABSTRACT	O
:	O
Enteroviruses	O
are	O
among	O
the	O
most	O
common	O
and	O
important	O
human	O
pathogens	O
for	O
which	O
there	O
are	O
no	O
specific	O
antiviral	B-CHED
agents	I-CHED
approved	O
by	O
the	O
US	O
Food	O
and	O
Drug	O
Administration	O
so	O
far	O
.	O

TITLE	O
:	O
MERS	O
-	O
CoV	O
and	O
H5N1	O
influenza	O
virus	O
antagonize	O
antigen	B-CHED
presentation	O
by	O
altering	O
the	O
epigenetic	O
landscape	O
.	O

Categorizing	O
by	O
function	O
,	O
we	O
observed	O
down	O
-	O
regulation	O
of	O
gene	O
expression	O
associated	O
with	O
antigen	B-CHED
presentation	O
following	O
both	O
H5N1	O
-	O
VN1203	O
and	O
MERS	O
-	O
CoV	O
infection	O
.	O

SPC	O
-	O
TK	O
mice	O
express	O
the	O
inducible	O
suicide	O
gene	O
thymidine	B-CHED
kinase	O
from	O
by	O
the	O
SPC	O
promoter	O
,	O
which	O
targets	O
alveolar	O
type	O
2	O
(	O
AT2	B-CHED
)	O
cells	O
for	O
depletion	O
in	O
response	O
to	O
ganciclovir	B-CHED
(	O
GCV	O
).	O

The	O
therapeutic	O
effect	O
of	O
two	O
different	O
doses	O
of	O
GBT1118	O
,	O
a	O
compound	O
that	O
increases	O
the	O
oxygen	B-CHED
affinity	O
of	O
hemoglobin	B-CHED
,	O
was	O
evaluated	O
in	O
a	O
murine	O
model	O
of	O
acute	O
lung	O
injury	O
induced	O
by	O
intratracheal	O
LPS	B-CHED
instillation	O
24	O
h	O
before	O
exposure	O
to	O
5	O
%	O
or	O
10	O
%	O
hypoxia	O
(	O
n	O
=	O
8	O
-	O
15	O
per	O
group	O
).	O

As	O
expected	O
,	O
administration	O
of	O
GBT1118	O
to	O
mice	O
significantly	O
increased	O
the	O
oxygen	B-CHED
affinity	O
of	O
hemoglobin	B-CHED
.	O

No	O
patient	O
had	O
previous	O
renal	O
failure	O
and	O
the	O
serum	O
creatinine	B-CHED
was	O
not	O
significantly	O
different	O
between	O
the	O
two	O
groups	O
at	O
the	O
time	O
of	O
ECMO	O
initiation	O
.	O

Four	O
strains	O
with	O
different	O
full	O
-	O
length	O
genomes	O
were	O
identified	O
(	O
CHN	B-CHED
/	O
GS	O
/	O
2016	O
/	O
1	O
,	O
CHN	B-CHED
/	O
GS	O
/	O
2016	O
/	O
2	O
,	O
CHN	B-CHED
/	O
GS	O
-/	O
2017	O
/	O
1	O
and	O
CHN	B-CHED
/	O
QH	O
/	O
2017	O
/	O
1	O
),	O
and	O
their	O
genomes	O
were	O
used	O
to	O
analyse	O
the	O
characteristics	O
of	O
PDCoV	O
currently	O
prevalent	O
in	O
Tibetan	O
pigs	O
.	O

Phylogenetic	O
analysis	O
of	O
the	O
complete	O
genome	O
and	O
spike	O
and	O
nucleocapsid	O
gene	O
sequences	O
revealed	O
that	O
these	O
strains	O
shared	O
ancestors	O
with	O
the	O
strain	O
CHN	B-CHED
-	O
AH	O
-	O
2004	O
,	O
which	O
was	O
found	O
in	O
pigs	O
from	O
the	O
Anhui	O
province	O
of	O
China	O
mainland	O
.	O

ABSTRACT	O
:	O
The	O
ARDS	O
Network	O
(	O
ARDSNet	O
)	O
used	O
a	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	B-CHED
)/	O
Fi	O
To	O
evaluate	O
whether	O
children	O
managed	O
with	O
PEEP	B-CHED
lower	O
than	O
recommended	O
by	O
the	O
ARDSNet	O
PEEP	B-CHED
/	O
Fi	O
This	O
was	O
a	O
multicenter	O
,	O
retrospective	O
analysis	O
of	O
patients	O
with	O
pediatric	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
PARDS	O
)	O
managed	O
without	O
a	O
formal	B-CHED
PEEP	B-CHED
/	O
Fi	O
Of	O
the	O
1	O
,	O
134	O
patients	O
with	O
PARDS	O
,	O
26	O
.	O
6	O
%	O
were	O
managed	O
with	O
lower	O
PEEP	B-CHED
relative	O
to	O
the	O
amount	O
of	O
Fi	O
Patients	O
with	O
PARDS	O
managed	O
with	O
lower	O
PEEP	B-CHED
relative	O
to	O
Fi	O

Fifteen	O
HCoV	O
-	O
OC43	O
positive	O
samples	O
of	O
2013	O
-	O
2014	O
were	O
selected	O
for	O
S	O
gene	O
sequencing	O
and	O
phylogenetic	O
analysis	O
,	O
and	O
the	O
results	O
showed	O
that	O
the	O
15	O
strains	O
could	O
be	O
divided	O
into	O
2	O
clusters	B-CHED
in	O
the	O
phylogenetic	O
tree	O
,	O
12	O
strains	O
of	O
which	O
formed	O
a	O
separate	O
cluster	O
that	O
was	O
closer	O
to	O
genotype	O
G	O
found	O
in	O
Malaysia	O
.	O

Pigs	O
inoculated	O
with	O
PEDV	O
had	O
increased	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
serum	O
haptoglobin	O
and	O
increased	O
insulin	B-CHED
-	O
to	O
-	O
glucose	B-CHED
ratios	O
compared	O
with	O
Control	O
pigs	O
at	O
dpi	O
5	O
.	O

The	O
clinical	O
course	O
for	O
these	O
patients	O
started	O
with	O
a	O
febrile	O
period	O
lasting	O
five	O
days	O
,	O
a	O
reduction	O
in	O
fever	O
was	O
coinciding	O
with	O
increased	O
respiratory	O
rate	O
and	O
oxygen	B-CHED
requirements	O
.	O

None	O
of	O
the	O
50	O
contacts	O
tested	O
positive	O
for	O
MERS	O
-	O
CoV	O
.	O
Resolution	O
of	O
the	O
fever	O
was	O
accompanied	O
by	O
an	O
increase	O
in	O
oxygen	B-CHED
requirements	O
and	O
respiratory	O
rate	O
also	O
lasting	O
several	O
days	O
.	O

None	O
of	O
the	O
50	O
contacts	O
tested	O
positive	O
for	O
MERS	O
-	O
CoV	O
.	O
CONCLUSIONS	O
:	O
Resolution	O
of	O
the	O
fever	O
was	O
accompanied	O
by	O
an	O
increase	O
in	O
oxygen	B-CHED
requirements	O
and	O
respiratory	O
rate	O
also	O
lasting	O
several	O
days	O
.	O

In	O
this	O
study	O
,	O
2768	O
eligible	O
patients	O
with	O
median	O
age	O
of	O
43	O
years	O
were	O
enrolled	O
including	O
pneumonia	O
(	O
1368	O
,	O
49	O
.	O
2	O
%),	O
bronchitis	O
(	O
435	O
,	O
15	O
.	O
7	O
%),	O
upper	O
respiratory	O
tract	O
infection	O
or	O
URTI	O
(	O
250	O
,	O
9	O
.	O
0	O
%),	O
and	O
unclassified	O
ARI	B-CHED
(	O
715	O
,	O
25	O
.	O
8	O
%).	O

ABSTRACT	O
:	O
Human	O
embryo	O
lung	O
cellular	O
protein	B-CHED
interacting	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
coronavirus	O
nonstructural	O
protein	B-CHED
-	O
10	O
(	O
HEPIS	O
)	O
is	O
a	O
novel	O
transcriptional	O
repressor	O
,	O
the	O
expression	O
profile	O
and	O
promoter	O
activity	O
of	O
which	O
have	O
not	O
been	O
well	O
studied	O
.	O

There	O
was	O
a	O
small	O
gain	O
in	O
QALYs	O
and	O
a	O
cost	O
saving	O
associated	O
with	O
simvastatin	B-CHED
.	O

The	O
results	O
showed	O
that	O
the	O
expression	O
of	O
RNA	O
virus	O
pattern	O
recognition	O
receptors	O
(	O
TLR3	O
,	O
7	O
,	O
and	O
MDA5	O
),	O
antimicrobial	B-CHED
peptides	B-CHED
(	O
avian	O
β	O
-	O
defensins	O
,	O
including	O
AvBD1	O
,	O
2	O
,	O
4	O
-	O
6	O
and	O
cathelicidins	O
,	O
including	O
CATH1	O
and	O
3	O
),	O
and	O
interferons	O
(	O
IFNα	O
,	O
β	O
,	O
γ	O
,	O
λ	O
)	O
were	O
upregulated	O
,	O
and	O
the	O
expression	O
of	O
cyclooxygenase	O
2	O
(	O
PG	O
synthase	O
)	O
and	O
the	O
level	O
of	O
PGE2	B-CHED
were	O
increased	O
in	O
the	O
uterine	O
mucosa	O
following	O
aIBV	O
inoculation	O
.	O

Future	O
studies	O
will	O
contribute	O
to	O
better	O
understand	O
the	O
cellular	O
antiviral	B-CHED
mechanism	O
against	O
PEDV	O
.	O

The	O
most	O
cited	O
causes	O
of	O
ARI	B-CHED
were	O
flu	O
syndrome	O
(	O
78	O
.	O
6	O
%),	O
common	O
cold	O
(	O
73	O
.	O
9	O
%),	O
pharyngitis	O
(	O
64	O
.	O
1	O
%),	O
and	O
pneumonia	O
(	O
54	O
.	O
5	O
%).	O

Children	O
'	O
s	O
history	O
of	O
respiratory	O
diseases	O
(	O
p	O
=	O
0	O
.	O
002	O
),	O
caregiver	O
'	O
s	O
age	O
(	O
p	O
=	O
0	O
.	O
010	O
)	O
and	O
marital	O
status	O
(	O
p	O
=	O
0	O
.	O
014	O
)	O
were	O
significantly	O
associated	O
with	O
tachypnea	O
,	O
the	O
most	O
severe	O
ARI	B-CHED
symptom	O
.	O

We	O
found	O
that	O
229E	O
-	O
HR1P	O
and	O
229E	O
-	O
HR2P	O
could	O
interact	O
to	O
form	O
a	O
stable	O
six	O
-	O
helix	O
bundle	O
and	O
inhibit	O
HCoV	O
-	O
229E	O
spike	O
protein	B-CHED
-	O
mediated	O
cell	O
-	O
cell	O
fusion	O
with	O
IC	O

Moreover	O
,	O
in	O
response	O
to	O
restimulation	O
with	O
the	O
PEDV	O
COE	O
antigen	B-CHED
in	O
vitro	O
,	O
a	O
significant	O
difference	O
in	O
splenocyte	O
proliferation	O
response	O
and	O
Th2	O
-	O
associated	O
cytokine	O
IL	O
-	O
4	O
level	O
was	O
observed	O
in	O
the	O
group	O
of	O
mice	O
orally	O
immunized	O
with	O
pPG	B-CHED
-	O
COE	O
-	O
Col	O
-	O
DCpep	O
/	O
L393	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
compared	O
to	O
the	O
groups	O
of	O
mice	O
that	O
received	O
pPG	B-CHED
-	O
COE	O
-	O
Col	O
/	O
L393	O
and	O
pPG	B-CHED
-	O
COE	O
-	O
DCpep	O
/	O
L393	O
,	O
respectively	O
.	O

Here	O
we	O
report	O
the	O
homo	O
-	O
oligomerization	O
profile	O
of	O
full	O
-	O
length	O
recombinant	O
EBOV	O
VP35	O
(	O
rVP35	O
)	O
assessed	O
by	O
size	O
-	O
exclusion	O
chromatography	O
and	O
native	O
polyacrylamide	B-CHED
gel	O
electrophoresis	O
.	O

Specific	O
diagnosis	O
is	O
made	O
by	O
the	O
detection	O
of	O
ECoV	O
in	O
feces	O
by	O
either	O
quantitative	O
real	O
-	O
time	O
PCR	O
,	O
electron	O
microscopy	O
or	O
antigen	B-CHED
-	O
capture	O
ELISA	O
.	O

TITLE	O
:	O
An	O
Exploratory	O
Reanalysis	O
of	O
the	O
Randomized	O
Trial	O
on	O
Efficacy	O
of	O
Corticosteroids	B-CHED
as	O
Rescue	O
Therapy	O
for	O
the	O
Late	O
Phase	O
of	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
.	O

We	O
hypothesize	O
a	O
causal	O
relationship	O
between	O
protocol	O
-	O
driven	O
rapid	O
discontinuation	O
of	O
methylprednisolone	B-CHED
post	O
extubation	O
and	O
return	O
to	O
mechanical	O
ventilation	O
.	O

After	O
treatment	O
discontinuation	O
,	O
more	O
methylprednisolone	B-CHED
-	O
treated	O
patients	O
returned	O
to	O
mechanical	O
ventilation	O
(	O
26	O
.	O
6	O
%	O
vs	O
6	O
.	O
7	O
%;	O
risk	O
ratio	O
,	O
3	O
.	O
98	O
;	O
CI	O
,	O
1	O
.	O
24	O
-	O
12	O
.	O
79	O
)-	O
consistent	O
with	O
reconstituted	O
systemic	O
inflammation	O
in	O
the	O
presence	O
of	O
adrenal	O
suppression	O
.	O

During	O
active	O
intervention	O
,	O
methylprednisolone	B-CHED
was	O
safe	O
and	O
effective	O
in	O
achieving	O
disease	O
resolution	O
.	O

This	O
is	O
an	O
ancillary	O
study	O
of	O
the	O
ISAACC	O
study	O
,	O
which	O
is	O
a	O
multicentre	O
,	O
prospective	O
,	O
open	O
-	O
label	B-CHED
,	O
parallel	O
,	O
randomized	O
,	O
and	O
controlled	O
trial	O
(	O
NCT01335087	O
)	O
in	O
patients	O
with	O
hospital	O
admission	O
for	O
ACS	O
.	O

We	O
collected	O
demographic	O
data	O
and	O
physiologic	O
data	O
for	O
CPP	O
,	O
intracranial	O
pressure	O
,	O
mechanical	O
ventilation	O
,	O
cumulative	O
fluid	O
balance	B-CHED
and	O
delta	O
/	O
driving	O
pressure	O
(	O
ΔP	O
).	O

Unfortunately	O
,	O
detailed	O
structural	O
information	O
is	O
still	O
limited	O
for	O
SARS	O
-	O
CoV	O
E	O
,	O
and	O
non	O
-	O
existent	O
for	O
other	O
CoV	O
E	O
proteins	B-CHED
.	O

To	O
obtain	O
a	O
better	O
understanding	O
of	O
the	O
molecular	O
events	O
at	O
the	O
earliest	O
time	O
points	O
,	O
we	O
used	O
RNA	O
-	O
Seq	O
to	O
quantify	O
and	O
compare	O
the	O
host	O
mRNA	B-CHED
and	O
miRNA	O
transcriptomes	O
induced	O
by	O
the	O
highly	O
pathogenic	O
influenza	O
A	O
H5N1	O
(	O
A	O
/	O
Vietnam	O
/	O
3212	O
/	O
04	O
)	O
or	O
low	O
virulent	O
H1N1	O
(	O
A	O
/	O
Hong	O
Kong	O
/	O
54	O
/	O
98	O
)	O
viruses	O
in	O
human	O
monocyte	O
-	O
derived	O
macrophages	O
at	O
1	O
-,	O
3	O
-,	O
and	O
6	O
-	O
h	O
post	O
infection	O
.	O

They	O
also	O
express	O
their	O
3	O
'	O
region	O
proteins	B-CHED
from	O
a	O
nested	O
set	O
of	O
3	O
'	O
co	O
-	O
terminal	O
subgenomic	O
messenger	O
RNAs	O
(	O
sg	O
mRNAs	O
).	O

Confirmation	O
of	O
the	O
disease	O
relies	O
on	O
finding	O
appropriate	O
cytological	O
or	O
histopathological	O
changes	O
in	O
association	O
with	O
positive	O
immunostaining	O
for	O
FCoV	O
antigen	B-CHED
.	O

The	O
60	O
-	O
year	O
-	O
old	O
man	B-CHED
died	O
as	O
a	O
result	O
of	O
renal	O
and	O
respiratory	O
failure	O
after	O
admission	O
to	O
a	O
hospital	O
in	O
Jeddah	O
,	O
Saudi	O
Arabia	O
.	O

To	O
address	O
this	O
need	O
,	O
we	O
are	O
developing	O
a	O
subunit	O
recombinant	O
protein	B-CHED
vaccine	O
comprising	O
residues	O
377	O
-	O
588	O
of	O
the	O
MERS	O
-	O
CoV	O
spike	O
protein	B-CHED
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
),	O
which	O
,	O
when	O
formulated	O
with	O
the	O
AddaVax	O
adjuvant	B-CHED
,	O
it	O
induces	O
a	O
significant	O
neutralizing	O
antibody	O
response	O
and	O
protection	O
against	O
MERS	O
-	O
CoV	O
challenge	O
in	O
vaccinated	O
animals	O
.	O

In	O
this	O
study	O
,	O
we	O
designed	O
a	O
new	O
primer	O
set	O
to	O
amplify	O
a	O
668	O
bp	O
-	O
region	O
within	O
the	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRP	O
)	O
gene	O
that	O
encodes	O
the	O
most	O
conserved	O
protein	B-CHED
domain	O
of	O
α	O
-,	O
β	O
-,	O
γ	O
-,	O
and	O
δ	O
-	O
CoVs	O
.	O

The	O
rate	O
of	O
treatment	O
change	O
(	O
RTC	O
)	O
was	O
established	O
according	O
to	O
whether	O
the	O
OLB	O
pathology	O
report	O
resulted	O
in	O
:	O
a	O
)	O
the	O
prescription	O
or	O
discontinuation	O
of	O
an	O
antimicrobial	B-CHED
;	O
b	O
)	O
the	O
indication	O
of	O
new	O
procedures	O
;	O
c	O
)	O
medical	O
interconsultation	O
;	O
or	O
d	O
)	O
limitation	O
of	O
therapeutic	O
effort	O
.	O

TITLE	O
:	O
A	O
nano	O
silicon	B-CHED
adjuvant	B-CHED
enhances	O
inactivated	O
transmissible	O
gastroenteritis	O
vaccine	O
through	O
activation	O
the	O
Toll	O
-	O
like	O
receptors	O
and	O
promotes	O
humoral	O
and	O
cellular	O
immune	O
responses	O
.	O

Macrolides	B-CHED
are	O
antibiotics	B-CHED
with	O
potent	O
immunomodulatory	O
and	O
anti	O
-	O
inflammatory	O
effects	O
that	O
may	O
be	O
beneficial	O
in	O
ARDS	O
treatment	O
.	O

The	O
primary	O
outcome	O
was	O
90	O
-	O
day	O
mortality	O
,	O
and	O
the	O
secondary	O
analysis	O
assessed	O
the	O
effect	O
of	O
azithromycin	B-CHED
on	O
time	O
to	O
successful	O
discontinuation	O
of	O
mechanical	O
ventilation	O
and	O
28	O
-	O
day	O
mortality	O
.	O

Succinylcholine	B-CHED
1	O
.	O
0	O
mg	O
/	O
kg	O
or	O
rocuronium	B-CHED
1	O
.	O
0	O
-	O
1	O
.	O
2	O
mg	O
/	O
kg	O
should	O
be	O
administered	O
to	O
achieve	O
excellent	O
intubation	O
conditions	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
VICC	O
with	O
MIT	B-CHED
,	O
in	O
terms	O
of	O
accuracy	O
,	O
biosafety	O
and	O
occupational	O
health	O
,	O
supply	O
and	O
equipment	O
costs	O
,	O
bioethics	O
and	O
animal	O
welfare	O
,	O
in	O
a	O
Brazilian	O
public	O
health	O
lab	O
.	O

Here	O
,	O
we	O
show	O
that	O
MHV	O
-	O
A59	O
S	O
protein	B-CHED
is	O
triggered	O
by	O
pH	O
8	O
.	O
0	O
at	O
37	O
°	O
C	O
to	O
induce	O
receptor	O
-	O
independent	O
syncytium	O
(	O
RIS	O
)	O
formation	O
on	O
293T	O
cells	O
,	O
and	O
that	O
the	O
conformational	O
changes	O
in	O
S	O
proteins	B-CHED
triggered	O
by	O
pH	O
8	O
.	O
0	O
are	O
very	O
similar	O
to	O
those	O
triggered	O
by	O
receptor	O
binding	O
.	O

We	O
systemically	O
mutated	O
each	O
of	O
15	O
histidine	B-CHED
residues	O
in	O
S	O
protein	B-CHED
and	O
found	O
that	O
H209	O
is	O
essential	O
for	O
pH	O
8	O
.	O
0	O
-	O
triggered	O
RIS	O
formation	O
,	O
while	O
H179	O
,	O
H441	O
,	O
H643	O
,	O
and	O
H759	O
also	O
play	O
important	O
roles	O
in	O
this	O
process	O
.	O

Further	O
studies	O
showed	O
that	O
TGEV	O
nsp7	O
protein	B-CHED
had	O
no	O
effect	O
on	O
GRP78	O
expression	O
,	O
could	O
not	O
induce	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
stress	O
and	O
activate	O
NF	O
-	O
κB	O
activity	O
.	O

Interestingly	O
,	O
the	O
IECs	O
expressing	O
nsp7	O
protein	B-CHED
secreted	O
lower	O
levels	O
of	O
IL	O
-	O
8	O
than	O
control	O
cells	O
.	O

TITLE	O
:	O
The	O
use	O
of	O
complementary	O
and	O
alternative	O
medicine	B-CHED
by	O
patients	O
with	O
cancer	O
:	O
a	O
cross	O
-	O
sectional	O
survey	O
in	O
Saudi	O
Arabia	O
.	O

TITLE	O
:	O
Addressing	O
the	O
selectivity	O
and	O
toxicity	O
of	O
antiviral	B-CHED
nucleosides	B-CHED
.	O

ABSTRACT	O
:	O
Nucleoside	B-CHED
and	O
nucleotide	B-CHED
analogs	O
have	O
played	O
significant	O
roles	O
in	O
antiviral	B-CHED
therapies	O
and	O
are	O
valued	O
for	O
their	O
impressive	O
potency	O
and	O
high	O
barrier	O
to	O
resistance	O
.	O

ABSTRACT	O
:	O
Respiratory	O
virus	O
infection	O
(	O
RVI	O
)	O
in	O
pediatric	O
solid	O
organ	O
transplant	O
(	O
SOT	O
)	O
recipients	O
poses	O
a	O
significant	O
risk	O
;	O
however	O
,	O
the	O
epidemiology	O
and	O
effects	O
of	O
an	O
RVI	O
after	O
pediatric	O
SOT	O
in	O
the	O
era	B-CHED
of	O
current	O
molecular	O
diagnostic	O
assays	O
are	O
unclear	O
.	O

TITLE	O
:	O
Structure	O
-	O
guided	O
design	O
of	O
potent	O
and	O
permeable	O
inhibitors	B-CHED
of	O
MERS	O
coronavirus	O
3CL	O
protease	O
that	O
utilize	O
a	O
piperidine	B-CHED
moiety	O
as	O
a	O
novel	O
design	O
element	O
.	O

In	O
patients	O
with	O
ACS	O
,	O
the	O
rates	O
of	O
MACEs	O
and	O
NACEs	O
were	O
not	O
significantly	O
lower	O
with	O
bivalirudin	B-CHED
than	O
with	O
UFH	O
,	O
irrespective	O
of	O
planned	O
GPI	B-CHED
use	O
.	O

TITLE	O
:	O
Antiviral	B-CHED
effect	O
of	O
lithium	B-CHED
chloride	I-CHED
on	O
porcine	O
epidemic	O
diarrhea	O
virus	O
in	O
vitro	O
.	O

Real	O
-	O
time	O
quantitative	O
PCR	O
and	O
indirect	O
immunofluorescence	O
assay	O
indicated	O
that	O
LiCl	B-CHED
effectively	O
inhibited	O
the	O
entry	O
and	O
replication	O
of	O
PEDV	O
in	O
Vero	O
cells	O
.	O

HIV	O
/	O
AIDS	O
,	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
and	O
the	O
more	O
recent	O
H1N1	O
influenza	O
are	O
only	O
a	O
few	O
of	O
the	O
numerous	O
examples	O
of	O
emerging	O
infectious	O
diseases	O
in	O
the	O
modern	O
era	B-CHED
.	O

ABSTRACT	O
:	O
Disseminated	O
intravascular	O
coagulations	O
(	O
DIC	B-CHED
),	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
and	O
acute	O
kidney	O
injury	O
(	O
AKI	O
)	O
are	O
major	O
organ	O
dysfunctions	O
that	O
occur	O
in	O
patients	O
with	O
sepsis	O
.	O

DIC	B-CHED
(	O
hazard	O
ratio	O
2	O
.	O
58	O
,	O
95	O
%	O
CI	O
1	O
.	O
53	O
-	O
4	O
.	O
55	O
)	O
and	O
AKI	O
stage	O
3	O
(	O
hazard	O
ratio	O
1	O
.	O
73	O
,	O
95	O
%	O
CI	O
1	O
.	O
07	O
-	O
2	O
.	O
80	O
)	O
were	O
also	O
significantly	O
associated	O
with	O
longer	O
survival	O
durations	O
.	O

We	O
found	O
that	O
imatinib	B-CHED
and	O
two	O
specific	O
Abl	B-CHED
kinase	O
inhibitors	B-CHED
,	O
GNF2	O
and	O
GNF5	O
,	O
reduce	O
IBV	O
titres	O
by	O
blocking	O
the	O
first	O
round	O
of	O
virus	O
infection	O
.	O

The	O
beneficial	O
effect	O
of	O
high	O
levels	O
of	O
positive	O
end	O
-	O
expiratory	O
pressure	O
and	O
prone	O
positioning	O
has	O
still	O
to	O
be	O
elucidated	O
in	O
AE	O
-	O
IPF	O
patients	O
,	O
as	O
well	O
as	O
the	O
precise	O
role	O
of	O
other	O
types	O
of	O
respiratory	O
assistance	O
(	O
e	O
.	O
g	O
.,	O
extracorporeal	O
membrane	O
oxygenation	O
)	O
or	O
innovative	O
therapies	O
(	O
e	O
.	O
g	O
.,	O
polymyxin	B-CHED
-	O
B	O
direct	O
hemoperfusion	O
).	O

Severity	O
of	O
infection	O
ranges	O
from	O
mild	O
,	O
self	O
-	O
limited	O
,	O
febrile	O
viral	O
-	O
like	O
illness	O
accompanied	O
by	O
nonspecific	O
symptoms	O
to	O
life	O
-	O
threatening	O
infection	O
complicated	O
by	O
severe	O
hemolytic	O
anemia	O
,	O
disseminated	O
intravascular	O
coagulation	O
(	O
DIC	B-CHED
),	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
and	O
renal	O
or	O
/	O
and	O
hepatic	O
failure	O
.	O

The	O
viruses	O
detected	O
most	O
frequently	O
in	O
either	O
diarrheic	O
or	O
nondiarrheic	O
dog	O
feces	O
were	O
CPV	O
-	O
2	O
(	O
54	O
.	O
3	O
%	O
of	O
the	O
positive	O
samples	O
),	O
CDV	B-CHED
(	O
45	O
.	O
1	O
%)	O
and	O
CCoV	O
(	O
30	O
.	O
4	O
%),	O
followed	O
by	O
CRV	O
(	O
8	O
.	O
2	O
%)	O
and	O
CAdV	O
(	O
4	O
.	O
9	O
%).	O

To	O
better	O
capture	O
this	O
scenario	O
,	O
we	O
provide	O
a	O
comprehensive	O
characterization	O
of	O
models	O
of	O
ALI	O
combining	O
two	O
injuries	O
:	O
intra	O
tracheal	O
(	O
i	O
.	O
t	O
.)	O
instillation	O
of	O
LPS	B-CHED
or	O
hypochloric	B-CHED
acid	I-CHED
(	O
HCl	B-CHED
)	O
followed	O
by	O
ventilator	O
-	O
induced	O
lung	O
injury	O
(	O
VILI	O
).	O

Phyto	O
-	O
constituents	O
such	O
as	O
afzelin	O
,	O
hyperoside	B-CHED
and	O
quercitrin	B-CHED
have	O
shown	O
to	O
reduce	O
inflammation	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
models	O
.	O

PEDV	O
and	O
PDCoV	O
data	O
stored	O
in	O
the	O
industry	O
DCP	B-CHED
database	O
were	O
imported	O
into	O
the	O
R	O
statistical	O
software	O
and	O
analysed	O
to	O
produce	O
weekly	O
frequency	O
of	O
incidence	O
counts	O
and	O
prevalence	O
counts	O
,	O
in	O
addition	O
to	O
yearly	O
herd	O
-	O
level	O
incidence	O
risk	O
and	O
prevalence	O
between	O
2014	O
and	O
2016	O
.	O

TITLE	O
:	O
Extravascular	O
lung	O
water	B-CHED
measurements	O
in	O
acute	O
respiratory	O
distress	O
syndrome	O
:	O
why	O
,	O
how	O
,	O
and	O
when	O
?	O

Television	O
and	O
radio	B-CHED
were	O
the	O
primary	O
sources	O
of	O
outbreak	O
information	O
regardless	O
of	O
socio	O
-	O
demographic	O
factors	O
.	O

TITLE	O
:	O
Enhanced	O
protection	O
in	O
mice	O
induced	O
by	O
immunization	O
with	O
inactivated	O
whole	O
viruses	O
compare	O
to	O
spike	O
protein	B-CHED
of	O
middle	O
east	O
respiratory	O
syndrome	O
coronavirus	O
.	O

Similar	O
levels	O
of	O
the	O
anti	O
-	O
S	O
protein	B-CHED
IgG	O
response	O
and	O
neutralizing	O
activity	O
were	O
induced	O
by	O
both	O
the	O
S	O
protein	B-CHED
and	O
IV	O
vaccines	O
.	O

In	O
addition	O
,	O
immune	O
responses	O
against	O
three	O
other	O
structural	O
proteins	B-CHED
,	O
the	O
envelope	O
(	O
E	O
),	O
membrane	O
(	O
M	O
),	O
and	O
nucleocapsid	O
(	O
N	O
)	O
proteins	B-CHED
,	O
were	O
also	O
detected	O
in	O
sera	O
of	O
mice	O
that	O
received	O
IV	O
.	O

Clinical	O
course	O
,	O
complications	O
,	O
antifungal	B-CHED
therapy	O
and	O
outcome	O
are	O
reviewed	O
.	O

A	O
≥	O
5	O
log	O
PVP	B-CHED
-	O
I	O
gargle	O
/	O
mouthwash	O
diluted	O
1	O
:	O
30	O
(	O
equivalent	O
to	O
a	O
concentration	O
of	O
0	O
.	O
23	O
%	O
PVP	B-CHED
-	O
I	O
)	O
showed	O
effective	O
bactericidal	O
activity	O
against	O
Klebsiella	O
pneumoniae	O
and	O
Streptococcus	O
pneumoniae	O
and	O
rapidly	O
inactivated	O
SARS	O
-	O
CoV	O
,	O
MERS	O
-	O
CoV	O
,	O
influenza	O
virus	O
A	O
(	O
H1N1	O
)	O
and	O
rotavirus	O
after	O
15	O
s	O
of	O
exposure	O
.	O

RESULTS	O
:	O
PVP	B-CHED
-	O
I	O
gargle	O
/	O
mouthwash	O
diluted	O
1	O
:	O
30	O
(	O
equivalent	O
to	O
a	O
concentration	O
of	O
0	O
.	O
23	O
%	O
PVP	B-CHED
-	O
I	O
)	O
showed	O
effective	O
bactericidal	O
activity	O
against	O
Klebsiella	O
pneumoniae	O
and	O
Streptococcus	O
pneumoniae	O
and	O
rapidly	O
inactivated	O
SARS	O
-	O
CoV	O
,	O
MERS	O
-	O
CoV	O
,	O
influenza	O
virus	O
A	O
(	O
H1N1	O
)	O
and	O
rotavirus	O
after	O
15	O
s	O
of	O
exposure	O
.	O

CONCLUSIONS	O
:	O
PVP	B-CHED
-	O
I	O
7	O
%	O
gargle	O
/	O
mouthwash	O
showed	O
rapid	O
bactericidal	O
activity	O
and	O
virucidal	O
efficacy	O
in	O
vitro	O
at	O
a	O
concentration	O
of	O
0	O
.	O
23	O
%	O
PVP	B-CHED
-	O
I	O
and	O
may	O
provide	O
a	O
protective	O
oropharyngeal	O
hygiene	O
measure	O
for	O
individuals	O
at	O
high	O
risk	O
of	O
exposure	O
to	O
oral	O
and	O
respiratory	O
pathogens	O
.	O

TITLE	O
:	O
Resiquimod	B-CHED
enhances	O
mucosal	O
and	O
systemic	O
immunity	O
against	O
avian	O
infectious	O
bronchitis	O
virus	O
vaccine	O
in	O
the	O
chicken	O
.	O

Model	O
studies	O
showed	O
that	O
the	O
inhibition	O
of	O
surfactant	B-CHED
was	O
due	O
to	O
both	O
elevated	O
cholesterol	B-CHED
and	O
an	O
interaction	O
between	O
cholesterol	B-CHED
and	O
oxidized	B-CHED
phospholipids	I-CHED
.	O

Survivors	O
had	O
higher	O
levels	O
for	O
each	O
of	O
these	O
lipids	B-CHED
except	O
for	O
five	O
membrane	O
lipids	B-CHED
.	O

ABSTRACT	O
:	O
A	O
series	O
of	O
tripeptidic	O
acylsulfonamide	O
inhibitors	B-CHED
of	O
HCV	O
NS3	O
protease	O
were	O
prepared	O
that	O
explored	O
structure	O
-	O
activity	O
relationships	O
(	O
SARs	O
)	O
at	O
the	O
P4	O
position	O
,	O
and	O
their	O
in	O
vitro	O
and	O
in	O
vivo	O
properties	O
were	O
evaluated	O
.	O

The	O
former	O
approach	O
provided	O
a	O
series	O
of	O
regioisomeric	O
N	O
-	O
methylated	O
ureas	B-CHED
while	O
the	O
latter	O
gave	O
rise	O
to	O
P4	O
reverse	O
carbamates	B-CHED
,	O
both	O
of	O
which	O
retained	O
potent	O
NS3	O
inhibitory	O
properties	O
while	O
relying	O
upon	O
an	O
alternative	O
H	O
-	O
bond	O
donor	B-CHED
topology	O
.	O

Here	O
we	O
unraveled	O
a	O
novel	O
escape	O
strategy	O
involving	O
Theiler	O
'	O
s	O
murine	O
encephalomyelitis	O
virus	O
(	O
TMEV	O
)	O
L	O
*	O
protein	B-CHED
.	O

ABSTRACT	O
:	O
Air	B-CHED
pollution	O
has	O
been	O
associated	O
with	O
increased	O
mortality	O
and	O
morbidity	O
in	O
several	O
studies	O
with	O
indications	O
that	O
its	O
effect	O
could	O
be	O
more	O
severe	O
in	O
children	O
.	O

In	O
experiments	O
in	O
vitro	O
,	O
three	O
human	O
APOBEC3	O
proteins	B-CHED
(	O
A3C	O
,	O
A3F	O
and	O
A3H	O
)	O
inhibited	O
HCoV	O
-	O
NL63	O
infection	O
and	O
limited	O
production	O
of	O
progeny	O
virus	O
,	O
but	O
did	O
not	O
cause	O
hypermutation	O
of	O
the	O
coronaviral	O
genome	O
.	O

Independent	O
predictors	O
of	O
MERS	O
-	O
CoV	O
infection	O
were	O
identified	O
,	O
including	O
chest	O
pain	O
(	O
OR	O
=	O
24	O
.	O
194	O
;	O
P	O
=	O
0	O
.	O
011	O
),	O
leukopenia	O
(	O
OR	O
=	O
6	O
.	O
080	O
;	O
P	O
=	O
0	O
.	O
049	O
),	O
and	O
elevated	O
aspartate	B-CHED
aminotransferase	O
(	O
AST	O
)	O
(	O
OR	O
=	O
11	O
.	O
179	O
;	O
P	O
=	O
0	O
.	O
013	O
).	O

Although	O
the	O
prevalence	O
of	O
carbapenem	B-CHED
resistance	O
was	O
high	O
in	O
Turkish	O
ICUs	O
,	O
it	O
was	O
not	O
associated	O
with	O
a	O
higher	O
risk	O
for	O
mortality	O
.	O

We	O
collected	O
1	O
-	O
3	O
samples	O
(	O
n	O
=	O
250	O
specimens	O
)	O
from	O
176	O
participants	O
between	O
October	O
2012	O
and	O
January	O
17	O
,	O
2013	O
:	O
participants	O
with	O
acute	O
respiratory	O
infection	O
(	O
ARI	B-CHED
;	O
cough	O
and	O
body	O
aches	O
or	O
chills	O
or	O
fever	O
/	O
feverishness	O
)	O
and	O
their	O
social	O
contacts	O
.	O

During	O
a	O
period	O
of	O
108	O
weeks	O
,	O
a	O
total	O
of	O
6955	O
(	O
5598	O
pediatric	O
and	O
1257	O
adult	O
)	O
patients	O
underwent	O
RV	O
PCR	O
tests	O
for	O
ARI	B-CHED
;	O
most	O
of	O
these	O
tests	O
were	O
administered	O
while	O
the	O
patients	O
were	O
admitted	O
(	O
n	O
=	O
6	O
,	O
920	O
;	O
99	O
.	O
5	O
%).	O

In	O
addition	O
,	O
education	O
,	O
vitamin	B-CHED
D	I-CHED
intake	O
and	O
family	O
history	O
of	O
urolithiasis	O
are	O
all	O
protective	O
factors	O
(	O
OR	O
<	O
1	O
).	O

TITLE	O
:	O
Transmembrane	O
Domains	O
of	O
Highly	O
Pathogenic	O
Viral	O
Fusion	O
Proteins	B-CHED
Exhibit	O
Trimeric	O
Association	O
ABSTRACT	O
:	O
Enveloped	O
viruses	O
require	O
viral	O
fusion	O
proteins	B-CHED
to	O
promote	O
fusion	O
of	O
the	O
viral	O
envelope	O
with	O
a	O
target	O
cell	O
membrane	O
.	O

To	O
drive	O
fusion	O
,	O
these	O
proteins	B-CHED
undergo	O
large	O
conformational	O
changes	O
that	O
must	O
occur	O
at	O
the	O
right	O
place	O
and	O
at	O
the	O
right	O
time	O
.	O

Regarding	O
the	O
Injury	O
Severity	O
Score	O
and	O
Abbreviated	O
Injury	O
Scale	O
(	O
AIS	O
),	O
there	O
were	O
no	O
significant	O
differences	O
between	O
the	O
groups	O
,	O
except	O
for	O
the	O
AIS	O
In	O
polytraumatized	O
patients	O
,	O
entrapment	O
has	O
a	O
minor	O
influence	O
on	O
the	O
outcome	O
and	O
treatment	O
in	O
the	O
prehospital	O
and	O
hospital	O
setting	O
when	O
using	O
physician	O
-	O
based	O
air	B-CHED
rescue	O
.	O

Our	O
patient	O
received	O
frequent	O
boluses	O
of	O
albumin	O
for	O
intermittent	O
circuit	O
chugging	O
contributing	O
to	O
a	O
net	O
positive	O
fluid	O
balance	B-CHED
of	O
roughly	O
6	O
liters	O
4	O
days	O
after	O
cannulation	O
.	O

Clinical	O
presentation	O
was	O
CMI	O
in	O
48	O
patients	O
(	O
74	O
%)	O
and	O
AMI	B-CHED
or	O
acute	O
-	O
on	O
-	O
CMI	O
in	O
17	O
(	O
26	O
%).	O

Results	O
showed	O
that	O
the	O
PACT	O
device	O
could	O
inactivate	O
FCV	B-CHED
,	O
which	O
passed	O
through	O
the	O
plasma	O
chamber	O
.	O

Of	O
the	O
46	O
patients	O
who	O
met	B-CHED
the	O
criteria	O
for	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
ECMO	O
consideration	O
,	O
5	O
received	O
ECMO	O
and	O
16	O
patients	O
had	O
at	O
least	O
1	O
contraindication	O
to	O
it	O
.	O

The	O
remaining	O
25	O
patients	O
met	B-CHED
ECMO	O
criteria	O
but	O
did	O
not	O
receive	O
the	O
treatment	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
immunogenicity	O
of	O
an	O
orf	O
virus	O
(	O
ORFV	O
)	O
vector	O
expressing	O
the	O
full	O
-	O
length	O
spike	O
(	O
S	O
)	O
protein	B-CHED
of	O
PEDV	O
(	O
ORFV	O
-	O
PEDV	O
-	O
S	O
)	O
in	O
pregnant	O
gilts	O
and	O
its	O
ability	O
to	O
confer	O
passive	O
immunity	O
and	O
protection	O
in	O
piglets	O
.	O

Despite	O
evidence	O
-	O
based	O
guidelines	O
,	O
antibiotics	B-CHED
are	O
still	O
commonly	O
used	O
to	O
treat	O
infections	O
likely	O
caused	O
by	O
respiratory	O
viruses	O
.	O

Patients	O
assigned	O
to	O
ventilation	O
with	O
low	O
PEEP	B-CHED
will	O
receive	O
the	O
lowest	O
possible	O
PEEP	B-CHED
between	O
0	O
and	O
5	O
cm	O
H	O
RELAx	O
will	O
be	O
the	O
first	O
sufficiently	O
sized	O
randomized	O
controlled	O
trial	O
in	O
invasively	O
ventilated	O
,	O
critically	O
ill	O
patients	O
with	O
uninjured	O
lungs	O
using	O
a	O
clinically	O
relevant	O
and	O
objective	O
endpoint	O
to	O
determine	O
whether	O
invasive	O
,	O
low	O
-	O
tidal	O
-	O
volume	O
ventilation	O
with	O
low	O
PEEP	B-CHED
is	O
noninferior	O
to	O
ventilation	O
with	O
high	O
PEEP	B-CHED
.	O

Although	O
several	O
vaccine	O
candidates	O
have	O
been	O
developed	O
,	O
there	O
is	O
still	O
no	O
clinically	O
available	O
vaccine	O
for	O
MERS	O
-	O
CoV	O
.	O
In	O
this	O
study	O
,	O
we	O
developed	O
two	O
types	O
of	O
MERS	O
-	O
CoV	O
vaccines	O
:	O
a	O
recombinant	O
adenovirus	O
serotype	O
5	O
encoding	O
the	O
MERS	O
-	O
CoV	O
spike	O
gene	O
(	O
Ad5	O
/	O
MERS	O
)	O
and	O
spike	O
protein	B-CHED
nanoparticles	B-CHED
formulated	O
with	O
aluminum	B-CHED
(	O
alum	O
)	O
adjuvant	B-CHED
.	O

Interestingly	O
,	O
Th1	O
cell	O
activation	O
was	O
induced	O
by	O
immunization	O
schedules	O
including	O
Ad5	O
/	O
MERS	O
,	O
but	O
not	O
by	O
those	O
including	O
only	O
spike	O
protein	B-CHED
nanoparticles	B-CHED
.	O

Thus	O
,	O
heterologous	O
prime	O
-	O
boost	O
may	O
induce	O
longer	O
-	O
lasting	O
immune	O
responses	O
against	O
MERS	O
-	O
CoV	O
because	O
of	O
an	O
appropriate	O
balance	B-CHED
of	O
Th1	O
/	O
Th2	O
responses	O
.	O

RESULTS	O
:	O
DTI	O
quantified	O
diffusion	O
alterations	O
in	O
the	O
corpus	O
callosum	O
and	O
corona	B-CHED
radiata	O
(	O
MD	O
increased	O
significantly	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
chronic	O
axonal	O
injury	O
in	O
the	O
corpus	O
callosum	O
,	O
corona	B-CHED
radiata	O
,	O
internal	O
capsule	O
,	O
external	O
capsule	O
,	O
posterior	O
thalamic	O
radiation	O
,	O
sagittal	O
stratum	O
,	O
and	O
superior	O
longitudinal	O
fasciculus	O
(	O
AD	O
increased	O
significantly	O
,	O
P	O
<	O
0	O
.	O
05	O
).	O

In	O
sputum	O
and	O
transtracheal	O
aspirate	O
,	O
sub	O
-	O
genomic	O
mRNA	B-CHED
was	O
detected	O
for	O
up	O
to	O
4	O
weeks	O
after	O
symptoms	O
developed	O
,	O
which	O
correlated	O
with	O
the	O
detection	O
of	O
genomic	O
RNA	O
.	O

Although	O
a	O
definite	O
diagnosis	O
cannot	O
be	O
achieved	O
on	O
the	O
basis	O
of	O
imaging	O
features	O
alone	O
,	O
recognition	O
of	O
viral	O
pneumonia	O
patterns	O
may	O
aid	O
in	O
differentiating	O
viral	O
pathogens	O
,	O
thus	O
reducing	O
the	O
use	O
of	O
antibiotics	B-CHED
.	O

Despite	O
the	O
insertion	O
of	O
two	O
surgical	O
drains	O
and	O
two	O
exploratory	O
laparotomies	O
in	O
which	O
no	O
obvious	O
intestinal	O
perforation	O
was	O
noted	O
,	O
the	O
free	O
air	B-CHED
in	O
the	O
abdomen	O
reaccumulated	O
.	O

Although	O
FSCD	O
has	O
been	O
reported	O
extensively	O
,	O
this	O
case	O
is	O
noteworthy	O
for	O
the	O
presence	O
of	O
suppurative	O
pancreatitis	O
and	O
the	O
positive	O
long	O
-	O
term	O
outcome	O
after	O
corticosteroid	B-CHED
therapy	O
.	O

A	O
total	O
of	O
133	O
calves	O
,	O
enrolled	O
at	O
24	O
to	O
72	O
h	O
of	O
age	O
,	O
received	O
a	O
daily	O
dose	O
of	O
0	O
.	O
96	O
g	O
of	O
egg	O
yolk	O
powder	O
with	O
anti	O
-	O
IL	O
-	O
10	O
antibodies	O
(	O
MAB	O
,	O
n	O
=	O
71	O
)	O
or	O
without	O
anti	O
-	O
IL	O
-	O
10	O
antibodies	O
(	O
MEP	B-CHED
,	O
n	O
=	O
62	O
)	O
split	O
between	O
2	O
feedings	O
for	O
the	O
first	O
11	O
d	O
on	O
feed	O
at	O
a	O
calf	O
ranch	O
.	O

On	O
d	O
56	O
,	O
the	O
risk	O
of	O
respiratory	O
disease	O
was	O
lower	O
for	O
MAB	O
compared	O
with	O
MEP	B-CHED
(	O
RR	O
=	O
0	O
.	O
40	O
;	O
confidence	O
interval	O
=	O
0	O
.	O
16	O
-	O
0	O
.	O
99	O
).	O

Total	O
health	O
score	O
,	O
diarrhea	O
days	O
,	O
average	O
respiratory	O
score	O
,	O
packed	O
cell	O
volume	O
,	O
and	O
serum	O
total	O
protein	B-CHED
were	O
not	O
affected	O
by	O
feeding	O
anti	O
-	O
IL	O
-	O
10	O
egg	O
antibodies	O
.	O

Male	O
C57BL	O
/	O
6	O
J	O
mice	O
were	O
intratracheally	O
injected	O
with	O
LPS	B-CHED
to	O
induce	O
ALI	O
.	O

The	O
mouse	O
macrophage	O
cell	O
line	O
(	O
J774	O
A	O
.	O
1	O
)	O
was	O
incubated	O
with	O
LPS	B-CHED
and	O
ATP	B-CHED
,	O
with	O
or	O
without	O
PFD	B-CHED
pre	O
-	O
treatment	O
.	O

In	O
vitro	O
,	O
the	O
experiments	O
revealed	O
that	O
PFD	B-CHED
significantly	O
suppressed	O
LPS	B-CHED
/	O
ATP	B-CHED
-	O
induced	O
production	O
of	O
reactive	B-CHED
oxygen	I-CHED
species	I-CHED
(	O
ROS	B-CHED
)	O
and	O
decreased	O
caspase	O
-	O
1	O
activation	O
and	O
the	O
level	O
of	O
IL	O
-	O
1β	O
in	O
J774	O
A	O
.	O
1	O
cells	O
.	O

TITLE	O
:	O
HCoV	O
-	O
229E	O
spike	O
protein	B-CHED
fusion	O
activation	O
by	O
trypsin	O
-	O
like	O
serine	B-CHED
proteases	O
is	O
mediated	O
by	O
proteolytic	O
processing	O
in	O
the	O
S2	O
'	O
region	O
.	O

Like	O
other	O
coronaviruses	O
,	O
HCoV	O
-	O
229E	O
exploits	O
cellular	O
proteases	O
to	O
activate	O
fusion	O
mediated	O
by	O
the	O
spike	O
protein	B-CHED
.	O

TITLE	O
:	O
Acetylcholine	B-CHED
receptor	O
antagonists	B-CHED
in	O
acute	O
respiratory	O
distress	O
syndrome	O
:	O
much	O
more	O
than	O
muscle	B-CHED
relaxants	I-CHED
.	O

ABSTRACT	O
:	O
Acetylcholine	B-CHED
receptor	O
antagonists	B-CHED
have	O
been	O
shown	O
to	O
improve	O
outcome	O
in	O
patients	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

It	O
is	O
nearly	O
12	O
times	O
more	O
potent	O
in	O
our	O
initial	O
in	O
vitro	O
visual	O
assay	O
(	O
EC50	O
:	O
>	O
1	O
µg	O
/	O
ml	O
)	O
and	O
nearly	O
8	O
times	O
more	O
potent	O
in	O
neutral	O
red	O
assay	O
(	O
EC50	O
:	O
>	O
1	O
.	O
3	O
µg	O
/	O
ml	O
)	O
compared	O
to	O
the	O
standard	O
drug	O
Ribavirin	B-CHED
(	O
EC50	O
:	O
12	O
µg	O
/	O
ml	O
;	O
visual	O
assay	O
and	O
EC50	O
:	O
9	O
.	O
9	O
µg	O
/	O
ml	O
;	O
neutral	O
red	O
assay	O
)	O
towards	O
Tacaribe	O
virus	O
(	O
TCRV	O
).	O

A	O
culture	O
system	O
for	O
the	O
production	O
of	O
MERS	O
coronavirus	O
-	O
like	O
particles	O
(	O
MERS	O
VLPs	O
)	O
was	O
determined	O
and	O
established	O
by	O
electron	O
microscopy	O
and	O
the	O
detection	O
of	O
coexpressed	O
viral	O
structural	O
proteins	B-CHED
.	O

ABSTRACT	O
:	O
The	O
data	O
characterizing	O
spontaneous	O
infections	O
of	O
Old	O
World	O
monkeys	O
:	O
measles	O
,	O
poliomyelitis	O
,	O
hepatitis	O
A	O
(	O
HPA	B-CHED
),	O
encephalomyocarditis	O
,	O
coronavirus	O
infection	O
,	O
simian	O
hemorrhagic	O
fever	O
(	O
SHF	O
),	O
are	O
presented	O
.	O

The	O
efficiency	O
of	O
poliomyelitis	O
,	O
measles	O
and	O
HPA	B-CHED
vaccines	O
is	O
shown	O
.	O

Taking	O
advantage	O
of	O
this	O
,	O
C6	O
was	O
further	O
applied	O
to	O
detect	O
the	O
S	O
protein	B-CHED
expression	O
in	O
vitro	O
by	O
fluorescence	O
staining	O
.	O

Meanwhile	O
,	O
the	O
coiled	O
-	O
coil	O
-	O
forming	O
Leu	B-CHED
/	O
Ile	B-CHED
heptad	O
repeat	O
sequences	O
within	O
the	O
S	O
protein	B-CHED
were	O
under	O
-	O
represented	O
during	O
peptide	B-CHED
array	O
scanning	O
,	O
in	O
agreement	O
with	O
that	O
long	O
peptide	B-CHED
lengths	O
were	O
required	O
to	O
attain	O
high	O
helix	O
-	O
mediated	O
interaction	O
avidity	O
.	O

To	O
date	O
,	O
there	O
is	O
a	O
lack	O
of	O
a	O
direct	O
evidence	O
for	O
the	O
interaction	O
between	O
pAPN	O
and	O
PEDV	O
S	O
protein	B-CHED
in	O
vitro	O
.	O

We	O
investigated	O
its	O
interactions	O
with	O
3	O
chlorine	B-CHED
disinfectants	B-CHED
to	O
determine	O
if	O
the	O
additive	O
would	O
adversely	O
affect	O
the	O
disinfectants	B-CHED
'	O
antimicrobial	B-CHED
efficacy	O
or	O
skin	O
safety	O
.	O

Against	O
human	O
coronavirus	O
229E	O
,	O
0	O
.	O
5	O
%	O
sodium	O
hypochlorite	B-CHED
alone	O
failed	O
disinfection	O
success	O
criteria	O
,	O
whereas	O
0	O
.	O
5	O
%	O
sodium	O
hypochlorite	B-CHED
with	O
color	O
additive	O
achieved	O
full	O
viral	O
inactivation	O
(≥	O
4	O
.	O
50	O
log	O
This	O
color	O
additive	O
can	O
be	O
combined	O
with	O
chlorine	B-CHED
disinfectants	B-CHED
without	O
adversely	O
affecting	O
antimicrobial	B-CHED
efficacy	O
or	O
skin	O
safety	O
.	O

ABSTRACT	O
:	O
Chimeric	O
antigen	B-CHED
receptor	O
(	O
CAR	O
)	O
therapy	O
targeting	O
CD19	O
is	O
an	O
effective	O
treatment	O
for	O
refractory	O
B	O
cell	O
malignancies	O
,	O
especially	O
acute	O
lymphoblastic	O
leukemia	O
(	O
ALL	O
)	O

Regarding	O
perioperative	O
administration	O
of	O
sivelestat	O
sodium	B-CHED
hydrate	I-CHED
,	O
the	O
postoperative	O
arterial	O
oxygen	B-CHED
partial	O
pressure	O
-	O
to	O
-	O
fractional	O
inspired	O
oxygen	B-CHED
ratio	O
(	O
P	O
/	O
F	O
)	O
and	O
C	O
-	O
reactive	O
protein	B-CHED
(	O
CRP	O
)	O
levels	O
in	O
the	O
administration	O
group	O
were	O
significantly	O
better	O
than	O
those	O
in	O
the	O
non	O
-	O
administration	O
group	O
on	O
postoperative	O
days	O
4	O
(	O
P	O
=	O
0	O
.	O
035	O
)	O
and	O
5	O
(	O
P	O
=	O
0	O
.	O
037	O
),	O
respectively	O
.	O

Genome	O
comparison	O
with	O
extant	O
global	O
PEDV	O
strains	O
revealed	O
a	O
high	O
nucleotide	B-CHED
identity	O
with	O
recently	O
reported	O
European	O
and	O
American	O
S	O
-	O
INDEL	O
PEDVs	O
.	O

RESULTS	O
:	O
Baseline	O
characteristics	O
indicated	O
that	O
APACHE	O
-	O
III	O
score	O
to	O
be	O
lower	O
in	O
statin	B-CHED
users	O
,	O
suggesting	O
some	O
beneficial	O
effects	O
.	O

Interestingly	O
,	O
in	O
parallel	O
silvestrol	B-CHED
affects	O
the	O
activity	O
of	O
the	O
antiviral	B-CHED
major	O
vault	O
protein	B-CHED
(	O
MVP	O
)	O
by	O
translocation	O
from	O
the	O
cytoplasm	O
to	O
the	O
perinuclear	O
membrane	O
.	O

TITLE	O
:	O
Could	O
Heme	B-CHED
Oxygenase	O
-	O
1	O
Be	O
a	O
New	O
Target	O
for	O
Therapeutic	O
Intervention	O
in	O
Malaria	O
-	O
Associated	O
Acute	O
Lung	O
Injury	O
/	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
?	O

Here	O
we	O
describe	O
a	O
few	O
general	O
methods	O
to	O
isolate	O
and	O
study	O
the	O
VNP	O
-	O
protein	B-CHED
corona	B-CHED
complexes	O
,	O
in	O
order	O
to	O
evaluate	O
the	O
impact	O
of	O
protein	B-CHED
corona	B-CHED
on	O
molecular	O
recognition	O
of	O
VNPs	O
by	O
target	O
cells	O
,	O
and	O
clearance	O
by	O
phagocytes	O
.	O

Furthermore	O
APN	O
and	O
EGFR	O
synergistically	O
stimulate	O
PI3K	O
/	O
AKT	O
as	O
well	O
as	O
MEK	B-CHED
/	O
ERK1	O
/	O
2	O
endocytosis	O
signaling	O
pathways	O
.	O

Patients	O
with	O
AKI	O
had	O
significantly	O
higher	O
serum	O
creatinine	B-CHED
(	O
P	O
<	O
.	O
001	O
)	O
and	O
lower	O
estimated	O
creatinine	B-CHED
clearance	O
(	O
P	O
<	O
.	O
001	O
)	O
compared	O
with	O
those	O
without	O
AKI	O
.	O

Patients	O
with	O
AKI	O
had	O
significantly	O
lower	O
PaO	B-CHED
AKI	O
is	O
common	O
in	O
children	O
with	O
ARF	O
.	O

His	O
cortisol	B-CHED
level	O
was	O
undetectable	O
;	O
he	O
was	O
diagnosed	O
with	O
adrenal	O
insufficiency	O
and	O
fludrocortisone	B-CHED
was	O
initiated	O
.	O

He	O
was	O
taking	O
prednisone	B-CHED
,	O
tacrolimus	B-CHED
,	O
and	O
everolimus	B-CHED
for	O
immunosuppression	O
and	O
valganciclovir	B-CHED
,	O
itraconazole	B-CHED
,	O
and	O
trimethoprim	B-CHED
-	I-CHED
sulfamethoxazole	I-CHED
for	O
antimicrobial	B-CHED
prophylaxis	O
.	O

Moreover	O
,	O
metabolic	O
profiling	O
of	O
mice	O
serum	O
and	O
subsequent	O
Ingenuity	O
Pathway	O
Analysis	O
suggested	O
that	O
ACGs	O
activated	O
protective	O
protein	B-CHED
networks	O
and	O
pathways	O
involving	O
inflammatory	O
regulators	O
and	O
apoptosis	O
-	O
related	O
factors	O
,	O
such	O
as	O
JNK	O
,	O
ERK1	O
/	O
2	O
and	O
caspase	O
-	O
3	O
/	O
7	O
,	O
suggesting	O
that	O
ACGs	O
-	O
dependent	O
effects	O
were	O
related	O
to	O
MAPKs	O
and	O
mitochondrial	O
apoptosis	O
pathways	O
.	O

Remarkably	O
,	O
ACGs	O
inhibited	O
the	O
LPS	B-CHED
-	O
dependent	O
TLR4	O
and	O
TRPC6	O
upregulation	O
observed	O
during	O
ALI	O
.	O

Nsp	O
3	O
is	O
a	O
multi	O
-	O
functional	O
protein	B-CHED
containing	O
a	O
conserved	O
ADP	B-CHED
-	O
ribose	B-CHED
-	O
1	O
″-	O
phosphatase	O
(	O
ADRP	O
)	O
domain	O
.	O

Replication	O
in	O
vitro	O
was	O
unaffected	O
by	O
the	O
ADRP	O
modifications	O
and	O
the	O
in	O
vivo	O
phenotype	O
of	O
the	O
rIBVs	O
was	O
found	O
to	O
be	O
apathogenic	O
,	O
indicating	O
that	O
restoration	O
of	O
the	O
triple	O
-	O
glycine	B-CHED
motif	O
is	O
not	O
sufficient	O
to	O
restore	O
virulence	O
to	O
the	O
apathogenic	O
Beaudette	O
strain	O
.	O

After	O
denaturation	O
and	O
renaturation	O
of	O
inclusion	O
bodies	O
,	O
the	O
S1	O
protein	B-CHED
was	O
obtained	O
by	O
using	O
purified	O
recombinant	O
S1	O
protein	B-CHED
in	O
immunized	O
female	O
BALB	O
/	O
c	O
mice	O
.	O

One	O
vaccine	O
candidate	O
is	O
based	O
on	O
live	O
-	O
attenuated	O
measles	O
virus	O
(	O
MV	O
)	O
vaccine	O
encoding	O
the	O
MERS	O
-	O
CoV	O
spike	O
glycoprotein	B-CHED
(	O
MERS	O
-	O
S	O
).	O

She	O
died	O
4	O
weeks	O
after	O
admission	O
due	O
to	O
hospital	O
-	O
acquired	O
pneumonia	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
probably	O
due	O
to	O
the	O
high	O
dose	O
of	O
steroids	B-CHED
.	O

Sera	O
were	O
screened	O
by	O
MERS	O
-	O
CoV	O
nucleocapsid	O
protein	B-CHED
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
and	O
indirect	O
immunofluorescence	O
,	O
with	O
results	O
confirmed	O
by	O
microneutralization	O
assay	O
.	O

TITLE	O
:	O
Use	O
of	O
ribavirin	B-CHED
in	O
viruses	O
other	O
than	O
hepatitis	O
C	O
.	O
A	O
review	O
of	O
the	O
evidence	O
.	O

ABSTRACT	O
:	O
Ribavirin	B-CHED
is	O
a	O
molecule	O
with	O
antiviral	B-CHED
activity	O
against	O
different	O
viruses	O
.	O

Moreover	O
,	O
TGEV	O
N	O
protein	B-CHED
induced	O
ER	O
stress	O
and	O
activated	O
NF	O
-	O
κB	O
,	O
which	O
was	O
responsible	O
for	O
the	O
up	O
-	O
regulation	O
of	O
IL	O
-	O
8	O
and	O
Bcl	O
-	O
2	O
expression	O
.	O

Although	O
FHS	O
-	O
1	O
cells	O
lost	B-CHED
the	O
expression	O
of	O
MHC	O
class	O
II	O
and	O
CD163	O
,	O
our	O
findings	O
indicate	O
that	O
FHS	O
-	O
1	O
is	O
a	O
feline	O
HS	O
cell	O
line	O
that	O
retains	O
functional	O
properties	O
of	O
dendritic	O
cells	O
/	O
macrophages	O
in	O
terms	O
of	O
phagocytic	O
and	O
antigen	B-CHED
uptake	O
/	O
processing	O
activities	O
.	O

TITLE	O
:	O
Epitope	B-CHED
selection	O
and	O
their	O
placement	O
for	O
increased	O
virus	O
neutralization	O
in	O
a	O
novel	O
vaccination	O
strategy	O
for	O
porcine	O
epidemic	O
diarrhea	O
virus	O
utilizing	O
the	O
Hepatitis	O
B	O
virus	O
core	O
antigen	B-CHED
.	O

Initially	O
,	O
several	O
multi	O
-	O
antigen	B-CHED
vaccine	O
candidates	O
were	O
able	O
to	O
elicit	O
antibodies	O
specific	O
to	O
three	O
out	O
of	O
four	O
B	O
-	O
cell	O
epitopes	O
inserted	O
into	O
the	O
chimeric	O
proteins	B-CHED
.	O

The	O
focus	O
of	O
the	O
newly	O
redesigned	O
vaccines	O
was	O
to	O
elicit	O
a	O
strong	O
immune	O
response	O
to	O
the	O
YSNIGVCK	O
amino	B-CHED
acid	I-CHED
motif	O
from	O
PEDV	O
.	O

Data	O
were	O
retrospectively	O
analyzed	O
from	O
patients	O
with	O
severe	O
sepsis	O
and	O
septic	O
shock	O
receiving	O
non	O
-	O
cardiac	O
operation	O
and	O
admitted	O
to	O
Department	O
of	O
Critical	O
Care	O
Medicine	B-CHED
of	O
the	O
Second	O
Affiliated	O
Hospital	O
of	O
Kunming	O
Medical	O
University	O
from	O
January	O
1st	O
,	O
2013	O
to	O
December	O
31st	O
,	O
2015	O
.	O
The	O
patients	O
were	O
divided	O
into	O
the	O
senior	O
group	O
(≥	O
65	O
years	O
old	O
)	O
and	O
the	O
younger	O
group	O
(＜	O
65	O
years	O
old	O
),	O
the	O
high	O
-	O
procalcitonin	O
(	O
PCT	O
)	O
group	O
(	O
PCT	O
＞	O
100	O
μg	O
/	O
L	O
)	O
and	O
the	O
control	O
group	O
(	O
PCT	O
≤	O
100	O
μg	O
/	O
L	O
).	O
The	O
stage	O
of	O
early	O
resuscitation	O
was	O
set	O
to	O
the	O
first	O
6	O
hours	O
.	O

We	O
also	O
show	O
that	O
the	O
SQSTM1	O
/	O
p62	O
receptor	O
protein	B-CHED
is	O
not	O
degraded	O
in	O
a	O
conventional	O
manner	O
during	O
infection	O
,	O
but	O
is	O
likely	O
cleaved	O
in	O
a	O
manner	O
similar	O
to	O
that	O
shown	O
for	O
coxsackievirus	O
B3	O
.	O

Immunoblotting	O
and	O
magnetic	O
beads	O
immunoisolation	O
complemented	O
by	O
standardized	O
flow	O
cytometry	O
and	O
nanoparticles	B-CHED
tracking	O
analyses	O
identified	O
in	O
the	O
ARDS	O
patients	O
a	O
subset	O
of	O
EVs	O
with	O
mesenchymal	O
stem	O
cell	O
(	O
MSC	O
)	O
origin	O
(	O
CD73	O
The	O
expression	O
pattern	O
of	O
Runx1	O
isoforms	O
might	O
be	O
a	O
reliable	O
circulatory	O
biomarker	B-CHED
of	O
ARDS	O
activity	O
and	O
a	O
novel	O
determinant	O
of	O
the	O
molecular	O
mechanism	O
for	O
lung	O
vascular	O
/	O
tissue	O
repair	O
and	O
recovery	O
after	O
severe	O
injury	O
.	O

The	O
factors	O
independently	O
related	O
to	O
mortality	O
were	O
prior	O
steroid	B-CHED
use	O
(	O
OR	O
20	O
.	O
2	O
,	O
95	O
%	O
CI	O
1	O
.	O
9	O
-	O
217	O
.	O
5	O
)	O
and	O
hemorrhage	O
(	O
OR	O
71	O
.	O
2	O
,	O
95	O
%	O
CI	O
4	O
.	O
9	O
-	O
>	O
999	O
.	O
9	O
).	O

When	O
comparing	O
the	O
space	O
-	O
time	O
permutation	O
and	O
multinomial	O
models	O
against	O
each	O
other	O
,	O
we	O
identified	O
spatial	O
and	O
temporal	O
overlap	O
in	O
two	O
of	O
the	O
three	O
statistically	O
significant	O
clusters	B-CHED
.	O

In	O
the	O
current	O
study	O
,	O
tissues	O
of	O
eight	O
dromedaries	O
receiving	O
inoculation	O
of	O
MERS	O
-	O
Coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
after	O
recombinant	O
Modified	O
-	O
Vaccinia	O
-	O
Virus	O
-	O
Ankara	O
(	O
MVA	B-CHED
-	O
S	O
)-	O
vaccination	O
(	O
n	O
=	O
4	O
),	O
MVA	B-CHED
-	O
vaccination	O
(	O
mock	O
vaccination	O
,	O
n	O
=	O
2	O
)	O
and	O
PBS	O
application	O
(	O
mock	O
vaccination	O
,	O
n	O
=	O
2	O
),	O
respectively	O
,	O
were	O
investigated	O
.	O

TITLE	O
:	O
Display	O
of	O
Porcine	O
Epidemic	O
Diarrhea	O
Virus	O
Spike	O
Protein	B-CHED
on	O
Baculovirus	O
to	O
Improve	O
Immunogenicity	O
and	O
Protective	O
Efficacy	O
.	O

TITLE	O
:	O
Protection	O
against	O
Virulent	O
Infectious	O
Bronchitis	O
Virus	O
Challenge	O
Conferred	O
by	O
a	O
Recombinant	O
Baculovirus	O
Co	O
-	O
Expressing	O
S1	O
and	O
N	O
Proteins	B-CHED
.	O

Lead	O
like	O
compounds	O
and	O
drug	O
molecules	O
which	O
are	O
capable	O
of	O
inhibiting	O
3C	O
-	O
like	O
protease	O
was	O
identified	O
by	O
structure	O
-	O
based	O
virtual	O
screening	O
and	O
ligand	B-CHED
-	O
based	O
virtual	O
screening	O
method	O
.	O

Their	O
clinical	O
phenotypes	O
including	O
laboratory	O
test	O
results	O
,	O
high	O
-	O
resolution	O
lung	O
computed	O
tomography	O
data	O
,	O
response	O
to	O
therapy	O
,	O
and	O
prognosis	O
were	O
compared	O
between	O
those	O
who	O
were	O
positive	O
and	O
negative	O
for	O
MAAs	O
,	O
such	O
as	O
antinuclear	O
antibody	O
(	O
ANA	O
),	O
anti	O
-	O
cyclic	O
citrullinated	O
peptide	B-CHED
(	O
CCP	B-CHED
),	O
anti	O
-	O
SSA	O
,	O
and	O
anti	O
-	O
SSB	O
antibodies	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
recombinant	O
PEDV	O
trimeric	O
S	O
glycoprotein	B-CHED
could	O
be	O
a	O
potential	O
subunit	O
vaccine	O
candidate	O
against	O
PEDV	O
,	O
but	O
IM	O
immunization	O
with	O
LTB	O
as	O
the	O
adjuvant	B-CHED
provided	O
insufficient	O
protection	O
.	O

Clinical	O
improvement	O
cannot	O
always	O
be	O
expected	O
in	O
spite	O
of	O
targeted	O
antibiotic	B-CHED
therapy	O
.	O

ABSTRACT	O
:	O
Newly	O
approved	O
immunotherapeutic	O
agents	O
,	O
like	O
CTLA	O
-	O
4	O
inhibitors	B-CHED
and	O
antibodies	O
against	O
PD	O
-	O
1	O
,	O
are	O
a	O
promising	O
therapeutic	O
option	O
in	O
cancer	O
therapy	O
.	O

Treating	O
the	O
patient	O
with	O
high	O
-	O
dose	O
immunosuppressive	O
steroids	B-CHED
led	O
to	O
an	O
overall	O
improvement	O
.	O

Direct	O
contact	O
was	O
the	O
main	O
transmission	O
route	O
for	O
the	O
InDel	O
strain	O
,	O
although	O
the	O
non	O
-	O
InDel	O
strain	O
was	O
transmitted	O
through	O
direct	O
contact	O
and	O
indirectly	O
through	O
the	O
air	B-CHED
.	O

Here	O
,	O
we	O
examined	O
entry	O
of	O
CRCoV	O
into	O
human	O
rectal	O
tumor	O
cells	O
(	O
HRT	O
-	O
18G	O
cell	O
line	O
)	O
by	O
analyzing	O
co	O
-	O
localization	O
of	O
single	O
virus	O
particles	O
with	O
cellular	O
markers	O
in	O
the	O
presence	O
or	O
absence	O
of	O
chemical	O
inhibitors	B-CHED
of	O
pathways	O
potentially	O
involved	O
in	O
virus	O
entry	O
.	O

The	O
nature	O
and	O
extent	O
of	O
inter	O
-	O
sectoral	O
collaboration	O
varied	O
according	O
to	O
the	O
sectors	O
involved	O
,	O
with	O
those	O
sectors	O
that	O
have	O
traditionally	O
had	O
good	O
collaboration	O
(	O
e	O
.	O
g	O
.	O
animal	O
health	O
and	O
food	O
safety	O
),	O
as	O
well	O
as	O
those	O
that	O
have	O
a	O
financial	O
incentive	O
for	O
controlling	O
infectious	O
diseases	O
(	O
e	O
.	O
g	O
.	O
agriculture	O
,	O
tourism	O
,	O
and	O
air	B-CHED
travel	O
)	O
seen	O
as	O
most	O
likely	O
to	O
have	O
integrated	O
public	O
health	O
preparedness	O
and	O
response	O
plans	O
.	O

Here	O
,	O
we	O
show	O
that	O
TMPRSS11A	O
,	O
another	O
member	O
of	O
the	O
TTSP	O
family	O
,	O
cleaves	O
and	O
activates	O
the	O
influenza	O
A	O
virus	O
(	O
FLUAV	O
)	O
HA	O
and	O
the	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
spike	O
protein	B-CHED
(	O
MERS	O
-	O
S	O
).	O

Whether	O
these	O
amino	B-CHED
acids	I-CHED
substitutions	O
and	O
the	O
N	O
-	O
glycosylation	O
site	O
substitutions	O
influence	O
the	O
antigenicity	O
and	O
pathogenicity	O
of	O
PEDV	O
remains	O
to	O
be	O
investigated	O
.	O

Meanwhile	O
,	O
amino	B-CHED
acid	I-CHED
substitutions	O
in	O
the	O
neutralizing	O
epitopes	O
may	O
have	O
conferred	O
the	O
capacity	O
for	O
immune	O
evasion	O
in	O
these	O
PEDV	O
field	O
strains	O
.	O

The	O
prevention	O
of	O
TRALI	O
in	O
the	O
SPF	O
mice	O
and	O
gut	O
flora	O
-	O
depleted	O
BF	O
mice	O
was	O
associated	O
with	O
decreased	O
plasma	O
macrophage	O
inflammatory	O
protein	B-CHED
-	O
2	O
levels	O
as	O
well	O
as	O
decreased	O
pulmonary	O
neutrophil	O
accumulation	O
.	O

DNA	O
sequencing	O
of	O
amplicons	O
of	O
the	O
16S	B-CHED
ribosomal	B-CHED
RNA	I-CHED
gene	O
revealed	O
a	O
varying	O
gastrointestinal	O
bacterial	O
composition	O
between	O
BF	O
and	O
SPF	O
mice	O
.	O

ABSTRACT	O
:	O
The	O
major	O
mechanism	O
of	O
antibody	O
-	O
mediated	O
neutralization	O
of	O
the	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
involves	O
competition	O
with	O
the	O
cellular	O
receptor	O
dipeptidyl	O
peptidase	O
4	O
(	O
DPP4	O
)	O
for	O
binding	O
to	O
the	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
the	O
spike	O
(	O
S	O
)	O
glycoprotein	B-CHED
.	O

The	O
oxygenation	O
index	O
(	O
PaO	B-CHED
A	O
total	O
of	O
32	O
patients	O
with	O
ARDS	O
were	O
selected	O
,	O
with	O
16	O
in	O
each	O
group	O
,	O
and	O
their	O
baseline	O
data	O
were	O
balanced	O
and	O
comparable	O
.	O

We	O
observed	O
respiratory	O
disease	O
resulting	O
from	O
exposure	O
to	O
the	O
icMERS	O
-	O
0	O
strain	O
as	O
measured	O
by	O
CT	O
in	O
rhesus	O
monkeys	O
with	O
concomitant	O
detection	O
of	O
virus	O
antigen	B-CHED
by	O
immunohistochemistry	O
.	O

ABSTRACT	O
:	O
Xylometazoline	O
hydrochloride	B-CHED
(	O
HCl	B-CHED
)	O
is	O
a	O
nasal	O
decongestant	O
that	O
causes	O
vasoconstriction	O
in	O
the	O
nasal	O
submucosa	O
.	O

TITLE	O
:	O
Heme	B-CHED
Oxygenase	O
-	O
1	O
Reduces	O
Sepsis	O
-	O
Induced	O
Endoplasmic	O
Reticulum	O
Stress	O
and	O
Acute	O
Lung	O
Injury	O
.	O

Heme	B-CHED
oxygenase	O
-	O
1	O
(	O
HO	O
-	O
1	O
),	O
an	O
ER	O
-	O
anchored	O
protein	B-CHED
,	O
exerts	O
antioxidant	B-CHED
and	O
protective	O
functions	O
under	O
ALI	O
.	O

The	O
effects	O
of	O
HO	O
-	O
1	O
on	O
ER	O
stress	O
during	O
septic	O
ALI	O
were	O
investigated	O
Compared	O
with	O
the	O
sham	O
group	O
,	O
ER	O
stress	O
in	O
septic	O
lung	O
increased	O
significantly	O
18	O
hours	O
after	O
CLP	O
,	O
which	O
was	O
significantly	O
reduced	O
by	O
pretreatment	O
with	O
the	O
ER	O
inhibitor	B-CHED
4	O
-	O
phenylbutyrate	O
(	O
4	O
-	O
PBA	B-CHED
).	O

Similarly	O
,	O
lung	O
ER	O
stress	O
-	O
related	O
genes	O
'	O
(	O
PERK	B-CHED
,	O
eIF2	O
-	O
ER	O
stress	O
was	O
activated	O
during	O
CLP	O
-	O
induced	O
ALI	O
,	O
which	O
may	O
represent	O
a	O
mechanism	O
by	O
which	O
CLP	O
induces	O
ALI	O
.	O

TITLE	O
:	O
Cyclophilins	O
and	O
cyclophilin	O
inhibitors	B-CHED
in	O
nidovirus	O
replication	O
.	O

A	O
total	O
of	O
96	O
laboratories	O
from	O
79	O
countries	O
participating	O
in	O
the	O
PTP	B-CHED
,	O
with	O
76	O
of	O
96	O
(	O
79	O
.	O
2	O
%)	O
reporting	O
correct	O
MERS	O
-	O
CoV	O
results	O
for	O
all	O
nine	O
scored	O
specimens	O
.	O

A	O
further	O
10	O
laboratories	O
(	O
10	O
.	O
4	O
%)	O
scored	O
correctly	O
in	O
eight	O
of	O
nine	O
specimens	O
of	O
the	O
PTP	B-CHED
.	O

Patients	O
who	O
needed	O
advanced	O
resuscitation	O
with	O
administration	O
of	O
epinephrine	B-CHED
had	O
lower	O
temperature	O
,	O
Glasgow	O
Coma	O
Scale	O
score	O
,	O
pH	O
,	O
and	O
bicarbonate	B-CHED
at	O
admission	O
and	O
higher	O
level	O
of	O
glucose	B-CHED
.	O

Tissue	O
inhibitor	B-CHED
of	O
matrix	O
metalloproteinase	O
-	O
3	O
(	O
TIMP	O
-	O
3	O
)	O
is	O
a	O
regulator	O
of	O
matrix	O
metalloproteinase	O
activity	O
,	O
inflammation	O
,	O
and	O
vascular	O
permeability	O
,	O
and	O
hence	O
has	O
plausibility	O
as	O
a	O
biomarker	B-CHED
for	O
the	O
systemic	O
response	O
to	O
TBI	O
.	O

ABSTRACT	O
:	O
Hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
and	O
the	O
malaria	O
parasite	O
Plasmodium	O
use	O
the	O
membrane	O
protein	B-CHED
CD81	O
to	O
invade	O
human	O
liver	O
cells	O
.	O

This	O
article	O
is	O
the	O
continued	O
form	O
of	O
the	O
previously	O
published	O
work	O
on	O
anti	O
-	O
infective	O
perspectives	O
of	O
chalcones	B-CHED
(	O
highlighted	O
till	O
2015	O
).	O

TITLE	O
:	O
Effect	O
of	O
Human	O
Coronavirus	O
OC43	O
Structural	O
and	O
Accessory	O
Proteins	B-CHED
on	O
the	O
Transcriptional	O
Activation	O
of	O
Antiviral	B-CHED
Response	O
Elements	O
.	O

The	O
transcriptional	O
activation	O
of	O
antiviral	B-CHED
response	O
elements	O
was	O
assessed	O
by	O
measuring	O
the	O
levels	O
of	O
firefly	O
luciferase	O
expressed	O
under	O
the	O
control	O
of	O
interferon	O
(	O
IFN	O
)-	O
stimulated	O
response	O
element	O
(	O
ISRE	O
),	O
IFN	O
-	O
β	O
promoter	O
,	O
or	O
nuclear	O
factor	O
kappa	O
B	O
response	O
element	O
(	O
NF	O
-	O
κB	O
-	O
RE	O
).	O

The	O
transcriptional	O
activity	O
of	O
ISRE	O
,	O
IFN	O
-	O
β	O
promoter	O
,	O
and	O
NF	O
-	O
κB	O
-	O
RE	O
was	O
significantly	O
reduced	O
in	O
the	O
presence	O
of	O
HCoV	O
-	O
OC43	O
ns2a	O
,	O
ns5a	O
,	O
M	O
,	O
or	O
N	O
protein	B-CHED
,	O
following	O
the	O
challenge	O
of	O
cells	O
with	O
Sendai	O
virus	O
,	O
IFN	O
-	O
α	O
or	O
tumor	O
necrosis	O
factor	O
-	O
α	O
.	O

TITLE	O
:	O
The	O
Antiviral	B-CHED
Effects	O
of	O
Na	O
,	O
K	O
-	O
ATPase	O
Inhibition	O
:	O
A	O
Minireview	O
.	O

Cardiac	O
glycosides	B-CHED
have	O
been	O
reported	O
to	O
be	O
effective	O
against	O
both	O
DNA	O
viruses	O
such	O
as	O
cytomegalovirus	O
and	O
herpes	O
simplex	O
and	O
RNA	O
viruses	O
such	O
as	O
influenza	O
,	O
chikungunya	O
,	O
coronavirus	O
,	O
and	O
respiratory	O
syncytial	O
virus	O
,	O
among	O
others	O
.	O

Marine	O
-	O
derived	O
fungi	O
have	O
been	O
evidenced	O
as	O
a	O
prolific	O
source	O
for	O
the	O
discovery	O
of	O
pharmacologically	O
-	O
active	O
lead	B-CHED
compounds	I-CHED
.	O

During	O
the	O
course	O
of	O
our	O
search	O
for	O
novel	O
bioactive	O
substances	O
from	O
marine	O
microorganisms	O
,	O
six	O
new	O
polyketides	B-CHED
,	O
including	O
two	O
octaketides	B-CHED
(	O

Phylogeny	O
results	O
indicated	O
that	O
the	O
nucleotide	B-CHED
sequences	O
of	O
all	O
isolates	O
were	O
like	O
those	O
reported	O
in	O
other	O
countries	O
.	O

The	O
addition	O
of	O
exogenous	O
cholesterol	B-CHED
to	O
MβCD	O
-	O
treated	O
cells	O
or	O
virions	O
moderately	O
restored	O
PDCoV	O
infectivity	O
.	O

Previously	O
,	O
we	O
reported	O
that	O
a	O
variety	O
of	O
cardenolides	O
impart	O
anti	O
-	O
transmissible	O
gastroenteritis	O
coronavirus	O
(	O
TGEV	O
)	O
activity	O
in	O
swine	O
testicular	O
(	O
ST	O
)	O
cells	O
,	O
through	O
targeting	O
of	O
the	O
cell	O
membrane	O
sodium	O
/	O
potassium	B-CHED
pump	O
,	O
Na	O

The	O
obtained	O
results	O
demonstrated	O
the	O
significant	O
effect	O
of	O
the	O
constructed	O
L	O
.	O
plantarum	O
expressing	O
S	O
-	O
DCpep	O
fusion	O
proteins	B-CHED
in	O
inducing	O
high	O
expression	O
levels	O
of	O
B7	O
molecules	O
on	O
DCs	O
,	O
as	O
well	O
as	O
high	O
levels	O
of	O
IgG	O
,	O
secretory	O
IgA	O
,	O
and	O
IFN	O
-	O
γ	O
and	O
IL	O
-	O
4	O
cytokines	O
compared	O
with	O
the	O
other	O
groups	O
.	O

We	O
also	O
demonstrated	O
that	O
both	O
full	O
-	O
length	O
and	O
naturally	O
truncated	O
ORF3	O
proteins	B-CHED
could	O
interact	O
with	O
the	O
S	O
protein	B-CHED
but	O
with	O
different	O
binding	O
affinity	O
,	O
which	O
correlate	O
with	O
the	O
ability	O
of	O
the	O
protein	B-CHED
to	O
regulate	O
virus	O
replication	O
in	O
cell	O
culture	O
.	O

We	O
assumed	O
that	O
strain	O
JS	O
-	O
2	O
/	O
2014	O
might	O
be	O
attenuated	O
by	O
the	O
90th	B-CHED
generation	O
.	O

Identification	O
of	O
the	O
HIV	B-CHED
-	I-CHED
1	I-CHED
Maturation	I-CHED
Inhibitor	I-CHED
4	O
-((	O
1	O
R	O
,	O
3a	O
S	O
,	O
5a	O
R	O
,	O
5b	O
R	O
,	O
7a	O
R	O
,	O
11a	O
S	O
,	O
11b	O
R	O
,	O
13a	O
R	O
,	O
13b	O
R	O
)-	O
3a	O
-((	O
2	O
-(	O
1	O
,	O
1	O
-	O
Dioxidothiomorpholino	O
)	O
ethyl	B-CHED
)	O
amino	O
)-	O
5a	O
,	O
5b	O
,	O
8	O
,	O
8	O
,	O
11a	O
-	O
pentamethyl	O
-	O
1	O
-(	O
prop	B-CHED
-	I-CHED
1	I-CHED
-	I-CHED
en	I-CHED
-	I-CHED
2	I-CHED
-	I-CHED
yl	I-CHED
)-	O
2	O
,	O
3	O
,	O
3a	O
,	O
4	O
,	O
5	O
,	O
5a	O
,	O
5b	O
,	O
6	O
,	O
7	O
,	O
7a	O
,	O
8	O
,	O
11	O
,	O
11a	O
,	O
11b	O
,	O
12	O
,	O
13	O
,	O
13a	O
,	O
13b	O
-	O
octadecahydro	O
-	O
1	O
H	O
-	O
cyclopenta	O
[	O
a	O
]	O
chrysen	B-CHED
-	O
9	O
-	O
yl	O
)	O
benzoic	B-CHED
Acid	I-CHED
(	O
GSK3532795	O
,	O
BMS	O
-	O
955176	O
).	O

ABSTRACT	O
:	O
GSK3532795	O
,	O
formerly	O
known	O
as	O
BMS	O
-	O
955176	O
(	O
1	O
),	O
is	O
a	O
potent	O
,	O
orally	O
active	O
,	O
second	O
-	O
generation	O
HIV	B-CHED
-	I-CHED
1	I-CHED
maturation	I-CHED
inhibitor	I-CHED
(	O
MI	O
)	O
that	O
advanced	O
through	O
phase	O
IIb	O
clinical	O
trials	O
.	O

Herein	O
,	O
we	O
highlight	O
the	O
key	O
insights	O
made	O
in	O
the	O
discovery	O
program	O
and	O
detail	O
the	O
evolution	O
of	O
the	O
structure	O
-	O
activity	O
relationships	O
(	O
SARs	O
)	O
that	O
led	O
to	O
the	O
design	O
of	O
the	O
specific	O
C	O
-	O
17	O
amine	B-CHED
moiety	O
in	O
1	O
.	O

ABSTRACT	O
:	O
Exposure	O
to	O
air	B-CHED
pollution	O
has	O
molecular	O
and	O
physiologic	O
effects	O
on	O
the	O
lung	O
that	O
may	O
increase	O
the	O
risk	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
after	O
injury	O
.	O

None	O
of	O
the	O
short	O
-	O
term	O
exposures	O
averaged	O
over	O
the	O
3	O
days	O
before	O
presentation	O
was	O
associated	O
with	O
ARDS	O
,	O
except	O
sulfur	B-CHED
dioxide	I-CHED
,	O
which	O
demonstrated	O
a	O
nonlinear	O
association	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
used	O
chitosan	B-CHED
and	O
recombinant	O
human	O
interleukin	O
-	O
2	O
as	O
an	O
adjuvant	B-CHED
(	O
JY	O
)	O
to	O
promote	O
the	O
systemic	O
and	O
mucosal	O
immune	O
responses	O
induced	O
by	O
the	O
H7N9	O
vaccine	O
.	O

ABSTRACT	O
:	O
Porcine	O
hemagglutinating	O
encephalomyelitis	O
virus	O
(	O
PHEV	O
)	O
is	O
a	O
member	O
of	O
the	O
genus	O
betacoronavirus	O
within	O
the	O
family	O
coronaviridae	O
,	O
which	O
invades	O
the	O
central	O
nervous	O
system	O
(	O
CNS	B-CHED
)	O
via	O
peripheral	O
nervous	O
system	O
and	O
causes	O
encephalomyelitis	O
or	O
vomiting	O
and	O
wasting	O
disease	O
(	O
VWD	O
)	O
in	O
sucking	O
piglets	O
.	O

Differential	O
mRNA	B-CHED
expression	O
analysis	O
identified	O
5621	O
genes	O
as	O
deregulated	O
in	O
peritoneal	O
cells	O
from	O
FIPV	O
infected	O
versus	O
normal	O
cats	O
;	O
956	O
genes	O
showed	O
>	O
2	O
.	O
0	O
Log	O

RESULTS	O
:	O
In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
ability	O
of	O
human	O
β	O
-	O
defensin	O
(	O
HBD	O
)	O
2	O
to	O
promote	O
antiviral	B-CHED
immunity	O
in	O
vitro	O
and	O
in	O
vivo	O
using	O
a	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
-	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
spike	O
protein	B-CHED
(	O
S	O
RBD	O
)	O
as	O
a	O
model	O
antigen	B-CHED
(	O
Ag	O
).	O

At	O
follow	O
-	O
up	O
,	O
no	O
patients	O
required	O
supplemental	O
oxygen	B-CHED
.	O

TITLE	O
:	O
A	O
Recombinant	O
Newcastle	O
Disease	O
Virus	O
(	O
NDV	O
)	O
Expressing	O
S	O
Protein	B-CHED
of	O
Infectious	O
Bronchitis	O
Virus	O
(	O
IBV	O
)	O
Protects	O
Chickens	O
against	O
IBV	O
and	O
NDV	O
.	O

Our	O
results	O
showed	O
that	O
the	O
rNDV	O
expressing	O
the	O
S	O
protein	B-CHED
of	O
IBV	O
provided	O
better	O
protection	O
than	O
the	O
rNDV	O
expressing	O
S1	O
or	O
S2	O
protein	B-CHED
of	O
IBV	O
,	O
indicating	O
that	O
the	O
S	O
protein	B-CHED
is	O
the	O
best	O
protective	O
antigen	B-CHED
of	O
IBV	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
nsp1	O
suppresses	O
host	O
gene	O
expression	O
in	O
expressed	O
cells	O
by	O
inhibiting	O
translation	O
and	O
inducing	O
endonucleolytic	O
cleavage	O
of	O
host	O
mRNAs	O
,	O
the	O
latter	O
of	O
which	O
leads	O
to	O
mRNA	B-CHED
decay	O
.	O

ABSTRACT	O
:	O
Antisynthetase	O
syndrome	O
is	O
a	O
clinical	O
entity	O
characterized	O
by	O
specific	O
anti	O
-	O
aminoacyl	B-CHED
-	I-CHED
tRNA	I-CHED
-	O
synthetase	O
antibodies	O
usually	O
associated	O
with	O
inflammatory	O
myopathy	O
and	O
interstitial	O
lung	O
disease	O
.	O

This	O
article	O
presents	O
a	O
clinical	O
case	O
of	O
antisynthetase	O
syndrome	O
with	O
severe	O
ARDS	O
successfully	O
treated	O
with	O
immunosuppressive	B-CHED
agents	I-CHED
and	O
ECMO	O
.	O

Field	O
measurements	O
showed	O
that	O
wrong	O
air	B-CHED
flow	O
direction	O
was	O
due	O
to	O
poor	O
construction	O
quality	O
or	O
maintenance	O
.	O

TITLE	O
:	O
Development	O
of	O
a	O
diagnostic	O
system	O
for	O
detection	O
of	O
specific	O
antibodies	O
and	O
antigens	B-CHED
against	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
.	O

Binding	O
of	O
the	O
receptor	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
the	O
spike	O
(	O
S	O
)	O
glycoprotein	B-CHED
to	O
dipeptidyl	O
peptidase	O
4	O
is	O
the	O
critical	O
step	O
in	O
MERS	O
-	O
CoV	O
infection	O
of	O
a	O
host	O
cell	O
.	O

Based	O
on	O
our	O
published	O
preliminary	O
data	O
,	O
we	O
hypothesized	O
that	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
stress	O
response	O
molecule	O
Protein	B-CHED
Kinase	O
R	O
-	O
like	O
Endoplasmic	O
Reticulum	O
Kinase	O
(	O
PERK	B-CHED
)	O
plays	O
a	O
role	O
in	O
transmitting	O
mechanosensory	O
signals	O
the	O
alveolar	O
epithelium	O
.	O

Our	O
data	O
indicate	O
that	O
stretch	O
-	O
induced	O
epithelial	O
ER	O
Ca	O
CONCLUSIONS	O
:	O
Our	O
study	O
provides	O
evidences	O
that	O
PERK	B-CHED
is	O
a	O
mediator	O
stretch	O
signals	O
in	O
the	O
alveolar	O
epithelium	O
.	O

The	O
requirement	O
for	O
the	O
virus	O
to	O
be	O
manipulated	O
in	O
a	O
biosafety	O
level	O
three	O
(	O
BSL	O
-	O
3	O
)	O
facility	O
has	O
impeded	O
development	O
of	O
urgently	O
-	O
needed	O
antiviral	B-CHED
agents	I-CHED
.	O

One	O
of	O
the	O
main	O
approaches	O
to	O
improve	O
MVA	B-CHED
immunogenicity	O
focuses	O
on	O
optimising	O
poxviral	O
promoters	O
that	O
drive	O
recombinant	O
vaccine	O
antigens	B-CHED
,	O
encoded	O
within	O
recombinant	O
MVA	B-CHED
vector	O
genome	O
.	O

A	O
number	O
of	O
promoters	O
were	O
described	O
or	O
optimised	O
to	O
improve	O
the	O
development	O
of	O
MVA	B-CHED
based	O
vaccines	O
such	O
as	O
p7	O
.	O
5	O
,	O
pF11	O
,	O
and	O
mH5	O
promoters	O
.	O

Surface	O
and	O
air	B-CHED
samples	O
were	O
collected	O
weekly	O
at	O
three	O
different	O
time	O
points	O
during	O
the	O
peak	O
period	O
of	O
seasonal	O
influenza	O
in	O
2015	O
-	O
16	O
in	O
Finland	O
.	O

Detection	O
of	O
pathogen	O
viral	O
nucleic	B-CHED
acids	I-CHED
indicates	O
respiratory	O
viral	O
surface	O
contamination	O
at	O
multiple	O
sites	O
associated	O
with	O
high	O
touch	O
rates	O
,	O
and	O
suggests	O
a	O
potential	O
risk	O
in	O
the	O
identified	O
airport	O
sites	O
.	O

E	O
.	O
coli	O
prokaryotic	O
expression	O
system	O
and	O
Bac	O
-	O
to	O
-	O
Bac	O
expression	O
system	O
were	O
used	O
to	O
identify	O
the	O
target	O
protein	B-CHED
of	O
each	O
monoclonal	O
antibody	O
.	O

Remarkably	O
,	O
4	O
mAbs	O
(	O
designed	O
2G8	O
,	O
2B11	O
,	O
3D9	O
,	O
1E3	O
)	O
neutralized	O
virus	O
infection	O
potently	O
,	O
of	O
which	O
2B11	O
and	O
1E3	O
targeted	O
the	O
conformational	O
epitope	B-CHED
of	O
the	O
PEDV	O
S	O
protein	B-CHED
.	O

Minor	O
differences	O
in	O
the	O
side	O
chain	O
length	O
as	O
well	O
as	O
lipophilicity	O
appeared	O
to	O
have	O
significant	O
impact	O
on	O
antiviral	B-CHED
activity	O
and	O
cytotoxicity	O
.	O

Patients	O
with	O
influenza	O
infection	O
were	O
likely	O
to	O
be	O
taken	O
to	O
emergency	O
rooms	O
and	O
have	O
respiratory	O
failure	O
with	O
higher	O
creatinine	B-CHED
kinase	O
levels	O
and	O
lower	O
white	O
blood	O
cell	O
counts	O
.	O

However	O
,	O
the	O
details	O
of	O
how	O
sialic	B-CHED
acid	I-CHED
and	O
low	O
pH	O
affect	O
virus	O
binding	O
to	O
the	O
host	O
cell	O
are	O
not	O
determined	O
,	O
and	O
the	O
functions	O
of	O
the	O
proteases	O
are	O
unknown	O
.	O

Despite	O
the	O
rise	O
in	O
neonatal	O
resuscitation	O
(	O
NR	O
)	O
training	O
programs	O
in	O
low	O
-	O
and	O
middle	O
-	O
income	O
countries	O
,	O
their	O
impact	O
on	O
the	O
quality	O
of	O
NR	O
skills	O
amongst	O
providers	O
with	O
limited	O
formal	B-CHED
medical	O
education	O
,	O
particularly	O
those	O
working	O
in	O
rural	O
primary	O
health	O
centers	O
(	O
PHCs	O
),	O
remains	O
incompletely	O
understood	O
.	O

Synthesized	O
QDs	O
was	O
further	O
conjugated	O
with	O
anti	O
-	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
antibodies	O
of	O
coronavirus	O
to	O
form	O
an	O
immunolink	O
at	O
the	O
presence	O
of	O
the	O
target	O
analyte	O
and	O
anti	O
-	O
IBV	O
antibody	O
-	O
conjugated	O
magneto	O
-	O
plasmonic	O
nanoparticles	B-CHED
(	O
MPNPs	O
).	O

Pulmonary	O
vascular	O
endothelial	O
cells	O
(	O
PVECs	O
)	O
function	O
as	O
an	O
important	O
pro	B-CHED
-	O
inflammatory	O
source	O
in	O
ARDS	O
,	O
suggesting	O
that	O
modulation	O
of	O
inflammatory	O
events	O
at	O
the	O
endothelial	O
level	O
may	O
have	O
a	O
therapeutic	O
benefit	O
.	O

In	O
vivo	O
,	O
sitagliptin	B-CHED
reduced	O
serum	O
DPP4	O
activity	O
,	O
bronchoalveolar	O
lavage	O
protein	B-CHED
concentration	O
,	O
cell	O
number	O
,	O
and	O
proinflammatory	O
cytokine	O
levels	O
after	O
LPS	B-CHED
and	O
alleviated	O
histological	O
findings	O
of	O
lung	O
injury	O
.	O

Chlorine	B-CHED
,	O
phosgene	B-CHED
,	O
hydrogen	B-CHED
sulfide	I-CHED
,	O
and	O
ammonia	B-CHED
are	O
either	O
of	O
intermediate	O
or	O
high	O
water	B-CHED
solubility	O
leading	O
to	O
immediate	O
reactions	O
with	O
mucous	O
membranes	O
of	O
the	O
face	O
,	O
throat	O
,	O
and	O
lungs	O
and	O
rapid	O
symptoms	O
onset	O
after	O
exposure	O
.	O

Moreover	O
,	O
HRG	O
suppressed	O
tumor	O
necrosis	O
factor	O
α	O
,	O
inducible	O
nitric	B-CHED
oxide	I-CHED
synthase	O
,	O
interleukin	O
6	O
,	O
and	O
neutrophil	O
elastase	O
mRNA	B-CHED
expression	O
and	O
myeloperoxidase	O
activity	O
in	O
the	O
lung	O
.	O

Together	O
,	O
these	O
findings	O
reveal	O
a	O
new	O
strategy	O
for	O
relatively	O
broad	O
-	O
spectrum	O
antiviral	B-CHED
drug	I-CHED
discovery	O
by	O
relying	O
on	O
the	O
tunability	O
of	O
the	O
α	O
-	O
helical	O
coiled	O
-	O
coil	O
domains	O
present	O
in	O
all	O
class	O
I	O
fusion	O
proteins	B-CHED
and	O
the	O
amphiphilic	O
nature	O
of	O
the	O
individual	O
helices	O
from	O
this	O
multihelix	O
motif	O
.	O

Virus	O
entry	O
of	O
HCoV	O
-	O
229E	O
is	O
mediated	O
by	O
its	O
spike	O
(	O
S	O
)	O
protein	B-CHED
,	O
where	O
the	O
S1	O
domain	O
facilitates	O
attachment	O
to	O
host	O
cells	O
and	O
the	O
S2	O
domain	O
is	O
involved	O
in	O
subsequent	O
fusion	O
of	O
the	O
virus	O
and	O
host	O
membranes	O
.	O

ABSTRACT	O
:	O
Anti	O
-	O
synthetase	O
(	O
AS	O
)	O
and	O
dermato	O
-	O
pulmonary	O
associated	O
with	O
anti	O
-	O
MDA	B-CHED
-	O
5	O
antibodies	O
(	O
aMDA	O
-	O
5	O
)	O
syndromes	O
are	O
near	O
one	O
of	O
the	O
other	O
autoimmune	O
inflammatory	O
myopathies	O
potentially	O
responsible	O
for	O
severe	O
acute	O
interstitial	O
lung	O
disease	O
.	O

C	O
-	O
reactive	O
protein	B-CHED
was	O
increased	O
(	O
139	O
[	O
40	O
-	O
208	O
]	O
mg	O
/	O
L	O
),	O
whereas	O
procalcitonine	O
was	O
not	O
(	O
0	O
.	O
30	O
[	O
0	O
.	O
12	O
-	O
0	O
.	O
56	O
]	O
ng	O
/	O
mL	O
).	O

Furthermore	O
,	O
pairwise	O
comparisons	O
of	O
0	O
DPT	B-CHED
to	O
2	O
,	O
4	O
,	O
and	O
6	O
DPT	B-CHED
results	O
detected	O
no	O
significant	O
differences	O
(	O
p	O
>	O
0	O
.	O
05	O
)	O
in	O
IgA	O
and	O
IgG	O
S	O
/	O
P	O
ratios	O
(	O
i	O
.	O
e	O
.,	O
treated	O
OF	O
samples	O
were	O
stable	O
over	O
time	O
).	O

In	O
some	O
enterocytes	O
,	O
pycnotic	O
nuclei	B-CHED
were	O
detected	O
.	O

Faecal	O
samples	O
were	O
screened	O
for	O
the	O
presence	O
of	O
CoVs	O
using	O
pan	B-CHED
-	O
CoV	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
assays	O
.	O

The	O
codon	O
optimized	O
S1	O
nucleotide	B-CHED
sequence	O
was	O
cloned	O
in	O
-	O
frame	O
into	O
a	O
prokaryotic	O
constitutive	O
expression	O
vector	O
,	O
pJHL65	O
.	O

PCR	O
amplification	O
of	O
the	O
conserved	O
coronaviral	O
protein	B-CHED
RdRp	O
detected	O
coronaviruses	O
in	O
26	O
.	O
65	O
%	O
of	O
bats	O
belonging	O
to	O
this	O
region	O
,	O
and	O
this	O
number	O
was	O
influenced	O
by	O
seasonal	O
changes	O
.	O

Extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
can	O
improve	O
oxygenation	O
and	O
remove	O
carbon	B-CHED
dioxide	I-CHED
by	O
extracorporeal	O
circuit	O
,	O
and	O
can	O
partially	O
or	O
completely	O
take	O
over	O
cardiopulmonary	O
function	O
.	O

Failure	O
of	O
clinical	O
therapeutic	O
trials	O
prompted	O
the	O
investigation	O
and	O
subsequent	O
discovery	O
of	O
two	O
distinct	O
phenotypes	O
of	O
ARDS	O
(	O
hyper	O
-	O
inflammatory	O
and	O
hypo	O
-	O
inflammatory	O
)	O
that	O
have	O
different	O
biomarker	B-CHED
profiles	O
and	O
clinical	O
courses	O
and	O
respond	O
differently	O
to	O
the	O
random	O
application	O
of	O
positive	O
end	O
expiratory	O
pressure	O
(	O
PEEP	B-CHED
)	O
and	O
fluid	O
management	O
strategies	O
.	O

High	O
-	O
frequency	O
oscillatory	O
ventilation	O
,	O
application	O
of	O
recruitment	O
maneuvers	O
,	O
higher	O
PEEP	B-CHED
,	O
extracorporeal	O
membrane	O
oxygenation	O
,	O
and	O
alternate	O
modes	O
of	O
mechanical	O
ventilation	O
have	O
failed	O
to	O
show	O
benefit	O
.	O

At	O
least	O
as	O
early	O
as	O
the	O
late	O
1800s	O
,	O
improved	O
living	O
conditions	O
(	O
such	O
as	O
better	O
sanitation	O
and	O
piped	O
water	B-CHED
supplies	O
),	O
particularly	O
in	O
high	O
-	O
income	O
countries	O
(	O
HICs	O
),	O
began	O
to	O
drive	O
down	O
the	O
infectious	O
disease	O
burden	O
.	O

This	O
article	O
reviews	O
the	O
clinical	O
effects	O
and	O
treatment	O
of	O
persons	O
who	O
use	O
cocaine	B-CHED
,	O
methamphetamines	O
,	O
3	B-CHED
,	I-CHED
4	I-CHED
-	I-CHED
methylenedioxymethamphetamine	I-CHED
(	O
MDMA	B-CHED
),	O
synthetic	O
cannabinoids	B-CHED
,	O
and	O
synthetic	O
cathinones	O
"("""	O
bath	O
salts	B-CHED
""")."	O

Cocaine	B-CHED
blocks	O
the	O
reuptake	O
of	O
the	O
monoamine	B-CHED
transporters	O
dopamine	B-CHED
,	O
norepinephrine	B-CHED
,	O
and	O
serotonin	B-CHED
.	O

We	O
designed	O
a	O
novel	O
IBV	O
vaccine	O
alternative	O
using	O
a	O
highly	O
innovative	O
platform	O
called	O
Self	O
-	O
Assembling	O
Protein	B-CHED
Nanoparticle	B-CHED
(	O
SAPN	O
).	O

Three	O
groups	O
of	O
chickens	O
were	O
immunized	O
at	O
four	O
weeks	O
of	O
age	O
with	O
the	O
vaccine	O
prototype	O
,	O
IBV	O
-	O
Flagellin	O
-	O
SAPN	O
,	O
a	O
negative	O
-	O
control	O
construct	O
Flagellin	O
-	O
SAPN	O
or	O
a	O
buffer	B-CHED
control	O
.	O

IBV	O
nonstructural	O
protein	B-CHED
5	O
(	O
nsp5	O
)	O
was	O
expressed	O
,	O
purified	O
from	O
Escherichia	O
coli	O
,	O
and	O
used	O
to	O
spot	O
the	O
initiator	O
integrated	O
poly	O
(	O
dimethylsiloxane	O
),	O
which	O
can	O
provide	O
a	O
near	O
""""	O
zero	O
""""	O
background	O
for	O
serological	O
assays	O
.	O

The	O
coefficients	O
of	O
variation	O
of	O
the	O
reproducibility	O
of	O
the	O
intra	O
-	O
and	O
inter	O
-	O
assays	O
for	O
CIT	B-CHED
ranged	O
from	O
0	O
.	O
8	O
to	O
18	O
.	O
63	O
%.	O

Intracranial	O
inoculation	O
should	O
continue	O
to	O
be	O
considered	O
a	O
preferred	O
method	O
for	O
studies	O
of	O
MHV	O
-	O
induced	O
optic	O
neuritis	O
and	O
central	O
nervous	O
system	O
(	O
CNS	B-CHED
)	O
demyelinating	O
disease	O
.	O

The	O
results	O
show	O
that	O
antibiotics	B-CHED
must	O
be	O
prescribed	O
carefully	O
in	O
children	O
with	O
FS	O
since	O
the	O
majority	O
of	O
cases	O
are	O
related	O
to	O
viral	O
causes	O
.	O

In	O
addition	O
,	O
exemplarily	O
in	O
patients	O
with	O
moderate	O
-	O
severe	O
ARDS	O
or	O
COPD	O
exacerbation	O
,	O
different	O
PEEP	B-CHED
levels	O
were	O
shown	O
to	O
have	O
an	O
influence	O
on	O
the	O
distribution	O
pattern	O
of	O
regional	O
time	O
constants	O
.	O

In	O
addition	O
,	O
exemplarily	O
in	O
patients	O
with	O
moderate	O
-	O
severe	O
ARDS	O
or	O
COPD	O
exacerbation	O
,	O
different	O
PEEP	B-CHED
levels	O
were	O
shown	O
to	O
have	O
an	O
influence	O
on	O
the	O
distribution	O
pattern	O
of	O
regional	O
time	O
constants	O
.	O

TITLE	O
:	O
Transmissible	O
gastroenteritis	O
virus	O
infection	O
decreases	O
arginine	B-CHED
uptake	O
by	O
downregulating	O
CAT	O
-	O
1	O
expression	O
.	O

In	O
order	O
to	O
determine	O
if	O
the	O
nucleocapsid	O
protein	B-CHED
of	O
MERS	O
-	O
CoV	O
(	O
MERS	O
-	O
N	O
)	O
plays	O
a	O
role	O
in	O
viral	O
-	O
host	O
interactions	O
,	O
a	O
murine	O
monoclonal	O
antibody	O
was	O
generated	O
so	O
as	O
to	O
allow	O
detection	O
of	O
the	O
protein	B-CHED
in	O
infected	O
cells	O
as	O
well	O
as	O
in	O
overexpression	O
system	O
.	O

In	O
the	O
OLA	O
group	O
,	O
5	O
cmH	B-CHED
OLA	O
significantly	O
improved	O
lung	O
aeration	O
,	O
arterial	O
oxygenation	O
,	O
and	O
gas	O
exchange	O
.	O

By	O
using	O
complete	O
nucleotide	B-CHED
sequences	O
of	O
S1	O
gene	O
we	O
determined	O
the	O
phylogeny	O
of	O
these	O
IBV	O
isolates	O
,	O
which	O
in	O
turn	O
allowed	O
us	O
to	O
define	O
six	O
lineages	O
/	O
genotypes	O
,	O
a	O
number	O
of	O
recombinants	O
and	O
a	O
novel	O
variant	O
.	O

Thus	O
,	O
we	O
explored	O
the	O
preventive	O
and	O
therapeutic	O
effects	O
of	O
tannic	O
acid	O
(	O
TA	O
),	O
a	O
natural	O
polyphenol	B-CHED
in	O
the	O
context	O
of	O
ALI	O
.	O

In	O
conclusion	O
,	O
TA	O
could	O
attenuate	O
LPS	B-CHED
-	O
induced	O
inflammation	O
and	O
may	O
be	O
a	O
potential	O
therapeutic	O
agent	O
for	O
ALI	O
-	O
associated	O
inflammation	O
in	O
clinical	O
settings	O
.	O

Results	O
indicated	O
that	O
AIF	O
translocated	O
from	O
the	O
mitochondria	O
to	O
nucleus	B-CHED
during	O
TGEV	O
infection	O
,	O
and	O
the	O
AIF	O
inhibitor	B-CHED
,	O
N	O
-	O
phenylmaleimide	O
(	O
NP	O
),	O
significantly	O
attenuated	O
the	O
apoptosis	O
.	O

Moreover	O
,	O
the	O
protein	B-CHED
levels	O
in	O
nucleus	B-CHED
and	O
the	O
mRNA	B-CHED
levels	O
of	O
AIF	O
were	O
inhibited	O
in	O
the	O
presence	O
of	O
the	O
p53	O
inhibitor	B-CHED
,	O
piﬁthrin	O
-	O
α	O
(	O
PFT	B-CHED
-	O
α	O
)	O
or	O
in	O
TGEV	O
-	O
infected	O
p53	O
-/-	O
cells	O
.	O

Furthermore	O
,	O
TGEV	O
-	O
induced	O
apoptosis	O
was	O
blocked	O
by	O
combination	O
of	O
three	O
or	O
more	O
inhibitors	B-CHED
,	O
such	O
as	O
pan	B-CHED
caspase	O
inhibitor	B-CHED
Z	O
-	O
VAD	O
-	O
FMK	O
,	O
NP	O
,	O
ABT	B-CHED
-	I-CHED
888	I-CHED
,	O
PDTC	O
,	O
PFT	B-CHED
-	O
α	O
,	O
to	O
treat	O
PK	O
-	O
15	O
cells	O
.	O

Normalised	O
metabolic	O
,	O
circulatory	O
and	O
ventilatory	O
demands	O
will	O
allow	O
one	O
to	O
single	O
out	O
the	O
oxygenation	O
defect	O
managed	O
with	O
high	O
PEEP	B-CHED
(	O
diffuse	O
recruitable	O
ARDS	O
)	O
under	O
early	O
spontaneous	O
ventilation	O
(	O
airway	O
pressure	O
release	O
ventilation	O
+	O
SV	O
or	O
low	O
-	O
pressure	O
support	O
).	O

Assuming	O
an	O
improved	O
overall	O
status	O
,	O
PaO	B-CHED

With	O
the	O
unavailability	O
of	O
vaccines	O
or	O
antiviral	B-CHED
drugs	I-CHED
to	O
prevent	O
and	O
/	O
or	O
treat	O
SFTSV	O
infection	O
,	O
early	O
rapid	O
diagnosis	O
is	O
critical	O
for	O
prevention	O
and	O
control	O
of	O
the	O
disease	O
.	O

We	O
conduct	O
experiments	O
with	O
a	O
four	O
-	O
month	O
human	O
tracking	O
data	O
set	O
collected	O
in	O
a	O
hospital	O
,	O
which	O
bore	B-CHED
a	O
big	O
nosocomial	O
outbreak	O
of	O
the	O
2003	O
SARS	O
in	O
Hong	O
Kong	O
.	O

ABSTRACT	O
:	O
Synthesis	O
and	O
biological	O
evaluation	O
of	O
a	O
novel	O
library	O
of	O
fused	O
1	B-CHED
,	I-CHED
2	I-CHED
,	I-CHED
3	I-CHED
-	I-CHED
triazole	I-CHED
derivatives	O
are	O
described	O
.	O

Chlordecone	B-CHED
also	O
accelerated	O
the	O
death	O
of	O
mice	O
infected	O
by	O
murine	O
hepatitis	O
virus	O
and	O
enhanced	O
the	O
entry	O
of	O
the	O
virus	O
into	O
the	O
cervical	O
spinal	O
cord	O
in	O
infected	O
mice	O
,	O
leading	O
to	O
considerable	O
neurological	O
damage	O
.	O

The	O
other	O
was	O
a	O
61	O
-	O
year	O
-	O
old	O
man	B-CHED
treated	O
with	O
fluconazole	B-CHED
and	O
then	O
amphotericin	O
for	O
3	O
weeks	O
,	O
with	O
progression	O
to	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
shock	O
.	O

Rapid	O
improvement	O
was	O
noted	O
in	O
both	O
cases	O
and	O
raises	O
the	O
possibility	O
that	O
the	O
addition	O
of	O
systemic	O
corticosteroids	B-CHED
may	O
hasten	O
recovery	O
in	O
patients	O
with	O
severe	O
coccidioidomycosis	O
.	O

ABSTRACT	O
:	O
Excessive	O
extravascular	O
lung	O
water	B-CHED
(	O
EVLW	O
)	O
is	O
associated	O
with	O
increased	O
morbidity	O
and	O
mortality	O
.	O

TITLE	O
:	O
Identification	O
of	O
Myricetin	B-CHED
as	O
an	O
Ebola	O
Virus	O
VP35	O
-	O
Double	O
-	O
Stranded	O
RNA	O
Interaction	O
Inhibitor	B-CHED
through	O
a	O
Novel	O
Fluorescence	O
-	O
Based	O
Assay	O
.	O

TITLE	O
:	O
Attenuation	O
of	O
replication	O
by	O
a	O
29	O
nucleotide	B-CHED
deletion	O
in	O
SARS	O
-	O
coronavirus	O
acquired	O
during	O
the	O
early	O
stages	O
of	O
human	O
-	O
to	O
-	O
human	O
transmission	O
.	O

ABSTRACT	O
:	O
A	O
29	O
nucleotide	B-CHED
deletion	O
in	O
open	O
reading	O
frame	O
8	O
(	O
ORF8	O
)	O
is	O
the	O
most	O
obvious	O
genetic	O
change	O
in	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
during	O
its	O
emergence	O
in	O
humans	O
.	O

Non	O
-	O
coding	O
RNAs	O
(	O
ncRNAs	O
)	O
are	O
not	O
translated	O
into	O
proteins	B-CHED
and	O
play	O
an	O
important	O
role	O
in	O
many	O
biological	O
and	O
pathological	O
processes	O
such	O
as	O
inflammation	O
,	O
viral	O
infection	O
,	O
and	O
mitochondrial	O
damage	O
.	O

Individual	O
TGEV	O
protein	B-CHED
screening	O
results	O
demonstrated	O
that	O
Nsp2	O
exhibited	O
a	O
high	O
potential	O
for	O
activating	O
NF	O
-	O
κB	O
and	O
enhancing	O
the	O
expression	O
of	O
pro	B-CHED
-	O
inflammatory	O
cytokines	O
.	O

With	O
the	O
help	O
of	O
this	O
case	O
report	O
we	O
want	O
to	O
call	O
attention	O
to	O
the	O
clinically	O
significant	O
alteration	O
in	O
vancomycin	B-CHED
pharmacokinetics	O
among	O
critically	O
ill	O
patients	O
.	O

A	O
47	O
-	O
year	O
-	O
old	O
man	B-CHED
was	O
admitted	O
with	O
progressive	O
shortness	O
of	O
breath	O
.	O

The	O
S	O
genes	O
contained	O
typical	O
insertions	O
and	O
deletions	O
that	O
were	O
also	O
found	O
in	O
other	O
recently	O
isolated	O
highly	O
virulent	O
PEDV	O
strains	O
from	O
China	O
and	O
other	O
countries	O
and	O
had	O
two	O
neighboring	O
unique	O
insertion	O
mutations	O
,	O
which	O
resulted	O
in	O
four	O
amino	B-CHED
acid	I-CHED
changes	O
in	O
the	O
S1	O
region	O
of	O
passages	O
P10	O
and	O
P60	O
.	O

TITLE	O
:	O
Novel	O
natural	O
non	O
-	O
nucleoside	B-CHED
inhibitors	B-CHED
of	O
HIV	O
-	O
1	O
reverse	O
transcriptase	O
identified	O
by	O
shape	O
-	O
and	O
structure	O
-	O
based	O
virtual	O
screening	O
techniques	O
.	O

Finally	O
,	O
we	O
found	O
that	O
the	O
TGEV	O
S1	O
protein	B-CHED
interacts	O
with	O
the	O
extracellular	O
region	O
of	O
TfR1	O
,	O
and	O
that	O
pre	O
-	O
incubating	O
TGEV	O
with	O
a	O
protein	B-CHED
fragment	O
containing	O
the	O
extracellular	O
region	O
of	O
TfR1	O
blocked	O
viral	O
infection	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
on	O
small	O
molecule	O
inhibitors	B-CHED
of	O
ferret	O
and	O
mink	O
coronaviruses	O
.	O

The	O
Impact	O
of	O
Events	O
Scale	O
-	O
Revised	O
(	O
IES	B-CHED
-	O
R	O
)	O
was	O
administered	O
to	O
the	O
practitioners	O
twice	O
,	O
once	O
during	O
the	O
hospital	O
shutdown	O
and	O
again	O
one	O
month	O
after	O
the	O
shutdown	O
.	O

ABSTRACT	O
:	O
Recent	O
advances	O
in	O
single	O
-	O
particle	O
cryo	O
-	O
electron	O
microscopy	O
(	O
cryoEM	O
)	O
have	O
resulted	O
in	O
determination	O
of	O
an	O
increasing	O
number	O
of	O
protein	B-CHED
structures	O
with	O
resolved	O
glycans	B-CHED
.	O

Building	O
upon	O
a	O
previous	O
Rosetta	O
framework	O
,	O
we	O
introduced	O
additional	O
features	O
and	O
score	O
terms	O
enabling	O
automatic	O
detection	O
,	O
setup	O
,	O
and	O
refinement	O
of	O
glycan	B-CHED
-	O
containing	O
structures	O
.	O

The	O
patient	O
was	O
initially	O
managed	O
with	O
intravenous	O
boluses	O
of	O
normal	O
saline	O
followed	O
by	O
continuous	O
insulin	B-CHED
infusion	O
.	O

Herein	O
,	O
we	O
employed	O
a	O
bioinorganic	O
perspective	O
to	O
develop	O
an	O
SAR	B-CHED
for	O
inhibition	O
of	O
the	O
metalloenzyme	O
influenza	O
RNA	O
polymerase	O
PA	O

ABSTRACT	O
:	O
The	O
spike	O
glycoprotein	B-CHED
(	O
S	O
)	O
of	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
comprises	O
two	O
subunits	O
,	O
S1	O
and	O
S2	O
.	O

In	O
this	O
study	O
,	O
we	O
selected	O
two	O
epitope	B-CHED
peptide	B-CHED
sequences	O
within	O
the	O
receptor	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
the	O
MERS	O
-	O
CoV	O
S	O
protein	B-CHED
.	O

Thus	O
,	O
we	O
successfully	O
produced	O
a	O
monoclonal	O
antibody	O
directed	O
against	O
the	O
RBD	O
domain	O
of	O
the	O
S	O
protein	B-CHED
which	O
could	O
be	O
used	O
in	O
the	O
development	O
of	O
diagnostics	O
and	O
therapeutic	O
applications	O
in	O
the	O
future	O
.	O

The	O
viral	O
spike	O
glycoprotein	B-CHED
(	O
S	O
)	O
utilizes	O
angiotensin	B-CHED
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
as	O
a	O
host	O
protein	B-CHED
receptor	O
and	O
mediates	O
fusion	O
of	O
the	O
viral	O
and	O
host	O
membranes	O
,	O
making	O
S	O
essential	O
to	O
viral	O
entry	O
into	O
host	O
cells	O
and	O
host	O
species	O
tropism	O
.	O

The	O
evaluation	O
of	O
viral	O
nucleic	B-CHED
acid	I-CHED
extraction	O
efficiency	O
is	O
different	O
between	O
NGS	O
and	O
qRT	O
-	O
PCR	O
analysis	O
.	O

The	O
presence	O
of	O
the	O
catechol	B-CHED
moiety	O
at	O
the	O
C	O
-	O
2	O
position	O
of	O
the	O
scaffold	O
emerged	O
as	O
critical	O
to	O
achieve	O
potent	O
anti	O
-	O
RNase	O
H	O
activity	O
,	O
which	O
also	O
encompassed	O
anti	O
-	O
RNA	O
dependent	O
DNA	O
polymerase	O
(	O
RDDP	O
)	O
activity	O
for	O
the	O
tricyclic	O
derivatives	O
.	O

TITLE	O
:	O
Extracorporeal	O
Membrane	O
Oxygenation	O
in	O
a	O
29	O
-	O
Year	O
-	O
Old	O
Man	B-CHED
with	O
ABSTRACT	O
:	O
The	O
use	O
of	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
in	O
patients	O
who	O
have	O
acute	O
respiratory	O
distress	O
syndrome	O
has	O
been	O
generally	O
beneficial	O
.	O

In	O
this	O
study	O
,	O
a	O
Chinese	O
PDCoV	O
strain	O
,	O
designated	O
CHN	B-CHED
-	O
HG	O
-	O
2017	O
,	O
was	O
isolated	O
from	O
feces	O
of	O
a	O
suckling	O
piglet	O
with	O
severe	O
watery	O
diarrhea	O
on	O
a	O
farm	O
located	O
in	O
central	O
China	O
.	O

Rescue	O
therapies	O
(	O
low	O
dose	O
steroids	B-CHED
,	O
adding	O
vasopressin	B-CHED
to	O
noradrenaline	B-CHED
,	O
proning	O
,	O
almitrine	B-CHED
,	O
NO	O
,	O
extracorporeal	O
membrane	O
oxygenation	O
,	O
etc	O
.)	O
are	O
complex	O
.	O

Immunization	O
with	O
the	O
TGEV	O
antigen	B-CHED
conjugated	O
to	O
GNPs	O
as	O
a	O
carrier	O
activates	O
the	O
respiratory	O
activity	O
of	O
lymphoid	O
cells	O
and	O
peritoneal	O
macrophages	O
,	O
which	O
is	O
directly	O
related	O
to	O
their	O
transforming	O
activity	O
and	O
to	O
the	O
activation	O
of	O
antibody	O
generation	O
.	O

In	O
infected	O
cells	O
,	O
PEDV	O
-	O
induced	O
apoptosis	O
is	O
accompanied	O
by	O
nuclear	O
concentration	O
and	O
fragmentation	O
as	O
a	O
result	O
of	O
caspase	O
-	O
3	O
and	O
caspase	O
-	O
8	O
activation	O
and	O
AIFM1	O
and	O
PARP	B-CHED
cleavage	O
.	O

Similarly	O
,	O
expression	O
of	O
S1	O
protein	B-CHED
from	O
wild	O
-	O
type	O
strain	O
BJ2011	O
or	O
cell	O
-	O
adapted	O
strain	O
CV777	O
,	O
also	O
induce	O
apoptosis	O
in	O
transfected	O
cells	O
.	O

S1	O
Spike	O
protein	B-CHED
is	O
one	O
of	O
the	O
most	O
critical	O
functional	O
proteins	B-CHED
that	O
contribute	O
to	O
cell	O
apoptosis	O
.	O

In	O
addition	O
,	O
we	O
showed	O
that	O
the	O
YxxΦ	O
motif	O
triggers	O
endocytosis	O
of	O
S	O
proteins	B-CHED
.	O

Thus	O
,	O
as	O
a	O
method	O
for	O
diagnosing	O
non	O
-	O
effusive	O
FIP	O
,	O
MLN	O
FNA	B-CHED
RT	O
-	O
qPCR	O
had	O
an	O
overall	O
sensitivity	O
of	O
90	O
.	O
0	O
%	O
and	O
specificity	O
of	O
96	O
.	O
1	O
%.	O

All	O
these	O
viruses	O
have	O
been	O
found	O
in	O
cerebrospinal	O
fluid	O
(	O
CSF	O
),	O
which	O
suggests	O
that	O
all	O
these	O
pathogens	O
,	O
once	O
in	O
the	O
lungs	O
,	O
can	O
spread	O
throughout	O
the	O
body	O
and	O
eventually	O
reach	O
the	O
CNS	B-CHED
.	O

To	O
study	O
the	O
effects	O
of	O
halogenated	O
agents	O
on	O
alveolar	O
epithelial	O
cells	O
under	O
""""	O
physiologic	O
""""	O
conditions	O
,	O
we	O
describe	O
an	O
easy	O
system	O
to	O
culture	O
cells	O
at	O
the	O
air	B-CHED
-	O
liquid	O
interface	O
and	O
expose	O
them	O
to	O
halogenated	O
agents	O
to	O
provide	O
precise	O
controlled	O
""""	O
air	B-CHED
""""	O
fractions	O
and	O
""""	O
medium	O
""""	O
concentrations	O
for	O
these	O
agents	O
.	O

The	O
curves	O
representing	O
the	O
concentrations	O
of	O
both	O
sevoflurane	B-CHED
and	O
isoflurane	B-CHED
dissolved	O
in	O
the	O
medium	O
showed	O
similar	O
courses	O
over	O
time	O
,	O
with	O
a	O
plateau	O
reached	O
at	O
one	O
hour	O
after	O
exposure	O
.	O

Pregnant	O
women	O
have	O
a	O
unique	O
immunological	O
profile	O
modulated	O
by	O
the	O
sex	B-CHED
hormones	I-CHED
required	O
to	O
maintain	O
pregnancy	O
,	O
namely	O
progesterone	B-CHED
and	O
estrogens	B-CHED
.	O

In	O
this	O
review	O
,	O
we	O
compile	O
research	O
findings	O
in	O
the	O
clinic	O
and	O
in	O
animal	O
models	O
that	O
elaborate	O
on	O
the	O
unique	O
features	O
of	O
H1N1	O
influenza	O
A	O
viral	O
pathogenesis	O
during	O
pregnancy	O
,	O
the	O
crosstalk	O
between	O
innate	O
immune	O
signaling	O
and	O
hormonal	O
regulation	O
during	O
pregnancy	O
,	O
and	O
the	O
role	O
of	O
pregnancy	O
hormones	B-CHED
in	O
modulating	O
cellular	O
responses	O
to	O
influenza	O
A	O
viral	O
infection	O
at	O
mid	O
-	O
gestation	O
.	O

The	O
patients	O
received	O
symptomatic	O
treatment	O
and	O
antivirals	B-CHED
where	O
appropriate	O
and	O
were	O
followed	O
telephonically	O
to	O
collect	O
data	O
on	O
illness	O
outcome	O
.	O

ABSTRACT	O
:	O
We	O
report	O
the	O
case	O
of	O
a	O
59	O
-	O
year	O
-	O
old	O
man	B-CHED
who	O
presented	O
to	O
the	O
University	O
of	O
Kentucky	O
Albert	O
B	O
.	O
Chandler	O
Medical	O
Center	O
(	O
Lexington	O
,	O
KY	O
,	O
USA	O
)	O
after	O
being	O
found	O
fallen	O
down	O
in	O
the	O
woods	O
.	O

A	O
comparative	O
genomics	O
study	O
revealed	O
similar	O
nucleotide	B-CHED
sequences	O
between	O
BP	O
-	O
caKII	O
,	O
K2	O
and	O
KM91	O
but	O
clearly	O
showed	O
different	O
mutations	O
among	O
them	O
.	O

Wild	O
-	O
type	O
(	O
wt	O
)	O
and	O
RAG2	O
In	O
wt	O
mice	O
,	O
lung	O
mechanics	O
,	O
body	O
weight	O
and	O
body	O
temperature	O
deteriorated	O
in	O
the	O
LPS	B-CHED
-	O
group	O
during	O
the	O
early	O
phase	O
(	O
up	O
to	O
d4	O
);	O
these	O
alterations	O
were	O
accompanied	O
by	O
increased	O
leukocyte	O
numbers	O
and	O
inflammatory	O
cytokine	O
levels	O
in	O
the	O
BALF	O
.	O

The	O
compliance	O
rates	O
for	O
the	O
entire	O
3	O
-	O
h	O
bundle	O
,	O
measurement	O
of	O
central	O
venous	O
pressure	O
,	O
and	O
assessment	O
of	O
central	O
venous	O
oxygen	B-CHED
saturation	O
were	O
64	O
%,	O
26	O
%,	O
and	O
7	O
%,	O
respectively	O
.	O

The	O
boy	O
had	O
a	O
significant	O
reduction	O
in	O
free	O
carnitine	B-CHED
in	O
blood	O
and	O
significant	O
increases	O
in	O
medium	O
-	O
and	O
long	O
-	O
chain	O
fatty	O
acyl	O
carnitine	B-CHED
,	O
urinary	O
glutaric	B-CHED
acid	I-CHED
,	O
3	O
-	O
hydroxy	B-CHED
glutaric	B-CHED
acid	I-CHED
,	O
isovalerylglycine	B-CHED
,	O
and	O
ethylmalonic	B-CHED
acid	I-CHED
,	O
suggesting	O
the	O
possibility	O
of	O
multiple	O
acyl	B-CHED
-	I-CHED
CoA	I-CHED
dehydrogenase	O
deficiency	O
.	O

Finally	O
,	O
he	O
was	O
diagnosed	O
with	O
multiple	O
acyl	B-CHED
-	I-CHED
CoA	I-CHED
dehydrogenase	O
deficiency	O
.	O

Reye	O
syndrome	O
and	O
sudden	O
death	O
symptoms	O
were	O
caused	O
by	O
nimesulide	B-CHED
-	O
induced	O
acute	O
metabolic	O
crisis	O
.	O

Admissions	O
for	O
trauma	O
or	O
pneumonia	O
,	O
higher	O
nonpulmonary	O
sequential	O
organ	O
failure	O
assessment	O
score	O
,	O
lower	O
partial	O
pressure	O
of	O
alveolar	O
oxygen	B-CHED
/	O
fraction	O
of	O
inspired	O
oxygen	B-CHED
,	O
and	O
higher	O
peak	O
inspiratory	O
pressure	O
were	O
independently	O
associated	O
with	O
worsening	O
.	O

On	O
the	O
outer	O
surface	O
,	O
virus	O
has	O
spike	O
like	O
glycoprotein	B-CHED
which	O
is	O
responsible	O
for	O
the	O
attachment	O
and	O
entrance	O
inside	O
host	O
cells	O
.	O

For	O
instance	O
,	O
skew	O
analysis	O
of	O
the	O
nucleotide	B-CHED
bias	O
of	O
several	O
viral	O
RNA	O
genomes	O
indicated	O
that	O
it	O
is	O
enriched	O
in	O
the	O
unpaired	O
,	O
single	O
-	O
stranded	O
genome	O
regions	O
,	O
thus	O
creating	O
an	O
even	O
more	O
striking	O
virus	O
-	O
specific	O
signature	O
.	O

Importantly	O
,	O
the	O
skew	O
value	O
trees	O
are	O
similar	O
to	O
the	O
trees	O
constructed	O
by	O
a	O
""""	O
classical	O
""""	O
model	O
of	O
evolutionary	O
nucleotide	B-CHED
substitution	O
.	O

These	O
results	O
indicate	O
that	O
the	O
Euclidean	O
distance	O
analysis	O
of	O
nucleotide	B-CHED
skew	O
data	O
forms	O
a	O
nice	O
addition	O
to	O
the	O
virology	O
toolbox	O
.	O

The	O
test	O
detects	O
a	O
cooperative	O
interaction	O
between	O
a	O
gold	B-CHED
nanoparticle	I-CHED
and	O
arguably	O
the	O
three	O
most	O
important	O
proteins	B-CHED
involved	O
in	O
the	O
immune	O
system	O
:	O
immunoglobulin	O
M	O
(	O
IgM	O
),	O
immunoglobulin	O
G	O
(	O
IgG	O
),	O
and	O
at	O
least	O
one	O
complement	O
protein	B-CHED
,	O
C3	O
,	O
in	O
the	O
blood	O
serum	O
.	O

They	O
received	O
significantly	O
lower	O
cumulative	O
doses	O
of	O
opioids	O
(	O
median	O
,	O
mg	O
/	O
kg	O
,	O
14	O
.	O
2	O
vs	O
16	O
.	O
2	O
;	O
P	O
<	O
.	O
001	O
)	O
and	O
benzodiazepines	B-CHED
(	O
10	O
.	O
6	O
vs	O
14	O
.	O
4	O
;	O
P	O
<	O
.	O
001	O
).	O

Importantly	O
,	O
TRIM8	O
could	O
negatively	O
meditate	O
AMP	O
-	O
activated	O
protein	B-CHED
kinase	O
-	O
α	O
(	O
AMPKα	O
)	O
activation	O
to	O
modulate	O
LPS	B-CHED
-	O
triggered	O
inflammatory	O
response	O
and	O
ROS	B-CHED
generation	O
in	O
vitro	O
.	O

The	O
diagnosis	O
can	O
be	O
difficult	O
as	O
excessive	O
urine	O
output	O
and	O
high	O
serum	O
sodium	O
can	O
often	O
be	O
attributed	O
to	O
high	O
insensible	O
water	B-CHED
loss	O
in	O
the	O
extremely	O
premature	O
newborn	O
.	O

TITLE	O
:	O
A	O
fatal	O
complication	O
of	O
tirofiban	B-CHED
in	O
an	O
octogenarian	O
:	O
Diffuse	O
alveolar	O
hemorrhage	O
.	O

TITLE	O
:	O
Pulsed	O
Dose	O
Oxygen	B-CHED
Delivery	O
During	O
Mechanical	O
Ventilation	O
:	O
Impact	O
on	O
Oxygenation	O
.	O

The	O
ventilator	O
communicates	O
with	O
the	O
concentrator	O
to	O
increase	O
or	O
decrease	O
oxygen	B-CHED
bolus	O
size	O
to	O
maintain	O
a	O
target	O
SpO2	O
of	O
94	O
%.	O

Additionally	O
,	O
Ras	B-CHED
-	O
related	O
C3	O
botulinum	O
toxin	O
substrate	O
1	O
(	O
Rac1	O
),	O
cell	O
division	O
cycle	O
42	O
(	O
Cdc42	O
),	O
and	O
downstream	O
regulatory	O
gene	O
p21	O
-	O
activated	O
protein	B-CHED
kinases	O
(	O
PAKs	O
)	O
are	O
recruited	O
as	O
downstream	O
mediators	O
of	O
PHEV	O
-	O
induced	O
dynamic	O
changes	O
of	O
the	O
cofilin	O
activity	O
pathway	O
.	O

Influenza	O
A	O
(	O
H1N1	O
,	O
H5N1	O
,	O
H3N2	B-CHED
,	O
and	O
H1N1pdm09	O
)	O
and	O
Influenza	O
B	O
are	O
common	O
among	O
the	O
Pakistani	O
population	O
.	O

Modified	O
Vaccinia	O
virus	O
Ankara	O
(	O
MVA	B-CHED
),	O
a	O
safety	O
-	O
tested	O
strain	O
of	O
vaccinia	O
virus	O
for	O
preclinical	O
and	O
clinical	O
vaccine	O
research	O
,	O
was	O
used	O
for	O
generating	O
MVA	B-CHED
-	O
MERS	O
-	O
N	O
expressing	O
recombinant	O
N	O
protein	B-CHED
.	O

The	O
identification	O
of	O
this	O
epitope	B-CHED
,	O
and	O
the	O
availability	O
of	O
the	O
MVA	B-CHED
-	O
MERS	O
-	O
N	O
candidate	O
vaccine	O
,	O
will	O
help	O
to	O
evaluate	O
MERS	O
-	O
N	O
-	O
specific	O
immune	O
responses	O
and	O
the	O
potential	O
immune	O
correlates	O
of	O
vaccine	O
-	O
mediated	O
protection	O
in	O
the	O
appropriate	O
murine	O
models	O
of	O
MERS	O
-	O
CoV	O
infection	O
.	O

TITLE	O
:	O
Development	O
of	O
Small	O
-	O
Molecule	O
MERS	O
-	O
CoV	O
Inhibitors	B-CHED
.	O

In	O
particular	O
,	O
the	O
experiment	O
with	O
an	O
external	O
wind	O
direction	O
and	O
speed	O
similar	O
to	O
those	O
during	O
the	O
hospitalization	O
of	O
the	O
initial	O
patient	O
revealed	O
that	O
the	O
air	B-CHED
change	O
rate	O
was	O
17	O
⁻	O
20	O
air	B-CHED
changes	O
per	O
hour	O
(	O
ACH	B-CHED
),	O
with	O
air	B-CHED
introduced	O
through	O
the	O
window	O
in	O
the	O
room	O
of	O
the	O
infected	O
patient	O
(	O
room	O
8104	O
).	O

ABSTRACT	O
:	O
Viral	O
infections	O
trigger	O
robust	O
secretion	O
of	O
interferons	O
and	O
other	O
antiviral	B-CHED
cytokines	O
by	O
infected	O
and	O
bystander	O
cells	O
,	O
which	O
in	O
turn	O
can	O
tune	O
the	O
immune	O
response	O
and	O
may	O
lead	O
to	O
viral	O
clearance	O
or	O
immune	O
suppression	O
.	O

TITLE	O
:	O
Identification	O
and	O
characterization	O
of	O
Coronaviridae	O
genomes	O
from	O
Vietnamese	O
bats	O
and	O
rats	O
based	O
on	O
conserved	O
protein	B-CHED
domains	O
.	O

TITLE	O
:	O
Advancements	O
in	O
Nucleic	B-CHED
Acid	I-CHED
Based	O
Therapeutics	O
against	O
Respiratory	O
Viral	O
Infections	O
.	O

These	O
therapeutic	O
nucleic	B-CHED
acids	I-CHED
can	O
be	O
efficiently	O
delivered	O
through	O
the	O
airways	O
.	O

Automated	O
VAE	O
surveillance	O
is	O
efficient	O
and	O
useful	O
as	O
a	O
quality	O
indicator	B-CHED
in	O
the	O
ICU	O
while	O
the	O
differences	O
in	O
the	O
interpretation	O
of	O
VARI	O
criteria	O
limit	O
its	O
role	O
in	O
the	O
design	O
of	O
global	O
protocols	O
and	O
preventive	O
strategies	O
.	O

TITLE	O
:	O
A	O
24	O
-	O
hour	O
perioperative	O
case	O
study	O
on	O
argatroban	B-CHED
use	O
for	O
left	O
ventricle	O
assist	O
device	O
insertion	O
during	O
cardiopulmonary	O
bypass	O
and	O
veno	O
-	O
arterial	O
extracorporeal	O
membrane	O
oxygenation	O
.	O

Following	O
a	O
positive	O
heparin	B-CHED
-	O
induced	O
thrombocytopenia	O
(	O
HIT	O
)	O
assay	O
,	O
a	O
total	O
circuit	O
exchange	O
was	O
required	O
to	O
eliminate	O
all	O
heparin	B-CHED
coating	O
and	O
argatroban	B-CHED
was	O
deemed	O
the	O
anticoagulant	B-CHED
of	O
choice	O
due	O
to	O
acute	O
kidney	O
injury	O
.	O

There	O
was	O
difficulty	O
achieving	O
an	O
activated	O
clotting	O
time	O
(	O
ACT	O
)	O
>	O
400	O
s	O
:	O
multiple	O
argatroban	B-CHED
bolus	O
doses	O
were	O
required	O
,	O
along	O
with	O
accelerated	O
up	O
-	O
titration	O
of	O
infusion	O
dosing	O
.	O

TITLE	O
:	O
Changing	O
epidemiological	O
patterns	O
of	O
HIV	O
and	O
AIDS	O
in	O
China	O
in	O
the	O
post	O
-	O
SARS	O
era	B-CHED
identified	O
by	O
the	O
nationwide	O
surveillance	O
system	O
.	O

Mice	O
were	O
killed	O
24	O
hours	O
after	O
the	O
administration	O
of	O
LPS	B-CHED
and	O
MMI	B-CHED
-	O
0100	O
.	O

The	O
mRNA	B-CHED
expression	O
of	O
ICAM	O
-	O
1	O
in	O
mouse	O
PMVECs	O
was	O
determined	O
using	O
RT	O
-	O
PCR	O
,	O
and	O
the	O
protein	B-CHED
expression	O
of	O
MK2	O
and	O
ICAM	O
-	O
1	O
in	O
mouse	O
PMVECs	O
was	O
analyzed	O
using	O
Western	O
blotting	O
and	O
immunohistochemistry	O
.	O

These	O
data	O
indicate	O
that	O
MMI	B-CHED
-	O
0100	O
ameliorates	O
lung	O
inflammation	O
in	O
a	O
mouse	O
model	O
of	O
ARDS	O
by	O
reducing	O
endothelial	O
expression	O
of	O
ICAM	O
-	O
1	O
.	O

Moreover	O
,	O
The	O
acute	O
physiology	O
and	O
chronic	O
health	O
evaluation	O
II	O
(	O
APACHE	O
II	O
),	O
CT	O
severity	O
index	O
(	O
CTSI	O
),	O
multiple	O
organ	O
failure	O
(	O
MOF	O
)	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
incidence	O
,	O
mortality	O
and	O
C	O
-	O
reactive	O
protein	B-CHED
(	O
CRP	B-CHED
),	O
white	O
blood	O
cell	O
count	O
(	O
WBC	O
),	O
procalcitonin	O
(	O
PCT	O
)	O
and	O
immature	O
granulocytes	O
in	O
persistent	O
SIRS	O
group	O
were	O
further	O
higher	O
than	O
those	O
in	O
the	O
temporary	O
SIRS	O
group	O
[	O
APACHE	O
II	O
:	O
9	O
(	O
6	O
,	O
12	O
)	O
vs	O
.	O
5	O
(	O
3	O
,	O
7	O
),	O
CTSI	O
:	O
6	O
(	O
4	O
,	O
6	O
)	O
vs	O
.	O
4	O
(	O
3	O
,	O
6	O
),	O
MOF	O
incidence	O
:	O
92	O
.	O
0	O
%	O
vs	O
.	O
32	O
.	O
8	O
%,	O
ARDS	O
incidence	O
:	O
39	O
.	O
9	O
%	O
vs	O
.	O
10	O
.	O
1	O
%,	O
morbidity	O
:	O
11	O
.	O
1	O
%	O
vs	O
.	O
4	O
.	O
2	O
%,	O
CRP	B-CHED
(	O
mg	O
/	O
L	O
):	O
25	O
.	O
00	O
(	O
0	O
.	O
80	O
,	O
212	O
.	O
25	O
)	O
vs	O
.	O
0	O
.	O
80	O
(	O
0	O
.	O
80	O
,	O
123	O
.	O
50	O
),	O
WBC	O
(×	O
10	O
Immature	O
granulocyte	O
in	O
peripheral	O
blood	O
is	O
a	O
potential	O
indicator	B-CHED
for	O
persistent	O
SIRS	O
in	O
AP	O
patients	O
.	O

Additionally	O
,	O
viral	O
replication	O
was	O
compared	O
in	O
Vero	O
and	O
IPEC	O
-	O
DQ	O
cells	O
at	O
the	O
presence	O
of	O
bovine	O
mucin	O
(	O
BM	O
),	O
porcine	O
gastric	O
mucin	O
(	O
PGM	B-CHED
),	O
swine	O
bile	O
and	O
bile	B-CHED
acids	I-CHED
during	O
inoculation	O
.	O

In	O
normal	O
circumstances	O
once	O
the	O
needs	O
are	O
met	B-CHED
both	O
SVR	O
and	O
CO	O
are	O
stabilized	O
on	O
a	O
new	O
steady	O
state	O
.	O

Interestingly	O
,	O
erythrocytes	O
from	O
Casd1	O
-	O
deficient	O
mice	O
also	O
lost	B-CHED
reactivity	O
to	O
TER	O
-	O
119	O
,	O
a	O
rat	O
monoclonal	O
antibody	O
that	O
is	O
widely	O
used	O
to	O
mark	O
the	O
murine	O
erythroid	O
lineage	O
.	O

The	O
sialic	B-CHED
acid	I-CHED
glyco	O
-	O
epitope	B-CHED
recognized	O
by	O
TER	O
-	O
119	O
on	O
erythrocytes	O
was	O
sensitive	O
to	O
the	O
sialic	B-CHED
acid	I-CHED
O	O
-	O
acetyl	B-CHED
esterase	O
activity	O
of	O
the	O
hemagglutinin	O
-	O
esterase	O
from	O
bovine	O
coronavirus	O
but	O
not	O
to	O
the	O
corresponding	O
enzyme	O
from	O
the	O
influenza	O
C	O
virus	O
.	O

ABSTRACT	O
:	O
Although	O
several	O
reports	O
suggest	O
that	O
the	O
entry	O
of	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
depends	O
on	O
lipid	B-CHED
rafts	O
and	O
low	O
pH	O
,	O
the	O
endocytic	O
route	O
and	O
intracellular	O
trafficking	O
are	O
unclear	O
.	O

No	O
specific	O
drug	O
treatment	O
exists	O
for	O
MERS	O
;	O
however	O
,	O
the	O
neutralizing	O
antibodies	O
,	O
ribavirin	B-CHED
and	O
interferon	O
have	O
been	O
shown	O
to	O
be	O
potentially	O
useful	O
anti	O
-	O
MERS	O
-	O
CoV	O
drugs	O
.	O

In	O
high	O
-	O
risk	O
patients	O
,	O
pre	O
-	O
emptive	O
treatment	O
with	O
antivirals	B-CHED
for	O
upper	O
respiratory	O
tract	O
infection	O
(	O
URTI	O
)	O
to	O
decrease	O
progression	O
to	O
LRTI	O
is	O
a	O
common	O
strategy	O
.	O

Heterozygous	O
deletion	O
of	O
Poldip2	O
was	O
found	O
to	O
reduce	O
LPS	B-CHED
-	O
induced	O
mortality	O
within	O
20	O
h	O
,	O
lung	O
inflammatory	O
signaling	O
,	O
and	O
leukocyte	O
infiltration	O
.	O

Tocolytics	B-CHED
aimed	O
to	O
stop	O
contractions	O
until	O
platelets	O
were	O
in	O
a	O
safe	O
range	O
previous	O
to	O
delivery	O
.	O

Using	O
click	O
chemistry	O
,	O
the	O
overexpressed	O
sterol	B-CHED
regulatory	O
element	O
binding	O
protein	B-CHED
(	O
SREBP	O
)	O
is	O
shown	O
to	O
interact	O
with	O
AM580	B-CHED
,	O
which	O
accounts	O
for	O
its	O
broad	O
-	O
spectrum	O
antiviral	B-CHED
activity	O
.	O

TITLE	O
:	O
Determination	O
of	O
host	O
proteins	B-CHED
composing	O
the	O
microenvironment	O
of	O
coronavirus	O
replicase	O
complexes	O
by	O
proximity	O
-	O
labeling	O
.	O

We	O
engineered	O
a	O
biotin	B-CHED
ligase	O
into	O
a	O
coronaviral	O
replication	O
/	O
transcription	O
complex	O
(	O
RTC	O
)	O
and	O
identified	O
>	O
500	O
host	O
proteins	B-CHED
constituting	O
the	O
RTC	O
microenvironment	O
.	O

The	O
mechanism	O
of	O
Griffithsin	O
'	O
s	O
action	O
against	O
PEDV	O
involved	O
both	O
preventing	O
viral	O
attachment	O
to	O
host	O
cells	O
and	O
disrupting	O
cell	O
-	O
to	O
-	O
cell	O
transmission	O
;	O
its	O
dual	O
mode	O
of	O
action	O
distinguished	O
Griffithsin	O
from	O
most	O
other	O
antiviral	B-CHED
drugs	I-CHED
.	O

Point	O
mutations	O
observed	O
in	O
the	O
receptor	O
-	O
binding	O
domain	O
and	O
hypervariable	O
region	O
of	O
the	O
S1	O
subunit	O
of	O
the	O
spike	O
protein	B-CHED
likely	O
have	O
an	O
effect	O
on	O
these	O
differences	O
in	O
biological	O
characteristics	O
,	O
although	O
the	O
influence	O
of	O
other	O
factors	O
-	O
such	O
as	O
host	O
innate	O
-	O
immune	O
responses	O
and	O
changes	O
in	O
genomic	O
regions	O
beyond	O
the	O
S1	O
protein	B-CHED
-	O
might	O
also	O
be	O
responsible	O
for	O
such	O
changes	O
.	O

Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
L	O
.	O
acidophilus	O
S	O
-	O
layer	O
protein	B-CHED
plays	O
an	O
inhibitory	O
role	O
during	O
PEDV	O
infection	O
of	O
Vero	O
cells	O
,	O
and	O
that	O
the	O
antagonistic	O
activity	O
of	O
the	O
protein	B-CHED
is	O
not	O
via	O
competition	O
with	O
PEDV	O
for	O
binding	O
sites	O
.	O

Moreover	O
,	O
these	O
peptides	B-CHED
,	O
particularly	O
HKU4	O
-	O
HR2P2	O
and	O
HKU4	O
-	O
HR2P3	O
,	O
exhibited	O
potent	O
inhibitory	O
activity	O
against	O
MERS	O
-	O
CoV	O
S	O
-	O
mediated	O
cell	O
⁻	O
cell	O
fusion	O
and	O
viral	O
infection	O
,	O
suggesting	O
that	O
these	O
HKU4	O
HR2	O
-	O
derived	O
peptides	B-CHED
could	O
be	O
candidates	O
for	O
futher	O
development	O
as	O
antiviral	B-CHED
agents	I-CHED
against	O
MERS	O
-	O
CoV	O
infection	O
.	O

After	O
four	O
rounds	O
of	O
biopanning	O
,	O
scFvs	O
that	O
showed	O
higher	O
affinity	O
to	O
the	O
PEDV	O
antigen	B-CHED
were	O
selected	O
for	O
further	O
study	O
.	O

The	O
continuous	O
net	O
reclassification	O
improvement	O
(	O
NRI	B-CHED
)	O
in	O
the	O
ARDS	O
group	O
resulting	O
from	O
AGPT2	O
inclusion	O
was	O
64	O
.	O
1	O
%	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
the	O
integrated	O
discrimination	O
improvement	O
(	O
IDI	O
)	O
index	O
was	O
0	O
.	O
057	O
(	O
P	O
=	O
0	O
.	O
003	O
).	O

Understanding	O
how	O
cellular	O
lipids	B-CHED
may	O
modulate	O
the	O
pathogenicity	O
of	O
human	O
-	O
pathogenic	O
coronaviruses	O
remains	O
poor	O
.	O

ABSTRACT	O
:	O
Paracetamol	B-CHED
is	O
a	O
popular	O
and	O
easily	O
available	O
drug	O
which	O
is	O
used	O
world	O
-	O
wide	O
as	O
analgesic	B-CHED
,	O
antipyretic	B-CHED
agent	O
.	O

The	O
optimal	O
mAb	O
4A11	O
was	O
coated	O
on	O
NC	O
membrane	O
as	O
the	O
capturing	O
reagent	B-CHED
and	O
the	O
mAb	O
A11H7	O
was	O
coupled	O
to	O
gold	B-CHED
nanoparticles	B-CHED
(	O
AuNPs	O
)	O
as	O
detection	O
reagent	B-CHED
for	O
the	O
new	O
ICA	B-CHED
.	O

Biomarker	B-CHED
panels	O
have	O
potential	O
applications	O
in	O
molecular	O
phenotyping	O
for	O
identifying	O
patients	O
at	O
risk	O
of	O
developing	O
ARDS	O
,	O
diagnosis	O
of	O
ARDS	O
,	O
risk	O
stratification	O
and	O
monitoring	O
.	O

This	O
study	O
investigated	O
the	O
association	O
of	O
macrolides	B-CHED
with	O
90	O
-	O
day	O
mortality	O
and	O
MERS	O
coronavirus	O
(	O
CoV	O
)	O
RNA	O
clearance	O
in	O
critically	O
ill	O
patients	O
with	O
MERS	O
.	O

Solving	O
viral	O
surface	O
protein	B-CHED
structures	O
also	O
supports	O
rapid	O
vaccine	O
antigen	B-CHED
design	O
and	O
application	O
of	O
platform	O
manufacturing	O
approaches	O
for	O
emerging	O
pathogens	O
.	O

(	O
n	O
=	O
1280	O
patients	O
)	O
met	B-CHED
our	O
inclusion	O
criteria	O
.	O

In	O
this	O
study	O
,	O
PEDV	O
recombinant	O
S1	O
protein	B-CHED
(	O
rS1	O
)	O
was	O
expressed	O
with	O
the	O
Bac	O
-	O
to	O
-	O
Bac	O
system	O
and	O
purified	O
by	O
nickel	B-CHED
-	O
affinity	O
chromatography	O
.	O

He	O
was	O
treated	O
with	O
intravenous	O
ceftriaxone	B-CHED
2g	O
per	O
day	O
for	O
21	O
days	O
,	O
leading	O
to	O
a	O
substantial	O
improvement	O
in	O
symptoms	O
.	O

ABSTRACT	O
:	O
Recent	O
outbreaks	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
and	O
Middle	O
East	O
respiratory	O
syndrome	O
,	O
along	O
with	O
the	O
threat	O
of	O
a	O
future	O
coronavirus	O
-	O
mediated	O
pandemic	O
,	O
underscore	O
the	O
importance	O
of	O
finding	O
ways	O
to	O
combat	B-CHED
these	O
viruses	O
.	O

The	O
trimeric	O
spike	O
transmembrane	O
glycoprotein	B-CHED
S	O
mediates	O
entry	O
into	O
host	O
cells	O
and	O
is	O
the	O
major	O
target	O
of	O
neutralizing	O
antibodies	O
.	O

Although	O
oxygenation	O
and	O
ventilation	O
can	O
be	O
assessed	O
non	O
-	O
invasively	O
via	O
pulse	O
oximetry	O
and	O
end	O
-	O
tidal	O
carbon	B-CHED
dioxide	I-CHED
monitoring	O
,	O
respectively	O
,	O
blood	O
gas	O
analysis	O
is	O
the	O
standard	O
.	O

The	O
calculation	O
only	O
accounts	O
for	O
dissolved	O
CO2	B-CHED
;	O
this	O
measurement	O
using	O
a	O
standard	O
chemistry	O
analysis	O
will	O
likely	O
be	O
called	O
a	O
""""	O
total	O
CO2	B-CHED
"""."	O

<	O
strong	O
>	O
RESULTS	O
</	O
strong	O
>	O
We	O
found	O
the	O
HIPK1	O
was	O
elevated	O
in	O
ALI	O
model	O
mice	O
while	O
interference	O
of	O
HIPK1	O
by	O
siRNA	O
attenuated	O
the	O
inflammation	O
and	O
oxidative	O
stress	O
indicators	O
(	O
H2O2	B-CHED
,	O
O	O
-	O
2	O
,	O
and	O
NO	O
).	O

The	O
overall	O
degree	O
of	O
nucleotide	B-CHED
sequence	O
identity	O
was	O
92	O
.	O
4	O
-	O
92	O
.	O
6	O
%	O
between	O
Polish	O
PL	O
/	O
G032	O
/	O
2015	O
and	O
Middle	O
Eastern	O
UAE	O
-	O
HKU30	O
QdCoV	O
isolates	O
.	O

CONCLUSIONS	O
:	O
Physicians	O
should	O
be	O
aware	O
of	O
this	O
infection	O
during	O
the	O
flu	O
season	O
and	O
quickly	O
adapt	O
the	O
specific	O
antibiotic	B-CHED
treatment	O
,	O
including	O
a	O
drug	O
inhibiting	O
toxin	O
production	O
.	O

KPF	O
attenuates	O
LPS	B-CHED
-	O
mediated	O
production	O
of	O
cytokines	O
as	O
well	O
as	O
activation	O
of	O
NF	O
-	O
κB	O
.	O
Furthermore	O
,	O
we	O
identified	O
that	O
KPF	O
prevents	O
increased	O
K63	O
-	O
linked	O
polyubiquitination	O
on	O
TNF	O
receptor	O
associated	O
factor	O
-	O
6	O
(	O
TRAF6	O
)	O
and	O
interleukin	O
-	O
1	O
receptor	O
-	O
associated	O
kinase	O
1	O
(	O
IRAK1	O
).	O

The	O
omega	O
values	O
of	O
cluster	O
1	O
(	O
C1	O
)	O
and	O
cluster	O
2	O
(	O
C2	O
)	O
were	O
0	O
.	O
15734	O
and	O
0	O
.	O
11613	O
,	O
respectively	O
,	O
and	O
naive	O
empirical	O
bayes	O
analysis	O
identified	O
two	O
amino	B-CHED
acid	I-CHED
positions	O
(	O
179	O
and	O
501	O
)	O
in	O
the	O
S	O
protein	B-CHED
in	O
C1	O
and	O
three	O
amino	B-CHED
acid	I-CHED
positions	O
(	O
113	O
,	O
501	O
,	O
and	O
525	O
)	O
in	O
that	O
of	O
C2	O
that	O
underwent	O
positive	O
selection	O
(	O
p	O
>	O
99	O
%).	O

To	O
determine	O
whether	O
PEEP	B-CHED
titration	O
guided	O
by	O
esophageal	O
pressure	O
(	O
PES	O
),	O
an	O
estimate	O
of	O
pleural	O
pressure	O
,	O
was	O
more	O
effective	O
than	O
empirical	O
high	O
PEEP	B-CHED
-	O
fraction	O
of	O
inspired	O
oxygen	B-CHED
(	O
Fio2	O
)	O
in	O
moderate	O
to	O
severe	O
ARDS	O
.	O

Participants	O
were	O
randomized	O
to	O
PES	O
-	O
guided	O
PEEP	B-CHED
(	O
n	O
=	O
102	O
)	O
or	O
empirical	O
high	O
PEEP	B-CHED
-	O
Fio2	O
(	O
n	O
=	O
98	O
).	O

The	O
plasma	O
metabolites	B-CHED
were	O
detected	O
with	O
gas	O
chromatography	O
-	O
mass	O
spectrometry	O
(	O
GC	O
-	O
MS	O
),	O
and	O
the	O
relevant	O
metabolic	O
pathways	O
were	O
predicted	O
using	O
the	O
Kyoto	O
Encyclopedia	O
of	O
Genes	O
and	O
Genomes	O
(	O
KEGG	O
)	O
database	O
.	O

A	O
total	O
of	O
222	O
metabolites	B-CHED
were	O
identified	O
in	O
our	O
study	O
,	O
of	O
which	O
128	O
were	O
significantly	O
altered	O
in	O
patients	O
with	O
ARDS	O
compared	O
with	O
healthy	O
controls	O
.	O

ABSTRACT	O
:	O
Since	O
pyrithiobac	O
(	O
PTB	O
)	O
is	O
a	O
successful	O
commercial	O
herbicide	B-CHED
with	O
very	O
low	O
toxicity	O
against	O
mammals	O
,	O
it	O
is	O
worth	O
exploring	O
its	O
derivatives	O
for	O
an	O
extensive	O
study	O
.	O

TITLE	O
:	O
Feasibility	O
and	O
safety	O
of	O
extracorporeal	O
CO	O
ABSTRACT	O
:	O
We	O
assessed	O
feasibility	O
and	O
safety	O
of	O
extracorporeal	O
carbon	B-CHED
dioxide	I-CHED
removal	O
(	O
ECCO	O
Prospective	O
multicenter	O
international	O
phase	O
2	O
study	O
.	O

Nanobodies	O
(	O
Nbs	B-CHED
)	O
are	O
camelid	O
heavy	O
chain	O
variable	O
domains	O
with	O
properties	O
distinct	O
from	O
those	O
of	O
conventional	O
antibodies	O
and	O
antibody	O
fragments	O
.	O

The	O
engineered	O
oligomeric	O
Nbs	B-CHED
were	O
very	O
stable	O
under	O
extreme	O
conditions	O
,	O
including	O
low	O
or	O
high	O
pH	O
,	O
protease	O
(	O
pepsin	O
),	O
chaotropic	O
denaturant	O
(	O
urea	B-CHED
),	O
and	O
high	O
temperature	O
.	O

Moderate	O
cytostatic	B-CHED
activity	O
against	O
cervix	O
carcinoma	O
(	O
HeLa	O
),	O
murine	O
leukemia	O
(	O
L1210	O
)	O
and	O
human	O
lymphocyte	O
(	O
CEM	O
)	O
tumor	O
cell	O
lines	O
was	O
displayed	O
by	O
the	O
protected	O
3	O
΄-	O
deoxy	O
derivatives	O
12b	O
,	O
12c	O
,	O
12d	O
,	O
and	O
the	O
3	O
΄-	O
deoxy	O
-	O
3	O
΄-	O
methyl	B-CHED
18a	O
,	O
18b	O
,	O
18c	O
.	O

Antiviral	B-CHED
evaluation	O
revealed	O
appreciable	O
activity	O
against	O
Coxsackie	O
virus	O
B4	O
,	O
Respiratory	O
syncytial	O
virus	O
,	O
Yellow	O
Fever	O
Virus	O
and	O
Human	O
Coronavirus	O
(	O
229E	O
)	O
for	O
the	O
3	O
΄-	O
deoxy	O
compounds	O
12b	O
,	O
14	O
,	O
and	O
the	O
3	O
΄-	O
deoxy	O
-	O
3	O
΄-	O
methyl	B-CHED
18a	O
,	O
18c	O
,	O
18d	O
,	O
accompanied	O
by	O
low	O
cytotoxicity	O
.	O

This	O
report	O
describes	O
the	O
total	O
and	O
facile	O
synthesis	O
of	O
modified	O
furanononucleosides	O
of	O
uracil	B-CHED
,	O
with	O
alterations	O
on	O
both	O
the	O
sugar	O
and	O
the	O
heterocyclic	O
portions	O
.	O

Antiviral	B-CHED
evaluation	O
revealed	O
appreciable	O
activity	O
against	O
Coxsackie	O
virus	O
B4	O
,	O
Respiratory	O
syncytial	O
virus	O
,	O
Yellow	O
Fever	O
Virus	O
and	O
Human	O
Coronavirus	O
(	O
229E	O
)	O
for	O
the	O
3	O
΄-	O
deoxy	O
compounds	O
12b	O
,	O
14	O
,	O
and	O
the	O
3	O
΄-	O
deoxy	O
-	O
3	O
΄-	O
methyl	B-CHED
18a	O
,	O
18c	O
,	O
18d	O
,	O
accompanied	O
by	O
low	O
cytotoxicity	O
.	O

Due	O
to	O
growth	O
of	O
antibiotic	B-CHED
-	O
resistant	O
bacteria	O
from	O
plasma	O
in	O
cell	O
cultures	O
used	O
for	O
PCV2	O
isolation	O
,	O
no	O
data	O
regarding	O
inactivation	O
of	O
PCV2	O
were	O
obtained	O
.	O

The	O
cornerstone	O
of	O
influenza	O
prevention	O
is	O
annual	O
vaccination	O
and	O
in	O
some	O
cases	O
antiviral	B-CHED
prophylaxis	O
.	O

Lung	O
injury	O
was	O
induced	O
by	O
instilling	O
lipopolysaccharide	B-CHED
(	O
LPS	B-CHED
)	O
intratracheally	O
.	O

To	O
inhibit	O
glutamine	B-CHED
metabolism	O
,	O
we	O
administered	O
a	O
glutamine	B-CHED
analogue	O
,	O
6	O
-	O
diazo	B-CHED
-	O
5	O
-	O
oxo	B-CHED
-	O
L	B-CHED
-	I-CHED
norleucine	I-CHED
(	O
DON	O
)	O
that	O
binds	O
to	O
glutamine	B-CHED
-	O
utilizing	O
enzymes	O
and	O
transporters	O
,	O
after	O
injury	O
was	O
well	O
established	O
.	O

Past	O
viral	O
infection	O
was	O
associated	O
with	O
elevated	O
neutrophil	O
concentrations	O
and	O
bacterial	O
isolates	O
in	O
BAL	B-CHED
fluid	O
,	O
including	O
recovery	O
of	O
classic	O
CF	O
bacterial	O
pathogens	O
.	O

When	O
antibiotics	B-CHED
were	O
prescribed	O
for	O
respiratory	O
-	O
related	O
indications	O
,	O
viruses	O
were	O
identified	O
in	O
52	O
%	O
of	O
those	O
instances	O
.	O

The	O
course	O
of	O
treatment	O
of	O
4	O
cases	O
of	O
ARDS	O
caused	O
by	O
acute	O
phosgene	B-CHED
poisoning	O
admitted	O
to	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
of	O
Jiangxi	O
Provincial	O
People	O
'	O
s	O
Hospital	O
in	O
April	O
2018	O
was	O
retrospectively	O
analyzed	O
.	O

The	O
distribution	O
of	O
NOX	O
family	O
proteins	B-CHED
in	O
lung	O
tissue	O
is	O
cell	O
type	O
dependent	O
.	O

The	O
mPCR	O
protocols	O
,	O
when	O
applied	O
to	O
these	O
respiratory	O
specimens	O
and	O
intestinal	O
samples	O
,	O
could	O
detect	O
7	O
viruses	O
simultaneously	O
,	O
allowing	O
rapid	O
investigation	O
of	O
CRV	O
(	O
CAV	O
-	O
2	O
,	O
CDV	B-CHED
,	O
CIV	O
and	O
CPIV	O
)	O
and	O
CEV	O
(	O
CAV	O
-	O
2	O
,	O
CanineCV	O
,	O
CCoV	O
and	O
CPV	O
)	O
status	O
and	O
prompt	O
evaluation	O
of	O
coinfection	O
.	O

TITLE	O
:	O
The	O
crystal	O
structure	O
of	O
main	O
protease	O
from	O
mouse	O
hepatitis	O
virus	O
A59	O
in	O
complex	O
with	O
an	O
inhibitor	B-CHED
.	O

To	O
study	O
the	O
receptor	O
interactions	O
as	O
a	O
determinant	O
for	O
tropism	O
and	O
pathogenicity	O
,	O
recombinant	O
S1	O
proteins	B-CHED
were	O
produced	O
and	O
analyzed	O
by	O
glycan	B-CHED
and	O
tissue	O
arrays	O
.	O

ABSTRACT	O
:	O
The	O
Middle	O
East	O
respiratory	O
syndrome	O
corona	B-CHED
virus	O
(	O
MERS	O
-	O
CoV	O
)	O
is	O
highly	O
pathogenic	O
.	O

The	O
biosensor	O
is	O
based	O
on	O
indirect	O
competition	O
between	O
free	O
virus	O
in	O
the	O
sample	O
and	O
immobilized	O
MERS	O
-	O
CoV	O
protein	B-CHED
for	O
a	O
fixed	O
concentration	O
of	O
antibody	O
added	O
to	O
the	O
sample	O
.	O

Voltammetric	O
response	O
is	O
detected	O
by	O
monitoring	O
the	O
change	O
in	O
the	O
peak	O
current	O
(	O
typically	O
acquired	O
at	O
a	O
working	O
potential	O
of	O
-	O
0	O
.	O
05	O
V	O
vs	O
.	O
Ag	O
/	O
AgCl	B-CHED
)	O
after	O
addition	O
of	O
different	O
concentrations	O
of	O
antigen	B-CHED
against	O
MERS	O
-	O
CoV	O
.	O
Electrochemical	O
measurements	O
using	O
ferrocyanide	B-CHED
/	O
ferricyanide	B-CHED
as	O
a	O
probe	O
were	O
recorded	O
using	O
square	O
wave	O
voltammetry	O
(	O
SWV	O
).	O

ABSTRACT	O
:	O
Acute	O
respiratory	O
tract	O
infections	O
(	O
ARI	B-CHED
)	O
constitute	O
a	O
substantial	O
disease	O
burden	O
in	O
adults	O
and	O
elderly	O
individuals	O
.	O

Whereas	O
the	O
PEDV	O
nsp13	O
barely	O
regulates	O
type	O
I	O
IFN	O
,	O
inflammatory	O
cytokines	O
(	O
IL	O
-	O
6	O
,	O
TNF	O
-	O
a	O
)	O
and	O
MHCII	O
,	O
nsp16	O
and	O
nsp14	O
(	O
to	O
a	O
lesser	O
extent	O
)	O
down	O
-	O
regulate	O
these	O
antiviral	B-CHED
effectors	O
.	O

The	O
""""	O
variant	O
""""	O
genotype	O
shared	O
similar	O
unique	O
deletions	O
and	O
amino	B-CHED
acid	I-CHED
changes	O
with	O
the	O
recent	O
PRCV	O
strain	O
identified	O
in	O
this	O
study	O
,	O
suggesting	O
a	O
recombination	O
event	O
occurred	O
between	O
the	O
''	O
variant	O
''	O
TGEV	O
and	O
PRCV	O
.	O

However	O
,	O
activation	O
of	O
the	O
ER	O
stress	O
response	O
was	O
significantly	O
reduced	O
in	O
cells	O
infected	O
with	O
rN3D	O
/	O
N6D	O
,	O
correlated	O
with	O
a	O
lower	O
level	O
of	O
apoptosis	O
and	O
reduced	O
production	O
of	O
pro	B-CHED
-	O
inflammatory	O
cytokines	O
.	O

He	O
initially	O
improved	O
after	O
prolonged	O
hospitalization	O
and	O
course	O
of	O
high	O
dose	O
steroids	B-CHED
.	O

The	O
nucleotide	B-CHED
identity	O
with	O
feline	O
coronavirus	O
was	O
91	O
.	O
5	O
%.	O

To	O
Protect	O
the	O
Spike	O
Protein	B-CHED
and	O
Promote	O
the	O
Release	O
of	O
Infectious	O
Virus	O
.	O

High	O
untreated	O
case	O
-	O
fatality	O
,	O
exceeding	O
40	O
%	O
in	O
some	O
historic	O
epidemics	O
,	O
can	O
be	O
reduced	O
to	O
less	O
than	O
5	O
%	O
by	O
antibiotic	B-CHED
treatment	O
,	O
but	O
elimination	O
of	O
spirochaetaemia	O
is	O
often	O
accompanied	O
by	O
a	O
severe	O
J	O
-	O
HR	O
.	O
Epidemics	O
are	O
controlled	O
by	O
sterilising	O
clothing	O
to	O
eliminate	O
lice	O
,	O
using	O
pediculicides	B-CHED
and	O
by	O
improving	O
personal	O
hygiene	O
.	O

The	O
following	O
parameters	O
were	O
associated	O
with	O
increased	O
mortality	O
,	O
age	O
,	O
WBC	O
,	O
neutrophil	O
count	O
,	O
serum	O
albumin	O
level	O
,	O
use	O
of	O
a	O
continuous	O
renal	O
replacement	O
therapy	O
(	O
CRRT	O
)	O
and	O
corticosteroid	B-CHED
use	O
.	O

The	O
odd	O
ratio	O
for	O
mortality	O
was	O
highest	O
for	O
CRRT	O
and	O
corticosteroid	B-CHED
use	O
(	O
4	O
.	O
95	O
and	O
3	O
.	O
85	O
,	O
respectively	O
).	O

The	O
expression	O
of	O
truncated	O
forms	O
of	O
the	O
S	O
protein	B-CHED
for	O
3F10	O
reaction	O
studies	O
proved	O
that	O
the	O
epitope	B-CHED
was	O
located	O
between	O
amino	B-CHED
acids	I-CHED
(	O
aa	O
)	O
674	O
and	O
791	O
.	O

PAP	B-CHED
was	O
positively	O
correlated	O
with	O
the	O
OSI	B-CHED
index	O
(	O
r	O
=	O
0	O
.	O
823	O
).	O

Cells	O
infected	O
with	O
most	O
cell	O
-	O
adapted	O
PEDVs	O
usually	O
displayed	O
large	O
syncytia	O
,	O
a	O
process	O
triggered	O
by	O
the	O
spike	O
protein	B-CHED
(	O
S	O
).	O

Further	O
mutational	O
analyses	O
revealed	O
that	O
a	O
single	O
mutation	O
at	O
the	O
amino	B-CHED
acid	I-CHED
residue	I-CHED
position	O
672	O
(	O
V672F	O
)	O
could	O
enable	O
the	O
chimeric	O
S	O
with	O
the	O
entire	O
RBD	O
derived	O
from	O
the	O
G2	O
strain	O
to	O
trigger	O
large	O
syncytia	O
.	O

The	O
National	O
Inpatient	O
Sample	O
(	O
NIS	B-CHED
)	O
from	O
years	O
2002	O
to	O
2012	O
was	O
queried	O
for	O
patients	O
aged	O
15	O
and	O
older	O
treated	O
with	O
ECMO	O
who	O
had	O
one	O
or	O
more	O
acute	O
traumatic	O
injuries	O
as	O
defined	O
by	O
the	O
International	O
Diagnostic	O
Codes	O
,	O
Ninth	O
Edition	O
(	O
ICD	O
-	O
9	O
).	O

We	O
generated	O
rAd5	O
constructs	O
expressing	O
CD40	O
-	O
targeted	O
S1	O
fusion	O
protein	B-CHED
(	O
rAd5	O
-	O
S1	O
/	O
F	O
/	O
CD40L	O
),	O
untargeted	O
S1	O
(	O
rAd5	O
-	O
S1	O
),	O
and	O
Green	O
Fluorescent	O
Protein	B-CHED
(	O
rAd5	O
-	O
GFP	O
),	O
and	O
evaluated	O
their	O
efficacy	O
and	O
safety	O
in	O
human	O
dipeptidyl	O
peptidase	O
4	O
transgenic	O
(	O
hDPP4	O
Tg	O
+)	O
mice	O
.	O

TITLE	O
:	O
Identification	O
and	O
Characterization	O
of	O
a	O
Human	O
Coronavirus	O
229E	O
Nonstructural	O
Protein	B-CHED
8	O
-	O
Associated	O
RNA	O
3	O
'-	O
Terminal	O
Adenylyltransferase	O
Activity	O
.	O

TITLE	O
:	O
High	O
-	O
Throughput	O
Screening	O
and	O
Identification	O
of	O
Potent	O
Broad	O
-	O
Spectrum	O
Inhibitors	B-CHED
of	O
Coronaviruses	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
during	O
virus	O
infection	O
,	O
the	O
replicase	O
proteins	B-CHED
containing	O
the	O
MAC	O
and	O
PLP2	O
mutations	O
were	O
more	O
rapidly	O
degraded	O
at	O
the	O
nonpermissive	O
temperature	O
than	O
were	O
the	O
wild	O
-	O
type	O
proteins	B-CHED
.	O

Three	O
days	O
after	O
initiation	O
of	O
ECMO	O
,	O
the	O
patient	O
developed	O
jaundice	O
,	O
with	O
increase	O
of	O
bilirubin	B-CHED
,	O
Gamma	O
-	O
glutamyltransferase	O
and	O
Alkaline	O
phosphatase	O
,	O
without	O
elevation	O
of	O
alanine	B-CHED
aminotransferase	O
and	O
INR	O
.	O

TITLE	O
:	O
3	O
-	O
Trifluoromethylpyrazolones	O
derived	O
nucleosides	B-CHED
:	O
Synthesis	O
and	O
antiviral	B-CHED
evaluation	O
.	O

The	O
goal	O
of	O
the	O
study	O
was	O
to	O
adapt	O
our	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
lab	O
-	O
developed	O
test	O
(	O
LDT	B-CHED
)	O
to	O
3	O
""""	O
Sample	O
to	O
Result	O
""""	O
(	O
S2R	O
)	O
systems	O
:	O
BD	O
MAX	O
(	O
BD	O
),	O
ELITe	O
InGenius	O
(	O
ELITechGroup	O
),	O
and	O
ARIES	O
(	O
Luminex	O
).	O

ABSTRACT	O
:	O
Heparin	B-CHED
has	O
been	O
used	O
for	O
decades	O
as	O
an	O
anticoagulant	B-CHED
in	O
patients	O
on	O
mechanical	O
circulatory	O
support	O
,	O
which	O
includes	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
and	O
ventricular	O
assist	O
devices	O
.	O

Efforts	O
to	O
develop	O
antibody	O
-	O
based	O
therapies	O
have	O
focused	O
on	O
neutralizing	O
antibodies	O
that	O
target	O
the	O
receptor	O
binding	O
domain	O
of	O
the	O
viral	O
spike	O
protein	B-CHED
thereby	O
blocking	O
receptor	O
binding	O
.	O

Here	O
,	O
we	O
developed	O
a	O
set	O
of	O
human	O
monoclonal	O
antibodies	O
that	O
target	O
functionally	O
distinct	O
domains	O
of	O
the	O
MERS	O
-	O
CoV	O
spike	O
protein	B-CHED
.	O

Collectively	O
,	O
these	O
antibodies	O
offer	O
new	O
ways	O
to	O
gain	O
humoral	O
protection	O
in	O
humans	O
against	O
the	O
emerging	O
MERS	O
-	O
CoV	O
by	O
targeting	O
different	O
spike	O
protein	B-CHED
epitopes	O
and	O
functions	O
.	O

Most	O
respiratory	O
virus	O
infections	O
are	O
managed	O
with	O
supportive	O
therapy	O
,	O
although	O
there	O
is	O
effective	O
antiviral	B-CHED
therapy	O
for	O
influenza	O
.	O

Finally	O
,	O
these	O
diffuse	O
injury	O
models	O
must	O
be	O
relatively	O
mild	O
to	O
allow	O
for	O
survival	O
,	O
as	O
their	O
diffuse	O
nature	O
does	O
not	O
allow	O
for	O
residual	O
healthy	O
lung	O
to	O
keep	O
an	O
animal	O
alive	O
long	O
enough	O
for	O
many	O
drug	O
and	O
regenerative	O
medicine	B-CHED
studies	O
.	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
nonstructural	O
protein	B-CHED
1	O
(	O
nsp1	O
)	O
is	O
a	O
key	O
factor	O
in	O
virus	O
-	O
induced	O
down	O
-	O
regulation	O
of	O
host	O
gene	O
expression	O
.	O

ABSTRACT	O
:	O
Surfactin	O
has	O
antiviral	B-CHED
activity	O
against	O
various	O
enveloped	O
viruses	O
by	O
inhibiting	O
viral	O
membrane	O
fusion	O
.	O

Structurally	O
,	O
SLP5	O
is	O
a	O
linear	O
lipopeptide	B-CHED
with	O
three	O
carboxyl	O
groups	O
.	O

To	O
determine	O
whether	O
Fc	O
fusion	O
affects	O
the	O
immunogenicity	O
of	O
MERS	O
-	O
CoV	O
antigen	B-CHED
,	O
we	O
constructed	O
a	O
Fcassociated	O
MERS	O
-	O
CoV	O
spike	O
protein	B-CHED
(	O
eS770	O
-	O
Fc	O
,	O
110	O
kDa	O
),	O
whereby	O
human	O
IgG4	O
Fc	O
domain	O
was	O
fused	O
to	O
MERS	O
-	O
CoV	O
spike	O
protein	B-CHED
(	O
eS770	O
)	O
via	O
a	O
Gly	B-CHED
/	O
Pro	B-CHED
linker	O
using	O
baculovirus	O
as	O
the	O
expression	O
system	O
.	O

The	O
system	O
consists	O
of	O
various	O
formal	B-CHED
and	O
informal	O
networks	O
of	O
organizations	O
that	O
serve	O
different	O
stakeholders	O
;	O
have	O
varying	O
goals	O
,	O
modalities	O
,	O
resources	O
,	O
and	O
accountability	O
;	O
operate	O
at	O
different	O
regional	O
levels	O
(	O
i	O
.	O
e	O
.,	O
local	O
,	O
national	O
,	O
regional	O
,	O
or	O
global	O
);	O
and	O
cut	O
across	O
the	O
public	O
,	O
private	O
-	O
for	O
-	O
profit	O
,	O
and	O
private	O
-	O
not	O
-	O
for	O
-	O
profit	O
sectors	O
.	O

Visfatin	O
,	O
which	O
is	O
known	O
as	O
an	O
obesity	O
-	O
related	O
cytokine	O
with	O
pro	B-CHED
-	O
inflammatory	O
activities	O
,	O
plays	O
a	O
role	O
in	O
regulation	O
of	O
inflammatory	O
cytokines	O
.	O

Results	O
from	O
hematoxylin	B-CHED
and	O
eosin	O
(	O
H	O
&	O
amp	O
;	O
E	O
)	O
and	O
immunohistochemistry	O
staining	O
also	O
showed	O
that	O
visfatin	O
protein	O
was	O
upregulated	O
in	O
mouse	O
sepsis	O
models	O
.	O

In	O
the	O
RT	O
-	O
PSR	O
assay	O
,	O
the	O
addition	O
of	O
a	O
mixture	B-CHED
of	O
dyes	B-CHED
allowed	O
a	O
positive	O
reaction	O
to	O
be	O
directly	O
observed	O
by	O
the	O
naked	O
eye	O
.	O

This	O
case	O
highlights	O
the	O
need	O
for	O
the	O
early	O
identification	O
of	O
viral	O
culprits	O
,	O
which	O
can	O
minimize	O
the	O
use	O
of	O
invasive	O
diagnostic	O
testing	O
and	O
antibiotic	B-CHED
usage	O
.	O

TITLE	O
:	O
A	O
pan	B-CHED
-	O
coronavirus	O
fusion	O
inhibitor	B-CHED
targeting	O
the	O
HR1	O
domain	O
of	O
human	O
coronavirus	O
spike	O
.	O

All	O
of	O
the	O
patients	O
were	O
initially	O
hypoxic	O
and	O
some	O
had	O
PaO	B-CHED

We	O
assessed	O
worker	O
seroprevalence	O
in	O
2	O
slaughterhouses	O
and	O
1	O
live	O
-	O
animal	O
market	O
in	O
Abu	B-CHED
Dhabi	O
,	O
United	O
Arab	O
Emirates	O
,	O
during	O
2014	O
-	O
2017	O
and	O
administered	O
an	O
epidemiologic	O
survey	O
in	O
2016	O
and	O
2017	O
.	O

He	O
was	O
on	O
high	O
dose	O
opioids	O
and	O
gabapentin	B-CHED
as	O
prescription	O
medications	O
.	O

However	O
,	O
the	O
patient	O
further	O
underwent	O
ligation	O
bullectomy	O
for	O
persistent	O
air	B-CHED
leakage	O
2	O
weeks	O
later	O
.	O

These	O
investigations	O
suggest	O
that	O
the	O
full	O
-	O
length	O
S	O
and	O
the	O
membrane	O
form	O
of	O
the	O
RBD	O
(	O
RBD	O
-	O
G	O
)	O
are	O
the	O
most	O
promising	O
vaccine	O
candidates	O
among	O
all	O
the	O
studied	O
forms	O
of	O
S	O
glycoprotein	B-CHED
.	O

TITLE	O
:	O
Vasoactive	O
intestinal	O
peptide	B-CHED
inhibits	O
the	O
activation	O
of	O
murine	O
fibroblasts	O
and	O
expression	O
of	O
interleukin	O
17	O
receptor	O
C	O
.	O
ABSTRACT	O
:	O
Acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
is	O
an	O
acute	O
,	O
severe	O
,	O
and	O
refractory	O
pulmonary	O
inflammation	O
with	O
high	O
morbidity	O
and	O
mortality	O
.	O

Treatment	O
with	O
the	O
p53	O
inhibitor	B-CHED
PFT	B-CHED
-	O
α	O
could	O
significantly	O
inhibit	O
PEDV	O
-	O
induced	O
apoptosis	O
.	O

We	O
also	O
observed	O
PEDV	O
infection	O
induced	O
time	O
-	O
dependent	O
ROS	B-CHED
accumulation	O
.	O

Computational	O
fluid	O
dynamics	O
was	O
used	O
to	O
analyse	O
the	O
indoor	O
airflow	O
and	O
passive	O
tracer	B-CHED
diffusion	O
during	O
the	O
index	O
patient	O
'	O
s	O
stay	O
.	O

Nine	O
days	O
after	O
admission	O
,	O
he	O
developed	O
severe	O
acute	O
hypoxia	O
and	O
tachycardia	O
with	O
arterial	O
oxygen	B-CHED
tension	O
(	O
PaO2	O
)	O
of	O
52	O
mmHg	O
requiring	O
a	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	B-CHED
)	O
of	O
14	O
cmH2O	O
and	O
fraction	O
of	O
inspired	O
oxygen	B-CHED
(	O
FiO2	O
)	O
of	O
1	O
.	O

Forty	O
patients	O
(	O
48	O
%	O
adenocarcinoma	O
)	O
met	B-CHED
our	O
inclusion	O
criteria	O
.	O

The	O
BCoV	O
nucleocapsid	O
(	O
N	O
)	O
protein	B-CHED
,	O
an	O
RNA	O
-	O
binding	O
protein	B-CHED
,	O
was	O
therefore	O
tested	O
as	O
a	O
candidate	O
.	O

ORF3a	O
induced	O
pro	B-CHED
-	O
IL	O
-	O
1β	O
transcription	O
through	O
activation	O
of	O
NF	O
-	O
κB	O
,	O
which	O
was	O
mediated	O
by	O
TRAF3	O
-	O
dependent	O
ubiquitination	O
and	O
processing	O
of	O
p105	O
.	O

Among	O
positive	O
samples	O
,	O
120	O
(	O
19	O
.	O
2	O
%)	O
samples	O
were	O
positive	O
for	O
H1N1	O
,	O
61	O
(	O
9	O
.	O
8	O
%)	O
for	O
H3N2	B-CHED
and	O
19	O
(	O
3	O
%)	O
were	O
positive	O
for	O
Influenza	O
B	O
.	O
Highest	O
number	O
of	O
positive	O
cases	O
occurred	O
in	O
the	O
month	O
of	O
January	O
,	O
i	O
.	O
e	O
.	O
148	O
(	O
74	O
%)	O
cases	O
.	O

People	O
with	O
ILI	O
and	O
SARI	O
should	O
be	O
tested	O
for	O
Influenza	O
viruses	O
to	O
avoid	O
unnecessary	O
use	O
of	O
antibiotics	B-CHED
.	O

Clinical	O
studies	O
have	O
shown	O
that	O
early	O
treatments	O
of	O
RSV	O
patients	O
with	O
ribavirin	B-CHED
improve	O
prognosis	O
,	O
even	O
if	O
the	O
use	O
of	O
this	O
drug	O
is	O
limited	O
due	O
to	O
myelosuppression	O
and	O
toxicity	O
effects	O
.	O

Two	O
peptides	B-CHED
(	O
16433	O
and	O
4934	O
)	O
in	O
the	O
nsp3	O
region	O
encoding	O
the	O
papain	O
1	O
and	O
2	O
proteases	O
were	O
identified	O
for	O
final	O
testing	O
.	O

Current	O
findings	O
showed	O
a	O
correlation	O
between	O
IAP	O
hospitalised	O
patients	O
in	O
ICU	O
and	O
shock	O
,	O
SIRS	O
,	O
APACHE	O
II	O
,	O
central	O
venous	O
oxygen	B-CHED
saturation	O
and	O
GCS	O
.	O

There	O
was	O
no	O
correlation	O
between	O
patient	O
participant	O
nasal	O
viral	O
load	O
and	O
recovery	O
of	O
viral	O
RNA	O
from	O
the	O
air	B-CHED
,	O
and	O
we	O
did	O
not	O
identify	O
any	O
significant	O
association	O
between	O
RNA	O
detection	O
from	O
the	O
air	B-CHED
and	O
patient	O
demographics	O
or	O
clinical	O
presentation	O
.	O

A	O
more	O
substantial	O
study	O
is	O
required	O
to	O
identify	O
patient	O
determinants	O
of	O
virus	O
emission	O
into	O
the	O
air	B-CHED
and	O
delineate	O
implications	O
for	O
evidence	O
-	O
based	O
policy	O
for	O
prevention	O
and	O
control	O
.	O

RESULTS	O
:	O
Results	O
:	O
We	O
found	O
the	O
intensification	O
of	O
lipid	B-CHED
peroxidation	O
:	O
a	O
significant	O
increase	O
of	O
diene	O
conjugates	O
in	O
serum	O
up	O
to	O
13	O
.	O
78	O
%,	O
the	O
level	O
of	O
which	O
depended	O
on	O
the	O
severity	O
of	O
disease	O
.	O

Eligible	O
patients	O
were	O
ICU	O
patients	O
who	O
met	B-CHED
the	O
definitions	O
of	O
severe	O
sepsis	O
,	O
and	O
1013	O
patients	O
were	O
included	O
.	O

Evaluating	O
the	O
dynamic	O
changes	O
in	O
the	O
DIC	B-CHED
status	O
may	O
improve	O
the	O
prediction	O
capability	O
.	O

TITLE	O
:	O
The	O
Protection	O
Potential	O
of	O
Antioxidant	B-CHED
Vitamins	B-CHED
Against	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
:	O
a	O
Rat	O
Trial	O
.	O

A	O
hypothetical	O
patient	O
,	O
hyperdynamic	O
and	O
slightly	O
anemic	O
with	O
VO2	B-CHED
=	O
200mL	O
/	O
minute	O
,	O
can	O
reach	O
an	O
arterial	O
oxygen	B-CHED
saturation	O
of	O
80	O
%,	O
while	O
maintaining	O
the	O
match	O
between	O
the	O
oxygen	B-CHED
transfer	O
by	O
ECMO	O
and	O
the	O
VO2	B-CHED
of	O
the	O
patient	O
.	O

47	O
nasopharyngeal	O
aspirates	O
of	O
children	O
≤	O
2	O
years	O
with	O
ARI	B-CHED
were	O
included	O
.	O

ABSTRACT	O
:	O
ADP	B-CHED
-	O
ribosylation	O
is	O
a	O
ubiquitous	O
post	O
-	O
translational	O
addition	O
of	O
either	O
monomers	O
or	O
polymers	B-CHED
of	O
ADP	B-CHED
-	O
ribose	B-CHED
to	O
target	O
proteins	B-CHED
by	O
ADP	B-CHED
-	O
ribosyltransferases	O
,	O
usually	O
by	O
interferon	O
-	O
inducible	O
diphtheria	O
toxin	O
-	O
like	O
enzymes	O
known	O
as	O
PARPs	B-CHED
.	O

Several	O
viral	O
families	O
,	O
including	O
Coronaviridae	O
,	O
Togaviridae	O
,	O
and	O
Hepeviridae	O
,	O
encode	O
for	O
macrodomain	O
proteins	B-CHED
that	O
bind	O
to	O
and	O
hydrolyze	O
ADP	B-CHED
-	O
ribose	B-CHED
from	O
proteins	B-CHED
and	O
are	O
critical	O
for	O
optimal	O
replication	O
and	O
virulence	O
.	O

Particularly	O
,	O
peptide	B-CHED
pregnancy	O
-	O
induced	O
hypertension	O
(	O
PIH	O
)	O
exhibits	O
potent	O
inhibitory	O
activity	O
with	O
IC	O

TITLE	O
:	O
FORMATION	O
OF	O
EXCESSIVE	O
AMOUNT	O
OF	O
ENDOGENOUS	O
CARBON	B-CHED
MONOXIDE	I-CHED
AND	O
INCREASE	O
OF	O
CARBOXYLATED	O
HEMOGLOBIN	B-CHED
CONTENT	O
IN	O
PATIENTS	O
WITH	O
POLYTRAUMA	O
.	O

The	O
purpose	O
of	O
the	O
study	O
was	O
the	O
investigation	O
of	O
endogenous	O
CO	O
production	O
in	O
the	O
body	O
of	O
patients	O
with	O
polytrauma	O
by	O
determining	O
the	O
percentage	O
of	O
carboxylated	O
hemoglobin	B-CHED
(	O
HbCO	O
%)	O
in	O
the	O
blood	O
using	O
photoplethysmometric	O
technology	O
,	O
as	O
well	O
as	O
determining	O
the	O
degree	O
of	O
danger	O
of	O
the	O
specified	O
products	O
to	O
the	O
body	O
of	O
patients	O
.	O

In	O
patients	O
with	O
thoracic	O
injury	O
,	O
the	O
content	O
of	O
carboxylated	O
hemoglobin	B-CHED
was	O
the	O
greater	O
,	O
the	O
more	O
severe	O
were	O
the	O
manifestations	O
of	O
acute	O
respiratory	O
failure	O
syndrome	O
,	O
which	O
was	O
detected	O
according	O
to	O
the	O
severity	O
of	O
arterial	O
hypoxemia	O
.	O

Bronchoalveolar	O
lavage	O
should	O
obtain	O
lower	O
respiratory	O
tract	O
samples	O
for	O
galactomannan	B-CHED
assay	O
,	O
direct	O
microscopy	O
,	O
culture	O
,	O
and	O
bacterial	O
,	O
fungal	O
and	O
viral	O
PCR	O
.	O

When	O
invasive	O
aspergillosis	O
is	O
confirmed	O
,	O
first	O
-	O
line	O
therapy	O
consists	O
of	O
isavuconazole	O
or	O
voriconazole	B-CHED
.	O

Influenza	O
A	O
(	O
H1N1	O
)	O
2009	O
(	O
A	O
/	O
H1N1	O
),	O
influenza	O
A	O
H3N2	B-CHED
,	O
and	O
influenza	O
B	O
were	O
tested	O
in	O
all	O
patients	O
by	O
RT	O
-	O
PCR	O
.	O

These	O
host	O
-	O
cell	O
derived	O
glycans	B-CHED
facilitate	O
diverse	O
structural	O
and	O
functional	O
roles	O
during	O
the	O
viral	O
life	O
-	O
cycle	O
,	O
ranging	O
from	O
immune	O
evasion	O
by	O
glycan	B-CHED
shielding	O
to	O
enhancement	O
of	O
immune	O
cell	O
infection	O
.	O

TITLE	O
:	O
Porcine	O
deltacoronavirus	O
nucleocapsid	O
protein	B-CHED
antagonizes	O
IFN	O
-	O
β	O
production	O
by	O
impairing	O
dsRNA	B-CHED
and	O
PACT	O
binding	O
to	O
RIG	O
-	O
I	O
.	O
ABSTRACT	O
:	O
Porcine	O
deltacoronavirus	O
(	O
PDCoV	O
)	O
is	O
an	O
emerging	O
swine	O
enteropathogenic	O
coronavirus	O
that	O
causes	O
watery	O
diarrhea	O
,	O
vomiting	O
and	O
mortality	O
in	O
newborn	O
piglets	O
.	O

Previous	O
studies	O
have	O
suggested	O
that	O
PDCoV	O
infection	O
antagonizes	O
RIG	O
-	O
I	O
-	O
like	O
receptor	O
(	O
RLR	O
)-	O
mediated	O
IFN	O
-	O
β	O
production	O
to	O
evade	O
host	O
innate	O
immune	O
defense	O
,	O
and	O
PDCoV	O
-	O
encoded	O
nonstructural	O
protein	B-CHED
nsp5	O
and	O
accessory	O
protein	B-CHED
NS6	O
are	O
associated	O
with	O
this	O
process	O
.	O

TITLE	O
:	O
In	O
vitro	O
antiviral	B-CHED
activity	O
of	O
fifteen	O
plant	O
extracts	O
against	O
avian	O
infectious	O
bronchitis	O
virus	O
.	O

The	O
patient	O
initially	O
required	O
norepinephrine	B-CHED
and	O
this	O
was	O
discontinued	O
after	O
the	O
first	O
session	O
of	O
HP	O
.	O

Laboratory	O
investigation	O
showed	O
high	O
erythrocyte	O
sedimentation	O
rate	O
and	O
C	O
reactive	O
protein	B-CHED
,	O
leucocytosis	O
,	O
anaemia	O
,	O
mild	O
thrombocytopaenia	O
,	O
renal	O
impairment	O
,	O
hyperbilirubinaemia	O
and	O
abnormal	O
liver	O
function	O
tests	O
;	O
arterial	O
blood	O
gas	O
analysis	O
showed	O
respiratory	O
alkalosis	O
with	O
severe	O
hypoxia	O
.	O

The	O
resulting	O
reverse	O
genetic	O
system	O
will	O
add	B-CHED
to	O
the	O
published	O
list	O
of	O
MERS	O
-	O
CoV	O
cDNAs	O
and	O
facilitate	O
the	O
development	O
of	O
Korean	O
isolate	O
-	O
specific	O
antiviral	B-CHED
measures	O
.	O

The	O
receptor	O
-	O
interacting	O
site	O
is	O
conserved	O
in	O
all	O
coronavirus	O
S	O
glycoproteins	B-CHED
that	O
engage	O
9	O
-	O
O	O
-	O
acetyl	B-CHED
-	O
sialogycans	O
,	O
with	O
an	O
architecture	O
similar	O
to	O
those	O
of	O
the	O
ligand	B-CHED
-	O
binding	O
pockets	O
of	O
coronavirus	O
hemagglutinin	O
esterases	O
and	O
influenza	O
virus	O
C	O
/	O
D	O
hemagglutinin	O
-	O
esterase	O
fusion	O
glycoproteins	B-CHED
.	O

One	O
-	O
thousand	O
nine	O
-	O
hundred	O
seventy	O
-	O
four	O
patients	O
met	B-CHED
inclusion	O
criteria	O
:	O
1	O
,	O
209	O
(	O
61	O
%)	O
with	O
no	O
acute	O
kidney	O
injury	O
,	O
468	O
(	O
24	O
%)	O
with	O
mild	O
-	O
moderate	O
acute	O
kidney	O
injury	O
,	O
and	O
297	O
(	O
15	O
%)	O
with	O
severe	O
acute	O
kidney	O
injury	O
.	O

Among	O
all	O
the	O
potential	O
targets	O
of	O
MERS	O
-	O
CoV	O
,	O
the	O
spike	O
glycoprotein	B-CHED
(	O
S	O
)	O
has	O
been	O
the	O
most	O
well	O
-	O
studied	O
due	O
to	O
its	O
critical	O
role	O
in	O
mediating	O
viral	O
entry	O
and	O
in	O
inducing	O
a	O
protective	O
antibody	O
response	O
in	O
infected	O
individuals	O
.	O

Monitoring	O
at	O
trough	O
and	O
peak	O
maternal	O
medication	O
levels	O
was	O
implemented	O
to	O
ascertain	O
acute	O
physiologic	O
effects	O
of	O
buprenorphine	B-CHED
administration	O
.	O

Heavier	O
smoking	O
dampened	O
maternal	O
heart	O
rate	O
variability	O
across	O
gestation	O
and	O
potentiated	O
reactivity	O
to	O
buprenorphine	B-CHED
at	O
24	O
and	O
36	O
weeks	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
aimed	O
to	O
investigate	O
the	O
effect	O
of	O
NBP	O
on	O
ALI	O
in	O
lipopolysaccharide	B-CHED
(	O
LPS	B-CHED
)-	O
treated	O
mice	O
.	O

Moreover	O
,	O
the	O
absence	O
of	O
SIRT1	O
notably	O
inhibited	O
NBP	O
-	O
induced	O
protective	O
effects	O
against	O
LPS	B-CHED
-	O
induced	O
increase	O
of	O
W	O
/	O
D	O
ratio	O
of	O
lung	O
,	O
histological	O
injury	O
of	O
lung	O
,	O
infiltration	O
of	O
inflammatory	O
cells	O
,	O
release	O
of	O
pro	B-CHED
-	O
inflammatory	O
cytokines	O
and	O
chemokines	O
,	O
and	O
oxidative	O
damage	O
.	O

ABSTRACT	O
:	O
The	O
introduction	O
of	O
blood	O
donor	B-CHED
screening	O
by	O
virus	O
nucleic	B-CHED
acid	I-CHED
amplification	O
technology	O
(	O
NAT	O
)	O
in	O
the	O
mid	O
to	O
late	O
1990s	O
was	O
driven	O
by	O
the	O
so	O
-	O
called	O
AIDS	O
and	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
epidemic	O
,	O
with	O
thousands	O
of	O
recipients	O
of	O
infected	O
blood	O
products	O
and	O
components	O
.	O

There	O
are	O
new	O
technologies	O
on	O
the	O
horizon	O
like	O
digital	O
droplet	O
PCR	O
,	O
next	O
-	O
generation	O
sequencing	O
,	O
lab	O
-	O
on	O
-	O
a	O
-	O
chip	O
,	O
and	O
digital	O
antigen	B-CHED
assays	O
,	O
which	O
are	O
comparably	O
sensitive	O
.	O

Donor	B-CHED
screening	O
NAT	O
also	O
contributed	O
significantly	O
to	O
our	O
knowledge	O
on	O
how	O
fast	O
viruses	O
replicate	O
,	O
and	O
on	O
the	O
respective	O
diagnostic	O
window	O
.	O

In	O
conjunction	O
with	O
animal	O
and	O
patient	O
studies	O
,	O
we	O
have	O
learned	O
more	O
about	O
the	O
minimal	O
infectious	O
dose	O
and	O
the	O
epidemics	O
in	O
the	O
donor	B-CHED
population	O
.	O

In	O
the	O
present	O
review	O
,	O
we	O
have	O
made	O
an	O
effort	O
to	O
compile	O
antiviral	B-CHED
literature	O
of	O
thiazoles	B-CHED
reported	O
from	O
the	O
year	O
2011	O
to	O
till	O
date	O
.	O

Nearly	O
,	O
50	O
research	O
articles	O
were	O
selected	O
to	O
compile	O
and	O
review	O
the	O
antiviral	B-CHED
literature	O
of	O
thiazoles	B-CHED
reported	O
from	O
the	O
year	O
2011	O
to	O
till	O
date	O
.	O

In	O
conclusion	O
,	O
this	O
review	O
provides	O
an	O
overview	O
of	O
antiviral	B-CHED
activities	O
of	O
thiazole	B-CHED
compounds	O
reported	O
from	O
the	O
year	O
2011	O
to	O
till	O
date	O
.	O

RESULTS	O
:	O
Opening	O
the	O
lung	O
procedure	O
was	O
safe	O
in	O
all	O
patients	O
with	O
optimal	O
PEEP	B-CHED
of	O
14	O
.	O
8	O
±	O
1	O
.	O
8	O
cmH	B-CHED
CONCLUSIONS	O
:	O
It	O
is	O
necessary	O
to	O
conduct	O
further	O
trials	O
to	O
find	O
out	O
the	O
effectiveness	O
of	O
this	O
ventilation	O
strategy	O
on	O
burns	O
injury	O
induced	O
ARDS	O
.	O

The	O
protocol	O
provides	O
the	O
administration	O
of	O
surfactant	B-CHED
(	O
50	O
mg	O
/	O
kg	O
)	O
divided	O
in	O
two	O
doses	O
:	O
the	O
first	O
dose	O
is	O
used	O
as	O
a	O
bronchoalveolar	O
lavage	O
while	O
the	O
second	O
as	O
supplementation	O
.	O

Blood	O
gas	O
exchange	O
variations	O
before	O
and	O
after	O
surfactant	B-CHED
use	O
were	O
recorded	O
.	O

Sixty	O
-	O
nine	O
children	O
,	O
age	O
0	O
-	O
24	O
months	O
,	O
affected	O
by	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
treated	O
with	O
exogenous	O
porcine	O
surfactant	B-CHED
were	O
enrolled	O
.	O

Fifty	O
-	O
four	O
children	O
(	O
78	O
.	O
3	O
%)	O
had	O
severe	O
ARDS	O
(	O
define	O
by	O
oxygen	B-CHED
arterial	O
pressure	O
and	O
inspired	O
oxygen	B-CHED
fraction	O
ratio	O
(	O
P	O
/	O
F	O
)	O
<	O
100	O
),	O
15	O
(	O
21	O
.	O
7	O
%)	O
had	O
moderate	O
ARDS	O
(	O
100	O
<	O
P	O
/	O
F	O
<	O
200	O
).	O

RESULTS	O
:	O
Sixty	O
-	O
nine	O
children	O
,	O
age	O
0	O
-	O
24	O
months	O
,	O
affected	O
by	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
treated	O
with	O
exogenous	O
porcine	O
surfactant	B-CHED
were	O
enrolled	O
.	O

The	O
prototype	O
compound	O
of	O
this	O
family	O
is	O
a	O
derivative	O
of	O
pentaerythritol	O
with	O
12	O
peripheral	O
Trp	B-CHED
groups	O
and	O
trivalent	O
spacer	O
arms	O
.	O

Nasopharyngeal	O
swab	O
and	O
tracheal	O
aspirate	O
samples	O
were	O
collected	O
to	O
extract	O
viral	O
nucleic	B-CHED
acid	I-CHED
.	O

TITLE	O
:	O
Dexmedetomidine	B-CHED
as	O
adjunctive	O
therapy	O
for	O
the	O
treatment	O
of	O
alcohol	O
withdrawal	O
syndrome	O
:	O
a	O
systematic	O
review	O
protocol	O
.	O

We	O
developed	O
multiple	O
assays	O
to	O
further	O
define	O
the	O
breadth	O
of	O
RDV	O
antiviral	B-CHED
activity	O
against	O
the	O
CoV	O
family	O
.	O

AAV	O
-	O
Pck2	O
overexpression	O
in	O
leg	O
muscles	O
of	O
male	O
C57BL6	O
/	O
J	O
mice	O
for	O
4	O
weeks	O
(	O
6	O
-	O
10	O
weeks	O
of	O
age	O
)	O
increased	O
Pck2	O
mRNA	B-CHED
(~	O
100	O
-	O
fold	O
),	O
protein	B-CHED
(	O
not	O
quantifiable	O
)	O
and	O
enzyme	O
activity	O
(~	O
3	O
-	O
fold	O
).	O

There	O
was	O
a	O
trend	O
(	O
p	O
=	O
0	O
.	O
0798	O
)	O
for	O
AAV	O
-	O
Pck2	O
overexpression	O
to	O
reduce	O
TA	O
muscle	O
weights	O
,	O
but	O
there	O
was	O
no	O
significant	O
effect	O
on	O
muscle	O
fibre	O
diameters	O
or	O
myosin	O
heavy	O
chain	O
isoform	O
(	O
MyHC	O
)	O
mRNA	B-CHED
expression	O
.	O

However	O
AAV	O
-	O
Pck2	O
overexpression	O
reduced	O
TA	O
muscle	O
weights	O
(	O
p	O
=	O
0	O
.	O
0434	O
),	O
particularly	O
in	O
the	O
Control	O
(	O
vehicle	O
treated	O
)	O
mice	O
(	O
p	O
=	O
0	O
.	O
059	O
for	O
AAV	O
x	O
Clenbuterol	B-CHED
interaction	O
)	O
and	O
increased	O
the	O
expression	O
of	O
Seryl	B-CHED
-	O
tRNA	B-CHED
Synthetase	O
(	O
Sars	O
)	O
mRNA	B-CHED
(	O
p	O
=	O
0	O
.	O
0477	O
).	O

TITLE	O
:	O
Avian	O
coronavirus	O
infection	O
induces	O
mannose	B-CHED
-	O
binding	O
lectin	O
production	O
in	O
dendritic	O
cell	O
precursors	O
of	O
chicken	O
lymphoid	O
organs	O
.	O

Finally	O
,	O
1	B-CHED
,	I-CHED
3	I-CHED
,	I-CHED
4	I-CHED
-	I-CHED
oxadiazole	I-CHED
derivative	O
1	O
was	O
directed	O
toward	O
reaction	O
with	O
hydrazine	B-CHED
derivatives	O
,	O
bromoacetophenone	O
and	O
ethylchloroacetate	O
affording	O
compounds	O
11a	O
,	O
b	O
,	O
12	O
and	O
13	O
,	O
resp	O
.	O

Antiviral	B-CHED
activity	O
of	O
the	O
synthesized	O
products	O
showed	O
that	O
5	O
-(	O
4	O
-	O
amino	O
-	O
3	O
-	O
ethyl	B-CHED
-	O
2	O
-	O
thioxo	B-CHED
-	O
2	O
,	O
3	O
-	O
dihydrothiazol	O
-	O
5	O
-	O
yl	O
)-	O
1	B-CHED
,	I-CHED
3	I-CHED
,	I-CHED
4	I-CHED
-	I-CHED
oxadiazole	I-CHED
-	O
2	O
(	O
3H	O
)-	O
thione	O
(	O
5a	O
)	O
and	O
5	O
-(	O
4	O
-	O
amino	O
-	O
3	O
-	O
phenyl	B-CHED
-	O
2	O
-	O
thioxo	B-CHED
-	O
2	O
,	O
3	O
-	O
dihydrothiazol	O
-	O
5	O
-	O
yl	O
)-	O
1	B-CHED
,	I-CHED
3	I-CHED
,	I-CHED
4	I-CHED
-	I-CHED
oxadiazole	I-CHED
-	O
2	O
(	O
3H	O
)-	O
thione	O
(	O
5b	O
)	O
acted	O
as	O
the	O
most	O
active	O
agents	O
against	O
Feline	O
herpes	O
virus	O
,	O
Feline	O
corona	B-CHED
virus	O
,	O
Herpes	O
simplex	O
virus	O
-	O
1	O
and	O
Herpes	O
simplex	O
virus	O
-	O
2	O
,	O
whereas	O
compound	O
2	O
-(	O
5	O
-(	O
2	O
-	O
phenylhydrazono	O
)-	O
4	O
,	O
5	O
-	O
dihydro	O
-	O
1	O
,	O
3	O
,	O
4	O
-	O
oxadiazol	O
-	O
2	O
-	O
yl	O
)	O
acetonitrile	B-CHED
(	O
11b	O
)	O
was	O
the	O
most	O
effective	O
against	O
Vaccinia	O
virus	O
,	O
Herpes	O
simplex	O
virus	O
(	O
TK	O
-	O
KOS	O
-	O
ACVr	O
),	O
Coxsackie	O
virus	O
B4	O
and	O
Vesicular	O
stomatitis	O
virus	O
.	O

Sixty	O
patients	O
with	O
severe	O
ARDS	O
(	O
PaO	B-CHED
Nebulized	O
heparin	B-CHED
(	O
10	O
,	O
000	O
IU	O
/	O
4	O
h	O
),	O
nebulized	O
streptokinase	O
(	O
250	O
,	O
000	O
IU	O
/	O
4	O
h	O
),	O
and	O
conservative	O
management	O
.	O

The	O
primary	O
outcome	O
was	O
the	O
change	O
in	O
PaO	B-CHED
Inhaled	O
streptokinase	O
serves	O
as	O
rescue	O
therapy	O
in	O
patients	O
with	O
severe	O
ARDS	O
with	O
improving	O
oxygenation	O
and	O
lung	O
mechanics	O
more	O
quickly	O
than	O
heparin	B-CHED
or	O
conventional	O
management	O
.	O

Such	O
evasion	O
is	O
related	O
to	O
the	O
unstable	O
nature	O
of	O
its	O
RNA	O
,	O
in	O
particular	O
the	O
S	O
glycoprotein	B-CHED
encoding	O
gene	O
,	O
which	O
raises	O
great	O
challenges	O
with	O
regard	O
to	O
the	O
control	O
of	O
the	O
disease	O
,	O
along	O
with	O
the	O
lack	O
of	O
proof	O
reading	O
mechanisms	O
of	O
the	O
RNA	O
polymerase	O
.	O

Phylogenetic	O
analysis	O
of	O
the	O
S1	O
nucleotide	B-CHED
sequences	O
showed	O
that	O
both	O
isolates	O
are	O
closely	O
related	O
to	O
the	O
Algerian	O
strains	O
,	O
and	O
formed	O
a	O
common	O
cluster	O
within	O
the	O
genotype	O
I	O
.	O
In	O
addition	O
,	O
these	O
isolates	O
were	O
non	O
-	O
recombinant	O
ones	O
,	O
confirming	O
that	O
they	O
are	O
unique	O
variants	O
.	O

TITLE	O
:	O
Effects	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
infection	O
on	O
tight	O
junction	O
protein	B-CHED
gene	O
expression	O
and	O
morphology	O
of	O
the	O
intestinal	O
mucosa	O
in	O
pigs	O
.	O

Therefore	O
,	O
we	O
aimed	O
to	O
determine	O
effects	O
of	O
lung	O
recruitment	O
maneuver	O
(	O
RM	O
)	O
and	O
titrated	O
PEEP	B-CHED
Data	O
sources	O
and	O
study	O
selection	O
proceeded	O
as	O
follows	O
:	O
PubMed	O
,	O
Ovid	O
,	O
EBSCO	O
,	O
and	O
Cochrane	O
Library	O
databases	O
were	O
searched	O
from	O
2003	O
to	O
May	O
2018	O
.	O

TITLE	O
:	O
Virus	O
Envelope	O
-	O
Like	O
Self	O
-	O
Assembled	O
Nanoparticles	B-CHED
Based	O
on	O
ABSTRACT	O
:	O
Pathogen	O
-	O
sized	O
particles	O
exhibit	O
better	O
performance	O
in	O
inducing	O
immune	O
responses	O
than	O
soluble	O
protein	B-CHED
antigens	B-CHED
.	O

However	O
,	O
engineering	O
safe	O
and	O
efficient	O
particulate	O
carrier	O
for	O
antigens	B-CHED
delivery	O
remains	O
a	O
major	O
challenge	O
.	O

Fraxin	O
might	O
inhibit	O
the	O
increase	O
in	O
reactive	B-CHED
oxygen	I-CHED
species	I-CHED
(	O
ROS	B-CHED
)	O
and	O
malondialdehyde	B-CHED
(	O
MDA	B-CHED
),	O
a	O
product	O
of	O
lipid	B-CHED
peroxidation	O
in	O
lung	O
tissues	O
.	O

Using	O
next	O
-	O
generation	O
sequencing	O
,	O
two	O
full	O
-	O
length	O
genomes	O
of	O
Amibara	O
isolates	O
were	O
successfully	O
decoded	O
;	O
both	O
isolates	O
belonged	O
to	O
the	O
C2	O
clade	O
based	O
on	O
phylogenetic	O
analysis	O
of	O
full	O
-	O
length	O
and	O
S	O
protein	B-CHED
sequences	O
.	O

The	O
viral	O
spike	O
protein	B-CHED
plays	O
pivotal	O
roles	O
in	O
mediating	O
receptor	O
-	O
recognition	O
and	O
membrane	O
-	O
fusion	O
,	O
and	O
is	O
therefore	O
a	O
key	O
factor	O
involved	O
in	O
viral	O
pathogenesis	O
and	O
inter	O
-	O
species	O
transmission	O
.	O

TITLE	O
:	O
High	O
Hemoglobin	B-CHED
Level	O
As	O
a	O
Limiting	O
Factor	O
for	O
Extracorporeal	O
Membrane	O
Oxygenation	O
.	O

We	O
demonstrated	O
that	O
the	O
U937	O
cell	O
model	O
is	O
robust	O
and	O
suitable	O
for	O
the	O
high	O
-	O
throughput	O
screening	O
of	O
immunomodulators	O
and	O
antivirals	B-CHED
against	O
influenza	O
infection	O
.	O

Gene	O
Ontology	O
analysis	O
suggested	O
that	O
cellular	O
macromolecule	B-CHED
and	O
protein	B-CHED
location	O
(	O
GO	O
-	O
BP	O
)	O
and	O
transcription	O
factor	O
binding	O
(	O
GO	O
-	O
MF	O
)	O
were	O
abundant	O
in	O
IBV	O
-	O
stimulated	O
avian	O
DCs	O
.	O

Finally	O
,	O
our	O
study	O
identified	O
2	O
TF	O
-	O
microRNA	O
and	O
53	O
TF	O
-	O
microRNA	O
-	O
mRNA	B-CHED
interactions	O
involving	O
1	O
TF	O
,	O
2	O
miRNAs	O
,	O
and	O
53	O
mRNAs	O
in	O
IBV	O
-	O
stimulated	O
avian	O
DCs	O
.	O

FASN	O
protein	B-CHED
levels	O
in	O
the	O
lung	O
of	O
high	O
fat	O
diet	O
mice	O
were	O
lower	O
by	O
immunoblotting	O
and	O
immunohistochemistry	O
.	O

TITLE	O
:	O
Staphylococcal	O
phosphatidylinositol	B-CHED
-	O
specific	O
phospholipase	O
C	O
potentiates	O
lung	O
injury	O
via	O
complement	O
sensitisation	O
.	O

Antiviral	B-CHED
resistance	O
compounds	O
the	O
overall	O
picture	O
despite	O
optimal	O
regimen	O
.	O

ABSTRACT	O
:	O
The	O
objective	O
of	O
this	O
clinical	O
trial	O
was	O
to	O
evaluate	O
the	O
effectiveness	O
of	O
zinc	B-CHED
supplementation	O
on	O
diarrhea	O
and	O
average	O
daily	O
weight	O
gain	O
(	O
ADG	O
)	O
in	O
pre	O
-	O
weaned	O
dairy	O
calves	O
.	O

Serum	O
total	O
protein	B-CHED
at	O
enrollment	O
and	O
body	O
weight	O
at	O
birth	O
,	O
treatment	O
end	O
,	O
and	O
hutch	O
exit	O
were	O
measured	O
.	O

To	O
define	O
the	O
evolution	O
of	O
recent	O
IBVs	O
in	O
Iran	O
,	O
a	O
genetic	O
analysis	O
based	O
on	O
hypervariable	O
nucleotide	B-CHED
sequences	O
of	O
S1	O
gene	O
was	O
carried	O
out	O
.	O

The	O
primary	O
end	O
point	O
was	O
the	O
change	O
in	O
the	O
plasma	O
N	O
-	O
terminal	O
pro	B-CHED
-	O
brain	O
natriuretic	O
peptide	B-CHED
(	O
NT	O
-	O
proBNP	O
)	O
level	O
from	O
baseline	O
to	O
the	O
7	O
-	O
month	O
follow	O
-	O
up	O
.	O

Recent	O
studies	O
indicated	O
that	O
Cxc	O
chemokine	O
ligand	B-CHED
5	O
(	O
CXCL5	O
),	O
an	O
inflammatory	O
chemokine	O
,	O
was	O
associated	O
with	O
tumorigenesis	O
.	O

MATERIAL	O
AND	O
METHODS	O
The	O
pathological	O
morphology	O
of	O
lung	O
tissue	O
and	O
degree	O
of	O
pulmonary	O
edema	O
were	O
assessed	O
by	O
hematoxylin	B-CHED
-	O
eosin	O
staining	O
and	O
pulmonary	O
edema	O
score	O
,	O
respectively	O
.	O

In	O
addition	O
,	O
CXCL5	O
neutralizing	O
antibody	O
effectively	O
alleviated	O
inflammatory	O
response	O
,	O
diffuse	O
alveolar	O
damage	O
,	O
and	O
pulmonary	O
edema	O
,	O
and	O
decreased	O
the	O
expression	O
levels	O
of	O
MMP2	O
and	O
MMP9	O
compared	O
to	O
LPS	B-CHED
-	O
induced	O
ARDS	O
.	O

ABSTRACT	O
:	O
A	O
fusion	O
protein	B-CHED
expressed	O
on	O
the	O
surface	O
of	O
enveloped	O
viruses	O
mediates	O
fusion	O
of	O
the	O
viral	O
and	O
cellular	O
membranes	O
to	O
facilitate	O
virus	O
infection	O
.	O

These	O
two	O
subunits	O
were	O
considered	O
to	O
be	O
by	O
-	O
products	O
derived	O
from	O
conformational	O
changes	O
and	O
were	O
useful	O
for	O
probing	O
the	O
intermediate	O
conformation	O
of	O
the	O
spike	O
protein	B-CHED
.	O

Receptor	O
binding	O
induces	O
the	O
membrane	O
-	O
binding	O
potential	O
of	O
the	O
trimer	O
,	O
in	O
which	O
at	O
least	O
one	O
HR	O
motif	O
forms	O
a	O
packed	O
-	O
hairpin	O
structure	O
,	O
while	O
membrane	O
fusion	O
subunits	O
are	O
covered	O
by	O
the	O
receptor	O
-	O
binding	O
subunit	O
,	O
thereby	O
preventing	O
the	O
spike	O
protein	B-CHED
from	O
forming	O
the	O
typical	O
homotrimeric	O
prehairpin	O
structure	O
predicted	O
by	O
the	O
current	O
model	O
of	O
class	O
I	O
viral	O
fusion	O
protein	B-CHED
.	O

We	O
have	O
previously	O
shown	O
that	O
the	O
virus	O
uses	O
heparan	B-CHED
sulfate	I-CHED
proteoglycans	B-CHED
(	O
HSPGs	O
)	O
as	O
the	O
initial	O
attachment	O
factors	O
,	O
facilitating	O
viral	O
entry	O
into	O
the	O
cell	O
.	O

To	O
emulate	O
such	O
distinct	O
surface	O
patterns	O
on	O
macromolecules	B-CHED
,	O
we	O
used	O
rigid	O
spherical	O
synthetic	O
dendrimers	O
(	O
polyphenylene	B-CHED
dendrimers	O
)	O
to	O
provide	O
controlled	O
amphiphilic	O
surface	O
patches	O
with	O
molecular	O
precision	O
.	O

Recent	O
studies	O
on	O
human	O
medicine	B-CHED
report	O
that	O
gut	O
microbiota	O
is	O
involved	O
in	O
the	O
development	O
of	O
systemic	O
disorders	O
and	O
could	O
influence	O
the	O
immune	O
response	O
to	O
viral	O
diseases	O
.	O

The	O
surface	O
spike	O
(	O
S	O
)	O
glycoprotein	B-CHED
of	O
MERS	O
-	O
CoV	O
,	O
which	O
binds	O
to	O
the	O
cellular	O
receptor	O
dipeptidyl	O
peptidase	O
4	O
(	O
DPP4	O
),	O
is	O
considered	O
as	O
a	O
major	O
target	O
for	O
MERS	O
-	O
CoV	O
vaccine	O
development	O
.	O

The	O
bovine	O
cells	O
that	O
were	O
exposed	O
to	O
the	O
UPR	O
inductors	O
brefeldin	B-CHED
A	I-CHED
,	O
dithiothreitol	B-CHED
,	O
and	O
thapsigargin	B-CHED
;	O
demonstrated	O
elevated	O
expression	O
levels	O
of	O
P53	O
compared	O
to	O
the	O
vehicle	O
-	O
treated	O
cells	O
.	O

Since	O
it	O
has	O
been	O
shown	O
that	O
a	O
mild	O
induction	O
of	O
the	O
unfolded	O
protein	B-CHED
response	O
opposes	O
inflammation	O
,	O
we	O
suggest	O
that	O
P53	O
is	O
involved	O
in	O
those	O
protective	O
activities	O
in	O
the	O
lung	O
.	O

We	O
report	O
on	O
a	O
-	O
48	O
-	O
year	O
-	O
old	O
man	B-CHED
with	O
TB	O
-	O
induced	O
ARDS	O
who	O
was	O
successfully	O
treated	O
by	O
short	O
-	O
term	O
use	O
of	O
VV	O
-	O
ECMO	O
(	O
5	O
days	O
).	O

TITLE	O
:	O
Successful	O
management	O
of	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
caused	O
by	O
sodium	B-CHED
polystyrene	I-CHED
sulfonate	I-CHED
aspiration	O
:	O
A	O
case	O
report	O
.	O

He	O
aspirated	O
sodium	B-CHED
polystyrene	I-CHED
sulfonate	I-CHED
while	O
consuming	O
the	O
drug	O
.	O

In	O
this	O
line	O
,	O
we	O
engineered	O
an	O
attenuated	O
virus	O
based	O
on	O
the	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
genome	O
,	O
expressing	O
a	O
chimeric	O
spike	O
protein	B-CHED
from	O
a	O
virulent	O
United	O
States	O
(	O
US	O
)	O
PEDV	O
strain	O
.	O

In	O
the	O
present	O
study	O
,	O
a	O
series	O
of	O
C	O
-	O
28	O
modified	O
pentacyclic	O
triterpene	B-CHED
saponins	O
via	O
conjugation	O
with	O
a	O
series	O
of	O
amide	B-CHED
derivatives	O
were	O
synthesized	O
and	O
their	O
antiviral	B-CHED
activities	O
against	O
influenza	O
A	O
/	O
Duck	O
/	O
Guangdong	O
/	O
99	O
virus	O
(	O
H5N1	O
)	O
in	O
MDCK	O
cells	O
were	O
evaluated	O
.	O

The	O
SARs	O
analysis	O
of	O
these	O
compounds	O
revealed	O
that	O
introduction	O
of	O
certain	O
amide	B-CHED
structures	O
at	O
the	O
17	O
-	O
COOH	O
of	O
ursolic	B-CHED
acid	I-CHED
could	O
significantly	O
enhance	O
both	O
their	O
antiviral	B-CHED
activity	O
and	O
selective	O
index	O
.	O

Mechanism	O
studies	O
demonstrated	O
that	O
these	O
title	O
triterpenoids	B-CHED
could	O
bind	O
tightly	O
to	O
the	O
viral	O
envelope	O
HA	O
to	O
block	O
the	O
attachment	O
of	O
viruses	O
to	O
host	O
cells	O
,	O
which	O
was	O
consistent	O
with	O
docking	O
studies	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
complete	O
genome	O
sequences	O
and	O
molecular	O
characteristics	O
of	O
novel	O
G2b	O
PEDV	O
variants	O
with	O
a	O
two	O
-	O
amino	O
-	O
acid	O
deletion	O
in	O
the	O
neutralizing	O
epitope	B-CHED
of	O
the	O
spike	O
(	O
S	O
)	O
gene	O
,	O
which	O
were	O
concurrently	O
identified	O
on	O
a	O
re	O
-	O
infected	O
farm	O
and	O
its	O
neighboring	O
farm	O
on	O
Jeju	O
Island	O
.	O

Taken	O
together	O
,	O
our	O
results	O
demonstrate	O
that	O
PDCoV	O
nsp15	O
is	O
an	O
IFN	O
antagonist	B-CHED
and	O
it	O
inhibits	O
interferon	O
-	O
β	O
production	O
via	O
an	O
endoribonuclease	O
activity	O
-	O
independent	O
mechanism	O
.	O

HLH	O
was	O
noted	O
in	O
7	O
(	O
32	O
%)	O
cases	O
at	O
a	O
median	O
(	O
IQR	O
)	O
hospital	O
stay	O
of	O
5	O
(	O
2	O
-	O
8	O
)	O
d	O
.	O
Children	O
with	O
HLH	O
had	O
significantly	O
higher	O
Pediatric	O
Index	O
of	O
Mortality	O
2	O
(	O
PIM	B-CHED
2	O
)	O
score	O
at	O
admission	O
and	O
higher	O
frequency	O
of	O
pain	O
abdomen	O
,	O
anemia	O
,	O
hypoalbuminemia	O
,	O
elevated	O
alanine	B-CHED
aminotransferase	O
(	O
ALT	B-CHED
)	O
and	O
ARDS	O
.	O

Group	O
A	O
was	O
given	O
continuous	O
hemofiltration	O
alone	O
,	O
and	O
group	O
B	O
was	O
given	O
continuous	O
hemofiltration	O
combined	O
with	O
octreotide	B-CHED
.	O

The	O
research	O
findings	O
showed	O
that	O
serum	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
-	O
α	O
),	O
interleukin	O
-	O
1	O
(	O
IL	O
-	O
1	O
),	O
IL	O
-	O
6	O
,	O
IL	O
-	O
8	O
,	O
diamine	B-CHED
oxidase	O
(	O
DAO	B-CHED
),	O
endotoxin	O
,	O
D	B-CHED
-	I-CHED
lactic	I-CHED
acid	I-CHED
levels	O
and	O
acute	O
physiology	O
and	O
chronic	O
health	O
evaluation	O
(	O
APACHE	O
II	O
)	O
and	O
systemic	O
inflammatory	O
response	O
syndrome	O
(	O
SIRS	O
)	O
scores	O
of	O
group	O
B	O
were	O
lower	O
than	O
those	O
of	O
group	O
A	O
(	O
all	O
p	O
<	O
0	O
.	O
001	O
)	O
after	O
treatment	O
.	O

Owing	O
to	O
the	O
complexity	O
of	O
PPE	B-CHED
ensemble	O
selection	O
and	O
evaluation	O
,	O
a	O
team	O
with	O
expertise	O
in	O
infectious	O
diseases	O
,	O
occupational	O
health	O
,	O
the	O
health	O
care	O
activity	O
,	O
and	O
related	O
disciplines	O
,	O
such	O
as	O
human	O
factors	O
,	O
should	O
be	O
engaged	O
.	O

RESULTS	O
:	O
The	O
approach	O
was	O
demonstrated	O
for	O
the	O
activity	O
of	O
intubation	O
of	O
a	O
patient	O
with	O
methicillin	B-CHED
-	O
resistant	O
Staphylococcus	O
aureus	O
or	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
coronavirus	O
.	O

This	O
suggests	O
that	O
protein	B-CHED
-	O
based	O
vaccines	O
formulated	O
using	O
RNA	O
adjuvant	B-CHED
function	O
as	O
live	O
-	O
attenuated	O
vaccines	O
.	O

The	O
highest	O
nucleotide	B-CHED
identity	O
was	O
99	O
.	O
9	O
%	O
compared	O
with	O
PEDV	O
-	O
SX	O
/	O
China	O
/	O
2017	O
strain	O
,	O
and	O
the	O
lowest	O
nucleotide	B-CHED
identity	O
was	O
60	O
.	O
0	O
%	O
compared	O
with	O
PEDV	O
/	O
Belgorod	O
/	O
dom	O
/	O
2008	O
strain	O
.	O

TITLE	O
:	O
Porcine	O
transmissible	O
gastroenteritis	O
virus	O
inhibits	O
NF	O
-	O
κB	O
activity	O
via	O
nonstructural	O
protein	B-CHED
3	O
to	O
evade	O
host	O
immune	O
system	O
.	O

The	O
amino	B-CHED
acid	I-CHED
residues	O
at	O
positions	O
590	O
-	O
1	O
,	O
215	O
in	O
Nsp3	O
compose	O
the	O
critical	O
domain	O
that	O
mediates	O
NF	O
-	O
κB	O
inhibition	O
.	O

Subsequently	O
,	O
confocal	O
microscopy	O
analysis	O
showed	O
that	O
the	O
aggregated	O
ORF3	O
localized	O
in	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
to	O
trigger	O
ER	O
stress	O
response	O
via	O
up	O
-	O
regulation	O
of	O
GRP78	O
protein	B-CHED
expression	O
and	O
activation	O
of	O
PERK	B-CHED
-	O
eIF2α	O
signaling	O
pathway	O
.	O

Swabs	O
were	O
taken	O
during	O
stable	O
periods	O
(	O
n	O
=	O
1909	O
),	O
at	O
URTI	O
onset	O
(	O
n	O
=	O
391	O
),	O
10	O
days	O
after	O
the	O
URTI	O
(	O
n	O
=	O
356	O
)	O
and	O
during	O
an	O
AECOPD	O
(	O
n	O
=	O
177	O
)	O
and	O
tested	O
using	O
a	O
multiplex	O
nucleic	B-CHED
acid	I-CHED
amplification	O
test	O
.	O

Subcellular	O
localization	O
analyses	O
revealed	O
that	O
the	O
MERS	O
-	O
CoV	O
M	O
protein	B-CHED
is	O
retained	O
intracellularly	O
in	O
the	O

These	O
results	O
suggested	O
that	O
HY	O
showed	O
potential	O
antiviral	B-CHED
activities	O
against	O
IBV	O
infection	O
involving	O
the	O
inhibition	O
of	O
apoptosis	O
and	O
ROS	B-CHED
generation	O
in	O
CEK	O
cells	O
.	O

Remarkably	O
,	O
both	O
Hsp90	O
inhibition	O
and	O
P53	O
induction	O
are	O
associated	O
with	O
the	O
activation	O
of	O
the	O
Unfolded	O
Protein	B-CHED
Response	O
element	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
show	O
that	O
the	O
incorporation	O
of	O
the	O
Rho	O
-	O
associated	O
protein	B-CHED
kinase	O
(	O
ROCK	O
)	O
inhibitor	B-CHED
(	O
Y	O
-	O
27632	O
)	O
during	O
cell	O
propagation	O
extends	O
the	O
life	O
span	O
of	O
primary	O
human	O
cells	O
in	O
vitro	O
and	O
thereby	O
facilitates	O
the	O
incorporation	O
of	O
lentivirus	O
-	O
based	O
expression	O
systems	O
.	O

Four	O
antibodies	O
against	O
the	O
SeACoV	O
spike	O
,	O
membrane	O
,	O
nucleocapsid	O
and	O
nonstructural	O
protein	B-CHED
3	O
capable	O
of	O
reacting	O
with	O
viral	O
antigens	B-CHED
in	O
SeACoV	O
-	O
infected	O
Vero	O
cells	O
were	O
generated	O
.	O

Average	O
95th	O
percentile	O
pressure	O
was	O
low	O
(	O
9	O
.	O
3	O
±	O
1	O
.	O
7	O
cmH	B-CHED
Adherence	O
to	O
CPAP	O
after	O
acute	O
,	O
traumatic	O
tetraplegia	O
is	O
low	O
.	O

Independent	O
risk	O
factors	O
for	O
infection	O
were	O
direct	O
contact	O
with	O
a	O
confirmed	O
case	O
-	O
patient	O
and	O
sharing	O
a	O
room	O
with	O
a	O
confirmed	O
case	O
-	O
patient	O
;	O
a	O
protective	O
factor	O
was	O
having	O
an	O
air	B-CHED
conditioner	O
in	O
the	O
bedroom	O
.	O

However	O
,	O
when	O
a	O
multivariate	O
analysis	O
was	O
performed	O
,	O
only	O
low	O
gestational	O
age	O
,	O
total	O
days	O
on	O
oxygen	B-CHED
supplement	O
and	O
high	O
bilirubin	B-CHED
levels	O
were	O
significant	O
regarding	O
the	O
development	O
of	O
ROP	O
.	O

However	O
,	O
when	O
a	O
multivariate	O
analysis	O
was	O
performed	O
,	O
only	O
low	O
gestational	O
age	O
,	O
total	O
days	O
on	O
oxygen	B-CHED
supplement	O
and	O
high	O
bilirubin	B-CHED
levels	O
were	O
significant	O
regarding	O
the	O
development	O
of	O
ROP	O
.	O

The	O
full	O
-	O
length	O
genomic	O
cDNA	O
was	O
transcribed	O
in	O
vitro	O
,	O
and	O
its	O
transcript	O
was	O
transfected	O
into	O
BHK	O
-	O
21	O
/	O
N	O
cells	O
that	O
could	O
stably	O
express	O
IBV	O
N	O
protein	B-CHED
.	O

Among	O
the	O
25	O
proteins	B-CHED
encoded	O
by	O
MERS	O
-	O
CoV	O
,	O
5	O
accessory	O
proteins	B-CHED
seem	O
to	O
be	O
involved	O
in	O
viral	O
evasion	O
of	O
the	O
host	O
immune	O
responses	O
.	O

CNS	B-CHED
involvement	O
observed	O
among	O
27	O
%.	O

We	O
present	O
an	O
unusual	O
case	O
of	O
left	O
upper	O
limb	O
acute	O
arterial	O
thrombosis	O
with	O
purpura	O
fulminans	O
like	O
skin	O
lesions	O
precipitated	O
by	O
swine	O
flu	O
(	O
H1N1	O
)	O
infection	O
with	O
adult	O
respiratory	O
distress	O
syndrome	O
subsequently	O
developing	O
acute	O
renal	O
failure	O
,	O
retinal	B-CHED
infarcts	O
,	O
multiple	O
acute	O
cerebral	O
infarcts	O
,	O
cardiac	O
valvular	O
vegetations	O
and	O
hemolytic	O
anemia	O
with	O
recurrent	O
bleeding	O
episodes	O
.	O

Acute	O
renal	O
injury	O
with	O
hypoperfusion	O
state	O
due	O
to	O
toxicity	O
at	O
cellular	O
level	O
,	O
redox	O
cycling	O
and	O
intracellular	O
reactive	O
oxidative	O
stress	O
generation	O
may	O
also	O
cause	O
death	O
in	O
early	O
stages	O
in	O
paraquat	B-CHED
poisoning	O
despite	O
optimal	O
management	O
.	O

TITLE	O
:	O
Characteristics	O
of	O
flavonoids	B-CHED
as	O
potent	O
MERS	O
-	O
CoV	O
3C	O
-	O
like	O
protease	B-CHED
inhibitors	I-CHED
.	O

The	O
experimental	O
and	O
computational	O
study	O
showed	O
that	O
flavonol	B-CHED
and	O
chalcone	B-CHED
are	O
favourite	O
scaffolds	O
to	O
bind	O
with	O
the	O
catalytic	O
site	O
of	O
MERS	O
-	O
CoV	O
3CLpro	O
.	O

It	O
was	O
also	O
deduced	O
that	O
some	O
flavonoid	B-CHED
derivatives	O
with	O
hydrophobic	O
or	O
carbohydrate	B-CHED
attached	O
to	O
their	O
core	O
structures	O
have	O
a	O
good	O
inhibitory	O
effect	O
.	O

TITLE	O
:	O
High	O
-	O
Carbohydrate	B-CHED
vs	O
High	O
-	O
Fat	O
Nutrition	O
for	O
Burn	O
Patients	O
.	O

In	O
the	O
present	O
study	O
,	O
with	O
the	O
aim	O
to	O
exploit	O
a	O
coumarin	B-CHED
-	O
based	O
scaffold	O
to	O
achieve	O
the	O
inhibition	O
of	O
multiple	O
viral	O
coded	O
enzymatic	O
functions	O
,	O
novel	O
4	O
-	O
hydroxy	B-CHED
-	O
2H	O
,	O
5H	O
-	O
pyrano	O
(	O
3	O
,	O
2	O
-	O
c	O
)	O
chromene	B-CHED
-	O
2	O
,	O
5	O
-	O
dione	O
derivatives	O
were	O
synthesized	O
.	O

ABSTRACT	O
:	O
Enteric	O
viruses	O
exploit	O
bacterial	O
components	O
,	O
including	O
lipopolysaccharides	B-CHED
(	O
LPS	B-CHED
)	O
and	O
peptidoglycan	B-CHED
(	O
PG	O
),	O
to	O
facilitate	O
infection	O
in	O
humans	O
.	O

TITLE	O
:	O
Probing	O
the	O
Effects	O
of	O
Pyrimidine	B-CHED
Functional	O
Group	O
Switches	O
on	O
Acyclic	O
Fleximer	O
Analogues	O
for	O
Antiviral	B-CHED
Activity	O
.	O

TITLE	O
:	O
A	O
Fusion	O
Peptide	B-CHED
in	O
the	O
Spike	O
Protein	B-CHED
of	O
MERS	O
Coronavirus	O
.	O

A	O
key	O
step	O
in	O
the	O
MERS	O
-	O
CoV	O
replication	O
cycle	O
is	O
the	O
fusion	O
of	O
the	O
virus	O
and	O
host	O
cell	O
membranes	O
mediated	O
by	O
the	O
virus	O
spike	O
protein	B-CHED
,	O
S	O
.	O
The	O
location	O
of	O
the	O
fusion	O
peptide	B-CHED
within	O
the	O
MERS	O
S	O
protein	B-CHED
has	O
not	O
been	O
precisely	O
mapped	O
.	O

ABSTRACT	O
:	O
Myocardial	O
calcification	O
,	O
a	O
rare	O
disease	O
that	O
leads	O
to	O
chronic	O
or	O
acute	O
heart	O
failure	O
and	O
with	O
a	O
poor	O
prognosis	O
,	O
occurs	O
in	O
patients	O
with	O
abnormal	O
calcium	B-CHED
-	O
phosphorus	B-CHED
metabolism	O
.	O

Silicone	B-CHED
pneumonitis	O
with	O
a	O
severe	O
acute	O
respiratory	O
failure	O
based	O
on	O
silicone	B-CHED
embolization	O
syndrome	O
was	O
diagnosed	O
.	O

The	O
diagnostic	O
potentials	O
of	O
specific	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
accessory	O
and	O
nonstructural	O
proteins	B-CHED
,	O
if	O
any	O
,	O
have	O
not	O
yet	O
been	O
investigated	O
.	O

Furthermore	O
,	O
a	O
total	O
of	O
851	O
serum	O
samples	O
from	O
diarrheal	O
pigs	O
of	O
different	O
ages	O
were	O
analyzed	O
by	O
ELISA	O
,	O
with	O
most	O
showing	O
immune	O
-	O
reactivity	O
towards	O
the	O
WV	O
,	O
S1	O
,	O
ORF3C	O
,	O
and	O
E	O
proteins	B-CHED
.	O

However	O
,	O
little	O
is	O
known	O
about	O
the	O
key	O
amino	B-CHED
acids	I-CHED
that	O
contribute	O
to	O
the	O
broad	O
-	O
spectrum	O
S2	O
epitopes	O
.	O

In	O
this	O
study	O
,	O
we	O
aimed	O
to	O
elucidate	O
the	O
specific	O
amino	B-CHED
acids	I-CHED
contributing	O
to	O
S2	O
epitopes	O
.	O

Site	O
mutagenesis	O
and	O
peptide	B-CHED
-	O
based	O
enzyme	O
-	O
linked	O
immunosorbent	O
assays	O
(	O
ELISAs	O
)	O
showed	O
that	O
16R	O
in	O
S2	O
protein	B-CHED
was	O
a	O
key	O
amino	B-CHED
acid	I-CHED
mediating	O
the	O
antigenicity	O
of	O
S2	O
protein	B-CHED
.	O

Taken	O
together	O
,	O
these	O
data	O
demonstrated	O
that	O
S2	O
-	O
derived	O
peptides	B-CHED
with	O
16R	O
could	O
be	O
used	O
as	O
novel	O
marker	O
-	O
based	O
antigens	B-CHED
for	O
developing	O
both	O
broad	O
-	O
spectrum	O
vaccines	O
and	O
serological	O
diagnostic	O
kits	O
to	O
control	O
IBV	O
.	O

Beyond	O
antimicrobial	B-CHED
treatment	O
,	O
no	O
targeted	O
molecular	O
therapies	O
have	O
yet	O
proven	O
effective	O
,	O
highlighting	O
the	O
need	O
for	O
additional	O
research	O
.	O

A	O
delay	O
in	O
antibiotic	B-CHED
treatment	O
resulted	O
in	O
ongoing	O
inflammation	O
and	O
renal	O
and	O
hepatic	O
dysfunction	O
despite	O
effective	O
bacterial	O
killing	O
.	O

TITLE	O
:	O
A	O
rare	O
case	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
caused	O
by	O
use	O
of	O
gadolinium	B-CHED
-	O
based	O
magnetic	O
resonance	O
imaging	O
contrast	B-CHED
media	I-CHED
.	O

ABSTRACT	O
:	O
Sickle	O
cell	O
disease	O
(	O
SCD	O
)	O
is	O
a	O
hereditary	O
hemoglobinopathy	O
resulting	O
in	O
sickling	O
hemoglobin	B-CHED
.	O

TITLE	O
:	O
Indole	B-CHED
:	O
A	O
privileged	O
scaffold	O
for	O
the	O
design	O
of	O
anti	O
-	O
cancer	O
agents	O
.	O

ABSTRACT	O
:	O
In	O
a	O
multicenter	O
cohort	O
study	O
including	O
22	O
oseltamivir	B-CHED
-	O
treated	O
patients	O
with	O
influenza	O
A	O
(	O
H1N1	O
)	O
pdm09	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
prevalence	O
of	O
the	O
H275Y	O
substitution	O
in	O
the	O
neuraminidase	O
,	O
responsible	O
for	O
highly	O
reduced	O
sensitivity	O
to	O
oseltamivir	B-CHED
,	O
was	O
23	O
%.	O

Additional	O
pandemics	O
of	O
MERS	O
-	O
CoV	O
are	O
expected	O
,	O
and	O
thus	O
novel	O
tools	O
and	O
reagents	B-CHED
for	O
therapy	O
and	O
diagnosis	O
are	O
urgently	O
needed	O
.	O

Here	O
,	O
we	O
used	O
phage	O
display	O
to	O
develop	O
novel	O
monoclonal	O
antibodies	O
(	O
mAbs	O
)	O
that	O
target	O
MERS	O
-	O
CoV	O
.	O
A	O
human	O
Fab	O
phage	O
display	O
library	O
was	O
panned	O
against	O
the	O
S2	O
subunit	O
of	O
the	O
MERS	O
-	O
CoV	O
spike	O
protein	B-CHED
(	O
MERS	O
-	O
S2P	O
),	O
yielding	O
three	O
unique	O
Fabs	O
(	O
S2A3	O
,	O
S2A6	O
,	O
and	O
S2D5	O
).	O

ABSTRACT	O
:	O
The	O
efficacy	O
of	O
ustekinumab	O
,	O
an	O
antagonist	B-CHED
of	O
the	O
p40	O
subunit	O
of	O
interleukin	O
-	O
12	O
and	O
interleukin	O
-	O
23	O
,	O
as	O
induction	O
and	O
maintenance	O
therapy	O
in	O
patients	O
with	O
ulcerative	O
colitis	O
is	O
unknown	O
.	O

Patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
intravenous	O
infusion	O
of	O
vitamin	B-CHED
C	I-CHED
(	O
50	O
mg	O
/	O
kg	O
in	O
dextrose	B-CHED
5	O
%	O
in	O
water	B-CHED
,	O
n	O
=	O
84	O
)	O
or	O
placebo	O
(	O
dextrose	B-CHED
5	O
%	O
in	O
water	B-CHED
only	O
,	O
n	O
=	O
83	O
)	O
every	O
6	O
hours	O
for	O
96	O
hours	O
.	O

The	O
primary	O
outcomes	O
were	O
change	O
in	O
organ	O
failure	O
as	O
assessed	O
by	O
a	O
modified	O
Sequential	O
Organ	O
Failure	O
Assessment	O
score	O
(	O
range	O
,	O
0	O
-	O
20	O
,	O
with	O
higher	O
scores	O
indicating	O
more	O
dysfunction	O
)	O
from	O
baseline	O
to	O
96	O
hours	O
,	O
and	O
plasma	O
biomarkers	O
of	O
inflammation	O
(	O
C	O
-	O
reactive	O
protein	B-CHED
levels	O
)	O
and	O
vascular	O
injury	O
(	O
thrombomodulin	O
levels	O
)	O
measured	O
at	O
0	O
,	O
48	O
,	O
96	O
,	O
and	O
168	O
hours	O
.	O

Further	O
research	O
is	O
needed	O
to	O
evaluate	O
the	O
potential	O
role	O
of	O
vitamin	B-CHED
C	I-CHED
for	O
other	O
outcomes	O
in	O
sepsis	O
and	O
ARDS	O
.	O

Furthermore	O
,	O
GHRH	O
antagonists	B-CHED
supported	O
the	O
integrity	O
of	O
endothelial	O
barrier	O
,	O
while	O
GHRH	O
and	O
GHRH	O
agonists	B-CHED
had	O
the	O
contrary	O
effects	O
,	O
as	O
reflected	O
in	O
measurements	O
of	O
transendothelial	O
resistance	O
.	O

Evidence	O
that	O
IPA	B-CHED
can	O
occur	O
in	O
nonimmunocompromised	O
hosts	O
is	O
increasing	O
.	O

The	O
integrin	O
αv	O
and	O
β3	O
subunits	O
were	O
both	O
involved	O
in	O
the	O
enhancement	O
of	O
PEDV	O
infection	O
,	O
the	O
Arg	B-CHED
-	O
Gly	B-CHED
-	O
Asp	B-CHED
peptides	B-CHED
targeting	O
integrin	O
αvβ3	O
significantly	O
inhibited	O
replication	O
of	O
PEDV	O
in	O
Vero	O
E6	O
cells	O
,	O
and	O
co	O
-	O
expression	O
of	O
integrin	O
αvβ3	O
with	O
pAPN	O
significantly	O
enhanced	O
replication	O
of	O
PEDV	O
in	O
Vero	O
E6	O
and	O
BHK	O
-	O
21	O
cells	O
.	O

Calves	O
that	O
drink	O
water	B-CHED
from	O
rivers	O
,	O
streams	O
,	O
and	O
ponds	O
had	O
a	O
higher	O
chance	O
of	O
being	O
infected	O
by	O
Eimeria	O
spp	O
.	O

So	O
,	O
we	O
speculate	O
that	O
circEZH2	O
may	O
regulate	O
TGEV	O
-	O
induced	O
mPTP	B-CHED
opening	O
via	O
NF	O
-	O
kB	O
pathway	O
.	O

Inhibitor	B-CHED
of	O
NF	O
-	O
κB	O
increased	O
TGEV	O
-	O
induced	O
mPTP	B-CHED
opening	O
.	O

TITLE	O
:	O
Standard	O
Expected	O
Years	O
of	O
Life	O
Lost	B-CHED
as	O
a	O
Neglected	O
Index	O
for	O
Calculating	O
the	O
Burden	O
of	O
Premature	O
Mortality	O
due	O
to	O
Middle	O
East	O
Respiratory	O
Syndrome	O
.	O

ABSTRACT	O
:	O
This	O
study	O
presents	O
standard	O
expected	O
years	O
of	O
life	O
lost	B-CHED
due	O
to	O
premature	O
mortality	O
for	O
calculating	O
the	O
burden	O
of	O
laboratory	O
-	O
confirmed	O
MERS	O
-	O
CoV	O
cases	O
that	O
have	O
occurred	O
from	O
January	O
1	O
,	O
2018	O
,	O
to	O
March	O
31	O
,	O
2019	O
,	O
worldwide	O
.	O

TITLE	O
:	O
P200	O
family	O
protein	B-CHED
IFI204	O
negatively	O
regulates	O
type	O
I	O
interferon	O
responses	O
by	O
targeting	O
IRF7	O
in	O
nucleus	B-CHED
.	O

Treatment	O
is	O
focused	O
on	O
withdrawal	O
of	O
medication	O
,	O
supportive	O
care	O
and	O
immunosuppression	O
such	O
as	O
high	O
-	O
dose	O
corticosteroid	B-CHED
therapy	O
.	O

Weekly	O
qualitative	O
PCR	O
analysis	O
was	O
done	O
to	O
monitor	O
viral	O
clearance	O
,	O
with	O
zanamivir	B-CHED
treatment	O
being	O
discontinued	O
upon	O
receipt	O
of	O
negative	O
results	O
.	O

After	O
Severe	O
Carbon	B-CHED
Monoxide	I-CHED
Poisoning	O
Is	O
Likely	O
Due	O
to	O
Cytopathic	O
Hypoxia	O
:	O
A	O
Case	O
Report	O
and	O
Discussion	O
.	O

TITLE	O
:	O
Immune	O
Predictors	O
of	O
Mortality	O
After	O
Ribonucleic	B-CHED
Acid	I-CHED
Virus	O
Infection	O
.	O

The	O
first	O
generation	O
of	O
antiviral	B-CHED
CQDs	O
was	O
derived	O
from	O
hydrothermal	O
carbonization	O
of	O
ethylenediamine	B-CHED
/	O
citric	B-CHED
acid	I-CHED
as	O
carbon	B-CHED
precursors	O
and	O
postmodified	O
with	O
boronic	B-CHED
acid	I-CHED
ligands	O
.	O

Viral	O
nucleocapsid	O
proteins	B-CHED
are	O
inevitable	O
for	O
genome	O
encapsidation	O
and	O
replication	O
.	O

Overall	O
,	O
the	O
long	O
-	O
term	O
prognosis	O
was	O
satisfactory	O
,	O
suggesting	O
that	O
this	O
procedure	O
is	O
less	O
invasive	O
and	O
effective	O
for	O
treatment	O
of	O
MAS	B-CHED
due	O
to	O
TA	O
,	O
in	O
emergencies	O
.	O

This	O
syndrome	O
has	O
been	O
best	O
characterized	O
after	O
buprenorphine	B-CHED
overdose	O
or	O
abuse	O
,	O
but	O
likely	O
occurs	O
with	O
others	O
.	O

This	O
constellation	O
of	O
events	O
is	O
referred	O
to	O
as	O
inadvertent	O
or	O
unintended	O
acetaminophen	B-CHED
overdose	O
or	O
more	O
colloquially	O
as	O
a	O
“	O
therapeutic	O
misadventure	O
”.	O

Pentazocine	B-CHED
.	O

Remifentanil	B-CHED
.	O

TITLE	O
:	O
LiverTox	O
:	O
Clinical	O
and	O
Research	O
Information	O
on	O
Drug	O
-	O
Induced	O
Liver	O
Injury	O
ABSTRACT	O
:	O
The	O
aminopenicillins	O
(	O
sometimes	O
referred	O
to	O
as	O
third	O
generation	O
penicillins	B-CHED
)	O
are	O
semisynthetic	O
modifications	O
of	O
natural	O
penicillin	B-CHED
that	O
have	O
the	O
advantage	O
of	O
a	O
broader	O
spectrum	O
of	O
activity	O
.	O

Like	O
the	O
natural	O
penicillins	B-CHED
,	O
aminopenicillins	O
have	O
a	O
thiazolidine	B-CHED
ring	O
structure	O
connected	O
to	O
a	O
beta	B-CHED
-	I-CHED
lactam	I-CHED
ring	I-CHED
which	O
makes	O
these	O
agents	O
susceptible	O
to	O
inactivation	O
by	O
beta	O
-	O
lactamase	O
,	O
the	O
usual	O
cause	O
of	O
bacterial	O
resistance	O
to	O
the	O
penicillins	B-CHED
.	O

These	O
interfaces	O
likely	O
play	O
a	O
role	O
in	O
the	O
S	O
-	O
protein	B-CHED
conformational	O
changes	O
associated	O
with	O
membrane	O
fusion	O
.	O

TITLE	O
:	O
The	O
S2	O
Subunit	O
of	O
QX	O
-	O
type	O
Infectious	O
Bronchitis	O
Coronavirus	O
Spike	O
Protein	B-CHED
Is	O
an	O
Essential	O
Determinant	O
of	O
Neurotropism	O
.	O

Pathogenicity	O
experiments	O
using	O
P120	O
in	O
piglets	O
revealed	O
significant	O
reductions	O
in	O
clinical	O
symptoms	O
,	O
histopathological	O
lesions	O
,	O
and	O
intestinal	O
PEDV	O
antigen	B-CHED
distribution	O
;	O
the	O
piglet	O
survival	O
rate	O
in	O
the	O
P120	O
group	O
was	O
100	O
%.	O

TITLE	O
:	O
Potentially	O
fatal	O
electrolyte	O
imbalance	O
caused	O
by	O
severe	O
hydrofluoric	B-CHED
acid	I-CHED
burns	O
combined	O
with	O
inhalation	O
injury	O
:	O
A	O
case	O
report	O
.	O

There	O
are	O
no	O
specific	O
antiviral	B-CHED
treatments	O
or	O
vaccines	O
available	O
.	O

Met	B-CHED
is	O
one	O
of	O
the	O
amino	B-CHED
acids	I-CHED
that	O
not	O
only	O
play	O
a	O
nutritional	O
role	O
but	O
also	O
participate	O
in	O
and	O
regulate	O
key	O
metabolic	O
pathways	O
and	O
immune	O
response	O
.	O

Many	O
differentially	O
expressed	O
lncRNAs	O
act	O
as	O
elements	O
to	O
competitively	O
attach	O
microRNAs	O
(	O
miRNAs	O
)	O
which	O
target	O
to	O
messenger	B-CHED
RNA	I-CHED
(	O
mRNAs	O
)	O
to	O
mediate	O
expression	O
of	O
genes	O
that	O
related	O
to	O
toll	O
-	O
like	O
receptors	O
(	O
TLRs	O
),	O
NOD	O
-	O
like	O
receptors	O
(	O
NLRs	O
),	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
),	O
and	O
RIG	O
-	O
I	O
-	O
like	O
receptors	O
(	O
RLRs	O
)	O
pathways	O
.	O

ABSTRACT	O
:	O
To	O
determine	O
the	O
prevalence	O
of	O
nucleic	B-CHED
acid	I-CHED
from	O
selected	O
cardiotropic	O
pathogens	O
in	O
endomyocardial	O
biopsy	O
samples	O
from	O
dogs	O
with	O
unexplained	O
myocardial	O
and	O
rhythm	O
disorders	O
(	O
UMRD	O
)	O
and	O
compare	O
prevalence	O
with	O
that	O
for	O
a	O
group	O
of	O
control	O
dogs	O
with	O
congenital	O
heart	O
disease	O
(	O
CHD	O
).	O

Biopsy	O
samples	O
were	O
evaluated	O
histologically	O
,	O
and	O
PCR	O
assays	O
were	O
used	O
for	O
detection	O
of	O
nucleic	B-CHED
acid	I-CHED
from	O
12	O
pathogens	O
.	O

The	O
AuNP	B-CHED
-	O
adjuvanted	O
protein	B-CHED
induced	O
a	O
strong	O
IgG	O
response	O
but	O
failed	O
to	O
improve	O
vaccine	O
efficacy	O
or	O
to	O
reduce	O
eosinophilic	O
infiltration	O
because	O
of	O
highly	O
allergic	O
inflammatory	O
responses	O
.	O

The	O
patient	O
was	O
a	O
34	O
years	O
old	O
male	O
who	O
presented	O
with	O
a	O
reduced	O
level	O
of	O
consciousness	O
and	O
acute	O
hearing	O
loss	O
after	O
suicidal	O
ingestion	O
of	O
40	O
mg	O
of	O
methadone	B-CHED
while	O
experiencing	O
family	O
-	O
related	O
stresses	O
.	O

Although	O
rare	O
,	O
ototoxicity	O
and	O
permanent	O
hearing	O
loss	O
may	O
happen	O
in	O
cases	O
of	O
methadone	B-CHED
poisoning	O
.	O

While	O
removal	O
of	O
sialic	B-CHED
acids	I-CHED
from	O
tissues	O
prevented	O
binding	O
of	O
all	O
proteins	B-CHED
to	O
all	O
tissues	O
,	O
binding	O
of	O
QX	O
-	O
RBD	O
to	O
trachea	O
and	O
kidney	O
could	O
not	O
be	O
blocked	O
by	O
preincubation	O
with	O
synthetic	O
alpha	O
-	O
2	O
,	O
3	O
-	O
linked	O
sialic	B-CHED
acids	I-CHED
.	O

Using	O
chimeric	O
RBD	O
proteins	B-CHED
,	O
we	O
discovered	O
that	O
the	O
region	O
encompassing	O
amino	B-CHED
acids	I-CHED
99	O
to	O
159	O
of	O
QX	O
-	O
RBD	O
was	O
required	O
to	O
establish	O
kidney	O
binding	O
.	O

The	O
present	O
study	O
used	O
immuno	O
-	O
informatics	O
and	O
computational	O
approaches	O
to	O
identify	O
conserved	O
B	O
-	O
and	O
T	O
cell	O
epitopes	O
for	O
the	O
MERS	O
-	O
COV	O
spike	O
(	O
S	O
)	O
protein	B-CHED
that	O
may	O
perform	O
a	O
significant	O
role	O
in	O
eliciting	O
the	O
resistance	O
response	O
to	O
MERS	O
-	O
COV	O
infection	O
.	O

However	O
,	O
he	O
still	O
required	O
high	O
-	O
flow	O
oxygen	B-CHED
therapy	O
.	O

Coronaviruses	O
(	O
CoVs	O
)	O
have	O
been	O
rising	O
targets	O
of	O
some	O
flavonoids	B-CHED
.	O

An	O
induced	O
-	O
fit	O
docking	O
analysis	O
indicated	O
that	O
S1	O
,	O
S2	O
and	O
S3	O
'	O
sites	O
are	O
involved	O
in	O
binding	O
with	O
flavonoids	B-CHED
.	O

With	O
the	O
systematic	O
analysis	O
,	O
the	O
three	O
flavonoids	B-CHED
are	O
suggested	O
to	O
be	O
templates	O
to	O
design	O
functionally	O
improved	O
inhibitors	B-CHED
.	O

Erythrocyte	O
sedimentation	O
rate	O
and	O
C	O
-	O
reactive	O
protein	B-CHED
were	O
elevated	O
.	O

A	O
single	O
indicator	B-CHED
does	O
not	O
exist	O
for	O
PARDS	O
diagnosis	O
.	O

EMGdi	O
and	O
trans	O
-	O
pulmonary	O
pressure	O
(∆	O
P	O
In	O
ARDS	O
patients	O
,	O
the	O
static	O
compliance	O
of	O
the	O
chest	O
wall	O
was	O
significantly	O
decreased	O
after	O
PPV	B-CHED
.	O

These	O
findings	O
have	O
important	O
implications	O
for	O
optimizing	O
antimicrobial	B-CHED
therapy	O
in	O
patients	O
receiving	O
ECMO	O
to	O
maximize	O
therapeutic	O
efficacy	O
.	O

ABSTRACT	O
:	O
The	O
N	O
-	O
terminal	O
fusion	O
peptide	B-CHED
(	O
residues	O
770	O
-	O
788	O
)	O
of	O
an	O
S2	O
glycoprotein	B-CHED
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
exposed	O
upon	O
receptor	O
binding	O
,	O
is	O
crucial	O
for	O
virus	O
entry	O
into	O
the	O
host	O
cell	O
.	O

Per	O
capita	O
GDP	B-CHED
had	O
a	O
similar	O
effect	O
,	O
except	O
for	O
between	O
-	O
municipality	O
inequality	O
of	O
professionals	O
and	O
within	O
-	O
municipality	O
inequality	O
of	O
field	O
epidemiological	O
investigators	O
.	O

TITLE	O
:	O
Nucleocapsid	O
proteins	B-CHED
from	O
other	O
swine	O
enteric	O
coronaviruses	O
differentially	O
modulate	O
PEDV	O
replication	O
.	O

TITLE	O
:	O
Pathogenicity	O
of	O
a	O
QX	O
-	O
like	O
strain	O
of	O
infectious	O
bronchitis	O
virus	O
and	O
effects	O
of	O
accessory	O
proteins	B-CHED
3a	O
and	O
3b	O
in	O
chickens	O
.	O

ABSTRACT	O
:	O
A	O
series	O
of	O
indazolyl	O
-	O
substituted	O
piperidin	O
-	O
4	O
-	O
yl	O
-	O
aminopyrimidines	B-CHED
(	O
IPAPYs	O
)	O
were	O
designed	O
from	O
two	O
potent	O
HIV	O
-	O
1	O
NNRTIs	O
piperidin	O
-	O
4	O
-	O
yl	O
-	O
aminopyrimidine	B-CHED
3c	O
and	O
diaryl	O
ether	B-CHED
4	O
as	O
the	O
lead	B-CHED
compounds	I-CHED
by	O
molecular	O
hybridization	O
strategy	O
.	O

Investigations	O
revealed	O
an	O
extremely	O
high	O
serum	O
myogenic	O
enzyme	O
levels	O
and	O
impaired	O
renal	O
function	O
with	O
serum	O
creatinine	B-CHED
level	O
of	O
510	O
μmol	O
/	O
L	O
,	O
consistent	O
with	O
the	O
diagnosis	O
of	O
rhabdomyolysis	O
,	O
AKI	O
stage	O
3	O
,	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

S0	O
,	O
a	O
truncated	O
region	O
of	O
the	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
spike	O
protein	B-CHED
,	O
has	O
been	O
suggested	O
as	O
a	O
candidate	O
antigen	B-CHED
for	O
PED	O
subunit	O
vaccines	O
;	O
however	O
,	O
poor	O
solubility	O
problems	O
when	O
the	O
protein	B-CHED
is	O
expressed	O
in	O

TITLE	O
:	O
Nucleocapsid	O
Protein	B-CHED
Recruitment	O
to	O
Replication	O
-	O
Transcription	O
Complexes	O
Plays	O
a	O
Crucial	O
Role	O
in	O
Coronaviral	O
Life	O
Cycle	O
.	O

Furthermore	O
,	O
it	O
underscores	O
the	O
fact	O
that	O
Addison	O
'	O
s	O
disease	O
can	O
occur	O
as	O
part	O
of	O
a	O
constellation	O
of	O
autoimmune	O
manifestations	O
within	O
the	O
context	O
of	O
an	O
underlying	O
polyglandular	O
syndrome	O
,	O
such	O
as	O
APS	B-CHED
type	O
1	O
.	O

In	O
this	O
report	O
,	O
HCoV	O
-	O
OC43	O
isolates	O
collected	O
from	O
HSCT	O
patients	O
were	O
retrospectively	O
characterized	O
to	O
identify	O
potential	O
clusters	B-CHED
of	O
infection	O
that	O
may	O
stand	O
for	O
a	O
hospital	O
transmission	O
.	O

In	O
patients	O
with	O
severe	O
leptospirosis	O
in	O
tropical	O
Australia	O
,	O
prompt	O
ICU	O
support	O
that	O
includes	O
early	O
antibiotics	B-CHED
,	O
protective	O
ventilation	O
strategies	O
,	O
conservative	O
fluid	O
resuscitation	O
,	O
traditional	O
thresholds	O
for	O
RRT	O
initiation	O
and	O
corticosteroid	B-CHED
therapy	O
is	O
associated	O
with	O
a	O
very	O
low	O
case	O
-	O
fatality	O
rate	O
.	O

Compared	O
with	O
controls	O
,	O
the	O
experimental	O
group	O
had	O
a	O
significantly	O
higher	O
proportion	O
of	O
antibiotics	B-CHED
discontinuation	O
or	O
de	O
-	O
escalation	O
in	O
the	O
ED	O
(	O
26	O
.	O
0	O
%	O
vs	O
16	O
.	O
1	O
%,	O
P	O
=	O
.	O
007	O
),	O
neuraminidase	B-CHED
inhibitor	I-CHED
uses	O
(	O
8	O
.	O
9	O
%	O
vs	O
0	O
.	O
6	O
%,	O
P	O
<	O
.	O
001	O
),	O
and	O
shorter	O
duration	O
of	O
intravenous	O
antibiotics	B-CHED
(	O
10	O
.	O
0	O
vs	O
14	O
.	O
5	O
days	O
,	O
P	O
<	O
.	O
001	O
).	O

Overall	O
,	O
we	O
identified	O
a	O
new	O
scaffold	O
as	O
a	O
suitable	O
platform	O
for	O
the	O
development	O
of	O
novel	O
dual	O
HIV	O
-	O
1	O
inhibitors	B-CHED
.	O

TITLE	O
:	O
Identification	O
of	O
the	O
immunodominant	O
neutralizing	O
regions	O
in	O
the	O
spike	O
glycoprotein	B-CHED
of	O
porcine	O
deltacoronavirus	O
.	O

Polyclonal	O
antisera	O
against	O
the	O
three	O
recombinant	O
proteins	B-CHED
were	O
produced	O
in	O
rabbits	O
and	O
mice	O
.	O

ABSTRACT	O
:	O
In	O
the	O
last	O
year	O
,	O
an	O
increasing	O
number	O
of	O
studies	O
have	O
reported	O
on	O
methicillin	B-CHED
-	O
resistant	O
Staphylococcus	O
aureus	O
(	O
MRSA	O
)	O
transmission	O
in	O
Africa	O
and	O
Asia	O
and	O
in	O
migrant	O
workers	O
.	O

Studies	O
focused	O
on	O
occupational	O
exposures	O
to	O
infectious	O
agents	O
,	O
dust	O
and	O
allergens	O
,	O
pesticides	B-CHED
,	O
and	O
occupational	O
injury	O
.	O

These	O
studies	O
highlighted	O
the	O
global	O
expansion	O
of	O
zoonotic	O
antibiotic	B-CHED
resistance	O
and	O
identified	O
novel	O
occupational	O
zoonoses	O
of	O
concern	O
.	O

ABSTRACT	O
:	O
Antibody	O
-	O
dependent	O
enhancement	O
(	O
ADE	B-CHED
)	O
of	O
viral	O
entry	O
has	O
been	O
a	O
major	O
concern	O
for	O
epidemiology	O
,	O
vaccine	O
development	O
,	O
and	O
antibody	O
-	O
based	O
drug	O
therapy	O
.	O

Our	O
study	O
reveals	O
a	O
novel	O
molecular	O
mechanism	O
for	O
antibody	O
-	O
enhanced	O
viral	O
entry	O
and	O
can	O
guide	O
future	O
vaccination	O
and	O
antiviral	B-CHED
strategies	O
.	O

TITLE	O
:	O
Genetic	O
diversity	O
of	O
MERS	O
-	O
CoV	O
spike	O
protein	B-CHED
gene	O
in	O
Saudi	O
Arabia	O
.	O

The	O
Spike	O
protein	B-CHED
gene	O
plays	O
a	O
significant	O
role	O
in	O
virus	O
attachment	O
to	O
host	O
cells	O
.	O

Our	O
data	O
demonstrate	O
that	O
miR	O
-	O
142a	O
-	O
3p	O
promotes	O
PHEV	O
proliferation	O
by	O
directly	O
targeting	O
Rab3a	O
mRNA	B-CHED
,	O
and	O
this	O
provides	O
new	O
insights	O
into	O
the	O
mechanisms	O
of	O
PHEV	O
-	O
related	O
pathogenesis	O
and	O
virus	O
-	O
host	O
interactions	O
.	O

The	O
tissue	O
tropism	O
is	O
determined	O
by	O
spike	O
(	O
S	O
)	O
protein	B-CHED
,	O
although	O
the	O
molecular	O
bases	B-CHED
for	O
enteric	O
tropism	O
remain	O
to	O
be	O
fully	O
characterized	O
.	O

The	O
data	O
indicated	O
that	O
U655	O
>	O
G	O
change	O
in	O
S	O
gene	O
(	O
S219A	O
in	O
S	O
protein	B-CHED
)	O
was	O
required	O
to	O
confer	O
enteric	O
tropism	O
to	O
a	O
respiratory	O
virus	O
that	O
already	O
contains	O
the	O
pAPN	O
and	O
sialic	B-CHED
acid	I-CHED
binding	O
domains	O
in	O
its	O
S	O
protein	B-CHED
.	O

Viruses	O
infecting	O
human	O
CNS	B-CHED
cells	O
could	O
then	O
cause	O
different	O
types	O
of	O
encephalopathy	O
,	O
including	O
encephalitis	O
,	O
and	O
long	O
-	O
term	O
neurological	O
diseases	O
.	O

Herein	O
,	O
we	O
present	O
a	O
global	O
portrait	O
of	O
some	O
of	O
the	O
most	O
prevalent	O
or	O
emerging	O
human	O
respiratory	O
viruses	O
that	O
have	O
been	O
associated	O
with	O
possible	O
pathogenic	O
processes	O
in	O
CNS	B-CHED
infection	O
,	O
with	O
a	O
special	O
emphasis	O
on	O
human	O
coronaviruses	O
.	O

In	O
this	O
study	O
,	O
IL	O
-	O
11	O
expression	O
at	O
mRNA	B-CHED
and	O
protein	B-CHED
levels	O
were	O
found	O
to	O
be	O
high	O
in	O
Vero	O
cells	O
and	O
the	O
jejunum	O
of	O
piglets	O
during	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
infection	O
,	O
while	O
IL	O
-	O
11	O
expression	O
was	O
found	O
to	O
be	O
positively	O
correlated	O
with	O
the	O
level	O
of	O
viral	O
infection	O
.	O

Prolonged	O
time	O
to	O
initiation	O
of	O
oseltamivir	B-CHED
and	O
higher	O
body	O
mass	O
index	O
were	O
statistically	O
significantly	O
associated	O
with	O
fatal	O
outcome	O
(	O
p	O
=	O
0	O
.	O
002	O
,	O
and	O
p	O
=	O
0	O
.	O
007	O
,	O
respectively	O
).	O

Early	O
antiviral	B-CHED
therapy	O
reduces	O
the	O
risk	O
of	O
unfavorable	O
outcome	O
.	O

Biochemical	O
assessment	O
of	O
the	O
spike	O
protein	B-CHED
is	O
critical	O
for	O
understanding	O
structure	O
-	O
function	O
relationships	O
and	O
the	O
roles	O
of	O
the	O
protein	B-CHED
in	O
the	O
viral	O
life	O
cycle	O
.	O

Coronavirus	O
spike	O
proteins	B-CHED
are	O
typically	O
proteolytically	O
processed	O
and	O
activated	O
by	O
host	O
cell	O
enzymes	O
such	O
as	O
trypsin	O
-	O
like	O
proteases	O
,	O
cathepsins	O
,	O
or	O
proprotein	O
-	O
convertases	O
.	O

Quickly	O
after	O
the	O
identification	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
-	O
CoV	O
(	O
MERS	O
-	O
CoV	O
),	O
both	O
in	O
vitro	O
ligation	O
and	O
BAC	O
-	O
based	O
reverse	O
genetic	O
technologies	O
were	O
engineered	O
for	O
MERS	O
-	O
CoV	O
to	O
study	O
its	O
basic	O
biological	O
properties	O
,	O
develop	O
live	O
-	O
attenuated	O
vaccines	O
,	O
and	O
test	O
antiviral	B-CHED
drugs	I-CHED
.	O

Coronavirus	O
(	O
CoV	O
)	O
has	O
an	O
exceptionally	O
large	O
RNA	O
genome	O
(~	O
30	O
kb	O
)	O
and	O
it	O
encodes	O
an	O
essential	O
replicase	O
,	O
the	O
nonstructural	O
protein	B-CHED
13	O
(	O
nsp13	O
),	O
a	O
member	O
of	O
superfamily	O
1	O
helicases	O
.	O

ABSTRACT	O
:	O
Indirect	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
enables	O
detection	O
and	O
quantification	O
of	O
antigen	B-CHED
-	O
specific	O
antibodies	O
in	O
biological	O
samples	O
such	O
as	O
human	O
or	O
animal	O
sera	O
.	O

Most	O
current	O
MERS	O
-	O
CoV	O
serological	O
assays	O
such	O
as	O
neutralization	O
,	O
immunofluorescence	O
,	O
or	O
protein	B-CHED
microarray	O
rely	O
on	O
handling	O
of	O
live	O
MERS	O
-	O
CoV	O
in	O
high	O
containment	O
laboratories	O
,	O
highly	O
trained	O
personnel	O
as	O
well	O
as	O
the	O
need	O
for	O
expensive	O
and	O
special	O
equipment	O
and	O
reagents	B-CHED
representing	O
a	O
hurdle	O
for	O
most	O
laboratories	O
especially	O
when	O
resources	O
are	O
limited	O
.	O

The	O
murine	O
dipeptidyl	O
peptidase	O
4	O
(	O
Dpp4	O
)	O
protein	B-CHED
is	O
not	O
a	O
functional	O
receptor	O
for	O
MERS	O
-	O
CoV	O
;	O
thus	O
,	O
mice	O
are	O
resistant	O
to	O
MERS	O
-	O
CoV	O
infection	O
.	O

She	O
was	O
treated	O
with	O
ceftriaxone	B-CHED
and	O
oseltamivir	B-CHED
and	O
slowly	O
improved	O
over	O
the	O
course	O
of	O
20	O
days	O
.	O

TITLE	O
:	O
Cryo	O
-	O
EM	O
analysis	O
of	O
a	O
feline	O
coronavirus	O
spike	O
protein	B-CHED
reveals	O
a	O
unique	O
structure	O
and	O
camouflaging	O
glycans	B-CHED
.	O

Further	O
investigation	O
revealed	O
that	O
the	O
cleavage	O
products	O
of	O
NEMO	O
lost	B-CHED
the	O
ability	O
to	O
activate	O
the	O
IFN	O
-	O
β	O
promoter	O
.	O

Other	O
treatments	O
included	O
plasmapheresis	O
,	O
intravenous	O
pulse	O
methylprednisolone	B-CHED
and	O
intravenous	O
antibiotics	B-CHED
.	O

ABSTRACT	O
:	O
A	O
platform	O
capable	O
of	O
specifically	O
delivering	O
an	O
antiviral	B-CHED
drug	I-CHED
to	O
the	O
liver	O
infected	O
with	O
hepatitis	O
B	O
is	O
a	O
major	O
concern	O
in	O
hepatology	O
.	O

TITLE	O
:	O
Comparative	O
therapeutic	O
efficacy	O
of	O
remdesivir	O
and	O
combination	O
lopinavir	O
,	O
ritonavir	B-CHED
,	O
and	O
interferon	O
beta	O
against	O
MERS	O
-	O
CoV	O
.	O
ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
is	O
the	O
causative	O
agent	O
of	O
a	O
severe	O
respiratory	O
disease	O
associated	O
with	O
more	O
than	O
2468	O
human	O
infections	O
and	O
over	O
851	O
deaths	O
in	O
27	O
countries	O
since	O
2012	O
.	O

Here	O
,	O
we	O
show	O
that	O
remdesivir	O
(	O
RDV	O
)	O
and	O
IFNb	O
have	O
superior	O
antiviral	B-CHED
activity	O
to	O
LPV	O
and	O
RTV	O
in	O
vitro	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
effect	O
of	O
ribavirin	B-CHED
and	O
recombinant	O
interferon	O
(	O
RBV	B-CHED
/	O
rIFN	O
)	O
therapy	O
on	O
the	O
outcomes	O
of	O
critically	O
ill	O
patients	O
with	O
Middle	O
East	O
respiratory	O
syndrome	O
(	O
MERS	O
),	O
accounting	O
for	O
time	O
-	O
varying	O
confounders	O
.	O

After	O
adjusting	O
for	O
baseline	O
and	O
time	O
-	O
varying	O
confounders	O
using	O
a	O
marginal	O
structural	O
model	O
,	O
RBV	B-CHED
/	O
rIFN	O
was	O
not	O
associated	O
with	O
changes	O
in	O
90	O
-	O
day	O
mortality	O
(	O
adjusted	O
odds	O
ratio	O
,	O
1	O
.	O
03	O
[	O
95	O
%	O
confidence	O
interval	O
{	O
CI	O
},	O
.	O
73	O
-	O
1	O
.	O
44	O
];	O
P	O
=	O
.	O
87	O
)	O
or	O
with	O
more	O
rapid	O
MERS	O
-	O
CoV	O
RNA	O
clearance	O
(	O
adjusted	O
hazard	O
ratio	O
,	O
0	O
.	O
65	O
[	O
95	O
%	O
CI	O
,	O
.	O
30	O
-	O
1	O
.	O
44	O
];	O
P	O
=	O
.	O
29	O
).	O

ABSTRACT	O
:	O
Rocaglates	O
,	O
a	O
class	O
of	O
natural	O
compounds	O
isolated	O
from	O
plants	O
of	O
the	O
genus	O
Aglaia	O
,	O
are	O
potent	O
inhibitors	B-CHED
of	O
translation	O
initiation	O
.	O

Since	O
HEV	O
has	O
a	O
polypurine	O
-	O
free	O
5	O
'-	O
UTR	O
that	O
folds	O
into	O
a	O
stable	O
hairpin	O
structure	O
,	O
we	O
hypothesized	O
that	O
RNA	O
clamping	O
by	O
Silvestrol	B-CHED
and	O
its	O
derivatives	O
may	O
also	O
occur	O
in	O
a	O
polypurine	O
-	O
independent	O
but	O
structure	O
-	O
dependent	O
manner	O
.	O

The	O
strain	O
CHN	B-CHED
-	O
JS	O
-	O
2017	O
was	O
isolated	O
and	O
identified	O
by	O
cytopathology	O
,	O
immunofluorescence	O
assays	O
,	O
transmission	O
electron	O
microscopy	O
,	O
and	O
sequence	O
analysis	O
.	O

TITLE	O
:	O
Lipopolysaccharides	B-CHED
increase	O
Kir2	O
.	O
1	O
expression	O
in	O
lung	O
endothelial	O
cells	O
.	O

The	O
following	O
explanatory	O
variables	O
were	O
then	O
assessed	O
:	O
age	O
,	O
sex	O
,	O
admission	O
source	O
,	O
body	O
mass	O
index	O
,	O
smoking	O
status	O
,	O
congestive	O
heart	O
failure	O
,	O
chronic	O
obstructive	O
pulmonary	O
disease	O
,	O
diabetes	O
mellitus	O
,	O
steroid	B-CHED
use	O
,	O
statin	B-CHED
use	O
,	O
infection	O
site	O
,	O
septic	O
shock	O
,	O
and	O
acute	O
physiology	O
and	O
chronic	O
health	O
evaluation	O
(	O
APACHE	O
)	O
II	O
score	O
.	O

Although	O
there	O
are	O
still	O
several	O
unanswered	O
questions	O
about	O
this	O
infection	O
,	O
we	O
evaluate	O
the	O
potential	O
for	O
international	O
dissemination	O
of	O
this	O
disease	O
via	O
commercial	O
air	B-CHED
travel	O
should	O
the	O
outbreak	O
continue	O
.	O

Here	O
,	O
four	O
different	O
S	O
subunit	O
proteins	B-CHED
,	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
;	O
358	O
-	O
606	O
aa	O
),	O
S1	O
(	O
1	O
-	O
751	O
aa	O
),	O
S2	O
(	O
752	O
-	O
1296	O
aa	O
),	O
and	O
SΔTM	O
(	O
1	O
-	O
1296	O
aa	O
),	O
were	O
generated	O
using	O
the	O
baculoviral	O
system	O
and	O
immunized	O
in	O
mice	O
to	O
develop	O
neutralizing	O
antibodies	O
.	O

TITLE	O
:	O
Prevalence	O
and	O
mutation	O
analysis	O
of	O
the	O
spike	O
protein	B-CHED
in	O
feline	O
enteric	O
coronavirus	O
and	O
feline	O
infectious	O
peritonitis	O
detected	O
in	O
household	O
and	O
shelter	O
cats	O
in	O
western	O
Canada	O
.	O

TITLE	O
:	O
Design	O
,	O
synthesis	O
and	O
molecular	O
docking	O
of	O
novel	O
triazole	B-CHED
derivatives	O
as	O
potential	O
CoV	O
helicase	O
inhibitors	B-CHED
.	O

Herein	O
we	O
investigated	O
the	O
anti	O
-	O
MERS	O
-	O
CoV	O
activity	O
of	O
newly	O
synthesized	O
sixteen	O
halogenated	O
triazole	B-CHED
compounds	I-CHED
through	O
the	O
inhibition	O
of	O
helicase	O
activity	O
using	O
the	O
FRET	O
assay	O
.	O

Hospitalized	O
patients	O
with	O
influenza	O
A	O
(	O
H1N1	O
)	O
pdm09	O
virus	O
were	O
significantly	O
younger	O
,	O
more	O
frequently	O
had	O
class	O
III	O
obesity	O
,	O
and	O
had	O
a	O
higher	O
risk	O
for	O
pneumonia	O
or	O
acute	O
respiratory	O
distress	O
syndrome	O
than	O
patients	O
infected	O
with	O
influenza	O
A	O
(	O
H3N2	B-CHED
)	O
or	O
B	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

The	O
recombination	O
may	O
occurred	O
within	O
the	O
viral	O
spike	O
glycoprotein	B-CHED
,	O
which	O
recognizes	O
a	O
cell	O
surface	O
receptor	O
.	O

From	O
Jan	O
10	O
,	O
2020	O
,	O
we	O
enrolled	O
a	O
family	O
of	O
six	O
patients	O
who	O
travelled	O
to	O
Wuhan	O
from	O
Shenzhen	O
between	O
Dec	B-CHED
29	O
,	O
2019	O
and	O
Jan	O
4	O
,	O
2020	O
.	O

The	O
Shaw	O
Foundation	O
Hong	O
Kong	O
,	O
Michael	O
Seak	O
-	O
Kan	O
Tong	O
,	O
Respiratory	O
Viral	O
Research	O
Foundation	O
Limited	O
,	O
Hui	O
Ming	O
,	O
Hui	O
Hoy	O
and	O
Chow	O
Sin	O
Lan	O
Charity	O
Fund	O
Limited	O
,	O
Marina	O
Man	B-CHED
-	O
Wai	O
Lee	O
,	O
the	O
Hong	O
Kong	O
Hainan	O
Commercial	O
Association	O
South	O
China	O
Microbiology	O
Research	O
Fund	O
,	O
Sanming	O
Project	O
of	O
Medicine	B-CHED
(	O
Shenzhen	O
),	O
and	O
High	O
Level	O
-	O
Hospital	O
Program	O
(	O
Guangdong	O
Health	O
Commission	O
).	O

She	O
survived	O
with	O
no	O
neurologic	O
sequelae	O
after	O
immediate	O
treatment	O
with	O
heparin	B-CHED
-	O
free	O
VV	O
-	O
ECMO	O
.	O

TITLE	O
:	O
Recent	O
discovery	O
and	O
development	O
of	O
inhibitors	B-CHED
targeting	O
coronaviruses	O
.	O

Phylogenetic	O
analysis	O
revealed	O
that	O
2019	O
-	O
nCoV	O
fell	O
within	O
the	O
subgenus	O
Sarbecovirus	O
of	O
the	O
genus	O
Betacoronavirus	O
,	O
with	O
a	O
relatively	O
long	O
branch	O
length	O
to	O
its	O
closest	O
relatives	O
bat	O
-	O
SL	O
-	O
CoVZC45	O
and	O
bat	O
-	O
SL	O
-	O
CoVZXC21	O
,	O
and	O
was	O
genetically	O
distinct	O
from	O
SARS	O
-	O
CoV	O
.	O
Notably	O
,	O
homology	O
modelling	O
revealed	O
that	O
2019	O
-	O
nCoV	O
had	O
a	O
similar	O
receptor	O
-	O
binding	O
domain	O
structure	O
to	O
that	O
of	O
SARS	O
-	O
CoV	O
,	O
despite	O
amino	B-CHED
acid	I-CHED
variation	O
at	O
some	O
key	O
residues	O
.	O

Importantly	O
,	O
structural	O
analysis	O
suggests	O
that	O
2019	O
-	O
nCoV	O
might	O
be	O
able	O
to	O
bind	O
to	O
the	O
angiotensin	B-CHED
-	O
converting	O
enzyme	O
2	O
receptor	O
in	O
humans	O
.	O

Bats	O
have	O
a	O
suite	O
of	O
antiviral	B-CHED
defenses	O
that	O
keep	O
the	O
amount	O
of	O
virus	O
in	O
check	O
.	O

However	O
,	O
no	O
one	O
has	O
previously	O
explored	O
how	O
these	O
unique	O
antiviral	B-CHED
defenses	O
of	O
bats	O
impact	O
the	O
viruses	O
themselves	O
.	O

Coronavirus	O
infection	O
(	O
regardless	O
of	O
the	O
various	O
types	O
of	O
corona	B-CHED
virus	O
)	O
is	O
primarily	O
attacked	O
by	O
immune	O
cells	O
including	O
mast	O
cells	O
(	O
MCs	O
),	O
which	O
are	O
located	O
in	O
the	O
submucosa	O
of	O
the	O
respiratory	O
tract	O
and	O
in	O
the	O
nasal	O
cavity	O
and	O
represent	O
a	O
barrier	O
of	O
protection	O
against	O
microorganisms	O
.	O

ABSTRACT	O
:	O
Since	O
Dec	B-CHED
31	O
,	O
2019	O
,	O
the	O
Chinese	O
city	O
of	O
Wuhan	O
has	O
reported	O
an	O
outbreak	O
of	O
atypical	O
pneumonia	O
caused	O
by	O
the	O
2019	O
novel	O
coronavirus	O
(	O
2019	O
-	O
nCoV	O
).	O

The	O
identified	O
camel	O
IFN	O
-	O
α	O
protein	B-CHED
and	O
the	O
subtypes	O
will	O
facilitate	O
a	O
better	O
understanding	O
of	O
the	O
host	O
immune	O
response	O
to	O
viral	O
infections	O
in	O
camel	O
and	O
the	O
development	O
of	O
potential	O
antiviral	B-CHED
biologicals	O
for	O
zoonotic	O
diseases	O
for	O
which	O
camel	O
act	O
as	O
a	O
reservoir	O
.	O

Diffuse	O
alveolar	O
hemorrhage	O
from	O
Goodpasture	O
'	O
s	O
Syndrome	O
has	O
manifested	O
following	O
inhalation	O
of	O
hydrocarbons	B-CHED
and	O
following	O
smoking	O
.	O

Our	O
objectives	O
were	O
to	O
describe	O
,	O
through	O
electrical	O
impedance	O
tomography	O
(	O
EIT	O
),	O
the	O
impact	O
of	O
PP	O
on	O
global	O
and	O
regional	O
ventilation	O
,	O
and	O
optimal	O
PEEP	B-CHED
level	O
.	O

We	O
estimate	O
the	O
risk	O
of	O
case	O
importation	O
to	O
Europe	O
from	O
affected	O
areas	O
in	O
China	O
via	O
air	B-CHED
travel	O
.	O

These	O
data	O
demonstrate	O
that	O
Nox2	O
/	O
ROS	B-CHED
/	O
ZO	O
-	O
1	O
axis	O
is	O
of	O
great	O
importance	O
in	O
AECs	O
damage	O
induced	O
by	O
LPS	B-CHED
,	O
and	O
the	O
utilization	O
of	O
VAS2870	O
to	O
inhibit	O
this	O
pathway	O
might	O
lighten	O
LPS	B-CHED
-	O
induced	O
ARDS	O
.	O

Phylogenetic	O
analysis	O
indicates	O
that	O
2019	O
-	O
nCoV	O
is	O
close	O
to	O
coronaviruses	O
(	O
CoVs	O
)	O
circulating	O
in	O
Rhinolophus	O
(	O
Horseshoe	O
bats	O
),	O
such	O
as	O
98	O
.	O
7	O
%	O
nucleotide	B-CHED
identity	O
to	O
partial	O
RdRp	O
gene	O
of	O
bat	O
coronavirus	O
strain	O
BtCoV	O
/	O
4991	O
(	O
GenBank	O
KP876546	O
,	O
370	O
nt	O
sequence	O
of	O
RdRp	O
and	O
lack	O
of	O
other	O
genome	O
sequence	O
)	O
and	O
87	O
.	O
9	O
%	O
nucleotide	B-CHED
identity	O
to	O
bat	O
coronavirus	O
strain	O
bat	O
-	O
SL	O
-	O
CoVZC45	O
and	O
bat	O
-	O
SL	O
-	O
CoVZXC21	O
.	O

TITLE	O
:	O
Immunoinformatics	O
-	O
aided	O
identification	O
of	O
T	O
cell	O
and	O
B	O
cell	O
epitopes	O
in	O
the	O
surface	O
glycoprotein	B-CHED
of	O
2019	O
-	O
nCoV	O
.	O
ABSTRACT	O
:	O
The	O
2019	O
novel	O
coronavirus	O
(	O
2019	O
-	O
nCoV	O
)	O
outbreak	O
has	O
caused	O
a	O
large	O
number	O
of	O
deaths	O
with	O
thousands	O
of	O
confirmed	O
cases	O
worldwide	O
,	O
especially	O
in	O
East	O
Asia	O
.	O

We	O
identified	O
five	O
CTL	O
epitopes	O
,	O
three	O
sequential	O
B	O
cell	O
epitopes	O
and	O
five	O
discontinuous	O
B	O
cell	O
epitopes	O
in	O
the	O
viral	O
surface	O
glycoprotein	B-CHED
.	O

Also	O
,	O
during	O
simulations	O
,	O
the	O
CTL	O
epitopes	O
were	O
observed	O
to	O
be	O
binding	O
MHC	O
class	O
I	O
peptide	B-CHED
-	O
binding	O
grooves	O
via	O
multiple	O
contacts	O
,	O
with	O
continuous	O
hydrogen	B-CHED
bonds	O
and	O
salt	B-CHED
bridge	O
anchors	O
,	O
indicating	O
their	O
potential	O
in	O
generating	O
immune	O
responses	O
.	O

It	O
is	O
extremely	O
important	O
to	O
disinfect	O
ophthalmic	B-CHED
examination	O
instruments	O
and	O
protect	O
ophthalmic	B-CHED
medical	O
care	O
during	O
the	O
epidemic	O
period	O
to	O
reduce	O
cross	O
-	O
infection	O
in	O
clinical	O
practice	O
and	O
reduce	O
the	O
infection	O
risk	O
of	O
ophthalmic	B-CHED
medical	O
staff	O
.	O

Other	O
biocidal	O
agents	O
such	O
as	O
0	O
.	O
05	O
-	O
0	O
.	O
2	O
%	O
benzalkonium	B-CHED
chloride	I-CHED
or	O
0	O
.	O
02	O
%	O
chlorhexidine	B-CHED
digluconate	I-CHED
are	O
less	O
effective	O
.	O

Griffithsin	O
(	O
GRFT	O
)	O
is	O
high	O
-	O
mannose	B-CHED
oligosaccharide	B-CHED
binding	O
lectin	O
that	O
has	O
shown	O
in	O
vivo	O
broad	O
-	O
spectrum	O
activity	O
against	O
viruses	O
including	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
,	O
human	O
immunodeficiency	O
virus	O
1	O
,	O
hepatitis	O
C	O
virus	O
,	O
and	O
Japanese	O
encephalitis	O
virus	O
.	O

In	O
this	O
study	O
,	O
we	O
evaluated	O
the	O
in	O
vitro	O
antiviral	B-CHED
activities	O
of	O
GRFT	O
and	O
its	O
synthetic	O
trimeric	O
tandemer	O
(	O
3mG	O
)	O
against	O
NiV	O
and	O
other	O
viruses	O
from	O
across	O
4	O
virus	O
families	O
.	O

TITLE	O
:	O
Regulation	O
of	O
the	O
ER	O
Stress	O
Response	O
by	O
the	O
Ion	O
Channel	O
Activity	O
of	O
the	O
Infectious	O
Bronchitis	O
Coronavirus	O
Envelope	O
Protein	B-CHED
Modulates	O
Virion	O
Release	O
,	O
Apoptosis	O
,	O
Viral	O
Fitness	O
,	O
and	O
Pathogenesis	O
.	O

EIC	O
mutations	O
were	O
also	O
implicated	O
in	O
regulating	O
IBV	O
-	O
induced	O
apoptosis	O
,	O
induction	O
of	O
pro	B-CHED
-	O
inflammatory	O
cytokines	O
,	O
and	O
viral	O
pathogenicity	O

Additionally	O
,	O
N	O
protein	B-CHED
-	O
mediated	O
FcRn	O
up	O
-	O
regulation	O
promotes	O
IgG	O
transcytosis	O
.	O

The	O
proportion	O
of	O
adverse	O
events	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
dexamethasone	B-CHED
group	O
and	O
control	O
group	O
.	O

Early	O
administration	O
of	O
dexamethasone	B-CHED
could	O
reduce	O
duration	O
of	O
mechanical	O
ventilation	O
and	O
overall	O
mortality	O
in	O
patients	O
with	O
established	O
moderate	O
-	O
to	O
-	O
severe	O
ARDS	O
.	O

This	O
virus	O
spread	O
in	O
the	O
absence	O
of	O
the	O
prototype	O
protein	B-CHED
receptors	O
was	O
increased	O
by	O
adaptive	O
S1A	O
mutations	O
.	O

Comprehensive	O
control	O
and	O
preventive	O
activities	O
should	O
include	O
actions	O
such	O
as	O
the	O
elimination	O
or	O
reduction	O
of	O
rat	O
and	O
mouse	O
populations	O
,	O
sanitary	O
education	O
,	O
reduction	O
of	O
shelters	O
for	O
the	O
animals	O
,	O
and	O
restriction	O
of	O
the	O
access	O
of	O
rodents	O
to	O
residences	O
,	O
water	B-CHED
,	O
and	O
food	O
supplies	O
.	O

This	O
observational	O
study	O
prospectively	O
enrolled	O
patients	O
with	O
multiple	O
bicortical	O
rib	B-CHED
fractures	O
with	O
hemothorax	O
caused	O
by	O
severe	O
blunt	O
chest	O
trauma	O
.	O

Rib	B-CHED
fixation	O
combined	O
with	O
VATS	O
could	O
shorten	O
the	O
length	O
of	O
ventilator	O
use	O
and	O
reduce	O
the	O
pneumonia	O
rate	O
in	O
patients	O
with	O
severe	O
chest	O
blunt	O
injury	O
with	O
ARF	O
.	O

STE	B-CHED
-	O
derived	O
and	O
conventional	O
parameters	O
were	O
recorded	O
.	O

Combination	O
of	O
Ribavirin	B-CHED
and	O
Interferon	O
-	O
α	O
is	O
recommended	O
by	O
the	O
5	O
(	O
th	O
)	O
edition	O
National	O
Health	O
Commission	O
'	O
s	O
Regimen	O
(	O
Revised	O
Edition	O
)	O
because	O
of	O
the	O
effect	O
on	O
MERS	O
(	O
Middle	O
East	O
Respiratory	O
Syndrome	O
),	O
and	O
the	O
effectiveness	O
of	O
Lopinavir	O
/	O
Ritonavir	B-CHED
and	O
Remdisivir	O
needs	O
to	O
be	O
confirmed	O
by	O
randomized	O
controlled	O
trial	O
(	O
RCT	O
),	O
given	O
the	O
situation	O
of	O
no	O
specific	O
antivirus	O
drug	O
on	O
NCP	O
is	O
unavailable	O
.	O

These	O
bats	O
are	O
used	O
in	O
Traditional	O
Chinese	O
Medicine	B-CHED
,	O
and	O
their	O
handling	O
poses	O
a	O
potential	O
risk	O
to	O
cause	O
zoonotic	O
coronavirus	O
epidemics	O
.	O

Furthermore	O
,	O
we	O
constructed	O
a	O
lncRNA	O
-	O
protein	B-CHED
-	O
coding	O
gene	O
co	O
-	O
expression	O
interaction	O
network	O
.	O

Our	O
study	O
provided	O
comprehensive	O
information	O
about	O
lncRNAs	O
that	O
would	O
be	O
a	O
useful	O
resource	O
for	O
studying	O
the	O
pathogenesis	O
of	O
and	O
designing	O
antiviral	B-CHED
therapy	O
for	O
PDCoV	O
infection	O
.	O

Likewise	O
,	O
detection	O
of	O
VEEV	O
capsid	O
protein	B-CHED
was	O
enhanced	O
in	O
the	O
presence	O
of	O
NT	O
particles	O
up	O
to	O
72	O
h	O
at	O
40	O
°	O
C	O
.	O

Considering	O
the	O
relatively	O
high	O
identity	O
of	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
in	O
2019	O
-	O
nCoV	O
and	O
SARS	O
-	O
CoV	O
,	O
it	O
is	O
urgent	O
to	O
assess	O
the	O
cross	O
-	O
reactivity	O
of	O
anti	O
-	O
SARS	O
CoV	O
antibodies	O
with	O
2019	O
-	O
nCoV	O
spike	O
protein	B-CHED
,	O
which	O
could	O
have	O
important	O
implications	O
for	O
rapid	O
development	O
of	O
vaccines	O
and	O
therapeutic	O
antibodies	O
against	O
2019	O
-	O
nCoV	O
.	O
Here	O
,	O
we	O
report	O
for	O
the	O
first	O
time	O
that	O
a	O
SARS	O
-	O
CoV	O
-	O
specific	O
human	O
monoclonal	O
antibody	O
,	O
CR3022	O
,	O
could	O
bind	O
potently	O
with	O
2019	O
-	O
nCoV	O
RBD	O
(	O
KD	O
of	O
6	O
.	O
3	O
nM	O
).	O

Interestingly	O
,	O
some	O
of	O
the	O
most	O
potent	O
SARS	O
-	O
CoV	O
-	O
specific	O
neutralizing	O
antibodies	O
(	O
e	O
.	O
g	O
.	O
m396	O
,	O
CR3014	O
)	O
that	O
target	O
the	O
ACE2	O
binding	O
site	O
of	O
SARS	O
-	O
CoV	O
failed	O
to	O
bind	O
2019	O
-	O
nCoV	O
spike	O
protein	B-CHED
,	O
implying	O
that	O
the	O
difference	O
in	O
the	O
RBD	O
of	O
SARS	O
-	O
CoV	O
and	O
2019	O
-	O
nCoV	O
has	O
a	O
critical	O
impact	O
for	O
the	O
cross	O
-	O
reactivity	O
of	O
neutralizing	O
antibodies	O
,	O
and	O
that	O
it	O
is	O
still	O
necessary	O
to	O
develop	O
novel	O
monoclonal	O
antibodies	O
that	O
could	O
bind	O
specifically	O
to	O
2019	O
-	O
nCoV	O
RBD	O
.	O

In	O
addition	O
,	O
to	O
know	O
the	O
timing	O
of	O
TLR	O
ligand	B-CHED
treatment	O
,	O
six	O
time	O
intervals	O
were	O
analyzed	O
viz	O
.	O

These	O
five	O
nutrients	B-CHED
are	O
highly	O
abundant	O
in	O
beef	O
,	O
and	O
have	O
important	O
physiological	O
roles	O
in	O
anti	O
-	O
oxidative	O
and	O
anti	O
-	O
inflammatory	O
reactions	O
,	O
as	O
well	O
as	O
neurological	O
,	O
muscular	O
,	O
retinal	B-CHED
,	O
immunological	O
and	O
cardiovascular	O
function	O
.	O

The	O
present	O
review	O
provides	O
the	O
public	O
with	O
the	O
much	O
-	O
needed	O
knowledge	O
of	O
nutritionally	O
and	O
physiologically	O
significant	O
amino	B-CHED
acids	I-CHED
,	O
dipeptides	B-CHED
and	O
creatine	B-CHED
in	O
animal	O
-	O
source	O
foods	O
(	O
including	O
beef	O
).	O

So	O
far	O
,	O
there	O
is	O
still	O
no	O
specific	O
medicine	B-CHED
.	O

It	O
recommended	O
chloroquine	B-CHED
phosphate	B-CHED
tablet	O
,	O
500mg	O
twice	O
per	O
day	O
for	O
10	O
days	O
for	O
patients	O
diagnosed	O
as	O
mild	O
,	O
moderate	O
and	O
severe	O
cases	O
of	O
novel	O
coronavirus	O
pneumonia	O
and	O
without	O
contraindications	O
to	O
chloroquine	B-CHED
.	O

We	O
also	O
provide	O
biophysical	O
and	O
structural	O
evidence	O
that	O
the	O
2019	O
-	O
nCoV	O
S	O
protein	B-CHED
binds	O
angiotensin	B-CHED
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
with	O
higher	O
affinity	O
than	O
does	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
CoV	O
S	O
.	O
Additionally	O
,	O
we	O
tested	O
several	O
published	O
SARS	O
-	O
CoV	O
RBD	O
-	O
specific	O
monoclonal	O
antibodies	O
and	O
found	O
that	O
they	O
do	O
not	O
have	O
appreciable	O
binding	O
to	O
2019	O
-	O
nCoV	O
S	O
,	O
suggesting	O
that	O
antibody	O
cross	O
-	O
reactivity	O
may	O
be	O
limited	O
between	O
the	O
two	O
RBDs	O
.	O

However	O
,	O
inappropriate	O
administration	O
of	O
diuretic	B-CHED
drugs	O
can	O
result	O
in	O
clinical	O
treatment	O
failure	O
and	O
cause	O
acute	O
pulmonary	O
edema	O
.	O

This	O
is	O
due	O
to	O
rapid	O
decreases	O
in	O
intravascular	O
volume	O
as	O
a	O
result	O
of	O
diuretic	B-CHED
treatment	O
.	O

CONCLUSIONS	O
:	O
We	O
report	O
the	O
first	O
case	O
of	O
pulmonary	O
edema	O
following	O
diuretic	B-CHED
therapy	O
to	O
stress	O
the	O
need	O
of	O
physicians	O
to	O
follow	O
guidelines	O
of	O
clinical	O
practice	O
.	O

TITLE	O
:	O
Use	O
of	O
corticosteroids	B-CHED
in	O
influenza	O
-	O
associated	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
severe	O
pneumonia	O
:	O
a	O
systemic	O
review	O
and	O
meta	O
-	O
analysis	O
.	O

Finally	O
,	O
antibodies	O
and	O
small	O
molecular	O
inhibitors	B-CHED
that	O
can	O
block	O
the	O
interaction	O
of	O
ACE2	O
with	O
RBD	O
should	O
be	O
developed	O
to	O
combat	B-CHED
the	O
virus	O
.	O

This	O
paper	O
aimed	O
to	O
improve	O
the	O
understanding	O
of	O
community	O
pharmacists	O
'	O
role	O
in	O
case	O
of	O
2019	O
-	O
CoV	O
outbreak	O
based	O
on	O
the	O
practical	O
experiences	O
in	O
consultation	O
with	O
the	O
recommendations	O
made	O
by	O
the	O
International	O
Pharmaceutical	B-CHED
Federation	O
on	O
the	O
Coronavirus	O
2019	O
-	O
nCoV	O
outbreak	O
.	O

In	O
this	O
review	O
,	O
we	O
discuss	O
the	O
role	O
of	O
host	O
factors	O
during	O
pregnancy	O
on	O
antiviral	B-CHED
immunity	O
and	O
their	O
implications	O
for	O
generating	O
protective	O
lactogenic	O
immunity	O
in	O
suckling	O
neonates	O
.	O

TITLE	O
:	O
[	O
Attention	O
should	O
be	O
paid	O
to	O
the	O
exposure	O
risk	O
of	O
patients	O
with	O
chronic	O
wounds	O
on	O
the	O
way	O
to	O
hospital	O
during	O
corona	B-CHED
virus	O
disease	O
2019	O
epidemic	O
prevention	O
and	O
control	O
].	O

The	O
above	O
underlying	O
diseases	O
and	O
ages	O
of	O
patients	O
are	O
the	O
susceptibility	O
factors	O
of	O
corona	B-CHED
virus	O
disease	O
2019	O
released	O
by	O
National	O
Health	O
Commission	O
of	O
China	O
.	O

We	O
identified	O
three	O
clusters	B-CHED
of	O
countries	O
that	O
share	O
the	O
same	O
exposure	O
to	O
the	O
risk	O
originating	O
from	O
the	O
provinces	O
of	O
Guangdong	O
,	O
Fujian	O
,	O
and	O
the	O
city	O
of	O
Beijing	O
,	O
respectively	O
.	O

Do	O
the	O
vaccines	O
generated	O
to	O
the	O
SARS	O
-	O
CoV	O
or	O
MERS	O
-	O
CoV	O
or	O
their	O
proteins	B-CHED
offer	O
protection	O
against	O
2019	O
-	O
nCoV	O
?	O

These	O
findings	O
can	O
support	O
evidence	O
-	O
based	O
policy	O
to	O
combat	B-CHED
the	O
spread	O
of	O
COVID	O
-	O
19	O
,	O
and	O
prospective	O
planning	O
to	O
mitigate	O
future	O
emerging	O
pathogens	O
.	O

Correlation	O
analysis	O
showed	O
that	O
the	O
PII	O
value	O
was	O
significantly	O
correlated	O
with	O
the	O
values	O
of	O
lymphocyte	O
count	O
,	O
monocyte	O
count	O
,	O
C	O
-	O
reactive	O
protein	B-CHED
,	O
procalcitonin	O
,	O
days	O
from	O
illness	O
onset	O
and	O
body	O
temperature	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

One	O
possible	O
answer	O
is	O
antibody	O
dependent	O
enhancement	O
(	O
ADE	B-CHED
)	O
of	O
SARS	O
-	O
CoV	O
-	O
2	O
due	O
to	O
prior	O
exposure	O
to	O
other	O
coronaviruses	O
.	O

ADE	B-CHED
modulates	O
the	O
immune	O
response	O
and	O
can	O
elicit	O
sustained	O
inflammation	O
,	O
lymphopenia	O
,	O
and	O
/	O
or	O
cytokine	O
storm	O
,	O
one	O
or	O
all	O
of	O
which	O
have	O
been	O
documented	O
in	O
severe	O
cases	O
and	O
deaths	O
.	O

ADE	B-CHED
also	O
requires	O
prior	O
exposure	O
to	O
similar	O
antigenic	O
epitopes	O
,	O
presumably	O
circulating	O
in	O
local	O
viruses	O
,	O
making	O
it	O
a	O
possible	O
explanation	O
for	O
the	O
observed	O
geographic	O
limitation	O
of	O
severe	O
cases	O
and	O
deaths	O
.	O

This	O
issue	O
has	O
rapidly	O
reviewed	O
and	O
published	O
articles	O
describing	O
COVID	O
-	O
19	O
,	O
including	O
the	O
drug	O
treatment	O
options	O
for	O
SARS	O
-	O
CoV	O
-	O
2	O
,	O
its	O
clinical	O
characteristics	O
,	O
and	O
therapies	O
involving	O
a	O
combination	O
of	O
Chinese	O
and	O
Western	O
medicine	B-CHED
,	O
the	O
efficacy	O
of	O
chloroquine	B-CHED
phosphate	B-CHED
in	O
the	O
treatment	O
of	O
COVID	O
-	O
19	O
associated	O
pneumonia	O
according	O
to	O
clinical	O
studies	O
,	O
and	O
reflections	O
on	O
the	O
system	O
of	O
reserve	O
medical	O
supplies	O
for	O
public	O
health	O
emergencies	O
.	O

Pretreatment	O
of	O
HNE	B-CHED
cells	O
with	O
glycopyrronium	O
or	O
formoterol	B-CHED
reduced	O
the	O
susceptibility	O
to	O
infection	O
,	O
and	O
pretreatment	O
with	O
the	O
three	O
drugs	O
inhibited	O
activation	O
of	O
nuclear	O
factor	O
-	O
kappa	O
B	O
p50	O
and	O
p65	O
proteins	B-CHED
.	O

Of	O
note	O
,	O
the	O
selectivity	O
value	O
for	O
RDV	O
-	O
TP	O
obtained	O
here	O
with	O
a	O
steady	O
-	O
state	O
approach	O
suggests	O
that	O
it	O
is	O
more	O
efficiently	O
incorporated	O
than	O
ATP	B-CHED
and	O
two	O
other	O
nucleotide	B-CHED
analogues	O
.	O

Early	O
antiviral	B-CHED
treatment	O
could	O
alleviate	O
disease	O
severity	O
and	O
prevent	O
illness	O
progression	O
,	O
and	O
we	O
found	O
lopinavir	O
/	O
ritonavir	B-CHED
combined	O
with	O
abidol	O
showed	O
antiviraleffects	O
in	O
COVID	O
-	O
19	O
.	O

older	O
age	O
,	O
elevated	O
lactate	B-CHED
level	O
and	O
elevated	O
creatinine	B-CHED
level	O
may	O
be	O
useful	O
for	O
identifying	O
patients	O
with	O
poor	O
outcome	O
and	O
intensive	O
medical	O
intervention	O
can	O
be	O
provided	O
for	O
patients	O
as	O
soon	O
as	O
possible	O
to	O
reduce	O
mortality	O
.	O

As	O
antimicrobials	B-CHED
,	O
nanoparticles	B-CHED
are	O
considered	O
to	O
be	O
one	O
of	O
the	O
vectors	O
for	O
the	O
administration	O
of	O
therapeutic	O
compounds	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
systematic	O
comparison	O
and	O
analysis	O
to	O
predict	O
the	O
interaction	O
between	O
the	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
coronavirus	O
spike	O
protein	B-CHED
and	O
the	O
host	O
receptor	O
,	O
angiotensin	B-CHED
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
).	O

Adjuvant	B-CHED
chemotherapy	O
should	O
reduce	O
the	O
intensity	O
of	O
treatment	O
and	O
shorten	O
the	O
therapy	O
time	O
.	O

ABSTRACT	O
:	O
Special	O
Expert	O
Group	O
for	O
Control	O
of	O
the	O
Epidemic	O
of	O
COVID	O
-	O
19	O
of	O
the	O
Chinese	O
Preventive	O
Medicine	B-CHED
Association	O
have	O
had	O
a	O
deep	O
discussion	O
on	O
how	O
to	O
promote	O
the	O
modernization	O
progress	O
of	O
current	O
disease	O
control	O
and	O
prevention	O
system	O
in	O
China	O
.	O

In	O
this	O
study	O
,	O
we	O
sought	O
to	O
gain	O
insights	O
for	O
vaccine	O
design	O
against	O
SARS	O
-	O
CoV	O
-	O
2	O
by	O
considering	O
the	O
high	O
genetic	O
similarity	O
between	O
SARS	O
-	O
CoV	O
-	O
2	O
and	O
SARS	O
-	O
CoV	O
,	O
which	O
caused	O
the	O
outbreak	O
in	O
2003	O
,	O
and	O
leveraging	O
existing	O
immunological	O
studies	O
of	O
SARS	O
-	O
CoV	O
.	O
By	O
screening	O
the	O
experimentally	O
-	O
determined	O
SARS	O
-	O
CoV	O
-	O
derived	O
B	O
cell	O
and	O
T	O
cell	O
epitopes	O
in	O
the	O
immunogenic	O
structural	O
proteins	B-CHED
of	O
SARS	O
-	O
CoV	O
,	O
we	O
identified	O
a	O
set	O
of	O
B	O
cell	O
and	O
T	O
cell	O
epitopes	O
derived	O
from	O
the	O
spike	O
(	O
S	O
)	O
and	O
nucleocapsid	O
(	O
N	O
)	O
proteins	B-CHED
that	O
map	O
identically	O
to	O
SARS	O
-	O
CoV	O
-	O
2	O
proteins	B-CHED
.	O

The	O
impact	O
of	O
early	O
corticosteroid	B-CHED
treatment	O
(≥	O
200	O
mg	O
hydrocortisone	B-CHED
equivalent	O
dose	O
within	O
3	O
days	O
after	O
ICU	O
admission	O
,	O
determined	O
by	O
a	O
sensitivity	O
analysis	O
)	O
on	O
hospital	O
mortality	O
(	O
the	O
primary	O
outcome	O
)	O
was	O
assessed	O
by	O
multivariable	O
logistic	O
regression	O
analysis	O
,	O
and	O
further	O
confirmed	O
in	O
a	O
propensity	O
score	O
-	O
matched	O
cohort	O
.	O

Early	O
corticosteroid	B-CHED
treatment	O
was	O
independently	O
associated	O
with	O
increased	O
hospital	O
mortality	O
in	O
overall	O
patients	O
[	O
adjusted	O
odds	O
ratio	O
(	O
95	O
%	O
CI	O
)	O
=	O
5	O
.	O
02	O
(	O
2	O
.	O
39	O
-	O
10	O
.	O
54	O
),	O
p	O
<	O
0	O
.	O
001	O
]	O
and	O
in	O
all	O
subgroups	O
.	O

The	O
primary	O
endpoints	O
included	O
symptom	O
improvement	O
and	O
virus	O
nucleic	B-CHED
acid	I-CHED
turning	O
negative	O
,	O
but	O
the	O
optimal	O
endpoint	O
has	O
not	O
been	O
determined	O
.	O

This	O
application	O
allows	O
the	O
identification	O
of	O
phylogenetic	O
clusters	B-CHED
and	O
genotypes	O
from	O
assembled	O
genomes	O
in	O
FASTA	O
format	O
.	O

TITLE	O
:	O
COVID	O
-	O
19	O
outbreak	O
on	O
the	O
Diamond	B-CHED
Princess	O
cruise	O
ship	O
:	O
estimating	O
the	O
epidemic	O
potential	O
and	O
effectiveness	O
of	O
public	O
health	O
countermeasures	O
.	O

TITLE	O
:	O
Comparison	O
of	O
different	O
samples	O
for	O
2019	O
novel	O
coronavirus	O
detection	O
by	O
nucleic	B-CHED
acid	I-CHED
amplification	O
tests	O
.	O

Therefore	O
,	O
it	O
is	O
possible	O
that	O
infected	O
patients	O
have	O
been	O
missed	O
by	O
using	O
nucleic	B-CHED
acid	I-CHED
detection	O
only	O
.	O

This	O
study	O
aimed	O
to	O
investigate	O
whether	O
the	O
administration	O
of	O
corticosteroids	B-CHED
to	O
patients	O
in	O
the	O
early	O
phase	O
of	O
moderate	O
to	O
severe	O
ARDS	O
is	O
associated	O
with	O
improved	O
outcomes	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
role	O
of	O
autophagy	O
in	O
the	O
development	O
of	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
induced	O
by	O
lipopolysaccharide	B-CHED
(	O
LPS	B-CHED
)	O
and	O
mechanical	O
ventilation	O
(	O
MV	O
).	O

The	O
sequence	O
of	O
the	O
ACE2	O
-	O
Fc	O
protein	B-CHED
is	O
provided	O
to	O
investigators	O
,	O
allowing	O
its	O
possible	O
use	O
in	O
recombinant	O
protein	B-CHED
expression	O
systems	O
to	O
start	O
producing	O
drug	O
today	O
to	O
treat	O
patients	O
under	O
compassionate	O
use	O
,	O
while	O
formal	B-CHED
clinical	O
trials	O
are	O
later	O
undertaken	O
.	O

The	O
effects	O
of	O
cluster	O
of	O
differentiation	O
4	O
(	O
CD4	O
)+	O
T	O
lymphocytes	O
,	O
inflammatory	O
indicators	O
,	O
and	O
glucocorticoid	B-CHED
treatment	O
on	O
viral	O
nucleic	B-CHED
acid	I-CHED
clearance	O
were	O
analyzed	O
.	O

Multivariate	O
logistic	O
analysis	O
indicated	O
that	O
age	O
(	O
odds	O
ratio	O
[	O
OR	O
],	O
8	O
.	O
546	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]:	O
1	O
.	O
628	O
-	O
44	O
.	O
864	O
;	O
P	O
=	O
0	O
.	O
011	O
),	O
history	O
of	O
smoking	O
(	O
OR	O
,	O
14	O
.	O
285	O
;	O
95	O
%	O
CI	O
:	O
1	O
.	O
577	O
-	O
25	O
.	O
000	O
;	O
P	O
=	O
0	O
.	O
018	O
),	O
maximum	O
body	O
temperature	O
at	O
admission	O
(	O
OR	O
,	O
8	O
.	O
999	O
;	O
95	O
%	O
CI	O
:	O
1	O
.	O
036	O
-	O
78	O
.	O
147	O
,	O
P	O
=	O
0	O
.	O
046	O
),	O
respiratory	O
failure	O
(	O
OR	O
,	O
8	O
.	O
772	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
942	O
-	O
40	O
.	O
000	O
;	O
P	O
=	O
0	O
.	O
016	O
),	O
albumin	O
(	O
OR	O
,	O
7	O
.	O
353	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
098	O
-	O
50	O
.	O
000	O
;	O
P	O
=	O
0	O
.	O
003	O
),	O
and	O
C	O
-	O
reactive	O
protein	B-CHED
(	O
OR	O
,	O
10	O
.	O
530	O
;	O
95	O
%	O
CI	O
:	O
1	O
.	O
224	O
-	O
34	O
.	O
701	O
,	O
P	O
=	O
0	O
.	O
028	O
)	O
were	O
risk	O
factors	O
for	O
disease	O
progression	O
.	O

TITLE	O
:	O
Anti	O
-	O
HCV	O
,	O
nucleotide	B-CHED
inhibitors	B-CHED
,	O
repurposing	O
against	O
COVID	O
-	O
19	O
.	O

Third	O
,	O
universal	O
masking	O
,	O
hand	O
hygiene	O
,	O
and	O
appropriate	O
use	O
of	O
personal	O
protective	O
equipment	O
(	O
PPE	B-CHED
)	O
were	O
promoted	O
.	O

What	O
effective	O
antiviral	B-CHED
drugs	I-CHED
are	O
available	O
?	O

Six	O
individuals	O
(	O
33	O
%)	O
required	O
supplemental	O
oxygen	B-CHED
;	O
of	O
these	O
,	O
2	O
required	O
intensive	O
care	O
.	O

ABSTRACT	O
:	O
Currently	O
there	O
is	O
no	O
effective	O
antiviral	B-CHED
therapy	O
for	O
SARS	O
-	O
CoV	O
-	O
2	O
infection	O
,	O
which	O
frequently	O
leads	O
to	O
fatal	O
inflammatory	O
responses	O
and	O
acute	O
lung	O
injury	O
.	O

Such	O
treatment	O
may	O
also	O
be	O
combined	O
with	O
systemic	O
anti	B-CHED
-	I-CHED
inflammatory	I-CHED
drugs	I-CHED
or	O
corticosteroids	B-CHED
.	O

ABSTRACT	O
:	O
Acute	O
respiratory	O
distress	O
syndrome	O
following	O
an	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
is	O
a	O
life	O
threatening	O
inflammatory	O
condition	O
predominantly	O
characterized	O
by	O
vascular	O
protein	B-CHED
leakage	O
,	O
neutrophil	O
recruitment	O
and	O
overexpression	O
of	O
proinflammatory	O
cytokines	O
.	O

Vehicle	O
,	O
nafithromycin	O
(	O
100	O
mg	O
/	O
kg	O
),	O
azithromycin	B-CHED
(	O
600	O
mg	O
/	O
kg	O
)	O
and	O
dexamethasone	B-CHED
(	O
20	O
mg	O
/	O
kg	O
)	O
were	O
administered	O
orally	O
,	O
1	O
h	O
prior	O
to	O
LPS	B-CHED
challenge	O
and	O
bronchoalveolar	O
lavage	O
(	O
BAL	B-CHED
)	O
fluid	O
was	O
collected	O
thereafter	O
at	O
18	O
,	O
24	O
and	O
48	O
h	O
to	O
determine	O
the	O
total	O
cell	O
count	O
,	O
total	O
protein	B-CHED
,	O
myeloperoxidase	O
(	O
MPO	O
),	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)-	O
α	O
and	O
interleukin	O
(	O
IL	O
)-	O
6	O
.	O

ABSTRACT	O
:	O
Hospital	O
-	O
associated	O
transmission	O
is	O
an	O
important	O
route	O
of	O
spreading	O
the	O
2019	O
novel	O
coronavirus	O
(	O
2019	O
-	O
nCoV	O
)	O
infection	O
and	O
pneumonia	O
(	O
Corona	B-CHED
Virus	O
Disease	O
2019	O
,	O
COVID	O
-	O
19	O
)	O
[	O
1	O
].	O

SARS	O
-	O
CoV	O
-	O
2	O
revealed	O
in	O
1	O
(	O
7	O
.	O
7	O
%)	O
of	O
13	O
environmental	O
samples	O
,	O
but	O
not	O
in	O
8	O
air	B-CHED
samples	O
collected	O
at	O
a	O
distance	O
of	O
10	O
cm	O
from	O
patient	O
'	O
s	O
chin	O
with	O
or	O
without	O
wearing	O
a	O
surgical	O
mask	O
.	O

Midazolam	O
,	O
Propofol	B-CHED
and	O
Morphine	B-CHED
or	O
fentanyl	B-CHED
were	O
used	O
for	O
sedation	O
and	O
analgesia	O
,	O
avoiding	O
patients	O
cough	O
and	O
agitated	O
during	O
the	O
procedure	O
.	O

Follow	O
-	O
up	O
CT	O
findings	O
showed	O
progressive	O
opacifications	O
,	O
consolidation	O
,	O
interstitial	O
thickening	O
,	O
fibrous	O
strips	O
and	O
air	B-CHED
bronchograms	O
,	O
compared	O
to	O
initial	O
CT	O
(	O
all	O
p	O
<	O
0	O
.	O
05	O
).	O

The	O
C	O
-	O
reactive	O
protein	B-CHED
,	O
erythrocyte	O
sedimentation	O
rate	O
and	O
lactate	B-CHED
dehydrogenase	O
showed	O
significantly	O
positive	O
correlation	O
with	O
the	O
severity	O
of	O
pneumonia	O
assessed	O
on	O
initial	O
CT	O
(	O
R	O
range	O
0	O
.	O
36	O
-	O
0	O
.	O
75	O
,	O
p	O
<	O
0	O
.	O
05	O
).	O

Collaborative	O
efforts	O
are	O
required	O
to	O
combat	B-CHED
the	O
novel	O
coronavirus	O
,	O
focusing	O
on	O
both	O
persistent	O
strict	O
domestic	O
interventions	O
and	O
vigilance	O
against	O
exogenous	O
imported	O
cases	O
.	O

Our	O
results	O
reveal	O
important	O
commonalities	O
between	O
SARS	O
-	O
CoV	O
-	O
2	O
and	O
SARS	O
-	O
CoV	O
infection	O
and	O
identify	O
a	O
potential	O
target	O
for	O
antiviral	B-CHED
intervention	O
.	O

We	O
sought	O
to	O
characterize	O
the	O
relationship	O
of	O
the	O
translated	O
proteins	B-CHED
of	O
2019	O
-	O
nCoV	O
with	O
other	O
species	O
of	O
Orthocoronavirinae	O
.	O

Clade	O
1	O
consisted	O
of	O
a	O
group	O
of	O
conserved	O
proteins	B-CHED
in	O
Orthocoronavirinae	O
comprising	O
Orf1ab	O
polyprotein	O
,	O
Nucleocapsid	O
protein	B-CHED
,	O
Spike	O
glycoprotein	B-CHED
,	O
and	O
Membrane	O
protein	B-CHED
.	O

Thus	O
,	O
we	O
speculated	O
that	O
knowledge	O
of	O
the	O
functional	O
changes	O
in	O
the	O
NS7b	O
and	O
NS8	O
proteins	B-CHED
during	O
evolution	O
may	O
provide	O
important	O
information	O
to	O
explore	O
the	O
human	O
infective	O
property	O
of	O
2019	O
-	O
nCoV	O
.	O

TITLE	O
:	O
[	O
The	O
preliminary	O
analysis	O
on	O
the	O
characteristics	O
of	O
the	O
cluster	O
for	O
the	O
Corona	B-CHED
Virus	O
Disease	O
].	O

Scientists	O
are	O
endeavoring	O
to	O
find	O
antivirals	B-CHED
specific	O
to	O
the	O
virus	O
.	O

TITLE	O
:	O
Clarithromycin	B-CHED
-	O
Associated	O
Acute	O
Liver	O
Failure	O
Leading	O
to	O
Fatal	O
,	O
Massive	O
Upper	O
Gastrointestinal	O
Hemorrhage	O
from	O
Profound	O
Coagulopathy	O
:	O
Case	O
Report	O
and	O
Systematic	O
Literature	O
Review	O
.	O

A	O
60	O
-	O
year	O
-	O
old	O
nonalcoholic	O
man	B-CHED
,	O
with	O
normal	O
baseline	O
liver	O
function	O
tests	O
,	O
was	O
admitted	O
with	O
diffuse	O
abdominal	O
pain	O
and	O
AST	O
=	O
499	O
U	O
/	O
L	O
and	O
ALT	B-CHED
=	O
539	O
U	O
/	O
L	O
,	O
six	O
days	O
after	O
completing	O
a	O
7	O
-	O
day	O
course	O
of	O
clarithromycin	B-CHED
500	O
mg	O
twice	O
daily	O
for	O
suspected	O
upper	O
respiratory	O
infection	O
.	O

AST	O
and	O
ALT	B-CHED
each	O
rose	O
to	O
about	O
1	O
,	O
000	O
U	O
/	O
L	O
on	O
day	O
-	O
2	O
of	O
admission	O
,	O
and	O
rose	O
to	O
≥	O
6	O
,	O
000	O
U	O
/	O
L	O
on	O
day	O
-	O
3	O
,	O
with	O
development	O
of	O
severe	O
hepatic	O
encephalopathy	O
and	O
severe	O
coagulopathy	O
.	O

TITLE	O
:	O
Radiation	O
induced	O
apoptosis	O
and	O
pulmonary	O
fibrosis	O
:	O
curcumin	B-CHED
an	O
effective	O
intervention	O
?	O

ABSTRACT	O
:	O
Coronaviruses	O
recognize	O
a	O
variety	O
of	O
receptors	O
using	O
different	O
domains	O
of	O
their	O
envelope	O
-	O
anchored	O
spike	O
protein	B-CHED
.	O

TITLE	O
:	O
In	O
Vitro	O
Antiviral	B-CHED
Activity	O
and	O
Projection	O
of	O
Optimized	O
Dosing	O
Design	O
of	O
Hydroxychloroquine	O
for	O
the	O
Treatment	O
of	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
Coronavirus	O
2	O
(	O
SARS	O
-	O
CoV	O
-	O
2	O
).	O

Hydroxychloroquine	O
(	O
EC50	O
=	O
0	O
.	O
72	O
μM	O
)	O
was	O
found	O
to	O
be	O
more	O
potent	O
than	O
chloroquine	B-CHED
(	O
EC50	O
=	O
5	O
.	O
47	O
μM	O
)	O
in	O
vitro	O
.	O

The	O
previous	O
epidemics	O
of	O
high	O
-	O
morbidity	O
human	O
coronaviruses	O
,	O
such	O
as	O
the	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
in	O
2003	O
,	O
and	O
the	O
Middle	O
East	O
respiratory	O
syndrome	O
corona	B-CHED
virus	O
(	O
MERS	O
-	O
CoV	O
)	O
in	O
2012	O
,	O
prompted	O
the	O
characterization	O
of	O
compounds	O
that	O
could	O
be	O
potentially	O
active	O
against	O
the	O
currently	O
emerging	O
novel	O
coronavirus	O
SARS	O
-	O
CoV	O
-	O
2	O
.	O

ABSTRACT	O
:	O
The	O
human	O
FcγRs	O
interact	O
with	O
antigen	B-CHED
-	O
complexed	O
IgG	O
ligands	O
to	O
both	O
activate	O
and	O
modulate	O
a	O
powerful	O
network	O
of	O
inflammatory	O
host	O
-	O
protective	O
effector	B-CHED
functions	O
that	O
are	O
key	O
to	O
the	O
normal	O
physiology	O
of	O
immune	O
resistance	O
to	O
pathogens	O
.	O

SARS	O
-	O
CoV	O
-	O
2	O
prefers	O
pyrimidine	B-CHED
rich	O
codons	O
to	O
purines	B-CHED
.	O

RESULTS	O
:	O
SARS	O
-	O
CoV	O
-	O
2	O
prefers	O
pyrimidine	B-CHED
rich	O
codons	O
to	O
purines	B-CHED
.	O

ABSTRACT	O
:	O
From	O
a	O
scientific	O
standpoint	O
,	O
the	O
world	O
is	O
more	O
prepared	O
than	O
ever	O
to	O
respond	O
to	O
infectious	O
disease	O
outbreaks	O
;	O
paradoxically	O
,	O
globalization	O
and	O
air	B-CHED
travel	O
,	O
antimicrobial	B-CHED
resistance	O
,	O
the	O
threat	O
of	O
bioterrorism	O
,	O
and	O
newly	O
emerging	O
pathogens	O
driven	O
by	O
ecological	O
,	O
socioeconomic	O
,	O
and	O
environmental	O
factors	O
,	O
have	O
increased	O
the	O
risk	O
of	O
global	O
epidemics	O
.	O
1	O
,	O
2	O
,	O
3	O
Following	O
the	O
2002	O
-	O
2003	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
global	O
efforts	O
to	O
build	O
global	O
emergency	O
response	O
capabilities	O
to	O
contain	O
infectious	O
disease	O
outbreaks	O
were	O
put	O
in	O
place	O
.	O
4	O
,	O
5	O
,	O
6	O
But	O
the	O
recent	O
H1N1	O
,	O
Ebola	O
,	O
and	O
Zika	O
global	O
epidemics	O
have	O
shown	O
unnecessary	O
delays	O
and	O
insufficient	O
coordination	O
in	O
response	O
efforts	O
.	O
7	O
,	O
8	O
,	O
9	O
,	O
10	O
In	O
a	O
thoughtful	O
and	O
compelling	O
essay	O
,	O
11	O
Thana	O
C	O
.	O
de	O
Campos	O
argues	O
that	O
greater	O
clarity	O
in	O
the	O
definition	O
of	O
pandemics	O
would	O
probably	O
result	O
in	O
more	O
timely	O
effective	O
emergency	O
responses	O
,	O
and	O
pandemic	O
preparedness	O
.	O

TITLE	O
:	O
A	O
high	O
ATP	B-CHED
concentration	O
enhances	O
the	O
cooperative	O
translocation	O
of	O
the	O
SARS	O
coronavirus	O
helicase	O
nsP13	O
in	O
the	O
unwinding	O
of	O
duplex	O
RNA	O
.	O

An	O
increased	O
ATP	B-CHED
concentration	O
in	O
the	O
unwinding	O
of	O
duplex	O
RNA	O
relieved	O
the	O
decrease	O
in	O
duplex	O
RNA	O
unwinding	O
.	O

Our	O
results	O
suggest	O
that	O
duplex	O
RNA	O
is	O
a	O
preferred	O
substrate	O
for	O
the	O
helicase	O
activity	O
of	O
nsP13	O
than	O
duplex	O
DNA	O
at	O
high	O
ATP	B-CHED
concentrations	O
.	O

Fifteen	O
pCCoV	O
strains	O
were	O
subjected	O
to	O
sequence	O
and	O
phylogenetic	O
analyses	O
,	O
showing	O
that	O
three	O
strains	O
(	O
98960	O
-	O
1	O
/	O
2016	O
,	O
98960	O
-	O
3	O
/	O
2016	O
,	O
98960	O
-	O
4	O
/	O
2016	O
)	O
did	O
not	O
cluster	O
either	O
with	O
Italian	O
or	O
European	O
CCoVs	O
,	O
being	O
more	O
closely	O
related	O
to	O
alphacoronaviruses	O
circulating	O
in	O
Asia	O
with	O
which	O
they	O
displayed	O
a	O
94	O
-	O
96	O
%	O
nucleotide	B-CHED
identity	O
in	O
partial	O
spike	O
protein	B-CHED
gene	O
sequences	O
.	O

In	O
this	O
short	O
communication	O
,	O
we	O
performed	O
phylogenetic	O
-	O
structural	O
sequence	O
analysis	O
of	O
pp1ab	O
protein	B-CHED
of	O
SARS	O
-	O
CoV	O
-	O
2	O
.	O

The	O
COVID	O
-	O
19	O
spike	O
protein	B-CHED
is	O
modeled	O
using	O
its	O
counterpart	O
,	O
the	O
SARS	O
spike	O
.	O

TITLE	O
:	O
Combination	O
of	O
western	O
medicine	B-CHED
and	O
Chinese	O
traditional	O
patent	O
medicine	B-CHED
in	O
treating	O
a	O
family	O
case	O
of	O
COVID	O
-	O
19	O
in	O
Wuhan	O
.	O

The	O
proportion	O
of	O
lymphocytes	O
in	O
the	O
elderly	O
group	O
was	O
significantly	O
lower	O
than	O
that	O
in	O
the	O
young	O
and	O
middle	O
-	O
aged	O
group	O
(	O
P	O
<	O
0	O
.	O
001	O
),	O
and	O
the	O
C	O
-	O
reactive	O
protein	B-CHED
was	O
significantly	O
higher	O
in	O
the	O
young	O
group	O
(	O
P	O
<	O
0	O
.	O
001	O
).	O

TITLE	O
:	O
Arbidol	O
combined	O
with	O
LPV	O
/	O
r	O
versus	O
LPV	O
/	O
r	O
alone	O
against	O
Corona	B-CHED
Virus	O
Disease	O
2019	O
:	O
A	O
retrospective	O
cohort	O
study	O
.	O

Important	O
questions	O
concerning	O
the	O
interaction	O
between	O
SARS	O
-	O
CoV	O
-	O
2	O
and	O
host	O
antiviral	B-CHED
defence	O
,	O
including	O
asymptomatic	O
and	O
presymptomatic	O
virus	O
shedding	O
,	O
are	O
also	O
discussed	O
.	O

PubMed	O
,	O
EMBASE	O
,	O
and	O
three	O
trial	O
Registries	O
were	O
searched	O
for	O
studies	O
on	O
the	O
use	O
of	O
chloroquine	B-CHED
in	O
patients	O
with	O
COVID	O
-	O
19	O
.	O

Chloroquine	B-CHED
seems	O
to	O
be	O
effective	O
in	O
limiting	O
the	O
replication	O
of	O
SARS	O
-	O
CoV	O
-	O
2	O
(	O
virus	O
causing	O
COVID	O
-	O
19	O
)	O
in	O
vitro	O
.	O

To	O
date	O
,	O
effective	O
treatment	O
is	O
lacking	O
;	O
however	O
,	O
clinical	O
trials	O
investigating	O
the	O
efficacy	O
of	O
several	O
agents	O
,	O
including	O
remdesivir	O
and	O
chloroquine	B-CHED
,	O
are	O
underway	O
in	O
China	O
.	O

Levels	O
of	O
potassium	B-CHED
,	O
albumin	O
,	O
lymphocyte	O
were	O
low	O
,	O
but	O
increased	O
persistently	O
after	O
treatment	O
.	O

RESULTS	O
:	O
Compared	O
with	O
general	O
COVID	O
-	O
19	O
patients	O
(	O
45	O
.	O
2	O
%),	O
refractory	O
patients	O
had	O
an	O
older	O
age	O
,	O
male	O
sex	O
,	O
more	O
underlying	O
comorbidities	O
,	O
lower	O
incidence	O
of	O
fever	O
,	O
higher	O
levels	O
of	O
maximum	O
temperature	O
among	O
fever	O
cases	O
,	O
higher	O
incidence	O
of	O
breath	O
shortness	O
and	O
anorexia	O
,	O
severer	O
disease	O
assessment	O
on	O
admission	O
,	O
high	O
levels	O
of	O
neutrophil	O
,	O
aspartate	B-CHED
aminotransferase	O
(	O
AST	O
),	O
lactate	B-CHED
dehydrogenase	O
(	O
LDH	O
)	O
and	O
C	O
-	O
reactive	O
protein	B-CHED
,	O
lower	O
levels	O
of	O
platelets	O
and	O
albumin	O
,	O
and	O
higher	O
incidence	O
of	O
bilateral	O
pneumonia	O
and	O
pleural	O
effusion	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

This	O
sample	O
belonged	O
to	O
Betacoronavirus	O
and	O
shared	O
a	O
more	O
than	O
99	O
%	O
nucleotide	B-CHED
(	O
nt	O
)	O
identity	O
with	O
the	O
Wuhan	O
SARS	O
-	O
CoV	O
-	O
2	O
isolates	O
.	O

Most	O
patients	O
received	O
antiviral	B-CHED
therapy	O
(	O
66	O
[	O
98	O
.	O
5	O
%]	O
of	O
67	O
patients	O
)	O
and	O
antibiotic	B-CHED
therapy	O
(	O
66	O
[	O
98	O
.	O
5	O
%]	O
of	O
67	O
patients	O
).	O

Calculating	O
the	O
composition	O
of	O
host	O
specific	O
slow	O
codons	O
and	O
slow	O
di	O
-	O
codons	O
in	O
the	O
viral	O
protein	B-CHED
coding	O
sequences	O
can	O
predict	O
the	O
order	O
of	O
viral	O
protein	B-CHED
synthesis	O
rates	O
between	O
different	O
virus	O
strains	O
.	O

Teicoplanin	O
,	O
an	O
antibiotic	B-CHED
used	O
to	O
treat	O
staphylococci	O
infection	O
,	O
previously	O
showed	O
efficacy	O
to	O
inhibit	O
the	O
first	O
stage	O
of	O
MERS	O
-	O
coronarivus	O
viral	O
cycle	O
in	O
human	O
cells	O
.	O

Data	O
showing	O
inhibition	O
of	O
HSV	O
-	O
1	O
and	O
CMV	O
replication	O
,	O
when	O
GA	O
is	O
administered	O
post	O
-	O
infection	O
,	O
suggest	O
a	O
possible	O
secondary	O
mechanism	O
targeting	O
protein	B-CHED
and	O
DNA	O
synthesis	O
.	O

To	O
date	O
,	O
no	O
specific	O
antiviral	B-CHED
treatment	O
has	O
proven	O
effective	O
;	O
hence	O
,	O
infected	O
people	O
primarily	O
rely	O
on	O
symptomatic	O
treatment	O
and	O
supportive	O
care	O
.	O

Most	O
of	O
the	O
efforts	O
for	O
developing	O
CoV	O
vaccines	O
and	O
drugs	O
target	O
the	O
spike	O
glycoprotein	B-CHED
or	O
S	O
protein	B-CHED
,	O
the	O
major	O
inducer	O
of	O
neutralizing	O
antibodies	O
.	O

Although	O
we	O
still	O
have	O
limited	O
information	O
on	O
the	O
epidemiology	O
of	O
this	O
virus	O
,	O
there	O
have	O
been	O
multiple	O
reports	O
of	O
superspreading	O
events	O
(	O
SSEs	O
),	O
which	O
are	O
associated	O
with	O
both	O
explosive	B-CHED
growth	O
early	O
in	O
an	O
outbreak	O
and	O
sustained	O
transmission	O
in	O
later	O
stages	O
.	O

In	O
hospitalized	O
adult	O
patients	O
with	O
severe	O
Covid	O
-	O
19	O
,	O
no	O
benefit	O
was	O
observed	O
with	O
lopinavir	O
-	O
ritonavir	B-CHED
treatment	O
beyond	O
standard	O
care	O
.	O

The	O
quantification	O
and	O
localization	O
of	O
the	O
mRNA	B-CHED
of	O
a	O
particular	O
gene	O
allows	O
characterizing	O
disease	O
states	O
more	O
directly	O
compared	O
to	O
an	O
analysis	O
on	O
the	O
DNA	O
level	O
.	O

This	O
is	O
particularly	O
needed	O
for	O
the	O
early	O
detection	O
of	O
virus	O
infections	O
as	O
now	O
required	O
for	O
Corona	B-CHED
diagnostic	O
.	O

Here	O
,	O
we	O
used	O
click	O
chemistry	O
and	O
alkyne	B-CHED
modified	O
DNA	O
oligonucleotides	B-CHED
for	O
preparing	O
multiple	O
-	O
fluorophore	O
containing	O
mRNA	B-CHED
probes	O
.	O

We	O
predict	O
that	O
these	O
individuals	O
are	O
""""	O
primed	O
""""	O
to	O
be	O
at	O
higher	O
risk	O
because	O
nicotine	B-CHED
can	O
directly	O
impact	O
the	O
putative	O
receptor	O
for	O
the	O
virus	O
(	O
ACE2	O
)	O
and	O
lead	O
to	O
deleterious	O
signaling	O
in	O
lung	O
epithelial	O
cells	O
.	O

We	O
focus	O
on	O
the	O
role	O
of	O
lipid	B-CHED
structures	O
,	O
such	O
as	O
lipid	B-CHED
rafts	O
and	O
cholesterol	B-CHED
,	O
involved	O
in	O
the	O
process	O
,	O
mediated	O
by	O
endocytosis	O
,	O
by	O
which	O
viruses	O
attach	O
to	O
and	O
infect	O
cells	O
.	O

More	O
research	O
into	O
these	O
molecules	O
and	O
methods	O
would	O
be	O
worthwhile	O
as	O
it	O
could	O
provide	O
insights	O
the	O
mechanism	O
of	O
transmission	O
of	O
SARS	O
-	O
COV	O
-	O
2	O
and	O
,	O
into	O
how	O
they	O
could	O
become	O
a	O
basis	O
for	O
new	O
antiviral	B-CHED
strategies	O
.	O

ABSTRACT	O
:	O
In	O
December	O
2019	O
,	O
a	O
new	O
outbreak	O
of	O
corona	B-CHED
virus	O
disease	O
2019	O
began	O
to	O
occur	O
.	O

TITLE	O
:	O
[	O
Several	O
suggestions	O
of	O
operation	O
for	O
colorectal	O
cancer	O
under	O
the	O
outbreak	O
of	O
corona	B-CHED
virus	O
disease	O
2019	O
in	O
China	O
].	O

As	O
of	O
Feb	O
15	O
,	O
2020	O
,	O
36	O
cases	O
of	O
COVID	O
-	O
19	O
were	O
linked	O
epidemiologically	O
to	O
the	O
first	O
three	O
clusters	B-CHED
of	O
circumscribed	O
local	O
transmission	O
in	O
Singapore	O
.	O

So	O
far	O
,	O
actions	O
have	O
been	O
taken	O
including	O
but	O
not	O
limited	O
to	O
nationwide	O
actions	O
and	O
online	O
education	O
regarding	O
special	O
procedures	O
of	O
airway	O
management	O
,	O
oxygen	B-CHED
therapy	O
,	O
ventilation	O
support	O
,	O
hemodynamic	O
management	O
,	O
sedation	O
,	O
and	O
analgesia	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
young	O
man	B-CHED
with	O
documented	O
nCoV	O
-	O
19	O
infection	O
evaluated	O
with	O
lung	O
ultrasound	O
and	O
discuss	O
potential	O
applications	O
of	O
lung	O
ultrasound	O
in	O
this	O
setting	O
.	O

Laboratory	O
detection	O
of	O
the	O
viral	O
nucleic	B-CHED
acid	I-CHED
can	O
yield	O
false	O
-	O
negative	O
results	O
,	O
and	O
serological	O
testing	O
of	O
virus	O
specific	O
IgG	O
and	O
IgM	O
antibodies	O
should	O
be	O
used	O
as	O
an	O
alternative	O
for	O
diagnosis	O
.	O

The	O
S1	O
protein	B-CHED
of	O
Pangolin	O
-	O
CoV	O
is	O
much	O
more	O
closely	O
related	O
to	O
SARS	O
-	O
CoV	O
-	O
2	O
than	O
to	O
RaTG13	O
.	O

We	O
identified	O
four	O
major	O
clusters	B-CHED
and	O
estimated	O
the	O
reproduction	O
number	O
at	O
1	O
.	O
5	O
(	O
95	O
%	O
CI	O
:	O
1	O
.	O
4	O
-	O
1	O
.	O
6	O
).	O

RESULTS	O
:	O
We	O
identified	O
four	O
major	O
clusters	B-CHED
and	O
estimated	O
the	O
reproduction	O
number	O
at	O
1	O
.	O
5	O
(	O
95	O
%	O
CI	O
:	O
1	O
.	O
4	O
-	O
1	O
.	O
6	O
).	O

All	O
of	O
the	O
patients	O
received	O
antiviral	B-CHED
therapy	O
(	O
135	O
[	O
100	O
%]	O
(	O
Kaletra	O
and	O
interferon	O
were	O
both	O
used	O
),	O
antibacterial	O
therapy	O
(	O
59	O
[	O
43	O
.	O
7	O
%]),	O
and	O
corticosteroids	B-CHED
(	O
36	O
[	O
26	O
.	O
7	O
%]).	O

It	O
has	O
been	O
a	O
good	O
8	O
years	O
since	O
I	O
'	O
ve	O
graduated	O
medical	O
school	O
,	O
with	O
nary	O
an	O
exposure	O
to	O
emergency	O
medicine	B-CHED
since	O
my	O
intern	O
days	O
.	O

SARS	O
-	O
CoV	O
-	O
2	O
may	O
use	O
co	O
-	O
receptors	O
/	O
auxiliary	O
proteins	B-CHED
as	O
ACE2	O
partner	O
to	O
facilitate	O
the	O
virus	O
entry	O
.	O

As	O
patients	O
can	O
have	O
inflammatory	O
changes	O
in	O
the	O
lungs	O
alongside	O
a	O
negative	O
early	O
nucleic	B-CHED
acid	I-CHED
test	O
,	O
chest	O
CT	O
,	O
in	O
combination	O
with	O
epidemiological	O
and	O
laboratory	O
tests	O
,	O
is	O
a	O
useful	O
examination	O
to	O
evaluate	O
the	O
disease	O
and	O
curative	O
effect	O
.	O

We	O
report	O
a	O
case	O
of	O
COVID	O
-	O
19	O
infection	O
in	O
a	O
64	O
-	O
year	O
-	O
old	O
man	B-CHED
who	O
developed	O
rapidly	O
worsening	O
respiratory	O
failure	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
that	O
required	O
intubation	O
.	O

The	O
interaction	O
interface	O
between	O
cat	O
/	O
dog	O
/	O
pangolin	O
/	O
Chinese	O
hamster	O
ACE2	O
and	O
SARS	O
-	O
CoV	O
/	O
SARS	O
-	O
CoV	O
-	O
2	O
S	O
protein	B-CHED
was	O
simulated	O
through	O
homology	O
modeling	O
.	O

Many	O
CoV	O
proteins	B-CHED
are	O
modified	O
by	O
PTMs	O
,	O
including	O
glycosylation	O
and	O
palmitoylation	O
of	O
the	O
spike	O
and	O
envelope	O
protein	B-CHED
,	O
N	O
-	O
or	O
O	O
-	O
linked	O
glycosylation	O
of	O
the	O
membrane	O
protein	B-CHED
,	O
phosphorylation	O
and	O
ADP	B-CHED
-	O
ribosylation	O
of	O
the	O
nucleocapsid	O
protein	B-CHED
,	O
and	O
other	O
PTMs	O
on	O
nonstructural	O
and	O
accessory	O
proteins	B-CHED
.	O

In	O
this	O
review	O
,	O
we	O
summarize	O
the	O
current	O
knowledge	O
on	O
PTMs	O
of	O
CoV	O
proteins	B-CHED
,	O
with	O
an	O
emphasis	O
on	O
their	O
impact	O
on	O
viral	O
replication	O
and	O
pathogenesis	O
.	O

TITLE	O
:	O
STAT3	O
roles	O
in	O
viral	O
infection	O
:	O
antiviral	B-CHED
or	O
proviral	O
?	O

Proteases	O
of	O
the	O
renin	O
-	O
angiotensin	B-CHED
system	O
serve	O
as	O
receptors	O
needed	O
for	O
entry	O
into	O
target	O
cells	O
;	O
this	O
article	O
describes	O
the	O
current	O
knowledge	O
on	O
the	O
involvement	O
of	O
this	O
system	O
in	O
HCoV	O
pathogenesis	O
.	O

In	O
view	O
of	O
the	O
earlier	O
evidence	O
about	O
effectiveness	O
of	O
repurposed	O
lopinavir	O
/	O
ritonavir	B-CHED
against	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
and	O
Middle	O
East	O
respiratory	O
syndrome	O
(	O
MERS	O
)	O
coronavirus	O
(	O
CoV	O
),	O
as	O
well	O
as	O
preliminary	O
docking	O
studies	O
conducted	O
by	O
the	O
ICMR	O
-	O
National	O
Institute	O
of	O
Virology	O
,	O
Pune	O
,	O
the	O
Central	O
Drugs	O
Standard	O
Control	O
Organization	O
approved	O
the	O
restricted	O
public	O
health	O
use	O
of	O
lopinavir	O
/	O
ritonavir	B-CHED
combination	O
amongst	O
symptomatic	O
COVID	O
-	O
19	O
patients	O
detected	O
in	O
the	O
country	O
.	O

Hospitalized	O
adult	O
patients	O
with	O
laboratory	O
-	O
confirmed	O
SARS	O
-	O
CoV	O
-	O
2	O
infection	O
with	O
any	O
one	O
of	O
the	O
following	O
criteria	O
will	O
be	O
eligible	O
to	O
receive	O
lopinavir	O
/	O
ritonavir	B-CHED
for	O
14	O
days	O
after	O
obtaining	O
written	O
informed	O
consent	O
:	O
(	O
i	O
)	O
respiratory	O
distress	O
with	O
respiratory	O
rate	O
≥	O
22	O
/	O
min	O
or	O
SpO2	O
of	O
<	O
94	O
per	O
cent	O
;	O
(	O
ii	O
)	O
lung	O
parenchymal	O
infiltrates	O
on	O
chest	O
X	O
-	O
ray	O
;	O
(	O
iii	O
)	O
hypotension	O
defined	O
as	O
systolic	O
blood	O
pressure	O
<	O
90	O
mmHg	O
or	O
need	O
for	O
vasopressor	O
/	O
inotropic	O
medication	O
;	O
(	O
iv	O
)	O
new	O
-	O
onset	O
organ	O
dysfunction	O
;	O
and	O
(	O
v	O
)	O
high	O
-	O
risk	O
groups	O
-	O
age	O
>	O
60	O
yr	O
,	O
diabetes	O
mellitus	O
,	O
renal	O
failure	O
,	O
chronic	O
lung	O
disease	O
and	O
immunocompromised	O
persons	O
.	O

Here	O
,	O
we	O
identified	O
the	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
in	O
SARS	O
-	O
CoV	O
-	O
2	O
S	O
protein	B-CHED
and	O
found	O
that	O
the	O
RBD	O
protein	B-CHED
bound	O
strongly	O
to	O
human	O
and	O
bat	O
angiotensin	B-CHED
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
receptors	O
.	O

TITLE	O
:	O
Cloning	O
,	O
Prokaryotic	O
Soluble	O
Expression	O
,	O
and	O
Analysis	O
of	O
Antiviral	B-CHED
Activity	O
of	O
Two	O
Novel	O
Feline	O
IFN	O
-	O
ω	O
Proteins	B-CHED
.	O

Two	O
chest	O
radiologists	O
independently	O
evaluated	O
the	O
imaging	O
in	O
terms	O
of	O
distribution	O
,	O
ground	O
-	O
glass	O
opacity	O
(	O
GGO	O
),	O
consolidation	O
,	O
air	B-CHED
bronchogram	O
,	O
stripe	O
,	O
enlarged	O
mediastinal	O
lymph	O
node	O
,	O
and	O
pleural	O
effusion	O
.	O

Classically	O
,	O
withdrawal	O
symptoms	O
mimic	O
symptoms	O
of	O
serotonin	B-CHED
syndrome	O
with	O
hypertension	O
,	O
increased	O
spasticity	O
,	O
clonus	O
,	O
hyperthermia	O
,	O
tachycardia	O
,	O
and	O
possibly	O
acute	O
psychosis	O
.	O

Interrogation	O
of	O
the	O
patient	O
'	O
s	O
ITB	O
pump	O
revealed	O
normal	O
function	O
,	O
and	O
the	O
patient	O
had	O
no	O
clinical	O
change	O
with	O
intravenous	O
benzodiazepines	B-CHED
,	O
but	O
his	O
condition	O
ultimately	O
improved	O
when	O
his	O
Baclofen	B-CHED
dosing	O
was	O
decreased	O
,	O
indicating	O
toxicity	O
instead	O
of	O
withdrawal	O
.	O

We	O
reviewed	O
TH17	O
responses	O
in	O
patients	O
with	O
SARS	O
-	O
CoV	O
-	O
2	O
and	O
proposed	O
an	O
FDA	O
approved	O
JAK2	O
inhibitor	B-CHED
Fedratinib	O
for	O
reducing	O
mortality	O
of	O
patients	O
with	O
TH17	O
type	O
immune	O
profiles	O
.	O

CONCLUSIONS	O
:	O
Despite	O
its	O
small	O
sample	O
size	O
our	O
survey	O
shows	O
that	O
hydroxychloroquine	O
treatment	O
is	O
significantly	O
associated	O
with	O
viral	O
load	O
reduction	O
/	O
disappearance	O
in	O
COVID	O
-	O
19	O
patients	O
and	O
its	O
effect	O
is	O
reinforced	O
by	O
azithromycin	B-CHED
.	O

Higher	O
rate	O
of	O
fever	O
,	O
cough	O
,	O
expectoration	O
,	O
and	O
headache	O
,	O
lower	O
lymphocytes	O
,	O
albumin	O
,	O
serum	O
sodium	O
levels	O
and	O
higher	O
total	O
bilirubin	B-CHED
,	O
creatine	B-CHED
kinase	O
,	O
lactate	B-CHED
dehydrogenase	O
and	O
C	O
-	O
reactive	O
protein	B-CHED
levels	O
and	O
lower	O
oxygenation	O
index	O
were	O
observed	O
in	O
pneumonia	O
patients	O
(	O
all	O
P	O
<	O
0	O
.	O
05	O
).	O

ABSTRACT	O
:	O
Tilorone	O
is	O
a	O
50	O
-	O
year	O
-	O
old	O
synthetic	O
small	O
-	O
molecule	O
compound	O
with	O
antiviral	B-CHED
activity	O
that	O
is	O
proposed	O
to	O
induce	O
interferon	O
after	O
oral	O
administration	O
.	O

ABSTRACT	O
:	O
Many	O
antimicrobial	B-CHED
peptides	B-CHED
(	O
AMPs	O
)	O
have	O
multiple	O
antimicrobial	B-CHED
immunity	O
effects	O
.	O

The	O
sequence	O
analysis	O
results	O
show	O
that	O
the	O
conserved	O
residues	O
among	O
the	O
peptide	B-CHED
sequences	O
,	O
the	O
maximum	O
of	O
the	O
sequences	O
are	O
70	O
%	O
alike	O
to	O
each	O
other	O
.	O

The	O
phylogenetic	O
analysis	O
reveals	O
the	O
evolutionary	O
relationships	O
of	O
temporins	O
(	O
AMPs	O
),	O
which	O
are	O
branched	O
into	O
seven	O
clusters	B-CHED
.	O

TITLE	O
:	O
Chronology	O
of	O
COVID	O
-	O
19	O
cases	O
on	O
the	O
Diamond	B-CHED
Princess	O
cruise	O
ship	O
and	O
ethical	O
considerations	O
:	O
a	O
report	O
from	O
Japan	O
.	O

Furthermore	O
,	O
he	O
observes	O
the	O
significant	O
abnormality	O
of	O
coagulation	O
function	O
and	O
proposes	O
that	O
the	O
early	O
intravenous	O
immunoglobulin	O
and	O
low	O
molecular	O
weight	O
heparin	B-CHED
anticoagulation	O
therapy	O
are	O
very	O
important	O
.	O

Because	O
the	O
ACE2	O
(	O
angiotensin	B-CHED
-	O
converting	O
enzyme	O
2	O
)	O
protein	B-CHED
is	O
the	O
receptor	O
that	O
facilitates	O
coronavirus	O
entry	O
into	O
cells	O
,	O
the	O
notion	O
has	O
been	O
popularized	O
that	O
treatment	O
with	O
renin	O
-	O
angiotensin	B-CHED
system	O
blockers	O
might	O
increase	O
the	O
risk	O
of	O
developing	O
a	O
severe	O
and	O
fatal	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
-	O
2	O
infection	O
.	O

ACE	O
(	O
angiotensin	B-CHED
-	O
converting	O
enzyme	O
)	O
inhibitors	B-CHED
do	O
not	O
inhibit	O
ACE2	O
because	O
ACE	O
and	O
ACE2	O
are	O
different	O
enzymes	O
.	O

The	O
work	O
can	O
,	O
nonetheless	O
,	O
be	O
described	O
in	O
traditional	O
bioinformatics	O
terms	O
,	O
and	O
readily	O
reproduced	O
by	O
others	O
,	O
albeit	O
with	O
the	O
caveat	O
that	O
new	O
data	O
and	O
research	O
into	O
2019	O
-	O
nCoV	O
is	O
emerging	O
and	O
evolving	O
at	O
an	O
explosive	B-CHED
pace	O
.	O

As	O
of	O
March	O
15	O
,	O
2020	O
,	O
there	O
are	O
over	O
3	O
,	O
700	O
confirmed	O
cases	O
and	O
68	O
deaths	O
ascribed	O
to	O
Covid	O
-	O
19	O
(	O
the	O
disease	O
caused	O
by	O
SARS	O
-	O
CoV	O
-	O
2	O
)	O
in	O
the	O
United	O
States	O
[	O
https	O
://	O
www	O
.	O
livescience	O
.	O
com	B-CHED
/	O
coronavirus	O
-	O
updates	O
-	O
unitedstates	O
.	O
html	O
].	O

C	O
-	O
reactive	O
protein	B-CHED
(	O
CRP	O
)	O
levels	O
were	O
also	O
significantly	O
higher	O
in	O
the	O
death	O
group	O
on	O
admission	O
(	O
109	O
.	O
25	O
[	O
35	O
.	O
00	O
,	O
170	O
.	O
28	O
]	O
mg	O
/	O
L	O
vs	O
.	O
3	O
.	O
22	O
[	O
1	O
.	O
04	O
,	O
21	O
.	O
80	O
]	O
mg	O
/	O
L	O
,	O
Z	O
=	O
10	O
.	O
206	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
showed	O
no	O
significant	O
improvement	O
after	O
treatment	O
(	O
109	O
.	O
25	O
[	O
35	O
.	O
0	O
,	O
170	O
.	O
28	O
]	O
mg	O
/	O
L	O
vs	O
.	O
81	O
.	O
60	O
[	O
27	O
.	O
23	O
,	O
179	O
.	O
08	O
]	O
mg	O
/	O
L	O
,	O
Z	O
=	O
1	O
.	O
219	O
,	O
P	O
=	O
0	O
.	O
233	O
).	O

The	O
patients	O
in	O
the	O
death	O
group	O
had	O
more	O
complications	O
such	O
as	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
89	O
.	O
9	O
%	O
vs	O
.	O
7	O
.	O
6	O
%,	O
χ	O
=	O
148	O
.	O
105	O
,	O
P	O
<	O
0	O
.	O
001	O
),	O
acute	O
cardiac	O
injury	O
(	O
59	O
.	O
6	O
%	O
vs	O
.	O
0	O
.	O
8	O
%,	O
χ	O
=	O
93	O
.	O
222	O
,	O
P	O
<	O
0	O
.	O
001	O
),	O
acute	O
kidney	O
injury	O
(	O
18	O
.	O
3	O
%	O
vs	O
.	O
0	O
,	O
χ	O
=	O
23	O
.	O
257	O
,	O
P	O
<	O
0	O
.	O
001	O
),	O
shock	O
(	O
11	O
.	O
9	O
%	O
vs	O
.	O
0	O
,	O
χ	O
=	O
14	O
.	O
618	O
,	O
P	O
<	O
0	O
.	O
001	O
),	O
and	O
disseminated	O
intravascular	O
coagulation	O
(	O
DIC	B-CHED
)	O
(	O
6	O
.	O
4	O
%	O
vs	O
.	O
0	O
,	O
χ	O
=	O
7	O
.	O
655	O
,	O
P	O
=	O
0	O
.	O
006	O
).	O

It	O
demonstrates	O
that	O
both	O
air	B-CHED
change	O
and	O
exhaust	O
airflow	O
rates	O
have	O
significant	O
effects	O
on	O
not	O
only	O
the	O
airflow	O
but	O
also	O
the	O
particle	O
distribution	O
within	O
a	O
mechanically	O
ventilated	O
space	O
.	O

TITLE	O
:	O
Analysis	O
of	O
Epidemiological	O
and	O
Clinical	O
features	O
in	O
older	O
patients	O
with	O
Corona	B-CHED
Virus	O
Disease	O
2019	O
(	O
COVID	O
-	O
19	O
)	O
out	O
of	O
Wuhan	O
.	O

